<SEC-DOCUMENT>0001613103-24-000072.txt : 20240620
<SEC-HEADER>0001613103-24-000072.hdr.sgml : 20240620
<ACCEPTANCE-DATETIME>20240620161651
ACCESSION NUMBER:		0001613103-24-000072
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		162
CONFORMED PERIOD OF REPORT:	20240426
FILED AS OF DATE:		20240620
DATE AS OF CHANGE:		20240620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Medtronic plc
		CENTRAL INDEX KEY:			0001613103
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0426

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36820
		FILM NUMBER:		241056445

	BUSINESS ADDRESS:	
		STREET 1:		20 ON HATCH, LOWER HATCH STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2
		BUSINESS PHONE:		01135314381700

	MAIL ADDRESS:	
		STREET 1:		20 ON HATCH, LOWER HATCH STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Medtronic Ltd
		DATE OF NAME CHANGE:	20150112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Medtronic Holdings Ltd
		DATE OF NAME CHANGE:	20140711

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kalani I Ltd
		DATE OF NAME CHANGE:	20140709
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mdt-20240426.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31d25153-b660-4ec0-ab44-7e01aa50312b,g:3d21d99d-9a64-4ef0-a05f-06b24f253785,d:a6bfc65eaa654c3ebf593baab4e46685-->
<html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:mdt="http://www.medtronic.com/20240426" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mdt-20240426</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-92">0001613103</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-93">4/26</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-94">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-95">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-96">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-97">D02 XH02</ix:nonNumeric><ix:nonNumeric contextRef="c-73" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-494">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-708">http://fasb.org/us-gaap/2023#OtherOperatingIncomeExpenseNet</ix:nonNumeric><ix:nonNumeric contextRef="c-28" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1022">http://fasb.org/us-gaap/2023#DebtCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1023">http://fasb.org/us-gaap/2023#DebtCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-331" name="us-gaap:DebtInstrumentTerm" id="f-1041">P6Y</ix:nonNumeric><ix:nonNumeric contextRef="c-334" name="us-gaap:DebtInstrumentTerm" id="f-1047">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-337" name="us-gaap:DebtInstrumentTerm" id="f-1053">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-340" name="us-gaap:DebtInstrumentTerm" id="f-1059">P8Y</ix:nonNumeric><ix:nonNumeric contextRef="c-343" name="us-gaap:DebtInstrumentTerm" id="f-1065">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-346" name="us-gaap:DebtInstrumentTerm" id="f-1071">P6Y</ix:nonNumeric><ix:nonNumeric contextRef="c-349" name="us-gaap:DebtInstrumentTerm" id="f-1077">P8Y</ix:nonNumeric><ix:nonNumeric contextRef="c-352" name="us-gaap:DebtInstrumentTerm" id="f-1083">P12Y</ix:nonNumeric><ix:nonNumeric contextRef="c-355" name="us-gaap:DebtInstrumentTerm" id="f-1089">P12Y</ix:nonNumeric><ix:nonNumeric contextRef="c-358" name="us-gaap:DebtInstrumentTerm" id="f-1095">P9Y</ix:nonNumeric><ix:nonNumeric contextRef="c-361" name="us-gaap:DebtInstrumentTerm" id="f-1101">P12Y</ix:nonNumeric><ix:nonNumeric contextRef="c-364" name="us-gaap:DebtInstrumentTerm" id="f-1107">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="c-367" name="us-gaap:DebtInstrumentTerm" id="f-1113">P12Y</ix:nonNumeric><ix:nonNumeric contextRef="c-370" name="us-gaap:DebtInstrumentTerm" id="f-1119">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="c-373" name="us-gaap:DebtInstrumentTerm" id="f-1125">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-376" name="us-gaap:DebtInstrumentTerm" id="f-1131">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="c-379" name="us-gaap:DebtInstrumentTerm" id="f-1137">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-382" name="us-gaap:DebtInstrumentTerm" id="f-1143">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="c-385" name="us-gaap:DebtInstrumentTerm" id="f-1149">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-388" name="us-gaap:DebtInstrumentTerm" id="f-1155">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="c-391" name="us-gaap:DebtInstrumentTerm" id="f-1161">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-394" name="us-gaap:DebtInstrumentTerm" id="f-1167">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-397" name="us-gaap:DebtInstrumentTerm" id="f-1173">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-400" name="us-gaap:DebtInstrumentTerm" id="f-1179">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-403" name="us-gaap:DebtInstrumentTerm" id="f-1185">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-406" name="us-gaap:DebtInstrumentTerm" id="f-1191">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1196">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="c-28" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1197">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1257">http://fasb.org/us-gaap/2023#InterestExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-1328">http://fasb.org/us-gaap/2023#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1329">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-28" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-1330">http://fasb.org/us-gaap/2023#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-28" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1331">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1461">http://fasb.org/us-gaap/2023#OtherOperatingIncomeExpenseNet</ix:nonNumeric><ix:nonNumeric contextRef="c-520" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="f-1568">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="c-520" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-1569">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2346">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-28" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2347">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2350">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-28" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2351">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2354">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-28" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2355">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mdt-20240426.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>mdt:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>mdt:segment</xbrli:measure></xbrli:unit><xbrli:unit id="reportingunit"><xbrli:measure>mdt:reportingUnit</xbrli:measure></xbrli:unit><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="plantiff"><xbrli:measure>mdt:plantiff</xbrli:measure></xbrli:unit><xbrli:unit id="claim"><xbrli:measure>mdt:claim</xbrli:measure></xbrli:unit><xbrli:unit id="lawsuit"><xbrli:measure>mdt:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2022Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2022Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20311.625PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20311.00PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2022Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2022Due2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20392.250PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20391.50PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2053Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-13</xbrli:startDate><xbrli:endDate>2022-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:AfferaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-30</xbrli:startDate><xbrli:endDate>2022-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:AfferaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:AfferaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:OtherAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:OtherAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:OtherAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-20</xbrli:startDate><xbrli:endDate>2024-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">mdt:MozarcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">mdt:MozarcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:MechanicalCirculatorySupportMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:MechanicalCirculatorySupportMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mdt:EnterpriseExcellenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mdt:SimplificationRestructuringProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-28</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdt:EquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdt:EquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2015CommercialPaperProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2625PercentThreeYear2022SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2625PercentThreeYear2022SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2625PercentThreeYear2022SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4250PercentFiveYear2023SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4250PercentFiveYear2023SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4250PercentFiveYear2023SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3000PercentSixYear2022SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3000PercentSixYear2022SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3000PercentSixYear2022SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2032Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2032Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2032Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3125PercentNineYear2022SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3125PercentNineYear2022SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3125PercentNineYear2022SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4500PercentTenYear2023SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4500PercentTenYear2023SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4500PercentTenYear2023SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3375PercentTwelveYear2022SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3375PercentTwelveYear2022SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3375PercentTwelveYear2022SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotesCIFSA2007Due2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotesCIFSA2007Due2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotesCIFSA2007Due2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-03</xbrli:startDate><xbrli:endDate>2024-06-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">mdt:TokyoInterBankOfferedRateTIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2023-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-27</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareBusinessRCSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareBusinessRCSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mdt:PurchasedTechnologyAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mdt:PurchasedTechnologyAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:IPRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:IPRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:IPRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:TwoThousandTwentyOneStockAwardAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:ColibriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-08</xbrli:startDate><xbrli:endDate>2023-02-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-15</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-15</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-15</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:DiabetesPumpRetainerRingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:DiabetesPumpRetainerRingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-14</xbrli:startDate><xbrli:endDate>2024-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_1"></div><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">April&#160;26</ix:nonNumeric>, 2024</ix:nonNumeric>.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.<br/>For the transition period from __________ to __________</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">1-36820</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><img src="mdt-20240426_g1.jpg" alt="mdtlogo2b05.jpg" style="height:101px;margin-bottom:5pt;vertical-align:text-bottom;width:448px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Medtronic plc</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"/><td style="width:38.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.837%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-8">Ireland</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">98-1183488</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">20 On Hatch, Lower Hatch Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Dublin 2</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-12">Ireland</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">+<ix:nonNumeric contextRef="c-1" name="dei:CountryRegion" id="f-13">353</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">1</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">438-1700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-16">Ordinary shares, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-17">MDT</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-19">0.250% Senior Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-20">MDT/25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-21">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-22">0.000% Senior Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-23">MDT/25A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-24">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:Security12bTitle" id="f-25">2.625% Senior Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:TradingSymbol" id="f-26">MDT/25B</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-27">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:Security12bTitle" id="f-28">1.125% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:TradingSymbol" id="f-29">MDT/27</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-30">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:Security12bTitle" id="f-31">0.375% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:TradingSymbol" id="f-32">MDT/28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-33">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:Security12bTitle" id="f-34">3.000% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:TradingSymbol" id="f-35">MDT/28A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-36">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:Security12bTitle" id="f-37">3.650% Senior Notes due 2029</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:TradingSymbol" id="f-38">MDT/29</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-39">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:Security12bTitle" id="f-40">1.625% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:TradingSymbol" id="f-41">MDT/31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-42">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-11" name="dei:Security12bTitle" id="f-43">1.000% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-11" name="dei:TradingSymbol" id="f-44">MDT/31A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-11" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-45">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-12" name="dei:Security12bTitle" id="f-46">3.125% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-12" name="dei:TradingSymbol" id="f-47">MDT/31B</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-12" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-48">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-13" name="dei:Security12bTitle" id="f-49">0.750% Senior Notes due 2032</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-13" name="dei:TradingSymbol" id="f-50">MDT/32</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-13" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-51">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-14" name="dei:Security12bTitle" id="f-52">3.375% Senior Notes due 2034</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-14" name="dei:TradingSymbol" id="f-53">MDT/34</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-14" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-54">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-15" name="dei:Security12bTitle" id="f-55">3.875% Senior Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-15" name="dei:TradingSymbol" id="f-56">MDT/36</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-15" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-57">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-16" name="dei:Security12bTitle" id="f-58">2.250% Senior Notes due 2039</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-16" name="dei:TradingSymbol" id="f-59">MDT/39A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-16" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-60">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-17" name="dei:Security12bTitle" id="f-61">1.500% Senior Notes due 2039</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-17" name="dei:TradingSymbol" id="f-62">MDT/39B</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-17" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-63">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-18" name="dei:Security12bTitle" id="f-64">1.375% Senior Notes due 2040</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-18" name="dei:TradingSymbol" id="f-65">MDT/40A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-18" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-66">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-19" name="dei:Security12bTitle" id="f-67">4.150% Senior Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-19" name="dei:TradingSymbol" id="f-68">MDT/43A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-19" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-69">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-20" name="dei:Security12bTitle" id="f-70">1.750% Senior Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-20" name="dei:TradingSymbol" id="f-71">MDT/49</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-20" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-72">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-21" name="dei:Security12bTitle" id="f-73">1.625% Senior Notes due 2050</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-21" name="dei:TradingSymbol" id="f-74">MDT/50</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-21" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-75">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-22" name="dei:Security12bTitle" id="f-76">4.150% Senior Notes due 2053</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-22" name="dei:TradingSymbol" id="f-77">MDT/53</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-22" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-78">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to section 12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-79">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-80">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-81">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-82">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"><tr><td style="width:1.0%"/><td style="width:18.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.078%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-83">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-84">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-85">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If&#160;an&#160;emerging&#160;growth&#160;company,&#160;indicate&#160;by&#160;check&#160;mark&#160;if&#160;the&#160;registrant&#160;has&#160;elected&#160;not&#160;to&#160;use&#160;the&#160;extended&#160;transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of&#160;the&#160;Exchange&#160;Act. &#9744; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has &#64257;led a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting &#64257;rm that prepared or issued its audit report.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-86">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-87">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-88">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aggregate market value of voting and non-voting common equity of Medtronic plc held by non-affiliates of the registrant as of October 27, 2023, based on the closing price of $69.43 as reported on the New York Stock Exchange: approximately $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="f-89">92.4</ix:nonFraction> billion. Number of Ordinary Shares outstanding on June&#160;17, 2024: <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-90">1,282,269,783</ix:nonFraction></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-91" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Portions of the registrant&#8217;s Proxy Statement for its 2024 Annual General Meeting are incorporated by reference into Part III hereof.</span></ix:nonNumeric><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.600%"><tr><td style="width:1.0%"/><td style="width:2.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_13">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_16">1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_19">1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_19">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_22">1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_22">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_2542">1C.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_2542">Cybersecurity</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_2542">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_25">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_25">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_28">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_28">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_31">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_31">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_34">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_37">5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_37">Market for Medtronic&#8217;s Common Equity, Related Shareholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_37">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_40">6. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_40">(Reserved)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_40">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_43">7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_43">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_118">7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_118">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_118">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_121">8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_121">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_121">50</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_124">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-98">238</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_124">50</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_127">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_127">52</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_145">Notes to</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_145"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_145">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_145">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_208">9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_208">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_208">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_211">9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_211">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_211">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_214">9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_214">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_214">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_2583">9C.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_2583">Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_214">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_217">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_220">10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_220">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_220">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_223">11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_223">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_223">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_226">12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_226">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_226">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_229">13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_229">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_229">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_232">14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_232">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_232">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_235">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_241">15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_241">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_241">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_244">16.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_244">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_244">114</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_247">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_247">115</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, and other written reports of Medtronic plc, organized under the laws of Ireland (together with its consolidated subsidiaries, Medtronic, the Company, or we, us, or our), and oral statements made by or with the approval of one of the Company&#8217;s executive officers from time to time, may include &#8220;forward-looking&#8221; statements. All statements other than statements of historical fact contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, business strategy and plans, objectives of management for future operations and current expectations or forecasts of future results, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Our forward-looking statements may include statements related to our growth and growth strategies, developments in the markets for our products, therapies and services, financial results, product development launches and effectiveness, research and development strategy, regulatory approvals, competitive strengths, the potential or anticipated direct or indirect impact of public health crises and geopolitical conflicts on our business, results of operations and/or financial condition, restructuring and cost-saving initiatives, intellectual property rights, litigation and tax matters, governmental proceedings and investigations, mergers and acquisitions, divestitures, market acceptance of our products, therapies and services, accounting estimates, financing activities, ongoing contractual obligations, working capital adequacy, value of our investments, our effective tax rate, our expected returns to shareholders, and sales efforts. In some cases, such statements may be identified by the use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;looking ahead,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and similar words or expressions. Forward-looking statements in this Annual Report include, but are not limited to, statements regarding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our ability to drive long-term shareholder value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development and future launches of products and continued or future acceptance of products, therapies and services in our segments; expected timing for completion of research studies relating to our products; integration of new technologies, including artificial intelligence (AI) and data analytics, into our products, therapies and services; market positioning and performance of our products, including stabilization of certain product markets; divestitures and the potential benefits thereof; the costs and benefits of integrating previous acquisitions; anticipated timing for United States (U.S.) Food and Drug Administration (U.S. FDA) and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; our ability to meet growing demand for our existing products; acquisitions and investment initiatives, including the timing of regulatory approvals as well as integration of acquired companies into our operations; the resolution of tax matters; the effectiveness of our development activities in reducing patient care costs and hospital stay lengths; our approach towards cost containment; our expectations regarding healthcare costs, including potential changes to reimbursement policies and pricing pressures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment of dividends and redemption of shares; the continued strength of our balance sheet and liquidity; our accounts receivable exposure; our human capital management with respect to our global workforce; and the potential impact of our compliance with governmental regulations and accounting guidance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations, financial condition, and/or cash flows. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described in the &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. One must carefully consider forward-looking statements and understand that such forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and involve a variety of risks and uncertainties, known and unknown, including, among others, those discussed in the sections entitled &#8220;Government Regulation&#8221; within &#8220;Item 1. Business&#8221; and &#8220;Item 1A. Risk Factors&#8221; in this Annual Report on Form 10-K, as well as those related to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">competition in the medical device industry,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in regulatory approvals,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">public health crises,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reduction or interruption in our supply,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to complete or achieve the intended benefits of acquisitions or divestitures,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">adverse regulatory action,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">laws and governmental regulations,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">litigation results,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">quality problems,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">healthcare policy changes,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">cybersecurity and privacy incidents,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">international operations, including the impact of armed conflicts,</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">self-insurance,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">commercial insurance,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in applicable tax rates,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">positions taken by taxing authorities,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">decreasing selling prices and pricing pressure,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">liquidity shortfalls,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">fluctuations in currency exchange rates,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inflation, or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disruption of our current plans and operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, no forward-looking statement may be guaranteed, and actual results may vary materially from those projected in the forward-looking statements. We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor with respect to all forward-looking statements. While we may elect to update these forward-looking statements at some point in the future, whether as a result of any new information, future events, or otherwise, we have no current intention of doing so except to the extent required by applicable law.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_16"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g2.jpg" alt="Infographic.jpg" style="height:152px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company. Medtronic was founded in 1949 and today serves healthcare systems, physicians, clinicians, and patients in more than 150 countries worldwide. We remain committed to a mission written by our founder in 1960 that directs us &#8220;to contribute to human welfare by the application of biomedical engineering in the research, design, manufacture, and sale of products to alleviate pain, restore health, and extend life.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Mission &#8212; to alleviate pain, restore health, and extend life &#8212; empowers insight-driven care and better outcomes for our world. We remain committed to being recognized as a company of dedication, honesty, integrity, and service. Building on this strong foundation, we are embracing our role as a healthcare technology leader and evolving our business strategy in four key areas:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging our pipeline to accelerate revenue growth: The combination of our end markets, recent product launches and robust pipeline is expected to continue accelerating our growth over both the near-and long-term. We aim to bring inventive and disruptive technology to large healthcare opportunities which enables us to better meet patient needs. Patients around the world deserve access to our life-saving products, and we are driven to use our local presence and scale to increase the adoption of our products and services in markets around the globe.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Serving more patients by accelerating innovation driven growth and delivering shareholder value: We listen to our patients and customers to better understand the challenges they face. From the patient journey, to creating agile partnerships that produce novel solutions, to making it easier for our customers to deploy our therapies &#8212; what we do is anchored in deep insight, and creates simpler, superior experiences.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Creating and disrupting markets with our technology: We are confident in our ability to maximize new technology, artificial intelligence (AI), and data and analytics to tailor therapies in real-time, facilitating remote monitoring and care delivery that conveniently manages conditions, and creates new standards of care.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Empowering our operating units to be more nimble and more competitive: Our operating model is organized to accelerate decision making, improve commercial execution, and more effectively leverage the scale of our company.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have four reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and services: the Cardiovascular Portfolio, the Neuroscience Portfolio, the Medical Surgical Portfolio, and the Diabetes Operating Unit. For more information regarding our segments, please see Note 19 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIOVASCULAR PORTFOLIO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cardiovascular Portfolio is made up of the Cardiac Rhythm &amp; Heart Failure, Structural Heart &amp; Aortic, and Coronary &amp; Peripheral Vascular divisions. The primary medical specialists who use our Cardiovascular products include electrophysiologists, implanting cardiologists, heart failure specialists, cardiovascular, cardiothoracic, and vascular surgeons, and interventional cardiologists and radiologists. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g3.jpg" alt="Cardiovascular Product Images.jpg" style="height:151px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiac Rhythm &amp; Heart Failure </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Cardiac Rhythm &amp; Heart Failure division includes the following Operating Units: Cardiac Rhythm Management and Cardiac Ablation Solutions. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">division develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Our products include implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, and information systems for the management of patients with Cardiac Rhythm &amp; Heart Failure devices. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implantable cardiac pacemakers including the Azure MRI SureScan, Adapta, Advisa MRI SureScan, and the Micra transcatheter pacing system. Azure pacemakers feature Medtronic-exclusive BlueSync technology, which enables automatic, secure wireless remote monitoring with increased device longevity. The 3830 lead, previously labeled for His-bundle pacing, has now been expanded to include left bundle branch area pacing effectively covering all current forms of conduction system pacing. The Micra transcatheter pacing system, which is leadless and does not have a subcutaneous device pocket like a conventional pacemaker, includes the Micra VR and the Micra AV device families. Both of these pacemakers treat patients with atrioventricular block.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implantable cardioverter defibrillators (ICDs), including the Aurora Extravascular-ICD, Visia AF MRI SureScan, Evera MRI SureScan, Primo MRI, and the Cobalt and Crome family of BlueSync-enabled ICDs, as well as defibrillator leads, including the Sprint Quattro Secure lead.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implantable cardiac resynchronization therapy devices (CRT-Ds and CRT-Ps) including the Claria/Amplia/Compia family of MRI Quad CRT-D SureScan systems and the Cobalt and Crome portfolio of BlueSync-enabled CRT-Ds, as well as the Percepta/Serena/Solara family of MRI Quad CRT-P SureScan systems. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cardiac ablation products include a full suite of electrophysiology solutions to treat patients with arrhythmias, including paroxysmal and persistent AF. The portfolio includes the PulseSelect Pulsed Field Ablation System, Arctic Front Advanced Cardiac Cryoablation System, the DiamondTemp Ablation system, Sphere 9 catheter, the first of its kind with high density mapping capabilities combined with radio frequency and pulsed field energies to deliver ablation lesions, and Affera Mapping and Navigation System with Prism-1 software aimed at integrating clinical information to improve patient outcomes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Insertable cardiac monitoring systems, including the Reveal LINQ and LINQ II. These devices are for patients who experience transient symptoms such as dizziness, palpitation, syncope (fainting) and chest pain, as well as Cryptogenic Stroke patients; which may indicate a cardiac arrhythmia that requires long-term monitoring or ongoing management. Both portfolio devices have unmatched accuracy and a streamlined workflow with AccuRhythm AI algorithms to reduce clinic workload and data burden. LINQ II, the premium portfolio device, offers extended device longevity and remote programming capabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TYRX products, including the Cardiac and Neuro Absorbable Antibacterial Envelopes, which are designed to stabilize electronic implantable devices and help prevent infection associated with implantable pacemakers and defibrillators. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Remote monitoring services and patient-centered software to enable efficient care coordination as well as services related to hospital operational efficiency. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medtronic stopped the distribution and sale of the HVAD System in June 2021. We continue a support program for patients with HVAD devices, and for caregivers and healthcare professionals who participate in their care.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Structural Heart &amp; Aortic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Structural Heart &amp; Aortic division includes the following Operating Units: Structural Heart &amp; Aortic and Cardiac Surgery. The division includes therapies to treat heart valve disorders and aortic disease. Our devices include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, surgical ablation products, and comprehensive line of products and therapies to treat aortic disease, such as aneurysms, dissections, and transections. Principal products offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CoreValve family of aortic valves, including the Evolut PRO, Evolut PRO+, Evolut FX, and Evolut FX+ TAVR systems for transcatheter aortic valve replacement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Surgical valve replacement and repair products for damaged or diseased heart valves, including both tissue and mechanical valves; blood-handling products that form a circulatory support system to maintain and monitor blood circulation and coagulation status, oxygen supply, and body temperature during arrested heart surgery; and surgical ablation systems and positioning and stabilization technologies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Endovascular stent grafts and accessories, including the Endurant II Stent Graft System for the treatment of abdominal aortic aneurysms, the Valiant Captivia Thoracic Stent Graft System for thoracic endovascular aortic repair procedures, and the Heli-FX EndoAnchor System. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Transcatheter Pulmonary Valves, including Harmony Transcatheter Pulmonary Valve (TPV) and Delivery Catheter System and Melody TPV/Ensemble II Delivery System. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coronary &amp; Peripheral Vascular</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Coronary &amp; Peripheral Vascular division includes the following Operating Units: Coronary &amp; Renal Denervation and Peripheral Vascular Health. The division is comprised of a comprehensive line of products and therapies to treat coronary artery disease as well as peripheral vascular disease and venous disease. Our products include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guide wires, diagnostic catheters, and accessories, peripheral drug coated balloons, stent and angioplasty systems, carotid embolic protection systems for the treatment of vascular disease outside the heart, and products for superficial and deep venous disease. Principal products offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Percutaneous Coronary Intervention products including our Onyx Frontier and Resolute Onyx drug-eluting stents, Euphora balloons, and Launcher guide catheters. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products to treat hypertension including our Symplicity Spyral Renal Denervation (RDN) system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Percutaneous angioplasty balloons including the IN.PACT family of drug-coated balloons, vascular stents including the Abre venous stent, directional atherectomy products including the HawkOne directional atherectomy system, and other procedure support tools. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products to treat superficial venous diseases in the lower extremities including the ClosureFast radiofrequency ablation system and the VenaSeal Closure System.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROSCIENCE PORTFOLIO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Neuroscience Portfolio is made up of the Cranial &amp; Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. The primary medical specialists who use the products of this group include spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, interventional radiologists, and ear, nose, and throat specialists.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g4.jpg" alt="Neuroscience Product Images.jpg" style="height:150px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cranial &amp; Spinal Technologies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Cranial &amp; Spinal Technologies division and Operating Unit develops, manufactures, and markets an integrated portfolio of devices and therapies for&#160;surgical technologies designed to improve the precision and workflow of neuro procedures, and a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. The division also provides biologic solutions for the orthopedic markets and offers unique and highly differentiated imaging, navigation, power instruments, and robotic guidance systems used in spine and cranial procedures. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Neurosurgery products, including platform technologies, implant therapies, and advanced energy products through the AiBLE spine technology ecosystem. This includes our StealthStation S8 surgical navigation system, Stealth Autoguide cranial robotic guidance platform, O-arm Imaging System, Mazor X robotic guidance systems used in robot-assisted spine procedures, UNiD adaptive spine intelligence AI-driven technology for surgical planning and personalized spinal implants, and our Midas Rex surgical drills, including our MR8 high-speed drill system.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products to treat a variety of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine, and stenosis. These products include our CATALYFT PL expandable interbody spacers, CD Horizon ModuLeX spinal system, and T2 STRATOSPHERE expandable corpectomy system. These products can also include titanium interbody implants and surface technologies, such as our Adaptix interbody system and incorporated Titan interbody fusion device with nanoLOCK technology.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products that facilitate less invasive thoracolumbar surgeries, including the CD Horizon Solera Voyager percutaneous fixation system and various retractor systems to access the spine through smaller incisions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products to treat conditions in the cervical region of the spine, including the ZEVO anterior cervical plate system, the Infinity Occipitocervical-Upper Thoracic (OCT) System, and Prestige LP cervical discs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biologic solutions products, including our Infuse Bone Graft (InductOs in the European Union (E.U.)), which contains a recombinant human bone morphogenetic protein-2, rhBMP-2, for certain spinal, trauma, and oral maxillofacial applications.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Demineralized bone matrix products, including Magnifuse, GRAFTON/GRAFTON PLUS, and the Mastergraft family of synthetic bone graft products &#8211; Matrix, Putty, Strip, and Granules.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Therapies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Specialty Therapies division includes the following Operating Units: Neurovascular; Ear, Nose, and Throat (ENT); and Pelvic Health. The division develops, manufactures, and markets products and therapies to treat patients afflicted with acute ischemic and hemorrhagic stroke, ENT diseases, and patients suffering from overactive bladder, and (non-obstructive) urinary retention. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Neurovascular products to treat diseases of the vasculature in and around the brain. This includes coils, neurovascular stent retrievers, and flow diversion products, as well as access and delivery products to support procedures. Products also include the Pipeline Flex and Pipeline Vantage embolization devices with Shield Technology, endovascular treatments for large or giant wide-necked brain aneurysms, the portfolio of Solitaire revascularization devices for treatment of acute ischemic stroke, the Riptide aspiration system, the Onyx Liquid Embolic System, and a portfolio of associated access catheters including our React aspiration catheters also for the treatment of acute ischemic stroke. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ENT products, including the Straightshot M5 microdebrider handpiece, the Integrated Power Console (IPC) system, NIM Vital nerve monitoring systems, Propel and Sinuva Sinus Implants from the acquisition of Intersect ENT, StealthStation ENT and StealthStation FlexENT navigation systems, as well as products for hearing restoration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelvic health products, including our InterStim X and InterStim II recharge-free neurostimulators, InterStim Micro rechargeable neurostimulators, and SureScan MRI leads. Our NURO System delivers Percutaneous Tibial Neuromodulation therapy to treat overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neuromodulation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Neuromodulation division and Operating Unit develops, manufactures, and markets spinal cord stimulation and brain modulation systems, implantable drug infusion systems for chronic pain, as well as interventional products. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Spinal cord stimulation products, including rechargeable and recharge-free devices and a large selection of leads used to treat chronic back and/or limb pain and chronic pain resulting from diabetic peripheral neuropathy. This includes the Intellis (rechargeable) and Vanta (recharge-free) spinal cord stimulation systems, with AdaptiveStim and SureScan MRI Technology, DTM (differential target multiplexed) proprietary waveform, the Evolve workflow algorithm, and Snapshot reporting, as well as the Inceptiv spinal cord stimulation system, which offers a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Brain modulation products, including those for the treatment of the disabling symptoms of Parkinson's disease, essential tremor, refractory epilepsy, severe, treatment-resistant obsessive-compulsive disorder (approved under a Humanitarian Device Exemption (HDE) in the U.S.), and chronic, intractable primary dystonia (approved under a HDE in the U.S.). Specifically, this includes our family of Activa neurostimulators, including Activa SC (single-channel primary cell battery), Activa PC (dual channel primary cell battery), and Activa RC (dual channel rechargeable battery), as well as our family of Percept neurostimulators, the Percept PC, Percept RC, and our SenSight directional lead system with the proprietary BrainSense technology. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implantable drug infusion systems, including our SynchroMed III Implantable Infusion System, that deliver small quantities of drug directly into the intrathecal space surrounding the spinal cord. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interventional products, including the Kyphon Balloon, the Kyphon V Premium, and Kyphon Assist systems and the OsteoCool RF Tumor ablation system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Accurian nerve ablation system, which conducts radio frequency ablation of nerve tissues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDICAL SURGICAL PORTFOLIO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Surgical Portfolio includes the Surgical &amp; Endoscopy and Acute Care &amp; Monitoring divisions. Products and therapies of this group are used primarily by healthcare systems, physicians' offices, ambulatory care centers, and other alternate site healthcare providers. While less frequent, some products and therapies are also used in home settings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g5.jpg" alt="Med Surg Product Images.jpg" style="height:150px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Surgical &amp; Endoscopy</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Surgical &amp; Endoscopy division includes the following Operating Units: Surgical and Endoscopy. The division develops, manufactures, and markets advanced and general surgical products, including advanced stapling devices, vessel sealing instruments, wound closure products, electrosurgery products, AI-powered surgical video and analytics platform, and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, minimally invasive gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions that are typically, but not exclusively, addressed by surgeons. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advanced stapling and energy products, including the Tri-Staple technology platform for endoscopic stapling, including the Endo GIA reloads and reinforced reloads with Tri-Staple technology and the Endo GIA ultra universal stapler, the Signia powered stapling system, the LigaSure exact dissector and L-Hook Laparoscopic Sealer/Divider, and the Sonicision 7 curved jaw cordless ultrasonic dissection system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Electrosurgical hardware and instruments, including the Valleylab FT10 energy platform, the Valleylab LS10 generator, and the Force TriVerse electrosurgical pencils.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Robotic and digital surgery technologies, including the Hugo robotic-assisted surgery (RAS) system designed for a broad range of soft-tissue procedures, and Touch Surgery Enterprise, an AI-powered surgical video management solution for the operating room.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products designed for the treatment of hernias, including the AbsorbaTack absorbable mesh fixation device for hernia repair, the Symbotex composite mesh for surgical laparoscopic and open ventral hernia repair, and ProGrip laparoscopic self-fixating mesh, a self-gripping, biocompatible solution for inguinal hernias.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suture and wound closure products, including the V-Loc barbed sutures, the Polysorb braided absorbable sutures, and the Monosof absorbable monofilament nylon sutures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Endoscopy products, including the GI Genius intelligent endoscopy module, the PillCam capsule endoscopy systems, the Bravo calibration-free reflux testing systems, the Endoflip Impedance Planimetry System, the Emprint ablation system with Thermosphere Technology, the ManoScan Bravo system, the Barrx platform through ablation with the Barrx 360 Express catheter, the Cool-tip radiofrequency ablation system, the HET bipolar system, the Beacon delivery system, and the Nexpowder endoscopic hemostasis system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acute Care &amp; Monitoring</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Acute Care &amp; Monitoring division develops, manufactures, and markets products in the fields of patient monitoring and airway management. In February 2024, the Company announced the decision to exit its ventilator product line and combine the remaining Patient Monitoring &amp; Respiratory Interventions businesses into one business unit called Acute Care &amp; Monitoring. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products focused on blood oxygen management and remote monitoring, including Nellcor pulse oximetry monitors and sensors, Healthcast Connectivity Solutions, and the RespArray patient monitor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products focused on reducing perioperative complications, including Bispectral Index (BIS) brain monitoring technology, INVOS cerebral/somatic oximetry systems, and WarmTouch convective warming. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products focused on airway management and respiratory monitoring, including Microstream capnography monitors, McGRATH MAC video laryngoscopes, Shiley Endotracheal Tubes, Shiley Tracheostomy Tubes, and DAR Breathing Systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIABETES OPERATING UNIT</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diabetes Operating Unit develops, manufactures, and markets products and services for the management of Type 1 and Type 2 diabetes. The primary medical specialists who use and/or prescribe our Diabetes products are endocrinologists and primary care physicians. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g6.jpg" alt="Diabetes Product Images.jpg" style="height:151px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Insulin pumps and consumables, including the MiniMed 780G system, powered by SmartGuard technology. The MiniMed 780G system provides smartphone and Bluetooth connectivity, a meal-time detection system, an adjustable glucose target down to 100 mg/dl, and has the capability to continuously deliver background insulin and monitor sugar levels.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continuous glucose monitoring (CGM) system, the Guardian Connect CGM system, which is worn by patients capturing glucose data to reveal patterns and potential problems, such as hyperglycemic and hypoglycemic episodes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The InPen smart insulin pen system combines a reusable Bluetooth-enabled insulin pen with an intuitive mobile app that helps users administer the appropriate insulin dose. The InPen application integrates with our CGM data to provide real-time CGM readings alongside insulin dose information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic Workforce Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic&#8217;s employees deliver on our Mission every day. We empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. We strive to be the employer of choice for the best and brightest global talent, where employees can grow and develop fulfilling careers. We aspire to create an inclusive, diverse, and equitable workplace that fosters innovation and creativity, and where employees feel a sense of belonging and well-being. Medtronic has 95,000+ full-time employees, of which 44% are based in the U.S. or Puerto Rico. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inclusion, Diversity &amp; Equity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that improving health for people from all walks of life depends on our ability to unleash the creative power of our diverse global employees. By breaking down barriers to Inclusion, Diversity and Equity (ID&amp;E), we open doors for everyone, driving progress and prosperity around the world. We integrate ID&amp;E principles throughout our Company to ensure every operating unit, team, and leader recognizes and celebrates the value of diverse experiences and backgrounds. As of the end of fiscal year 2024, 41% of our U.S. workforce is ethnically diverse; women comprise 51% of our global workforce; 44% of our manager and above employees are women; and 28% of our U.S. managers are ethnically diverse. Additionally, Medtronic employee resource groups (ERGs) are employee-led affinity groups that provide career development and networking opportunities for members and strengthen ties between employees of many different backgrounds, cultures, and interests. In fiscal year 2024, there were 13 ERGs and Diversity Networks across 300+ hubs or chapters in over 65 countries with more than 35,000 employees involved.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pay Equity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our most recent reported period available, in the United States, we have achieved 100% pay equity for gender and ethnically diverse employees. Globally we have achieved 99% pay equity for gender. We are actively working to resolve any remaining pay inequities by continuing to expand the annual pay equity analyses for each country we operate in. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Workforce Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation framework is designed to celebrate the value and contributions of our employees. We are committed to transparent communications on compensation. Our competitive approach to compensation reflects industry benchmarks and local market standards. Our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs include annual and long-term equity-based incentives that provide the means to share in the Company&#8217;s success, based on business and individual performance. To attract and retain the best leaders, we offer competitive benefits and cash and equity incentives. We reward high-performing employees with an ownership stake in the Company through restricted stock, and employees have the opportunity to purchase stock at a significant discount through our Employee Stock Purchase Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Learning &amp; Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The skills and dedication of our employees drive our business performance. Our comprehensive professional development programs empower our people to build rewarding careers and help us attract world-class talent from global and diverse populations. Our suite of professional development programs ensures that our employees, regardless of level, location, language or learning preferences, have access to opportunities to develop and grow.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have shifted away from degree requirements to focus on skills-based certification for certain roles within Medtronic. Additionally, as members of the Multiple Pathways Initiative, we have used a skills-based approach to offering opportunities to expanded pools of external talent that have previously been held back due to lack of access to undergraduate education. Internally, eligible U.S. and Puerto Rico employees can now participate through MAPS (Medtronic Advancement Pathways and Skill-building) in undergraduate courses from top-tier universities to enhance or obtain new skills, at no cost to the employee. Our change in approach has opened opportunities for employees who have been otherwise restricted from career advancement due to degree requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Engagement and Culture</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our Organizational Health Survey, we gain valuable insight into the Medtronic employee experience and identify where we can improve in key priority areas: 1) Employee Engagement, 2) Inclusion, 3) Innovation, 4) Ethics and 5) Quality culture as part of our commitment to Put Patients First in our everyday decisions and actions. In our most recent survey ending in the fourth quarter of fiscal year 2024, more than 87% of our employees responded. Medtronic carefully reviews and implements actions based on employee feedback in order to partner and create an inclusive, innovative and supportive environment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our culture, how we show up and get things done, is critical to achieving our vision. The Medtronic Mindset builds on our core values of integrity, quality, inclusion, and collaboration. It urges us to act boldly, compete to win, move with speed and decisiveness, foster belonging, and deliver results&#8230; the right way. Our culture helps us meet the needs of our patients and customers, and ensures our Mission endures for many years to come.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health &amp; Safety</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a large, global employer, our ability to attract and retain talent is based in part on our commitment to maintain a safe workplace and support the well-being of our employees. Medtronic has a comprehensive approach to providing robust support for our employees and their families in natural disasters, public health crises, civil unrest and armed conflicts, bereavement, and other challenging events. Along with other programs, the Medtronic Employee Assistance Program and the Medtronic Employee Emergency Assistance Fund have historically supported employees and their families when faced with difficult times by providing a variety of services such as mental health, safety, and financial resources and support at no cost. These programs have proven invaluable in navigating our employees through unique challenges, including in fiscal year 2024. The Medtronic Employee Emergency Assistance Fund is supported by donations from employees and the Medtronic Foundation, and over the last five years has provided $4 million in grants to employees experiencing unexpected events creating a financial hardship.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on Human Capital Management at Medtronic, please refer to our 2023 Sustainability Report as well as Medtronic&#8217;s 2023 Global Inclusion, Diversity and Equity Report available on our company website.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER FACTORS IMPACTING OUR OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets in which we participate are subject to rapid technological advances and innovations. Constant improvement of existing products and introduction of new products is necessary to maintain market leadership. Our research and development (R&amp;D) efforts are directed toward maintaining or achieving technological leadership in the markets we serve to help ensure that patients using our devices and therapies receive the most advanced and effective treatment possible. We remain committed to developing technological enhancements and new indications for existing products, and less invasive and new technologies for new and emerging markets to address unmet patient needs. That commitment leads to our initiation and participation in hundreds of clinical trials each fiscal year as the demand for clinical and economic evidence remains high. Furthermore, our development activities are intended to help reduce patient care costs and the length of hospital stays in the future. We have not engaged in significant customer or government-sponsored research.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&amp;D activities include improving existing products and therapies, expanding their indications and applications for use, developing new therapies and procedures, and entering into arrangements with third parties to fund the development of certain technologies. We continue to focus on optimizing innovation, improving our R&amp;D productivity, driving growth in emerging markets, generating clinical evidence, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessing our R&amp;D programs based on their ability to address unmet clinical needs, produce better patient outcomes, and create new standards of care.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property and Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of patents, trademarks, tradenames, copyrights, trade secrets, and agreements, including non-disclosure agreements, to protect our business and proprietary technology. In addition, we have entered into exclusive and non-exclusive licenses relating to a wide array of third-party technologies. In the aggregate, these intellectual property assets and licenses are of material importance to our business; however, we believe that no single intellectual property asset or license is material in relation to our business as a whole. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in an industry characterized by extensive intellectual property litigation. Intellectual property litigation may result in significant damage awards and injunctions that could prevent the manufacture and sale of affected products or result in significant royalty payments in order to continue selling the products. At any given time, we are generally involved as both a plaintiff and a defendant in a number of patent infringement actions, the outcomes of which may not be known for prolonged periods of time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Distribution</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our medical devices and therapies through a combination of direct sales representatives and independent distributors globally. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals. Our medical supply products are used primarily in hospitals, surgical centers, and alternate care facilities, such as home care and long-term care facilities, and are marketed to materials managers, group purchasing organizations (GPOs) and integrated delivery networks (IDNs). We often negotiate with GPOs and IDNs, which enter into supply contracts for the benefit of their member facilities. Our four largest markets are the U.S., Western Europe, China, and Japan. Emerging markets are an area of increasing focus and opportunity, as we believe they remain under-penetrated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketing and sales strategy is focused on rapid, cost-effective delivery of high-quality products to a diverse group of customers worldwide. To achieve this objective, our marketing and sales teams are organized around physician specialties. This focus enables us to develop highly knowledgeable and dedicated sales representatives who are able to foster strong relationships with physicians and other customers and enhance our ability to cross-sell complementary products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not dependent on any single customer for more than 10 percent of our total net sales. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition, Industry, and Cost Containment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in both the therapeutic and diagnostic medical markets in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> more</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> than 150 countries throughout the world. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our product lines face a mix of competitors ranging from large manufacturers with multiple business lines to small manufacturers offering a limited selection of products. In addition, we face competition from providers of other medical therapies, such as pharmaceutical companies, including those producing glucagon-like peptide-1s (GLP-1s).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major shifts in industry market share have occurred in connection with product corrective actions, physician advisories, safety alerts, results of clinical trials to support superiority claims, and publications about our products, reflecting the importance of product quality, product efficacy and quality systems in the medical device industry. In the current environment of managed care, economically motivated customers, consolidation among healthcare providers, increased competition, declining reimbursement rates, and national and provincial tender pricing, competitively priced product offerings are essential to our business. In order to continue to compete effectively, we must continue to create or acquire advanced technology, incorporate this technology into proprietary products, obtain regulatory approvals in a timely manner, maintain high-quality manufacturing processes, and successfully market these products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and private sector initiatives to limit the growth of healthcare costs, including price regulation, competitive pricing, bidding and tender mechanics, coverage and payment policies, comparative effectiveness of therapies, technology assessments and managed-care arrangements, are continuing in many countries where we do business, including the U.S. These initiatives put increased emphasis on the delivery of more cost-effective medical devices and therapies. Government programs, including Medicare and Medicaid, private healthcare insurance, managed-care plans, and volume-based procurement tenders in China, have attempted to control costs by limiting the amount of reimbursement they will pay for particular procedures or treatments, tying reimbursement to outcomes, shifting to population health management, and other mechanisms. Hospitals, which purchase our technology, are also seeking to reduce costs through a variety of mechanisms, including, for example, centralized purchasing, and in some cases, limiting the number of vendors that may participate in the purchasing program. Hospitals are also aligning interests with physicians through employment and other arrangements, such as gainsharing, where a hospital agrees with physicians to share any realized cost savings resulting from changes in practice patterns such as device standardization. This has created an increased level of price sensitivity among customers for our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Production and Availability of Raw Materials</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture products at manufacturing facilities located in various countries throughout the world. We purchase many of the components and raw materials used in manufacturing our products from numerous suppliers in various countries. Certain components and raw materials are available only from a sole supplier. We work closely with our suppliers and have plans and measures in place to help ensure continuity of supply while maintaining high quality and reliability. Generally, we have been able to obtain adequate supplies of such raw materials and components. However, due to the U.S. FDA&#8217;s manufacturing requirements and those of other regulatory authorities, we may not be able to quickly establish additional or replacement sources for certain components or materials if we experience a sudden or unexpected reduction or interruption in supply and are unable to develop alternative sources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information related to our manufacturing facilities refer to &#8220;Item 2. Properties&#8221; in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and products are subject to extensive regulation by numerous government agencies, including the U.S. FDA, European regulatory authorities such as the Medicines and Healthcare products Regulatory Agency in the United Kingdom, the Health Products Regulatory Authority in the Republic of Ireland and the Federal Institute for Drugs and Medical Devices in Germany, the China </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">National Medical Product Administration (NMPA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other government agencies inside and outside the U.S. To varying degrees, each of these agencies requires us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing, distribution, and post-marketing surveillance of our products. Our business is also affected by patient and data privacy laws and government payor cost containment initiatives, as well as environmental health and safety laws and regulations. In addition, as a result of the release and availability of Artificial Intelligence (AI) technologies, including generative AI platforms, we have seen a global trend toward more comprehensive and refined regulation of AI that will impact our business, such as the White House's Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence and the EU AI Act, that are designed to ensure the ethical use, security, and privacy of AI and create standards for transparency, accountability, and fairness.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Approval and Monitoring</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries where we do business, including the U.S., E.U. countries, Japan, and China, our products are subjected to approval and other regulatory requirements regarding performance, safety, and quality. For instance, authorization to commercially distribute a new medical device in the U.S. is generally obtained in one of two primary ways. The first, known as pre-market notification or the 510(k) process, requires us to demonstrate that our medical device is substantially equivalent to a legally marketed medical device. The second, more rigorous process, known as pre-market approval, requires us to independently demonstrate that a medical device is safe and effective for its intended use. This process is generally much more time-consuming and expensive than the 510(k) process.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the E.U., conformity with the marketing authorization requirements is represented by the CE Mark. To obtain a CE Mark, defined products must meet minimum standards of performance, safety, and quality (i.e., the essential requirements), and then, according to their classification, comply with one or more of a selection of conformity assessment routes. The competent authorities of the E.U. countries separately regulate the clinical research for medical devices and the market surveillance of products once they are placed on the market. The Medical Device Regulation was published by the E.U. in 2017, and it imposes significant additional pre-market and post-market requirements (EU MDR). The regulation provided an implementation period and became effective on May 26, 2021. The European Commission recently extended the implementation period to the end of 2027 for high-risk devices and to the end of 2028 for medium and low risk devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global regulatory environment is increasingly stringent and unpredictable. While harmonization of global regulations has been pursued, requirements continue to differ among countries. We expect this global regulatory environment will continue to evolve, which could impact the cost, the time needed to approve, and ultimately, our ability to maintain existing approvals or obtain future approvals for our products. Regulations of the U.S. FDA and other regulatory agencies in and outside the U.S. impose extensive compliance and monitoring obligations on our business. These agencies review our design and manufacturing processes, labeling, record keeping, and manufacturers&#8217; required reports of adverse experiences and other information to identify potential problems with marketed products. We are also subject to periodic inspections for compliance with applicable quality system regulations, which govern the methods used in, and the facilities and controls used for, the design, manufacture, packaging, and servicing of finished medical devices intended for human use. In addition, the U.S. FDA and other regulatory bodies, both in and outside the U.S. (including the Federal Trade Commission, the Office of the Inspector General of the Department of Health and Human Services, the U.S. Department of Justice, and various state Attorneys General), monitor the promotion and advertising of our products. Any adverse regulatory action, depending on its magnitude, may limit our ability to effectively market and sell our products, limit our ability to obtain future pre-market approvals or result in a substantial modification to our business practices and operations. For additional information, see "Item 1A. Risk Factors" under, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Regulations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movement of products, services, technology, know-how, and investment across borders subjects us to extensive trade laws and regulations. These laws and regulations govern, among other things, our import, export and other international trade activities. We are subject to the risk that these laws and regulations could change in a way that would expose us to additional costs and burdens, as well as penalties if not complied with. Some governments impose economic sanctions and other trade restrictions against certain countries, persons or entities. We also sell and provide goods, technology and services to agents, representatives and distributors who may in turn sell or provide such items to customers and other end-users in their own countries or by means of their own cross-border transactions. If we, or the third parties through which we do business, are not in compliance with applicable import, export control or economic sanctions laws and regulations, we may be subject to civil or criminal enforcement action, and varying degrees of liability. Such actions may disrupt or delay sales of our products or services or result in restrictions on our distribution and sales of products or services that may materially impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Boycott Laws</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. laws and regulations, U.S. companies and their subsidiaries and affiliates outside the U.S. are prohibited from participating or agreeing to participate in unsanctioned foreign boycotts in connection with certain business activities, including the sale, purchase, transfer, shipping or financing of goods or services within the U.S. or between the U.S. and countries outside of the U.S. If we, or certain third parties through which we sell or provide goods or services, violate anti-boycott laws and regulations, we may be subject to civil or criminal enforcement action and varying degrees of liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security Laws and Regulations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a business with a significant global footprint, compliance with evolving regulations and standards in data privacy and cybersecurity has resulted, and may continue to result, in increased costs, new compliance challenges, and the threat of increased regulatory enforcement activity. Our business relies on the secure electronic transmission, storage and hosting of sensitive information, including personal information, protected health information, financial information, intellectual property and other sensitive information related to our products and therapies, customers, patients, and workforce.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operational footprint comes with the obligation for compliance and adherence to individual data security, confidentiality and breach notification laws at the State Level, Federal Level, and International Level. Examples of those laws include, in the U.S., the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended, the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and various State privacy laws that have become effective recently. We are also subject to various other country-specific requirements around the world, such as the General Data Protection Regulation (GDPR) in the European Economic Area, the United Kingdom&#8217;s version of the same, and China's Personal Information Protection Law (PIPL). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the laws and regulations continue to expand, differ from jurisdiction to jurisdiction, and are subject to evolving (and at times inconsistent) governmental interpretation, compliance with these laws and regulations may require significant additional cost expenditures or changes in products or business that increase competition or reduce revenue. Noncompliance could result in the imposition of fines, penalties, or orders to stop noncompliant activities, withdrawal of noncompliant products from a market, and reputational harm.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations Governing Reimbursement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery of our devices is subject to regulation by the U.S. Department of Health and Human Services (HHS) and comparable state and non-U.S. agencies responsible for reimbursement and regulation of healthcare items and services. U.S. laws and regulations are imposed primarily in connection with federally funded healthcare programs, such as the Medicare and Medicaid programs, as well as the government&#8217;s interest in regulating the quality and cost of healthcare. Other governments also impose regulations in connection with their healthcare reimbursement programs and the delivery of healthcare items and services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal healthcare laws apply when we or customers submit claims for items or services that are reimbursed under federally-funded healthcare programs, including laws related to kickbacks, false claims, self-referrals or other healthcare fraud. There are often similar state false claims, anti-kickback, and anti-self-referral and insurance laws that apply to state Medicaid and other healthcare programs and private third-party payors. In addition, as a manufacturer of U.S. FDA-approved devices reimbursable by federal healthcare programs, we are subject to the Physician Payments Sunshine Act, which requires us to annually report certain payments and other transfers of value we make to U.S.-licensed physicians or U.S. teaching hospitals. Similarly, other jurisdictions impose transparency reporting obligations relating to health care professional payments. Any failure to comply with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implementation of legislative or regulatory reforms to reimbursement systems, or adverse decisions relating to our products by administrators of these systems in coverage or reimbursement, could significantly reduce reimbursement or result in the denial of coverage, which could have an impact on the acceptance of and demand for our products and the prices that our customers are willing to pay for them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Health and Safety Laws</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various environmental health and safety laws and regulations both within and outside the U.S. Like other companies in our industry, our manufacturing and other operations involve the use and transportation of substances regulated under environmental health and safety laws including those related to the use, storage, transportation, and disposal of hazardous materials.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.medtronic.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (Exchange Act) are made available under the &#8220;Our Company &#8211; Investors&#8221; caption and &#8220;Financials &#8211; SEC Filings&#8221; sub caption of our website as soon as reasonably practicable after we electronically file them with, or furnish them to, the Securities and Exchange Commission (SEC).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our corporate governance, including our Principles of Corporate Governance, Code of Conduct (including our Code of Ethics for Senior Financial Officers and any related amendments or waivers), Code of Business Conduct and Ethics for Members of the Board of Directors, and information concerning our executive officers, directors and Board committees (including committee charters) is available through our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.medtronic.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the &#8220;Our Company &#8211; Governance&#8221; caption. Information relating to transactions in Medtronic securities by directors and officers is available through our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.medtronic.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the &#8220;Our Company &#8211; Investors&#8221; caption and the &#8220;Financial Information &#8211; SEC Filings&#8221; sub caption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website and the information contained on or connected to our website are not incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including the Company, that file electronically with the SEC. The public may obtain any documents that we file with the SEC at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We file annual reports, quarterly reports, proxy statements, and other documents with the SEC under the Exchange Act.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_19"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our securities involves a variety of risks and uncertainties, known and unknown, including, among others, those discussed below. Each of the following risks should be carefully considered, together with all the other information included in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and in our other filings with the SEC. Furthermore, additional risks and uncertainty not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Our business, results of operations, financial condition, and cash flow and prospects could be materially and adversely affected by any of these risks or uncertainties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business and Operational Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive industry and we may be unable to compete effectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in both the therapeutic and diagnostic medical markets in more than 150 countries throughout the world. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. In the product lines in which we compete, we face a range of competitors from large companies with multiple business lines to small, specialized manufacturers that offer a limited selection of niche products. Development by other companies of new or improved products, processes, technologies, or the introduction of reprocessed products or generic versions when our proprietary products lose their patent protection may make our existing or planned products less competitive. In addition, we face competition from providers of alternative medical therapies, such as pharmaceutical companies, including those producing GLP-1s.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ability to compete depends upon many factors both within and beyond our control, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product performance and reliability,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product technology and innovation,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product quality and safety,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">breadth of product lines,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product support services,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supplier and supply availability and performance,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customer support,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effectiveness and price,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reimbursement approval from healthcare insurance providers, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to the regulatory environment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may increase as additional companies enter our markets or modify their existing products to compete directly with ours. In addition, academic institutions, governmental agencies and other public and private research organizations also may conduct research, seek patent protection and establish collaborative arrangements for discovery, research, clinical development and marketing of products similar to ours. These companies and institutions compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring necessary product technologies. From time to time we have lost, and may in the future lose, market share in connection with product problems, physician advisories, safety alerts and publications about our products, which highlights the importance of product quality, product efficacy and quality systems to our business. In the current environment of managed care, consolidation among healthcare providers, increased competition, declining reimbursement rates, and national and provincial tender pricing, as recently experienced in China, competitively priced product offerings are essential to our success. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to differentiate our product and keep pace with emerging technologies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued growth and success depend on our ability to develop, acquire and market new and differentiated products, technologies and intellectual property, and as a result we also face competition for marketing, distribution, and collaborative development agreements, establishing relationships with academic and research institutions and licenses to intellectual property. In order to continue to compete effectively, we must continue to create, invest in or acquire advanced technology, incorporate this technology into our proprietary products, obtain regulatory approvals in a timely manner, and manufacture and successfully market our products. For example, data science, machine learning and AI are all impacting our products and operations and the competitive landscape in which we operate, and the application of these technologies is rapidly evolving at the same time as new laws and regulations of AI are being developed in jurisdictions around the world. Compliance with developing regulations may require significant expenditures or may limit our ability to effectively use these technologies. There can be no assurance that the application of AI in our products and operations will be successful, or that we will not experience data security and privacy incidents in connection with our use of these technologies. Given these factors, we cannot guarantee that we will be able to compete effectively or continue our level of success.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reduction or interruption in supply or other manufacturing difficulties may adversely affect our manufacturing operations and related product sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of our products requires the timely delivery of a sufficient amount of quality components and materials and is highly exacting and complex, due in part to complex trade and strict regulatory requirements. We manufacture the majority of our products and procure critical third-party services, such as sterilization services, at numerous facilities worldwide. We purchase many of the components, raw materials and services needed to manufacture these products from numerous suppliers in various countries. We seek to maintain continuity of supply by use of multiple options for sourcing where possible. We have generally been able to obtain adequate supplies of such raw materials, components and services, although global shortages of certain components such as semiconductors and resins have recently caused, and may in the future cause, disruptions to our product manufacturing supply chain. In addition, for reasons of quality assurance, cost effectiveness, or availability, certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers. Although we work closely with our suppliers to try to ensure continuity of supply while maintaining high quality and reliability, the supply of these components, raw materials and services may, at times, be interrupted or insufficient. In addition, due to the stringent regulations and requirements of trade and regulatory agencies, including the U.S. FDA, regarding the manufacture of our products, we may not be able to quickly establish additional or replacement sources. Additionally, many regulatory agencies are imposing new and evolving regulatory requirements on safe use of chemicals, including ethylene oxides (EtOs) and polyfluoroalkyl substances (PFAS), and their potential impact on health and the environment which also may impact supply constraints. Furthermore, the prices of commodities and other materials used in our products, which are often volatile and outside of our control, could adversely impact our supply. We use resins, other petroleum-based materials and pulp as raw materials in some of our products, and the prices of oil and gas also significantly affect our costs for freight and utilities. A reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture our products in a timely or cost-effective manner and could result in lost sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other disruptions in the manufacturing process or product sales, trade and fulfillment systems for any reason, including infrastructure, information and equipment malfunction, failure to follow specific protocols and procedures, supplier or Company facility shut-downs, defective raw materials, labor shortages, natural disasters such as hurricanes, tornadoes, earthquakes, or wildfires, property damage or facility closures from riots or public protests, and other environmental factors and the impact of epidemics, pandemics, or other public health crises, and actions by businesses, communities and governments in response, could lead to launch delays, product shortages, unanticipated costs, lost revenues and damage to our reputation. For example, in the past we have experienced a global information technology systems interruption that affected our customer ordering, distribution, and manufacturing processes, and we were adversely impacted by the global COVID-19 pandemic, and may in the future be adversely impacted by COVID-19 resurgence or other pandemics and the related responses of governments and of our partners, including suppliers, manufacturers, distributors and other businesses. Furthermore, any failure to identify and address manufacturing problems prior to the release of products to our customers could result in quality or safety issues.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our products require sterilization before sale and several of our key products are manufactured or sterilized at a particular facility, with constrained capacity and limited options for alternate sterilization facilities. If an event occurs that causes damage to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or closure of one or more of such facilities, such as the Illinois Environmental Protection Agency's decision to close a supplier's sterilization facility in February 2019, we may be unable to manufacture or sterilize relevant products to the required quality specifications or at all. Due to the time required to approve and license a manufacturing or sterilization facility, a third-party may not be available on a timely basis to replace production capacity in the event manufacturing or sterilization capacity is reduced or lost.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health crises have had, and may continue to have, an adverse effect on certain aspects of our business, results of operations, financial condition, and cash flows. The nature and extent of future impacts are highly uncertain and unpredictable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations and interactions with healthcare systems, providers and patients around the world expose us to risks associated with public health crises, including epidemics and pandemics such as COVID-19. Public health crises may continue to have an adverse impact on certain aspects of our Company and business, including the demand for and supply of certain of our products, operations, supply chains and distribution systems, and our ability to generate cash flow.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development efforts rely upon investments and investment collaborations, and we cannot guarantee that any previous or future investments or investment collaborations will be successful.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Mission is to provide a broad range of therapies to restore patients to fuller, healthier lives, which requires a wide variety of technologies, products and capabilities. The rapid pace of technological development in the medical industry and the specialized expertise required in different areas of medicine make it difficult for one company alone to develop a broad portfolio of technological solutions. In addition to internally generated growth through our research and development efforts, historically we have relied, and expect to continue to rely, upon investments and investment collaborations to provide us access to new technologies both in areas served by our existing businesses as well as in new areas.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to make future investments where we believe that we can stimulate the development or acquisition of new technologies and products to further our strategic objectives and strengthen our existing businesses. Investments and investment collaborations in and with medical technology companies are inherently risky, and we cannot guarantee that any of our previous or future investments or investment collaborations will be successful or will not materially adversely affect our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The continuing development of many of our products depends upon us maintaining strong relationships with healthcare professionals.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to maintain our working relationships with healthcare professionals, many of our products may not be developed and marketed in line with the needs and expectations of the professionals who use and support our products, which could cause a decline in our earnings and profitability. The research, development, marketing and sales of many of our new and improved products depends on our maintaining working relationships with healthcare professionals. We rely on these professionals to provide us with considerable knowledge and experience regarding the development, marketing and sale of our products. Healthcare professionals assist us as researchers, marketing and product consultants, inventors, trainers, and public speakers. If we are unable to maintain strong relationships with these professionals, the development and marketing of our products could suffer, which could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have debt obligations that create risk.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to use a portion of our operating cash flow to pay interest or principal on our outstanding indebtedness instead of for other corporate purposes, including funding future expansion of our business. We may also incur additional indebtedness in the future to supplement our existing liquidity and cash generated from operations to satisfy our needs for working capital and capital expenditures, to pursue growth initiatives, and to make returns of capital to shareholders. Changes in business and economic conditions will impact interest rates and can cause periods of tightened credit availability and volatility in borrowing terms. In addition, there can be no assurance that we will be able to maintain our credit rating. At the time we may incur such additional indebtedness, or refinance or restructure existing indebtedness, we may be unable to obtain capital market financing with similar terms and currency denomination to our existing indebtedness, or at all, which could have a material adverse effect on our business and results of operations. At any time, the fair value of our debt outstanding will fluctuate based on several factors including foreign currency exchange rate and interest rate movements, credit conditions and our credit rating.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to integrate acquired businesses into our operations successfully, or challenges related to the Company's strategic initiatives, including divestitures and third-party funding arrangements, as well as liabilities or claims relating to such acquired businesses, divestitures, or arrangements could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our strategy to develop and identify new products and technologies and optimize our portfolio of products, we have made several significant acquisitions, divestitures and third-party research and development funding arrangements in recent years, and may make additional acquisitions, divestitures and arrangements in the future. Our integration of the operations of acquired businesses, or a divestiture of part of our existing businesses, requires significant efforts, including the coordination of information technologies, research and development, sales and marketing, operations, manufacturing, and finance. These efforts result in additional expenses and involve </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant amounts of management&#8217;s time that cannot then be dedicated to other projects. Our failure to manage and coordinate the growth of acquired companies successfully could also have an adverse impact on our business. Further, acquired businesses may have liabilities, or be subject to claims, litigation or investigations that we did not anticipate or which exceed our estimates at the time of the acquisition. In addition, we cannot be certain that the businesses we acquire will become profitable or remain so. Factors that will affect the success of our acquisitions include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the presence or absence of adequate internal controls and/or significant fraud in the financial systems of acquired companies,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to integrate information technology systems of acquired companies in a secure and reliable manner,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liabilities, claims, litigation, investigations, or other adverse developments relating to acquired businesses or the business practices of acquired companies, including investigations by governmental entities, potential Foreign Corrupt Practices Act (FCPA) or product liability claims, intellectual property disputes, earnout or other contingent payment disputes, or other unanticipated liabilities,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any decrease in customer loyalty and product orders caused by dissatisfaction with the combined companies&#8217; product lines and sales and marketing practices, including price increases,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain key employees, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to achieve synergies among acquired companies, such as increasing sales of the integrated company&#8217;s products, achieving cost savings, and effectively combining technologies to develop new products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also could experience negative effects on our business, results of operations, financial condition, and cash flows from acquisition-related charges, amortization of intangible assets and asset impairment charges.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the potential exists that expected strategic benefits from any planned or completed divestiture, or third-party funding arrangement, by the Company may not be realized or may take longer to realize than expected, and there can be no assurance that disputes will not arise under the Company's third-party funding arrangements, or transition service agreements that have or may be executed as part of a divestiture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Regulatory Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical devices and technologies, as well as our business activities, are subject to a complex set of regulations and rigorous enforcement, including by the U.S. FDA, U.S. Department of Justice, Health and Human Services Office of the Inspector General, and numerous other federal, state, and non-U.S. governmental authorities. To varying degrees, each of these agencies requires us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of our products. As a part of the regulatory process of obtaining marketing clearance for new products and new indications for existing products, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations, and trial endpoints. Unfavorable clinical data from existing or future clinical trials may adversely impact our ability to obtain product approvals, our position in, and share of, the markets in which we participate, and our business, results of operations, financial condition, and cash flows. We cannot guarantee that we will be able to obtain or maintain marketing clearance for our new products or enhancements or modifications to existing products, and the failure to maintain approvals or obtain approval or clearance could have a material adverse effect on our business, results of operations, financial condition, and cash flows. Even if we are able to obtain approval or clearance, it may:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant amount of time,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of substantial resources,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve stringent clinical and pre-clinical testing, as well as increased post-market surveillance,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve modifications, repairs or replacements of our products, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the proposed uses of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both before and after a product is commercially released, we have ongoing responsibilities under the U.S. FDA and other applicable non-U.S. government agency regulations. For instance, many of our facilities and procedures and those of our suppliers are also subject to periodic inspections by the U.S. FDA to assess compliance with applicable regulations. The results of these inspections can include, and have in the past included, inspectional observations on the U.S. FDA&#8217;s Form 483, warning letters, or other forms of enforcement, such as a consent decree. If the U.S. FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our medical products are ineffective or pose an unreasonable health risk, the U.S. FDA could detain or seize adulterated or misbranded medical products, order a recall, repair, replacement, or refund of such products, refuse to grant pending pre-market approval applications or require certificates of non-U.S. governments for exports, and/or require us to notify health professionals and others that the devices present unreasonable risks of substantial harm to the public health, and in certain rare circumstances, ban medical devices. The U.S. FDA and other non-U.S. government agencies may also assess civil or criminal penalties against us, our officers or employees and impose operating </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrictions on a company-wide basis. The U.S. FDA may also recommend prosecution to the U.S. Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future pre-market clearances or approvals, and could result in a substantial modification to our business practices and operations. Furthermore, we occasionally receive subpoenas or other requests for information from various governmental agencies around the world, and while these investigations typically relate primarily to financial arrangements with healthcare providers, regulatory compliance and product promotional practices, we cannot predict the timing, outcome or impact of any such investigations. Any adverse outcome in one or more of these investigations could include the commencement of civil and/or criminal proceedings, substantial fines, penalties, and/or administrative remedies, including exclusion from government reimbursement programs and/or entry into Corporate Integrity Agreements (CIAs) with governmental agencies. In addition, resolution of any of these matters could involve the imposition of additional, costly compliance obligations. These potential consequences, as well as any adverse outcome from government investigations, could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. FDA has taken the position that device manufacturers are prohibited from promoting their products other than for the uses and indications set forth in the approved product labeling, and any failure to comply could subject us to significant civil or criminal exposure, administrative obligations and costs, and/or other potential penalties from, and/or agreements with, the federal government. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental regulations in the U.S. and outside the U.S. are constantly changing and may become increasingly stringent. In the E.U, for example, the Medical Device Regulation which became effective in May 2021 includes significant additional pre-market and post-market requirements. Penalties for regulatory non-compliance could be severe, including fines and revocation or suspension of a company&#8217;s business license, mandatory price reductions and criminal sanctions. The development and implementation of future laws and regulations may have a material adverse effect on us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quality problems have in the past and could in the future lead to recalls or safety alerts, product liability claims, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality is extremely important to us and our customers due to the impact on patients, and the serious and potentially costly consequences of adverse product performance. Our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices. In addition, many of our products are often used in intensive care settings with seriously ill patients and some of the medical devices we manufacture and sell are designed to be implanted in the human body for long periods of time or indefinitely. Component failures, manufacturing nonconformances, design issues, off-label use, or inadequate disclosure of product-related risks or product-related information with respect to our products, could result in an unsafe condition or injury to, or death of, a patient. These problems have in the past and could in the future lead to recall of, or issuance of a safety alert relating to, our products, as well as product liability claims and lawsuits, including class actions, which could ultimately result, in certain cases, in the removal from the body of such products and claims regarding costs associated therewith. Due to the strong name recognition of the Medtronic brand, a material adverse event involving one of our products could result in diminished market acceptance and demand for all products within that brand, and could harm our reputation and ability to market products in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strong product quality is critical to the success of our goods and services. If we fall short of these standards and our products are the subject of recalls or safety alerts, our reputation could be damaged, we could lose customers and our revenue and results of operations could decline. Our success also can depend on our ability to manufacture to exact specification precision-engineered components, subassemblies and finished devices from multiple materials. If our components fail to meet these standards or fail to adapt to evolving standards, our reputation, competitive advantage and market share could be harmed. In certain situations, we may undertake a voluntary recall of products or temporarily shut down production lines based on performance relative to our own internal safety and quality monitoring and testing data.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing problems, including future product liability claims or recalls, regardless of their ultimate outcome, could harm our reputation and have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our devices, products and therapies are purchased principally by hospitals or physicians that typically bill various third-party payors, such as governmental healthcare programs (e.g., Medicare, Medicaid and comparable non-U.S. programs), private insurance plans and managed care plans, for the healthcare services provided to their patients. The ability of our customers to obtain appropriate reimbursement for products and services from third-party payors is critical because it affects which products customers purchase and the prices they are willing to pay. As a result, our devices, products and therapies are subject to regulation regarding quality and cost by HHS, including the Centers for Medicare &amp; Medicaid Services (CMS), as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of health care goods and services, including laws and regulations related to fair competition, kickbacks, false claims, self-referrals and healthcare fraud. Many states have similar laws that apply to reimbursement by state Medicaid and other funded programs as well as in some cases to all payors. In certain circumstances, insurance companies attempt to bring a private cause of action against a manufacturer for causing false claims. In addition, as a manufacturer of U.S. FDA-approved devices reimbursable by federal healthcare programs, we are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to the Physician Payments Sunshine Act, which requires us to annually report certain payments and other transfers of value we make to U.S. licensed physicians, certain allied health professionals, and U.S. teaching hospitals. Any failure to comply with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to risks relating to changes in government and private medical reimbursement programs and policies, and changes in legal regulatory requirements in the U.S. and around the world. Implementation of further legislative or administrative reforms to these reimbursement systems, or adverse decisions relating to coverage of or reimbursement for our products by administrators of these systems, could have an impact on the acceptance of and demand for our products and the prices that our customers are willing to pay for them.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in our payment of significant monetary damages and/or royalty payments, negatively impacting our ability to sell current or future products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are substantially dependent on patent and other proprietary rights and rely on a combination of patents, trademarks, tradenames, copyrights, trade secrets, and agreements (such as employee and non-disclosure) to protect our business and proprietary intellectual property. We also operate in an industry characterized by extensive intellectual property litigation. Intellectual property litigation can result in significant damage awards and injunctions that could prevent our manufacture and sale of affected products or require us to pay significant royalties in order to continue to manufacture or sell affected products. At any given time, we are generally involved as both a plaintiff and a defendant in a number of intellectual property actions, the outcomes of which may not be known for prolonged periods of time. While it is not possible to predict the outcome of intellectual property litigation, it is possible that the results of such litigation could require us to pay significant monetary damages and/or royalty payments, negatively impact our ability to sell current or future products, or that enforcement actions to protect our patent and proprietary rights against others could be unsuccessful, any of which could have a material adverse impact on our business, results of operations, financial condition, and cash flows. In addition, any public announcements related to litigation or administrative proceedings initiated or threatened against us could cause our stock price to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we intend to defend against any threats to our intellectual property, our patents, trademarks, tradenames, copyrights, trade secrets or agreements (such as employee, non-disclosure and non-competition agreements) may not adequately protect our intellectual property. Further, pending patent applications may not result in patents being issued to us, patents issued to or licensed by us may be challenged or circumvented by competitors and such patents may be found invalid, unenforceable or too limited in scope to protect our technology or provide us with any competitive advantage. In addition, our patents will expire over time, our ability to protect novel business models is uncertain, and infringement may go undetected. Third parties could obtain patents that may require us to negotiate licenses to conduct our business, and such licenses may not be available on reasonable terms or at all. In addition, license agreements could be terminated. We also rely on non-disclosure and non-competition agreements with certain employees, consultants and other parties to protect, in part, trade secrets and other proprietary rights. We cannot be certain that these agreements will not be breached, that such provisions will be enforceable, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information, or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge. Moreover, in the U.S. the Federal Trade Commission and various states have adopted laws and regulations that purport to ban or severely restrict the use of non-competition agreements, which may limit our ability to use and enforce non-competition agreements with employees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the laws of certain countries in which we market or manufacture some of our products do not protect our intellectual property rights to the same extent as the laws of the U.S., which could make it easier for competitors to capture market position. For example, business in China comprises approximately seven percent of our total revenues. This may increase our vulnerability to our technology being reverse engineered or our trade secrets being compromised. If we are unable to protect our intellectual property in China or other countries, it could have a material adverse effect on our business, results of operations, financial condition, and cash flows. Competitors also may harm our sales by designing products that substantially mirror the capabilities of our products or technology without infringing our intellectual property rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare policy changes may have a material adverse effect on us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been and continue to be actions and proposals by several governments, regulators and third-party payors globally, including the U.S. federal and state governments and the government in China, to control healthcare costs and, more generally, to reform healthcare systems. Certain of these actions and proposals, among other things, limit the prices we are able to charge for our products or the amounts of reimbursement available for our products, increase the importance of our ability to compete on cost, and could limit the acceptance and availability of our products. These actions and proposals could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on the proper function, security and availability of our information technology systems and data, as well as those of third parties throughout our global supply chain and our customer and payor base, to operate our business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation or competitive position.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on sophisticated information technology systems to operate our business. That technology includes systems that could be used to process, transmit and store sensitive data. Additionally, many of our products and services include integrated software and information technology that collects data regarding patients or connects to other internal systems. One of the most prevalent attacks on large organizations has been ransomware which can have a devastating impact on an organization&#8217;s operations. Our ransomware readiness program has required and will continue to require investment and will not guarantee that we will be immune from an incident or be able to respond rapidly enough to prevent a negative impact on our business. Like all organizations, we routinely experience attempted interference with the integrity of, and interruptions in, our technology systems via events such as cyber-attacks, malicious intrusions, or other breakdowns. The consequences could mean data breaches, interference with the integrity of our products and data, compromise of intellectual property or other proprietary information, or other significant disruptions. Furthermore, we rely on third-party vendors to supply and/or support certain aspects of our information technology systems and resulting products, and customers and payors use information technology systems to process payments relating to our products and services. These third-party systems could also become vulnerable to cyber-attack, malicious intrusions, breakdowns, interference, or other significant disruptions, and may contain defects in design or manufacture or other problems that could result in system disruption or compromise the information security of our own systems. In addition, our global profile and international operations expose us to geopolitical events or issues which may increase cybersecurity risks on a global basis. Lastly, we continue to grow in part through new business acquisitions and, as a result, may face risks associated with defects and vulnerabilities in acquired businesses&#8217; systems, or difficulties or other breakdowns or disruptions in connection with the integration of the acquisitions into our information technology systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our worldwide operations mean that we are subject to laws and regulations, including data protection and cybersecurity laws and regulations, in many jurisdictions. The variety of U.S. and international privacy and cybersecurity laws and regulations impacting our operations are described in &#8220;Item 1. Business" &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Factors Impacting Our Operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Data Privacy and Security Laws and Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any data security breaches, cyber-attacks, malicious intrusions or significant disruptions could result in actions by regulatory bodies and/or civil litigation, any of which could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation, or competitive position.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our information technology systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems. We experience continuing changes in information processing technology, legal and regulatory standards, patient and customer information use cases, techniques used to obtain unauthorized access to data and information systems, and the information technology needs associated with our changing products and services. We also face business and regulatory risks relating to our use of AI systems in our business operations and products. These systems are susceptible to flaws, biases, malfunctions or manipulations, which may disrupt our operations, result in erroneous decision-making, elevate our cyber risk profile, or expose us to penalties from non-compliance with emerging regulations. There can be no assurance that our efforts to keep pace with continuing changes in information processing technologies, including AI systems, and to deploy these technologies to our business operations and products will be successful or that additional systems issues will not arise in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our information technology systems, products or services or sensitive data are compromised, there are many consequences that could result. Consequences include, but are not limited to, patients or employees being exposed to financial or medical identity theft or suffering a loss of product functionality, losing existing customers or have difficulty attracting new customers, experiencing difficulty preventing, detecting, and controlling fraud, being exposed to the loss or misuse of confidential information, having disputes with customers, physicians, and other healthcare professionals, suffering regulatory sanctions or penalties under federal laws, state laws, or the laws of other jurisdictions, experiencing increases in operating expenses or an impairment in our ability to conduct our operations, incurring expenses or losing revenues as a result of a data privacy breach, product failure, information technology outages or disruptions, or suffering other adverse consequences including lawsuits or other legal action and damage to our reputation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure to comply with anti-corruption laws could materially adversely affect our business and result in civil and/or criminal sanctions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. FCPA, the Irish Criminal Justice (Corruption Offences) Act 2018, and similar anti-corruption laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business and to ensure adequate internal controls, books, and records. Because of the predominance of government-administered healthcare systems in many jurisdictions around the world, many of our customer relationships outside of the U.S. are with governmental entities and are therefore potentially subject to such laws. We also participate in public-private partnerships and other commercial and policy arrangements with governments around the globe.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global enforcement of anti-corruption laws has increased in recent years, including investigations and enforcement proceedings leading to assessment of significant fines and penalties against companies and individuals. Our international operations create a risk of unauthorized </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments or offers of payments by one of our employees, consultants, sales agents, or distributors. We maintain various controls aligned with legal requirements to prevent and prohibit improper practices, including policies, programs, and training for our employees and third party intermediaries acting on our behalf. However, existing safeguards and any future improvements may not always be effective, and our employees, consultants, sales agents or distributors may engage in conduct for which we could be held responsible. In addition, regulators could seek to hold us liable for conduct committed by companies in which we invest or that we acquire. Any alleged or actual violations of these regulations may subject us to government scrutiny, criminal or civil sanctions and other liabilities, including exclusion from government contracting, and could disrupt our business, adversely affect our reputation and result in a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing international business operations could adversely impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control (OFAC) and the U.S. Commerce Department&#8217;s Bureau of Industry and Security (BIS) administer certain laws and regulations that restrict U.S. persons and, in some instances, non-U.S. persons, in conducting activities, transacting business with, or making investments in, certain countries, governments, entities and individuals subject to U.S. economic sanctions or export restrictions. Our international operations subject us to these laws and regulations, which are complex, restrict our business dealings with certain countries, governments, entities, and individuals, and are constantly changing. Further restrictions may be enacted, amended, enforced or interpreted in a manner that materially impacts our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, certain of our subsidiaries have limited business dealings in countries subject to comprehensive sanctions, including Iran, Syria, Cuba, and the region of Crimea, as well as Russia and Belarus. Certain of our subsidiaries sell medical devices, and may provide related services, to distributors and other purchasing bodies in such countries or regions. These business dealings represent an insignificant amount of our consolidated revenues and income, but expose us to a heightened risk of violating applicable sanctions regulations. Violations of these regulations are punishable by civil penalties, including fines, denial of export privileges, injunctions, asset seizures, debarment from government contracts and revocations or restrictions of licenses, as well as criminal fines and imprisonment. We have established policies and procedures designed to assist with our compliance with such laws and regulations. However, such regulations may impact our ability to continue operations in certain countries and require additional licenses which we may not be able to obtain or maintain. There can be no assurance that our policies and procedures will prevent us from violating these regulations in every transaction in which we may engage, and such a violation could adversely affect our reputation, business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Climate change, or legal, regulatory or market measures to address climate change may materially adversely affect our financial condition and business operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere presents risks to our current and future operations. We face current and long-term operational risks and have in the past experienced business interruptions from severe weather events and other natural conditions, such as hurricanes, tornadoes, droughts, extreme temperatures, wildfires or flooding. Such severe weather events caused by or related to climate change or other conditions caused by natural disasters have in the past and could in the future increase our operational costs, pose physical risks to our facilities and adversely impact our supply chain, including: manufacturing and distribution networks, the availability and cost of raw materials and components, energy supply, transportation, or other inputs necessary for the operation of our business. The impacts of climate change on global water resources may result in water scarcity, which could impact our ability to access sufficient quantities of water in certain locations and result in increased costs. Although it is difficult to predict and adequately prepare to meet the challenges to our business posed by climate change, concerns over climate change also could result in new laws or regulations that are more stringent than current legal or regulatory requirements, and we may experience increased compliance burdens and costs to meet the regulatory obligations as well as adverse impacts on raw material sourcing, manufacturing operations and the distribution of our products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to environmental laws and regulations and the risk of environmental liabilities, violations and litigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to environmental, health, and safety laws, and regulations concerning, among other things, the generation, handling, transportation, and disposal of hazardous substances or wastes, the remediation of hazardous substances or materials at various sites, and emissions or discharges into the land, air or water. We are further subject to numerous laws and regulations concerning, among other things, chemical constituents in medical products and end-of-life disposal and take-back programs for medical devices. Our operations and those of certain third-party suppliers involve the use of substances subject to these laws and regulations, primarily those used in manufacturing and sterilization processes. If we or our suppliers violate these environmental laws and regulations, facilities could be shut down and violators could be fined, or otherwise sanctioned. New laws and regulations, violations of these laws or regulations, stricter enforcement of existing requirements, or the discovery of previously unknown contamination could require us to incur costs or could become the basis for new or increased liabilities that could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks related to our environmental, social and governance (ESG) practices and initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is continued focus from our stakeholders, as well as regulatory authorities in the U.S., E.U. and other global jurisdictions in which we operate, on ESG practices and disclosure. If we do not succeed in meeting or are perceived as not meeting, stated goals and objectives, in any number of ESG matters, such as environmental stewardship, ID&amp;E initiatives, supply chain practices, good corporate governance, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">workplace conduct and support for local communities, or if we do not effectively respond to new or revised legal, regulatory or reporting requirements concerning climate change or other sustainability concerns, we may be subject to regulatory fines and penalties, our reputation or the reputation of our brands may suffer, we may be unable to attract and retain top talent, and our stock price may be negatively affected. In addition, enhanced and sometimes conflicting ESG laws, regulations and expectations in the jurisdictions in which we do business may increase compliance burdens and costs for third parties throughout our global supply chain, which could cause disruption in the sourcing, manufacturing and distribution of our products and adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we have made several public disclosures of objectives and targets (targets) relating to product stewardship, ID&amp;E, patient safety and product quality, access and innovation, and climate stewardship, including our ambition to be carbon neutral in our operations by 2030 and to achieve net zero emissions by 2045. Although we intend to achieve these targets, we may be required to expend significant resources to do so, which could increase our operational costs. In addition, there can be no assurance of the extent to which any of our targets will be achieved, or that any future investments we make to achieve such targets will meet investor, legal and/or any other regulatory expectations and requirements. If we are unable to meet our targets, we may face litigation and could incur regulatory fines and penalties or adverse publicity and reaction from investors, advocacy groups or other stakeholders that may adversely impact our business, demand for our products and services, and/or our financial condition and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance program may not be adequate to cover future losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to self-insure most of our insurable risks across the Company, and we made this decision based on cost and availability factors in the insurance marketplace. We manage and maintain a portion of our self-insured program through a wholly-owned captive insurance company. We continue to maintain a directors and officers liability insurance policy with third-party insurers that provides coverage for the directors and officers of the Company. We continue to monitor the insurance marketplace to evaluate the value of obtaining insurance coverage for other categories of losses in the future. Although we believe, based on historical loss trends, that our self-insurance program accruals and our existing insurance coverage will be adequate to cover future losses, historical trends may not be indicative of future losses. The absence of third-party insurance coverage for other categories of losses increases our exposure to unanticipated claims and these losses could have a material adverse impact on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two global minimum tax. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which will be effective for Medtronic in fiscal year 2025. We continue to evaluate the impacts of the enacted Pillar Two legislation. The tax laws, inclusive of Pillar Two legislation, in the U.S., Ireland and other countries in which we and our affiliates do business could change on a prospective or retroactive basis, and any such changes could have a material impact on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to ongoing tax audits in the various jurisdictions in which we operate. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision. However, there can be no assurance that we will accurately predict the outcomes of these audits, and the actual outcomes of these audits could have a material impact on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded reserves for potential payments of tax to various tax authorities related to uncertain tax positions. However, the calculation of such tax liabilities involves the application of complex tax laws, regulations and treaties (where applicable) in many jurisdictions. Therefore, any dispute with a tax authority may result in a payment that is significantly different from current estimates. If payment of these amounts ultimately proves to be less than the recorded amounts, the reversal of the liabilities generally would result in tax benefits being recognized in the period when we determine the liabilities are no longer necessary. If our estimate of tax liabilities proves to be less than the amount for which it is ultimately liable, we would incur additional charges, and such charges could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcome of Medtronic, Inc.'s U.S. tax litigation could have a material adverse impact on our financial condition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2009, the IRS issued its audit report for Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreements with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of our key manufacturing sites. The Tax Court issued its opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023. An adverse outcome in this matter could materially and adversely affect our business, results of operations, financial condition, and cash flows. See Note 18 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future potential changes to the U.S. tax laws could result in us being treated as a U.S. corporation for U.S. federal tax purposes, and the IRS may not agree with the conclusion that we should be treated as a foreign corporation for U.S. federal income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Medtronic plc is organized under the laws of Ireland, we would generally be classified as a foreign corporation under the general rule that a corporation is considered tax resident in the jurisdiction of its organization or incorporation for U.S. federal income tax purposes. Even so, the IRS may assert that we should be treated as a U.S. corporation (and, therefore, a U.S. tax resident) for U.S. federal income tax purposes pursuant to Section 7874 of the U.S. Internal Revenue Code of 1986, as amended (the Code). In addition, a retroactive change to U.S. tax laws in this area could change this classification. If we were to be treated as a U.S. corporation for federal tax purposes, we could be subject to substantially greater U.S. tax liability than currently contemplated as a non-U.S. corporation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or other governmental action relating to the denial of U.S. federal or state governmental contracts to U.S. companies that redomicile abroad could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various U.S. federal and state legislative proposals that would deny governmental contracts to U.S. companies that move their corporate location abroad may affect us. We are unable to predict the likelihood that, or final form in which, any such proposed legislation might become law, the nature of the regulations that may be promulgated under any future legislative enactments, or the effect such enactments and increased regulatory scrutiny may have on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Jurisdiction of Incorporation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are incorporated in Ireland, and Irish law differs from the laws in effect in the U.S. and may afford less protection to holders of our securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shareholders may have more difficulty protecting their interests than would shareholders of a corporation incorporated in a jurisdiction of the United States. It may not be possible to enforce court judgments obtained in the U.S. against us in Ireland based on the civil liability provisions of the U.S. federal or state securities laws. In addition, there is some uncertainty as to whether the courts of Ireland would recognize or enforce judgments of U.S. courts obtained against us or our directors or officers based on the civil liabilities provisions of the U.S. federal or state securities laws or hear actions against us or those persons based on those laws. We have been advised that the U.S. currently does not have a treaty with Ireland providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely on U.S. federal or state securities laws, would not automatically be enforceable in Ireland.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an Irish company, we are governed by the Irish Companies Act 2014, which differs in some material respects from laws generally applicable to U.S. corporations and shareholders, including, among others, differences relating to interested director and officer transactions and shareholder lawsuits. Likewise, the duties of directors and officers of an Irish company generally are owed to the company only. Shareholders of Irish companies generally do not have a personal right of action against directors or officers of the company and may exercise such rights of action on behalf of the company only in limited circumstances. Accordingly, holders of our securities may have more difficulty protecting their interests than would holders of securities of a corporation incorporated in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As an Irish public limited company, certain capital structure decisions require shareholder approval, which may limit Medtronic&#8217;s flexibility to manage its capital structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Irish law, our authorized share capital can be increased by an ordinary resolution of our shareholders and the directors may issue new ordinary or preferred shares, without shareholder approval, once authorized to do so by our articles of association or by an ordinary resolution of our shareholders. Additionally, subject to specified exceptions, Irish law grants statutory preemption rights to existing shareholders where shares are being issued for cash consideration but allows shareholders to disapply such statutory preemption rights either in our articles of association or by way of special resolution. Such disapplication can either be generally applicable or be in respect of a particular allotment of shares. Accordingly, at our 2023 Annual General Meeting, our Shareholders authorized our Board of Directors to issue up to 20% of our issued ordinary shares and further authorized our Board of Directors to issue such shares for cash without first offering them to our existing shareholders. Both of these authorizations will expire on April 19, 2025, unless renewed by shareholders for a further period. We anticipate seeking new authorizations at our 2024 Annual General Meeting and in subsequent years. We cannot provide any assurance that these authorizations will always be approved, which could limit our ability to issue equity and thereby adversely affect the holders of our securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A transfer of our shares, other than ones effected by means of the transfer of book-entry interests in the Depository Trust Company, may be subject to Irish stamp duty.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers of our shares effected by means of the transfer of book entry interests in the Depository Trust Company (DTC) will not be subject to Irish stamp duty. However, if a shareholder holds our shares directly rather than beneficially through DTC, any transfer of shares could be subject to Irish stamp duty (currently at the rate of 1% of the higher of the price paid or the market value of the shares acquired). Payment of Irish stamp duty is generally a legal obligation of the transferee. The potential for stamp duty could adversely affect the price of shares.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In certain limited circumstances, dividends we pay may be subject to Irish dividend withholding tax and dividends received by Irish residents and certain other shareholders may be subject to Irish income tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain limited circumstances, dividend withholding tax (currently at a rate of 25%) may arise in respect of dividends paid on our shares. A number of exemptions from dividend withholding tax exist such that shareholders resident in the U.S. and other specified countries that have a tax treaty with Ireland may be entitled to exemptions from dividend withholding tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders resident in the U.S. that hold their shares through DTC will not be subject to dividend withholding tax, provided the addresses of the beneficial owners of such shares in the records of the brokers holding such shares are recorded as being in the U.S. (and such brokers have further transmitted the relevant information to a qualifying intermediary appointed by us). However, other shareholders may be subject to dividend withholding tax, which could adversely affect the price of their shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders entitled to an exemption from Irish dividend withholding tax on dividends received from us will not be subject to Irish income tax in respect of those dividends unless they have some connection with Ireland other than their shareholding in our Company (for example, they are resident in Ireland). Shareholders who are not resident nor ordinarily resident in Ireland, but who receive dividends subject to Irish dividend withholding tax, will generally have no further liability to Irish income tax on those dividends.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Irish capital acquisitions tax (CAT) could apply to a gift or inheritance of our shares irrespective of the place of residence, ordinary residence or domicile of the parties. This is because our shares will be regarded as property situated in Ireland. The person who receives the gift or inheritance has primary liability for CAT. Gifts and inheritances passing between spouses are exempt from CAT. Children currently have a tax-free threshold of &#8364;335,000 in respect of taxable gifts or inheritances received from their parents. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Economic and Industry Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the prices of our goods and services, customer purchasing patterns and stocking dynamics, and/or inflationary costs may have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have had, and may continue to have, periods when prices for certain of our goods and services decrease due to pricing pressure from managed care organizations and other third-party payors on our customers; increased market power of our customers as the healthcare industry consolidates; periodic variation in timing, volume, and pricing associated with customer purchasing patterns and stocking dynamics; and increased competition among medical engineering and manufacturing services providers. We have also recently experienced, and may continue to experience, rising costs due to inflation. If the prices for our goods and services change for any reason or inflation continues to rise, we may be unable to sufficiently reduce our expenses or offset rising costs through increased prices to customers. As a result, our business, results of operations, financial condition, and cash flows may be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to a variety of risks associated with global operations that could adversely affect our profitability and operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop, manufacture, distribute and sell our products globally. We intend to continue to expand our operations and to pursue growth opportunities outside the U.S., especially in emerging markets. Operations in different countries including emerging markets could expose us to additional and greater risks and potential costs, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in currency exchange rates,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">healthcare reform legislation,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to comply with different regulatory regimes worldwide that are subject to change and that could restrict our ability to manufacture and sell our products,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">local product preferences and product requirements,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer-term receivables than are typical in the U.S.,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic sanctions, export controls, trade protection measures, tariffs and other border taxes, and import or export licensing requirements,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">less intellectual property protection in some countries outside the U.S. than exists in the U.S.,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different labor regulations and workforce instability,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability, including as a result of armed conflicts and insurrections,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on local currency conversion or cash extraction,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially negative consequences from changes in or interpretations of tax laws, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic instability and inflation, recession or interest rate fluctuations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing global economic competition and trade tensions between the U.S. and China present risk to Medtronic. Although we have been able to mitigate some of the impact on Medtronic from increased duties imposed by both sides (through petitioning both governments for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tariff exclusions and other mitigations), the risk remains of additional tariffs and other kinds of restrictions. Tariff exclusions awarded to Medtronic by the U.S. Government require periodic renewal, and policies for granting exclusions could shift. The U.S. and China, which comprises approximately seven percent of our total revenues, could impose other types of restrictions such as limitations on government procurement or technology export restrictions, which could affect Medtronic&#8217;s access to the markets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Russia-Ukraine conflict and resulting sanctions and export restrictions are creating barriers to doing business in Russia and Belarus and adversely impacting global supply chains. While we have no manufacturing, distribution or direct material suppliers in the region, we continue to closely monitor the potential raw material/sub-tier supplier impact in both Russia and Ukraine including materials like palladium and neon, which are both dependent on Russia supply. Additional sanctions, export restrictions, and potential countermeasures within Russia, along with geopolitical shifts in Asia and disruptions relating to Israel's conflict in Gaza, may lead to greater uncertainty that could cause additional adverse impacts on global supply chains and our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More generally, several governments including the U.S. have raised the possibility of policies to induce &#8220;re-shoring&#8221; of supply chains, less reliance on imported supplies, and greater national production. Examples include potential &#8220;Buy America&#8221; requirements in the U.S. If such steps triggered retaliation in other markets restricting access to foreign products in purchases by their government-owned healthcare systems, the result could be a significant impact on Medtronic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other significant changes or disruptions to international trade arrangements, such as termination or modifications of other existing trade agreements, may adversely affect our business, results of operations, financial condition, and cash flows. In addition, a significant amount of our trade receivables are with national healthcare systems in many countries. Repayment of these receivables is dependent upon the political and financial stability of those countries. In light of these global economic fluctuations, we continue to monitor the creditworthiness of customers. Failure to receive payment of all or a significant portion of these receivables could adversely affect our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, changes in currency exchange rates may impact the reported value of our revenues, expenses, and cash flows. In addition, the impact of currency devaluations in countries experiencing significant currency exchange fluctuations could negatively impact the Company's operating results. We cannot predict changes in currency exchange rates, the impact of exchange rate changes, nor the degree to which we will be able to manage the impact of currency exchange rate changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market disruptions resulting in diminished liquidity, or healthcare professional and staff strikes or other work stoppages, could adversely affect our revenues, results of operation, or financial condition. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions in international markets and supporting financial services and uncertainty about economic conditions (for instance, resulting from credit scarcity, geopolitical risks and sovereign debt deterioration), have in the past caused periods of tightened credit availability and increased volatility in liquidity and borrowing terms. If these conditions were to recur or worsen, we may experience reduced demand for a number of our products. We also could experience reduced sales and profits due to delayed payments or the insolvency of healthcare professionals, hospitals and other customers, suppliers and vendors who experience liquidity issues, including as a result of cybersecurity incidents impacting private and government health insurance payors. In addition, healthcare professional and staff strikes or other work stoppages have in the past and may in the future cause reduced demand for our products. As a result, our business, results of operations, financial condition, and cash flows could be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation in the healthcare industry and the growing prevalence of ambulatory surgery centers (ASCs) could have an adverse effect on our revenues and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many healthcare industry companies, including healthcare systems, distributors, manufacturers, providers, and insurers, are consolidating or have formed strategic alliances. As the healthcare industry consolidates, competition to provide goods and services to industry participants will become more intense. Further, this consolidation creates larger enterprises with greater negotiating power, which can be used to negotiate price concessions. In addition, the movement of procedures to ASCs could also create downward pricing pressure. If we must reduce our prices because of industry consolidation or ASC procedures, or if we lose customers as a result of consolidation or ASC procedures, our business, results of operations, financial condition, and cash flows could be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare industry cost-containment measures could result in reduced sales of our medical devices and medical device components.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our customers, and the healthcare providers to whom our customers supply medical devices, rely on third-party payors, including government programs and private health insurance plans, to reimburse some or all of the cost of the procedures in which medical devices that incorporate components we manufacture or assemble are used. The continuing efforts of governmental authorities, insurance companies and other payors of healthcare costs to contain or reduce these costs could lead to patients being unable to obtain approval for payment from these third-party payors. If third-party payor payment approval cannot be obtained by patients, sales of finished medical devices that include our components may decline significantly and our customers may reduce or eliminate purchases of our components. The cost-containment measures that healthcare providers are instituting, both in the U.S. and outside of the U.S., could harm our ability to operate profitably. For example, managed care organizations have successfully negotiated volume discounts for pharmaceuticals, and GPOs and IDNs have also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concentrated purchasing decisions for some customers, which has led to downward pricing pressure for medical device companies, including us.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_22"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_2542"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed and implemented a cybersecurity risk management program to help us identify, assess, and mitigate cybersecurity risks relevant to our business, based on the National Institute of Standards and Technology (NIST) Cyber Security Framework 2.0.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program includes:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dedicated cybersecurity professionals who analyze cybersecurity threats, define cybersecurity policy and requirements, implement protections, and monitor and respond to cybersecurity incidents,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity regulatory based risk assessments for the Company&#8217;s systems and applications (where required),</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a formal incident response plan, in which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incidents are classified based upon the severity, impact, and the potential harm that can be caused by the incident,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annual information security training program for all employees, including phishing awareness training,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity works closely with application development and infrastructure &amp; operation teams to embed security considerations into the foundation of technology,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engagement of third-party service providers to conduct assessment of the Company&#8217;s cybersecurity risk management program, penetration testing, and vulnerability testing,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third-party risk assessment process for service providers, suppliers, and vendors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given the smart technology within our devices, our product security includes design protocols and is supported by quality systems testing and use scanning tools to assess and detect vulnerabilities that could affect our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks from cybersecurity threats are integrated into Medtronic&#8217;s enterprise risk management (ERM) program. The ERM program establishes a risk management framework that seeks to identify, assess, and mitigate risks that could materially impact the Company&#8217;s business and operation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company&#8217;s business or operations. However, despite our security measures, there can be no assurance that the Company, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially affect us. See Item 1A. Risk Factors under, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;We rely on the proper function, security and availability of our information technology systems and data, as well as those of third parties throughout our global supply chain and our customer and payor base, to operate our business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation or competitive position.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 28 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors is engaged in the Company&#8217;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#8217;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#8217;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#8217;s cybersecurity risk management program from the CISO and CIO.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_25"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic's principal executive office is located in Ireland and is leased by the Company, while its main operational offices are located in the Minneapolis, Minnesota metropolitan area and are owned by the Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's total manufacturing and research space is approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> square feet. Approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36 percent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the manufacturing or research facilities are owned by Medtronic and the remaining balance is leased. The following is a summary of the Company's largest manufacturing facilities by location:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location Country or State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Square Feet (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic also maintains sales and administrative offices outside the U.S. at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> locations in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> countries. A majority of these locations are leased. The Company is using substantially all of its currently available productive space to develop, manufacture, and market its products. The Company's facilities are well-maintained, suitable for their respective uses, and adequate for current needs. </span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_28"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with Item 103 of Regulation S-K, we have adopted a $1 million disclosure threshold for proceedings under environmental laws to which a governmental authority is a party, as we believe matters under this threshold are not material to the Company. A discussion of the Company&#8217;s legal proceedings and other loss contingencies are described in Note 18 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_31"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_37"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Medtronic&#8217;s Common Equity, Related Shareholder Matters, and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ordinary shares are listed on the New York Stock Exchange under the symbol &#8220;MDT.&#8221;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the shares repurchased by the Company during the fourth quarter of fiscal year 2024: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price<br/>Paid per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased as a Part of<br/>Publicly Announced<br/>Program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Approximate Dollar Value of Shares that may yet be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/27/2024-2/23/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700,959,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/24/2024-3/29/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143,724,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2024-4/26/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293,724,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,467,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,467,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293,724,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company's Board of Directors authorized the repurchase of $6.0 billion of the Company's ordinary shares. In March 2024, the Company's Board of Directors authorized an incremental $5.0 billion for share repurchases. There is no specific time-period associated with these repurchase authorizations. For additional discussion, see Note 11 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;17, 2024, there were approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 20,132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shareholders of record of the Company&#8217;s ordinary shares. Ordinary cash dividends declared and paid totaled $0.69 per share for each quarter of fiscal year 2024 and $0.68 per share for each quarter of fiscal year 2023. On </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;23, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company announced an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increase </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Medtronic's cash dividends for the first quarter of fiscal year 2025, raising the amount to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total shareholder return on Medtronic&#8217;s ordinary shares with the cumulative total shareholder return on the Standard &amp; Poor&#8217;s (S&amp;P) 500 Index and the S&amp;P 500 Health Care Equipment Index for the last five fiscal years. The graph assumes that $100 was invested at market close on April&#160;26, 2019 in Medtronic&#8217;s ordinary shares, the S&amp;P 500 Index, and the S&amp;P 500 Health Care Equipment Index and that all dividends were reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g7.jpg" alt="1613" style="height:330px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.904%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Company/Index</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic plc</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.95&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Health Care Equipment Index</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on the Company's equity compensation plans, see "Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters" in this Annual Report on Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Irish Restrictions on Import and Export of Capital </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as indicated below, there are no restrictions on non-residents of Ireland dealing in Irish domestic securities, which includes ordinary shares of Irish companies. Except as indicated below, dividends and redemption proceeds also continue to be freely transferable to non-resident holders of such securities. The Financial Transfers Act, 1992 provides that the Irish Minister for Finance can make provision for the restriction of financial transfers between Ireland and other countries. For the purposes of this Act, &#8220;financial transfers&#8221; include all transfers which would be movements of capital or payments within the meaning of the treaties governing the E.U. if they had been made between Member States of the E.U. To date, the Irish Minister for Finance has restricted financial transfers between Ireland and a number of third countries and the list is subject to on-going change.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any transfer of, or payment in respect of, a share or interest in a share involving the government of any country that is currently the subject of United Nations or E.U. sanctions, any person or body controlled by any of the foregoing, or by any person acting on behalf of the foregoing, may be subject to restrictions pursuant to such sanctions as implemented into Irish law.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Irish Taxes Applicable to U.S. Holders </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid by Medtronic will generally be subject to Irish dividend withholding tax (currently at a rate of 25 percent) unless an exemption applies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid to U.S. residents will not be subject to Irish dividend withholding tax provided that:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the case of a beneficial owner of Medtronic shares held in the Depository Trust Company (DTC), the address of the beneficial owner in the records of his or her broker is in the United States and this information is provided by the broker to the Company&#8217;s qualifying intermediary; or</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the case of a record owner, the record owner has provided to the Company&#8217;s transfer agent a valid U.S. Certification of Residence (Form 6166) or valid Irish Non-Resident Form V2.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Irish income tax may also arise with respect to dividends paid on Medtronic&#8217;s ordinary shares. A U.S. resident who meets one of the exemptions from dividend withholding tax described above and who does not hold Medtronic shares through a branch or agency in Ireland through which a trade is carried on generally will not have any Irish income tax liability on a dividend paid by Medtronic. In addition, if a U.S. shareholder is subject to the dividend withholding tax, the withholding payment discharges any Irish income tax liability, provided the shareholder furnishes to the Irish Revenue authorities a statement of the dividend withholding tax imposed.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the U.S./Ireland Double Tax Treaty contains provisions regarding withholding, due to the wide scope of the exemptions from dividend withholding tax available under Irish domestic law, it would generally be unnecessary for a U.S. resident shareholder to rely on the treaty provisions.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_40"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDERSTANDING OUR FINANCIAL INFORMATION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on focuses on our financial results for the fiscal year ended April&#160;26, 2024 (fiscal year 2024) and the fiscal year ended April&#160;28, 2023 (fiscal year 2023). A discussion on our results of operations for fiscal year 2023 as compared to the year ended April&#160;29, 2022 (fiscal year 2022) is included in Part II, Item 7. "Mana</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gement's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;28, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on June </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22, 2023, and is i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncorporated by reference into this Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You should read this discussion and analysis along with our consolidated financial statements and related notes thereto at April&#160;26, 2024 and April&#160;28, 2023 and for fiscal years 2024, 2023, and 2022, which are presented within "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Management&#8217;s Discussion and Analysis, we present certain financial measures that facilitate management's review of the operational performance of the Company and as a basis for strategic planning; however, such financial measures are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, financial measures presented in accordance with U.S. GAAP. We believe that non-GAAP financial measures provide information useful to investors in understanding the Company's underlying operational performance and trends and may facilitate comparisons with the performance of other companies in the medical technologies industry.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As presented in the GAAP to Non-GAAP Reconciliations section on the following pages, our non-GAAP financial measures exclude the impact of amortization of intangible assets and certain charges or benefits that contribute to or reduce earnings and that may affect financial trends and include certain charges or benefits that result from transactions or events that we believe may or may not recur with similar materiality or impact to our operations in future periods (Non-GAAP Adjustments). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event there is a Non-GAAP Adjustment recognized in our operating results, the tax cost or benefit attributable to that item is separately calculated and reported. Because the effective rate can be significantly impacted by the Non-GAAP Adjustments that take place during the period, we often refer to our tax rate using both the effective rate and the non-GAAP nominal tax rate (Non-GAAP Nominal Tax Rate). The Non-GAAP Nominal Tax Rate is calculated as the income tax provision, adjusted for the impact of Non-GAAP Adjustments, as a percentage of income before income taxes, excluding Non-GAAP Adjustments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Free cash flow is a non-GAAP financial measure calculated by subtracting property, plant, and equipment additions from operating cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the &#8220;GAAP to Non-GAAP Reconciliations," "Income Taxes," and "Free Cash Flow" sections for reconciliations of the non-GAAP financial measures to their most directly comparable financial measures prepared in accordance with U.S. GAAP.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE LEVEL OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a summary of revenue, diluted earnings per share, and cash flow for fiscal years 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><img src="mdt-20240426_g8.jpg" alt="Executive Level Overview Infographic Q4 FY24 v4.jpg" style="height:421px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">GAAP to Non-GAAP Reconciliations </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The tables below present reconciliations of our Non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with U.S. GAAP for fiscal years 2024 and 2023. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year ended April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Before Income Taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Tax Provision (Benefit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Attributable to Medtronic</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Tax Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain)/loss on minority investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year ended April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Before Income Taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Tax Provision (Benefit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Attributable to Medtronic</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Tax Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain)/loss on minority investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt redemption premium and other charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (9)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.29&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program, consulting expenses, and asset write-offs. </span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The charges predominantly include $439 million of charges related to the February 20, 2024 decision to exit the Company's ventilator product line, which primarily includes long-lived intangible asset impairments and inventory write-downs. In addition, other charges primarily consist of changes in fair value of contingent consideration and associated costs related to the previously contemplated separation of the PMRI businesses. </span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The net charge primarily relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision and the establishment of a valuation allowance against certain net operating losses which were partially offset by a benefit from the change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The charges predominantly include non-cash pre-tax impairments, primarily related to goodwill, changes in the carrying value of the disposal group, and other associated costs, as a result of the April 2023 sale of half of the Company's Renal Care Solutions (RCS) business; business combination costs, and associated costs related to the previously contemplated separation of the PMRI businesses. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Certain litigation includes $35 million income related to the one-time payment received as a result of the Intellectual Property Agreement entered into with Edwards Lifesciences in April 2023.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The charges relate to the early redemption of approximately $2.3 billion of debt and were recorded within interest expense, net within the consolidated statements of income.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The charge primarily relates to a $764 million reserve adjustment that was a direct result of the U.S. Tax Court opinion, issued in August 2022, on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico. Additional charges relate to the reduction of deferred tax assets due to the disallowance of certain interest deductions and the change in the reporting currency for certain carryover attributes, and the amortization on previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Free Cash Flow </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Free cash flow, a non-GAAP financial measure, is calculated by subtracting additions to property, plant, and equipment from net cash provided by operating activities. Management uses this non-GAAP financial measure, in addition to U.S. GAAP financial measures, to evaluate our operating results. Free cash flow should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Reconciliations between net cash provided by operating activities (the most comparable U.S. GAAP measure) and free cash flow are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.866%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the Summary of Cash Flows section for drivers of the change in cash provided by operating activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NET SALES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment and Division </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period revenue has been recast to reflect the new reporting structure. The activity of the Company's Renal Care Solutions business and the ventilator product line were moved out of Medical Surgical and into the Other line, and the retained PMRI businesses were combined into one business unit called Acute Care &amp; Monitoring in Medical Surgical. Refer to Note 19 to the consolidated financial statements for additional information regarding the Company's new reporting structure. The charts below illustrate the percent of net sales by segment for fiscal years 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g9.jpg" alt="128" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/><img src="mdt-20240426_g10.jpg" alt="129" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes net sales by segment and division for fiscal years 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Sales by Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac Rhythm &amp; Heart Failure</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Heart &amp; Aortic </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary &amp; Peripheral Vascular </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cranial &amp; Spinal Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Therapies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical &amp; Endoscopy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Care &amp; Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment and Market Geography</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below illustrate the percent of net sales by market geography for fiscal years 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g11.jpg" alt="352" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/><img src="mdt-20240426_g12.jpg" alt="353" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes net sales by market geography for each of our segments for fiscal years 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.906%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Developed Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">U.S. includes the United States and U.S. territories.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net sales for fiscal year 2024 was driven by growth in most businesses, including Surgical, Cranial &amp; Spinal Technologies, Diabetes, and Cardiac Pacing, as well as strength in international markets. The net sales increase was partially offset by a $265 million one-time payment received in the fourth quarter of fiscal year 2023 as a result of an intellectual property agreement, as further discussed in the Cardiovascular net sales section below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Looking ahead, a number of macro-economic and geopolitical factors could negatively impact our business, including without limitation: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Competitive product launches and pricing pressure, geographic macro-economic risks including fluctuations in currency exchange rates, general price inflation, changes in interest rates, reimbursement challenges, impacts from changes in the mix of our product offerings, delays in product registration approvals, replacement cycle challenges, and supply chain challenges from time to time; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">National and provincial tender pricing for certain products, particularly in China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The sanctions and other measures being imposed in response to the Russia-Ukraine conflict are having and could continue to have impacts on revenue and supply chain. The financial impact of the conflict in fiscal year 2024, including on accounts receivable and inventory reserves, was not material. For fiscal year 2024, the business of the Company in these countries represented less than 1% of the Company's consolidated revenues and assets. Although the implications of this conflict are difficult to predict at this time, the ongoing conflict may increase pressure on the global economy and supply chains, resulting in increased future volatility risk for our business operations and performance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Although the long-term implications of Israel's conflict are difficult to predict at this time, the financial and operational impact of the conflict in fiscal year 2024, including on accounts receivable and inventory reserves, was not material. As of April 26, 2024, the Company had 6 facilities and approximately 1,500 employees in Israel. For fiscal year 2024, the business of the Company in Israel represented less than 1% of the Company's consolidated revenues and assets.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_55"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiovascular </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular products include pacemakers, insertable cardiac monitors, cardiac resynchronization therapy devices, implantable cardioverter defibrillators, leads and delivery systems, electrophysiology catheters, products for the treatment of atrial fibrillation, information systems for the management of patients with Cardiac Rhythm &amp; Heart Failure devices, products designed to reduce surgical site infections, coronary and peripheral stents and related delivery systems, balloons and related delivery systems, endovascular stent graft systems, heart valve replacement technologies, cardiac tissue ablation systems, and open heart and coronary bypass grafting surgical products. Cardiovascular also includes Care Management Services and Cath Lab Managed Services (CLMS) within the Cardiac Rhythm &amp; Heart Failure division. Cardiovascular net sales for fiscal year 2024 were $11.8 billion, an increase of 3 percent as compared to fiscal year 2023. The net sales increase was primarily due to the strong performance of Micra, transcatheter aortic valve replacement (TAVR), and Perfusion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below illustrate the percent of Cardiovascular net sales by division for fiscal years 2024 and 2023: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g13.jpg" alt="1268" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/><img src="mdt-20240426_g14.jpg" alt="1269" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiac Rhythm &amp; Heart Failure (CRHF) net sales increased 4 percent in fiscal year 2024 as compared to fiscal year 2023. The net sales increase was driven by continued adoption of Micra AV2 and Micra VR2 and growth from the launch of the PulseSelect pulsed field ablation (PFA) system and the Aurora extravascular implantable cardioverter defibrillator (EV-ICD) system. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Structural Heart &amp; Aortic (SHA) net sales were flat in fiscal year 2024 as compared to fiscal year 2023. Net sales were impacted by the $265 million of revenue from a one-time payment received in the fourth quarter of fiscal year 2023 as a result of the intellectual property agreement entered into with Edwards Lifesciences, offset by growth in TAVR, including strong growth in Western Europe and Japan from adoption of Evolut FX TAVR system, and in Cardiac Surgery driven by growth of Perfusion, particularly in the U.S. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coronary &amp; Peripheral Vascular (CPV) net sales increased 4 percent in fiscal year 2024 as compared to fiscal year 2023. The net sales increase was driven by growth from guide catheters, balloons, as well as growth in Vascular Embolization products. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the macro-economic and geopolitical factors described in the Net Sales section, looking ahead, we expect Cardiovascular could be affected by the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued global penetration of our Micra transcatheter pacing portfolio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth from the Azure XT and Azure S SureScan pacing systems and the 3830 lead.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global adoption of Aurora Extravascular ICD.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Growth of the Cobalt and Crome portfolio of ICDs and CRT-Ds. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Growth of the CRT-P quadripolar pacing system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued growth, adoption, and utilization of the TYRX Envelope for implantable devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued use and acceptance of Reveal LINQ and expansion of the LINQ II cardiac monitor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance, adoption, and growth of our innovative portfolio of products in the electrophysiology (EP) segment, including the Arctic Front cryoablation system, PulseSelect PFA, and Affera mapping and ablation system. The PulseSelect PFA system received CE Mark in November 2023 was approved by the U.S. FDA in December 2023 and was the first PFA technology to receive U.S. FDA approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform. This includes Evolut PRO which provides enhanced hemodynamics, reliable delivery, enhanced durability, advanced sealing, and Evolut FX, a system designed to improve the overall procedural experience through enhancements in deliverability, implant visibility, and deployment stability. The Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access. The system was approved by the U.S. FDA in March 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market acceptance and reimbursement for the Symplicity Spyral renal denervation system, also known as the Symplicity blood pressure procedure, for the treatment of hypertension. The Symplicity blood pressure procedure was approved by the U.S. FDA in November 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of the Onyx Frontier DES platform. Onyx Frontier is a DES that introduces an enhanced delivery system and is used for complex percutaneous coronary intervention (PCI).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acceptance and growth of IN.PACT 018 drug-coated balloons (DCB). IN.PACT 018 adds to the existing IN.PACT Admiral DCB portfolio and is used to treat femoropopliteal disease.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neuroscience</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience's products include various spinal implants, bone graft substitutes, biologic products, image-guided surgery and intra-operative imaging systems, robotic guidance systems used in the robot-assisted spine procedures, and systems that incorporate advanced energy surgical instruments. Neuroscience's products also focus on therapies to treat the diseases of the vasculature in and around the brain, including coils, neurovascular stents, and flow diversion products, as well as products to treat ear, nose, and throat (ENT), and the treatment of overactive bladder and urinary retention. Neuroscience also manufactures products related to implantable neurostimulation therapies and drug delivery systems for the treatment of chronic pain, movement disorders, and epilepsy. Neuroscience&#8217;s net sales for fiscal year 2024 were $9.4 billion, an increase of 5 percent as compared to fiscal year 2023. The net sales increase was primarily due to growth in Cranial &amp; Spinal Technologies and ENT.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graphs below illustrate the percent of Neuroscience net sales by division for fiscal years 2024 and 2023:</span></div><div style="margin-top:8pt;text-align:center"><img src="mdt-20240426_g15.jpg" alt="1276" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/><img src="mdt-20240426_g16.jpg" alt="1277" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cranial &amp; Spinal Technologies (CST) net sales for fiscal year 2024 increased 7 percent as compared to fiscal year 2023. The net sales increase was driven by growth of AiBLE spinal ecosystem capital and Core Spine and Biologics product pull-through.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty Therapies (Specialty) net sales for fiscal year 2024 increased 3 percent as compared to fiscal year 2023. The net sales increase was driven by growth in ENT.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuromodulation (NM) net sales for fiscal year 2024 increased 3 percent as compared to fiscal year 2023. The net sales increase was driven by growth within Brain Modulation, including growth from the Western European launch of the Percept RC neurostimulator, as well as Pain Stim growth in the U.S.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the macro-economic and geopolitical factors described in the Net Sales section, looking ahead we expect Neuroscience could be affected by the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued adoption and growth of our integrated solutions through the AiBLE offering, which integrates spinal implants with enabling technologies (StealthStation, O-arm Imaging Systems, and Midas), Mazor robotics, and UNiD Adaptive Spine Intelligence AI-driven technology for surgical planning and personalized spinal implants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market acceptance and continued global adoption of innovative new spine products and procedural solutions within our CST operating unit, such as Catalyft PL, ModuLeX, CD Horizon Voyager System, and our Infinity OCT System, as well as continued growth from Titan spine titanium interbody implants with Nanolock technology.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued growth of Pipeline Embolization Devices, endovascular treatments for large or giant wide-necked brain aneurysms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of the Solitaire X revascularization device for treatment of acute ischemic stroke and our React Catheter and Riptide aspiration system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of our Pelvic Health therapies, including our InterStim therapy with InterStim X and InterStim II recharge-free neurostimulators and InterStim Micro rechargeable neurostimulator for patients suffering from overactive bladder, (non-obtrusive) urinary retention, and chronic fecal incontinence, </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of our ENT therapies, including capital equipment sales of the Stealth Station ENT surgical navigation system and intraoperative NIM nerve monitoring system, and the Propel sinus implants used in the treatment of chronic rhinosinusitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth from spinal cord stimulation (SCS) therapy for treating chronic pain and Diabetic Peripheral Neuropathy (DPN) on the Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator. The Inceptiv closed-loop rechargeable SCS received U.S. FDA approval in April 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of our Percept family of deep brain stimulation (DBS) devices with proprietary BrainSense technology for objectifying and personalizing the treatment of Parkinson's Disease, epilepsy, and other movement disorders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, which include hemorrhagic stroke intravascular device and our next-generation spine enabling technologies.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_58"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Surgical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Surgical&#8217;s products span the entire continuum of patient care from diagnosis to recovery, with a focus on diseases within thoracic, colorectal, gynecology, bariatric, hernia, and preventable complications. The products include those for advanced and general surgical products, surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, advanced ablation, interventional lung, airway products, and sensors and monitors for pulse oximetry, capnography, level of consciousness and cerebral oximetry. Medical Surgical&#8217;s net sales for fiscal year 2024 were $8.4 billion, an increase of 5 percent as compared to fiscal year 2023. The net sales increase was primarily driven by strength across both Surgical &amp; Endoscopy and Acute Care &amp; Monitoring.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below illustrate the percent of Medical Surgical net sales by division for fiscal years 2024 and 2023:</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><img src="mdt-20240426_g17.jpg" alt="1265" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/><img src="mdt-20240426_g18.jpg" alt="1266" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surgical &amp; Endoscopy (SE) net sales for fiscal year 2024 increased 6 percent as compared to fiscal year 2023. The net sales increase was predominantly attributable to growth in Advanced Surgical Technologies and General Surgical Technologies, primarily driven by supply expansion, as well as continued growth in Advanced Energy, Wound Management, Electrosurgery, GI Genius, and EndoFlip.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acute Care &amp; Monitoring (ACM) net sales for fiscal year 2024 increased 4 percent as compared to fiscal year 2023. The net sales increase was primarily driven by growth in Nellcor pulse oximetry products and McGRATH MAC video laryngoscopes.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the macro-economic and geopolitical factors described in the Net Sales section, looking ahead we expect Medical Surgical could be affected by the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acceptance and continued growth of Open-to-MIS (minimally invasive surgery) techniques and tools through our efforts to transition open surgery to MIS. Open-to-MIS initiative focuses on capturing the market opportunity that exists in transitioning open procedures to MIS, whether through traditional MIS, advanced instrumentation, or robotics. Through our approach, in parallel, we also expand our presence and optimize open surgery in current open surgery markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued global acceptance and future growth of powered stapling and energy platform.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to execute ongoing strategies addressing the near-term pressures to bariatric surgery procedure volumes in the U.S. from pharmaceuticals, and growth of surgical soft tissue robotics procedures in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to create markets and drive products and procedures into emerging markets with our high quality and cost-effective surgical products designed for customers in emerging markets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth in patient monitoring and airway management. Key products in this area include Microstream Capnography, Nellcor pulse oximetry system with OxiMax technology, Shiley tracheostomy and endotracheal tubes, and McGRATH MAC video laryngoscopes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acceptance of less invasive standards of care in chronic and colorectal, as well as hepatology products, including products that span the care continuum from diagnostics to therapeutics. Recently launched products include GI Genius.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanding the use of less invasive treatments and furthering our commitment to improving options for women with abnormal uterine bleeding. Our expanded and strengthened surgical offerings complement our global gynecology business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global adoption of robotic-assisted surgery and installations of Hugo robotic assisted surgery (RAS) system for urologic, bariatric, gynecologic, hernia, and general surgery procedures. This includes continued integration and adoption of Touch Surgery Enterprise with the first artificial intelligence powered surgical videos and analytics platform to make it easier to train and discover new techniques within the robotics platform. The Hugo RAS system, which received CE Mark in October 2021, as well as secured additional regulatory approvals outside the U.S., is designed to help reduce unwanted variability, improve patient outcomes, and, by extension, lower per procedure cost.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, which include our Hugo RAS system in the U.S., the adoption of AI in Endoscopy, Signia powered stapling devices, and our next-gen Ligasure and Sonicision vessel sealing devices.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diabetes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diabetes' products include insulin pumps, continuous glucose monitoring (CGM) systems, and consumables. Diabetes' sales for fiscal year 2024 were $2.5 billion, an increase of 10 percent as compared to fiscal year 2023. The increase in net sales was primarily driven by strong international growth as a result of the continued international expansion of the MiniMed 780G insulin pump system and integrated CGM. The launch of the MiniMed 780G insulin pump system in the U.S., during the first quarter of fiscal year 2024, also contributed to the net sales growth.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the macro-economic and geopolitical factors described in the Net Sales section, looking ahead we expect Diabetes could be affected by the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth for the MiniMed 780G insulin pump system, which is powered by SmartGuard technology and features the added benefits of meal detection technology that automatically adjusts and corrects sugar levels every five minutes. The global adoption of our Automated Insulin Delivery (AID) systems has resulted in strong sensor attachment rates. The MiniMed 780G insulin pump system with the Guardian 4 Sensor was approved by the U.S. FDA in late April 2023. The MiniMed 780G insulin pump system with Simplera Sync received CE Mark in early January 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of the Guardian Connect CGM system, which displays glucose information directly to a smartphone to provide patients access to their glucose levels seamlessly and discretely. The Guardian Connect CGM system is available on both Apple iOS and Android devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market acceptance and growth of our InPen smart pen system, which allows users to have their Medtronic CGM readings in real-time alongside insulin dose information, all in one view. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued pump, CGM, and consumable competition in an expanding global market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in medical reimbursement policies and programs, along with additional payor coverage on insulin pumps.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, including our next-generation sensor Simplera, which has been submitted for approval to the U.S. FDA and received CE Mark in September 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COSTS AND EXPENSES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of cost of products sold, research and development, and selling, general, and administrative expenses as a percent of net sales:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20240426_g19.jpg" alt="179" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of products sold for fiscal year 2024 was $11.2 billion as compared to $10.7 billion for fiscal year 2023. The increase in cost of products sold as a percentage of net sales was primarily attributable to increased labor and direct material manufacturing costs, predominantly due to inflationary pressures, as well as $70&#160;million of inventory write-downs associated with our February 2024 decision to exit our ventilator product line. For additional information about the ventilator inventory write-down, refer to Note 3 of the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expense   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to deliver the best possible experiences for patients, physicians, and caregivers we serve; to create technologies that expand what&#8217;s possible across the human body to transform lives; to turn data and insights into real action to serve patient needs, improving care; and to expand healthcare access and deliver positive outcomes. Research and development expense was $2.7 billion for fiscal years 2024 and 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General, and Administrative Expense  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our goal is to continue to leverage selling, general, and administrative expense management initiatives. Selling, general, and administrative expense primarily consists of salaries and wages, other administrative costs, such as professional fees and marketing expenses, certain acquisition and divestiture-related costs, and restructuring associated expenses. Selling, general, and administrative expense for fiscal year 2024 was $10.7 billion as compared to $10.4 billion for fiscal year 2023. The increase in selling, general, and administrative expense is primarily due to reduced incentive performance in the prior year.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_70"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other costs and expenses (income):</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_73"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets includes the amortization expense of our definite-lived intangible assets, consisting of purchased patents, trademarks, tradenames, customer relationships, purchased technology, and other intangible assets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Charges, Net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In fiscal year 2024, restructuring costs primarily related to employee termination benefits and facility consolidations to support cost reduction initiatives. In fiscal year 2023, restructuring charges primarily related to the Enterprise Excellence and Simplification restructuring programs, both of which were substantially completed as of the end of fiscal year 2023. Enterprise Excellence was designed to leverage the Company&#8217;s global size and scale to focus on global operations, and functional and commercial optimization, and had total cumulative pre-tax charges of $1.8 billion. Simplification was designed to focus the organization on accelerating innovation, enhancing customer experience, driving revenue growth and winning market share, and had total cumulative pre-tax charges of $0.5 billion. In addition, in the fourth quarter of fiscal year 2023, the Company incurred $0.3 billion of restructuring charges primarily related to employee termination benefits to support cost reduction initiatives. These charges were incremental to charges incurred under our Enterprise Excellence and Simplification programs noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our restructuring programs, refer to Note 4 of the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_79"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Litigation Charges, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   We classify specified certain litigation charges and gains related to significant legal matters as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">certain litigation charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. For additional information, refer to Note 18 of the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_82"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Expense (Income), Net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other operating expense (income), net primarily includes royalty expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in the fair value of contingent consideration, certain acquisition and-divestiture related items, income from funded research and development arrangements, and commitments to the Medtronic Foundation and Medtronic LABS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in other operating expense (income), net was largely driven by an increase in acquisition and divestiture-related expenses in fiscal year 2024. In fiscal year 2024, there were $369&#160;million of charges related to the Company's decision to exit the ventilator product line in the fourth quarter of fiscal year 2024, which primarily included intangible asset impairments of $295&#160;million and other charges for contract cancellation costs and severance. Fiscal year 2023 included non-cash charges of $136&#160;million, primarily related to impairments of goodwill and changes in the carrying value of the disposal group, as a result of the April 1, 2023 sale of half of the Company's RCS business. Also contributing to the increase in acquisition and divestiture related expenses was a change in the fair value of contingent consideration, which resulted in $156&#160;million of expense in fiscal year 2024 as compared to $24&#160;million of income in fiscal year 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in other operating expense (income), net was also driven by the net currency impact of remeasurement expense and our hedging programs, which resulted in a net gain of $68 million combined for fiscal year 2024 as compared to a net gain of $465 million for fiscal year 2023, partially offset by a decrease of $94&#160;million in Puerto Rico Excise Taxes. As a result of newly enacted tax legislation in Puerto Rico, the Company is no longer subject to Puerto Rico Excise Tax, but is now subject to a higher withholding tax, which is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Fiscal year 2023 also included $70&#160;million in commitments to the Medtronic Foundation and Medtronic LABS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding the acquisition and divestiture-related charges is described in Note 3 of the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_85"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Non-Operating Income, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Other non-operating income, net includes the non-service component of net periodic pension and postretirement benefit cost, investment gains and losses, and interest income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in other non-operating income, net for fiscal year 2024 is primarily attributable to an increase in net losses on our minority investment portfolio, partially offset by an increase in interest income driven by higher returns on cash and cash equivalents and investments. Net losses on minority investments were $308&#160;million for fiscal year 2024 as compared to a net gain of $33&#160;million for fiscal year 2023. Interest income was $597&#160;million and $386&#160;million for fiscal year 2024 and 2023, respectively. </span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Interest expense, net includes interest incurred on our outstanding borrowings, amortization of debt issuance costs and debt premiums or discounts, amortization of amounts excluded from the effectiveness assessment of certain net investment hedges, and charges recognized in connection with the early redemption of senior notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest expense, net for fiscal year 2024 was primarily driven by increased rates on our global liquidity structures, the impact of higher coupons on Senior Notes issued in the second quarter of fiscal year 2023, and the higher outstanding commercial paper balance. Partially offsetting the increase for fiscal year 2024 was $197 million in after-tax unrealized gains representing amounts excluded from the effectiveness assessment of certain net investment hedges as compared to $107 million for fiscal year 2023. Also partially offsetting the increase in interest expense, net was the $53&#160;million charge incurred as a result of the early redemption of approximately $2.3&#160;billion of senior notes during the first quarter of fiscal year 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCOME TAXES</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.035%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP income tax provision</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Nominal Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference between the effective tax rate and Non-GAAP Nominal Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Israeli Central-Lod District Court issued its decision in Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office in June 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a $187&#160;million income tax charge during fiscal year 2024 and filed an appeal with the Supreme Court of Israel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for fiscal year 2024 was 23.4 percent, as compared to 29.5 percent in fiscal year 2023. The decrease in our effective tax rate primarily relates to the decrease in certain tax adjustments discussed below which is partially offset by an increase in Puerto Rico withholding taxes and year-over-year changes in operational results by jurisdiction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Non-GAAP Nominal Tax Rate for fiscal year 2024 was 16.0 percent, as compared to 13.8 percent in fiscal year 2023. The increase in our Non-GAAP Nominal Tax Rate primarily relates to an increase in Puerto Rico withholding taxes and year-over-year changes in operational results by jurisdiction, inclusive of the operational tax costs and benefits discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, we recognized $19 million of operational tax costs. The operational tax costs included a $16 million cost from the impact of stock-based compensation, and a $3 million net cost associated with the resolution of certain income tax audits, finalization of certain tax returns, and changes to uncertain tax position reserves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, we recognized $110 million of operational tax benefits. The operational tax benefits included an $11 million cost from the impact of stock-based compensation, and a $121 million benefit associated with the resolution of certain income tax audits, finalization of certain tax returns, changes to uncertain tax position reserves, and changes to certain deferred income tax balances.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An increase in our Non-GAAP Nominal Tax Rate of one percent would result in an additional income tax provision for fiscal years 2024 and 2023 of approximately</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$83 million and</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$82 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Tax Adjustments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, the net cost from certain tax adjustments of $299 million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $187&#160;million associated with a reserve adjustment related to the Israeli Central-Lod District Court decision with respect to a deemed taxable transfer of intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $124 million related to a change in valuation allowance on previously recorded net operating losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $95&#160;million related to a Swiss Cantonal tax rate change on previously recorded deferred tax assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $50 million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $33 million associated with a change in the Company&#8217;s permanent reinvestment assertion on certain historical earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the net cost from certain tax adjustments of $910 million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $764 million associated with a reserve adjustment that was a direct result of the U.S. Tax Court opinion, issued in August 2022, on the prior year previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $55 million related to the disallowance of certain interest deductions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $30 million related to the change in reporting currency for certain carryover attributes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $28 million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $33 million primarily associated with the sale of half of the Company&#8217;s RCS business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain tax adjustments will affect the comparability of our operating results between periods. Therefore, we consider these Non-GAAP Adjustments. Refer to the "Executive Level Overview" section of this Management's Discussion and Analysis for further discussion of these adjustments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which will be effective for the Company in fiscal year 2025. The Company is continuing to evaluate the potential impacts of proposed and enacted legislative changes as new guidance becomes available. There are no impacts of this global minimum tax in the consolidated financial statements for the fiscal year ended April 26, 2024.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in a strong financial position, and we believe our balance sheet and liquidity as of April&#160;26, 2024 provide us with flexibility, and our cash, cash equivalents, and current investments, along with our credit facility and related commercial paper programs will satisfy our foreseeable operating needs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity and capital structure are evaluated regularly within the context of our annual operating and strategic planning processes. We consider the liquidity necessary to fund our operations, which includes working capital needs, investments in research and development, property, plant, and equipment, and other operating costs. We also consider capital allocation alternatives that balance returning value to shareholders through dividends and share repurchases, satisfying maturing debt, and acquiring businesses and technology.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of cash provided by (used in) operating, investing, and financing activities, the effect of exchange rate changes on cash and cash equivalents, and the net change in cash and cash equivalents:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,171)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The $748 million increase in net cash provided was primarily driven by an increase in cash collected from customers due to an increase in sales. The increase in net cash was partially offset by timing of payments to vendors, as well as an increase in cash paid for interest and litigation. For more information on litigation payments, refer to Note 18 of the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing Activities   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.1 billion decrease in net cash used was primarily attributable to a decrease in cash paid for acquisitions of $1.7 billion, partially offset by an increase in net purchases of investments of $136 million and cash paid for additions of property, plant, and equipment of $128 million. For more information on the acquisitions, refer to Note 3 of the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Activities   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was a $510 million decrease in net cash used primarily due to proceeds from commercial paper in the current year and prior year net debt repayments, partially offset by increased share repurchases. In the current period, there was an increase in commercial paper that was issued and outstanding at year-end of $1.1&#160;billion. This increase in cash provided by financing activities was offset by an increase in share repurchases of $1.5 billion. In the fourth quarter of fiscal year 2023, the Company issued two tranches of USD-denominated Senior Notes resulting in cash proceeds of approximately $2.0&#160;billion, net of discounts and issuance costs. The Company used the net proceeds to repay in full the &#165;297&#160;billion Fiscal 2023 Loan Agreement discussed below for $2.3&#160;billion of total consideration. In the second quarter of fiscal year 2023, the Company issued four tranches of Euro-denominated Senior Notes for approximately $3.4&#160;billion. The Company used a portion of the net proceeds to repay at maturity &#8364;750&#160;million of Medtronic Global Holdings S.C.A </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Medtronic Luxco) Senior Notes for $772&#160;million of total consideration in December 2022 and &#8364;2.8&#160;billion of Medtronic Luxco Senior Notes for $2.9&#160;billion of total consideration in March 2023. In the first quarter of fiscal year 2023, the Company issued short-term borrowings of approximately $2.3&#160;billion under the Fiscal 2023 Loan Agreement and used the proceeds to fund the early redemption of senior notes for total consideration of $2.3&#160;billion. For more information on the issuance and redemption of senior notes and the Term Loan, refer to the Debt and Capital section. </span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_97"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Capital</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital structure consists of equity and interest-bearing debt. We primarily utilize unsecured senior debt obligations to meet our financing needs and, to a lesser extent, bank borrowings. From time to time, we may repurchase our outstanding debt obligations in the open market or through privately negotiated transactions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt at April&#160;26, 2024 was $25.0 billion, as compared to $24.4 billion at April&#160;28, 2023. The increase in total debt was driven by commercial paper outstanding of $1.1&#160;billion, partially offset by fluctuations in exchange rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into a term loan agreement (Fiscal 2023 Loan Agreement) with Mizuho Bank, Ltd. for an aggregate principal amount of up to &#165;300&#160;billion with a term of 364 days. In May and June 2022, Medtronic Luxco borrowed an aggregate of &#165;297&#160;billion, or approximately $2.3&#160;billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $1.9&#160;billion of Medtronic Inc. Senior Notes for $1.9&#160;billion of total consideration, and $368&#160;million of Medtronic Luxco Senior Notes for $376&#160;million of total consideration. The Company recognized a total loss on debt extinguishment of $53&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income during fiscal year 2023, which primarily included cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. During the fourth quarter of fiscal year 2023, the Company repaid the term loan in full, including interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we issued four tranches of Euro-denominated Senior Notes with an aggregate principal of &#8364;3.5&#160;billion, with maturities ranging from fiscal year 2026 to 2035, resulting in cash proceeds of approximately $3.4&#160;billion, net of discounts and issuance costs. The Company used the net proceeds to repay at maturity &#8364;750&#160;million of 0.000% Medtronic Luxco Senior Notes for $772&#160;million&#160;of total consideration in December 2022 and &#8364;1.5&#160;billion of 0.375% Medtronic Luxco Senior Notes and &#8364;1.25&#160;billion of 0.000% Medtronic Luxco Senior Notes for $2.9&#160;billion of total consideration in March 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Medtronic Luxco issued two tranches of USD-denominated Senior Notes with an aggregate principal of $2.0&#160;billion, with maturities ranging from 2028 to 2033, resulting in cash proceeds of approximately $2.0&#160;billion, net of discounts and issuance costs. The Company used the net proceeds supplemented by additional cash to repay the &#165;297&#160;billion Fiscal 2023 Loan Agreement discussed above for $2.3&#160;billion of total consideration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to year-end, on June 3, 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of &#8364;3.0&#160;billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately $3.2&#160;billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchase our ordinary shares on occasion as part of our focus on returning value to our shareholders. In March 2019, the Company's Board of Directors authorized the repurchase of $6.0 billion of the Company's ordinary shares. In March 2024, the Company's Board of Directors authorized the repurchase of an incremental $5.0 billion of the Company's ordinary shares. There is no specific time period associated with these repurchase authorizations. During fiscal years 2024 and 2023, we repurchased a total of 25 million and 6 million shares, respectively, under these programs at an average price of $83.04 and $91.31, respectively. At April&#160;26, 2024, we had approximately $5.3 billion remaining under the share repurchase program authorized by our Board of Directors. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on credit arrangements, see Note 6 of the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our liquidity sources at April&#160;26, 2024 included $1.3 billion of cash and cash equivalents and $6.7 billion of current investments. Additionally, we maintain commercial paper programs and a Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments primarily include available-for-sale debt securities, including U.S. and non-U.S. government and agency securities, corporate debt securities, mortgage-backed securities, certificates of deposit, and other asset-backed securities. See Note 5 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K for additional information regarding fair value measurements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain multicurrency commercial paper programs for short-term financing, which allow us to issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate amount outstanding at any time of $3.5 billion. At April&#160;26, 2024 and April&#160;28, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, we had $1.1 billion and no commercial paper outstanding, respectively. The issuance of commercial paper reduces the amount of credit available under our existing line of credit, as explained below.</span></div><div style="margin-bottom:7.7pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a $3.5 billion five-year syndicated credit facility (Credit Facility), which expires in December 2028. At each anniversary date of the Credit Facility, we can request a one-year extension of the maturity date. The Credit Facility provides backup funding for the commercial paper programs and may also be used for general corporate purposes. The Credit Facility provides us with the ability to increase our borrowing capacity by an additional $1.0 billion at any time during the term of the agreement. At April&#160;26, 2024 and April&#160;28, 2023, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-bottom:7.7pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rates on advances of our Credit Facility are determined by a pricing matrix based on our long-term debt ratings assigned by Standard &amp; Poor's Ratings Services (S&amp;P) and Moody's Investors Service (Moody&#8217;s). Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. We are in compliance with all covenants related to the Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our S&amp;P and Moody's long-term debt ratings and short-term debt ratings:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agency Rating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard &amp; Poor's Ratings Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Moody's Investors Service </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P-2</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Agency ratings are subject to change, and there may be no assurance that an agency will continue to provide ratings and/or maintain its current ratings. A security rating is not a recommendation to buy, sell or hold securities, and may be subject to revision or withdrawal at any time by the rating agency, and each rating should be evaluated independently of any other rating.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S&amp;P and Moody's long-term debt ratings and short-term debt ratings at April&#160;26, 2024 were unchanged as compared to the ratings at April&#160;28, 2023. We do not expect the S&amp;P and Moody's ratings to have a significant impact on our liquidity or future flexibility to access additional liquidity given our balance sheet, Credit Facility, and related commercial paper programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Cash Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have future contractual obligations and other minimum commercial commitments that are entered into in the normal course of business, some of which are recorded in our consolidated balance sheet. We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position, and/or cash flows. </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented below is a summary of our off-balance sheet contractual obligations and other minimum commercial commitments at April&#160;26, 2024, as well as long-term contractual obligations reflected in the balance sheet at April&#160;26, 2024.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity by Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Contractual obligations related to off-balance sheet arrangements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments to fund minority investments, milestone payments, and royalty obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Contractual obligations reflected in the balance sheet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes commitments related to the funding of minority investments, estimated milestone payments, and royalty obligations. While it is not certain if and/or when payments will be made, the maturity dates included in the table reflect our best estimates. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the contractual interest payments on our outstanding debt and excludes the impacts of debt premium and discount amortization. See Note 6 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K for additional information on our debt agreements.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes inventory purchase commitments, research and development, and other arrangements that are legally binding and specify minimum purchase quantities or spending amounts. These purchase commitments do not exceed our projected requirements and are in the normal course of business. Excludes open purchase orders with a remaining term of less than one year.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes defined benefit plan obligations, guarantee obligations, uncertain tax positions, non-current tax liabilities, and litigation settlements for which we cannot make a reliable estimate of the period of cash settlement. For further information, see Notes 13, 15, and 18 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the current and non-current portion of our contractual maturities of debt, excluding deferred financing costs and debt discounts, net. See Note 6 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K for additional information on our debt agreements.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the fair value of our current and non-current portions of contingent consideration. While it is not certain if and/or when payments will be made, the maturity dates included in this table reflect our best estimates. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents the tax obligations associated with the transition tax that resulted from U.S. Tax Reform. The transition tax will be paid over an eight-year period and will not accrue interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into agreements that require us to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of our products or the negligence of our personnel or claims alleging that our products infringe third-party patents or other intellectual property. Our maximum exposure under these indemnification provisions is unable to be estimated, and we have not accrued any liabilities within our consolidated financial statements or included any indemnification provisions in the table above. Historically, we have not experienced significant losses on these types of indemnification agreements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 18 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K provides information regarding amounts we have accrued related to legal matters. In accordance with U.S. GAAP, we record a liability in our consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. Actual settlements may be different than estimated and could have a material effect on our consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record tax liabilities in our consolidated financial statements for amounts that we expect to repatriate from subsidiaries (to the extent the repatriation would be subject to tax); however, no tax liabilities are recorded for amounts we consider to be permanently reinvested. We expect to have access to the majority of our cash flows in the future. In addition, we continue to evaluate our legal entity structure supporting our business operations, and to the extent such evaluation results in a change to our overall business structure, we may be required to accrue for additional tax obligations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the contractual obligations and other minimum commercial commitments outlined above, we have recurring cash requirements arising from the normal operation of our business that include capital expenditures, research and developments costs, and other operational costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our balance sheet and liquidity provide us with flexibility, and our cash, cash equivalents, current investments, Credit Facility and related commercial paper programs, as well as our ability to generate operating cash flows, will satisfy our current and future contractual obligations and cash requirements.&#160;We regularly review our capital needs and consider various investing and financing alternatives to support our requirements.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_103"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACQUISITIONS AND DISPOSITIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding acquisitions and disposition activity is included in Note 3 of the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" within this Annual Report on Form 10-K.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_109"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have used various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our significant accounting policies are disclosed in Note 1 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements, in conformity with U.S. GAAP, requires us to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates reflect our best judgment about economic and market conditions and the potential effects on the valuation and/or carrying value of assets and liabilities based upon relevant information available. We base our estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting estimates include the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   We are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. Estimating probable losses from our litigation and governmental proceedings is inherently difficult, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines, or punitive damages, or could result in a change in business practice. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies when a loss is known or considered probable, and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. Our significant legal proceedings are discussed in Note 18 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Reserves  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We establish reserves when, despite our belief that our tax return positions are fully supportable, we believe that certain positions are likely to be challenged and that we may or may not prevail. Under U.S. GAAP, if we determine that a tax position is more likely than not of being sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50 percent likely of being realized upon settlement. We presume that all tax positions will be examined by a taxing authority with full knowledge of all relevant information. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions across our global operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly monitor our tax positions and tax liabilities. We reevaluate the technical merits of our tax positions and recognize an uncertain tax benefit, or derecognize a previously recorded tax benefit, when there is (i) a completion of a tax audit, (ii) effective settlement of an issue, (iii) a change in applicable tax law including a tax case or legislative guidance, or (iv) the expiration of the applicable statute of limitations. These reserves are subject to a high degree of estimation and management judgment. Although we believe that we have adequately reserved for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate, consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Intangible Assets and Goodwill   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we acquire a business, the assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. Intangible assets primarily include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development. Determining the fair value of intangible assets acquired as part of a business combination requires us to make significant estimates. These estimates include the amount and timing of projected future cash flows of each project or technology, the discount rate used to discount those cash flows to present value, and the assessment of the asset&#8217;s life cycle. The estimates could be impacted by legal, technical, regulatory, economic, and competitive risks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The test for impairment of goodwill requires us to make several estimates related to projected future cash flows to determine the fair value of the goodwill reporting units. Our estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value. We assess the impairment of goodwill at the reporting unit level annually as of the first day of the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. As a result of our operating segment realignments during the current fiscal year, additional impairment of goodwill tests were performed. The results of the tests are disclosed in Note 9 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also test definite-lived intangible assets for impairment when an event occurs or circumstances change that would indicate the carrying amount of the assets or asset group may be impaired. We assess the impairment of indefinite-lived intangible assets annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tests for goodwill and intangible assets are based on future cash flows that require significant judgment with respect to future revenue and expense growth rates, appropriate discount rates, asset groupings, and other assumptions and estimates. The test for goodwill also utilizes revenue and earnings multiples using comparable public company information. We use estimates that are consistent with the highest and best use of the assets based on a market participant's view of the assets being evaluated. Actual results may differ from our estimates due to a number of factors including, among others, changes in competitive conditions, timing of regulatory approval, results of clinical trials, changes in worldwide economic conditions, and fluctuations in currency exchange rates. </span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_112"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding new accounting pronouncements is included in Note 1 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUPPLEMENTAL GUARANTOR FINANCIAL INFORMATION </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Medtronic plc and Medtronic, Inc. each have provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Senior Notes (Medtronic Luxco Senior Notes). The following is a summary of these guarantees:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees of Medtronic Senior Notes</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Parent Company Guarantor - Medtronic plc</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Issuer - Medtronic, Inc.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Guarantor - Medtronic Luxco</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees of Medtronic Luxco Senior Notes</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Parent Company Guarantor - Medtronic plc</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Issuer - Medtronic Luxco</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Guarantor - Medtronic, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees of CIFSA Senior Notes</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Parent Company Guarantor - Medtronic plc</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Issuer - CIFSA</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present summarized financial information for the fiscal year ended April&#160;26, 2024 for the obligor groups of Medtronic and Medtronic Luxco Senior Notes, and CIFSA Senior Notes. The obligor group consists of the parent company guarantor, subsidiary issuer, and subsidiary guarantors for the applicable senior notes. The summarized financial information is presented after elimination of (i) intercompany transactions and balances among the guarantors and issuers and (ii) equity in earnings from and investments in any subsidiary that is a non-guarantor or issuer.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summarized results of operations information for the fiscal year ended April&#160;26, 2024 was as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medtronic &amp; Medtronic Luxco Senior Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CIFSA Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,723)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Medtronic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summarized balance sheet information for the fiscal year ended April&#160;26, 2024 was as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medtronic &amp; Medtronic Luxco Senior Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CIFSA Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Medtronic Senior Notes and Medtronic Luxco Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, and Medtronic, Inc. Refer to the guarantee summary above for further details.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The CIFSA Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, CIFSA, and CIFSA Subsidiary Guarantors. Refer to the guarantee summary above for further details.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes receivables due from non-guarantor subsidiaries of $14.3&#160;billion and $1.7&#160;billion for Medtronic &amp; Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes loans receivable due from non-guarantor subsidiaries of $5.2&#160;billion and $19.1&#160;billion for Medtronic &amp; Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes payables due to non-guarantor subsidiaries of $21.8&#160;billion and $42.1&#160;billion for Medtronic &amp; Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes loans payable due to non-guarantor subsidiaries of $7.7&#160;billion and $7.7&#160;billion for Medtronic &amp; Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENCY EXCHANGE RATE RISK</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, we are exposed to currency exchange rate changes, which may cause fluctuations in earnings and cash flows. Fluctuations in the currency exchange rates of currency exposures that are unhedged, such as in certain emerging markets, may result in future earnings and cash flow volatility. The gross notional amount of all currency exchange rate derivative instruments outstanding at April&#160;26, 2024 and April&#160;28, 2023 was $23.7&#160;billion and $22.0 billion, respectively. At April&#160;26, 2024, these contracts were in a net unrealized gain position of $593&#160;million. Additional information regarding our currency exchange rate derivative instruments is included in Note 7 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sensitivity analysis of changes in the fair value of all currency exchange rate derivative contracts at April&#160;26, 2024 and April&#160;28, 2023 indicates that, if the U.S. dollar uniformly strengthened/weakened by 10 percent against all currencies, the fair value of these contracts would increase/decrease by approximately $1.7&#160;billion and $1.6&#160;billion, respectively. Any gains and losses on the fair value of derivative contracts would generally be offset by gains and losses on the underlying transactions. These offsetting gains and losses are not reflected in the above analysis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTEREST RATE RISK</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate risk on our short-term investments and our borrowings. We manage interest rate risk in the aggregate, while focusing on our immediate and intermediate liquidity needs. Our debt portfolio at April&#160;26, 2024 was comprised of debt predominantly denominated in U.S. dollars and Euros, which is primarily fixed rate debt. We are also exposed to interest rate changes affecting our investments in interest rate sensitive instruments, which include our marketable debt securities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sensitivity analysis of the impact on our interest rate-sensitive financial instruments of a hypothetical 50 basis point change in interest rates, as compared to interest rates at April&#160;26, 2024 and April&#160;28, 2023, indicates that the fair value of these instruments would change by $</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $61&#160;million, respectively.</span></div><div style="margin-bottom:1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of current market conditions and the impact on our financial condition and results of operations, see the &#8220;Liquidity&#8221; section of the Management's Discussion and Analysis in "Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report on Form 10-K. For additional discussion of market risk, see Notes 5 and 7 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_124"></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Medtronic plc</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Medtronic plc and its subsidiaries (the &#8220;Company&#8221;) as of April 26, 2024 and April 28, 2023, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended April 26, 2024, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended April 26, 2024 appearing under Item 15 (a)(1) (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of April 26, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of April 26, 2024 and April 28, 2023, and the results of its operations and its cash flows for each of the three years in the period ended April 26, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of April 26, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Reserve for the Uncertain Tax Position Related to Puerto Rico Manufacturing </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 13 and 18 to the consolidated financial statements, management records reserves for uncertain tax positions related to unresolved matters with the Internal Revenue Service (IRS) and other taxing authorities. A remaining unresolved issue with the IRS relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's manufacturing sites. These reserves are subject to a high degree of estimation and management judgment. Total reserves relating to uncertain tax positions as of April 26, 2024 were $2.824 billion, of which the Puerto Rico manufacturing reserve makes up a significant portion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the income tax reserve for the uncertain tax position related to Puerto Rico manufacturing is a critical audit matter are (i) the significant judgment by management when determining the reserve, including a high degree of estimation uncertainty relative to the unresolved issue with the IRS involving one of the Company&#8217;s manufacturing sites; and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to management&#8217;s measurement of the income tax reserve for the uncertain tax position related to Puerto Rico manufacturing, as the nature of the evidence is often highly subjective.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the recognition of the income tax reserves for uncertain tax positions, as well as controls over measurement of the reserve for the uncertain tax position related to Puerto Rico manufacturing. These procedures also included, among others (i) testing management&#8217;s process for determining the reserve, (ii) evaluating the status and results of the related U.S. Tax Court case, and (iii) evaluating the consistency of the reserve calculation with the relevant documents related to the U.S. Tax Court case. Evaluating the reasonableness of the measurement of the reserve included evaluating whether the methodology and assumptions used by the Company were consistent with the U.S. Tax Court&#8217;s ruling.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.466%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-99">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-100">Minneapolis, Minnesota</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2024</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1963.</span><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-101">32,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-102">31,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-103">31,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-104">11,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-105">10,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-106">10,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-107">2,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-108">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-109">2,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-110">10,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-111">10,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-112">10,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-113">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-114">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-115">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" scale="6" id="f-116">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" scale="6" id="f-117">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" scale="6" id="f-118">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-119">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-120">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-121">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-122">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-123">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-124">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-125">5,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-126">5,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-127">5,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-128">412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-129">515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-130">318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-131">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-132">636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-133">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-134">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-135">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-136">5,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-137">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-138">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-139">456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-140">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-141">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-142">5,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-143">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-144">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-145">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Medtronic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-146">3,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-147">3,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-148">5,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-149">2.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-150">2.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-151">3.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-152">2.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-153">2.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-154">3.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-155">1,327.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-156">1,329.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-157">1,342.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-158">1,330.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-159">1,332.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-160">1,351.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-161">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-162">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-163">5,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-164">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-165">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-166">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="f-167">848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="f-168">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-169">2,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" scale="6" id="f-170">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" scale="6" id="f-171">596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-172">2,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in retirement obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-173">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-174">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-175">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-176">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-177">381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-178">727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-179">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-180">1,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-181">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income including noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-182">3,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-183">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-184">6,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-185">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-186">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-187">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income attributable to Medtronic</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-188">3,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-189">2,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-190">6,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-191">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-192">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-193">6,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-194">6,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, less allowances and credit losses of $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-195">173</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-196">176</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-197">6,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-198">5,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-199">5,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-200">5,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-201">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-202">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-203">21,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-204">21,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-205">6,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-206">5,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-207">40,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-208">41,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-209">13,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-210">14,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-211">3,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-212">3,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-213">4,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-214">3,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-215">89,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-216">90,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current debt obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-217">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DebtCurrent" scale="6" id="f-218">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-219">2,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-220">2,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-221">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-222">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-223">1,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-224">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-225">3,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-226">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-227">10,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-228">9,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-229">23,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-230">24,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued compensation and retirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-231">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-232">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-233">1,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-234">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-235">515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-236">708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-237">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-238">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-239">39,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-240">39,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies (Notes 3, 16, and 18)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-27" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-241"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-28" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-242"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares&#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-243"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-244">0.0001</ix:nonFraction></ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="9" id="f-245"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="9" id="f-246">2.6</ix:nonFraction></ix:nonFraction> billion shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-247"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-248">1,311,337,531</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-249"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-250">1,330,809,036</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="f-251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-253">23,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-254">24,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-255">30,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-256">30,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-257">3,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-258">3,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-259">50,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-260">51,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-261">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-262">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-263">50,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-264">51,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-265">89,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-266">90,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Equity</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.309%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>&#160;Shareholders&#8217;<br/>&#160;Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-267">1,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-269">26,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-270">28,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-271">3,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-272">51,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-273">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-274">51,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-275">5,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-276">5,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-277">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-278">5,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-279">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-280">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-281">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-282">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to shareholders ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-283">2.52</ix:nonFraction> per ordinary share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-284">3,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-285">3,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-286">3,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under stock purchase and award plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-287">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-288">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-289">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-290">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-291">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-292">2,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-293">2,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-294">2,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-295">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-296">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-297">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes to noncontrolling ownership interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-298">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-299">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-300">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-301">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 29, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-302">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-304">24,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-305">30,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-306">2,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-307">52,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-308">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-309">52,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-310">3,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-311">3,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-312">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-313">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-314">1,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-315">1,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-316">1,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to shareholders ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-317">2.72</ix:nonFraction> per ordinary share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-318">3,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-319">3,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-320">3,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under stock purchase and award plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-321">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-322">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-323">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-324">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-325">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="f-326">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="f-327">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="f-328">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-329">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-330">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-331">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes to noncontrolling ownership interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-332">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-333">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-334">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-335">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-336">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-338">24,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-339">30,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-340">3,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-341">51,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-342">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-343">51,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-344">3,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-345">3,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-346">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-347">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-348">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-349">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-350">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-351">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to shareholders ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-352">2.76</ix:nonFraction> per ordinary share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-353">3,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-354">3,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-355">3,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under stock purchase and award plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-356">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-357">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-358">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-359">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-360">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-361">2,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-362">2,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-363">2,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-364">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-365">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-366">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes to noncontrolling ownership interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-367">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-368">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-369">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-371">23,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-372">30,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-373">3,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-374">50,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-375">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-376">50,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-377">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-378">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-379">5,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-380">2,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-381">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-382">2,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-383">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-384">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-385">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-386">508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-387">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-388">604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-389">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-390">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-391">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-393">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and related inventory write-downs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="f-395">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="f-397">515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-398">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-399">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-400">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable" scale="6" id="f-401">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable" scale="6" id="f-402">576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable" scale="6" id="f-403">477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-404">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-405">939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-406">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-407">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-408">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-409">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-410">345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-411">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-412">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-413">6,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-414">6,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-415">7,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-416">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-417">1,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-418">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-419">1,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-420">1,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-421">1,368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="f-422">7,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="f-423">7,514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="f-424">9,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="f-425">7,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="f-426">7,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="f-427">9,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-428">261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-429">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-430">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-431">2,366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-432">3,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-433">1,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in current debt obligations, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="f-434">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:fixed-zero" scale="6" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:fixed-zero" scale="6" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings (maturities greater than 90 days)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-438">2,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments from short-term borrowings (maturities greater than 90 days)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-441">2,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-444">5,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-447">6,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-448">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-449">3,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-450">3,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-451">3,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="f-452">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="f-453">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="f-454">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-455">2,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-456">645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-457">2,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-458">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-459">409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-460">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-461">4,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-462">4,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-463">5,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-464">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-465">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-466">231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-467">259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-468">2,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-469">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-470">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-471">3,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-472">3,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-473">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-474">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-475">3,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-476">1,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-477">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-478">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-479">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-480">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-481">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-482" continuedAt="f-482-1" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="f-482-1" continuedAt="f-482-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Operations   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc (Medtronic or the Company)&#160;is the leading global healthcare technology company&#8211; alleviating pain, restoring health, and extending life for millions of people around the world. The Company provides innovative products and therapies to serve healthcare systems, physicians, clinicians, and patients. Medtronic was founded in 1949 and is headquartered in Dublin, Ireland. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-483" continuedAt="f-483-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation  </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-483-1"> The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-484" escape="true">Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-485" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible asset, equity investment, and liability valuations. Actual results may or may not differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FiscalPeriod" id="f-486" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year-End</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;26, 2024 and April&#160;28, 2023 and for each of the three fiscal years ended April&#160;26, 2024 (fiscal year 2024), April&#160;28, 2023 (fiscal year 2023), and April&#160;29, 2022 (fiscal year 2022).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-487" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-488" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#8217;s investment and are adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-489" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-490" continuedAt="f-490-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories  </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-490-1"> Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-482-2" continuedAt="f-482-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-491" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant, and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of property, plant, and equipment asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.</span></div></ix:nonNumeric><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-492" continuedAt="f-492-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Goodwill and Intangible Assets </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-492-1">  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#8217;s net assets exceeds the estimated fair value of the reporting unit.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-493" continuedAt="f-493-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from <span style="-sec-ix-hidden:f-494">three</span> to <ix:nonNumeric contextRef="c-74" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-495">20</ix:nonNumeric> years. Amortization is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">amortization of intangible assets</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-493-1"> in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable, the Company calculates the excess of an asset group's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group, which includes intangible assets, is estimated by utilizing a discounted cash flow analysis.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-496" escape="true">Acquired IPR&amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#8217;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;D with no alternative future use acquired outside of a business combination is expensed immediately.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="mdt:ContingentConsiderationPolicyTextBlock" id="f-497" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain of the Company&#8217;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#8217;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-482-3" continuedAt="f-482-4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:SelfInsuranceReservePolicyTextBlock" id="f-498" continuedAt="f-498-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance  </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-498-1"> The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#8217; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="f-499" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Assumptions  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. See Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-500" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a cash flow hedge or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-501" continuedAt="f-501-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs are unobservable for the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency forward contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, certificates of deposits, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#8217;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-482-4" continuedAt="f-482-5"><ix:continuation id="f-501-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible assets, and IPR&amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-502" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general, and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and were $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-503">341</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-504">351</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-505">354</ix:nonFraction> million in fiscal years 2024, 2023, and 2022, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-506" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-507" continuedAt="f-507-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-507-1">  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-508" continuedAt="f-508-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-508-1">  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#8217;s tax return but has not yet been recognized as an expense in the consolidated statements of income.</ix:continuation>&#160;See Footnote 13 for more information on the Company's uncertain tax positions and tax policies.</span></div><ix:nonNumeric contextRef="c-1" name="mdt:OtherOperatingIncomeExpenseNetPolicyTextBlock" id="f-509" continuedAt="f-509-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Expense (Income), Net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other operating expense (income), net primarily includes royalty expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in fair value of contingent consideration, certain </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-482-5"><ix:continuation id="f-509-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition and divestiture-related items, income from funded research and development arrangements, and commitments to the Medtronic Foundation and Medtronic LABS.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="mdt:OtherNonoperatingIncomeExpenseNetPolicyTextBlock" id="f-510" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Non-Operating Income, Net   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-511" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency Translation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-512" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-513" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplier Finance Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#8212; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#8217;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023. The adoption of this standard did not have a material impact on the Company&#8217;s Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Yet Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_148"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-514" continuedAt="f-514-1" escape="true">Revenue </ix:nonNumeric></span></div><ix:continuation id="f-514-1" continuedAt="f-514-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Prior period revenue has been recast to reflect the new reporting structure. The activity of the Company's Renal Care Solutions business and the ventilator product line were moved out of Medical Surgical and into the Other line, and the retained PMRI businesses were combined into one business unit called Acute Care &amp; Monitoring in Medical Surgical. Refer to Note 19 to the consolidated financial statements for additional information regarding the Company's reporting structure.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-514-2" continuedAt="f-514-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-515" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below illustrates net sales by segment and division for fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Sales by Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac Rhythm &amp; Heart Failure</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-516">5,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-517">5,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-518">5,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Heart &amp; Aortic </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-519">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-520">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-521">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary &amp; Peripheral Vascular </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-522">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-523">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-524">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-525">11,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-526">11,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-527">11,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cranial &amp; Spinal Technologies </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-528">4,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-529">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-530">4,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Therapies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-531">2,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-532">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-533">2,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-534">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-535">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-536">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-537">9,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-538">8,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-539">8,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical &amp; Endoscopy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-540">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-541">6,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-542">6,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Care &amp; Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-543">1,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-544">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-545">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-546">8,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-547">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-548">8,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-549">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-550">2,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-551">2,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-552">32,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-553">30,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-554">30,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-555">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-556">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-557">727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-558">32,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-559">31,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-560">31,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The table below illustrates net sales by market geography for each segment for fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.778%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Developed Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-561">5,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-562">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-563">5,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-564">3,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-565">3,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-566">3,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-567">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-568">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-569">2,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-570">6,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-571">6,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-572">5,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-573">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-574">1,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-575">1,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-576">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-577">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-578">1,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-579">3,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-580">3,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-581">3,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-582">3,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-583">2,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-584">3,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-585">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-586">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-587">1,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-588">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-589">849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-590">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-591">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-592">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-593">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-594">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-595">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-596">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-597">16,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-598">16,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-599">15,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-600">9,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-601">9,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-602">9,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-603">5,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-604">5,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-605">5,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-606">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-607">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-608">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-609">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-610">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-611">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-612">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-613">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-614">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-615">16,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-616">16,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-617">16,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-618">9,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-619">9,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-620">10,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-621">5,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-622">5,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-623">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">U.S. includes the United States and U.S. territories.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At April&#160;26, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-8" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="f-624">1.0</ix:nonFraction>&#160;billion of rebates were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-625">574</ix:nonFraction>&#160;million of rebates were classified as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheet. At April&#160;28, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-8" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="f-626">1.1</ix:nonFraction> billion of rebates were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-627">555</ix:nonFraction> million of rebates were classified as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheet. During fiscal year 2024, adjustments to rebate and return reserves recognized in revenue that were included in the rebate and return reserves at the beginning of the period were <ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-628">not</ix:nonFraction> material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-514-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue and Remaining Performance Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue at April&#160;26, 2024 and April&#160;28, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-629">453</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-630">405</ix:nonFraction>&#160;million, respectively. At April&#160;26, 2024 and April&#160;28, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-631">352</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-632">314</ix:nonFraction>&#160;million was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-633">101</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-634">91</ix:nonFraction>&#160;million was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. During the fiscal year ended&#160;April&#160;26, 2024, the Company recognized&#160;$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-635">324</ix:nonFraction> million&#160;of revenue that was included in deferred revenue as of&#160;April&#160;28, 2023. During the fiscal year ended April&#160;28, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-636">240</ix:nonFraction> million of revenue that was included in deferred revenue at April&#160;29, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At April&#160;26, 2024, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="f-637">0.5</ix:nonFraction>&#160;billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="f-638">two years</ix:nonNumeric>.</span></div></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_151"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-639" continuedAt="f-639-1" escape="true">Acquisitions and Dispositions </ix:nonNumeric></span></div><ix:continuation id="f-639-1" continuedAt="f-639-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had acquisitions during fiscal years 2024 and 2023 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future, yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The results of operations of acquired businesses have been included in the Company&#8217;s consolidated statements of income since the date each business was acquired. The results of operations of acquired businesses and the pro forma impact of the acquisitions during fiscal years 2024 and 2023 was not significant, either individually or in the aggregate, to the consolidated results of the Company. Purchase price allocation adjustments for fiscal years 2024 and 2023 business combinations were not significant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2024</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of net assets acquired during the fiscal year ended April&#160;26, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-640">335</ix:nonFraction>&#160;million. Based on preliminary valuations, assets acquired were primarily comprised of $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-641">131</ix:nonFraction>&#160;million of goodwill, $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-642">150</ix:nonFraction>&#160;million of IPR&amp;D, and $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-643">29</ix:nonFraction>&#160;million of technology-based intangible assets with estimated useful lives of <ix:nonNumeric contextRef="c-192" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-644">10</ix:nonNumeric> years. For tax purposes, $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:GoodwillImpairmentLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-645">51</ix:nonFraction>&#160;million of goodwill is deductible while $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:GoodwillNotAllocatedAmount" format="ixt:num-dot-decimal" scale="6" id="f-646">80</ix:nonFraction>&#160;million is not deductible. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:BusinessAcquisitionPriceContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-647">30</ix:nonFraction>&#160;million of non-cash contingent consideration liabilities in connection with these business combinations during the fiscal year ended April&#160;26, 2024, which are comprised of revenue and product development milestone-based payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intersect ENT</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2022, the Company acquired Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader. The acquisition expands the Neuroscience segment portfolio of products used during ENT procedures, and combined with the Company's navigation, powered instruments, and existing tissue health products, offers a broader suite of solutions to assist surgeons treating patients who suffer from chronic rhinosinusitis (CRS). Total consideration, net of cash acquired, for the transaction, in which the Company acquired all outstanding shares of Intersect ENT for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-648">28.25</ix:nonFraction> per share, was $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="f-649">1.2</ix:nonFraction>&#160;billion consisting of $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-650">1.1</ix:nonFraction>&#160;billion of cash and $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-651">98</ix:nonFraction>&#160;million previously held investments in Intersect ENT. The Company acquired $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-652">615</ix:nonFraction>&#160;million of goodwill, $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-653">635</ix:nonFraction>&#160;million of technology-based intangible assets, $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-654">35</ix:nonFraction>&#160;million of customer-related intangible assets, and $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-655">13</ix:nonFraction>&#160;million of tradenames with estimated useful lives of <ix:nonNumeric contextRef="c-193" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-656">20</ix:nonNumeric> years. The goodwill is not deductible for tax purposes. Revenue and net loss attributable to Intersect ENT since the date of acquisition as well as costs incurred in connection with the acquisition included in the consolidated statements of income were not significant for fiscal year 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affera, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Company acquired Affera, Inc. (Affera) a privately-held company focused on the development of cardiac mapping and navigation systems and catheter-based cardiac ablation technologies. The acquisition expands the Cardiovascular segment suite of advanced cardiac ablation products and accessories, including its first cardiac mapping and navigation platform. Total consideration, net of cash acquired for the transaction, was $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-657">904</ix:nonFraction>&#160;million. The Company acquired $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-658">660</ix:nonFraction> million of goodwill and $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-659">300</ix:nonFraction> million of IPR&amp;D, which was capitalized into intangible assets during the fourth quarter of fiscal year 2023. The goodwill is not deductible for tax purposes. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="mdt:BusinessAcquisitionContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-660">201</ix:nonFraction> million of non-cash contingent consideration liabilities in connection with the acquisition, which are comprised of product development milestone-based payments. Revenue and net loss attributable to Affera since the date of acquisition as well as costs incurred in connection with the acquisition included in the consolidated statements of income were not significant for fiscal year 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-639-2" continuedAt="f-639-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-661" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of the assets acquired and liabilities assumed were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intersect ENT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affera</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="f-662">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="f-663">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="f-664">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:fixed-zero" scale="6" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:Goodwill" scale="6" id="f-666">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:Goodwill" scale="6" id="f-667">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="f-668">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="f-669">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="f-670">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="f-671">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="6" id="f-672">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="6" id="f-673">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="6" id="f-674">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="6" id="f-675">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="f-676">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="f-677">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="6" id="f-678">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="6" id="f-679">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="f-680">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="f-681">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-682">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="f-683">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Acquisitions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquisitions, other than Intersect ENT and Affera, the acquisition date fair value of net assets acquired during fiscal year 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-684">123</ix:nonFraction> million. Assets acquired were primarily comprised of $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-685">66</ix:nonFraction> million of goodwill and $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-686">57</ix:nonFraction>&#160;million of technology-based intangible assets with estimated useful lives of <ix:nonNumeric contextRef="c-202" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-687">16</ix:nonNumeric> years. The goodwill is deductible for tax purposes. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-6" name="mdt:BusinessAcquisitionPriceContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-688">73</ix:nonFraction>&#160;million of non-cash contingent consideration liabilities in connection with these acquisitions during fiscal year 2023, which are comprised of revenue and product development milestone-based payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disposal Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ventilator Product Line Exit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2024, the Company announced the decision to exit its ventilator product line and retain and combine the remaining Patient Monitoring and Respiratory Interventions (PMRI) businesses into one business unit called Acute Care and Monitoring (ACM). In connection with this decision, the Company recorded pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="6" id="f-689">439</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-690">369</ix:nonFraction>&#160;million recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="f-691">70</ix:nonFraction>&#160;million recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income in fiscal year 2024. The charges included $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" format="ixt:num-dot-decimal" scale="6" id="f-692">371</ix:nonFraction>&#160;million of non-cash impairments and write-downs primarily related to $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-693">295</ix:nonFraction>&#160;million of long-lived intangible asset impairments and $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-694">70</ix:nonFraction>&#160;million of inventory-write downs. The other charges primarily related to contract cancellation costs and severance. The Company will continue to honor existing ventilator contracts to serve the needs of its customers and their patients.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renal Care Solutions (RCS) Disposition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, the Company and DaVita Inc. (DaVita) entered into a definitive agreement for the Company to sell half of its RCS business, and on April 1, 2023, completed the transaction. This sale is part of an agreement between Medtronic and DaVita to form a new, independent kidney care-focused medical device company (&#8220;Mozarc Medical&#8221; or "Mozarc") with equal equity ownership. At closing, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="f-695">45</ix:nonFraction>&#160;million cash consideration, recorded non-cash contingent consideration receivables valued at $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-696">195</ix:nonFraction>&#160;million, made an additional cash investment of $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-6" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-697">224</ix:nonFraction>&#160;million, and retained a <ix:nonFraction unitRef="number" contextRef="c-208" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-698">50</ix:nonFraction>% non-controlling equity interest in Mozarc valued at $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-6" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="6" id="f-699">307</ix:nonFraction>&#160;million. For the contingent consideration receivables, the maximum consideration the Company could receive in the future is $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-700">300</ix:nonFraction>&#160;million based on the achievement of certain milestones, as further described below. The Company recorded non-cash pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-701">136</ix:nonFraction>&#160;million in fiscal year 2023, primarily related to impairment of goodwill and changes in the carrying amount of the disposal group, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Refer to Note 9 to the consolidated financial statements for additional information on the goodwill impairment. Refer to Note 5 to the consolidated financial statements for additional information on the Company&#8217;s retained <ix:nonFraction unitRef="number" contextRef="c-212" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-702">50</ix:nonFraction>% equity investment in Mozarc as a result of this transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the sale of the RCS business did not meet the criteria to be classified as discontinued operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-639-3" continuedAt="f-639-4"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Mechanical Circulatory Support (MCS) Business Exit</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company announced the decision to stop the distribution and sale of the Medtronic HVAD System. In connection with this decision, the Company recorded pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="6" id="f-703">881</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-704">58</ix:nonFraction>&#160;million recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> costs of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-705">823</ix:nonFraction>&#160;million recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statement of income in fiscal year 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charges included $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" format="ixt:num-dot-decimal" scale="6" id="f-706">515</ix:nonFraction>&#160;million of non-cash impairments and write-downs primarily related to $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-707">409</ix:nonFraction>&#160;million of <span style="-sec-ix-hidden:f-708">intangible asset impairments</span> and $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-709">58</ix:nonFraction>&#160;million of inventory write-downs. The Company also recorded charges of $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="f-710">366</ix:nonFraction>&#160;million for commitments and obligations associated with the decision, which included charges for patient support obligations, restructuring, and other associated costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration liabilities at April&#160;26, 2024 and April&#160;28, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-711">149</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-712">206</ix:nonFraction> million, respectively. At April&#160;26, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-713">96</ix:nonFraction> million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-714">53</ix:nonFraction> million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. At April&#160;28, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-715">34</ix:nonFraction> million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-716">171</ix:nonFraction> million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="f-717" continuedAt="f-717-1" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-718">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-719">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:BusinessAcquisitionPriceContingentConsideration" scale="6" id="f-720">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:BusinessAcquisitionPriceContingentConsideration" scale="6" id="f-721">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:BusinessAcquisitionContingentConsiderationMilestonePayment" scale="6" id="f-722">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:BusinessAcquisitionContingentConsiderationMilestonePayment" scale="6" id="f-723">154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-724">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-725">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture-related and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" format="ixt:fixed-zero" scale="6" id="f-726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="mdt:BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" scale="6" id="f-727">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-728">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-729">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-730" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:26.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue and other performance-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-731">80</ix:nonFraction>&#160;</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-216" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-732">16.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-217" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-733">28.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-218" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-734">20.3</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product development and other milestone-based payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-735">69</ix:nonFraction>&#160;</span></td><td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-736">5.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-221" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-737">5.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-222" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-738">5.5</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-639-4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of our RCS business as further discussed above, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2025 through 2029. The fair value of the contingent consideration receivable at April 26, 2024 and April 28, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-739">58</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-740">195</ix:nonFraction>&#160;million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, and was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. </span></div><ix:continuation id="f-717-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" scale="6" id="f-741">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" format="ixt:fixed-zero" scale="6" id="f-742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="mdt:BusinessAcquisitionPriceContingentConsideration" format="ixt:fixed-zero" scale="6" id="f-743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="mdt:BusinessAcquisitionPriceContingentConsideration" scale="6" id="f-744">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" sign="-" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" scale="6" id="f-745">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" format="ixt:fixed-zero" scale="6" id="f-746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" scale="6" id="f-747">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" scale="6" id="f-748">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_154"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-749" continuedAt="f-749-1" escape="true">Restructuring Charges </ix:nonNumeric></span></div><ix:continuation id="f-749-1" continuedAt="f-749-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2024, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-750">389</ix:nonFraction> million of restructuring and associated costs primarily related to employee termination benefits and facility consolidations to support cost reduction initiatives. In fiscal years 2023 and 2022, restructuring costs primarily related to Enterprise Excellence and Simplification restructuring programs, both of which were substantially completed as of the end fiscal year 2023. Enterprise Excellence was designed to leverage the Company&#8217;s global size and scale to focus on global operations, and functional and commercial optimization, and had total cumulative pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="f-751">1.8</ix:nonFraction> billion. Simplification was designed to focus the organization on accelerating innovation, enhancing customer experience, driving revenue growth and winning market share, and had total cumulative pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="f-752">0.5</ix:nonFraction> billion. In addition, in the fourth quarter of fiscal year 2023, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-753">0.3</ix:nonFraction> billion of restructuring charges primarily related to employee termination benefits to support cost reduction initiatives. These charges were incremental to charges incurred under our Enterprise Excellence and Simplification programs noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and voluntary early retirement benefits in fiscal year 2023. Associated costs primarily include salaries and wages of employees that are fully-dedicated to restructuring programs, consulting fees, and asset write-offs.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-754" continuedAt="f-754-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of restructuring costs in the consolidated statements of income: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-755">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-756">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-757">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-758">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-759">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-760">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-761">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-762">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-763">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring and associated costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-764">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-765">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-766">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) In fiscal year 2023, restructuring charges, net included $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-767">94</ix:nonFraction>&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-754-1" continuedAt="f-754-2"><ix:continuation id="f-749-2" continuedAt="f-749-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the activity related to restructuring programs for fiscal years 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Termination Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Associated and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-768">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-769">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-770">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-771">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-772">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-773">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-774">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-775">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-776">433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="f-777">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="f-778">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="f-779">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-780">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-781">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-782">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-783">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-784">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-785">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-786">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-787">161</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-788">453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled non-cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="f-789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="f-790">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="f-791">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="f-792">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:RestructuringReserveAccrualAdjustment1" format="ixt:fixed-zero" scale="6" id="f-793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="f-794">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-795">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-796">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-797">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In fiscal year 2023, restructuring charges, net included $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-798">94</ix:nonFraction>&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages. These costs are not included in the table summarizing restructuring charges above, as they are associated with costs that are accounted for under the pension and post-retirement rules.</span></div></ix:continuation></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-754-2" continuedAt="f-754-3"><ix:continuation id="f-749-3" continuedAt="f-749-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"><ix:continuation id="f-754-3"><ix:continuation id="f-749-4">Accrual adjustments relate to certain employees identified for termination finding other positions within the Company or contract terminations being settled for less than originally estimated.</ix:continuation></ix:continuation> </span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_157"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-799" continuedAt="f-799-1" escape="true">Financial Instruments </ix:nonNumeric></span></div><ix:continuation id="f-799-1" continuedAt="f-799-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-800" continuedAt="f-800-1" escape="true">The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;26, 2024 and April&#160;28, 2023:</ix:nonNumeric></span></div><ix:continuation id="f-800-1" continuedAt="f-800-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.904%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-801">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-803">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-804">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-805">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-807">3,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-808">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-809">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-810">3,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-811">3,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-813">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-815">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-816">804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-817">804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-819">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-820">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-821">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-822">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-823">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-825">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-826">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-828">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-829">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-831">941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-832">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-833">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-834">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-835">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-837">6,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-838">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-839">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-840">6,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-841">6,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-843">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-845">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-846">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-848">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-849">6,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-850">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-851">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-852">6,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-853">6,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-854">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-799-2" continuedAt="f-799-3"><ix:continuation id="f-800-2"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.904%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-855">527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-857">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-858">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-859">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-861">4,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-862">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-863">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-864">3,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-865">3,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-867">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-869">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-870">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-871">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-873">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-875">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-876">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-877">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-879">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-882">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-883">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-885">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-888">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-889">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-294" xsi:nil="true" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" id="f-890"/></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-891">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-893">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-894">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-895">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-897">6,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-898">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-899">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-900">5,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-901">5,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-903">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-904">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-905">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-906">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-907">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-908">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-909">6,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-910">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-911">305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-912">6,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-913">6,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-914">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost of debt securities excludes accrued interest, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-915" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the gross unrealized losses and fair values of the Company&#8217;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;26, 2024 and April&#160;28, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-916">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-917">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-918">2,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-919">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-920">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-921">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-922">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-923">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-926">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-927">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-930">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-931">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-932">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-934">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-935">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-936">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-937">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-938">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-939">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-940">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-941">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-942">2,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-943">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-944">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-945">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-946">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-947">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-948">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-949">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-950">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-951">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-953">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-954">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-955">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-958">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-959">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-960">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-961">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-962">4,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-963">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the fiscal years ended April&#160;26, 2024 and April&#160;28, 2023. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-799-3" continuedAt="f-799-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:GainLossOnInvestmentsTextBlock" id="f-964" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to the Company&#8217;s available-for-sale debt securities portfolio is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 29, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-965">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-966">7,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-967">9,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-968">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-969">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-970">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-971">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-972">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-973">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-974" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of available-for-sale debt securities at April&#160;26, 2024 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-975">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="f-976">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-977">3,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-978">3,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="f-979">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="f-980">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-981">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="f-982">967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-983">6,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-984">6,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the consolidated statements of income. For fiscal years 2024, 2023, and 2022 there was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-985">597</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-986">386</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-987">186</ix:nonFraction>&#160;million of interest income, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities, Equity Method Investments, and Other Investments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in equity securities with readily determinable fair values, equity method investments for which the Company has elected the fair value option, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments for which the Company has elected the fair value option are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses a discounted cash flow methodology, taking into consideration various assumptions including discount rate, and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values, and that are not accounted for via the fair value option, are included within Level 3 of the fair value hierarchy, as they are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="c-1" name="mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" id="f-988" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's equity and other investments at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;26, 2024 and April&#160;28, 2023, which are classified as primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments with readily determinable fair value (marketable equity securities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-989">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-990">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments for which the fair value option has been elected</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="f-991">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="f-992">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments without readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-993">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-994">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="f-995">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="f-996">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity and other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-997">1,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-998">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses on the Company's portfolio of equity and other investments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. During the fiscal year ended April&#160;26, 2024, there were $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-6" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-999">291</ix:nonFraction>&#160;million of net unrealized losses on equity securities and other investments still held at April&#160;26, 2024. During the fiscal year ended April&#160;28, 2023, there were $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-6" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1000">56</ix:nonFraction>&#160;million of net unrealized gains on equity securities and other investments still held at April&#160;28, 2023. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-799-4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mozarc Medical Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described in Note 3, on April 1, 2023 the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a <ix:nonFraction unitRef="number" contextRef="c-208" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-1001">50</ix:nonFraction>% equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. During the fiscal year ended April&#160;26, 2024, the Company recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="6" id="f-1002">220</ix:nonFraction>&#160;million, primarily driven by the timing of anticipated product launches, historical financial results, and projections of future cash flows.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-1003" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1004">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-1006">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="f-1007">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional cash investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:AdditionalCashInvestment" format="ixt:fixed-zero" scale="6" id="f-1008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:AdditionalCashInvestment" scale="6" id="f-1009">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" scale="6" id="f-1010">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" format="ixt:fixed-zero" scale="6" id="f-1011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1012">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1013">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_160"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1014" continuedAt="f-1014-1" escape="true">Financing Arrangements </ix:nonNumeric></span></div><ix:continuation id="f-1014-1" continuedAt="f-1014-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="f-1015" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt obligations consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank borrowings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="f-1016">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="f-1017">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-1018">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-1019">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="f-1020">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="f-1021">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1022"><span style="-sec-ix-hidden:f-1023">Current debt obligations</span></span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1024">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DebtCurrent" scale="6" id="f-1025">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Paper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   On January 26, 2015, Medtronic Global Holdings S.C.A. (Medtronic Luxco), an entity organized under the laws of Luxembourg, entered into various agreements pursuant to which Medtronic Luxco may issue United States Dollar-denominated unsecured commercial paper notes (the 2015 CP Program) on a private placement basis, and on January 31, 2020 Medtronic Luxco entered into various agreements pursuant to which Medtronic Luxco may issue Euro-denominated unsecured commercial paper notes (the 2020 CP Program) on a private placement basis. The maximum aggregate amount outstanding at any time under the 2015 CP Program and the 2020 CP Program together may not exceed the equivalent of $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-8" name="mdt:CommercialPaperMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1026">3.5</ix:nonFraction>&#160;billion. The Company and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the 2015 CP Program and the 2020 CP Program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="f-1027">1.1</ix:nonFraction>&#160;billion commercial paper outstanding at April&#160;26, 2024. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately <ix:nonNumeric contextRef="c-322" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="f-1028">20</ix:nonNumeric> days and the weighted average interest rate was <ix:nonFraction unitRef="number" contextRef="c-321" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" format="ixt:num-dot-decimal" scale="-2" id="f-1029">5.45</ix:nonFraction> percent. There was <ix:nonFraction unitRef="usd" contextRef="c-323" decimals="0" name="us-gaap:DebtCurrent" format="ixt:fixed-zero" scale="0" id="f-1030">no</ix:nonFraction> commercial paper outstanding at April&#160;28, 2023. During fiscal year 2023, the weighted average original maturity of the commercial paper outstanding was approximately <ix:nonNumeric contextRef="c-324" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="f-1031">22</ix:nonNumeric> days and the weighted average interest rate was <ix:nonFraction unitRef="number" contextRef="c-325" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" format="ixt:num-dot-decimal" scale="-2" id="f-1032">4.34</ix:nonFraction> percent. The issuance of commercial paper reduces the amount of credit available under the Company's existing credit facility, defined below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Line of Credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   On December 12, 2023, Medtronic Luxco, as borrower, entered into an amendment to its amended and restated credit agreement (Credit Facility), by and among Medtronic, Medtronic, Inc., Medtronic Luxco, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent and issuing bank, extending the maturity date of the Credit Facility to December 2028.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility provides for a $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1033">3.5</ix:nonFraction> billion&#160;<ix:nonNumeric contextRef="c-327" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1034">five-year</ix:nonNumeric> unsecured revolving credit facility (Credit Facility). At each anniversary date of the Credit Facility, we can request a <ix:nonNumeric contextRef="c-327" name="mdt:LineOfCreditFacilityLengthOfExtension" format="ixt-sec:durwordsen" id="f-1035">one-year</ix:nonNumeric> extension of the maturity date. The Credit Facility provides the Company with the ability to increase its borrowing capacity by an additional $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="INF" name="mdt:LineOfCreditFacilityAdditionalBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1036">1.0</ix:nonFraction> billion at any time during the term of the agreement. The Company and Medtronic, Inc. have guaranteed the obligations of the borrowers under the Credit Facility, and Medtronic Luxco will also guarantee the obligations of any designated borrower. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At April&#160;26, 2024 and April&#160;28, 2023, <ix:nonFraction unitRef="usd" contextRef="c-328" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-1037"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-1038">no</ix:nonFraction></ix:nonFraction> amounts were outstanding under the Credit Facility.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1014-2" continuedAt="f-1014-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rates on advances on the Credit Facility are determined by a pricing matrix based on the Company&#8217;s long-term debt ratings, assigned by Standard &amp; Poor&#8217;s Ratings Services and Moody&#8217;s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with all covenants related to the Credit Facility.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-1039" escape="true"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term debt obligations consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.238%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity by Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-330" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1040">0.250</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1041">six</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1042">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-330" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1043">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1044">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-332" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1045">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-333" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1046">2.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1047">three</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1048">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-333" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1049">2.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1050">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-335" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1051">2.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-336" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1052">0.000</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1053">five</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1054">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-336" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1055">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1056">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-338" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1057">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-339" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1058">1.125</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1059">eight</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1060">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-339" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1061">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1062">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-341" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1063">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-342" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1064">4.250</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1065">five</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1066">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-342" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1067">4.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1068">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-344" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1069">4.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-345" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1070">3.000</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1071">six</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1072">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-345" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1073">3.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1074">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-347" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1075">3.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-348" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1076">0.375</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1077">eight</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1078">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-348" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1079">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1080">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-350" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1081">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-351" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1082">1.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1083">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1084">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-351" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1085">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1086">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-353" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1087">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-354" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1088">1.000</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1089">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1090">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-354" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1091">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1092">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-356" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1093">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-357" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1094">3.125</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1095">nine</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1096">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-357" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1097">3.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1098">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-359" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1099">3.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-360" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1100">0.750</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1101">twelve</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1102">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-360" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1103">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1104">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-362" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1105">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-363" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1106">4.500</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1107">ten</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1108">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-363" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1109">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1110">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-365" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1111">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-366" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1112">3.375</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1113">twelve</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1114">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-366" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1115">3.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1116">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-368" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1117">3.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-369" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1118">4.375</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1119">twenty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1120">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-369" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1121">4.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1122">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-371" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1123">4.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-372" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1124">6.550</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1125">thirty</span>-year 2007 CIFSA senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1126">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-372" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1127">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1128">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-374" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1129">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-375" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1130">2.250</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1131">twenty</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1132">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-375" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1133">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1134">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-377" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1135">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-378" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1136">6.500</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1137">thirty</span>-year 2009 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1138">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-378" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1139">6.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1140">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-380" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1141">6.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-381" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1142">1.500</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1143">twenty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1144">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-381" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1145">1.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1146">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-383" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1147">1.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-384" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1148">5.550</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1149">thirty</span>-year 2010 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1150">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-384" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1151">5.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1152">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-386" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1153">5.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-387" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1154">1.375</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1155">twenty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1156">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-387" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1157">1.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1158">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-389" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1159">1.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-390" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1160">4.500</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1161">thirty</span>-year 2012 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1162">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-390" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1163">4.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1164">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-392" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1165">4.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-393" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1166">4.000</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1167">thirty</span>-year 2013 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1168">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-393" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1169">4.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1170">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-395" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1171">4.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-396" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1172">4.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1173">thirty</span>-year 2014 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1174">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-396" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1175">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1176">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-398" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1177">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-399" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1178">4.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1179">thirty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1180">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-399" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1181">4.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1182">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-401" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1183">4.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1184">1.750</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1185">thirty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1186">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-402" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1187">1.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1188">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-404" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1189">1.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-405" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1190">1.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1191">thirty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1192">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-405" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1193">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1194">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-407" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1195">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1196"><span style="-sec-ix-hidden:f-1197">Finance lease obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-1198">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1199">10.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-1200">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1201">9.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-2051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="f-1202">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="f-1203">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-1204">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-1205">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-1206">23,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-1207">24,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Notes   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Medtronic Luxco issued <ix:nonFraction unitRef="tranche" contextRef="c-408" decimals="INF" name="mdt:DebtInstrumentNumberofTranches" format="ixt-sec:numwordsen" scale="0" id="f-1208">four</ix:nonFraction> tranches of Euro-denominated Senior Notes with an aggregate principal of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1209">3.5</ix:nonFraction>&#160;billion, with maturities ranging from fiscal year 2026 to 2035, resulting in cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-8" name="us-gaap:ProceedsFromRepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="f-1210">3.4</ix:nonFraction>&#160;billion, net of discounts and issuance costs. The Company used the net proceeds to repay at maturity &#8364;<ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="f-1211">750</ix:nonFraction>&#160;million of Medtronic Luxco Senior Notes for $<ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="f-1212">772</ix:nonFraction>&#160;million&#160;of total consideration in December 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-412" decimals="-8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1213">2.8</ix:nonFraction>&#160;billion of Medtronic Luxco Senior Notes for $<ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-8" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="f-1214">2.9</ix:nonFraction>&#160;billion of total consideration in March 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1014-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Medtronic Luxco issued <ix:nonFraction unitRef="tranche" contextRef="c-414" decimals="INF" name="mdt:DebtInstrumentNumberofTranches" format="ixt-sec:numwordsen" scale="0" id="f-1215">two</ix:nonFraction> tranches of USD-denominated Senior Notes with an aggregate principal of $<ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1216">2.0</ix:nonFraction>&#160;billion, with maturities ranging from fiscal year 2028 to 2033, resulting in cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-8" name="us-gaap:ProceedsFromRepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="f-1217">2.0</ix:nonFraction>&#160;billion, net of discounts and issuance costs. The Company used the net proceeds supplemented by additional cash to repay the &#165;<ix:nonFraction unitRef="eur" contextRef="c-413" decimals="-9" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="f-1218">297</ix:nonFraction>&#160;billion Fiscal 2023 Loan Agreement discussed below for $<ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-8" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="f-1219">2.3</ix:nonFraction>&#160;billion of total consideration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to year-end, on June 3, 2024, Medtronic Inc. issued <ix:nonFraction unitRef="tranche" contextRef="c-416" decimals="INF" name="mdt:DebtInstrumentNumberofTranches" format="ixt-sec:numwordsen" scale="0" id="f-1220">four</ix:nonFraction> tranches of EUR-denominated Senior Notes with an aggregate principal of &#8364;<ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1221">3.0</ix:nonFraction>&#160;billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-8" name="us-gaap:ProceedsFromRepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="f-1222">3.2</ix:nonFraction>&#160;billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Euro-denominated debt issued in September 2022 is designated as a net investment hedge of certain of the Company's European operations. Refer to Note 7 for additional information regarding the net investment hedge.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Agreements   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Medtronic Luxco entered into a term loan agreement (Fiscal 2023 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2023 Loan Agreement provides an unsecured term loan in an aggregate principal amount of up to &#165;<ix:nonFraction unitRef="jpy" contextRef="c-419" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1223">300</ix:nonFraction>&#160;billion with a term of <ix:nonNumeric contextRef="c-420" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="f-1224">364</ix:nonNumeric> days. Borrowings under the Fiscal 2023 Loan Agreement bear interest at the TIBOR Rate (as defined in the Fiscal 2023 Loan Agreement) plus a margin of <ix:nonFraction unitRef="number" contextRef="c-421" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1225">0.40</ix:nonFraction>% per annum. Medtronic plc and Medtronic, Inc. guaranteed the obligations of Medtronic Luxco under the Fiscal 2023 Loan Agreement. In May and June 2022, Medtronic Luxco borrowed an aggregate of &#165;<ix:nonFraction unitRef="jpy" contextRef="c-420" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="9" id="f-1226">297</ix:nonFraction>&#160;billion, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-8" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="9" id="f-1227">2.3</ix:nonFraction>&#160;billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $<ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1228">1.9</ix:nonFraction>&#160;billion of Medtronic Inc.'s <ix:nonFraction unitRef="number" contextRef="c-423" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1229">3.500</ix:nonFraction>% Senior Notes due 2025 for $<ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-8" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="f-1230">1.9</ix:nonFraction>&#160;billion of total consideration, and $<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1231">368</ix:nonFraction>&#160;million of Medtronic Luxco's <ix:nonFraction unitRef="number" contextRef="c-426" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1232">3.350</ix:nonFraction>% Senior Notes due 2027 for $<ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-1233">376</ix:nonFraction>&#160;million of total consideration. The Company recognized a total loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-1234">53</ix:nonFraction>&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income during fiscal year 2023, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. During the fourth quarter of fiscal year 2023, the Company repaid the term loan in full, including interest.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1235" escape="true"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1236">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-1237">2,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="f-1238">1,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1239">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1240">2,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1241">16,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1242">25,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal years 2024, 2023, and 2022, there was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpenseBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1243">916</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:InterestExpenseBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1244">743</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:InterestExpenseBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1245">553</ix:nonFraction> million of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and charges recognized in connection with the early redemption of senior notes, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024, the estimated fair value of the Company&#8217;s Senior Notes was $<ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="f-1246">21.2</ix:nonFraction> billion compared to a principal value of $<ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1247">24.0</ix:nonFraction> billion. At April&#160;28, 2023, the estimated fair value was $<ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="f-1248">21.7</ix:nonFraction> billion compared to a principal value of $<ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1249">24.5</ix:nonFraction> billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.</span></div></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_166"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-1250" continuedAt="f-1250-1" escape="true">Derivatives and Currency Exchange Risk Management </ix:nonNumeric></span></div><ix:continuation id="f-1250-1" continuedAt="f-1250-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company uses derivative instruments and foreign currency denominated debt to manage the impact that currency exchange rate and interest rate changes have on reported financial statements. The Company does not enter into derivative contracts for speculative purposes.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1250-2" continuedAt="f-1250-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cash Flow Hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, foreign currency forward and option contracts are designated as a cash flow hedge. Changes in the fair value of these derivatives are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash flow hedges will mature within the subsequent <ix:nonNumeric contextRef="c-431" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durwordsen" id="f-1251">three-year</ix:nonNumeric> period. At April&#160;26, 2024 and April&#160;28, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1252">229</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1253">93</ix:nonFraction> million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company expects that $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1254">158</ix:nonFraction> million of after-tax net unrealized gains at April&#160;26, 2024 will be recognized in the consolidated statements of income over the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instruments that are designated as net investment hedges, the gains or losses are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on a straight-line basis over the term of the hedge. During the twelve months ended April&#160;26, 2024 and April&#160;28, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="f-1255">197</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="f-1256">107</ix:nonFraction> million, respectively, of after-tax unrealized gains related to excluded components in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1257">interest expense</span>, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cash flows related to the Company&#8217;s derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Undesignated Derivatives</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency forward exchange contracts to offset the Company&#8217;s exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Company&#8217;s undesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Instruments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-1258" continuedAt="f-1258-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of the Company's outstanding instruments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in billions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1259">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1260">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1261">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1262">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1263">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1264">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undesignated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1265">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1266">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;26, 2024, includes derivative contracts with a notional value of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-1267">5.0</ix:nonFraction> billion, or $<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-1268">5.4</ix:nonFraction> billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#165;<ix:nonFraction unitRef="jpy" contextRef="c-441" decimals="-9" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-1269">322</ix:nonFraction> billion, or $<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-1270">2.1</ix:nonFraction> billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;26, 2024, includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-436" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-1271">16.0</ix:nonFraction> billion, or $<ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-1272">17.1</ix:nonFraction> billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2051.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1250-3" continuedAt="f-1250-4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments</span></div><ix:continuation id="f-1258-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.704%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Reclassified into Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1273">416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1274">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1275">953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1276">312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1277">703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1278">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1279">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1280">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1281">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1282">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1283">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1284">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1285">431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1286">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-1287">2,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1291">202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1292">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="f-1293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-1297">1,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1298">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-1299">3,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" scale="6" id="f-1300">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" scale="6" id="f-1301">706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" scale="6" id="f-1302">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="f-1303">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="f-1304">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="f-1305">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheet Presentation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-1306" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;26, 2024 and April&#160;28, 2023. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1307">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1308">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1309">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1310">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1311">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1312">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1313">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1314">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1315">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1316">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1317">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1318">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1319">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1320">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1321">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-467" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1322">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1323">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1324">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1325">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1326">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1250-4" continuedAt="f-1250-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-1327" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"><tr><td style="width:1.0%"/><td style="width:47.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.220%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1328">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1329">Derivative Liabilities</span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1330">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1331">Derivative Liabilities</span></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1332">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1333">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1334">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1335">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OffsettingLiabilitiesTableTextBlock" id="f-1337" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:OffsettingAssetsTableTextBlock" id="f-1336" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1338">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="f-1339">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="f-1340">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" scale="6" id="f-1341">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1342">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="f-1343">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="f-1344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" format="ixt:fixed-zero" scale="6" id="f-1345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability" scale="6" id="f-1346">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" format="ixt:fixed-zero" scale="6" id="f-1347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" scale="6" id="f-1348"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" scale="6" id="f-1349">101</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet" scale="6" id="f-1350">492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1351">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="f-1352">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="f-1353">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" scale="6" id="f-1354">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1355">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="f-1356">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="f-1357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" scale="6" id="f-1358">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability" scale="6" id="f-1359">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" format="ixt:fixed-zero" scale="6" id="f-1360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" scale="6" id="f-1361">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet" scale="6" id="f-1362">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist principally of interest-bearing investments, derivative contracts, and trade accounts receivable. Global concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash and cash equivalents, investments, and certain other financial instruments (including currency exchange rate and interest rate derivative contracts) with various major financial institutions. The Company performs periodic evaluations of the relative credit standings of these financial institutions and limits the amount of credit exposure with any one institution. In addition, the Company has collateral credit agreements with its primary derivatives counterparties. Under these agreements, either party is required to post eligible collateral when the market value of transactions covered by the agreement exceeds specific thresholds, thus limiting credit exposure for both parties. As of April&#160;26, 2024 and April&#160;28, 2023, the Company received net cash collateral of $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" format="ixt:num-dot-decimal" scale="6" id="f-1363"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" format="ixt:num-dot-decimal" scale="6" id="f-1364">101</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" format="ixt:num-dot-decimal" scale="6" id="f-1365">11</ix:nonFraction> million, respectively, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="f-1250-5" continuedAt="f-1250-6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from its counterparties. Cash collateral posted is recorded as a reduction in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the offset recorded as an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. Cash collateral received is recorded as an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the offset recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1250-6"> in the consolidated balance sheets.</ix:continuation> </span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_169"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-1366" continuedAt="f-1366-1" escape="true">Inventories </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-1367" escape="true"><ix:continuation id="f-1366-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-1368">3,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-1369">3,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-1370">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-1371">789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-1372">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-1373">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1374">5,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1375">5,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ia6bfc65eaa654c3ebf593baab4e46685_172"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-1376" continuedAt="f-1376-1" escape="true">Goodwill and Other Intangible Assets </ix:nonNumeric></span></div><ix:continuation id="f-1376-1" continuedAt="f-1376-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-1377" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill by segment: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1378">7,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1379">11,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1380">19,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1381">2,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1382">40,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1383">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1384">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1387">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1388">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1389">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1392">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of RCS business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-1393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-1394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="f-1395">208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-1396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="f-1397">208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1398">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1399">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1400">170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1401">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1402">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1403">7,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1404">11,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1405">19,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1406">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1407">41,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1408">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1412">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1413">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1417">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1418">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1419">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1420">458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-1421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1422">565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1423">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1424">11,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1425">19,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1426">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1427">40,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described in Note 19, the Company had changes to the operating segments during fiscal year 2024. As of the beginning of fiscal year 2024, the Medical Surgical portfolio was separated into <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1428">two</ix:nonFraction> operating segments, and each new operating segment was considered a standalone reporting unit as of the beginning of fiscal year 2024. As a result of this change, the Company allocated all goodwill that was previously assigned to the Medical Surgical reporting unit to the Surgical/Endoscopy reporting unit and the Patient Monitoring/Respiratory Interventions (PMRI) reporting unit using a relative fair value allocation approach. The effected reporting units were tested for impairment before and after the alignment. <ix:nonFraction unitRef="usd" contextRef="c-108" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1429">No</ix:nonFraction> goodwill impairment was identified in either test as of the beginning of the fiscal year 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the fourth quarter of fiscal year 2024, the Company's operating segments changed again resulting in the <ix:nonFraction unitRef="reportingunit" contextRef="c-484" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-1430">two</ix:nonFraction> reporting units created in the first quarter to be combined into the Medical Surgical reporting unit. All goodwill that was previously assigned to the <ix:nonFraction unitRef="segment" contextRef="c-485" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-1431">two</ix:nonFraction> reporting units was combined into the Medical Surgical reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1432"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1433">no</ix:nonFraction></ix:nonFraction>t recognize any goodwill impairment charges during fiscal years 2024 or 2022. As a result of the agreement with DaVita, as disclosed in Note 3, the Company allocated $<ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" format="ixt:num-dot-decimal" scale="6" id="f-1434">208</ix:nonFraction>&#160;million of goodwill to the RCS business that met the criteria to be classified as held for sale during the first quarter of fiscal year 2023 and was subsequently sold on April 1, 2023. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1435">61</ix:nonFraction>&#160;million of goodwill impairment charges during fiscal year 2023. The goodwill impairment charges are recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1376-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-1437" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="f-1436" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gross carrying amount and accumulated amortization of intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1438">16,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1439">8,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1440">16,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1441">7,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1442">11,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1443">6,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1444">11,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1445">6,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1446">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1447">274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1448">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1449">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1450">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1451">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1452">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1453">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1454">28,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1455">15,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1456">29,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1457">14,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-496" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1458">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1459">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1460">295</ix:nonFraction>&#160;million of <span style="-sec-ix-hidden:f-1461">definite-lived intangible asset impairment charges</span> in connection with the decision to exit its ventilator product line. The intangible asset impairment charges primarily related to purchased technology, customer-related intangibles, and trade names. During fiscal year 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1462">409</ix:nonFraction>&#160;million of definite-lived intangible asset impairment charges in connection with the Company's decision to stop the distribution and sale of the Medtronic HVAD System. The intangible asset impairment charge primarily related to purchased technology and patents. The intangible asset impairment charges are recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Refer to Note 3 for additional information on what led to the impairments in fiscal year 2024 and 2022. The Company did <ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-1463">no</ix:nonFraction>t recognize any definite-lived intangible asset impairment charges during fiscal year 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible asset impairment charges were <ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-1464"><ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-1465"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-1466">not</ix:nonFraction></ix:nonFraction></ix:nonFraction> significant for fiscal year 2024, 2023, or 2022. Due to the nature of IPR&amp;D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="f-1467"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="f-1468"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="f-1469">1.7</ix:nonFraction></ix:nonFraction></ix:nonFraction> billion for fiscal years 2024, 2023 and 2022. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-1470" continuedAt="f-1470-1" escape="true">Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;26, 2024, excluding any possible future amortization associated with acquired IPR&amp;D which has not met technological feasibility, is as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1470-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1471">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-1472">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="f-1473">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1474">1,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1475">1,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_175"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-1476" continuedAt="f-1476-1" escape="true">Property, Plant, and Equipment </ix:nonNumeric></span></div><ix:continuation id="f-1476-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-1477" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment balances and corresponding estimated useful lives were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives <br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1478">6,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1479">6,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generally <ix:nonNumeric contextRef="c-503" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1480">2</ix:nonNumeric>-10, up to <ix:nonNumeric contextRef="c-504" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1481"><ix:nonNumeric contextRef="c-501" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1482">15</ix:nonNumeric></ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1483">2,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1484">2,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="c-507" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1485">10</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-1486">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-1487">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="c-510" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1488">20</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1489">2,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1490">2,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="c-513" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1491">40</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1492">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1493">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1494">14,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1495">14,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1496">7,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1497">8,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1498">6,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1499">5,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1500">954</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1501">999</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1502">974</ix:nonFraction> million was recognized in fiscal years 2024, 2023, and 2022, respectively.</span></div></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_178"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1503" continuedAt="f-1503-1" escape="true">Shareholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="f-1503-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Capital   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="9" id="f-1504">2.6</ix:nonFraction> billion Ordinary Shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1505">0.0001</ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="mdt:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-1506">40</ix:nonFraction> thousand Euro Deferred Shares, &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-27" decimals="INF" name="mdt:DeferredStockParorStatedValuePerShare" scale="0" id="f-1507">1.00</ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1508">127.5</ix:nonFraction> million Preferred Shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1509">0.20</ix:nonFraction> par value; and <ix:nonFraction unitRef="shares" contextRef="c-516" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-1510">500</ix:nonFraction> thousand A Preferred Shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-516" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1511">1.00</ix:nonFraction> par value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Euro Deferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="mdt:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-1512">40</ix:nonFraction> thousand Euro Deferred Shares, with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-27" decimals="INF" name="mdt:DeferredStockParorStatedValuePerShare" scale="0" id="f-1513">1.00</ix:nonFraction> per share. At April&#160;26, 2024, <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="mdt:DeferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1514"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="mdt:DeferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1515">no</ix:nonFraction></ix:nonFraction>&#160;Euro Deferred Shares were issued or outstanding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1516">127.5</ix:nonFraction> million of Preferred Shares, with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1517">0.20</ix:nonFraction> per share. At April&#160;26, 2024, <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1518"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1519">no</ix:nonFraction></ix:nonFraction>&#160;Preferred&#160;Shares were issued or outstanding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A Preferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes <ix:nonFraction unitRef="shares" contextRef="c-516" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-1520">500</ix:nonFraction> thousand A Preferred Shares, with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-516" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1521">1.00</ix:nonFraction> per share. At April&#160;26, 2024, <ix:nonFraction unitRef="shares" contextRef="c-516" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="f-1522">no</ix:nonFraction> A Preferred Shares were outstanding. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing, declaration, and payment of future dividends to holders of the Company's ordinary shares falls within the discretion of the Company's Board of Directors and depends upon many factors, including the statutory requirements of Irish law, the Company's earnings and financial condition, the capital requirements of the Company's businesses, industry practice and any other factors the Board of Directors deems relevant.&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ordinary Share Repurchase Program   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares are repurchased on occasion to support the Company&#8217;s stock-based compensation programs and to return capital to shareholders. During fiscal years 2024 and 2023, the Company repurchased approximately <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="f-1523">25</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="f-1524">6</ix:nonFraction> million shares, respectively, at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="mdt:StockRepurchaseProgramAveragePurchasePrice" scale="0" id="f-1525">83.04</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="mdt:StockRepurchaseProgramAveragePurchasePrice" scale="0" id="f-1526">91.31</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company's Board of Directors authorized $<ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1527">6.0</ix:nonFraction> billion for repurchase of the Company's ordinary shares. In March 2024, the Company's Board of Directors authorized an incremental $<ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1528">5.0</ix:nonFraction>&#160;billion for share repurchases. There is no specific time-period associated with these repurchase authorizations. At April&#160;26, 2024, the Company had used $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="f-1529">5.7</ix:nonFraction> billion of the $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1530">11.0</ix:nonFraction>&#160;billion authorized under the repurchase program, leaving approximately $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1531">5.3</ix:nonFraction> billion available for future repurchases. The Company accounts for repurchases of ordinary shares using the par value method and shares repurchased are cancelled.</span></div></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_181"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1532" continuedAt="f-1532-1" escape="true">Stock Purchase and Award Plans </ix:nonNumeric></span></div><ix:continuation id="f-1532-1" continuedAt="f-1532-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2024, the Company granted stock awards under the 2021 Medtronic plc Long Term Incentive Plan (2021 Plan). The 2021 Plan provides for the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock and cash-based awards. At April&#160;26, 2024, there were approximately <ix:nonFraction unitRef="shares" contextRef="c-519" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1533">88</ix:nonFraction> million shares available for future grants under the 2021 Plan.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1532-2" continuedAt="f-1532-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation Expense   </span><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-1534" continuedAt="f-1534-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2024, 2023, and 2022:</span></ix:nonNumeric></div><ix:continuation id="f-1534-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1535">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1536">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1537">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1538">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1539">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1540">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1541">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1542">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1543">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1544">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1545">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1546">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1547">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1548">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1549">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1550">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1551">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1552">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1553">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1554">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1555">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1556">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1557">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1558">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1559">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1560">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1561">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1562">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1563">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1564">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1565">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1566">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1567">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Options are granted at the exercise price, which is equal to the closing price of the Company&#8217;s ordinary shares on the grant date. The majority of the Company&#8217;s options are non-qualified options with a <span style="-sec-ix-hidden:f-1568">ten</span>-year life and a <span style="-sec-ix-hidden:f-1569">four</span>-year ratable vesting term. The Company uses the Black-Scholes option pricing model (Black-Scholes model) to determine the fair value of stock options at the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company&#8217;s stock price, and expected dividends. Expected volatility is based on a blend of historical volatility and an implied volatility of the Company&#8217;s ordinary shares. Implied volatility is based on market traded options of the Company&#8217;s ordinary shares.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1570" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1571">18.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1572">17.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1573">22.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions used:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1574">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-25" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1575">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-26" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1576">6.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1577">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1578">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1579">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1580">24.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1581">24.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1582">23.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1583">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1584">2.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1585">1.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1586" continuedAt="f-1586-1" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during fiscal year 2024:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Remaining Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;28, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-535" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1587">30,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-535" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1588">93.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-520" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-1589">4,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-520" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1590">86.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-520" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-1591">1,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-520" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1592">65.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-520" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1593">1,905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-520" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1594">98.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-536" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1595">32,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-536" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1596">93.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-520" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1597">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-1598">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-536" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1599">8,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-536" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1600">95.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-520" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1601">8.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="f-1602">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-536" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-1603">22,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-536" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1604">92.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-520" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1605">3.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-1606">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1532-3" continuedAt="f-1532-4"><ix:continuation id="f-1586-1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds from options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1607">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1608">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1609">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1610">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1611">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1612">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1613">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1614">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1615">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to outstanding stock options at April&#160;26, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1616">90</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-520" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1617">2.4</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Restricted stock units are expensed over the vesting period and are subject to forfeiture if employment terminates prior to the lapse of the restrictions. The expense recognized for restricted stock units is equal to the grant date fair value, which is equal to the closing stock price on the date of grant. The majority of the Company's restricted stock units either have a <ix:nonNumeric contextRef="c-537" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1618">four-year</ix:nonNumeric> ratable vesting term or cliff vest after <ix:nonNumeric contextRef="c-538" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1619">three years</ix:nonNumeric>. Restricted stock units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on restricted stock units during the vesting period.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-1620" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity during fiscal year 2024:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;28, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-539" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1621">5,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-539" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1622">102.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-540" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1623">3,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-540" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1624">82.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-540" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1625">1,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-540" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1626">102.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-540" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1627">526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-540" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1628">99.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-541" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1629">6,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-541" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1630">92.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2024, 2023, and 2022:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per restricted stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-540" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1631">82.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-542" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1632">91.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-543" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1633">127.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of restricted stock vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1634">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1635">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1636">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to restricted stock vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1637">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1638">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1639">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to restricted stock as of April&#160;26, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-1640">361</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-540" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1641">2.6</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Share Units  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Performance share units typically cliff vest after <ix:nonNumeric contextRef="c-526" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1642">three years</ix:nonNumeric>. The awards include three metrics: relative total shareholder return (rTSR), revenue growth, and return on investor capital (ROIC). rTSR is considered a market condition metric, and the expense is determined at the grant date and will not be adjusted even if the market condition is not met. Revenue growth and ROIC are considered performance metrics, and the expense is recorded over the performance period, which will be reassessed each reporting period based on the probability of achieving the various performance conditions. The number of shares earned at the end of the <ix:nonNumeric contextRef="c-526" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1643">three-year</ix:nonNumeric> period will vary, based on only actual performance, from <ix:nonFraction unitRef="number" contextRef="c-544" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1644">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-545" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1645">200</ix:nonFraction>% of the target number of performance share units granted. Performance share units are subject to forfeiture if employment terminates prior to the lapse of the restrictions. Performance share units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on performance share units for each component of the award during the vesting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value of the performance share units for each component individually. The fair value of the rTSR metric will be determined using the Monte Carlo valuation model. The fair value of the revenue growth and ROIC metrics are equal to the closing stock price on the grant date. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1532-4" continuedAt="f-1532-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="f-1646" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit activity during fiscal year 2024:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;28, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-546" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1647">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-546" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1648">119.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-526" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1649">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-526" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1650">104.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-526" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1651">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-526" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1652">129.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-526" decimals="-3" name="mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" scale="3" id="f-1653">455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-526" decimals="2" name="mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" scale="0" id="f-1654">147.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-526" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1655">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-526" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1656">113.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-547" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1657">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-547" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1658">106.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2024, 2023, and 2022: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per performance share units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-526" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1659">104.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-527" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1660">98.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-528" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1661">149.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of performance share units vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1662">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="6" id="f-1663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="6" id="f-1664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to performance share units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1665">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:fixed-zero" scale="6" id="f-1666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:fixed-zero" scale="6" id="f-1667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to performance share units as of April&#160;26, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-1668">89</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-526" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1669">1.6</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="f-1532-5" continuedAt="f-1532-6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees Stock Purchase Plan (ESPP)  </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1532-6"> The Company's shareholders approved the Medtronic plc 2024 Employee Stock Purchase Plan (2024 Plan) on October 19, 2023, which provides for a maximum of <ix:nonFraction unitRef="shares" contextRef="c-548" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1670">30</ix:nonFraction>&#160;million ordinary shares to be purchased by participating employees. The 2024 Plan replaced the Medtronic plc Amended and Restated 2014 Employees Stock Purchase Plan (2014 Plan) starting January 1, 2024. The 2024 Plan allows participating employees to purchase the Company's ordinary shares at a discount through payroll deductions. The expense recognized for shares purchased under the Company&#8217;s 2014 Plan and 2024 Plan is equal to the <ix:nonFraction unitRef="number" contextRef="c-549" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" format="ixt:num-dot-decimal" scale="-2" id="f-1671">15</ix:nonFraction> percent discount the employee receives. Employees purchased <ix:nonFraction unitRef="shares" contextRef="c-549" decimals="-6" name="mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1672">3</ix:nonFraction> million shares at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-549" decimals="2" name="mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" scale="0" id="f-1673">71.10</ix:nonFraction> per share in fiscal year 2024. At April&#160;26, 2024, approximately <ix:nonFraction unitRef="shares" contextRef="c-550" decimals="-6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="f-1674">29</ix:nonFraction> million ordinary shares were available for future purchase under the 2024 Plan.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1675" continuedAt="f-1675-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-1675-1" continuedAt="f-1675-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision is based on income before income taxes reported for financial statement purposes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1676" continuedAt="f-1676-1" escape="true">The components of income before income taxes, based on tax jurisdiction, are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1676-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1677">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="f-1678">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1679">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1680">4,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1681">4,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1682">5,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1683">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1684">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1685">5,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1686" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1687">756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1688">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1689">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1690">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1691">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1692">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1693">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1694">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1695">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax (benefit) expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1696">435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1697">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1698">402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1699">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1700">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1701">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1702">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1703">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1704">611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1705">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1706">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1707">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1675-2" continuedAt="f-1675-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1708" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss, capital loss, and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1709">11,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1710">10,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1711">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1712">2,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization" format="ixt:num-dot-decimal" scale="6" id="f-1713">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization" scale="6" id="f-1714">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="f-1715">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="f-1716">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="f-1717">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="f-1718">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" format="ixt:fixed-zero" scale="6" id="f-1719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" scale="6" id="f-1720">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1721">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1722">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1723">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1724">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="f-1725">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="f-1726">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease obligations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsLeaseObligations" scale="6" id="f-1727">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DeferredTaxAssetsLeaseObligations" scale="6" id="f-1728">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state benefit on uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" scale="6" id="f-1729">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" scale="6" id="f-1730">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsInterestLimitation" scale="6" id="f-1731">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DeferredTaxAssetsInterestLimitation" scale="6" id="f-1732">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities and derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" sign="-" name="mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" scale="6" id="f-1733">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" sign="-" name="mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" scale="6" id="f-1734">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1735">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1736">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1737">18,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1738">16,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1739">13,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1740">11,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1741">5,006</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1742">4,756</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1743">1,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1744">1,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="f-1745">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="f-1746">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="f-1747">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="f-1748">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1749">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1750">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis difference of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries" scale="6" id="f-1751">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries" scale="6" id="f-1752">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" scale="6" id="f-1753">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" format="ixt:fixed-zero" scale="6" id="f-1754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1755">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1756">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1757">1,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1758">2,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PrepaidTaxes" scale="6" id="f-1759">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:PrepaidTaxes" scale="6" id="f-1760">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:IncomeTaxReceivable" scale="6" id="f-1761">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:IncomeTaxReceivable" scale="6" id="f-1762">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1763">3,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1764">3,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported as (after valuation allowance and jurisdictional netting):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsNetofValuationAllowanceOther" scale="6" id="f-1765">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:DeferredTaxAssetsNetofValuationAllowanceOther" scale="6" id="f-1766">885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1767">3,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1768">3,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-1769">515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-1770">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1771">3,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1772">3,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No deferred taxes have been provided on the approximately $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="9" id="f-1773">86.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-8" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="9" id="f-1774">83.7</ix:nonFraction> billion of undistributed earnings of the Company&#8217;s subsidiaries at April&#160;26, 2024 and April&#160;28, 2023, respectively, since these earnings have been, and under current plans will continue to be, permanently reinvested in these subsidiaries. Due to the number of legal entities and jurisdictions involved, the complexity of the legal entity structure of the Company, and the complexity of the tax laws in the relevant jurisdictions, the Company believes it is not practicable to estimate, within any reasonable range, the amount of additional taxes which may be payable upon distribution of these undistributed earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="f-1775">11.3</ix:nonFraction> billion of tax effected net operating loss carryforwards in certain non-U.S. jurisdictions, of which</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="9" id="f-1776">5.1</ix:nonFraction> billion have no expiration, and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="9" id="f-1777">6.2</ix:nonFraction> billion will expire during fiscal years 2025 through 2041. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1675-3" continuedAt="f-1675-4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in these net operating loss carryforwards are $<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="f-1778">4.0</ix:nonFraction> billion of tax effected net operating losses generated in fiscal year 2008 as a result of the receipt of a favorable tax ruling from certain non-U.S. taxing authorities; and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="f-1779">5.1</ix:nonFraction>&#160;billion of tax effected net operating losses generated during fiscal year 2023 as a result of an intercompany reorganization. The Company has recorded a full valuation allowance against these net operating losses, as management does not believe that it is more likely than not that these net operating losses will be utilized. Certain of the remaining non-U.S. net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-8" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="9" id="f-1780">2.2</ix:nonFraction> billion have a valuation allowance recorded against the carryforwards, as management does not believe that it is more likely than not that these net operating losses will be utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1781">81</ix:nonFraction> million of tax effected U.S. federal net operating loss carryforwards, of which $<ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1782">56</ix:nonFraction>&#160;million have no expiration. The remaining loss carryforwards will expire during fiscal years 2025 through 2036. For U.S. state purposes, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1783">90</ix:nonFraction> million of tax effected net operating loss carryforwards at April&#160;26, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1784">12</ix:nonFraction>&#160;million of which have no expiration. The remaining U.S. state loss carryforwards will expire during fiscal years 2025 through 2042.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024, the Company also had $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1785">292</ix:nonFraction> million of tax credits available to reduce future income taxes payable, of which</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1786">122</ix:nonFraction> million have no expiration. The remaining credits will expire during fiscal years 2025 through 2043. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="9" id="f-1787">13.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-8" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="9" id="f-1788">11.3</ix:nonFraction> billion at April&#160;26, 2024 and April&#160;28, 2023, respectively, primarily related to the uncertainty of the utilization of certain deferred tax assets which are primarily comprised of tax loss and credit carryforwards in various jurisdictions. The increase in the valuation allowance during fiscal year 2024 is primarily related to the finalization of certain tax returns as well as an increase in the Swiss Cantonal tax rate applied to previously recorded deferred tax assets and associated valuation allowances. These valuation allowances would result in a reduction to the income tax provision in the consolidated statements of income if they are ultimately not required.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1789" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1790">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1791">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1792">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1793">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1794">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1795">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1796">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1797">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1798">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" format="ixt:fixed-zero" scale="-2" id="f-1799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" scale="-2" id="f-1800">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" scale="-2" id="f-1801">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1802">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1803">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1804">10.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1805">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1806">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1807">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="f-1808">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="f-1809">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="f-1810">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Base erosion anti-abuse tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" scale="-2" id="f-1811">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" format="ixt:fixed-zero" scale="-2" id="f-1812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" scale="-2" id="f-1813">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign derived intangible income benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-1814">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-1815">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-1816">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1817">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1818">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1819">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="f-1820">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="f-1821">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="f-1822">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1823">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1824">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1825">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1826">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1827">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1828">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Israeli Central-Lod District Court issued its decision in Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office in June 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="6" id="f-1829">187</ix:nonFraction>&#160;million income tax charge during fiscal year 2024 and filed an appeal with the Supreme Court of Israel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, the net cost from certain tax adjustments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="6" id="f-1830">299</ix:nonFraction>&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:num-dot-decimal" scale="6" id="f-1831">187</ix:nonFraction>&#160;million associated with a reserve adjustment related to the Israeli Central-Lod District Court decision with respect to a deemed taxable transfer of intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1832">124</ix:nonFraction>&#160;million related to a change in valuation allowance on previously recorded net operating losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1833">95</ix:nonFraction>&#160;million related to a Swiss Cantonal tax rate change on previously recorded deferred tax assets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1675-4" continuedAt="f-1675-5"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1834">50</ix:nonFraction>&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" format="ixt:num-dot-decimal" scale="6" id="f-1835">33</ix:nonFraction>&#160;million associated with a change in the Company&#8217;s permanent reinvestment assertion on certain historical earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the net benefit from certain tax adjustments of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="6" id="f-1836">910</ix:nonFraction>&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statement of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" format="ixt:num-dot-decimal" scale="6" id="f-1837">764</ix:nonFraction>&#160;million associated with the August 18, 2022 U.S. Tax Court (Tax Court) Opinion on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006 (Opinion). While the Opinion rejected the IRS&#8217;s position and the Tax Court determined the methodology advanced by Medtronic was appropriate for purposes of determining the intercompany royalty rate between Puerto Rico and the U.S., it determined that the royalty rate should be higher, thereby increasing income allocated to the U.S. and consequently subject to U.S. tax. This case relates only to fiscal years 2005 and 2006. The Company has assumed the Tax Court findings will be applied for all years following fiscal year 2006. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" format="ixt:num-dot-decimal" scale="6" id="f-1838">55</ix:nonFraction>&#160;million related to the disallowance of certain interest deductions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" format="ixt:num-dot-decimal" scale="6" id="f-1839">30</ix:nonFraction>&#160;million related to the change in reporting currency for certain carryover attributes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1840">28</ix:nonFraction>&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:num-dot-decimal" scale="6" id="f-1841">33</ix:nonFraction>&#160;million primarily associated with the sale of half of the Company&#8217;s RCS business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2022, the net benefit from certain tax adjustments of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="6" id="f-1842">50</ix:nonFraction>&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" format="ixt:num-dot-decimal" scale="6" id="f-1843">82</ix:nonFraction>&#160;million associated with a step up in tax basis for Swiss Cantonal purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="mdt:EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount" format="ixt:num-dot-decimal" scale="6" id="f-1844">82</ix:nonFraction>&#160;million related to a change in tax rates on intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1845">47</ix:nonFraction>&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" format="ixt:num-dot-decimal" scale="6" id="f-1846">41</ix:nonFraction>&#160;million associated with a change in the Company&#8217;s permanent reinvestment assertion on certain historical earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:num-dot-decimal" scale="6" id="f-1847">26</ix:nonFraction>&#160;million primarily associated with an intercompany sale of assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the Company&#8217;s operations in Puerto Rico, Singapore, Dominican Republic, Costa Rica, and China have various tax holidays and tax incentive grants. The tax reductions as compared to the local statutory rate favorably impacted earnings by $<ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxHolidays" format="ixt:num-dot-decimal" scale="6" id="f-1848">229</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxHolidays" format="ixt:num-dot-decimal" scale="6" id="f-1849">115</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxHolidays" format="ixt:num-dot-decimal" scale="6" id="f-1850">248</ix:nonFraction> million in fiscal years 2024, 2023, and 2022, respectively, and diluted earnings per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="c-555" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="f-1851">0.17</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-556" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="f-1852">0.09</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-557" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="f-1853">0.18</ix:nonFraction>, in fiscal years 2024, 2023, and 2022, respectively. The tax holidays are conditional upon the Company meeting certain thresholds required under statutory law. The tax incentive grants, unless extended, will expire between fiscal years 2025 and 2049. The tax incentive grants which expired during fiscal year 2024 did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which will be effective for the Company in fiscal year 2025. The Company is continuing to evaluate the potential impacts of proposed and enacted legislative changes as new guidance becomes available. There are no impacts of this global minimum tax in the consolidated financial statements for the fiscal year ended April&#160;26, 2024.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1675-5" continuedAt="f-1675-6"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="f-1854">2.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="f-1855">2.7</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="f-1856">1.7</ix:nonFraction> billion of gross unrecognized tax benefits at April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1857" continuedAt="f-1857-1" escape="true">A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2024, 2023, and 2022 is as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1857-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of fiscal year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1858">2,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1859">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1860">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross increases:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1861">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1862">980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1863">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1864">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1865">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1866">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross decreases:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1867">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1868">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1869">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1870">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1871">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1872">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation lapses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1873">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1874">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1875">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1876">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1877">2,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1878">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash advance paid to taxing authorities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:CashAdvancePaidinConnectionWithProposedSettlements" scale="6" id="f-1879">934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:CashAdvancePaidinConnectionWithProposedSettlements" scale="6" id="f-1880">918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:CashAdvancePaidinConnectionWithProposedSettlements" scale="6" id="f-1881">859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid" format="ixt:num-dot-decimal" scale="6" id="f-1882">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid" format="ixt:num-dot-decimal" scale="6" id="f-1883">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid" scale="6" id="f-1884">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If all of the Company&#8217;s unrecognized tax benefits at April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022 were recognized, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="f-1885">2.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="f-1886">2.5</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="f-1887">1.6</ix:nonFraction> billion would impact the Company&#8217;s effective tax rate, respectively. Although the Company believes that it has adequately reserved for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on the Company&#8217;s effective tax rate in future periods. The Company has recorded gross unrecognized tax benefits, net of cash advance, of $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="9" id="f-1888">1.8</ix:nonFraction> billion as a noncurrent liability. The Company estimates that within the next 12 months it is reasonably possible that its uncertain tax positions, excluding interest, could decrease by as much as $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="f-1889">15</ix:nonFraction>&#160;million, net as a result of statute of limitation lapses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to income tax matters in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income and records the liability in the current or noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets, as appropriate. During fiscal years 2024, 2023, and 2022, the Company recognized gross interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:IncomeTaxExaminationInterestIncomeExpenseGross" format="ixt:num-dot-decimal" scale="6" id="f-1890">134</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:IncomeTaxExaminationInterestIncomeExpenseGross" format="ixt:num-dot-decimal" scale="6" id="f-1891">86</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:IncomeTaxExaminationInterestIncomeExpenseGross" format="ixt:num-dot-decimal" scale="6" id="f-1892">17</ix:nonFraction> million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. The Company had $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-1893">19</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-1894">61</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-1895">117</ix:nonFraction> million of accrued gross interest and penalties at April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. These reserves are subject to a high degree of estimation and management judgment. Resolution of these significant unresolved matters, or positions taken by the IRS or other tax authorities during future tax audits, could have a material impact on the Company&#8217;s financial results in future periods. The Company continues to believe that its reserves for uncertain tax positions are appropriate and that it has meritorious defenses for its tax filings and will vigorously defend them during the audit process, appellate process, and through litigation in courts, as necessary.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1675-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfIncomeTaxExaminationsTextBlock" id="f-1896" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earliest Year Open</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - federal and state</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 for additional information regarding the status of current tax audits and proceedings.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1897" continuedAt="f-1897-1" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="f-1897-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-1898" escape="true">Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1899" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the computation of basic and diluted earnings per share:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to ordinary shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1900">3,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1901">3,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1902">5,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-1903">1,327.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-1904">1,329.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-1905">1,342.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-520" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1906">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-521" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1907">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-522" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1908">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-523" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" scale="6" id="f-1909">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-524" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" scale="6" id="f-1910">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-525" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" scale="6" id="f-1911">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-526" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1912">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-527" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1913">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-528" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1914">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-1915">1,330.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-1916">1,332.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-1917">1,351.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1918">2.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1919">2.83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1920">3.75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1921">2.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1922">2.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1923">3.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of weighted average diluted shares outstanding excludes options to purchase approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-558" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-1924">28</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="c-559" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-1925">23</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="c-560" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-1926">5</ix:nonFraction> million ordinary shares in fiscal year 2024, 2023, and 2022, respectively because their effect would have been anti-dilutive on the Company&#8217;s earnings per share.</span></div></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_190"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1927" continuedAt="f-1927-1" escape="true">Retirement Benefit Plans </ix:nonNumeric></span></div><ix:continuation id="f-1927-1" continuedAt="f-1927-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net expense related to these plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="f-1928">451</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="f-1929">494</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="f-1930">459</ix:nonFraction> million in fiscal years 2024, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Company maintains qualified pension plans designed to provide guaranteed minimum retirement benefits to all eligible U.S. participants. Pension coverage for non-U.S. employees is provided, to the extent deemed appropriate, through separate plans. In addition to the benefits provided under the qualified pension plan, retirement benefits associated with wages in excess of the IRS allowable limits are provided to certain employees under a non-qualified plan. U.S. and Puerto Rico employees are also eligible to receive a medical benefit component, in addition to normal retirement benefits, through the Company&#8217;s post-retirement benefits. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024 and April&#160;28, 2023, the funded status of the Company&#8217;s benefit plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1931">484</ix:nonFraction> million overfunded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1932">103</ix:nonFraction> million overfunded, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the Company offered certain eligible U.S. employees voluntary early retirement packages, resulting in charges of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1933">94</ix:nonFraction>&#160;million, primarily related to U.S. pension benefits. The charges were recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">restructuring charges, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income. See Note 4 for additional information on restructuring charges. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1927-2" continuedAt="f-1927-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="f-1934" continuedAt="f-1934-1" escape="true">The change in benefit obligation and funded status of the Company&#8217;s U.S. and Non-U.S. pension benefits are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1934-1" continuedAt="f-1934-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated benefit obligation at end of year:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1935">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1936">3,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1937">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1938">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in projected benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1939">3,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1940">3,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1941">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1942">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1943">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1944">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1945">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1946">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1947">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1948">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1949">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1950">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1951">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="f-1953">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="f-1954">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments, settlements, and amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="f-1955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" scale="6" id="f-1956">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" scale="6" id="f-1957">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" scale="6" id="f-1958">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1959">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1960">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1961">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1962">303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1963">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1964">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1965">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1966">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" format="ixt:fixed-zero" scale="6" id="f-1967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" scale="6" id="f-1968">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" format="ixt:fixed-zero" scale="6" id="f-1969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" format="ixt:fixed-zero" scale="6" id="f-1970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="f-1971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="f-1972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="f-1973">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="f-1974">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1975">3,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1976">3,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1977">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1978">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1979">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1980">3,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1981">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1982">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-1983">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-1984">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-1985">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-1986">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1987">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1988">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1989">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1990">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="f-1993">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="f-1994">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="f-1997">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="f-1998">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-1999">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-2000">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-2001">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-2002">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-2003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-2004">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="f-2005">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="f-2006">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2007">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2008">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2009">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2010">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funded status at end of year:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2011">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2012">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2013">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2014">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2015">3,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2016">3,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2017">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2018">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over (under) funded status of the plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-2019">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-2020">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-2021">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-2022">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset (liability)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2023">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2024">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2025">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2026">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized on the consolidated<br/>balance sheets consist of:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-2027">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-2028">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-2029">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-2030">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-2031">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-2032">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-2033">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-2034">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="f-2035">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="f-2036">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="f-2037">235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="f-2038">228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2039">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2040">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2041">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2042">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other<br/>comprehensive loss:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service (credit) cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2043">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2044">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2045">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2046">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-2047">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-2048">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-2049">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-2050">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-2051">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-2052">873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-2053">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-2054">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of April 24, 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.</span></div></ix:continuation><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-1934-2" continuedAt="f-1934-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This represents a portion of the total voluntary early retirement package charges for fiscal year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-1934-3">.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1927-3" continuedAt="f-1927-4"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain countries outside the U.S., fully funding pension plans is not a common practice, as funding provides no income tax benefit. Consequently, certain pension plans were partially funded at April&#160;26, 2024 and April&#160;28, 2023. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="f-2055" continuedAt="f-2055-1" escape="true">U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:</ix:nonNumeric></span></div><ix:continuation id="f-2055-1"><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="f-2056">773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="f-2057">731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="f-2058">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="f-2059">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="f-2060">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="f-2061">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="f-2062" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2063">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2064">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="f-2065">819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="f-2066">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="f-2067" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost of the plans includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2068">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2069">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2070">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2071">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2072">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2073">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2074">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2075">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2076">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2077">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2078">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2079">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2080">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2081">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2082">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2083">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2084">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2085">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-2086">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="f-2087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="f-2088">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-2089">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-2090">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-2091">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss (gain)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2092">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2093">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2094">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2095">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2096">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2097">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement and curtailment (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-2098">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-2099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-2100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="f-2101">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="f-2102">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="f-2103">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="f-2105">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit (credit) cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2110">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2111">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2112">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2113">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2114">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2115">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost other than the service component are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="f-2116" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other changes in plan assets and projected benefit obligations recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for fiscal year 2024 are as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S.<br/>Pension<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="f-2117">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="f-2118">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="f-2120">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2121">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2122">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and settlement recognition of actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" scale="6" id="f-2123">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" scale="6" id="f-2124">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" format="ixt:fixed-zero" scale="6" id="f-2125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" scale="6" id="f-2126">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-2127">355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-2128">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" sign="-" name="mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-2129">378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-2130">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1927-4" continuedAt="f-1927-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="f-2131" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; projected benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-575" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2132">5.54</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-576" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2133">5.75</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-577" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2134">4.73</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-578" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2135">4.99</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-579" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2136">4.23</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-580" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2137">4.48</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-581" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2138">1.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-582" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2139">26.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-583" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2140">1.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-584" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2141">10.70</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-585" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2142">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-586" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2143">25.40</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-561" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2144">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-562" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2145">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-565" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2146">4.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-563" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2147">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-564" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2148">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-566" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2149">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; net periodic benefit cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-587" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2150">4.73</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-588" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2151">4.99</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-589" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2152">4.23</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-590" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2153">4.48</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-591" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2154">2.80</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-592" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2155">3.46</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-593" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2156">1.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-594" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2157">10.70</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-595" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2158">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-596" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2159">25.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-597" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2160">0.25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-598" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2161">12.80</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-587" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2162">4.68</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-588" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2163">5.07</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-589" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2164">4.12</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-590" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2165">4.51</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-591" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2166">2.50</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-592" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2167">3.51</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-593" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2168">1.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-594" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2169">10.70</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-595" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2170">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-596" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2171">25.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-597" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2172">0.24</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-598" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2173">12.80</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-587" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2174">4.73</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-588" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2175">4.90</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-589" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2176">3.90</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-590" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2177">4.23</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-591" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2178">2.08</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-592" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2179">2.87</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-593" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2180">1.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-594" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2181">10.70</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-595" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2182">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-596" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2183">25.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-597" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2184">0.08</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-598" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2185">12.80</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-587" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2186">6.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-588" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2187">8.10</ix:nonFraction>% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-589" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2188">5.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-590" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2189">7.20</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-591" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2190">5.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-592" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2191">7.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-569" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2192">4.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-570" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2193">3.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-574" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2194">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-567" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2195">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-568" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2196">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-591" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2197">3.90</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-592" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2198">4.83</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-569" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2199">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-570" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2200">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-574" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2201">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a full yield curve approach methodology to estimate the service and interest cost components of net periodic pension cost and net periodic post-retirement benefit cost for the Company&#8217;s pension and other post-retirement benefits. The full yield curve approach applies specific spot rates along the yield curve to their underlying projected cash flows in estimation of the cost components. The current yield curves represent high quality, long-term fixed income instruments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets assumptions are determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Investment Strategy  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors trusts that hold the assets for U.S. pension plans and other U.S. post-retirement benefit plans, primarily retiree medical benefits. For investment purposes, the Medtronic U.S. pension and other U.S. post-retirement benefit plans employ similar investment strategies with different asset allocation targets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a Qualified Plan Committee (the Plan Committee) that sets investment guidelines for U.S. pension plans and other U.S. post-retirement benefit plans with the assistance of external consultants. These guidelines are established based on market conditions, risk tolerance, funding requirements, and expected benefit payments. The Plan Committee also oversees the investment allocation process, selects the investment managers, and monitors asset performance. As pension liabilities are long-term in nature, the Company employs a long-term total return approach to maximize the long-term rate of return on plan assets for a prudent level of risk. An annual analysis on the risk versus the return of the investment portfolio is conducted to justify the expected long-term rate of return assumption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment portfolios contain a diversified allocation of investment categories, including equities, fixed income securities, hedge funds, and private equity. Securities are also diversified in terms of domestic and international, short- and long-term, growth and value styles, large cap and small cap stocks, and active and passive management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., pension plan assets are typically managed by decentralized fiduciary committees. There is significant variation in policy asset allocation from country to country. Local regulations, funding rules, and financial and tax considerations are part of the funding and investment allocation process in each country. The weighted average target asset allocations at April&#160;26, 2024 for the plans are</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="number" contextRef="c-599" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2202">42</ix:nonFraction>% equity securities, <ix:nonFraction unitRef="number" contextRef="c-600" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2203">34</ix:nonFraction>% debt securities, and <ix:nonFraction unitRef="number" contextRef="c-601" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2204">24</ix:nonFraction>% other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plans did not hold any investments in the Company&#8217;s ordinary shares at April&#160;26, 2024 or April&#160;28, 2023.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1927-5" continuedAt="f-1927-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="f-2205" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. plans target asset allocations at April&#160;26, 2024, compared to the U.S. plans actual asset allocations at April&#160;26, 2024 and April&#160;28, 2023 by asset category, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target Allocation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;26, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;26, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;28, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Category:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-602" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2206">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-602" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2207">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-603" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2208">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-604" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2209">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-604" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2210">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-605" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2211">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-606" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2212">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-606" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2213">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-607" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2214">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-561" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2215">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-561" decimals="INF" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2216">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-562" decimals="INF" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2217">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strong performance on equity securities during the fiscal year resulted in asset allocations different than targets. Management expects to move the allocations closer to target over the intermediate term. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Asset Fair Values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The following is a description of the valuation methodologies used for retirement benefit plan assets measured at fair value: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term investments include money market funds. These investments are valued at the closing price reported in the active markets in which the individual security is traded.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mutual funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Comprised of investments in equity and fixed income securities held in pooled investment vehicles. The valuations of mutual funds are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are publicly reported.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity commingled trusts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Comprised of investments in equity securities held in pooled investment vehicles. The valuations of equity commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed income commingled trusts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprised of investments in fixed income securities held in pooled investment vehicles. The valuations of fixed income commingled trusts are based on the respective net asset values which are determined by the fund, either daily or monthly depending on the investment, at market close. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the fund, less its liabilities.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Partnership units:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Partnership units include investment partnerships that provide exposure to long/short equity, absolute return strategies, private equity investments, and real estate investments. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the partnerships, less its liabilities. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered investment companies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Valued at net asset values which are not publicly reported. The net asset values are calculated based on the valuation of the underlying assets. The underlying assets are valued at the quoted market prices of shares held by the plan at year-end in the active market on which the individual securities are traded.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance contracts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Comprised of investments in collective (group) insurance contracts, consisting of individual insurance policies. The policyholder is the employer, and each member is the owner/beneficiary of their individual insurance policy. These policies are a part of the insurance company&#8217;s general portfolio and participate in the insurer&#8217;s profit-sharing policy on an excess yield basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement using net asset value as a practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported net asset value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The methods described above may produce fair values that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1927-6" continuedAt="f-1927-7"><ix:nonNumeric contextRef="c-1" name="mdt:FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" id="f-2218" continuedAt="f-2218-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;26, 2024 and April&#160;28, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Pension Benefits</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2219">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2220">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2224">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2225">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2229">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2233">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2234">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-625" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2238">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2239">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2243">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2244">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-633" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2245">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-634" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-635" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2248">3,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-637" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2249">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-638" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2250">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-639" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2254">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-643" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2255">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2259">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2263">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2264">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2268">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2269">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2272">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2274">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2275">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2277">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2278">2,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="mdt:FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock" id="f-2279" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a reconciliation of the beginning and ending balances of U.S. pension benefit assets measured at fair value that used significant unobservable inputs (Level 3):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partnership Units</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;29, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="6" id="f-2280">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total realized gains, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="f-2281">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="f-2282">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" scale="6" id="f-2283">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;28, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-2284">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1927-7" continuedAt="f-1927-8"><ix:continuation id="f-2218-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-U.S. Pension Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2285">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2289">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2290">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2293">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2295">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2298">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-682" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2299">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2300">1,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-684" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-685" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2304">1,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-688" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2305">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-691" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2308">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-692" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2310">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-693" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-694" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2313">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2314">1,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. pension benefit assets that are valued using significant unobservable inputs (Level 3) was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2315">42</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2316">44</ix:nonFraction>&#160;million as of April&#160;26, 2024 and April&#160;28, 2023, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the fair value hierarchy classification on an annual basis. During the year, the Company reclassified certain investments in the U.S. pension plan from Level 3 to investments measured using net asset value as a practical expedient. Outside of the reclassification, there were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no transfers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into or out of Level 3 for both the U.S. and non-U.S. pension plans during the fiscal years ended April&#160;26, 2024 and April&#160;28, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Funding  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is the Company&#8217;s policy to fund retirement costs within the limits of allowable tax deductions. During fiscal year 2024, the Company made discretionary contributions of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="f-2317">32</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the U.S. pension plan. Internationally, the Company contributed approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="f-2318">40</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for pension benefits during fiscal year 2024. The Company anticipates that it will make contributions of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="f-2319">30</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="f-2320">45</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to its U.S. pension benefit plans and non-U.S. pension benefit plans, respectively, in fiscal year 2025. Based on the guidelines under the U.S. Employee Retirement Income Security Act of 1974 and the various guidelines which govern the plans outside the U.S., the majority of anticipated fiscal year 2025 contributions will be discretionary. The Company believes that pension assets, returns on invested pension assets, and Company contributions will be able to meet its pension and other post-retirement obligations in the future.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="f-2321" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="f-2322">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="f-2323">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="f-2324">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="f-2325">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="f-2326">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="f-2327">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="f-2328">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="f-2329">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="f-2330">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="f-2331">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 &#8211; 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="f-2332">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="f-2333">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post-retirement Benefit Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The net periodic benefit cost associated with the Company&#8217;s post-retirement benefit plans was income of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="6" id="f-2334">16</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="6" id="f-2335">11</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="6" id="f-2336">20</ix:nonFraction> million in fiscal years 2024, 2023, and 2022, respectively. The Company&#8217;s projected benefit obligation for all post-retirement benefit plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2337">235</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2338">261</ix:nonFraction> million at April&#160;26, 2024 and April&#160;28, 2023, respectively. The Company&#8217;s fair value of plan assets for all post-retirement benefit plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2339">308</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2340">302</ix:nonFraction> million at April&#160;26, 2024 and April&#160;28, 2023, respectively. The post-retirement benefit plan assets at both April&#160;26, 2024 and April&#160;28, 2023 primarily comprised of equity and fixed commingled trusts, consistent with the U.S. retirement benefit plan assets outlined in the fair value leveling tables above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Contribution Savings Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company has defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security during retirement by providing employees with an incentive to make regular savings. Company contributions to the plans are based on employee contributions </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1927-8"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Company performance. Expense recognized under these plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2341">471</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2342">390</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2343">403</ix:nonFraction> million in fiscal years 2024, 2023, and 2022, respectively.</span></div></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_193"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-2344" continuedAt="f-2344-1" escape="true">Leases </ix:nonNumeric></span></div><ix:continuation id="f-2344-1" continuedAt="f-2344-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">typically do not provide an implicit rate, the Company&#8217;s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for fiscal year 2024, 2023, and 2022 were not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases were not material to the consolidated financial statements at April&#160;26, 2024 or April&#160;28, 2023 or for fiscal year 2024, 2023 and 2022. Finance lease right-of-use assets are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">property, plant, and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and finance lease liabilities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">current debt obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="mdt:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-2345" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;26, 2024 and April&#160;28, 2023: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2346"><span style="-sec-ix-hidden:f-2347">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-2348">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-2349">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2350"><span style="-sec-ix-hidden:f-2351">Other accrued expenses</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-2352">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-2353">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2354"><span style="-sec-ix-hidden:f-2355">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-2356">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-2357">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-2358" continuedAt="f-2358-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;26, 2024 and April&#160;28, 2023: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-27" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-2359">8.8</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-28" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-2360">9.1</ix:nonNumeric> Years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-2361">3.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-2362">2.4</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022: </span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-2363">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-2364">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-2365">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-2366">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-2367">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-2368">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="f-2369">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="f-2370">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="f-2371">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2344-2"><ix:continuation id="f-2358-1"><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-2372">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-2373">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-2374">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-2375">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-2376">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-2377">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-2378" escape="true"><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company's operating leases at April&#160;26, 2024:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-2379">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-2380">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-2381">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-2382">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-2383">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="f-2384">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expected lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="f-2385">1,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-2386">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-2387">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and the Company's net investments in sales-type leases are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. Lessor income and the related assets and lease maturities were not material to the consolidated financial statements at or for the fiscal year ended April&#160;26, 2024 and April&#160;28, 2023.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_196"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="f-2388" continuedAt="f-2388-1" escape="true">Accumulated Other Comprehensive Loss </ix:nonNumeric></span></div><ix:continuation id="f-2388-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-2389" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.974%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Loss) Gain on Investment Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in Retirement Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2390">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2391">519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2392">1,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2393">1,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2394">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2395">3,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2396">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2397">2,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2398">2,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2399">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2400">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2401">1,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2402">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2405">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2406">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2407">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2408">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2409">2,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2410">2,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2411">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2412">727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2413">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2414">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-713" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2415">2,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2416">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2417">773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2418">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2419">2,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2420">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2421">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2422">596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2423">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2424">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2425">704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2426">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2429">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2430">565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2431">530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2432">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2433">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2434">596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2435">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2436">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2437">1,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2438">258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2439">2,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2440">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2441">741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2442">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2443">3,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2444">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2445">846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2446">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2447">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2448">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2449">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2450">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2453">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2454">302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2455">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2456">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2457">846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2458">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2459">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2460">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2461">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2462">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2463">3,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2464">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2465">529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2466">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2467">3,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during fiscal years 2024, 2023, and 2022 was an expense of $<ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2468">4</ix:nonFraction> million, a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2469">21</ix:nonFraction>&#160;million, and a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2470">51</ix:nonFraction>&#160;million, respectively. During fiscal years 2024, 2023, and 2022, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $<ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2471">5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2472">9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2473">1</ix:nonFraction>&#160;million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Note 5 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2024, 2023, and 2022, the income tax on cumulative translation adjustment was an expense of $<ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2474">3</ix:nonFraction> million, a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2475">5</ix:nonFraction>&#160;million, and a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2476">8</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2024, 2023, and 2022, there were <ix:nonFraction unitRef="usd" contextRef="c-729" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="0" id="f-2477"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="0" id="f-2478"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="0" id="f-2479">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> tax impacts on net investment hedges. Refer to Note 7 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. The income tax on the net change in retirement obligations in other comprehensive income before reclassifications during fiscal years 2024, 2023, and 2022 resulted in an expense of $<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2480">79</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2481">6</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2482">134</ix:nonFraction>&#160;million, respectively. During fiscal years 2024, 2023, and 2022, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of&#160;$<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2483">2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2484">9</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2485">20</ix:nonFraction>&#160;million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Note 15 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during fiscal years 2024, 2023, and 2022 was&#160;an expense of $<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2486">103</ix:nonFraction> million,&#160;$<ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2487">56</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2488">152</ix:nonFraction>&#160;million, respectively. Amounts reclassified from AOCI related to cash flow hedges included income taxes of $<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2489">66</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2490">133</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2491">26</ix:nonFraction>&#160;million for fiscal years 2024, 2023, and 2022, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating expense (income), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7 for additional information.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_199"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="c-1" name="us-gaap:LossContingencyDisclosures" id="f-2492" continuedAt="f-2492-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-2492-1" continuedAt="f-2492-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#8217;s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">certain litigation charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income. During fiscal years 2024, 2023, and 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="f-2493">149</ix:nonFraction>&#160;million of certain litigation charges, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="f-2494">30</ix:nonFraction>&#160;million of certain litigation income, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="f-2495">95</ix:nonFraction>&#160;million of certain litigation charges, respectively. At April 26, 2024 and April 28, 2023, accrued litigation was approximately $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-2496">0.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-2497">0.3</ix:nonFraction>&#160;billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages and/or royalty payments, and negatively impact the Company's ability to sell current or future products, which could have a material adverse impact on the Company's business, results of operations, financial condition, and cash flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Colibri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company&#8217;s Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately $<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-2498">106</ix:nonFraction>&#160;million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hernia Mesh Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of May 15, 2024, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately <ix:nonFraction unitRef="plantiff" contextRef="c-738" decimals="-1" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="f-2499">8,350</ix:nonFraction> individual plaintiffs, and certain plaintiffs&#8217; </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2492-2" continuedAt="f-2492-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">law firms have advised the Company that they may file additional cases in the future. Approximately <ix:nonFraction unitRef="plantiff" contextRef="c-739" decimals="-2" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="f-2500">6,700</ix:nonFraction> plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately <ix:nonFraction unitRef="plantiff" contextRef="c-740" decimals="-2" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="f-2501">500</ix:nonFraction> plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately <ix:nonFraction unitRef="claim" contextRef="c-741" decimals="-1" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="f-2502">1,150</ix:nonFraction> actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus <ix:nonFraction unitRef="lawsuit" contextRef="c-741" decimals="0" name="mdt:LossContingencyLawsuitsNumber" format="ixt-sec:numwordsen" scale="0" id="f-2503">six</ix:nonFraction> one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diabetes Pump Retainer Ring Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of May 14, 2024, <ix:nonFraction unitRef="lawsuit" contextRef="c-742" decimals="0" name="mdt:LossContingencyLawsuitsNumber" scale="0" id="f-2504">27</ix:nonFraction> lawsuits have been filed on behalf of a total of <ix:nonFraction unitRef="plantiff" contextRef="c-743" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="f-2505">107</ix:nonFraction> individual plaintiffs, and certain plaintiffs&#8217; law firms have notified the Company that they may file additional lawsuits in the future on behalf of thousands of additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In March 2021, the parties notified the court that they had agreed on a settlement in principle of all issues in this matter, and in September 2022 the parties filed a joint motion for final approval by the court. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of remedial activities. The final court order did not result in a change to the Company's previous accrual for this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accrued expenses for these various environmental proceedings are included within accrued litigation as discussed above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Corruption Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has regular and ongoing interactions with governmental agencies, and its practice is to cooperate with such inquiries. In addition, from time to time, the Company self-discloses potential concerns to governmental regulators. Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in China regarding certain activities, including in China. The Company is committed to regularly evaluating and, as appropriate, strengthening its anti-corruption compliance programs and practices. Any possible future determination that certain of our operations and activities, and/or those of our third-party distributors, are not in compliance with existing laws could result in the imposition of fines, penalties, and equitable remedies in the United States or in other jurisdictions. The Company has not recorded an expense in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court (Tax Court) reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS&#8217;s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2492-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic, Inc.&#8217;s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 13 for additional discussion of income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates&#8217; products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company&#8217;s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div></ix:continuation><div id="ia6bfc65eaa654c3ebf593baab4e46685_202"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-2506" continuedAt="f-2506-1" escape="true">Segment and Geographic Information </ix:nonNumeric></span></div><ix:continuation id="f-2506-1" continuedAt="f-2506-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the reportable segments during the fiscal year ended April&#160;26, 2024. We continue to have <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-2507">four</ix:nonFraction> reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. However, there were changes to the operating segments during fiscal year 2024 as a result of how the Chief Operating Decision Maker (CODM) assesses business performance. During the first quarter of fiscal year 2024, the Medical Surgical Portfolio was separated into <ix:nonFraction unitRef="segment" contextRef="c-484" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-2508">two</ix:nonFraction> operating segments as a result of the previously contemplated separation of the PMRI businesses, which were previously aggregated based upon similar economic and operating characteristics. In addition, during the first quarter of fiscal year 2024, there were certain Medical Surgical businesses that were moved to the Other line, which primarily related to wind-down activity of the Company's Renal Care Solutions business that was contributed to Mozarc Medical in April 2023. Subsequently, as a result of the February 2024 decision to exit the Company's ventilator product line and retain and combine the remaining PMRI businesses into one business unit as further discussed in Note 3, the <ix:nonFraction unitRef="segment" contextRef="c-485" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-2509">two</ix:nonFraction> operating segments within the Medical Surgical Portfolio were combined into one operating segment, and the Company's ventilator product line, which was in the Medical Surgical Portfolio, was moved to the Other line during the fourth quarter of fiscal year 2024. Prior period amounts have been recast to reflect the new reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management has chosen to organize the entity based upon therapy solutions provided by each segment. The <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-2510">four</ix:nonFraction> principal segments are strategic businesses that are managed separately, as each one develops and manufactures products and provides services oriented toward targeted therapy solutions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Cardiovascular Portfolio segment derives its revenues include products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart and vascular-related disorders and diseases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Medical Surgical Portfolio segment derives its revenues include those focused on diseases of the respiratory system, gastrointestinal tract, lungs, pelvic region, obesity, and other preventable complications. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2506-2" continuedAt="f-2506-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products from which the Diabetes Operating Unit segment derives its revenues include those focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment disclosures are on a performance basis, consistent with internal management reporting. Net sales of the Company's segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. Refer to Note 2 for discussion on net sales by segment. There are certain corporate and centralized expenses that are not allocated to the segments. The Company's management evaluates the performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest income or expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments. Prior period amounts have been recast to reallocate certain expenses from segment operating profit to centralized distribution costs to conform to classifications used in the current year as a result in a change to the segment operating profit metric used by the CODM to assess business performance and allocate resources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-2511" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Operating Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2512">4,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2513">4,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2514">4,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2515">3,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2516">3,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2517">3,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2518">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2519">3,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2520">3,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2521">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2522">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2523">588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2524">11,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2525">11,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2526">12,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-759" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2527">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-760" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2528">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-761" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2529">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="mdt:CorporateOverhead" format="ixt:num-dot-decimal" scale="6" id="f-2530">1,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="mdt:CorporateOverhead" format="ixt:num-dot-decimal" scale="6" id="f-2531">1,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="mdt:CorporateOverhead" format="ixt:num-dot-decimal" scale="6" id="f-2532">1,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="f-2533">719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="f-2534">636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="f-2535">553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2536">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2537">515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2538">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2539">1,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2540">1,698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2541">1,733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-2542">393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-2543">355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-2544">358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="mdt:CentralizedDistributionCosts" format="ixt:num-dot-decimal" scale="6" id="f-2545">1,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="mdt:CentralizedDistributionCosts" format="ixt:num-dot-decimal" scale="6" id="f-2546">1,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="mdt:CentralizedDistributionCosts" format="ixt:num-dot-decimal" scale="6" id="f-2547">1,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" sign="-" name="mdt:ForeignCurrencyCosts" scale="6" id="f-2548">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" sign="-" name="mdt:ForeignCurrencyCosts" scale="6" id="f-2549">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" sign="-" name="mdt:ForeignCurrencyCosts" scale="6" id="f-2550">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2551">389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2552">647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2553">335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-2554">777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-2555">345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-2556">838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-2557">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" sign="-" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-2558">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-2559">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="mdt:ImpairmentofInProcessResearchandDevelopment" format="ixt:fixed-zero" scale="6" id="f-2560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="mdt:ImpairmentofInProcessResearchandDevelopment" format="ixt:fixed-zero" scale="6" id="f-2561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="mdt:ImpairmentofInProcessResearchandDevelopment" scale="6" id="f-2562">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="mdt:MedicalDeviceRegulations" scale="6" id="f-2563">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="mdt:MedicalDeviceRegulations" scale="6" id="f-2564">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="mdt:MedicalDeviceRegulations" scale="6" id="f-2565">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments to the Medtronic Foundation and Medtronic LABS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="mdt:SpecialChargesGains" format="ixt:fixed-zero" scale="6" id="f-2566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="mdt:SpecialChargesGains" scale="6" id="f-2567">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="mdt:SpecialChargesGains" format="ixt:fixed-zero" scale="6" id="f-2568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2569">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2570">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2571">5,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Includes the net impact of remeasurement and the Company's hedging programs recorded in other operating expense (income), net.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2506-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="f-2572" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets and Depreciation Expense </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-765" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2573">16,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-766" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2574">16,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2575">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2576">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2577">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-767" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2578">18,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-768" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2579">18,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2580">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2581">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2582">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-769" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2583">33,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-770" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2584">34,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2585">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2586">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2587">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-771" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2588">3,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-772" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2589">3,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2590">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2591">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2592">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-773" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2593">71,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2594">73,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2595">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2596">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2597">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-6" name="us-gaap:Assets" scale="6" id="f-2598">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-776" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2599">1,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-759" decimals="-6" name="us-gaap:Depreciation" format="ixt:fixed-zero" scale="6" id="f-2600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-760" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2601">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-761" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2602">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-777" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2603">17,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-778" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2604">16,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-779" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2605">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-780" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2606">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-781" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2607">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2608">89,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2609">90,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2610">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2611">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2612">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. Geographic property, plant, and equipment are attributed to the country based on the physical location of the assets. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="f-2613" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales for fiscal years 2024, 2023, and 2022, and property, plant, and equipment, net at April&#160;26, 2024 and April&#160;28, 2023 for the Company's country of domicile, countries with significant concentrations, and all other countries: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-782" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2614">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-783" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2615">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-784" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2616">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-785" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-2617">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-786" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-2618">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2619">16,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2620">16,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2621">16,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-787" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2622">4,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-788" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2623">4,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-789" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2624">15,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-790" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2625">14,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2626">15,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-792" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2627">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2628">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other countries, excluding Ireland</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-794" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2629">32,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-795" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2630">31,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-796" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2631">31,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-797" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2632">5,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-798" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2633">5,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2634">32,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2635">31,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2636">31,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2637">6,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2638">5,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No single customer represented over 10 percent of the Company&#8217;s consolidated net sales in fiscal years 2024, 2023, or 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_211"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) and changes in the Company&#8217;s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this annual report, our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) are effective.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company (as defined in Exchange Act Rule 13a-15(f)). Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, management concluded that the Company&#8217;s internal control over financial reporting was effective as of April&#160;26, 2024. The effectiveness of the Company's internal control over financial reporting as of April&#160;26, 2024 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended April&#160;26, 2024, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. </span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_214"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 10b5-1 Director and Officer Trading Arrangements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended April 26, 2024, <ix:nonNumeric contextRef="c-485" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-2639"><ix:nonNumeric contextRef="c-485" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-2640"><ix:nonNumeric contextRef="c-485" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-2641"><ix:nonNumeric contextRef="c-485" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-2642">none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement,"</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> as those terms are defined in Item 408 of Regulation S-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act Section 3(r) Disclosure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As reported in our Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024, Medtronic has engaged in certain activities that it is required to disclose pursuant to Section 13(r)(1)(D)(ii) of the Securities Exchange Act of 1934, as amended. In particular, during the first quarter of fiscal year 2024, Medtronic engaged in certain regulatory activities involving Russia&#8217;s Federal Security Service (&#8220;FSB&#8221;) related to its medical devices that were expressly authorized by the U.S. Government under applicable economic sanctions regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal year 2024, in the normal course of business and consistent with the OFAC authorizations as in effect at the time, Medtronic Russia filed a total of one notification with the FSB, as required under local Russian law for the import of medical devices that make use of encryption functionality. These activities did not directly result in any revenues or profits for Medtronic. Medtronic did not engage in these activities during the second, third, and fourth quarters of fiscal year 2024. To the extent that notifications with the FSB remain permissible under U.S. law, Medtronic may decide to continue engaging in such activities for the limited purposes of complying with local law requirements in Russia.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_2583"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_217"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_220"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part III of this Annual Report on Form 10-K incorporates information by reference from the Company's 2024 definitive proxy statement, which will be filed no later than 120 days after April&#160;26, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers, and Corporate Governance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sections entitled &#8220;Proposal 1 &#8212; Election of Directors &#8212; Directors and Nominees&#8221; and &#8220;Corporate Governance &#8212; Committees of the Board and Meetings&#8221; in the Company's Proxy Statement for our 2024 Annual General Meeting of Shareholders, which will be filed no later than 120 days after April&#160;26, 2024, are incorporated herein by reference.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-2643">adopted</ix:nonNumeric> an insider trading policy which governs the purchase, sale, and/or any other dispositions of our securities by directors, officers and employees and other covered persons and is designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. A copy of our insider trading policy is filed with this Annual Report on Form 10-K as Exhibit 19.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below are the names and ages of our Executive Officers of Medtronic, as well as information regarding their positions with Medtronic, their periods of service in these capacities, and their business experiences. There are no family relationships among any of the officers named, nor is there any arrangement or understanding pursuant to which any person was selected as an officer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the name, age, and position as of April&#160;26, 2024 of each of our Executive Officers:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Position with the Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey S. Martha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ivan K. Fong</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary of the Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert ten Hoedt </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Global Regions</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Marinaro</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Medical Surgical Portfolio and Surgical Operating Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen L. Parkhill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sean Salmon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Cardiovascular Portfolio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory L. Smith</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Global Operations and Supply Chain</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett Wall</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Neuroscience Portfolio</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geoffrey S. Martha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 54, is Chairman of the Board of Directors and Chief Executive Officer of Medtronic. Mr. Martha assumed the role of CEO on April 27, 2020 and became Chairman of the Board on December 11, 2020. Prior to his role as Chairman and CEO, he served as President of Medtronic from November 2019 through April 2020 and joined the Board of Directors in November 2019. Previously, Mr. Martha served as Executive Vice President and President, Restorative Therapies Group, a role he held since August 2015. Mr. Martha previously served as Senior Vice President of Strategy and Business Development of the Company beginning in January 2015 and of Medtronic, Inc. beginning in August 2011. Prior to that, he served as Managing Director of Business Development at GE Healthcare from April 2007 to July 2011; General Manager for GE Capital Technology Finance Services from November 2003 to March 2007; Senior Vice President, Business Development for GE Capital Vendor Financial Services from February 2002 to October 2003; General Manager for GE Capital Colonial Pacific Leasing from February 2001 to January 2002; and Vice President, Business Development for Potomac Federal, the GE Capital federal financing investment bank from May 1998 to January 2001.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ivan K. Fong</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 62, has been Executive Vice President, General Counsel and Corporate Secretary of the Company since February 2022. Prior to that, he held several leadership positions at 3M Company from 2012 to 2022, including Executive Vice President, Chief Legal and Policy Officer and Secretary. Prior to joining 3M Company, Mr. Fong served as General Counsel of the U.S. Department of Homeland Security from 2009 to 2012. Prior to his role with the U.S. Government, he was Chief Legal Officer and Secretary for Cardinal Health, Inc from 2005 to 2009.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Robert ten Hoedt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 63, is Executive Vice President and President of the Global Regions. He previously served as Executive Vice President and President, EMEA Region of the Company since January 2015 and of Medtronic, Inc. since May 2014, as well as President, APAC Region since March 2022. Prior to that, he was Senior Vice President and President, EMEA and Canada from 2009 to 2014; Vice President CardioVascular Europe and Central Asia from 2006 to 2009; Vice President and General Manager, Vitatron from 1999 to 2006; Gastro-Uro leader from 1994 to 1999; and Marketing Manager, Neurological from 1991 to 1994.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Michael Marinaro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, age 53, has served as Executive Vice President and President, Surgical Operating Unit since February 2023. Mr. Marinaro previously served as President of Surgical Robotics and, prior thereto, was President of the Cardiac Rhythm Management Operating Unit. Mr. Marinaro joined Medtronic in 2000 and has led numerous businesses across the company during that time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Karen L. Parkhill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 58, joined the Company as Executive Vice President and Chief Financial Officer in June 2016. From 2011 to 2016, Ms. Parkhill served as Vice Chairman and Chief Financial Officer of Comerica Incorporated. Ms. Parkhill was a member of Comerica&#8217;s Management Executive Committee and the Comerica Bank Board of Directors. Prior to joining Comerica, Ms. Parkhill worked for J.P. Morgan Chase &amp; Co. in various capacities from 1992 to 2011, including serving as Chief Financial Officer of the Commercial Banking business from 2007 to 2011.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sean Salmon, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">age 59, has been Executive Vice President and President of Medtronic's Cardiovascular Portfolio since January 2021. Mr. Salmon previously served as Executive Vice President and President of the Diabetes Operating Unit (previously known as Diabetes Group) from October 2019 to May 2022. Prior to that, he served as Senior Vice President and President of Coronary and Structural Heart Business within the Cardiac and Vascular Group of the Company beginning in July 2014. Mr. Salmon is a seasoned leader who has been with Medtronic since 2004 and spent the past 16 years in increasingly senior levels of management. Prior to joining Medtronic, Mr. Salmon worked at CR Bard and Johnson &amp; Johnson.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Gregory Smith,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> age 60, is Executive Vice President, Global Operations and Supply Chain, a position he has held since April 2021. Prior to joining Medtronic, he was Executive Vice President of U.S. Supply Chain at Walmart. In addition, Mr. Smith served as Senior Vice President, Global Operations at The Goodyear Tire &amp; Rubber Company, and held leadership roles at ConAgra Foods, United Signature Foods, VDK Frozen Foods and Quaker Oats.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brett Wall, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">age 59, is Executive Vice President and President of Medtronic&#8217;s Neuroscience Portfolio. Mr. Wall previously served as Senior Vice President and President of the Brain Therapies division of Medtronic within the Restorative Therapies Group from March 2016 to November 2019. Prior to that, Mr. Wall served as SVP and President of Medtronic&#8217;s Neurovascular business. Prior to joining Medtronic, he served as Covidien&#8217;s SVP and President of Neurovascular as well as Senior Vice President and President of the International Vascular Therapies business for Covidien. Mr. Wall also served as Senior Vice President and President, International at ev3, Inc. From 2000 to 2008, Brett held various marketing and sales positions with ev3, Inc. and Micro Therapeutics, Inc. Mr. Wall has also worked at Boston Scientific as Director of Marketing, Cardiovascular, Asia Pacifica and Marketing Manager, Japan, from September 1995 to September 2000.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_223"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 11 will be included in our Proxy Statement for the 2024 Annual General Meeting of Shareholders under the headings &#8220;Corporate Governance &#8212; Director Compensation,&#8221; &#8220;Corporate Governance &#8212; Committees of the Board and Meetings,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Executive Compensation,&#8221; and &#8220;Compensation Committee Report,&#8221; and is incorporated herein by reference. The Proxy Statement will be filed no later than 120 days after April&#160;26, 2024.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_226"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by Item 12 will be included in our Proxy Statement for the 2024 Annual General Meeting of Shareholders under the headings &#8220;Share Ownership Information &#8212; Significant Shareholders,&#8221; &#8220;Share Ownership Information &#8212; Beneficial Ownership of Management,&#8221; and &#8220;Executive Compensation &#8212; Equity Compensation Plan Information,&#8221; and is incorporated herein by reference. The Proxy Statement will be filed no later than 120 days after April&#160;26, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_229"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 13 will be included in our Proxy Statement for the 2024 Annual General Meeting of Shareholders under the headings &#8220;Corporate Governance &#8212; Director Independence&#8221; and &#8220;Corporate Governance &#8212; Related Party Transactions and Other Matters,&#8221; and is incorporated herein by reference. The Proxy Statement will be filed no later than 120 days after April&#160;26, 2024.</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_232"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 14 will be included in our Proxy Statement for the 2024 Annual General Meeting of Shareholders under the headings &#8220;Corporate Governance &#8212; Committees of the Board and Meetings&#8221; and &#8220;Audit and Non-Audit Fees,&#8221; and is incorporated herein by reference. The Proxy Statement will be filed no later than 120 days after April&#160;26, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_238"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.866%"><tr><td style="width:1.0%"/><td style="width:3.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1. Financial Statement Schedule</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule II. Valuation and Qualifying Accounts &#8212; fiscal years ended April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="f-2644" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDTRONIC PLC AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II &#8211; VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges to Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges to Other Accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Changes (Debit) Credit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at End of<br/>Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for doubtful accounts and credit losses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 26, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-799" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2645">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-800" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-2646">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-800" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-2647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-800" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2648">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-801" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2649">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 28, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-802" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2650">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-803" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-2651">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-803" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-2652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-803" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2653">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-799" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2654">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 29, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-804" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2655">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-805" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-2656">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-805" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-2657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-805" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2658">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-802" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2659">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax valuation allowance: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 26, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-806" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2660">11,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-807" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="6" id="f-2661">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-807" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-2662">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-807" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2663">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-808" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2664">13,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-807" decimals="-6" name="mdt:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" scale="6" id="f-2665">545</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-807" decimals="-6" name="mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" scale="6" id="f-2666">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 28, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2667">6,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="6" id="f-2668">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-2669">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2670">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-806" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2671">11,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" scale="6" id="f-2672">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="6" id="f-2673">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 29, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2674">5,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-2675">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-2676">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2677">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2678">6,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.458%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a) Primarily consists of uncollectible accounts written off, less recoveries.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b) Reflects the impact from acquisitions.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c) Primarily reflects carryover attribute utilization and expiration.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(d) Primarily reflects the effects of currency fluctuations.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(e) Primarily reflects the impacts from tax rate changes.</span></td></tr></table></div></ix:nonNumeric><div id="ia6bfc65eaa654c3ebf593baab4e46685_241"></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.600%"><tr><td style="width:1.0%"/><td style="width:4.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2. Exhibits</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515020681/d859999dex31.htm">Certificate of Incorporation of Medtronic plc (incorporated by reference to Exhibit 3.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312517030983/d338710dex32.htm">Amended and Restated Memorandum and Articles of Association of Medtronic plc (incorporated by reference to Exhibit 3.2 to Medtronic plc&#8217;s Registration Statement on Form S-3, filed on February 6, 2017, File No. 333-215895).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000095013709001623/c49806exv4w1.htm">Form of Indenture between Medtronic, Inc. and Wells Fargo Bank, National Association regarding 2009 offering (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Registration Statement on Form S-3, filed on March 9, 2009, File No. 333-157777).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000095013709001761/c50013exv4w1.htm">First Supplemental Indenture, dated March 12, 2009, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on March 12, 2009, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000095012310025103/c56981exv4w1.htm">Second Supplemental Indenture, dated March 16, 2010, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on March 16, 2010, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000095012311025816/c63508exv4w1.htm">Third Supplemental Indenture, dated March 15, 2011, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current report on Form 8-K, filed on March 16, 2011, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312512123407/d318842dex42.htm">Fourth Supplemental Indenture, dated March 19, 2012, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.2 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on March 20, 2012, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312513126071/d508677dex41.htm">Fifth Supplemental Indenture, dated March 26, 2013, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on March 26, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312514072613/d684319dex42.htm">Sixth Supplemental Indenture, dated February 27, 2014, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Form of Global Note thereof) (incorporated by reference to Exhibit 4.2 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on February 27, 2014, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex42.htm">Seventh Supplemental Indenture, dated as of January 26, 2015, by and among Medtronic plc, Medtronic, Inc., Medtronic Global Holdings S.C.A. and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 4.2 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312514439048/d835649dex41.htm">Indenture, dated December 10, 2014, between Medtronic, Inc. and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current Report on Form 8-K filed with the Commission on December 10, 2014, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312514439048/d835649dex42.htm">First Supplemental Indenture, dated December 10, 2014, between Medtronic, Inc. and Wells Fargo Bank, National Association (including Form of Floating Rate Senior Notes due 2020, Form of 1.500% Senior Notes due 2018, Form of 2.500% Senior Notes due 2020, Form of 3.150% Senior Notes due 2022, Form of 3.500% Senior Notes due 2025, Form of 4.375% Senior Notes due 2035 and Form of 4.625% Senior Notes due 2045) (incorporated by reference to Exhibit 4.2 of Medtronic, Inc.&#8217;s Current Report on Form 8-K filed with the Commission on December 10, 2014, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex43.htm">Second Supplemental Indenture, dated as of January 26, 2015, by and among Medtronic plc and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 4.3 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex44.htm">Third Supplemental Indenture, dated as of January 26, 2015, by and among Medtronic Global Holdings S.C.A. and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 4.4 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312523060059/d449390dex49.htm">Fourth Supplemental Indenture to Medtronic, Inc. Senior Indenture, dated as of February  22, 2023, among Medtronic Global Holdings, S.C.A., Medtronic, Inc. and Medtronic plc and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, N.A.), as trustee (incorporated by reference to Exhibit  4.9 to Medtronic plc&#8217;s Registration Statement on Form S-3, filed on March 3, 2023)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312524152334/d811133dex41.htm">Fifth Supplemental Indenture to Medtronic, Inc. Senior Indenture, dated as of June  3, 2024, among Medtronic, Inc., Medtronic plc, Medtronic Global Holdings S.C.A., Computershare Trust Company, N.A., as trustee, and Elavon Financial Services DAC, UK Branch (incorporated by reference to Exhibit 4.1 to Medtronic plc&#8217;s Form 8-K, filed on June 3, 2024)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1385187/000119312507222875/dex41a.htm">Indenture, dated as of October 22, 2007, by and among Covidien International Finance S.A., Covidien Ltd. and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1(a) to Covidien plc&#8217;s Current Report on Form 8-K filed on October 22, 2007, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1385187/000119312507222875/dex41e.htm">Fourth Supplemental Indenture, dated as of October 22, 2007, by and among Covidien International Finance S.A., Covidien Ltd. and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1(e) to Covidien plc&#8217;s Current Report on Form 8-K filed on October 22, 2007, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1385187/000119312509125706/dex41.htm">Fifth Supplemental Indenture, dated as of June 4, 2009, by and among Covidien International Finance S.A., Covidien Ltd., Covidien plc and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1 to Covidien plc&#8217;s Current Report on Form 8-K12G3 filed on June 5, 2009, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1385187/000119312510148405/dex41.htm">Sixth Supplemental Indenture, dated as of June 28, 2010, among Covidien International Finance S.A., Covidien Ltd., Covidien plc and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1 to Covidien plc&#8217;s Current Report on Form 8-K filed on June 28, 2010, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1385187/000119312512253576/d359452dex41.htm">Seventh Supplemental Indenture, dated as of May 30, 2012, among Covidien International Finance S.A., Covidien Ltd., Covidien plc and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1 to Covidien plc&#8217;s Current Report on Form 8-K filed on May 30, 2012, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1385187/000119312513224369/d540273dex41.htm">Eighth Supplemental Indenture, dated as of May 16, 2013, among Covidien International Finance S.A., Covidien Ltd., Covidien plc and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1 to Covidien plc&#8217;s Current Report on Form 8-K filed on May 16, 2013, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex45.htm">Ninth Supplemental Indenture, dated as of January 26, 2015, by and among Medtronic plc, Medtronic Global Holdings S.C.A., Covidien public limited company, Covidien International Finance S.A., Covidien Ltd. and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.5 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312517099886/d290589dex41.htm">Senior Indenture, dated as of March 28, 2017, by and among Medtronic plc, Medtronic Global Holdings S.C.A., Medtronic, Inc., and Wells Fargo Bank, N.A. (incorporated by reference to Exhibit&#160;4.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on March 28, 2017, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312517099886/d290589dex42.htm">First Supplemental Indenture, dated as of March 28, 2017, by and among Medtronic plc, Medtronic Global Holdings S.C.A., Medtronic, Inc., and Wells Fargo Bank, N.A. (incorporated by reference to Exhibit&#160;4.2 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on March 28, 2017, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312519066295/d710754dex41.htm">Second Supplemental Indenture, dated as of March 7, 2019, by and among Medtronic plc, Medtronic Global Holdings S.C.A., Medtronic, Inc., Wells Fargo Bank, N.A., and Elavon Financial Services DAC, UK Branch (incorporated by reference to Exhibit&#160;4.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on March 7, 2019, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312519187797/d762838dex41.htm">Third Supplemental Indenture, dated as of July 2, 2019, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC (incorporated by reference to Exhibit 4.1 to Medtronic plc' Current Report on Form 8-K, filed July 2, 2019, File No. 001-36820)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001613103/000119312520257811/d19681dex41.htm">Fourth Supplemental Indenture, dated as of September 29, 2020, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC, as paying agent (including the forms of the 2023 Notes, the 2025 Notes, the 2028 Notes, the 2032 Notes, the 2040 Notes and the 2050 Notes) (incorporated by reference to Exhibit 4.1 to Medtronic plc' Current Report on Form 8-K, filed September 29, 2020, File No. 001-36820)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000119312522248112/d406839d8k.htm">Fifth Supplemental Indenture, dated as of September 21, 2022, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC, as paying agent (including the forms of the 2025 Notes, the 2028 Notes, the 2031 Notes and the 2034 Notes) (incorporated by reference to Exhibit 4.1 to Medtronic plc&#8217;s Current Report on Form 8-K filed on September 21, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312523060059/d449390dex42.htm">Sixth Supplemental Indenture, dated as of February 22, 2023, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee (incorporated by reference to Exhibit 4.2 to Medtronic plc&#8217;s Registration Statement on Form S-3, filed on March 3, 2023, File No. 333-270272).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000119312523085642/d490503d8k.htm">Seventh Supplemental Indenture, dated as of March 30, 2023, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee (including the forms of the 2028 Notes and the 2033 Notes) (incorporated by reference to Exhibit 4.2 to Medtronic plc&#8217;s Current Report on Form 8-K filed on March 30, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#4.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex430.htm">Description of  Registrant's Securities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312518348880/d672316dex101.htm">Amended and Restated Credit Agreement, dated as of December 12, 2018, by and among Medtronic Global Holdings, SCA, certain subsidiaries named therein, Medtronic, Inc., Medtronic PLC, the lenders from time to time party thereto, and Bank of America, N.A. as Administration Agent (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on December 13, 2018, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000007/exhibit101amendedandre.htm">Amendment No. 1 and Extension Agreement to the Amended and Restated Credit Agreement, dated as of December 12, 2019, among Medtronic Global Holdings S.C.A., Medtronic, Inc., Medtronic PLC, the Lenders party thereto and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 10-Q, filed on February 28, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000016/exhibit1001termloanagr.htm">Term Loan Agreement, dated as of May 12, 2020, among Medtronic Global Holdings S.C.A., Medtronic, Inc., Medtronic PLC, the Lenders party thereto and Mizuho Bank, LTD., as Administrative Agent (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on May 12, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000119312522135320/d347836d8k.htm">Term Loan Agreement, dated as of May 2, 2022, by and among Medtronic Global Holdings S.C.A., Medtronic, Inc., Medtronic plc, and Mizuho Bank, Ltd., as administrative agent and as lender (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on May 2, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex101.htm">Form of Deed of Indemnification (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex102.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1014.htm">Change of Control Severance Plan - Section 16B Officers (as amended and restated as of January 26, 2015) (incorporated by reference to Exhibit 10.14 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312516576336/d184885dex101.htm">Letter Agreement by and between Medtronic, Inc. and Karen Parkhill dated May 2, 2016 (incorporated by reference to Exhibit 10.1 to Medtronic, plc&#8217;s Current Report on Form 8-K, filed on May 4, 2016, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310322000046/mdt-20220729.htm">Letter Agreement by and between Medtronic, Inc. and Ivan K. Fong dated November 19, 2021 (incorporated by reference to Exhibit 10.1 to Medtronic, plc&#8217;s Quarterly Report on Form 10-Q, filed on September 1, 2022).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310319000056/officeofchairmanandchi.htm">Office of Chairman and Chief Executive Officer Letter Agreement (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q, filed on December 3, 2019, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1025.htm">Form of Offer Letter Amendment (incorporated by reference to Exhibit 10.25 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108000478/medtronic080932_ex10-3.htm">1998 Outside Director Stock Compensation Plan (as amended and restated effective as of January 1, 2008) (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 25, 2008, filed on, filed on March 4, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515021907/d858587dex102.htm">Amendment to the 1998 Outside Director Stock Compensation Plan (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108000478/medtronic080932_ex10-4.htm">2003 Long-Term Incentive Plan (as amended and restated effective January 1, 2008) (incorporated by reference to Exhibit 10.4 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2008, filed on March 4, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515021907/d858587dex103.htm">Amendment to the 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000110465905009815/a05-4434_1ex10d3.htm">Form of Restricted Stock Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2005, filed on March 7, 2005, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000110465905009815/a05-4434_1ex10d1.htm">Form of Non-Qualified Stock Option Agreement under 2003 Long-Term Incentive Plan (four year vesting) (incorporated by reference to Exhibit 10.1 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2005, filed on March 7, 2005, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000110465905009815/a05-4434_1ex10d2.htm">Form of Non-Qualified Stock Option Agreement under 2003 Long-Term Incentive Plan (immediate vesting) (incorporated by reference to Exhibit 10.2 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2005, filed on March 7, 2005, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710105001490/med052766_ex10-20.htm">Form of Restricted Stock Units Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.20 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 29, 2005, filed on June 29, 2005, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710105001490/med052766_ex10-21.htm">Form of Performance Share Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.21 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 29, 2005, filed on June 29, 2005, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710106001326/medtronic062430s1_ex10-23.htm">Form of Non-Qualified Stock Option Agreement under 2003 Long-Term Incentive Plan effective June 22, 2006 (incorporated by reference to Exhibit 10.23 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 28, 2006, filed on June 28, 2006, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710106001326/medtronic062430s1_ex10-24.htm">Form of Restricted Stock Award Agreement under 2003 Long-Term Incentive Plan effective June 22, 2006 (incorporated by reference to Exhibit 10.24 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 28, 2006, filed on June 28, 2006, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710106001326/medtronic062430s1_ex10-25.htm">Form of Restricted Stock Unit Award Agreement under 2003 Long-Term Incentive Plan effective June 22, 2006 (incorporated by reference to Exhibit 10.25 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 28, 2006, filed on June 28, 2006, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710106001326/medtronic062430s1_ex10-26.htm">Form of Performance Award Agreement under 2003 Long-Term Incentive Plan effective June 22, 2006 (incorporated by reference to Exhibit 10.26 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 28, 2006, filed on June 28, 2006, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710107002582/medtronic074976_ex10-3.htm">Form of Restricted Stock Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 26, 2007, filed on December 4, 2007, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710107002582/medtronic074976_ex10-4.htm">Form of Restricted Stock Unit Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 26, 2007, filed on December 4, 2007, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108001392/medtronic082604s1_ex10-39.htm">Form of Non-Qualified Stock Option Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.39 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 25, 2008, filed on June 24, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108001392/medtronic082604s1_ex10-40.htm">Form of Restricted Stock Unit Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.40 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 25, 2008, filed on June 24, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108001392/medtronic082604s1_ex10-41.htm">Form of Restricted Stock Unit Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.41 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 25, 2008, filed on June 24, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108000478/medtronic080932_ex10-5.htm">Israeli Amendment to the 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.5 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 25, 2008, filed on March 4, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710109002528/medtronic095603_ex10-2.htm">2008 Stock Award and Incentive Plan (as amended and restated effective August 27, 2009) (incorporated by reference to Exhibit 10.2 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2009, filed on December 9, 2009, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.32</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex104.htm">Amendment to the 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.33</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108001858/medtronic083633_ex10-2.htm">Form of Restricted Stock Unit Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.2 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 25, 2008, filed on September 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.34</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108001858/medtronic083633_ex10-3.htm">Form of Restricted Stock Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 25, 2008, filed on September 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.35</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108001858/medtronic083633_ex10-4.htm">Form of Restricted Stock Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 25, 2008, filed on September 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.36</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108001858/medtronic083633_ex10-5.htm">Form of Restricted Stock Unit Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.5 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 25, 2008, filed on September 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.37</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108001858/medtronic083633_ex10-6.htm">Form of Non-Qualified Stock Option Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.6 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 25, 2008, filed on September 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.38</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710112001054/medtronic122599_ex10-42.htm">Terms of Non-Employee Director Compensation under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.42 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 27, 2012, filed on June 26, 2012, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108002439/medtronic084960_ex10-1.htm">Form of Non-Employee Director Initial Option Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.1 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 24, 2008, filed on December 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108002439/medtronic084960_ex10-2.htm">Form of Non-Employee Director Annual Option Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.2 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 24, 2008, filed on December 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108002439/medtronic084960_ex10-3.htm">Form of Non-Employee Director Deferred Unit Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 24, 2008, filed on December 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.42</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310315000028/mdt-20150425xex1065.htm">Form of Non-Employee Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.65 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 24, 2015, filed on June 23, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.43</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1010.htm">Israeli Amendment to the Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.10 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310317000027/mdt-2018q1xex101.htm">Form of Restricted Stock Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.1 to Medtronic plc's Quarterly Report on Form 10-K for the quarter ended July 28, 2017, filed on September 1, 2017, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.45</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310317000055/exhibit101medtronicplcamen.htm">Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan (as amended and restated generally effective December 8, 2017) (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on December 12, 2017, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310318000024/exhibit1050.htm">Form of Non-qualified Stock Option Agreement Amended and Restated 2013 Stock Award and Incentive Plan  (incorporated by reference to Exhibit 10.50 to Medtronic plc&#8217;s Annual Report on Form 10-K, filed June 22, 2018, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310318000024/exhibit1051.htm">Form of Restricted Stock Unit Award Agreement Amended and Restated 2013 Stock Award and Incentive Plan  (incorporated by reference to Exhibit 10.51 to Medtronic plc&#8217;s Annual Report on Form 10-K, filed June 22, 2018, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.48</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310318000024/exhibit1052.htm">Form of Restricted Stock Award Agreement Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.52 to Medtronic plc&#8217;s Annual Report on Form 10-K, filed June 22, 2018, File No. 001-36820)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.49</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310318000024/exhibit1053.htm">Form of Long Term Performance Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.53 to Medtronic plc&#8217;s Annual Report on Form 10-K, filed June 22, 2018, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1031.htm">Form of Non-Qualified Stock Option Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.31 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.51</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000051/ex101-formofperformanc.htm">Form of Performance Share Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.52</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000089710108002439/medtronic084960_ex10-3.htm">Form of Non-Employee Director Deferred Unit Award Agreement under the 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 24, 2008, filed on December 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.53</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex102.htm">Form of Non-Qualified Stock Option Agreement under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.2 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex103.htm">Form of Restricted Stock Unit Award Agreement (U.S. Employees) under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.55</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex104.htm">Form of Restricted Stock Unit Award Agreement (Non-U.S. Employees) under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex105.htm">Form of Restricted Stock Unit Award Agreement (Time-Based) under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.5 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex108.htm">Form of Restricted Stock Unit Award Agreement (Israeli-Employees) under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.8 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.58</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1048.htm">Form of Non-Qualified Stock Option Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.48 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.59</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1049.htm">Form of Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.49 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.60</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1050.htm">Form of Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.50 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.61</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1051.htm">Form of Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.51 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.62</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1053.htm">Form of Stock Option Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.53 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.63</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1054.htm">Form of Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.54 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000021/mdt202010k-ex1069.htm">Form of Restricted Stock Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan  (incorporated by reference to Exhibit 10.69 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 24, 2020, filed on June 19, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.65</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000021/mdt202010k-ex1070.htm">Form of Non-Qualified Stock Option Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.70 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 24, 2020, filed on June 19, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.66</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1011.htm">Medtronic plc Incentive Plan (as amended and restated effective January 26, 2015) (incorporated by reference to Exhibit 10.11 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.67</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1015.htm">Medtronic plc Supplemental Executive Retirement Plan (as restated generally effective January 26, 2015) (incorporated by reference to Exhibit 10.15 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.68</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000051/ex103-medtronicnonxqua.htm">Medtronic Non-Qualified Retirement Plan Supplemental (restated November 6, 2020, and formerly known as the Supplemental Executive Retirement Plan) (incorporated by reference to Exhibit 10.3 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.69</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515023510/d859659dex422.htm">Medtronic plc Savings and Investment Plan (as amended and restated generally effective January 26, 2015) (incorporated by reference to Exhibit 4.22 to Medtronic plc&#8217;s Registration Statement on Form S-8 filed on January 28, 2015, File No. 333-201737).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.70</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515023510/d859659dex423.htm">Medtronic plc Puerto Rico Employees&#8217; Savings and Investment Plan (as amended and restated generally effective January 26, 2015) (incorporated by reference to Exhibit 4.23 to Medtronic plc&#8217;s Registration Statement on Form S-8 filed on January 28, 2015, File No. 333-201737).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.71</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1013.htm">Medtronic plc Capital Accumulation Plan Deferral Program (as amended and restated generally effective January 26, 2015) (incorporated by reference to Exhibit 10.13 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.72</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1613103/000161310316000123/exhibit101-medtronicplccap.htm">Capital Accumulation Plan Deferral Program (as amended and restated generally effective January 1, 2017) (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 28, 2016, filed on December 5, 2016, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.73</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000051/ex102-amendedandrestat.htm">Amended and Restated Covidien Supplemental Savings and Retirement Plan (restated November 6, 2020) (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000051/ex104-medtroniccapital.htm">Medtronic Capital Accumulation Plan Deferral Program (restated November 6, 2020) (incorporated by reference to Exhibit 10.4 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.75</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001613103/000161310321000065/exhibit1001-amendmentno3an.htm">Amendment No. 3 and Extension Agreement to the Amended and Restated Credit Agreement, dated as of December 13, 2021, by and among Medtronic Global Holdings S.C.A., certain subsidiaries of Medtronic plc from time to time party thereto, Medtronic, Inc., Medtronic plc, the lenders from time to time party thereto and Bank of America N.A., as administrative agent. (incorporated by reference to Exhibit 10.01 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on December 14, 2021, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.76</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex101.htm">Medtronic Capital Accumulation Plan Deferral Program (as restated generally effective January 1, 2017) (Conformed through the Amendment generally effective as of January 1, 2022)  (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.77</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex102.htm">2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.78</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex103.htm">Performance Share Unit Agreement 2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.3 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.79</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex104.htm">Non-Qualified Stock Option Agreement 2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.4 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.80</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex105.htm">Restricted Stock Unit Award Agreement for awards vesting 100% on the third anniversary of the grant date - 2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.5 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.81</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex106.htm">Restricted Stock Unit Award Agreement for awards vesting ratably on the first, second, third, and fourth anniversary of the grant date - 2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.6 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.82</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310323000008/mdt-2023q310xqxex101.htm">Amendment No. 4 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2022 (incorporated by reference to Exhibit 10.1 to Medtronic plc's Quarterly Report on Form 10-Q for the quarter ended January 27, 2023, filed on March 1, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310323000008/mdt-20230127.htm">Annex I to Amendment No. 4 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2022 (incorporated by reference to Exhibit 10.1 to Medtronic plc's Quarterly Report on Form 10-Q for the quarter ended January 27, 2023, filed on March 1, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.84</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310323000040/mdt-20230428.htm">Amendment No. 2 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2020 (incorporated by reference to Exhibit 10.85 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 28, 2023, filed on June 22, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310323000040/mdt-20230428.htm">Medtronic Nonqualified Retirement Plan Supplement dated as of April 28, 2023 (incorporated by reference to Exhibit 10.86 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 28, 2023, filed on June 22, 2023, File No. 001-36820)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.86</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1613103/000161310323000128/mdt-20230728.htm">Performance Share Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q filed on August 31, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1613103/000161310323000128/mdt-20230728.htm">Restricted Stock Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q filed on August 31, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.88</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1613103/000161310323000128/mdt-20230728.htm">Restricted Stock Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q filed on August 31, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.89</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1613103/000161310323000128/mdt-20230728.htm">Non-Qualified Stock Option Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q filed on August 31, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.90</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1613103/000161310323000128/mdt-20230728.htm">Medtronic plc 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K filed on October 23, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410xex19.htm">Medtronic plc Global Insider Trading Policy</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex21.htm">List of Subsidiaries of Medtronic plc. </a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex22.htm">List of Senior Notes, Issuers and Guarantors.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex23.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex24.htm">Power of Attorney.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#32.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex321.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#32.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex322.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202410kxex97.htm">Medtronic plc Policy For The Recovery of Erroneously Awarded Compensation</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document </span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document </span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.LAB </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document </span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.PRE </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document </span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"/><td style="width:3.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.403%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Exhibits that are management contracts or compensatory plans or arrangements.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#Filed herewith</span></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_244"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has not elected to include such summary information.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="ia6bfc65eaa654c3ebf593baab4e46685_247"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia6bfc65eaa654c3ebf593baab4e46685_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medtronic plc</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">/s/ Geoffrey S. Martha</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Geoffrey S. Martha</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medtronic plc</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ Geoffrey S. Martha</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geoffrey S. Martha</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Karen L. Parkhill</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Karen L. Parkhill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ Jennifer M. Kirk</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jennifer M. Kirk</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Global Controller and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Accounting Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Craig Arnold*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott C. Donnelly*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lidia Fonseca*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Andrea J. Goldsmith, Ph.D.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Randall J. Hogan*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gregory P. Lewis*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kevin E. Lofton*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geoffrey S. Martha</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Elizabeth G. Nabel, M.D.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denise M. O&#8217;Leary*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kendall J. Powell*</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Ivan K. Fong, by signing his name hereto, does hereby sign this document on behalf of each of the above named directors of the registrant pursuant to powers of attorney duly executed by such persons.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ Ivan K. Fong</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ivan K. Fong</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.30
<SEQUENCE>2
<FILENAME>mdt-202410kxex430.htm
<DESCRIPTION>EX-4.30
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0a4e2c03e8b44361b24fb464ce2c2260_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exhibit 4.30</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the &#8220;Ordinary Shares&#8221;), of Medtronic plc, a company incorporated under the laws of Ireland (&#8220;Medtronic&#8221; or &#8220;Medtronic plc&#8221;), (ii) the 0.250% Senior Notes due 2025, 0.000% Senior Notes due 2025, 2.625% Senior Notes due 2025, 1.125% Senior Notes due 2027, 0.375% Senior Notes due 2028, 3.000% Senior Notes due 2028, 1.625% Senior Notes due 2031, 1.00% Senior Notes due 2031, 3.125% Senior Notes due 2031, 0.750% Senior Notes due 2032, 3.375% Senior Notes due 2034, 2.250% Senior Notes due 2039, 1.500% Senior Notes due 2039, 1.375% Senior Notes due 2040, 1.750% Senior Notes due 2049, and 1.625% Senior Notes due 2050, issued by Medtronic Global Holdings S.C.A., an entity incorporated and existing under the laws of Luxembourg (&#8220;Medtronic Luxco&#8221;), and (iii) the 3.650% Senior Notes due 2029, 3.875% Senior Notes due 2036, 4.150% Senior Notes due 2043, and 4.150% Senior Notes due 2053, issued by Medtronic Inc., a Minnesota corporation, which are all of the securities of Medtronic and its subsidiaries registered pursuant to Section 12 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF MEDTRONIC ORDINARY SHARES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description of Medtronic&#8217;s share capital is a summary. This summary does not purport to be complete and is qualified in its entirety by reference to the Irish Companies Act 2014 (as amended) (the &#34;Irish Companies Act&#34;) and the complete text of Medtronic&#8217;s memorandum and articles of association, as they may be amended from time to time (the &#8220;Articles of Association&#8221;). Copies of the Articles of Association have been filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as exhibit 3.1 to Medtronic&#8217;s Annual Report on Form 10-K.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Capital Structure </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Authorized Share Capital </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc is authorized to issue 2.6 billion ordinary shares, $0.0001 par value&#59; 40 thousand euro deferred shares, &#8364;1.00 par value&#59; 127.5 million preferred shares, $0.20 par value&#59; and 500 thousand A preferred shares, $1.00 par value.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic may issue shares subject to the maximum authorized share capital contained in the Articles of Association. The authorized share capital may be increased or reduced by a resolution approved by a simple majority of the votes of Medtronic&#8217;s shareholders cast at a general meeting (referred to under Irish law as an &#8220;ordinary resolution&#8221;). The shares comprising the authorized share capital of Medtronic may be divided into shares of such nominal value as the resolution shall prescribe. As a matter of Irish company law, the directors of a company may issue new ordinary or preferred shares without shareholder approval once authorized to do so by the Articles of Association or by an ordinary resolution adopted by the shareholders at a general meeting. The authorization may be granted for a maximum period of five years, at which point it must be renewed by the shareholders by an ordinary resolution. Medtronic's shareholders adopted an ordinary resolution at the 2023 annual general meeting of Medtronic on October 19, 2023 authorizing the board of directors to issue up to an aggregate nominal amount of $26,623.12 (being equivalent to approximately 20% of the aggregate nominal value of the issued share capital of Medtronic as of August 7, 2023) for a period of 18 months from October 19, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rights and restrictions to which the ordinary shares, euro deferred shares and A preferred shares are subject are prescribed in the Articles of Association. The Articles of Association entitle the Medtronic board of directors, without shareholder approval, to determine the terms of the preferred shares issued by Medtronic. Preferred shares may be preferred as to dividends, rights upon liquidation or voting in such manner as the directors of Medtronic may resolve. The preferred shares may also be redeemable at the option of the holder of the preferred shares or at the option of Medtronic, and may be convertible into or exchangeable for shares of any other class or classes of Medtronic, depending on the terms of such preferred shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holders of the A preferred shares are entitled in priority to any payments of dividends on any other class of shares in Medtronic to be paid a dividend in the amount per A preferred share equal to twice the dividend to be paid per ordinary share and in addition on a return of assets, whether on liquidation or otherwise, the A preferred shares entitle the holders to repayment of the capital paid up on those shares (including any share premium) in priority to any repayment of capital to the holders of any other shares. The holders of the A preferred shares are not entitled to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">any further participation in the assets or profits of Medtronic, nor are the holders of the A preferred shares, which are non-voting shares, entitled to receive notice of, attend, speak or vote at any general meeting of Medtronic. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holders of euro deferred shares are not entitled to receive any dividend or distribution and are not entitled to receive notice of, attend, speak or vote at any general meeting of Medtronic. On a return of assets, the euro deferred shares will entitle the holder only to the repayment of amounts paid up on such shares after repayment of the capital paid up on the ordinary shares plus the payment of $5,000,000 on each ordinary share. There are no euro deferred shares in issue.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Irish law does not recognize fractional shares held of record. Accordingly, the Articles of Association do not provide for the issuance of fractional shares of Medtronic, and the official Irish register of Medtronic does not reflect any fractional shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Whenever an alteration or reorganization of the share capital of Medtronic would result in any Medtronic shareholder becoming entitled to fractions of a share, the Medtronic board of directors may, on behalf of those shareholders that would become entitled to fractions of a share, arrange for the sale of the shares representing fractions and the distribution of the net proceeds of sale in due proportion among the shareholders who would have been entitled to the fractions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Preemption Rights, Share Warrants and Share Options </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Irish law certain statutory preemption rights apply automatically in favor of shareholders where shares are to be issued for cash. Medtronic initially opted out of these preemption rights in the Articles of Association as permitted under Irish company law. Because Irish law requires this opt-out to be renewed every five years by a resolution approved by not less than 75% of the votes of the shareholders of Medtronic cast at a general meeting (referred to under Irish law as a &#8220;special resolution&#8221;), the Articles of Association provide that this opt-out must be so renewed. If the opt-out is not renewed, shares issued for cash must be offered to existing shareholders of Medtronic on a pro rata basis to their existing shareholding before the shares can be issued to any new shareholders. The statutory preemption rights do not apply where shares are issued for non-cash consideration (such as in a stock-for-stock acquisition) and do not apply to the issue of non-equity shares (that is, shares that have the right to participate only up to a specified amount in any income or capital distribution) or where shares are issued pursuant to an employee stock option or similar equity plan. Medtronic's shareholders passed a special resolution at the 2023 annual general meeting of Medtronic on October 19, 2023 authorizing the Medtronic board of directors to opt out of preemption rights with respect to the issuance of equity securities up to an aggregate nominal value of $26,623.12 (being equivalent to approximately 20% of the aggregate nominal value of the issued ordinary share capital of Medtronic as of August 7, 2023) for a period of 18 months from October 19, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association of Medtronic provide that, subject to any shareholder approval requirement under any laws, regulations or the rules of any stock exchange to which Medtronic is subject, the board is authorized, from time to time, in its discretion, to grant such persons, for such periods and upon such terms as the board deems advisable, options to purchase such number of shares of any class or classes or of any series of any class as the board may deem advisable, and to cause warrants or other appropriate instruments evidencing such options to be issued. The Irish Companies Act provides that directors may issue share warrants or options without shareholder approval once authorized to do so by the Articles of Association or an ordinary resolution of shareholders. Medtronic is subject to the rules of the NYSE and the U.S. Internal Revenue Code of 1986, as amended, which require shareholder approval of certain equity plan and share issuances. Medtronic&#8217;s board of directors may issue shares upon exercise of warrants or options without shareholder approval or authorization (up to the relevant authorized share capital limit). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividends </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Irish law, dividends and distributions may be made only from distributable reserves. Distributable reserves generally means accumulated realized profits less accumulated realized losses and includes reserves created by way of capital reduction. In addition, no distribution or dividend may be made unless the net assets of Medtronic are equal to, or in excess of, the aggregate of Medtronic&#8217;s called up share capital plus undistributable reserves and the distribution does not reduce Medtronic&#8217;s net assets below such aggregate. Undistributable reserves include the share </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">premium account, the par value of Medtronic shares acquired by Medtronic and the amount by which Medtronic&#8217;s accumulated unrealized profits, so far as not previously utilized by any capitalization, exceed Medtronic&#8217;s accumulated unrealized losses, so far as not previously written off in a reduction or reorganization of capital. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The determination as to whether or not Medtronic has sufficient distributable reserves to fund a dividend must be made by reference to &#8220;relevant financial statements&#8221; of Medtronic. The &#8220;relevant financial statements&#8221; will be either the last set of unconsolidated annual audited financial statements or other financial statements properly prepared in accordance with the Irish Companies Act, which give a &#8220;true and fair view&#8221; of Medtronic&#8217;s unconsolidated financial position and accord with accepted accounting practice. The &#8220;relevant financial statements&#8221; must be filed in the Companies Registration Office (the official public registry for companies in Ireland). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association authorize the directors to declare dividends out of funds lawfully available for the purpose without shareholder approval. The board of directors may also recommend a dividend to be approved and declared by the Medtronic shareholders at a general meeting. The board of directors may direct that the payment be made by distribution of assets, shares or cash and no dividend issued may exceed the amount recommended by the directors. Dividends may be declared and paid in the form of cash or non-cash assets and may be paid in U.S. dollars or any other currency. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The directors of Medtronic may deduct from any dividend payable to any shareholder any amounts payable by such shareholder to Medtronic in relation to the shares of Medtronic. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The directors may also authorize Medtronic to issue shares with preferred rights to participate in dividends declared by Medtronic. The holders of preferred shares may, depending on their terms, rank senior to the Medtronic ordinary shares in terms of dividend rights and&#47;or be entitled to claim arrears of a declared dividend out of subsequently declared dividends in priority to ordinary shareholders. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of Medtronic Ordinary Shares&#8212;Capital Structure&#8212;Authorized Share Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional information on dividend rights.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Share Repurchases, Redemptions and Conversions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Overview </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that any ordinary share which Medtronic has agreed to acquire will be deemed to be a redeemable share, unless the board resolves otherwise. Accordingly, for Irish company law purposes, the repurchase of ordinary shares by Medtronic may technically be effected as a redemption of those shares as described below under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of Medtronic Ordinary Shares&#8212;Share Repurchases, Redemptions and Conversions&#8212;Repurchases and Redemptions by Medtronic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#8221; If the Articles of Association did not contain such provision, all repurchases by Medtronic would be subject to many of the same rules that apply to purchases of Medtronic ordinary shares by subsidiaries described below under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;Purchases by Subsidiaries of Medtronic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#8221; including the shareholder approval requirements described below and the requirement that any on-market purchases be effected on a &#8220;recognized stock exchange.&#8221; Except where otherwise noted, references to repurchasing or buying back ordinary shares of Medtronic refer to the redemption of ordinary shares by Medtronic or the purchase of ordinary shares of Medtronic by a subsidiary of Medtronic, in each case in accordance with the Articles of Association and Irish company law as described below. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Repurchases and Redemptions by Medtronic </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Irish law, a company may issue redeemable shares and redeem them out of distributable reserves or the proceeds of a new issue of shares for that purpose. Medtronic may only issue redeemable shares if the nominal value of the issued share capital that is not redeemable is not less than 10% of the nominal value of the total issued share capital of Medtronic. All redeemable shares must also be fully-paid. Based on the provision of the Articles of Association described above, shareholder approval will not be required to redeem Medtronic shares. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic may also be given an additional general authority by its shareholders to purchase its own shares on-market, which would take effect on the same terms and be subject to the same conditions as applicable to purchases by Medtronic&#8217;s subsidiaries as described below. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The board of directors of Medtronic may also issue preferred shares which may be redeemed at the option of either Medtronic or the shareholder, depending on the terms of such preferred shares. Please see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of Medtronic Ordinary Shares&#8212;Capital Structure&#8212;Authorized Share Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional information on preferred shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Repurchased and redeemed shares may be cancelled or held as treasury shares. The nominal value of treasury shares held by Medtronic at any time must not exceed 10% of the aggregate of the par value and share premium received in respect of the allotment of  Medtronic shares together with the par value of any shares acquired by Medtronic. Medtronic may not exercise any voting rights in respect of any shares held as treasury shares. Treasury shares may be cancelled by Medtronic or re-issued subject to certain conditions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that Medtronic may not, directly or indirectly, purchase or agree to purchase any shares entitled to vote from a person who beneficially owns more than five percent of the voting power of Medtronic for more than the market value thereof if the shares have been beneficially owned by the person for less than two years, unless the purchase or agreement to purchase is approved at a meeting of shareholders by the affirmative vote of the holders of not less than a majority of the issued and outstanding shares of Medtronic entitled to vote or Medtronic makes an offer, of at least equal value per share, to all holders of shares of the class or series and to all holders of any class or series into which the securities may be converted. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Purchases by Subsidiaries of Medtronic </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Irish law, an Irish or non-Irish subsidiary may purchase shares of Medtronic either on-market or off-market. For a subsidiary of Medtronic to make on-market purchases of Medtronic ordinary shares, the shareholders of Medtronic must provide general authorization for such purchase by way of ordinary resolution. However, as long as this general authority has been granted, no specific shareholder authority for a particular on-market purchase by a subsidiary of Medtronic ordinary shares is required. For an off-market purchase by a subsidiary of Medtronic, the proposed purchase contract must be authorized by special resolution of the shareholders before the contract is entered into. The person whose shares are to be bought back cannot vote in favor of the special resolution and, from the date of the notice of the meeting at which the resolution approving the contract is to be proposed, the purchase contract must be on display or must be available for inspection by shareholders at the registered office of Medtronic. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order for a subsidiary of Medtronic to make an on-market purchase of Medtronic&#8217;s shares, such shares must be purchased on a &#8220;recognized stock exchange.&#8221; The NYSE, on which the shares of Medtronic are listed, is specified as a recognized stock exchange for this purpose by Irish company law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The number of shares held by the subsidiaries of Medtronic at any time will count as treasury shares and will be included in any calculation of the permitted treasury share threshold of 10% of the aggregate of the par value and share premium in respect of the allotment of Medtronic shares together with the par value of any shares acquired by Medtronic. While a subsidiary holds shares of Medtronic, it cannot exercise any voting rights in respect of those shares. The acquisition of the shares of Medtronic by a subsidiary must be funded out of distributable reserves of the subsidiary. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lien on Shares, Calls on Shares and Forfeiture of Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that Medtronic has a first and paramount lien on every share for all debts and liabilities of any shareholder to the company, whether presently due or not, payable in respect of such share. Subject to the terms of their allotment, directors may call for any unpaid amounts in respect of any shares to be paid, and if payment is not made, the shares may be forfeited. These provisions are standard inclusions in the articles of association of an Irish company limited by shares such as Medtronic and will only be applicable to shares of Medtronic that have not been fully paid up. See also &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;Transfer and Registration of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; below. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consolidation and Division&#59; Subdivision </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Articles of Association, Medtronic may, by ordinary resolution, consolidate and divide all or any of its share capital into shares of larger nominal value than its existing shares or subdivide its shares into smaller amounts than is fixed by its memorandum of association. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reduction of Share Capital </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic may, by ordinary resolution, reduce its authorized but unissued share capital in any way. Medtronic also may, by special resolution and subject to confirmation by the Irish High Court, reduce or cancel its issued share capital in any manner permitted by the Irish Companies Act. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Annual Meetings of Shareholders </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic is required to hold an annual general meeting at intervals of no more than 15 months, provided that an annual general meeting is held in each calendar year no more than nine months after Medtronic's fiscal year-end. Any annual general meeting may be held outside of Ireland, provided that technological means are provided to enable shareholders to participate in the meeting without leaving Ireland.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notice of an annual general meeting must be given to all Medtronic shareholders and to the auditors of Medtronic. The Articles of Association provide for a minimum notice period of 21 days, which is the minimum permitted under Irish law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The only matters which must, as a matter of Irish company law, be transacted at an annual general meeting are (i) the consideration of the statutory financial statements and reports of the directors and auditors, (ii) the review by the members of the company's affairs and (iii) the appointment or re-appointment of the auditors and the fixing of the auditor&#8217;s remuneration (or delegation of same). If no resolution is made in respect of the reappointment of an existing auditor at an annual general meeting, the existing auditor will be deemed to have continued in office. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Extraordinary General Meetings of Shareholders </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Extraordinary general meetings of Medtronic may be convened by (i) the board of directors, (ii) any two directors, (iii) the chief executive officer, (iv) the chief financial officer, (v) on requisition of the shareholders holding not less than 10% of the paid up share capital of Medtronic carrying voting rights or (vi) on requisition of Medtronic&#8217;s auditors. Extraordinary general meetings are generally held for the purposes of approving shareholder resolutions as may be required from time to time. At any extraordinary general meeting, only such business will be conducted as is set forth in the notice thereof or is proposed pursuant to and in accordance with the procedures and requirements set out in the Articles of Association. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notice of an extraordinary general meeting must be given to all Medtronic shareholders and to the auditors of Medtronic. Under Irish law and the Articles of Association, the minimum notice periods are 21 days&#8217; notice in writing for an extraordinary general meeting to approve a special resolution and 14 days&#8217; notice in writing for any other extraordinary general meeting. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the case of an extraordinary general meeting convened by shareholders of Medtronic, the proposed purpose of the meeting must be set out in the requisition notice. Upon receipt of any such valid requisition notice, the Medtronic board of directors has 21 days to convene a meeting of Medtronic shareholders to vote on the matters set out in the requisition notice. This meeting must be held within two months of the receipt of the requisition notice. If the board of directors does not convene the meeting within such 21-day period, the requisitioning shareholders, or any of them representing more than one half of the total voting rights of all of them, may themselves convene a meeting, which meeting must be held within three months of Medtronic&#8217;s receipt of the requisition notice. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the board of directors becomes aware that the net assets of Medtronic are not greater than half of the amount of Medtronic&#8217;s called-up share capital, the directors of Medtronic must convene an extraordinary general meeting of Medtronic shareholders not later than 28 days from the date that they learn of this fact to consider how to address the situation. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Quorum for General Meetings </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that no business may be transacted at any general meeting unless a quorum is present. One or more shareholders present in person or by proxy at any meeting of shareholders holding not less than a majority of the issued and outstanding shares entitled to vote at the meeting in question will constitute a quorum for such meeting. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Voting </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that all votes will be decided on a poll and that the board or the chairman may determine the manner in which the poll is to be taken and the manner in which the votes are to be counted. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Every shareholder is entitled to one vote for each ordinary share that he or she holds as of the record date for the meeting. Voting rights may be exercised by shareholders registered in Medtronic&#8217;s share register as of the record date for the meeting or by a duly appointed proxy, which proxy need not be a shareholder. Where interests in shares are held by a nominee trust company, this company may exercise the rights of the beneficial holders on their behalf as their proxy. All proxies must be appointed in the manner prescribed by the Articles of Association, which provide that the Medtronic board may permit shareholders to notify Medtronic of their proxy appointments electronically. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Irish company law requires special resolutions of the shareholders at a general meeting to approve certain matters. Examples of matters requiring special resolutions include&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"><tr><td style="width:1.0%"></td><td style="width:3.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amending the objects or memorandum of association of Medtronic&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amending the Articles of Association&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">approving a change of name of Medtronic&#59;</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Variation of Rights Attaching to a Class or Series of Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Articles of Association and the Irish Companies Act, any variation of class rights attaching to the issued shares of Medtronic must be approved by an ordinary resolution of the shareholders of the affected class or with the consent in writing of the holders of the majority of the issued shares of that class of shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provisions of the Articles of Association relating to general meetings apply to general meetings of the holders of any class of shares except that the necessary quorum is determined in reference to the shares of the holders of the class. Accordingly, for general meetings of holders of a particular class of shares, a quorum consists of one or more shareholders present in person or by proxy holding not less than a majority of the issued and outstanding shares of the class entitled to vote at the meeting in question. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisitions </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An Irish public limited company may be acquired in a number of ways, including&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a court-approved scheme of arrangement under the Irish Companies Act. A scheme of arrangement with shareholders requires a court order from the Irish High Court and the approval of a majority in number representing 75% in value of each class of shareholder present and voting in person or by proxy at a meeting called to approve the scheme&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">through a tender or takeover offer by a third party for all of the shares of Medtronic. Where the holders of 80% or more of Medtronic&#8217;s shares have accepted an offer for their shares in Medtronic, the remaining shareholders may also be statutorily required to transfer their shares. If the bidder does not exercise its &#8220;squeeze out&#8221; right, then the non-accepting shareholders also have a statutory right to require the bidder to acquire their shares on the same terms. If shares of Medtronic were to be listed on the Irish Stock Exchange or another regulated stock exchange in the European Union, the &#8220;squeeze out&#8221; threshold would be increased to 90%&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">by way of a merger with a company incorporated in the European Economic Area (&#8220;EEA&#8221;) under the EU Cross-Border Mergers Directive (EU) 2017&#47;1132 (as amended) or with another Irish company under the Irish Companies Act. Such a merger must be approved by a special resolution. Shareholders also may be entitled to have their shares acquired for cash. See the section entitled &#8220;Description of Share Capital&#8212;Appraisal Rights&#8221;</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Appraisal Rights </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Generally, under Irish law, shareholders of an Irish company do not have statutory appraisal rights. If  Medtronic is being merged as the transferor company with another EEA company under the EU Cross-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Border Mergers Directive (EU) 2017&#47;1132 (as amended) as implemented in Ireland by the European Union (Cross- Border Conversions, Mergers and Divisions) Regulations 2023 or if Medtronic is being merged with another Irish company under the Irish Companies Act, (i) any of Medtronic's shareholders who voted against the special resolution approving the merger or (ii) if 90% of Medtronic's shares are held by the successor company, any other of Medtronic's shareholders, may be entitled to require that the successor company acquire its shares for cash. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disclosure of Interests in Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Irish Companies Act, Medtronic shareholders must notify Medtronic if, as a result of a transaction, the shareholder will become interested in 3% or more of the shares of Medtronic or if, as a result of a transaction a shareholder who was interested in more than 3% of the shares of Medtronic ceases to be so interested. Where a shareholder is interested in more than 3% of the shares of Medtronic, the shareholder must notify Medtronic of any alteration of his or her interest that brings his or her total holding through the nearest whole percentage number, whether an increase or a reduction. The relevant percentage figure is calculated by reference to the aggregate nominal value of the shares in which the shareholder is interested as a proportion of the entire nominal value of the issued share capital of Medtronic (or any such class of share capital in issue). Where the percentage level of the shareholder&#8217;s interest does not amount to a whole percentage, this figure may be rounded down to the next whole number. Medtronic must be notified within five business days of the transaction or alteration of the shareholder&#8217;s interests that gave rise to the notification requirement. If a shareholder fails to comply with these notification requirements, the shareholder&#8217;s rights in respect of any Medtronic shares it holds will not be enforceable, either directly or indirectly. However, such person may apply to the court to have the rights attaching to such shares reinstated. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to these disclosure requirements, Medtronic, under the Irish Companies Act, may, by notice in writing, require a person whom Medtronic knows or has reasonable cause to believe to be, or at any time during the three years immediately preceding the date on which such notice is issued to have been, interested in shares comprised in Medtronic&#8217;s relevant share capital to&#58; (i) indicate whether or not it is the case and (ii) where such person holds or has </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during that time held an interest in the shares of Medtronic, to provide additional information, including the person&#8217;s own past or present interests in shares of Medtronic. If the recipient of the notice fails to respond within the reasonable time period specified in the notice, Medtronic may apply to court for an order directing that the affected shares be subject to certain restrictions, as prescribed by the Irish Companies Act. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Medtronic is in an offer period pursuant to the Irish Takeover Rules, accelerated disclosure provisions apply for persons holding an interest in Medtronic securities of 1% or more. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the beneficial ownership disclosures of the U.S. federal securities laws will apply with respect to beneficial ownership of Medtronic shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-Takeover Provisions </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business Combinations with Interested Shareholders </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic's Articles of Association provide that, subject to certain exceptions, Medtronic may not engage in certain business combinations with any person that acquires beneficial ownership of 10% or more of Medtronic's outstanding voting shares for a period of four years following the date on which the person became a 10% shareholder unless prior to the person becoming a 10% shareholder, a committee of Medtronic's disinterested directors approve the business combination or the acquisition of shares.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Control Share Acquisition</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain exceptions, Medtronic's Articles of Association restrict the ability of persons who acquire between twenty percent and thirty percent of the voting rights of Medtronic to exercise the voting rights of the acquired shares in excess of twenty percent absent approval by an ordinary resolution of the disinterested shareholders. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Irish Takeover Rules and Substantial Acquisition Rules </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A transaction in which a third party seeks to acquire 30% or more of the voting rights of Medtronic will be governed by the Irish Takeover Panel Act 1997 and the Irish Takeover Rules made thereunder and will be regulated by the Irish Takeover Panel. The &#8220;General Principles&#8221; of the Irish Takeover Rules and certain important aspects of the Irish Takeover Rules are described below. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">General Principles </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Irish Takeover Rules are built on the following General Principles, which will apply to any transaction regulated by the Irish Takeover Panel&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in the event of an offer, all holders of securities of the target company should be afforded equivalent treatment and, if a person acquires control of a company, the other holders of securities must be protected&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the holders of the securities of the target company must have sufficient time and information to enable them to reach a properly informed decision on the offer&#59; where it advises the holders of securities, the board of the target company must give its views on the effects of implementation of the offer on employment, conditions of employment and the locations of the target company&#8217;s places of business&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the board of the target company must act in the interests of the company as a whole and must not deny the holders of securities the opportunity to decide on the merits of the offer&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">false markets must not be created in the securities of the target company, the bidder or of any other company concerned by the offer in such a way that the rise or fall of the prices of the securities becomes artificial and the normal functioning of the markets is distorted&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a bidder must announce an offer only after ensuring that he or she can fulfill in full, any cash consideration, if such is offered, and after taking all reasonable measures to secure the implementation of any other type of consideration&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a target company must not be hindered in the conduct of its affairs for longer than is reasonable by an offer for its securities&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a substantial acquisition of securities (whether such acquisition is to be effected by one transaction or a series of transactions) shall take place only at an acceptable speed and shall be subject to adequate and timely disclosure.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Mandatory Bid </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under certain circumstances, a person who acquires shares or other voting rights in Medtronic may be required under the Irish Takeover Rules to make a mandatory cash offer for the remaining outstanding shares in Medtronic at a price not less than the highest price paid for the shares by the acquirer (or any parties acting in concert with the acquirer) during the previous 12 months. This mandatory bid requirement is triggered if an acquisition of shares would increase the aggregate holding of an acquirer (including the holdings of any parties acting in concert with the acquirer) to shares representing 30% or more of the voting rights in Medtronic, unless the Irish Takeover Panel otherwise consents. An acquisition of shares by a person holding (together with its concert parties) shares representing between 30% and 50% of the voting rights in Medtronic would also trigger the mandatory bid requirement if, after giving effect to the acquisition, the percentage of the voting rights held by that person (together with its concert parties) would increase by 0.05% within a 12-month period. Any person (excluding any parties acting in concert with the holder) holding shares representing more than 50% of the voting rights of a company is not subject to these mandatory offer requirements in purchasing additional securities. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Voluntary Bid&#59; Requirements to Make a Cash Offer and Minimum Price Requirements </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a person makes a voluntary offer to acquire outstanding ordinary shares of Medtronic, the offer price must be no less than the highest price paid for Medtronic ordinary shares by the bidder or its concert parties during the three-month period prior to the commencement of the offer period. The Irish Takeover Panel has the power to extend the &#8220;look back&#8221; period to 12 months if the Irish Takeover Panel, taking into account the General Principles, believes it is appropriate to do so. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the bidder or any person acting in concert with it has acquired ordinary shares of Medtronic (i) during the period of 12 months prior to the commencement of the offer period which represent more than 10% of the total ordinary shares of Medtronic or (ii) at any time after the commencement of the offer period, the offer must be in cash (or accompanied by a full cash alternative) and the price per Medtronic ordinary share must not be less than the highest price paid by the bidder or any person acting in concert with it during, in the case of (i), the 12-month period prior to the commencement of the offer period or, in the case of (ii), the offer period. The Irish Takeover Panel may apply this rule to a bidder who, together with any person acting in concert with it, has acquired less than 10% of the total ordinary shares of Medtronic in the 12-month period prior to the commencement of the offer period if the Irish Takeover Panel, taking into account the General Principles, considers it just and proper to do so. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An offer period will generally commence from the date of the first announcement of the offer or proposed offer. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Articles of Association provide that an offeror who has completed a tender offer for Medtronic may not, within two years after the last purchase in the tender offer, acquire additional shares, whether by purchase, merger, exchange or otherwise, unless the shareholders in those additional acquisitions are given terms that are substantially equivalent to those provided in the earlier tender offer or unless the proposed additional acquisitions are approved by an independent committee of Medtronic&#8217;s board of directors prior to the tender </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">offer. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Takeover Timeline</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Irish Takeover Rules, in certain circumstances a strict 42-day deadline will be imposed within which a person with whom we are in talks, or from whom we have received an approach, regarding a possible offer is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">required to make a firm offer for Medtronic, or announce they will not be making an offer. The Irish Takeover Panel may agree to extend this deadline at our request. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Substantial Acquisition Rules </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Irish Takeover Rules also contain rules governing substantial acquisitions of shares and other voting securities which restrict the speed at which a person may increase his or her holding of shares and rights over shares to an aggregate of between 15% and 30% of the voting rights of Medtronic. Except in certain circumstances, an acquisition or series of acquisitions of shares or rights over shares representing 10% or more of the voting rights of Medtronic is prohibited, if such acquisition(s), when aggregated with shares or rights already held, would result in the acquirer holding 15% or more but less than 30% of the voting rights of Medtronic and such acquisitions are made within a period of seven days. These rules also require accelerated disclosure of acquisitions of shares or rights over shares relating to such holdings. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shareholder Rights Plan </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association expressly authorize Medtronic&#8217;s board of directors to adopt a shareholder rights plan, subject to applicable law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Irish law does not expressly authorize or prohibit companies from issuing share purchase rights or adopting a shareholder rights plan as an anti-takeover measure and there is no directly relevant case law on this issue.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Frustrating Action </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Irish Takeover Rules, the Medtronic board of directors is not permitted to take any action which might frustrate an offer for the shares of Medtronic once the Medtronic board of directors has received an approach which may lead to an offer or has reason to believe an offer is or may be imminent, subject to certain exceptions. Potentially frustrating actions such as (i) the issue of shares, options or convertible securities, (ii) material acquisitions or disposals, (iii) entering into contracts other than in the ordinary course of business or (iv) any action, other than seeking alternative offers, which may result in frustration of an offer, are prohibited during the course of an offer or at any time during which the board has reason to believe an offer is or may be imminent. Exceptions to this prohibition are available where&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the action is approved by Medtronic&#8217;s shareholders at a general meeting&#59; or</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Irish Takeover Panel has given its consent, where&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">it is satisfied the action would not constitute frustrating action&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic shareholders that hold 50% of the voting rights state in writing that they approve the proposed action and would vote in favor of it at a general meeting&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the action is taken in accordance with a contract entered into prior to the announcement of the offer&#59; or</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iv)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the decision to take such action was made before the announcement of the offer and either has been at least partially implemented or is in the ordinary course of business.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Governance </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association of Medtronic allocate authority over the day-to-day management of Medtronic to the Medtronic board of directors. The Medtronic board of directors may then, by resolution approved by the affirmative vote of a majority of the board, delegate any of its powers, authorities and discretions (with power to sub-delegate) to any committee, consisting of one or more directors, or delegate to any director, officer or member of management of Medtronic or any of its subsidiaries such of its powers as it considers desirable to be exercised by him or her, but </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">regardless, the directors will remain responsible, as a matter of Irish law, for the proper management of the affairs of Medtronic. Committees may meet and adjourn as they determine proper. Unless otherwise determined by the board of directors, the quorum necessary for the transaction of business at any committee meeting shall be a majority of the members of the committee. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic has a standing Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, Quality Committee, Finance and Financial Risk Committee and Technology and Value Creation Committee. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Appointment of Directors </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Irish Companies Act provides for a minimum of two directors. Medtronic's Articles of Association provide for a minimum of three directors and a maximum of fifteen. The board of directors has sole authority to determine its size within these parameters.  Directors of Medtronic will be elected by way of an ordinary resolution at a general meeting. This majority voting standard could result in the number of directors falling below the prescribed minimum number of directors due to the failure of nominees to be elected. If the number of the directors is reduced below the fixed minimum number, the remaining director or directors must appoint, as soon as practicable, an additional director or additional directors to make up such minimum or must convene a general meeting of Medtronic for the purpose of making such appointment. In the event of a &#8220;contested election&#8221; of directors, directors shall be elected by the vote of a plurality of the votes cast at any meeting for the election of directors at which a quorum is present. Each director of Medtronic must retire from office at each annual shareholder meeting and shall be re-eligible for re-election. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No person may be appointed director unless nominated in accordance with the Articles of Association. The Articles of Association provide that, with respect to an annual or extraordinary general meeting of shareholders, nominations of persons for election to the Medtronic board of directors may be made by (i) the affirmative vote of the Medtronic board of directors or a committee thereof, (ii) any shareholder who is entitled to vote at the meeting and who has complied with the advance notice procedures provided for in the Articles of Association, (iii) with respect to election at an extraordinary general meeting requisitioned in accordance with section 178(3) of the Irish Companies Act, by a shareholder who holds ordinary shares or other shares carrying the general right to vote at general meetings of the company and who makes such nomination in the written requisition of the extraordinary general meeting in accordance with the Articles of Association and the Irish Companies Act relating to nominations of directors and the proper bringing of business before an extraordinary general meeting, or (iv) any shareholder who is entitled to vote at the meeting and who has complied with the &#34;proxy access&#34; provisions contained in the Articles of Association. Medtronic&#8217;s Articles of Association contain &#8220;proxy access&#8221; provisions which give an eligible shareholder (or group of up to 20 such shareholders) that has owned 3% or more of the voting power continuously for at least three years, the right to nominate up to 20% of the directors and to have those nominees included in Medtronic&#8217;s proxy materials, subject to the other terms and conditions of Medtronic's articles of association.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Removal of Directors </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Irish Companies Act, the shareholders may, by an ordinary resolution, remove a director from office before the expiration of his or her term at a meeting held on no less than 28 days&#8217; notice and at which the director is entitled to be heard. The power of removal is without prejudice to any claim for damages for breach of contract (e.g., employment contract) that the director may have against Medtronic in respect of his or her removal. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The board of directors may fill any vacancy occurring on the board of directors. If the Medtronic board of directors fills a vacancy, the director shall hold office until the next election of directors and until his or her successor shall be elected. A vacancy on the board of directors created by the removal of a director may be filled by the Medtronic board of directors. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Duration&#59; Dissolution&#59; Rights upon Liquidation </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic&#8217;s duration is unlimited. Medtronic may be dissolved and wound up at any time by way of a shareholders&#8217; voluntary winding up or a creditors&#8217; winding up. In the case of a shareholders&#8217; voluntary winding-up, a special resolution of shareholders is required. Medtronic may also be dissolved by way of court order on the application of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">creditor, or by the Companies Registration Office as an enforcement measure where Medtronic has failed to file certain returns. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rights of the shareholders to a return of Medtronic&#8217;s assets on dissolution or winding up, following the settlement of all claims of creditors, may be prescribed in the Articles of Association or the terms of any preferred shares issued by the directors of Medtronic from time to time. The holders of preferred shares in particular may have the right to priority in a dissolution or winding up of Medtronic. If the Articles of Association contain no specific provisions in respect of a dissolution or winding up then, subject to the priorities of any creditors, the assets will be distributed to shareholders in proportion to the paid-up nominal value of the shares held. The Articles of Association provide that the ordinary shareholders of Medtronic are entitled to participate pro rata in a winding up, but their right to do so may be subject to the rights of any preferred shareholders to participate under the terms of any series or class of preferred shares. Please see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of Medtronic Ordinary Shares&#8212;Capital Structure&#8212;Authorized Share Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional information on rights upon a liquidation. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uncertificated Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Irish Companies Act, a shareholder is entitled to be issued a share certificate on request and subject to payment of a nominal fee. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Stock Exchange Listing </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic ordinary shares are listed on the New York Stock Exchange under the ticker symbol &#8220;MDT.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">No Sinking Fund </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic ordinary shares have no sinking fund provisions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Transfer and Registration of Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transfer agent for Medtronic maintains the share register, registration in which is determinative of membership in Medtronic. A shareholder of Medtronic who holds shares beneficially is not holder of record of such shares. Instead, the depository or other nominee is the holder of record of those shares. Accordingly, a transfer of shares from a person who holds such shares beneficially to a person who also holds such shares beneficially through a depository or other nominee will not be registered in Medtronic&#8217;s official share register, as the depository or other nominee will remain the record holder of any such shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A written instrument of transfer is required under Irish law in order to register on Medtronic&#8217;s official share register any transfer of shares (i) from a person who holds such shares directly to any other person, (ii) from a person who holds such shares beneficially to a person who holds such shares directly or (iii) from a person who holds such shares beneficially to another person who holds such shares beneficially where the transfer involves a change in the depository or other nominee that is the record owner of the transferred shares. An instrument of transfer is also required for a shareholder who directly holds shares to transfer those shares into his or her own broker account (or vice versa). Such instruments of transfer may give rise to Irish stamp duty, which must be paid prior to registration of the transfer on Medtronic&#8217;s official Irish share register. However, a shareholder who directly holds shares may transfer those shares into his or her own broker account (or vice versa) without giving rise to Irish stamp duty provided there is no change in the ultimate beneficial ownership of the shares as a result of the transfer and the transfer is not made in contemplation of a sale of the shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any transfer of Medtronic ordinary shares that is subject to Irish stamp duty will not be registered in the name of the buyer unless an instrument of transfer is duly stamped and provided to the transfer agent. The Articles of Association allow Medtronic, in its absolute discretion, to create an instrument of transfer and pay (or procure the payment of) any stamp duty, which is the legal obligation of a buyer. In the event of any such payment, Medtronic is (on behalf of itself or its affiliates) entitled to (i) seek reimbursement from the buyer or seller (at its discretion), (ii) set-off the amount of the stamp duty against future dividends payable to the buyer or seller (at its discretion) and (iii) claim a lien against the Medtronic ordinary shares on which it has paid stamp duty. Parties to a share transfer may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">assume that any stamp duty arising in respect of a transaction in Medtronic ordinary shares has been paid unless one or both of such parties is otherwise notified by Medtronic. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association delegate to Medtronic&#8217;s secretary (or such other person as may be nominated by the secretary for this purpose) the authority to execute an instrument of transfer on behalf of a transferring party. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to help ensure that the official share register is regularly updated to reflect trading of Medtronic ordinary shares occurring through normal electronic systems, Medtronic intends to regularly produce any required instruments of transfer in connection with any transactions for which it pays stamp duty (subject to the reimbursement and set-off rights described above). In the event that Medtronic notifies one or both of the parties to a share transfer that it believes stamp duty is required to be paid in connection with the transfer and that it will not pay the stamp duty, the parties may either themselves arrange for the execution of the required instrument of transfer (and may request a form of instrument of transfer from Medtronic for this purpose) or request that Medtronic execute an instrument of transfer on behalf of the transferring party in a form determined by Medtronic. In either event, if the parties to the share transfer have the instrument of transfer duly stamped (to the extent required) and then provide it to Medtronic&#8217;s transfer agent, the buyer will be registered as the legal owner of the relevant shares on Medtronic&#8217;s official Irish share register (subject to the matters described below). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The directors may suspend registration of transfers from time to time, not exceeding 30 days in aggregate each year.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF DEBT SECURITIES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description of Medtronic&#8217;s registered debt securities is a summary. This summary does not purport to be complete and is qualified in its entirety by reference to the Medtronic Luxco, and Medtronic Inc., Base Indenture and Supplemental Indentures (each as hereinafter defined). Copies of the Medtronic Luxco Base Indenture and Medtronic Luxco Supplemental Indentures and the Medtronic Inc. Base Indenture and Medtronic Inc. Supplemental Indentures have been filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as exhibits </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respectively, to our Annual Report on Form 10-K for the fiscal year ended April 26, 2024. Copies of have been filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as exhibits 4.10, 4.11, 4.12, 4.13, 4.14, 4.22, 4.23, 4.24, 4.25, 4.26, 4.27, 4.28, and 4.29, respectively, to our Annual Report on Form 10-K for the fiscal year ended April 26, 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic Luxco series of notes was issued as a separate series of senior debt securities, under a Senior Indenture, dated March 28, 2017 (the &#8220;Medtronic Luxco Base Indenture&#8221;) among Medtronic Luxco, as issuer, Medtronic and Medtronic, Inc. as guarantors, and Computershare Trust Company National Association (as successor to Wells Fargo Bank, National Association) as trustee, as supplemented by the Second Supplemental Indenture, dated as of March 7, 2019 (the &#8220;Second Supplemental Indenture&#8221;), the Third Supplemental Indenture, dated as of July 2, 2019 (the &#8220;Third Supplemental Indenture&#8221;), the Fourth Supplemental Indenture, dated as of September 29, 2020 (the &#8220;Fourth Supplemental Indenture&#8221;), the Fifth Supplemental Indenture, dated as of September 21, 2022 (the &#8220;Fifth Supplemental Indenture&#8221;), the Sixth Supplemental Indenture, dated as of February 22, 2023 (the &#8220;Sixth Supplemental Indenture&#8221;), and the Seventh Supplemental Indenture, dated as of March 30, 2023 (the &#8220;Seventh Supplemental Indenture&#8221; and together with the Second, Third, Fourth, Fifth, Sixth, and Seventh Supplemental Indentures, (the &#8220;Medtronic Luxco Supplemental Indentures&#8221;). The Medtronic Luxco Base Indenture, together with the Medtronic Luxco Supplemental Indentures, shall be referred to throughout this description of debt securities as the &#8220;Medtronic Luxco Indenture.&#8221; Each series of notes is a general unsecured senior obligation of Medtronic Luxco and is fully and unconditionally guaranteed by Medtronic and Medtronic, Inc., on a joint and several basis. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic, Inc. series of notes was issued as a separate series of senior debt securities, under a Senior Indenture, dated December 10, 2014 (the &#8220;Medtronic Inc. Base Indenture&#8221;) among Medtronic Inc., as issuer, Medtronic and Medtronic Luxco as guarantors, and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association) as trustee, as supplemented by the Second Supplemental Indenture, dated as of January 26, 2015 (the &#8220;Medtronic Inc. Second Supplemental Indenture&#8221;), the Third Supplemental Indenture, dated as of January 26, 2015 (the &#8220;Medtronic Inc. Third Supplemental Indenture&#8221;), the Fourth Supplemental Indenture, dated as of February 22, 2023 (the &#8220;Medtronic Inc. Fourth Supplemental Indenture&#8221;), the Fifth Supplemental Indenture, dated as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of June 3, 2024 (the &#8220;Medtronic Inc. Fifth Supplemental Indenture&#8221;) and together with the Second, Third, Fourth, and Fifth Supplemental Indentures, the &#8220;Medtronic Inc. Supplemental Indentures&#8221;). The Medtronic Inc. Base Indenture, together with the Medtronic Inc. Supplemental Indentures, shall be referred to throughout this description of debt securities as the &#8220;Medtronic Inc. Indenture.&#8221; Each series of notes is a general unsecured senior obligation of Medtronic Inc. and is fully and unconditionally guaranteed by Medtronic and Medtronic Luxco, on a joint and several basis. The Medtronic Luxco Indenture, together with the Medtronic, Inc. Indenture, shall be referred to throughout this description of debt securities as the &#8220;Indentures.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The notes of each series are Issued only in registered form, without coupons, in minimum denominations of &#8364;100,000 and integral multiples of &#8364;1,000 in excess thereof. The notes of each series are issued in the form of one or more global securities that are deposited initially with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear Bank SA&#47;NV (&#8220;Euroclear&#8221;) and Clearstream Banking S.A. (&#8220;Clearstream&#8221;). U.S. Bank National Association acts as registrar for the notes. The notes may be presented for registration of transfer and exchange at the offices of the registrar. Medtronic Luxco entered into agency agreements with Elavon Financial Services DAC, UK Branch (&#8220;Elavon&#8221;) as paying agent and&#47;or calculation agent with respect to each series of notes. Medtronic Luxco may change any paying agent, calculation agent and registrar without notice to holders of the notes and may act as a paying agent, calculation agent or registrar. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Maturity</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each series of notes will mature and bear interest as provided in the following table&#58; </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Issuer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Maturity</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Payment Dates</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Record Dates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.250% 2025 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.250%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.000% 2025 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2025</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.000%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.625% 2025 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.625%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.125% 2027 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2027</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.125%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.375% 2028 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2028</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.375%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.000% 2028 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2028</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.000%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.650% 2029 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2029</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.650%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.625% 2031 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2031</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.000% 2031 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2, 2031</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.000%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.125% 2031 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2031</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.125%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.750% 2032 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2032</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.750%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.375% 2034 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2031</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.375%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.875% 2036 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2036</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.875%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.250% 2039 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2039</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.250%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.500% 2039 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2, 2039</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.500%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.375% 2040 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2040</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.375%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4.150% 2043 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2043</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.150%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.750% 2049 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2, 2049</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.750%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.625% 2050 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2050</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Inc.</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4.150% 2053 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2053</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.150%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The notes are not subject to any sinking fund. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Interest </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fixed Rate Notes </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 1.125% 2027 notes, the 1.625% 2031 notes, and the 2.250% 2039 notes bear interest from the date of issuance, payable annually in arrears on March 7 of each year. The 0.250% 2025 notes, the 1.000% 2031 notes, the 1.500% 2039 notes, and the 1.750% 2049 notes bear interest from the date of issuance, payable annually in arrears on July 2 of each year. The 0.000% 2025 notes, the 2.625% 2025 notes, the 0.375% 2028 notes, the 3.000% 2028 notes, the 3.650% 2029 notes, the 3.125% 2031 notes, the 0.750% 2032 notes, the 3.375% 2034 notes, the 3.875% 2036 notes, the 1.375% 2040 notes, the 4.150% 2043 notes, the 1.625% 2050 notes, and the 4.150% 2053 notes bear interest from the date of issuance, payable annually in arrears on October 15 of each year. The Interest is payable to the persons in whose names such notes are registered at the close of business on the business day (for this purpose, a day on which Clearstream and Euroclear are open for business) immediately preceding the relevant interest payment. Interest on the fixed rate notes will be computed on the basis of the actual number of days in the period for which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes, to, but excluding, the next scheduled interest payment date. This payment convention is referred to as Actual&#47;Actual (ICMA) as defined in the rulebook of the International Capital Market Association. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any interest payment date would otherwise be a day that is not a business day, such interest payment date will be postponed to the next date that is a business day and no interest will accrue on the amounts payable from and after such interest payment date to the next business day. If the maturity date of any series of fixed rate notes falls on a day that is not a business day, the related payment of principal, premium, if any, and interest will be made on the next business day as if it were made on the date such payment was due, and no interest will accrue on the amounts so payable for the period from and after such date to the next business day.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Guarantees </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of Medtronic and Medtronic, Inc. (each, a &#8220;Luxco Guarantor&#8221; and together, the &#8220;Luxco Guarantors&#8221;) fully and unconditionally guarantee, on a joint and several basis, the due and punctual payment of all obligations of Medtronic Luxco under the Medtronic Luxco notes, whether for the payment of principal of, premium, if any, or interest or certain additional amounts on the notes, when and as the same shall become due and payable, whether at maturity, declaration of acceleration, upon redemption, repurchase or otherwise. Each of Medtronic and Medtronic Luxco (each, a &#8220;Medtronic, Inc. Guarantor&#8221; and together, the &#8220;Medtronic, Inc. Guarantors&#8221;) fully and unconditionally guarantee, on a joint and several basis, the due and punctual payment of all obligations of Medtronic, Inc. under the Medtronic, Inc. notes, whether for the payment of principal of, premium, if any, or interest or certain additional amounts on the notes, when and as the same shall become due and payable, whether at maturity, declaration of acceleration, upon redemption, repurchase or otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notwithstanding the foregoing, each Guarantor will be automatically and unconditionally released from all obligations under its guarantee, and such guarantees shall terminate and be discharged and be of no further force and effect upon the occurrence of certain circumstances. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The guarantees of the notes may be subject to review under United States federal or state fraudulent transfer law or similar laws in other applicable jurisdictions, which could limit their enforceability. The guarantees will provide that the obligations of each Guarantor will be limited as necessary to prevent that guarantee from constituting a fraudulent conveyance or fraudulent transfer under applicable law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ranking </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic Luxco notes are unsecured senior obligations of Medtronic Luxco and rank equally in right of payment with each other and with all of Medtronic Luxco&#8217;s other existing and future unsecured senior obligations, including its outstanding guarantees of senior notes of other indebtedness of Medtronic, Inc. and other subsidiaries of Medtronic, including Covidien International Finance S.A., a wholly-owned indirect subsidiary of Medtronic Luxco. Additionally, the notes are effectively subordinated to any existing and future secured indebtedness of Medtronic Luxco, to the extent of the assets securing such indebtedness. The notes rank senior in right of payment to any existing and future subordinated indebtedness of Medtronic Luxco. The notes are also structurally subordinated to all existing and any future obligations of Medtronic Luxco&#8217;s subsidiaries (other than Medtronic, Inc. because of its guarantee of the notes).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The guarantees are unsecured senior obligations of each of Medtronic and Medtronic, Inc., and rank equally with all other unsecured senior obligations of Medtronic and Medtronic, Inc. as applicable. The guarantees of the notes rank equally in right of payment with all other existing and future unsecured senior obligations of Medtronic and Medtronic, Inc.&#59; be effectively subordinated to any existing and future secured indebtedness of Medtronic plc and Medtronic, Inc. to the extent of the assets securing such indebtedness&#59; and be structurally subordinated to all existing and future debt and other obligations of Medtronic&#8217;s and Medtronic, Inc.&#8217;s subsidiaries, respectively, including, with respect to Medtronic, Covidien International Finance S.A., a wholly-owned indirect subsidiary of Medtronic Luxco. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic, Inc. notes are unsecured senior obligations of Medtronic, Inc. and rank equally in right of payment with each other and with all of Medtronic Inc.&#8217;s other existing and future unsecured senior obligations, including its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">outstanding guarantees of senior notes of other indebtedness of Medtronic Luxco. The notes rank senior in right of payment to any existing and future subordinated indebtedness of Medtronic, Inc. The notes are also structurally subordinated to all existing and any future obligations of Medtronic, Inc.&#8217;s subsidiaries.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The guarantees are unsecured senior obligations of each of Medtronic and Medtronic Luxco, and rank equally with all other unsecured senior obligations of Medtronic and Medtronic Luxco as applicable. The guarantees of the notes rank equally in right of payment with all other existing and future unsecured senior obligations of Medtronic and Medtronic Luxco&#59; be effectively subordinated to any existing and future secured indebtedness of Medtronic and Medtronic Luxco to the extent of the assets securing such indebtedness&#59; and be structurally subordinated to all existing and future debt and other obligations of Medtronic plc&#8217;s and Medtronic, Inc.&#8217;s subsidiaries, respectively, including, with respect to Medtronic, Covidien International Finance S.A., a wholly-owned indirect subsidiary of Medtronic Luxco. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Optional Redemption </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medtronic Luxco and Medtronic, Inc. may redeem any series of the fixed rate notes, in whole or in part, in the case of the 0.250%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025 notes, the 0.000% 2025 notes, the 2.625% 2025 notes, the 1.125% 2027 notes, the 0.375% 2028 notes, the 3.000% 2028 notes, the 3.650% 2029 notes, the 1.625% 2031 notes, the 1.000% 2031 notes, the 3.125% 2031 notes, the 0.750% 2032 notes, the 3.375% 2034 notes, the 3.875% 2036 notes, the 2.250% 2039 notes, the 1.500% 2039 notes, the 1.375% 2040 notes, the 4.150% 2043 notes, the 1.750% 2049 notes, the 1.625% 2050 notes, and the 4.150% 2053 notes at any time prior to the applicable Par Call Date at a redemption price equal to the greater of&#58;  </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100% of the principal amount of the fixed rate notes of the applicable series being redeemed&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the sum, as determined by a Quotation Agent (defined below), of the present values of the Remaining Scheduled Payments (as defined below) of principal and interest on the notes of such series to be redeemed (excluding any portion of such payments of interest accrued as of the date of redemption and assuming, in the case of the 0.250% 2025 notes, the 0.000% 2025 notes, the 2.625% 2025 notes, the 1.125% 2027 notes, the 0.375% 2028 notes, the 3.000% 2028 notes, the 3.650% 2029 notes, the 1.625% 2031 notes, the 1.000% 2031 notes, the 3.125% 2031 notes, the 0.750% 2032 notes, the 3.375% 2034 notes, the 3.875% 2036 notes, the 2.250% 2039 notes, the 1.500% 2039 notes, the1.375% 2040 notes, the 4.150% 2043 notes, the 1.750% 2049 notes, the 1.625% 2050 notes, and the 4.150% 2053 notes, that such notes matured on the applicable Par Call Date), discounted to the redemption date on an annual basis (ACTUAL&#47;ACTUAL(ICMA)) at the Comparable Bond Rate (defined below), plus 15 basis points, in the case of the 0.250% 2025 notes, the 0.000% 2025 notes, and the 3.650% 2029 notes, 20 basis points, in the case of the 2.625% 2025 notes, the 1.125% 2027 notes, the 0.375% 2028 notes, the 1.000% 2031 notes, the 0.750% 2032 notes, the 3.875% 2036 notes, and the 4.150% 2043 notes, 25 basis points, in the case of the 3.000% 2028 notes, the 1.625% 2031 notes, the 3.125% 2031 notes, the 3.375% 2034 notes, the 1.500% 2039 notes the 1.750 % 2049 notes, and the 4.150% 2053 notes, and 30 basis points, in the case of the 2.250% 2039 notes the 1.375% 2040 notes, and the 1.625% 2050 notes&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">plus, in each case, accrued and unpaid interest to, but not including, the date of redemption. These notes may be redeemed in part in the minimum authorized denomination or in any integral multiple of such amount. Unless Medtronic Luxco or Medtronic, Inc. defaults in payment of the redemption price, on and after the redemption date, interest will cease to accrue on the fixed rate notes or portions thereof called for redemption.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, at any time on and after the applicable Par Call Date, the 0.250% 2025 notes, the 0.000% 2025 notes, the 2.625% 2025 notes, the 1.125% 2027 notes, the 0.375% 2028 notes, the 3.000% 2028 notes, the 3.650% 2029 notes, the 1.625% 2031 notes, the 1.000% 2031 notes, the 3.125% 2031 notes, the 0.750% 2032 notes, the 3.375% 2034 notes, the 3.875% 2036 notes, the 2.250% 2039 notes, the 1.500% 2039 notes, the 1.375% 2040 notes, the 4.150% 2043 notes, the 1.750% 2049 notes, the 1.625% 2050 notes, and the 4.150% 2053 notes, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">will be redeemable at Medtronic Luxco&#8217;s or Medtronic, Inc.&#8217;s option, in whole or in part, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the date of redemption. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco, or Medtronic, Inc., will provide notice of any optional redemption to each holder of notes of the series to be redeemed at least 15 days, but not more than 60 days, before the redemption date. A notice of redemption may, at the discretion of Medtronic Luxco, or Medtronic, Inc., be subject to one or more conditions precedent, including, but not limited to, completion of an equity offering, a financing, or other corporate transaction. In addition, if such redemption or notice is subject to satisfaction of one or more conditions precedent, such notice shall state that, in Medtronic Luxco&#8217;s, or Medtronic, Inc.&#8217;s, discretion, the redemption date may be postponed until up to 60 days following the notice of redemption, and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied by the redemption date (including as it may be postponed). Medtronic Luxco, or Medtronic, Inc., will give notice of such redemption to the trustee at least 10 days prior to the date Medtronic Luxco, or Medtronic, Inc., mails the notice of redemption to each holder (or such shorter time as may be acceptable to the trustee). Unless Medtronic Luxco, or Medtronic, Inc., defaults in payment of the redemption price on the redemption date, on and after the redemption date, interest will cease to accrue on the fixed rate notes or portions thereof called for redemption. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If Medtronic Luxco, or Medtronic, Inc., does not redeem all of the fixed rate notes of a particular series, the trustee shall select the fixed rate notes of that series to be redeemed in any manner that it deems fair and appropriate consistent with the applicable procedures of the despositary. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any notice to holders of fixed rate notes of a redemption hereunder shall include the appropriate calculation of the redemption price, but does not need to include the redemption price itself. The actual redemption price, calculated as described above, will be set forth in an officers&#8217; certificate delivered to the trustee no later than two business days prior to the redemption date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Comparable Bond Rate&#8221; means, for any redemption date, the rate per annum equal to the annual equivalent yield to maturity or interpolated yield to maturity (on a day count basis), computed as the third business day immediately preceding that redemption date, of the Comparable Government Issue (as defined below), assuming a price for the Comparable Government Issue (expressed as a percentage of its principal amount) equal to the Comparable Price (as defined below) for that redemption date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Comparable Government Issue&#8221; means the euro-denominated security issued by the German federal government selected by a Quotation Agent as having an actual or interpolated maturity comparable to the remaining term of the fixed rate notes to be redeemed (assuming that the notes to be redeemed matured on the applicable Par Call Date) that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the notes to be redeemed. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Comparable Price&#8221; means, with respect to any redemption date, (1) the average of the Reference Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest of the Reference Dealer Quotations, (2) if Medtronic Luxco, or Medtronic, Inc., obtains fewer than four Reference Dealer Quotations, the arithmetic average of those quotations or (3) if Medtronic Luxco, or Medtronic, Inc., obtains only one Reference Dealer Quotation, such Reference Dealer Quotation. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Par Call Date&#8221; means&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in the case of the 0.250% 2025 notes, April 2, 2025&#59; in the case of the 0.000% 2025 notes, September 15, 2025&#59; in the case of the 2.625% 2025 notes, September 15, 2025&#59; in the case of the 1.125% 2027 notes, December 7, 2026&#59; in the case of the 0.375% 2028 notes, July 15, 2028&#59; in the case of the 3.000% 2028 notes, July 15, 2028&#59; in the case of the 3.650% 2029 notes, September 15, 2029&#59; in the case of the 1.625% 2031 notes, December 7, 2030&#59; in the case of the 1.000% 2031 notes, April 2, 2031&#59; in the case of the 3.125% 2031 notes, July 15, 2031&#59; in the case of the 2032 notes, July 15, 2032&#59; in the case of the 3.375% 2034 notes, July 15, 2034&#59; in the case of the 3.875% 2036 notes, July 15, 2036&#59; in the case of the 2.250% 2039 notes, December 7, 2038&#59; in the case of the 1.500% 2039 notes, April 2, 2039&#59; in the case of the 1.375% 2040 notes, April 15, 2040&#59; in the case of the 4.150% 2043 notes, April 15, 2043&#59; in the case of the 1.750% 2049 notes, January 2, 2049&#59; in the case of the 1.625% 2050 notes, April 15, 2050&#59; and in the case of the 4.150% 2053 notes, April 15, 2053&#59;. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Quotation Agent&#8221; means the Reference Dealer appointed by Medtronic Luxco, or Medtronic, Inc. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reference Dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> means (1) each of Barclays Bank PLC and Merrill Lynch International and their respective successors in the case of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the 1.125% 2027 notes, the 1.625% 2031 notes, and the 2.250% 2039 notes, and each of Barclays Bank PLC, Goldman Sachs &#38; Co LLC and Merrill Lynch International, in the case of the 0.250% 2025 notes, the 1.000% 2031 notes, the 1.500% 2039 notes, and the 1.750% 2049 notes, each of Barclays Bank PLC, BofA Securities Europe SA, Mizuho Securities Europe GmbH and Deutsche Bank Aktiengesellschaft in the case of the 0.000% 2025 notes, the 0.375% 2028 notes, the 0.750% 2032 notes, the 1.375% 2040 notes and the 1.625% 2050 notes, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">each of Barclays Bank PLC, BofA Securities Europe SA, Citigroup Global Markets Limited and HSBC Continental Europe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> in the case of the 2.625% 2025 notes, the 3.000% 2028 notes, the 3.125% 2031 notes, and the 3.375% 2034 notes, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and each of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc in the case of the 3.650% 2029 notes, the 3.875% 2036 notes, the 4.150% 2043 notes, and the 4.150% 2053 notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#59;, provided, however, that if any of the foregoing shall cease to be a broker or dealer of, and&#47;or a market maker in, German government bonds (a &#8220;Primary Bond Dealer&#8221;), Medtronic Luxco, or Medtronic, Inc., shall substitute another Primary Bond Dealer and (2) any other Primary Bond Dealers selected by Medtronic Luxco, or Medtronic, Inc. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reference Dealer Quotations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> means, with respect to each Reference Dealer and any redemption date, the average, as determined by the Quotation Agent, of the bid and asked prices for the Comparable Government Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Quotation Agent by that Reference Dealer at 11&#58;00 a.m., London time, on the third business day preceding that redemption date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Remaining Scheduled Payments&#8221; means, with respect to each fixed rate note to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due after the related redemption date but for such redemption (assuming that the fixed rate notes to be redeemed matured on the applicable Par Call Date)&#59; provided, however, that, if such redemption date is not an interest payment date with respect to such note, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to such redemption date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Redemption Upon Changes in Withholding Taxes </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medtronic Luxco, or Medtronic, Inc., may redeem all, but not less than all, of the notes of any series in the event of certain changes in the tax laws, regulations, rulings or treaties of Luxembourg, Ireland, the United States or any other jurisdiction in which Medtronic Luxco, Medtronic, Inc., or any Guarantor is then organized (or any taxing authority thereof or therein) (a &#8220;Taxing Jurisdiction&#8221;) if, in the written opinion of independent counsel chosen by Medtronic Luxco, Medtronic plc or Medtronic, Inc., there is a material probability that Medtronic Luxco, Medtronic plc or Medtronic, Inc. will become obligated to pay certain additional amounts with respect to the notes. This redemption would be at a redemption price equal to 100% of the principal amount of the notes of such series being redeemed, together with accrued and unpaid interest, if any, to, but not including, the redemption date.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Payment of Additional Amounts </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain exceptions and limitations, all payments made by Medtronic Luxco, Medtronic, Inc., or any Guarantor under or with respect to the notes and guarantees will be made free and clear of and without withholding or deduction for or on account of any present or future taxes, duties, levies, imposts, assessments or governmental charges of whatever nature imposed or levied by or on behalf of any Taxing Jurisdiction, unless Medtronic Luxco, Medtronic, Inc. or any Guarantor, as the case may be, is required to withhold or deduct taxes by law or by the interpretation or administration thereof. In the event that Medtronic Luxco, Medtronic, Inc., or any Guarantor is required to so withhold or deduct any amount for or on account of any taxes from any payment made under or with respect to the notes or the guarantees, as the case may be, subject to certain exceptions and limitations Medtronic Luxco, Medtronic, Inc., or the applicable Guarantor, as the case may be, will pay such additional amounts (&#8220;Additional Amounts&#8221;) as may be necessary so that the net amount received by each holder of notes (including Additional Amounts) after such withholding or deduction will equal the amount that such holder would have received if such taxes had not been required to be withheld or deducted. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Events of Default </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of the following events will constitute an event of default for each series of notes under the Indentures&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to pay any interest on the notes of that series when due and payable and such failure continues for 30 days&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to pay principal of or any premium on the notes of that series at its maturity, acceleration, redemption or otherwise&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to perform or the breach of any other covenant or warranty in the Indenture applicable to such series and such failure continues for 60 days after written notice as provided in such Indenture&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to pay principal when due at maturity or a default that results in the acceleration of maturity of Medtronic plc&#8217;s or any Restricted Subsidiary&#8217;s (defined below) indebtedness for borrowed money in an aggregate amount of $150 million or more&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc&#8217;s, Medtronic, Inc.&#8217;s, or Medtronic Luxco&#8217;s guarantee ceases to be in full force and effect or is declared to be null and void and unenforceable or such guarantee is found to be invalid or Medtronic plc, Medtronic, Inc., or Medtronic Luxo denies its liability under its guarantee (other than by reason of release of a Guarantor in accordance with the terms of the Indenture)&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">certain events in bankruptcy, insolvency, examinership or reorganization, voluntary or involuntary, relating to Medtronic Luxco, Medtronic or Medtronic, Inc.&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">any other event of default provided with respect to notes of such series.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an event of default, other than an event of default specified in the sixth bullet point above, occurs with respect to notes of any series and is continuing, either the applicable trustee or the holders of at least 25% in principal amount of the outstanding notes of that series may declare the principal amount of all notes of that series to be due and payable immediately&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, that under certain circumstances the holders of a majority in aggregate principal amount of outstanding notes of that series may rescind and annul such declaration and its consequences. If an event of default specified in the sixth bullet point above occurs and is continuing, the entire principal amount of, and accrued interest, if any, on each series of notes then outstanding shall become immediately due and payable. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The applicable trustee, after the occurrence of a default with respect to any series of notes, shall give to the holders of notes of that series notice of all uncured defaults known to it (the term default to mean the events specified above without grace periods)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, that, except in the case of default in the payment of principal of (or premium, if any) or interest, if any, on any note, the trustee shall be protected in withholding such notice if it in good faith determines that the withholding of such notice is in the interest of the holders of the notes of such series. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holders of a majority in principal amount of the outstanding notes of any series affected will have the right, subject to certain limitations, to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the notes of such series, and to waive certain defaults. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In case an event of default shall occur and be continuing, each trustee shall exercise such of its rights and powers under the Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs. Subject to such provisions, the trustees will be under no obligation to exercise any of their rights or powers under the Indenture at the request or direction of any of the holders of notes unless such holders shall have offered to the applicable trustee reasonable security or indemnity against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indenture requires us to deliver to the trustees annual statements as to the performance of our obligations under the Indenture and as to any events of default thereunder. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A default in the payment of any of our notes or under any related guarantee, or a default with respect to our notes or any related guarantee that causes such notes to be accelerated, may give rise to a cross-default under our other indebtedness. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Restricted Subsidiary&#8221; means (i) each of Medtronic Luxco and Medtronic, Inc. and (ii) any other subsidiary of Medtronic which owns or leases a Principal Property, except any subsidiary substantially all of the assets of which are located, or substantially all of the business of which is carried on, outside the United States and its territories and possessions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Principal Property&#8221; means any plant, office facility, warehouse, distribution center or equipment located within the United States (other than its territories or possessions) and owned by Medtronic or any subsidiary, the gross book value (without deduction of any depreciation reserves) of which on the date as of which the determination is being made exceeds 2% of the Consolidated Net Tangible Assets of Medtronic, except any such property which Medtronic&#8217;s board of directors, in its good faith opinion, determines is not of material importance to the business conducted by Medtronic and its subsidiaries, taken as a whole, as evidenced by a certified copy of a board resolution.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Modification of the Indentures </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Modifications and amendments of the Indentures may be made by us and the applicable trustee with the consent of the holders of not less than a majority in aggregate principal amount of the outstanding notes of each series affected by the modification or waiver&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, that no such modification or amendment may without the consent of the holder of each noteholder affected thereby, extend the stated maturity of the principal of, or any installment of principal of or interest on, any note, reduce the principal amount of, or premium or interest on, any note, change the place of payment where coin or currency in which the principal of, or any premium or interest on, any note is payable, impair the right to institute suit for the enforcement of any payment on or with respect to any note, reduce the percentage in principal amount of outstanding notes, the consent of the holders of which is required for modification or amendment of the Indentures or for waiver of compliance with certain provisions of the Indentures or for waiver of certain defaults or modify any of the above provisions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holders of not less than a majority in aggregate principal amount of the outstanding notes of each series may, on behalf of the holders of all notes of that series, waive compliance by us with certain restrictive provisions of the Indentures that may be amended by such majority. The holders of not less than a majority in aggregate principal amount of the outstanding notes of each series may, on behalf of the holders of all notes of such series, waive any past default under the Indenture, except a default (1) in the payment of principal of, or any premium or interest on, any note or (2) in respect of a covenant or provision of the Indentures which cannot be modified or amended without the consent of the holder of each note of the affected series. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Modifications and amendments of the Indentures may be made by us and the trustee without the consent of any holders of any series of notes for any of the following purposes&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to evidence the succession of another person to us or any guarantor and the assumption by any such successor of our or such Guarantor&#8217;s covenants under the Indentures and in the notes&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to add to our covenants or the covenants applicable to any guarantor for the benefit of the holders or to surrender any right or power in the Indentures conferred upon us or any Guarantor&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to add any additional events of default for the benefit of the holders&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to secure the notes or any related guarantee&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to evidence and provide for the acceptance of appointment hereunder by a successor trustee&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to cure any ambiguity, to correct or supplement any provision in the Indentures or in any supplemental indentures which may be inconsistent with any other provision of such indenture or supplemental indenture, or to make any other provisions with respect to matters or questions arising under the Indentures&#59; provided such action shall not adversely affect the interests of the holders in any material respect&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to conform the Indentures or any supplemental indentures to the description of the notes set forth in any prospectus or prospectus supplement related to such series of notes&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to comply with the requirements of the SEC in order to effect or maintain the qualifications of the indenture under the Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;)&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to add to or change any of the provisions of the Indentures to such extent as shall be necessary to permit or facilitate the issuance of notes in bearer form or to facilitate the issuance of notes in uncertificated form&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to provide for the issuance and establish the forms or terms and conditions of notes of any series as permitted by the Indentures&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to add or release a Guarantor as permitted by the Indentures&#59; or</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to comply with the rules of any applicable securities depositary.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes will not be considered outstanding, and therefore will not be eligible to vote on any matter, if we have deposited or set aside in trust money for their payment or redemption. Notes will also not be eligible to vote if they have been fully defeased. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will generally be entitled to set any day as a record date for the purpose of determining the holders of outstanding notes that are entitled to vote or take other action under the Indenture. In certain limited circumstances, the trustee will be entitled to set a record date for action by holders. If we or the trustee set a record date for a vote or other action to be taken, that vote or action may be taken only by persons who are holders of outstanding notes on the record date and must be taken within 180 days following the record date or a shorter period that we may specify (or as the trustee may specify, if it set the record date). We may shorten or lengthen (but not beyond 180 days) this period from time to time. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other Provisions of the Notes</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Indentures contain provisions that restrict our ability, and the ability of certain of our subsidiaries, to incur secured debt and to engage in sale and leaseback transactions. The Indentures do not restrict our ability to convey or transfer our properties and assets other than as an entirety or substantially as an entirety to any other person. The Indentures contain no other restrictive covenants, including those that would afford holders of the notes protection in the event of a highly-leveraged transaction involving Medtronic Luxco, Medtronic, Inc., or any affiliates or other events that may adversely affect our creditworthiness or the value of the notes. The Indentures also do not contain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">any covenants relating to total unsecured indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders, current ratios or acquisitions and divestitures.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regarding the Trustees </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indenture trustee&#8217;s current address is Wells Fargo Bank, National Association, 600 South 4th Street, 6th Floor, Minneapolis, Minnesota 55415. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indenture provides that, except during the continuance of an event of default, the trustee will perform only such duties as are specifically set forth in the Indenture. During the existence of an event of default, the trustee will exercise such rights and powers vested in its exercise as a prudent person would exercise under the circumstances in the conduct of such person&#8217;s own affairs. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indenture and certain provisions of the Trust Indenture Act contain limitations on the rights of the trustees, should a trustee become a creditor of us, Medtronic plc or Medtronic, Inc. to obtain payment of claims in certain cases or to realize on certain property received by it in respect of any such claim as security or otherwise. A trustee is permitted to engage in other transactions with us or any affiliate of ours. If there arises any conflicting interest (as defined in the Indenture or in the Trust Indenture Act), it must eliminate such conflict or resign. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain ordinary banking relationships and credit facilities with Wells Fargo Bank, National Association. In addition, Wells Fargo Bank, National Association is the trustee for certain of our affiliates&#8217; other debt securities, is the transfer agent for Medtronic plc&#8217;s ordinary shares, and from time to time provides services relating to our investment management, stock repurchase and foreign currency hedging programs. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Listing </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The notes are listed on the New York Stock Exchange. Medtronic Luxco and Medtronic, Inc. will use commercially reasonable efforts to maintain such listing and satisfy the requirements for such continued listing as long as the notes are outstanding. The New York Stock Exchange is not a regulated market for the purposes of MiFID II. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Governing Law </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indentures and the notes are governed by and construed in accordance with the laws of the State of New York. For the avoidance of doubt, the applicability of Articles 84 to 94-8 of the Luxembourg law dated August 10, 1915 on commercial companies, as amended, shall be excluded. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No holder of notes may initiate proceedings against Medtronic Luxco or Medtronic, Inc. based on Article 98 of the Luxembourg law dated August 10, 1915 on commercial companies, as amended. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Book-Entry System&#59; Delivery and Form </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Global Clearance and Settlement </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The notes of each series are issued in the form of one or more global notes in fully registered form, without coupons, and deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear and Clearstream. Except as described herein, certificates will not be issued in exchange for beneficial interests in the global notes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Except as set forth below, the global notes may be transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beneficial interests in the global notes are be represented, and transfers of such beneficial interests will be effected, through accounts of financial institutions acting on behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream. Those beneficial interests are in denominations of &#8364;100,000 and integral multiples of &#8364;1,000 in excess thereof. Investors may hold notes directly through Euroclear or Clearstream, if they are participants in such systems, or indirectly through organizations that are participants in such systems. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have been advised by Clearstream and Euroclear, respectively, as follows&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clearstream </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clearstream has advised that it is incorporated under the laws of Luxembourg and licensed as a bank and professional depositary. Clearstream holds securities for its participating organizations and facilitates the clearance and settlement of securities transactions among its participants through electronic book-entry changes in accounts of its participants, thereby eliminating the need for physical movement of certificates. Clearstream provides to its participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream interfaces with domestic markets in several countries. Clearstream has established an electronic bridge with the Euroclear Operator (as defined below) to facilitate the settlement of trades between the nominees of Clearstream and Euroclear. As a registered bank in Luxembourg, Clearstream is subject to regulation by the Luxembourg Commission for the Supervision of the Financial Sector. Clearstream customers are recognized financial institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing corporations and certain other organizations and may include the underwriters. Indirect access to Clearstream is also available to others, such as banks, brokers, dealers and trust companies that clear through, or maintain a custodial relationship with, a Clearstream participant, either directly or indirectly. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions with respect to notes held beneficially through Clearstream will be credited to cash accounts of Clearstream participants in accordance with its rules and procedures. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Euroclear </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Euroclear has advised that it was created in 1968 to hold securities for its participants and to clear and settle transactions between Euroclear participants through simultaneous electronic book-entry delivery against payment, thereby eliminating the need for physical movement of certificates and any risk from lack of simultaneous transfers of securities and cash. Euroclear includes various other services, including securities lending and borrowing and interfaces with domestic markets in several countries. All operations are conducted by the Euroclear Operator, and all Euroclear securities clearance accounts and Euroclear cash accounts are accounts with the Euroclear Operator. Euroclear participants include banks (including central banks), securities brokers and dealers and other professional financial intermediaries and may include the underwriters. Indirect access to Euroclear is also available to other firms that clear through or maintain a custodial relationship with a Euroclear participant, either directly or indirectly. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities clearance accounts and cash accounts with the Euroclear Operator are governed by the Terms and Conditions Governing Use of Euroclear and the related operating procedures of Euroclear, and applicable Belgian law (collectively, the &#8220;Terms and Conditions&#8221;). The Terms and Conditions govern transfers of securities and cash within Euroclear, withdrawals of securities and cash from Euroclear, and receipts of payments with respect to securities in Euroclear. All securities in Euroclear are held on a fungible basis without attribution of specific certificates to specific securities clearance accounts. The Euroclear Operator acts under the Terms and Conditions only on behalf of Euroclear participants, and has no records of or relationship with persons holding through Euroclear participants. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions with respect to the notes held beneficially through Euroclear will be credited to the cash accounts of Euroclear participants in accordance with the Terms and Conditions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Euroclear and Clearstream Arrangements </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">So long as Euroclear or Clearstream or their nominee or their common depositary is the registered holder of the global notes, Euroclear, Clearstream or such nominee, as the case may be, will be considered the sole owner or holder of the notes represented by such global notes for all purposes under the Indenture and the notes. Payments of principal, interest and additional amounts, if any, in respect of the global notes will be made to Euroclear, Clearstream, such nominee or such common depositary, as the case may be, as registered holder thereof. None of us, the trustee, any underwriter and any affiliate of any of the above or any person by whom any of the above is controlled (as such term is defined in the Securities Act) will have any responsibility or liability for any records </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">relating to or payments made on account of beneficial ownership interests in the global notes or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions of principal, premium, if any, and interest with respect to the global notes will be credited in euro to the extent received by Euroclear or Clearstream from the paying agent to the cash accounts of Euroclear or Clearstream customers in accordance with the relevant system&#8217;s rules and procedures. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because Euroclear and Clearstream can only act on behalf of participants, who in turn act on behalf of indirect participants, the ability of a person having an interest in the global notes to pledge such interest to persons or entities which do not participate in the relevant clearing system, or otherwise take actions in respect of such interest, may be affected by the lack of a physical certificate in respect of such interest. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Initial Settlement </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We understand that investors that hold their notes through Clearstream or Euroclear accounts will follow the settlement procedures that are applicable to conventional eurobonds in registered form. Subject to applicable procedures of Clearstream and Euroclear, notes will be credited to the securities custody accounts of Clearstream and Euroclear participants on the business day following the settlement date, for value on the settlement date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Secondary Market Trading </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because the purchaser determines the place of delivery, it is important to establish at the time of trading of any notes where both the purchaser&#8217;s and seller&#8217;s accounts are located to ensure that settlement can be made on the desired value date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We understand that secondary market trading between Clearstream and&#47;or Euroclear participants will occur in the ordinary way following the applicable rules and operating procedures of Clearstream and Euroclear. Secondary market trading will be settled using procedures applicable to conventional eurobonds in global registered form. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investors will only be able to make and receive deliveries, payments and other communications involving the notes through Clearstream and Euroclear on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other institutions are open for business in the United States. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, because of time-zone differences, there may be problems with completing transactions involving Clearstream and Euroclear on the same business day as in the United States. U.S. investors who wish to transfer their interests in the notes, or to make or receive a payment or delivery of the notes, on a particular day, may find that the transactions will not be performed until the next business day in Luxembourg or Brussels, depending on whether Clearstream or Euroclear is used. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clearstream or Euroclear will credit payments to the cash accounts of Clearstream customers or Euroclear participants, as applicable, in accordance with the relevant system&#8217;s rules and procedures, to the extent received by its depositary. Clearstream or the Euroclear Operator, as the case may be, will take any other action permitted to be taken by a holder under the Indenture on behalf of a Clearstream customer or Euroclear participant only in accordance with its relevant rules and procedures. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clearstream and Euroclear have agreed to the foregoing procedures in order to facilitate transfers of the notes among participants of Clearstream and Euroclear. However, they are under no obligation to perform or continue to perform those procedures, and they may discontinue those procedures at any time. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exchange of Global Notes for Certificated Notes </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain conditions, the notes represented by the global notes are exchangeable for certificated notes in definitive form of like tenor in minimum denominations of &#8364;100,000 principal amount and multiples of &#8364;1,000 in excess thereof if&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the common depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for the global notes and we fail to appoint a successor depositary within 90 calendar days&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco or Medtronic, Inc., at its option, notifies the trustee in writing that it elects to cause the issuance of certificated notes&#59; or</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">there has occurred and is continuing an Event of Default with respect to the notes.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In all cases, certificated notes delivered in exchange for any global note or beneficial interest therein will be registered in the names, and issued in any approved denominations, requested by or on behalf of the common depositary (in accordance with its customary procedures). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Payments </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments (including principal, premium and interest) and transfers with respect to notes in certificated form may be executed at the office or agency maintained for such purpose in London (initially the corporate trust office of the paying agent) or, at Medtronic Luxco&#8217;s or Medtronic, Inc.&#8217;s option, by check mailed to the holders thereof at the respective addresses set forth in the register of holders of the notes (maintained by the registrar), provided that all payments (including principal, premium and interest) on notes in certificated form, for which the holders thereof have given wire transfer instructions, will be required to be made by wire transfer of immediately available funds to the accounts specified by the holders thereof. No service charge will be made for any registration of transfer, but payment of a sum sufficient to cover any tax or governmental charge payable in connection with that registration may be required. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>3
<FILENAME>mdt-202410xex19.htm
<DESCRIPTION>EX-19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i12c0eddfa7df429ca430190b4adf60e3_128"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 19</font></div></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:32px;margin-bottom:5pt;vertical-align:text-bottom;width:132px"></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#1010eb;font-family:'Avenir Next LT Pro',sans-serif;font-size:24pt;font-weight:700;line-height:100%">Global Insider Trading Policy</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#1010eb;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Purpose</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Securities and Exchange Commission (SEC) and other government bodies created rules to prevent unethical use of nonpublic information. This policy outlines the requirements employees must follow to comply with these rules and applicable laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#1010eb;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Scope</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This policy applies to all Medtronic employees and members of the Board of Directors.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#1010eb;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Policy Statement (Details)</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">BACKGROUND</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Summary</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The federal securities laws prohibit any employee of Medtronic plc or its subsidiaries (collectively, the &#8220;Company&#8221;) or any member of its Board of Directors from purchasing or selling securities on the basis of material nonpublic information about the Company and other companies that may have transactions or business relationships with the Company, and from tipping material nonpublic information to others. These laws impose severe sanctions, including the possibility of significant prison sentences, on individuals who violate them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">This insider trading policy is being adopted with the goal of helping&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">to prevent inadvertent violations of the insider trading laws&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">to avoid even the appearance of impropriety on the part of those employed by, or associated with, the Company&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">to protect the Company from controlling person liability&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">to protect the reputation of the Company, its Directors and its employees.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">What Type of Information Is &#8220;Material&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#63;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Information about the Company is considered material if a reasonable shareholder would consider the information important in making a decision to buy, hold or sell the Company&#8217;s securities. Any information that could be expected to affect the Company&#8217;s stock price, whether it is positive or negative, should be considered material. It is not possible to define all categories of material information, but information about any of the following subjects, including where applicable that the Company has plans or is in discussions with respect to any of these subjects, are examples of the type of information which is likely to be considered material&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the Company&#8217;s revenues or earnings&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a significant merger or acquisition involving the Company&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">information concerning upcoming FDA actions or other significant legal or regulatory developments, including significant clinical trial results or a significant product recall&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a change in control or a significant change in management of the Company&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the purchase or sale by the Company of a significant amount of its securities&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a change in the Company&#8217;s dividend or securities repurchase policies&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global Insider Trading Policy 1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a stock split&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a default on outstanding debt of the Company or a bankruptcy filing&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a significant product release, a significant development, invention or discovery, or significant legal or regulatory developments that affect the Company, including its intellectual property rights&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">significant licensing or collaboration discussions or agreements&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a significant cybersecurity incident, such as a data breach, or any other significant disruption in the Company&#8217;s operations, or loss, potential loss, breach or unauthorized access of its property, devices or information, whether at its facilities or through its information technology infrastructure&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a conclusion by the Company or a notification from its auditors that any of the Company&#8217;s previously issued financial statements should no longer be relied upon&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a change in the Company&#8217;s auditors.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The above list is illustrative only and is not intended to provide a comprehensive list of circumstances that could give rise to material information.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">When Is Information &#8220;Nonpublic&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#63;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Information concerning the Company is considered nonpublic if it has not been disseminated in a manner making it available to investors generally. Information will generally be considered nonpublic unless (1) the information has been disclosed in a press release, in a public filing made with the Securities and Exchange Commission (such as a Report on Form 10-K, Form 10-Q, or Form 8-K), on the Company&#8217;s Investor Relations website, or through a news wire service or broadly accessible news outlet, and (2) a sufficient amount of time has passed so that the information has had an opportunity to be disseminated within the marketplace, which will generally be upon the completion of one full trading day after the public disclosure. For example, if information is disclosed after-market on a Thursday, it would be considered broadly disseminated by the close of regular trading on Friday.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">What are &#8220;Securities&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#63;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The policy applies to transactions in Company common stock, options to purchase common stock, or any other type of securities issued by the Company, including (but not limited to) preferred stock, convertible debentures and warrants, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company&#8217;s Securities. This policy also applies to transactions in the securities of companies (1) with which the Company does business, such as the Company&#8217;s distributors, vendors, customers and suppliers, and (2) that are involved in a potential transaction or business relationship with Company.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">DEFINITIONS</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As used in this policy, the following terms have the meanings specified below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Covered Persons</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> means&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all employees&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all Directors&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all family members of Directors and employees who share the same address as, or are financially dependent upon, the Director or employee and any other person who shares the same address as the Director or employee (other than (1)&#160;an employee or tenant of the Director or employee or (2) another unrelated person whom the General Counsel, Corporate Secretary, an Assistant Secretary or another individual designated by the General Counsel or Corporate Secretary (each, </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a member of the Corporate Secretary&#8217;s office) determines should not be covered by this policy)&#59; and</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all corporations, partnerships, trusts or other entities (other than the Company) controlled by any of the above persons, unless the entity has implemented policies or procedures designed to ensure that such person cannot influence transactions by the entity involving Company securities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Designated Employees</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> has the meaning given to such term in Section 4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> means a member of the Board of Directors of Medtronic plc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Executive Committee Members</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> means employees of the Company who report to the Chief Executive Officer of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Pre-Clearance Person</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> has the meaning given to such term in Section 5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Section 16 Officers</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> means employees of the Company subject to Section 16 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Trading Plan</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> has the meaning given to such term in Section 6.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">GENERAL PROHIBITIONS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Prohibitions While Aware of Material Nonpublic Information</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Except as explicitly provided in Section 6, no Covered Person may&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">purchase, sell or donate any securities of the Company (or recommend to another person or entity that they do so) while aware of any material nonpublic information concerning the Company&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">disclose to any other person any material nonpublic information concerning the Company if such person may misuse that information, such as by purchasing or selling Company securities or tipping that information to others&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">purchase, sell or donate any securities of another company (or recommend to another person or entity that they do so) while aware of any material nonpublic information concerning such other company which the person or entity subject to this policy learned in the course of their service as a Director or employee of the Company&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">disclose to any other person any material nonpublic information concerning another company (which the person or entity subject to this policy learned in the course of their service as a Director or employee of the Company) if such person may misuse that information, such as by purchasing or selling that company&#8217;s securities or tipping that information to others.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Prohibitions on Short Sales and Derivative Transactions</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">No Covered Person may&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">engage in short sales of Company securities, including short sales &#8220;against the box&#8221;&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">engage in purchases or sales of puts, calls or other derivative securities based on the Company&#8217;s securities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Pledges, and Hedges</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">No Director or Section 16 Officer may (i) purchase Company securities on margin, borrow against Company securities held in a margin account, or pledge Company securities as collateral for a loan, or (ii)&#160;enter into hedging or monetization transactions or similar arrangements with respect to Company securities. The Company cautions and advises all other Covered Persons to seek their own legal counsel </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">in connection with purchasing Company securities on margin, borrowing against Company securities held in a margin account, or pledging Company securities as collateral for a loan, or (ii)&#160;entering into hedging or monetization transactions or similar arrangements with respect to Company securities.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Reminder of Obligations After Cessation of Service</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">If a person ceases to be a Director or employee of the Company at a time when he or she is aware of material nonpublic information, the applicable prohibitions shall continue to apply to such person until that information has become public or is no longer material.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">TRADING PROHIBITIONS DURING RESTRICTED PERIODS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Quarterly Restricted Periods</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Except as explicitly provided in this policy, no person or entity listed below may purchase, sell or donate any securities of the Company during the period beginning the second Monday prior to the end of each fiscal quarter and ending upon the completion of one full trading day after the public announcement of earnings for such quarter (a &#8220;quarterly restricted period&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Persons Covered by Quarterly Restrictions</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The quarterly restricted period prohibitions apply to&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all Directors&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all Section 16 Officers, Executive Committee Members and employees who report to Executive Committee Members&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">such other employees as are designated from time to time by a member of the Corporate Secretary&#8217;s office as being subject to quarterly restricted period prohibitions (together with Section 16 Officer, Executive Committee Members and employees who report to Executive Committee Members, the &#8220;Designated Employees&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all family members of Directors and Designated Employees who share the same address as, or are financially dependent on, the Director or Designated Employee and any other person who shares the same address as the Director or Designated Employee (other than (1) an employee or tenant of the Director or Designated Employee or (2) another unrelated person whom a member of the Corporate Secretary&#8217;s office determines should not be covered by this policy)&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all corporations, partnerships, trusts or other entities (other than the Company) controlled by any of the above persons, unless the entity has implemented policies or procedures designed to ensure that such person cannot influence transactions by the entity involving Company securities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Corporate News Restricted Periods</font></div><div style="margin-bottom:12pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The Company may from time to time notify Directors and other employees that an additional restricted period (a &#8220;corporate news restricted period&#8221;) is in effect in view of significant events or developments involving the Company. In such event, except as explicitly provided in this policy, no such individual may purchase, sell or donate any securities of the Company during such corporate news restricted period or inform anyone else that a corporate news restricted period is in effect. (In this policy, quarterly restricted periods and corporate news restricted periods are each referred to as a &#8220;restricted period&#8221;.)</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">PRECLEARANCE BY DIRECTORS AND SECTION 16 OFFICERS</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Notice and Pre-Clearance of Transactions</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Pre-Transaction Clearance</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">No Director or Section 16 Officer (a &#8220;Pre-Clearance Person&#8221;) may purchase, sell, donate or otherwise acquire or dispose of securities of the Company (other than in a transaction that is excepted from this </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">policy under Section 6), or adopt, modify, or terminate any Trading Plan, unless such person pre-clears the transaction or plan with a member of the Corporate Secretary&#8217;s office. </font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">A request for pre-clearance shall be made in accordance with the procedures established by the Corporate Secretary. A member of the Corporate Secretary&#8217;s office shall have sole discretion to decide whether to clear any contemplated transaction or plan. (The Chief Financial Officer shall have sole discretion to decide whether to clear transactions by the General Counsel if the General Counsel is a Section 16 Officer.) </font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">All trades and plans that are pre- cleared must be effected (or adopted, amended, or terminated) within four business days of receipt of the pre-clearance unless a specific exception has been granted by a member of the Corporate Secretary&#8217;s office. A pre-cleared trade (or any portion of a pre-cleared trade) that has not been effected or a plan that has not been adopted, amended, or terminated during the four business day period must be pre-cleared again prior to execution. Notwithstanding receipt of pre-clearance, if the Pre-Clearance Person becomes aware of material non-public information or becomes subject to a restricted period before the transaction is effected, the transaction may not be completed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Post-Transaction Notice</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Each Pre-Clearance Person shall also ensure that a member of the Corporate Secretary&#8217;s office receives immediate notice of the occurrence of any purchase, sale or other acquisition or disposition of securities of the Company, and of the entry into, modification, or early termination of any plan that contemplates future transaction in Company securities. Such notification must be in writing (including by e-mail) and should include the identity of the covered person, the type of transaction, the date of the transaction, the number of shares involved and the purchase or sale price.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Deemed Time of a Transaction</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">  </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">For purposes of these notification obligations, a purchase, sale or other acquisition or disposition shall be deemed to occur at the time the person becomes irrevocably committed to it (for example, in the case of an open market purchase or sale, when the trade is executed, not when it settles).</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">EXCEPTIONS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The prohibitions in Sections 3 and 4 on purchases, sales and donations of Company securities do not apply to&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations, in each case in a manner permitted by the applicable equity award agreement&#59; provided, however, that the securities so acquired may not be sold (either outright or in connection with a &#8220;cashless&#8221; exercise transaction through a broker) while the employee or Director is aware of material nonpublic information or, in the case of someone who is subject to a restricted period prohibition, during a restricted period&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">acquisitions or dispositions of Company common stock under the Company&#8217;s 401(k), employee stock purchase plan, individual account plan or dividend reinvestment plan which are made pursuant to standing instructions not entered into or modified while the employee or Director is aware of material nonpublic information or, in the case of someone who is subject to restricted period prohibition, during a restricted period&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">other purchases of securities directly from the Company or sales of securities directly to the Company&#59; or</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">transactions made pursuant to a binding contract, written plan or specific instruction (a &#8220;Trading Plan&#8221;) which is adopted and operated in compliance with Rule 10b5-1&#59; provided such Trading Plan complies with the Company&#8217;s Rule 10b5-1 Plan Guidelines included at the end of this policy.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The prohibitions in Sections 3 and 4 on donations of Company securities do not apply to bona fide gifts to family members or family trusts who are also subject to this policy under Section 3.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">PENALTIES FOR VIOLATION</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Violation of any of the foregoing rules is grounds for disciplinary action by the Company, including termination of employment for cause.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">OTHER MATTERS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Regulation BTR</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">If the Company is required to impose a &#8220;pension fund blackout period&#8221; under Regulation BTR, each Director and Section 16 Officer shall not, directly or indirectly sell, purchase or otherwise transfer during such blackout period any equity securities of the Company acquired in connection with his or her service as a Director or officer of the Company, except as permitted by Regulation BTR.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Limitation of Liability</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">None of the Company, the Chief Financial Officer, the General Counsel, members of the Corporate Secretary&#8217;s office or the Company&#8217;s other employees will have any liability for any action taken or inaction in connection with the administration of this insider trading policy. Notwithstanding any pre-clearance of a transaction described in Section 5 or review of a Trading Plan described in Section 6, none of the Company, the Chief Financial Officer, the General Counsel, members of the Corporate Secretary&#8217;s office or the Company&#8217;s other employees assumes any liability for the legality or consequences of such transaction or Trading Plan to the person engaging in or adopting such transaction or Trading Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Administration</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The General Counsel is generally responsible for the administration of this policy, which includes authority to interpret and construe this policy and make determinations in connection with such administration. The General Counsel may select others to assist in such administration.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Questions</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Questions regarding this policy should be directed to a member of the Corporate Secretary&#8217;s office.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Rule 10b5-1 Guidelines</font></div><div style="padding-right:-6.75pt;text-align:center"><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MEDTRONIC PLC</font></div><div style="padding-right:-11.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULE 10b5-1 PLAN GUIDELINES</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 10b5-1 of the Securities and Exchange Act of 1934 provides a defense from insider trading liability for an insider of a publicly traded company (each a &#8220;Trading Individual&#8221;) who, at a time when they are not in possession of material nonpublic information (&#8220;MNPI&#8221;) and are not subject to any restricted period, sets up a plan or instruction to buy or sell stock that specifies in advance the amount, pricing and timing of transactions, or delegates discretion on these matters to an independent third party. The following guidelines have been adopted by Medtronic plc (the &#8220;Company&#8221;) to provide guidance on adopting and using trading plans under Rule 10b5-1 (each, a &#8220;10b5-1 Plan&#8221;) and apply to any Medtronic employee or director desiring to enter into a 10b5-1 Plan for Company securities.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">The 10b5-1 Plan</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All 10b5-1 Plans must be in writing.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Once a 10b5-1 Plan is adopted, a Trading Individual must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded, or the date of the trade. The 10b5-1 Plan must either specify in advance the amount, pricing and timing of transactions, establish in advance a formula or algorithm for determining the amount, price and timing of transactions, or delegate discretion on these matters to an independent third party who is not aware of MNPI when effecting purchases or sales.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Trading Individual must submit and receive approval from the Corporate Secretary or Assistant Secretary (or his&#47;her delegate) of a proposed Rule 10b5-1 Plan prior to adopting a 10b5-1 Plan or making any modification to an existing 10b5-1 Plan. No further pre-approval of transactions conducted pursuant to the Rule 10b5-1 Plan will be required.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">10b5-1 Plans should be for a minimum term of 6 months and include a specified expiration date, with a maximum term of two years.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Single transaction trading plans are strongly discouraged, and in no event may more than one single transaction plan be adopted in any 12-month period.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Overlapping plans are not allowed, provided that Trading Individuals may enter into a &#8220;sell-to-cover&#8221; plan with respect to tax obligations that arise from the vesting of compensatory equity awards (but not the exercise of stock options) in addition to a traditional 10b5-1 Plan.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New and modified Rule 10b5-1 Plans must reflect a &#8220;cooling off&#8221; period before the first trade thereunder&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">For directors and Section 16 officers, the first trade under a new or modified 10b5-1 Plan cannot occur until the later of (i) 90 days or (ii) or two business days after the filing of the next 10-K or 10-Q, but in any case, not longer than 120 days following the date of adoption of the 10b5-1 Plan or modification of the 10b5-1 Plan.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">For persons other than directors or Section 16 officers, the first trade under a new or modified 10b5-1 Plan may not occur until 30 calendar days after the date of adoption of the 10b5-1 Plan or modification of the 10b-51 Plan.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trading plans must comply in all respects with the Company&#8217;s Global Insider Trading Policy and any other applicable Company policies.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The 10b5-1 Plan must permit the Company to suspend trading for any Trading Individual who holds shares subject to an underwriting lockup, for the duration of such lockup. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">The Trading Individual </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Trading Individual may only adopt, modify or direct early termination of a 10b5-1 Plan at a time when he or she&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">is not in possession of MNPI regarding the Company or its securities&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">is not subject to any restricted period under the Company&#8217;s Global Insider Trading Policy.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Directors and Section 16 officers must certify to the Company (either as part of the 10b5-1 Plan or by separate document) that (i) such individual is not in possession of MNPI at the time of entrance into </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or modification of the 10b5-1 Plan and (ii) such individual is adopting the plan in good faith and not as part of a plan or scheme to evade the prohibitions in Rule 10b-5. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When adopting, modifying, terminating earlier than the previously established expiration date or taking other action with respect to a 10b5-1 Plan, the Trading Individual must take any such action in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) of the Exchange Act or Rule 10b-5 promulgated under the Exchange Act. Therefore, although Trading Individuals are not prohibited from modifying or terminating existing Rule 10b5-1 Plans, a Rule 10b5-1 Plan should be adopted with the intention that it will not be amended or terminated prior to its expiration. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Trading Individual should be aware that the Company will disclose the adoption, modification and termination of any 10b5-1 Plans by directors and Section 16 officers in its annual reports on Form 10-K and quarterly reports on Form 10-Q.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Trading Individual must agree to cooperate with the Company in any reporting and publicizing of the trading plan.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adoption of a trading plan does not preclude trading outside of the 10b5-1 Plan that otherwise is in accordance with the Company&#8217;s Global Insider Trading Policy. However&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Trading Individuals may not enter into or alter corresponding transactions or positions, including hedging transactions, that reduce or eliminate the economic consequences of the transactions under the Rule 10b5-1 Plan.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Trading Individuals may not engage in transactions outside of the 10b5-1 Plan if such transactions would affect the number of shares that can be sold under the 10b5-1 Plan (e.g., for Trading Individuals subject to Rule 144, an outside-the-plan transaction cannot reduce the pre-established volume of shares that can be sold under the 10b5-1 Plan).</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Any Trading Individual who is a director or officer is cautioned to ensure that any trading outside of a 10b5-1 Plan does not create short swing profits with respect to potential transactions under the 10b5-1 Plan (i.e., if sales may occur under the 10b5-1 Plan, the Trading Person would generally want to avoid any purchases outside of the 10b5-1 Plan to avoid potential short swing profits if the purchase is at a lower price than any sale made within 6 months of the purchase).</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>4
<FILENAME>mdt-202410kxex21.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i10c7cb9d9a42428c80070a19f87e4001_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 21</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.489%"><tr><td style="width:1.0%"></td><td style="width:70.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Medtronic plc and Subsidiaries</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">At April 26, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2074417 Alberta ULC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A&#38;E Products de Honduras S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Honduras</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A&#38;E Products do Brasil Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A&#38;E Products Group, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Medical Technologies GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affera, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AI Biomed Corp</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aircraft Medical Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Airox </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arterial Vascular Engineering Canada, Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arterial Vascular Engineering UK Limited </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Suture do Brasil Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avenu Medical, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Batts LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Batts, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Between Investeringsgroep B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biostar Biomedikal M&#252;hendislik Anonim Sirketi</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bo Yao (Shanghai) Medical Device Co. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CardioInsight Technologies Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carlisle Philippines, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carmel Biosensors Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CCI Istanbul Teknolojik Hizmetler Limited Sirketi</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changzhou Chuangzhihui Incubator Management Co.,Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changzhou Kangdi Medical Stapler Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changzhou Kanghui Medical Innovation Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CircuLite, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comercial Kendall (Chile) Limitada</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companion Medical, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien (China) Medical Devices Technology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien (Shanghai) Management Consulting Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Adhesives Italia Srl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien AG</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Argentina S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Canada Holdings LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Caribbean, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Delaware VI Corp.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Eurasia LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien France Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Group Holdings Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Group S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Healthcare International Trading (Shanghai) Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Holding Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Holdings International Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Holdings S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien International (US) Holdings A, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien International Finance S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien International S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Ireland Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Israel Holdings Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Israel Investments Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Israel Surgical Research Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Japan, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien llc</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien LP</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Manufacturing Grenoble</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Medical Products (Shanghai) Manufacturing L.L.C.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Peru S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Philippines, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Private Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Pty Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Sales LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Swiss Holding GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien UK Holding Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Uruguay S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien US Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Ventures Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Davis &#38; Geck Caribe Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabeter Nederland B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digital Surgery Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epix Therapeutics, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ev3, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lafayette Holdings LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floreane Medical Implants</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GC Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia Packaging, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Given Imaging, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Given Imaging B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Given Imaging Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Given Imaging Vietnam Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Graphic Controls (Barbados), Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HeartWare, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HeartWare International LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Argentina SA</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Health Services Egypt LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Health Services Lebanon Sarl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebanon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Health Services Pakistan (Private) Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Managed Services SAS</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Saglik Hizmetleri Ltd STI</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India Medtronic Private Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Health Solutions Chile S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Health Solutions International S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersect ENT, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Invatec S.p.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Invatec Technology Center GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall de Mexico, S.A. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall de Venezuela, C.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall Innovadores en Cuidados al Paciente S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KLHC, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Klue, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyphon South Africa (Proprietary) Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Design Systems, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M-Smart Medical Technology (Shanghai) Co. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Makani II Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt DAR Srl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt Holdings B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt Medical Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt US LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marblehead Medical LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mazor Robotics Ltd. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDT Hung&#225;ria Kereskedelmi Korl&#225;tolt Felel&#337;ss&#233;g&#369; T&#225;rsas&#225;g</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDT Turkey Finansal Dan&#305;&#351;manl&#305;k Limited &#350;irketi</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Education Y. K.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Medtronic Nigeria Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicrea Australia Pty Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicrea International </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicrea USA, Corp</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medina Medical, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medinse S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic &#8211; Sequoia (Cayman) Innovation Investment Management Partners, Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Africa) (Proprietary) Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Changzhou) Medical Devices Technology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Chengdu) Management Consulting Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Schweiz) A.G. (Medtronic (Suisse) S.A.)</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Shanghai) Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Shanghai) Management Co. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Taiwan) Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Thailand) Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ablation Frontiers LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Adriatic d.o.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Advanced Energy LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Advanced Energy Luxembourg S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic AF Luxembourg S.&#224; r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic AG</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Aktiebolag</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Arabia Regional Headquarter</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ardian Luxembourg S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic ATS Medical, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Australasia Pty Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Bakken Research Center B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Bangladesh Pvt. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bangladesh</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Belgium S.A.&#47;N.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic BioPharma B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic BioPharma S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Bulgaria EOOD</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulgaria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Canada ULC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Care Management Services, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Cash Pool LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Changzhou Medical Device Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic China Kanghui Holdings</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic China Venture Fund (Cayman), L.P.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic China, LLC.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Colombia S.A. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Comercial Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Comercial Panam&#225;, S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic CoreValve LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic CryoCath LP</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic CV Luxembourg S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Czechia s.r.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Danmark A&#47;S</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Diabetes (Chengdu) Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic do Brasil Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Dominican Republic S.A.S.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Dominicana (Manufactura), S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Egypt LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Empalme S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Engineering and Innovation Center Private Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Europe Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malta</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Europe S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Fabrication </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Finance Holdings ULC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Finance Hungary Kft.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Finland Oy</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic France </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Global Holdings GP S.&#224; r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Global Holdings S.C.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Group Holding, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Hellas Medical Device Commercial Single Member S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holding, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holding B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holding Company S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holding Hungary Kft.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holding Switzerland G.m.b.H.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holdings France</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holdings S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Hong Kong Medical Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Hungaria Kereskedelmi Kft</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ib&#233;rica S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Innovation Center (Israel) Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Integrated Health Solutions LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International, Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Holding LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Technology, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Trading, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Trading Holding LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Trading Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Trading S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Interventional Vascular, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Invatec LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic IP Holding International Luxembourg S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ireland Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ireland Manufacturing Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Italia S.p.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Japan Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Jolife LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Kazakhstan Limited Liability Partnership</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kazakhstan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic KL Holdings LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Korea Holdings Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Korea Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Labs PBC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Latin America, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Logistics LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Luxembourg Global Holdings S.&#224; r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Malaysia Sdn. Bhd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Medical CR S de RL</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Medikal Teknoloji Ticaret Limited Sirketi</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Mediterranean Offshore SAL</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebanon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic META FZ-LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Mexico S. de R.L. de C.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic MiniMed, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Monitoring, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Navigation, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Navigation Israel Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic New Zealand Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Norge AS</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Oesterreich G.m.b.H.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Pacific Trading, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Pakistan (Private) Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Philippines, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Poland Sp. Z o.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Poland Finance Sp.z.o.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Portugal, Lda</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic PS Medical, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Puerto Rico Operations Co.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic RCS Holding GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Romania SRL</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic S. de R.L. de C.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic S.A.I.C.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Saudi Arabia Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Servicios S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sequoia (Cayman) Innovation Investment Management Partners, Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Shared Services Americas S.A.S.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Shared Services SRL</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Singapore Operations Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Slovakia s.r.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sofamor Danek Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sofamor Danek Deggendorf GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sofamor Danek USA, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sofamor Danek, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Srbija d.o.o. Beograd-Novi Beograd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sweden Finance AB</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Trading Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Trading NL BV</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ukraine Limited Liability Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukraine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic ULN, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic USA, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Vascular Galway Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Vascular, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ventor Technologies Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Vietnam Company Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic VT, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic World Trade Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Xomed, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Xomed LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic, trgovina z medicinsko tehnologijo in opremo d.o.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michigan Critical Care Consultants, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Micro Therapeutics, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Distribution Corp.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Pty Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMJ, S.A. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSCH LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N.G.C. Medical Srl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NayaMed International S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nederelandse Obesitas Kliniek Zuid B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N.O.K. Nederlandse Obesitas Kliniek B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nederlandse Obesitas Kliniek West B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nederlandse Obesitas kliniek Zeeland B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett Ireland Holdings Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett Ireland Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett Mexico, S.A. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett UK Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Wave Surgical, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Australia Pty Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Belgium B.V.                                                                                                 </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Denmark ApS                                                                                              </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Finland Oy                                                                                                      </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Germany GmbH                                                                                          </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Global Holdings S.&#224; r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Japan Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB New Zealand Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutrino Health Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesitas International B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesitas Nederland B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Old Colony State Insurance Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vermont</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oridion Capnography, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oridion Medical 1987 Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oridion Systems Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osteotech, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plastics Holding Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polyken Technologies Europe, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polysuture Industria e Comercio Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT. Covidien Indonesia</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Medtronic Indonesia</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTB International LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raychem Tecnologias, S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retail Group de Mexico S.A. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RF Surgical Systems LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanatis GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sapheon LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai MedTech Service Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Medtronic Zhikang Medical Devices Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Mei Jing Mwi Zhong Venture Capital Partnership (Limited Partnership)</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Mei Zhong Private Fund Management Co., Ltd. China</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai MyanCor Medical Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sherwood Medical Company I</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore MyanCor Medical Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Societe De Fabrication de Material Orthopedique En Abrege Sofamor</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sofradim Production</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SonarMed Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sophono, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SpinalGraft Technologies, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Superdimension, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzhou Medtronic Venture Capital Partnership Enterprise (L.P.)</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzhou Medtronic-Sequoia Innovation Investment Management Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Titan Spine, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tissue Science Laboratories Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Twelve, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.S.C. Puerto Rico, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.S.C. Puerto Rico (NY), Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Surgical Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USSC FSC, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USSC Medical GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valera Holdings S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valleylab Holding Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vascular Medcure, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visionsense Corp.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visionsense Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visualase, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vitatron Holding B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VNUS Medical Technologies II, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warsaw Orthopedic Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WEM Equipamentos Electronicos Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">World Heart Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zephyr Technology LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zorginitiatieven B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22
<SEQUENCE>5
<FILENAME>mdt-202410kxex22.htm
<DESCRIPTION>EX-22
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic40ccd003f25490d9e306f7c1fb98740_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 22</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Senior Notes, Issuers and Guarantors</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registered Senior Notes Issued Under</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Issuer</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Guarantors</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indenture, dated as of October 22, 2007</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Covidien International Finance S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Covidien Ltd., Covidien plc, Medtronic plc and Medtronic Global Holdings, S.C.A.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indenture, dated as of March 12, 2009</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc and Medtronic Global Holdings, S.C.A.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indenture, dated as of December 10, 2014</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc and Medtronic Global Holdings S.C.A.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Indenture, dated as of March 28, 2017</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Global Holdings S.C.A.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc and Medtronic, Inc.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>6
<FILENAME>mdt-202410kxex23.htm
<DESCRIPTION>EX-23
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ida59211566934741901b02323c0cfd26_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form</font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">S-3 (No. 333-270272)</font><font style="color:#ff0000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">and Form S-8 (</font><font style="background-color:#ffffff;color:#242424;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">Nos. 333-201737, 333-221962, 333-261841, and 333-275959</font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">) of Medtronic plc of our report dated June 20, 2024 relating to the financial statements,</font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">financial statement schedule</font><font style="color:#ff0000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">Minneapolis, Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2024</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>7
<FILENAME>mdt-202410kxex24.htm
<DESCRIPTION>EX-24
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibfeed29dd9364b6dbf2f734ce59a3955_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 24</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K. FONG and COURTNEY NELSON WILLS, acting individually or jointly, their true and lawful attorneys-in-fact and agents, with full power to act for them and in their name, place and stead, in any and all capacities, to do any and all acts and execute any and all documents which either such attorney and agent may deem necessary or desirable to enable Medtronic plc to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission in respect thereof, in connection with the filing with the Commission of Medtronic&#8217;s Annual Report on Form 10-K for the fiscal year ended April 26, 2024, including specifically, but without limiting the generality of the foregoing, power and authority to sign the names of the undersigned directors to the Form 10-K and to any instruments and documents filed as part of or in connection with the Form 10-K or any amendments thereto&#59; and the undersigned hereby ratify and confirm all actions taken and documents signed by each said attorney and agent as provided herein.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned have set their hands this 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of June, 2024.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Craig Arnold</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin E. Lofton</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig Arnold</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin E. Lofton</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott C. Donnelly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Geoffrey S. Martha</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott C. Donnelly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey S. Martha</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Lidia L. Fonseca</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Elizabeth G. Nabel, M.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lidia L. Fonseca</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth G. Nabel, M.D.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Andrea Goldsmith, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Denise M. O&#8217;Leary</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrea Goldsmith, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denise M. O&#8217;Leary</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Randall J. Hogan</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Kendall J. Powell</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randall J. Hogan</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall J. Powell</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Gregory P. Lewis</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory P. Lewis</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>mdt-202410kxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iab8c314956324bd180ba7d6237a8da0a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Geoffrey S. Martha, certify that&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Medtronic plc&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:28.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Geoffrey S. Martha</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey S. Martha</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>mdt-202410kxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i53cb4bfac36a4ac0ae51d33c97f9f33f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Karen L. Parkhill, certify that&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Medtronic plc&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Karen L. Parkhill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen L. Parkhill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>mdt-202410kxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1e48b5678b314cefbeec6da4093d0667_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this annual report on Form 10-K of Medtronic plc for the fiscal year ended April&#160;26, 2024, the undersigned hereby certifies, in his capacity as Chief Executive Officer of Medtronic plc, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic plc. </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Geoffrey S. Martha </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey S. Martha </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>mdt-202410kxex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i073378420e97486fbfc2306cbecd8bec_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this annual report on Form 10-K of Medtronic plc for the fiscal year ended April&#160;26, 2024, the undersigned hereby certifies, in her capacity as Chief Financial Officer of Medtronic plc, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic plc. </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Karen L. Parkhill</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen L. Parkhill </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>12
<FILENAME>mdt-202410kxex97.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7ca931c314c34cf5a9af69690583340a_1"></div><div style="min-height:62.64pt;width:100%"><div style="margin-bottom:1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 97</font></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt solid #002855;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#002855;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:15.60pt">MEDTRONIC PLC</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#002855;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:15.60pt">POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Description</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Medtronic plc, an Irish public limited company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;) has adopted this Policy for the Recovery of Erroneously Awarded Compensation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;), pursuant to the requirements of the New York Stock Exchange listing standards and Exchange Act Rule 10D-1.  The Policy sets forth the circumstances under which the Company will recover certain incentive compensation paid to the Executive Officers of the Company in connection with certain financial restatements.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Each Executive Officer shall be required to sign and return to the Company the Acknowledgement Form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">, pursuant to which such Executive Officer will agree to be bound by the terms and comply with this Policy in exchange for adequate and reasonable consideration&#59; provided, however, that any failure by an Executive Officer to return a signed Acknowledgement Form does not affect the validity or enforceability of this Policy. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Definitions </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:19.36pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Clawback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means the three completed fiscal years immediately preceding the earlier of (i) the date the Company&#8217;s board of directors concludes, or reasonably should have concluded, that such a Covered Accounting Restatement is required to be prepared or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare a Covered Accounting Restatement (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Clawback Trigger Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;), and any transition period (that results from a change in the Company&#8217;s fiscal year) of less than nine months within or immediately following those three completed fiscal years.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:20.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means the Compensation Committee of the Board of Directors of the Company.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:20.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Covered Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means an accounting restatement prepared due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial restatements (i.e., a &#8220;Big R&#8221; restatement), or that would result in a material misstatement if the error were corrected only in the current period or left uncorrected in the current period (i.e., a &#8220;little r&#8221; restatement).  For the avoidance of doubt, a Covered Accounting Restatement will not include changes to the Company&#8217;s financial statements that do not represent error corrections under accounting standards applicable to the Company at the time of the accounting restatement, including as a result of a (i) retrospective application of a change in accounting principle, (ii) retrospective revision to reportable segment information due to a change in the structure of the Company&#8217;s internal organization, (iii) retrospective reclassification due to a discontinued operation, (iv) retrospective application </font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">of a change in reporting entity, and (v) retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:19.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Covered Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means any Incentive-Based Compensation (i) received by a current or former Executive Officer after beginning service as an Executive Officer, provided that the current or former Executive Officer served as an Executive Officer at any time during the performance period applicable to such Incentive-Based Compensation and (ii) received on or after October 2, 2023 the (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;).  For purposes of this Policy, Incentive-Based Compensation is deemed to be &#8220;received&#8221; in the fiscal year in which the financial reporting measure included in the Incentive-Based Compensation award is attained or satisfied, regardless of whether the payment or grant occurs before or after such fiscal year, and regardless of whether the Incentive-Based Compensation continues to be subject to a service-based vesting condition.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:20.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; has the meaning assigned to it in Section 303A.14 of the New York Stock Exchange Listed Company Manual.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Financial Reporting Measure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means (i) any measure determined in accordance with accounting principles used in the Company&#8217;s financial statements, whether presented in or outside of the Company&#8217;s financial statements and whether or not included in a filing with the Securities and Exchange Commission, (ii) any measures derived wholly or in part from such measures (including non-GAAP measures), and (iii) other performance measures affected by accounting-related information, including stock price, total shareholder return and relative total shareholder return.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:19.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means any compensation that is granted, earned or vested based wholly or in part on the attainment of any Financial Reporting Measure, which may include awards granted under the Company&#8217;s annual incentive plan as well as performance-based restricted stock units, and which may include Incentive-Based Compensation contributed to a plan, other than a tax-qualified retirement plan.  For the avoidance of doubt, Incentive-Based Compensation shall not include equity awards that vest solely based on continued service and were not granted based on the attainment of any financial reporting measure.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">General Rules</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;In the event the Company determines it is required to prepare a Covered Accounting Restatement, the Committee shall review any Covered Incentive-Based Compensation received by a current or former Executive Officer of the Company during the Clawback Period. In the event the Committee determines that the amount of any such Covered Incentive-Based Compensation that was received during the Clawback Period exceeds the amount that otherwise would have been received had it been determined based on the restated results (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;), the amount of such Erroneously Awarded Compensation shall be recovered on a pre-tax basis.</font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Recovery under this Policy with respect to an Executive Officer shall not require the finding of any misconduct by such Executive Officer or such Executive Officer being found responsible for the accounting error leading to the Covered Accounting Restatement. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">For purposes of this section, Incentive-Based Compensation is deemed to be &#8220;received&#8221; in the fiscal year in which the financial reporting measure included in the Incentive-Based Compensation award is attained or satisfied, regardless of whether the payment or grant occurs before or after such fiscal year.  </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Calculation of Erroneously Awarded Compensation</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;In the event any applicable Covered Incentive-Based Compensation has been granted in the form of equity or equity-based awards, and such awards remain outstanding as of the Clawback Trigger Date, the Erroneously Awarded Compensation shall be calculated as the number of shares received in excess of the number that should have been received (or the corresponding value of such shares). In the event that any applicable Covered Incentive-Based Compensation is in a nonqualified deferred compensation plan, the Company shall calculate the amount contributed to the notional account based on the Erroneously Awarded Compensation and any earnings accrued to-date on that notional amount, and that sum shall be considered &#8220;Erroneously Awarded Compensation&#8221; with respect to that plan.   </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">For the avoidance of doubt, in the event Covered Incentive-Based Compensation is attained only partially based on the achievement of financial reporting measures, only the portion of such compensation based on or derived from the financial reporting measures shall be subject to recovery.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;In the event the Erroneously Awarded Compensation is not able to be calculated directly from information in an accounting restatement (e.g., equity awards subject to total shareholder return (&#8220;TSR&#8221;) or stock price measures), in order to determine the amount of such Erroneously Awarded Compensation that shall be subject to recovery, the Committee shall use a reasonable estimate of the effect of the Covered Accounting Restatement on the TSR or stock price upon which the Covered Incentive-Based Compensation was received.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Method for Recovery</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;The Committee shall, in its discretion, determine the appropriate means for recovery of any Erroneously Awarded Compensation, including but not limited to the cancellation of outstanding and future annual or long-term incentive compensation or requiring repayment by the applicable Executive Officer, provided that the recovery occurs reasonably promptly. The Committee may consider all applicable facts and circumstances in determining the appropriate means for recovery, including pursuing an appropriate balance of cost and speed.</font></div><div><font><br></font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Recovery shall be required in all circumstances unless the Committee determines that recovery would be impracticable and that one of the conditions set forth in Section 303A.14(c)(1)(iv)(A), (B), or (C) of the New York Stock Exchange Listed Company Manual are met.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Non-Exclusive&#59; Conflicts</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;This Policy is in addition to any and all other rights the Company may have to pursue remedies against an employee or former employee in connection with an accounting restatement or for misconduct or similar behavior in the course of employment by the Company, all of which are expressly retained by the Company.  Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company pursuant to the terms of the Company&#8217;s Incentive Compensation Forfeiture Policy and any similar policy in any employment agreement, equity award agreement or similar agreement or any other legal remedies available to the Company.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">The Company will not enter into any agreement that exempts any Incentive-based Compensation from the application of this Policy or that waives the Company&#8217;s right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">The provisions of this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision shall be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Indemnification Prohibition</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">The Company is not permitted to indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company&#8217;s enforcement of its rights under this Policy. The Company is also prohibited from paying or reimbursing an Executive Officer for purchasing insurance to cover any such loss. To the extent of a conflict with any agreement with an Executive Officer that purports to provide indemnification rights to the Executive Officer that conflict with the foregoing, this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).  </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Amendment or Termination</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;The Committee may amend or terminate this Policy from time to time in its discretion, including as required to comply with any applicable law or regulation.  Any such amendment will be binding on employees who continue in employment after the effective date of such amendment.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Administration</font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. The Committee has full and final authority to make all determinations under this Policy, in each case to the extent permitted under applicable rules and regulations and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. All determinations and decisions made by the Committee hereunder shall be final, conclusive and binding on all persons. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Any action or inaction by the Committee with respect to an Executive Officer under this Policy in no way limits the Committee&#8217;s actions or decisions not to act with respect to any other Executive Officer under this Policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Executive Officer other than as set forth in this Policy. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">This Policy is intended to comply with the requirements set forth in Section 303A.14 of the New York Stock Exchange Listed Company Manual (as such rule may be amended) and shall be construed and interpreted in accordance with such intent. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Successors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;This Policy shall be binding and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators, and other legal representatives.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Governing Law&#59; Venue</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">The validity, enforceability, construction and interpretation of this Policy shall be governed by the laws of the State of Minnesota.  Any dispute regarding this Policy shall be exclusively decided by a state court in the State of Minnesota&#59; provided that if such court declines to exercise jurisdiction, the dispute shall be decided by the U.S. District Court for the District of Minnesota.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt"> </font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><div id="i7ca931c314c34cf5a9af69690583340a_4"></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="margin-bottom:1pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Acknowledgement Form</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Medtronic plc </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Policy for the Recovery of Erroneously Awarded Compensation</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Medtronic plc Policy for the Recovery of Erroneously Awarded Compensation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;). Capitalized terms used but not otherwise defined in this Acknowledgement Form (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Acknowledgement Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;) shall have the meanings ascribed to such terms in the Policy. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">By signing this Acknowledgement Form, the undersigned acknowledges and agrees that, in exchange for receipt of adequate and reasonable consideration, the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned&#8217;s employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner permitted by, the Policy and the Committee&#8217;s determinations thereunder.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Signature</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Printed Name</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Date</font></div><div style="margin-bottom:1pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>mdt-20240426.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31d25153-b660-4ec0-ab44-7e01aa50312b,g:3d21d99d-9a64-4ef0-a05f-06b24f253785-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mdt="http://www.medtronic.com/20240426" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.medtronic.com/20240426">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20240426_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20240426_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20240426_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20240426_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.medtronic.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.medtronic.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofIncome">
        <link:definition>0000003 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.medtronic.com/role/Revenue">
        <link:definition>0000011 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDispositions" roleURI="http://www.medtronic.com/role/AcquisitionsandDispositions">
        <link:definition>0000012 - Disclosure - Acquisitions and Dispositions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCharges" roleURI="http://www.medtronic.com/role/RestructuringCharges">
        <link:definition>0000013 - Disclosure - Restructuring Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.medtronic.com/role/FinancialInstruments">
        <link:definition>0000014 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangements" roleURI="http://www.medtronic.com/role/FinancingArrangements">
        <link:definition>0000015 - Disclosure - Financing Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagement" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement">
        <link:definition>0000016 - Disclosure - Derivatives and Currency Exchange Risk Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.medtronic.com/role/Inventories">
        <link:definition>0000017 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>0000018 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.medtronic.com/role/PropertyPlantandEquipment">
        <link:definition>0000019 - Disclosure - Property, Plant, and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.medtronic.com/role/ShareholdersEquity">
        <link:definition>0000020 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlans" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlans">
        <link:definition>0000021 - Disclosure - Stock Purchase and Award Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.medtronic.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.medtronic.com/role/EarningsPerShare">
        <link:definition>0000023 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlans" roleURI="http://www.medtronic.com/role/RetirementBenefitPlans">
        <link:definition>0000024 - Disclosure - Retirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.medtronic.com/role/Leases">
        <link:definition>0000025 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLoss" roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss">
        <link:definition>0000026 - Disclosure - Accumulated Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.medtronic.com/role/CommitmentsandContingencies">
        <link:definition>0000027 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformation" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformation">
        <link:definition>0000028 - Disclosure - Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccounts" roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts">
        <link:definition>0000029 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.medtronic.com/role/RevenueTables">
        <link:definition>9954472 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDispositionsTables" roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsTables">
        <link:definition>9954473 - Disclosure - Acquisitions and Dispositions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesTables" roleURI="http://www.medtronic.com/role/RestructuringChargesTables">
        <link:definition>9954474 - Disclosure - Restructuring Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.medtronic.com/role/FinancialInstrumentsTables">
        <link:definition>9954475 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsTables" roleURI="http://www.medtronic.com/role/FinancingArrangementsTables">
        <link:definition>9954476 - Disclosure - Financing Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementTables" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables">
        <link:definition>9954477 - Disclosure - Derivatives and Currency Exchange Risk Management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.medtronic.com/role/InventoriesTables">
        <link:definition>9954478 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>9954479 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentTables">
        <link:definition>9954480 - Disclosure - Property, Plant, and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansTables" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansTables">
        <link:definition>9954481 - Disclosure - Stock Purchase and Award Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.medtronic.com/role/IncomeTaxesTables">
        <link:definition>9954482 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.medtronic.com/role/EarningsPerShareTables">
        <link:definition>9954483 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansTables" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansTables">
        <link:definition>9954484 - Disclosure - Retirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.medtronic.com/role/LeasesTables">
        <link:definition>9954485 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossTables" roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables">
        <link:definition>9954486 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationTables" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationTables">
        <link:definition>9954487 - Disclosure - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954488 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails">
        <link:definition>9954489 - Disclosure - Revenue - Disaggregation of Net Sales by Segment and Division (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails">
        <link:definition>9954490 - Disclosure - Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.medtronic.com/role/RevenueNarrativeDetails">
        <link:definition>9954491 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDispositionsNarrativeDetails" roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails">
        <link:definition>9954492 - Disclosure - Acquisitions and Dispositions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails" roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails">
        <link:definition>9954493 - Disclosure - Acquisitions and Dispositions - Schedule of Fair Value of the Assets Acquired and Liabilities Assumed - Intersect ENT Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails" roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails">
        <link:definition>9954494 - Disclosure - Acquisitions and Dispositions - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails">
        <link:definition>9954495 - Disclosure - Acquisitions and Dispositions - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails" roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails">
        <link:definition>9954496 - Disclosure - Acquisitions and Dispositions - Reconciliation of Level 3 Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesNarrativeDetails" roleURI="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails">
        <link:definition>9954497 - Disclosure - Restructuring Charges - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesClassificationofRestructuringCostsDetails" roleURI="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails">
        <link:definition>9954498 - Disclosure - Restructuring Charges - Classification of Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" roleURI="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails">
        <link:definition>9954499 - Disclosure - Restructuring Charges - Activity Related to Restructuring Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails">
        <link:definition>9954500 - Disclosure - Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails">
        <link:definition>9954501 - Disclosure - Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>9954502 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails">
        <link:definition>9954503 - Disclosure - Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails">
        <link:definition>9954504 - Disclosure - Financial Instruments - Summary of Equity and Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDebtandEquitySecuritiesDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails">
        <link:definition>9954505 - Disclosure - Financial Instruments - Debt and Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsCurrentDebtObligationsDetails" roleURI="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails">
        <link:definition>9954506 - Disclosure - Financing Arrangements - Current Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsNarrativeDetails" roleURI="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails">
        <link:definition>9954507 - Disclosure - Financing Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsLongtermDebtDetails" roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails">
        <link:definition>9954508 - Disclosure - Financing Arrangements - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsLongtermDebtMaturitiesDetails" roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails">
        <link:definition>9954509 - Disclosure - Financing Arrangements - Long-term Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails">
        <link:definition>9954510 - Disclosure - Derivatives and Currency Exchange Risk Management - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails">
        <link:definition>9954511 - Disclosure - Derivatives and Currency Exchange Risk Management- Outsatnding instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails">
        <link:definition>9954512 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>9954513 - Disclosure - Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails">
        <link:definition>9954514 - Disclosure - Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9954515 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails">
        <link:definition>9954516 - Disclosure - Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1">
        <link:definition>9954516 - Disclosure - Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.medtronic.com/role/InventoriesDetails">
        <link:definition>9954517 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails">
        <link:definition>9954518 - Disclosure - Goodwill and Other Intangible Assets - Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>9954519 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails">
        <link:definition>9954520 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>9954521 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>9954522 - Disclosure - Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.medtronic.com/role/ShareholdersEquityDetails">
        <link:definition>9954523 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansNarrativeDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails">
        <link:definition>9954524 - Disclosure - Stock Purchase and Award Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails">
        <link:definition>9954525 - Disclosure - Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansValuationAssumptionsDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails">
        <link:definition>9954526 - Disclosure - Stock Purchase and Award Plans - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansStockOptionsActivityDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails">
        <link:definition>9954527 - Disclosure - Stock Purchase and Award Plans - Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansRestrictedStockActivityDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails">
        <link:definition>9954528 - Disclosure - Stock Purchase and Award Plans - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails">
        <link:definition>9954529 - Disclosure - Stock Purchase and Award Plans - Performance Share Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails">
        <link:definition>9954530 - Disclosure - Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxBenefitProvisionDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails">
        <link:definition>9954531 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954532 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1" roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1">
        <link:definition>9954532 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954533 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9954534 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails">
        <link:definition>9954535 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" roleURI="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails">
        <link:definition>9954536 - Disclosure - Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>9954537 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansNarativeDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails">
        <link:definition>9954538 - Disclosure - Retirement Benefit Plans - Narative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails">
        <link:definition>9954539 - Disclosure - Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansNetPeriodicCostandAOCIDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails">
        <link:definition>9954540 - Disclosure - Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails">
        <link:definition>9954541 - Disclosure - Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansFairValueMeasurementDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails">
        <link:definition>9954542 - Disclosure - Retirement Benefit Plans - Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansFutureBenefitPaymentsDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails">
        <link:definition>9954543 - Disclosure - Retirement Benefit Plans - Future Benefit Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails" roleURI="http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails">
        <link:definition>9954544 - Disclosure - Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails" roleURI="http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails">
        <link:definition>9954545 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofTotalOperatingLeaseCostDetails" roleURI="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails">
        <link:definition>9954546 - Disclosure - Leases - Components of Total Operating Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>9954547 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeasesDetails" roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails">
        <link:definition>9954548 - Disclosure - Leases - Maturities of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeasesDetails_1" roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1">
        <link:definition>9954548 - Disclosure - Leases - Maturities of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossDetails" roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails">
        <link:definition>9954549 - Disclosure - Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.medtronic.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954550 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationNarrativeDetails" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails">
        <link:definition>9954551 - Disclosure - Segment and Geographic Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails">
        <link:definition>9954552 - Disclosure - Segment and Geographic Information - Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails">
        <link:definition>9954553 - Disclosure - Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails">
        <link:definition>9954554 - Disclosure - Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsDetails" roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails">
        <link:definition>9954555 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" abstract="false" name="DerivativeAssetLiabilityFairValueGrossAssetLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" abstract="false" name="OtherNonoperatingIncomeExpenseNetPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due2050Member" abstract="true" name="SeniorNotes2019Due2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2028Member" abstract="true" name="SeniorNotes2020Due2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_IncomeTaxExaminationInterestIncomeExpenseGross" abstract="false" name="IncomeTaxExaminationInterestIncomeExpenseGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_A4250PercentFiveYear2023SeniorNotesMember" abstract="true" name="A4250PercentFiveYear2023SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20392.250PercentMember" abstract="true" name="SeniorNotes2019Due20392.250PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2032Member" abstract="true" name="SeniorNotes2020Due2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_OtherAccruedExpensesMember" abstract="true" name="OtherAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotesDue2029Member" abstract="true" name="SeniorNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due2026Member" abstract="true" name="SeniorNotes2019Due2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due2027Member" abstract="true" name="SeniorNotes2019Due2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" abstract="false" name="DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_IPRDMember" abstract="true" name="IPRDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdt_BuildingsAndLeaseholdImprovementsMember" abstract="true" name="BuildingsAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2022Due2025Member" abstract="true" name="SeniorNotes2022Due2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2014Due2044Member" abstract="true" name="SeniorNotes2014Due2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" abstract="false" name="UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" abstract="false" name="UnrecognizedTaxBenefitsNetofCashAdvancePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_PartnershipUnitsMember" abstract="true" name="PartnershipUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock" abstract="false" name="FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" abstract="false" name="EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_RestructuringChargesIncludingAccrualAdjustments" abstract="false" name="RestructuringChargesIncludingAccrualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mdt_MedicalDeviceRegulations" abstract="false" name="MedicalDeviceRegulations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SeniorNotesDue2043Member" abstract="true" name="SeniorNotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_EmployeesStockPurchasePlanMember" abstract="true" name="EmployeesStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_ForeignCurrencyCosts" abstract="false" name="ForeignCurrencyCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" abstract="false" name="DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_IntersectENTMember" abstract="true" name="IntersectENTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2010Due2040Member" abstract="true" name="SeniorNotes2010Due2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" abstract="false" name="OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SeniorNotesDue2053Member" abstract="true" name="SeniorNotesDue2053Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20311.625PercentMember" abstract="true" name="SeniorNotes2019Due20311.625PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_EquityInvestmentsMember" abstract="true" name="EquityInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_TokyoInterBankOfferedRateTIBORMember" abstract="true" name="TokyoInterBankOfferedRateTIBORMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_IncomeTaxesandInterestPaidAbstract" abstract="true" name="IncomeTaxesandInterestPaidAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2025Member" abstract="true" name="SeniorNotes2020Due2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" abstract="false" name="DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" abstract="false" name="DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" abstract="false" name="DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_RevenueMilestoneMember" abstract="true" name="RevenueMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2022Due2031Member" abstract="true" name="SeniorNotes2022Due2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20391.50PercentMember" abstract="true" name="SeniorNotes2019Due20391.50PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due2025Member" abstract="true" name="SeniorNotes2019Due2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_MechanicalCirculatorySupportMember" abstract="true" name="MechanicalCirculatorySupportMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2022Due2028Member" abstract="true" name="SeniorNotes2022Due2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2022Due2034Member" abstract="true" name="SeniorNotes2022Due2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_ContingentConsiderationPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_ScheduleOfDebtTable" abstract="true" name="ScheduleOfDebtTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mdt_OtherPlanAssetsMember" abstract="true" name="OtherPlanAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_A3000PercentSixYear2022SeniorNotesMember" abstract="true" name="A3000PercentSixYear2022SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredStockSharesOutstanding" abstract="false" name="DeferredStockSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_SimplificationRestructuringProgramMember" abstract="true" name="SimplificationRestructuringProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsLeaseObligations" abstract="false" name="DeferredTaxAssetsLeaseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" abstract="true" name="BusinessAcquisitionContingentConsiderationAtFairValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" abstract="true" name="DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_CranialAndSpinalTechnologiesDivisionMember" abstract="true" name="CranialAndSpinalTechnologiesDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_MedicalSurgicalMember" abstract="true" name="MedicalSurgicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20311.00PercentMember" abstract="true" name="SeniorNotes2019Due20311.00PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_CoronaryAndPeripheralVascularDivisionMember" abstract="true" name="CoronaryAndPeripheralVascularDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_AfferaIncMember" abstract="true" name="AfferaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2015Due2035Member" abstract="true" name="SeniorNotes2015Due2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" abstract="false" name="FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" abstract="false" name="DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_RenalCareBusinessRCSMember" abstract="true" name="RenalCareBusinessRCSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2040Member" abstract="true" name="SeniorNotes2020Due2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DiabetesGroupMember" abstract="true" name="DiabetesGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_MozarcMember" abstract="true" name="MozarcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_OffsettingAssetsandLiabilitiesTable" abstract="true" name="OffsettingAssetsandLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mdt_DerivativeAssetLiabilityAbstract" abstract="true" name="DerivativeAssetLiabilityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_PurchasedTechnologyAndPatentsMember" abstract="true" name="PurchasedTechnologyAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_AcuteCareMonitoringMember" abstract="true" name="AcuteCareMonitoringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" abstract="true" name="UnrecognizedTaxBenefitsGrossIncreasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due2032Member" abstract="true" name="SeniorNotes2019Due2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" abstract="false" name="DeferredTaxLiabilitiesInvestmentInSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2050Member" abstract="true" name="SeniorNotes2020Due2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2015Due20253.500PercentMember" abstract="true" name="SeniorNotes2015Due20253.500PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember" abstract="true" name="JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" abstract="false" name="RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" abstract="true" name="TotalOtherCountriesExcludingUnitedStatesandIrelandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_MedtronicLuxcoMember" abstract="true" name="MedtronicLuxcoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_SeniorNotes2015Due2045Member" abstract="true" name="SeniorNotes2015Due2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" abstract="true" name="IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SpecialChargesGains" abstract="false" name="SpecialChargesGains" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SeniorNotesDue2036Member" abstract="true" name="SeniorNotesDue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_ImpairmentofInProcessResearchandDevelopment" abstract="false" name="ImpairmentofInProcessResearchandDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2033Member" abstract="true" name="SeniorNotes2020Due2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_A4500PercentTenYear2023SeniorNotesMember" abstract="true" name="A4500PercentTenYear2023SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_LineOfCreditFacilityLengthOfExtension" abstract="false" name="LineOfCreditFacilityLengthOfExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mdt_DebtInstrumentNumberofTranches" abstract="false" name="DebtInstrumentNumberofTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdt_ColibriMember" abstract="true" name="ColibriMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2026Member" abstract="true" name="SeniorNotes2020Due2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2051Member" abstract="true" name="SeniorNotes2020Due2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" abstract="true" name="UnrecognizedTaxBenefitsGrossDecreasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredStockParorStatedValuePerShare" abstract="false" name="DeferredStockParorStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mdt_DeferredStockSharesAuthorized" abstract="false" name="DeferredStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_RegisteredInvestmentCompanyMember" abstract="true" name="RegisteredInvestmentCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_TotalOtherCountriesExcludingIrelandMember" abstract="true" name="TotalOtherCountriesExcludingIrelandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_HerniaMeshLitigationMember" abstract="true" name="HerniaMeshLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_ProductDevelopmentMilestoneMember" abstract="true" name="ProductDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2029Member" abstract="true" name="SeniorNotes2020Due2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_AssociatedAndOtherCostsMember" abstract="true" name="AssociatedAndOtherCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_BusinessAcquisitionPriceContingentConsideration" abstract="false" name="BusinessAcquisitionPriceContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" abstract="false" name="OtherOperatingIncomeExpenseNetPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_SeniorNotesCIFSA2007Due2038Member" abstract="true" name="SeniorNotesCIFSA2007Due2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsNetofValuationAllowanceOther" abstract="false" name="DeferredTaxAssetsNetofValuationAllowanceOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_InsuranceContractMember" abstract="true" name="InsuranceContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" abstract="false" name="ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_CorporateOverhead" abstract="false" name="CorporateOverhead" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_RenalCareSolutionsMember" abstract="true" name="RenalCareSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" abstract="false" name="BusinessAcquisitionContingentConsiderationMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_NeuromodulationDivisionMember" abstract="true" name="NeuromodulationDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" abstract="false" name="EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" abstract="false" name="EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherAcquisitionsMember" abstract="true" name="OtherAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_NeuroscienceGroupMember" abstract="true" name="NeuroscienceGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_MedtronicLuxcoSeniorNotesMember" abstract="true" name="MedtronicLuxcoSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_BusinessAcquisitionContingentConsiderationRollForward" abstract="true" name="BusinessAcquisitionContingentConsiderationRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" abstract="true" name="DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_CashAdvancePaidinConnectionWithProposedSettlements" abstract="false" name="CashAdvancePaidinConnectionWithProposedSettlements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SurgicalInnovationsDivisionMember" abstract="true" name="SurgicalInnovationsDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" abstract="false" name="EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" abstract="false" name="BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_CommercialPaperMaximumBorrowingCapacity" abstract="false" name="CommercialPaperMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DiabetesPumpRetainerRingLitigationMember" abstract="true" name="DiabetesPumpRetainerRingLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" abstract="false" name="DeferredTaxAssetsResearchAndDevelopmentCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_A2625PercentThreeYear2022SeniorNotesMember" abstract="true" name="A2625PercentThreeYear2022SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_StructuralHeartAndAorticDivisionMember" abstract="true" name="StructuralHeartAndAorticDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_CentralizedDistributionCosts" abstract="false" name="CentralizedDistributionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" abstract="false" name="OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_A2015CommercialPaperProgramMember" abstract="true" name="A2015CommercialPaperProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_IncreaseDecreaseInTaxRateAbstract" abstract="true" name="IncreaseDecreaseInTaxRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due2031Member" abstract="true" name="SeniorNotes2019Due2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due2039Member" abstract="true" name="SeniorNotes2019Due2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2017Due20273.350PercentMember" abstract="true" name="SeniorNotes2017Due20273.350PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A3125PercentNineYear2022SeniorNotesMember" abstract="true" name="A3125PercentNineYear2022SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_CardiacRhythmandHeartFailureDivisionMember" abstract="true" name="CardiacRhythmandHeartFailureDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_A3375PercentTwelveYear2022SeniorNotesMember" abstract="true" name="A3375PercentTwelveYear2022SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due2041Member" abstract="true" name="SeniorNotes2020Due2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SpecialtyTherapiesDivisionMember" abstract="true" name="SpecialtyTherapiesDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2013Due2043Member" abstract="true" name="SeniorNotes2013Due2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_VentilatorProductLineExitMember" abstract="true" name="VentilatorProductLineExitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember" abstract="true" name="MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_StockRepurchaseProgramAveragePurchasePrice" abstract="false" name="StockRepurchaseProgramAveragePurchasePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mdt_DeferredStockSharesIssued" abstract="false" name="DeferredStockSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_AdditionalCashInvestment" abstract="false" name="AdditionalCashInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due2049Member" abstract="true" name="SeniorNotes2019Due2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SeniorNotes2009Due2039Member" abstract="true" name="SeniorNotes2009Due2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_TotalReportableSegmentsMember" abstract="true" name="TotalReportableSegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_EnterpriseExcellenceMember" abstract="true" name="EnterpriseExcellenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2012Due2042Member" abstract="true" name="SeniorNotes2012Due2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DebtLineItems" abstract="true" name="DebtLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_OffsettingAssetsandLiabilitiesLineItems" abstract="true" name="OffsettingAssetsandLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_BusinessAcquisitionContingentConsiderationLiability" abstract="false" name="BusinessAcquisitionContingentConsiderationLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneStockAwardAndIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_CardiovascularMember" abstract="true" name="CardiovascularMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due2040Member" abstract="true" name="SeniorNotes2019Due2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsInterestLimitation" abstract="false" name="DeferredTaxAssetsInterestLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_AmendedandRestatedRevolvingCreditAgreementMember" abstract="true" name="AmendedandRestatedRevolvingCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_A2024EmployeeStockPurchasePlanMember" abstract="true" name="A2024EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>mdt-20240426_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31d25153-b660-4ec0-ab44-7e01aa50312b,g:3d21d99d-9a64-4ef0-a05f-06b24f253785-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_497bf942-91f7-4420-9871-0afe5d09431d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7187c679-3a8e-4d24-802b-2e9259e7c82f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_497bf942-91f7-4420-9871-0afe5d09431d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7187c679-3a8e-4d24-802b-2e9259e7c82f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_840bf75a-14ea-40bf-8098-ee20a9eb353a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_497bf942-91f7-4420-9871-0afe5d09431d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_840bf75a-14ea-40bf-8098-ee20a9eb353a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5a02d731-50fd-4ccb-9484-a88e59fe89bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_497bf942-91f7-4420-9871-0afe5d09431d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5a02d731-50fd-4ccb-9484-a88e59fe89bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8551f3d9-fb36-449f-85ce-caf0cac21b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_497bf942-91f7-4420-9871-0afe5d09431d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8551f3d9-fb36-449f-85ce-caf0cac21b6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b6c233ae-3932-41e6-9033-bc9995c406e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_497bf942-91f7-4420-9871-0afe5d09431d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b6c233ae-3932-41e6-9033-bc9995c406e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_19f69885-5e35-437d-9ef4-b73675f842c0" xlink:href="mdt-20240426.xsd#mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_497bf942-91f7-4420-9871-0afe5d09431d" xlink:to="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_19f69885-5e35-437d-9ef4-b73675f842c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_a3972203-e994-46a7-bf2e-94ac24529469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_497bf942-91f7-4420-9871-0afe5d09431d" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_a3972203-e994-46a7-bf2e-94ac24529469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_3234b41b-a7ae-48b1-9628-17f6cf053a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_497bf942-91f7-4420-9871-0afe5d09431d" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_3234b41b-a7ae-48b1-9628-17f6cf053a59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a1b5123-c060-487a-b16a-a3263b90477f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_538f0146-7123-4737-b76f-1fe6c668d65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a1b5123-c060-487a-b16a-a3263b90477f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_538f0146-7123-4737-b76f-1fe6c668d65e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0fb9dd58-6bf1-4ec2-ad0a-f3e0fd913e00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a1b5123-c060-487a-b16a-a3263b90477f" xlink:to="loc_us-gaap_OperatingIncomeLoss_0fb9dd58-6bf1-4ec2-ad0a-f3e0fd913e00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5c48b600-f3a3-4e44-a6da-71e7e6570f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a1b5123-c060-487a-b16a-a3263b90477f" xlink:to="loc_us-gaap_InterestExpense_5c48b600-f3a3-4e44-a6da-71e7e6570f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1073dcc2-e3de-41d6-84d5-0ead0a8d6e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_94edf445-25d4-4151-991b-7e9a6c7c3bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1073dcc2-e3de-41d6-84d5-0ead0a8d6e86" xlink:to="loc_us-gaap_ProfitLoss_94edf445-25d4-4151-991b-7e9a6c7c3bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_aa4743a1-bf9f-4858-8525-63d1ee74b9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1073dcc2-e3de-41d6-84d5-0ead0a8d6e86" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_aa4743a1-bf9f-4858-8525-63d1ee74b9ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_560abf6a-0ef1-4140-829d-8cc71b87798c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_122869d6-c7fd-4de3-98b2-5516dd69b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_560abf6a-0ef1-4140-829d-8cc71b87798c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_122869d6-c7fd-4de3-98b2-5516dd69b7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_74800d70-08bc-44cd-8f97-e222c2d43448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_560abf6a-0ef1-4140-829d-8cc71b87798c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_74800d70-08bc-44cd-8f97-e222c2d43448" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_738c2faf-fcf3-4438-8d12-2e71e43457a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1233d281-e614-4f01-9f33-398eadf623d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_738c2faf-fcf3-4438-8d12-2e71e43457a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1233d281-e614-4f01-9f33-398eadf623d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_46703cbf-7f79-4ff7-9e6f-4307e2dda2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_738c2faf-fcf3-4438-8d12-2e71e43457a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_46703cbf-7f79-4ff7-9e6f-4307e2dda2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_c61c198e-8a47-41dd-88bb-69f17d6f51df" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_738c2faf-fcf3-4438-8d12-2e71e43457a7" xlink:to="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_c61c198e-8a47-41dd-88bb-69f17d6f51df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5488f0d2-d4f2-4d96-8c3b-72477fc85e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_738c2faf-fcf3-4438-8d12-2e71e43457a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5488f0d2-d4f2-4d96-8c3b-72477fc85e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a72039c5-6bb7-4725-b71a-d921de8e7e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_738c2faf-fcf3-4438-8d12-2e71e43457a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a72039c5-6bb7-4725-b71a-d921de8e7e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b94f107e-15dc-461a-945b-d273b19d1f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_00005cab-e87c-4208-85b5-fe8dddad7157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b94f107e-15dc-461a-945b-d273b19d1f1b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_00005cab-e87c-4208-85b5-fe8dddad7157" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff7c9ba4-9eef-4d84-b08d-5ba31a0acde3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b94f107e-15dc-461a-945b-d273b19d1f1b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff7c9ba4-9eef-4d84-b08d-5ba31a0acde3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7fa0c129-494c-4f24-9fd3-303185b48fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_84f6c849-1213-40d2-b0d5-24959585a3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7fa0c129-494c-4f24-9fd3-303185b48fdd" xlink:to="loc_us-gaap_ProfitLoss_84f6c849-1213-40d2-b0d5-24959585a3f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0a08598b-e793-4228-94fb-42916c8ec548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7fa0c129-494c-4f24-9fd3-303185b48fdd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0a08598b-e793-4228-94fb-42916c8ec548" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_eafff909-e1bb-4395-9f4b-f46793fb6454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4a0e6d00-a9de-4626-8caa-17d9e051c49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_eafff909-e1bb-4395-9f4b-f46793fb6454" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4a0e6d00-a9de-4626-8caa-17d9e051c49e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_6a04c838-702b-4212-8ffe-c229a445f33a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_eafff909-e1bb-4395-9f4b-f46793fb6454" xlink:to="loc_us-gaap_DebtCurrent_6a04c838-702b-4212-8ffe-c229a445f33a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4ee25093-0f1c-4227-b218-20d41a4b5a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_eafff909-e1bb-4395-9f4b-f46793fb6454" xlink:to="loc_us-gaap_AccountsPayableCurrent_4ee25093-0f1c-4227-b218-20d41a4b5a3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_56be04c1-1450-4573-8c9e-e998e0d81a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_eafff909-e1bb-4395-9f4b-f46793fb6454" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_56be04c1-1450-4573-8c9e-e998e0d81a73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_eafb77a6-7758-4f7c-ad87-3fef9157cef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_eafff909-e1bb-4395-9f4b-f46793fb6454" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_eafb77a6-7758-4f7c-ad87-3fef9157cef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_496013f3-cc76-41a7-95d7-907619bd3363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a21cc1eb-bad6-4e47-a98c-3ae827303501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_496013f3-cc76-41a7-95d7-907619bd3363" xlink:to="loc_us-gaap_CommonStockValue_a21cc1eb-bad6-4e47-a98c-3ae827303501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_65e3a006-f2f6-411e-901b-9b19545cbd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_496013f3-cc76-41a7-95d7-907619bd3363" xlink:to="loc_us-gaap_AdditionalPaidInCapital_65e3a006-f2f6-411e-901b-9b19545cbd5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4eab6cc3-f60a-4ad5-9594-780f78e529c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_496013f3-cc76-41a7-95d7-907619bd3363" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4eab6cc3-f60a-4ad5-9594-780f78e529c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dfa6f01f-d6fc-43e8-a79a-921885875623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_496013f3-cc76-41a7-95d7-907619bd3363" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dfa6f01f-d6fc-43e8-a79a-921885875623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9dc2ca36-e74a-4433-9801-cc8d4a0899f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3fc5a0bc-6db1-4710-99a8-0399cbcf82c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9dc2ca36-e74a-4433-9801-cc8d4a0899f1" xlink:to="loc_us-gaap_LiabilitiesCurrent_3fc5a0bc-6db1-4710-99a8-0399cbcf82c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_aa5bac21-66df-4bb0-a8d4-61065ca8d540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9dc2ca36-e74a-4433-9801-cc8d4a0899f1" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_aa5bac21-66df-4bb0-a8d4-61065ca8d540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_30fdecee-24ad-49f6-a43b-ce11d0a1861e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9dc2ca36-e74a-4433-9801-cc8d4a0899f1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_30fdecee-24ad-49f6-a43b-ce11d0a1861e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_25a50cac-24cb-48ec-bf0d-e7cabb744d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9dc2ca36-e74a-4433-9801-cc8d4a0899f1" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_25a50cac-24cb-48ec-bf0d-e7cabb744d80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c2110f61-69b7-45ae-a89a-e98540c988b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9dc2ca36-e74a-4433-9801-cc8d4a0899f1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c2110f61-69b7-45ae-a89a-e98540c988b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_e264a396-99a7-4b97-892b-b9ef8007c498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9dc2ca36-e74a-4433-9801-cc8d4a0899f1" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_e264a396-99a7-4b97-892b-b9ef8007c498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ab631b26-13fa-472c-8404-151be16ecdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a48f388b-1042-44e1-ac72-46affd35024c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ab631b26-13fa-472c-8404-151be16ecdf1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a48f388b-1042-44e1-ac72-46affd35024c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5ff19f80-06c6-4de6-9d42-d940a7b0dd70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ab631b26-13fa-472c-8404-151be16ecdf1" xlink:to="loc_us-gaap_Goodwill_5ff19f80-06c6-4de6-9d42-d940a7b0dd70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a316d9cb-d560-47f1-ab4e-66f3f42ab4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ab631b26-13fa-472c-8404-151be16ecdf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a316d9cb-d560-47f1-ab4e-66f3f42ab4b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f674090-9766-49e8-acb8-b54d685bea55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ab631b26-13fa-472c-8404-151be16ecdf1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f674090-9766-49e8-acb8-b54d685bea55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d05cfe26-d821-4ee9-992f-474cf356d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ab631b26-13fa-472c-8404-151be16ecdf1" xlink:to="loc_us-gaap_AssetsCurrent_d05cfe26-d821-4ee9-992f-474cf356d1ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_a4556518-252b-48c1-a6c3-3180a5819610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ab631b26-13fa-472c-8404-151be16ecdf1" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_a4556518-252b-48c1-a6c3-3180a5819610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d6c0354e-5cd0-4b44-b910-65300de2ca54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bfd4ca92-81b8-4fb4-9dd8-75b1dd593176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d6c0354e-5cd0-4b44-b910-65300de2ca54" xlink:to="loc_us-gaap_StockholdersEquity_bfd4ca92-81b8-4fb4-9dd8-75b1dd593176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_be364266-5a9e-4d1a-b55c-bc653171726d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d6c0354e-5cd0-4b44-b910-65300de2ca54" xlink:to="loc_us-gaap_MinorityInterest_be364266-5a9e-4d1a-b55c-bc653171726d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_91202651-e7be-41fc-a85b-4756882990cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e99ad22d-3ea1-49f0-b6cc-804a43accb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_91202651-e7be-41fc-a85b-4756882990cd" xlink:to="loc_us-gaap_Liabilities_e99ad22d-3ea1-49f0-b6cc-804a43accb8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b25926e3-365f-4f27-a04a-40c4820e0dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_91202651-e7be-41fc-a85b-4756882990cd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b25926e3-365f-4f27-a04a-40c4820e0dc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_96f0df6c-50b6-4611-941e-149f2a23f240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_91202651-e7be-41fc-a85b-4756882990cd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_96f0df6c-50b6-4611-941e-149f2a23f240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2ecb8bdf-a9fe-4bf1-a8d0-14979658f7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1db5eac9-cb77-4a36-9b70-5bb125760657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ecb8bdf-a9fe-4bf1-a8d0-14979658f7ac" xlink:to="loc_us-gaap_OtherAssetsCurrent_1db5eac9-cb77-4a36-9b70-5bb125760657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bfc28516-e7ee-464a-85e6-494701ff6623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ecb8bdf-a9fe-4bf1-a8d0-14979658f7ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bfc28516-e7ee-464a-85e6-494701ff6623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5c0fccdb-66a4-4c4a-bc37-3acb87c8c063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ecb8bdf-a9fe-4bf1-a8d0-14979658f7ac" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5c0fccdb-66a4-4c4a-bc37-3acb87c8c063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_73774559-bcf2-475c-b716-0dd35bcf2d47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ecb8bdf-a9fe-4bf1-a8d0-14979658f7ac" xlink:to="loc_us-gaap_InventoryNet_73774559-bcf2-475c-b716-0dd35bcf2d47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_544445ee-f28d-4a50-8be7-0d70f78266bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ecb8bdf-a9fe-4bf1-a8d0-14979658f7ac" xlink:to="loc_us-gaap_ShortTermInvestments_544445ee-f28d-4a50-8be7-0d70f78266bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6bbf574b-efc6-435a-847a-83599b459982" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6514ee0b-934d-4fd8-8b53-838bb9bdb8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6bbf574b-efc6-435a-847a-83599b459982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6514ee0b-934d-4fd8-8b53-838bb9bdb8cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52909acf-d6d7-4d32-8283-0c1d07691129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6bbf574b-efc6-435a-847a-83599b459982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52909acf-d6d7-4d32-8283-0c1d07691129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65bdc3ca-3549-4ef6-84cc-c3432e92ad9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6bbf574b-efc6-435a-847a-83599b459982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65bdc3ca-3549-4ef6-84cc-c3432e92ad9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b580709a-0c69-4a13-bee4-04d093383b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6bbf574b-efc6-435a-847a-83599b459982" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b580709a-0c69-4a13-bee4-04d093383b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94be43cf-7e7b-497b-9bf4-a989628b859e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_83e53d4f-b877-432b-86f9-a6b786d829b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94be43cf-7e7b-497b-9bf4-a989628b859e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_83e53d4f-b877-432b-86f9-a6b786d829b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_cb4bfea0-3c84-46b5-81ae-4c2fe08b8da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94be43cf-7e7b-497b-9bf4-a989628b859e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_cb4bfea0-3c84-46b5-81ae-4c2fe08b8da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4a11c6fc-95bf-4bcb-aa34-107cbf640636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94be43cf-7e7b-497b-9bf4-a989628b859e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4a11c6fc-95bf-4bcb-aa34-107cbf640636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12940410-d3f1-4af3-85d1-57315ec7603d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94be43cf-7e7b-497b-9bf4-a989628b859e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12940410-d3f1-4af3-85d1-57315ec7603d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_dac54b35-0cec-427f-b666-d533eb81d15b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94be43cf-7e7b-497b-9bf4-a989628b859e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_dac54b35-0cec-427f-b666-d533eb81d15b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_87d59d76-4ad5-4e39-ad67-36fe3727c0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_87d59d76-4ad5-4e39-ad67-36fe3727c0b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_47201e01-6607-4b27-a73c-fe8bc332241c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_47201e01-6607-4b27-a73c-fe8bc332241c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_987f2464-e49a-430a-8ff5-72743696caad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_ProfitLoss_987f2464-e49a-430a-8ff5-72743696caad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b601897c-1632-408a-b487-69529c5aaf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b601897c-1632-408a-b487-69529c5aaf9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_3d2ff7e1-75b5-4313-9986-158ba4aff00b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_3d2ff7e1-75b5-4313-9986-158ba4aff00b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_ceaad87a-d922-408c-8276-047463928049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_ceaad87a-d922-408c-8276-047463928049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d96e9ee4-05b2-4aae-b12e-061d073ac6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d96e9ee4-05b2-4aae-b12e-061d073ac6b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_766cda0f-88e6-40a5-a492-265d8bd3f772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_766cda0f-88e6-40a5-a492-265d8bd3f772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1b12fb1a-60cf-4720-b667-e8adc4952b14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1b12fb1a-60cf-4720-b667-e8adc4952b14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b19c8f7a-1f8e-42f3-975c-4595ab65da8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_AssetImpairmentCharges_b19c8f7a-1f8e-42f3-975c-4595ab65da8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9d94b4d4-cbca-4de2-96e2-729ecd53acc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_ShareBasedCompensation_9d94b4d4-cbca-4de2-96e2-729ecd53acc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_81758ad1-64b3-4cbd-bf87-42e4df7ee7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0824a6b2-5176-4df3-9ba5-c43db9d494a5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_81758ad1-64b3-4cbd-bf87-42e4df7ee7c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_19f08c5d-4be0-4be8-a4bc-18e9247f2094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_19f08c5d-4be0-4be8-a4bc-18e9247f2094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a397cf53-fb74-48de-aad2-8fcfb2592739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a397cf53-fb74-48de-aad2-8fcfb2592739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_05b74327-defd-4865-9e18-f02e6927959f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_05b74327-defd-4865-9e18-f02e6927959f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_0fc4b58f-614b-4e77-ae06-565e5914327d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_0fc4b58f-614b-4e77-ae06-565e5914327d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1a5f4b12-1d2e-4c0e-b4da-100fade99ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1a5f4b12-1d2e-4c0e-b4da-100fade99ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b811e40a-e4a9-4474-aa94-28b9649ee45d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b811e40a-e4a9-4474-aa94-28b9649ee45d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_101e125c-ed4d-4797-9716-9228e61de546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_101e125c-ed4d-4797-9716-9228e61de546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_de8c6eb1-78e4-41c9-b9f4-ad5512cb4e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_de8c6eb1-78e4-41c9-b9f4-ad5512cb4e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_69eaacd1-a6a7-46dd-9cd6-cc8c6ca606e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66432e2b-c12d-432e-b430-74596f5ccd22" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_69eaacd1-a6a7-46dd-9cd6-cc8c6ca606e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c3caefd1-8808-4faf-a77b-9843f2ebf80b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c32b5f00-e5dd-4d79-88db-b01856c70dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c3caefd1-8808-4faf-a77b-9843f2ebf80b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c32b5f00-e5dd-4d79-88db-b01856c70dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b28e9e58-7fdb-4e1a-bc22-7bac0cbfc7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c3caefd1-8808-4faf-a77b-9843f2ebf80b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b28e9e58-7fdb-4e1a-bc22-7bac0cbfc7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_f79011e2-09c6-431a-9a2f-ad99f5874c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c3caefd1-8808-4faf-a77b-9843f2ebf80b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_f79011e2-09c6-431a-9a2f-ad99f5874c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1ed33a8-9313-480f-9bfc-d4e977bcae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_5ef9d4f0-67d1-4a5d-81d8-a0390e88cc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1ed33a8-9313-480f-9bfc-d4e977bcae7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_5ef9d4f0-67d1-4a5d-81d8-a0390e88cc8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8f0d5619-0ef8-4fbb-8b53-a0ac302ef9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1ed33a8-9313-480f-9bfc-d4e977bcae7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8f0d5619-0ef8-4fbb-8b53-a0ac302ef9e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ebf92a9c-b6e4-4de6-8723-adbb5d28cc02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1ed33a8-9313-480f-9bfc-d4e977bcae7d" xlink:to="loc_us-gaap_Goodwill_ebf92a9c-b6e4-4de6-8723-adbb5d28cc02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_25e3f10b-c82e-4385-842a-c58c87fe3c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1ed33a8-9313-480f-9bfc-d4e977bcae7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_25e3f10b-c82e-4385-842a-c58c87fe3c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0c70997d-43ff-4da7-b2df-00e4e0900aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1ed33a8-9313-480f-9bfc-d4e977bcae7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0c70997d-43ff-4da7-b2df-00e4e0900aa6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4c78b72f-bd27-42b8-a731-0ab90ef03efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23382bf8-b79d-4e8e-b38c-b397631f6ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4c78b72f-bd27-42b8-a731-0ab90ef03efc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23382bf8-b79d-4e8e-b38c-b397631f6ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d49c16e8-60ec-4490-bfaf-863a00d619ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4c78b72f-bd27-42b8-a731-0ab90ef03efc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d49c16e8-60ec-4490-bfaf-863a00d619ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_d38bf95e-0a77-46fb-9f2f-0a260f3e72a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4c78b72f-bd27-42b8-a731-0ab90ef03efc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_d38bf95e-0a77-46fb-9f2f-0a260f3e72a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1c1395a1-cf78-4989-8077-b5779b466271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1a9f1a2d-d6f0-420f-8a36-5f51ce0dff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1c1395a1-cf78-4989-8077-b5779b466271" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1a9f1a2d-d6f0-420f-8a36-5f51ce0dff9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_146281ac-7412-455a-ad3d-2c42896566fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1c1395a1-cf78-4989-8077-b5779b466271" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_146281ac-7412-455a-ad3d-2c42896566fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f2318773-f421-4ba3-a8a2-ead480db604c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1c1395a1-cf78-4989-8077-b5779b466271" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f2318773-f421-4ba3-a8a2-ead480db604c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_703d57a4-98df-4d69-9612-b369fbf64829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1c1395a1-cf78-4989-8077-b5779b466271" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_703d57a4-98df-4d69-9612-b369fbf64829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_28188e28-684c-427b-a4d0-6d5f209c909d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6e8a63ca-dbcf-4db6-b963-116fcd4af781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_28188e28-684c-427b-a4d0-6d5f209c909d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6e8a63ca-dbcf-4db6-b963-116fcd4af781" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9ac8ad4c-06d5-4955-a585-7a1dd258fbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_28188e28-684c-427b-a4d0-6d5f209c909d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9ac8ad4c-06d5-4955-a585-7a1dd258fbf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_d51bc5cf-4283-40c7-bb4b-f546ba1a2ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_28188e28-684c-427b-a4d0-6d5f209c909d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_d51bc5cf-4283-40c7-bb4b-f546ba1a2ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_48cdb73a-0e06-4ebf-81b1-06377476f050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_28188e28-684c-427b-a4d0-6d5f209c909d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_48cdb73a-0e06-4ebf-81b1-06377476f050" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_610128af-abc4-43fb-baed-eca7f0f78480" xlink:href="mdt-20240426.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_ffe335a7-cc8a-4c6b-a4ad-f483890f0325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_610128af-abc4-43fb-baed-eca7f0f78480" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_ffe335a7-cc8a-4c6b-a4ad-f483890f0325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8f5df616-b914-4a2c-bf4f-7f190664bd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_610128af-abc4-43fb-baed-eca7f0f78480" xlink:to="loc_us-gaap_EquityMethodInvestments_8f5df616-b914-4a2c-bf4f-7f190664bd7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_ea368021-9f6b-4581-8f9e-e0d05504a489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_610128af-abc4-43fb-baed-eca7f0f78480" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_ea368021-9f6b-4581-8f9e-e0d05504a489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_98c27835-60ad-4d84-8e79-5a3c0627bb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_610128af-abc4-43fb-baed-eca7f0f78480" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_98c27835-60ad-4d84-8e79-5a3c0627bb1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsCurrentDebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_e06aba85-2cb8-4bfd-9923-f835ed0a982d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_2e6c4190-fd5f-458e-8d0b-b2bfd5c4f36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_e06aba85-2cb8-4bfd-9923-f835ed0a982d" xlink:to="loc_us-gaap_ShortTermBorrowings_2e6c4190-fd5f-458e-8d0b-b2bfd5c4f36a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_d27d1b1d-6e89-4192-b024-21855fbe526f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_e06aba85-2cb8-4bfd-9923-f835ed0a982d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_d27d1b1d-6e89-4192-b024-21855fbe526f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_9f3326ba-0515-4889-9967-8da047c143dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaper"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_e06aba85-2cb8-4bfd-9923-f835ed0a982d" xlink:to="loc_us-gaap_CommercialPaper_9f3326ba-0515-4889-9967-8da047c143dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ea69a911-d997-47d1-8743-f29fc2708c67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_c13d502c-8b97-4b7d-99ae-9683ed6bae66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ea69a911-d997-47d1-8743-f29fc2708c67" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_c13d502c-8b97-4b7d-99ae-9683ed6bae66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_30c79d33-1405-4c8a-81b6-1fd1655bf37e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ea69a911-d997-47d1-8743-f29fc2708c67" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_30c79d33-1405-4c8a-81b6-1fd1655bf37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_899eaabd-cc73-4d3b-8602-e71f3373b7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ea69a911-d997-47d1-8743-f29fc2708c67" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_899eaabd-cc73-4d3b-8602-e71f3373b7ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b1a52c41-8281-41e2-ad73-70058f48bcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ea69a911-d997-47d1-8743-f29fc2708c67" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b1a52c41-8281-41e2-ad73-70058f48bcc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsLongtermDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2b67e91a-552a-4d12-bacf-4dae5a5f3d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_56d1e469-c8d9-4b52-864b-c27d34eaa1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2b67e91a-552a-4d12-bacf-4dae5a5f3d0d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_56d1e469-c8d9-4b52-864b-c27d34eaa1e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5d122899-e0ae-4807-86f5-87c28fcc79e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2b67e91a-552a-4d12-bacf-4dae5a5f3d0d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5d122899-e0ae-4807-86f5-87c28fcc79e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ccee20de-6b49-4a8e-8649-38b366a3025a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2b67e91a-552a-4d12-bacf-4dae5a5f3d0d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ccee20de-6b49-4a8e-8649-38b366a3025a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_317fe99e-1505-4f95-b70f-c1a29c736202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2b67e91a-552a-4d12-bacf-4dae5a5f3d0d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_317fe99e-1505-4f95-b70f-c1a29c736202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_49fae688-bc8a-4ce1-a43d-629d914561ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2b67e91a-552a-4d12-bacf-4dae5a5f3d0d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_49fae688-bc8a-4ce1-a43d-629d914561ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_d109b679-ff05-4f53-8d89-3be1de1db375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2b67e91a-552a-4d12-bacf-4dae5a5f3d0d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_d109b679-ff05-4f53-8d89-3be1de1db375" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_7385ce91-920b-4a99-8270-b827a3d61774" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_746d4f2b-400f-48cf-b4da-b957fbfed8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_7385ce91-920b-4a99-8270-b827a3d61774" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_746d4f2b-400f-48cf-b4da-b957fbfed8a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_1d95f120-4fd9-46f3-83bb-2564ed39a5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_7385ce91-920b-4a99-8270-b827a3d61774" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_1d95f120-4fd9-46f3-83bb-2564ed39a5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_5d9479a5-fc7d-4c54-80c4-4e487bfdb92d" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_acfed57a-ae68-47ac-85ec-ea1366d9a8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_5d9479a5-fc7d-4c54-80c4-4e487bfdb92d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_acfed57a-ae68-47ac-85ec-ea1366d9a8d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7146d69d-b801-41fe-a72f-609ee4aad9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_5d9479a5-fc7d-4c54-80c4-4e487bfdb92d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7146d69d-b801-41fe-a72f-609ee4aad9bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_4677ab9d-4562-4b47-bd12-09a2472fc88f" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_3e5d8e1b-9a34-4e1a-a6d5-85b283bed7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_4677ab9d-4562-4b47-bd12-09a2472fc88f" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_3e5d8e1b-9a34-4e1a-a6d5-85b283bed7c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4b8bbc95-91fe-4832-9d6e-516d7a2bef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_4677ab9d-4562-4b47-bd12-09a2472fc88f" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4b8bbc95-91fe-4832-9d6e-516d7a2bef2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_96d1504d-d6ba-49d1-93e2-ad27b7e7fd2e" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4dc44880-ece5-4df2-bf97-759c9126568f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_96d1504d-d6ba-49d1-93e2-ad27b7e7fd2e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4dc44880-ece5-4df2-bf97-759c9126568f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4f3ca234-b771-4edc-bed4-11fb0058bb40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_96d1504d-d6ba-49d1-93e2-ad27b7e7fd2e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4f3ca234-b771-4edc-bed4-11fb0058bb40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_539ad1dc-82a7-454e-a241-64a130b159f5" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_9991f30c-d19b-42d7-bcb7-e06660154b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_539ad1dc-82a7-454e-a241-64a130b159f5" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_9991f30c-d19b-42d7-bcb7-e06660154b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_2fa18a25-9b98-4d11-974f-7491b99f6e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_539ad1dc-82a7-454e-a241-64a130b159f5" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_2fa18a25-9b98-4d11-974f-7491b99f6e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_23c6493f-9cdc-4616-a434-9054ef824826" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_143d9286-4a3e-4bc1-98bc-26f3fc1315bc" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_23c6493f-9cdc-4616-a434-9054ef824826" xlink:to="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_143d9286-4a3e-4bc1-98bc-26f3fc1315bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_dfb63698-d750-4225-a0b0-81a83aa766de" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_23c6493f-9cdc-4616-a434-9054ef824826" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_dfb63698-d750-4225-a0b0-81a83aa766de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_91adeef5-e28e-4294-a1f0-702fa90f62ea" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_23c6493f-9cdc-4616-a434-9054ef824826" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_91adeef5-e28e-4294-a1f0-702fa90f62ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_e28d2843-1af4-48f8-9127-2ac11c9bfef5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_304d59a9-3462-4dee-a3eb-73db1ccebffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_e28d2843-1af4-48f8-9127-2ac11c9bfef5" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_304d59a9-3462-4dee-a3eb-73db1ccebffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_481ee05b-3628-47c2-b6a6-715e77fe0737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_e28d2843-1af4-48f8-9127-2ac11c9bfef5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_481ee05b-3628-47c2-b6a6-715e77fe0737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_44943d60-5e26-4309-b9e7-3f7611b4caca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_e28d2843-1af4-48f8-9127-2ac11c9bfef5" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_44943d60-5e26-4309-b9e7-3f7611b4caca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_11dc7766-8b26-46f6-9585-e4744c1b4480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4d8a1992-3fd3-498e-aa90-94f1930687fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_11dc7766-8b26-46f6-9585-e4744c1b4480" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4d8a1992-3fd3-498e-aa90-94f1930687fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_508ec268-b4c9-4926-9756-fb0c44a11ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_11dc7766-8b26-46f6-9585-e4744c1b4480" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_508ec268-b4c9-4926-9756-fb0c44a11ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_54c36ddd-2287-45a0-8cf8-0334fba9b234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_11dc7766-8b26-46f6-9585-e4744c1b4480" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_54c36ddd-2287-45a0-8cf8-0334fba9b234" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_dca4af52-a3b6-4d46-b428-c806b6ee2b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_cdbac47b-228d-4256-b41a-8b4007b33607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_dca4af52-a3b6-4d46-b428-c806b6ee2b9e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_cdbac47b-228d-4256-b41a-8b4007b33607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_d59e2b69-df22-4139-980c-c90e961c8366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_dca4af52-a3b6-4d46-b428-c806b6ee2b9e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_d59e2b69-df22-4139-980c-c90e961c8366" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/InventoriesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bca71695-3eee-4d14-b4a7-d3f3c0d718fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_02ddf8a0-d002-439f-a352-0ce6d2942b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bca71695-3eee-4d14-b4a7-d3f3c0d718fd" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_02ddf8a0-d002-439f-a352-0ce6d2942b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_720d9188-3a87-4c43-a47f-c1197dd269b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bca71695-3eee-4d14-b4a7-d3f3c0d718fd" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_720d9188-3a87-4c43-a47f-c1197dd269b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f6902c67-5764-4d94-8b74-4916555156f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bca71695-3eee-4d14-b4a7-d3f3c0d718fd" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f6902c67-5764-4d94-8b74-4916555156f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#PropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_494480e0-7926-4f6b-a541-fa053c7be206" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_fc16c858-481f-46e1-a880-6c1889a5fc05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_494480e0-7926-4f6b-a541-fa053c7be206" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_fc16c858-481f-46e1-a880-6c1889a5fc05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_58b7124b-db44-46bd-905d-bd73c2758b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_494480e0-7926-4f6b-a541-fa053c7be206" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_58b7124b-db44-46bd-905d-bd73c2758b95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_972eec99-7075-48ca-a818-51e529004f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1dcfa257-cf8d-41a8-98e8-4993aabed47c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_972eec99-7075-48ca-a818-51e529004f5c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1dcfa257-cf8d-41a8-98e8-4993aabed47c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2956fd6b-2644-49f9-832e-b8a7f9e949c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_972eec99-7075-48ca-a818-51e529004f5c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2956fd6b-2644-49f9-832e-b8a7f9e949c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51907899-5695-4e5c-9d5b-05da99e78a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_65804935-7aa6-40c1-818f-d960cd734a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51907899-5695-4e5c-9d5b-05da99e78a9c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_65804935-7aa6-40c1-818f-d960cd734a2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2d50098d-e180-48ba-8f4d-c3ec384eb2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51907899-5695-4e5c-9d5b-05da99e78a9c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2d50098d-e180-48ba-8f4d-c3ec384eb2fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8057f57e-e190-4ec1-90ea-6b57c74e156d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d1abd092-209f-4a60-a41c-7334ad8413d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8057f57e-e190-4ec1-90ea-6b57c74e156d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d1abd092-209f-4a60-a41c-7334ad8413d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6fbdad99-63c8-474c-acc6-ee505c1406b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8057f57e-e190-4ec1-90ea-6b57c74e156d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6fbdad99-63c8-474c-acc6-ee505c1406b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b4e74aa3-9cfc-44be-af72-e9e8483e12e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f8b4dc34-7249-4899-a639-00f198cd1dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b4e74aa3-9cfc-44be-af72-e9e8483e12e2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f8b4dc34-7249-4899-a639-00f198cd1dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d93fecb3-ef92-40c1-9633-15a75efab963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b4e74aa3-9cfc-44be-af72-e9e8483e12e2" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d93fecb3-ef92-40c1-9633-15a75efab963" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e4d9f5a2-d2b2-444e-b464-fda4906717c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_52077160-d173-4ebf-bb29-52803994817e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e4d9f5a2-d2b2-444e-b464-fda4906717c8" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_52077160-d173-4ebf-bb29-52803994817e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_76a00911-0773-4ffa-bb53-25b90ba8c368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e4d9f5a2-d2b2-444e-b464-fda4906717c8" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_76a00911-0773-4ffa-bb53-25b90ba8c368" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a91d2593-c8d9-4fa6-a713-66b0cbe121c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0af0f0db-e6a9-4180-bf03-efeb8faf03a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a91d2593-c8d9-4fa6-a713-66b0cbe121c6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0af0f0db-e6a9-4180-bf03-efeb8faf03a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_24a9c84f-cd25-42a0-914d-93027b0c70ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a91d2593-c8d9-4fa6-a713-66b0cbe121c6" xlink:to="loc_us-gaap_PrepaidTaxes_24a9c84f-cd25-42a0-914d-93027b0c70ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_fbfa10d7-a236-42cf-9afa-d924c2ecf8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a91d2593-c8d9-4fa6-a713-66b0cbe121c6" xlink:to="loc_us-gaap_IncomeTaxReceivable_fbfa10d7-a236-42cf-9afa-d924c2ecf8e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f6c2ad36-7575-4bb8-a35a-fa19576732f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a91d2593-c8d9-4fa6-a713-66b0cbe121c6" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_f6c2ad36-7575-4bb8-a35a-fa19576732f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_253b5d56-bd1f-4e47-8f31-2093bb6208e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_71089325-c440-414a-84c0-3eba957bb7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_253b5d56-bd1f-4e47-8f31-2093bb6208e2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_71089325-c440-414a-84c0-3eba957bb7e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_9b68047f-a457-4636-a25b-da14412ddc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_253b5d56-bd1f-4e47-8f31-2093bb6208e2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_9b68047f-a457-4636-a25b-da14412ddc9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8bf716d6-1010-4bbf-951c-6c082746a227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_253b5d56-bd1f-4e47-8f31-2093bb6208e2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8bf716d6-1010-4bbf-951c-6c082746a227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f889e6f1-e98f-478e-87b0-a9a989c4a05e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_253b5d56-bd1f-4e47-8f31-2093bb6208e2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f889e6f1-e98f-478e-87b0-a9a989c4a05e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_01c57eba-f2cc-49e8-b816-2b395f6bced1" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_253b5d56-bd1f-4e47-8f31-2093bb6208e2" xlink:to="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_01c57eba-f2cc-49e8-b816-2b395f6bced1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a3ade4d5-02b8-4445-9dbe-1a3616ae4b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_253b5d56-bd1f-4e47-8f31-2093bb6208e2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a3ade4d5-02b8-4445-9dbe-1a3616ae4b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_1725bfde-a16e-413c-abf5-5a20bb977974" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_253b5d56-bd1f-4e47-8f31-2093bb6208e2" xlink:to="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_1725bfde-a16e-413c-abf5-5a20bb977974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7b797aee-a152-459a-a360-efb9643c48ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_901dd194-31e5-4a26-8862-d23023953c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7b797aee-a152-459a-a360-efb9643c48ba" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_901dd194-31e5-4a26-8862-d23023953c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4b8ff48a-d3c3-488d-9953-d5318cc55ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7b797aee-a152-459a-a360-efb9643c48ba" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4b8ff48a-d3c3-488d-9953-d5318cc55ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a0795f86-478e-423f-916a-b0dcfb7fe7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a0795f86-478e-423f-916a-b0dcfb7fe7d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_a57c3ea8-79c8-48c1-90cb-44c45761f28f" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_a57c3ea8-79c8-48c1-90cb-44c45761f28f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d66734a8-2d35-4886-ab96-747d0ef35492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d66734a8-2d35-4886-ab96-747d0ef35492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_31c34c09-64a7-40b8-8d0e-bc827353f464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_31c34c09-64a7-40b8-8d0e-bc827353f464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions_76feba5d-b100-43ff-a732-fb5acf286adb" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions_76feba5d-b100-43ff-a732-fb5acf286adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8be05b82-0444-4673-a572-e3a623006744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8be05b82-0444-4673-a572-e3a623006744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4c501072-f3de-450f-b7d5-1778d75ff5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4c501072-f3de-450f-b7d5-1778d75ff5fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_11a6e834-c003-4efa-b709-0552e89a2ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_11a6e834-c003-4efa-b709-0552e89a2ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_f3788951-43a4-4c36-9fea-78327e28b40d" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_f3788951-43a4-4c36-9fea-78327e28b40d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsInterestLimitation_d1ac2500-45d7-45f4-8986-4422db63cc73" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsInterestLimitation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_mdt_DeferredTaxAssetsInterestLimitation_d1ac2500-45d7-45f4-8986-4422db63cc73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsLeaseObligations_7254c230-ffb3-45bb-87b0-9a65a3a48072" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsLeaseObligations"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_mdt_DeferredTaxAssetsLeaseObligations_7254c230-ffb3-45bb-87b0-9a65a3a48072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_4b63d992-fbc4-4e42-a9ae-6502b802ee6d" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_4b63d992-fbc4-4e42-a9ae-6502b802ee6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_af199236-1ade-415a-8921-a35be39fff85" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_af199236-1ade-415a-8921-a35be39fff85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_185a4235-cf9a-4d34-aa73-38098257f6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_79ad22d5-da1f-4527-a9f4-523c3c5d7d83" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_185a4235-cf9a-4d34-aa73-38098257f6d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_693b0700-df2a-4966-a258-106a990c34a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_b51f3632-05b2-449f-911a-b40b975e1b3e" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsNetofValuationAllowanceOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_693b0700-df2a-4966-a258-106a990c34a8" xlink:to="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_b51f3632-05b2-449f-911a-b40b975e1b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_e3f7aef9-09ad-48ce-8d50-fb445b251c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_693b0700-df2a-4966-a258-106a990c34a8" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_e3f7aef9-09ad-48ce-8d50-fb445b251c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b4c8adba-14c1-47b6-b76d-22c7fd865460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_693b0700-df2a-4966-a258-106a990c34a8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b4c8adba-14c1-47b6-b76d-22c7fd865460" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_834a9f25-1d8a-4d13-89c0-04144f422607" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_834a9f25-1d8a-4d13-89c0-04144f422607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_98fceefc-0f07-4184-8931-c6289c46f34c" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_98fceefc-0f07-4184-8931-c6289c46f34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_5cab9624-6807-43ae-8ae1-8e886f5927e8" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_5cab9624-6807-43ae-8ae1-8e886f5927e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_aa6b747d-38ec-4ea2-b5fa-4514b568580e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_aa6b747d-38ec-4ea2-b5fa-4514b568580e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_a106a4c2-1757-462e-ae41-f8c4666a3992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_a106a4c2-1757-462e-ae41-f8c4666a3992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8486dc34-d983-4d12-b7cb-d503926a0bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8486dc34-d983-4d12-b7cb-d503926a0bb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_44677b46-e68f-4029-b938-2b767faa3957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_44677b46-e68f-4029-b938-2b767faa3957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_a175b7fb-b177-4a1d-b3b8-91a3bfb6fb53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_a175b7fb-b177-4a1d-b3b8-91a3bfb6fb53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_864d3d1b-6d01-45a6-b13a-20da3c0cf909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_864d3d1b-6d01-45a6-b13a-20da3c0cf909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_25b483fa-8ebc-4e86-9aff-84e10f3d806a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_25b483fa-8ebc-4e86-9aff-84e10f3d806a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_b842656e-bf5c-4cc9-b418-42d8f66460f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_b842656e-bf5c-4cc9-b418-42d8f66460f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1d48a196-a5f3-4942-a058-6aa1ed4a8cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63897f6d-904a-4bbf-a09d-24c69b5291fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1d48a196-a5f3-4942-a058-6aa1ed4a8cc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c4d001ce-19e9-4bbd-846d-cf1a170f49d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28b569db-6ff0-4a46-8502-3172aeae5bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c4d001ce-19e9-4bbd-846d-cf1a170f49d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28b569db-6ff0-4a46-8502-3172aeae5bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_91b8cab5-657f-4fcf-b210-35ce609df8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c4d001ce-19e9-4bbd-846d-cf1a170f49d1" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_91b8cab5-657f-4fcf-b210-35ce609df8fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_1b27cdbe-c2a4-48ab-a317-0dc04ace3784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c4d001ce-19e9-4bbd-846d-cf1a170f49d1" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_1b27cdbe-c2a4-48ab-a317-0dc04ace3784" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_78283ce8-43f0-4a5f-86a9-e2a60d5fbcff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_94c3efff-9ad8-407f-b7d3-46306f078049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_78283ce8-43f0-4a5f-86a9-e2a60d5fbcff" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_94c3efff-9ad8-407f-b7d3-46306f078049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_1aed2691-6c5c-4a0a-9f83-cf19f137a88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_78283ce8-43f0-4a5f-86a9-e2a60d5fbcff" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_1aed2691-6c5c-4a0a-9f83-cf19f137a88b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c14fb235-f7f8-4836-95c5-bd1ab054fe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_cb8a1020-a031-42f6-ab9f-0d17f60ca162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c14fb235-f7f8-4836-95c5-bd1ab054fe5f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_cb8a1020-a031-42f6-ab9f-0d17f60ca162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_13f15415-a535-4cbc-b4a5-1ee8f8af97de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c14fb235-f7f8-4836-95c5-bd1ab054fe5f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_13f15415-a535-4cbc-b4a5-1ee8f8af97de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_6635f482-f14c-44d1-ab1d-485bca7450df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c14fb235-f7f8-4836-95c5-bd1ab054fe5f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_6635f482-f14c-44d1-ab1d-485bca7450df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_918b4da9-476a-4a40-a211-11ee36dc171b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d6da965f-f2bc-4d8e-b6bc-4162f8f8998b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_918b4da9-476a-4a40-a211-11ee36dc171b" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d6da965f-f2bc-4d8e-b6bc-4162f8f8998b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_f014f337-4893-44b2-b1ad-821a56b55e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_918b4da9-476a-4a40-a211-11ee36dc171b" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_f014f337-4893-44b2-b1ad-821a56b55e03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansNetPeriodicCostandAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_af8820e5-55ca-401f-8d1f-05359d19a075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_10a29ccc-71a4-4612-a869-16b4db38e901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_af8820e5-55ca-401f-8d1f-05359d19a075" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_10a29ccc-71a4-4612-a869-16b4db38e901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_6d7a53a0-e042-42a7-b880-32fefdb6c215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_af8820e5-55ca-401f-8d1f-05359d19a075" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_6d7a53a0-e042-42a7-b880-32fefdb6c215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_ce852ba1-0793-4b3a-a676-413a85a7ad1e" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_af8820e5-55ca-401f-8d1f-05359d19a075" xlink:to="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_ce852ba1-0793-4b3a-a676-413a85a7ad1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_8aa85f91-7d9e-43a5-971a-a829e286a9a8" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_af8820e5-55ca-401f-8d1f-05359d19a075" xlink:to="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_8aa85f91-7d9e-43a5-971a-a829e286a9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_ea75e5e6-3fc0-4255-ac7e-ac7aa31d9393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_af8820e5-55ca-401f-8d1f-05359d19a075" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_ea75e5e6-3fc0-4255-ac7e-ac7aa31d9393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a60d9d70-6521-42db-b61d-ef8ddb7287ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_812a8b06-2e7f-4916-b8af-8341e150177c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a60d9d70-6521-42db-b61d-ef8ddb7287ad" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_812a8b06-2e7f-4916-b8af-8341e150177c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_f11ca511-9036-4dca-bef4-7e58eef83aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a60d9d70-6521-42db-b61d-ef8ddb7287ad" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_f11ca511-9036-4dca-bef4-7e58eef83aae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_11da52e5-f0f1-4362-91fe-827653eaeb52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a60d9d70-6521-42db-b61d-ef8ddb7287ad" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_11da52e5-f0f1-4362-91fe-827653eaeb52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f2830e6f-e6c1-4a84-9313-64acec2de1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a60d9d70-6521-42db-b61d-ef8ddb7287ad" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f2830e6f-e6c1-4a84-9313-64acec2de1a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_d5966454-48c1-4797-ade4-913149a28375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a60d9d70-6521-42db-b61d-ef8ddb7287ad" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_d5966454-48c1-4797-ade4-913149a28375" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e6842996-b762-4e0c-9bc8-27f309d7ebb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a60d9d70-6521-42db-b61d-ef8ddb7287ad" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e6842996-b762-4e0c-9bc8-27f309d7ebb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_11a347f6-5da8-4f39-922b-b5a36c50f946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a60d9d70-6521-42db-b61d-ef8ddb7287ad" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_11a347f6-5da8-4f39-922b-b5a36c50f946" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#LeasesComponentsofTotalOperatingLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_940da916-1ae7-4936-935a-0528a790532c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_fb43e5f4-34b4-4de8-ac06-a0678498bf04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_940da916-1ae7-4936-935a-0528a790532c" xlink:to="loc_us-gaap_OperatingLeaseCost_fb43e5f4-34b4-4de8-ac06-a0678498bf04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3ea5b7c0-635f-46d3-85b2-5e3101c7bbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_940da916-1ae7-4936-935a-0528a790532c" xlink:to="loc_us-gaap_ShortTermLeaseCost_3ea5b7c0-635f-46d3-85b2-5e3101c7bbbd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#LeasesMaturitiesofOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4bca2ead-55e5-46a5-9fa0-3dd1e680a380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6c498b8a-b193-4150-a976-02638996860b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4bca2ead-55e5-46a5-9fa0-3dd1e680a380" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6c498b8a-b193-4150-a976-02638996860b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9973c5b2-faa5-4be2-9bc1-bfab787e162b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4bca2ead-55e5-46a5-9fa0-3dd1e680a380" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9973c5b2-faa5-4be2-9bc1-bfab787e162b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9fcaf3c7-3e0b-4d3c-bcaa-e6edaf7541e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4bca2ead-55e5-46a5-9fa0-3dd1e680a380" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9fcaf3c7-3e0b-4d3c-bcaa-e6edaf7541e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9f306258-6c93-4664-bd07-8993d5780491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4bca2ead-55e5-46a5-9fa0-3dd1e680a380" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9f306258-6c93-4664-bd07-8993d5780491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_40796b0b-0260-4a1f-b88b-de184b8f8249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4bca2ead-55e5-46a5-9fa0-3dd1e680a380" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_40796b0b-0260-4a1f-b88b-de184b8f8249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d21bc5cc-28a7-42db-88dc-b5216f3c5357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4bca2ead-55e5-46a5-9fa0-3dd1e680a380" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d21bc5cc-28a7-42db-88dc-b5216f3c5357" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1" xlink:type="simple" xlink:href="mdt-20240426.xsd#LeasesMaturitiesofOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5b3adac-2e15-416d-9b76-60db3c4ad1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6df67255-128d-4d50-ab29-8d6043678846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5b3adac-2e15-416d-9b76-60db3c4ad1b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6df67255-128d-4d50-ab29-8d6043678846" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_55065687-a4ef-427e-a398-6cad94ae2efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5b3adac-2e15-416d-9b76-60db3c4ad1b1" xlink:to="loc_us-gaap_OperatingLeaseLiability_55065687-a4ef-427e-a398-6cad94ae2efd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1496df8a-d411-4162-8d13-d8fbb4ac57ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a5adf5ad-c302-46cf-890d-6c2f860e31fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1496df8a-d411-4162-8d13-d8fbb4ac57ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a5adf5ad-c302-46cf-890d-6c2f860e31fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6c6fb136-7055-4673-89d4-f3512a03c80c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1496df8a-d411-4162-8d13-d8fbb4ac57ad" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6c6fb136-7055-4673-89d4-f3512a03c80c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_02d5e8a6-5adc-4774-a428-8df9c3f2a5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_02d5e8a6-5adc-4774-a428-8df9c3f2a5e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c5d1f4fd-a4d8-4994-aad3-04b7df48a0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_us-gaap_OperatingIncomeLoss_c5d1f4fd-a4d8-4994-aad3-04b7df48a0fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CentralizedDistributionCosts_741d66d6-c0c3-471d-b998-9cdc4a1e5752" xlink:href="mdt-20240426.xsd#mdt_CentralizedDistributionCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_mdt_CentralizedDistributionCosts_741d66d6-c0c3-471d-b998-9cdc4a1e5752" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialChargesGains_c49e5684-42a7-4e1e-8377-a732f7929ac0" xlink:href="mdt-20240426.xsd#mdt_SpecialChargesGains"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_mdt_SpecialChargesGains_c49e5684-42a7-4e1e-8377-a732f7929ac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ImpairmentofInProcessResearchandDevelopment_c818d721-ed5d-49f7-bb36-d9ed9dd3e3b9" xlink:href="mdt-20240426.xsd#mdt_ImpairmentofInProcessResearchandDevelopment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_mdt_ImpairmentofInProcessResearchandDevelopment_c818d721-ed5d-49f7-bb36-d9ed9dd3e3b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_52251ec8-4214-4529-95cf-7fefb6e4579c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_us-gaap_ShareBasedCompensation_52251ec8-4214-4529-95cf-7fefb6e4579c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_dcbe0a87-089b-4753-a3e4-5971bd0310e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_dcbe0a87-089b-4753-a3e4-5971bd0310e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyCosts_1e3af266-5bdb-4c17-a470-234e05e780a4" xlink:href="mdt-20240426.xsd#mdt_ForeignCurrencyCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_mdt_ForeignCurrencyCosts_1e3af266-5bdb-4c17-a470-234e05e780a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8a660014-562d-4e56-b736-3bd79e9e92e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8a660014-562d-4e56-b736-3bd79e9e92e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalDeviceRegulations_3f7bedd1-14a9-4acf-9921-bf52185ed77e" xlink:href="mdt-20240426.xsd#mdt_MedicalDeviceRegulations"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_mdt_MedicalDeviceRegulations_3f7bedd1-14a9-4acf-9921-bf52185ed77e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_212c671a-e2c4-4b2c-b971-57e3f003a030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_us-gaap_RestructuringCharges_212c671a-e2c4-4b2c-b971-57e3f003a030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CorporateOverhead_6074ed07-c828-492e-a947-2becde7adcb6" xlink:href="mdt-20240426.xsd#mdt_CorporateOverhead"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_mdt_CorporateOverhead_6074ed07-c828-492e-a947-2becde7adcb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_2bbd1449-28d2-4d6c-a511-2ad44e0dbecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_2bbd1449-28d2-4d6c-a511-2ad44e0dbecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b4cc5cef-7c65-4127-890c-2ac1189afd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ed0b297-45a8-499a-b32e-ed115e69de81" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b4cc5cef-7c65-4127-890c-2ac1189afd0d" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>mdt-20240426_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31d25153-b660-4ec0-ab44-7e01aa50312b,g:3d21d99d-9a64-4ef0-a05f-06b24f253785-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.medtronic.com/role/Cover" xlink:type="simple" xlink:href="mdt-20240426.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_471bd74b-806b-4cb1-906a-2d34d79bb5f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntitiesTable_471bd74b-806b-4cb1-906a-2d34d79bb5f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0e9d1d24-a742-40dd-9d59-d5f58c000616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_471bd74b-806b-4cb1-906a-2d34d79bb5f9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0e9d1d24-a742-40dd-9d59-d5f58c000616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0e9d1d24-a742-40dd-9d59-d5f58c000616_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0e9d1d24-a742-40dd-9d59-d5f58c000616" xlink:to="loc_us-gaap_ClassOfStockDomain_0e9d1d24-a742-40dd-9d59-d5f58c000616_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0e9d1d24-a742-40dd-9d59-d5f58c000616" xlink:to="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1cd2611a-eca8-41a8-8ac7-59c3e89d17cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_us-gaap_CommonStockMember_1cd2611a-eca8-41a8-8ac7-59c3e89d17cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2025Member_488f5acd-8303-40d7-b0e1-774163345594" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due2025Member_488f5acd-8303-40d7-b0e1-774163345594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2025Member_87c2c22d-7bd1-4be9-840f-caaec52b124c" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2025Member_87c2c22d-7bd1-4be9-840f-caaec52b124c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2025Member_6240e5fc-3d8f-4015-9077-fe6f99b3bf01" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2022Due2025Member_6240e5fc-3d8f-4015-9077-fe6f99b3bf01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2027Member_d3a80197-8479-4fc0-b26d-db068b3c160f" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due2027Member_d3a80197-8479-4fc0-b26d-db068b3c160f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2028Member_4270bf77-1470-48f2-bee2-6526e9e3ac62" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2028Member_4270bf77-1470-48f2-bee2-6526e9e3ac62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2028Member_f9b75c24-e2a2-44b4-9206-c87ca1084a9c" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2022Due2028Member_f9b75c24-e2a2-44b4-9206-c87ca1084a9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2029Member_a89c34c1-8ff8-4fd5-bb4b-5e274e380612" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotesDue2029Member_a89c34c1-8ff8-4fd5-bb4b-5e274e380612" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20311.625PercentMember_83c95fa9-0e5f-4273-8942-ad4cb76bd1af" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20311.625PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due20311.625PercentMember_83c95fa9-0e5f-4273-8942-ad4cb76bd1af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20311.00PercentMember_31e0b342-8775-4eb5-8c99-c09940e0453f" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20311.00PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due20311.00PercentMember_31e0b342-8775-4eb5-8c99-c09940e0453f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2031Member_c7546e32-4050-4ff5-b5cb-362bf5b408ee" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2022Due2031Member_c7546e32-4050-4ff5-b5cb-362bf5b408ee" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2032Member_9f51a67c-00b7-431e-8aa6-28fc6aaa6b65" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2032Member_9f51a67c-00b7-431e-8aa6-28fc6aaa6b65" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2034Member_8cf251ec-d123-4797-85fc-5a839db61207" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2022Due2034Member_8cf251ec-d123-4797-85fc-5a839db61207" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2036Member_19b927a7-998f-4c6a-9db0-5dc6a0cc4f47" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotesDue2036Member_19b927a7-998f-4c6a-9db0-5dc6a0cc4f47" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20392.250PercentMember_9788d5bc-8b59-4e2c-a665-bf07f0a4dc2e" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20392.250PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due20392.250PercentMember_9788d5bc-8b59-4e2c-a665-bf07f0a4dc2e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20391.50PercentMember_9097a848-f23e-483c-bab1-aaa19b0497fb" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20391.50PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due20391.50PercentMember_9097a848-f23e-483c-bab1-aaa19b0497fb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2040Member_4781844a-d69b-4eda-9cef-d694d8c2163d" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2040Member_4781844a-d69b-4eda-9cef-d694d8c2163d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2043Member_0b4f63ba-440e-4537-bb74-9d419e2b55a9" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotesDue2043Member_0b4f63ba-440e-4537-bb74-9d419e2b55a9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2049Member_4d1f4d95-c94c-4b5c-a0c2-9c8aa5b40800" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due2049Member_4d1f4d95-c94c-4b5c-a0c2-9c8aa5b40800" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2050Member_7945af02-d27a-40e9-bda5-4a88df7338f0" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2050Member_7945af02-d27a-40e9-bda5-4a88df7338f0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2053Member_1ef60863-1682-4855-a8dd-f5aee1c1c4c2" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2053Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotesDue2053Member_1ef60863-1682-4855-a8dd-f5aee1c1c4c2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9336ce50-bc37-471b-b99b-8501de4b4a82" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentType_9336ce50-bc37-471b-b99b-8501de4b4a82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_50008cc5-24b7-4fb1-b815-c258f2515cb2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentAnnualReport_50008cc5-24b7-4fb1-b815-c258f2515cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0bc972a5-427c-4e28-b646-bb075edf8205" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentPeriodEndDate_0bc972a5-427c-4e28-b646-bb075edf8205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e9c1ed8a-a521-47b9-9143-a1da75e86f90" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentTransitionReport_e9c1ed8a-a521-47b9-9143-a1da75e86f90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_427527d3-4309-45ff-9355-bb73508019ce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityFileNumber_427527d3-4309-45ff-9355-bb73508019ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_df21d1dc-b00f-48fb-8b89-916c4b1f24e5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityRegistrantName_df21d1dc-b00f-48fb-8b89-916c4b1f24e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_131dbd0c-5b6d-4f9d-98e1-435902dce8ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityIncorporationStateCountryCode_131dbd0c-5b6d-4f9d-98e1-435902dce8ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_82004d1d-b3a7-4d19-afa9-3da9e86aa34b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityTaxIdentificationNumber_82004d1d-b3a7-4d19-afa9-3da9e86aa34b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cea29712-c3df-45bf-bb51-16b40aba25eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityAddressAddressLine1_cea29712-c3df-45bf-bb51-16b40aba25eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9b0b351d-0f8e-4922-a1c7-0c3ca9467135" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityAddressCityOrTown_9b0b351d-0f8e-4922-a1c7-0c3ca9467135" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_df9c4492-d255-45a7-a95f-7d9ce87c616b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityAddressCountry_df9c4492-d255-45a7-a95f-7d9ce87c616b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_e3d09383-30a5-491d-9e5c-66218e8d715e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_CountryRegion_e3d09383-30a5-491d-9e5c-66218e8d715e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_91b1e5eb-7c2c-473d-8d14-8245c6ebf65e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_CityAreaCode_91b1e5eb-7c2c-473d-8d14-8245c6ebf65e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b7d06938-c64c-4aad-a1a9-8277839771ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_LocalPhoneNumber_b7d06938-c64c-4aad-a1a9-8277839771ad" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e364fca3-2c45-4dc9-bcbd-48566b00f465" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_Security12bTitle_e364fca3-2c45-4dc9-bcbd-48566b00f465" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e595d24e-e72b-4bf4-8bfe-47556146d853" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_TradingSymbol_e595d24e-e72b-4bf4-8bfe-47556146d853" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9d7ae12f-39fe-4a16-98c6-f4ae9280165e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_SecurityExchangeName_9d7ae12f-39fe-4a16-98c6-f4ae9280165e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_426bf5ed-abe9-4d3d-a963-808cc7900f96" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_426bf5ed-abe9-4d3d-a963-808cc7900f96" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_e92fb4bb-1a4f-4e2e-ab15-7af3d829e3c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityVoluntaryFilers_e92fb4bb-1a4f-4e2e-ab15-7af3d829e3c2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3e71bee3-adb9-45fd-92cd-3358c80adf8d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityCurrentReportingStatus_3e71bee3-adb9-45fd-92cd-3358c80adf8d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bfb6cc65-c8c6-4705-b5ec-a0afb736f2da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityInteractiveDataCurrent_bfb6cc65-c8c6-4705-b5ec-a0afb736f2da" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c4bb6ec8-f3df-4739-a503-9ae677b7c681" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityFilerCategory_c4bb6ec8-f3df-4739-a503-9ae677b7c681" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_59d398fe-baaa-4cd8-9dfd-334e0d026595" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntitySmallBusiness_59d398fe-baaa-4cd8-9dfd-334e0d026595" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c8ef1822-8f5b-45c6-a32a-fc49ad8717ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityEmergingGrowthCompany_c8ef1822-8f5b-45c6-a32a-fc49ad8717ba" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_aef4d3c7-e043-41d2-93cf-cc75dfffb3c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_IcfrAuditorAttestationFlag_aef4d3c7-e043-41d2-93cf-cc75dfffb3c0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_d838e217-925d-41f8-917b-3f61b38190ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_d838e217-925d-41f8-917b-3f61b38190ff" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f55a1d60-141e-4a78-b3f1-c25a42844d93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityShellCompany_f55a1d60-141e-4a78-b3f1-c25a42844d93" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_989857ad-e292-45e5-b54e-ab1475397ebf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityPublicFloat_989857ad-e292-45e5-b54e-ab1475397ebf" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5c0b643d-9785-4842-9a09-f1b6f315dfd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5c0b643d-9785-4842-9a09-f1b6f315dfd7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7b200ab4-4564-4381-9c5c-080d7022c871" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7b200ab4-4564-4381-9c5c-080d7022c871" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_548d8d5f-5b81-4e65-bdda-b56d99a0d5d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityCentralIndexKey_548d8d5f-5b81-4e65-bdda-b56d99a0d5d5" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5bc3c50c-35c4-4827-958b-0abe6d61539b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_CurrentFiscalYearEndDate_5bc3c50c-35c4-4827-958b-0abe6d61539b" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e0901d6d-0d30-4695-ac26-8ea594e70472" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_AmendmentFlag_e0901d6d-0d30-4695-ac26-8ea594e70472" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c8cb8346-8edc-426c-85c2-2e7842e4a341" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c8cb8346-8edc-426c-85c2-2e7842e4a341" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f45730e3-becc-40c8-8ba1-dfa9cde96eab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentFiscalYearFocus_f45730e3-becc-40c8-8ba1-dfa9cde96eab" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7e4b60b5-e3ae-439e-9b85-d6afe3ba5e95" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityAddressPostalZipCode_7e4b60b5-e3ae-439e-9b85-d6afe3ba5e95" xlink:type="arc" order="35"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_53a2247e-09d5-4faa-ac7a-c8f07148a2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_67255037-fbfe-404e-8387-89c58af282c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_53a2247e-09d5-4faa-ac7a-c8f07148a2ed" xlink:to="loc_us-gaap_StatementTable_67255037-fbfe-404e-8387-89c58af282c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_404eb318-dea5-435d-b860-d4763dc2a645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_67255037-fbfe-404e-8387-89c58af282c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_404eb318-dea5-435d-b860-d4763dc2a645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_404eb318-dea5-435d-b860-d4763dc2a645_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_404eb318-dea5-435d-b860-d4763dc2a645" xlink:to="loc_us-gaap_EquityComponentDomain_404eb318-dea5-435d-b860-d4763dc2a645_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fd625831-ea57-48fa-aa74-34417711e68c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_404eb318-dea5-435d-b860-d4763dc2a645" xlink:to="loc_us-gaap_EquityComponentDomain_fd625831-ea57-48fa-aa74-34417711e68c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fd625831-ea57-48fa-aa74-34417711e68c" xlink:to="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e3946087-241c-40df-ae78-c314494e26b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:to="loc_us-gaap_CommonStockMember_e3946087-241c-40df-ae78-c314494e26b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c2d7c8a7-ff3d-4bba-b2e2-56b23ff97f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c2d7c8a7-ff3d-4bba-b2e2-56b23ff97f8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ca64877a-9f51-4380-b886-12611be80091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:to="loc_us-gaap_RetainedEarningsMember_ca64877a-9f51-4380-b886-12611be80091" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d14b88d1-52c3-4b70-a2b1-edf38336b380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d14b88d1-52c3-4b70-a2b1-edf38336b380" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c247ca59-3e8f-4c28-a048-8a72114a4aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fd625831-ea57-48fa-aa74-34417711e68c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c247ca59-3e8f-4c28-a048-8a72114a4aab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53a2247e-09d5-4faa-ac7a-c8f07148a2ed" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a7f49241-2ab3-4bac-ab09-f4a9ed1921ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a7f49241-2ab3-4bac-ab09-f4a9ed1921ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a90a3fea-e244-4c95-8574-7110532e88f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a90a3fea-e244-4c95-8574-7110532e88f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ea3feddc-24c6-423e-bc95-bd9d1dea55f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_ProfitLoss_ea3feddc-24c6-423e-bc95-bd9d1dea55f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_172f3b4a-2fae-488e-bed1-76720068bd65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_172f3b4a-2fae-488e-bed1-76720068bd65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_359289e4-db80-428e-bf03-cd4e8e3bda74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_DividendsCommonStockCash_359289e4-db80-428e-bf03-cd4e8e3bda74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_543aa0cd-479c-4c16-89f5-4ca272e7cf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_543aa0cd-479c-4c16-89f5-4ca272e7cf4d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_51beb794-7f8d-495c-a339-590329e1b3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_51beb794-7f8d-495c-a339-590329e1b3ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0a43292d-a0f3-41dc-bb3c-cf08574369f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0a43292d-a0f3-41dc-bb3c-cf08574369f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3196daf0-91c4-4faa-9cfa-80e454a79390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3196daf0-91c4-4faa-9cfa-80e454a79390" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_74c28ecb-614b-4158-95d6-c89525437ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_74c28ecb-614b-4158-95d6-c89525437ad4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d2fd5360-ea42-4173-99fc-24e720c3e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d2fd5360-ea42-4173-99fc-24e720c3e89d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4ec011fe-d5bc-40bc-a0db-d0416fca639c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3af6b7e6-502f-4055-9e06-016c322dbd10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_95bba605-0974-4d76-884d-0eff568cbe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8f905156-5591-4f68-8a28-69c91d851571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_95bba605-0974-4d76-884d-0eff568cbe6e" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8f905156-5591-4f68-8a28-69c91d851571" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e521104-7c80-4a8f-8c25-b818f141d10e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8f905156-5591-4f68-8a28-69c91d851571" xlink:to="loc_srt_RangeAxis_7e521104-7c80-4a8f-8c25-b818f141d10e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e521104-7c80-4a8f-8c25-b818f141d10e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7e521104-7c80-4a8f-8c25-b818f141d10e" xlink:to="loc_srt_RangeMember_7e521104-7c80-4a8f-8c25-b818f141d10e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff5c21e1-5c3a-44b7-ba6c-9d9606576c5b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7e521104-7c80-4a8f-8c25-b818f141d10e" xlink:to="loc_srt_RangeMember_ff5c21e1-5c3a-44b7-ba6c-9d9606576c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cc543df1-e726-4ed8-ac5a-f6f00414ade4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ff5c21e1-5c3a-44b7-ba6c-9d9606576c5b" xlink:to="loc_srt_MinimumMember_cc543df1-e726-4ed8-ac5a-f6f00414ade4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_099b6077-bdd7-44e4-a8d5-2f0a871dd146" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ff5c21e1-5c3a-44b7-ba6c-9d9606576c5b" xlink:to="loc_srt_MaximumMember_099b6077-bdd7-44e4-a8d5-2f0a871dd146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7319614-8be4-4144-862a-7ebb9914e8e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8f905156-5591-4f68-8a28-69c91d851571" xlink:to="loc_srt_ProductOrServiceAxis_e7319614-8be4-4144-862a-7ebb9914e8e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7319614-8be4-4144-862a-7ebb9914e8e7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e7319614-8be4-4144-862a-7ebb9914e8e7" xlink:to="loc_srt_ProductsAndServicesDomain_e7319614-8be4-4144-862a-7ebb9914e8e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8798a20-fa4c-4888-b2f6-ae63f8a26e17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e7319614-8be4-4144-862a-7ebb9914e8e7" xlink:to="loc_srt_ProductsAndServicesDomain_b8798a20-fa4c-4888-b2f6-ae63f8a26e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_9993520f-5367-4a69-8f04-c25205b588f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b8798a20-fa4c-4888-b2f6-ae63f8a26e17" xlink:to="loc_us-gaap_ShippingAndHandlingMember_9993520f-5367-4a69-8f04-c25205b588f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d0b32a65-d22c-497d-83d0-8dbe426bcc43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_95bba605-0974-4d76-884d-0eff568cbe6e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d0b32a65-d22c-497d-83d0-8dbe426bcc43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_edbf5cbd-844e-478e-aec9-54f44ff3ee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d0b32a65-d22c-497d-83d0-8dbe426bcc43" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_edbf5cbd-844e-478e-aec9-54f44ff3ee8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_764ab82a-589b-49dc-9bb7-2c4f6393a7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_95bba605-0974-4d76-884d-0eff568cbe6e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_764ab82a-589b-49dc-9bb7-2c4f6393a7dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_352020a6-0ea6-4853-9eb0-2e75aa89da32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_764ab82a-589b-49dc-9bb7-2c4f6393a7dd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_352020a6-0ea6-4853-9eb0-2e75aa89da32" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8a07851b-5902-46ed-b584-a8c63c681a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c213d0d4-afad-454f-841f-2d223b5eff09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8a07851b-5902-46ed-b584-a8c63c681a23" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c213d0d4-afad-454f-841f-2d223b5eff09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a2db0b0-9f38-4d86-82a7-454b32f13c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c213d0d4-afad-454f-841f-2d223b5eff09" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a2db0b0-9f38-4d86-82a7-454b32f13c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a2db0b0-9f38-4d86-82a7-454b32f13c77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a2db0b0-9f38-4d86-82a7-454b32f13c77" xlink:to="loc_us-gaap_SegmentDomain_8a2db0b0-9f38-4d86-82a7-454b32f13c77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bdc99ee5-7979-4d4c-9a49-c6da90b937fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a2db0b0-9f38-4d86-82a7-454b32f13c77" xlink:to="loc_us-gaap_SegmentDomain_bdc99ee5-7979-4d4c-9a49-c6da90b937fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:href="mdt-20240426.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bdc99ee5-7979-4d4c-9a49-c6da90b937fc" xlink:to="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_36cac49d-6e3a-4215-9be5-c2922959487b" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:to="loc_mdt_CardiovascularMember_36cac49d-6e3a-4215-9be5-c2922959487b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_da888a61-7bec-45e4-8260-3e3cd0a278a2" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:to="loc_mdt_NeuroscienceGroupMember_da888a61-7bec-45e4-8260-3e3cd0a278a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_07d4e269-d2d4-44b4-b1c4-9da1eb506d4f" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:to="loc_mdt_MedicalSurgicalMember_07d4e269-d2d4-44b4-b1c4-9da1eb506d4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_97f99d40-8e12-472c-8607-75aa8b85e052" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:to="loc_mdt_DiabetesGroupMember_97f99d40-8e12-472c-8607-75aa8b85e052" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a0ad47fa-5558-4703-a0d4-28a736bc047f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bdc99ee5-7979-4d4c-9a49-c6da90b937fc" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a0ad47fa-5558-4703-a0d4-28a736bc047f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_ae1416c3-ec5e-44d3-911b-e6290558b9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c213d0d4-afad-454f-841f-2d223b5eff09" xlink:to="loc_us-gaap_SubsegmentsAxis_ae1416c3-ec5e-44d3-911b-e6290558b9ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_ae1416c3-ec5e-44d3-911b-e6290558b9ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_ae1416c3-ec5e-44d3-911b-e6290558b9ac" xlink:to="loc_us-gaap_SubsegmentsDomain_ae1416c3-ec5e-44d3-911b-e6290558b9ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_ae1416c3-ec5e-44d3-911b-e6290558b9ac" xlink:to="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiacRhythmandHeartFailureDivisionMember_4ff5f4fc-dccd-482e-9299-037fd09e1651" xlink:href="mdt-20240426.xsd#mdt_CardiacRhythmandHeartFailureDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_CardiacRhythmandHeartFailureDivisionMember_4ff5f4fc-dccd-482e-9299-037fd09e1651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StructuralHeartAndAorticDivisionMember_970232ba-342e-422a-8adb-77c4b9ef93ab" xlink:href="mdt-20240426.xsd#mdt_StructuralHeartAndAorticDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_StructuralHeartAndAorticDivisionMember_970232ba-342e-422a-8adb-77c4b9ef93ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CoronaryAndPeripheralVascularDivisionMember_81ce824d-7907-474d-b893-127745ad976e" xlink:href="mdt-20240426.xsd#mdt_CoronaryAndPeripheralVascularDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_CoronaryAndPeripheralVascularDivisionMember_81ce824d-7907-474d-b893-127745ad976e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CranialAndSpinalTechnologiesDivisionMember_edc00896-a989-4e1e-9425-ea602a226500" xlink:href="mdt-20240426.xsd#mdt_CranialAndSpinalTechnologiesDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_CranialAndSpinalTechnologiesDivisionMember_edc00896-a989-4e1e-9425-ea602a226500" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialtyTherapiesDivisionMember_b359980a-b225-4a73-a3c0-d11f04e280d3" xlink:href="mdt-20240426.xsd#mdt_SpecialtyTherapiesDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_SpecialtyTherapiesDivisionMember_b359980a-b225-4a73-a3c0-d11f04e280d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuromodulationDivisionMember_0ea11690-9d3c-4677-ba17-ebf860b934fd" xlink:href="mdt-20240426.xsd#mdt_NeuromodulationDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_NeuromodulationDivisionMember_0ea11690-9d3c-4677-ba17-ebf860b934fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SurgicalInnovationsDivisionMember_469c831b-44f6-4b39-a397-e3a4798075cb" xlink:href="mdt-20240426.xsd#mdt_SurgicalInnovationsDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_SurgicalInnovationsDivisionMember_469c831b-44f6-4b39-a397-e3a4798075cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AcuteCareMonitoringMember_9d9527da-d8c1-4bad-8aef-9f08a0371c55" xlink:href="mdt-20240426.xsd#mdt_AcuteCareMonitoringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_AcuteCareMonitoringMember_9d9527da-d8c1-4bad-8aef-9f08a0371c55" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d58e013-28dc-48dd-89eb-4991d133a262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8a07851b-5902-46ed-b584-a8c63c681a23" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d58e013-28dc-48dd-89eb-4991d133a262" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f0a38aaa-c61a-4a38-8a31-d692b3a7c658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d9bd75e5-7188-4be9-9ace-9ddca0a1d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f0a38aaa-c61a-4a38-8a31-d692b3a7c658" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d9bd75e5-7188-4be9-9ace-9ddca0a1d87d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_24d48a83-4076-4e82-9b8b-b35b4424fa42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d9bd75e5-7188-4be9-9ace-9ddca0a1d87d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_24d48a83-4076-4e82-9b8b-b35b4424fa42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_24d48a83-4076-4e82-9b8b-b35b4424fa42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_24d48a83-4076-4e82-9b8b-b35b4424fa42" xlink:to="loc_us-gaap_SegmentDomain_24d48a83-4076-4e82-9b8b-b35b4424fa42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_907b73d9-1047-4885-9a61-5698cf1ab1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_24d48a83-4076-4e82-9b8b-b35b4424fa42" xlink:to="loc_us-gaap_SegmentDomain_907b73d9-1047-4885-9a61-5698cf1ab1d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:href="mdt-20240426.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_907b73d9-1047-4885-9a61-5698cf1ab1d4" xlink:to="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_f5b2668a-3b44-4253-ab26-79c9d1202a47" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:to="loc_mdt_CardiovascularMember_f5b2668a-3b44-4253-ab26-79c9d1202a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_d167bdc2-c5ac-4aff-846a-664d0f7dab47" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:to="loc_mdt_NeuroscienceGroupMember_d167bdc2-c5ac-4aff-846a-664d0f7dab47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_c66a3af5-d6cb-4ca0-9db6-7d2aceb1ec22" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:to="loc_mdt_MedicalSurgicalMember_c66a3af5-d6cb-4ca0-9db6-7d2aceb1ec22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_d327f2e5-2ab3-485e-972a-8c89afa5121b" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:to="loc_mdt_DiabetesGroupMember_d327f2e5-2ab3-485e-972a-8c89afa5121b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a03d62fd-f33b-49f2-95ed-5dd7f3dc40eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_907b73d9-1047-4885-9a61-5698cf1ab1d4" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a03d62fd-f33b-49f2-95ed-5dd7f3dc40eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9dc5d7bb-2f24-487c-9aa6-f4deea098686" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d9bd75e5-7188-4be9-9ace-9ddca0a1d87d" xlink:to="loc_srt_StatementGeographicalAxis_9dc5d7bb-2f24-487c-9aa6-f4deea098686" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9dc5d7bb-2f24-487c-9aa6-f4deea098686_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9dc5d7bb-2f24-487c-9aa6-f4deea098686" xlink:to="loc_srt_SegmentGeographicalDomain_9dc5d7bb-2f24-487c-9aa6-f4deea098686_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9dc5d7bb-2f24-487c-9aa6-f4deea098686" xlink:to="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0a56735f-7472-40d1-be99-e9fa3c2235c2" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:to="loc_country_US_0a56735f-7472-40d1-be99-e9fa3c2235c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember_5ea354f7-ec75-4d26-874c-22701b053990" xlink:href="mdt-20240426.xsd#mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:to="loc_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember_5ea354f7-ec75-4d26-874c-22701b053990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember_fceeab9c-2cdb-4b3d-8249-cc6428198ae2" xlink:href="mdt-20240426.xsd#mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:to="loc_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember_fceeab9c-2cdb-4b3d-8249-cc6428198ae2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3141a3c7-bf95-4c9e-8efb-97cb4e175e96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f0a38aaa-c61a-4a38-8a31-d692b3a7c658" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3141a3c7-bf95-4c9e-8efb-97cb4e175e96" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2f5263c6-a665-4586-af43-135b54232691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2f5263c6-a665-4586-af43-135b54232691" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f6b16258-7ec5-44c6-ab55-568690289ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2f5263c6-a665-4586-af43-135b54232691" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f6b16258-7ec5-44c6-ab55-568690289ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f6b16258-7ec5-44c6-ab55-568690289ae6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f6b16258-7ec5-44c6-ab55-568690289ae6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f6b16258-7ec5-44c6-ab55-568690289ae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f6b16258-7ec5-44c6-ab55-568690289ae6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_31219817-6276-4585-bfe7-db54ef8b8120" xlink:href="mdt-20240426.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:to="loc_mdt_OtherAccruedExpensesMember_31219817-6276-4585-bfe7-db54ef8b8120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1bae683b-7815-4c6e-a3be-1806d2633390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:to="loc_us-gaap_AccountsReceivableMember_1bae683b-7815-4c6e-a3be-1806d2633390" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_2b082ced-fe51-4ccd-ba34-4181d96bf953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:to="loc_us-gaap_OtherLiabilitiesMember_2b082ced-fe51-4ccd-ba34-4181d96bf953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_ffd19318-cdce-4f95-9263-2a0673c8f141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_ffd19318-cdce-4f95-9263-2a0673c8f141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_270735ac-a6ee-4f80-a458-b51c1caafa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_ContractWithCustomerLiability_270735ac-a6ee-4f80-a458-b51c1caafa1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_911a6e03-f656-482f-9a59-4a2cefe2052e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_911a6e03-f656-482f-9a59-4a2cefe2052e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_66da9028-9cfd-4585-b046-a629216177ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_66da9028-9cfd-4585-b046-a629216177ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_5fafcf51-e358-4ec3-9bd2-f700dfd48bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_5fafcf51-e358-4ec3-9bd2-f700dfd48bba" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_529a088a-2545-4487-ba2c-0b9fb3d70077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_529a088a-2545-4487-ba2c-0b9fb3d70077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_529a088a-2545-4487-ba2c-0b9fb3d70077_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_529a088a-2545-4487-ba2c-0b9fb3d70077" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_529a088a-2545-4487-ba2c-0b9fb3d70077_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_529a088a-2545-4487-ba2c-0b9fb3d70077" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_54d20b9d-753a-4cfc-8272-2752b2ab788e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_54d20b9d-753a-4cfc-8272-2752b2ab788e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IntersectENTMember_8d93bfd5-9450-440e-bdf9-b70d15c85f5b" xlink:href="mdt-20240426.xsd#mdt_IntersectENTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:to="loc_mdt_IntersectENTMember_8d93bfd5-9450-440e-bdf9-b70d15c85f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AfferaIncMember_8367d351-26f7-44b4-b92f-e89361524366" xlink:href="mdt-20240426.xsd#mdt_AfferaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:to="loc_mdt_AfferaIncMember_8367d351-26f7-44b4-b92f-e89361524366" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAcquisitionsMember_62f16168-9891-4084-9a49-0d8b186355c4" xlink:href="mdt-20240426.xsd#mdt_OtherAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:to="loc_mdt_OtherAcquisitionsMember_62f16168-9891-4084-9a49-0d8b186355c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0b280be-a78a-47e4-9fee-7692fd0f608e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0b280be-a78a-47e4-9fee-7692fd0f608e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0b280be-a78a-47e4-9fee-7692fd0f608e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0b280be-a78a-47e4-9fee-7692fd0f608e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0b280be-a78a-47e4-9fee-7692fd0f608e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0b280be-a78a-47e4-9fee-7692fd0f608e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b0325fd4-0a1e-436a-b940-549504515162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b0325fd4-0a1e-436a-b940-549504515162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_a1621031-7ae1-4fe5-b4af-793abf2f917e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_a1621031-7ae1-4fe5-b4af-793abf2f917e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_04d93864-9c4d-4c01-938e-aca963dfc6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:to="loc_us-gaap_TradeNamesMember_04d93864-9c4d-4c01-938e-aca963dfc6c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6648792f-2f50-4921-862f-34544e21650a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6648792f-2f50-4921-862f-34544e21650a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0001a253-291a-457d-972e-5839e1fef70a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0001a253-291a-457d-972e-5839e1fef70a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0001a253-291a-457d-972e-5839e1fef70a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0001a253-291a-457d-972e-5839e1fef70a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0001a253-291a-457d-972e-5839e1fef70a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_958efb04-7f57-494a-9bf4-a421725d9d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0001a253-291a-457d-972e-5839e1fef70a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_958efb04-7f57-494a-9bf4-a421725d9d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_03d264c6-33c6-4402-a2e8-03c7badbd361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_958efb04-7f57-494a-9bf4-a421725d9d6c" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_03d264c6-33c6-4402-a2e8-03c7badbd361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd5eeb49-fa9c-4851-bc6b-392d631c77e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd5eeb49-fa9c-4851-bc6b-392d631c77e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dd5eeb49-fa9c-4851-bc6b-392d631c77e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd5eeb49-fa9c-4851-bc6b-392d631c77e7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dd5eeb49-fa9c-4851-bc6b-392d631c77e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd5eeb49-fa9c-4851-bc6b-392d631c77e7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember_ffaec31b-b076-4bc4-8d04-454a9f8a6186" xlink:href="mdt-20240426.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:to="loc_mdt_VentilatorProductLineExitMember_ffaec31b-b076-4bc4-8d04-454a9f8a6186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareSolutionsMember_35a04322-09b3-48a5-9bfb-4a214a1c3892" xlink:href="mdt-20240426.xsd#mdt_RenalCareSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:to="loc_mdt_RenalCareSolutionsMember_35a04322-09b3-48a5-9bfb-4a214a1c3892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MechanicalCirculatorySupportMember_ba0ed687-2a98-4f86-9571-abd1ee3de659" xlink:href="mdt-20240426.xsd#mdt_MechanicalCirculatorySupportMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:to="loc_mdt_MechanicalCirculatorySupportMember_ba0ed687-2a98-4f86-9571-abd1ee3de659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_41b07f0f-c874-4994-9463-9cdd4e524774" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_srt_ConsolidatedEntitiesAxis_41b07f0f-c874-4994-9463-9cdd4e524774" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_41b07f0f-c874-4994-9463-9cdd4e524774_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_41b07f0f-c874-4994-9463-9cdd4e524774" xlink:to="loc_srt_ConsolidatedEntitiesDomain_41b07f0f-c874-4994-9463-9cdd4e524774_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_05f8c379-4341-4711-b5d7-8c4eda9035f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_41b07f0f-c874-4994-9463-9cdd4e524774" xlink:to="loc_srt_ConsolidatedEntitiesDomain_05f8c379-4341-4711-b5d7-8c4eda9035f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_b68f40ac-2481-4db8-962e-0b01ded4c879" xlink:href="mdt-20240426.xsd#mdt_MozarcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_05f8c379-4341-4711-b5d7-8c4eda9035f1" xlink:to="loc_mdt_MozarcMember_b68f40ac-2481-4db8-962e-0b01ded4c879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f5438c15-882b-4325-8e84-7e5ba8758321" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_srt_OwnershipAxis_f5438c15-882b-4325-8e84-7e5ba8758321" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f5438c15-882b-4325-8e84-7e5ba8758321_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_f5438c15-882b-4325-8e84-7e5ba8758321" xlink:to="loc_srt_OwnershipDomain_f5438c15-882b-4325-8e84-7e5ba8758321_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_81498d5e-ff8b-4301-9c45-667614c2aa1b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_f5438c15-882b-4325-8e84-7e5ba8758321" xlink:to="loc_srt_OwnershipDomain_81498d5e-ff8b-4301-9c45-667614c2aa1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_4e1d1c7d-8d65-4db4-97cb-1e17a00fab9f" xlink:href="mdt-20240426.xsd#mdt_MozarcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_81498d5e-ff8b-4301-9c45-667614c2aa1b" xlink:to="loc_mdt_MozarcMember_4e1d1c7d-8d65-4db4-97cb-1e17a00fab9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_73bc10a8-6610-4367-8c21-921058c417b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_srt_RangeAxis_73bc10a8-6610-4367-8c21-921058c417b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_73bc10a8-6610-4367-8c21-921058c417b3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_73bc10a8-6610-4367-8c21-921058c417b3" xlink:to="loc_srt_RangeMember_73bc10a8-6610-4367-8c21-921058c417b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8522dfe2-3a07-4162-8f20-09d1666faa83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_73bc10a8-6610-4367-8c21-921058c417b3" xlink:to="loc_srt_RangeMember_8522dfe2-3a07-4162-8f20-09d1666faa83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c38a862f-1f0e-44d1-a4d4-d208a153fa32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8522dfe2-3a07-4162-8f20-09d1666faa83" xlink:to="loc_srt_MaximumMember_c38a862f-1f0e-44d1-a4d4-d208a153fa32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ed97d7c1-f236-47cc-bbc5-998f8008ad63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ed97d7c1-f236-47cc-bbc5-998f8008ad63" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ed97d7c1-f236-47cc-bbc5-998f8008ad63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ed97d7c1-f236-47cc-bbc5-998f8008ad63" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ed97d7c1-f236-47cc-bbc5-998f8008ad63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94bc75c0-7341-4a3f-a211-961613f35097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ed97d7c1-f236-47cc-bbc5-998f8008ad63" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94bc75c0-7341-4a3f-a211-961613f35097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_eba991e4-2793-4fd9-a4ab-24fe1ff6b0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_94bc75c0-7341-4a3f-a211-961613f35097" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_eba991e4-2793-4fd9-a4ab-24fe1ff6b0ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_827f974f-8cbf-417e-a7df-b06020bb615a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_827f974f-8cbf-417e-a7df-b06020bb615a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_827f974f-8cbf-417e-a7df-b06020bb615a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_827f974f-8cbf-417e-a7df-b06020bb615a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_827f974f-8cbf-417e-a7df-b06020bb615a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7ee62d07-586f-4422-aec8-73b49a202d91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_827f974f-8cbf-417e-a7df-b06020bb615a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7ee62d07-586f-4422-aec8-73b49a202d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_72517243-11ac-4e9c-b83d-8fba99cc996b" xlink:href="mdt-20240426.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7ee62d07-586f-4422-aec8-73b49a202d91" xlink:to="loc_mdt_OtherAccruedExpensesMember_72517243-11ac-4e9c-b83d-8fba99cc996b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_cf992e47-9f5d-412c-869c-f9052d55ff62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7ee62d07-586f-4422-aec8-73b49a202d91" xlink:to="loc_us-gaap_OtherLiabilitiesMember_cf992e47-9f5d-412c-869c-f9052d55ff62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_937a025b-4c62-48b0-ba3c-0b8b809dd806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_937a025b-4c62-48b0-ba3c-0b8b809dd806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8492931d-970c-4c00-b82c-c83aafc0cc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_Goodwill_8492931d-970c-4c00-b82c-c83aafc0cc4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a373d67b-ea60-4da2-b8d8-7f4950eb3726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a373d67b-ea60-4da2-b8d8-7f4950eb3726" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_78af22c1-c10b-4a28-a927-7998126417a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_78af22c1-c10b-4a28-a927-7998126417a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88c9f7f7-ae17-410c-b61d-0bc0254ea6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88c9f7f7-ae17-410c-b61d-0bc0254ea6ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax_434bc7ee-ec7b-43c1-9c73-61a74441f175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_GoodwillImpairmentLossNetOfTax_434bc7ee-ec7b-43c1-9c73-61a74441f175" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillNotAllocatedAmount_ed817edd-b482-498d-9a17-98f4b36d596e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillNotAllocatedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_GoodwillNotAllocatedAmount_ed817edd-b482-498d-9a17-98f4b36d596e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionPriceContingentConsideration_9a83de7a-826f-4050-942d-c37dc8fc8160" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionPriceContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_BusinessAcquisitionPriceContingentConsideration_9a83de7a-826f-4050-942d-c37dc8fc8160" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_738cf3c6-6939-487f-a6d2-b885a543608c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_738cf3c6-6939-487f-a6d2-b885a543608c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_11ccfaef-3b2e-441d-9489-dfde0efeea77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_11ccfaef-3b2e-441d-9489-dfde0efeea77" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a56bb65f-d155-4852-94bc-9d1bff9714f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a56bb65f-d155-4852-94bc-9d1bff9714f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationLiability_30590978-95aa-425d-97fa-7bdb6fef678c" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationLiability_30590978-95aa-425d-97fa-7bdb6fef678c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_10ce81a7-45a9-453d-a545-e7e575f8fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_10ce81a7-45a9-453d-a545-e7e575f8fad4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_adaf8f0d-ed1a-4918-a4fb-d787335c43d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessExitCosts1_adaf8f0d-ed1a-4918-a4fb-d787335c43d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_cca44394-e561-4c3e-a971-2eb86e69f4ba" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_cca44394-e561-4c3e-a971-2eb86e69f4ba" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_9c335719-bdb4-4a98-b604-98adb7162bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_9c335719-bdb4-4a98-b604-98adb7162bfc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_3edf2687-e633-4517-baed-8dede2937b51" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_3edf2687-e633-4517-baed-8dede2937b51" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f01b0dc5-2077-4a61-b808-33a3d0e850d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f01b0dc5-2077-4a61-b808-33a3d0e850d9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_5ecddfcd-455b-41c1-98e2-cbe57b32bdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_InventoryWriteDown_5ecddfcd-455b-41c1-98e2-cbe57b32bdb5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7a386fe0-aaa4-4b4d-90b7-677fcc73624c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7a386fe0-aaa4-4b4d-90b7-677fcc73624c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_97a3749c-348e-471e-ae89-c8d25f490c12" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_97a3749c-348e-471e-ae89-c8d25f490c12" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_bb60f7a5-4380-4a0c-849a-7eadb72c1666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_bb60f7a5-4380-4a0c-849a-7eadb72c1666" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0b1cc3e5-6501-4ed7-8bd6-61b0abc3ae0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0b1cc3e5-6501-4ed7-8bd6-61b0abc3ae0a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_51f9f8d0-22f9-4923-9f9e-23bc9d6652bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_MinorityInterest_51f9f8d0-22f9-4923-9f9e-23bc9d6652bc" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_115c9f91-a652-4320-90e0-0145a5c8dcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_AssetImpairmentCharges_115c9f91-a652-4320-90e0-0145a5c8dcb0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_aeddde07-c092-4516-8ac6-f5bf3087a5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_aeddde07-c092-4516-8ac6-f5bf3087a5ae" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_66972e7f-cfed-4332-9b5f-cafe7c83488c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_66972e7f-cfed-4332-9b5f-cafe7c83488c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1b9da810-4680-4fd6-b2f3-8b1d1874daff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1b9da810-4680-4fd6-b2f3-8b1d1874daff" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_6729963d-266b-4f52-b8c9-9b84e5361901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_OtherCommitment_6729963d-266b-4f52-b8c9-9b84e5361901" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_84785421-a0e2-42de-8792-23fdc1be0737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_84785421-a0e2-42de-8792-23fdc1be0737" xlink:type="arc" order="29"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13015686-d0c7-4aa9-8430-68bcb91e3e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13015686-d0c7-4aa9-8430-68bcb91e3e9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_069ee4b0-dcf1-4e22-89e1-4a29414a8ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13015686-d0c7-4aa9-8430-68bcb91e3e9a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_069ee4b0-dcf1-4e22-89e1-4a29414a8ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_069ee4b0-dcf1-4e22-89e1-4a29414a8ea4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_069ee4b0-dcf1-4e22-89e1-4a29414a8ea4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_069ee4b0-dcf1-4e22-89e1-4a29414a8ea4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d466dee-3ee6-4407-99b3-c46553183b93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_069ee4b0-dcf1-4e22-89e1-4a29414a8ea4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d466dee-3ee6-4407-99b3-c46553183b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IntersectENTMember_85dca1f4-7a10-4f69-a953-090e0ac500d0" xlink:href="mdt-20240426.xsd#mdt_IntersectENTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d466dee-3ee6-4407-99b3-c46553183b93" xlink:to="loc_mdt_IntersectENTMember_85dca1f4-7a10-4f69-a953-090e0ac500d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AfferaIncMember_9cbfe43c-d53a-4f29-99d2-645882f04860" xlink:href="mdt-20240426.xsd#mdt_AfferaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d466dee-3ee6-4407-99b3-c46553183b93" xlink:to="loc_mdt_AfferaIncMember_9cbfe43c-d53a-4f29-99d2-645882f04860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ca63adea-9588-4105-ae63-99a453c344c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ca63adea-9588-4105-ae63-99a453c344c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e129bd59-df0a-4864-a005-5adb834e41c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e129bd59-df0a-4864-a005-5adb834e41c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1b224cc3-c842-44ec-bb17-02640ec38043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_Goodwill_1b224cc3-c842-44ec-bb17-02640ec38043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_caf49d29-73d9-4bf6-80db-44baac459432" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_caf49d29-73d9-4bf6-80db-44baac459432" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_74051a1b-fb06-4f27-bd1b-22bbe631bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_74051a1b-fb06-4f27-bd1b-22bbe631bd48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_811a7e77-d2f2-4a1d-b3f7-d09663096741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_811a7e77-d2f2-4a1d-b3f7-d09663096741" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_ad27e3aa-3812-4154-8e7b-379584870168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_ad27e3aa-3812-4154-8e7b-379584870168" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0ca8a9b9-a7a3-41c6-a905-7d993dd43699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0ca8a9b9-a7a3-41c6-a905-7d993dd43699" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_f691529b-225e-4952-884a-2542a260d513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_f691529b-225e-4952-884a-2542a260d513" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2770607d-b6c5-4afd-bf56-17b19387b118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2770607d-b6c5-4afd-bf56-17b19387b118" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_67e57aab-6008-496b-84ec-ad6d27821d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_67e57aab-6008-496b-84ec-ad6d27821d95" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4814e179-8848-45db-bcd6-789f5cdefb22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4814e179-8848-45db-bcd6-789f5cdefb22" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f942be11-d028-4648-8c7f-4204c9b53aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f942be11-d028-4648-8c7f-4204c9b53aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f942be11-d028-4648-8c7f-4204c9b53aa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f942be11-d028-4648-8c7f-4204c9b53aa8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f942be11-d028-4648-8c7f-4204c9b53aa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5d17d053-63be-4d86-bd77-2fcd1319c1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f942be11-d028-4648-8c7f-4204c9b53aa8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5d17d053-63be-4d86-bd77-2fcd1319c1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9c3cf5d1-c7b5-4887-a6f4-c95e089f68b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5d17d053-63be-4d86-bd77-2fcd1319c1a3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9c3cf5d1-c7b5-4887-a6f4-c95e089f68b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b773592e-f9a6-4233-b80b-a38e3c12a81e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b773592e-f9a6-4233-b80b-a38e3c12a81e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b773592e-f9a6-4233-b80b-a38e3c12a81e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b773592e-f9a6-4233-b80b-a38e3c12a81e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b773592e-f9a6-4233-b80b-a38e3c12a81e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1b58361-ebc3-492d-b06a-8e9e930b6588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b773592e-f9a6-4233-b80b-a38e3c12a81e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1b58361-ebc3-492d-b06a-8e9e930b6588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_61978744-9c35-484e-97f0-609c5fe86b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1b58361-ebc3-492d-b06a-8e9e930b6588" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_61978744-9c35-484e-97f0-609c5fe86b97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b8e953c2-44d1-4137-88bf-51164be599bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b8e953c2-44d1-4137-88bf-51164be599bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b8e953c2-44d1-4137-88bf-51164be599bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b8e953c2-44d1-4137-88bf-51164be599bf" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b8e953c2-44d1-4137-88bf-51164be599bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_4321d139-fc50-4817-98ca-cf2d72968ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b8e953c2-44d1-4137-88bf-51164be599bf" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_4321d139-fc50-4817-98ca-cf2d72968ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RevenueMilestoneMember_9b669654-4bee-451e-aad3-677fe7fa6619" xlink:href="mdt-20240426.xsd#mdt_RevenueMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4321d139-fc50-4817-98ca-cf2d72968ae5" xlink:to="loc_mdt_RevenueMilestoneMember_9b669654-4bee-451e-aad3-677fe7fa6619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ProductDevelopmentMilestoneMember_e5544271-a686-4f89-a2d5-d7c9d1faf87c" xlink:href="mdt-20240426.xsd#mdt_ProductDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4321d139-fc50-4817-98ca-cf2d72968ae5" xlink:to="loc_mdt_ProductDevelopmentMilestoneMember_e5544271-a686-4f89-a2d5-d7c9d1faf87c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1cd5e61d-44e5-4e61-8578-af5fd40a1b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1cd5e61d-44e5-4e61-8578-af5fd40a1b67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1cd5e61d-44e5-4e61-8578-af5fd40a1b67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1cd5e61d-44e5-4e61-8578-af5fd40a1b67" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1cd5e61d-44e5-4e61-8578-af5fd40a1b67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_35a96169-8b56-40f6-bb32-7aa4794c9d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1cd5e61d-44e5-4e61-8578-af5fd40a1b67" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_35a96169-8b56-40f6-bb32-7aa4794c9d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2749fd2b-2944-4982-a5b5-004b776f8fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_35a96169-8b56-40f6-bb32-7aa4794c9d4d" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2749fd2b-2944-4982-a5b5-004b776f8fe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ed8cb92-3653-42c1-b1e1-28728ca7169b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_srt_RangeAxis_7ed8cb92-3653-42c1-b1e1-28728ca7169b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ed8cb92-3653-42c1-b1e1-28728ca7169b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7ed8cb92-3653-42c1-b1e1-28728ca7169b" xlink:to="loc_srt_RangeMember_7ed8cb92-3653-42c1-b1e1-28728ca7169b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7ed8cb92-3653-42c1-b1e1-28728ca7169b" xlink:to="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_06fc6b42-3fef-46a6-9eec-f5456c968e10" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:to="loc_srt_MinimumMember_06fc6b42-3fef-46a6-9eec-f5456c968e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_538d5ea2-2847-48eb-b001-9148b4e45548" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:to="loc_srt_MaximumMember_538d5ea2-2847-48eb-b001-9148b4e45548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_086230f7-424c-4904-ac24-a7e4c436e252" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:to="loc_srt_WeightedAverageMember_086230f7-424c-4904-ac24-a7e4c436e252" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7366140f-b1ee-4072-8d26-ad24aee12215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4814e179-8848-45db-bcd6-789f5cdefb22" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7366140f-b1ee-4072-8d26-ad24aee12215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5ef83df9-370a-453d-896a-55dd0f2bb0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4814e179-8848-45db-bcd6-789f5cdefb22" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5ef83df9-370a-453d-896a-55dd0f2bb0a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6d78976f-a1bf-42da-8e89-b8934addcaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5ef83df9-370a-453d-896a-55dd0f2bb0a8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6d78976f-a1bf-42da-8e89-b8934addcaf4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_917b805b-c292-40f2-9f67-f03104b691b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4cd4c7a0-83e0-4d96-8a85-13c59ef04271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_917b805b-c292-40f2-9f67-f03104b691b5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4cd4c7a0-83e0-4d96-8a85-13c59ef04271" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7cad13e8-d004-461e-82ac-cc05aaf316e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4cd4c7a0-83e0-4d96-8a85-13c59ef04271" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7cad13e8-d004-461e-82ac-cc05aaf316e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cad13e8-d004-461e-82ac-cc05aaf316e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7cad13e8-d004-461e-82ac-cc05aaf316e5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cad13e8-d004-461e-82ac-cc05aaf316e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_680119b4-2e26-49df-b342-46b01ab3dd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7cad13e8-d004-461e-82ac-cc05aaf316e5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_680119b4-2e26-49df-b342-46b01ab3dd3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8c355f8f-006e-478d-bf35-30798748bc20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_680119b4-2e26-49df-b342-46b01ab3dd3d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8c355f8f-006e-478d-bf35-30798748bc20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_360ba430-931c-4437-9a1f-99ac58461beb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4cd4c7a0-83e0-4d96-8a85-13c59ef04271" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_360ba430-931c-4437-9a1f-99ac58461beb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_360ba430-931c-4437-9a1f-99ac58461beb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_360ba430-931c-4437-9a1f-99ac58461beb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_360ba430-931c-4437-9a1f-99ac58461beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_98511b27-43bd-47ee-8c65-f41358b61cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_360ba430-931c-4437-9a1f-99ac58461beb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_98511b27-43bd-47ee-8c65-f41358b61cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_afd0458d-caeb-4018-9e7c-b0f5ae88fde6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_98511b27-43bd-47ee-8c65-f41358b61cc5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_afd0458d-caeb-4018-9e7c-b0f5ae88fde6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_917b805b-c292-40f2-9f67-f03104b691b5" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_8ee39148-11f9-49f2-8e5f-31e3e0488ad7" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_8ee39148-11f9-49f2-8e5f-31e3e0488ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionPriceContingentConsideration_8167dbb2-2456-4610-9530-3da490c35e1d" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionPriceContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:to="loc_mdt_BusinessAcquisitionPriceContingentConsideration_8167dbb2-2456-4610-9530-3da490c35e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_a98256f2-dafa-4653-a1e6-8dd6d9a86c85" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_a98256f2-dafa-4653-a1e6-8dd6d9a86c85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_8e640f4d-1936-41a7-9f84-dcd755ae1399" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RestructuringChargesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dafeba6d-9208-4d69-b46e-c2c500468018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_800498d6-c7b7-4199-bc1e-2c112eef8fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dafeba6d-9208-4d69-b46e-c2c500468018" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_800498d6-c7b7-4199-bc1e-2c112eef8fb4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a23dd8a3-2b4a-4607-b7b4-cb6644cd5bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_800498d6-c7b7-4199-bc1e-2c112eef8fb4" xlink:to="loc_us-gaap_RestructuringPlanAxis_a23dd8a3-2b4a-4607-b7b4-cb6644cd5bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a23dd8a3-2b4a-4607-b7b4-cb6644cd5bcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_a23dd8a3-2b4a-4607-b7b4-cb6644cd5bcf" xlink:to="loc_us-gaap_RestructuringPlanDomain_a23dd8a3-2b4a-4607-b7b4-cb6644cd5bcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_13bbf872-a368-44b1-8334-0a77c0834c64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_a23dd8a3-2b4a-4607-b7b4-cb6644cd5bcf" xlink:to="loc_us-gaap_RestructuringPlanDomain_13bbf872-a368-44b1-8334-0a77c0834c64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EnterpriseExcellenceMember_fe28303d-36ed-4533-b802-fd9c2afb4f6a" xlink:href="mdt-20240426.xsd#mdt_EnterpriseExcellenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_13bbf872-a368-44b1-8334-0a77c0834c64" xlink:to="loc_mdt_EnterpriseExcellenceMember_fe28303d-36ed-4533-b802-fd9c2afb4f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SimplificationRestructuringProgramMember_d988ac4c-797a-49f5-8f3d-954389495c98" xlink:href="mdt-20240426.xsd#mdt_SimplificationRestructuringProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_13bbf872-a368-44b1-8334-0a77c0834c64" xlink:to="loc_mdt_SimplificationRestructuringProgramMember_d988ac4c-797a-49f5-8f3d-954389495c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9aa23279-8a50-498e-afab-601b9ebe4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dafeba6d-9208-4d69-b46e-c2c500468018" xlink:to="loc_us-gaap_RestructuringCharges_9aa23279-8a50-498e-afab-601b9ebe4f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f08724e7-42ff-4284-a3a5-621abd3fb033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dafeba6d-9208-4d69-b46e-c2c500468018" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f08724e7-42ff-4284-a3a5-621abd3fb033" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RestructuringChargesClassificationofRestructuringCostsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dba1334f-5ca8-4c30-8728-84234c8463e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d31dcb06-84c7-4ac6-ae4d-2abbc9fd732c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dba1334f-5ca8-4c30-8728-84234c8463e9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d31dcb06-84c7-4ac6-ae4d-2abbc9fd732c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7426b5d4-33e3-4c7b-a60b-affd5d443b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d31dcb06-84c7-4ac6-ae4d-2abbc9fd732c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7426b5d4-33e3-4c7b-a60b-affd5d443b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7426b5d4-33e3-4c7b-a60b-affd5d443b62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7426b5d4-33e3-4c7b-a60b-affd5d443b62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7426b5d4-33e3-4c7b-a60b-affd5d443b62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7426b5d4-33e3-4c7b-a60b-affd5d443b62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3970e800-9ff5-4116-83f8-544e8f5e1524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:to="loc_us-gaap_CostOfSalesMember_3970e800-9ff5-4116-83f8-544e8f5e1524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fe998210-3f94-47c5-a692-5c5f69dc9184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fe998210-3f94-47c5-a692-5c5f69dc9184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_509c49d3-3e90-4094-90b5-53c9527590ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:to="loc_us-gaap_RestructuringChargesMember_509c49d3-3e90-4094-90b5-53c9527590ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a69e0794-b6a7-4c77-8801-faa98b51efca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d31dcb06-84c7-4ac6-ae4d-2abbc9fd732c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a69e0794-b6a7-4c77-8801-faa98b51efca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a69e0794-b6a7-4c77-8801-faa98b51efca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a69e0794-b6a7-4c77-8801-faa98b51efca" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a69e0794-b6a7-4c77-8801-faa98b51efca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f6bde3f4-c778-4051-aa2c-480ff717ef94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a69e0794-b6a7-4c77-8801-faa98b51efca" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f6bde3f4-c778-4051-aa2c-480ff717ef94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_e27f4130-1dc1-4637-9fd5-4811f50e812b" xlink:href="mdt-20240426.xsd#mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f6bde3f4-c778-4051-aa2c-480ff717ef94" xlink:to="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_e27f4130-1dc1-4637-9fd5-4811f50e812b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b1588c09-7328-42e3-a8d0-0d0907e88190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dba1334f-5ca8-4c30-8728-84234c8463e9" xlink:to="loc_us-gaap_RestructuringCharges_b1588c09-7328-42e3-a8d0-0d0907e88190" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e7fea6de-d324-461a-8a33-078d5e9bd995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c6d050b5-9092-4300-aee8-d2d4efdb7166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e7fea6de-d324-461a-8a33-078d5e9bd995" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c6d050b5-9092-4300-aee8-d2d4efdb7166" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e6c05d20-5fcf-403f-b02d-30da88bca971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c6d050b5-9092-4300-aee8-d2d4efdb7166" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e6c05d20-5fcf-403f-b02d-30da88bca971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e6c05d20-5fcf-403f-b02d-30da88bca971_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e6c05d20-5fcf-403f-b02d-30da88bca971" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e6c05d20-5fcf-403f-b02d-30da88bca971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e6c05d20-5fcf-403f-b02d-30da88bca971" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_83c0a216-c970-4fc1-bc01-5718fefbb927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:to="loc_us-gaap_EmployeeSeveranceMember_83c0a216-c970-4fc1-bc01-5718fefbb927" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssociatedAndOtherCostsMember_4c820cce-ad26-43ce-9712-6bdbf16cd7c5" xlink:href="mdt-20240426.xsd#mdt_AssociatedAndOtherCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:to="loc_mdt_AssociatedAndOtherCostsMember_4c820cce-ad26-43ce-9712-6bdbf16cd7c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_cf8cc443-9efe-457c-be64-4eae3ab3b9af" xlink:href="mdt-20240426.xsd#mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:to="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_cf8cc443-9efe-457c-be64-4eae3ab3b9af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e7fea6de-d324-461a-8a33-078d5e9bd995" xlink:to="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b3a7868b-7c68-45f3-a958-b2518e2efeba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_us-gaap_RestructuringReserve_b3a7868b-7c68-45f3-a958-b2518e2efeba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesIncludingAccrualAdjustments_d1fa051e-f9c0-43d6-8087-3e8bb07e9fd9" xlink:href="mdt-20240426.xsd#mdt_RestructuringChargesIncludingAccrualAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_mdt_RestructuringChargesIncludingAccrualAdjustments_d1fa051e-f9c0-43d6-8087-3e8bb07e9fd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_0a00a769-c64b-4004-b623-022b9ceb43a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_us-gaap_PaymentsForRestructuring_0a00a769-c64b-4004-b623-022b9ceb43a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_42f705b2-244e-4e6f-ab5d-bc8db8599cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_42f705b2-244e-4e6f-ab5d-bc8db8599cd8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_b8f0954d-c02e-47c8-8501-90c7ab8f9953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_b8f0954d-c02e-47c8-8501-90c7ab8f9953" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_12b7ec39-23ca-4cc1-9f59-bbb8e915e653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_945357d0-ab87-4144-88a6-53c8c5f255cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e7fea6de-d324-461a-8a33-078d5e9bd995" xlink:to="loc_us-gaap_RestructuringCharges_945357d0-ab87-4144-88a6-53c8c5f255cf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54c29ed3-cda2-4d05-bc98-1e7d7a42dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54c29ed3-cda2-4d05-bc98-1e7d7a42dc12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54c29ed3-cda2-4d05-bc98-1e7d7a42dc12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54c29ed3-cda2-4d05-bc98-1e7d7a42dc12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54c29ed3-cda2-4d05-bc98-1e7d7a42dc12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54c29ed3-cda2-4d05-bc98-1e7d7a42dc12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6b7637b3-0b61-405f-9549-294c7f447ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6b7637b3-0b61-405f-9549-294c7f447ee7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e86562a9-787b-4737-a048-0abe521b06a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e86562a9-787b-4737-a048-0abe521b06a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b5c3d847-04b6-49f0-8de0-554a6f516522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b5c3d847-04b6-49f0-8de0-554a6f516522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f5a7a33b-7a6f-4406-bd6d-72b4988575a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f5a7a33b-7a6f-4406-bd6d-72b4988575a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5a7a33b-7a6f-4406-bd6d-72b4988575a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f5a7a33b-7a6f-4406-bd6d-72b4988575a6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5a7a33b-7a6f-4406-bd6d-72b4988575a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f5a7a33b-7a6f-4406-bd6d-72b4988575a6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d9446256-0d8f-45a8-b1c7-6e55d19c8981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d9446256-0d8f-45a8-b1c7-6e55d19c8981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d52f85f8-95a7-47ee-b5f5-4ca14d49293f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d52f85f8-95a7-47ee-b5f5-4ca14d49293f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_453cf000-4a5e-4d1e-a233-5d26050fcbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_453cf000-4a5e-4d1e-a233-5d26050fcbc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5e20a374-86b5-4c7b-8410-f15035024327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5e20a374-86b5-4c7b-8410-f15035024327" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_c4019d69-a4dc-44ee-8296-a7b061d1ce89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_CertificatesOfDepositMember_c4019d69-a4dc-44ee-8296-a7b061d1ce89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_17593dae-ef46-4ddc-a07e-e81d6ab88f01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_17593dae-ef46-4ddc-a07e-e81d6ab88f01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember_dd58a76d-6d72-470e-a849-676b99b8f3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_AuctionRateSecuritiesMember_dd58a76d-6d72-470e-a849-676b99b8f3ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bf85f521-cfbf-4c24-b0de-9cada45ca070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bf85f521-cfbf-4c24-b0de-9cada45ca070" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bf85f521-cfbf-4c24-b0de-9cada45ca070_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf85f521-cfbf-4c24-b0de-9cada45ca070" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bf85f521-cfbf-4c24-b0de-9cada45ca070_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_84f3017c-7962-411b-bb4b-f963bec34971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf85f521-cfbf-4c24-b0de-9cada45ca070" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_84f3017c-7962-411b-bb4b-f963bec34971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_f46a49b9-2b4d-4765-89b6-e86386ea2c61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_84f3017c-7962-411b-bb4b-f963bec34971" xlink:to="loc_us-gaap_InvestmentsMember_f46a49b9-2b4d-4765-89b6-e86386ea2c61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_090d4562-2827-4187-9c68-79b621b61f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_84f3017c-7962-411b-bb4b-f963bec34971" xlink:to="loc_us-gaap_OtherAssetsMember_090d4562-2827-4187-9c68-79b621b61f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2b37d209-f4c2-4bbc-a61e-9ae6cba8132c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2b37d209-f4c2-4bbc-a61e-9ae6cba8132c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22889595-1f80-4b2a-bfaf-7df07a309c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22889595-1f80-4b2a-bfaf-7df07a309c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_77127220-2835-4e6f-9728-f066fee505ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_77127220-2835-4e6f-9728-f066fee505ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_91ab701d-40df-4a69-8abd-28f730489d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_91ab701d-40df-4a69-8abd-28f730489d9b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_285c7ed1-4e06-4f0c-9578-ea3642d531bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c537960-5556-461a-9580-13648d66803e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_285c7ed1-4e06-4f0c-9578-ea3642d531bd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c537960-5556-461a-9580-13648d66803e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f62ee04a-57d9-4a91-b6a1-3d35f904b73d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c537960-5556-461a-9580-13648d66803e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f62ee04a-57d9-4a91-b6a1-3d35f904b73d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f62ee04a-57d9-4a91-b6a1-3d35f904b73d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f62ee04a-57d9-4a91-b6a1-3d35f904b73d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f62ee04a-57d9-4a91-b6a1-3d35f904b73d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f62ee04a-57d9-4a91-b6a1-3d35f904b73d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2b60f0f6-99ef-4455-977b-3db1fdb56fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2b60f0f6-99ef-4455-977b-3db1fdb56fc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c7562bf8-ca56-4012-b900-bee0266e9401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c7562bf8-ca56-4012-b900-bee0266e9401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_043bbb30-2820-4305-afe4-ce4f9d6f7461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_043bbb30-2820-4305-afe4-ce4f9d6f7461" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9b0f197c-c890-42dd-91a3-45ed1b015336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9b0f197c-c890-42dd-91a3-45ed1b015336" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember_231b1c5b-eb40-4cf4-a9b9-c158268ea4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_AuctionRateSecuritiesMember_231b1c5b-eb40-4cf4-a9b9-c158268ea4b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_2d63cf00-d8e2-470b-b656-ad47d4aad9f5" xlink:href="mdt-20240426.xsd#mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_285c7ed1-4e06-4f0c-9578-ea3642d531bd" xlink:to="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_2d63cf00-d8e2-470b-b656-ad47d4aad9f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b465d551-76ed-4ee9-83fd-eac49f7a481c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_2d63cf00-d8e2-470b-b656-ad47d4aad9f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b465d551-76ed-4ee9-83fd-eac49f7a481c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2d1365a0-3a78-4276-ba70-ea1c63310181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_2d63cf00-d8e2-470b-b656-ad47d4aad9f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2d1365a0-3a78-4276-ba70-ea1c63310181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_f4139f12-ead8-4e99-a1af-4fc70b34d138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_285c7ed1-4e06-4f0c-9578-ea3642d531bd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_f4139f12-ead8-4e99-a1af-4fc70b34d138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cc8484e7-94a1-4178-92a8-8272a7556928" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_f4139f12-ead8-4e99-a1af-4fc70b34d138" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cc8484e7-94a1-4178-92a8-8272a7556928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_12527aba-406d-41ce-8006-6de02794e872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_f4139f12-ead8-4e99-a1af-4fc70b34d138" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_12527aba-406d-41ce-8006-6de02794e872" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_6e3ef697-a1c0-439e-9dd4-0567a45db067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_6e3ef697-a1c0-439e-9dd4-0567a45db067" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_628fc6bd-6c55-4e08-bb5a-cd85ba11ac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_6e3ef697-a1c0-439e-9dd4-0567a45db067" xlink:to="loc_us-gaap_FinancialInstrumentAxis_628fc6bd-6c55-4e08-bb5a-cd85ba11ac8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_628fc6bd-6c55-4e08-bb5a-cd85ba11ac8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_628fc6bd-6c55-4e08-bb5a-cd85ba11ac8a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_628fc6bd-6c55-4e08-bb5a-cd85ba11ac8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_818ccdce-69e6-41c3-b4b7-18692bb3e2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_628fc6bd-6c55-4e08-bb5a-cd85ba11ac8a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_818ccdce-69e6-41c3-b4b7-18692bb3e2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquityInvestmentsMember_5f3d20e1-c582-4404-afe4-9faa3f8637ac" xlink:href="mdt-20240426.xsd#mdt_EquityInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_818ccdce-69e6-41c3-b4b7-18692bb3e2d3" xlink:to="loc_mdt_EquityInvestmentsMember_5f3d20e1-c582-4404-afe4-9faa3f8637ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5fd6c401-29f6-453d-971e-b5cb44672b35" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_6e3ef697-a1c0-439e-9dd4-0567a45db067" xlink:to="loc_srt_OwnershipAxis_5fd6c401-29f6-453d-971e-b5cb44672b35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5fd6c401-29f6-453d-971e-b5cb44672b35_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5fd6c401-29f6-453d-971e-b5cb44672b35" xlink:to="loc_srt_OwnershipDomain_5fd6c401-29f6-453d-971e-b5cb44672b35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_27c8fc27-7ae2-4c57-9262-a19608e0d0ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5fd6c401-29f6-453d-971e-b5cb44672b35" xlink:to="loc_srt_OwnershipDomain_27c8fc27-7ae2-4c57-9262-a19608e0d0ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_f5b6dc39-f25a-4c66-85e4-cd2e5fe8a0da" xlink:href="mdt-20240426.xsd#mdt_MozarcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_27c8fc27-7ae2-4c57-9262-a19608e0d0ae" xlink:to="loc_mdt_MozarcMember_f5b6dc39-f25a-4c66-85e4-cd2e5fe8a0da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_8467ce06-220b-4d9e-a064-45c6070633c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_8467ce06-220b-4d9e-a064-45c6070633c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2278dca3-02ea-4427-bdf0-22d7a22aaaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2278dca3-02ea-4427-bdf0-22d7a22aaaa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c85984c3-03d8-4f92-8e47-89c6c5579f28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c85984c3-03d8-4f92-8e47-89c6c5579f28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_270277c1-0b29-4958-aad4-5663499337b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_270277c1-0b29-4958-aad4-5663499337b6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_44e10977-4e61-401b-b8ee-2351d377218f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_44e10977-4e61-401b-b8ee-2351d377218f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8a9cc736-7017-4103-acec-6b7e17c17174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_44e10977-4e61-401b-b8ee-2351d377218f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8a9cc736-7017-4103-acec-6b7e17c17174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8a9cc736-7017-4103-acec-6b7e17c17174_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8a9cc736-7017-4103-acec-6b7e17c17174" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8a9cc736-7017-4103-acec-6b7e17c17174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ce333537-0dc3-499f-ba8f-c9fbf4e59e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8a9cc736-7017-4103-acec-6b7e17c17174" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ce333537-0dc3-499f-ba8f-c9fbf4e59e97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_fcd2cf97-17ee-4cc0-ba40-04658d7a790e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ce333537-0dc3-499f-ba8f-c9fbf4e59e97" xlink:to="loc_us-gaap_OtherAssetsMember_fcd2cf97-17ee-4cc0-ba40-04658d7a790e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4dd0813c-afe4-4291-ae74-b62567e0883d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4dd0813c-afe4-4291-ae74-b62567e0883d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_9e431f48-765b-4222-8c80-50a9aa9feda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_9e431f48-765b-4222-8c80-50a9aa9feda3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e7929f6a-59fc-456b-af89-c1e0e286d386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e7929f6a-59fc-456b-af89-c1e0e286d386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_41c61b5e-9388-4a12-aed4-bbe1b749d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_us-gaap_EquityMethodInvestments_41c61b5e-9388-4a12-aed4-bbe1b749d31f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_34969c32-e34c-4e18-8eb2-ab97608342d8" xlink:href="mdt-20240426.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_34969c32-e34c-4e18-8eb2-ab97608342d8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsCurrentDebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:href="mdt-20240426.xsd#mdt_DebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ScheduleOfDebtTable_7422549d-819b-4cba-8715-bda30e9eb41b" xlink:href="mdt-20240426.xsd#mdt_ScheduleOfDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_mdt_ScheduleOfDebtTable_7422549d-819b-4cba-8715-bda30e9eb41b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_ebc3f6aa-2f12-45fb-93fb-1df0dbeb2a26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdt_ScheduleOfDebtTable_7422549d-819b-4cba-8715-bda30e9eb41b" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_ebc3f6aa-2f12-45fb-93fb-1df0dbeb2a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_ebc3f6aa-2f12-45fb-93fb-1df0dbeb2a26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_ebc3f6aa-2f12-45fb-93fb-1df0dbeb2a26" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_ebc3f6aa-2f12-45fb-93fb-1df0dbeb2a26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_c3f43af6-c531-48ad-a1d4-ef2e3cd61a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_ebc3f6aa-2f12-45fb-93fb-1df0dbeb2a26" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_c3f43af6-c531-48ad-a1d4-ef2e3cd61a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_24b10a26-7a01-47b4-9adc-bbd17b8f14f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_c3f43af6-c531-48ad-a1d4-ef2e3cd61a2e" xlink:to="loc_us-gaap_NotesPayableToBanksMember_24b10a26-7a01-47b4-9adc-bbd17b8f14f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bbe99e9e-27f1-4a5c-bd11-a31313bc33a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdt_ScheduleOfDebtTable_7422549d-819b-4cba-8715-bda30e9eb41b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bbe99e9e-27f1-4a5c-bd11-a31313bc33a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bbe99e9e-27f1-4a5c-bd11-a31313bc33a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bbe99e9e-27f1-4a5c-bd11-a31313bc33a0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bbe99e9e-27f1-4a5c-bd11-a31313bc33a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_55d263ec-742f-4143-9fe5-c063a93e8811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bbe99e9e-27f1-4a5c-bd11-a31313bc33a0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_55d263ec-742f-4143-9fe5-c063a93e8811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5bd91337-6896-4c4d-b24e-e4baad5f6f84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_55d263ec-742f-4143-9fe5-c063a93e8811" xlink:to="loc_us-gaap_SeniorNotesMember_5bd91337-6896-4c4d-b24e-e4baad5f6f84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_3d57a94b-3c65-4879-b228-e705900ec364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_ShortTermBorrowings_3d57a94b-3c65-4879-b228-e705900ec364" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_7d04c11e-3455-4af2-b27f-d45999689f10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_7d04c11e-3455-4af2-b27f-d45999689f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_e863642a-cd99-49bc-89fb-d7682fcb2402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_CommercialPaper_e863642a-cd99-49bc-89fb-d7682fcb2402" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c150a7bf-5529-45df-8d19-eab589425b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_DebtCurrent_c150a7bf-5529-45df-8d19-eab589425b4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bce83db9-5bae-4041-9400-224757a46377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bce83db9-5bae-4041-9400-224757a46377" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f2a26695-bf40-4000-b2ca-d63095a56945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_DebtInstrumentAxis_f2a26695-bf40-4000-b2ca-d63095a56945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f2a26695-bf40-4000-b2ca-d63095a56945_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f2a26695-bf40-4000-b2ca-d63095a56945" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f2a26695-bf40-4000-b2ca-d63095a56945_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f2a26695-bf40-4000-b2ca-d63095a56945" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2015CommercialPaperProgramMember_0a854387-abaa-40bf-8a0f-40d87c9a0542" xlink:href="mdt-20240426.xsd#mdt_A2015CommercialPaperProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_A2015CommercialPaperProgramMember_0a854387-abaa-40bf-8a0f-40d87c9a0542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember_e6d9d43a-b0a1-48a3-9686-dde1d41c31c8" xlink:href="mdt-20240426.xsd#mdt_AmendedandRestatedRevolvingCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember_e6d9d43a-b0a1-48a3-9686-dde1d41c31c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoSeniorNotesMember_53a43942-97a3-4304-ab2e-476cebbd6bdb" xlink:href="mdt-20240426.xsd#mdt_MedtronicLuxcoSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_MedtronicLuxcoSeniorNotesMember_53a43942-97a3-4304-ab2e-476cebbd6bdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20253.500PercentMember_ce565cef-35ce-4b42-ac8a-e8dd216a5792" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2015Due20253.500PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_SeniorNotes2015Due20253.500PercentMember_ce565cef-35ce-4b42-ac8a-e8dd216a5792" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2017Due20273.350PercentMember_d937cc4a-c6cc-40cb-8201-d925f9cf3043" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2017Due20273.350PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_SeniorNotes2017Due20273.350PercentMember_d937cc4a-c6cc-40cb-8201-d925f9cf3043" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_981e3d4b-a2e5-4f15-9278-5925f4d2d1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_981e3d4b-a2e5-4f15-9278-5925f4d2d1e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_981e3d4b-a2e5-4f15-9278-5925f4d2d1e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_981e3d4b-a2e5-4f15-9278-5925f4d2d1e3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_981e3d4b-a2e5-4f15-9278-5925f4d2d1e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2f0eb80b-902d-42bf-b8a8-40d27025e5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_981e3d4b-a2e5-4f15-9278-5925f4d2d1e3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2f0eb80b-902d-42bf-b8a8-40d27025e5ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9a1cb2ec-ff46-4e6c-8318-de2ece3eb1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2f0eb80b-902d-42bf-b8a8-40d27025e5ac" xlink:to="loc_us-gaap_CommercialPaperMember_9a1cb2ec-ff46-4e6c-8318-de2ece3eb1e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e761395c-ec9c-44d6-8245-12459d3c0257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2f0eb80b-902d-42bf-b8a8-40d27025e5ac" xlink:to="loc_us-gaap_LoansPayableMember_e761395c-ec9c-44d6-8245-12459d3c0257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_367b2995-82ef-4a83-bada-497d4cbb37de" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_srt_RangeAxis_367b2995-82ef-4a83-bada-497d4cbb37de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_367b2995-82ef-4a83-bada-497d4cbb37de_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_367b2995-82ef-4a83-bada-497d4cbb37de" xlink:to="loc_srt_RangeMember_367b2995-82ef-4a83-bada-497d4cbb37de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c34c3fa-285f-4d16-b8ef-1683bdc3f0a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_367b2995-82ef-4a83-bada-497d4cbb37de" xlink:to="loc_srt_RangeMember_0c34c3fa-285f-4d16-b8ef-1683bdc3f0a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b2b3ef81-720f-400c-9ab7-dd73b4a412f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c34c3fa-285f-4d16-b8ef-1683bdc3f0a4" xlink:to="loc_srt_MinimumMember_b2b3ef81-720f-400c-9ab7-dd73b4a412f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_498234fe-21cd-427f-9a3e-aa35eb2783fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_CreditFacilityAxis_498234fe-21cd-427f-9a3e-aa35eb2783fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_498234fe-21cd-427f-9a3e-aa35eb2783fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_498234fe-21cd-427f-9a3e-aa35eb2783fb" xlink:to="loc_us-gaap_CreditFacilityDomain_498234fe-21cd-427f-9a3e-aa35eb2783fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_045a986b-48ab-4cf1-b2c1-d34c622a8be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_498234fe-21cd-427f-9a3e-aa35eb2783fb" xlink:to="loc_us-gaap_CreditFacilityDomain_045a986b-48ab-4cf1-b2c1-d34c622a8be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_192535be-4be2-4b81-beaf-6f016f425f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_045a986b-48ab-4cf1-b2c1-d34c622a8be4" xlink:to="loc_us-gaap_LineOfCreditMember_192535be-4be2-4b81-beaf-6f016f425f2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e62f5560-f004-4d62-b46e-31603ec111cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e62f5560-f004-4d62-b46e-31603ec111cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e62f5560-f004-4d62-b46e-31603ec111cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e62f5560-f004-4d62-b46e-31603ec111cb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e62f5560-f004-4d62-b46e-31603ec111cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_49d746af-5bbf-436a-860d-e0a909a77d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e62f5560-f004-4d62-b46e-31603ec111cb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_49d746af-5bbf-436a-860d-e0a909a77d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_db3c2491-3018-4cdf-ac79-21c59f2b3564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_49d746af-5bbf-436a-860d-e0a909a77d26" xlink:to="loc_us-gaap_SeniorNotesMember_db3c2491-3018-4cdf-ac79-21c59f2b3564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6095f114-5fd3-4a28-9f2e-fadb940b6162" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_dei_LegalEntityAxis_6095f114-5fd3-4a28-9f2e-fadb940b6162" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6095f114-5fd3-4a28-9f2e-fadb940b6162_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6095f114-5fd3-4a28-9f2e-fadb940b6162" xlink:to="loc_dei_EntityDomain_6095f114-5fd3-4a28-9f2e-fadb940b6162_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_73c475b0-c41d-4df0-8ddc-8bbfc2ac6db5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6095f114-5fd3-4a28-9f2e-fadb940b6162" xlink:to="loc_dei_EntityDomain_73c475b0-c41d-4df0-8ddc-8bbfc2ac6db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoMember_0421f3bf-779f-4142-b73b-2d60e19880f6" xlink:href="mdt-20240426.xsd#mdt_MedtronicLuxcoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_73c475b0-c41d-4df0-8ddc-8bbfc2ac6db5" xlink:to="loc_mdt_MedtronicLuxcoMember_0421f3bf-779f-4142-b73b-2d60e19880f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2b2a38cf-1495-4821-b062-65c3ea37b9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_VariableRateAxis_2b2a38cf-1495-4821-b062-65c3ea37b9c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2b2a38cf-1495-4821-b062-65c3ea37b9c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_2b2a38cf-1495-4821-b062-65c3ea37b9c5" xlink:to="loc_us-gaap_VariableRateDomain_2b2a38cf-1495-4821-b062-65c3ea37b9c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0f008c2b-daf6-4971-8e3a-538992ce4f13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_2b2a38cf-1495-4821-b062-65c3ea37b9c5" xlink:to="loc_us-gaap_VariableRateDomain_0f008c2b-daf6-4971-8e3a-538992ce4f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TokyoInterBankOfferedRateTIBORMember_80ab5e58-3705-4a88-9703-f2f2f1ce282a" xlink:href="mdt-20240426.xsd#mdt_TokyoInterBankOfferedRateTIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0f008c2b-daf6-4971-8e3a-538992ce4f13" xlink:to="loc_mdt_TokyoInterBankOfferedRateTIBORMember_80ab5e58-3705-4a88-9703-f2f2f1ce282a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8cba31ed-1802-40ae-a5a1-9220170477bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8cba31ed-1802-40ae-a5a1-9220170477bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8cba31ed-1802-40ae-a5a1-9220170477bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8cba31ed-1802-40ae-a5a1-9220170477bf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8cba31ed-1802-40ae-a5a1-9220170477bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d4f2b172-9065-4aa8-9ca2-8579f18f93b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8cba31ed-1802-40ae-a5a1-9220170477bf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d4f2b172-9065-4aa8-9ca2-8579f18f93b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_17a0789a-f256-4088-8a71-b2a8b024d0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d4f2b172-9065-4aa8-9ca2-8579f18f93b7" xlink:to="loc_us-gaap_SubsequentEventMember_17a0789a-f256-4088-8a71-b2a8b024d0bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommercialPaperMaximumBorrowingCapacity_ed8b2e37-ae52-4183-975a-83c080ea6666" xlink:href="mdt-20240426.xsd#mdt_CommercialPaperMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_mdt_CommercialPaperMaximumBorrowingCapacity_ed8b2e37-ae52-4183-975a-83c080ea6666" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_1d1541b2-94e3-48ba-ab7b-ef1771f9c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtCurrent_1d1541b2-94e3-48ba-ab7b-ef1771f9c37b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_45071b08-1223-4ce8-a767-9885b5d73df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentTerm_45071b08-1223-4ce8-a767-9885b5d73df9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_5f16f552-f67d-4b7d-80f4-80ac30661a21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_5f16f552-f67d-4b7d-80f4-80ac30661a21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_a07e62f0-e2c7-4db5-bd3f-18691a1142fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_a07e62f0-e2c7-4db5-bd3f-18691a1142fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1a11efd6-11cd-4611-8dba-bba79ffa6530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1a11efd6-11cd-4611-8dba-bba79ffa6530" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityLengthOfExtension_97dfc365-ec24-4440-a05f-502cd9ff4f0b" xlink:href="mdt-20240426.xsd#mdt_LineOfCreditFacilityLengthOfExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_mdt_LineOfCreditFacilityLengthOfExtension_97dfc365-ec24-4440-a05f-502cd9ff4f0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_af603251-3d42-4bbb-9a34-fe8854200143" xlink:href="mdt-20240426.xsd#mdt_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_af603251-3d42-4bbb-9a34-fe8854200143" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_df138e8d-b843-4caf-809b-ff5a58840967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_LineOfCredit_df138e8d-b843-4caf-809b-ff5a58840967" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtInstrumentNumberofTranches_e9672dcb-c7c0-4dbb-8c04-3c8d73ad6190" xlink:href="mdt-20240426.xsd#mdt_DebtInstrumentNumberofTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_mdt_DebtInstrumentNumberofTranches_e9672dcb-c7c0-4dbb-8c04-3c8d73ad6190" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d1ff2307-4b5c-494c-b8f5-977e52215287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d1ff2307-4b5c-494c-b8f5-977e52215287" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_af4565a6-adb7-47ef-a2e3-1fb6ba8a3b93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_af4565a6-adb7-47ef-a2e3-1fb6ba8a3b93" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_410d5b5a-7af5-4a97-a47c-64e53cbc0c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_410d5b5a-7af5-4a97-a47c-64e53cbc0c6e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_4f2da78c-05ec-461f-82c9-2233f41d2589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_4f2da78c-05ec-461f-82c9-2233f41d2589" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b1f86f7-e6f1-402a-8d9a-d8a9160c276d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b1f86f7-e6f1-402a-8d9a-d8a9160c276d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_361e4481-b7f1-4d65-8253-9749f5bccdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_361e4481-b7f1-4d65-8253-9749f5bccdf2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_8edaea39-4fa2-4798-ad87-65264ce604b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_RepaymentsOfDebt_8edaea39-4fa2-4798-ad87-65264ce604b5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4200e2cc-1a70-4caf-8d29-09dc4eb4d179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4200e2cc-1a70-4caf-8d29-09dc4eb4d179" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_45dee1de-6f0c-45fc-8f7e-88d1e06dabdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_45dee1de-6f0c-45fc-8f7e-88d1e06dabdd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b5c70227-c362-4fd8-8d9a-9c129237fd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b5c70227-c362-4fd8-8d9a-9c129237fd3a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_2dce46f3-801e-44a0-852f-cf5b4df62254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_InterestExpenseBorrowings_2dce46f3-801e-44a0-852f-cf5b4df62254" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_aa19a7f0-e4d8-4167-b165-aba3ea00bd59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_LongTermDebtFairValue_aa19a7f0-e4d8-4167-b165-aba3ea00bd59" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7f6f6d21-a74d-4715-8b68-19fe38769cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DebtInstrumentTable_7f6f6d21-a74d-4715-8b68-19fe38769cf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_418da51a-229e-4bac-b3a5-5fc59dd14396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7f6f6d21-a74d-4715-8b68-19fe38769cf0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_418da51a-229e-4bac-b3a5-5fc59dd14396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_418da51a-229e-4bac-b3a5-5fc59dd14396_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_418da51a-229e-4bac-b3a5-5fc59dd14396" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_418da51a-229e-4bac-b3a5-5fc59dd14396_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e6dc2e5f-8a18-44bd-b940-79edf7530ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_418da51a-229e-4bac-b3a5-5fc59dd14396" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e6dc2e5f-8a18-44bd-b940-79edf7530ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_699ee9ec-be82-492b-bb8c-8fa4ad536a84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e6dc2e5f-8a18-44bd-b940-79edf7530ddc" xlink:to="loc_us-gaap_SeniorNotesMember_699ee9ec-be82-492b-bb8c-8fa4ad536a84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f7122f7a-593b-4b47-9f66-561dff73aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7f6f6d21-a74d-4715-8b68-19fe38769cf0" xlink:to="loc_us-gaap_DebtInstrumentAxis_f7122f7a-593b-4b47-9f66-561dff73aaf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f7122f7a-593b-4b47-9f66-561dff73aaf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f7122f7a-593b-4b47-9f66-561dff73aaf0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f7122f7a-593b-4b47-9f66-561dff73aaf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f7122f7a-593b-4b47-9f66-561dff73aaf0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2026Member_44fb4668-522b-4b2e-8b44-0b065d6dd1ca" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2026Member_44fb4668-522b-4b2e-8b44-0b065d6dd1ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2625PercentThreeYear2022SeniorNotesMember_2214995a-d14d-4762-99eb-9b841278e8a0" xlink:href="mdt-20240426.xsd#mdt_A2625PercentThreeYear2022SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A2625PercentThreeYear2022SeniorNotesMember_2214995a-d14d-4762-99eb-9b841278e8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2026Member_d4b14aba-dfe3-4a46-abe5-981857b7e51f" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2026Member_d4b14aba-dfe3-4a46-abe5-981857b7e51f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2027Member_aac47d57-d320-474b-9544-94ba98a4f5bd" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2027Member_aac47d57-d320-474b-9544-94ba98a4f5bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4250PercentFiveYear2023SeniorNotesMember_e9a9ff41-99eb-4377-a43b-5f771dddbbf0" xlink:href="mdt-20240426.xsd#mdt_A4250PercentFiveYear2023SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A4250PercentFiveYear2023SeniorNotesMember_e9a9ff41-99eb-4377-a43b-5f771dddbbf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3000PercentSixYear2022SeniorNotesMember_5e096475-4719-4dd1-8b39-e90d218e2199" xlink:href="mdt-20240426.xsd#mdt_A3000PercentSixYear2022SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A3000PercentSixYear2022SeniorNotesMember_5e096475-4719-4dd1-8b39-e90d218e2199" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2029Member_ec353a94-5ae3-4dfe-b78a-066268955943" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2029Member_ec353a94-5ae3-4dfe-b78a-066268955943" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2031Member_69177812-3ca5-48b3-ab13-8cc076347a7c" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2031Member_69177812-3ca5-48b3-ab13-8cc076347a7c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2032Member_464bd13d-f36e-42ed-857c-05cf9384a843" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2032Member_464bd13d-f36e-42ed-857c-05cf9384a843" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3125PercentNineYear2022SeniorNotesMember_7ead19a2-f054-4e6d-a890-a382fec924ba" xlink:href="mdt-20240426.xsd#mdt_A3125PercentNineYear2022SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A3125PercentNineYear2022SeniorNotesMember_7ead19a2-f054-4e6d-a890-a382fec924ba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2033Member_d1764f6d-3360-41fa-8c32-d61d0d02bdca" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2033Member_d1764f6d-3360-41fa-8c32-d61d0d02bdca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4500PercentTenYear2023SeniorNotesMember_a0273f6c-9576-4253-a436-f1b41614cce7" xlink:href="mdt-20240426.xsd#mdt_A4500PercentTenYear2023SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A4500PercentTenYear2023SeniorNotesMember_a0273f6c-9576-4253-a436-f1b41614cce7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3375PercentTwelveYear2022SeniorNotesMember_f9415fc9-9ec2-48f1-896c-0088d2e77512" xlink:href="mdt-20240426.xsd#mdt_A3375PercentTwelveYear2022SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A3375PercentTwelveYear2022SeniorNotesMember_f9415fc9-9ec2-48f1-896c-0088d2e77512" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due2035Member_69e57228-28da-4942-8157-fda43bacbed3" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2015Due2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2015Due2035Member_69e57228-28da-4942-8157-fda43bacbed3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesCIFSA2007Due2038Member_86b59b4d-e20f-4a4c-958d-7558b607df05" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesCIFSA2007Due2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotesCIFSA2007Due2038Member_86b59b4d-e20f-4a4c-958d-7558b607df05" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2039Member_197b067f-1391-4e86-b513-f9969ac498f6" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2039Member_197b067f-1391-4e86-b513-f9969ac498f6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2009Due2039Member_ccde6162-e2ba-4e7d-8a9f-f84f6b8bdc3e" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2009Due2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2009Due2039Member_ccde6162-e2ba-4e7d-8a9f-f84f6b8bdc3e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2040Member_19aa35c8-67df-4555-8dfc-304c10875844" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2040Member_19aa35c8-67df-4555-8dfc-304c10875844" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2010Due2040Member_f5dba55b-c914-417a-8f25-1e05012ae6e4" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2010Due2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2010Due2040Member_f5dba55b-c914-417a-8f25-1e05012ae6e4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2041Member_0896d332-56a4-4af5-a034-c806ff849c85" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2041Member_0896d332-56a4-4af5-a034-c806ff849c85" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2012Due2042Member_55766dc0-8878-4c1a-a67e-a4556c9b5dc2" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2012Due2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2012Due2042Member_55766dc0-8878-4c1a-a67e-a4556c9b5dc2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2013Due2043Member_fa0c4b5e-898f-4c8d-8358-3b26e77ce29e" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2013Due2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2013Due2043Member_fa0c4b5e-898f-4c8d-8358-3b26e77ce29e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2014Due2044Member_26899381-7a15-4794-9d77-44ab572a6b30" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2014Due2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2014Due2044Member_26899381-7a15-4794-9d77-44ab572a6b30" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due2045Member_87388ced-c3d7-4aca-b545-ae3dd4979e0a" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2015Due2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2015Due2045Member_87388ced-c3d7-4aca-b545-ae3dd4979e0a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2050Member_59edaac8-0f02-4aaf-a7dd-21028e3c304f" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2050Member_59edaac8-0f02-4aaf-a7dd-21028e3c304f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2051Member_1932d5be-dd69-41da-ba37-d2203d9a2386" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2051Member_1932d5be-dd69-41da-ba37-d2203d9a2386" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9d40bbea-8ace-4edc-91cb-6a922ba3e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9d40bbea-8ace-4edc-91cb-6a922ba3e6dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_28259c62-fcaa-486a-b246-a69eb0853068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DebtInstrumentTerm_28259c62-fcaa-486a-b246-a69eb0853068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_354fe5d0-ef04-4037-ac81-753285896b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_354fe5d0-ef04-4037-ac81-753285896b24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5b6ead98-e018-476e-be3a-773212e1fafc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5b6ead98-e018-476e-be3a-773212e1fafc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_a19d0e56-2726-4c0a-ae20-8a54ae45e270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_a19d0e56-2726-4c0a-ae20-8a54ae45e270" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_090bcc2b-7b32-410e-aa16-c7700a363769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_090bcc2b-7b32-410e-aa16-c7700a363769" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5c6a51a7-85a6-4384-9c4f-7084ef8f2c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5c6a51a7-85a6-4384-9c4f-7084ef8f2c82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d9867e83-050d-4110-a73b-f63327e80855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d9867e83-050d-4110-a73b-f63327e80855" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_5c47e694-ea31-4e62-8d9d-1740ab9c02f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_5c47e694-ea31-4e62-8d9d-1740ab9c02f9" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ce63bf05-fc30-4a87-a2ff-82f8e7802c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ce63bf05-fc30-4a87-a2ff-82f8e7802c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ce63bf05-fc30-4a87-a2ff-82f8e7802c91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ce63bf05-fc30-4a87-a2ff-82f8e7802c91" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ce63bf05-fc30-4a87-a2ff-82f8e7802c91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0d2e2e19-6d18-4ff0-ba23-1b5ad1b2b5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ce63bf05-fc30-4a87-a2ff-82f8e7802c91" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0d2e2e19-6d18-4ff0-ba23-1b5ad1b2b5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3c98c4ff-d43d-4a93-8ae4-6930e776e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0d2e2e19-6d18-4ff0-ba23-1b5ad1b2b5cf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3c98c4ff-d43d-4a93-8ae4-6930e776e6d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_99bcac06-af03-47f6-a47a-b29362a0d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:to="loc_us-gaap_HedgingDesignationAxis_99bcac06-af03-47f6-a47a-b29362a0d0f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_99bcac06-af03-47f6-a47a-b29362a0d0f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_99bcac06-af03-47f6-a47a-b29362a0d0f7" xlink:to="loc_us-gaap_HedgingDesignationDomain_99bcac06-af03-47f6-a47a-b29362a0d0f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b32fdd5e-0a3a-4c2a-9052-603754361aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_99bcac06-af03-47f6-a47a-b29362a0d0f7" xlink:to="loc_us-gaap_HedgingDesignationDomain_b32fdd5e-0a3a-4c2a-9052-603754361aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_25e29c16-b6dd-4d66-a80b-ce0125d5a779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b32fdd5e-0a3a-4c2a-9052-603754361aa7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_25e29c16-b6dd-4d66-a80b-ce0125d5a779" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e782496-eeb8-41bd-b5da-fc8aa79c9b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e782496-eeb8-41bd-b5da-fc8aa79c9b3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1e782496-eeb8-41bd-b5da-fc8aa79c9b3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e782496-eeb8-41bd-b5da-fc8aa79c9b3c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1e782496-eeb8-41bd-b5da-fc8aa79c9b3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1523cb10-d8e4-43fd-8e50-c349edcfa160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e782496-eeb8-41bd-b5da-fc8aa79c9b3c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1523cb10-d8e4-43fd-8e50-c349edcfa160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_fab77039-aa24-4639-916a-a99696f6ccda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1523cb10-d8e4-43fd-8e50-c349edcfa160" xlink:to="loc_us-gaap_CashFlowHedgingMember_fab77039-aa24-4639-916a-a99696f6ccda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_8480c603-6d4a-40e2-835c-14c3f242494a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_8480c603-6d4a-40e2-835c-14c3f242494a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_b38005e1-a28f-4884-a065-e042da6b91bd" xlink:href="mdt-20240426.xsd#mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_b38005e1-a28f-4884-a065-e042da6b91bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_697342d3-2e47-4708-8a86-a633a8cb3068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_697342d3-2e47-4708-8a86-a633a8cb3068" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_4d30bbc7-0dba-4307-a2fc-4c4baabb0c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_4d30bbc7-0dba-4307-a2fc-4c4baabb0c06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a6cbb50b-8c9a-4166-9633-299ad07f5598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a6cbb50b-8c9a-4166-9633-299ad07f5598" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_1bbf0d51-14bd-4134-9d73-f2026da5d979" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_1bbf0d51-14bd-4134-9d73-f2026da5d979" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4299e7af-5727-4621-94b1-bdabf82188bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4299e7af-5727-4621-94b1-bdabf82188bf" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_840d93d7-19e4-49d2-8b34-3173f0535847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_840d93d7-19e4-49d2-8b34-3173f0535847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_840d93d7-19e4-49d2-8b34-3173f0535847_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_840d93d7-19e4-49d2-8b34-3173f0535847" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_840d93d7-19e4-49d2-8b34-3173f0535847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b56558d6-1fea-470e-9be8-9583bd58ea1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_840d93d7-19e4-49d2-8b34-3173f0535847" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b56558d6-1fea-470e-9be8-9583bd58ea1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f59e11c4-df17-42b4-9d3c-0105da3a3eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b56558d6-1fea-470e-9be8-9583bd58ea1b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f59e11c4-df17-42b4-9d3c-0105da3a3eaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember_c7209a6b-c1f2-475e-addd-3dd4d142bdfd" xlink:href="mdt-20240426.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b56558d6-1fea-470e-9be8-9583bd58ea1b" xlink:to="loc_mdt_ForeignCurrencyDenominatedDebtMember_c7209a6b-c1f2-475e-addd-3dd4d142bdfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2c26b0b1-f50b-4630-ae4f-a66e567e0bff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2c26b0b1-f50b-4630-ae4f-a66e567e0bff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2c26b0b1-f50b-4630-ae4f-a66e567e0bff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2c26b0b1-f50b-4630-ae4f-a66e567e0bff" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2c26b0b1-f50b-4630-ae4f-a66e567e0bff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_fe54e58d-cd98-4f4d-866f-e0523536a0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2c26b0b1-f50b-4630-ae4f-a66e567e0bff" xlink:to="loc_us-gaap_HedgingRelationshipDomain_fe54e58d-cd98-4f4d-866f-e0523536a0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2588e71e-da4e-461e-8dce-8192a68fae5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_fe54e58d-cd98-4f4d-866f-e0523536a0db" xlink:to="loc_us-gaap_CashFlowHedgingMember_2588e71e-da4e-461e-8dce-8192a68fae5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_59781697-d435-421e-82a9-3c900e825198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_fe54e58d-cd98-4f4d-866f-e0523536a0db" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_59781697-d435-421e-82a9-3c900e825198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_785446f5-4be4-41c9-9453-46fbe34bdcef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:to="loc_us-gaap_HedgingDesignationAxis_785446f5-4be4-41c9-9453-46fbe34bdcef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_785446f5-4be4-41c9-9453-46fbe34bdcef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_785446f5-4be4-41c9-9453-46fbe34bdcef" xlink:to="loc_us-gaap_HedgingDesignationDomain_785446f5-4be4-41c9-9453-46fbe34bdcef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b8516867-eeee-4929-a1ba-dca0e944a870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_785446f5-4be4-41c9-9453-46fbe34bdcef" xlink:to="loc_us-gaap_HedgingDesignationDomain_b8516867-eeee-4929-a1ba-dca0e944a870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3ef5d369-7cdb-47b9-81bc-111e34643cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b8516867-eeee-4929-a1ba-dca0e944a870" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3ef5d369-7cdb-47b9-81bc-111e34643cd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_00327a6d-df09-41bc-8572-c91fb218d044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b8516867-eeee-4929-a1ba-dca0e944a870" xlink:to="loc_us-gaap_NondesignatedMember_00327a6d-df09-41bc-8572-c91fb218d044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6db2c4f8-01ad-4fcb-adea-a1148d9cf812" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:to="loc_srt_StatementGeographicalAxis_6db2c4f8-01ad-4fcb-adea-a1148d9cf812" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6db2c4f8-01ad-4fcb-adea-a1148d9cf812_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6db2c4f8-01ad-4fcb-adea-a1148d9cf812" xlink:to="loc_srt_SegmentGeographicalDomain_6db2c4f8-01ad-4fcb-adea-a1148d9cf812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_93fdff9f-5403-4025-98e1-343197bb5d6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6db2c4f8-01ad-4fcb-adea-a1148d9cf812" xlink:to="loc_srt_SegmentGeographicalDomain_93fdff9f-5403-4025-98e1-343197bb5d6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_8c53916f-c9d2-4173-95cd-f6663da6355e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_93fdff9f-5403-4025-98e1-343197bb5d6f" xlink:to="loc_srt_EuropeMember_8c53916f-c9d2-4173-95cd-f6663da6355e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_985680c7-37c3-4139-8a8e-b03cc1e2744d" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_93fdff9f-5403-4025-98e1-343197bb5d6f" xlink:to="loc_country_JP_985680c7-37c3-4139-8a8e-b03cc1e2744d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_a8ae2d31-37fd-4c1c-8605-e78d21f7502f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4299e7af-5727-4621-94b1-bdabf82188bf" xlink:to="loc_us-gaap_DerivativeNotionalAmount_a8ae2d31-37fd-4c1c-8605-e78d21f7502f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_74e7423b-dbf1-4e90-90b8-a734984f3071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_74e7423b-dbf1-4e90-90b8-a734984f3071" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_88677d30-be3c-4021-a15d-120bfdfbe14a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_74e7423b-dbf1-4e90-90b8-a734984f3071" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_88677d30-be3c-4021-a15d-120bfdfbe14a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_88677d30-be3c-4021-a15d-120bfdfbe14a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_88677d30-be3c-4021-a15d-120bfdfbe14a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_88677d30-be3c-4021-a15d-120bfdfbe14a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ad4c67b6-92ca-4ec4-9382-dc822b7168b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_88677d30-be3c-4021-a15d-120bfdfbe14a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ad4c67b6-92ca-4ec4-9382-dc822b7168b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ab9609bf-67ce-4940-a467-ab61f4246a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ad4c67b6-92ca-4ec4-9382-dc822b7168b0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ab9609bf-67ce-4940-a467-ab61f4246a8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember_419bf938-2527-41f1-a5f0-9a77b588d3d7" xlink:href="mdt-20240426.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ad4c67b6-92ca-4ec4-9382-dc822b7168b0" xlink:to="loc_mdt_ForeignCurrencyDenominatedDebtMember_419bf938-2527-41f1-a5f0-9a77b588d3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d616c671-dfa4-4e46-bca7-b0ecf074eead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_74e7423b-dbf1-4e90-90b8-a734984f3071" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d616c671-dfa4-4e46-bca7-b0ecf074eead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d616c671-dfa4-4e46-bca7-b0ecf074eead_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d616c671-dfa4-4e46-bca7-b0ecf074eead" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d616c671-dfa4-4e46-bca7-b0ecf074eead_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_258e71c7-8539-47a0-853f-61606a554a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d616c671-dfa4-4e46-bca7-b0ecf074eead" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_258e71c7-8539-47a0-853f-61606a554a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_b54620ef-570f-48ba-847e-2cee8790f18d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_258e71c7-8539-47a0-853f-61606a554a24" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_b54620ef-570f-48ba-847e-2cee8790f18d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_1f094bc3-51b2-4fc6-8ffd-41d6d10374bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_258e71c7-8539-47a0-853f-61606a554a24" xlink:to="loc_us-gaap_CostOfSalesMember_1f094bc3-51b2-4fc6-8ffd-41d6d10374bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_f9a37364-bc0b-4cfd-a3ea-c83c893a0824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_f9a37364-bc0b-4cfd-a3ea-c83c893a0824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d3fa4e34-374a-44a2-ba1e-31503bf1cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d3fa4e34-374a-44a2-ba1e-31503bf1cc5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_67e42a4c-e1e6-4428-bd65-a4d69ca8ef47" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_67e42a4c-e1e6-4428-bd65-a4d69ca8ef47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ee58820c-d196-4064-9bd5-b79ce03f149e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ee58820c-d196-4064-9bd5-b79ce03f149e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_20633db1-e1e1-4d8c-9716-156274cdaaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_20633db1-e1e1-4d8c-9716-156274cdaaa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_0e6aadb2-6313-40a0-bfa5-02eb19596ce8" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_0e6aadb2-6313-40a0-bfa5-02eb19596ce8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f0042f48-40b6-4fa3-989a-131ab96a82d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cf58256e-21e9-421d-81ba-2ba4891cae43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f0042f48-40b6-4fa3-989a-131ab96a82d3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cf58256e-21e9-421d-81ba-2ba4891cae43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ce1d8f4f-cb6b-4a44-9039-63312ca9156b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cf58256e-21e9-421d-81ba-2ba4891cae43" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ce1d8f4f-cb6b-4a44-9039-63312ca9156b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ce1d8f4f-cb6b-4a44-9039-63312ca9156b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ce1d8f4f-cb6b-4a44-9039-63312ca9156b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ce1d8f4f-cb6b-4a44-9039-63312ca9156b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ccb3350c-0893-40a8-8edd-e47e98f223f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ce1d8f4f-cb6b-4a44-9039-63312ca9156b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ccb3350c-0893-40a8-8edd-e47e98f223f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_7626043e-3af2-4db7-8f09-b93b817bcddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ccb3350c-0893-40a8-8edd-e47e98f223f9" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_7626043e-3af2-4db7-8f09-b93b817bcddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ca1959d7-5a9e-4c8c-8180-4d26a01e5571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cf58256e-21e9-421d-81ba-2ba4891cae43" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ca1959d7-5a9e-4c8c-8180-4d26a01e5571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ca1959d7-5a9e-4c8c-8180-4d26a01e5571_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ca1959d7-5a9e-4c8c-8180-4d26a01e5571" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ca1959d7-5a9e-4c8c-8180-4d26a01e5571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_70b9cb4d-2636-4b33-a7f6-ec318c1a433b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ca1959d7-5a9e-4c8c-8180-4d26a01e5571" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_70b9cb4d-2636-4b33-a7f6-ec318c1a433b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5c7fd146-d0f0-4c14-a0c5-5bb1985948df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70b9cb4d-2636-4b33-a7f6-ec318c1a433b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5c7fd146-d0f0-4c14-a0c5-5bb1985948df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_ff2ed353-b85d-421c-89ad-211c4eb6b952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f0042f48-40b6-4fa3-989a-131ab96a82d3" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_ff2ed353-b85d-421c-89ad-211c4eb6b952" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_1995a9cb-19a0-4e01-a4dc-ba446909f97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1995a9cb-19a0-4e01-a4dc-ba446909f97d" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_56dd2126-0c93-4b4a-9093-eb1ab395e0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:to="loc_us-gaap_HedgingDesignationAxis_56dd2126-0c93-4b4a-9093-eb1ab395e0d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_56dd2126-0c93-4b4a-9093-eb1ab395e0d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_56dd2126-0c93-4b4a-9093-eb1ab395e0d7" xlink:to="loc_us-gaap_HedgingDesignationDomain_56dd2126-0c93-4b4a-9093-eb1ab395e0d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f7de666e-f3cf-449b-9fcf-7e6d8669514c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_56dd2126-0c93-4b4a-9093-eb1ab395e0d7" xlink:to="loc_us-gaap_HedgingDesignationDomain_f7de666e-f3cf-449b-9fcf-7e6d8669514c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4c9bc72c-58fc-44dc-abdf-6b862f8c4c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f7de666e-f3cf-449b-9fcf-7e6d8669514c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4c9bc72c-58fc-44dc-abdf-6b862f8c4c7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_dd6b1115-96af-41c0-b2c9-86ea07ff7c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f7de666e-f3cf-449b-9fcf-7e6d8669514c" xlink:to="loc_us-gaap_NondesignatedMember_dd6b1115-96af-41c0-b2c9-86ea07ff7c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4651ec9a-ca6d-4cd4-b376-a5b79b3352f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4651ec9a-ca6d-4cd4-b376-a5b79b3352f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4651ec9a-ca6d-4cd4-b376-a5b79b3352f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4651ec9a-ca6d-4cd4-b376-a5b79b3352f5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4651ec9a-ca6d-4cd4-b376-a5b79b3352f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cb84bee4-e27a-4444-9d27-f3fe1aadc31c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4651ec9a-ca6d-4cd4-b376-a5b79b3352f5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cb84bee4-e27a-4444-9d27-f3fe1aadc31c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a7bdd183-0adb-4874-aaf1-3f940579c92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cb84bee4-e27a-4444-9d27-f3fe1aadc31c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a7bdd183-0adb-4874-aaf1-3f940579c92e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8c80b676-4dcc-4d40-8baa-46aa7e9b5dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8c80b676-4dcc-4d40-8baa-46aa7e9b5dac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8c80b676-4dcc-4d40-8baa-46aa7e9b5dac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8c80b676-4dcc-4d40-8baa-46aa7e9b5dac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8c80b676-4dcc-4d40-8baa-46aa7e9b5dac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8c80b676-4dcc-4d40-8baa-46aa7e9b5dac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_7d868479-daed-4e3c-9e6a-844808a5e4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_7d868479-daed-4e3c-9e6a-844808a5e4e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_e939c519-7e27-481e-be25-1df64a3ccdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:to="loc_us-gaap_OtherAssetsMember_e939c519-7e27-481e-be25-1df64a3ccdf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_899a9aec-0dad-48c8-abdd-b9272d59b45f" xlink:href="mdt-20240426.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:to="loc_mdt_OtherAccruedExpensesMember_899a9aec-0dad-48c8-abdd-b9272d59b45f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_bf38d212-39c4-4b95-b532-b35116e1c6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:to="loc_us-gaap_OtherLiabilitiesMember_bf38d212-39c4-4b95-b532-b35116e1c6c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ba45d732-bdce-4c55-817c-b332a528bab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1995a9cb-19a0-4e01-a4dc-ba446909f97d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ba45d732-bdce-4c55-817c-b332a528bab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fe8437dc-e13b-48fd-990f-b6c8947b5f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1995a9cb-19a0-4e01-a4dc-ba446909f97d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fe8437dc-e13b-48fd-990f-b6c8947b5f70" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172332ea-24c3-4ff7-8659-18d170c568c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172332ea-24c3-4ff7-8659-18d170c568c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a34e63c0-698d-4d31-aa03-4c76c7c2d4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172332ea-24c3-4ff7-8659-18d170c568c5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a34e63c0-698d-4d31-aa03-4c76c7c2d4a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a34e63c0-698d-4d31-aa03-4c76c7c2d4a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a34e63c0-698d-4d31-aa03-4c76c7c2d4a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a34e63c0-698d-4d31-aa03-4c76c7c2d4a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d98517e8-b585-4a32-b9ff-f11a9dbcb00e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a34e63c0-698d-4d31-aa03-4c76c7c2d4a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d98517e8-b585-4a32-b9ff-f11a9dbcb00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c40e319c-6b55-46fd-b282-e1a8cb65f2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d98517e8-b585-4a32-b9ff-f11a9dbcb00e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c40e319c-6b55-46fd-b282-e1a8cb65f2a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_e70dfc12-3d01-48f7-9be5-3db83be0379e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:to="loc_us-gaap_DerivativeAssets_e70dfc12-3d01-48f7-9be5-3db83be0379e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0ef9e2ea-2854-48aa-81fc-3864887aa862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:to="loc_us-gaap_DerivativeLiabilities_0ef9e2ea-2854-48aa-81fc-3864887aa862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_246198bd-110f-48dc-9397-b5d1b496a941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_246198bd-110f-48dc-9397-b5d1b496a941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_02ccb457-dc08-47a6-9f44-c55eec2b45ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_02ccb457-dc08-47a6-9f44-c55eec2b45ed" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:href="mdt-20240426.xsd#mdt_OffsettingAssetsandLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesTable_deeace38-0fda-46d4-95e7-002604d0d6cf" xlink:href="mdt-20240426.xsd#mdt_OffsettingAssetsandLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:to="loc_mdt_OffsettingAssetsandLiabilitiesTable_deeace38-0fda-46d4-95e7-002604d0d6cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0125611e-c544-4ad1-8def-136029b951a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesTable_deeace38-0fda-46d4-95e7-002604d0d6cf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0125611e-c544-4ad1-8def-136029b951a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0125611e-c544-4ad1-8def-136029b951a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0125611e-c544-4ad1-8def-136029b951a9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0125611e-c544-4ad1-8def-136029b951a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_48b26456-cf72-4a4a-9151-eac119fbe92c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0125611e-c544-4ad1-8def-136029b951a9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_48b26456-cf72-4a4a-9151-eac119fbe92c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3f55bf4e-b856-4b5a-b797-248f81f60905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_48b26456-cf72-4a4a-9151-eac119fbe92c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3f55bf4e-b856-4b5a-b797-248f81f60905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_029c06d5-df17-4083-bf29-6cfc13fb6378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_029c06d5-df17-4083-bf29-6cfc13fb6378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4327863e-c302-474f-9803-19636c60cc70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4327863e-c302-474f-9803-19636c60cc70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_3dc42cff-d393-48a3-be8b-1a70299c4d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_3dc42cff-d393-48a3-be8b-1a70299c4d38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_a0473c02-a15b-441b-b794-5588e631ec1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_a0473c02-a15b-441b-b794-5588e631ec1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_2b8f82d9-7b1b-46b5-bf73-29d36a42b983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_2b8f82d9-7b1b-46b5-bf73-29d36a42b983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_34762764-4a91-4bcf-94aa-9b8ebc33556e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_34762764-4a91-4bcf-94aa-9b8ebc33556e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_a2b26c04-b5b9-4880-8dd3-93a28a7afecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_a2b26c04-b5b9-4880-8dd3-93a28a7afecf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_38fa804c-2960-4422-8a2a-683fa7ebe71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_38fa804c-2960-4422-8a2a-683fa7ebe71b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:to="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_3ddfe8a0-d91e-4bb5-ab2a-2e8f283bf0e2" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:to="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_3ddfe8a0-d91e-4bb5-ab2a-2e8f283bf0e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_67324df1-0a5d-4629-a60f-ba7071b9ceac" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_67324df1-0a5d-4629-a60f-ba7071b9ceac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_a15db34d-ee0f-4177-b2ed-8297e98a0522" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_a15db34d-ee0f-4177-b2ed-8297e98a0522" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_50f7bf47-0c5d-48b5-99de-e73a14e00666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:to="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_50f7bf47-0c5d-48b5-99de-e73a14e00666" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ec9982de-ec9d-41d0-b63b-2aeb8c892150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_17c85c1b-abb7-45e3-abfb-e55b4fe858fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_ec9982de-ec9d-41d0-b63b-2aeb8c892150" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_17c85c1b-abb7-45e3-abfb-e55b4fe858fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_edf530a6-4f93-475f-bfb4-8c4352058a66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_17c85c1b-abb7-45e3-abfb-e55b4fe858fb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_edf530a6-4f93-475f-bfb4-8c4352058a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_edf530a6-4f93-475f-bfb4-8c4352058a66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_edf530a6-4f93-475f-bfb4-8c4352058a66" xlink:to="loc_us-gaap_SegmentDomain_edf530a6-4f93-475f-bfb4-8c4352058a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_edf530a6-4f93-475f-bfb4-8c4352058a66" xlink:to="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_f4bc0c09-c2ee-4a93-8d53-a9b2af0d4406" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:to="loc_mdt_CardiovascularMember_f4bc0c09-c2ee-4a93-8d53-a9b2af0d4406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_8468ed85-5325-4d30-95ad-dfcaed74a35a" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:to="loc_mdt_NeuroscienceGroupMember_8468ed85-5325-4d30-95ad-dfcaed74a35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_236e8ed7-6424-48be-9443-587f29755d9d" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:to="loc_mdt_MedicalSurgicalMember_236e8ed7-6424-48be-9443-587f29755d9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_24f2c2f5-6ea4-473f-bcaf-0d271af1ad77" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:to="loc_mdt_DiabetesGroupMember_24f2c2f5-6ea4-473f-bcaf-0d271af1ad77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ec9982de-ec9d-41d0-b63b-2aeb8c892150" xlink:to="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fb8adda3-cd41-42c4-b18a-a8ec4ba3bbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_Goodwill_fb8adda3-cd41-42c4-b18a-a8ec4ba3bbe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_5b591a6e-3b5b-4b48-9991-cae00ce773b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_5b591a6e-3b5b-4b48-9991-cae00ce773b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_795d60d2-f733-45ea-94c7-8ea8f1c17651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_795d60d2-f733-45ea-94c7-8ea8f1c17651" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_496e29e0-c4af-4151-879c-b83b0d5d1c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_496e29e0-c4af-4151-879c-b83b0d5d1c8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5c81da1f-f5b8-46e4-af10-1d1bf10404c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5c81da1f-f5b8-46e4-af10-1d1bf10404c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_44c0998d-0f4a-49d5-88f8-168bad9dbc44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5ff00d46-cce7-45f1-ad67-ab555b194199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5ff00d46-cce7-45f1-ad67-ab555b194199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5ff00d46-cce7-45f1-ad67-ab555b194199_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5ff00d46-cce7-45f1-ad67-ab555b194199" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5ff00d46-cce7-45f1-ad67-ab555b194199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5ff00d46-cce7-45f1-ad67-ab555b194199" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareBusinessRCSMember_223fac16-b745-4d7d-983d-7640c0c444ce" xlink:href="mdt-20240426.xsd#mdt_RenalCareBusinessRCSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:to="loc_mdt_RenalCareBusinessRCSMember_223fac16-b745-4d7d-983d-7640c0c444ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember_6f9db3e1-6200-4de8-8f71-84060695de29" xlink:href="mdt-20240426.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:to="loc_mdt_VentilatorProductLineExitMember_6f9db3e1-6200-4de8-8f71-84060695de29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MechanicalCirculatorySupportMember_c6032a50-213f-4cc2-9c6c-6af2c2580323" xlink:href="mdt-20240426.xsd#mdt_MechanicalCirculatorySupportMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:to="loc_mdt_MechanicalCirculatorySupportMember_c6032a50-213f-4cc2-9c6c-6af2c2580323" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IPRDMember_9ef05d01-d6e2-49d0-afb6-1b7ec3bd1685" xlink:href="mdt-20240426.xsd#mdt_IPRDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:to="loc_mdt_IPRDMember_9ef05d01-d6e2-49d0-afb6-1b7ec3bd1685" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_95f3192b-92bc-4bf8-aa4c-199cd1755f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_95f3192b-92bc-4bf8-aa4c-199cd1755f88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_95f3192b-92bc-4bf8-aa4c-199cd1755f88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_95f3192b-92bc-4bf8-aa4c-199cd1755f88" xlink:to="loc_us-gaap_SegmentDomain_95f3192b-92bc-4bf8-aa4c-199cd1755f88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e643cd6a-69b9-452f-ac0f-e3229400944b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_95f3192b-92bc-4bf8-aa4c-199cd1755f88" xlink:to="loc_us-gaap_SegmentDomain_e643cd6a-69b9-452f-ac0f-e3229400944b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_93aeb73e-fe84-4a92-a526-a63d780048fb" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e643cd6a-69b9-452f-ac0f-e3229400944b" xlink:to="loc_mdt_MedicalSurgicalMember_93aeb73e-fe84-4a92-a526-a63d780048fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_d1f6d6b6-0fc8-44aa-ad67-36d800651d17" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e643cd6a-69b9-452f-ac0f-e3229400944b" xlink:to="loc_mdt_NeuroscienceGroupMember_d1f6d6b6-0fc8-44aa-ad67-36d800651d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f47c1a6c-af07-4ef0-8594-17619db0fcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f47c1a6c-af07-4ef0-8594-17619db0fcbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f47c1a6c-af07-4ef0-8594-17619db0fcbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f47c1a6c-af07-4ef0-8594-17619db0fcbd" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f47c1a6c-af07-4ef0-8594-17619db0fcbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9738c736-ffa9-4a43-ae10-8af0c2a2c75f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f47c1a6c-af07-4ef0-8594-17619db0fcbd" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9738c736-ffa9-4a43-ae10-8af0c2a2c75f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_79fbacce-c2e6-4650-83e9-44a17922320b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9738c736-ffa9-4a43-ae10-8af0c2a2c75f" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_79fbacce-c2e6-4650-83e9-44a17922320b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8942a6a7-9cc6-43ac-8f2e-173b193a5aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8942a6a7-9cc6-43ac-8f2e-173b193a5aea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1d0a9430-00d2-4652-9d7b-3ef75eddabf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1d0a9430-00d2-4652-9d7b-3ef75eddabf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_199b3e47-444e-4b58-8394-b3b8a3e8c046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_NumberOfReportingUnits_199b3e47-444e-4b58-8394-b3b8a3e8c046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_6946fc9a-826e-4b4e-8bd5-f890e5f15ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_6946fc9a-826e-4b4e-8bd5-f890e5f15ab6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8efa201b-e095-4684-a0fe-304b33349f72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8efa201b-e095-4684-a0fe-304b33349f72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_16658456-709b-40c3-a34b-c67e494726fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_16658456-709b-40c3-a34b-c67e494726fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e207701e-21aa-4167-9719-85852f80dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e207701e-21aa-4167-9719-85852f80dbb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4f8d0b79-e6cc-455b-8e2f-132b20f06933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4f8d0b79-e6cc-455b-8e2f-132b20f06933" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fd9fb894-75b6-467e-b139-100c113967ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fd9fb894-75b6-467e-b139-100c113967ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_450f542c-29df-4d9a-9a14-c47e45851871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fd9fb894-75b6-467e-b139-100c113967ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_450f542c-29df-4d9a-9a14-c47e45851871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_450f542c-29df-4d9a-9a14-c47e45851871_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_450f542c-29df-4d9a-9a14-c47e45851871" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_450f542c-29df-4d9a-9a14-c47e45851871_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_450f542c-29df-4d9a-9a14-c47e45851871" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_a0f1f68c-6ce5-42a2-b68b-6bf5ecb4b673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_a0f1f68c-6ce5-42a2-b68b-6bf5ecb4b673" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PurchasedTechnologyAndPatentsMember_142a24fd-e6d7-4786-b8ab-f7f9d3e5a8f8" xlink:href="mdt-20240426.xsd#mdt_PurchasedTechnologyAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:to="loc_mdt_PurchasedTechnologyAndPatentsMember_142a24fd-e6d7-4786-b8ab-f7f9d3e5a8f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_7e6e6daa-8d49-425d-8e9b-a6013dd3311f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_7e6e6daa-8d49-425d-8e9b-a6013dd3311f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_71583728-8e18-429c-8282-6edecfd355a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_71583728-8e18-429c-8282-6edecfd355a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a1ae7a33-9cb0-4636-a692-b4f85d94f46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fd9fb894-75b6-467e-b139-100c113967ad" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a1ae7a33-9cb0-4636-a692-b4f85d94f46b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a1ae7a33-9cb0-4636-a692-b4f85d94f46b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a1ae7a33-9cb0-4636-a692-b4f85d94f46b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a1ae7a33-9cb0-4636-a692-b4f85d94f46b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6229d30d-b8f3-4217-9e94-d8e0935fd2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a1ae7a33-9cb0-4636-a692-b4f85d94f46b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6229d30d-b8f3-4217-9e94-d8e0935fd2e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_01af7e12-abfb-44e8-be76-1484ca0407d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6229d30d-b8f3-4217-9e94-d8e0935fd2e0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_01af7e12-abfb-44e8-be76-1484ca0407d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_89188968-1932-4256-9de3-8714e80fc237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_89188968-1932-4256-9de3-8714e80fc237" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3b8e59f4-4ae7-4dda-8494-fb743342867e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3b8e59f4-4ae7-4dda-8494-fb743342867e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7cc68767-c7d7-479b-a188-105a7fef0949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7cc68767-c7d7-479b-a188-105a7fef0949" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e61b61e8-13fc-422b-8508-ffe7197f5260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e61b61e8-13fc-422b-8508-ffe7197f5260" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_479fb036-8fbc-479b-8237-88a7e9b493b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e61b61e8-13fc-422b-8508-ffe7197f5260" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_479fb036-8fbc-479b-8237-88a7e9b493b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_479fb036-8fbc-479b-8237-88a7e9b493b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_479fb036-8fbc-479b-8237-88a7e9b493b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_479fb036-8fbc-479b-8237-88a7e9b493b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_479fb036-8fbc-479b-8237-88a7e9b493b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_e47e61fd-538d-4bd5-bdfe-c1900eba9a98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_us-gaap_EquipmentMember_e47e61fd-538d-4bd5-bdfe-c1900eba9a98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ae56715e-a5c5-4857-81a4-54b2a995cc76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ae56715e-a5c5-4857-81a4-54b2a995cc76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_a1add6a4-7ae8-41e7-8377-52a44585c4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_a1add6a4-7ae8-41e7-8377-52a44585c4ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BuildingsAndLeaseholdImprovementsMember_0c5d0536-32a7-4cd7-9b73-650899aeb9a3" xlink:href="mdt-20240426.xsd#mdt_BuildingsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_mdt_BuildingsAndLeaseholdImprovementsMember_0c5d0536-32a7-4cd7-9b73-650899aeb9a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d53b03d4-211c-4587-8ee8-887268e84a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_us-gaap_ConstructionInProgressMember_d53b03d4-211c-4587-8ee8-887268e84a0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa76052b-7bf0-4340-8205-9137142b682f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e61b61e8-13fc-422b-8508-ffe7197f5260" xlink:to="loc_srt_RangeAxis_aa76052b-7bf0-4340-8205-9137142b682f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa76052b-7bf0-4340-8205-9137142b682f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aa76052b-7bf0-4340-8205-9137142b682f" xlink:to="loc_srt_RangeMember_aa76052b-7bf0-4340-8205-9137142b682f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28674956-56b4-4f90-8b97-9f0abc999d04" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aa76052b-7bf0-4340-8205-9137142b682f" xlink:to="loc_srt_RangeMember_28674956-56b4-4f90-8b97-9f0abc999d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ea4272ae-6f8e-487b-a1fa-2f0a528af54f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_28674956-56b4-4f90-8b97-9f0abc999d04" xlink:to="loc_srt_MinimumMember_ea4272ae-6f8e-487b-a1fa-2f0a528af54f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4bed73e-fce2-45d6-962c-e655df5f7000" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_28674956-56b4-4f90-8b97-9f0abc999d04" xlink:to="loc_srt_MaximumMember_a4bed73e-fce2-45d6-962c-e655df5f7000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aaf7365d-3891-400b-be4d-8e4e3ca6ef4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aaf7365d-3891-400b-be4d-8e4e3ca6ef4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3c0b4d9f-c21b-41cf-add5-2ee2a1655ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3c0b4d9f-c21b-41cf-add5-2ee2a1655ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_d8f47f72-db74-4302-a16d-82407d0e8b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_d8f47f72-db74-4302-a16d-82407d0e8b6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ef659f42-47a1-4a6d-9b44-d0ac104dfee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ef659f42-47a1-4a6d-9b44-d0ac104dfee9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8e78a1c5-c992-49a4-996e-a2b43e9e9442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_Depreciation_8e78a1c5-c992-49a4-996e-a2b43e9e9442" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b30f9e8b-7668-4d7e-acf9-3f8347561bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b30f9e8b-7668-4d7e-acf9-3f8347561bc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb21ef80-53ba-4972-bae9-4aa9212c6f37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b30f9e8b-7668-4d7e-acf9-3f8347561bc3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb21ef80-53ba-4972-bae9-4aa9212c6f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bb21ef80-53ba-4972-bae9-4aa9212c6f37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb21ef80-53ba-4972-bae9-4aa9212c6f37" xlink:to="loc_us-gaap_ClassOfStockDomain_bb21ef80-53ba-4972-bae9-4aa9212c6f37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_08af9e85-0e15-4e34-9d67-d6fa3318b657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb21ef80-53ba-4972-bae9-4aa9212c6f37" xlink:to="loc_us-gaap_ClassOfStockDomain_08af9e85-0e15-4e34-9d67-d6fa3318b657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1bc752a0-fdc2-40d0-96de-acbe2959a479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_08af9e85-0e15-4e34-9d67-d6fa3318b657" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1bc752a0-fdc2-40d0-96de-acbe2959a479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ddb5fb0f-3e48-4790-af1c-1968c714ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ddb5fb0f-3e48-4790-af1c-1968c714ce22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc900f95-2cf8-4126-990b-1a7a09bd68a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc900f95-2cf8-4126-990b-1a7a09bd68a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesAuthorized_dff9c925-7a76-4cf4-8621-c5a4567083ac" xlink:href="mdt-20240426.xsd#mdt_DeferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_DeferredStockSharesAuthorized_dff9c925-7a76-4cf4-8621-c5a4567083ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockParorStatedValuePerShare_0c6efa56-d90f-4355-9a4f-2d550a9d4506" xlink:href="mdt-20240426.xsd#mdt_DeferredStockParorStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_DeferredStockParorStatedValuePerShare_0c6efa56-d90f-4355-9a4f-2d550a9d4506" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8972db29-b201-4ba4-b4e8-be0cac943ead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8972db29-b201-4ba4-b4e8-be0cac943ead" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2845e402-91d4-4ed7-9c11-f02a8bd80246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2845e402-91d4-4ed7-9c11-f02a8bd80246" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesIssued_c3857a7e-6578-4022-87e2-164d267e3baf" xlink:href="mdt-20240426.xsd#mdt_DeferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_DeferredStockSharesIssued_c3857a7e-6578-4022-87e2-164d267e3baf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesOutstanding_b036edc4-4dc7-4378-9c90-c324a0e4ce99" xlink:href="mdt-20240426.xsd#mdt_DeferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_DeferredStockSharesOutstanding_b036edc4-4dc7-4378-9c90-c324a0e4ce99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ed446327-9788-4de7-be40-0e27800ff593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ed446327-9788-4de7-be40-0e27800ff593" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3fd8aace-4089-438d-bbe3-6f7c28424c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3fd8aace-4089-438d-bbe3-6f7c28424c26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_755fcc25-819a-4c53-880a-360e965f904e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_755fcc25-819a-4c53-880a-360e965f904e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StockRepurchaseProgramAveragePurchasePrice_580fb9e2-1a35-497e-b4e9-9b32c0369bf2" xlink:href="mdt-20240426.xsd#mdt_StockRepurchaseProgramAveragePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_StockRepurchaseProgramAveragePurchasePrice_580fb9e2-1a35-497e-b4e9-9b32c0369bf2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_017cf2a2-aa13-4105-a795-67e867b36e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_017cf2a2-aa13-4105-a795-67e867b36e27" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_e93b482f-0578-4f06-8e83-f54efcf28830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_e93b482f-0578-4f06-8e83-f54efcf28830" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_028b503c-808b-4037-8a87-cf55b9d4bc64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_028b503c-808b-4037-8a87-cf55b9d4bc64" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_681e69d4-6ec8-4623-ab50-69e5581a21c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:to="loc_us-gaap_PlanNameAxis_681e69d4-6ec8-4623-ab50-69e5581a21c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_681e69d4-6ec8-4623-ab50-69e5581a21c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_681e69d4-6ec8-4623-ab50-69e5581a21c5" xlink:to="loc_us-gaap_PlanNameDomain_681e69d4-6ec8-4623-ab50-69e5581a21c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ed0fce63-f536-4f3f-96a8-7565ca2ad918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_681e69d4-6ec8-4623-ab50-69e5581a21c5" xlink:to="loc_us-gaap_PlanNameDomain_ed0fce63-f536-4f3f-96a8-7565ca2ad918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_bad1107c-e7eb-4fcf-a7da-0aa67eb6cfc1" xlink:href="mdt-20240426.xsd#mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ed0fce63-f536-4f3f-96a8-7565ca2ad918" xlink:to="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_bad1107c-e7eb-4fcf-a7da-0aa67eb6cfc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2024EmployeeStockPurchasePlanMember_74681008-787e-4ef4-86f3-7bf2979135de" xlink:href="mdt-20240426.xsd#mdt_A2024EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ed0fce63-f536-4f3f-96a8-7565ca2ad918" xlink:to="loc_mdt_A2024EmployeeStockPurchasePlanMember_74681008-787e-4ef4-86f3-7bf2979135de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac80a445-0cb8-484c-85c6-1099331cab11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:to="loc_us-gaap_AwardTypeAxis_ac80a445-0cb8-484c-85c6-1099331cab11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac80a445-0cb8-484c-85c6-1099331cab11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac80a445-0cb8-484c-85c6-1099331cab11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac80a445-0cb8-484c-85c6-1099331cab11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac80a445-0cb8-484c-85c6-1099331cab11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8bdd66cd-80af-4382-8479-13b9f3d9a078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8bdd66cd-80af-4382-8479-13b9f3d9a078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e8a8f95f-8d9f-4334-8c65-5e76904fe28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:to="loc_us-gaap_RestrictedStockMember_e8a8f95f-8d9f-4334-8c65-5e76904fe28e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_234250e8-7072-4b57-ac04-97d61765a035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockMember_e8a8f95f-8d9f-4334-8c65-5e76904fe28e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_234250e8-7072-4b57-ac04-97d61765a035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f0ae3ed0-6322-4152-93d9-c02c9f89a3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:to="loc_us-gaap_PerformanceSharesMember_f0ae3ed0-6322-4152-93d9-c02c9f89a3de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7f5da921-8064-49cb-bcc3-fe1e01c691aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:to="loc_us-gaap_EmployeeStockMember_7f5da921-8064-49cb-bcc3-fe1e01c691aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c3e6edb0-0554-41e9-8a3c-5f3ee48fe1f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:to="loc_srt_RangeAxis_c3e6edb0-0554-41e9-8a3c-5f3ee48fe1f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3e6edb0-0554-41e9-8a3c-5f3ee48fe1f1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c3e6edb0-0554-41e9-8a3c-5f3ee48fe1f1" xlink:to="loc_srt_RangeMember_c3e6edb0-0554-41e9-8a3c-5f3ee48fe1f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbea25f6-35e6-4aff-b4b4-ceb50e82d601" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c3e6edb0-0554-41e9-8a3c-5f3ee48fe1f1" xlink:to="loc_srt_RangeMember_cbea25f6-35e6-4aff-b4b4-ceb50e82d601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ab9fc31c-73fd-494c-b70d-a59c77f07290" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cbea25f6-35e6-4aff-b4b4-ceb50e82d601" xlink:to="loc_srt_MinimumMember_ab9fc31c-73fd-494c-b70d-a59c77f07290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_073b8a16-0aa2-43a2-80e1-4bcc153ac122" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cbea25f6-35e6-4aff-b4b4-ceb50e82d601" xlink:to="loc_srt_MaximumMember_073b8a16-0aa2-43a2-80e1-4bcc153ac122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e006ac4c-bc28-4a7e-a99a-7c0e4fdd1dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e006ac4c-bc28-4a7e-a99a-7c0e4fdd1dbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bba105e6-b55c-44d0-9eb0-76ccc7103d94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bba105e6-b55c-44d0-9eb0-76ccc7103d94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db88a320-2a97-43cd-885d-4e850e9a0407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db88a320-2a97-43cd-885d-4e850e9a0407" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4a6e2b18-ec96-481e-9610-36640a981dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4a6e2b18-ec96-481e-9610-36640a981dcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cdfe367d-2030-4ac2-8ad6-963506eb02f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cdfe367d-2030-4ac2-8ad6-963506eb02f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f08c6fa4-3ed9-42a5-80d9-6648afa5041f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f08c6fa4-3ed9-42a5-80d9-6648afa5041f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b95bf7b7-df72-4c76-a5c5-bc26d05f4e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b95bf7b7-df72-4c76-a5c5-bc26d05f4e5b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_466cad6b-a412-4b0b-bcd3-dafe228ec30d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_466cad6b-a412-4b0b-bcd3-dafe228ec30d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_67ae4b3f-6af8-4698-8e8a-13f2681e13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_67ae4b3f-6af8-4698-8e8a-13f2681e13d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_b1c0a072-7992-4f07-a160-2078e3010bb6" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_b1c0a072-7992-4f07-a160-2078e3010bb6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_6e7d290c-49c8-46e8-960b-744df8d6c90c" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_6e7d290c-49c8-46e8-960b-744df8d6c90c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce7c1bee-78a3-4a57-bc08-b4fb9fcb330e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce7c1bee-78a3-4a57-bc08-b4fb9fcb330e" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44c58a9c-43a9-43c8-8241-44bc72657c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44c58a9c-43a9-43c8-8241-44bc72657c92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b842211c-173d-40d1-bee2-58e7aea264ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44c58a9c-43a9-43c8-8241-44bc72657c92" xlink:to="loc_us-gaap_AwardTypeAxis_b842211c-173d-40d1-bee2-58e7aea264ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b842211c-173d-40d1-bee2-58e7aea264ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b842211c-173d-40d1-bee2-58e7aea264ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b842211c-173d-40d1-bee2-58e7aea264ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b842211c-173d-40d1-bee2-58e7aea264ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c8ec517b-e5a7-4bad-bc37-7aa58871ccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c8ec517b-e5a7-4bad-bc37-7aa58871ccf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a6843470-48a8-4c58-b6ad-779ede533189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a6843470-48a8-4c58-b6ad-779ede533189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0e8289d3-6c61-473e-b881-5c1a949d386b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:to="loc_us-gaap_PerformanceSharesMember_0e8289d3-6c61-473e-b881-5c1a949d386b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EmployeesStockPurchasePlanMember_24fb22bb-7c1a-49b6-a18c-eab83a12c2d7" xlink:href="mdt-20240426.xsd#mdt_EmployeesStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:to="loc_mdt_EmployeesStockPurchasePlanMember_24fb22bb-7c1a-49b6-a18c-eab83a12c2d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d4c87658-83ac-4ca8-8cd4-4a900cc4e199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44c58a9c-43a9-43c8-8241-44bc72657c92" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d4c87658-83ac-4ca8-8cd4-4a900cc4e199" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d4c87658-83ac-4ca8-8cd4-4a900cc4e199_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d4c87658-83ac-4ca8-8cd4-4a900cc4e199" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d4c87658-83ac-4ca8-8cd4-4a900cc4e199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d4c87658-83ac-4ca8-8cd4-4a900cc4e199" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_be29c230-ed3a-463a-bc47-e7fc6b94803f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:to="loc_us-gaap_CostOfSalesMember_be29c230-ed3a-463a-bc47-e7fc6b94803f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_84fcebda-c569-41ca-a6d1-3a67c6ddf8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_84fcebda-c569-41ca-a6d1-3a67c6ddf8c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d1b3927c-ce5e-4944-9843-9fa237a24bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d1b3927c-ce5e-4944-9843-9fa237a24bbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_81721d35-5757-4f32-8006-6587803b1f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_81721d35-5757-4f32-8006-6587803b1f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3a54bf27-cf99-46d7-a708-629d9d634e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3a54bf27-cf99-46d7-a708-629d9d634e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_825a2c42-29c0-4769-b8d7-f981ea229b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_825a2c42-29c0-4769-b8d7-f981ea229b8f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f68f5825-9397-463a-a0b0-f97f96592455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f68f5825-9397-463a-a0b0-f97f96592455" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_475844df-86e6-4565-aea4-79e1e5ded49b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f68f5825-9397-463a-a0b0-f97f96592455" xlink:to="loc_us-gaap_AwardTypeAxis_475844df-86e6-4565-aea4-79e1e5ded49b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_475844df-86e6-4565-aea4-79e1e5ded49b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_475844df-86e6-4565-aea4-79e1e5ded49b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_475844df-86e6-4565-aea4-79e1e5ded49b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c18d29fb-1698-47e7-ae14-f94297dd43c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_475844df-86e6-4565-aea4-79e1e5ded49b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c18d29fb-1698-47e7-ae14-f94297dd43c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_728e4051-8f44-4bde-88e4-805cbb728758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c18d29fb-1698-47e7-ae14-f94297dd43c7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_728e4051-8f44-4bde-88e4-805cbb728758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75007a37-713a-4672-8645-930cf56e4372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75007a37-713a-4672-8645-930cf56e4372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b7c86498-f17d-479f-8ab5-1bed8c5004ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b7c86498-f17d-479f-8ab5-1bed8c5004ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6d10cbd6-c317-4d63-86c8-2cae4e4f89a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6d10cbd6-c317-4d63-86c8-2cae4e4f89a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b2424109-eff9-4efb-8ec6-eb35b6566ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b2424109-eff9-4efb-8ec6-eb35b6566ccc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1dacc765-869a-430f-852c-40f1e8e97a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f6c0a571-1b6b-4eec-a9fd-79bf84d3eb50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f6c0a571-1b6b-4eec-a9fd-79bf84d3eb50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7b80abf0-eeeb-4069-b952-cd18b11329b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7b80abf0-eeeb-4069-b952-cd18b11329b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e50041f-8c68-468d-ae61-3a2dc424ca01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e50041f-8c68-468d-ae61-3a2dc424ca01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f88f54f8-fcb6-4b7c-9b7a-fd554e024f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f88f54f8-fcb6-4b7c-9b7a-fd554e024f30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1d1fcdea-ff7d-4269-a2c9-909fcfb73527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1d1fcdea-ff7d-4269-a2c9-909fcfb73527" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6b1d4d7c-e03b-49ab-a02f-51dd970b7570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6b1d4d7c-e03b-49ab-a02f-51dd970b7570" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a9432889-bec6-4566-9fd2-051acabe602f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_be9a4568-758c-421f-9778-912b97ced4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_be9a4568-758c-421f-9778-912b97ced4a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21578d86-0449-4c52-9ec8-e7eae45a9cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21578d86-0449-4c52-9ec8-e7eae45a9cad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7caf61f1-fdc4-484b-a19c-102c91c5ebcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7caf61f1-fdc4-484b-a19c-102c91c5ebcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_78d42d4f-f96d-4e25-bdea-ce2d83e6ed32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_78d42d4f-f96d-4e25-bdea-ce2d83e6ed32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7b0c927-dcd5-4eab-923c-ec6c15dc6358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7b0c927-dcd5-4eab-923c-ec6c15dc6358" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9419552b-29c5-49b4-872f-8b5a1b1c112a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9419552b-29c5-49b4-872f-8b5a1b1c112a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ec27797d-59c0-43e7-b1e4-d9e943c97bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ec27797d-59c0-43e7-b1e4-d9e943c97bdd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_84f218ad-5fda-482a-b359-192524b118c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_84f218ad-5fda-482a-b359-192524b118c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4046ecbd-5fe4-4de6-a65e-7f364c87c652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4046ecbd-5fe4-4de6-a65e-7f364c87c652" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f0d93268-d670-4636-9e62-c5e4207a353e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f0d93268-d670-4636-9e62-c5e4207a353e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_38e060a4-9779-4405-87d4-1f5ea572a531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_38e060a4-9779-4405-87d4-1f5ea572a531" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_008eafa0-b2ec-4ed9-a620-9e6812422658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_008eafa0-b2ec-4ed9-a620-9e6812422658" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_853cf027-1a81-44c8-a180-cba412e5f495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_008eafa0-b2ec-4ed9-a620-9e6812422658" xlink:to="loc_us-gaap_AwardTypeAxis_853cf027-1a81-44c8-a180-cba412e5f495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_853cf027-1a81-44c8-a180-cba412e5f495_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_853cf027-1a81-44c8-a180-cba412e5f495" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_853cf027-1a81-44c8-a180-cba412e5f495_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_551bbd7f-7d3f-41ff-8f57-4b356a7a982a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_853cf027-1a81-44c8-a180-cba412e5f495" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_551bbd7f-7d3f-41ff-8f57-4b356a7a982a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bb7ec18e-6bd0-45ed-9e9f-ea6ae57437a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_551bbd7f-7d3f-41ff-8f57-4b356a7a982a" xlink:to="loc_us-gaap_RestrictedStockMember_bb7ec18e-6bd0-45ed-9e9f-ea6ae57437a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_848478a2-33a3-44de-8790-8c95c7d47870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_848478a2-33a3-44de-8790-8c95c7d47870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e7d61c1-4932-42a3-a55a-2ae614dabf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e7d61c1-4932-42a3-a55a-2ae614dabf5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1f89eb2b-8b3e-4f7a-85cb-77976968ee47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1f89eb2b-8b3e-4f7a-85cb-77976968ee47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ea495ae5-34b3-4b09-8b72-b414b253386d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ea495ae5-34b3-4b09-8b72-b414b253386d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d40b9ec-5d67-4227-9c54-4163a13534f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e77b98bf-9f85-47af-83ae-f5a68f6bc7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e77b98bf-9f85-47af-83ae-f5a68f6bc7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_808bab66-75e2-4be9-b848-4cfd70908261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_808bab66-75e2-4be9-b848-4cfd70908261" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_05cd7d1d-da9d-4e8d-b793-3c619a1f4662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_05cd7d1d-da9d-4e8d-b793-3c619a1f4662" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8a17770-ca65-48d6-81a9-1d5a1b705889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8a17770-ca65-48d6-81a9-1d5a1b705889" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a2da5d96-c2f9-4a9f-9256-72d3267cd09c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_aea33fcb-6eb1-451e-a837-ade774120499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_aea33fcb-6eb1-451e-a837-ade774120499" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_4eb6aeb7-530f-430b-b6e7-0fc7e237ced1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_4eb6aeb7-530f-430b-b6e7-0fc7e237ced1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0be94789-9141-441a-b62c-651af3b11562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0be94789-9141-441a-b62c-651af3b11562" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_099372f6-7f7c-4122-acc9-42ddeb18cecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0be94789-9141-441a-b62c-651af3b11562" xlink:to="loc_us-gaap_AwardTypeAxis_099372f6-7f7c-4122-acc9-42ddeb18cecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_099372f6-7f7c-4122-acc9-42ddeb18cecd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_099372f6-7f7c-4122-acc9-42ddeb18cecd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_099372f6-7f7c-4122-acc9-42ddeb18cecd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84aa8d31-1571-4ffa-b01c-aee36c4c9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_099372f6-7f7c-4122-acc9-42ddeb18cecd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84aa8d31-1571-4ffa-b01c-aee36c4c9d56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_937ccf88-5297-42a1-8773-4037a847111d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84aa8d31-1571-4ffa-b01c-aee36c4c9d56" xlink:to="loc_us-gaap_PerformanceSharesMember_937ccf88-5297-42a1-8773-4037a847111d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_050a3c07-ed9a-4ca2-b123-26ae4da6c180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_050a3c07-ed9a-4ca2-b123-26ae4da6c180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8f55d450-19cc-4a83-b69c-185278bdff7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8f55d450-19cc-4a83-b69c-185278bdff7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_da83df51-22bc-4310-9f46-5c423454cd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_da83df51-22bc-4310-9f46-5c423454cd76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_eded1d84-807a-45c6-a056-2893efdf0fd6" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_eded1d84-807a-45c6-a056-2893efdf0fd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_62594e00-5b65-442c-bb8e-8916760a2e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_62594e00-5b65-442c-bb8e-8916760a2e76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_601434e3-ab35-4e37-934a-c7c06ee2dca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9136140e-31a4-4acc-88e3-8b22aad5dece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9136140e-31a4-4acc-88e3-8b22aad5dece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63f716b8-8907-4183-b945-45aa03d3666d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63f716b8-8907-4183-b945-45aa03d3666d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3b08fcf5-3a35-4296-891f-fd62e762589d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3b08fcf5-3a35-4296-891f-fd62e762589d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_ecba8bfc-0fa4-4b19-82b2-9e0d27da447f" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_ecba8bfc-0fa4-4b19-82b2-9e0d27da447f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b913c3c7-74bd-4622-bd2f-ffdae8759bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b913c3c7-74bd-4622-bd2f-ffdae8759bf1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a311016c-c7a8-482a-bf84-2a46b3935b61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7acf4feb-6b16-4763-920b-3629c6301412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7acf4feb-6b16-4763-920b-3629c6301412" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b5a04acd-773e-4c03-897a-fdaf05ad62a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b5a04acd-773e-4c03-897a-fdaf05ad62a3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8a9a8419-14bb-4043-965c-e60999f1946d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8a9a8419-14bb-4043-965c-e60999f1946d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4269cfba-1473-40f1-9539-815fd15d6f44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8a9a8419-14bb-4043-965c-e60999f1946d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4269cfba-1473-40f1-9539-815fd15d6f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4269cfba-1473-40f1-9539-815fd15d6f44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4269cfba-1473-40f1-9539-815fd15d6f44" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4269cfba-1473-40f1-9539-815fd15d6f44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4269cfba-1473-40f1-9539-815fd15d6f44" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_5e7b7ed5-2ab0-43f7-8c43-bc96be423b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:to="loc_us-gaap_ForeignCountryMember_5e7b7ed5-2ab0-43f7-8c43-bc96be423b7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3b02520a-d916-49ae-a5e1-ef2208000d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:to="loc_us-gaap_DomesticCountryMember_3b02520a-d916-49ae-a5e1-ef2208000d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a088b84d-d0ee-465d-bf33-a77a1d341131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a088b84d-d0ee-465d-bf33-a77a1d341131" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ce05553b-7556-4176-bd90-7e6788058224" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8a9a8419-14bb-4043-965c-e60999f1946d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ce05553b-7556-4176-bd90-7e6788058224" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ce05553b-7556-4176-bd90-7e6788058224_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ce05553b-7556-4176-bd90-7e6788058224" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ce05553b-7556-4176-bd90-7e6788058224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c1c47933-c652-44ae-b020-2541f76ae920" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ce05553b-7556-4176-bd90-7e6788058224" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c1c47933-c652-44ae-b020-2541f76ae920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_6d459580-c138-4ff5-bb1f-fcc8fa93c93a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c1c47933-c652-44ae-b020-2541f76ae920" xlink:to="loc_srt_SubsidiariesMember_6d459580-c138-4ff5-bb1f-fcc8fa93c93a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_5c81a73c-c463-4ed2-84dc-20ceafdd13d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_5c81a73c-c463-4ed2-84dc-20ceafdd13d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9e8885da-1c1a-4154-af6b-9ff0d089541e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9e8885da-1c1a-4154-af6b-9ff0d089541e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_da7737f5-96dc-4c1b-9b01-45819429d171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_da7737f5-96dc-4c1b-9b01-45819429d171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_496df1d4-0208-4052-b41b-fb9985c3fc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_496df1d4-0208-4052-b41b-fb9985c3fc73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_ceb4f0a1-9607-4305-bb5b-465e437746c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_ceb4f0a1-9607-4305-bb5b-465e437746c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a58e1d70-40ac-431c-a501-74188789f77a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a58e1d70-40ac-431c-a501-74188789f77a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1ed2548c-0553-499e-937f-8dfa77fc8304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1ed2548c-0553-499e-937f-8dfa77fc8304" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_b40a03fb-c482-49c2-9bf4-e1f6c56ebb0d" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_b40a03fb-c482-49c2-9bf4-e1f6c56ebb0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_af2d6093-8af7-4de6-9ad1-7dcabc52e8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_af2d6093-8af7-4de6-9ad1-7dcabc52e8b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_7d2c4bcd-7ca7-4fa6-abbf-23736982a799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_7d2c4bcd-7ca7-4fa6-abbf-23736982a799" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_c548bdee-dead-4eee-b218-a4ced5ec2074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_c548bdee-dead-4eee-b218-a4ced5ec2074" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_8a84ff63-24c5-4329-9933-4cbd5fbbb2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_8a84ff63-24c5-4329-9933-4cbd5fbbb2d6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_59fa7395-9721-4aee-b32a-436d7fe3a1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_59fa7395-9721-4aee-b32a-436d7fe3a1f1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0d9ffe0e-0c9a-46a5-be05-12be3d1bef81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0d9ffe0e-0c9a-46a5-be05-12be3d1bef81" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_f1615812-c2ad-4d98-910f-1512edc9abe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_f1615812-c2ad-4d98-910f-1512edc9abe1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_03c25ebb-d06b-4cd5-9563-942164c98a26" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_03c25ebb-d06b-4cd5-9563-942164c98a26" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_a13b9aa6-439b-4ffc-a671-04450c301718" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_a13b9aa6-439b-4ffc-a671-04450c301718" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_a6a9b9e1-bd47-437c-83fe-f5aff45395d9" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_a6a9b9e1-bd47-437c-83fe-f5aff45395d9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_ed2ea977-a34c-4916-9ff7-9bc89b64b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_ed2ea977-a34c-4916-9ff7-9bc89b64b4a3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_73b832ab-9d0f-425b-8895-3df5fe287755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_73b832ab-9d0f-425b-8895-3df5fe287755" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount_d4a99e54-cd75-4f89-ad86-24e16e1b444d" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount_d4a99e54-cd75-4f89-ad86-24e16e1b444d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxHolidays_5d6bdea4-e538-4562-8277-db2e00a00d63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxHolidays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxHolidays_5d6bdea4-e538-4562-8277-db2e00a00d63" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_b93cf512-5d07-463d-86e4-9dfc725ee3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_b93cf512-5d07-463d-86e4-9dfc725ee3c9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2744342b-247a-4781-88b7-9ea83993883c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2744342b-247a-4781-88b7-9ea83993883c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_23eeb2b7-27a8-48f6-a1d6-d0b2ebdf71b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_23eeb2b7-27a8-48f6-a1d6-d0b2ebdf71b0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_048c9c3e-8ec3-4aaf-80d8-4e6015ea2c75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_048c9c3e-8ec3-4aaf-80d8-4e6015ea2c75" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_251f1335-5ebe-466a-9b43-94821036e6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_251f1335-5ebe-466a-9b43-94821036e6eb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_0083f02b-b3ce-4a3e-8197-275a8e24d357" xlink:href="mdt-20240426.xsd#mdt_IncomeTaxExaminationInterestIncomeExpenseGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_0083f02b-b3ce-4a3e-8197-275a8e24d357" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_46ab454b-cf6c-4a87-8d75-de2d2cf458ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_46ab454b-cf6c-4a87-8d75-de2d2cf458ab" xlink:type="arc" order="28"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_dc75c742-11a9-4fb7-98fb-d8d25fe2b706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_725e48e9-f94d-4afe-b5d6-9ff4b9cf224f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dc75c742-11a9-4fb7-98fb-d8d25fe2b706" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_725e48e9-f94d-4afe-b5d6-9ff4b9cf224f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_02a7129c-f89f-4e2c-a99e-fe557dd10b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_725e48e9-f94d-4afe-b5d6-9ff4b9cf224f" xlink:to="loc_us-gaap_AwardTypeAxis_02a7129c-f89f-4e2c-a99e-fe557dd10b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02a7129c-f89f-4e2c-a99e-fe557dd10b57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_02a7129c-f89f-4e2c-a99e-fe557dd10b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02a7129c-f89f-4e2c-a99e-fe557dd10b57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_02a7129c-f89f-4e2c-a99e-fe557dd10b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_961bf9bb-5f27-47d4-9bd4-30fe20f6e857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_961bf9bb-5f27-47d4-9bd4-30fe20f6e857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_423b8208-7c3a-47e0-b812-edb3c0949e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_423b8208-7c3a-47e0-b812-edb3c0949e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0ae51c7c-7fea-4570-824d-26e281fe3eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:to="loc_us-gaap_PerformanceSharesMember_0ae51c7c-7fea-4570-824d-26e281fe3eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_99d3d3cb-ecc5-42bf-ad41-3533499b4ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dc75c742-11a9-4fb7-98fb-d8d25fe2b706" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_99d3d3cb-ecc5-42bf-ad41-3533499b4ced" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d645ff4b-87fc-4e0b-b5a9-dd3a862dd4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_99d3d3cb-ecc5-42bf-ad41-3533499b4ced" xlink:to="loc_us-gaap_NetIncomeLoss_d645ff4b-87fc-4e0b-b5a9-dd3a862dd4c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dc75c742-11a9-4fb7-98fb-d8d25fe2b706" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6485d2e-06a2-47fc-86f8-caa4374f5e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6485d2e-06a2-47fc-86f8-caa4374f5e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_d5de3362-7e9f-4ea9-b189-4c4d422c7476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_d5de3362-7e9f-4ea9-b189-4c4d422c7476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0071e845-d099-4e17-af74-9ed5f045f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_d5de3362-7e9f-4ea9-b189-4c4d422c7476" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0071e845-d099-4e17-af74-9ed5f045f50c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_875a2de5-3767-4633-90ad-e801a579edd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_d5de3362-7e9f-4ea9-b189-4c4d422c7476" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_875a2de5-3767-4633-90ad-e801a579edd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4869bc30-3199-49f3-9d61-9d27006ad387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4869bc30-3199-49f3-9d61-9d27006ad387" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_00b24ec3-f4bf-4307-8940-b21979b259dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_EarningsPerShareBasic_00b24ec3-f4bf-4307-8940-b21979b259dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b6932ba-bc54-482e-948e-ce82ed0403e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b6932ba-bc54-482e-948e-ce82ed0403e3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#EarningsPerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fcc02695-1eaa-4514-8a15-6be12cd63eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc5ecaac-74ea-4e50-a6ed-32f300863dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fcc02695-1eaa-4514-8a15-6be12cd63eac" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc5ecaac-74ea-4e50-a6ed-32f300863dd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cc48959-e152-4436-9570-63981c36076d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc5ecaac-74ea-4e50-a6ed-32f300863dd7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cc48959-e152-4436-9570-63981c36076d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cc48959-e152-4436-9570-63981c36076d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cc48959-e152-4436-9570-63981c36076d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cc48959-e152-4436-9570-63981c36076d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc7e0a26-7e65-4966-a3b4-9ca7b4474237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cc48959-e152-4436-9570-63981c36076d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc7e0a26-7e65-4966-a3b4-9ca7b4474237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0b46b7e5-e7e8-4818-86e4-05f6b7f35816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc7e0a26-7e65-4966-a3b4-9ca7b4474237" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0b46b7e5-e7e8-4818-86e4-05f6b7f35816" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_533675f8-225a-4058-a19b-db3dd8e9622f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fcc02695-1eaa-4514-8a15-6be12cd63eac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_533675f8-225a-4058-a19b-db3dd8e9622f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansNarativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5fc8c8f6-ff86-40d8-a244-2ecd328f7353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5fc8c8f6-ff86-40d8-a244-2ecd328f7353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5fc8c8f6-ff86-40d8-a244-2ecd328f7353_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5fc8c8f6-ff86-40d8-a244-2ecd328f7353" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5fc8c8f6-ff86-40d8-a244-2ecd328f7353_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9cd907ea-f69b-4cf9-aaf9-92a25d390119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5fc8c8f6-ff86-40d8-a244-2ecd328f7353" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9cd907ea-f69b-4cf9-aaf9-92a25d390119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5591fffb-4d03-4029-a273-e05ec502b5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9cd907ea-f69b-4cf9-aaf9-92a25d390119" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5591fffb-4d03-4029-a273-e05ec502b5bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9e04344e-c827-41bf-b984-e0d12b30f99e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9cd907ea-f69b-4cf9-aaf9-92a25d390119" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9e04344e-c827-41bf-b984-e0d12b30f99e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5772477d-c551-45df-86ee-d0531def4f37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5772477d-c551-45df-86ee-d0531def4f37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5772477d-c551-45df-86ee-d0531def4f37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5772477d-c551-45df-86ee-d0531def4f37" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5772477d-c551-45df-86ee-d0531def4f37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cdd68780-f392-465e-9736-ca4abab18768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5772477d-c551-45df-86ee-d0531def4f37" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cdd68780-f392-465e-9736-ca4abab18768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_ab2a25a6-14b7-41ee-9a0c-94527aa894d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cdd68780-f392-465e-9736-ca4abab18768" xlink:to="loc_us-gaap_DomesticPlanMember_ab2a25a6-14b7-41ee-9a0c-94527aa894d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_92b08c7a-9faf-4f6c-9e71-205cbbe739a6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_ab2a25a6-14b7-41ee-9a0c-94527aa894d4" xlink:to="loc_country_US_92b08c7a-9faf-4f6c-9e71-205cbbe739a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_0d58626f-636f-43dd-86e1-6cf19e1dac05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cdd68780-f392-465e-9736-ca4abab18768" xlink:to="loc_us-gaap_ForeignPlanMember_0d58626f-636f-43dd-86e1-6cf19e1dac05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_23caa0a9-a107-4d05-80df-732ffe7bff63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_23caa0a9-a107-4d05-80df-732ffe7bff63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_23caa0a9-a107-4d05-80df-732ffe7bff63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_23caa0a9-a107-4d05-80df-732ffe7bff63" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_23caa0a9-a107-4d05-80df-732ffe7bff63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_23caa0a9-a107-4d05-80df-732ffe7bff63" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_d731c839-b7bf-435b-b930-3a46932b69ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_d731c839-b7bf-435b-b930-3a46932b69ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_fb5121d8-cf68-4039-a788-357a6b5b1379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_fb5121d8-cf68-4039-a788-357a6b5b1379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember_591edf5f-c2b0-4b41-a366-2abd7b28dfee" xlink:href="mdt-20240426.xsd#mdt_OtherPlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:to="loc_mdt_OtherPlanAssetsMember_591edf5f-c2b0-4b41-a366-2abd7b28dfee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d62c1b41-f3b0-47fc-9374-bc400d41763d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_srt_RangeAxis_d62c1b41-f3b0-47fc-9374-bc400d41763d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d62c1b41-f3b0-47fc-9374-bc400d41763d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d62c1b41-f3b0-47fc-9374-bc400d41763d" xlink:to="loc_srt_RangeMember_d62c1b41-f3b0-47fc-9374-bc400d41763d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c78bfa9b-9ab4-42b1-8ade-fc1f3aa07d3f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d62c1b41-f3b0-47fc-9374-bc400d41763d" xlink:to="loc_srt_RangeMember_c78bfa9b-9ab4-42b1-8ade-fc1f3aa07d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e13a1ee8-312d-4724-aedd-4a0b892fdb72" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c78bfa9b-9ab4-42b1-8ade-fc1f3aa07d3f" xlink:to="loc_srt_MinimumMember_e13a1ee8-312d-4724-aedd-4a0b892fdb72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1220cb84-b74d-4605-86ed-745eccb0c964" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c78bfa9b-9ab4-42b1-8ade-fc1f3aa07d3f" xlink:to="loc_srt_MaximumMember_1220cb84-b74d-4605-86ed-745eccb0c964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e541d450-15b5-43be-a87f-f706b9c73aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e541d450-15b5-43be-a87f-f706b9c73aea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e541d450-15b5-43be-a87f-f706b9c73aea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e541d450-15b5-43be-a87f-f706b9c73aea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e541d450-15b5-43be-a87f-f706b9c73aea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80413244-87a6-4b2e-b7e1-21b4c4acb75c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e541d450-15b5-43be-a87f-f706b9c73aea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80413244-87a6-4b2e-b7e1-21b4c4acb75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3eee7679-cc01-4a35-85c6-0940ab761791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80413244-87a6-4b2e-b7e1-21b4c4acb75c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3eee7679-cc01-4a35-85c6-0940ab761791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_72a851ac-5cb8-41a1-aa88-b6a60c56a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_72a851ac-5cb8-41a1-aa88-b6a60c56a7bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_adf93486-882c-4d37-a5c4-f7186c1cc9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_adf93486-882c-4d37-a5c4-f7186c1cc9f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_d35feeb6-1831-4433-8da0-4a1fa793b150" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_d35feeb6-1831-4433-8da0-4a1fa793b150" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_0924570c-5662-41cb-81ac-b18ea9dc99ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_0924570c-5662-41cb-81ac-b18ea9dc99ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_84e1aa11-1f95-467f-b0a6-a495b6d96eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_84e1aa11-1f95-467f-b0a6-a495b6d96eb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1d6b63de-a88d-421b-b05d-da485baa4647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1d6b63de-a88d-421b-b05d-da485baa4647" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_2d18216c-14b3-488f-9b54-1c150b85afdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_2d18216c-14b3-488f-9b54-1c150b85afdd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_434e989f-912a-4589-9952-ca910bbe9d15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_434e989f-912a-4589-9952-ca910bbe9d15" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7ad89b66-cbb2-4424-93cc-322a7494d210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7ad89b66-cbb2-4424-93cc-322a7494d210" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6d4fa81c-8e8f-4189-a0bd-281c4b27c9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6d4fa81c-8e8f-4189-a0bd-281c4b27c9f2" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d3eb5cd-b1d6-4146-8229-f70b8a628360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d3eb5cd-b1d6-4146-8229-f70b8a628360" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_cd0b82d0-d751-4d4f-b31b-bb62f891ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d3eb5cd-b1d6-4146-8229-f70b8a628360" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_cd0b82d0-d751-4d4f-b31b-bb62f891ef13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cd0b82d0-d751-4d4f-b31b-bb62f891ef13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_cd0b82d0-d751-4d4f-b31b-bb62f891ef13" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cd0b82d0-d751-4d4f-b31b-bb62f891ef13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_45797b40-b786-4c31-a5b0-0edc895502ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_cd0b82d0-d751-4d4f-b31b-bb62f891ef13" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_45797b40-b786-4c31-a5b0-0edc895502ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_3ba97d2c-dce5-4704-9bce-8363818abd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_45797b40-b786-4c31-a5b0-0edc895502ac" xlink:to="loc_us-gaap_DomesticPlanMember_3ba97d2c-dce5-4704-9bce-8363818abd6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_efff59f3-2440-4370-8f09-8fbe2a53fbf2" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_3ba97d2c-dce5-4704-9bce-8363818abd6e" xlink:to="loc_country_US_efff59f3-2440-4370-8f09-8fbe2a53fbf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_432ef2e8-9272-425e-857e-68e1d9acd35c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_45797b40-b786-4c31-a5b0-0edc895502ac" xlink:to="loc_us-gaap_ForeignPlanMember_432ef2e8-9272-425e-857e-68e1d9acd35c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_575f08ab-2ba9-48a3-9ec5-f9d372431752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d3eb5cd-b1d6-4146-8229-f70b8a628360" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_575f08ab-2ba9-48a3-9ec5-f9d372431752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_575f08ab-2ba9-48a3-9ec5-f9d372431752_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_575f08ab-2ba9-48a3-9ec5-f9d372431752" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_575f08ab-2ba9-48a3-9ec5-f9d372431752_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7c8ba108-cacf-45c1-8e41-e0164d652530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_575f08ab-2ba9-48a3-9ec5-f9d372431752" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7c8ba108-cacf-45c1-8e41-e0164d652530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c148418a-c380-4851-ade0-1f098b17ad7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7c8ba108-cacf-45c1-8e41-e0164d652530" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c148418a-c380-4851-ade0-1f098b17ad7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_75e193c2-78c7-4c3c-a014-e70e92f83cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_75e193c2-78c7-4c3c-a014-e70e92f83cc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c1974df3-9ffe-438d-ae12-fcf558a211be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c1974df3-9ffe-438d-ae12-fcf558a211be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_f4312bc9-4c10-4d95-9ccb-88f795a32b18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_f4312bc9-4c10-4d95-9ccb-88f795a32b18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_96906dd8-9932-4f0d-9f21-95bd4e39020c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_96906dd8-9932-4f0d-9f21-95bd4e39020c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_a3413f2d-c938-4ee4-8a76-af4f57803e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_a3413f2d-c938-4ee4-8a76-af4f57803e25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_22b70c43-5353-4721-8b08-0e49f65e7fba" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_22b70c43-5353-4721-8b08-0e49f65e7fba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_dad518d0-2e71-4e7e-95d2-ce40ec9eb7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_dad518d0-2e71-4e7e-95d2-ce40ec9eb7c6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_a083cf19-3e33-409f-a00e-22a18ef7ba73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_a083cf19-3e33-409f-a00e-22a18ef7ba73" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_23b986db-173b-47cc-8b3c-1eda28283afd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_23b986db-173b-47cc-8b3c-1eda28283afd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_677d3b2d-40bc-4a8b-bcdc-054c28f3f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_677d3b2d-40bc-4a8b-bcdc-054c28f3f99b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_27d16d30-f128-4124-bd41-45b0f70fbd45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7b8552fd-d2d1-47d9-aea6-c3d250db8d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7b8552fd-d2d1-47d9-aea6-c3d250db8d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_fcc8a614-592b-4574-bb36-4f223713a88d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_fcc8a614-592b-4574-bb36-4f223713a88d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_18ff8ce9-4db0-4573-ac42-0233264ae409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_18ff8ce9-4db0-4573-ac42-0233264ae409" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_59ccca7f-7a92-4753-8ae1-d5b0c0b32397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_59ccca7f-7a92-4753-8ae1-d5b0c0b32397" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_6c5cb2d1-4254-4183-8073-ca30a287f9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_6c5cb2d1-4254-4183-8073-ca30a287f9eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_80145063-9c0b-4056-8dca-bfbc67b0fb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_80145063-9c0b-4056-8dca-bfbc67b0fb2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_fd28e682-1fb9-48ba-948b-fc8909e899a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_fd28e682-1fb9-48ba-948b-fc8909e899a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_dd315bbc-a96d-4cd3-9bf8-7b36aeabec83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_92d2ad5c-3704-4968-b3ff-eb190ef8bbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_3034b77b-8347-4bad-8e53-5af0e55ce0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_a956c265-f515-4c20-a9ea-057383768092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_a956c265-f515-4c20-a9ea-057383768092" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_40dfc978-3f02-43a2-90d8-676e1faf7dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_40dfc978-3f02-43a2-90d8-676e1faf7dd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_b47b2aad-7b95-4061-a681-5b2fb5e9bce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_b47b2aad-7b95-4061-a681-5b2fb5e9bce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_13f2f211-827f-47fc-9b41-12ed0416ff02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_13f2f211-827f-47fc-9b41-12ed0416ff02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_69661414-99d1-4d5d-aed0-bdb06673d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_69661414-99d1-4d5d-aed0-bdb06673d33e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a0c9b6a0-e099-408a-b5d8-366cd628131a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_09c72076-5acd-4b4b-bbeb-8a2491dc3a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_09c72076-5acd-4b4b-bbeb-8a2491dc3a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_23ce0711-afc4-46e5-a549-b99d206dc8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_23ce0711-afc4-46e5-a549-b99d206dc8fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_9a07669f-2911-4b30-baf2-beb85af6edcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_9a07669f-2911-4b30-baf2-beb85af6edcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_fd7cfae9-7f0c-4773-868d-cfa8eb0ab5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_fd7cfae9-7f0c-4773-868d-cfa8eb0ab5e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_c0bfbf67-77f9-47e9-822f-997f6f6af1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_c0bfbf67-77f9-47e9-822f-997f6f6af1f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_efa03736-a25a-468c-9235-e050a0783499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_efa03736-a25a-468c-9235-e050a0783499" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_f24a8749-1fb8-4399-869d-baa3c64e779f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_f24a8749-1fb8-4399-869d-baa3c64e779f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_7d27c683-2a9f-4954-bfb2-3a5546eb83c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_f24a8749-1fb8-4399-869d-baa3c64e779f" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_7d27c683-2a9f-4954-bfb2-3a5546eb83c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_a4859f50-a52b-4ba1-b78d-01a50392757e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_f24a8749-1fb8-4399-869d-baa3c64e779f" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_a4859f50-a52b-4ba1-b78d-01a50392757e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansNetPeriodicCostandAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac727959-9731-45f2-a90c-62d6cea76df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7de28421-9787-4fe0-a024-8f3a4e70eedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac727959-9731-45f2-a90c-62d6cea76df6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7de28421-9787-4fe0-a024-8f3a4e70eedd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_238e1461-93b8-4a7d-a718-a960e81ea9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7de28421-9787-4fe0-a024-8f3a4e70eedd" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_238e1461-93b8-4a7d-a718-a960e81ea9d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_238e1461-93b8-4a7d-a718-a960e81ea9d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_238e1461-93b8-4a7d-a718-a960e81ea9d8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_238e1461-93b8-4a7d-a718-a960e81ea9d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3e076ed7-f3a5-4cda-870c-e15386d946bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_238e1461-93b8-4a7d-a718-a960e81ea9d8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3e076ed7-f3a5-4cda-870c-e15386d946bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f237827f-21d0-4763-8110-a1a08ed80d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3e076ed7-f3a5-4cda-870c-e15386d946bc" xlink:to="loc_us-gaap_DomesticPlanMember_f237827f-21d0-4763-8110-a1a08ed80d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_43ca2c17-b6f4-4d72-a677-8ef20012e68a" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_f237827f-21d0-4763-8110-a1a08ed80d03" xlink:to="loc_country_US_43ca2c17-b6f4-4d72-a677-8ef20012e68a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_86e1510b-fa78-4384-9a2c-98dd2252ed79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3e076ed7-f3a5-4cda-870c-e15386d946bc" xlink:to="loc_us-gaap_ForeignPlanMember_86e1510b-fa78-4384-9a2c-98dd2252ed79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_23c15bd5-61fa-47ce-985b-985e03d60c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7de28421-9787-4fe0-a024-8f3a4e70eedd" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_23c15bd5-61fa-47ce-985b-985e03d60c3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_23c15bd5-61fa-47ce-985b-985e03d60c3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_23c15bd5-61fa-47ce-985b-985e03d60c3c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_23c15bd5-61fa-47ce-985b-985e03d60c3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_383d31e2-9ecc-48e5-b1c1-a8e74fc814fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_23c15bd5-61fa-47ce-985b-985e03d60c3c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_383d31e2-9ecc-48e5-b1c1-a8e74fc814fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1dae0495-3c26-42b1-aee3-2b3eeabc8c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_383d31e2-9ecc-48e5-b1c1-a8e74fc814fd" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1dae0495-3c26-42b1-aee3-2b3eeabc8c9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac727959-9731-45f2-a90c-62d6cea76df6" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_244600e8-09ce-4064-b145-184ac3615c59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_244600e8-09ce-4064-b145-184ac3615c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_f0742131-ace1-40cc-b15d-f6e027f4a593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_f0742131-ace1-40cc-b15d-f6e027f4a593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_0e021864-829d-4d75-ab8a-6201780d7063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_0e021864-829d-4d75-ab8a-6201780d7063" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9de98442-a2f6-4d94-b479-bcbf164163a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9de98442-a2f6-4d94-b479-bcbf164163a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2937cea1-07a3-42ca-b855-1994bf43a8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2937cea1-07a3-42ca-b855-1994bf43a8a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_f94e20a9-ff4b-4b08-9e42-109dd7423e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_f94e20a9-ff4b-4b08-9e42-109dd7423e83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_1a46c6da-37f1-4e6f-a9d0-464af73c6f33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_1a46c6da-37f1-4e6f-a9d0-464af73c6f33" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44a4fd15-ef82-4901-a258-2c61c497c5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44a4fd15-ef82-4901-a258-2c61c497c5c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac727959-9731-45f2-a90c-62d6cea76df6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_8d79923c-5a7a-45e7-af0a-beed80094d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_8d79923c-5a7a-45e7-af0a-beed80094d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_36383b70-e151-432c-a71c-b25dd65ed3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_36383b70-e151-432c-a71c-b25dd65ed3c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8ce916c7-02f6-4730-a6e7-3ca44cb4d0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8ce916c7-02f6-4730-a6e7-3ca44cb4d0c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_456249ca-8856-4a3f-85ae-abf24519dce2" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_456249ca-8856-4a3f-85ae-abf24519dce2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_03b07ee3-dbb4-4b93-87a2-4d6c16ee9cba" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_03b07ee3-dbb4-4b93-87a2-4d6c16ee9cba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_8442b76d-7bc0-4642-82a3-8e65ab860657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_8442b76d-7bc0-4642-82a3-8e65ab860657" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_8b8f1173-e215-4b24-a00a-24cc95f8c211" xlink:href="mdt-20240426.xsd#mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_8b8f1173-e215-4b24-a00a-24cc95f8c211" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_854c7c9d-3337-4e04-8221-0f7f31af8ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_854c7c9d-3337-4e04-8221-0f7f31af8ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_854c7c9d-3337-4e04-8221-0f7f31af8ee1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_854c7c9d-3337-4e04-8221-0f7f31af8ee1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_854c7c9d-3337-4e04-8221-0f7f31af8ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_84f18cf9-44a6-4017-b2b8-746218cf7809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_854c7c9d-3337-4e04-8221-0f7f31af8ee1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_84f18cf9-44a6-4017-b2b8-746218cf7809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_eb214279-d60d-491b-a5b8-9a8e3a8825cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_84f18cf9-44a6-4017-b2b8-746218cf7809" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_eb214279-d60d-491b-a5b8-9a8e3a8825cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb80256-64ee-4223-aa7e-d9ccdfe225bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb80256-64ee-4223-aa7e-d9ccdfe225bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5fb80256-64ee-4223-aa7e-d9ccdfe225bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb80256-64ee-4223-aa7e-d9ccdfe225bb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5fb80256-64ee-4223-aa7e-d9ccdfe225bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_371d02d9-6456-4da7-b9e3-6253f68c96c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb80256-64ee-4223-aa7e-d9ccdfe225bb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_371d02d9-6456-4da7-b9e3-6253f68c96c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_8fdad39c-e71b-4dd4-b639-93c4cd88083c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_371d02d9-6456-4da7-b9e3-6253f68c96c6" xlink:to="loc_us-gaap_DomesticPlanMember_8fdad39c-e71b-4dd4-b639-93c4cd88083c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_8bc77574-e537-423a-a17e-8a1ed14a083f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_8fdad39c-e71b-4dd4-b639-93c4cd88083c" xlink:to="loc_country_US_8bc77574-e537-423a-a17e-8a1ed14a083f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_26fa1c01-7c58-4697-9e62-c4f3f91c5634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_371d02d9-6456-4da7-b9e3-6253f68c96c6" xlink:to="loc_us-gaap_ForeignPlanMember_26fa1c01-7c58-4697-9e62-c4f3f91c5634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a5684a4-2706-4458-9f6b-6b5f27636714" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:to="loc_srt_RangeAxis_0a5684a4-2706-4458-9f6b-6b5f27636714" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a5684a4-2706-4458-9f6b-6b5f27636714_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0a5684a4-2706-4458-9f6b-6b5f27636714" xlink:to="loc_srt_RangeMember_0a5684a4-2706-4458-9f6b-6b5f27636714_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d8c200c-83aa-405e-9f2a-cb2045248dc3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0a5684a4-2706-4458-9f6b-6b5f27636714" xlink:to="loc_srt_RangeMember_0d8c200c-83aa-405e-9f2a-cb2045248dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0d22e148-8c6a-4af9-95f1-61584dc73c36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d8c200c-83aa-405e-9f2a-cb2045248dc3" xlink:to="loc_srt_MinimumMember_0d22e148-8c6a-4af9-95f1-61584dc73c36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2759e471-7361-4a8f-b0ac-d5b1b58eded8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d8c200c-83aa-405e-9f2a-cb2045248dc3" xlink:to="loc_srt_MaximumMember_2759e471-7361-4a8f-b0ac-d5b1b58eded8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6c4171ff-a6c0-4560-9c60-67076570406c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6c4171ff-a6c0-4560-9c60-67076570406c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_6c4171ff-a6c0-4560-9c60-67076570406c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6c4171ff-a6c0-4560-9c60-67076570406c" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_6c4171ff-a6c0-4560-9c60-67076570406c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6c4171ff-a6c0-4560-9c60-67076570406c" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_e34221b5-ed04-4f72-bdce-9583456fed39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_e34221b5-ed04-4f72-bdce-9583456fed39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_7102d53a-33b5-460a-8c4c-3aca6a4ffb87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_7102d53a-33b5-460a-8c4c-3aca6a4ffb87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember_429123fc-8522-4289-b5b9-f2d832ad6f68" xlink:href="mdt-20240426.xsd#mdt_OtherPlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:to="loc_mdt_OtherPlanAssetsMember_429123fc-8522-4289-b5b9-f2d832ad6f68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ea3274da-023c-4511-9f2d-15c80d027009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ea3274da-023c-4511-9f2d-15c80d027009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3e0b5a90-810c-4819-b863-6ec6167f04f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ea3274da-023c-4511-9f2d-15c80d027009" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3e0b5a90-810c-4819-b863-6ec6167f04f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_52dd77c4-e316-4e4a-9fc4-43254b85da94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ea3274da-023c-4511-9f2d-15c80d027009" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_52dd77c4-e316-4e4a-9fc4-43254b85da94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_703a05d0-a0e9-4249-a5e3-f4f0d2fb656c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_703a05d0-a0e9-4249-a5e3-f4f0d2fb656c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_a0ab533c-ff13-4841-8b6d-72e7b7219eb4" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_a0ab533c-ff13-4841-8b6d-72e7b7219eb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_e8775f4d-db7c-4c28-b1da-e9a64661296c" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_e8775f4d-db7c-4c28-b1da-e9a64661296c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_bdf3d32a-4831-4e3e-83df-7882e719a453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_bdf3d32a-4831-4e3e-83df-7882e719a453" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_d5d8b383-9b39-4f2a-bd1d-0006ac45923e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_d5d8b383-9b39-4f2a-bd1d-0006ac45923e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_fd24c63f-c8ee-45e9-8c07-fe66a76f973e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_fd24c63f-c8ee-45e9-8c07-fe66a76f973e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_c8a45680-9976-4b9b-b244-7d60b54dfc61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_fd24c63f-c8ee-45e9-8c07-fe66a76f973e" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_c8a45680-9976-4b9b-b244-7d60b54dfc61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_16ac26b9-0bce-4566-9438-b0bff8e0306e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_fd24c63f-c8ee-45e9-8c07-fe66a76f973e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_16ac26b9-0bce-4566-9438-b0bff8e0306e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a8b8eaf4-0333-41b2-a49c-b2af87479791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a8b8eaf4-0333-41b2-a49c-b2af87479791" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cd3f080d-191f-4f6a-9eeb-36c33ef81730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cd3f080d-191f-4f6a-9eeb-36c33ef81730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cd3f080d-191f-4f6a-9eeb-36c33ef81730_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cd3f080d-191f-4f6a-9eeb-36c33ef81730" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cd3f080d-191f-4f6a-9eeb-36c33ef81730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2055f775-dce8-4bae-8379-551aeb5cdd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cd3f080d-191f-4f6a-9eeb-36c33ef81730" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2055f775-dce8-4bae-8379-551aeb5cdd76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_aa7379f8-8c60-4cf4-9f08-de2d5e965fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2055f775-dce8-4bae-8379-551aeb5cdd76" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_aa7379f8-8c60-4cf4-9f08-de2d5e965fe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_1555b3f8-d265-424d-93c0-9c589458571a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_1555b3f8-d265-424d-93c0-9c589458571a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1555b3f8-d265-424d-93c0-9c589458571a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1555b3f8-d265-424d-93c0-9c589458571a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1555b3f8-d265-424d-93c0-9c589458571a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3ca436b0-78aa-4c44-9e10-e69d096a596e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1555b3f8-d265-424d-93c0-9c589458571a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3ca436b0-78aa-4c44-9e10-e69d096a596e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_4ef091a6-3986-4639-8767-28dcfe96b4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3ca436b0-78aa-4c44-9e10-e69d096a596e" xlink:to="loc_us-gaap_DomesticPlanMember_4ef091a6-3986-4639-8767-28dcfe96b4e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d96309e3-fc83-4e1e-b2c1-7cad9d7eacc0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_4ef091a6-3986-4639-8767-28dcfe96b4e4" xlink:to="loc_country_US_d96309e3-fc83-4e1e-b2c1-7cad9d7eacc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d50bf2dd-8857-4337-bf8d-601f54b3c440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3ca436b0-78aa-4c44-9e10-e69d096a596e" xlink:to="loc_us-gaap_ForeignPlanMember_d50bf2dd-8857-4337-bf8d-601f54b3c440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b2afdcc8-0476-4adb-9119-a0b9d468bd75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b2afdcc8-0476-4adb-9119-a0b9d468bd75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b2afdcc8-0476-4adb-9119-a0b9d468bd75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b2afdcc8-0476-4adb-9119-a0b9d468bd75" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b2afdcc8-0476-4adb-9119-a0b9d468bd75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b2afdcc8-0476-4adb-9119-a0b9d468bd75" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_996d4874-47d3-4a4b-8fd2-68a58a918371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_996d4874-47d3-4a4b-8fd2-68a58a918371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_cbb9bfdb-ae5f-4e64-b0ad-0af6e472daa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_us-gaap_MutualFundMember_cbb9bfdb-ae5f-4e64-b0ad-0af6e472daa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_1a05ebd4-ae3e-4cf6-b25e-0b4ba4fadf20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_us-gaap_EquityFundsMember_1a05ebd4-ae3e-4cf6-b25e-0b4ba4fadf20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_5cfc5ed9-af15-447c-baa4-e0af5e027dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_us-gaap_FixedIncomeFundsMember_5cfc5ed9-af15-447c-baa4-e0af5e027dc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember_b1d04b12-774f-4699-9293-c984a059be2e" xlink:href="mdt-20240426.xsd#mdt_PartnershipUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_mdt_PartnershipUnitsMember_b1d04b12-774f-4699-9293-c984a059be2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RegisteredInvestmentCompanyMember_17fca39c-7696-4fc7-9295-bdb04903e74c" xlink:href="mdt-20240426.xsd#mdt_RegisteredInvestmentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_mdt_RegisteredInvestmentCompanyMember_17fca39c-7696-4fc7-9295-bdb04903e74c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_InsuranceContractMember_e6013d06-4934-483e-8ecb-c927d9150c53" xlink:href="mdt-20240426.xsd#mdt_InsuranceContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_mdt_InsuranceContractMember_e6013d06-4934-483e-8ecb-c927d9150c53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_387a185a-a9e9-4433-a3d4-a59e9058adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_387a185a-a9e9-4433-a3d4-a59e9058adb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_387a185a-a9e9-4433-a3d4-a59e9058adb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_387a185a-a9e9-4433-a3d4-a59e9058adb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_387a185a-a9e9-4433-a3d4-a59e9058adb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_387a185a-a9e9-4433-a3d4-a59e9058adb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8d2d4336-76a1-4aee-b379-5c9a0a070f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8d2d4336-76a1-4aee-b379-5c9a0a070f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e2a58461-ced7-4241-9573-d036f2e6e6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e2a58461-ced7-4241-9573-d036f2e6e6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4a0f31fa-f822-4531-92b2-538427d139c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4a0f31fa-f822-4531-92b2-538427d139c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_06a34d59-ff60-477e-ad55-3e4b56598890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_06a34d59-ff60-477e-ad55-3e4b56598890" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0e0957c3-cca8-413a-86b2-307f5243e213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0e0957c3-cca8-413a-86b2-307f5243e213" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0e0957c3-cca8-413a-86b2-307f5243e213_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0e0957c3-cca8-413a-86b2-307f5243e213" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0e0957c3-cca8-413a-86b2-307f5243e213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81a6aab9-a3ea-4bf2-b7db-97accfa07824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0e0957c3-cca8-413a-86b2-307f5243e213" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81a6aab9-a3ea-4bf2-b7db-97accfa07824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember_213ff565-f58b-42ec-b4fd-08550d361dd7" xlink:href="mdt-20240426.xsd#mdt_PartnershipUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81a6aab9-a3ea-4bf2-b7db-97accfa07824" xlink:to="loc_mdt_PartnershipUnitsMember_213ff565-f58b-42ec-b4fd-08550d361dd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cf0745e7-b1ca-43c6-b6d3-0606b3a1b3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a8b8eaf4-0333-41b2-a49c-b2af87479791" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cf0745e7-b1ca-43c6-b6d3-0606b3a1b3d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a8b8eaf4-0333-41b2-a49c-b2af87479791" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_784205de-b7ef-476f-90a9-759ea0525fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_784205de-b7ef-476f-90a9-759ea0525fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_f3cc774e-8d5a-4edb-babf-0c9a1f2b3e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_f3cc774e-8d5a-4edb-babf-0c9a1f2b3e20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_f836ad99-0a2c-4597-9eb6-6d4809b7ae47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_f836ad99-0a2c-4597-9eb6-6d4809b7ae47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_b8b9805e-a44f-478b-be7c-4266aa9f56f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_b8b9805e-a44f-478b-be7c-4266aa9f56f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_e5132c7a-2216-4e0b-8e26-3a05d9f4e6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansFutureBenefitPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_01b51995-6128-4a8c-b75d-354452191f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a597b48-2fac-45fb-8caa-a0dd392ab68c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_01b51995-6128-4a8c-b75d-354452191f6c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a597b48-2fac-45fb-8caa-a0dd392ab68c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2440fab7-f208-47cd-8cda-d8769b7dc109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a597b48-2fac-45fb-8caa-a0dd392ab68c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2440fab7-f208-47cd-8cda-d8769b7dc109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2440fab7-f208-47cd-8cda-d8769b7dc109_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2440fab7-f208-47cd-8cda-d8769b7dc109" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2440fab7-f208-47cd-8cda-d8769b7dc109_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_722d0bc0-6c27-48c8-8a95-1f7f2466e161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2440fab7-f208-47cd-8cda-d8769b7dc109" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_722d0bc0-6c27-48c8-8a95-1f7f2466e161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f3eb64a5-99b2-4196-bded-0299caeeff87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_722d0bc0-6c27-48c8-8a95-1f7f2466e161" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f3eb64a5-99b2-4196-bded-0299caeeff87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_579303ab-2767-4654-a43c-a07e819578b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a597b48-2fac-45fb-8caa-a0dd392ab68c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_579303ab-2767-4654-a43c-a07e819578b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_579303ab-2767-4654-a43c-a07e819578b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_579303ab-2767-4654-a43c-a07e819578b0" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_579303ab-2767-4654-a43c-a07e819578b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ee17ec2b-5377-4889-8071-ee86db79b8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_579303ab-2767-4654-a43c-a07e819578b0" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ee17ec2b-5377-4889-8071-ee86db79b8d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e90b7c37-85fc-4b68-ad07-ad47b45bfb40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ee17ec2b-5377-4889-8071-ee86db79b8d4" xlink:to="loc_us-gaap_DomesticPlanMember_e90b7c37-85fc-4b68-ad07-ad47b45bfb40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1149fe5a-44f0-45e9-a5c3-21287f0f0f04" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_e90b7c37-85fc-4b68-ad07-ad47b45bfb40" xlink:to="loc_country_US_1149fe5a-44f0-45e9-a5c3-21287f0f0f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ec95ac24-4822-42a7-80a8-96d3817249c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ee17ec2b-5377-4889-8071-ee86db79b8d4" xlink:to="loc_us-gaap_ForeignPlanMember_ec95ac24-4822-42a7-80a8-96d3817249c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_01b51995-6128-4a8c-b75d-354452191f6c" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_540d8777-c26e-4d18-b0b6-d6605eb86bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_540d8777-c26e-4d18-b0b6-d6605eb86bd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_dbf242d0-21a6-4daa-8abe-43a4b0718951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_dbf242d0-21a6-4daa-8abe-43a4b0718951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_fac1b8ba-36a3-40b2-99ee-da68a7b8acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_fac1b8ba-36a3-40b2-99ee-da68a7b8acb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_bf575b67-9940-441a-98f3-3db39d9b5cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_bf575b67-9940-441a-98f3-3db39d9b5cac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_8b6b7055-bdf4-4af9-9b81-d23420b6fd35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_8b6b7055-bdf4-4af9-9b81-d23420b6fd35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_50b5465c-f404-4cc0-9a15-0fe84c991607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_50b5465c-f404-4cc0-9a15-0fe84c991607" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c51619f8-d2d4-4e7c-851d-db0bc49360f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c51619f8-d2d4-4e7c-851d-db0bc49360f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9c286be8-a3a4-4dae-a6e7-f7d60eca3016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c51619f8-d2d4-4e7c-851d-db0bc49360f9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9c286be8-a3a4-4dae-a6e7-f7d60eca3016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c286be8-a3a4-4dae-a6e7-f7d60eca3016_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c286be8-a3a4-4dae-a6e7-f7d60eca3016" xlink:to="loc_us-gaap_EquityComponentDomain_9c286be8-a3a4-4dae-a6e7-f7d60eca3016_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b66dad6-f67e-4dea-8ef5-8181db9490db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c286be8-a3a4-4dae-a6e7-f7d60eca3016" xlink:to="loc_us-gaap_EquityComponentDomain_6b66dad6-f67e-4dea-8ef5-8181db9490db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b66dad6-f67e-4dea-8ef5-8181db9490db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cc8ce864-64f4-4ca3-9c59-afd03b3842fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cc8ce864-64f4-4ca3-9c59-afd03b3842fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_45ff56bf-10d3-474e-a716-7c434c2848fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_45ff56bf-10d3-474e-a716-7c434c2848fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_b3a360bf-a37f-4e8c-a193-1d84d1c3f652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_b3a360bf-a37f-4e8c-a193-1d84d1c3f652" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_63b5ae6e-510a-4b49-9df0-6118fb71be73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_63b5ae6e-510a-4b49-9df0-6118fb71be73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_08c4838a-f859-422c-90ca-3c73157bcded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_08c4838a-f859-422c-90ca-3c73157bcded" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e7dcb6c-59a2-4b10-ae8f-f0e54f9dc380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e7dcb6c-59a2-4b10-ae8f-f0e54f9dc380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6f0fccb8-89d1-45e1-b786-e8463ff25b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6f0fccb8-89d1-45e1-b786-e8463ff25b62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5e33e328-f42f-48e7-b35c-a358be4c6171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5e33e328-f42f-48e7-b35c-a358be4c6171" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_09c529fb-e6d7-4dce-ae62-15bb4fd70ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_09c529fb-e6d7-4dce-ae62-15bb4fd70ae9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a0311e0-1463-4a62-b957-990681d80f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_037c5d55-556f-4f6f-afc1-a4b1c03964e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_037c5d55-556f-4f6f-afc1-a4b1c03964e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_2ea16ecb-d7ff-4d2e-a2c4-dab89ddd08ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_2ea16ecb-d7ff-4d2e-a2c4-dab89ddd08ad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_775fa926-07b5-4b82-b7bc-6704d9886c5d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:to="loc_srt_LitigationCaseAxis_775fa926-07b5-4b82-b7bc-6704d9886c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_775fa926-07b5-4b82-b7bc-6704d9886c5d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_775fa926-07b5-4b82-b7bc-6704d9886c5d" xlink:to="loc_srt_LitigationCaseTypeDomain_775fa926-07b5-4b82-b7bc-6704d9886c5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_775fa926-07b5-4b82-b7bc-6704d9886c5d" xlink:to="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_HerniaMeshLitigationMember_425d66aa-0d1c-4603-8c1d-166dd4faaf12" xlink:href="mdt-20240426.xsd#mdt_HerniaMeshLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:to="loc_mdt_HerniaMeshLitigationMember_425d66aa-0d1c-4603-8c1d-166dd4faaf12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ColibriMember_a86aaf5e-9fec-448a-8666-240b839589a2" xlink:href="mdt-20240426.xsd#mdt_ColibriMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:to="loc_mdt_ColibriMember_a86aaf5e-9fec-448a-8666-240b839589a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesPumpRetainerRingLitigationMember_94507204-2ef8-4777-a3c8-cfe2a576c701" xlink:href="mdt-20240426.xsd#mdt_DiabetesPumpRetainerRingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:to="loc_mdt_DiabetesPumpRetainerRingLitigationMember_94507204-2ef8-4777-a3c8-cfe2a576c701" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_51203797-b8e6-4f15-9eb9-ea0253e4f82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:to="loc_us-gaap_LitigationStatusAxis_51203797-b8e6-4f15-9eb9-ea0253e4f82d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_51203797-b8e6-4f15-9eb9-ea0253e4f82d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_51203797-b8e6-4f15-9eb9-ea0253e4f82d" xlink:to="loc_us-gaap_LitigationStatusDomain_51203797-b8e6-4f15-9eb9-ea0253e4f82d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_25311fc7-ea95-4c64-b0c0-5df4a164ced1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_51203797-b8e6-4f15-9eb9-ea0253e4f82d" xlink:to="loc_us-gaap_LitigationStatusDomain_25311fc7-ea95-4c64-b0c0-5df4a164ced1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_cd318884-fb0b-475c-8413-ee47975bb2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_25311fc7-ea95-4c64-b0c0-5df4a164ced1" xlink:to="loc_us-gaap_PendingLitigationMember_cd318884-fb0b-475c-8413-ee47975bb2dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a2a2a21b-fd6b-45e3-bc3a-512bd219919b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:to="loc_srt_StatementGeographicalAxis_a2a2a21b-fd6b-45e3-bc3a-512bd219919b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a2a2a21b-fd6b-45e3-bc3a-512bd219919b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a2a2a21b-fd6b-45e3-bc3a-512bd219919b" xlink:to="loc_srt_SegmentGeographicalDomain_a2a2a21b-fd6b-45e3-bc3a-512bd219919b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a2a2a21b-fd6b-45e3-bc3a-512bd219919b" xlink:to="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_0b330aaf-3492-48e6-8514-f00619a51a07" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:to="loc_stpr_MA_0b330aaf-3492-48e6-8514-f00619a51a07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN_96601eb4-c17e-46a2-a018-919808643144" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:to="loc_stpr_MN_96601eb4-c17e-46a2-a018-919808643144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_65da1990-2806-42c0-b6c7-bb4ec2de389e" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:to="loc_stpr_CA_65da1990-2806-42c0-b6c7-bb4ec2de389e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9d8b8a39-6f27-4266-96fe-9d397a131ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9d8b8a39-6f27-4266-96fe-9d397a131ddf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9d8b8a39-6f27-4266-96fe-9d397a131ddf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9d8b8a39-6f27-4266-96fe-9d397a131ddf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9d8b8a39-6f27-4266-96fe-9d397a131ddf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4bce0938-ad7e-4702-aebe-d3d717f2db8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9d8b8a39-6f27-4266-96fe-9d397a131ddf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4bce0938-ad7e-4702-aebe-d3d717f2db8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_781a5f5d-3550-4bd7-ac68-04ea73f358dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4bce0938-ad7e-4702-aebe-d3d717f2db8b" xlink:to="loc_us-gaap_SubsequentEventMember_781a5f5d-3550-4bd7-ac68-04ea73f358dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_96a123fd-65c0-4589-ac1a-0312e01a6932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_96a123fd-65c0-4589-ac1a-0312e01a6932" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e6640316-ba0a-4fb9-a552-224ddb9cbe55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e6640316-ba0a-4fb9-a552-224ddb9cbe55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7accf7b0-8346-475e-9e4f-bf3c9c03c131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7accf7b0-8346-475e-9e4f-bf3c9c03c131" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_702ec6fe-5ed1-4197-80ec-59a63a38ff33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_702ec6fe-5ed1-4197-80ec-59a63a38ff33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_155de917-eb3f-486d-86cb-9321bd7eee17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_155de917-eb3f-486d-86cb-9321bd7eee17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LossContingencyLawsuitsNumber_f4b67b98-f42f-4dcc-9f6d-109fdb916742" xlink:href="mdt-20240426.xsd#mdt_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_mdt_LossContingencyLawsuitsNumber_f4b67b98-f42f-4dcc-9f6d-109fdb916742" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93514a0-066d-4dab-801f-da29e7445643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93514a0-066d-4dab-801f-da29e7445643" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_605db78f-2bad-48ea-8fe1-8469d8b53cb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93514a0-066d-4dab-801f-da29e7445643" xlink:to="loc_srt_ConsolidationItemsAxis_605db78f-2bad-48ea-8fe1-8469d8b53cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_605db78f-2bad-48ea-8fe1-8469d8b53cb2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_605db78f-2bad-48ea-8fe1-8469d8b53cb2" xlink:to="loc_srt_ConsolidationItemsDomain_605db78f-2bad-48ea-8fe1-8469d8b53cb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_afff4b56-3058-4729-b631-917be874c748" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_605db78f-2bad-48ea-8fe1-8469d8b53cb2" xlink:to="loc_srt_ConsolidationItemsDomain_afff4b56-3058-4729-b631-917be874c748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_20a88ca3-e6ba-42fd-873a-0e90d4149817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_afff4b56-3058-4729-b631-917be874c748" xlink:to="loc_us-gaap_OperatingSegmentsMember_20a88ca3-e6ba-42fd-873a-0e90d4149817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_5210f520-8bba-4fec-857c-5b71f944d7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_afff4b56-3058-4729-b631-917be874c748" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_5210f520-8bba-4fec-857c-5b71f944d7cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c7fdc189-0e3e-40bd-a2c9-8f4a6a45dc77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93514a0-066d-4dab-801f-da29e7445643" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c7fdc189-0e3e-40bd-a2c9-8f4a6a45dc77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7fdc189-0e3e-40bd-a2c9-8f4a6a45dc77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c7fdc189-0e3e-40bd-a2c9-8f4a6a45dc77" xlink:to="loc_us-gaap_SegmentDomain_c7fdc189-0e3e-40bd-a2c9-8f4a6a45dc77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c7fdc189-0e3e-40bd-a2c9-8f4a6a45dc77" xlink:to="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_608df336-e5cc-4f95-87ac-5e2ddeea2601" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_mdt_CardiovascularMember_608df336-e5cc-4f95-87ac-5e2ddeea2601" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_2d71becd-ac07-495a-9487-5c8612a4f294" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_mdt_NeuroscienceGroupMember_2d71becd-ac07-495a-9487-5c8612a4f294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_97825e76-cfa9-422a-a57d-5b11071f8f18" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_mdt_MedicalSurgicalMember_97825e76-cfa9-422a-a57d-5b11071f8f18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_db89ed8e-4843-4428-98a1-2e755cd90b53" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_mdt_DiabetesGroupMember_db89ed8e-4843-4428-98a1-2e755cd90b53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_cb121412-6fb9-4f67-975a-cffc6f37ed3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_us-gaap_AllOtherSegmentsMember_cb121412-6fb9-4f67-975a-cffc6f37ed3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_78539b78-b333-4df1-9f82-ef5765b538ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_OperatingIncomeLoss_78539b78-b333-4df1-9f82-ef5765b538ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CorporateOverhead_1c1b47b0-8821-4870-ac3c-2103b19d965f" xlink:href="mdt-20240426.xsd#mdt_CorporateOverhead"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_CorporateOverhead_1c1b47b0-8821-4870-ac3c-2103b19d965f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1bc3f9a0-94c3-4725-bf35-d4aaec2ab347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1bc3f9a0-94c3-4725-bf35-d4aaec2ab347" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_aead40fb-06f1-4028-920e-917fc340a0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_aead40fb-06f1-4028-920e-917fc340a0dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1ad24e3b-542c-4df6-92c7-f7a7fdf2eaba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1ad24e3b-542c-4df6-92c7-f7a7fdf2eaba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e6853f76-3832-4e06-b3c3-b6e35fe7f235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_ShareBasedCompensation_e6853f76-3832-4e06-b3c3-b6e35fe7f235" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CentralizedDistributionCosts_1ac99d7e-76c3-4ad2-b03f-e37987d2774b" xlink:href="mdt-20240426.xsd#mdt_CentralizedDistributionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_CentralizedDistributionCosts_1ac99d7e-76c3-4ad2-b03f-e37987d2774b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyCosts_ebab21b1-5bdf-4733-ab5e-9b23117a55af" xlink:href="mdt-20240426.xsd#mdt_ForeignCurrencyCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_ForeignCurrencyCosts_ebab21b1-5bdf-4733-ab5e-9b23117a55af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3a6bd0a1-e1e0-40af-bf89-a358ade4dc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_RestructuringCharges_3a6bd0a1-e1e0-40af-bf89-a358ade4dc4f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_299b58fa-8573-4dc6-9fb1-c5b188822f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_299b58fa-8573-4dc6-9fb1-c5b188822f54" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_97165ae5-5eb6-45a1-b82f-849a7a365d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_97165ae5-5eb6-45a1-b82f-849a7a365d8b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ImpairmentofInProcessResearchandDevelopment_e99df122-b9fb-4e60-8155-d15e6d30646d" xlink:href="mdt-20240426.xsd#mdt_ImpairmentofInProcessResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_ImpairmentofInProcessResearchandDevelopment_e99df122-b9fb-4e60-8155-d15e6d30646d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalDeviceRegulations_1e12d8c3-7c33-4173-b794-488916e37c26" xlink:href="mdt-20240426.xsd#mdt_MedicalDeviceRegulations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_MedicalDeviceRegulations_1e12d8c3-7c33-4173-b794-488916e37c26" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialChargesGains_4920da8e-6cb4-4995-8912-f112f355177e" xlink:href="mdt-20240426.xsd#mdt_SpecialChargesGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_SpecialChargesGains_4920da8e-6cb4-4995-8912-f112f355177e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d31faaa9-7210-4606-bcb1-f3bf0c531f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d31faaa9-7210-4606-bcb1-f3bf0c531f34" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_afbe4a64-995d-4dc8-9fb6-55ad139dd1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_25795aaa-2ef7-44dc-bec6-f0b115ea7f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_afbe4a64-995d-4dc8-9fb6-55ad139dd1da" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_25795aaa-2ef7-44dc-bec6-f0b115ea7f27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_46b9e770-190e-408e-9f23-73ca13e70951" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_25795aaa-2ef7-44dc-bec6-f0b115ea7f27" xlink:to="loc_srt_ConsolidationItemsAxis_46b9e770-190e-408e-9f23-73ca13e70951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_46b9e770-190e-408e-9f23-73ca13e70951_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_46b9e770-190e-408e-9f23-73ca13e70951" xlink:to="loc_srt_ConsolidationItemsDomain_46b9e770-190e-408e-9f23-73ca13e70951_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c4457b57-ef5b-4e1f-8110-df31cbb70d0e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_46b9e770-190e-408e-9f23-73ca13e70951" xlink:to="loc_srt_ConsolidationItemsDomain_c4457b57-ef5b-4e1f-8110-df31cbb70d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_08a2c33d-81e8-4ac4-a89a-5c49adbc587b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c4457b57-ef5b-4e1f-8110-df31cbb70d0e" xlink:to="loc_us-gaap_OperatingSegmentsMember_08a2c33d-81e8-4ac4-a89a-5c49adbc587b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_1e02e3e9-a93a-4d85-9e08-c91a83c0d766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c4457b57-ef5b-4e1f-8110-df31cbb70d0e" xlink:to="loc_us-gaap_CorporateNonSegmentMember_1e02e3e9-a93a-4d85-9e08-c91a83c0d766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5ff0fd88-df33-4fb7-9c8f-e966bfda75d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_25795aaa-2ef7-44dc-bec6-f0b115ea7f27" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5ff0fd88-df33-4fb7-9c8f-e966bfda75d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5ff0fd88-df33-4fb7-9c8f-e966bfda75d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5ff0fd88-df33-4fb7-9c8f-e966bfda75d5" xlink:to="loc_us-gaap_SegmentDomain_5ff0fd88-df33-4fb7-9c8f-e966bfda75d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5ff0fd88-df33-4fb7-9c8f-e966bfda75d5" xlink:to="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_50a2f695-39a5-4860-85cf-505b8cbf1708" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_mdt_CardiovascularMember_50a2f695-39a5-4860-85cf-505b8cbf1708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_6127eebd-eb8b-47a1-9c0c-d2e1571de96b" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_mdt_NeuroscienceGroupMember_6127eebd-eb8b-47a1-9c0c-d2e1571de96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_448dd5e5-6765-44e3-bb24-7c689ed1be29" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_mdt_MedicalSurgicalMember_448dd5e5-6765-44e3-bb24-7c689ed1be29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_25142f52-3cef-4cbc-9351-b848093afbf6" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_mdt_DiabetesGroupMember_25142f52-3cef-4cbc-9351-b848093afbf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_6d8e9f7c-8cbd-415c-b66c-fb16b3c05078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_us-gaap_AllOtherSegmentsMember_6d8e9f7c-8cbd-415c-b66c-fb16b3c05078" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_45b17f15-7a85-4142-9256-abf1d4e51211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_afbe4a64-995d-4dc8-9fb6-55ad139dd1da" xlink:to="loc_us-gaap_Assets_45b17f15-7a85-4142-9256-abf1d4e51211" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5c253191-d3f2-4c3a-aa61-fde5448118cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_afbe4a64-995d-4dc8-9fb6-55ad139dd1da" xlink:to="loc_us-gaap_Depreciation_5c253191-d3f2-4c3a-aa61-fde5448118cf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4f8a6fd-e9de-415e-a3e3-79748d900b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c572f8ed-03af-4db8-86ac-8632467e4b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4f8a6fd-e9de-415e-a3e3-79748d900b85" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c572f8ed-03af-4db8-86ac-8632467e4b26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_20a4d8d1-4626-422a-8273-39bc680e5795" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c572f8ed-03af-4db8-86ac-8632467e4b26" xlink:to="loc_srt_StatementGeographicalAxis_20a4d8d1-4626-422a-8273-39bc680e5795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_20a4d8d1-4626-422a-8273-39bc680e5795_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_20a4d8d1-4626-422a-8273-39bc680e5795" xlink:to="loc_srt_SegmentGeographicalDomain_20a4d8d1-4626-422a-8273-39bc680e5795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_95b3024b-04c9-4960-bd42-86f4017834f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_20a4d8d1-4626-422a-8273-39bc680e5795" xlink:to="loc_srt_SegmentGeographicalDomain_95b3024b-04c9-4960-bd42-86f4017834f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_20fb0b0c-cd2f-4282-948b-d4c766839d9b" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_95b3024b-04c9-4960-bd42-86f4017834f6" xlink:to="loc_country_IE_20fb0b0c-cd2f-4282-948b-d4c766839d9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingIrelandMember_0f92d7fc-ef1b-4f44-88d0-7a0c4594b011" xlink:href="mdt-20240426.xsd#mdt_TotalOtherCountriesExcludingIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_95b3024b-04c9-4960-bd42-86f4017834f6" xlink:to="loc_mdt_TotalOtherCountriesExcludingIrelandMember_0f92d7fc-ef1b-4f44-88d0-7a0c4594b011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3127efe1-6204-425b-9d32-481c2286f748" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember_0f92d7fc-ef1b-4f44-88d0-7a0c4594b011" xlink:to="loc_country_US_3127efe1-6204-425b-9d32-481c2286f748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_c2f3df98-a7a4-43cb-a3d1-4608544515bb" xlink:href="mdt-20240426.xsd#mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember_0f92d7fc-ef1b-4f44-88d0-7a0c4594b011" xlink:to="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_c2f3df98-a7a4-43cb-a3d1-4608544515bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c86e67c7-07df-4987-ac0e-94082215f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4f8a6fd-e9de-415e-a3e3-79748d900b85" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c86e67c7-07df-4987-ac0e-94082215f0c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9c0df76a-6910-4ca7-abca-d6f9ec4f719f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4f8a6fd-e9de-415e-a3e3-79748d900b85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9c0df76a-6910-4ca7-abca-d6f9ec4f719f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_477d4b87-20b7-4799-a087-c17138c1f2c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_04342f68-fa1a-447b-82f5-22c4c648e13f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_477d4b87-20b7-4799-a087-c17138c1f2c9" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_04342f68-fa1a-447b-82f5-22c4c648e13f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_977fbbba-6cde-42c4-96a7-206029ddbf01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_04342f68-fa1a-447b-82f5-22c4c648e13f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_977fbbba-6cde-42c4-96a7-206029ddbf01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_977fbbba-6cde-42c4-96a7-206029ddbf01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_977fbbba-6cde-42c4-96a7-206029ddbf01" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_977fbbba-6cde-42c4-96a7-206029ddbf01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4379af19-e83c-4474-b2f7-7595f30b29b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_977fbbba-6cde-42c4-96a7-206029ddbf01" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_4379af19-e83c-4474-b2f7-7595f30b29b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_b480f9d6-ca54-44f9-84b8-d6858befe0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4379af19-e83c-4474-b2f7-7595f30b29b7" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_b480f9d6-ca54-44f9-84b8-d6858befe0e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_a884f5fa-8e23-4ee1-9985-b66225cec227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4379af19-e83c-4474-b2f7-7595f30b29b7" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_a884f5fa-8e23-4ee1-9985-b66225cec227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_477d4b87-20b7-4799-a087-c17138c1f2c9" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_cda92da5-083e-4959-999d-c27961c35326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_cda92da5-083e-4959-999d-c27961c35326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_fccc5ca6-5182-4bcd-b962-8125f7568f46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_fccc5ca6-5182-4bcd-b962-8125f7568f46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_f39c2322-5b6f-4d06-a4de-6777c3aa3580" xlink:href="mdt-20240426.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_f39c2322-5b6f-4d06-a4de-6777c3aa3580" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7b95400d-6a77-430b-898b-8757b12af0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7b95400d-6a77-430b-898b-8757b12af0ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_6d2880bc-a05b-404b-97ba-658cdba28d33" xlink:href="mdt-20240426.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_6d2880bc-a05b-404b-97ba-658cdba28d33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6912aa46-7bcc-4b45-a437-383d8975f22b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6912aa46-7bcc-4b45-a437-383d8975f22b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_5f189fdb-7b5a-49a9-8b5f-9aa6fccf93c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_5f189fdb-7b5a-49a9-8b5f-9aa6fccf93c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_41b0b3c1-602a-4130-a30a-5fb8bf817c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>mdt-20240426_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31d25153-b660-4ec0-ab44-7e01aa50312b,g:3d21d99d-9a64-4ef0-a05f-06b24f253785-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20391.50PercentMember_5e22a984-1202-4734-b321-51692735e44e_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20391.50PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.500% Senior Notes due 2039</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20391.50PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20391.50PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2039, 1.50 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20391.50PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20391.50PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2039, 1.50 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20391.50PercentMember" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20391.50PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20391.50PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20391.50PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ad90e8d8-e1d9-43a7-b178-4f97aac3525f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d858c30-e143-464b-a55c-ae58e101dc1d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_30d98497-b68f-4e69-b1e6-e296742acd66_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_63e1aadc-c4d8-4498-b09c-3465d0a0a237_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassified into Income, net investment hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e50b75a-ccdb-48de-b4b8-2b50596e5280_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_bf566bbf-9597-40be-a8cb-be0c271950fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments from short-term borrowings (maturities greater than 90 days)</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_75479bb3-c61f-48b0-a7ab-7704e2c8d6d0_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefit Plan Assumptions</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AdditionalCashInvestment_a01c73e3-c310-4653-9d68-3a8c28f1a922_terseLabel_en-US" xlink:label="lab_mdt_AdditionalCashInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional cash investment</link:label>
    <link:label id="lab_mdt_AdditionalCashInvestment_label_en-US" xlink:label="lab_mdt_AdditionalCashInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Investment</link:label>
    <link:label id="lab_mdt_AdditionalCashInvestment_documentation_en-US" xlink:label="lab_mdt_AdditionalCashInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Cash Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AdditionalCashInvestment" xlink:href="mdt-20240426.xsd#mdt_AdditionalCashInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AdditionalCashInvestment" xlink:to="lab_mdt_AdditionalCashInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_a4964334-81d1-44f7-9da4-f95049c4970a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e5c8108e-b1e1-4469-abe5-69396d44ced4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of the Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f657a9c6-032a-4de4-a771-facabfbb298c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0d6d0efc-aa58-4dd0-97c2-a809eb7ef3da_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_3754754a-d973-4a97-900c-84c5fe9f7ce4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_3807f266-fc0b-4e69-9d17-4fef8acbe4a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign derived intangible income benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, FDII, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_bd4971bb-bfc1-4f61-9791-60d8f288d8a6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_d2199708-82d4-45d1-bd3f-2d88de7f688e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_6fe99157-6a0c-40cc-a850-d7bc5cfa1299_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_1e5e7c00-78a9-41d9-b44b-7b717784da00_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_ed2bc7d1-ea89-45ca-a43f-8bb6fa3f9fcd_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_1600f6c6-8782-4df1-8127-c899d8fb26f1_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal and state benefit on uncertain tax positions</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Federal And State Benefit On Uncertain Tax Positions</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tax effect as of the balance sheet date of the amount of estimated future tax deductions arising from the federal and state benefit on uncertain tax positions, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:to="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due2050Member_a35be8d1-c065-4ac7-96d2-fa32a4462157_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.750 percent thirty-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2050Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2050 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2050Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2050Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due2050Member" xlink:to="lab_mdt_SeniorNotes2019Due2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ee1d4004-2d51-4564-a143-95145e705336_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_40215c26-46c8-4175-8fde-021fabdf2793_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_94e1f5d7-962e-4bac-b1d8-c8763e36f290_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_d1573ce5-3c72-48ee-91f6-c76fefcf339e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4a80d10d-2612-4f55-aa64-71446083ed29_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ffde04e9-1e01-46c9-bfbf-8d988011a129_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_d8452976-fdf1-4766-bea0-77b347d8b3d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographical Region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_e1d78200-d1f3-4a31-a02e-d96dc0d1544c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plans with projected benefit obligations in excess of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_6614668a-2f53-4287-91b8-1cfe87f57e8b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_2a4cf494-4652-4f38-9b99-b889383dbbe8_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aeac6c8c-8bdc-42f3-a21f-9490cdf4f001_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_c3f55484-cc8f-4fc8-9b79-6e3cbf840b7f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible asset indefinite lived excluding goodwill statement of income or comprehensive income extensible enumeration not disclosed flag</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IPRDMember_56192b7a-ed24-4b4e-a4bb-2c83b517b792_terseLabel_en-US" xlink:label="lab_mdt_IPRDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_mdt_IPRDMember_label_en-US" xlink:label="lab_mdt_IPRDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPR&amp;D [Member]</link:label>
    <link:label id="lab_mdt_IPRDMember_documentation_en-US" xlink:label="lab_mdt_IPRDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IPRDMember" xlink:href="mdt-20240426.xsd#mdt_IPRDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IPRDMember" xlink:to="lab_mdt_IPRDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_a99b0857-dc1a-4c18-9b1b-05e0d4c81b84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_adfe2580-d6a4-4dc4-9b53-fd89f1748782_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e0df3822-b08c-497c-8dd7-6fff860e306a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_bcb356a2-c78c-428b-8dae-a3e752379b68_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_6afccd69-c08f-4f10-909f-5fa299a7b5de_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of businesses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_baaa9081-04d4-4925-8a80-a8c5a7c8c16b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired/Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_077ddd4f-6f27-4c32-9a3b-3d68aa9344c8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_dd356e62-5c58-4bdc-bfd3-973f256df8f6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, (Gain) Loss [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_62ab702f-362b-46d7-b6ff-8c9b1ac55ca6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_3a9ac8e0-f041-4f1c-859e-209f453ff61d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (losses) and gains on equity and other investments still held</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_6f928ef2-5e78-488c-931a-b201500be345_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_b73d92b8-f1a2-48f8-94d8-d649371f9060_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss, capital loss, and credit carryforwards</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating and Capital Losses, and Tax Credit Carryforwards</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss, capital loss and tax credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:to="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_6dd6ea34-e679-4f17-875b-65ef66224347_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2f22fba1-7a16-4d88-8e3c-7e327f89ded5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, less allowances and credit losses of $173 and $176, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_9cf34940-5fcd-4c72-967a-076b7a1c4237_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsInterestLimitation_1077857f-359e-430e-8c9d-7d7d5bfd92c1_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest limitation</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsInterestLimitation_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Interest Limitation</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsInterestLimitation_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Interest Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsInterestLimitation" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsInterestLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsInterestLimitation" xlink:to="lab_mdt_DeferredTaxAssetsInterestLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_a658e3a5-1cb5-493e-870d-f3769f415af5_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_6f9166d1-d6fd-4315-b14f-b9aaf92237aa_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_6693462f-26fe-48c1-9f7a-dd573d8e20f2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsLeaseObligations_8dff29a3-f195-42cf-9d6a-9a2d249396c5_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease obligations</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsLeaseObligations_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Obligations</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsLeaseObligations_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsLeaseObligations" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsLeaseObligations" xlink:to="lab_mdt_DeferredTaxAssetsLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_efd58d08-7586-45b9-9a21-2f2b57b8f453_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_966c4057-c90c-4798-b860-eb002057d848_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_92870cb3-c393-437c-9f62-5a5c7a7f8958_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_060af650-5366-421b-b366-553ac53551b4_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3fa41fa3-addf-4f56-be3a-fcf6f39ccb0e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_9531f5b5-be9d-4cc1-8063-15266ff61ee2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial valuation</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_515f3cab-701f-4424-8ede-c0aa74827448_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_d1328c55-6e5b-4222-b601-98e43bdb07e8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2664b171-4252-4725-a68c-1fb160020372_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0819ded2-8b1b-43ab-8177-1c32b76739de_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_da99899c-5eaf-403f-b33e-35ec3b20e2dc_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e7077694-4f60-4dab-8171-8978d285bd4f_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_2fff53ae-a677-4849-8190-37cec3847dd9_terseLabel_en-US" xlink:label="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross interest expense</link:label>
    <link:label id="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_label_en-US" xlink:label="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Interest Income (Expense), Gross</link:label>
    <link:label id="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_documentation_en-US" xlink:label="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Interest Income (Expense), Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:href="mdt-20240426.xsd#mdt_IncomeTaxExaminationInterestIncomeExpenseGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:to="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_a49767a5-1684-49df-ad71-10c555eceac9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_63d07389-157d-4323-bb5c-e8f6c70b8261_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_7df57406-0d20-4b93-9eec-7d277500bb42_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid income taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ded25661-5555-4259-a253-ce17ee4b6db2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_af935932-0f2a-48b0-932b-cd9449abacff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_231aed35-f801-4bef-af63-751dcf1cef18_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_ff4b9b46-bfb4-474f-89f9-4d8d7d20c9af_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RestructuringChargesIncludingAccrualAdjustments_30e5316a-2d1d-4917-bf18-68f833ce2243_terseLabel_en-US" xlink:label="lab_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges</link:label>
    <link:label id="lab_mdt_RestructuringChargesIncludingAccrualAdjustments_label_en-US" xlink:label="lab_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Including Accrual Adjustments</link:label>
    <link:label id="lab_mdt_RestructuringChargesIncludingAccrualAdjustments_documentation_en-US" xlink:label="lab_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Including Accrual Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:href="mdt-20240426.xsd#mdt_RestructuringChargesIncludingAccrualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:to="lab_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_62e4a022-86d0-4a74-9a1c-e73d57bb1ab7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_ac4a778b-6002-4738-a260-68a1ba486118_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_73c699e5-52ad-40d1-b649-aa286adcdcfc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_ab183da0-3e21-4b13-9197-6acda755f8d0_terseLabel_en-US" xlink:label="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental expense related to acceptance of voluntary early retirement packages</link:label>
    <link:label id="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_label_en-US" xlink:label="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:label id="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_documentation_en-US" xlink:label="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:to="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a8ec0ce-c574-44ff-a95c-7a59b70c0b5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_803f1b2a-27ef-42f0-8380-d93a5103d0f3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior service (credit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9d484d2f-bd09-4479-b77d-74d5b7e21257_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c3d1e88e-b80a-4690-89e4-f560be1208fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5fd29b8a-fe6d-45a4-9bd3-4d6dd0fa8094_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_01ec4911-18c7-4dea-9800-ac5fc7e4894c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_HerniaMeshLitigationMember_f24a2ac9-3427-461b-a502-6bc774b95ffe_terseLabel_en-US" xlink:label="lab_mdt_HerniaMeshLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hernia Mesh Litigation</link:label>
    <link:label id="lab_mdt_HerniaMeshLitigationMember_label_en-US" xlink:label="lab_mdt_HerniaMeshLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hernia Mesh Litigation [Member]</link:label>
    <link:label id="lab_mdt_HerniaMeshLitigationMember_documentation_en-US" xlink:label="lab_mdt_HerniaMeshLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hernia Mesh Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_HerniaMeshLitigationMember" xlink:href="mdt-20240426.xsd#mdt_HerniaMeshLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_HerniaMeshLitigationMember" xlink:to="lab_mdt_HerniaMeshLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d8e0d8b9-7e73-42fa-8d82-01b264ba272b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment Balances and Corresponding Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d3051b24-7f54-4aca-89d1-2959719e86bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff9ab7c5-0aeb-4fe2-be38-a0cb134098ed_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_4e7c6cfa-83ed-4017-b28d-94810988d122_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_83ed72b9-9473-41ec-80dc-462e740b2a84_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c3c85908-7604-4e3d-a6ad-b440022770b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_848d919f-fffd-49c7-8e89-3d9f635765f8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5e479414-f55b-4245-b56d-c8dab99798bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_54684991-1363-4dec-80d7-aaa23735ca10_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8aefdeb2-03f8-4eb2-b2f4-5c948ea837c0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4a024a61-902f-48bc-9a4b-957c7cd18cea_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_51850c99-6b14-4bd6-8d75-9e97337fd19f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_2237d3d8-76c0-4a7c-8a44-3c335a682ca5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_22e0ffc9-4f35-4975-b686-1db7f871b4c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_2493227b-66ec-4f6e-aca1-8a9db981fdaf_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b4d505b8-e173-4693-a871-4aa40f344d0f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_47f40535-bc6e-422e-b02e-ed9ef7a3b9dc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_3e1ffb9d-8670-43a8-abf0-1e894e512adb_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_6f104fe8-3c36-41e0-8867-190a6f3059c7_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation Expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_b81c2015-9870-4177-b21e-5bc51aa93ebe_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_e0bbbf40-1094-441a-b512-a490902a1522_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7dcee604-6f57-4b24-9fe2-8fe1ca1a54e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_d8acc363-33f3-47fb-ac19-fd832fd9d434_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_c5fb6b70-906b-4942-8054-7912431de7b9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes to noncontrolling ownership interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_477bc99d-5662-454c-946b-02e2ad7497cf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_4fb4889b-01c0-4194-a102-c07b20fc2547_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions and interest</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_4b7b9305-e866-4a7e-b4f8-8d9c5e45cc23_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Activities Related to Debt Securities Portfolio</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_0cd5f976-8163-4dce-89fc-f22e5f70d056_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_e7e2c38c-7f7b-48a1-ba0f-210628e3a956_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_bb2b5597-300f-4405-baa6-b133351defe6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_177d0967-01fd-4cbc-8dfe-ca471b915e50_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_1f0acc09-8931-40f4-b3f8-4aa7cf938330_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_36441e65-b3a6-44dd-b1dd-5522713fdff6_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_28daada0-8a2c-40d1-8a6b-487aed3a334d_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition and divestiture-related items</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_175057ed-8cf0-4b79-9413-9edbb317dd11_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b568413e-71ed-426a-9bff-024634ba3e07_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d01ff6d4-1bfc-482c-b693-6068fe1be15f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_b79553a4-461b-4efe-9438-0b95fa8688df_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, excluded component, gain (loss), recognized in earnings</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c18265f5-56d9-460f-8d04-6db3d7566bcb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_fcb49b9c-fa02-4d2c-9149-41beb596ec97_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f25fca84-1c8a-40a0-96ba-158bd65f88bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a279de0b-9832-473a-9c46-6c549e637da3_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_8e78bf68-64fc-4729-9b6f-c5ee6e35b968_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_2c7f3ca5-24f7-4908-8243-2d8af33ea99e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_43f5bfae-4f6e-4ed8-afaa-7ab08b567315_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_698775da-431e-47f8-b896-27eaa35bec76_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized in AOCI, net investment hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due2039Member_bca72c28-f892-4cdf-81ce-3500cc271fa6_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.250 percent twenty-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2039Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2039 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2039Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2039 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2039Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due2039Member" xlink:to="lab_mdt_SeniorNotes2019Due2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6cb68985-444a-40a6-9e85-bc6b895d9099_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_129f516a-1cc0-4c3e-a4cf-07690b4d2dff_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_fad57c76-fe05-4b31-884f-6306c267a0a5_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_91bc80a3-abf7-4fd2-9759-86d0071aec13_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9ca6a8d3-f3ec-4127-941a-757070a27d43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Tax (Benefit) Provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_44df21a6-935a-4fce-aeea-3cccc9041af3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled non-cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5e5b6ff-6830-4833-8234-ee4037607b09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_ce1e5258-ee5c-4d53-a78c-ad39554e9fcb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_bcd36b72-1a5b-4467-aec9-bd316ccf9448_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_StructuralHeartAndAorticDivisionMember_a129bf6e-9579-4a47-96d0-ae2c992619d0_terseLabel_en-US" xlink:label="lab_mdt_StructuralHeartAndAorticDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Structural Heart &amp; Aortic</link:label>
    <link:label id="lab_mdt_StructuralHeartAndAorticDivisionMember_label_en-US" xlink:label="lab_mdt_StructuralHeartAndAorticDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Structural Heart And Aortic Division [Member]</link:label>
    <link:label id="lab_mdt_StructuralHeartAndAorticDivisionMember_documentation_en-US" xlink:label="lab_mdt_StructuralHeartAndAorticDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Structural Heart And Aortic Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StructuralHeartAndAorticDivisionMember" xlink:href="mdt-20240426.xsd#mdt_StructuralHeartAndAorticDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_StructuralHeartAndAorticDivisionMember" xlink:to="lab_mdt_StructuralHeartAndAorticDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_07c7937e-b221-4a58-ae4c-3c838454e21e_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_36eaeeb8-4a45-460b-bae2-866b6b6e7a90_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_716f3920-23b5-4f85-9820-6ed257106cf0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_43a895a9-c534-4267-86f5-d2607222e226_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3c4649ed-4add-446d-bf37-f1a28e09e820_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0a8b1eff-e187-4a91-a4ab-8e2ba8d9bc4d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_3c358970-e76d-40b8-b7ef-5693b4ff74de_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future employer contributions in next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingLiabilitiesTableTextBlock_85d316e8-45bd-4597-b81a-19de16662153_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Offsetting Liabilities</link:label>
    <link:label id="lab_us-gaap_OffsettingLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SimplificationRestructuringProgramMember_3d0f150f-655b-4cf7-beb1-adef954449f0_terseLabel_en-US" xlink:label="lab_mdt_SimplificationRestructuringProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Simplification</link:label>
    <link:label id="lab_mdt_SimplificationRestructuringProgramMember_label_en-US" xlink:label="lab_mdt_SimplificationRestructuringProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Simplification Restructuring Program [Member]</link:label>
    <link:label id="lab_mdt_SimplificationRestructuringProgramMember_documentation_en-US" xlink:label="lab_mdt_SimplificationRestructuringProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Simplification Restructuring Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SimplificationRestructuringProgramMember" xlink:href="mdt-20240426.xsd#mdt_SimplificationRestructuringProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SimplificationRestructuringProgramMember" xlink:to="lab_mdt_SimplificationRestructuringProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0b4a5e55-65a1-424c-9c03-1a7f778c731d_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_711b3e31-2e3d-40af-9d8d-01ca36eef519_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_f9913a22-0f1d-46d5-8694-5da52d9eaa24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Before Income Taxes, Based on Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d3f54536-3db2-42b8-be40-24861dd5a48a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_33054a7a-c6a3-4169-b382-514a7bca85bc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Critical assumptions &#8211; projected benefit obligation:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_ac7552c8-21fe-425d-8652-a7dc255fd05a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration for the transaction, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_975b9c74-5dfd-4cea-bcb6-bff5f40f8b7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2a1e745d-48f5-4f80-8d82-428c8f52b620_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b4d343ca-157a-47d8-9685-6ba8ac188481_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_90d0cdeb-c9fd-42aa-a24d-9101a0e74695_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c5050144-fdcc-4369-b354-db0c097c7101_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4e1239be-df68-4bc8-a0d9-9a5ba9d51796_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cd66b5b3-9170-4005-98d5-1e6a47cb00f7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_57d9e46a-0247-4d9b-96d1-ab16fcbb6ee3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_aab0a34d-7956-4b94-95c7-64bdc63b651d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_9e27c6f9-f291-44cb-9ed1-529903215175_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives and Currency Exchange Risk Management</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_7b610e12-c910-498d-9b4d-8f7fdcdcd3c2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_c1b900b5-1db3-41c4-abd2-d4e98571d21c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_7cf9469a-2cad-4da0-be42-818234d00c1a_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlement and curtailment (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_f399ca47-da73-48ef-a5a7-687a2976893e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption of senior notes, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d886c96b-e469-441c-94a5-6a4072dd385a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_e4b4e4b0-e424-4dcc-9905-626b837f40f6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_98336c49-929a-4a3b-b564-618672c110ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_56a5f3c9-a304-4490-86d9-3a8a841f1e77_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_c6a018c4-54ec-4a0c-94e7-3f13fbfbbc34_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, tax adjustments for reserves, amount</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Adjustments For Reserves, Amount</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotesDue2043Member_a4f07ab3-7838-496f-bb43-3359ecaa6606_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.150% Senior Notes due 2043</link:label>
    <link:label id="lab_mdt_SeniorNotesDue2043Member_label_en-US" xlink:label="lab_mdt_SeniorNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2043 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotesDue2043Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2043Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotesDue2043Member" xlink:to="lab_mdt_SeniorNotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_9e0c0c74-a117-43d0-8bbb-ed6bcd5ed02c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill as a result of acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SpecialChargesGains_e5bfdd6f-2165-4edd-bf67-4947900d1ac0_negatedLabel_en-US" xlink:label="lab_mdt_SpecialChargesGains" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Commitments to the Medtronic Foundation and Medtronic LABS</link:label>
    <link:label id="lab_mdt_SpecialChargesGains_label_en-US" xlink:label="lab_mdt_SpecialChargesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Special Charges (Gains)</link:label>
    <link:label id="lab_mdt_SpecialChargesGains_documentation_en-US" xlink:label="lab_mdt_SpecialChargesGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special Charges (Gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialChargesGains" xlink:href="mdt-20240426.xsd#mdt_SpecialChargesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SpecialChargesGains" xlink:to="lab_mdt_SpecialChargesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_9914b759-00ed-487a-889f-230a403117ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards, expiring in future years</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ed85215b-ff35-4dca-8f72-ac4bb632c4c6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_cc712307-4be8-43d9-8967-383148238b0b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_64358344-dfef-4975-a75d-65fe14f9bfdf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesLineItems_e07d5c39-d310-4e1f-be20-7b8e6780f88a_terseLabel_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Line Items]</link:label>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesLineItems_label_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Line Items]</link:label>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesLineItems_documentation_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Offsetting Assets and Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:href="mdt-20240426.xsd#mdt_OffsettingAssetsandLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:to="lab_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CommercialPaperMaximumBorrowingCapacity_c36303eb-9aa8-4704-9d2d-fcd61931addb_terseLabel_en-US" xlink:label="lab_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper, maximum borrowing capacity</link:label>
    <link:label id="lab_mdt_CommercialPaperMaximumBorrowingCapacity_label_en-US" xlink:label="lab_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_mdt_CommercialPaperMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Paper, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:href="mdt-20240426.xsd#mdt_CommercialPaperMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:to="lab_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aea8a4fb-269f-4fbb-b39f-ffdbcf5de0f9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Purchase and Award Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_594bda21-1db7-4b1e-908c-d797b4cf5923_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EmployeesStockPurchasePlanMember_9c06ccbc-236e-4479-b859-88702151face_terseLabel_en-US" xlink:label="lab_mdt_EmployeesStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_mdt_EmployeesStockPurchasePlanMember_label_en-US" xlink:label="lab_mdt_EmployeesStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mdt_EmployeesStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mdt_EmployeesStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EmployeesStockPurchasePlanMember" xlink:href="mdt-20240426.xsd#mdt_EmployeesStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EmployeesStockPurchasePlanMember" xlink:to="lab_mdt_EmployeesStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_809d8609-b02e-416a-b3b1-69b86845f1d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_b861f076-9b2d-4c37-b538-d44cf71614ac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aa29204b-41d4-4c32-9e43-fcc50b1d51f1_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowances and credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_bcb7bd11-f29d-4406-9a51-1441fb568991_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and tradenames</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EnterpriseExcellenceMember_caf32638-d31a-446f-b9b8-7ebd5d2f1049_terseLabel_en-US" xlink:label="lab_mdt_EnterpriseExcellenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enterprise Excellence</link:label>
    <link:label id="lab_mdt_EnterpriseExcellenceMember_label_en-US" xlink:label="lab_mdt_EnterpriseExcellenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enterprise Excellence [Member]</link:label>
    <link:label id="lab_mdt_EnterpriseExcellenceMember_documentation_en-US" xlink:label="lab_mdt_EnterpriseExcellenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enterprise Excellence [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EnterpriseExcellenceMember" xlink:href="mdt-20240426.xsd#mdt_EnterpriseExcellenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EnterpriseExcellenceMember" xlink:to="lab_mdt_EnterpriseExcellenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_646fcd79-2699-4f90-8242-c6098d86f53f_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Self-Insurance</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Self Insurance Reserve [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:to="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_3ec428eb-9c4f-4dad-aaf6-44715eaacc01_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_79f71f85-a01d-49b4-986b-3411e59f1ded_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DebtInstrumentNumberofTranches_7cc38e49-afa4-40e4-8d88-a79166433986_terseLabel_en-US" xlink:label="lab_mdt_DebtInstrumentNumberofTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_mdt_DebtInstrumentNumberofTranches_label_en-US" xlink:label="lab_mdt_DebtInstrumentNumberofTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:label id="lab_mdt_DebtInstrumentNumberofTranches_documentation_en-US" xlink:label="lab_mdt_DebtInstrumentNumberofTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtInstrumentNumberofTranches" xlink:href="mdt-20240426.xsd#mdt_DebtInstrumentNumberofTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DebtInstrumentNumberofTranches" xlink:to="lab_mdt_DebtInstrumentNumberofTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_71ee7a14-3c1a-47b8-83c3-6d35eedbc0d2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_7199822d-7b2f-4d50-b77a-521a0295e1be_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ddf7b8c9-3c6a-4625-b2dd-9c93d5027d70_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_2fb229e2-3a29-4ded-ba1e-810438a0d262_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6760f789-c631-48b4-8857-3ebfa9823adb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f1f159ee-7fe7-401f-9195-a5e33e504022_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_b80c4fed-1b4c-4d10-a95f-77475663e8f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_317c33c3-44a3-4332-9df0-71547e087398_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and Dispositions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_93b57d6d-289a-4855-b5e9-31dcd818f0c5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock_010f4da8-7823-4b73-ae49-464790491210_terseLabel_en-US" xlink:label="lab_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Retirement Benefit Plan Assets, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Retirement Benefit Plan Assets, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label id="lab_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock_documentation_en-US" xlink:label="lab_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the fair value measurement of retirement benefit plan assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock" xlink:href="mdt-20240426.xsd#mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock" xlink:to="lab_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e6437e95-f2a3-48c7-9244-6ff5fe2fcecc_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8567e045-41dd-4e60-a03a-5c6f6169c478_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_7c0a21c7-47fe-4611-921f-27ab8db84359_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15954602-aa9c-4057-bd83-da091afd420a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9c72a594-e328-438e-b03e-df7446a6b8d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_a50dd4d3-f45b-4236-902b-63f7a3ee5fae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ForeignCurrencyDenominatedDebtMember_70fda936-0995-4056-b0e9-1c6dabce4b2d_terseLabel_en-US" xlink:label="lab_mdt_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency denominated debt</link:label>
    <link:label id="lab_mdt_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_mdt_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_mdt_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_mdt_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember" xlink:href="mdt-20240426.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_mdt_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1bf5508-b10e-4823-b4b6-433f47acd8c9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f60aae1d-8785-4f23-a4a6-0cdae9742768_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_ad9a126e-e5ae-42bc-b20a-03a97f1bca40_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2015Due2035Member_34c661b9-8478-4fa2-91e1-8bdfd9661f85_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2015Due2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.375 percent twenty-year 2015 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due2035Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2015Due2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2035 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due2035Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2015Due2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due2035Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2015Due2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2015Due2035Member" xlink:to="lab_mdt_SeniorNotes2015Due2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ca0de5c8-5176-498e-b10f-6bb6f8c884b1_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_baa95910-9151-4dab-8cc8-841400d5fc62_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_39da96e3-2c40-45d6-a70f-fd8379b2411e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_5a91394e-5f21-4efa-aa9c-3ed97fdce683_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ec8163f7-b501-4b6c-ae57-940a29497c4f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_41d3b47b-5283-43e5-bd7d-2bbd4caecae9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_7831f06e-e12b-47c9-87fa-7016824706dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_04059acc-ca72-4e35-bfba-0abcf4c1dd3e_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_13578419-a12b-42e0-bc40-cdf49e71f6bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_4dfa829d-80dc-4ce6-8049-972fa6761423_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e530d29-348b-477d-9f3a-78c734d18b5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_23bdf786-06de-4d47-aacb-2b0043dac1a2_terseLabel_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate &#8211; interest cost</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_label_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_documentation_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:to="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f1d8d79f-cc23-4059-91ce-a1ee101008b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_04f3049d-5eb9-44d2-bf96-6ee3835785be_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_7481b240-ce8f-4c9f-ab0c-b6799a4782e4_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense related to internal restructuring and intercompany sale of assets</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_d6777d05-10ac-435a-bc16-b3dcd8aecd13_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b61a9f51-b4a5-4f8d-b9b1-088eee978524_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_68fed266-8de2-4189-b54d-269077579419_terseLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_0d4452fa-e3dc-4e69-a19b-7d40a740be1c_periodStartLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_e1fce74c-5b08-47fb-a3a9-828b4f62bdb2_periodEndLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_label_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_documentation_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:to="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_5306778b-148c-43be-aaae-22e9b740fd7c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_0d0ee24f-08c2-456a-aa55-834aaae3a471_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_8f925698-d621-4b6e-8b72-f9f195ce4959_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4b53d2ba-4a4e-40f3-a09f-5c99129803eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CoronaryAndPeripheralVascularDivisionMember_3be551fe-f7e5-4370-aa21-680e7f8f3c28_terseLabel_en-US" xlink:label="lab_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coronary &amp; Peripheral Vascular</link:label>
    <link:label id="lab_mdt_CoronaryAndPeripheralVascularDivisionMember_label_en-US" xlink:label="lab_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coronary And Peripheral Vascular Division [Member]</link:label>
    <link:label id="lab_mdt_CoronaryAndPeripheralVascularDivisionMember_documentation_en-US" xlink:label="lab_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coronary And Peripheral Vascular Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:href="mdt-20240426.xsd#mdt_CoronaryAndPeripheralVascularDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:to="lab_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_43ce54fb-067b-40f6-bc49-c9d0c5fe9011_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_a54b94f9-7e37-4728-89f4-de77a6e00e9c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Plan settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_475b8412-f24e-4502-80eb-df41da6c70c9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_26f514f0-58f3-4d9a-bad0-36f3dbd7335c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_27ef1d59-cb5f-457b-b50f-6a254459be81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_bd4329a1-eb88-42f7-8ccb-005938d90f48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_2a176c11-cb22-4aae-8a4d-eec144688b92_negatedLabel_en-US" xlink:label="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Plan curtailments, settlements, and amendments</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_label_en-US" xlink:label="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_documentation_en-US" xlink:label="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:to="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4e989b7f-bae5-4c49-b215-2e06fb1e1e56_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_105fcbd0-3e06-4c85-9c8f-e36a44526b05_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_071ac15b-09b0-40eb-be25-2ebb2811dc6d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements_911384a3-027e-4daa-82d6-687b5b43ad14_negatedTerseLabel_en-US" xlink:label="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash advance paid to taxing authorities</link:label>
    <link:label id="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements_label_en-US" xlink:label="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Advance Paid in Connection With Proposed Settlements</link:label>
    <link:label id="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements_documentation_en-US" xlink:label="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Advance Paid in Connection With Proposed Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:href="mdt-20240426.xsd#mdt_CashAdvancePaidinConnectionWithProposedSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:to="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_NeuroscienceGroupMember_cc045346-067c-42de-9517-70c76ba61eba_terseLabel_en-US" xlink:label="lab_mdt_NeuroscienceGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_mdt_NeuroscienceGroupMember_e254515f-4a30-4873-be3a-3e5e2603830a_verboseLabel_en-US" xlink:label="lab_mdt_NeuroscienceGroupMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_mdt_NeuroscienceGroupMember_label_en-US" xlink:label="lab_mdt_NeuroscienceGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuroscience Group [Member]</link:label>
    <link:label id="lab_mdt_NeuroscienceGroupMember_documentation_en-US" xlink:label="lab_mdt_NeuroscienceGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuroscience Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_NeuroscienceGroupMember" xlink:to="lab_mdt_NeuroscienceGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_c9fab1c2-c91a-4fc7-8b77-2408ae8aa860_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_db113dcf-dcb2-4fcd-83da-f79628d1d7ed_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_22e98b04-12ba-4538-8323-6701b0ebc5d5_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_cea95366-ad8d-4ee0-8a48-874042224052_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ea18a506-35a7-45f2-8920-20b5abb4eefd_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ad3f36f2-895f-41e2-96c0-da7cfaac2d71_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AuditInformationAbstract_label_en-US" xlink:label="lab_mdt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_mdt_AuditInformationAbstract_documentation_en-US" xlink:label="lab_mdt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AuditInformationAbstract" xlink:href="mdt-20240426.xsd#mdt_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AuditInformationAbstract" xlink:to="lab_mdt_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CorporateOverhead_9e393288-c5a3-4de5-94c8-d19046722b09_negatedTerseLabel_en-US" xlink:label="lab_mdt_CorporateOverhead" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_mdt_CorporateOverhead_label_en-US" xlink:label="lab_mdt_CorporateOverhead" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Overhead</link:label>
    <link:label id="lab_mdt_CorporateOverhead_documentation_en-US" xlink:label="lab_mdt_CorporateOverhead" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate overhead expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CorporateOverhead" xlink:href="mdt-20240426.xsd#mdt_CorporateOverhead"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CorporateOverhead" xlink:to="lab_mdt_CorporateOverhead" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_4daca917-8a3e-4f61-8318-24ad2bef0663_terseLabel_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance adjustments (in dollar per share)</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_label_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_documentation_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:to="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f14ffd4a-0667-4689-9420-1e8e705b2290_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d6155e98-0816-4f56-9cdb-b3b2cd4c22d8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_750e02e2-a3ad-422a-8d88-a0ac646c0aab_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized loss on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_940b420f-d713-444e-847d-e07e30501c78_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments with readily determinable fair value (marketable equity securities)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1da008e8-c981-4ff5-86dc-f8c0dcb903f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognized in income, cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b84c0cf1-a60b-4ffb-88ae-2b1d3540ff2f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_28e0a27d-3629-4010-946d-e5765735c6a9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of ordinary shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_96c3f8ba-4eae-4aca-b8d0-9a7a8088f68e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_aa0879f2-d8d0-47c8-81f4-11b1b519ece9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7e5d9223-b943-47b6-9abc-49b81ad0f7ce_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_4e8ccb01-058b-44a0-8564-582dc6fe6866_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1b58e402-9329-461b-ba7b-58f8e21b3731_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_70c05e83-4265-4492-b82f-b03d1bd26b0a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_bc84a310-b1a3-49ee-b4b8-44ab6374ab25_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_afae98f9-03df-4871-9e0d-bcd7a0127e4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_affb1831-1ff8-45f5-bc7e-dfee6a1dbdeb_verboseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Other</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsNetofValuationAllowanceOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:to="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8de17025-7aa3-4746-8f86-f4bdf2851b42_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e6a928b0-2b3d-4c5d-bfb2-252465f2b019_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_34d38f84-9f2c-402f-8a08-35bc0773d34b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredStockSharesOutstanding_c3423cfd-8218-48d4-b336-c9497adaf60f_terseLabel_en-US" xlink:label="lab_mdt_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_mdt_DeferredStockSharesOutstanding_label_en-US" xlink:label="lab_mdt_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Outstanding</link:label>
    <link:label id="lab_mdt_DeferredStockSharesOutstanding_documentation_en-US" xlink:label="lab_mdt_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesOutstanding" xlink:href="mdt-20240426.xsd#mdt_DeferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredStockSharesOutstanding" xlink:to="lab_mdt_DeferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_78bacf23-96e3-4dae-8173-17fbfe22fb22_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalization of research and development</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Research and Development Capitalization</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Research and Development Capitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:to="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2051Member_3f1efa78-bf5c-456a-97a5-bab41bff234b_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625 percent thirty-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2051Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2051 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2051Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2051Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2051Member" xlink:to="lab_mdt_SeniorNotes2020Due2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dd9b9db-a095-421a-997e-f9da6d854e97_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bd8d0584-2608-4e03-a7df-73d4e2b70e9f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Critical assumptions &#8211; net periodic benefit cost:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_f1b02e31-30dd-4cd8-ac9f-bfedf32266a4_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base erosion anti-abuse tax</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_084fa9fd-ccdb-4a36-bfa5-b881f519f319_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_9d167e1b-4d3a-4f0a-99fd-9b36d0b979ba_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_a01e6cc8-2836-43df-840e-bc4640e2a6a3_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated reasonably possible decrease in uncertain tax positions excluding interest over the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesTable_e0ad6f04-db1c-4c78-9985-c2967b425989_terseLabel_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Table]</link:label>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesTable_label_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Table]</link:label>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesTable_documentation_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesTable" xlink:href="mdt-20240426.xsd#mdt_OffsettingAssetsandLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesTable" xlink:to="lab_mdt_OffsettingAssetsandLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_LineOfCreditFacilityLengthOfExtension_6b80bdc7-7f67-496b-bbff-5f3d7d79df60_terseLabel_en-US" xlink:label="lab_mdt_LineOfCreditFacilityLengthOfExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Length of extension from maturity date</link:label>
    <link:label id="lab_mdt_LineOfCreditFacilityLengthOfExtension_label_en-US" xlink:label="lab_mdt_LineOfCreditFacilityLengthOfExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Length of Extension</link:label>
    <link:label id="lab_mdt_LineOfCreditFacilityLengthOfExtension_documentation_en-US" xlink:label="lab_mdt_LineOfCreditFacilityLengthOfExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Length of Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityLengthOfExtension" xlink:href="mdt-20240426.xsd#mdt_LineOfCreditFacilityLengthOfExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_LineOfCreditFacilityLengthOfExtension" xlink:to="lab_mdt_LineOfCreditFacilityLengthOfExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d03cf6f9-fa55-4c16-ad08-31d9173822e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_c2c19225-ed36-4bcb-b9a7-e7956a4c19a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_c8510b32-3f62-4dcf-a281-7be1b71b51c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4169b9eb-0a77-41f5-8f36-369a76f7e678_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_4d87567f-4536-4855-ad6d-bdc066db2a2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Current Debt Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Short-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ForeignCurrencyCosts_5547ce30-08e7-46a2-9558-f5287befb5b7_negatedTerseLabel_en-US" xlink:label="lab_mdt_ForeignCurrencyCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency</link:label>
    <link:label id="lab_mdt_ForeignCurrencyCosts_label_en-US" xlink:label="lab_mdt_ForeignCurrencyCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Costs</link:label>
    <link:label id="lab_mdt_ForeignCurrencyCosts_documentation_en-US" xlink:label="lab_mdt_ForeignCurrencyCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyCosts" xlink:href="mdt-20240426.xsd#mdt_ForeignCurrencyCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ForeignCurrencyCosts" xlink:to="lab_mdt_ForeignCurrencyCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_985cf482-c768-4dc9-9d59-e73ef0e9f72a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebate obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredStockParorStatedValuePerShare_0f02780f-63f6-4ed9-8690-fc2d2d247833_terseLabel_en-US" xlink:label="lab_mdt_DeferredStockParorStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock, par value (in euros per share)</link:label>
    <link:label id="lab_mdt_DeferredStockParorStatedValuePerShare_label_en-US" xlink:label="lab_mdt_DeferredStockParorStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_mdt_DeferredStockParorStatedValuePerShare_documentation_en-US" xlink:label="lab_mdt_DeferredStockParorStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockParorStatedValuePerShare" xlink:href="mdt-20240426.xsd#mdt_DeferredStockParorStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredStockParorStatedValuePerShare" xlink:to="lab_mdt_DeferredStockParorStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_ce971d5a-3f79-4112-bfe9-e2f835290e3c_negatedTotalLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_110bb10e-ad04-447b-a8f9-3a01d3e68af8_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Post-retirement benefit plans, net periodic benefit cost, income</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_0c436f40-3da0-412e-aee3-26ae855bbf6e_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit (credit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_TotalReportableSegmentsMember_b870d9d2-a44c-43ff-af02-290642b13b68_terseLabel_en-US" xlink:label="lab_mdt_TotalReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable segment net sales</link:label>
    <link:label id="lab_mdt_TotalReportableSegmentsMember_label_en-US" xlink:label="lab_mdt_TotalReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Reportable Segments [Member]</link:label>
    <link:label id="lab_mdt_TotalReportableSegmentsMember_documentation_en-US" xlink:label="lab_mdt_TotalReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember" xlink:href="mdt-20240426.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_TotalReportableSegmentsMember" xlink:to="lab_mdt_TotalReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_1fccc321-d3ac-4dc4-96af-9fcfe54635eb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairments and related inventory write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_8f1b6336-e063-4bd7-a948-75135e9c0bf0_terseLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedge</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:to="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e7269123-fe93-4d6e-b8b1-ba4db1b956a1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0989ea10-2f4c-4019-a1fb-d5f4e3cb6fb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6bc331e9-c846-4a68-8e3f-2153a8625014_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_c1095d1e-2c05-4316-9294-c5b60a115d4d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_edbbac15-a2a8-43cd-8491-44ef5a3bf431_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan assets at fair value</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_7d583955-19d5-4128-869a-141c471ea735_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_ed504ed0-0400-4380-b0a0-bed6774c3b09_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_0bd4fe35-41e3-4236-8459-345a6bb7d5f0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_984a9b18-594b-49eb-932c-242fd2584ac0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_48ab13ef-0035-4621-857e-b0a407b814db_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_b3777db7-f868-452a-8ad0-89b5ad0fdf84_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ContingentConsiderationPolicyTextBlock_e77f5cf7-c947-4b68-bb34-a558d30d3b9f_terseLabel_en-US" xlink:label="lab_mdt_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_mdt_ContingentConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_mdt_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:label id="lab_mdt_ContingentConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_mdt_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an entity's accounting policy for contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ContingentConsiderationPolicyTextBlock" xlink:href="mdt-20240426.xsd#mdt_ContingentConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ContingentConsiderationPolicyTextBlock" xlink:to="lab_mdt_ContingentConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ba474003-ea4f-4e4c-96c9-627b7ed46f7b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_7934fef1-47b4-41b6-b01f-bb5844bd1d3c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_TokyoInterBankOfferedRateTIBORMember_098c77ad-adf0-49c6-a943-dec4b236e948_terseLabel_en-US" xlink:label="lab_mdt_TokyoInterBankOfferedRateTIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TIBOR Rate</link:label>
    <link:label id="lab_mdt_TokyoInterBankOfferedRateTIBORMember_label_en-US" xlink:label="lab_mdt_TokyoInterBankOfferedRateTIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tokyo Inter-bank Offered Rate (TIBOR) [Member]</link:label>
    <link:label id="lab_mdt_TokyoInterBankOfferedRateTIBORMember_documentation_en-US" xlink:label="lab_mdt_TokyoInterBankOfferedRateTIBORMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tokyo Inter-bank Offered Rate (TIBOR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TokyoInterBankOfferedRateTIBORMember" xlink:href="mdt-20240426.xsd#mdt_TokyoInterBankOfferedRateTIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_TokyoInterBankOfferedRateTIBORMember" xlink:to="lab_mdt_TokyoInterBankOfferedRateTIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AssociatedAndOtherCostsMember_4fdbb6a0-376e-4b66-bbf1-36a035d2ed62_terseLabel_en-US" xlink:label="lab_mdt_AssociatedAndOtherCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated and Other Costs</link:label>
    <link:label id="lab_mdt_AssociatedAndOtherCostsMember_label_en-US" xlink:label="lab_mdt_AssociatedAndOtherCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associated and Other Costs [Member]</link:label>
    <link:label id="lab_mdt_AssociatedAndOtherCostsMember_documentation_en-US" xlink:label="lab_mdt_AssociatedAndOtherCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Associated and Other Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssociatedAndOtherCostsMember" xlink:href="mdt-20240426.xsd#mdt_AssociatedAndOtherCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AssociatedAndOtherCostsMember" xlink:to="lab_mdt_AssociatedAndOtherCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_a6d9185b-19ef-4327-b2b0-4e6aaf29b812_terseLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Foreign Exchange Adjustment</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign exchange adjustment to pension and other postretirement benefit plans (gain) loss included in accumulated other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:to="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a361764f-99e9-42fe-826f-78aae0c8c91e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_fc058ae6-9ba5-439d-be6d-3e55d9c9aed9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1a966e2c-a2d1-4cc6-9ebf-b34a537f6ae7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. state taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d4f4b7e9-4508-476a-9ba8-5208436eddcf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_449b4b1d-c5a1-47b9-b31c-8bec7a94831b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_e7fa7a6b-08a8-49ad-8efb-d984e6e33863_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2d6624dd-83f8-4d56-83f9-2b695cc4d199_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-retirement benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_b625d072-d1ad-482f-b725-226a747b5de7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8d9d2f9c-58a8-4ccf-ad1e-fcfd0bdbb7b2_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed7285e8-6ee0-4964-b175-afef3538e0b6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c6b08597-ea3e-45ea-8e36-c7579e49c5e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_bdd9b4ff-f288-4788-a28d-9168e88ae819_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a472e8d3-871b-452a-8273-9aee88db2d11_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_1d1bce1a-b910-42b0-810f-ef1cd30a96c3_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_b09cbae0-4a5d-4f55-b1d4-9115b014fa07_terseLabel_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_label_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Net of Cash Advance Paid</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_documentation_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Net of Cash Advance Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:href="mdt-20240426.xsd#mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:to="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_67bbf05d-b6b2-466d-b9d5-b9ede05865ed_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_60373c02-33ec-412a-bbf6-fc48f032aac0_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2014Due2044Member_690192eb-2193-41b9-a02f-60a68b132b58_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2014Due2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.625 percent thirty-year 2014 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2014Due2044Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2014Due2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2014 Due 2044 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2014Due2044Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2014Due2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2044 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2014Due2044Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2014Due2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2014Due2044Member" xlink:to="lab_mdt_SeniorNotes2014Due2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_0d7145ea-9fc9-451a-bef9-fb1ede69a073_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other operating expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_98b2b879-8cc6-4214-89ca-afb4685f9061_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_2a1c6180-f293-4b00-b786-c4a355896bae_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_66f01c6d-d22a-4ba6-af92-4165260132fe_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredStockSharesAuthorized_4659e072-35ab-47dd-8b27-1f2574c8ad61_terseLabel_en-US" xlink:label="lab_mdt_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_mdt_DeferredStockSharesAuthorized_label_en-US" xlink:label="lab_mdt_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Authorized</link:label>
    <link:label id="lab_mdt_DeferredStockSharesAuthorized_documentation_en-US" xlink:label="lab_mdt_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesAuthorized" xlink:href="mdt-20240426.xsd#mdt_DeferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredStockSharesAuthorized" xlink:to="lab_mdt_DeferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_a684f2ad-fdc7-4ae3-bcf2-5b7baf8485dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_2b6319f0-b6b0-4d74-b11a-c3c34015d01b_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_d43c2940-e34a-4065-878d-cdd882924ec3_terseLabel_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increases:</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_label_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits Gross Increases [Abstract]</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_documentation_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:href="mdt-20240426.xsd#mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:to="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_88033df0-7e4c-4db2-bd64-159051c10a41_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_ce2879da-f332-45d7-abd5-72bb3fb262e4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_071a105c-d7fd-4c1c-9334-9dd289dc9705_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7d1e2521-0db6-49d7-bc86-d5f6e23e3c95_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70fc0a66-6ef8-4d9d-bdef-8711d08ab311_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e3b172ed-0ce8-4561-b27b-7170a7e16831_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized that was previously included in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_91502e69-3af3-4f24-90f5-774acaaf3634_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_cdf32d35-ecc0-43af-af95-c13e41205ff7_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e18d82d3-ea2f-4194-a9ce-d95c621986dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_dd21c5a6-0e5c-4c66-b1d1-fa47bb57fc0d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_cfd5a4d8-889f-499d-ae38-a48d9bb914bd_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_9c9c2b07-7925-4ae0-948b-0a0d0c1e1470_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_5fc603e9-7ed3-4e93-a258-1886a190917c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_44665916-50a3-486a-a54b-f9bcaa8433c3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb31855a-9505-4c45-80b9-69b7033a2799_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b1862f17-32aa-4e2c-89b1-ecd52a533040_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_02c3483e-dd9a-44ef-9b47-3e36b9987e15_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_080db02c-a284-42d4-b583-fbfb290896a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used:</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_baee21d6-1993-48d9-aebc-243c08d17c2e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_061d17cc-abc5-48d6-a2dd-6ad111cd7c1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_70aa89a0-a31b-427c-ad44-ef8f96122e37_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AFS Debt Maturities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_ef2a5643-23cd-4a0d-8d1e-746d21c96dbf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Future Benefit Payments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets_4917f43c-573d-4c27-98fe-11a547cc425b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intercompany sale of assets</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3f207b12-a8f8-4b28-ae3d-8edeff844667_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MedtronicLuxcoMember_88fc8587-1a2e-4d5b-8b68-a9812849800a_terseLabel_en-US" xlink:label="lab_mdt_MedtronicLuxcoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medtronic Luxco</link:label>
    <link:label id="lab_mdt_MedtronicLuxcoMember_label_en-US" xlink:label="lab_mdt_MedtronicLuxcoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medtronic Luxco [Member]</link:label>
    <link:label id="lab_mdt_MedtronicLuxcoMember_documentation_en-US" xlink:label="lab_mdt_MedtronicLuxcoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medtronic Luxco [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoMember" xlink:href="mdt-20240426.xsd#mdt_MedtronicLuxcoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MedtronicLuxcoMember" xlink:to="lab_mdt_MedtronicLuxcoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_37474a94-f131-4221-b7de-3321a6e885e5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5a185c57-78aa-4606-947f-6ec7d7ec9826_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges to Other Accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MozarcMember_10dda6d6-a194-4043-8d1f-e1433111ea05_terseLabel_en-US" xlink:label="lab_mdt_MozarcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mozarc</link:label>
    <link:label id="lab_mdt_MozarcMember_label_en-US" xlink:label="lab_mdt_MozarcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mozarc [Member]</link:label>
    <link:label id="lab_mdt_MozarcMember_documentation_en-US" xlink:label="lab_mdt_MozarcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mozarc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember" xlink:href="mdt-20240426.xsd#mdt_MozarcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MozarcMember" xlink:to="lab_mdt_MozarcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1bda68a4-dd8b-4b36-96b1-8b49a8c584f9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ded6b989-8446-4c33-9679-afed4d56647e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0966345f-4e5c-48ca-8e84-651012110786_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_9db27d56-232e-4b9e-bf53-614cb8630d72_negatedTerseLabel_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Pension and post-retirement benefits</link:label>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_label_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Pension And Post-retirement Benefits</link:label>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_documentation_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Pension And Post-retirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:to="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ce6457a7-132b-4e24-b843-74b154153a71_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_f9af64cf-425c-45f8-b646-80f66ddeff3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_4625ad2d-26e7-4f08-a0df-e608d98a3d56_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net change in retirement obligations</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ProductDevelopmentMilestoneMember_3e1e4164-3955-4e08-9404-b17de5b1a903_terseLabel_en-US" xlink:label="lab_mdt_ProductDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product development and other milestone-based payments</link:label>
    <link:label id="lab_mdt_ProductDevelopmentMilestoneMember_label_en-US" xlink:label="lab_mdt_ProductDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Development Milestone [Member]</link:label>
    <link:label id="lab_mdt_ProductDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_mdt_ProductDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A milestone in achieving certain product development target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ProductDevelopmentMilestoneMember" xlink:href="mdt-20240426.xsd#mdt_ProductDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ProductDevelopmentMilestoneMember" xlink:to="lab_mdt_ProductDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_d5213b20-a2a5-44a1-8c36-9795d2ac8884_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_578bb3f8-2077-4782-9241-65d913a6b4bf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IncreaseDecreaseInTaxRateAbstract_68622609-d16e-4b72-ad00-c7978295caeb_terseLabel_en-US" xlink:label="lab_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in tax rate resulting from:</link:label>
    <link:label id="lab_mdt_IncreaseDecreaseInTaxRateAbstract_label_en-US" xlink:label="lab_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Tax Rate [Abstract]</link:label>
    <link:label id="lab_mdt_IncreaseDecreaseInTaxRateAbstract_documentation_en-US" xlink:label="lab_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:href="mdt-20240426.xsd#mdt_IncreaseDecreaseInTaxRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:to="lab_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_5caab09d-dc07-410c-aa6f-6a3b5cb57068_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Statute of limitation lapses</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f2037f51-bc1e-485b-a0fe-807efe140449_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_ad2b5a1b-afa5-432e-86e5-643f8dbbf889_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_6dd6de7a-b659-45b5-968b-a031e3d3400d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt discount, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_9364276a-e4cc-41ff-bcc9-06e4c51849a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4fbef2a6-9a98-4500-857e-89864e0ca059_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e369508-4df7-4748-9620-0032f8e0a314_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50ca2bba-e69b-487d-862d-389d69e235a4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_a5982f2e-c9fe-448e-a43d-700e8644e792_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_372c3f1c-76dd-4c83-aefe-13c5c74baa14_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_49578460-3b18-4228-bd3c-2902eee15c6c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_dedbe789-a3d9-486e-b53f-0385402a9187_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3756c58e-92bc-4c89-9a8a-dfaf82b596ec_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba5529b4-080b-4721-989e-012569d93fa9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_8059a795-25c9-4e0c-8dd0-d352d73a2896_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedge unrealized gains to be reclassified over the next twelve months</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_89da9d72-e296-4ac1-8f5a-81c5391b63a2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_462bc5c6-1fd4-4a59-a89d-a3613c27352c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_c59e80e5-7d3f-4241-a17b-fa29cad96f5c_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Post-retirement benefit plans, benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_652e78c1-d049-4b83-a102-5602c959cc1a_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_3b371f30-106d-4400-8b1f-f0fe5e9bc3a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_d8320579-c206-474a-b248-6af09bc7a5ef_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_df7f30f4-e912-4e7e-898a-4c5759ead042_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_29cced45-9945-4e6c-bacc-8124adedd4d1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0fafcc61-bdfb-4c28-a784-bac1eb751c0a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_db8b7592-2bf4-477f-91b1-4469c82a2c69_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_1874be38-9d2a-4670-ac1b-670a6a0ec69e_terseLabel_en-US" xlink:label="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges, net</link:label>
    <link:label id="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_label_en-US" xlink:label="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Net of Restructuring Reversals Including Cost of Product Sold Impact</link:label>
    <link:label id="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_documentation_en-US" xlink:label="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retirement obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:href="mdt-20240426.xsd#mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:to="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_60c235f8-dba5-4581-a411-da3b28927c46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2032Member_480ad5fa-149c-4ef3-a566-d5fb80729c67_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.750% Senior Notes due 2032</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2032Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2032 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2032Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2032</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2032Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2032Member" xlink:to="lab_mdt_SeniorNotes2020Due2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_9ec1550d-3659-427c-9c28-b49252f0dd06_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_d780618e-919e-4d3d-91df-3af3809514f5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_850e2198-9577-4eb1-9aa8-e461b88eb2e5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_36a40df7-babc-44d4-8c9b-1eab43c5edb5_totalLabel_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and other investments</link:label>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_label_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments</link:label>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_documentation_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:href="mdt-20240426.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:to="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c45e5c8-8cf1-44ad-b06c-4c4d486f5553_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_18396ec9-a76e-4464-8571-bb44b6cd0ec0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_9522228c-c93f-4c61-a88a-d3cdbf2a95f7_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_46e3ea43-4446-40f1-894d-08b1decafae0_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d09b0e99-04b9-4998-9b0d-03db896d1853_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_420f2d2b-feeb-4513-a208-a635ce4c8859_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_64dc6559-f9d1-484a-822b-714daa935d98_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency exchange rate changes and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_c3139e6a-83c3-4757-b3bb-66a03bc5e891_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_16cc9e34-ab02-42fd-9fa4-648d2ef9f74b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7c5ac614-abb7-44cc-adf5-cc0d0c284161_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_93816cb8-8971-4195-93b8-cbcb217899ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_03d8c996-83ed-4e45-a0e6-d515757a1a1b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual adjustments</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4bba6204-ddd2-4443-86f1-26b768532719_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Post-retirement benefit plans, fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_bb386fb8-74f7-4677-8fd9-ae0cb861ae7f_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0f305cc9-c0b4-42d3-835f-a3b6f53cf752_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b90c46c5-fd87-4fb3-9e4a-6563cbfcb525_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_fb81deae-d29c-42ba-ba98-07436069f3c5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_504141dc-dd48-414c-9d9a-0bea6374b0f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_96aba770-1161-416a-a5ba-bd12e42cb11f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A4250PercentFiveYear2023SeniorNotesMember_7bb9c3d6-8504-4be6-8e13-3dac9efc8101_terseLabel_en-US" xlink:label="lab_mdt_A4250PercentFiveYear2023SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.250 percent five-year 2023 senior notes</link:label>
    <link:label id="lab_mdt_A4250PercentFiveYear2023SeniorNotesMember_label_en-US" xlink:label="lab_mdt_A4250PercentFiveYear2023SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.250 Percent Five-year 2023 Senior Notes [Member]</link:label>
    <link:label id="lab_mdt_A4250PercentFiveYear2023SeniorNotesMember_documentation_en-US" xlink:label="lab_mdt_A4250PercentFiveYear2023SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.250 Percent Five-year 2023 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4250PercentFiveYear2023SeniorNotesMember" xlink:href="mdt-20240426.xsd#mdt_A4250PercentFiveYear2023SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A4250PercentFiveYear2023SeniorNotesMember" xlink:to="lab_mdt_A4250PercentFiveYear2023SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_c15733e0-b96b-4825-8c67-400827977122_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_74d300a0-7b8b-45a0-800e-6363a074ca7b_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_7027e8a9-1d72-4750-9dcd-0c3bc5d5abff_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0ba0e098-2745-45fd-af86-086e8f8dbcf5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification, Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_033c8d0e-e778-4f94-9787-c317f0756382_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_642db5dc-39d4-4436-91f6-b247916ad991_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase accounting adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2009Due2039Member_fd004f0b-2e82-4cd0-baa0-8b8b2410886e_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2009Due2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.500 percent thirty-year 2009 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2009Due2039Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2009Due2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2009 Due 2039 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2009Due2039Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2009Due2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2039 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2009Due2039Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2009Due2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2009Due2039Member" xlink:to="lab_mdt_SeniorNotes2009Due2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b52134f9-f430-47dc-bf47-80024003e5c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_21391c4e-91a7-47d2-bed0-d6bf0eb0c6f8_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2010Due2040Member_f11dad1d-931c-48ad-9ca7-1fb6c9f58af3_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2010Due2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.550 percent thirty-year 2010 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2010Due2040Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2010Due2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2010 Due 2040 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2010Due2040Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2010Due2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2040 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2010Due2040Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2010Due2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2010Due2040Member" xlink:to="lab_mdt_SeniorNotes2010Due2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_fc2304c6-3f1d-4dee-8d70-bab9d8ead824_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_c103cfaf-7954-4a24-9188-586b132e59bf_negatedTerseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on available-for-sale securities and derivative financial instruments</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:to="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_afd62eeb-26c6-4e7b-b1bc-c06959a9c49c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_LossContingencyLawsuitsNumber_b6710ad0-6465-4452-94c6-ad8d104cb46d_terseLabel_en-US" xlink:label="lab_mdt_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, lawsuits, number</link:label>
    <link:label id="lab_mdt_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_mdt_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_mdt_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_mdt_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LossContingencyLawsuitsNumber" xlink:href="mdt-20240426.xsd#mdt_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_LossContingencyLawsuitsNumber" xlink:to="lab_mdt_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e3991e02-dce8-4f4c-84c8-e275674971e3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_d398b005-d23b-47d7-bf0d-749c3536359f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_fa5b2a5f-a4d0-4edb-988e-e7cdfe21ac6d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e065684f-b652-448a-b33e-071450997536_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_3c5ec8cf-bca1-4984-970b-2b10a32957ab_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_826833a0-306b-407d-ae82-789ed8d8343c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_dff9f0f3-114c-4d2c-80f2-e85771cb6b51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_e40a0e8d-75b0-4ba3-aac1-517da97ac4ea_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Restructuring Reserves</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_48d5f6f1-60e9-4963-ac91-7285b3972f8d_terseLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_label_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_documentation_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:to="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_2e0b63c8-455c-430e-8319-0a8050fafab0_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Assets and Depreciation Expense from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_dada15dc-050f-4a89-b93d-4d11378be227_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Fair Value, Amount Offset Against Collateral, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:to="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_77c96705-f4ac-44a2-bbd2-86bc254701ed_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_81e750ba-1296-4f8a-9be5-229058d21795_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e50564fd-7aca-4289-93e2-8ce807da7c81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_4f30d2c3-ac72-4a31-ac66-72d898fd109c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use leases</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_42b2a24d-8644-4043-8e6b-b840a28b23ce_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_07b3bbca-d13a-451d-bc38-55ad37ff9238_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e0ca1641-177d-4efc-a043-c90474c9e299_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_abfeb717-7f99-4631-a9e4-3177e80da6b5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due2025Member_4a66a27c-a85b-42a7-ab93-9052d81119c0_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.250% Senior Notes due 2025</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2025Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2025 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2025Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2025Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due2025Member" xlink:to="lab_mdt_SeniorNotes2019Due2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_4de714c7-d1a2-46f7-b0c3-317b0dbef6c7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of plaintiffs (in plaintiffs)</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_e139cf1a-f4a8-479a-a18e-2ee233625cf5_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_8a060737-ec3f-4c89-8f2b-9b06d2affb8e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Assets Target Allocations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Allocations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_59a9a067-0e6a-4e90-bc4b-f1ad69160edf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts recognized on the consolidated balance sheets consist of:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30d04f08-7bca-459c-beaf-d7f1f487a511_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9ddf7513-3e18-4821-af94-59218253c091_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:to="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_c81a5953-a00e-489c-b5de-95a2b7b1460f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated benefit obligation at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_eaad819d-b3ad-4a16-ac5f-f42f1bd7e12b_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward, no expiration</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:to="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_77f31336-9bce-4ba1-9da1-20512d49f482_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c9beade8-515a-4a3c-8eca-293cc027063b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherAccruedExpensesMember_e437c810-389d-40df-bcf1-d14e26737791_terseLabel_en-US" xlink:label="lab_mdt_OtherAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_mdt_OtherAccruedExpensesMember_label_en-US" xlink:label="lab_mdt_OtherAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Expenses [Member]</link:label>
    <link:label id="lab_mdt_OtherAccruedExpensesMember_documentation_en-US" xlink:label="lab_mdt_OtherAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember" xlink:href="mdt-20240426.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherAccruedExpensesMember" xlink:to="lab_mdt_OtherAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c9aa34d5-bfeb-4a94-9e0c-9ee124d0b56f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CranialAndSpinalTechnologiesDivisionMember_ade33041-0031-4b91-99d8-4ece46c0b94c_terseLabel_en-US" xlink:label="lab_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cranial &amp; Spinal Technologies</link:label>
    <link:label id="lab_mdt_CranialAndSpinalTechnologiesDivisionMember_label_en-US" xlink:label="lab_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cranial And Spinal Technologies Division [Member]</link:label>
    <link:label id="lab_mdt_CranialAndSpinalTechnologiesDivisionMember_documentation_en-US" xlink:label="lab_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cranial And Spinal Technologies Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:href="mdt-20240426.xsd#mdt_CranialAndSpinalTechnologiesDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:to="lab_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_0f293031-c66c-432c-b70a-69f5fb223479_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating segment</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_42154d72-850e-46ae-9ed6-743727822dc7_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based payments (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_74783da1-174f-4bd7-9f82-53affd39f9ad_totalLabel_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross Amount of Recognized Assets (Liabilities)</link:label>
    <link:label id="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_label_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset (Liability), Fair Value, Gross Asset (Liability)</link:label>
    <link:label id="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_documentation_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Asset (Liability), Fair Value, Gross Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:to="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember_aadb520e-3753-42ed-ac9b-68ea015158d8_terseLabel_en-US" xlink:label="lab_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. Developed Markets</link:label>
    <link:label id="lab_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember_label_en-US" xlink:label="lab_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Australia, New Zealand, Korea, Canada, and Western Europe [Member]</link:label>
    <link:label id="lab_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember_documentation_en-US" xlink:label="lab_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Japan, Australia, New Zealand, Korea, Canada, and Western Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember" xlink:href="mdt-20240426.xsd#mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember" xlink:to="lab_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_532e85db-4671-41dd-bc5e-e2c7cd264c0f_terseLabel_en-US" xlink:label="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]</link:label>
    <link:label id="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_documentation_en-US" xlink:label="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:href="mdt-20240426.xsd#mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:to="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_8fdf9580-ceb4-4d22-b8d5-7b87c13d5450_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_7e7dea46-0712-4c56-aa9c-3c66e0ff9b1b_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_0b0c8583-b214-43da-abd1-aceea4ede952_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_74a77c8c-f1d8-48aa-b286-be10b25848f2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationLiability_04ef793e-57ad-4078-a662-ae61338dab8e_terseLabel_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationLiability_label_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration, Liability</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationLiability_documentation_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationLiability" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationLiability" xlink:to="lab_mdt_BusinessAcquisitionContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_d2dda67b-b79b-49a8-9e28-3ddc0f582c78_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b0b9e58f-cff8-47c1-abea-a63374bb9380_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_d08bb25e-d075-47e1-8ac5-0ca39f3f837b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued litigations charges</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_07492d1f-889c-4668-b8b9-551f2cf47aef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_67a62e7b-dd1f-41a5-97de-91ec5ce59bcb_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_81b4521c-5b74-41b2-8311-3e12477b6c7f_terseLabel_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average purchase price (in dollars per share)</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_label_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_documentation_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:to="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_c81a9b1e-5ff1-4ae4-bc67-ad025b3bf510_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BusinessAcquisitionPriceContingentConsideration_d333e1b3-0772-4321-a3dc-b313364b2ab3_terseLabel_en-US" xlink:label="lab_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price contingent consideration</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionPriceContingentConsideration_label_en-US" xlink:label="lab_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Price Contingent Consideration</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionPriceContingentConsideration_documentation_en-US" xlink:label="lab_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Price Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionPriceContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:to="lab_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5eef5e73-9cde-4114-9da7-e5518755c235_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_d39916eb-7c60-4607-9441-5c0e0c0b447e_terseLabel_en-US" xlink:label="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental defined benefit, defined contribution and post-retirement</link:label>
    <link:label id="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_label_en-US" xlink:label="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Defined Benefit, Defined Contribution, And Post-Retirement Charges [Member]</link:label>
    <link:label id="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_documentation_en-US" xlink:label="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incremental Defined Benefit, Defined Contribution, And Post-Retirement Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:href="mdt-20240426.xsd#mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:to="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_96a3ff4e-84e5-4ac6-b3b7-6a76d54123ca_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2022Due2031Member_dd678d5c-c013-4e9e-852f-d589534e348d_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.125% Senior Notes due 2031</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due2031Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2031 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due2031Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2031Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2022Due2031Member" xlink:to="lab_mdt_SeniorNotes2022Due2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_fbb1452b-dca7-49b3-ab20-daa377aabea6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards, valuation allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_066741ff-26ef-407e-b065-9ed9c302288d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">More than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MechanicalCirculatorySupportMember_da72c5f5-6a7c-42e6-9087-653add2217ad_terseLabel_en-US" xlink:label="lab_mdt_MechanicalCirculatorySupportMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mechanical Circulatory Support</link:label>
    <link:label id="lab_mdt_MechanicalCirculatorySupportMember_label_en-US" xlink:label="lab_mdt_MechanicalCirculatorySupportMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mechanical Circulatory Support [Member]</link:label>
    <link:label id="lab_mdt_MechanicalCirculatorySupportMember_documentation_en-US" xlink:label="lab_mdt_MechanicalCirculatorySupportMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mechanical Circulatory Support</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MechanicalCirculatorySupportMember" xlink:href="mdt-20240426.xsd#mdt_MechanicalCirculatorySupportMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MechanicalCirculatorySupportMember" xlink:to="lab_mdt_MechanicalCirculatorySupportMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due2040Member_06010bd1-d974-4c6a-afb5-ed3dfbc22d0c_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.500 percent twenty-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2040Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2040 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2040Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2040Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due2040Member" xlink:to="lab_mdt_SeniorNotes2019Due2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_90675d1a-18df-471b-b145-1d5dc725941e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_f15868cd-5696-41ba-8ad5-3f35d2aad101_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a89364a2-4181-4d1d-b83d-e0d85b01bb36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c5234aa6-2f19-43bb-bc6d-98a248d0ca66_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EquityInvestmentsMember_e2f71867-9f7e-4050-9ae9-4fb84879827f_verboseLabel_en-US" xlink:label="lab_mdt_EquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity and Other Investments</link:label>
    <link:label id="lab_mdt_EquityInvestmentsMember_label_en-US" xlink:label="lab_mdt_EquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Investments [Member]</link:label>
    <link:label id="lab_mdt_EquityInvestmentsMember_documentation_en-US" xlink:label="lab_mdt_EquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquityInvestmentsMember" xlink:href="mdt-20240426.xsd#mdt_EquityInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EquityInvestmentsMember" xlink:to="lab_mdt_EquityInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_4e79d421-bbce-41f8-8181-8f8d68ca79d5_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of net actuarial loss (gain)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_a601b11f-c47d-4e12-bf95-dc74a6f5e7b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Performance Share Unit Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_ca05ea36-8601-4cfe-a01e-7543e055e906_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_StockRepurchaseProgramAveragePurchasePrice_ef7ecb17-c09d-45ae-9931-3828b3527163_terseLabel_en-US" xlink:label="lab_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average repurchase price (in dollars per share)</link:label>
    <link:label id="lab_mdt_StockRepurchaseProgramAveragePurchasePrice_label_en-US" xlink:label="lab_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Average Purchase Price</link:label>
    <link:label id="lab_mdt_StockRepurchaseProgramAveragePurchasePrice_documentation_en-US" xlink:label="lab_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average purchase price of common shares under a stock repurchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:href="mdt-20240426.xsd#mdt_StockRepurchaseProgramAveragePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:to="lab_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5356a13a-c3d3-4395-a887-90db9f173b56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_baccbd57-e07e-4e7d-929a-23b958a75af7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7b8305f2-9bdf-4327-8b98-bae6f34e9a83_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_f099cbd2-b0b7-4ff0-9e59-8541dd3a95e9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period over which remaining performance obligations are expected to be recognized as revenue</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5d2588d4-0dff-42dc-a8e7-1225719f104f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income including noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_16cbab81-42a8-4f60-bc75-e2fd10ec4ace_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_c0745041-cba9-4477-b490-c5a62966b8dd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain tax adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_227c63c4-6098-4075-adbf-b689fe5c19b6_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_b0beb859-4c66-49f7-9575-5e67ca883acb_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of ordinary shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2012Due2042Member_718b960c-750c-4f4c-a811-05b27f87f4b4_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2012Due2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.500 percent thirty-year 2012 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2012Due2042Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2012Due2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2012 Due 2042 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2012Due2042Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2012Due2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2042 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2012Due2042Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2012Due2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2012Due2042Member" xlink:to="lab_mdt_SeniorNotes2012Due2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_80b7b438-583d-4dae-a706-9bcbee9e00ea_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_30ab5108-8007-4ebb-863b-7afdbc868a83_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_fab5e9d4-f1ad-4651-a89f-1093ebcb87ca_negatedTotalLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">(Gain) Loss Reclassified into Income</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before TaxeclassificationBeforeTax</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before TaxeclassificationBeforeTax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" xlink:to="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ce82fd04-447a-4097-93f6-72b2f9fd9269_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Margin added per annum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5e03d65f-188d-4836-81cf-465a944734d7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_902d9b2a-aa68-4090-826b-82056f535948_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate &#8211; benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9d5d7fe2-6775-4d7d-b57f-fec8e2dc5148_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_db5b9c52-9bb1-4de5-a176-176eb9475137_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Charge associated with tax basis for Swiss Cantonal</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_534a1742-3cb5-4a08-9ba3-330c7a101fc5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_817d315f-49b7-4322-bb1e-b8af1f2241d8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_7bb3aff4-8b4c-46bd-bfaa-7cfeeaa4748a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_f3d505d5-0122-4c75-8ab6-3c91ebfb50e5_negatedTotalLabel_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_documentation_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:to="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_26b66b60-76b4-4c01-8cbc-5291c1ae62f9_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_925396ea-d11d-41d3-b8d9-0b5ed6c43f0c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts and Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6aaba601-3749-44f5-86f9-352fccd774ce_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_955279cc-e0aa-43f0-8e92-cb12d0833f33_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_b9256132-8297-4a49-8c73-442e98404740_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_a8e9b434-5319-46de-b44e-9546b621e03c_terseLabel_en-US" xlink:label="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non-Operating Income, Net</link:label>
    <link:label id="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_label_en-US" xlink:label="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net [Policy Text Block]</link:label>
    <link:label id="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_documentation_en-US" xlink:label="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:href="mdt-20240426.xsd#mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:to="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_66e17e28-2c33-42bc-9d01-04beb73665f0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_f06a4345-ed9f-48f4-8151-1b410e50cadf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_ec4d2548-7a8d-460d-a451-782df0354341_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_09c6364e-ec67-4eaa-a829-af8378f3b9de_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_3fdec425-aeff-4e08-a1df-49cd515663eb_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Pension Benefits</link:label>
    <link:label id="lab_country_US_5f573f0f-6c9c-4d70-9c92-1eeb9b088cfc_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_70b333eb-8cc4-4403-9ba2-cfbf1cc29a24_netLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_c93626d7-c9dd-47f5-92ee-71c1254da3ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_e9391d48-8ecd-4ed3-8e64-222f95369905_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_53a7ce8e-248e-4288-8ff7-448a3fd2e508_negatedTerseLabel_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Performance adjustments (in shares)</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_label_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_documentation_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:to="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c9987336-656e-452e-b846-ee02b7341e9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ed5612ad-4bca-4de7-95ec-770ef7d6f451_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4e1af1f3-e1d2-4fe0-a16e-265356815e28_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total expected lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_50d078ea-b8a4-48cc-8b71-e55664619d92_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired/Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_5db80824-d56c-4266-865b-0e3372235f92_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_7da3b631-2d7e-4eec-b731-1975c27bff83_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_2ea80c80-89c8-4058-8ff6-ee7d563c2cb9_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_7b57ff8d-f299-41b5-9e00-8416b7df9b2d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due2026Member_b54f6621-a2b5-47e1-877f-be1fdf74db22_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.250 percent six-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2026Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2026 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2026Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2026Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due2026Member" xlink:to="lab_mdt_SeniorNotes2019Due2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_714f3318-fd77-4a51-b6ac-c81e58aa7eaa_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_babf35a3-dfdc-40a2-a4fa-dc786a505133_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1dd9bb91-51a2-4fc6-b360-6e6d91333c56_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold, excluding amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_46a312cf-0941-4a90-b683-cfcb4c049981_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_f973f184-c9d0-4bca-bff1-37af930b0c5f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_178e9546-3e25-471c-ae61-aad6af594942_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingAssetsTableTextBlock_18789c2c-41f0-43cb-a1d3-fb66ab4d6cca_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Offsetting Assets</link:label>
    <link:label id="lab_us-gaap_OffsettingAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingAssetsTableTextBlock" xlink:to="lab_us-gaap_OffsettingAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_4e42ff65-4a19-4220-af87-e4e2f8f4f23f_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Tax Authorities</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_2296666b-9098-4a65-b0ba-1d3137b1049a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_63810791-59fd-44e3-be29-95b0d9ab18a7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5c33f28d-5af9-434b-a239-162679b54829_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_838c91de-0535-4070-ab52-ac9217839913_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating profit</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5b895d6e-aa73-4553-a1bd-c7a5b9f3d2bf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable segment operating profit</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A3125PercentNineYear2022SeniorNotesMember_ca25fef9-4707-445b-ac6b-87745f187455_terseLabel_en-US" xlink:label="lab_mdt_A3125PercentNineYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.125 percent nine-year 2022 senior notes</link:label>
    <link:label id="lab_mdt_A3125PercentNineYear2022SeniorNotesMember_label_en-US" xlink:label="lab_mdt_A3125PercentNineYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.125 Percent Nine-year 2022 Senior Notes [Member]</link:label>
    <link:label id="lab_mdt_A3125PercentNineYear2022SeniorNotesMember_documentation_en-US" xlink:label="lab_mdt_A3125PercentNineYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.125 Percent Nine-year 2022 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3125PercentNineYear2022SeniorNotesMember" xlink:href="mdt-20240426.xsd#mdt_A3125PercentNineYear2022SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A3125PercentNineYear2022SeniorNotesMember" xlink:to="lab_mdt_A3125PercentNineYear2022SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A3375PercentTwelveYear2022SeniorNotesMember_29cbfe70-1976-4796-be9d-6e234ae91150_terseLabel_en-US" xlink:label="lab_mdt_A3375PercentTwelveYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.375 percent twelve-year 2022 senior notes</link:label>
    <link:label id="lab_mdt_A3375PercentTwelveYear2022SeniorNotesMember_label_en-US" xlink:label="lab_mdt_A3375PercentTwelveYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.375 Percent Twelve-year 2022 Senior Notes [Member]</link:label>
    <link:label id="lab_mdt_A3375PercentTwelveYear2022SeniorNotesMember_documentation_en-US" xlink:label="lab_mdt_A3375PercentTwelveYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.375 Percent Twelve-year 2022 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3375PercentTwelveYear2022SeniorNotesMember" xlink:href="mdt-20240426.xsd#mdt_A3375PercentTwelveYear2022SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A3375PercentTwelveYear2022SeniorNotesMember" xlink:to="lab_mdt_A3375PercentTwelveYear2022SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_d6f57e0d-aea3-4618-b317-a89c6be19c7e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_e0ff06c9-4c7b-45cb-83ef-3dd20dc8cf96_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_76d0a976-cad5-44e4-b913-b7a37594a0f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense associated with the amortization of the previously established deferred tax assets</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_5f376219-027a-4ce7-b836-696e6a7256fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_ed23f470-b461-4206-b683-ab5ad42c312a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_b3711bd7-894f-4126-a18c-f207957d3775_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_3ff220c2-2763-4d7c-b1d8-4ca99dc587df_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_28aa4208-153e-405f-9d8a-65d6ab0dfcd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_66057a16-5ee4-409c-ac8c-07a2291f1968_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5df02861-35b7-4be6-8278-68ec9d66c428_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_6ba24e9a-63b7-42e5-be31-96a0ee0f0517_negatedTerseLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization and settlement recognition of actuarial (gain) loss</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Gain (Loss) Recognized in Net Periodic Benefit Cost, before Tax</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2012 Element. Before tax amount of the income statement impact of the reclassification adjustment for actuarial gain (loss) recognized as a component of net periodic benefit cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:to="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f7a38944-26c6-499b-8298-68a6651c44bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_63724007-60bb-4aca-abc6-377b3352dc47_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateralized Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_6e394579-d0f8-44ff-91c0-ab38e86e320c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Committed line of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2022Due2034Member_8c0c8a46-5022-4327-b4b6-bc6995b386fb_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.375% Senior Notes due 2034</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due2034Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2034 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due2034Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2034</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2034Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2022Due2034Member" xlink:to="lab_mdt_SeniorNotes2022Due2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_4fa537da-1232-4e98-9811-4acf5086232a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due2027Member_6ef01a47-7b42-4451-9965-4409daf61c3d_verboseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">1.125% Senior Notes due 2027</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2027Member_e69a515d-0772-422b-baec-bece85f37da0_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.125 percent eight-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2027Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2027 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2027Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2027Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due2027Member" xlink:to="lab_mdt_SeniorNotes2019Due2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_6f3a8bac-d164-409d-b217-83aade893c99_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_1c4c9ffb-bd42-41be-bb02-e3be3e2d7386_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_9e9ff694-29ba-4d81-a91b-2091b08a0737_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b8dc98c5-a5cb-4665-ac7c-9b18f3716678_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_291eab93-e53d-47df-9634-e487c1d07991_terseLabel_en-US" xlink:label="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total recognized in net periodic benefit cost and other comprehensive income</link:label>
    <link:label id="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax</link:label>
    <link:label id="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_documentation_en-US" xlink:label="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Before tax amount, net of reclassifications, of pension and other postretirement benefit plans (gain) loss included in comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="mdt-20240426.xsd#mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_862649d2-042b-4c65-88ea-5944240e380c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_PurchasedTechnologyAndPatentsMember_09cb941a-9aa3-4020-94e4-24d7422d401b_terseLabel_en-US" xlink:label="lab_mdt_PurchasedTechnologyAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased technology and patents</link:label>
    <link:label id="lab_mdt_PurchasedTechnologyAndPatentsMember_label_en-US" xlink:label="lab_mdt_PurchasedTechnologyAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchased Technology and Patents [Member]</link:label>
    <link:label id="lab_mdt_PurchasedTechnologyAndPatentsMember_documentation_en-US" xlink:label="lab_mdt_PurchasedTechnologyAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchased technology and patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PurchasedTechnologyAndPatentsMember" xlink:href="mdt-20240426.xsd#mdt_PurchasedTechnologyAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_PurchasedTechnologyAndPatentsMember" xlink:to="lab_mdt_PurchasedTechnologyAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_163d0f65-e0b0-42af-9041-762e5e9ef8f3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_447047d0-0622-4111-adc0-309a52dce524_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_84f2b335-6927-4438-8946-42c59fe47728_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_78578920-32f9-403b-a80e-ab4bf0ea9357_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_72a8ba42-3a64-4f9d-9359-6744c4dd39b6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_0bb92bf5-06a5-4985-83a8-34edaf9984d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Arrangements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_441676e9-d26a-4a83-adec-41ac84ca3284_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_aded6478-2228-40c8-bbb5-79a3812abc92_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d30b64f-9e62-49b4-be0a-177221b0379b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherPlanAssetsMember_5c145cda-eb90-4282-8048-e544ff1a53a3_terseLabel_en-US" xlink:label="lab_mdt_OtherPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mdt_OtherPlanAssetsMember_label_en-US" xlink:label="lab_mdt_OtherPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Plan Assets [Member]</link:label>
    <link:label id="lab_mdt_OtherPlanAssetsMember_documentation_en-US" xlink:label="lab_mdt_OtherPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other categories of plan assets not specified in the taxonomy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember" xlink:href="mdt-20240426.xsd#mdt_OtherPlanAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherPlanAssetsMember" xlink:to="lab_mdt_OtherPlanAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1b245d87-cc04-4bc7-8406-cb58d4717183_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_62f3635b-f301-4515-ae93-9f9bd180edce_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance share units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_fe371e56-6a44-4431-830d-2f2723b2840d_netLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Employee performance share units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_b12757c3-049c-4931-8787-47a74e2ea244_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0eaabd17-8859-461f-a117-f3b37b519617_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b2670ef3-a8c0-4e1f-94fa-89a675fe9860_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_1792d38b-c224-4549-adb7-a852bb899f2b_terseLabel_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares purchased by employees (in shares)</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_label_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_documentation_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:to="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IntersectENTMember_287c7e2b-e5a7-4ece-98e8-176987a5cd48_terseLabel_en-US" xlink:label="lab_mdt_IntersectENTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intersect ENT</link:label>
    <link:label id="lab_mdt_IntersectENTMember_label_en-US" xlink:label="lab_mdt_IntersectENTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intersect ENT [Member]</link:label>
    <link:label id="lab_mdt_IntersectENTMember_documentation_en-US" xlink:label="lab_mdt_IntersectENTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intersect ENT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IntersectENTMember" xlink:href="mdt-20240426.xsd#mdt_IntersectENTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IntersectENTMember" xlink:to="lab_mdt_IntersectENTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_f27db07a-bb95-4af2-9f1b-cb9514618a84_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BuildingsAndLeaseholdImprovementsMember_796d3711-33a7-49ec-9b18-24de8ff0c910_terseLabel_en-US" xlink:label="lab_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings and leasehold improvements</link:label>
    <link:label id="lab_mdt_BuildingsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings and Leasehold Improvements [Member]</link:label>
    <link:label id="lab_mdt_BuildingsAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:href="mdt-20240426.xsd#mdt_BuildingsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:to="lab_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_be429b9c-fa1f-4cd7-8543-c74c530b587b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of claimants (in claimants)</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_92b2d1aa-e190-4a5b-9774-f98f94ff2f37_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RevenueMilestoneMember_912d6f97-bcf9-40cc-8315-710d5c343dea_terseLabel_en-US" xlink:label="lab_mdt_RevenueMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue and other performance-based payments</link:label>
    <link:label id="lab_mdt_RevenueMilestoneMember_label_en-US" xlink:label="lab_mdt_RevenueMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Milestone [Member]</link:label>
    <link:label id="lab_mdt_RevenueMilestoneMember_documentation_en-US" xlink:label="lab_mdt_RevenueMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RevenueMilestoneMember" xlink:href="mdt-20240426.xsd#mdt_RevenueMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RevenueMilestoneMember" xlink:to="lab_mdt_RevenueMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_314bad34-f367-4409-815c-12d7f36d5404_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Notes 3, 16, and 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2041Member_72e3a6ed-00f5-4367-ae4a-bb67176222ee_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.375 percent twenty-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2041Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2041 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2041Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2041</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2041Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2041Member" xlink:to="lab_mdt_SeniorNotes2020Due2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_336fe8de-e7ce-42df-8570-f55d3383a81e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_d5a38709-cf3b-49cd-816a-6668b084cb4a_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_6a6e2cf5-c33a-4ee5-b9ad-ddf0583cf12e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Debt Security [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:to="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MedtronicLuxcoSeniorNotesMember_8586a983-316e-418f-ac09-4b09281b1573_terseLabel_en-US" xlink:label="lab_mdt_MedtronicLuxcoSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medtronic Luxco Senior Notes</link:label>
    <link:label id="lab_mdt_MedtronicLuxcoSeniorNotesMember_label_en-US" xlink:label="lab_mdt_MedtronicLuxcoSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medtronic Luxco Senior Notes [Member]</link:label>
    <link:label id="lab_mdt_MedtronicLuxcoSeniorNotesMember_documentation_en-US" xlink:label="lab_mdt_MedtronicLuxcoSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medtronic Luxco Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoSeniorNotesMember" xlink:href="mdt-20240426.xsd#mdt_MedtronicLuxcoSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MedtronicLuxcoSeniorNotesMember" xlink:to="lab_mdt_MedtronicLuxcoSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_3420ae64-0617-4943-b1b4-197f5cbf5ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_ca0dec19-6c38-44e6-b856-b1eee6d6dbe3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_551bd698-9282-40b6-b546-257103e01996_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S.</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_52611d0e-41f9-410a-91ba-2c8fcb93c835_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. Pension Benefits</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_13f29d29-72ea-4d9f-b6ac-58cbfb452020_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_434835ef-66b8-467f-9d7e-8e22b479b4af_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2015Due2045Member_bff94059-21a9-46c0-a407-556378b991f5_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2015Due2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.625 percent thirty-year 2015 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due2045Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2015Due2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2045 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due2045Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2015Due2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due2045Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2015Due2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2015Due2045Member" xlink:to="lab_mdt_SeniorNotes2015Due2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_32069115-37b4-43f8-9adc-b80df542b2c3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_5c2252e2-b1b6-4275-b6de-c0ec2d680683_negatedLabel_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Outside basis difference of subsidiaries</link:label>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_label_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Investment In Subsidiaries</link:label>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_documentation_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Investment In Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:to="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e4d2c072-b772-481d-8567-552abb84832e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a793b596-6dc3-427c-9621-504fa1c780df_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_b07f3e25-0e18-460e-8d3e-f02cb787d53a_negatedLabel_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_label_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration, Milestone Payment</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_documentation_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent milestone payments in business acquisition transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:to="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_725a4fdc-16ce-4e74-ab36-e486ad41aefc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f68d14-1451-4448-8562-99fdd3a1140a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_8a39be24-b6f0-4bcb-b4ac-f58c7357870d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value - Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_f44a4a23-c80f-4399-90c8-9d754d16d8f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Amount of Recognized Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_ecfe2f7d-0e7b-4881-b400-f510889b34ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact on diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0eb00ff5-570b-496a-8ce3-fed7e6bfb152_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_54f94a0f-4bb8-4cc7-b10a-659e3d6ac121_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MedicalDeviceRegulations_ce1cde94-d901-4c03-9793-acea5a39328e_negatedTerseLabel_en-US" xlink:label="lab_mdt_MedicalDeviceRegulations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Medical device regulations</link:label>
    <link:label id="lab_mdt_MedicalDeviceRegulations_label_en-US" xlink:label="lab_mdt_MedicalDeviceRegulations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Device Regulations</link:label>
    <link:label id="lab_mdt_MedicalDeviceRegulations_documentation_en-US" xlink:label="lab_mdt_MedicalDeviceRegulations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Device Regulations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalDeviceRegulations" xlink:href="mdt-20240426.xsd#mdt_MedicalDeviceRegulations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MedicalDeviceRegulations" xlink:to="lab_mdt_MedicalDeviceRegulations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_4137f316-a155-4dec-bd1a-9dfad83e3583_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_935f8719-3295-4626-a40a-14508b2b8ee5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_4f774ace-7944-49c9-b178-9fd21fb38fab_terseLabel_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross decreases:</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_label_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits Gross Decreases [Abstract]</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_documentation_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:href="mdt-20240426.xsd#mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:to="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_c21a2f0a-f903-4ff9-b16c-10621acf74c7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_a985a6c0-69b9-456a-8f6a-b5ff07e98e24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e066b94c-7bc7-469e-9c16-cb16a5eb344c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_7f2c724a-7bd5-4713-933e-fcffb4081d74_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_88c78738-b2d7-4318-abed-e487eca8f4f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99d8c85a-8abd-4706-8092-433ecfd2e41f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ImpairmentofInProcessResearchandDevelopment_d718db8b-90b9-48d9-abeb-86fa852a106f_negatedTerseLabel_en-US" xlink:label="lab_mdt_ImpairmentofInProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D charges</link:label>
    <link:label id="lab_mdt_ImpairmentofInProcessResearchandDevelopment_label_en-US" xlink:label="lab_mdt_ImpairmentofInProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of In Process Research and Development</link:label>
    <link:label id="lab_mdt_ImpairmentofInProcessResearchandDevelopment_documentation_en-US" xlink:label="lab_mdt_ImpairmentofInProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impairment of In Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ImpairmentofInProcessResearchandDevelopment" xlink:href="mdt-20240426.xsd#mdt_ImpairmentofInProcessResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ImpairmentofInProcessResearchandDevelopment" xlink:to="lab_mdt_ImpairmentofInProcessResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_65a46553-6037-4277-9eff-05eb091a7334_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_bbb1dcfc-f08d-42b4-a263-309a84511252_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_882149f5-98c7-47a2-aabe-d833f5ce56b5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_556b7666-68be-4318-bcc5-29e64fc90a89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_cb1ee698-5c98-4bd4-9fdf-990a0eea79db_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of senior notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_bae90882-58aa-4d39-8f23-bb75572fda9f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Medtronic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4c0163b8-e421-42b2-9c3a-30b248346d83_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to ordinary shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f8b1a3f0-0d0f-4c74-a247-e578ac1e6173_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_42a12b90-ac81-4c34-ba24-6cbbaae0aadf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_3e0c454d-f6a5-4eaa-8e1f-58fbc1b0cff6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0cf3e1f2-2757-4d76-b4a1-62e58bd35f0c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_67902734-348c-4b91-b78d-8df998294d7e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_8c47a90e-99e2-492f-bc06-a5030732c27a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_982f3e69-ab9d-4142-ba21-33f624bf14ce_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9d2e4116-92e4-4dfe-9991-5cab47e33b02_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_04c9cebe-95a2-4ac8-b521-f6890855cbdb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8b671a70-1802-44c4-85a5-4c67a5490516_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_3ddef05d-b142-4276-bdb8-f8fe343b8fcd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency exchange rate changes and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_ad11d6e8-920a-4984-bd31-ad520d9f838b_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RenalCareBusinessRCSMember_672ce795-a521-4b76-99cf-dde1b8f0a331_terseLabel_en-US" xlink:label="lab_mdt_RenalCareBusinessRCSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renal Care Business (RCS)</link:label>
    <link:label id="lab_mdt_RenalCareBusinessRCSMember_label_en-US" xlink:label="lab_mdt_RenalCareBusinessRCSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Renal Care Business (RCS) [Member]</link:label>
    <link:label id="lab_mdt_RenalCareBusinessRCSMember_documentation_en-US" xlink:label="lab_mdt_RenalCareBusinessRCSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Renal Care Business (RCS)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareBusinessRCSMember" xlink:href="mdt-20240426.xsd#mdt_RenalCareBusinessRCSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RenalCareBusinessRCSMember" xlink:to="lab_mdt_RenalCareBusinessRCSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ba591cf-c1b2-4fb5-aac0-57cac8a37021_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, (Gain) Loss [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4efbfcfa-1fa2-4107-bc0a-0fdc4dc178ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fe6fdc49-8946-4b1b-96ac-5762a8813fe6_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_579b7fe6-a337-4557-a39a-803df3af992b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognized in AOCI, Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c682e98c-582a-4a33-945c-a44e596678db_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_54a60c63-774a-44ff-80ea-d5fd9b8724e4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold, excluding amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_96588574-bc63-4cb8-bbd4-f46204ac5cf8_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9a1f1782-0599-4196-a9ab-6136f1ac6282_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Recognized asset (liability)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_05a17cc6-909d-4bd1-9584-a02ab4b4e840_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Major Tax Jurisdictions Which Remain Subject to Examination</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Income Tax Examinations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxExaminationsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9e067495-c389-47d1-bd47-2ea489aecb42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_b015e4e5-2728-4779-907d-2307c0a39b27_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotesCIFSA2007Due2038Member_556c5869-c7cb-452b-8bdc-262d80f758cf_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotesCIFSA2007Due2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.550 percent thirty-year 2007 CIFSA senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotesCIFSA2007Due2038Member_label_en-US" xlink:label="lab_mdt_SeniorNotesCIFSA2007Due2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes CIFSA 2007 Due 2038 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotesCIFSA2007Due2038Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotesCIFSA2007Due2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes CIFSA 2007 Due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesCIFSA2007Due2038Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesCIFSA2007Due2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotesCIFSA2007Due2038Member" xlink:to="lab_mdt_SeniorNotesCIFSA2007Due2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_06db563a-b335-4c63-9944-1aaffed8539f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gross Carrying Amount of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_67151678-b1ab-4e61-8879-1e720969a1a3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_1e96aa78-f269-402d-9308-2202c322e1a6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency exchange rate contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DebtLineItems_851207c6-d02e-4117-9a91-fbeceed11163_terseLabel_en-US" xlink:label="lab_mdt_DebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt [Line Items]</link:label>
    <link:label id="lab_mdt_DebtLineItems_label_en-US" xlink:label="lab_mdt_DebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt [Line Items]</link:label>
    <link:label id="lab_mdt_DebtLineItems_documentation_en-US" xlink:label="lab_mdt_DebtLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtLineItems" xlink:href="mdt-20240426.xsd#mdt_DebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DebtLineItems" xlink:to="lab_mdt_DebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e87d7daf-4620-48a4-bb95-714e16c2125b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_5cc9e2b3-0377-4200-ac44-5445b68fd869_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_aa901a94-2426-4d94-b9eb-b6d0d0a2e6c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_801a4d1e-4bc8-4217-bba1-8c11b6608b14_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_PartnershipUnitsMember_0ba866c7-99f4-4319-a730-aaea47d07245_terseLabel_en-US" xlink:label="lab_mdt_PartnershipUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partnership units</link:label>
    <link:label id="lab_mdt_PartnershipUnitsMember_label_en-US" xlink:label="lab_mdt_PartnershipUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partnership Units [Member]</link:label>
    <link:label id="lab_mdt_PartnershipUnitsMember_documentation_en-US" xlink:label="lab_mdt_PartnershipUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Partnership units include partnerships, private equity investments, and real asset investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember" xlink:href="mdt-20240426.xsd#mdt_PartnershipUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_PartnershipUnitsMember" xlink:to="lab_mdt_PartnershipUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_InsuranceContractMember_06640ef4-1ef3-4ef1-b5ba-41dab6732e11_terseLabel_en-US" xlink:label="lab_mdt_InsuranceContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance contracts</link:label>
    <link:label id="lab_mdt_InsuranceContractMember_label_en-US" xlink:label="lab_mdt_InsuranceContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Contract [Member]</link:label>
    <link:label id="lab_mdt_InsuranceContractMember_documentation_en-US" xlink:label="lab_mdt_InsuranceContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_InsuranceContractMember" xlink:href="mdt-20240426.xsd#mdt_InsuranceContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_InsuranceContractMember" xlink:to="lab_mdt_InsuranceContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_2fde3bd7-1240-4b6d-9809-b8e817acfaef_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_20dfe4b4-b7d6-481d-985d-f08049f8a20f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_b8c56c3d-377f-405c-a6f1-1211dac36013_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in current debt obligations, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SubsidiariesMember_4b4d87bc-6f28-409a-bc67-46f644fc4e91_terseLabel_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries</link:label>
    <link:label id="lab_srt_SubsidiariesMember_label_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember" xlink:to="lab_srt_SubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8cc21e96-494a-41b2-bcad-e7608e712066_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_e6b64615-ce9d-4e7f-b1bc-713abbf1b0d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends to shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f91bc83c-459b-46a1-b09e-7cf532846e15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investment securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_4a503a73-e639-4609-984f-bc514bad0fd0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funded status at end of year:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_522f19f4-28c3-41d5-83aa-aae44483ac06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_4a1b0cec-efee-4e9a-b250-b25975545df2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_8e20d6f1-ca0a-4825-b3e1-c04bbdc973ff_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Debt Securities Contractual Maturities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DiabetesGroupMember_c1e31140-1f40-479b-9822-fe754189747d_terseLabel_en-US" xlink:label="lab_mdt_DiabetesGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_mdt_DiabetesGroupMember_4305be9d-45ec-4bc1-828c-5735a39cd748_verboseLabel_en-US" xlink:label="lab_mdt_DiabetesGroupMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_mdt_DiabetesGroupMember_label_en-US" xlink:label="lab_mdt_DiabetesGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diabetes Group [Member]</link:label>
    <link:label id="lab_mdt_DiabetesGroupMember_documentation_en-US" xlink:label="lab_mdt_DiabetesGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diabetes Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DiabetesGroupMember" xlink:to="lab_mdt_DiabetesGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_c770e732-1a93-4365-aa26-f6c8b1508559_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_96341c6b-dfbe-49de-bae3-9e773298de0d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7fe6aa9f-e172-4c3b-9358-9396872c6327_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3c9798dd-b4fa-4702-a8db-4bf81498b65f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_48bd5172-9245-46c2-b5d5-f2bb927d7ace_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and retirement benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_38bf0639-bf5b-43e8-980e-7651fa1ac3e0_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_b75bb9e5-00eb-4229-be97-25d9f9bddf06_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_03adaa8b-c903-48a3-b629-0d3b96a09d59_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3f70e279-9198-4559-b5d1-0bf32a48bd7e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_3e902422-7b9f-466e-ac7c-bfc024191b65_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in projected benefit obligation:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_aa2bfc9f-9520-4c01-86d1-bdee44a21f22_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption of senior notes, consideration</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_31b4413c-16e3-4e90-9d5b-75a8416a3381_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_db07562a-2a9d-4a65-9bc4-c71c0562fb91_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_781b463b-2bb7-4089-9b04-c1cdb8401d6c_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undistributed earnings from non-U.S. subsidiaries</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A3000PercentSixYear2022SeniorNotesMember_dd5fd3b5-decc-4ec7-9214-57fed1bd58e8_terseLabel_en-US" xlink:label="lab_mdt_A3000PercentSixYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.000 percent six-year 2022 senior notes</link:label>
    <link:label id="lab_mdt_A3000PercentSixYear2022SeniorNotesMember_label_en-US" xlink:label="lab_mdt_A3000PercentSixYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.000 Percent Six-year 2022 Senior Notes [Member]</link:label>
    <link:label id="lab_mdt_A3000PercentSixYear2022SeniorNotesMember_documentation_en-US" xlink:label="lab_mdt_A3000PercentSixYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.000 Percent Six-year 2022 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3000PercentSixYear2022SeniorNotesMember" xlink:href="mdt-20240426.xsd#mdt_A3000PercentSixYear2022SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A3000PercentSixYear2022SeniorNotesMember" xlink:to="lab_mdt_A3000PercentSixYear2022SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A2024EmployeeStockPurchasePlanMember_49094f48-7107-490e-904b-d1b18c74cc22_terseLabel_en-US" xlink:label="lab_mdt_A2024EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mdt_A2024EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mdt_A2024EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mdt_A2024EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mdt_A2024EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2024EmployeeStockPurchasePlanMember" xlink:href="mdt-20240426.xsd#mdt_A2024EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A2024EmployeeStockPurchasePlanMember" xlink:to="lab_mdt_A2024EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0a77cc16-197a-4c83-bccb-c207f6a072f7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_f1e23f7a-21a3-4274-ab7c-c9f4b7c140f8_terseLabel_en-US" xlink:label="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Classification of Operating Leases and Amounts of Right-of-Use Assets and Lease Liabilities</link:label>
    <link:label id="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="mdt-20240426.xsd#mdt_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_61083aca-2134-4f4e-82ee-76b00a78822d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_d5edd40d-787b-4154-b452-7356b6371948_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_52823b39-1e0e-46de-a58c-a23c6483192a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2033Member_0fcc9819-0452-4799-b95d-bcaa5ed748c3_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.750 percent twelve-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2033Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2033 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2033Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2033Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2033Member" xlink:to="lab_mdt_SeniorNotes2020Due2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1b5946da-73f0-4ef0-8d48-3a64feb5ce67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value, option gain (loss)</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1bbdf6c-d291-4804-ad39-44bd00bf5077_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_4fa2608c-6032-4c8f-932d-48766d549a54_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions_794e7c33-d05a-45cc-9542-53823efb2c5c_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension and post-retirement benefits</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits and Pensions</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from pension and postretirement benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" xlink:to="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f4076ac6-4a59-4213-b0aa-cbc61561ffcf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9a441411-cdb3-4b5e-8d5a-939eaf9c381d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_cb83811d-f80b-4071-ba7b-150f47741a74_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dbf930cd-1d6d-4bc2-ae4c-8b63ea3dd865_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to restricted stock awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f7d765aa-a696-4cf0-b78f-163cc3488dd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2c8f7b4a-702d-477f-9e04-638d268e5266_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares purchased by employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e07c487e-e1de-450b-a0f1-cce935af9d26_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_2c83f00d-01f0-46fc-ab33-4043a2645984_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_17c2e56d-20e2-4457-9b9d-4baf1fa50dd1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_2ef77753-0602-4821-9be8-5fc4dcfb8c17_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_44b54c7d-f48c-40f9-816d-5dd069058c44_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotesDue2053Member_1106ef51-8ef5-4e0c-bd45-444c22f7853d_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotesDue2053Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.150% Senior Notes due 2053</link:label>
    <link:label id="lab_mdt_SeniorNotesDue2053Member_label_en-US" xlink:label="lab_mdt_SeniorNotesDue2053Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2053 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotesDue2053Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotesDue2053Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2053</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2053Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2053Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotesDue2053Member" xlink:to="lab_mdt_SeniorNotesDue2053Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2029Member_2bc943a1-f1f8-4a9d-aa75-e66c1d397e47_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.375 percent eight-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2029Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2029 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2029Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2029Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2029Member" xlink:to="lab_mdt_SeniorNotes2020Due2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_fb19adbe-5649-4bd8-a833-68a0b5dfa834_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IncomeTaxesandInterestPaidAbstract_260b50cd-43d1-4821-b9aa-374d9b933016_terseLabel_en-US" xlink:label="lab_mdt_IncomeTaxesandInterestPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for:</link:label>
    <link:label id="lab_mdt_IncomeTaxesandInterestPaidAbstract_label_en-US" xlink:label="lab_mdt_IncomeTaxesandInterestPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes and Interest Paid [Abstract]</link:label>
    <link:label id="lab_mdt_IncomeTaxesandInterestPaidAbstract_documentation_en-US" xlink:label="lab_mdt_IncomeTaxesandInterestPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes and Interest Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxesandInterestPaidAbstract" xlink:href="mdt-20240426.xsd#mdt_IncomeTaxesandInterestPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IncomeTaxesandInterestPaidAbstract" xlink:to="lab_mdt_IncomeTaxesandInterestPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_364c6aeb-39c9-4bbe-8394-31e960d18f47_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_e02a44ed-9d31-4ae0-9e60-4f7969ad2954_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ScheduleOfDebtTable_01cede27-e7a8-45cc-869b-3960aa1cc338_terseLabel_en-US" xlink:label="lab_mdt_ScheduleOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Debt [Table]</link:label>
    <link:label id="lab_mdt_ScheduleOfDebtTable_label_en-US" xlink:label="lab_mdt_ScheduleOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Debt [Table]</link:label>
    <link:label id="lab_mdt_ScheduleOfDebtTable_documentation_en-US" xlink:label="lab_mdt_ScheduleOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ScheduleOfDebtTable" xlink:href="mdt-20240426.xsd#mdt_ScheduleOfDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ScheduleOfDebtTable" xlink:to="lab_mdt_ScheduleOfDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4196a8ed-de30-482f-b5cf-0eb12e0f6a71_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_919ff004-1af7-4bf4-8ecc-fc8656a5ce54_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_537554d9-f5fc-4dae-b0a6-f3c91ba17636_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a866cff7-a827-4d75-a1a6-e807ee19e1ef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d8fed416-7c7e-4fa3-a742-d8f53a9c9a8e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (Loss) Gain on Investment Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_b10c926e-f9a2-49c4-b325-d0e1536a5c9a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_c55b8003-3e27-4d20-b303-aac9ce100cf6_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_bf7666cc-b642-4881-9900-36e6a18125cb_terseLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operation, other operating expense, net</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_documentation_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:to="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_e786962f-1da2-483e-a469-ec3dfcf15731_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_75e6f916-287c-4eaf-aae3-f4de0fb49b57_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f1e6db05-27db-4a94-96c0-34d67cee2c6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e0a0e85a-f4a9-47fe-beb4-d4cc82ea7835_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d35b42f7-e4ab-4e84-af6b-879699464602_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_29482ea6-8827-46a7-a6a7-52a7db35ec4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_57fe858d-f84a-4f3b-9757-f6eeacdf0a3c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_72667c66-e710-4341-a183-a76f9541b291_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e245253-5247-4789-8a3a-67d5b83bf17b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36c5ae56-a96f-4f73-b7c6-70edd3413576_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_3c8f84d6-41f0-4812-913c-f7b044212106_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_21ec7564-2d92-40de-9c92-3f3bdfc6b5bb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actual Allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_238363d1-fbcd-4b88-aa92-48b5a331ba3a_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_4d06427d-ceb8-4983-b771-219b5319040e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_beb49b6b-cbfe-4c3b-867a-f7c90098ac64_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_f6e1bc8b-71f3-44ff-8970-fe17829819b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1c09b118-ecd6-44a8-9e97-2a6bfe207619_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_4b560c74-fc7c-47a2-866a-09139c2c46a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_94f69988-bd6e-404a-9aac-abf9a7f372e7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_27d740f8-8de2-4bef-8beb-0a45768a58b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1544d382-bd7f-470e-afe7-b5c91a0701e4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_12cb9059-7ff5-4841-ad9f-8265f3d2e156_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SurgicalInnovationsDivisionMember_384d5ee2-55f9-4857-a4e6-ff20753caae4_terseLabel_en-US" xlink:label="lab_mdt_SurgicalInnovationsDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Surgical &amp; Endoscopy</link:label>
    <link:label id="lab_mdt_SurgicalInnovationsDivisionMember_label_en-US" xlink:label="lab_mdt_SurgicalInnovationsDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surgical Innovations Division [Member]</link:label>
    <link:label id="lab_mdt_SurgicalInnovationsDivisionMember_documentation_en-US" xlink:label="lab_mdt_SurgicalInnovationsDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Surgical Innovations Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SurgicalInnovationsDivisionMember" xlink:href="mdt-20240426.xsd#mdt_SurgicalInnovationsDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SurgicalInnovationsDivisionMember" xlink:to="lab_mdt_SurgicalInnovationsDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_496cf761-58ed-4a57-93de-effa13b76b87_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLossNetOfTax_ebe8c837-df97-4ddf-a822-49ea89ccc683_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, net of tax</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:to="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_a82cb9fc-02bd-4e10-b5db-8ceda29d3ef5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_3c069945-9642-4991-b4b7-0a817412cc42_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at Beginning of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_759a1b65-78fc-4d10-849e-0a10022e11c0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at End of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_719d6a59-4960-4437-a99c-224fa5f7272f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period over which unrecognized compensation is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CardiacRhythmandHeartFailureDivisionMember_9f8248ed-34d1-4bb2-91f5-d671847c6ecb_terseLabel_en-US" xlink:label="lab_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardiac Rhythm &amp; Heart Failure</link:label>
    <link:label id="lab_mdt_CardiacRhythmandHeartFailureDivisionMember_label_en-US" xlink:label="lab_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiac Rhythm and Heart Failure Division [Member]</link:label>
    <link:label id="lab_mdt_CardiacRhythmandHeartFailureDivisionMember_documentation_en-US" xlink:label="lab_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardiac Rhythm and Heart Failure Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:href="mdt-20240426.xsd#mdt_CardiacRhythmandHeartFailureDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:to="lab_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_36189c6b-66c6-4669-a16b-a1b7535d4482_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_21689440-b396-45db-b87c-85a5a03cc917_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Medtronic</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_8362fd82-f3c8-41db-9a47-80dd4119b17c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DerivativeAssetLiabilityAbstract_3ae070d2-f421-4b1c-9e59-44cd05debaed_terseLabel_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mdt_DerivativeAssetLiabilityAbstract_label_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset (Liability) [Abstract]</link:label>
    <link:label id="lab_mdt_DerivativeAssetLiabilityAbstract_documentation_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Asset (Liability) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityAbstract" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract" xlink:to="lab_mdt_DerivativeAssetLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_5eaa1e11-c56b-4665-9761-ab6461f3d614_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank borrowings</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_62a92391-02ec-4c3c-a36b-d23d42174009_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net underfunded status of the plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_5c2cfaa3-212f-447b-9d62-b757a1592a20_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Over (under) funded status of the plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_ddbf17b0-27f1-4394-b5fa-e00c71af8222_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax charge</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_599b065b-cd21-4e4e-8f6c-606545326b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5077e334-8d71-4c9e-ad94-4887dcc6a8f5_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_74e0f420-1d4d-4237-988b-0d6fd452069d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense_e883be2d-d9cd-4837-ac3a-ede43156fa18_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_ef08f05b-48eb-4ace-b82c-8255a2f94fd3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan assets at fair value</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_dcefffa2-f502-4771-a3cb-1c27427036b6_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets/(Liabilities):</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotesDue2029Member_d20a96b8-3f2e-47b9-be30-9a0247915cf5_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.650% Senior Notes due 2029</link:label>
    <link:label id="lab_mdt_SeniorNotesDue2029Member_label_en-US" xlink:label="lab_mdt_SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2029 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotesDue2029Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2029Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotesDue2029Member" xlink:to="lab_mdt_SeniorNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6f2c5d56-e58b-4366-8191-e7e293bc8a7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wtd. Avg. Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_48f6f0b1-ddaf-4a05-a571-1fa99c0d42ca_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_2207e06d-fbb1-4ba2-802c-a6263da7bb2c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ee92a253-891e-4c93-bfd5-01ae25a0841d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income tax penalties and interest</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_42729b73-f988-45a7-954f-b718ef02c251_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_cc7d41a2-cc73-4f09-8171-aeac206c5d53_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_98ee0234-b81f-4cd3-9049-e38f0da352ed_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges, net</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4df2bb08-e565-43c4-a161-3bca1b04cb34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_089b84cc-b3d2-4bc5-a1d1-0bfe4a0429ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f967bbf4-ab6b-45ab-adbc-570b7f409a3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_46ef5bf0-24ba-45d9-b55d-3d98f993707a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b837048e-ce99-414a-9c3f-93d8a91695a6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_295e03fe-b6a7-4749-8807-406787fe3615_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_775359b2-9905-4b87-aa3a-95f8925e76cc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_a133b6e6-dd35-4580-ab6d-a419abe00eb0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3e81deb1-64c1-4084-9399-5775917909fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_2fbd1079-9d51-4065-91a2-1d0e6935db5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2595fe20-3352-4e84-a0ab-91a2fbb5199d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares under stock purchase and award plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_16ec25dc-7424-4c39-a253-dccc313e7888_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_14e5f634-2ec5-4fe9-8b15-86253ba1935e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_2f656a8b-8e76-48de-963d-8a62ce51af14_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_9667be5b-cfdb-4fdb-ae69-af82816752fc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_929d736b-523b-4d20-8289-d139a46344d7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior service cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_0ddcd9db-02fd-4151-b8e2-4f9758f02451_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method and other investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e7a5ec15-c700-4a87-8f60-545d0730b62a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_221d5c72-10e1-4639-b270-06750b3d1a7c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4f1fe7e6-8e96-45ce-a74a-d0760ead9653_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AcuteCareMonitoringMember_181d4542-eff0-41b7-aa39-2a2275dd784c_terseLabel_en-US" xlink:label="lab_mdt_AcuteCareMonitoringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acute Care &amp; Monitoring</link:label>
    <link:label id="lab_mdt_AcuteCareMonitoringMember_label_en-US" xlink:label="lab_mdt_AcuteCareMonitoringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acute Care &amp; Monitoring [Member]</link:label>
    <link:label id="lab_mdt_AcuteCareMonitoringMember_documentation_en-US" xlink:label="lab_mdt_AcuteCareMonitoringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acute Care &amp; Monitoring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AcuteCareMonitoringMember" xlink:href="mdt-20240426.xsd#mdt_AcuteCareMonitoringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AcuteCareMonitoringMember" xlink:to="lab_mdt_AcuteCareMonitoringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_3992bf52-9a5c-4db8-8078-c05d71181906_terseLabel_en-US" xlink:label="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on interest rate cash flow hedges</link:label>
    <link:label id="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Interest Rate Cash Flow Hedges, Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_documentation_en-US" xlink:label="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of unrealized gain (loss), net of tax as of the balance sheet date, related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="mdt-20240426.xsd#mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_9b9e7b38-72df-41e1-bf4a-40400ad1ce09_terseLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash impairments</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_label_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Non-cash Impairments</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_documentation_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Non-cash Impairments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:to="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_f771f608-fade-4462-8977-5b210c566fde_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8da60b32-0731-4aff-8a6c-f405ebb2c0af_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of ordinary shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_08d9ebff-8194-4ddf-95cb-3bb804612a21_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ef62fef6-bc75-4947-8567-408f8fc6e1a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_c9fe6a0f-f1de-4e64-820f-258646649654_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_9bee7f88-bc95-40f4-bd27-7dbe7f50dbd0_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed income commingled trusts</link:label>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Income Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeFundsMember" xlink:to="lab_us-gaap_FixedIncomeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_b13ac1ab-0897-4ec8-b5b0-c6ee18d81dff_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_2fc36ed9-9083-4ba1-938a-abaf7090a969_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases and sales, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_6d431f63-7120-416e-a3a8-78b40302d3a9_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_ec34468e-21c3-48dd-9254-e9bff7d73092_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6a78788-c447-4d30-951d-bdbe53f4b237_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_e9fb0560-a783-42ac-93df-dff22674d529_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_68a190e8-4b44-40cb-a9be-13b25fe6c1a5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_85da10a5-7a5c-4d37-9c44-c7ee4d3c155f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain litigation charges, net</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_ac581863-c0dc-4342-b903-449bdb5da768_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Certain litigation charges, net</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CardiovascularMember_f6a456e9-8996-4a51-9717-95186ad56e3b_terseLabel_en-US" xlink:label="lab_mdt_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardiovascular</link:label>
    <link:label id="lab_mdt_CardiovascularMember_5d49fdf9-6e83-4f0d-84f9-70e9299f138b_verboseLabel_en-US" xlink:label="lab_mdt_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cardiovascular</link:label>
    <link:label id="lab_mdt_CardiovascularMember_label_en-US" xlink:label="lab_mdt_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiovascular [Member]</link:label>
    <link:label id="lab_mdt_CardiovascularMember_documentation_en-US" xlink:label="lab_mdt_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardiovascular</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CardiovascularMember" xlink:to="lab_mdt_CardiovascularMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_e3958542-a2a8-4980-912e-80f1ae553bbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_1cdc7549-c9cf-475e-9e7f-d9b168dd80df_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_37c7ff41-a729-4b92-9ba8-5839e234490f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_efacb6d3-9548-4d09-859f-7635841a5998_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c6057d01-4769-44ee-a2c9-08ca8b666ce3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer to held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_adeb30ed-6c28-4b00-a066-dfa688253f8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e394913-21d9-40ca-acbb-1fbf7ed85499_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_7d12d57a-6ca3-4b70-9494-38549dcd0591_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax reconciliation, disallowance of interest deductions, amount</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:to="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5a5972ca-2465-433e-9022-dd780b6d1156_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_d944f1ad-8889-4fff-9a04-bd49ddc2d613_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combinations</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_05ecb2a4-2f6b-4f98-89f3-cd1bc63b21f3_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_c3dc91bb-80d1-4818-abe0-b5271ece70b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from short-term borrowings (maturities greater than 90 days)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AfferaIncMember_dd41f1fd-9dcb-4e20-b47c-ef5e65fb18be_terseLabel_en-US" xlink:label="lab_mdt_AfferaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affera</link:label>
    <link:label id="lab_mdt_AfferaIncMember_label_en-US" xlink:label="lab_mdt_AfferaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affera Inc [Member]</link:label>
    <link:label id="lab_mdt_AfferaIncMember_documentation_en-US" xlink:label="lab_mdt_AfferaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affera Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AfferaIncMember" xlink:href="mdt-20240426.xsd#mdt_AfferaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AfferaIncMember" xlink:to="lab_mdt_AfferaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b267bc90-9432-4a67-a782-1edd92cd0de9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3d59a2ce-7072-4353-8082-c9909367feb2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_cb55a431-6670-4af0-b2e4-0f43fed7a8bf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value - Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_2928747b-a1b8-4c59-8c0e-a393afba825a_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Amount of Recognized Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e20847c5-3b54-463c-9524-608bf99fc956_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b58ab572-e8ff-4c71-8204-6803b1b92489_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due2049Member_d5d861b7-5a61-4336-95e5-80d2c8276d3e_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.750% Senior Notes due 2049</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2049Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2049 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2049Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2049Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due2049Member" xlink:to="lab_mdt_SeniorNotes2019Due2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_96c5e0a9-5aab-425b-80d0-31b7860dcbb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory Balances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_4dce4c5f-cd89-410c-970c-133924706875_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain tax adjustments, provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1bf257fe-5167-483c-8e48-ac988bf72ac2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c78096e8-2efe-4b35-8b1b-218dcf115be5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ddb29a01-a6c5-4c1b-9442-6f6094f3b328_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2050Member_20fe5f8b-8a69-4ee4-a85f-1c83beac2f10_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625% Senior Notes due 2050</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2050Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2050 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2050Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2050Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2050Member" xlink:to="lab_mdt_SeniorNotes2020Due2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4b6586ea-07b9-49b5-918d-ce6d9ca6fe63_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_a9040c28-1858-4a1d-87d6-cceaedc1f4cb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total recognized in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_170c2e2b-5620-4d6b-8d54-ca2a6a04c67d_terseLabel_en-US" xlink:label="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Operating Expense (Income), Net</link:label>
    <link:label id="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_label_en-US" xlink:label="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net [Policy Text Block]</link:label>
    <link:label id="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_documentation_en-US" xlink:label="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:href="mdt-20240426.xsd#mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:to="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_0d10533a-3d1a-4814-aaef-7f92e78bc42a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits, net of cash advance, noncurrent liability</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4ffeac9d-9e81-4ca6-9344-5c035f7aa7d6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_52f2b29c-b0a1-4c79-851d-88bcee3d4f05_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3cb3444d-f7a3-4a62-961f-83c28c9eee6e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_22f7a92f-6956-4f99-a820-a96956b3f3b1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges to Income</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_3ee5d154-82d4-40ab-ac10-af8a6c360cef_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense under defined contribution plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_ba3f3e15-be62-4f2a-8023-e5561616c5e8_terseLabel_en-US" xlink:label="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_label_en-US" xlink:label="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty One Stock Award and Incentive Plan [Member]</link:label>
    <link:label id="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_documentation_en-US" xlink:label="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty One Stock Award and Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:href="mdt-20240426.xsd#mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:to="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_7a2312fe-f8a1-4abd-af3f-c379dbb73310_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AuctionRateSecuritiesMember_2ab9695b-ba25-4999-9367-b47864e54184_terseLabel_en-US" xlink:label="lab_us-gaap_AuctionRateSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auction rate securities</link:label>
    <link:label id="lab_us-gaap_AuctionRateSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AuctionRateSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auction Rate Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AuctionRateSecuritiesMember" xlink:to="lab_us-gaap_AuctionRateSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b1232920-3447-43a9-8015-d888023b81b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_15cf7f99-ef27-4d97-b6c4-16a762876ad0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Change in Retirement Obligations</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A4500PercentTenYear2023SeniorNotesMember_f7409b1d-7041-4703-b1bd-7127cd3ed028_terseLabel_en-US" xlink:label="lab_mdt_A4500PercentTenYear2023SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.500 percent ten-year 2023 senior notes</link:label>
    <link:label id="lab_mdt_A4500PercentTenYear2023SeniorNotesMember_label_en-US" xlink:label="lab_mdt_A4500PercentTenYear2023SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.500 Percent Ten-year 2023 Senior Notes [Member]</link:label>
    <link:label id="lab_mdt_A4500PercentTenYear2023SeniorNotesMember_documentation_en-US" xlink:label="lab_mdt_A4500PercentTenYear2023SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.500 Percent Ten-year 2023 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4500PercentTenYear2023SeniorNotesMember" xlink:href="mdt-20240426.xsd#mdt_A4500PercentTenYear2023SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A4500PercentTenYear2023SeniorNotesMember" xlink:to="lab_mdt_A4500PercentTenYear2023SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3d87d42e-d760-4e3a-9934-8d351fadf01c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9aaa63d0-84b8-4da8-b5be-e4855167e558_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a0c332c3-1353-481a-a899-1877f22490c0_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_d0c2f190-05f8-4da5-ab71-026bc1539731_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_89af8adc-2346-4950-a2bb-ef709e855985_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_84b7c149-a614-4e5a-85ba-64e4d48b9f82_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares&#8212; par value $0.0001, 2.6 billion shares authorized, 1,311,337,531 and 1,330,809,036 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2d7b6838-e9ee-4d32-b446-207d93ec03a1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d9cf461a-4075-4d70-bc11-0a3112c3af70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments measured at net asset value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotesDue2036Member_c1caa41e-f72f-4680-8074-c3c7ced276a8_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.875% Senior Notes due 2036</link:label>
    <link:label id="lab_mdt_SeniorNotesDue2036Member_label_en-US" xlink:label="lab_mdt_SeniorNotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2036 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotesDue2036Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2036Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotesDue2036Member" xlink:to="lab_mdt_SeniorNotesDue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_2cf30eca-27fe-4c77-8ad2-759214db2b61_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_d143b1a2-c9cf-4560-b249-7dd4bd28ce9b_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_0c72338e-a184-4f13-9f93-ca5f295ca346_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification, Other liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_731de5c2-acce-4c2a-a43c-0c017ff83b12_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e6327753-4ab7-480e-b3a1-39cb42bdefc2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax (benefit) expense:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_adb877d8-c2ed-4b8a-a40d-b621fa2de8f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_d8eaa0e1-5ec8-4e4b-b1f4-c80d4b5223b1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7bc277e8-aaa6-48e1-a0af-f53c390abb67_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_48ead56e-7904-4aa9-a9cb-a94bc5464f9b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFundsMember_795215e5-beae-4be5-8301-1dc9ab9df2b8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity commingled trusts</link:label>
    <link:label id="lab_us-gaap_EquityFundsMember_label_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFundsMember" xlink:to="lab_us-gaap_EquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5ecd2f2b-017f-4889-9697-6c31ba858128_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_39b56a58-5ecb-45f7-8cf1-9d6389cc5a39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c8da2ccb-b9da-470e-a927-25712b03c7d2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e9f5e94c-94f0-4e7b-8909-bb75a7bda958_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2015Due20253.500PercentMember_66423ba5-8cb1-4312-817a-092a8349497e_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2025, 3.500 percent</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due20253.500PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2025, 3.500 percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due20253.500PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2025, 3.500 percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2015Due20253.500PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:to="lab_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8d8a85b4-30ae-41f1-8a03-15427349180a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2022Due2028Member_e5087ccd-fab0-4bda-87f6-27c7bfe882c8_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.000% Senior Notes due 2028</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due2028Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2028 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due2028Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2028Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2022Due2028Member" xlink:to="lab_mdt_SeniorNotes2022Due2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_be2d0fc5-34dd-4f50-97d6-489ea27d0d31_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_363ec02e-5ff9-43f8-bd66-83b1510aff4f_terseLabel_en-US" xlink:label="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Measurements, Retirement Benefit Plan Assets</link:label>
    <link:label id="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Retirement Benefit Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure related to retirement benefit plan assets that are measured at fair value in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:href="mdt-20240426.xsd#mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:to="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a6853a5c-894b-4c86-8cb9-33b175793e5c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_64d46ee8-0b37-4332-9dba-d86ea00010f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount authorized for repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5a1e29ba-e260-4d7c-8050-361980232a72_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84c58fb4-cf4d-4b49-8037-431279e3e320_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_864222a1-0fdd-4ea9-9ad8-1f0b1a010275_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_eb68e582-d6b5-4534-a9f9-668132bae4ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits at beginning of fiscal year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_dc46268a-84ee-4a93-ada0-7ca91df8454b_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits at end of fiscal year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_cda62c63-76f1-4d64-b264-22f074b1c173_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e99fe2e4-236a-44c0-b69a-15ed34fa0955_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses_95b1fe30-d8b4-478a-9e6b-4c79efa3f30f_terseLabel_en-US" xlink:label="lab_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestiture-related and other</link:label>
    <link:label id="lab_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses_label_en-US" xlink:label="lab_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bussiness Acquisition, Contingent Consideration, Divestiture Related and Other Expenses</link:label>
    <link:label id="lab_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses_documentation_en-US" xlink:label="lab_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bussiness Acquisition, Contingent Consideration, Divestiture Related and Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" xlink:href="mdt-20240426.xsd#mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" xlink:to="lab_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxHolidays_8276f0b8-95a1-4cf0-84af-fa4a57f42687_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax reductions from tax holiday</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxHolidays_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Holiday, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxHolidays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_a4b7e908-d541-40be-8d11-effa227c1dea_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 &#8211; 2034</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_4c2a5b48-49c2-4e52-b5cb-971678c23f6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in the Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_102f1d36-8b90-40b4-9a52-bc93afd26a01_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_91018948-a7d1-40f4-a806-5f45e69a2a32_terseLabel_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_label_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Other Countries, Excluding United States and Ireland [Member]</link:label>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_documentation_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Other Countries, Excluding United States and Ireland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:href="mdt-20240426.xsd#mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:to="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ef2c3109-ff83-4411-9f42-6de14054e3a5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MedicalSurgicalMember_b9d25d83-78bb-4939-a07e-da20e6d33cc5_terseLabel_en-US" xlink:label="lab_mdt_MedicalSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Surgical</link:label>
    <link:label id="lab_mdt_MedicalSurgicalMember_8f2905fe-3d97-4349-9661-260763c721e0_verboseLabel_en-US" xlink:label="lab_mdt_MedicalSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Medical Surgical</link:label>
    <link:label id="lab_mdt_MedicalSurgicalMember_label_en-US" xlink:label="lab_mdt_MedicalSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Surgical [Member]</link:label>
    <link:label id="lab_mdt_MedicalSurgicalMember_documentation_en-US" xlink:label="lab_mdt_MedicalSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Surgical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MedicalSurgicalMember" xlink:to="lab_mdt_MedicalSurgicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cc195e87-ce4d-490d-9779-e487933fa705_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_90c984ca-29c7-4472-ac4e-604cea44a803_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other Changes (Debit) Credit</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_51769c4b-6091-402d-831b-b856c3cfdf7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrealized gains, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_239ff591-50a9-4eba-beb3-146aad48b264_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_21abbe47-5236-45f5-b61b-8437c6cff205_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_58ec485d-6c3b-4069-86b4-314da0a0c773_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ddf5c631-b985-4a66-a6b3-550ef987631e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9ba47239-6395-4ef6-a58d-61945454fef5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of settlement paid</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_95b2f42a-5e15-4c25-a6d0-c1b854898c04_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9f8abd32-2209-4939-8e88-cd9e0ce79588_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_db6a890c-4a2f-4f9b-b286-20ab55f3e110_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reported as (after valuation allowance and jurisdictional netting):</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets and Liabilities, Balance Sheet, Reported Amount [Abstract]</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:to="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A2625PercentThreeYear2022SeniorNotesMember_e54e9cb3-a05c-49d0-b0b3-e308c6632dc7_terseLabel_en-US" xlink:label="lab_mdt_A2625PercentThreeYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.625 percent three-year 2022 senior notes</link:label>
    <link:label id="lab_mdt_A2625PercentThreeYear2022SeniorNotesMember_label_en-US" xlink:label="lab_mdt_A2625PercentThreeYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2..625 Percent Three-Year 2022 Senior Notes [Member]</link:label>
    <link:label id="lab_mdt_A2625PercentThreeYear2022SeniorNotesMember_documentation_en-US" xlink:label="lab_mdt_A2625PercentThreeYear2022SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2..625 Percent Three-Year 2022 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2625PercentThreeYear2022SeniorNotesMember" xlink:href="mdt-20240426.xsd#mdt_A2625PercentThreeYear2022SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A2625PercentThreeYear2022SeniorNotesMember" xlink:to="lab_mdt_A2625PercentThreeYear2022SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0fd584f5-2c51-44a4-810f-0bb7d63bed23_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_d6582b9b-1f4d-4c2d-ad2a-e1fefefeb635_terseLabel_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash collateral received</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_5a069288-ed83-48e6-a356-654ea1fab5df_negatedTotalLabel_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_label_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_documentation_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:to="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_bdc8aeea-a4e1-496c-a6f0-16c3a57c3aa0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02a8bfb0-dd6f-4c39-b3c5-70d402eaaef4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f6c4822f-bd2c-43a8-b97f-f4751d70746a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to options exercised</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_41325dd8-09f5-4d11-aa5d-b43d84e74d59_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to restricted stock vested</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_66e4a5e7-4636-4c52-a3d9-093d2f93547e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. tax on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_2c395674-2192-4c6f-aada-9e8f6b7be986_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_9cf5f219-68ce-4408-8d8f-1b9d9a611da7_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_838c5deb-bf20-47a0-84cc-e6acdb37713c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_735de097-0ca4-45f3-87f5-058b032e46c9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6dca1136-f4ba-4e7e-80f6-7f30e6a9dd2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2ce93cb6-98ab-4159-b62e-3660e078df79_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_88f7761a-a25f-4cde-87ba-29d2263579e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_label_en-US" xlink:label="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:to="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_43985943-1294-4591-8a53-b0b5cd4d9506_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_648eb11a-3fbd-454e-894c-a74ca77eb214_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_2e3671a3-3f53-4759-bee7-c71499e4ab38_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_f37f0c82-d434-4df1-a567-8bcbe1307402_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2026Member_8a36db75-cfbd-495d-904c-38b4d7e4f3e8_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.000 percent five-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2026Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2026 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2026Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2026Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2026Member" xlink:to="lab_mdt_SeniorNotes2020Due2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3f1f1128-6ed8-46e7-b2a1-3442a5d1519c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_b78ea8cb-9b30-4233-860d-2825507f22b3_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_335f95b4-6913-4d54-a11b-b747271611cc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_01f45b1b-5426-40de-8313-0b5a3421e5a3_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_c8f3c9ee-6664-4ed5-92fe-6e2414d87ec9_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_10a7e154-4366-4366-a1b0-ed4adeccf6ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_82e6318f-32cc-4a5b-b8a1-b1ffaf35bf24_terseLabel_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate &#8211; service cost</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_label_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_documentation_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:to="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_ac25e95d-8e89-478f-87bd-d6d85c26fb86_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CentralizedDistributionCosts_04a0523c-5191-411b-82a5-4c186a665e34_negatedTerseLabel_en-US" xlink:label="lab_mdt_CentralizedDistributionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Centralized distribution costs</link:label>
    <link:label id="lab_mdt_CentralizedDistributionCosts_label_en-US" xlink:label="lab_mdt_CentralizedDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Centralized Distribution Costs</link:label>
    <link:label id="lab_mdt_CentralizedDistributionCosts_documentation_en-US" xlink:label="lab_mdt_CentralizedDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Centralized Distribution Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CentralizedDistributionCosts" xlink:href="mdt-20240426.xsd#mdt_CentralizedDistributionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CentralizedDistributionCosts" xlink:to="lab_mdt_CentralizedDistributionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember_9c59d286-440b-49d2-8166-21c7c2464316_terseLabel_en-US" xlink:label="lab_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Emerging Markets</link:label>
    <link:label id="lab_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember_label_en-US" xlink:label="lab_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea [Member]</link:label>
    <link:label id="lab_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember_documentation_en-US" xlink:label="lab_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember" xlink:href="mdt-20240426.xsd#mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember" xlink:to="lab_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8f5d61d5-6e4b-4164-8197-2a8ee3938806_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RegisteredInvestmentCompanyMember_6432ba6d-8f8d-4fac-8b32-23d1fbc85f76_terseLabel_en-US" xlink:label="lab_mdt_RegisteredInvestmentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registered investment companies</link:label>
    <link:label id="lab_mdt_RegisteredInvestmentCompanyMember_label_en-US" xlink:label="lab_mdt_RegisteredInvestmentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Registered Investment Company [Member]</link:label>
    <link:label id="lab_mdt_RegisteredInvestmentCompanyMember_documentation_en-US" xlink:label="lab_mdt_RegisteredInvestmentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RegisteredInvestmentCompanyMember" xlink:href="mdt-20240426.xsd#mdt_RegisteredInvestmentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RegisteredInvestmentCompanyMember" xlink:to="lab_mdt_RegisteredInvestmentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20392.250PercentMember_f4d977ce-709d-432c-bcd5-b72b29806d6f_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20392.250PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.250% Senior Notes due 2039</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20392.250PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20392.250PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2039, 2.250 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20392.250PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20392.250PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2039, 2.250 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20392.250PercentMember" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20392.250PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20392.250PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20392.250PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_50064948-ee9d-48ac-aecf-92ceca6bb755_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible asset finite lived statement of income or comprehensive income extensible enumeration not disclosed flag</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_c9f866a2-2561-4105-9363-b08c7b6136c6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DiabetesPumpRetainerRingLitigationMember_f90f53f8-94dc-4860-8f62-fe36164e234d_terseLabel_en-US" xlink:label="lab_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diabetes Pump Retainer Ring Litigation</link:label>
    <link:label id="lab_mdt_DiabetesPumpRetainerRingLitigationMember_label_en-US" xlink:label="lab_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diabetes Pump Retainer Ring Litigation [Member]</link:label>
    <link:label id="lab_mdt_DiabetesPumpRetainerRingLitigationMember_documentation_en-US" xlink:label="lab_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diabetes Pump Retainer Ring Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:href="mdt-20240426.xsd#mdt_DiabetesPumpRetainerRingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:to="lab_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ab151653-6360-44a0-bb35-06ac73bc737b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0f0e844d-9262-4b6a-bd76-446172134197_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of (Gain) Loss on Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_158f9d78-61f4-492c-9265-6307c5781b75_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_eda1e779-1e07-4796-9c41-802e7c45a5ee_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_102247b4-0752-45cd-bf11-40e5d51c9066_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7fd3ee74-c399-4c6c-967e-b6ba99d89922_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_223de86d-1655-47b1-bc49-5e75874e353a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The discount rate from market value on purchase date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17dad3be-29ba-42c0-9efe-9fd2f8177132_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_af50c3d7-1796-4cfb-b0d3-32a832588c23_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a9a4e259-f376-4b16-b5f3-b52122a67be9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7c06efb7-dcab-47cd-8641-49b7c9674512_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_a67983ea-8bfe-428a-ac06-1547d2fa97ca_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_4d51a4f3-7360-4b94-ac99-ff3d8003ca7f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. Tax Authorities</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_586bec07-cb93-4c68-8c56-85c3491256ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1a17befe-6b0a-4401-813c-1c3a1739b0e7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_cb8c9ba0-7de9-4916-b49d-44910c2cb395_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4912c7aa-7246-48ec-852b-b0c4328a60bc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember_981b472c-1f5a-4b18-9860-e787da093cee_terseLabel_en-US" xlink:label="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.5 Billion Revolving Credit Facility</link:label>
    <link:label id="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember_label_en-US" xlink:label="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended and Restated Revolving Credit Agreement [Member]</link:label>
    <link:label id="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember_documentation_en-US" xlink:label="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended and Restated Revolving Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:href="mdt-20240426.xsd#mdt_AmendedandRestatedRevolvingCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:to="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_231d3868-8e21-4be8-acc9-eb28e39cb1b3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7b4bab60-c7fa-48d8-bbbd-27096bde8606_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wtd. Avg. Grant Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A2015CommercialPaperProgramMember_cc3e4e4b-3a03-45ea-ad77-4213d86de20f_terseLabel_en-US" xlink:label="lab_mdt_A2015CommercialPaperProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Commercial Paper Program</link:label>
    <link:label id="lab_mdt_A2015CommercialPaperProgramMember_label_en-US" xlink:label="lab_mdt_A2015CommercialPaperProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 Commercial Paper Program [Member]</link:label>
    <link:label id="lab_mdt_A2015CommercialPaperProgramMember_documentation_en-US" xlink:label="lab_mdt_A2015CommercialPaperProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 Commercial Paper Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2015CommercialPaperProgramMember" xlink:href="mdt-20240426.xsd#mdt_A2015CommercialPaperProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A2015CommercialPaperProgramMember" xlink:to="lab_mdt_A2015CommercialPaperProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_1658c82e-3801-4afc-99c3-f02fdd5283db_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2028Member_441cc23f-7217-4ed4-8406-a907e5ff3210_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.375% Senior Notes due 2028</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2028Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2028 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2028Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2028Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2028Member" xlink:to="lab_mdt_SeniorNotes2020Due2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6b39a017-0b22-4d17-956f-478ffd5efa76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fc413366-5c0c-467a-bdbd-b2b42a6a8b3d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_d2ff5717-cf34-4d62-aed1-43bd74c17d52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments not designated as hedging instruments, (gain) loss, net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20311.00PercentMember_c0e5a12b-c1d5-49d2-8120-99f61884aa97_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20311.00PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.000% Senior Notes due 2031</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20311.00PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20311.00PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2031, 1.00 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20311.00PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20311.00PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2031, 1.00 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20311.00PercentMember" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20311.00PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20311.00PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20311.00PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_4da7af89-dbac-4e25-8112-6f1305022d59_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_f49f71ed-5593-4bca-a5ae-50c584c41e9e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1c52f3c-3742-4059-8daa-2490a513aa92_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_1a30dd35-325e-4716-91a9-50bfc9611cff_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Year-End</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_66ef7628-cbc0-457a-bd85-d136350a95b2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liabilities:</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:to="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_38b0bf29-701a-4185-be81-4c8e91d15571_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments for which the fair value option has been elected</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_63b7789f-5b83-4885-aaa6-5245f26b9e16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification, Other assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_14223e7a-b796-465d-a12d-2e7e9358fb52_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_94c30e14-2a35-47b0-8953-f117e25c79fa_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_2088f893-1901-4bb2-a60c-4b58c50a8137_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_9bddd15f-a67c-4375-bc01-15b91d9a10fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_f7e943bd-b684-46c3-8d76-024027c05a58_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_7b20a374-db45-4888-9c65-9319c119943f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_a816db4f-72f8-4998-a541-d750b8d3ce2e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_14aa70bf-6263-4997-a5f8-93ccc1003d1a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_40bd4dbf-69a1-48c2-968d-7ffa7d535cac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_95e45f81-aa2d-4137-97b7-75d4bf7812d7_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2040Member_48dd29b5-cb95-4d5d-b314-c43b68a0d632_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.375% Senior Notes due 2040</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2040Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2040 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2040Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2040Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2040Member" xlink:to="lab_mdt_SeniorNotes2020Due2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1e3c6cc0-fad2-4925-8908-f7ff84eaad66_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dea53390-f994-4cd7-88cf-984689ad5780_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_12182526-3917-41c1-acf2-77d7637f6b6a_terseLabel_en-US" xlink:label="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional borrowing capacity</link:label>
    <link:label id="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:label id="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="mdt-20240426.xsd#mdt_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_2c6f6652-254f-47a2-acbd-25fc11239c43_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business exit costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b3105e98-3f81-4dee-b568-5cbbd72471e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_e29bf126-4644-4e23-b5fe-0a0650fb886d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2017Due20273.350PercentMember_f01ec1d8-9e7a-4e80-a7b2-e989a11ae01d_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes 2017 Due 2027, 3.350 Percent</link:label>
    <link:label id="lab_mdt_SeniorNotes2017Due20273.350PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2017 Due 2027, 3.350 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2017Due20273.350PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2017 Due 2027, 3.350 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2017Due20273.350PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:to="lab_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_85611254-66a3-4de9-ae9f-41fca7d32340_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d53719ee-1910-4357-a161-b4e745a073c3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_4a1650a2-4996-4c8d-a8b5-6f9c2e5e6af6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated expected restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_0c4d9ca6-71dd-4d91-9c26-30a83daad173_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillNotAllocatedAmount_3bcff908-d463-4349-9eb5-59db87865de2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillNotAllocatedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, non deductible amount</link:label>
    <link:label id="lab_us-gaap_GoodwillNotAllocatedAmount_label_en-US" xlink:label="lab_us-gaap_GoodwillNotAllocatedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Not Allocated, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillNotAllocatedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillNotAllocatedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillNotAllocatedAmount" xlink:to="lab_us-gaap_GoodwillNotAllocatedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_39b94ca0-69ef-461b-a0c1-1a4befed0b7a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2b505cb6-5e54-4ed5-b623-5cba0bbab95d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ce1b52c5-79ad-4521-a174-005f155d846b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_86e2d296-ccd2-47d2-9866-23c469712de2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards, no expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_e86f3c84-93aa-4b1a-b387-93547c267a20_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_5fd19ab3-b53f-4e68-b4c1-89dc7f988311_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restructuring and associated costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_4274b573-6eff-4ef7-9b32-f3d11cba5b63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_40e76284-fb50-42ee-8d20-a7592b14b4f1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_a715023e-8ee5-4a1d-b5bb-f80475af6e48_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on outstanding borrowings</link:label>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_label_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseBorrowings" xlink:to="lab_us-gaap_InterestExpenseBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9d021a57-2c31-4722-ace2-c92597073f1b_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount available for future repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_66eef232-5c70-425f-8695-9fab354a0966_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0abd0966-a394-4cd3-a3d6-d61d8a7860a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_e923a442-2f1e-4280-8394-0ef62c942aa9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank borrowings</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_14bf6108-9b20-48c9-afba-3006329be7f3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_b45d71d4-0fe3-43ad-9bb3-286a08d2d3b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96858279-82c9-48bc-bfff-c9172a12ac1f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7aa51c9e-81c7-4723-b45b-209d9643cdf7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2022Due2025Member_b79547bb-afd0-4306-8689-445f3d363253_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.625% Senior Notes due 2025</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due2025Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2025 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due2025Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2022Due2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2025Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2022Due2025Member" xlink:to="lab_mdt_SeniorNotes2022Due2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2468a7c-2357-4b97-9ab2-8d5643a13598_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount_6461f456-b044-4201-b725-009408566ddd_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense (benefit) related to tax basis adjustment, intercompany intellectual property transactions</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Basis Adjustment of Intangible Assets, Amount</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Basis Adjustment of Intangible Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_f2f5fb78-2327-4aaa-a952-800e89e7315e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_60c9caee-8bd9-42f8-bf8f-c3e0de110dbf_terseLabel_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity and Other Investments</link:label>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_label_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]</link:label>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:href="mdt-20240426.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:to="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_57243ae6-8224-4c6c-b062-fdde35912322_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications from AOCI, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_528bb4f7-aed1-4530-9fbd-abddce703543_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_38de1940-9b3d-4e59-939d-9487234c4d13_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_aff6618a-a4f6-4de9-86b5-7746960ae5bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of restricted stock vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_9a11e34c-e3cd-44e4-bb03-b0292fb173e1_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_117f3c12-85f1-41c5-baeb-0fa648a32b5a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_ca39e040-2d5c-4be1-8095-9c9f37b4c340_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_8d680d96-b214-4419-9bdd-688a3430a523_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_NeuromodulationDivisionMember_f3b3ffd3-fed2-49ba-bdd6-b47032eca37f_terseLabel_en-US" xlink:label="lab_mdt_NeuromodulationDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuromodulation</link:label>
    <link:label id="lab_mdt_NeuromodulationDivisionMember_label_en-US" xlink:label="lab_mdt_NeuromodulationDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuromodulation Division [Member]</link:label>
    <link:label id="lab_mdt_NeuromodulationDivisionMember_documentation_en-US" xlink:label="lab_mdt_NeuromodulationDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuromodulation Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuromodulationDivisionMember" xlink:href="mdt-20240426.xsd#mdt_NeuromodulationDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_NeuromodulationDivisionMember" xlink:to="lab_mdt_NeuromodulationDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_ba3133c3-b3b4-4fc8-bb44-003a08aa98b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1e37f632-49f0-4337-b0b3-a060adf3efae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_a67cf142-49d3-4ca6-8409-7678d4f0dbbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_0d5e5812-632d-48a9-b390-526729abde1c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_00259e93-5ed2-4669-a80b-12fed333e441_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts Recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c221cbdd-bb04-407a-8e39-65aa270df1cc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_647600c3-10df-4e3d-8a25-4e3650dc63a5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_d083bef9-8262-42e5-bcd7-5b30f22a4544_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1a347b45-cd83-441e-b498-7d6f1ddf18e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_a51ea94a-2b2f-4be7-8cc0-e6c75fcf03ca_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts recognized in accumulated other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_37a1cb75-bc4e-4a77-a9d0-57c24303f4a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other Changes (Debit) Credit, Adjustments</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8ce35a32-bb0b-4fa7-908d-418cd89afa6c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares under stock purchase and award plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0b292fef-e90d-49be-ba5e-deba740c96fc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_745b1fd6-a0cd-4a23-8268-799300bcfd48_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d859f71f-d01a-4e18-9625-b6c46bba6c34_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_18fea5e7-7300-4d3c-bb9d-4a05d15024d6_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_28fe5b5b-ece0-4dc2-a5f5-1d4b41f90137_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_fd788cda-00d0-45b8-8b27-629419a342c0_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5500f330-e403-4f66-bbae-92bb95915163_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_9592f0e6-fa51-41f4-a04c-0fc1c8180afd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Termination Benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_4cc863d4-bd90-42ee-a3bd-9950b70a6139_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_3d859c56-86ac-4d14-9a81-230b305bd75f_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_7683c654-2fa1-4bf4-bd16-ec5ec14a7cf6_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3f3750b6-b59a-4d9f-a3ba-35aedb44c663_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ff5834a4-8a11-44f7-a83c-c33f3fcb91fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b2385729-6938-43a8-8b2c-b015a64d353b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_cbfa9541-6971-4ebf-a537-01faa15d92a7_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f724ca50-4938-4aa1-b8a9-751453bf6cc1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_f489724e-820e-4ee5-aa7f-3a0c2ba12af6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total realized gains, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_254c33a8-f8bc-4d12-9b7c-ad1c54ee6e6b_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a7dc3be5-148c-43d2-95fb-d0afe5b6c8e1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_35f40edf-1aa1-402c-b526-4d477a8dc57b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_bd9d81a0-c1f8-424b-8bf5-54a59dab1500_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SpecialtyTherapiesDivisionMember_37ef866a-7245-46ea-9246-31142a8816b0_terseLabel_en-US" xlink:label="lab_mdt_SpecialtyTherapiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Specialty Therapies</link:label>
    <link:label id="lab_mdt_SpecialtyTherapiesDivisionMember_label_en-US" xlink:label="lab_mdt_SpecialtyTherapiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Specialty Therapies Division [Member]</link:label>
    <link:label id="lab_mdt_SpecialtyTherapiesDivisionMember_documentation_en-US" xlink:label="lab_mdt_SpecialtyTherapiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Specialty Therapies Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialtyTherapiesDivisionMember" xlink:href="mdt-20240426.xsd#mdt_SpecialtyTherapiesDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SpecialtyTherapiesDivisionMember" xlink:to="lab_mdt_SpecialtyTherapiesDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_144d47aa-7d99-463b-bd46-7801e214db61_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingIrelandMember_c4f150d9-19ec-4e34-977f-10ea3f775967_terseLabel_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total other countries, excluding Ireland</link:label>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingIrelandMember_label_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Other Countries, Excluding Ireland [Member]</link:label>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingIrelandMember_documentation_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Other Countries, Excluding Ireland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:href="mdt-20240426.xsd#mdt_TotalOtherCountriesExcludingIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:to="lab_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8419b34c-af5c-4cbe-a93a-89b5ebd35004_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_79e098ba-1317-40a5-9e1a-01f7756efc6b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_a8f93aa7-9fdd-4025-ad28-9415a310c4a3_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_bf83e742-b131-482e-ad4e-900fb30fbf2c_terseLabel_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charge to adjustments</link:label>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_label_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments</link:label>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_documentation_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:href="mdt-20240426.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:to="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_3e67e0bd-5ff6-4d1a-be76-2d72314ace75_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_66d8cb12-86c9-4fdf-b36f-994a4baff162_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_760b3833-b45c-4e7b-8b36-9620765eddaa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_67fb7d93-792b-4ca0-9d7e-b4e88b2203a9_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelatedIntangibleAssetsMember_bb165e5a-aee0-46eb-a362-039a2487798a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer-related</link:label>
    <link:label id="lab_us-gaap_CustomerRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MN_48056254-9a03-4606-9f92-e9ef2f516dbc_terseLabel_en-US" xlink:label="lab_stpr_MN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minnesota</link:label>
    <link:label id="lab_stpr_MN_label_en-US" xlink:label="lab_stpr_MN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MINNESOTA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MN" xlink:to="lab_stpr_MN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_33d8ef04-e058-4168-ad6e-e1c0fcc5232a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_19bb2d8c-4f6d-4b0f-8b22-b7054d846481_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_298b271b-c07d-496b-9105-ba02fd428bf6_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_6b864d93-5df8-46e4-a0e9-2ba1a709ae41_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b66cf15f-583a-4d8c-b436-ef7b9c48226b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due2025Member_90172ec0-849e-4ed3-8784-0778122eb9c3_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.000% Senior Notes due 2025</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2025Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2025 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due2025Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2025Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due2025Member" xlink:to="lab_mdt_SeniorNotes2020Due2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RenalCareSolutionsMember_e0ef5b40-53a4-4d55-98b8-f02d8b4a366f_terseLabel_en-US" xlink:label="lab_mdt_RenalCareSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renal Care Solutions</link:label>
    <link:label id="lab_mdt_RenalCareSolutionsMember_label_en-US" xlink:label="lab_mdt_RenalCareSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Renal Care Solutions [Member]</link:label>
    <link:label id="lab_mdt_RenalCareSolutionsMember_documentation_en-US" xlink:label="lab_mdt_RenalCareSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Renal Care Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareSolutionsMember" xlink:href="mdt-20240426.xsd#mdt_RenalCareSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RenalCareSolutionsMember" xlink:to="lab_mdt_RenalCareSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherAcquisitionsMember_5fd9338a-c816-4c93-9be9-db64b6e98313_terseLabel_en-US" xlink:label="lab_mdt_OtherAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Acquisitions</link:label>
    <link:label id="lab_mdt_OtherAcquisitionsMember_label_en-US" xlink:label="lab_mdt_OtherAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Acquisitions [Member]</link:label>
    <link:label id="lab_mdt_OtherAcquisitionsMember_documentation_en-US" xlink:label="lab_mdt_OtherAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAcquisitionsMember" xlink:href="mdt-20240426.xsd#mdt_OtherAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherAcquisitionsMember" xlink:to="lab_mdt_OtherAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due2031Member_993c7eeb-34d7-45b8-b0ea-3878ee4517fa_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625 percent twelve-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2031Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2031 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2031Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2031Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due2031Member" xlink:to="lab_mdt_SeniorNotes2019Due2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8903eac8-d2d7-488d-a230-b7df43833aa0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c0180f9e-2acf-4339-9be2-c1687b582150_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_953f545e-d4b4-4aaa-8b8d-899f946e36c0_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_c17863e0-edbd-41f9-b045-c5885d919904_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_c0efc2f7-3004-4b83-a5d8-c1f614a4acc5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_4d3df3d8-74b2-4f84-97c5-471dbff290da_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity Related to the Company's Available for Sale Securities Portfolio</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e928635-59f5-45bf-9ea8-e2f88253ef8a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9aa3d440-8e37-418e-9095-c3c119ad36a4_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted &#8211; weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_dc0ff02d-44a4-4874-94d9-e8d48f9dde04_negatedTerseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Puerto Rico excise tax</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Puerto Rico Excise Tax</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to Puerto Rico excise tax from intercompany purchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_e8542cde-7cc0-4f1e-84ec-8b9f275a6eac_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_1a8e7f6d-0738-4be5-a1a1-4a8ab5774f20_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative assets:</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsAbstract" xlink:to="lab_us-gaap_DerivativeAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_96adf593-b07c-4c2b-91a8-682fae79d846_terseLabel_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments [Roll Forward]</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_label_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration, at Fair Value [Roll Forward]</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_documentation_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:to="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_f53b9692-d734-45cf-a3da-c751dc717907_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_253292ec-e625-45e5-b38b-a0432c2527de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sale of RCS business</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_7cdea423-5295-4783-a9a9-868ecb9863ef_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, unrealized currency losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Unrealized Currency Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_27fa9141-49d9-4e46-80dc-adaf1bc77a5a_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe0e2dee-d299-45db-b578-c0275356d6b9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_d5eadaf0-62cf-4358-8db5-982fb5e61811_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0a470444-2128-4f74-b83a-8d57a2e6cee3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_cdc19d06-d4a0-4248-b6be-7dd2104f4c57_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20311.625PercentMember_785ec3c2-17c8-4a82-a9f9-3607c73b2521_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20311.625PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625% Senior Notes due 2031</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20311.625PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20311.625PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2031, 1.625 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20311.625PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20311.625PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2031, 1.625 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20311.625PercentMember" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20311.625PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20311.625PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20311.625PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_efb0c367-4be5-4412-9ae2-29c674ab3ccb_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9566032c-9db5-4b99-9983-7cd5cbaf5c73_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2a53a56d-048b-4e0e-9f1e-a52e632f45c9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_ed1eab3b-b576-48b1-98fa-d7d6514aef9b_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment reconciling items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_8b7e3686-5b6e-44da-8f96-852797c75bf6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_e0f3dda2-abbc-4e9d-afc0-a979a643d773_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Shares</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_158db83f-180e-4173-8464-7efc2cc3f7ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_ca2deac0-07f5-4974-80c0-534f6fbcef21_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredStockSharesIssued_f1afd224-7e22-4693-83fe-3b31f10c16b3_terseLabel_en-US" xlink:label="lab_mdt_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock, issued (in shares)</link:label>
    <link:label id="lab_mdt_DeferredStockSharesIssued_label_en-US" xlink:label="lab_mdt_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Issued</link:label>
    <link:label id="lab_mdt_DeferredStockSharesIssued_documentation_en-US" xlink:label="lab_mdt_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesIssued" xlink:href="mdt-20240426.xsd#mdt_DeferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredStockSharesIssued" xlink:to="lab_mdt_DeferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_d41067a8-5636-4146-b90f-d00acedfb536_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_8f119d13-6a3b-4ea9-9d99-3c3679a0dba7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_5bb82e7e-3d61-447c-b14f-dc9b3161f8e8_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension benefits</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6748a601-5aa5-4002-9b64-76037ec3c9d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Retirement Benefit Plan Assets Measured at Fair Value Using Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9454e53-aef6-4da3-8fa2-6b9d19747e2b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_8e10d4e7-21af-4fd5-9bd8-e317093a4454_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Target allocations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_d6c54b81-78f5-4df5-a20d-74e762e94ef8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Target Allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_642ab028-b890-4752-ba9f-b5ad396f565e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously held investments in Intersect ENT</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_58d6d4df-47ff-4880-8ab6-8c852485a96e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_52b43831-ce2c-4bdc-9929-e0f71efb7d46_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_915ae550-ba10-46f8-ba9f-627b02c1840d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57df299e-eef9-46dd-b7ac-e1f853020a8a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic - weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_65cff111-f5c3-46a6-8a07-3c617c376c3a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_ee2773a6-93af-4767-811b-5ab9775baf4a_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_8e6c559c-23e4-454e-8d10-02b2afe6d13c_negatedTerseLabel_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Charges to Other Accounts, net</link:label>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_label_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net</link:label>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_documentation_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:href="mdt-20240426.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:to="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward_9516fc93-b820-4fa5-b1a4-24e4045a1288_terseLabel_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning and Ending Balances of Contingent Payments [Roll Forward]</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward_label_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Roll Forward]</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward_documentation_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:to="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_85f3f419-3236-4c25-97d3-79411374e6ca_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plans with accumulated benefit obligations in excess of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2013Due2043Member_86e02859-a384-4368-9f81-89020f77dd2d_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2013Due2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.000 percent thirty-year 2013 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2013Due2043Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2013Due2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2013 Due 2043 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2013Due2043Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2013Due2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2043 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2013Due2043Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2013Due2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2013Due2043Member" xlink:to="lab_mdt_SeniorNotes2013Due2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ColibriMember_6eccc41d-f42b-4514-9019-c2394ffa1f00_terseLabel_en-US" xlink:label="lab_mdt_ColibriMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Colibri</link:label>
    <link:label id="lab_mdt_ColibriMember_label_en-US" xlink:label="lab_mdt_ColibriMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Colibri [Member]</link:label>
    <link:label id="lab_mdt_ColibriMember_documentation_en-US" xlink:label="lab_mdt_ColibriMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Colibri</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ColibriMember" xlink:href="mdt-20240426.xsd#mdt_ColibriMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ColibriMember" xlink:to="lab_mdt_ColibriMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5d76fcf6-beb4-4c96-b0c8-2bd624460458_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_VentilatorProductLineExitMember_8755f77c-4450-4e50-898b-b6c1592daf9a_terseLabel_en-US" xlink:label="lab_mdt_VentilatorProductLineExitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ventilator Product Line Exit</link:label>
    <link:label id="lab_mdt_VentilatorProductLineExitMember_label_en-US" xlink:label="lab_mdt_VentilatorProductLineExitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ventilator Product Line Exit [Member]</link:label>
    <link:label id="lab_mdt_VentilatorProductLineExitMember_documentation_en-US" xlink:label="lab_mdt_VentilatorProductLineExitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ventilator Product Line Exit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember" xlink:href="mdt-20240426.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_VentilatorProductLineExitMember" xlink:to="lab_mdt_VentilatorProductLineExitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c1b5de22-b23e-47f5-aa90-947310ad0c2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_84c48acb-5fdf-45bf-865b-4f6716a18aa3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_21c70501-86bd-4651-b38d-f3e4893ac85c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments by Category and Related Balance Sheet Presentation</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due2032Member_7a3010e7-47ce-47ad-bf93-91d512c59aaa_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.000 percent twelve-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2032Member_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2032 [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due2032Member_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2032 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2032Member" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due2032Member" xlink:to="lab_mdt_SeniorNotes2019Due2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8aedddfc-f620-47e2-a662-6bb56f192cf9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_758330ca-1901-4a0a-b32f-786c75d27f82_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>mdt-20240426_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31d25153-b660-4ec0-ab44-7e01aa50312b,g:3d21d99d-9a64-4ef0-a05f-06b24f253785-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.medtronic.com/role/Cover" xlink:type="simple" xlink:href="mdt-20240426.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ca7e8ead-3a39-4efc-83f1-5d54fbf7426c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_471bd74b-806b-4cb1-906a-2d34d79bb5f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca7e8ead-3a39-4efc-83f1-5d54fbf7426c" xlink:to="loc_dei_EntitiesTable_471bd74b-806b-4cb1-906a-2d34d79bb5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0e9d1d24-a742-40dd-9d59-d5f58c000616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_471bd74b-806b-4cb1-906a-2d34d79bb5f9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0e9d1d24-a742-40dd-9d59-d5f58c000616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0e9d1d24-a742-40dd-9d59-d5f58c000616" xlink:to="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1cd2611a-eca8-41a8-8ac7-59c3e89d17cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_us-gaap_CommonStockMember_1cd2611a-eca8-41a8-8ac7-59c3e89d17cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2025Member_488f5acd-8303-40d7-b0e1-774163345594" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due2025Member_488f5acd-8303-40d7-b0e1-774163345594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2025Member_87c2c22d-7bd1-4be9-840f-caaec52b124c" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2025Member_87c2c22d-7bd1-4be9-840f-caaec52b124c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2025Member_6240e5fc-3d8f-4015-9077-fe6f99b3bf01" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2022Due2025Member_6240e5fc-3d8f-4015-9077-fe6f99b3bf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2027Member_d3a80197-8479-4fc0-b26d-db068b3c160f" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due2027Member_d3a80197-8479-4fc0-b26d-db068b3c160f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2028Member_4270bf77-1470-48f2-bee2-6526e9e3ac62" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2028Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2028Member_4270bf77-1470-48f2-bee2-6526e9e3ac62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2028Member_f9b75c24-e2a2-44b4-9206-c87ca1084a9c" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2022Due2028Member_f9b75c24-e2a2-44b4-9206-c87ca1084a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2029Member_a89c34c1-8ff8-4fd5-bb4b-5e274e380612" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotesDue2029Member_a89c34c1-8ff8-4fd5-bb4b-5e274e380612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20311.625PercentMember_83c95fa9-0e5f-4273-8942-ad4cb76bd1af" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20311.625PercentMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due20311.625PercentMember_83c95fa9-0e5f-4273-8942-ad4cb76bd1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20311.00PercentMember_31e0b342-8775-4eb5-8c99-c09940e0453f" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20311.00PercentMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due20311.00PercentMember_31e0b342-8775-4eb5-8c99-c09940e0453f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2031Member_c7546e32-4050-4ff5-b5cb-362bf5b408ee" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2031Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2022Due2031Member_c7546e32-4050-4ff5-b5cb-362bf5b408ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2032Member_9f51a67c-00b7-431e-8aa6-28fc6aaa6b65" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2032Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2032Member_9f51a67c-00b7-431e-8aa6-28fc6aaa6b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due2034Member_8cf251ec-d123-4797-85fc-5a839db61207" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2022Due2034Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2022Due2034Member_8cf251ec-d123-4797-85fc-5a839db61207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2036Member_19b927a7-998f-4c6a-9db0-5dc6a0cc4f47" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2036Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotesDue2036Member_19b927a7-998f-4c6a-9db0-5dc6a0cc4f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20392.250PercentMember_9788d5bc-8b59-4e2c-a665-bf07f0a4dc2e" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20392.250PercentMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due20392.250PercentMember_9788d5bc-8b59-4e2c-a665-bf07f0a4dc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20391.50PercentMember_9097a848-f23e-483c-bab1-aaa19b0497fb" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due20391.50PercentMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due20391.50PercentMember_9097a848-f23e-483c-bab1-aaa19b0497fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2040Member_4781844a-d69b-4eda-9cef-d694d8c2163d" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2040Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2040Member_4781844a-d69b-4eda-9cef-d694d8c2163d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2043Member_0b4f63ba-440e-4537-bb74-9d419e2b55a9" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2043Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotesDue2043Member_0b4f63ba-440e-4537-bb74-9d419e2b55a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2049Member_4d1f4d95-c94c-4b5c-a0c2-9c8aa5b40800" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2049Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2019Due2049Member_4d1f4d95-c94c-4b5c-a0c2-9c8aa5b40800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2050Member_7945af02-d27a-40e9-bda5-4a88df7338f0" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2050Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotes2020Due2050Member_7945af02-d27a-40e9-bda5-4a88df7338f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesDue2053Member_1ef60863-1682-4855-a8dd-f5aee1c1c4c2" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesDue2053Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b0d4c83-a3be-4ffb-851c-5076d2330ca2" xlink:to="loc_mdt_SeniorNotesDue2053Member_1ef60863-1682-4855-a8dd-f5aee1c1c4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_471bd74b-806b-4cb1-906a-2d34d79bb5f9" xlink:to="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9336ce50-bc37-471b-b99b-8501de4b4a82" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentType_9336ce50-bc37-471b-b99b-8501de4b4a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_50008cc5-24b7-4fb1-b815-c258f2515cb2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentAnnualReport_50008cc5-24b7-4fb1-b815-c258f2515cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0bc972a5-427c-4e28-b646-bb075edf8205" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentPeriodEndDate_0bc972a5-427c-4e28-b646-bb075edf8205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e9c1ed8a-a521-47b9-9143-a1da75e86f90" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentTransitionReport_e9c1ed8a-a521-47b9-9143-a1da75e86f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_427527d3-4309-45ff-9355-bb73508019ce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityFileNumber_427527d3-4309-45ff-9355-bb73508019ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_df21d1dc-b00f-48fb-8b89-916c4b1f24e5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityRegistrantName_df21d1dc-b00f-48fb-8b89-916c4b1f24e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_131dbd0c-5b6d-4f9d-98e1-435902dce8ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityIncorporationStateCountryCode_131dbd0c-5b6d-4f9d-98e1-435902dce8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_82004d1d-b3a7-4d19-afa9-3da9e86aa34b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityTaxIdentificationNumber_82004d1d-b3a7-4d19-afa9-3da9e86aa34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cea29712-c3df-45bf-bb51-16b40aba25eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityAddressAddressLine1_cea29712-c3df-45bf-bb51-16b40aba25eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9b0b351d-0f8e-4922-a1c7-0c3ca9467135" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityAddressCityOrTown_9b0b351d-0f8e-4922-a1c7-0c3ca9467135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_df9c4492-d255-45a7-a95f-7d9ce87c616b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityAddressCountry_df9c4492-d255-45a7-a95f-7d9ce87c616b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_e3d09383-30a5-491d-9e5c-66218e8d715e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_CountryRegion_e3d09383-30a5-491d-9e5c-66218e8d715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_91b1e5eb-7c2c-473d-8d14-8245c6ebf65e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_CityAreaCode_91b1e5eb-7c2c-473d-8d14-8245c6ebf65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b7d06938-c64c-4aad-a1a9-8277839771ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_LocalPhoneNumber_b7d06938-c64c-4aad-a1a9-8277839771ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e364fca3-2c45-4dc9-bcbd-48566b00f465" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_Security12bTitle_e364fca3-2c45-4dc9-bcbd-48566b00f465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e595d24e-e72b-4bf4-8bfe-47556146d853" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_TradingSymbol_e595d24e-e72b-4bf4-8bfe-47556146d853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9d7ae12f-39fe-4a16-98c6-f4ae9280165e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_SecurityExchangeName_9d7ae12f-39fe-4a16-98c6-f4ae9280165e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_426bf5ed-abe9-4d3d-a963-808cc7900f96" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_426bf5ed-abe9-4d3d-a963-808cc7900f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_e92fb4bb-1a4f-4e2e-ab15-7af3d829e3c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityVoluntaryFilers_e92fb4bb-1a4f-4e2e-ab15-7af3d829e3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3e71bee3-adb9-45fd-92cd-3358c80adf8d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityCurrentReportingStatus_3e71bee3-adb9-45fd-92cd-3358c80adf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bfb6cc65-c8c6-4705-b5ec-a0afb736f2da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityInteractiveDataCurrent_bfb6cc65-c8c6-4705-b5ec-a0afb736f2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c4bb6ec8-f3df-4739-a503-9ae677b7c681" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityFilerCategory_c4bb6ec8-f3df-4739-a503-9ae677b7c681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_59d398fe-baaa-4cd8-9dfd-334e0d026595" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntitySmallBusiness_59d398fe-baaa-4cd8-9dfd-334e0d026595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c8ef1822-8f5b-45c6-a32a-fc49ad8717ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityEmergingGrowthCompany_c8ef1822-8f5b-45c6-a32a-fc49ad8717ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_aef4d3c7-e043-41d2-93cf-cc75dfffb3c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_IcfrAuditorAttestationFlag_aef4d3c7-e043-41d2-93cf-cc75dfffb3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_d838e217-925d-41f8-917b-3f61b38190ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_d838e217-925d-41f8-917b-3f61b38190ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f55a1d60-141e-4a78-b3f1-c25a42844d93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityShellCompany_f55a1d60-141e-4a78-b3f1-c25a42844d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_989857ad-e292-45e5-b54e-ab1475397ebf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityPublicFloat_989857ad-e292-45e5-b54e-ab1475397ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5c0b643d-9785-4842-9a09-f1b6f315dfd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5c0b643d-9785-4842-9a09-f1b6f315dfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7b200ab4-4564-4381-9c5c-080d7022c871" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7b200ab4-4564-4381-9c5c-080d7022c871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_548d8d5f-5b81-4e65-bdda-b56d99a0d5d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityCentralIndexKey_548d8d5f-5b81-4e65-bdda-b56d99a0d5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5bc3c50c-35c4-4827-958b-0abe6d61539b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_CurrentFiscalYearEndDate_5bc3c50c-35c4-4827-958b-0abe6d61539b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e0901d6d-0d30-4695-ac26-8ea594e70472" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_AmendmentFlag_e0901d6d-0d30-4695-ac26-8ea594e70472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c8cb8346-8edc-426c-85c2-2e7842e4a341" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c8cb8346-8edc-426c-85c2-2e7842e4a341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f45730e3-becc-40c8-8ba1-dfa9cde96eab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_DocumentFiscalYearFocus_f45730e3-becc-40c8-8ba1-dfa9cde96eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7e4b60b5-e3ae-439e-9b85-d6afe3ba5e95" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_679afcb7-6a16-4ebd-8c5b-ea798df296be" xlink:to="loc_dei_EntityAddressPostalZipCode_7e4b60b5-e3ae-439e-9b85-d6afe3ba5e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AuditInformation" xlink:type="simple" xlink:href="mdt-20240426.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AuditInformationAbstract_a0c3a7bf-979b-456a-abfc-8e1c1be94958" xlink:href="mdt-20240426.xsd#mdt_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_76103fff-b3d9-47e2-8c32-7daf9c43a90e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_AuditInformationAbstract_a0c3a7bf-979b-456a-abfc-8e1c1be94958" xlink:to="loc_dei_AuditorFirmId_76103fff-b3d9-47e2-8c32-7daf9c43a90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_0b54afe5-b3bd-49fb-9000-a551b50f8b23" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_AuditInformationAbstract_a0c3a7bf-979b-456a-abfc-8e1c1be94958" xlink:to="loc_dei_AuditorName_0b54afe5-b3bd-49fb-9000-a551b50f8b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_1f0e9304-94d9-4c2d-ae62-72cc645695b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_AuditInformationAbstract_a0c3a7bf-979b-456a-abfc-8e1c1be94958" xlink:to="loc_dei_AuditorLocation_1f0e9304-94d9-4c2d-ae62-72cc645695b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_809bc893-3288-4564-acbb-b7681de74ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_809bc893-3288-4564-acbb-b7681de74ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_100b5c8e-23be-48cd-a50b-90bcc5d33a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_100b5c8e-23be-48cd-a50b-90bcc5d33a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_bd5d4138-faa3-47a7-b205-d45c306d8e07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_100b5c8e-23be-48cd-a50b-90bcc5d33a39" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_bd5d4138-faa3-47a7-b205-d45c306d8e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1fbe5926-462d-4574-b6dd-2b13d8985064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_100b5c8e-23be-48cd-a50b-90bcc5d33a39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1fbe5926-462d-4574-b6dd-2b13d8985064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_18090b99-4740-4ea4-b96f-9ec9024ae7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_100b5c8e-23be-48cd-a50b-90bcc5d33a39" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_18090b99-4740-4ea4-b96f-9ec9024ae7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_aa7d879b-18fc-4de5-8e7d-518bcde9a255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_100b5c8e-23be-48cd-a50b-90bcc5d33a39" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_aa7d879b-18fc-4de5-8e7d-518bcde9a255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_afee5ec9-1ce8-4fa0-995a-a09fbfce9d56" xlink:href="mdt-20240426.xsd#mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_100b5c8e-23be-48cd-a50b-90bcc5d33a39" xlink:to="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_afee5ec9-1ce8-4fa0-995a-a09fbfce9d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_7e5ca484-754d-4e53-b56d-999b4684a2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_100b5c8e-23be-48cd-a50b-90bcc5d33a39" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_7e5ca484-754d-4e53-b56d-999b4684a2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_e203b7fa-c325-4311-acdf-5731fa3c3532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_100b5c8e-23be-48cd-a50b-90bcc5d33a39" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_e203b7fa-c325-4311-acdf-5731fa3c3532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ec24aaf0-a382-49aa-8674-13041a9c8fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_OperatingIncomeLoss_ec24aaf0-a382-49aa-8674-13041a9c8fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_23a81ed0-17b4-4964-b2ad-e2f898716791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_23a81ed0-17b4-4964-b2ad-e2f898716791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5d194da3-c31a-4594-8f4a-c76c5b84fb52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_InterestExpense_5d194da3-c31a-4594-8f4a-c76c5b84fb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a573cddd-55bf-4c74-9af7-73d14351c0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a573cddd-55bf-4c74-9af7-73d14351c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0a1b805b-e214-4e25-9a6f-c5088ad1d206" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0a1b805b-e214-4e25-9a6f-c5088ad1d206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_52a5438c-b468-43d6-b3b1-90f8b194400f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_ProfitLoss_52a5438c-b468-43d6-b3b1-90f8b194400f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_15a6f0b6-0d7f-48c7-a52e-2b86d032b40a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_15a6f0b6-0d7f-48c7-a52e-2b86d032b40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c19998ec-9b08-4aba-89a7-aa7dce7a7329" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_NetIncomeLoss_c19998ec-9b08-4aba-89a7-aa7dce7a7329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_48271314-cb43-4e70-acc1-bb2bb5e7b339" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_EarningsPerShareBasic_48271314-cb43-4e70-acc1-bb2bb5e7b339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bd7f67a7-6583-44a5-91e7-616fb2cd2c64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bd7f67a7-6583-44a5-91e7-616fb2cd2c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1e55ae4b-9f0f-4d16-b087-d831da2b6639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1e55ae4b-9f0f-4d16-b087-d831da2b6639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4becc240-b31e-4680-905a-6bdb7034f3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1098cdde-825e-49bc-9e0f-dd4bd3963e78" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4becc240-b31e-4680-905a-6bdb7034f3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_003bfc5e-38ea-49e8-9b78-fd9960234af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27719b22-b4d6-4e5b-902b-9587720950e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_003bfc5e-38ea-49e8-9b78-fd9960234af4" xlink:to="loc_us-gaap_ProfitLoss_27719b22-b4d6-4e5b-902b-9587720950e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f773ec10-b773-468f-87a9-faa9c136c533" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_003bfc5e-38ea-49e8-9b78-fd9960234af4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f773ec10-b773-468f-87a9-faa9c136c533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fc4b6b2b-b5ff-4a38-8e79-ec1c80d46859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f773ec10-b773-468f-87a9-faa9c136c533" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fc4b6b2b-b5ff-4a38-8e79-ec1c80d46859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_78d01788-2c67-4794-875b-7e9038e28578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f773ec10-b773-468f-87a9-faa9c136c533" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_78d01788-2c67-4794-875b-7e9038e28578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_c7163487-47f1-41da-8dde-e2bfd30154e5" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f773ec10-b773-468f-87a9-faa9c136c533" xlink:to="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_c7163487-47f1-41da-8dde-e2bfd30154e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_714997b7-563b-446d-9cf3-37053eb42b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f773ec10-b773-468f-87a9-faa9c136c533" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_714997b7-563b-446d-9cf3-37053eb42b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9dc6d175-8d7f-43fa-8805-bd8bd8cc07c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f773ec10-b773-468f-87a9-faa9c136c533" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9dc6d175-8d7f-43fa-8805-bd8bd8cc07c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_578bc364-ece1-4058-8cfa-af6a626d6744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f773ec10-b773-468f-87a9-faa9c136c533" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_578bc364-ece1-4058-8cfa-af6a626d6744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f35ea15b-3daf-433c-b4fc-4d7d7cc36c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_003bfc5e-38ea-49e8-9b78-fd9960234af4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f35ea15b-3daf-433c-b4fc-4d7d7cc36c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c73179b4-5ed3-4332-9076-9b38637f16a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_003bfc5e-38ea-49e8-9b78-fd9960234af4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c73179b4-5ed3-4332-9076-9b38637f16a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_af33d472-3a33-4793-9dd0-8601e802d1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_003bfc5e-38ea-49e8-9b78-fd9960234af4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_af33d472-3a33-4793-9dd0-8601e802d1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_13bb97e8-8a46-4e25-8762-e73eb26281d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6e34d261-fa74-4a09-a83e-ef98eac39286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13bb97e8-8a46-4e25-8762-e73eb26281d5" xlink:to="loc_us-gaap_AssetsAbstract_6e34d261-fa74-4a09-a83e-ef98eac39286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9ca58cc5-daa1-40e1-bc01-e1919eb96a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e34d261-fa74-4a09-a83e-ef98eac39286" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9ca58cc5-daa1-40e1-bc01-e1919eb96a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e624814-abea-4a14-9406-f649e2c95aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ca58cc5-daa1-40e1-bc01-e1919eb96a48" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e624814-abea-4a14-9406-f649e2c95aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_821c1b24-e516-4dfc-96f4-72d03d2dd4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ca58cc5-daa1-40e1-bc01-e1919eb96a48" xlink:to="loc_us-gaap_ShortTermInvestments_821c1b24-e516-4dfc-96f4-72d03d2dd4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f888aa8e-2126-416b-a6f4-8c929c0217da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ca58cc5-daa1-40e1-bc01-e1919eb96a48" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f888aa8e-2126-416b-a6f4-8c929c0217da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_39fef78c-7962-419c-acac-a37638bd4e91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ca58cc5-daa1-40e1-bc01-e1919eb96a48" xlink:to="loc_us-gaap_InventoryNet_39fef78c-7962-419c-acac-a37638bd4e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1181226a-b592-4074-a4c0-2f17de2e7d99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ca58cc5-daa1-40e1-bc01-e1919eb96a48" xlink:to="loc_us-gaap_OtherAssetsCurrent_1181226a-b592-4074-a4c0-2f17de2e7d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3bad3ec7-d2cf-4ee0-8955-522076c22599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9ca58cc5-daa1-40e1-bc01-e1919eb96a48" xlink:to="loc_us-gaap_AssetsCurrent_3bad3ec7-d2cf-4ee0-8955-522076c22599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_372c6721-aa6b-45a3-adac-23f6c09ab1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e34d261-fa74-4a09-a83e-ef98eac39286" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_372c6721-aa6b-45a3-adac-23f6c09ab1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_42bf1c56-e190-4c10-aa86-221e975549f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e34d261-fa74-4a09-a83e-ef98eac39286" xlink:to="loc_us-gaap_Goodwill_42bf1c56-e190-4c10-aa86-221e975549f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fb8d397f-31e0-4b76-81d6-342e4b4f7f73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e34d261-fa74-4a09-a83e-ef98eac39286" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fb8d397f-31e0-4b76-81d6-342e4b4f7f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b93bfe7a-3934-43d7-a9b2-a00a9a203c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e34d261-fa74-4a09-a83e-ef98eac39286" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b93bfe7a-3934-43d7-a9b2-a00a9a203c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7d87e47c-449b-40fa-a942-7527e21c9d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e34d261-fa74-4a09-a83e-ef98eac39286" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7d87e47c-449b-40fa-a942-7527e21c9d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9c407353-ba16-4380-ab7a-ace60dbafe7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e34d261-fa74-4a09-a83e-ef98eac39286" xlink:to="loc_us-gaap_Assets_9c407353-ba16-4380-ab7a-ace60dbafe7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13bb97e8-8a46-4e25-8762-e73eb26281d5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3669f661-2827-46a1-b07b-73b5cc0241bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3669f661-2827-46a1-b07b-73b5cc0241bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c3f4a11d-ceb2-40ab-baeb-8c7d89b4072f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3669f661-2827-46a1-b07b-73b5cc0241bb" xlink:to="loc_us-gaap_DebtCurrent_c3f4a11d-ceb2-40ab-baeb-8c7d89b4072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0978b788-7cca-4a68-a65c-a144147e0fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3669f661-2827-46a1-b07b-73b5cc0241bb" xlink:to="loc_us-gaap_AccountsPayableCurrent_0978b788-7cca-4a68-a65c-a144147e0fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_e0cc3364-46b7-4689-8a85-233fabaf15d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3669f661-2827-46a1-b07b-73b5cc0241bb" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_e0cc3364-46b7-4689-8a85-233fabaf15d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_6428da79-3f6c-43d3-943d-5dd107923c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3669f661-2827-46a1-b07b-73b5cc0241bb" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_6428da79-3f6c-43d3-943d-5dd107923c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3e392637-b24b-4b4a-b9a3-c0e2a66281c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3669f661-2827-46a1-b07b-73b5cc0241bb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3e392637-b24b-4b4a-b9a3-c0e2a66281c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_315f85fd-ec03-4a7d-80e9-6ee39356efd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3669f661-2827-46a1-b07b-73b5cc0241bb" xlink:to="loc_us-gaap_LiabilitiesCurrent_315f85fd-ec03-4a7d-80e9-6ee39356efd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2f9729ae-8e53-4a42-8073-023a78e444ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2f9729ae-8e53-4a42-8073-023a78e444ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_82af64e6-d277-408e-8c2e-cf7c49260d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_82af64e6-d277-408e-8c2e-cf7c49260d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1a81ecfd-1dcd-4e42-9c2d-90dc8eb89cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1a81ecfd-1dcd-4e42-9c2d-90dc8eb89cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_32f9c639-41b6-4841-9e76-2756efd3bb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_32f9c639-41b6-4841-9e76-2756efd3bb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_85ecb8bc-615a-4826-a9f6-576cad9f5e12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_85ecb8bc-615a-4826-a9f6-576cad9f5e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fe1dfcc8-2c80-4911-908d-126bc0fb17f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_Liabilities_fe1dfcc8-2c80-4911-908d-126bc0fb17f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1633d456-eac3-4247-8cbe-bae7ea4aa8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1633d456-eac3-4247-8cbe-bae7ea4aa8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b15d4cf4-2717-48fc-ae46-474f212a2304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b15d4cf4-2717-48fc-ae46-474f212a2304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b17409d5-4dc4-4253-939a-44601f2dfa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b15d4cf4-2717-48fc-ae46-474f212a2304" xlink:to="loc_us-gaap_CommonStockValue_b17409d5-4dc4-4253-939a-44601f2dfa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ad16108c-6e83-4e5a-840c-6202b1c2e655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b15d4cf4-2717-48fc-ae46-474f212a2304" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ad16108c-6e83-4e5a-840c-6202b1c2e655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7d7464bf-5e36-4c01-b2fa-40b42e484636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b15d4cf4-2717-48fc-ae46-474f212a2304" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7d7464bf-5e36-4c01-b2fa-40b42e484636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9c1ca30f-f196-4ac9-a6b4-03ceab064986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b15d4cf4-2717-48fc-ae46-474f212a2304" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9c1ca30f-f196-4ac9-a6b4-03ceab064986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_810b105d-9533-42a6-b968-faf8439744c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b15d4cf4-2717-48fc-ae46-474f212a2304" xlink:to="loc_us-gaap_StockholdersEquity_810b105d-9533-42a6-b968-faf8439744c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_53b52fc6-3134-4e80-b8ba-5b16059fef2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b15d4cf4-2717-48fc-ae46-474f212a2304" xlink:to="loc_us-gaap_MinorityInterest_53b52fc6-3134-4e80-b8ba-5b16059fef2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d74bb049-6958-4659-844d-b6a347af3c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b15d4cf4-2717-48fc-ae46-474f212a2304" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d74bb049-6958-4659-844d-b6a347af3c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_553dbd76-8bd1-4ca7-991c-c49bdf036ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f26ecfc5-7d73-450b-b03b-9548b53b8e2c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_553dbd76-8bd1-4ca7-991c-c49bdf036ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dd2ac3d4-668f-4edc-a762-fa50e4d79cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b7d20e99-2682-4e6c-98e1-0ffc0f3611c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd2ac3d4-668f-4edc-a762-fa50e4d79cf2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b7d20e99-2682-4e6c-98e1-0ffc0f3611c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5ae93bc3-53d8-4591-a273-2fda67460245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd2ac3d4-668f-4edc-a762-fa50e4d79cf2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5ae93bc3-53d8-4591-a273-2fda67460245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_902d4fb9-2ca0-4856-aced-0e1ec5fd8b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd2ac3d4-668f-4edc-a762-fa50e4d79cf2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_902d4fb9-2ca0-4856-aced-0e1ec5fd8b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_19c522e9-b244-4dd8-9c82-7c9fe6b888bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd2ac3d4-668f-4edc-a762-fa50e4d79cf2" xlink:to="loc_us-gaap_CommonStockSharesIssued_19c522e9-b244-4dd8-9c82-7c9fe6b888bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_97daac88-8961-42e5-b932-c939d97b1f65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd2ac3d4-668f-4edc-a762-fa50e4d79cf2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_97daac88-8961-42e5-b932-c939d97b1f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8086dd75-dc2a-4d66-a032-1d0ad374cc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_67255037-fbfe-404e-8387-89c58af282c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8086dd75-dc2a-4d66-a032-1d0ad374cc1a" xlink:to="loc_us-gaap_StatementTable_67255037-fbfe-404e-8387-89c58af282c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_404eb318-dea5-435d-b860-d4763dc2a645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_67255037-fbfe-404e-8387-89c58af282c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_404eb318-dea5-435d-b860-d4763dc2a645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fd625831-ea57-48fa-aa74-34417711e68c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_404eb318-dea5-435d-b860-d4763dc2a645" xlink:to="loc_us-gaap_EquityComponentDomain_fd625831-ea57-48fa-aa74-34417711e68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fd625831-ea57-48fa-aa74-34417711e68c" xlink:to="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e3946087-241c-40df-ae78-c314494e26b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:to="loc_us-gaap_CommonStockMember_e3946087-241c-40df-ae78-c314494e26b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c2d7c8a7-ff3d-4bba-b2e2-56b23ff97f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c2d7c8a7-ff3d-4bba-b2e2-56b23ff97f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ca64877a-9f51-4380-b886-12611be80091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:to="loc_us-gaap_RetainedEarningsMember_ca64877a-9f51-4380-b886-12611be80091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d14b88d1-52c3-4b70-a2b1-edf38336b380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_2033890f-05e1-42ce-b1e6-311171531145" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d14b88d1-52c3-4b70-a2b1-edf38336b380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c247ca59-3e8f-4c28-a048-8a72114a4aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fd625831-ea57-48fa-aa74-34417711e68c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c247ca59-3e8f-4c28-a048-8a72114a4aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_53a2247e-09d5-4faa-ac7a-c8f07148a2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_67255037-fbfe-404e-8387-89c58af282c8" xlink:to="loc_us-gaap_StatementLineItems_53a2247e-09d5-4faa-ac7a-c8f07148a2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53a2247e-09d5-4faa-ac7a-c8f07148a2ed" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a7f49241-2ab3-4bac-ab09-f4a9ed1921ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a7f49241-2ab3-4bac-ab09-f4a9ed1921ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a90a3fea-e244-4c95-8574-7110532e88f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a90a3fea-e244-4c95-8574-7110532e88f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ea3feddc-24c6-423e-bc95-bd9d1dea55f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_ProfitLoss_ea3feddc-24c6-423e-bc95-bd9d1dea55f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_172f3b4a-2fae-488e-bed1-76720068bd65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_172f3b4a-2fae-488e-bed1-76720068bd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_359289e4-db80-428e-bf03-cd4e8e3bda74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_DividendsCommonStockCash_359289e4-db80-428e-bf03-cd4e8e3bda74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_543aa0cd-479c-4c16-89f5-4ca272e7cf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_543aa0cd-479c-4c16-89f5-4ca272e7cf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_51beb794-7f8d-495c-a339-590329e1b3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_51beb794-7f8d-495c-a339-590329e1b3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0a43292d-a0f3-41dc-bb3c-cf08574369f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0a43292d-a0f3-41dc-bb3c-cf08574369f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3196daf0-91c4-4faa-9cfa-80e454a79390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3196daf0-91c4-4faa-9cfa-80e454a79390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_74c28ecb-614b-4158-95d6-c89525437ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_74c28ecb-614b-4158-95d6-c89525437ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d2fd5360-ea42-4173-99fc-24e720c3e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d2fd5360-ea42-4173-99fc-24e720c3e89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4ec011fe-d5bc-40bc-a0db-d0416fca639c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4ec011fe-d5bc-40bc-a0db-d0416fca639c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3af6b7e6-502f-4055-9e06-016c322dbd10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad784440-f19f-4630-92bb-4f946f2650d8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3af6b7e6-502f-4055-9e06-016c322dbd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_aa0ee600-283c-4893-ab46-91568772ae49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_a6c48eb2-cbe7-4c99-86f5-8c89fdbe516f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_aa0ee600-283c-4893-ab46-91568772ae49" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_a6c48eb2-cbe7-4c99-86f5-8c89fdbe516f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mdt-20240426.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b98a2ec7-cd13-4980-901a-225ec0074841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_961dfee2-cf29-4db9-b69a-0550fc009f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b98a2ec7-cd13-4980-901a-225ec0074841" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_961dfee2-cf29-4db9-b69a-0550fc009f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c4535bc1-e54f-4baa-ac29-0f125711280e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_961dfee2-cf29-4db9-b69a-0550fc009f12" xlink:to="loc_us-gaap_ProfitLoss_c4535bc1-e54f-4baa-ac29-0f125711280e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_961dfee2-cf29-4db9-b69a-0550fc009f12" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dbeec304-9dc9-4bb8-b79f-c464c4314ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dbeec304-9dc9-4bb8-b79f-c464c4314ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fb6c4b49-a18a-493d-8b10-b2475a5f1fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fb6c4b49-a18a-493d-8b10-b2475a5f1fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a7f5a3c5-c6e5-4a3d-bf6c-b1c93c7b91c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a7f5a3c5-c6e5-4a3d-bf6c-b1c93c7b91c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fe187491-1e51-49aa-b79d-4b6b320e0ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:to="loc_us-gaap_ShareBasedCompensation_fe187491-1e51-49aa-b79d-4b6b320e0ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1f4ddb3b-b9f0-4c53-9ba4-f22a5b6fe6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1f4ddb3b-b9f0-4c53-9ba4-f22a5b6fe6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3bef089b-c7fb-4971-b66d-9fba12c52c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:to="loc_us-gaap_AssetImpairmentCharges_3bef089b-c7fb-4971-b66d-9fba12c52c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_52d78594-6104-4b3b-974c-93f045f2ecbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_52d78594-6104-4b3b-974c-93f045f2ecbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6b13078-9f52-4769-8c53-789ff55b5c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb32bf48-ec0d-4a28-9296-c4e01d850fd4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6b13078-9f52-4769-8c53-789ff55b5c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_f1d385b4-662d-413d-bc57-dc9be736cd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6b13078-9f52-4769-8c53-789ff55b5c26" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_f1d385b4-662d-413d-bc57-dc9be736cd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eedf31cc-45d9-452e-ad22-27945f00502c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6b13078-9f52-4769-8c53-789ff55b5c26" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eedf31cc-45d9-452e-ad22-27945f00502c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a61b7ef7-ff0d-40ce-8c9a-41b4a1352514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6b13078-9f52-4769-8c53-789ff55b5c26" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a61b7ef7-ff0d-40ce-8c9a-41b4a1352514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_571909d0-5044-4f1a-b3f5-cb2fc103f420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6b13078-9f52-4769-8c53-789ff55b5c26" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_571909d0-5044-4f1a-b3f5-cb2fc103f420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_724b9331-8a7c-4f79-bf3e-18a40a65c11d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_961dfee2-cf29-4db9-b69a-0550fc009f12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_724b9331-8a7c-4f79-bf3e-18a40a65c11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0007bf5c-cda5-410d-9187-430e3f999b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b98a2ec7-cd13-4980-901a-225ec0074841" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0007bf5c-cda5-410d-9187-430e3f999b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c914b65c-ee0a-4075-bea7-c0e9b77edd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0007bf5c-cda5-410d-9187-430e3f999b04" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c914b65c-ee0a-4075-bea7-c0e9b77edd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_caa8552d-dcb0-41f7-b6f3-154087f7ead8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0007bf5c-cda5-410d-9187-430e3f999b04" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_caa8552d-dcb0-41f7-b6f3-154087f7ead8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_04e4128a-d53c-44ae-8eb5-ac5460ebdba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0007bf5c-cda5-410d-9187-430e3f999b04" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_04e4128a-d53c-44ae-8eb5-ac5460ebdba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_60bca047-7418-4a13-acd0-edf507629bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0007bf5c-cda5-410d-9187-430e3f999b04" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_60bca047-7418-4a13-acd0-edf507629bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e1fe0ed6-d0e4-4a78-95bf-77081d415706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0007bf5c-cda5-410d-9187-430e3f999b04" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e1fe0ed6-d0e4-4a78-95bf-77081d415706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_efdb71c4-d312-431b-9fad-236bb89766c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0007bf5c-cda5-410d-9187-430e3f999b04" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_efdb71c4-d312-431b-9fad-236bb89766c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b98a2ec7-cd13-4980-901a-225ec0074841" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_5272bea7-ba4b-452e-a38a-fbbbe978387f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_5272bea7-ba4b-452e-a38a-fbbbe978387f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_bb1306ad-3eb1-4594-9d9d-11360afbb3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_bb1306ad-3eb1-4594-9d9d-11360afbb3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_72f122dd-f1b9-4f42-a540-8e0ec261ff5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_72f122dd-f1b9-4f42-a540-8e0ec261ff5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f6b5a8b9-e9d8-4016-9cd5-22343fff0ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f6b5a8b9-e9d8-4016-9cd5-22343fff0ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ffd888a4-3ab6-4e6b-953f-3849d96a8ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ffd888a4-3ab6-4e6b-953f-3849d96a8ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_1b9b8440-dcb7-442c-b38e-4ed536c7c54a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_1b9b8440-dcb7-442c-b38e-4ed536c7c54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e6238ee9-46ab-45c2-a81b-e45f170b4ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e6238ee9-46ab-45c2-a81b-e45f170b4ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9b3c05d2-02dc-46f0-be7b-1200a27a03ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9b3c05d2-02dc-46f0-be7b-1200a27a03ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_afdcd516-d387-46a6-b533-2fbe0fa57bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_afdcd516-d387-46a6-b533-2fbe0fa57bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b50b80a-31a1-4c12-8f9a-59bd1bf57b63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_31e72f65-ac73-4fa6-8f1c-8007cc9ce461" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b50b80a-31a1-4c12-8f9a-59bd1bf57b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac6b28ae-3067-4012-a381-3879b98fb54e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b98a2ec7-cd13-4980-901a-225ec0074841" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac6b28ae-3067-4012-a381-3879b98fb54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_686ef640-046d-47fd-a07d-1abe7bae5990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b98a2ec7-cd13-4980-901a-225ec0074841" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_686ef640-046d-47fd-a07d-1abe7bae5990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a79f3c5a-2b65-4796-8313-ef6a3254f3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b98a2ec7-cd13-4980-901a-225ec0074841" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a79f3c5a-2b65-4796-8313-ef6a3254f3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b249cf40-479c-42c6-b0cd-b6b48534e541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b98a2ec7-cd13-4980-901a-225ec0074841" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b249cf40-479c-42c6-b0cd-b6b48534e541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9db5c6f6-8569-4cfd-9967-47b2bc2af37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b98a2ec7-cd13-4980-901a-225ec0074841" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9db5c6f6-8569-4cfd-9967-47b2bc2af37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxesandInterestPaidAbstract_16e2bcf5-c39c-4889-829b-cd7cb09d23b1" xlink:href="mdt-20240426.xsd#mdt_IncomeTaxesandInterestPaidAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9db5c6f6-8569-4cfd-9967-47b2bc2af37b" xlink:to="loc_mdt_IncomeTaxesandInterestPaidAbstract_16e2bcf5-c39c-4889-829b-cd7cb09d23b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_ab3fd889-15cf-499f-8eff-d7ffa0f3f5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncomeTaxesandInterestPaidAbstract_16e2bcf5-c39c-4889-829b-cd7cb09d23b1" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_ab3fd889-15cf-499f-8eff-d7ffa0f3f5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ea604d25-3778-4c58-9649-453a00877796" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncomeTaxesandInterestPaidAbstract_16e2bcf5-c39c-4889-829b-cd7cb09d23b1" xlink:to="loc_us-gaap_InterestPaidNet_ea604d25-3778-4c58-9649-453a00877796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mdt-20240426.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fe000b11-fd1b-4868-a359-29f305ac04ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c51acf52-287f-4894-9f0b-062cd8b62279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fe000b11-fd1b-4868-a359-29f305ac04ce" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c51acf52-287f-4894-9f0b-062cd8b62279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/Revenue" xlink:type="simple" xlink:href="mdt-20240426.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2c076476-bb99-4221-9865-c0918efe0972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_62f4d336-211d-431f-9ddc-cef4f18e72dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2c076476-bb99-4221-9865-c0918efe0972" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_62f4d336-211d-431f-9ddc-cef4f18e72dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositions" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositions"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1a7fc633-a9c4-4be3-86d0-ddabca68f947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f7f2ecad-7087-4560-af7d-aa06fb7ef538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1a7fc633-a9c4-4be3-86d0-ddabca68f947" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f7f2ecad-7087-4560-af7d-aa06fb7ef538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringCharges" xlink:type="simple" xlink:href="mdt-20240426.xsd#RestructuringCharges"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3a302b93-c987-41db-b8ad-de14c7e12b32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a15f5dfe-8ab3-4a5e-92db-7e8c5ba728fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3a302b93-c987-41db-b8ad-de14c7e12b32" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a15f5dfe-8ab3-4a5e-92db-7e8c5ba728fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_545ccff4-d7aa-42f8-9912-cad43bcbdc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_ee4aba01-0817-4613-b883-b70427d61083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_545ccff4-d7aa-42f8-9912-cad43bcbdc3c" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_ee4aba01-0817-4613-b883-b70427d61083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangements" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangements"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ae4c445e-e19c-4b51-927f-a72c93816f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3d591423-909b-41a4-b00d-3ab360d9019d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ae4c445e-e19c-4b51-927f-a72c93816f2f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3d591423-909b-41a4-b00d-3ab360d9019d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagement"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cec3c280-19d9-4dbf-99a4-26b1e737725d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_e948b78c-bf4a-4245-af6c-86ff38ed2897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cec3c280-19d9-4dbf-99a4-26b1e737725d" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_e948b78c-bf4a-4245-af6c-86ff38ed2897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/Inventories" xlink:type="simple" xlink:href="mdt-20240426.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e57b4757-1c32-4b73-9ec1-b130c32c3a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_65addc77-8270-4d53-b26c-01163cfdf6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e57b4757-1c32-4b73-9ec1-b130c32c3a78" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_65addc77-8270-4d53-b26c-01163cfdf6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="mdt-20240426.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e37c121b-f80a-43b4-9b88-7daec0a7f1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3f409e7d-2350-418f-ad78-b54357eb903e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e37c121b-f80a-43b4-9b88-7daec0a7f1e7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3f409e7d-2350-418f-ad78-b54357eb903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="mdt-20240426.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_55d70639-5530-4490-96b3-85e3b18286e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ca353b94-624e-49ec-9575-7eac3c633aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_55d70639-5530-4490-96b3-85e3b18286e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ca353b94-624e-49ec-9575-7eac3c633aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="mdt-20240426.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6aff4304-ec63-4914-97b1-e2f0de651f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_618d37a1-8c9a-477b-8cfa-af1fb42d366f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6aff4304-ec63-4914-97b1-e2f0de651f02" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_618d37a1-8c9a-477b-8cfa-af1fb42d366f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlans" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlans"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb9c481c-20de-4bac-9baa-e77c944b3370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cbade35c-7fc5-449e-b9d2-b4afb7daf2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb9c481c-20de-4bac-9baa-e77c944b3370" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cbade35c-7fc5-449e-b9d2-b4afb7daf2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3be42fcc-4492-415f-933a-fcf00b1970ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e71b89ed-aee4-45a4-8f6e-76adcd366650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3be42fcc-4492-415f-933a-fcf00b1970ef" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e71b89ed-aee4-45a4-8f6e-76adcd366650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShare" xlink:type="simple" xlink:href="mdt-20240426.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d253ed77-eafd-4d0e-9afb-baf6cd91fe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_101d86de-cb02-4191-b93c-03d60c6c2b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d253ed77-eafd-4d0e-9afb-baf6cd91fe4f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_101d86de-cb02-4191-b93c-03d60c6c2b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlans" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fba564a6-6801-428d-b6e4-e658e2350833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d8afcd5a-177a-4f8e-b5d9-26472640063e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fba564a6-6801-428d-b6e4-e658e2350833" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d8afcd5a-177a-4f8e-b5d9-26472640063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/Leases" xlink:type="simple" xlink:href="mdt-20240426.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_30d60d2e-a7f3-4a06-a9a7-16328a029029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6aeb1750-ede0-408c-89b6-658f23354edd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_30d60d2e-a7f3-4a06-a9a7-16328a029029" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6aeb1750-ede0-408c-89b6-658f23354edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="simple" xlink:href="mdt-20240426.xsd#AccumulatedOtherComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fcc9d775-7772-42f1-84a4-66683463ec07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_fb57239b-71ab-454c-8f20-56a8ab1a3cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fcc9d775-7772-42f1-84a4-66683463ec07" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_fb57239b-71ab-454c-8f20-56a8ab1a3cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mdt-20240426.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d763a244-44fb-40f6-a098-223319a1e444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_0ad277c1-95b9-4eee-ab56-0a2e0386dc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d763a244-44fb-40f6-a098-223319a1e444" xlink:to="loc_us-gaap_LossContingencyDisclosures_0ad277c1-95b9-4eee-ab56-0a2e0386dc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformation" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformation"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3f97aac7-edf0-443a-97a3-a9353fb14bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_b418a208-6999-4db2-a62c-f67b5a7484a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3f97aac7-edf0-443a-97a3-a9353fb14bcd" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_b418a208-6999-4db2-a62c-f67b5a7484a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="simple" xlink:href="mdt-20240426.xsd#ScheduleIIValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_24d2c868-284c-4f86-93ea-bc7ec93e328e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c0d03683-5797-43cc-82b0-e159458b65fc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_24d2c868-284c-4f86-93ea-bc7ec93e328e" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c0d03683-5797-43cc-82b0-e159458b65fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mdt-20240426.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e5b145c8-54c8-4fab-b291-8e8321ba5d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e5b145c8-54c8-4fab-b291-8e8321ba5d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_57cd71ee-a29e-4f63-846a-186dc802e306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_57cd71ee-a29e-4f63-846a-186dc802e306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a7d94759-e9be-48b9-ae4f-a02ec1acac41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_UseOfEstimates_a7d94759-e9be-48b9-ae4f-a02ec1acac41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_0b4dd398-8e22-4559-854f-2cccba219fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_FiscalPeriod_0b4dd398-8e22-4559-854f-2cccba219fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e89cf255-f4c5-4eab-9550-2380e8fd4243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e89cf255-f4c5-4eab-9550-2380e8fd4243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_60d686a6-1fe9-412f-a346-39018065edf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_60d686a6-1fe9-412f-a346-39018065edf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2a60fd42-5e06-4eab-beb4-705c35ab274a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2a60fd42-5e06-4eab-beb4-705c35ab274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1c26a40a-87bc-45d5-a85d-3f6f2df03366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_1c26a40a-87bc-45d5-a85d-3f6f2df03366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d0fc5fa7-d5a5-4277-8434-b40b2291fb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d0fc5fa7-d5a5-4277-8434-b40b2291fb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f0e624ea-09fb-4989-83bf-3b09486ba185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f0e624ea-09fb-4989-83bf-3b09486ba185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_864d1e6f-139b-43de-a30e-e47286924c51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_864d1e6f-139b-43de-a30e-e47286924c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_f120f248-9544-4bcf-a894-0d99cdd0dc32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_f120f248-9544-4bcf-a894-0d99cdd0dc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ContingentConsiderationPolicyTextBlock_3e6ff69d-43d5-47cd-bca3-dc4184df9838" xlink:href="mdt-20240426.xsd#mdt_ContingentConsiderationPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_mdt_ContingentConsiderationPolicyTextBlock_3e6ff69d-43d5-47cd-bca3-dc4184df9838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_f9fbc2a1-8dcc-4583-88a1-200fd2fe52eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_f9fbc2a1-8dcc-4583-88a1-200fd2fe52eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_4cad7c36-206a-461e-82c4-13350fde034a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_4cad7c36-206a-461e-82c4-13350fde034a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_7c7636e1-a9cf-42d0-bb84-c5652912f70e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_7c7636e1-a9cf-42d0-bb84-c5652912f70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_79334149-e1ea-43c0-b133-a251837db4af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_79334149-e1ea-43c0-b133-a251837db4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9de26d2b-6690-4161-9fe2-3977b695f452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9de26d2b-6690-4161-9fe2-3977b695f452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5b4928d8-0026-4136-aa57-d0f5e4178d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5b4928d8-0026-4136-aa57-d0f5e4178d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_989fbf73-9db6-4e39-8ab6-ec167484cb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_989fbf73-9db6-4e39-8ab6-ec167484cb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_7553f96d-f614-4cc7-a12b-7b63d29e7131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_7553f96d-f614-4cc7-a12b-7b63d29e7131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_abec66d1-065d-4f6e-b791-7a7e982f9e87" xlink:href="mdt-20240426.xsd#mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_abec66d1-065d-4f6e-b791-7a7e982f9e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_accb29f0-1a99-4c93-811c-f8713eb74563" xlink:href="mdt-20240426.xsd#mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_accb29f0-1a99-4c93-811c-f8713eb74563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b51b2831-6799-4d43-b370-932a34dbc655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b51b2831-6799-4d43-b370-932a34dbc655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_13143560-fdee-4e47-b279-20746e6fe2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_13143560-fdee-4e47-b279-20746e6fe2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cad5855a-c566-4cb1-bf6f-7a3369e594e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cad5855a-c566-4cb1-bf6f-7a3369e594e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_6612979b-be84-4ab1-9264-36962813e90f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170bdeb4-005d-4b2b-b078-e267123b0a92" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_6612979b-be84-4ab1-9264-36962813e90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_425828ab-0e82-4f99-9839-f77f69d3269b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4c1ffae3-449c-4d14-9a17-da8197cf487a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_425828ab-0e82-4f99-9839-f77f69d3269b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4c1ffae3-449c-4d14-9a17-da8197cf487a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8071afcb-a8d8-4dc2-8bed-5ca732852c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3b427482-a613-4d3f-b91c-246702293f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8071afcb-a8d8-4dc2-8bed-5ca732852c54" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3b427482-a613-4d3f-b91c-246702293f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_c63456a0-4a89-4e2e-994e-015f5f887f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8071afcb-a8d8-4dc2-8bed-5ca732852c54" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_c63456a0-4a89-4e2e-994e-015f5f887f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_af9de275-bead-4e67-887e-fe4ff49a5b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8071afcb-a8d8-4dc2-8bed-5ca732852c54" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_af9de275-bead-4e67-887e-fe4ff49a5b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#RestructuringChargesTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0fea75a5-7d33-4140-b2b7-22fd4564a651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_181f8205-6d71-4df0-9302-30e779493a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0fea75a5-7d33-4140-b2b7-22fd4564a651" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_181f8205-6d71-4df0-9302-30e779493a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_e47b3284-3b11-414b-a47c-40a9ac901c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3c223824-f8f4-411f-a830-03e7b0d67f03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_e47b3284-3b11-414b-a47c-40a9ac901c1b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3c223824-f8f4-411f-a830-03e7b0d67f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_13f4e2e7-ec89-4afb-b66f-fd3ab7a736eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_e47b3284-3b11-414b-a47c-40a9ac901c1b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_13f4e2e7-ec89-4afb-b66f-fd3ab7a736eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_689a4147-2b8f-4bb6-965a-9ac84e3f50fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_e47b3284-3b11-414b-a47c-40a9ac901c1b" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_689a4147-2b8f-4bb6-965a-9ac84e3f50fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_df6f39bf-8930-41b2-8208-595dfbbaff63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_e47b3284-3b11-414b-a47c-40a9ac901c1b" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_df6f39bf-8930-41b2-8208-595dfbbaff63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_1b447437-c86e-47d5-badb-9b725e067f2b" xlink:href="mdt-20240426.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_e47b3284-3b11-414b-a47c-40a9ac901c1b" xlink:to="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_1b447437-c86e-47d5-badb-9b725e067f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_811e4b8c-ad07-4fc2-befa-8faadb4ef0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_e47b3284-3b11-414b-a47c-40a9ac901c1b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_811e4b8c-ad07-4fc2-befa-8faadb4ef0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ca64835b-8a87-408a-9c1a-8a5eeb7defe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_100f7aec-f9b2-44c5-98bf-4a1d8e55a1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ca64835b-8a87-408a-9c1a-8a5eeb7defe4" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_100f7aec-f9b2-44c5-98bf-4a1d8e55a1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b6b4f081-171a-4f4c-95b4-d7b1079e6a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ca64835b-8a87-408a-9c1a-8a5eeb7defe4" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b6b4f081-171a-4f4c-95b4-d7b1079e6a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0088bf37-0306-4b38-97d4-7ee592ada8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ca64835b-8a87-408a-9c1a-8a5eeb7defe4" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0088bf37-0306-4b38-97d4-7ee592ada8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_429b7d94-59cf-40be-a471-ee412bfc271d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5b5e4e04-131a-41fc-9818-cf64fe2479cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_429b7d94-59cf-40be-a471-ee412bfc271d" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5b5e4e04-131a-41fc-9818-cf64fe2479cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_88e64453-4864-4186-b6c2-2168878bb71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_429b7d94-59cf-40be-a471-ee412bfc271d" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_88e64453-4864-4186-b6c2-2168878bb71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_31719b5c-7cef-407f-81f4-f8bc3fdc9d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_429b7d94-59cf-40be-a471-ee412bfc271d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_31719b5c-7cef-407f-81f4-f8bc3fdc9d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTableTextBlock_958d16b4-828a-46fb-8f33-5ddecd7b0504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_429b7d94-59cf-40be-a471-ee412bfc271d" xlink:to="loc_us-gaap_OffsettingAssetsTableTextBlock_958d16b4-828a-46fb-8f33-5ddecd7b0504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingLiabilitiesTableTextBlock_b89f36ef-aeb7-4dcb-a6ef-640f443ad8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_429b7d94-59cf-40be-a471-ee412bfc271d" xlink:to="loc_us-gaap_OffsettingLiabilitiesTableTextBlock_b89f36ef-aeb7-4dcb-a6ef-640f443ad8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/InventoriesTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9f1817b2-52cb-448b-8543-9aa912c75548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a8d48842-4a0f-451e-97d9-8b5a4d184efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9f1817b2-52cb-448b-8543-9aa912c75548" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a8d48842-4a0f-451e-97d9-8b5a4d184efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28585e2e-ef96-4306-8676-e104e43df73c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_19498e3e-c4b5-4e59-a085-b3bd6082a8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28585e2e-ef96-4306-8676-e104e43df73c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_19498e3e-c4b5-4e59-a085-b3bd6082a8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e57eb472-275c-4b24-868c-eb31559f0150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28585e2e-ef96-4306-8676-e104e43df73c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e57eb472-275c-4b24-868c-eb31559f0150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_b543a632-0a33-4ea3-b077-6b31a235450b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28585e2e-ef96-4306-8676-e104e43df73c" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_b543a632-0a33-4ea3-b077-6b31a235450b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_097c3dcd-a623-492a-abfa-3ad60a9ac18e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28585e2e-ef96-4306-8676-e104e43df73c" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_097c3dcd-a623-492a-abfa-3ad60a9ac18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_87f9ca37-0cfe-4e24-9fe6-7751c40c3166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_27294b71-53e7-448e-94af-9490a4758ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_87f9ca37-0cfe-4e24-9fe6-7751c40c3166" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_27294b71-53e7-448e-94af-9490a4758ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_352494db-1c9b-4f4e-ae99-e81c0c8f42bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8b986c88-49fb-4ec1-bb74-7df4b48915c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_352494db-1c9b-4f4e-ae99-e81c0c8f42bc" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8b986c88-49fb-4ec1-bb74-7df4b48915c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e75a6a50-1fcc-4c30-96d2-80dc1cddcf81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_352494db-1c9b-4f4e-ae99-e81c0c8f42bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e75a6a50-1fcc-4c30-96d2-80dc1cddcf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c5d90da0-5cda-4c39-8271-da7f7c001675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_352494db-1c9b-4f4e-ae99-e81c0c8f42bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c5d90da0-5cda-4c39-8271-da7f7c001675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7c2190df-f61e-4fbd-9713-459877d7fc57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_352494db-1c9b-4f4e-ae99-e81c0c8f42bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7c2190df-f61e-4fbd-9713-459877d7fc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_f38294f9-8e22-4799-94b7-252b54086414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_352494db-1c9b-4f4e-ae99-e81c0c8f42bc" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_f38294f9-8e22-4799-94b7-252b54086414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d7d6b1c4-cdf5-4677-804f-4cd79d72bc52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_aabb9984-0fee-4261-b1bc-3f94f4e9da6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7d6b1c4-cdf5-4677-804f-4cd79d72bc52" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_aabb9984-0fee-4261-b1bc-3f94f4e9da6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a83f397e-6306-41c8-a21e-54b75ac5be35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7d6b1c4-cdf5-4677-804f-4cd79d72bc52" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a83f397e-6306-41c8-a21e-54b75ac5be35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ea5972e1-cb1d-4187-aaba-dab7260caea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7d6b1c4-cdf5-4677-804f-4cd79d72bc52" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ea5972e1-cb1d-4187-aaba-dab7260caea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c0d3460d-6f2f-42d9-a633-891fe0629165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7d6b1c4-cdf5-4677-804f-4cd79d72bc52" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c0d3460d-6f2f-42d9-a633-891fe0629165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_f7e9260d-d8ff-4e9a-956f-2f8a449b0d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7d6b1c4-cdf5-4677-804f-4cd79d72bc52" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_f7e9260d-d8ff-4e9a-956f-2f8a449b0d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_653cb987-6317-4b8d-9c65-a31768a9966b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxExaminationsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7d6b1c4-cdf5-4677-804f-4cd79d72bc52" xlink:to="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_653cb987-6317-4b8d-9c65-a31768a9966b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_680cf0fa-8a8e-430d-a42e-3698c03fb6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5cdb92dc-1805-4868-8b37-247eba2776a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_680cf0fa-8a8e-430d-a42e-3698c03fb6d4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5cdb92dc-1805-4868-8b37-247eba2776a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_b27c8323-9fc3-488d-b9de-7afb881dd3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_b27c8323-9fc3-488d-b9de-7afb881dd3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_1e4d4083-09b2-4a26-8b25-f613dedda7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_1e4d4083-09b2-4a26-8b25-f613dedda7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_6fd0a366-b377-419f-ba1f-827aa0e84b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_6fd0a366-b377-419f-ba1f-827aa0e84b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_afa6bc21-f89a-4832-88b0-e9ac90ee598a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_afa6bc21-f89a-4832-88b0-e9ac90ee598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_bfc187be-16c5-4edc-a380-6afcc33b0320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_bfc187be-16c5-4edc-a380-6afcc33b0320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_34f25505-b7d1-4959-bc3a-4a8446b97b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_34f25505-b7d1-4959-bc3a-4a8446b97b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_9319c4fc-9e1f-455d-95ee-c0314ca7e839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_9319c4fc-9e1f-455d-95ee-c0314ca7e839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_a1838f00-6f99-4c5f-a883-43bc053e805c" xlink:href="mdt-20240426.xsd#mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_a1838f00-6f99-4c5f-a883-43bc053e805c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock_4d48e4e7-87a7-459f-985b-fe7f4ed51755" xlink:href="mdt-20240426.xsd#mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock_4d48e4e7-87a7-459f-985b-fe7f4ed51755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_198962b2-84ce-43fc-9740-e39ebde9a3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ef1a6e60-d5a9-41af-8b05-49421d81a5db" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_198962b2-84ce-43fc-9740-e39ebde9a3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_90c78a5e-48d8-420b-b2b7-f119fcbfffc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_fab3648e-2cab-4833-9edc-c7de28c0cdf1" xlink:href="mdt-20240426.xsd#mdt_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90c78a5e-48d8-420b-b2b7-f119fcbfffc8" xlink:to="loc_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_fab3648e-2cab-4833-9edc-c7de28c0cdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c5017474-85af-439a-a6e2-e2f02442c029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90c78a5e-48d8-420b-b2b7-f119fcbfffc8" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c5017474-85af-439a-a6e2-e2f02442c029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dc352af9-c968-49ec-a1d5-861e7180e8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90c78a5e-48d8-420b-b2b7-f119fcbfffc8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dc352af9-c968-49ec-a1d5-861e7180e8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#AccumulatedOtherComprehensiveLossTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fda5f713-b86a-4de1-a864-b4ae3a59a91f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e58ebaae-c968-4f0c-8f93-b6928e229c21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fda5f713-b86a-4de1-a864-b4ae3a59a91f" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e58ebaae-c968-4f0c-8f93-b6928e229c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationTables" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformationTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2bb1dd26-c121-44c6-a3eb-b6ab2528df5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_5490f6c0-2dff-49de-8664-716b8c186119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2bb1dd26-c121-44c6-a3eb-b6ab2528df5e" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_5490f6c0-2dff-49de-8664-716b8c186119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_cb184625-f332-40b4-86c8-0863eb4ca633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2bb1dd26-c121-44c6-a3eb-b6ab2528df5e" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_cb184625-f332-40b4-86c8-0863eb4ca633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_6b856eb1-102b-4f37-8747-1d991ee136a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2bb1dd26-c121-44c6-a3eb-b6ab2528df5e" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_6b856eb1-102b-4f37-8747-1d991ee136a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4c6ad01c-f031-4c47-92ab-3f45efedc5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8f905156-5591-4f68-8a28-69c91d851571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c6ad01c-f031-4c47-92ab-3f45efedc5d0" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8f905156-5591-4f68-8a28-69c91d851571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e521104-7c80-4a8f-8c25-b818f141d10e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8f905156-5591-4f68-8a28-69c91d851571" xlink:to="loc_srt_RangeAxis_7e521104-7c80-4a8f-8c25-b818f141d10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff5c21e1-5c3a-44b7-ba6c-9d9606576c5b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7e521104-7c80-4a8f-8c25-b818f141d10e" xlink:to="loc_srt_RangeMember_ff5c21e1-5c3a-44b7-ba6c-9d9606576c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cc543df1-e726-4ed8-ac5a-f6f00414ade4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ff5c21e1-5c3a-44b7-ba6c-9d9606576c5b" xlink:to="loc_srt_MinimumMember_cc543df1-e726-4ed8-ac5a-f6f00414ade4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_099b6077-bdd7-44e4-a8d5-2f0a871dd146" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ff5c21e1-5c3a-44b7-ba6c-9d9606576c5b" xlink:to="loc_srt_MaximumMember_099b6077-bdd7-44e4-a8d5-2f0a871dd146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7319614-8be4-4144-862a-7ebb9914e8e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8f905156-5591-4f68-8a28-69c91d851571" xlink:to="loc_srt_ProductOrServiceAxis_e7319614-8be4-4144-862a-7ebb9914e8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8798a20-fa4c-4888-b2f6-ae63f8a26e17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e7319614-8be4-4144-862a-7ebb9914e8e7" xlink:to="loc_srt_ProductsAndServicesDomain_b8798a20-fa4c-4888-b2f6-ae63f8a26e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_9993520f-5367-4a69-8f04-c25205b588f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b8798a20-fa4c-4888-b2f6-ae63f8a26e17" xlink:to="loc_us-gaap_ShippingAndHandlingMember_9993520f-5367-4a69-8f04-c25205b588f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_95bba605-0974-4d76-884d-0eff568cbe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8f905156-5591-4f68-8a28-69c91d851571" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_95bba605-0974-4d76-884d-0eff568cbe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d0b32a65-d22c-497d-83d0-8dbe426bcc43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_95bba605-0974-4d76-884d-0eff568cbe6e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d0b32a65-d22c-497d-83d0-8dbe426bcc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_edbf5cbd-844e-478e-aec9-54f44ff3ee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d0b32a65-d22c-497d-83d0-8dbe426bcc43" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_edbf5cbd-844e-478e-aec9-54f44ff3ee8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_764ab82a-589b-49dc-9bb7-2c4f6393a7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_95bba605-0974-4d76-884d-0eff568cbe6e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_764ab82a-589b-49dc-9bb7-2c4f6393a7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_352020a6-0ea6-4853-9eb0-2e75aa89da32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_764ab82a-589b-49dc-9bb7-2c4f6393a7dd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_352020a6-0ea6-4853-9eb0-2e75aa89da32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4477d597-4b9a-49e8-98d8-f26e42645e19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c213d0d4-afad-454f-841f-2d223b5eff09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4477d597-4b9a-49e8-98d8-f26e42645e19" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c213d0d4-afad-454f-841f-2d223b5eff09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a2db0b0-9f38-4d86-82a7-454b32f13c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c213d0d4-afad-454f-841f-2d223b5eff09" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a2db0b0-9f38-4d86-82a7-454b32f13c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bdc99ee5-7979-4d4c-9a49-c6da90b937fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a2db0b0-9f38-4d86-82a7-454b32f13c77" xlink:to="loc_us-gaap_SegmentDomain_bdc99ee5-7979-4d4c-9a49-c6da90b937fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:href="mdt-20240426.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bdc99ee5-7979-4d4c-9a49-c6da90b937fc" xlink:to="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_36cac49d-6e3a-4215-9be5-c2922959487b" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:to="loc_mdt_CardiovascularMember_36cac49d-6e3a-4215-9be5-c2922959487b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_da888a61-7bec-45e4-8260-3e3cd0a278a2" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:to="loc_mdt_NeuroscienceGroupMember_da888a61-7bec-45e4-8260-3e3cd0a278a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_07d4e269-d2d4-44b4-b1c4-9da1eb506d4f" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:to="loc_mdt_MedicalSurgicalMember_07d4e269-d2d4-44b4-b1c4-9da1eb506d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_97f99d40-8e12-472c-8607-75aa8b85e052" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_8e16081b-2159-4e7b-83a6-a15234970345" xlink:to="loc_mdt_DiabetesGroupMember_97f99d40-8e12-472c-8607-75aa8b85e052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a0ad47fa-5558-4703-a0d4-28a736bc047f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bdc99ee5-7979-4d4c-9a49-c6da90b937fc" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a0ad47fa-5558-4703-a0d4-28a736bc047f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_ae1416c3-ec5e-44d3-911b-e6290558b9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c213d0d4-afad-454f-841f-2d223b5eff09" xlink:to="loc_us-gaap_SubsegmentsAxis_ae1416c3-ec5e-44d3-911b-e6290558b9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_ae1416c3-ec5e-44d3-911b-e6290558b9ac" xlink:to="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiacRhythmandHeartFailureDivisionMember_4ff5f4fc-dccd-482e-9299-037fd09e1651" xlink:href="mdt-20240426.xsd#mdt_CardiacRhythmandHeartFailureDivisionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_CardiacRhythmandHeartFailureDivisionMember_4ff5f4fc-dccd-482e-9299-037fd09e1651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StructuralHeartAndAorticDivisionMember_970232ba-342e-422a-8adb-77c4b9ef93ab" xlink:href="mdt-20240426.xsd#mdt_StructuralHeartAndAorticDivisionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_StructuralHeartAndAorticDivisionMember_970232ba-342e-422a-8adb-77c4b9ef93ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CoronaryAndPeripheralVascularDivisionMember_81ce824d-7907-474d-b893-127745ad976e" xlink:href="mdt-20240426.xsd#mdt_CoronaryAndPeripheralVascularDivisionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_CoronaryAndPeripheralVascularDivisionMember_81ce824d-7907-474d-b893-127745ad976e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CranialAndSpinalTechnologiesDivisionMember_edc00896-a989-4e1e-9425-ea602a226500" xlink:href="mdt-20240426.xsd#mdt_CranialAndSpinalTechnologiesDivisionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_CranialAndSpinalTechnologiesDivisionMember_edc00896-a989-4e1e-9425-ea602a226500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialtyTherapiesDivisionMember_b359980a-b225-4a73-a3c0-d11f04e280d3" xlink:href="mdt-20240426.xsd#mdt_SpecialtyTherapiesDivisionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_SpecialtyTherapiesDivisionMember_b359980a-b225-4a73-a3c0-d11f04e280d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuromodulationDivisionMember_0ea11690-9d3c-4677-ba17-ebf860b934fd" xlink:href="mdt-20240426.xsd#mdt_NeuromodulationDivisionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_NeuromodulationDivisionMember_0ea11690-9d3c-4677-ba17-ebf860b934fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SurgicalInnovationsDivisionMember_469c831b-44f6-4b39-a397-e3a4798075cb" xlink:href="mdt-20240426.xsd#mdt_SurgicalInnovationsDivisionMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_SurgicalInnovationsDivisionMember_469c831b-44f6-4b39-a397-e3a4798075cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AcuteCareMonitoringMember_9d9527da-d8c1-4bad-8aef-9f08a0371c55" xlink:href="mdt-20240426.xsd#mdt_AcuteCareMonitoringMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_94003ac1-ddd6-42a4-b341-bc89a353cc23" xlink:to="loc_mdt_AcuteCareMonitoringMember_9d9527da-d8c1-4bad-8aef-9f08a0371c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8a07851b-5902-46ed-b584-a8c63c681a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c213d0d4-afad-454f-841f-2d223b5eff09" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8a07851b-5902-46ed-b584-a8c63c681a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d58e013-28dc-48dd-89eb-4991d133a262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8a07851b-5902-46ed-b584-a8c63c681a23" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d58e013-28dc-48dd-89eb-4991d133a262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee206153-cf3a-4b02-a2b3-589fd387a0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d9bd75e5-7188-4be9-9ace-9ddca0a1d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee206153-cf3a-4b02-a2b3-589fd387a0b0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d9bd75e5-7188-4be9-9ace-9ddca0a1d87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_24d48a83-4076-4e82-9b8b-b35b4424fa42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d9bd75e5-7188-4be9-9ace-9ddca0a1d87d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_24d48a83-4076-4e82-9b8b-b35b4424fa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_907b73d9-1047-4885-9a61-5698cf1ab1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_24d48a83-4076-4e82-9b8b-b35b4424fa42" xlink:to="loc_us-gaap_SegmentDomain_907b73d9-1047-4885-9a61-5698cf1ab1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:href="mdt-20240426.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_907b73d9-1047-4885-9a61-5698cf1ab1d4" xlink:to="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_f5b2668a-3b44-4253-ab26-79c9d1202a47" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:to="loc_mdt_CardiovascularMember_f5b2668a-3b44-4253-ab26-79c9d1202a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_d167bdc2-c5ac-4aff-846a-664d0f7dab47" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:to="loc_mdt_NeuroscienceGroupMember_d167bdc2-c5ac-4aff-846a-664d0f7dab47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_c66a3af5-d6cb-4ca0-9db6-7d2aceb1ec22" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:to="loc_mdt_MedicalSurgicalMember_c66a3af5-d6cb-4ca0-9db6-7d2aceb1ec22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_d327f2e5-2ab3-485e-972a-8c89afa5121b" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_27494211-9417-4f44-b8ff-11fdeefee7ea" xlink:to="loc_mdt_DiabetesGroupMember_d327f2e5-2ab3-485e-972a-8c89afa5121b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a03d62fd-f33b-49f2-95ed-5dd7f3dc40eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_907b73d9-1047-4885-9a61-5698cf1ab1d4" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a03d62fd-f33b-49f2-95ed-5dd7f3dc40eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9dc5d7bb-2f24-487c-9aa6-f4deea098686" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d9bd75e5-7188-4be9-9ace-9ddca0a1d87d" xlink:to="loc_srt_StatementGeographicalAxis_9dc5d7bb-2f24-487c-9aa6-f4deea098686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9dc5d7bb-2f24-487c-9aa6-f4deea098686" xlink:to="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0a56735f-7472-40d1-be99-e9fa3c2235c2" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:to="loc_country_US_0a56735f-7472-40d1-be99-e9fa3c2235c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember_5ea354f7-ec75-4d26-874c-22701b053990" xlink:href="mdt-20240426.xsd#mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:to="loc_mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember_5ea354f7-ec75-4d26-874c-22701b053990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember_fceeab9c-2cdb-4b3d-8249-cc6428198ae2" xlink:href="mdt-20240426.xsd#mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7da466d5-6035-442c-98c8-25eedb3d39eb" xlink:to="loc_mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember_fceeab9c-2cdb-4b3d-8249-cc6428198ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f0a38aaa-c61a-4a38-8a31-d692b3a7c658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d9bd75e5-7188-4be9-9ace-9ddca0a1d87d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f0a38aaa-c61a-4a38-8a31-d692b3a7c658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3141a3c7-bf95-4c9e-8efb-97cb4e175e96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f0a38aaa-c61a-4a38-8a31-d692b3a7c658" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3141a3c7-bf95-4c9e-8efb-97cb4e175e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e4eafaac-4deb-45d6-98f7-299f4a25ecf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2f5263c6-a665-4586-af43-135b54232691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e4eafaac-4deb-45d6-98f7-299f4a25ecf8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2f5263c6-a665-4586-af43-135b54232691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f6b16258-7ec5-44c6-ab55-568690289ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2f5263c6-a665-4586-af43-135b54232691" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f6b16258-7ec5-44c6-ab55-568690289ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f6b16258-7ec5-44c6-ab55-568690289ae6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_31219817-6276-4585-bfe7-db54ef8b8120" xlink:href="mdt-20240426.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:to="loc_mdt_OtherAccruedExpensesMember_31219817-6276-4585-bfe7-db54ef8b8120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1bae683b-7815-4c6e-a3be-1806d2633390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:to="loc_us-gaap_AccountsReceivableMember_1bae683b-7815-4c6e-a3be-1806d2633390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_2b082ced-fe51-4ccd-ba34-4181d96bf953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fae9be6b-8c08-45d9-8eb1-15f48eddb6d4" xlink:to="loc_us-gaap_OtherLiabilitiesMember_2b082ced-fe51-4ccd-ba34-4181d96bf953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2f5263c6-a665-4586-af43-135b54232691" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_ffd19318-cdce-4f95-9263-2a0673c8f141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_ffd19318-cdce-4f95-9263-2a0673c8f141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_270735ac-a6ee-4f80-a458-b51c1caafa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_ContractWithCustomerLiability_270735ac-a6ee-4f80-a458-b51c1caafa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_911a6e03-f656-482f-9a59-4a2cefe2052e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_911a6e03-f656-482f-9a59-4a2cefe2052e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_66da9028-9cfd-4585-b046-a629216177ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_66da9028-9cfd-4585-b046-a629216177ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_5fafcf51-e358-4ec3-9bd2-f700dfd48bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2b46ac6-d5da-4e4d-9d2f-277fc583a7ef" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_5fafcf51-e358-4ec3-9bd2-f700dfd48bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a211ab62-f933-4e8d-8f88-52d50026f864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a211ab62-f933-4e8d-8f88-52d50026f864" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_529a088a-2545-4487-ba2c-0b9fb3d70077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_529a088a-2545-4487-ba2c-0b9fb3d70077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_529a088a-2545-4487-ba2c-0b9fb3d70077" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_54d20b9d-753a-4cfc-8272-2752b2ab788e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_54d20b9d-753a-4cfc-8272-2752b2ab788e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IntersectENTMember_8d93bfd5-9450-440e-bdf9-b70d15c85f5b" xlink:href="mdt-20240426.xsd#mdt_IntersectENTMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:to="loc_mdt_IntersectENTMember_8d93bfd5-9450-440e-bdf9-b70d15c85f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AfferaIncMember_8367d351-26f7-44b4-b92f-e89361524366" xlink:href="mdt-20240426.xsd#mdt_AfferaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:to="loc_mdt_AfferaIncMember_8367d351-26f7-44b4-b92f-e89361524366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAcquisitionsMember_62f16168-9891-4084-9a49-0d8b186355c4" xlink:href="mdt-20240426.xsd#mdt_OtherAcquisitionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8db3262c-02a4-4eaf-b147-a5a03fcf9d1c" xlink:to="loc_mdt_OtherAcquisitionsMember_62f16168-9891-4084-9a49-0d8b186355c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0b280be-a78a-47e4-9fee-7692fd0f608e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0b280be-a78a-47e4-9fee-7692fd0f608e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0b280be-a78a-47e4-9fee-7692fd0f608e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b0325fd4-0a1e-436a-b940-549504515162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b0325fd4-0a1e-436a-b940-549504515162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_a1621031-7ae1-4fe5-b4af-793abf2f917e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_a1621031-7ae1-4fe5-b4af-793abf2f917e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_04d93864-9c4d-4c01-938e-aca963dfc6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:to="loc_us-gaap_TradeNamesMember_04d93864-9c4d-4c01-938e-aca963dfc6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6648792f-2f50-4921-862f-34544e21650a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4199c123-04f7-4ece-a24e-0a1b4ed36f21" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6648792f-2f50-4921-862f-34544e21650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0001a253-291a-457d-972e-5839e1fef70a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0001a253-291a-457d-972e-5839e1fef70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_958efb04-7f57-494a-9bf4-a421725d9d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0001a253-291a-457d-972e-5839e1fef70a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_958efb04-7f57-494a-9bf4-a421725d9d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_03d264c6-33c6-4402-a2e8-03c7badbd361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_958efb04-7f57-494a-9bf4-a421725d9d6c" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_03d264c6-33c6-4402-a2e8-03c7badbd361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd5eeb49-fa9c-4851-bc6b-392d631c77e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd5eeb49-fa9c-4851-bc6b-392d631c77e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd5eeb49-fa9c-4851-bc6b-392d631c77e7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember_ffaec31b-b076-4bc4-8d04-454a9f8a6186" xlink:href="mdt-20240426.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:to="loc_mdt_VentilatorProductLineExitMember_ffaec31b-b076-4bc4-8d04-454a9f8a6186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareSolutionsMember_35a04322-09b3-48a5-9bfb-4a214a1c3892" xlink:href="mdt-20240426.xsd#mdt_RenalCareSolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:to="loc_mdt_RenalCareSolutionsMember_35a04322-09b3-48a5-9bfb-4a214a1c3892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MechanicalCirculatorySupportMember_ba0ed687-2a98-4f86-9571-abd1ee3de659" xlink:href="mdt-20240426.xsd#mdt_MechanicalCirculatorySupportMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8c390ec-06ed-4bec-a28d-9e7798ce072b" xlink:to="loc_mdt_MechanicalCirculatorySupportMember_ba0ed687-2a98-4f86-9571-abd1ee3de659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_41b07f0f-c874-4994-9463-9cdd4e524774" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_srt_ConsolidatedEntitiesAxis_41b07f0f-c874-4994-9463-9cdd4e524774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_05f8c379-4341-4711-b5d7-8c4eda9035f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_41b07f0f-c874-4994-9463-9cdd4e524774" xlink:to="loc_srt_ConsolidatedEntitiesDomain_05f8c379-4341-4711-b5d7-8c4eda9035f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_b68f40ac-2481-4db8-962e-0b01ded4c879" xlink:href="mdt-20240426.xsd#mdt_MozarcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_05f8c379-4341-4711-b5d7-8c4eda9035f1" xlink:to="loc_mdt_MozarcMember_b68f40ac-2481-4db8-962e-0b01ded4c879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f5438c15-882b-4325-8e84-7e5ba8758321" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_srt_OwnershipAxis_f5438c15-882b-4325-8e84-7e5ba8758321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_81498d5e-ff8b-4301-9c45-667614c2aa1b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_f5438c15-882b-4325-8e84-7e5ba8758321" xlink:to="loc_srt_OwnershipDomain_81498d5e-ff8b-4301-9c45-667614c2aa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_4e1d1c7d-8d65-4db4-97cb-1e17a00fab9f" xlink:href="mdt-20240426.xsd#mdt_MozarcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_81498d5e-ff8b-4301-9c45-667614c2aa1b" xlink:to="loc_mdt_MozarcMember_4e1d1c7d-8d65-4db4-97cb-1e17a00fab9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_73bc10a8-6610-4367-8c21-921058c417b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_srt_RangeAxis_73bc10a8-6610-4367-8c21-921058c417b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8522dfe2-3a07-4162-8f20-09d1666faa83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_73bc10a8-6610-4367-8c21-921058c417b3" xlink:to="loc_srt_RangeMember_8522dfe2-3a07-4162-8f20-09d1666faa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c38a862f-1f0e-44d1-a4d4-d208a153fa32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8522dfe2-3a07-4162-8f20-09d1666faa83" xlink:to="loc_srt_MaximumMember_c38a862f-1f0e-44d1-a4d4-d208a153fa32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ed97d7c1-f236-47cc-bbc5-998f8008ad63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ed97d7c1-f236-47cc-bbc5-998f8008ad63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94bc75c0-7341-4a3f-a211-961613f35097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ed97d7c1-f236-47cc-bbc5-998f8008ad63" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94bc75c0-7341-4a3f-a211-961613f35097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_eba991e4-2793-4fd9-a4ab-24fe1ff6b0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_94bc75c0-7341-4a3f-a211-961613f35097" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_eba991e4-2793-4fd9-a4ab-24fe1ff6b0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_827f974f-8cbf-417e-a7df-b06020bb615a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_827f974f-8cbf-417e-a7df-b06020bb615a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7ee62d07-586f-4422-aec8-73b49a202d91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_827f974f-8cbf-417e-a7df-b06020bb615a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7ee62d07-586f-4422-aec8-73b49a202d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_72517243-11ac-4e9c-b83d-8fba99cc996b" xlink:href="mdt-20240426.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7ee62d07-586f-4422-aec8-73b49a202d91" xlink:to="loc_mdt_OtherAccruedExpensesMember_72517243-11ac-4e9c-b83d-8fba99cc996b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_cf992e47-9f5d-412c-869c-f9052d55ff62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7ee62d07-586f-4422-aec8-73b49a202d91" xlink:to="loc_us-gaap_OtherLiabilitiesMember_cf992e47-9f5d-412c-869c-f9052d55ff62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a5bd4e5-aca7-4eee-88ed-40ceb5f66bae" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_937a025b-4c62-48b0-ba3c-0b8b809dd806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_937a025b-4c62-48b0-ba3c-0b8b809dd806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8492931d-970c-4c00-b82c-c83aafc0cc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_Goodwill_8492931d-970c-4c00-b82c-c83aafc0cc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a373d67b-ea60-4da2-b8d8-7f4950eb3726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a373d67b-ea60-4da2-b8d8-7f4950eb3726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_78af22c1-c10b-4a28-a927-7998126417a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_78af22c1-c10b-4a28-a927-7998126417a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88c9f7f7-ae17-410c-b61d-0bc0254ea6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88c9f7f7-ae17-410c-b61d-0bc0254ea6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax_434bc7ee-ec7b-43c1-9c73-61a74441f175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_GoodwillImpairmentLossNetOfTax_434bc7ee-ec7b-43c1-9c73-61a74441f175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillNotAllocatedAmount_ed817edd-b482-498d-9a17-98f4b36d596e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillNotAllocatedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_GoodwillNotAllocatedAmount_ed817edd-b482-498d-9a17-98f4b36d596e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionPriceContingentConsideration_9a83de7a-826f-4050-942d-c37dc8fc8160" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionPriceContingentConsideration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_BusinessAcquisitionPriceContingentConsideration_9a83de7a-826f-4050-942d-c37dc8fc8160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_738cf3c6-6939-487f-a6d2-b885a543608c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_738cf3c6-6939-487f-a6d2-b885a543608c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_11ccfaef-3b2e-441d-9489-dfde0efeea77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_11ccfaef-3b2e-441d-9489-dfde0efeea77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a56bb65f-d155-4852-94bc-9d1bff9714f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a56bb65f-d155-4852-94bc-9d1bff9714f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationLiability_30590978-95aa-425d-97fa-7bdb6fef678c" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationLiability_30590978-95aa-425d-97fa-7bdb6fef678c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_10ce81a7-45a9-453d-a545-e7e575f8fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_10ce81a7-45a9-453d-a545-e7e575f8fad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_adaf8f0d-ed1a-4918-a4fb-d787335c43d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessExitCosts1_adaf8f0d-ed1a-4918-a4fb-d787335c43d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_cca44394-e561-4c3e-a971-2eb86e69f4ba" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_cca44394-e561-4c3e-a971-2eb86e69f4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_9c335719-bdb4-4a98-b604-98adb7162bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_9c335719-bdb4-4a98-b604-98adb7162bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_3edf2687-e633-4517-baed-8dede2937b51" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_3edf2687-e633-4517-baed-8dede2937b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f01b0dc5-2077-4a61-b808-33a3d0e850d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f01b0dc5-2077-4a61-b808-33a3d0e850d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_5ecddfcd-455b-41c1-98e2-cbe57b32bdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_InventoryWriteDown_5ecddfcd-455b-41c1-98e2-cbe57b32bdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7a386fe0-aaa4-4b4d-90b7-677fcc73624c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7a386fe0-aaa4-4b4d-90b7-677fcc73624c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_97a3749c-348e-471e-ae89-c8d25f490c12" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_97a3749c-348e-471e-ae89-c8d25f490c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_bb60f7a5-4380-4a0c-849a-7eadb72c1666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_bb60f7a5-4380-4a0c-849a-7eadb72c1666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0b1cc3e5-6501-4ed7-8bd6-61b0abc3ae0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0b1cc3e5-6501-4ed7-8bd6-61b0abc3ae0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_51f9f8d0-22f9-4923-9f9e-23bc9d6652bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_MinorityInterest_51f9f8d0-22f9-4923-9f9e-23bc9d6652bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_115c9f91-a652-4320-90e0-0145a5c8dcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_AssetImpairmentCharges_115c9f91-a652-4320-90e0-0145a5c8dcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_aeddde07-c092-4516-8ac6-f5bf3087a5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_aeddde07-c092-4516-8ac6-f5bf3087a5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_66972e7f-cfed-4332-9b5f-cafe7c83488c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_66972e7f-cfed-4332-9b5f-cafe7c83488c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1b9da810-4680-4fd6-b2f3-8b1d1874daff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1b9da810-4680-4fd6-b2f3-8b1d1874daff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_6729963d-266b-4f52-b8c9-9b84e5361901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_OtherCommitment_6729963d-266b-4f52-b8c9-9b84e5361901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_84785421-a0e2-42de-8792-23fdc1be0737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb280c49-7892-40a1-aea9-8ac1fd4ef1cc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_84785421-a0e2-42de-8792-23fdc1be0737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_56bce290-2d8a-4158-a2ae-d7a8d1223519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13015686-d0c7-4aa9-8430-68bcb91e3e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_56bce290-2d8a-4158-a2ae-d7a8d1223519" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13015686-d0c7-4aa9-8430-68bcb91e3e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_069ee4b0-dcf1-4e22-89e1-4a29414a8ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13015686-d0c7-4aa9-8430-68bcb91e3e9a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_069ee4b0-dcf1-4e22-89e1-4a29414a8ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d466dee-3ee6-4407-99b3-c46553183b93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_069ee4b0-dcf1-4e22-89e1-4a29414a8ea4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d466dee-3ee6-4407-99b3-c46553183b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IntersectENTMember_85dca1f4-7a10-4f69-a953-090e0ac500d0" xlink:href="mdt-20240426.xsd#mdt_IntersectENTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d466dee-3ee6-4407-99b3-c46553183b93" xlink:to="loc_mdt_IntersectENTMember_85dca1f4-7a10-4f69-a953-090e0ac500d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AfferaIncMember_9cbfe43c-d53a-4f29-99d2-645882f04860" xlink:href="mdt-20240426.xsd#mdt_AfferaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d466dee-3ee6-4407-99b3-c46553183b93" xlink:to="loc_mdt_AfferaIncMember_9cbfe43c-d53a-4f29-99d2-645882f04860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13015686-d0c7-4aa9-8430-68bcb91e3e9a" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ca63adea-9588-4105-ae63-99a453c344c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ca63adea-9588-4105-ae63-99a453c344c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e129bd59-df0a-4864-a005-5adb834e41c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e129bd59-df0a-4864-a005-5adb834e41c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1b224cc3-c842-44ec-bb17-02640ec38043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_Goodwill_1b224cc3-c842-44ec-bb17-02640ec38043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_caf49d29-73d9-4bf6-80db-44baac459432" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_caf49d29-73d9-4bf6-80db-44baac459432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_74051a1b-fb06-4f27-bd1b-22bbe631bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_74051a1b-fb06-4f27-bd1b-22bbe631bd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_811a7e77-d2f2-4a1d-b3f7-d09663096741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_811a7e77-d2f2-4a1d-b3f7-d09663096741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_ad27e3aa-3812-4154-8e7b-379584870168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_ad27e3aa-3812-4154-8e7b-379584870168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0ca8a9b9-a7a3-41c6-a905-7d993dd43699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0ca8a9b9-a7a3-41c6-a905-7d993dd43699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_f691529b-225e-4952-884a-2542a260d513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_f691529b-225e-4952-884a-2542a260d513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2770607d-b6c5-4afd-bf56-17b19387b118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2770607d-b6c5-4afd-bf56-17b19387b118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_67e57aab-6008-496b-84ec-ad6d27821d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9192ff42-c51f-4ec5-b814-65e8a4f73995" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_67e57aab-6008-496b-84ec-ad6d27821d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_73306569-5d11-4a01-a121-3f7ca50b8572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_321ed6fd-de69-4ff1-8be5-e1dc6f5b39ea" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_73306569-5d11-4a01-a121-3f7ca50b8572" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_321ed6fd-de69-4ff1-8be5-e1dc6f5b39ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7109bfb4-0476-493c-9341-d119caf560d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_321ed6fd-de69-4ff1-8be5-e1dc6f5b39ea" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7109bfb4-0476-493c-9341-d119caf560d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionPriceContingentConsideration_2e80b959-edbd-4bd1-89e8-e0882f2fa611" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionPriceContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_321ed6fd-de69-4ff1-8be5-e1dc6f5b39ea" xlink:to="loc_mdt_BusinessAcquisitionPriceContingentConsideration_2e80b959-edbd-4bd1-89e8-e0882f2fa611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_b388b967-f12d-4767-870d-51cf5fad48dc" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_321ed6fd-de69-4ff1-8be5-e1dc6f5b39ea" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_b388b967-f12d-4767-870d-51cf5fad48dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4f74fffd-ec3e-45aa-be11-c733d49cff83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_321ed6fd-de69-4ff1-8be5-e1dc6f5b39ea" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4f74fffd-ec3e-45aa-be11-c733d49cff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses_da6e3bcb-e9e5-4b08-8ee2-17184122abca" xlink:href="mdt-20240426.xsd#mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_321ed6fd-de69-4ff1-8be5-e1dc6f5b39ea" xlink:to="loc_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses_da6e3bcb-e9e5-4b08-8ee2-17184122abca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_da73cdfa-894d-48a1-949b-9be629c27465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_321ed6fd-de69-4ff1-8be5-e1dc6f5b39ea" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_da73cdfa-894d-48a1-949b-9be629c27465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e71b01c7-cc3f-459b-b447-c7bde57f0d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e71b01c7-cc3f-459b-b447-c7bde57f0d89" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f942be11-d028-4648-8c7f-4204c9b53aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f942be11-d028-4648-8c7f-4204c9b53aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5d17d053-63be-4d86-bd77-2fcd1319c1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f942be11-d028-4648-8c7f-4204c9b53aa8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5d17d053-63be-4d86-bd77-2fcd1319c1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9c3cf5d1-c7b5-4887-a6f4-c95e089f68b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5d17d053-63be-4d86-bd77-2fcd1319c1a3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9c3cf5d1-c7b5-4887-a6f4-c95e089f68b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b773592e-f9a6-4233-b80b-a38e3c12a81e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b773592e-f9a6-4233-b80b-a38e3c12a81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1b58361-ebc3-492d-b06a-8e9e930b6588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b773592e-f9a6-4233-b80b-a38e3c12a81e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1b58361-ebc3-492d-b06a-8e9e930b6588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_61978744-9c35-484e-97f0-609c5fe86b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1b58361-ebc3-492d-b06a-8e9e930b6588" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_61978744-9c35-484e-97f0-609c5fe86b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b8e953c2-44d1-4137-88bf-51164be599bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b8e953c2-44d1-4137-88bf-51164be599bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_4321d139-fc50-4817-98ca-cf2d72968ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b8e953c2-44d1-4137-88bf-51164be599bf" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_4321d139-fc50-4817-98ca-cf2d72968ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RevenueMilestoneMember_9b669654-4bee-451e-aad3-677fe7fa6619" xlink:href="mdt-20240426.xsd#mdt_RevenueMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4321d139-fc50-4817-98ca-cf2d72968ae5" xlink:to="loc_mdt_RevenueMilestoneMember_9b669654-4bee-451e-aad3-677fe7fa6619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ProductDevelopmentMilestoneMember_e5544271-a686-4f89-a2d5-d7c9d1faf87c" xlink:href="mdt-20240426.xsd#mdt_ProductDevelopmentMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4321d139-fc50-4817-98ca-cf2d72968ae5" xlink:to="loc_mdt_ProductDevelopmentMilestoneMember_e5544271-a686-4f89-a2d5-d7c9d1faf87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1cd5e61d-44e5-4e61-8578-af5fd40a1b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1cd5e61d-44e5-4e61-8578-af5fd40a1b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_35a96169-8b56-40f6-bb32-7aa4794c9d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1cd5e61d-44e5-4e61-8578-af5fd40a1b67" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_35a96169-8b56-40f6-bb32-7aa4794c9d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2749fd2b-2944-4982-a5b5-004b776f8fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_35a96169-8b56-40f6-bb32-7aa4794c9d4d" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2749fd2b-2944-4982-a5b5-004b776f8fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ed8cb92-3653-42c1-b1e1-28728ca7169b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_srt_RangeAxis_7ed8cb92-3653-42c1-b1e1-28728ca7169b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7ed8cb92-3653-42c1-b1e1-28728ca7169b" xlink:to="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_06fc6b42-3fef-46a6-9eec-f5456c968e10" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:to="loc_srt_MinimumMember_06fc6b42-3fef-46a6-9eec-f5456c968e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_538d5ea2-2847-48eb-b001-9148b4e45548" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:to="loc_srt_MaximumMember_538d5ea2-2847-48eb-b001-9148b4e45548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_086230f7-424c-4904-ac24-a7e4c436e252" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50abaa25-de77-402c-b162-bf11600a4215" xlink:to="loc_srt_WeightedAverageMember_086230f7-424c-4904-ac24-a7e4c436e252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4814e179-8848-45db-bcd6-789f5cdefb22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0f465b2f-7355-42a1-bd72-c7979cd1b581" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4814e179-8848-45db-bcd6-789f5cdefb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7366140f-b1ee-4072-8d26-ad24aee12215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4814e179-8848-45db-bcd6-789f5cdefb22" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7366140f-b1ee-4072-8d26-ad24aee12215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5ef83df9-370a-453d-896a-55dd0f2bb0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4814e179-8848-45db-bcd6-789f5cdefb22" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5ef83df9-370a-453d-896a-55dd0f2bb0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6d78976f-a1bf-42da-8e89-b8934addcaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5ef83df9-370a-453d-896a-55dd0f2bb0a8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6d78976f-a1bf-42da-8e89-b8934addcaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2ad12413-1d81-46fc-b679-2018e7ee2291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4cd4c7a0-83e0-4d96-8a85-13c59ef04271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2ad12413-1d81-46fc-b679-2018e7ee2291" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4cd4c7a0-83e0-4d96-8a85-13c59ef04271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7cad13e8-d004-461e-82ac-cc05aaf316e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4cd4c7a0-83e0-4d96-8a85-13c59ef04271" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7cad13e8-d004-461e-82ac-cc05aaf316e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_680119b4-2e26-49df-b342-46b01ab3dd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7cad13e8-d004-461e-82ac-cc05aaf316e5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_680119b4-2e26-49df-b342-46b01ab3dd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8c355f8f-006e-478d-bf35-30798748bc20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_680119b4-2e26-49df-b342-46b01ab3dd3d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8c355f8f-006e-478d-bf35-30798748bc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_360ba430-931c-4437-9a1f-99ac58461beb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4cd4c7a0-83e0-4d96-8a85-13c59ef04271" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_360ba430-931c-4437-9a1f-99ac58461beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_98511b27-43bd-47ee-8c65-f41358b61cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_360ba430-931c-4437-9a1f-99ac58461beb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_98511b27-43bd-47ee-8c65-f41358b61cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_afd0458d-caeb-4018-9e7c-b0f5ae88fde6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_98511b27-43bd-47ee-8c65-f41358b61cc5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_afd0458d-caeb-4018-9e7c-b0f5ae88fde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_917b805b-c292-40f2-9f67-f03104b691b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4cd4c7a0-83e0-4d96-8a85-13c59ef04271" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_917b805b-c292-40f2-9f67-f03104b691b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionContingentConsiderationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_917b805b-c292-40f2-9f67-f03104b691b5" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_8ee39148-11f9-49f2-8e5f-31e3e0488ad7" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_8ee39148-11f9-49f2-8e5f-31e3e0488ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionPriceContingentConsideration_8167dbb2-2456-4610-9530-3da490c35e1d" xlink:href="mdt-20240426.xsd#mdt_BusinessAcquisitionPriceContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:to="loc_mdt_BusinessAcquisitionPriceContingentConsideration_8167dbb2-2456-4610-9530-3da490c35e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_a98256f2-dafa-4653-a1e6-8dd6d9a86c85" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_a98256f2-dafa-4653-a1e6-8dd6d9a86c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_8e640f4d-1936-41a7-9f84-dcd755ae1399" xlink:href="mdt-20240426.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_a57688da-0ecb-448a-ac0d-72fdeff8ea58" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_8e640f4d-1936-41a7-9f84-dcd755ae1399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RestructuringChargesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_db7a48d5-df7c-47a3-8cdd-799a4b4242c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_800498d6-c7b7-4199-bc1e-2c112eef8fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_db7a48d5-df7c-47a3-8cdd-799a4b4242c9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_800498d6-c7b7-4199-bc1e-2c112eef8fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a23dd8a3-2b4a-4607-b7b4-cb6644cd5bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_800498d6-c7b7-4199-bc1e-2c112eef8fb4" xlink:to="loc_us-gaap_RestructuringPlanAxis_a23dd8a3-2b4a-4607-b7b4-cb6644cd5bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_13bbf872-a368-44b1-8334-0a77c0834c64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_a23dd8a3-2b4a-4607-b7b4-cb6644cd5bcf" xlink:to="loc_us-gaap_RestructuringPlanDomain_13bbf872-a368-44b1-8334-0a77c0834c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EnterpriseExcellenceMember_fe28303d-36ed-4533-b802-fd9c2afb4f6a" xlink:href="mdt-20240426.xsd#mdt_EnterpriseExcellenceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_13bbf872-a368-44b1-8334-0a77c0834c64" xlink:to="loc_mdt_EnterpriseExcellenceMember_fe28303d-36ed-4533-b802-fd9c2afb4f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SimplificationRestructuringProgramMember_d988ac4c-797a-49f5-8f3d-954389495c98" xlink:href="mdt-20240426.xsd#mdt_SimplificationRestructuringProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_13bbf872-a368-44b1-8334-0a77c0834c64" xlink:to="loc_mdt_SimplificationRestructuringProgramMember_d988ac4c-797a-49f5-8f3d-954389495c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dafeba6d-9208-4d69-b46e-c2c500468018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_800498d6-c7b7-4199-bc1e-2c112eef8fb4" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_dafeba6d-9208-4d69-b46e-c2c500468018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9aa23279-8a50-498e-afab-601b9ebe4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dafeba6d-9208-4d69-b46e-c2c500468018" xlink:to="loc_us-gaap_RestructuringCharges_9aa23279-8a50-498e-afab-601b9ebe4f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f08724e7-42ff-4284-a3a5-621abd3fb033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dafeba6d-9208-4d69-b46e-c2c500468018" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f08724e7-42ff-4284-a3a5-621abd3fb033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RestructuringChargesClassificationofRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3832dd49-3ca5-4f78-8a7b-12aaec870fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d31dcb06-84c7-4ac6-ae4d-2abbc9fd732c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3832dd49-3ca5-4f78-8a7b-12aaec870fb4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d31dcb06-84c7-4ac6-ae4d-2abbc9fd732c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7426b5d4-33e3-4c7b-a60b-affd5d443b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d31dcb06-84c7-4ac6-ae4d-2abbc9fd732c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7426b5d4-33e3-4c7b-a60b-affd5d443b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7426b5d4-33e3-4c7b-a60b-affd5d443b62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3970e800-9ff5-4116-83f8-544e8f5e1524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:to="loc_us-gaap_CostOfSalesMember_3970e800-9ff5-4116-83f8-544e8f5e1524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fe998210-3f94-47c5-a692-5c5f69dc9184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fe998210-3f94-47c5-a692-5c5f69dc9184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_509c49d3-3e90-4094-90b5-53c9527590ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ffeea95f-087c-4f31-a40f-5dafa16884d9" xlink:to="loc_us-gaap_RestructuringChargesMember_509c49d3-3e90-4094-90b5-53c9527590ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a69e0794-b6a7-4c77-8801-faa98b51efca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d31dcb06-84c7-4ac6-ae4d-2abbc9fd732c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a69e0794-b6a7-4c77-8801-faa98b51efca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f6bde3f4-c778-4051-aa2c-480ff717ef94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a69e0794-b6a7-4c77-8801-faa98b51efca" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f6bde3f4-c778-4051-aa2c-480ff717ef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_e27f4130-1dc1-4637-9fd5-4811f50e812b" xlink:href="mdt-20240426.xsd#mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f6bde3f4-c778-4051-aa2c-480ff717ef94" xlink:to="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_e27f4130-1dc1-4637-9fd5-4811f50e812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dba1334f-5ca8-4c30-8728-84234c8463e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d31dcb06-84c7-4ac6-ae4d-2abbc9fd732c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_dba1334f-5ca8-4c30-8728-84234c8463e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b1588c09-7328-42e3-a8d0-0d0907e88190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dba1334f-5ca8-4c30-8728-84234c8463e9" xlink:to="loc_us-gaap_RestructuringCharges_b1588c09-7328-42e3-a8d0-0d0907e88190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b947c6e6-035f-438d-bc28-b9cf711d5365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c6d050b5-9092-4300-aee8-d2d4efdb7166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b947c6e6-035f-438d-bc28-b9cf711d5365" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c6d050b5-9092-4300-aee8-d2d4efdb7166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e6c05d20-5fcf-403f-b02d-30da88bca971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c6d050b5-9092-4300-aee8-d2d4efdb7166" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e6c05d20-5fcf-403f-b02d-30da88bca971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e6c05d20-5fcf-403f-b02d-30da88bca971" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_83c0a216-c970-4fc1-bc01-5718fefbb927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:to="loc_us-gaap_EmployeeSeveranceMember_83c0a216-c970-4fc1-bc01-5718fefbb927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssociatedAndOtherCostsMember_4c820cce-ad26-43ce-9712-6bdbf16cd7c5" xlink:href="mdt-20240426.xsd#mdt_AssociatedAndOtherCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:to="loc_mdt_AssociatedAndOtherCostsMember_4c820cce-ad26-43ce-9712-6bdbf16cd7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_cf8cc443-9efe-457c-be64-4eae3ab3b9af" xlink:href="mdt-20240426.xsd#mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbf0c6ed-61a6-432a-8c89-604daf320965" xlink:to="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_cf8cc443-9efe-457c-be64-4eae3ab3b9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e7fea6de-d324-461a-8a33-078d5e9bd995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c6d050b5-9092-4300-aee8-d2d4efdb7166" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_e7fea6de-d324-461a-8a33-078d5e9bd995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e7fea6de-d324-461a-8a33-078d5e9bd995" xlink:to="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b3a7868b-7c68-45f3-a958-b2518e2efeba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_us-gaap_RestructuringReserve_b3a7868b-7c68-45f3-a958-b2518e2efeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesIncludingAccrualAdjustments_d1fa051e-f9c0-43d6-8087-3e8bb07e9fd9" xlink:href="mdt-20240426.xsd#mdt_RestructuringChargesIncludingAccrualAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_mdt_RestructuringChargesIncludingAccrualAdjustments_d1fa051e-f9c0-43d6-8087-3e8bb07e9fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_0a00a769-c64b-4004-b623-022b9ceb43a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_us-gaap_PaymentsForRestructuring_0a00a769-c64b-4004-b623-022b9ceb43a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_42f705b2-244e-4e6f-ab5d-bc8db8599cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_42f705b2-244e-4e6f-ab5d-bc8db8599cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_b8f0954d-c02e-47c8-8501-90c7ab8f9953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_b8f0954d-c02e-47c8-8501-90c7ab8f9953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_12b7ec39-23ca-4cc1-9f59-bbb8e915e653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_76365518-fef4-4e06-808b-0879f38881a5" xlink:to="loc_us-gaap_RestructuringReserve_12b7ec39-23ca-4cc1-9f59-bbb8e915e653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_945357d0-ab87-4144-88a6-53c8c5f255cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e7fea6de-d324-461a-8a33-078d5e9bd995" xlink:to="loc_us-gaap_RestructuringCharges_945357d0-ab87-4144-88a6-53c8c5f255cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_0bbd13d8-7629-49fa-aaf8-6b5a73cc25af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_0bbd13d8-7629-49fa-aaf8-6b5a73cc25af" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54c29ed3-cda2-4d05-bc98-1e7d7a42dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54c29ed3-cda2-4d05-bc98-1e7d7a42dc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54c29ed3-cda2-4d05-bc98-1e7d7a42dc12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6b7637b3-0b61-405f-9549-294c7f447ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6b7637b3-0b61-405f-9549-294c7f447ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e86562a9-787b-4737-a048-0abe521b06a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e86562a9-787b-4737-a048-0abe521b06a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b5c3d847-04b6-49f0-8de0-554a6f516522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a86e47ee-f51b-48c3-98e4-471e559bfa3d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b5c3d847-04b6-49f0-8de0-554a6f516522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f5a7a33b-7a6f-4406-bd6d-72b4988575a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f5a7a33b-7a6f-4406-bd6d-72b4988575a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f5a7a33b-7a6f-4406-bd6d-72b4988575a6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d9446256-0d8f-45a8-b1c7-6e55d19c8981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d9446256-0d8f-45a8-b1c7-6e55d19c8981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d52f85f8-95a7-47ee-b5f5-4ca14d49293f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d52f85f8-95a7-47ee-b5f5-4ca14d49293f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_453cf000-4a5e-4d1e-a233-5d26050fcbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_453cf000-4a5e-4d1e-a233-5d26050fcbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5e20a374-86b5-4c7b-8410-f15035024327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5e20a374-86b5-4c7b-8410-f15035024327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_c4019d69-a4dc-44ee-8296-a7b061d1ce89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_CertificatesOfDepositMember_c4019d69-a4dc-44ee-8296-a7b061d1ce89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_17593dae-ef46-4ddc-a07e-e81d6ab88f01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_17593dae-ef46-4ddc-a07e-e81d6ab88f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember_dd58a76d-6d72-470e-a849-676b99b8f3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e6d7a2-10b3-4363-83a0-58c2f90f8b04" xlink:to="loc_us-gaap_AuctionRateSecuritiesMember_dd58a76d-6d72-470e-a849-676b99b8f3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bf85f521-cfbf-4c24-b0de-9cada45ca070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bf85f521-cfbf-4c24-b0de-9cada45ca070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_84f3017c-7962-411b-bb4b-f963bec34971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf85f521-cfbf-4c24-b0de-9cada45ca070" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_84f3017c-7962-411b-bb4b-f963bec34971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_f46a49b9-2b4d-4765-89b6-e86386ea2c61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_84f3017c-7962-411b-bb4b-f963bec34971" xlink:to="loc_us-gaap_InvestmentsMember_f46a49b9-2b4d-4765-89b6-e86386ea2c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_090d4562-2827-4187-9c68-79b621b61f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_84f3017c-7962-411b-bb4b-f963bec34971" xlink:to="loc_us-gaap_OtherAssetsMember_090d4562-2827-4187-9c68-79b621b61f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b797e693-013d-421b-a374-3a0dcc1ecf21" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2b37d209-f4c2-4bbc-a61e-9ae6cba8132c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2b37d209-f4c2-4bbc-a61e-9ae6cba8132c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22889595-1f80-4b2a-bfaf-7df07a309c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22889595-1f80-4b2a-bfaf-7df07a309c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_77127220-2835-4e6f-9728-f066fee505ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_77127220-2835-4e6f-9728-f066fee505ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_91ab701d-40df-4a69-8abd-28f730489d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_928d6098-262f-418f-9f85-6095612df438" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_91ab701d-40df-4a69-8abd-28f730489d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_ba4c5739-f320-4b4a-a39e-88c79caa623b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c537960-5556-461a-9580-13648d66803e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ba4c5739-f320-4b4a-a39e-88c79caa623b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c537960-5556-461a-9580-13648d66803e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f62ee04a-57d9-4a91-b6a1-3d35f904b73d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c537960-5556-461a-9580-13648d66803e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f62ee04a-57d9-4a91-b6a1-3d35f904b73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f62ee04a-57d9-4a91-b6a1-3d35f904b73d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2b60f0f6-99ef-4455-977b-3db1fdb56fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2b60f0f6-99ef-4455-977b-3db1fdb56fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c7562bf8-ca56-4012-b900-bee0266e9401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c7562bf8-ca56-4012-b900-bee0266e9401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_043bbb30-2820-4305-afe4-ce4f9d6f7461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_043bbb30-2820-4305-afe4-ce4f9d6f7461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9b0f197c-c890-42dd-91a3-45ed1b015336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9b0f197c-c890-42dd-91a3-45ed1b015336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember_231b1c5b-eb40-4cf4-a9b9-c158268ea4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73eae319-ca3d-46cd-b26f-82fe2e9451bd" xlink:to="loc_us-gaap_AuctionRateSecuritiesMember_231b1c5b-eb40-4cf4-a9b9-c158268ea4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_285c7ed1-4e06-4f0c-9578-ea3642d531bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c537960-5556-461a-9580-13648d66803e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_285c7ed1-4e06-4f0c-9578-ea3642d531bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_2d63cf00-d8e2-470b-b656-ad47d4aad9f5" xlink:href="mdt-20240426.xsd#mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_285c7ed1-4e06-4f0c-9578-ea3642d531bd" xlink:to="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_2d63cf00-d8e2-470b-b656-ad47d4aad9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b465d551-76ed-4ee9-83fd-eac49f7a481c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_2d63cf00-d8e2-470b-b656-ad47d4aad9f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b465d551-76ed-4ee9-83fd-eac49f7a481c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2d1365a0-3a78-4276-ba70-ea1c63310181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_2d63cf00-d8e2-470b-b656-ad47d4aad9f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2d1365a0-3a78-4276-ba70-ea1c63310181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_f4139f12-ead8-4e99-a1af-4fc70b34d138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_285c7ed1-4e06-4f0c-9578-ea3642d531bd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_f4139f12-ead8-4e99-a1af-4fc70b34d138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cc8484e7-94a1-4178-92a8-8272a7556928" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_f4139f12-ead8-4e99-a1af-4fc70b34d138" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cc8484e7-94a1-4178-92a8-8272a7556928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_12527aba-406d-41ce-8006-6de02794e872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_f4139f12-ead8-4e99-a1af-4fc70b34d138" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_12527aba-406d-41ce-8006-6de02794e872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_9af4a068-a054-4bdc-8a11-42c4c0d664ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_6e3ef697-a1c0-439e-9dd4-0567a45db067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_9af4a068-a054-4bdc-8a11-42c4c0d664ec" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_6e3ef697-a1c0-439e-9dd4-0567a45db067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_628fc6bd-6c55-4e08-bb5a-cd85ba11ac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_6e3ef697-a1c0-439e-9dd4-0567a45db067" xlink:to="loc_us-gaap_FinancialInstrumentAxis_628fc6bd-6c55-4e08-bb5a-cd85ba11ac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_818ccdce-69e6-41c3-b4b7-18692bb3e2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_628fc6bd-6c55-4e08-bb5a-cd85ba11ac8a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_818ccdce-69e6-41c3-b4b7-18692bb3e2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquityInvestmentsMember_5f3d20e1-c582-4404-afe4-9faa3f8637ac" xlink:href="mdt-20240426.xsd#mdt_EquityInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_818ccdce-69e6-41c3-b4b7-18692bb3e2d3" xlink:to="loc_mdt_EquityInvestmentsMember_5f3d20e1-c582-4404-afe4-9faa3f8637ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5fd6c401-29f6-453d-971e-b5cb44672b35" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_6e3ef697-a1c0-439e-9dd4-0567a45db067" xlink:to="loc_srt_OwnershipAxis_5fd6c401-29f6-453d-971e-b5cb44672b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_27c8fc27-7ae2-4c57-9262-a19608e0d0ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5fd6c401-29f6-453d-971e-b5cb44672b35" xlink:to="loc_srt_OwnershipDomain_27c8fc27-7ae2-4c57-9262-a19608e0d0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_f5b6dc39-f25a-4c66-85e4-cd2e5fe8a0da" xlink:href="mdt-20240426.xsd#mdt_MozarcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_27c8fc27-7ae2-4c57-9262-a19608e0d0ae" xlink:to="loc_mdt_MozarcMember_f5b6dc39-f25a-4c66-85e4-cd2e5fe8a0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_6e3ef697-a1c0-439e-9dd4-0567a45db067" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_8467ce06-220b-4d9e-a064-45c6070633c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_8467ce06-220b-4d9e-a064-45c6070633c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2278dca3-02ea-4427-bdf0-22d7a22aaaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2278dca3-02ea-4427-bdf0-22d7a22aaaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c85984c3-03d8-4f92-8e47-89c6c5579f28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c85984c3-03d8-4f92-8e47-89c6c5579f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_270277c1-0b29-4958-aad4-5663499337b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bff26e4a-a68b-476b-9165-a2d0ba1122bc" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_270277c1-0b29-4958-aad4-5663499337b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_8c2eb4f9-4292-4f63-8778-b16afbb20d10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_42c7b225-65db-4dc7-8a99-ec1b09049ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_8c2eb4f9-4292-4f63-8778-b16afbb20d10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_42c7b225-65db-4dc7-8a99-ec1b09049ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4e894f87-965b-4e32-8a2e-e15b84ca36b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_42c7b225-65db-4dc7-8a99-ec1b09049ac8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4e894f87-965b-4e32-8a2e-e15b84ca36b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_60139773-9498-4be1-9437-f47fd32e9e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_42c7b225-65db-4dc7-8a99-ec1b09049ac8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_60139773-9498-4be1-9437-f47fd32e9e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_060cb876-44e3-41dc-87c0-dd1140f4bab7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_42c7b225-65db-4dc7-8a99-ec1b09049ac8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_060cb876-44e3-41dc-87c0-dd1140f4bab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_5a390aa3-d232-4616-a0ca-a909d3268700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_8c2eb4f9-4292-4f63-8778-b16afbb20d10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_5a390aa3-d232-4616-a0ca-a909d3268700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_15584794-d64c-4fa3-b03e-5a9c065516e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_5a390aa3-d232-4616-a0ca-a909d3268700" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_15584794-d64c-4fa3-b03e-5a9c065516e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5126d053-c778-497b-9ee5-49ef217b31e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_5a390aa3-d232-4616-a0ca-a909d3268700" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5126d053-c778-497b-9ee5-49ef217b31e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_39456b01-764a-40f8-be1a-e2e6072ffa63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_5a390aa3-d232-4616-a0ca-a909d3268700" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_39456b01-764a-40f8-be1a-e2e6072ffa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_52531760-4aea-42cc-af7a-faaa5c5e16b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_5a390aa3-d232-4616-a0ca-a909d3268700" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_52531760-4aea-42cc-af7a-faaa5c5e16b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_f2cb174f-883d-4843-a4e7-b8b48cc5b6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_5a390aa3-d232-4616-a0ca-a909d3268700" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_f2cb174f-883d-4843-a4e7-b8b48cc5b6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_590b4c56-579b-4a1e-bc4a-a475cbcd623b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_8c2eb4f9-4292-4f63-8778-b16afbb20d10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_590b4c56-579b-4a1e-bc4a-a475cbcd623b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_77ca6e4a-58e7-4a10-a871-be75e8ebfc45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_590b4c56-579b-4a1e-bc4a-a475cbcd623b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_77ca6e4a-58e7-4a10-a871-be75e8ebfc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_873abe56-ce59-4c8d-a7f9-f2d7b30ed444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_590b4c56-579b-4a1e-bc4a-a475cbcd623b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_873abe56-ce59-4c8d-a7f9-f2d7b30ed444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1bb77eff-5c18-40e2-8458-8b78cbf3696a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_590b4c56-579b-4a1e-bc4a-a475cbcd623b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1bb77eff-5c18-40e2-8458-8b78cbf3696a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_1c4029ad-1138-4fcd-9158-18b7a8551e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_590b4c56-579b-4a1e-bc4a-a475cbcd623b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_1c4029ad-1138-4fcd-9158-18b7a8551e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_d2e4f771-0a72-4521-88e5-426da3b37f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_590b4c56-579b-4a1e-bc4a-a475cbcd623b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_d2e4f771-0a72-4521-88e5-426da3b37f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_80273b96-d084-49f3-96c2-8102bf701404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_44e10977-4e61-401b-b8ee-2351d377218f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_80273b96-d084-49f3-96c2-8102bf701404" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_44e10977-4e61-401b-b8ee-2351d377218f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8a9cc736-7017-4103-acec-6b7e17c17174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_44e10977-4e61-401b-b8ee-2351d377218f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8a9cc736-7017-4103-acec-6b7e17c17174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ce333537-0dc3-499f-ba8f-c9fbf4e59e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8a9cc736-7017-4103-acec-6b7e17c17174" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ce333537-0dc3-499f-ba8f-c9fbf4e59e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_fcd2cf97-17ee-4cc0-ba40-04658d7a790e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ce333537-0dc3-499f-ba8f-c9fbf4e59e97" xlink:to="loc_us-gaap_OtherAssetsMember_fcd2cf97-17ee-4cc0-ba40-04658d7a790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_44e10977-4e61-401b-b8ee-2351d377218f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4dd0813c-afe4-4291-ae74-b62567e0883d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4dd0813c-afe4-4291-ae74-b62567e0883d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_9e431f48-765b-4222-8c80-50a9aa9feda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_9e431f48-765b-4222-8c80-50a9aa9feda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e7929f6a-59fc-456b-af89-c1e0e286d386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e7929f6a-59fc-456b-af89-c1e0e286d386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_41c61b5e-9388-4a12-aed4-bbe1b749d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_us-gaap_EquityMethodInvestments_41c61b5e-9388-4a12-aed4-bbe1b749d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_34969c32-e34c-4e18-8eb2-ab97608342d8" xlink:href="mdt-20240426.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4f10e80a-fbdf-4c6d-b764-f28860fccdc7" xlink:to="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_34969c32-e34c-4e18-8eb2-ab97608342d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancialInstrumentsDebtandEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_3a897cda-13b9-43e0-bc8a-f946c0c5b440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_5c3414ef-2f71-4431-8bb1-2614f857276a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3a897cda-13b9-43e0-bc8a-f946c0c5b440" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_5c3414ef-2f71-4431-8bb1-2614f857276a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_97e54138-9dcc-4705-8378-e41f51d05b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3a897cda-13b9-43e0-bc8a-f946c0c5b440" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_97e54138-9dcc-4705-8378-e41f51d05b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AdditionalCashInvestment_1e9d268a-1ecf-4094-9a88-8c857397d4f4" xlink:href="mdt-20240426.xsd#mdt_AdditionalCashInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3a897cda-13b9-43e0-bc8a-f946c0c5b440" xlink:to="loc_mdt_AdditionalCashInvestment_1e9d268a-1ecf-4094-9a88-8c857397d4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_45142a08-b653-4632-926f-56137d6e0ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3a897cda-13b9-43e0-bc8a-f946c0c5b440" xlink:to="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_45142a08-b653-4632-926f-56137d6e0ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_3c92d423-fc46-4e36-905a-e22e7c79e266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3a897cda-13b9-43e0-bc8a-f946c0c5b440" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_3c92d423-fc46-4e36-905a-e22e7c79e266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsCurrentDebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2506d054-bfa1-41b4-a1ff-6077b4042860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ScheduleOfDebtTable_7422549d-819b-4cba-8715-bda30e9eb41b" xlink:href="mdt-20240426.xsd#mdt_ScheduleOfDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2506d054-bfa1-41b4-a1ff-6077b4042860" xlink:to="loc_mdt_ScheduleOfDebtTable_7422549d-819b-4cba-8715-bda30e9eb41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_ebc3f6aa-2f12-45fb-93fb-1df0dbeb2a26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_ScheduleOfDebtTable_7422549d-819b-4cba-8715-bda30e9eb41b" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_ebc3f6aa-2f12-45fb-93fb-1df0dbeb2a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_c3f43af6-c531-48ad-a1d4-ef2e3cd61a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_ebc3f6aa-2f12-45fb-93fb-1df0dbeb2a26" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_c3f43af6-c531-48ad-a1d4-ef2e3cd61a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_24b10a26-7a01-47b4-9adc-bbd17b8f14f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_c3f43af6-c531-48ad-a1d4-ef2e3cd61a2e" xlink:to="loc_us-gaap_NotesPayableToBanksMember_24b10a26-7a01-47b4-9adc-bbd17b8f14f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bbe99e9e-27f1-4a5c-bd11-a31313bc33a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_ScheduleOfDebtTable_7422549d-819b-4cba-8715-bda30e9eb41b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bbe99e9e-27f1-4a5c-bd11-a31313bc33a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_55d263ec-742f-4143-9fe5-c063a93e8811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bbe99e9e-27f1-4a5c-bd11-a31313bc33a0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_55d263ec-742f-4143-9fe5-c063a93e8811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5bd91337-6896-4c4d-b24e-e4baad5f6f84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_55d263ec-742f-4143-9fe5-c063a93e8811" xlink:to="loc_us-gaap_SeniorNotesMember_5bd91337-6896-4c4d-b24e-e4baad5f6f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:href="mdt-20240426.xsd#mdt_DebtLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_ScheduleOfDebtTable_7422549d-819b-4cba-8715-bda30e9eb41b" xlink:to="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_3d57a94b-3c65-4879-b228-e705900ec364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_ShortTermBorrowings_3d57a94b-3c65-4879-b228-e705900ec364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_7d04c11e-3455-4af2-b27f-d45999689f10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_7d04c11e-3455-4af2-b27f-d45999689f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_e863642a-cd99-49bc-89fb-d7682fcb2402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_CommercialPaper_e863642a-cd99-49bc-89fb-d7682fcb2402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c150a7bf-5529-45df-8d19-eab589425b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_DebtCurrent_c150a7bf-5529-45df-8d19-eab589425b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bce83db9-5bae-4041-9400-224757a46377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_b3bf4f03-f7d1-4c65-a7b5-bfadf412d0ea" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bce83db9-5bae-4041-9400-224757a46377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_19ce1e04-5080-4066-aa80-c1ed41479115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_19ce1e04-5080-4066-aa80-c1ed41479115" xlink:to="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f2a26695-bf40-4000-b2ca-d63095a56945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_DebtInstrumentAxis_f2a26695-bf40-4000-b2ca-d63095a56945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f2a26695-bf40-4000-b2ca-d63095a56945" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2015CommercialPaperProgramMember_0a854387-abaa-40bf-8a0f-40d87c9a0542" xlink:href="mdt-20240426.xsd#mdt_A2015CommercialPaperProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_A2015CommercialPaperProgramMember_0a854387-abaa-40bf-8a0f-40d87c9a0542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember_e6d9d43a-b0a1-48a3-9686-dde1d41c31c8" xlink:href="mdt-20240426.xsd#mdt_AmendedandRestatedRevolvingCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember_e6d9d43a-b0a1-48a3-9686-dde1d41c31c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoSeniorNotesMember_53a43942-97a3-4304-ab2e-476cebbd6bdb" xlink:href="mdt-20240426.xsd#mdt_MedtronicLuxcoSeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_MedtronicLuxcoSeniorNotesMember_53a43942-97a3-4304-ab2e-476cebbd6bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20253.500PercentMember_ce565cef-35ce-4b42-ac8a-e8dd216a5792" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2015Due20253.500PercentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_SeniorNotes2015Due20253.500PercentMember_ce565cef-35ce-4b42-ac8a-e8dd216a5792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2017Due20273.350PercentMember_d937cc4a-c6cc-40cb-8201-d925f9cf3043" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2017Due20273.350PercentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_154b13a3-9d72-4425-a2a5-aadee1886c00" xlink:to="loc_mdt_SeniorNotes2017Due20273.350PercentMember_d937cc4a-c6cc-40cb-8201-d925f9cf3043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_981e3d4b-a2e5-4f15-9278-5925f4d2d1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_981e3d4b-a2e5-4f15-9278-5925f4d2d1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2f0eb80b-902d-42bf-b8a8-40d27025e5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_981e3d4b-a2e5-4f15-9278-5925f4d2d1e3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2f0eb80b-902d-42bf-b8a8-40d27025e5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9a1cb2ec-ff46-4e6c-8318-de2ece3eb1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2f0eb80b-902d-42bf-b8a8-40d27025e5ac" xlink:to="loc_us-gaap_CommercialPaperMember_9a1cb2ec-ff46-4e6c-8318-de2ece3eb1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e761395c-ec9c-44d6-8245-12459d3c0257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2f0eb80b-902d-42bf-b8a8-40d27025e5ac" xlink:to="loc_us-gaap_LoansPayableMember_e761395c-ec9c-44d6-8245-12459d3c0257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_367b2995-82ef-4a83-bada-497d4cbb37de" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_srt_RangeAxis_367b2995-82ef-4a83-bada-497d4cbb37de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c34c3fa-285f-4d16-b8ef-1683bdc3f0a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_367b2995-82ef-4a83-bada-497d4cbb37de" xlink:to="loc_srt_RangeMember_0c34c3fa-285f-4d16-b8ef-1683bdc3f0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b2b3ef81-720f-400c-9ab7-dd73b4a412f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c34c3fa-285f-4d16-b8ef-1683bdc3f0a4" xlink:to="loc_srt_MinimumMember_b2b3ef81-720f-400c-9ab7-dd73b4a412f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_498234fe-21cd-427f-9a3e-aa35eb2783fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_CreditFacilityAxis_498234fe-21cd-427f-9a3e-aa35eb2783fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_045a986b-48ab-4cf1-b2c1-d34c622a8be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_498234fe-21cd-427f-9a3e-aa35eb2783fb" xlink:to="loc_us-gaap_CreditFacilityDomain_045a986b-48ab-4cf1-b2c1-d34c622a8be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_192535be-4be2-4b81-beaf-6f016f425f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_045a986b-48ab-4cf1-b2c1-d34c622a8be4" xlink:to="loc_us-gaap_LineOfCreditMember_192535be-4be2-4b81-beaf-6f016f425f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e62f5560-f004-4d62-b46e-31603ec111cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e62f5560-f004-4d62-b46e-31603ec111cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_49d746af-5bbf-436a-860d-e0a909a77d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e62f5560-f004-4d62-b46e-31603ec111cb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_49d746af-5bbf-436a-860d-e0a909a77d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_db3c2491-3018-4cdf-ac79-21c59f2b3564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_49d746af-5bbf-436a-860d-e0a909a77d26" xlink:to="loc_us-gaap_SeniorNotesMember_db3c2491-3018-4cdf-ac79-21c59f2b3564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6095f114-5fd3-4a28-9f2e-fadb940b6162" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_dei_LegalEntityAxis_6095f114-5fd3-4a28-9f2e-fadb940b6162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_73c475b0-c41d-4df0-8ddc-8bbfc2ac6db5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6095f114-5fd3-4a28-9f2e-fadb940b6162" xlink:to="loc_dei_EntityDomain_73c475b0-c41d-4df0-8ddc-8bbfc2ac6db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoMember_0421f3bf-779f-4142-b73b-2d60e19880f6" xlink:href="mdt-20240426.xsd#mdt_MedtronicLuxcoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_73c475b0-c41d-4df0-8ddc-8bbfc2ac6db5" xlink:to="loc_mdt_MedtronicLuxcoMember_0421f3bf-779f-4142-b73b-2d60e19880f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2b2a38cf-1495-4821-b062-65c3ea37b9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_VariableRateAxis_2b2a38cf-1495-4821-b062-65c3ea37b9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0f008c2b-daf6-4971-8e3a-538992ce4f13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_2b2a38cf-1495-4821-b062-65c3ea37b9c5" xlink:to="loc_us-gaap_VariableRateDomain_0f008c2b-daf6-4971-8e3a-538992ce4f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TokyoInterBankOfferedRateTIBORMember_80ab5e58-3705-4a88-9703-f2f2f1ce282a" xlink:href="mdt-20240426.xsd#mdt_TokyoInterBankOfferedRateTIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0f008c2b-daf6-4971-8e3a-538992ce4f13" xlink:to="loc_mdt_TokyoInterBankOfferedRateTIBORMember_80ab5e58-3705-4a88-9703-f2f2f1ce282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8cba31ed-1802-40ae-a5a1-9220170477bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8cba31ed-1802-40ae-a5a1-9220170477bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d4f2b172-9065-4aa8-9ca2-8579f18f93b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8cba31ed-1802-40ae-a5a1-9220170477bf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d4f2b172-9065-4aa8-9ca2-8579f18f93b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_17a0789a-f256-4088-8a71-b2a8b024d0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d4f2b172-9065-4aa8-9ca2-8579f18f93b7" xlink:to="loc_us-gaap_SubsequentEventMember_17a0789a-f256-4088-8a71-b2a8b024d0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59545731-8368-4d93-9e28-547e252b7455" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommercialPaperMaximumBorrowingCapacity_ed8b2e37-ae52-4183-975a-83c080ea6666" xlink:href="mdt-20240426.xsd#mdt_CommercialPaperMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_mdt_CommercialPaperMaximumBorrowingCapacity_ed8b2e37-ae52-4183-975a-83c080ea6666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_1d1541b2-94e3-48ba-ab7b-ef1771f9c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtCurrent_1d1541b2-94e3-48ba-ab7b-ef1771f9c37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_45071b08-1223-4ce8-a767-9885b5d73df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentTerm_45071b08-1223-4ce8-a767-9885b5d73df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_5f16f552-f67d-4b7d-80f4-80ac30661a21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_5f16f552-f67d-4b7d-80f4-80ac30661a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_a07e62f0-e2c7-4db5-bd3f-18691a1142fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_a07e62f0-e2c7-4db5-bd3f-18691a1142fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1a11efd6-11cd-4611-8dba-bba79ffa6530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1a11efd6-11cd-4611-8dba-bba79ffa6530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityLengthOfExtension_97dfc365-ec24-4440-a05f-502cd9ff4f0b" xlink:href="mdt-20240426.xsd#mdt_LineOfCreditFacilityLengthOfExtension"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_mdt_LineOfCreditFacilityLengthOfExtension_97dfc365-ec24-4440-a05f-502cd9ff4f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_af603251-3d42-4bbb-9a34-fe8854200143" xlink:href="mdt-20240426.xsd#mdt_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_af603251-3d42-4bbb-9a34-fe8854200143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_df138e8d-b843-4caf-809b-ff5a58840967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_LineOfCredit_df138e8d-b843-4caf-809b-ff5a58840967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtInstrumentNumberofTranches_e9672dcb-c7c0-4dbb-8c04-3c8d73ad6190" xlink:href="mdt-20240426.xsd#mdt_DebtInstrumentNumberofTranches"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_mdt_DebtInstrumentNumberofTranches_e9672dcb-c7c0-4dbb-8c04-3c8d73ad6190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d1ff2307-4b5c-494c-b8f5-977e52215287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d1ff2307-4b5c-494c-b8f5-977e52215287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_af4565a6-adb7-47ef-a2e3-1fb6ba8a3b93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_af4565a6-adb7-47ef-a2e3-1fb6ba8a3b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_410d5b5a-7af5-4a97-a47c-64e53cbc0c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_410d5b5a-7af5-4a97-a47c-64e53cbc0c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_4f2da78c-05ec-461f-82c9-2233f41d2589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_4f2da78c-05ec-461f-82c9-2233f41d2589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b1f86f7-e6f1-402a-8d9a-d8a9160c276d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b1f86f7-e6f1-402a-8d9a-d8a9160c276d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_361e4481-b7f1-4d65-8253-9749f5bccdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_361e4481-b7f1-4d65-8253-9749f5bccdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_8edaea39-4fa2-4798-ad87-65264ce604b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_RepaymentsOfDebt_8edaea39-4fa2-4798-ad87-65264ce604b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4200e2cc-1a70-4caf-8d29-09dc4eb4d179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4200e2cc-1a70-4caf-8d29-09dc4eb4d179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_45dee1de-6f0c-45fc-8f7e-88d1e06dabdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_45dee1de-6f0c-45fc-8f7e-88d1e06dabdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b5c70227-c362-4fd8-8d9a-9c129237fd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b5c70227-c362-4fd8-8d9a-9c129237fd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_2dce46f3-801e-44a0-852f-cf5b4df62254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_InterestExpenseBorrowings_2dce46f3-801e-44a0-852f-cf5b4df62254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_aa19a7f0-e4d8-4167-b165-aba3ea00bd59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8cb1c75-9484-42de-86e9-124d46952dd7" xlink:to="loc_us-gaap_LongTermDebtFairValue_aa19a7f0-e4d8-4167-b165-aba3ea00bd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8ab65473-d814-48c7-8a14-d74f94aca265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7f6f6d21-a74d-4715-8b68-19fe38769cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ab65473-d814-48c7-8a14-d74f94aca265" xlink:to="loc_us-gaap_DebtInstrumentTable_7f6f6d21-a74d-4715-8b68-19fe38769cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_418da51a-229e-4bac-b3a5-5fc59dd14396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7f6f6d21-a74d-4715-8b68-19fe38769cf0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_418da51a-229e-4bac-b3a5-5fc59dd14396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e6dc2e5f-8a18-44bd-b940-79edf7530ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_418da51a-229e-4bac-b3a5-5fc59dd14396" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e6dc2e5f-8a18-44bd-b940-79edf7530ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_699ee9ec-be82-492b-bb8c-8fa4ad536a84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e6dc2e5f-8a18-44bd-b940-79edf7530ddc" xlink:to="loc_us-gaap_SeniorNotesMember_699ee9ec-be82-492b-bb8c-8fa4ad536a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f7122f7a-593b-4b47-9f66-561dff73aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7f6f6d21-a74d-4715-8b68-19fe38769cf0" xlink:to="loc_us-gaap_DebtInstrumentAxis_f7122f7a-593b-4b47-9f66-561dff73aaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f7122f7a-593b-4b47-9f66-561dff73aaf0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2026Member_44fb4668-522b-4b2e-8b44-0b065d6dd1ca" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2026Member_44fb4668-522b-4b2e-8b44-0b065d6dd1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2625PercentThreeYear2022SeniorNotesMember_2214995a-d14d-4762-99eb-9b841278e8a0" xlink:href="mdt-20240426.xsd#mdt_A2625PercentThreeYear2022SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A2625PercentThreeYear2022SeniorNotesMember_2214995a-d14d-4762-99eb-9b841278e8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2026Member_d4b14aba-dfe3-4a46-abe5-981857b7e51f" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2026Member_d4b14aba-dfe3-4a46-abe5-981857b7e51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2027Member_aac47d57-d320-474b-9544-94ba98a4f5bd" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2027Member_aac47d57-d320-474b-9544-94ba98a4f5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4250PercentFiveYear2023SeniorNotesMember_e9a9ff41-99eb-4377-a43b-5f771dddbbf0" xlink:href="mdt-20240426.xsd#mdt_A4250PercentFiveYear2023SeniorNotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A4250PercentFiveYear2023SeniorNotesMember_e9a9ff41-99eb-4377-a43b-5f771dddbbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3000PercentSixYear2022SeniorNotesMember_5e096475-4719-4dd1-8b39-e90d218e2199" xlink:href="mdt-20240426.xsd#mdt_A3000PercentSixYear2022SeniorNotesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A3000PercentSixYear2022SeniorNotesMember_5e096475-4719-4dd1-8b39-e90d218e2199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2029Member_ec353a94-5ae3-4dfe-b78a-066268955943" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2029Member_ec353a94-5ae3-4dfe-b78a-066268955943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2031Member_69177812-3ca5-48b3-ab13-8cc076347a7c" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2031Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2031Member_69177812-3ca5-48b3-ab13-8cc076347a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2032Member_464bd13d-f36e-42ed-857c-05cf9384a843" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2032Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2032Member_464bd13d-f36e-42ed-857c-05cf9384a843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3125PercentNineYear2022SeniorNotesMember_7ead19a2-f054-4e6d-a890-a382fec924ba" xlink:href="mdt-20240426.xsd#mdt_A3125PercentNineYear2022SeniorNotesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A3125PercentNineYear2022SeniorNotesMember_7ead19a2-f054-4e6d-a890-a382fec924ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2033Member_d1764f6d-3360-41fa-8c32-d61d0d02bdca" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2033Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2033Member_d1764f6d-3360-41fa-8c32-d61d0d02bdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4500PercentTenYear2023SeniorNotesMember_a0273f6c-9576-4253-a436-f1b41614cce7" xlink:href="mdt-20240426.xsd#mdt_A4500PercentTenYear2023SeniorNotesMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A4500PercentTenYear2023SeniorNotesMember_a0273f6c-9576-4253-a436-f1b41614cce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3375PercentTwelveYear2022SeniorNotesMember_f9415fc9-9ec2-48f1-896c-0088d2e77512" xlink:href="mdt-20240426.xsd#mdt_A3375PercentTwelveYear2022SeniorNotesMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_A3375PercentTwelveYear2022SeniorNotesMember_f9415fc9-9ec2-48f1-896c-0088d2e77512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due2035Member_69e57228-28da-4942-8157-fda43bacbed3" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2015Due2035Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2015Due2035Member_69e57228-28da-4942-8157-fda43bacbed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotesCIFSA2007Due2038Member_86b59b4d-e20f-4a4c-958d-7558b607df05" xlink:href="mdt-20240426.xsd#mdt_SeniorNotesCIFSA2007Due2038Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotesCIFSA2007Due2038Member_86b59b4d-e20f-4a4c-958d-7558b607df05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2039Member_197b067f-1391-4e86-b513-f9969ac498f6" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2039Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2039Member_197b067f-1391-4e86-b513-f9969ac498f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2009Due2039Member_ccde6162-e2ba-4e7d-8a9f-f84f6b8bdc3e" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2009Due2039Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2009Due2039Member_ccde6162-e2ba-4e7d-8a9f-f84f6b8bdc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2040Member_19aa35c8-67df-4555-8dfc-304c10875844" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2040Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2040Member_19aa35c8-67df-4555-8dfc-304c10875844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2010Due2040Member_f5dba55b-c914-417a-8f25-1e05012ae6e4" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2010Due2040Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2010Due2040Member_f5dba55b-c914-417a-8f25-1e05012ae6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2041Member_0896d332-56a4-4af5-a034-c806ff849c85" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2041Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2041Member_0896d332-56a4-4af5-a034-c806ff849c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2012Due2042Member_55766dc0-8878-4c1a-a67e-a4556c9b5dc2" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2012Due2042Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2012Due2042Member_55766dc0-8878-4c1a-a67e-a4556c9b5dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2013Due2043Member_fa0c4b5e-898f-4c8d-8358-3b26e77ce29e" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2013Due2043Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2013Due2043Member_fa0c4b5e-898f-4c8d-8358-3b26e77ce29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2014Due2044Member_26899381-7a15-4794-9d77-44ab572a6b30" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2014Due2044Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2014Due2044Member_26899381-7a15-4794-9d77-44ab572a6b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due2045Member_87388ced-c3d7-4aca-b545-ae3dd4979e0a" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2015Due2045Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2015Due2045Member_87388ced-c3d7-4aca-b545-ae3dd4979e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due2050Member_59edaac8-0f02-4aaf-a7dd-21028e3c304f" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2019Due2050Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2019Due2050Member_59edaac8-0f02-4aaf-a7dd-21028e3c304f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due2051Member_1932d5be-dd69-41da-ba37-d2203d9a2386" xlink:href="mdt-20240426.xsd#mdt_SeniorNotes2020Due2051Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51e0f543-9566-4add-8044-f1ee1352b8b0" xlink:to="loc_mdt_SeniorNotes2020Due2051Member_1932d5be-dd69-41da-ba37-d2203d9a2386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7f6f6d21-a74d-4715-8b68-19fe38769cf0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9d40bbea-8ace-4edc-91cb-6a922ba3e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9d40bbea-8ace-4edc-91cb-6a922ba3e6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_28259c62-fcaa-486a-b246-a69eb0853068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DebtInstrumentTerm_28259c62-fcaa-486a-b246-a69eb0853068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_354fe5d0-ef04-4037-ac81-753285896b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_354fe5d0-ef04-4037-ac81-753285896b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5b6ead98-e018-476e-be3a-773212e1fafc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5b6ead98-e018-476e-be3a-773212e1fafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_a19d0e56-2726-4c0a-ae20-8a54ae45e270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_a19d0e56-2726-4c0a-ae20-8a54ae45e270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_090bcc2b-7b32-410e-aa16-c7700a363769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_090bcc2b-7b32-410e-aa16-c7700a363769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5c6a51a7-85a6-4384-9c4f-7084ef8f2c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5c6a51a7-85a6-4384-9c4f-7084ef8f2c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d9867e83-050d-4110-a73b-f63327e80855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d9867e83-050d-4110-a73b-f63327e80855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_5c47e694-ea31-4e62-8d9d-1740ab9c02f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52929b5e-c4b4-4e9b-8970-f164b77ad4a8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_5c47e694-ea31-4e62-8d9d-1740ab9c02f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#FinancingArrangementsLongtermDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5f63276d-39a8-4d8b-baa0-6c36009ea4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_8b22dca5-9c11-4720-b930-f58968147cca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f63276d-39a8-4d8b-baa0-6c36009ea4f0" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_8b22dca5-9c11-4720-b930-f58968147cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d9b1f9e4-94a7-4bca-a8d4-ffbbc66684f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8b22dca5-9c11-4720-b930-f58968147cca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d9b1f9e4-94a7-4bca-a8d4-ffbbc66684f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d0390589-c983-4968-838a-575da7c9a07d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8b22dca5-9c11-4720-b930-f58968147cca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d0390589-c983-4968-838a-575da7c9a07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dab37245-b088-4c91-bb16-4fe3863d960d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8b22dca5-9c11-4720-b930-f58968147cca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dab37245-b088-4c91-bb16-4fe3863d960d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_58020eca-1855-47fb-a89f-3c602b7c5827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8b22dca5-9c11-4720-b930-f58968147cca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_58020eca-1855-47fb-a89f-3c602b7c5827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5522bb96-bf97-41e4-ad1e-e9df3432564d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8b22dca5-9c11-4720-b930-f58968147cca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5522bb96-bf97-41e4-ad1e-e9df3432564d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a620e96e-bc65-4c71-9432-f82c9f6b40bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8b22dca5-9c11-4720-b930-f58968147cca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a620e96e-bc65-4c71-9432-f82c9f6b40bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_34f94e63-6374-404e-8f07-9ccb75885766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_8b22dca5-9c11-4720-b930-f58968147cca" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_34f94e63-6374-404e-8f07-9ccb75885766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_47977d3e-d1db-4500-a3d6-a4227341fe54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_47977d3e-d1db-4500-a3d6-a4227341fe54" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ce63bf05-fc30-4a87-a2ff-82f8e7802c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ce63bf05-fc30-4a87-a2ff-82f8e7802c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0d2e2e19-6d18-4ff0-ba23-1b5ad1b2b5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ce63bf05-fc30-4a87-a2ff-82f8e7802c91" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0d2e2e19-6d18-4ff0-ba23-1b5ad1b2b5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3c98c4ff-d43d-4a93-8ae4-6930e776e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0d2e2e19-6d18-4ff0-ba23-1b5ad1b2b5cf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3c98c4ff-d43d-4a93-8ae4-6930e776e6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_99bcac06-af03-47f6-a47a-b29362a0d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:to="loc_us-gaap_HedgingDesignationAxis_99bcac06-af03-47f6-a47a-b29362a0d0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b32fdd5e-0a3a-4c2a-9052-603754361aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_99bcac06-af03-47f6-a47a-b29362a0d0f7" xlink:to="loc_us-gaap_HedgingDesignationDomain_b32fdd5e-0a3a-4c2a-9052-603754361aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_25e29c16-b6dd-4d66-a80b-ce0125d5a779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b32fdd5e-0a3a-4c2a-9052-603754361aa7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_25e29c16-b6dd-4d66-a80b-ce0125d5a779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e782496-eeb8-41bd-b5da-fc8aa79c9b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e782496-eeb8-41bd-b5da-fc8aa79c9b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1523cb10-d8e4-43fd-8e50-c349edcfa160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e782496-eeb8-41bd-b5da-fc8aa79c9b3c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1523cb10-d8e4-43fd-8e50-c349edcfa160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_fab77039-aa24-4639-916a-a99696f6ccda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1523cb10-d8e4-43fd-8e50-c349edcfa160" xlink:to="loc_us-gaap_CashFlowHedgingMember_fab77039-aa24-4639-916a-a99696f6ccda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b1365736-9d36-494d-97e2-8f68fe87ea41" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_8480c603-6d4a-40e2-835c-14c3f242494a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_8480c603-6d4a-40e2-835c-14c3f242494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_b38005e1-a28f-4884-a065-e042da6b91bd" xlink:href="mdt-20240426.xsd#mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_b38005e1-a28f-4884-a065-e042da6b91bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_697342d3-2e47-4708-8a86-a633a8cb3068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_697342d3-2e47-4708-8a86-a633a8cb3068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_4d30bbc7-0dba-4307-a2fc-4c4baabb0c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_4d30bbc7-0dba-4307-a2fc-4c4baabb0c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a6cbb50b-8c9a-4166-9633-299ad07f5598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a6cbb50b-8c9a-4166-9633-299ad07f5598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_1bbf0d51-14bd-4134-9d73-f2026da5d979" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_973bc81f-eb57-40f9-8f06-73434a054d95" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_1bbf0d51-14bd-4134-9d73-f2026da5d979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_062555f1-c8c6-42db-919f-64624cf1fbea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_062555f1-c8c6-42db-919f-64624cf1fbea" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_840d93d7-19e4-49d2-8b34-3173f0535847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_840d93d7-19e4-49d2-8b34-3173f0535847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b56558d6-1fea-470e-9be8-9583bd58ea1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_840d93d7-19e4-49d2-8b34-3173f0535847" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b56558d6-1fea-470e-9be8-9583bd58ea1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f59e11c4-df17-42b4-9d3c-0105da3a3eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b56558d6-1fea-470e-9be8-9583bd58ea1b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f59e11c4-df17-42b4-9d3c-0105da3a3eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember_c7209a6b-c1f2-475e-addd-3dd4d142bdfd" xlink:href="mdt-20240426.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b56558d6-1fea-470e-9be8-9583bd58ea1b" xlink:to="loc_mdt_ForeignCurrencyDenominatedDebtMember_c7209a6b-c1f2-475e-addd-3dd4d142bdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2c26b0b1-f50b-4630-ae4f-a66e567e0bff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2c26b0b1-f50b-4630-ae4f-a66e567e0bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_fe54e58d-cd98-4f4d-866f-e0523536a0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2c26b0b1-f50b-4630-ae4f-a66e567e0bff" xlink:to="loc_us-gaap_HedgingRelationshipDomain_fe54e58d-cd98-4f4d-866f-e0523536a0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2588e71e-da4e-461e-8dce-8192a68fae5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_fe54e58d-cd98-4f4d-866f-e0523536a0db" xlink:to="loc_us-gaap_CashFlowHedgingMember_2588e71e-da4e-461e-8dce-8192a68fae5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_59781697-d435-421e-82a9-3c900e825198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_fe54e58d-cd98-4f4d-866f-e0523536a0db" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_59781697-d435-421e-82a9-3c900e825198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_785446f5-4be4-41c9-9453-46fbe34bdcef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:to="loc_us-gaap_HedgingDesignationAxis_785446f5-4be4-41c9-9453-46fbe34bdcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b8516867-eeee-4929-a1ba-dca0e944a870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_785446f5-4be4-41c9-9453-46fbe34bdcef" xlink:to="loc_us-gaap_HedgingDesignationDomain_b8516867-eeee-4929-a1ba-dca0e944a870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3ef5d369-7cdb-47b9-81bc-111e34643cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b8516867-eeee-4929-a1ba-dca0e944a870" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3ef5d369-7cdb-47b9-81bc-111e34643cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_00327a6d-df09-41bc-8572-c91fb218d044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b8516867-eeee-4929-a1ba-dca0e944a870" xlink:to="loc_us-gaap_NondesignatedMember_00327a6d-df09-41bc-8572-c91fb218d044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6db2c4f8-01ad-4fcb-adea-a1148d9cf812" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:to="loc_srt_StatementGeographicalAxis_6db2c4f8-01ad-4fcb-adea-a1148d9cf812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_93fdff9f-5403-4025-98e1-343197bb5d6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6db2c4f8-01ad-4fcb-adea-a1148d9cf812" xlink:to="loc_srt_SegmentGeographicalDomain_93fdff9f-5403-4025-98e1-343197bb5d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_8c53916f-c9d2-4173-95cd-f6663da6355e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_93fdff9f-5403-4025-98e1-343197bb5d6f" xlink:to="loc_srt_EuropeMember_8c53916f-c9d2-4173-95cd-f6663da6355e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_985680c7-37c3-4139-8a8e-b03cc1e2744d" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_JP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_93fdff9f-5403-4025-98e1-343197bb5d6f" xlink:to="loc_country_JP_985680c7-37c3-4139-8a8e-b03cc1e2744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4299e7af-5727-4621-94b1-bdabf82188bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b77d354f-9ce4-4f3a-93dc-7899e4c5cbf8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4299e7af-5727-4621-94b1-bdabf82188bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_a8ae2d31-37fd-4c1c-8605-e78d21f7502f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4299e7af-5727-4621-94b1-bdabf82188bf" xlink:to="loc_us-gaap_DerivativeNotionalAmount_a8ae2d31-37fd-4c1c-8605-e78d21f7502f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ac522a3e-e764-42e9-8633-7da15191ff1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_74e7423b-dbf1-4e90-90b8-a734984f3071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ac522a3e-e764-42e9-8633-7da15191ff1d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_74e7423b-dbf1-4e90-90b8-a734984f3071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_88677d30-be3c-4021-a15d-120bfdfbe14a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_74e7423b-dbf1-4e90-90b8-a734984f3071" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_88677d30-be3c-4021-a15d-120bfdfbe14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ad4c67b6-92ca-4ec4-9382-dc822b7168b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_88677d30-be3c-4021-a15d-120bfdfbe14a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ad4c67b6-92ca-4ec4-9382-dc822b7168b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ab9609bf-67ce-4940-a467-ab61f4246a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ad4c67b6-92ca-4ec4-9382-dc822b7168b0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ab9609bf-67ce-4940-a467-ab61f4246a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember_419bf938-2527-41f1-a5f0-9a77b588d3d7" xlink:href="mdt-20240426.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ad4c67b6-92ca-4ec4-9382-dc822b7168b0" xlink:to="loc_mdt_ForeignCurrencyDenominatedDebtMember_419bf938-2527-41f1-a5f0-9a77b588d3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d616c671-dfa4-4e46-bca7-b0ecf074eead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_74e7423b-dbf1-4e90-90b8-a734984f3071" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d616c671-dfa4-4e46-bca7-b0ecf074eead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_258e71c7-8539-47a0-853f-61606a554a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d616c671-dfa4-4e46-bca7-b0ecf074eead" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_258e71c7-8539-47a0-853f-61606a554a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_b54620ef-570f-48ba-847e-2cee8790f18d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_258e71c7-8539-47a0-853f-61606a554a24" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_b54620ef-570f-48ba-847e-2cee8790f18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_1f094bc3-51b2-4fc6-8ffd-41d6d10374bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_258e71c7-8539-47a0-853f-61606a554a24" xlink:to="loc_us-gaap_CostOfSalesMember_1f094bc3-51b2-4fc6-8ffd-41d6d10374bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_74e7423b-dbf1-4e90-90b8-a734984f3071" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_f9a37364-bc0b-4cfd-a3ea-c83c893a0824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_f9a37364-bc0b-4cfd-a3ea-c83c893a0824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d3fa4e34-374a-44a2-ba1e-31503bf1cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d3fa4e34-374a-44a2-ba1e-31503bf1cc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_67e42a4c-e1e6-4428-bd65-a4d69ca8ef47" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_67e42a4c-e1e6-4428-bd65-a4d69ca8ef47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ee58820c-d196-4064-9bd5-b79ce03f149e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ee58820c-d196-4064-9bd5-b79ce03f149e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_20633db1-e1e1-4d8c-9716-156274cdaaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_20633db1-e1e1-4d8c-9716-156274cdaaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_0e6aadb2-6313-40a0-bfa5-02eb19596ce8" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1c80ebe4-ff4b-41dd-892e-5d277eaa1736" xlink:to="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax_0e6aadb2-6313-40a0-bfa5-02eb19596ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_590a5261-45c1-4971-8737-398b1fb15e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cf58256e-21e9-421d-81ba-2ba4891cae43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_590a5261-45c1-4971-8737-398b1fb15e70" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cf58256e-21e9-421d-81ba-2ba4891cae43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ce1d8f4f-cb6b-4a44-9039-63312ca9156b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cf58256e-21e9-421d-81ba-2ba4891cae43" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ce1d8f4f-cb6b-4a44-9039-63312ca9156b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ccb3350c-0893-40a8-8edd-e47e98f223f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ce1d8f4f-cb6b-4a44-9039-63312ca9156b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ccb3350c-0893-40a8-8edd-e47e98f223f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_7626043e-3af2-4db7-8f09-b93b817bcddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ccb3350c-0893-40a8-8edd-e47e98f223f9" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_7626043e-3af2-4db7-8f09-b93b817bcddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ca1959d7-5a9e-4c8c-8180-4d26a01e5571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cf58256e-21e9-421d-81ba-2ba4891cae43" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ca1959d7-5a9e-4c8c-8180-4d26a01e5571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_70b9cb4d-2636-4b33-a7f6-ec318c1a433b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ca1959d7-5a9e-4c8c-8180-4d26a01e5571" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_70b9cb4d-2636-4b33-a7f6-ec318c1a433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5c7fd146-d0f0-4c14-a0c5-5bb1985948df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70b9cb4d-2636-4b33-a7f6-ec318c1a433b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5c7fd146-d0f0-4c14-a0c5-5bb1985948df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f0042f48-40b6-4fa3-989a-131ab96a82d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cf58256e-21e9-421d-81ba-2ba4891cae43" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f0042f48-40b6-4fa3-989a-131ab96a82d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_ff2ed353-b85d-421c-89ad-211c4eb6b952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f0042f48-40b6-4fa3-989a-131ab96a82d3" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_ff2ed353-b85d-421c-89ad-211c4eb6b952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8c13904e-18ac-4df2-974e-dcdf6474463e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8c13904e-18ac-4df2-974e-dcdf6474463e" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_56dd2126-0c93-4b4a-9093-eb1ab395e0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:to="loc_us-gaap_HedgingDesignationAxis_56dd2126-0c93-4b4a-9093-eb1ab395e0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f7de666e-f3cf-449b-9fcf-7e6d8669514c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_56dd2126-0c93-4b4a-9093-eb1ab395e0d7" xlink:to="loc_us-gaap_HedgingDesignationDomain_f7de666e-f3cf-449b-9fcf-7e6d8669514c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4c9bc72c-58fc-44dc-abdf-6b862f8c4c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f7de666e-f3cf-449b-9fcf-7e6d8669514c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4c9bc72c-58fc-44dc-abdf-6b862f8c4c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_dd6b1115-96af-41c0-b2c9-86ea07ff7c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f7de666e-f3cf-449b-9fcf-7e6d8669514c" xlink:to="loc_us-gaap_NondesignatedMember_dd6b1115-96af-41c0-b2c9-86ea07ff7c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4651ec9a-ca6d-4cd4-b376-a5b79b3352f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4651ec9a-ca6d-4cd4-b376-a5b79b3352f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cb84bee4-e27a-4444-9d27-f3fe1aadc31c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4651ec9a-ca6d-4cd4-b376-a5b79b3352f5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cb84bee4-e27a-4444-9d27-f3fe1aadc31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a7bdd183-0adb-4874-aaf1-3f940579c92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cb84bee4-e27a-4444-9d27-f3fe1aadc31c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a7bdd183-0adb-4874-aaf1-3f940579c92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8c80b676-4dcc-4d40-8baa-46aa7e9b5dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8c80b676-4dcc-4d40-8baa-46aa7e9b5dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8c80b676-4dcc-4d40-8baa-46aa7e9b5dac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_7d868479-daed-4e3c-9e6a-844808a5e4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_7d868479-daed-4e3c-9e6a-844808a5e4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_e939c519-7e27-481e-be25-1df64a3ccdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:to="loc_us-gaap_OtherAssetsMember_e939c519-7e27-481e-be25-1df64a3ccdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_899a9aec-0dad-48c8-abdd-b9272d59b45f" xlink:href="mdt-20240426.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:to="loc_mdt_OtherAccruedExpensesMember_899a9aec-0dad-48c8-abdd-b9272d59b45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_bf38d212-39c4-4b95-b532-b35116e1c6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8e6c0de1-088a-43f2-93e7-52143488ebf1" xlink:to="loc_us-gaap_OtherLiabilitiesMember_bf38d212-39c4-4b95-b532-b35116e1c6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_1995a9cb-19a0-4e01-a4dc-ba446909f97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fab5b9de-f8d0-478a-b0df-f63bb3a56da3" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_1995a9cb-19a0-4e01-a4dc-ba446909f97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ba45d732-bdce-4c55-817c-b332a528bab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1995a9cb-19a0-4e01-a4dc-ba446909f97d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ba45d732-bdce-4c55-817c-b332a528bab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fe8437dc-e13b-48fd-990f-b6c8947b5f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1995a9cb-19a0-4e01-a4dc-ba446909f97d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fe8437dc-e13b-48fd-990f-b6c8947b5f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_87d9d3ff-8477-4a9e-bbe4-ae6dc98965d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172332ea-24c3-4ff7-8659-18d170c568c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_87d9d3ff-8477-4a9e-bbe4-ae6dc98965d3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172332ea-24c3-4ff7-8659-18d170c568c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a34e63c0-698d-4d31-aa03-4c76c7c2d4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172332ea-24c3-4ff7-8659-18d170c568c5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a34e63c0-698d-4d31-aa03-4c76c7c2d4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d98517e8-b585-4a32-b9ff-f11a9dbcb00e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a34e63c0-698d-4d31-aa03-4c76c7c2d4a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d98517e8-b585-4a32-b9ff-f11a9dbcb00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c40e319c-6b55-46fd-b282-e1a8cb65f2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d98517e8-b585-4a32-b9ff-f11a9dbcb00e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c40e319c-6b55-46fd-b282-e1a8cb65f2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172332ea-24c3-4ff7-8659-18d170c568c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_e70dfc12-3d01-48f7-9be5-3db83be0379e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:to="loc_us-gaap_DerivativeAssets_e70dfc12-3d01-48f7-9be5-3db83be0379e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0ef9e2ea-2854-48aa-81fc-3864887aa862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:to="loc_us-gaap_DerivativeLiabilities_0ef9e2ea-2854-48aa-81fc-3864887aa862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_246198bd-110f-48dc-9397-b5d1b496a941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_246198bd-110f-48dc-9397-b5d1b496a941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_02ccb457-dc08-47a6-9f44-c55eec2b45ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e535579f-665f-4a9f-9ab1-79608427fa88" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_02ccb457-dc08-47a6-9f44-c55eec2b45ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d30bb572-e795-44d0-84bb-a1cd17fa3340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesTable_deeace38-0fda-46d4-95e7-002604d0d6cf" xlink:href="mdt-20240426.xsd#mdt_OffsettingAssetsandLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d30bb572-e795-44d0-84bb-a1cd17fa3340" xlink:to="loc_mdt_OffsettingAssetsandLiabilitiesTable_deeace38-0fda-46d4-95e7-002604d0d6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0125611e-c544-4ad1-8def-136029b951a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesTable_deeace38-0fda-46d4-95e7-002604d0d6cf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0125611e-c544-4ad1-8def-136029b951a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_48b26456-cf72-4a4a-9151-eac119fbe92c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0125611e-c544-4ad1-8def-136029b951a9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_48b26456-cf72-4a4a-9151-eac119fbe92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3f55bf4e-b856-4b5a-b797-248f81f60905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_48b26456-cf72-4a4a-9151-eac119fbe92c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3f55bf4e-b856-4b5a-b797-248f81f60905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:href="mdt-20240426.xsd#mdt_OffsettingAssetsandLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesTable_deeace38-0fda-46d4-95e7-002604d0d6cf" xlink:to="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_029c06d5-df17-4083-bf29-6cfc13fb6378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_029c06d5-df17-4083-bf29-6cfc13fb6378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4327863e-c302-474f-9803-19636c60cc70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4327863e-c302-474f-9803-19636c60cc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_3dc42cff-d393-48a3-be8b-1a70299c4d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_3dc42cff-d393-48a3-be8b-1a70299c4d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_a0473c02-a15b-441b-b794-5588e631ec1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_dd951323-dcdc-4131-89a0-e2c074cbf4e6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_a0473c02-a15b-441b-b794-5588e631ec1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_2b8f82d9-7b1b-46b5-bf73-29d36a42b983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_2b8f82d9-7b1b-46b5-bf73-29d36a42b983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_34762764-4a91-4bcf-94aa-9b8ebc33556e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_34762764-4a91-4bcf-94aa-9b8ebc33556e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_a2b26c04-b5b9-4880-8dd3-93a28a7afecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_a2b26c04-b5b9-4880-8dd3-93a28a7afecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_38fa804c-2960-4422-8a2a-683fa7ebe71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_f96e4b97-7f5b-4c3f-adb7-d4a19aedde8a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_38fa804c-2960-4422-8a2a-683fa7ebe71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_da4f1a4a-26d3-4068-b8da-f81b08cb7569" xlink:to="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_3ddfe8a0-d91e-4bb5-ab2a-2e8f283bf0e2" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:to="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_3ddfe8a0-d91e-4bb5-ab2a-2e8f283bf0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_67324df1-0a5d-4629-a60f-ba7071b9ceac" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_67324df1-0a5d-4629-a60f-ba7071b9ceac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_a15db34d-ee0f-4177-b2ed-8297e98a0522" xlink:href="mdt-20240426.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_a15db34d-ee0f-4177-b2ed-8297e98a0522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_50f7bf47-0c5d-48b5-99de-e73a14e00666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_0a89daa3-1b7e-4427-85b3-639d2e6ee25a" xlink:to="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_50f7bf47-0c5d-48b5-99de-e73a14e00666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/InventoriesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d9d980d7-c69f-4ffd-91b5-2cf28c0dcde4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_eddee0e6-7e1e-4e91-95ae-5a7114956f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d9d980d7-c69f-4ffd-91b5-2cf28c0dcde4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_eddee0e6-7e1e-4e91-95ae-5a7114956f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8deee512-3368-4527-affb-bfb31b236d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d9d980d7-c69f-4ffd-91b5-2cf28c0dcde4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8deee512-3368-4527-affb-bfb31b236d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_af8422be-6f9c-4aed-89e5-18d58e70fa59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d9d980d7-c69f-4ffd-91b5-2cf28c0dcde4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_af8422be-6f9c-4aed-89e5-18d58e70fa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c22a66f0-0ae2-438e-9d9d-94e4c1bfbddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d9d980d7-c69f-4ffd-91b5-2cf28c0dcde4" xlink:to="loc_us-gaap_InventoryNet_c22a66f0-0ae2-438e-9d9d-94e4c1bfbddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_31510fcf-c12a-4cea-a072-9d4af7ec7881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_17c85c1b-abb7-45e3-abfb-e55b4fe858fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_31510fcf-c12a-4cea-a072-9d4af7ec7881" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_17c85c1b-abb7-45e3-abfb-e55b4fe858fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_edf530a6-4f93-475f-bfb4-8c4352058a66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_17c85c1b-abb7-45e3-abfb-e55b4fe858fb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_edf530a6-4f93-475f-bfb4-8c4352058a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_edf530a6-4f93-475f-bfb4-8c4352058a66" xlink:to="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_f4bc0c09-c2ee-4a93-8d53-a9b2af0d4406" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:to="loc_mdt_CardiovascularMember_f4bc0c09-c2ee-4a93-8d53-a9b2af0d4406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_8468ed85-5325-4d30-95ad-dfcaed74a35a" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:to="loc_mdt_NeuroscienceGroupMember_8468ed85-5325-4d30-95ad-dfcaed74a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_236e8ed7-6424-48be-9443-587f29755d9d" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:to="loc_mdt_MedicalSurgicalMember_236e8ed7-6424-48be-9443-587f29755d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_24f2c2f5-6ea4-473f-bcaf-0d271af1ad77" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_666e3d50-f141-4940-90ec-1cc9fcd6f4dd" xlink:to="loc_mdt_DiabetesGroupMember_24f2c2f5-6ea4-473f-bcaf-0d271af1ad77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ec9982de-ec9d-41d0-b63b-2aeb8c892150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_17c85c1b-abb7-45e3-abfb-e55b4fe858fb" xlink:to="loc_us-gaap_GoodwillLineItems_ec9982de-ec9d-41d0-b63b-2aeb8c892150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ec9982de-ec9d-41d0-b63b-2aeb8c892150" xlink:to="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fb8adda3-cd41-42c4-b18a-a8ec4ba3bbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_Goodwill_fb8adda3-cd41-42c4-b18a-a8ec4ba3bbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_5b591a6e-3b5b-4b48-9991-cae00ce773b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_5b591a6e-3b5b-4b48-9991-cae00ce773b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_795d60d2-f733-45ea-94c7-8ea8f1c17651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_795d60d2-f733-45ea-94c7-8ea8f1c17651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_496e29e0-c4af-4151-879c-b83b0d5d1c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_496e29e0-c4af-4151-879c-b83b0d5d1c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5c81da1f-f5b8-46e4-af10-1d1bf10404c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5c81da1f-f5b8-46e4-af10-1d1bf10404c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_44c0998d-0f4a-49d5-88f8-168bad9dbc44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6a933ee7-70ce-4b1f-8a37-03b50018d693" xlink:to="loc_us-gaap_Goodwill_44c0998d-0f4a-49d5-88f8-168bad9dbc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1fad178a-893a-4efd-8593-392983847760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1fad178a-893a-4efd-8593-392983847760" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5ff00d46-cce7-45f1-ad67-ab555b194199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5ff00d46-cce7-45f1-ad67-ab555b194199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5ff00d46-cce7-45f1-ad67-ab555b194199" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareBusinessRCSMember_223fac16-b745-4d7d-983d-7640c0c444ce" xlink:href="mdt-20240426.xsd#mdt_RenalCareBusinessRCSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:to="loc_mdt_RenalCareBusinessRCSMember_223fac16-b745-4d7d-983d-7640c0c444ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember_6f9db3e1-6200-4de8-8f71-84060695de29" xlink:href="mdt-20240426.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:to="loc_mdt_VentilatorProductLineExitMember_6f9db3e1-6200-4de8-8f71-84060695de29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MechanicalCirculatorySupportMember_c6032a50-213f-4cc2-9c6c-6af2c2580323" xlink:href="mdt-20240426.xsd#mdt_MechanicalCirculatorySupportMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:to="loc_mdt_MechanicalCirculatorySupportMember_c6032a50-213f-4cc2-9c6c-6af2c2580323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IPRDMember_9ef05d01-d6e2-49d0-afb6-1b7ec3bd1685" xlink:href="mdt-20240426.xsd#mdt_IPRDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_951d5bf7-d7da-43cb-b36a-6039880e5ac7" xlink:to="loc_mdt_IPRDMember_9ef05d01-d6e2-49d0-afb6-1b7ec3bd1685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_95f3192b-92bc-4bf8-aa4c-199cd1755f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_95f3192b-92bc-4bf8-aa4c-199cd1755f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e643cd6a-69b9-452f-ac0f-e3229400944b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_95f3192b-92bc-4bf8-aa4c-199cd1755f88" xlink:to="loc_us-gaap_SegmentDomain_e643cd6a-69b9-452f-ac0f-e3229400944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_93aeb73e-fe84-4a92-a526-a63d780048fb" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e643cd6a-69b9-452f-ac0f-e3229400944b" xlink:to="loc_mdt_MedicalSurgicalMember_93aeb73e-fe84-4a92-a526-a63d780048fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_d1f6d6b6-0fc8-44aa-ad67-36d800651d17" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e643cd6a-69b9-452f-ac0f-e3229400944b" xlink:to="loc_mdt_NeuroscienceGroupMember_d1f6d6b6-0fc8-44aa-ad67-36d800651d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f47c1a6c-af07-4ef0-8594-17619db0fcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f47c1a6c-af07-4ef0-8594-17619db0fcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9738c736-ffa9-4a43-ae10-8af0c2a2c75f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f47c1a6c-af07-4ef0-8594-17619db0fcbd" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9738c736-ffa9-4a43-ae10-8af0c2a2c75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_79fbacce-c2e6-4650-83e9-44a17922320b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9738c736-ffa9-4a43-ae10-8af0c2a2c75f" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_79fbacce-c2e6-4650-83e9-44a17922320b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_feb3a041-8014-4d3b-ad92-f9e964004cc0" xlink:to="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8942a6a7-9cc6-43ac-8f2e-173b193a5aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8942a6a7-9cc6-43ac-8f2e-173b193a5aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1d0a9430-00d2-4652-9d7b-3ef75eddabf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1d0a9430-00d2-4652-9d7b-3ef75eddabf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_199b3e47-444e-4b58-8394-b3b8a3e8c046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_NumberOfReportingUnits_199b3e47-444e-4b58-8394-b3b8a3e8c046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_6946fc9a-826e-4b4e-8bd5-f890e5f15ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_6946fc9a-826e-4b4e-8bd5-f890e5f15ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8efa201b-e095-4684-a0fe-304b33349f72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8efa201b-e095-4684-a0fe-304b33349f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_16658456-709b-40c3-a34b-c67e494726fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_16658456-709b-40c3-a34b-c67e494726fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e207701e-21aa-4167-9719-85852f80dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e207701e-21aa-4167-9719-85852f80dbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4f8d0b79-e6cc-455b-8e2f-132b20f06933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_76ab6d1c-de31-4a6d-b493-302b45983d15" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4f8d0b79-e6cc-455b-8e2f-132b20f06933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_239ec260-407c-463b-afa5-636c9edccdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fd9fb894-75b6-467e-b139-100c113967ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_239ec260-407c-463b-afa5-636c9edccdfb" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fd9fb894-75b6-467e-b139-100c113967ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_450f542c-29df-4d9a-9a14-c47e45851871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fd9fb894-75b6-467e-b139-100c113967ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_450f542c-29df-4d9a-9a14-c47e45851871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_450f542c-29df-4d9a-9a14-c47e45851871" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_a0f1f68c-6ce5-42a2-b68b-6bf5ecb4b673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_a0f1f68c-6ce5-42a2-b68b-6bf5ecb4b673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PurchasedTechnologyAndPatentsMember_142a24fd-e6d7-4786-b8ab-f7f9d3e5a8f8" xlink:href="mdt-20240426.xsd#mdt_PurchasedTechnologyAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:to="loc_mdt_PurchasedTechnologyAndPatentsMember_142a24fd-e6d7-4786-b8ab-f7f9d3e5a8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_7e6e6daa-8d49-425d-8e9b-a6013dd3311f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_7e6e6daa-8d49-425d-8e9b-a6013dd3311f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_71583728-8e18-429c-8282-6edecfd355a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6b55585-22dc-499d-b468-a26038acac08" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_71583728-8e18-429c-8282-6edecfd355a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a1ae7a33-9cb0-4636-a692-b4f85d94f46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fd9fb894-75b6-467e-b139-100c113967ad" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a1ae7a33-9cb0-4636-a692-b4f85d94f46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6229d30d-b8f3-4217-9e94-d8e0935fd2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a1ae7a33-9cb0-4636-a692-b4f85d94f46b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6229d30d-b8f3-4217-9e94-d8e0935fd2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_01af7e12-abfb-44e8-be76-1484ca0407d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6229d30d-b8f3-4217-9e94-d8e0935fd2e0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_01af7e12-abfb-44e8-be76-1484ca0407d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fd9fb894-75b6-467e-b139-100c113967ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_89188968-1932-4256-9de3-8714e80fc237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_89188968-1932-4256-9de3-8714e80fc237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3b8e59f4-4ae7-4dda-8494-fb743342867e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3b8e59f4-4ae7-4dda-8494-fb743342867e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7cc68767-c7d7-479b-a188-105a7fef0949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_623523e2-6213-4608-bae7-6648d509d598" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7cc68767-c7d7-479b-a188-105a7fef0949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72cc5668-e627-45d6-8452-cdab6eac348a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_efa76e16-7ced-4c1b-8092-e8bf8e1bdbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72cc5668-e627-45d6-8452-cdab6eac348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_efa76e16-7ced-4c1b-8092-e8bf8e1bdbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6863c2ac-a4e2-4450-8b92-58d413e3031d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72cc5668-e627-45d6-8452-cdab6eac348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6863c2ac-a4e2-4450-8b92-58d413e3031d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5d73522c-cc2a-4cae-807e-426899585cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72cc5668-e627-45d6-8452-cdab6eac348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5d73522c-cc2a-4cae-807e-426899585cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c9ccc844-010f-49ef-9659-a438ea6100d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72cc5668-e627-45d6-8452-cdab6eac348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c9ccc844-010f-49ef-9659-a438ea6100d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1af41958-c703-4efd-8d81-7124d8d65972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72cc5668-e627-45d6-8452-cdab6eac348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1af41958-c703-4efd-8d81-7124d8d65972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6bce5d7e-eca2-4182-b81e-924e4e3bb258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e61b61e8-13fc-422b-8508-ffe7197f5260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6bce5d7e-eca2-4182-b81e-924e4e3bb258" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e61b61e8-13fc-422b-8508-ffe7197f5260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_479fb036-8fbc-479b-8237-88a7e9b493b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e61b61e8-13fc-422b-8508-ffe7197f5260" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_479fb036-8fbc-479b-8237-88a7e9b493b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_479fb036-8fbc-479b-8237-88a7e9b493b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_e47e61fd-538d-4bd5-bdfe-c1900eba9a98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_us-gaap_EquipmentMember_e47e61fd-538d-4bd5-bdfe-c1900eba9a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ae56715e-a5c5-4857-81a4-54b2a995cc76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ae56715e-a5c5-4857-81a4-54b2a995cc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_a1add6a4-7ae8-41e7-8377-52a44585c4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_a1add6a4-7ae8-41e7-8377-52a44585c4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BuildingsAndLeaseholdImprovementsMember_0c5d0536-32a7-4cd7-9b73-650899aeb9a3" xlink:href="mdt-20240426.xsd#mdt_BuildingsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_mdt_BuildingsAndLeaseholdImprovementsMember_0c5d0536-32a7-4cd7-9b73-650899aeb9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d53b03d4-211c-4587-8ee8-887268e84a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2993ef99-d3d8-4110-acae-4d5eecd35078" xlink:to="loc_us-gaap_ConstructionInProgressMember_d53b03d4-211c-4587-8ee8-887268e84a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa76052b-7bf0-4340-8205-9137142b682f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e61b61e8-13fc-422b-8508-ffe7197f5260" xlink:to="loc_srt_RangeAxis_aa76052b-7bf0-4340-8205-9137142b682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28674956-56b4-4f90-8b97-9f0abc999d04" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aa76052b-7bf0-4340-8205-9137142b682f" xlink:to="loc_srt_RangeMember_28674956-56b4-4f90-8b97-9f0abc999d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ea4272ae-6f8e-487b-a1fa-2f0a528af54f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_28674956-56b4-4f90-8b97-9f0abc999d04" xlink:to="loc_srt_MinimumMember_ea4272ae-6f8e-487b-a1fa-2f0a528af54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4bed73e-fce2-45d6-962c-e655df5f7000" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_28674956-56b4-4f90-8b97-9f0abc999d04" xlink:to="loc_srt_MaximumMember_a4bed73e-fce2-45d6-962c-e655df5f7000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e61b61e8-13fc-422b-8508-ffe7197f5260" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aaf7365d-3891-400b-be4d-8e4e3ca6ef4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aaf7365d-3891-400b-be4d-8e4e3ca6ef4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3c0b4d9f-c21b-41cf-add5-2ee2a1655ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3c0b4d9f-c21b-41cf-add5-2ee2a1655ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_d8f47f72-db74-4302-a16d-82407d0e8b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_d8f47f72-db74-4302-a16d-82407d0e8b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ef659f42-47a1-4a6d-9b44-d0ac104dfee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ef659f42-47a1-4a6d-9b44-d0ac104dfee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8e78a1c5-c992-49a4-996e-a2b43e9e9442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1f7a20f3-1801-44c0-8e3a-9b43065e7612" xlink:to="loc_us-gaap_Depreciation_8e78a1c5-c992-49a4-996e-a2b43e9e9442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_fb3e4d91-3130-40f7-aa90-5de1959fb201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b30f9e8b-7668-4d7e-acf9-3f8347561bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_fb3e4d91-3130-40f7-aa90-5de1959fb201" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b30f9e8b-7668-4d7e-acf9-3f8347561bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb21ef80-53ba-4972-bae9-4aa9212c6f37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b30f9e8b-7668-4d7e-acf9-3f8347561bc3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb21ef80-53ba-4972-bae9-4aa9212c6f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_08af9e85-0e15-4e34-9d67-d6fa3318b657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb21ef80-53ba-4972-bae9-4aa9212c6f37" xlink:to="loc_us-gaap_ClassOfStockDomain_08af9e85-0e15-4e34-9d67-d6fa3318b657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1bc752a0-fdc2-40d0-96de-acbe2959a479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_08af9e85-0e15-4e34-9d67-d6fa3318b657" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1bc752a0-fdc2-40d0-96de-acbe2959a479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b30f9e8b-7668-4d7e-acf9-3f8347561bc3" xlink:to="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ddb5fb0f-3e48-4790-af1c-1968c714ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ddb5fb0f-3e48-4790-af1c-1968c714ce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc900f95-2cf8-4126-990b-1a7a09bd68a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc900f95-2cf8-4126-990b-1a7a09bd68a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesAuthorized_dff9c925-7a76-4cf4-8621-c5a4567083ac" xlink:href="mdt-20240426.xsd#mdt_DeferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_DeferredStockSharesAuthorized_dff9c925-7a76-4cf4-8621-c5a4567083ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockParorStatedValuePerShare_0c6efa56-d90f-4355-9a4f-2d550a9d4506" xlink:href="mdt-20240426.xsd#mdt_DeferredStockParorStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_DeferredStockParorStatedValuePerShare_0c6efa56-d90f-4355-9a4f-2d550a9d4506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8972db29-b201-4ba4-b4e8-be0cac943ead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8972db29-b201-4ba4-b4e8-be0cac943ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2845e402-91d4-4ed7-9c11-f02a8bd80246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2845e402-91d4-4ed7-9c11-f02a8bd80246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesIssued_c3857a7e-6578-4022-87e2-164d267e3baf" xlink:href="mdt-20240426.xsd#mdt_DeferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_DeferredStockSharesIssued_c3857a7e-6578-4022-87e2-164d267e3baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesOutstanding_b036edc4-4dc7-4378-9c90-c324a0e4ce99" xlink:href="mdt-20240426.xsd#mdt_DeferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_DeferredStockSharesOutstanding_b036edc4-4dc7-4378-9c90-c324a0e4ce99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ed446327-9788-4de7-be40-0e27800ff593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ed446327-9788-4de7-be40-0e27800ff593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3fd8aace-4089-438d-bbe3-6f7c28424c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3fd8aace-4089-438d-bbe3-6f7c28424c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_755fcc25-819a-4c53-880a-360e965f904e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_755fcc25-819a-4c53-880a-360e965f904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StockRepurchaseProgramAveragePurchasePrice_580fb9e2-1a35-497e-b4e9-9b32c0369bf2" xlink:href="mdt-20240426.xsd#mdt_StockRepurchaseProgramAveragePurchasePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_mdt_StockRepurchaseProgramAveragePurchasePrice_580fb9e2-1a35-497e-b4e9-9b32c0369bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_017cf2a2-aa13-4105-a795-67e867b36e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_017cf2a2-aa13-4105-a795-67e867b36e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_e93b482f-0578-4f06-8e83-f54efcf28830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_e93b482f-0578-4f06-8e83-f54efcf28830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_028b503c-808b-4037-8a87-cf55b9d4bc64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0737b50d-1b26-42d7-9aaf-18343c3ab11f" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_028b503c-808b-4037-8a87-cf55b9d4bc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39d7978f-4b98-4dba-827a-5e184de83708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39d7978f-4b98-4dba-827a-5e184de83708" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_681e69d4-6ec8-4623-ab50-69e5581a21c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:to="loc_us-gaap_PlanNameAxis_681e69d4-6ec8-4623-ab50-69e5581a21c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ed0fce63-f536-4f3f-96a8-7565ca2ad918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_681e69d4-6ec8-4623-ab50-69e5581a21c5" xlink:to="loc_us-gaap_PlanNameDomain_ed0fce63-f536-4f3f-96a8-7565ca2ad918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_bad1107c-e7eb-4fcf-a7da-0aa67eb6cfc1" xlink:href="mdt-20240426.xsd#mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ed0fce63-f536-4f3f-96a8-7565ca2ad918" xlink:to="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_bad1107c-e7eb-4fcf-a7da-0aa67eb6cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2024EmployeeStockPurchasePlanMember_74681008-787e-4ef4-86f3-7bf2979135de" xlink:href="mdt-20240426.xsd#mdt_A2024EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ed0fce63-f536-4f3f-96a8-7565ca2ad918" xlink:to="loc_mdt_A2024EmployeeStockPurchasePlanMember_74681008-787e-4ef4-86f3-7bf2979135de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac80a445-0cb8-484c-85c6-1099331cab11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:to="loc_us-gaap_AwardTypeAxis_ac80a445-0cb8-484c-85c6-1099331cab11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac80a445-0cb8-484c-85c6-1099331cab11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8bdd66cd-80af-4382-8479-13b9f3d9a078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8bdd66cd-80af-4382-8479-13b9f3d9a078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e8a8f95f-8d9f-4334-8c65-5e76904fe28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:to="loc_us-gaap_RestrictedStockMember_e8a8f95f-8d9f-4334-8c65-5e76904fe28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_234250e8-7072-4b57-ac04-97d61765a035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockMember_e8a8f95f-8d9f-4334-8c65-5e76904fe28e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_234250e8-7072-4b57-ac04-97d61765a035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f0ae3ed0-6322-4152-93d9-c02c9f89a3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:to="loc_us-gaap_PerformanceSharesMember_f0ae3ed0-6322-4152-93d9-c02c9f89a3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7f5da921-8064-49cb-bcc3-fe1e01c691aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a0e8be-5de1-4af6-ae9e-383ea43953d3" xlink:to="loc_us-gaap_EmployeeStockMember_7f5da921-8064-49cb-bcc3-fe1e01c691aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c3e6edb0-0554-41e9-8a3c-5f3ee48fe1f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:to="loc_srt_RangeAxis_c3e6edb0-0554-41e9-8a3c-5f3ee48fe1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbea25f6-35e6-4aff-b4b4-ceb50e82d601" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c3e6edb0-0554-41e9-8a3c-5f3ee48fe1f1" xlink:to="loc_srt_RangeMember_cbea25f6-35e6-4aff-b4b4-ceb50e82d601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ab9fc31c-73fd-494c-b70d-a59c77f07290" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cbea25f6-35e6-4aff-b4b4-ceb50e82d601" xlink:to="loc_srt_MinimumMember_ab9fc31c-73fd-494c-b70d-a59c77f07290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_073b8a16-0aa2-43a2-80e1-4bcc153ac122" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cbea25f6-35e6-4aff-b4b4-ceb50e82d601" xlink:to="loc_srt_MaximumMember_073b8a16-0aa2-43a2-80e1-4bcc153ac122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f4806e-bfc5-4144-88b2-1ff5ce012fdb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e006ac4c-bc28-4a7e-a99a-7c0e4fdd1dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e006ac4c-bc28-4a7e-a99a-7c0e4fdd1dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bba105e6-b55c-44d0-9eb0-76ccc7103d94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bba105e6-b55c-44d0-9eb0-76ccc7103d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db88a320-2a97-43cd-885d-4e850e9a0407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db88a320-2a97-43cd-885d-4e850e9a0407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4a6e2b18-ec96-481e-9610-36640a981dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4a6e2b18-ec96-481e-9610-36640a981dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cdfe367d-2030-4ac2-8ad6-963506eb02f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cdfe367d-2030-4ac2-8ad6-963506eb02f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f08c6fa4-3ed9-42a5-80d9-6648afa5041f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f08c6fa4-3ed9-42a5-80d9-6648afa5041f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b95bf7b7-df72-4c76-a5c5-bc26d05f4e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b95bf7b7-df72-4c76-a5c5-bc26d05f4e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_466cad6b-a412-4b0b-bcd3-dafe228ec30d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_466cad6b-a412-4b0b-bcd3-dafe228ec30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_67ae4b3f-6af8-4698-8e8a-13f2681e13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_67ae4b3f-6af8-4698-8e8a-13f2681e13d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_b1c0a072-7992-4f07-a160-2078e3010bb6" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_b1c0a072-7992-4f07-a160-2078e3010bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_6e7d290c-49c8-46e8-960b-744df8d6c90c" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_6e7d290c-49c8-46e8-960b-744df8d6c90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce7c1bee-78a3-4a57-bc08-b4fb9fcb330e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75a24e60-9116-478c-9efb-7d2943ea5b08" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce7c1bee-78a3-4a57-bc08-b4fb9fcb330e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_470d7d6f-389c-498b-991f-519e9678c1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44c58a9c-43a9-43c8-8241-44bc72657c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_470d7d6f-389c-498b-991f-519e9678c1e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44c58a9c-43a9-43c8-8241-44bc72657c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b842211c-173d-40d1-bee2-58e7aea264ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44c58a9c-43a9-43c8-8241-44bc72657c92" xlink:to="loc_us-gaap_AwardTypeAxis_b842211c-173d-40d1-bee2-58e7aea264ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b842211c-173d-40d1-bee2-58e7aea264ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c8ec517b-e5a7-4bad-bc37-7aa58871ccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c8ec517b-e5a7-4bad-bc37-7aa58871ccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a6843470-48a8-4c58-b6ad-779ede533189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a6843470-48a8-4c58-b6ad-779ede533189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0e8289d3-6c61-473e-b881-5c1a949d386b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:to="loc_us-gaap_PerformanceSharesMember_0e8289d3-6c61-473e-b881-5c1a949d386b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EmployeesStockPurchasePlanMember_24fb22bb-7c1a-49b6-a18c-eab83a12c2d7" xlink:href="mdt-20240426.xsd#mdt_EmployeesStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f1fe617-4ee7-4d99-be5c-bde3b4446d62" xlink:to="loc_mdt_EmployeesStockPurchasePlanMember_24fb22bb-7c1a-49b6-a18c-eab83a12c2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d4c87658-83ac-4ca8-8cd4-4a900cc4e199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44c58a9c-43a9-43c8-8241-44bc72657c92" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d4c87658-83ac-4ca8-8cd4-4a900cc4e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d4c87658-83ac-4ca8-8cd4-4a900cc4e199" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_be29c230-ed3a-463a-bc47-e7fc6b94803f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:to="loc_us-gaap_CostOfSalesMember_be29c230-ed3a-463a-bc47-e7fc6b94803f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_84fcebda-c569-41ca-a6d1-3a67c6ddf8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_84fcebda-c569-41ca-a6d1-3a67c6ddf8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d1b3927c-ce5e-4944-9843-9fa237a24bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_946a250c-951f-4899-8868-2cc7652e42ba" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d1b3927c-ce5e-4944-9843-9fa237a24bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44c58a9c-43a9-43c8-8241-44bc72657c92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_81721d35-5757-4f32-8006-6587803b1f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_81721d35-5757-4f32-8006-6587803b1f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3a54bf27-cf99-46d7-a708-629d9d634e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3a54bf27-cf99-46d7-a708-629d9d634e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_825a2c42-29c0-4769-b8d7-f981ea229b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92ed9fc3-1d4f-49d7-a008-beeed6ac8109" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_825a2c42-29c0-4769-b8d7-f981ea229b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b82699b-554d-4e5d-9126-ca4d52643097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_29690d60-c7f9-4988-b6c1-9eb320566575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b82699b-554d-4e5d-9126-ca4d52643097" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_29690d60-c7f9-4988-b6c1-9eb320566575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1b86ef9d-b6ea-4c5d-bf2e-7513b32c8ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b82699b-554d-4e5d-9126-ca4d52643097" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1b86ef9d-b6ea-4c5d-bf2e-7513b32c8ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76dc1dbc-fc24-4d0f-a3a9-f0786be6db4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1b86ef9d-b6ea-4c5d-bf2e-7513b32c8ec5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76dc1dbc-fc24-4d0f-a3a9-f0786be6db4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e8bde28-1e4d-4530-ab40-4c2dd4536921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1b86ef9d-b6ea-4c5d-bf2e-7513b32c8ec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e8bde28-1e4d-4530-ab40-4c2dd4536921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4f883474-fad5-4810-89a4-c7936e0451ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1b86ef9d-b6ea-4c5d-bf2e-7513b32c8ec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4f883474-fad5-4810-89a4-c7936e0451ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1a7e07e8-0b96-4745-bf4c-ee222f64aa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1b86ef9d-b6ea-4c5d-bf2e-7513b32c8ec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1a7e07e8-0b96-4745-bf4c-ee222f64aa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d83ee8e-f0b5-43cc-b478-1a586626112b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f68f5825-9397-463a-a0b0-f97f96592455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d83ee8e-f0b5-43cc-b478-1a586626112b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f68f5825-9397-463a-a0b0-f97f96592455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_475844df-86e6-4565-aea4-79e1e5ded49b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f68f5825-9397-463a-a0b0-f97f96592455" xlink:to="loc_us-gaap_AwardTypeAxis_475844df-86e6-4565-aea4-79e1e5ded49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c18d29fb-1698-47e7-ae14-f94297dd43c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_475844df-86e6-4565-aea4-79e1e5ded49b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c18d29fb-1698-47e7-ae14-f94297dd43c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_728e4051-8f44-4bde-88e4-805cbb728758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c18d29fb-1698-47e7-ae14-f94297dd43c7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_728e4051-8f44-4bde-88e4-805cbb728758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f68f5825-9397-463a-a0b0-f97f96592455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75007a37-713a-4672-8645-930cf56e4372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75007a37-713a-4672-8645-930cf56e4372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b7c86498-f17d-479f-8ab5-1bed8c5004ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b7c86498-f17d-479f-8ab5-1bed8c5004ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6d10cbd6-c317-4d63-86c8-2cae4e4f89a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6d10cbd6-c317-4d63-86c8-2cae4e4f89a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b2424109-eff9-4efb-8ec6-eb35b6566ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b2424109-eff9-4efb-8ec6-eb35b6566ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1dacc765-869a-430f-852c-40f1e8e97a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55e7ad1a-010a-4e4b-bd41-e8f7343d993d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1dacc765-869a-430f-852c-40f1e8e97a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f6c0a571-1b6b-4eec-a9fd-79bf84d3eb50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f6c0a571-1b6b-4eec-a9fd-79bf84d3eb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7b80abf0-eeeb-4069-b952-cd18b11329b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7b80abf0-eeeb-4069-b952-cd18b11329b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e50041f-8c68-468d-ae61-3a2dc424ca01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e50041f-8c68-468d-ae61-3a2dc424ca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f88f54f8-fcb6-4b7c-9b7a-fd554e024f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f88f54f8-fcb6-4b7c-9b7a-fd554e024f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1d1fcdea-ff7d-4269-a2c9-909fcfb73527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1d1fcdea-ff7d-4269-a2c9-909fcfb73527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6b1d4d7c-e03b-49ab-a02f-51dd970b7570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6b1d4d7c-e03b-49ab-a02f-51dd970b7570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a9432889-bec6-4566-9fd2-051acabe602f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ae96df5-533c-41c3-a50c-1824154c9e1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a9432889-bec6-4566-9fd2-051acabe602f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_be9a4568-758c-421f-9778-912b97ced4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_be9a4568-758c-421f-9778-912b97ced4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21578d86-0449-4c52-9ec8-e7eae45a9cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21578d86-0449-4c52-9ec8-e7eae45a9cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7caf61f1-fdc4-484b-a19c-102c91c5ebcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7caf61f1-fdc4-484b-a19c-102c91c5ebcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_78d42d4f-f96d-4e25-bdea-ce2d83e6ed32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_78d42d4f-f96d-4e25-bdea-ce2d83e6ed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7b0c927-dcd5-4eab-923c-ec6c15dc6358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7b0c927-dcd5-4eab-923c-ec6c15dc6358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9419552b-29c5-49b4-872f-8b5a1b1c112a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9419552b-29c5-49b4-872f-8b5a1b1c112a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ec27797d-59c0-43e7-b1e4-d9e943c97bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ec27797d-59c0-43e7-b1e4-d9e943c97bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_84f218ad-5fda-482a-b359-192524b118c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1f047f3-b233-4d33-a994-f758247777fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_84f218ad-5fda-482a-b359-192524b118c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4046ecbd-5fe4-4de6-a65e-7f364c87c652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4046ecbd-5fe4-4de6-a65e-7f364c87c652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f0d93268-d670-4636-9e62-c5e4207a353e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f0d93268-d670-4636-9e62-c5e4207a353e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_38e060a4-9779-4405-87d4-1f5ea572a531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ccf76cb-f31f-4a73-ad07-0903be7a0eda" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_38e060a4-9779-4405-87d4-1f5ea572a531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33bc3100-363a-4d4f-9795-b4e2092d7253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_008eafa0-b2ec-4ed9-a620-9e6812422658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33bc3100-363a-4d4f-9795-b4e2092d7253" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_008eafa0-b2ec-4ed9-a620-9e6812422658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_853cf027-1a81-44c8-a180-cba412e5f495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_008eafa0-b2ec-4ed9-a620-9e6812422658" xlink:to="loc_us-gaap_AwardTypeAxis_853cf027-1a81-44c8-a180-cba412e5f495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_551bbd7f-7d3f-41ff-8f57-4b356a7a982a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_853cf027-1a81-44c8-a180-cba412e5f495" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_551bbd7f-7d3f-41ff-8f57-4b356a7a982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bb7ec18e-6bd0-45ed-9e9f-ea6ae57437a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_551bbd7f-7d3f-41ff-8f57-4b356a7a982a" xlink:to="loc_us-gaap_RestrictedStockMember_bb7ec18e-6bd0-45ed-9e9f-ea6ae57437a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_008eafa0-b2ec-4ed9-a620-9e6812422658" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_848478a2-33a3-44de-8790-8c95c7d47870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_848478a2-33a3-44de-8790-8c95c7d47870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e7d61c1-4932-42a3-a55a-2ae614dabf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e7d61c1-4932-42a3-a55a-2ae614dabf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1f89eb2b-8b3e-4f7a-85cb-77976968ee47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1f89eb2b-8b3e-4f7a-85cb-77976968ee47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ea495ae5-34b3-4b09-8b72-b414b253386d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ea495ae5-34b3-4b09-8b72-b414b253386d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d40b9ec-5d67-4227-9c54-4163a13534f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98f6ea7c-66f2-45ca-a489-0780af1b2fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d40b9ec-5d67-4227-9c54-4163a13534f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e77b98bf-9f85-47af-83ae-f5a68f6bc7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e77b98bf-9f85-47af-83ae-f5a68f6bc7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_808bab66-75e2-4be9-b848-4cfd70908261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_808bab66-75e2-4be9-b848-4cfd70908261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_05cd7d1d-da9d-4e8d-b793-3c619a1f4662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_05cd7d1d-da9d-4e8d-b793-3c619a1f4662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8a17770-ca65-48d6-81a9-1d5a1b705889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8a17770-ca65-48d6-81a9-1d5a1b705889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a2da5d96-c2f9-4a9f-9256-72d3267cd09c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_95e5d37c-10a4-426e-9e89-92e54764db4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a2da5d96-c2f9-4a9f-9256-72d3267cd09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_aea33fcb-6eb1-451e-a837-ade774120499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_aea33fcb-6eb1-451e-a837-ade774120499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_4eb6aeb7-530f-430b-b6e7-0fc7e237ced1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acec41ad-9a97-41b4-9129-0ca3e87ce03d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_4eb6aeb7-530f-430b-b6e7-0fc7e237ced1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ed16660-e799-4171-a5ed-a588501c46d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0be94789-9141-441a-b62c-651af3b11562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ed16660-e799-4171-a5ed-a588501c46d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0be94789-9141-441a-b62c-651af3b11562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_099372f6-7f7c-4122-acc9-42ddeb18cecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0be94789-9141-441a-b62c-651af3b11562" xlink:to="loc_us-gaap_AwardTypeAxis_099372f6-7f7c-4122-acc9-42ddeb18cecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84aa8d31-1571-4ffa-b01c-aee36c4c9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_099372f6-7f7c-4122-acc9-42ddeb18cecd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84aa8d31-1571-4ffa-b01c-aee36c4c9d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_937ccf88-5297-42a1-8773-4037a847111d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84aa8d31-1571-4ffa-b01c-aee36c4c9d56" xlink:to="loc_us-gaap_PerformanceSharesMember_937ccf88-5297-42a1-8773-4037a847111d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0be94789-9141-441a-b62c-651af3b11562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_050a3c07-ed9a-4ca2-b123-26ae4da6c180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_050a3c07-ed9a-4ca2-b123-26ae4da6c180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8f55d450-19cc-4a83-b69c-185278bdff7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8f55d450-19cc-4a83-b69c-185278bdff7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_da83df51-22bc-4310-9f46-5c423454cd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_da83df51-22bc-4310-9f46-5c423454cd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_eded1d84-807a-45c6-a056-2893efdf0fd6" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_eded1d84-807a-45c6-a056-2893efdf0fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_62594e00-5b65-442c-bb8e-8916760a2e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_62594e00-5b65-442c-bb8e-8916760a2e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_601434e3-ab35-4e37-934a-c7c06ee2dca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b777f4d4-aef7-450b-bad8-8fc820088072" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_601434e3-ab35-4e37-934a-c7c06ee2dca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9136140e-31a4-4acc-88e3-8b22aad5dece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9136140e-31a4-4acc-88e3-8b22aad5dece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63f716b8-8907-4183-b945-45aa03d3666d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63f716b8-8907-4183-b945-45aa03d3666d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3b08fcf5-3a35-4296-891f-fd62e762589d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3b08fcf5-3a35-4296-891f-fd62e762589d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_ecba8bfc-0fa4-4b19-82b2-9e0d27da447f" xlink:href="mdt-20240426.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_ecba8bfc-0fa4-4b19-82b2-9e0d27da447f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b913c3c7-74bd-4622-bd2f-ffdae8759bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b913c3c7-74bd-4622-bd2f-ffdae8759bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a311016c-c7a8-482a-bf84-2a46b3935b61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d6e32447-0fb4-41c6-b65f-ac531d31284a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a311016c-c7a8-482a-bf84-2a46b3935b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7acf4feb-6b16-4763-920b-3629c6301412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7acf4feb-6b16-4763-920b-3629c6301412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b5a04acd-773e-4c03-897a-fdaf05ad62a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcab1e06-4bea-4eb5-990f-ebd0477896ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b5a04acd-773e-4c03-897a-fdaf05ad62a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_75b84c7e-bf6b-48b9-866d-5a4657b11583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_56942b77-c9c5-4dae-9272-9e14a50d93ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75b84c7e-bf6b-48b9-866d-5a4657b11583" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_56942b77-c9c5-4dae-9272-9e14a50d93ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9d2dd470-f10b-4dff-b325-b258ff0a3086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75b84c7e-bf6b-48b9-866d-5a4657b11583" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9d2dd470-f10b-4dff-b325-b258ff0a3086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9ea56f46-1808-49d3-8697-9a825e02b9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75b84c7e-bf6b-48b9-866d-5a4657b11583" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9ea56f46-1808-49d3-8697-9a825e02b9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_96a64d1c-1df1-4088-820e-569ad40c7a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_41b5ba7f-2817-4e25-94ee-73cb35707ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96a64d1c-1df1-4088-820e-569ad40c7a37" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_41b5ba7f-2817-4e25-94ee-73cb35707ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ec1b9ffa-1f01-4e22-9b28-cd875dced345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_41b5ba7f-2817-4e25-94ee-73cb35707ce5" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ec1b9ffa-1f01-4e22-9b28-cd875dced345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f7f2f7a4-b19c-476b-812e-b1f3aa68ae97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_41b5ba7f-2817-4e25-94ee-73cb35707ce5" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f7f2f7a4-b19c-476b-812e-b1f3aa68ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_741eaec9-5e76-4f2b-af5e-c45d41bea79c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_41b5ba7f-2817-4e25-94ee-73cb35707ce5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_741eaec9-5e76-4f2b-af5e-c45d41bea79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5966127-9f5c-49b3-8535-71647901414b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96a64d1c-1df1-4088-820e-569ad40c7a37" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5966127-9f5c-49b3-8535-71647901414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c0719868-1483-4eb8-a8b4-5792ec004b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5966127-9f5c-49b3-8535-71647901414b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c0719868-1483-4eb8-a8b4-5792ec004b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4942d771-7ec2-47a7-864f-8bbce95fdb83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5966127-9f5c-49b3-8535-71647901414b" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4942d771-7ec2-47a7-864f-8bbce95fdb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_615caaa7-d570-4e37-8859-0aad13597245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5966127-9f5c-49b3-8535-71647901414b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_615caaa7-d570-4e37-8859-0aad13597245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_58bbb3b2-a225-4679-8d86-2e58795ba2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96a64d1c-1df1-4088-820e-569ad40c7a37" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_58bbb3b2-a225-4679-8d86-2e58795ba2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dd3af538-3ce1-4e34-a030-6a3d7d046536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7af4c2ba-f781-4b60-9698-bb7c3139a118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd3af538-3ce1-4e34-a030-6a3d7d046536" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7af4c2ba-f781-4b60-9698-bb7c3139a118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7af4c2ba-f781-4b60-9698-bb7c3139a118" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_c03c4529-c684-45df-aaa5-1b029846b6bf" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_c03c4529-c684-45df-aaa5-1b029846b6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7393c113-1de2-4eb8-bf60-8253e901106f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7393c113-1de2-4eb8-bf60-8253e901106f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_0755b46b-b64d-40a8-9ff1-15a44e5e24ce" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_0755b46b-b64d-40a8-9ff1-15a44e5e24ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e579d364-4004-4b82-9798-195bac6fe83a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e579d364-4004-4b82-9798-195bac6fe83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_171ceea7-b69b-4079-8cfc-54c582bf8eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_171ceea7-b69b-4079-8cfc-54c582bf8eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions_fd9c9ac3-c1a6-43c6-a895-c933f1b4a595" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions_fd9c9ac3-c1a6-43c6-a895-c933f1b4a595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6885528d-ff3f-444e-868c-91e03ce544df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6885528d-ff3f-444e-868c-91e03ce544df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_2b073f51-4912-4ebe-96dc-cbaef6e187ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_2b073f51-4912-4ebe-96dc-cbaef6e187ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_f5b539d0-e6b7-4576-b6ee-6082c89154d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_f5b539d0-e6b7-4576-b6ee-6082c89154d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsLeaseObligations_1f7cb1e8-d850-40da-9a18-2890caef3d9d" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsLeaseObligations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_mdt_DeferredTaxAssetsLeaseObligations_1f7cb1e8-d850-40da-9a18-2890caef3d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_3eafee63-4f9a-4177-8841-608e03e9415a" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_3eafee63-4f9a-4177-8841-608e03e9415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsInterestLimitation_e30f117f-8bfc-4850-8583-be1d13def4d1" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsInterestLimitation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_mdt_DeferredTaxAssetsInterestLimitation_e30f117f-8bfc-4850-8583-be1d13def4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_ae616dc0-e461-49f3-a79d-a83bac6722d4" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_ae616dc0-e461-49f3-a79d-a83bac6722d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4bd5c335-7298-481a-80ee-5ebd2e095434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4bd5c335-7298-481a-80ee-5ebd2e095434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b5cb1de0-1e50-440d-817f-bf040f7708de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b5cb1de0-1e50-440d-817f-bf040f7708de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4faa4122-077b-4751-96ec-98aad211a467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4faa4122-077b-4751-96ec-98aad211a467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5d4b4ce8-c14f-40f3-95ed-a9470c60ec3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f7196303-3ed5-4048-9342-6f0a59d56e65" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5d4b4ce8-c14f-40f3-95ed-a9470c60ec3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7af4c2ba-f781-4b60-9698-bb7c3139a118" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ab71e8cf-ffe2-454d-8130-60b58a8bc027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ab71e8cf-ffe2-454d-8130-60b58a8bc027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_934b5183-7a00-49c6-bb03-4db0de99e028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_934b5183-7a00-49c6-bb03-4db0de99e028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f7ac7f3a-1fc4-4c8e-ba04-7456526ff272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f7ac7f3a-1fc4-4c8e-ba04-7456526ff272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7e2e221c-c821-4484-99b3-3f8e3b1748ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7e2e221c-c821-4484-99b3-3f8e3b1748ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_c5f44f18-2e08-449e-bdd8-ff206eb58a6f" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:to="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_c5f44f18-2e08-449e-bdd8-ff206eb58a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_ceb9f34d-ca70-47b9-b38c-9c0c7e726b69" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:to="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_ceb9f34d-ca70-47b9-b38c-9c0c7e726b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d8b048f5-b164-4543-8498-3cf34cb1fb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d8b048f5-b164-4543-8498-3cf34cb1fb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_4276a029-2214-4d27-874d-b703350eab97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8e4fbb9e-b79c-41c0-966b-18f37ef1d503" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_4276a029-2214-4d27-874d-b703350eab97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_283688a8-d8a2-452a-82ea-89f965e0299a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7af4c2ba-f781-4b60-9698-bb7c3139a118" xlink:to="loc_us-gaap_PrepaidTaxes_283688a8-d8a2-452a-82ea-89f965e0299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_8b3e1c65-7537-4bda-a107-fa0d9b51940f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7af4c2ba-f781-4b60-9698-bb7c3139a118" xlink:to="loc_us-gaap_IncomeTaxReceivable_8b3e1c65-7537-4bda-a107-fa0d9b51940f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_78d7f07c-a14d-41ff-bf90-f15c896ceedf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7af4c2ba-f781-4b60-9698-bb7c3139a118" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_78d7f07c-a14d-41ff-bf90-f15c896ceedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_9316056e-9e0f-40ec-a6c6-eefa7a36ce5a" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7af4c2ba-f781-4b60-9698-bb7c3139a118" xlink:to="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_9316056e-9e0f-40ec-a6c6-eefa7a36ce5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_2eb85bc3-0a05-4af6-bdf6-cf82f684a6bb" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsNetofValuationAllowanceOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_9316056e-9e0f-40ec-a6c6-eefa7a36ce5a" xlink:to="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_2eb85bc3-0a05-4af6-bdf6-cf82f684a6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8135147f-cfc4-43de-a337-88e171eebe88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_9316056e-9e0f-40ec-a6c6-eefa7a36ce5a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8135147f-cfc4-43de-a337-88e171eebe88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1b01f441-c05f-4af8-a968-ae3d6c38641d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_9316056e-9e0f-40ec-a6c6-eefa7a36ce5a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1b01f441-c05f-4af8-a968-ae3d6c38641d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_feb17ebd-d815-40be-b6ef-c53ea3c4075c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8a9a8419-14bb-4043-965c-e60999f1946d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_feb17ebd-d815-40be-b6ef-c53ea3c4075c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8a9a8419-14bb-4043-965c-e60999f1946d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4269cfba-1473-40f1-9539-815fd15d6f44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8a9a8419-14bb-4043-965c-e60999f1946d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4269cfba-1473-40f1-9539-815fd15d6f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4269cfba-1473-40f1-9539-815fd15d6f44" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_5e7b7ed5-2ab0-43f7-8c43-bc96be423b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:to="loc_us-gaap_ForeignCountryMember_5e7b7ed5-2ab0-43f7-8c43-bc96be423b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3b02520a-d916-49ae-a5e1-ef2208000d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:to="loc_us-gaap_DomesticCountryMember_3b02520a-d916-49ae-a5e1-ef2208000d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a088b84d-d0ee-465d-bf33-a77a1d341131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4c70a46-1f84-4f15-b176-fed56c5e3fe0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a088b84d-d0ee-465d-bf33-a77a1d341131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ce05553b-7556-4176-bd90-7e6788058224" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8a9a8419-14bb-4043-965c-e60999f1946d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ce05553b-7556-4176-bd90-7e6788058224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c1c47933-c652-44ae-b020-2541f76ae920" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ce05553b-7556-4176-bd90-7e6788058224" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c1c47933-c652-44ae-b020-2541f76ae920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_6d459580-c138-4ff5-bb1f-fcc8fa93c93a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c1c47933-c652-44ae-b020-2541f76ae920" xlink:to="loc_srt_SubsidiariesMember_6d459580-c138-4ff5-bb1f-fcc8fa93c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8a9a8419-14bb-4043-965c-e60999f1946d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_5c81a73c-c463-4ed2-84dc-20ceafdd13d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_5c81a73c-c463-4ed2-84dc-20ceafdd13d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9e8885da-1c1a-4154-af6b-9ff0d089541e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9e8885da-1c1a-4154-af6b-9ff0d089541e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_da7737f5-96dc-4c1b-9b01-45819429d171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_da7737f5-96dc-4c1b-9b01-45819429d171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_496df1d4-0208-4052-b41b-fb9985c3fc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_496df1d4-0208-4052-b41b-fb9985c3fc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_ceb4f0a1-9607-4305-bb5b-465e437746c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_ceb4f0a1-9607-4305-bb5b-465e437746c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a58e1d70-40ac-431c-a501-74188789f77a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a58e1d70-40ac-431c-a501-74188789f77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1ed2548c-0553-499e-937f-8dfa77fc8304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1ed2548c-0553-499e-937f-8dfa77fc8304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_b40a03fb-c482-49c2-9bf4-e1f6c56ebb0d" xlink:href="mdt-20240426.xsd#mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_b40a03fb-c482-49c2-9bf4-e1f6c56ebb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_af2d6093-8af7-4de6-9ad1-7dcabc52e8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_af2d6093-8af7-4de6-9ad1-7dcabc52e8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_7d2c4bcd-7ca7-4fa6-abbf-23736982a799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_7d2c4bcd-7ca7-4fa6-abbf-23736982a799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_c548bdee-dead-4eee-b218-a4ced5ec2074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_c548bdee-dead-4eee-b218-a4ced5ec2074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_8a84ff63-24c5-4329-9933-4cbd5fbbb2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_8a84ff63-24c5-4329-9933-4cbd5fbbb2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_59fa7395-9721-4aee-b32a-436d7fe3a1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_59fa7395-9721-4aee-b32a-436d7fe3a1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0d9ffe0e-0c9a-46a5-be05-12be3d1bef81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0d9ffe0e-0c9a-46a5-be05-12be3d1bef81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_f1615812-c2ad-4d98-910f-1512edc9abe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_f1615812-c2ad-4d98-910f-1512edc9abe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_03c25ebb-d06b-4cd5-9563-942164c98a26" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_03c25ebb-d06b-4cd5-9563-942164c98a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_a13b9aa6-439b-4ffc-a671-04450c301718" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_a13b9aa6-439b-4ffc-a671-04450c301718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_a6a9b9e1-bd47-437c-83fe-f5aff45395d9" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_a6a9b9e1-bd47-437c-83fe-f5aff45395d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_ed2ea977-a34c-4916-9ff7-9bc89b64b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_ed2ea977-a34c-4916-9ff7-9bc89b64b4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_73b832ab-9d0f-425b-8895-3df5fe287755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_73b832ab-9d0f-425b-8895-3df5fe287755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount_d4a99e54-cd75-4f89-ad86-24e16e1b444d" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount_d4a99e54-cd75-4f89-ad86-24e16e1b444d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxHolidays_5d6bdea4-e538-4562-8277-db2e00a00d63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxHolidays"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxHolidays_5d6bdea4-e538-4562-8277-db2e00a00d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_b93cf512-5d07-463d-86e4-9dfc725ee3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_b93cf512-5d07-463d-86e4-9dfc725ee3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2744342b-247a-4781-88b7-9ea83993883c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2744342b-247a-4781-88b7-9ea83993883c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_23eeb2b7-27a8-48f6-a1d6-d0b2ebdf71b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_23eeb2b7-27a8-48f6-a1d6-d0b2ebdf71b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_048c9c3e-8ec3-4aaf-80d8-4e6015ea2c75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_048c9c3e-8ec3-4aaf-80d8-4e6015ea2c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_251f1335-5ebe-466a-9b43-94821036e6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_251f1335-5ebe-466a-9b43-94821036e6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_0083f02b-b3ce-4a3e-8197-275a8e24d357" xlink:href="mdt-20240426.xsd#mdt_IncomeTaxExaminationInterestIncomeExpenseGross"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_0083f02b-b3ce-4a3e-8197-275a8e24d357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_46ab454b-cf6c-4a87-8d75-de2d2cf458ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_294c882a-2538-4ea2-bb22-a4a7dd619d87" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_46ab454b-cf6c-4a87-8d75-de2d2cf458ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bda2c58f-ff6b-4719-b993-2901f43aa3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f196480f-3323-4ffa-939b-743133046862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bda2c58f-ff6b-4719-b993-2901f43aa3c4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f196480f-3323-4ffa-939b-743133046862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:href="mdt-20240426.xsd#mdt_IncreaseDecreaseInTaxRateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bda2c58f-ff6b-4719-b993-2901f43aa3c4" xlink:to="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bb033d12-34b2-427e-bc74-5fe8497f257b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bb033d12-34b2-427e-bc74-5fe8497f257b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8904566e-4f7f-4cdf-871b-8cb64eb8b0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8904566e-4f7f-4cdf-871b-8cb64eb8b0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_3acb6a0d-f428-492e-ad28-2edffdbf2ca3" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_3acb6a0d-f428-492e-ad28-2edffdbf2ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6852d6d4-5f90-43c2-8a34-a7608f4cd090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6852d6d4-5f90-43c2-8a34-a7608f4cd090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_6abe87cf-d926-4f19-80b3-ecc48bdac9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_6abe87cf-d926-4f19-80b3-ecc48bdac9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_3d4df6fb-479c-482a-8ec4-204370b095d7" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_3d4df6fb-479c-482a-8ec4-204370b095d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_34245c8d-365d-452e-822d-c228b54326bf" xlink:href="mdt-20240426.xsd#mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_34245c8d-365d-452e-822d-c228b54326bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_0fae8400-cd8d-4875-8b6c-cfc4c2774ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_0fae8400-cd8d-4875-8b6c-cfc4c2774ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_d91471fb-d8f5-4d55-92a5-ba6bebb3d052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_d91471fb-d8f5-4d55-92a5-ba6bebb3d052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_5b1215b6-b485-4598-84af-65c84a0b6d88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_5b1215b6-b485-4598-84af-65c84a0b6d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9a07bad3-b908-468e-9b3e-38085381116c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_bde56ac0-2770-40f2-a045-7b0a7941ff3a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9a07bad3-b908-468e-9b3e-38085381116c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f73fa156-34ba-414e-b3aa-0277e51d6e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bda2c58f-ff6b-4719-b993-2901f43aa3c4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f73fa156-34ba-414e-b3aa-0277e51d6e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_38ae1e9d-6607-4dd7-9a47-3eb4a77d7c25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7bcd5fae-0a5c-4270-92ad-4e41cb19fe8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38ae1e9d-6607-4dd7-9a47-3eb4a77d7c25" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7bcd5fae-0a5c-4270-92ad-4e41cb19fe8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_36ca60fb-fc2d-4c40-af65-8f8eef4d4255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7bcd5fae-0a5c-4270-92ad-4e41cb19fe8d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_36ca60fb-fc2d-4c40-af65-8f8eef4d4255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_72f5e38b-39fe-4eab-a74d-739bf0c3f5bf" xlink:href="mdt-20240426.xsd#mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7bcd5fae-0a5c-4270-92ad-4e41cb19fe8d" xlink:to="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_72f5e38b-39fe-4eab-a74d-739bf0c3f5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b8f4413a-fa44-41fd-9fb2-6d20b97bfca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_72f5e38b-39fe-4eab-a74d-739bf0c3f5bf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b8f4413a-fa44-41fd-9fb2-6d20b97bfca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_97209c79-bcf7-4bde-9bcb-8773637f7aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_72f5e38b-39fe-4eab-a74d-739bf0c3f5bf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_97209c79-bcf7-4bde-9bcb-8773637f7aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_934bcf0f-e211-4202-a148-e46807d1f200" xlink:href="mdt-20240426.xsd#mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7bcd5fae-0a5c-4270-92ad-4e41cb19fe8d" xlink:to="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_934bcf0f-e211-4202-a148-e46807d1f200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a309fd1a-0d80-4577-875f-424111cb31ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_934bcf0f-e211-4202-a148-e46807d1f200" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a309fd1a-0d80-4577-875f-424111cb31ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_c78c2003-6f16-4a61-9802-04cce8f7f897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_934bcf0f-e211-4202-a148-e46807d1f200" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_c78c2003-6f16-4a61-9802-04cce8f7f897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_675988db-1823-4897-bea4-2710a42dda9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_934bcf0f-e211-4202-a148-e46807d1f200" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_675988db-1823-4897-bea4-2710a42dda9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a8cc5719-568b-424e-8758-ab2aa236a78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7bcd5fae-0a5c-4270-92ad-4e41cb19fe8d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a8cc5719-568b-424e-8758-ab2aa236a78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CashAdvancePaidinConnectionWithProposedSettlements_32a0b309-6dbf-49f0-8d0a-586d6a89a752" xlink:href="mdt-20240426.xsd#mdt_CashAdvancePaidinConnectionWithProposedSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7bcd5fae-0a5c-4270-92ad-4e41cb19fe8d" xlink:to="loc_mdt_CashAdvancePaidinConnectionWithProposedSettlements_32a0b309-6dbf-49f0-8d0a-586d6a89a752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_7453ff5c-6369-48ad-a1f0-30ca4b411195" xlink:href="mdt-20240426.xsd#mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7bcd5fae-0a5c-4270-92ad-4e41cb19fe8d" xlink:to="loc_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_7453ff5c-6369-48ad-a1f0-30ca4b411195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b2dd6dfb-31f9-4fe7-a5df-dfe5175dbcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_725e48e9-f94d-4afe-b5d6-9ff4b9cf224f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2dd6dfb-31f9-4fe7-a5df-dfe5175dbcc4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_725e48e9-f94d-4afe-b5d6-9ff4b9cf224f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_02a7129c-f89f-4e2c-a99e-fe557dd10b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_725e48e9-f94d-4afe-b5d6-9ff4b9cf224f" xlink:to="loc_us-gaap_AwardTypeAxis_02a7129c-f89f-4e2c-a99e-fe557dd10b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_02a7129c-f89f-4e2c-a99e-fe557dd10b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_961bf9bb-5f27-47d4-9bd4-30fe20f6e857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_961bf9bb-5f27-47d4-9bd4-30fe20f6e857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_423b8208-7c3a-47e0-b812-edb3c0949e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_423b8208-7c3a-47e0-b812-edb3c0949e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0ae51c7c-7fea-4570-824d-26e281fe3eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af57150c-94bf-435f-a119-4e3d10a0e9f7" xlink:to="loc_us-gaap_PerformanceSharesMember_0ae51c7c-7fea-4570-824d-26e281fe3eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_dc75c742-11a9-4fb7-98fb-d8d25fe2b706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_725e48e9-f94d-4afe-b5d6-9ff4b9cf224f" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_dc75c742-11a9-4fb7-98fb-d8d25fe2b706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_99d3d3cb-ecc5-42bf-ad41-3533499b4ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dc75c742-11a9-4fb7-98fb-d8d25fe2b706" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_99d3d3cb-ecc5-42bf-ad41-3533499b4ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d645ff4b-87fc-4e0b-b5a9-dd3a862dd4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_99d3d3cb-ecc5-42bf-ad41-3533499b4ced" xlink:to="loc_us-gaap_NetIncomeLoss_d645ff4b-87fc-4e0b-b5a9-dd3a862dd4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dc75c742-11a9-4fb7-98fb-d8d25fe2b706" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6485d2e-06a2-47fc-86f8-caa4374f5e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6485d2e-06a2-47fc-86f8-caa4374f5e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_d5de3362-7e9f-4ea9-b189-4c4d422c7476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_d5de3362-7e9f-4ea9-b189-4c4d422c7476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0071e845-d099-4e17-af74-9ed5f045f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_d5de3362-7e9f-4ea9-b189-4c4d422c7476" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0071e845-d099-4e17-af74-9ed5f045f50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_875a2de5-3767-4633-90ad-e801a579edd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_d5de3362-7e9f-4ea9-b189-4c4d422c7476" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_875a2de5-3767-4633-90ad-e801a579edd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4869bc30-3199-49f3-9d61-9d27006ad387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4869bc30-3199-49f3-9d61-9d27006ad387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_00b24ec3-f4bf-4307-8940-b21979b259dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_EarningsPerShareBasic_00b24ec3-f4bf-4307-8940-b21979b259dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b6932ba-bc54-482e-948e-ce82ed0403e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_530bda95-93de-4d94-9be6-b401db3f4030" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b6932ba-bc54-482e-948e-ce82ed0403e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4559fe0b-b89c-4308-9d43-306a1e9accf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc5ecaac-74ea-4e50-a6ed-32f300863dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4559fe0b-b89c-4308-9d43-306a1e9accf3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc5ecaac-74ea-4e50-a6ed-32f300863dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cc48959-e152-4436-9570-63981c36076d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc5ecaac-74ea-4e50-a6ed-32f300863dd7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cc48959-e152-4436-9570-63981c36076d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc7e0a26-7e65-4966-a3b4-9ca7b4474237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cc48959-e152-4436-9570-63981c36076d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc7e0a26-7e65-4966-a3b4-9ca7b4474237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0b46b7e5-e7e8-4818-86e4-05f6b7f35816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc7e0a26-7e65-4966-a3b4-9ca7b4474237" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0b46b7e5-e7e8-4818-86e4-05f6b7f35816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fcc02695-1eaa-4514-8a15-6be12cd63eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc5ecaac-74ea-4e50-a6ed-32f300863dd7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fcc02695-1eaa-4514-8a15-6be12cd63eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_533675f8-225a-4058-a19b-db3dd8e9622f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fcc02695-1eaa-4514-8a15-6be12cd63eac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_533675f8-225a-4058-a19b-db3dd8e9622f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansNarativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d5ffac0f-b542-4c77-8ba0-3cd2cdf93f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d5ffac0f-b542-4c77-8ba0-3cd2cdf93f49" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5fc8c8f6-ff86-40d8-a244-2ecd328f7353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5fc8c8f6-ff86-40d8-a244-2ecd328f7353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9cd907ea-f69b-4cf9-aaf9-92a25d390119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5fc8c8f6-ff86-40d8-a244-2ecd328f7353" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9cd907ea-f69b-4cf9-aaf9-92a25d390119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5591fffb-4d03-4029-a273-e05ec502b5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9cd907ea-f69b-4cf9-aaf9-92a25d390119" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5591fffb-4d03-4029-a273-e05ec502b5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9e04344e-c827-41bf-b984-e0d12b30f99e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9cd907ea-f69b-4cf9-aaf9-92a25d390119" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9e04344e-c827-41bf-b984-e0d12b30f99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5772477d-c551-45df-86ee-d0531def4f37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5772477d-c551-45df-86ee-d0531def4f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cdd68780-f392-465e-9736-ca4abab18768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5772477d-c551-45df-86ee-d0531def4f37" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cdd68780-f392-465e-9736-ca4abab18768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_ab2a25a6-14b7-41ee-9a0c-94527aa894d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cdd68780-f392-465e-9736-ca4abab18768" xlink:to="loc_us-gaap_DomesticPlanMember_ab2a25a6-14b7-41ee-9a0c-94527aa894d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_92b08c7a-9faf-4f6c-9e71-205cbbe739a6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_ab2a25a6-14b7-41ee-9a0c-94527aa894d4" xlink:to="loc_country_US_92b08c7a-9faf-4f6c-9e71-205cbbe739a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_0d58626f-636f-43dd-86e1-6cf19e1dac05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cdd68780-f392-465e-9736-ca4abab18768" xlink:to="loc_us-gaap_ForeignPlanMember_0d58626f-636f-43dd-86e1-6cf19e1dac05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_23caa0a9-a107-4d05-80df-732ffe7bff63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_23caa0a9-a107-4d05-80df-732ffe7bff63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_23caa0a9-a107-4d05-80df-732ffe7bff63" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_d731c839-b7bf-435b-b930-3a46932b69ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_d731c839-b7bf-435b-b930-3a46932b69ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_fb5121d8-cf68-4039-a788-357a6b5b1379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_fb5121d8-cf68-4039-a788-357a6b5b1379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember_591edf5f-c2b0-4b41-a366-2abd7b28dfee" xlink:href="mdt-20240426.xsd#mdt_OtherPlanAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_98f8443f-b451-45ac-bc64-e5246b74cc5c" xlink:to="loc_mdt_OtherPlanAssetsMember_591edf5f-c2b0-4b41-a366-2abd7b28dfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d62c1b41-f3b0-47fc-9374-bc400d41763d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_srt_RangeAxis_d62c1b41-f3b0-47fc-9374-bc400d41763d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c78bfa9b-9ab4-42b1-8ade-fc1f3aa07d3f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d62c1b41-f3b0-47fc-9374-bc400d41763d" xlink:to="loc_srt_RangeMember_c78bfa9b-9ab4-42b1-8ade-fc1f3aa07d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e13a1ee8-312d-4724-aedd-4a0b892fdb72" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c78bfa9b-9ab4-42b1-8ade-fc1f3aa07d3f" xlink:to="loc_srt_MinimumMember_e13a1ee8-312d-4724-aedd-4a0b892fdb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1220cb84-b74d-4605-86ed-745eccb0c964" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c78bfa9b-9ab4-42b1-8ade-fc1f3aa07d3f" xlink:to="loc_srt_MaximumMember_1220cb84-b74d-4605-86ed-745eccb0c964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e541d450-15b5-43be-a87f-f706b9c73aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e541d450-15b5-43be-a87f-f706b9c73aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80413244-87a6-4b2e-b7e1-21b4c4acb75c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e541d450-15b5-43be-a87f-f706b9c73aea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80413244-87a6-4b2e-b7e1-21b4c4acb75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3eee7679-cc01-4a35-85c6-0940ab761791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80413244-87a6-4b2e-b7e1-21b4c4acb75c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3eee7679-cc01-4a35-85c6-0940ab761791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b1aab8ff-27ce-485f-913f-37f258072f30" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_72a851ac-5cb8-41a1-aa88-b6a60c56a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_72a851ac-5cb8-41a1-aa88-b6a60c56a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_adf93486-882c-4d37-a5c4-f7186c1cc9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_adf93486-882c-4d37-a5c4-f7186c1cc9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_d35feeb6-1831-4433-8da0-4a1fa793b150" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_d35feeb6-1831-4433-8da0-4a1fa793b150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_0924570c-5662-41cb-81ac-b18ea9dc99ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_0924570c-5662-41cb-81ac-b18ea9dc99ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_84e1aa11-1f95-467f-b0a6-a495b6d96eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_84e1aa11-1f95-467f-b0a6-a495b6d96eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1d6b63de-a88d-421b-b05d-da485baa4647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1d6b63de-a88d-421b-b05d-da485baa4647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_2d18216c-14b3-488f-9b54-1c150b85afdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_2d18216c-14b3-488f-9b54-1c150b85afdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_434e989f-912a-4589-9952-ca910bbe9d15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_434e989f-912a-4589-9952-ca910bbe9d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7ad89b66-cbb2-4424-93cc-322a7494d210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7ad89b66-cbb2-4424-93cc-322a7494d210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6d4fa81c-8e8f-4189-a0bd-281c4b27c9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c3054ada-f8df-4181-88db-235d407f363c" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6d4fa81c-8e8f-4189-a0bd-281c4b27c9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d0e52d5d-a010-4be5-a144-6b6bd5be3623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d3eb5cd-b1d6-4146-8229-f70b8a628360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d0e52d5d-a010-4be5-a144-6b6bd5be3623" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d3eb5cd-b1d6-4146-8229-f70b8a628360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_cd0b82d0-d751-4d4f-b31b-bb62f891ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d3eb5cd-b1d6-4146-8229-f70b8a628360" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_cd0b82d0-d751-4d4f-b31b-bb62f891ef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_45797b40-b786-4c31-a5b0-0edc895502ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_cd0b82d0-d751-4d4f-b31b-bb62f891ef13" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_45797b40-b786-4c31-a5b0-0edc895502ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_3ba97d2c-dce5-4704-9bce-8363818abd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_45797b40-b786-4c31-a5b0-0edc895502ac" xlink:to="loc_us-gaap_DomesticPlanMember_3ba97d2c-dce5-4704-9bce-8363818abd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_efff59f3-2440-4370-8f09-8fbe2a53fbf2" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_3ba97d2c-dce5-4704-9bce-8363818abd6e" xlink:to="loc_country_US_efff59f3-2440-4370-8f09-8fbe2a53fbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_432ef2e8-9272-425e-857e-68e1d9acd35c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_45797b40-b786-4c31-a5b0-0edc895502ac" xlink:to="loc_us-gaap_ForeignPlanMember_432ef2e8-9272-425e-857e-68e1d9acd35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_575f08ab-2ba9-48a3-9ec5-f9d372431752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d3eb5cd-b1d6-4146-8229-f70b8a628360" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_575f08ab-2ba9-48a3-9ec5-f9d372431752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7c8ba108-cacf-45c1-8e41-e0164d652530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_575f08ab-2ba9-48a3-9ec5-f9d372431752" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7c8ba108-cacf-45c1-8e41-e0164d652530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c148418a-c380-4851-ade0-1f098b17ad7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7c8ba108-cacf-45c1-8e41-e0164d652530" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c148418a-c380-4851-ade0-1f098b17ad7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d3eb5cd-b1d6-4146-8229-f70b8a628360" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_75e193c2-78c7-4c3c-a014-e70e92f83cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_75e193c2-78c7-4c3c-a014-e70e92f83cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c1974df3-9ffe-438d-ae12-fcf558a211be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c1974df3-9ffe-438d-ae12-fcf558a211be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_f4312bc9-4c10-4d95-9ccb-88f795a32b18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_f4312bc9-4c10-4d95-9ccb-88f795a32b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_96906dd8-9932-4f0d-9f21-95bd4e39020c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_96906dd8-9932-4f0d-9f21-95bd4e39020c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_a3413f2d-c938-4ee4-8a76-af4f57803e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_a3413f2d-c938-4ee4-8a76-af4f57803e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_22b70c43-5353-4721-8b08-0e49f65e7fba" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_22b70c43-5353-4721-8b08-0e49f65e7fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_dad518d0-2e71-4e7e-95d2-ce40ec9eb7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_dad518d0-2e71-4e7e-95d2-ce40ec9eb7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_a083cf19-3e33-409f-a00e-22a18ef7ba73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_a083cf19-3e33-409f-a00e-22a18ef7ba73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_23b986db-173b-47cc-8b3c-1eda28283afd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_23b986db-173b-47cc-8b3c-1eda28283afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_677d3b2d-40bc-4a8b-bcdc-054c28f3f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_677d3b2d-40bc-4a8b-bcdc-054c28f3f99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_27d16d30-f128-4124-bd41-45b0f70fbd45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_72044495-3ec2-4b34-8cf8-3906bb613e06" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_27d16d30-f128-4124-bd41-45b0f70fbd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7b8552fd-d2d1-47d9-aea6-c3d250db8d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7b8552fd-d2d1-47d9-aea6-c3d250db8d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_fcc8a614-592b-4574-bb36-4f223713a88d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_fcc8a614-592b-4574-bb36-4f223713a88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_18ff8ce9-4db0-4573-ac42-0233264ae409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_18ff8ce9-4db0-4573-ac42-0233264ae409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_59ccca7f-7a92-4753-8ae1-d5b0c0b32397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_59ccca7f-7a92-4753-8ae1-d5b0c0b32397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_6c5cb2d1-4254-4183-8073-ca30a287f9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_6c5cb2d1-4254-4183-8073-ca30a287f9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_80145063-9c0b-4056-8dca-bfbc67b0fb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_80145063-9c0b-4056-8dca-bfbc67b0fb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_fd28e682-1fb9-48ba-948b-fc8909e899a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_fd28e682-1fb9-48ba-948b-fc8909e899a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_dd315bbc-a96d-4cd3-9bf8-7b36aeabec83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5097b0f3-dfd4-41d4-bafa-76ff2d9e5e79" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_dd315bbc-a96d-4cd3-9bf8-7b36aeabec83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_92d2ad5c-3704-4968-b3ff-eb190ef8bbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_92d2ad5c-3704-4968-b3ff-eb190ef8bbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_3034b77b-8347-4bad-8e53-5af0e55ce0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_3034b77b-8347-4bad-8e53-5af0e55ce0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_a956c265-f515-4c20-a9ea-057383768092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_a956c265-f515-4c20-a9ea-057383768092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_40dfc978-3f02-43a2-90d8-676e1faf7dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_5a2845e8-ecc5-46bf-8a84-96ccf67d8983" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_40dfc978-3f02-43a2-90d8-676e1faf7dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_b47b2aad-7b95-4061-a681-5b2fb5e9bce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_b47b2aad-7b95-4061-a681-5b2fb5e9bce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_13f2f211-827f-47fc-9b41-12ed0416ff02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_13f2f211-827f-47fc-9b41-12ed0416ff02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_69661414-99d1-4d5d-aed0-bdb06673d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_69661414-99d1-4d5d-aed0-bdb06673d33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a0c9b6a0-e099-408a-b5d8-366cd628131a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_92fe5bc6-6877-4aff-8ed6-89badd166063" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a0c9b6a0-e099-408a-b5d8-366cd628131a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_09c72076-5acd-4b4b-bbeb-8a2491dc3a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_09c72076-5acd-4b4b-bbeb-8a2491dc3a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_23ce0711-afc4-46e5-a549-b99d206dc8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_23ce0711-afc4-46e5-a549-b99d206dc8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_9a07669f-2911-4b30-baf2-beb85af6edcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_4dac3ffd-0c7e-4f49-8b71-4f6a6dbba16c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_9a07669f-2911-4b30-baf2-beb85af6edcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_fd7cfae9-7f0c-4773-868d-cfa8eb0ab5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_fd7cfae9-7f0c-4773-868d-cfa8eb0ab5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_c0bfbf67-77f9-47e9-822f-997f6f6af1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_c0bfbf67-77f9-47e9-822f-997f6f6af1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_efa03736-a25a-468c-9235-e050a0783499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_00f4596d-38a9-4a97-9a58-f07f1e4f81a7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_efa03736-a25a-468c-9235-e050a0783499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_f24a8749-1fb8-4399-869d-baa3c64e779f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0c88c62f-6ccb-417e-a165-c8073cffb5a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_f24a8749-1fb8-4399-869d-baa3c64e779f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_7d27c683-2a9f-4954-bfb2-3a5546eb83c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_f24a8749-1fb8-4399-869d-baa3c64e779f" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_7d27c683-2a9f-4954-bfb2-3a5546eb83c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_a4859f50-a52b-4ba1-b78d-01a50392757e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_f24a8749-1fb8-4399-869d-baa3c64e779f" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_a4859f50-a52b-4ba1-b78d-01a50392757e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansNetPeriodicCostandAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8158a45-271d-48b4-9443-33b5354a949a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7de28421-9787-4fe0-a024-8f3a4e70eedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d8158a45-271d-48b4-9443-33b5354a949a" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7de28421-9787-4fe0-a024-8f3a4e70eedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_238e1461-93b8-4a7d-a718-a960e81ea9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7de28421-9787-4fe0-a024-8f3a4e70eedd" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_238e1461-93b8-4a7d-a718-a960e81ea9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3e076ed7-f3a5-4cda-870c-e15386d946bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_238e1461-93b8-4a7d-a718-a960e81ea9d8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3e076ed7-f3a5-4cda-870c-e15386d946bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f237827f-21d0-4763-8110-a1a08ed80d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3e076ed7-f3a5-4cda-870c-e15386d946bc" xlink:to="loc_us-gaap_DomesticPlanMember_f237827f-21d0-4763-8110-a1a08ed80d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_43ca2c17-b6f4-4d72-a677-8ef20012e68a" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_f237827f-21d0-4763-8110-a1a08ed80d03" xlink:to="loc_country_US_43ca2c17-b6f4-4d72-a677-8ef20012e68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_86e1510b-fa78-4384-9a2c-98dd2252ed79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3e076ed7-f3a5-4cda-870c-e15386d946bc" xlink:to="loc_us-gaap_ForeignPlanMember_86e1510b-fa78-4384-9a2c-98dd2252ed79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_23c15bd5-61fa-47ce-985b-985e03d60c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7de28421-9787-4fe0-a024-8f3a4e70eedd" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_23c15bd5-61fa-47ce-985b-985e03d60c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_383d31e2-9ecc-48e5-b1c1-a8e74fc814fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_23c15bd5-61fa-47ce-985b-985e03d60c3c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_383d31e2-9ecc-48e5-b1c1-a8e74fc814fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1dae0495-3c26-42b1-aee3-2b3eeabc8c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_383d31e2-9ecc-48e5-b1c1-a8e74fc814fd" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1dae0495-3c26-42b1-aee3-2b3eeabc8c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac727959-9731-45f2-a90c-62d6cea76df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7de28421-9787-4fe0-a024-8f3a4e70eedd" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac727959-9731-45f2-a90c-62d6cea76df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac727959-9731-45f2-a90c-62d6cea76df6" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_244600e8-09ce-4064-b145-184ac3615c59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_244600e8-09ce-4064-b145-184ac3615c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_f0742131-ace1-40cc-b15d-f6e027f4a593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_f0742131-ace1-40cc-b15d-f6e027f4a593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_0e021864-829d-4d75-ab8a-6201780d7063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_0e021864-829d-4d75-ab8a-6201780d7063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9de98442-a2f6-4d94-b479-bcbf164163a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9de98442-a2f6-4d94-b479-bcbf164163a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2937cea1-07a3-42ca-b855-1994bf43a8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2937cea1-07a3-42ca-b855-1994bf43a8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_f94e20a9-ff4b-4b08-9e42-109dd7423e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_f94e20a9-ff4b-4b08-9e42-109dd7423e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_1a46c6da-37f1-4e6f-a9d0-464af73c6f33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_1a46c6da-37f1-4e6f-a9d0-464af73c6f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44a4fd15-ef82-4901-a258-2c61c497c5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1fa2378e-196e-4a25-abfb-0167b91d5196" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44a4fd15-ef82-4901-a258-2c61c497c5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac727959-9731-45f2-a90c-62d6cea76df6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_8d79923c-5a7a-45e7-af0a-beed80094d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_8d79923c-5a7a-45e7-af0a-beed80094d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_36383b70-e151-432c-a71c-b25dd65ed3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_36383b70-e151-432c-a71c-b25dd65ed3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8ce916c7-02f6-4730-a6e7-3ca44cb4d0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8ce916c7-02f6-4730-a6e7-3ca44cb4d0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_456249ca-8856-4a3f-85ae-abf24519dce2" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_456249ca-8856-4a3f-85ae-abf24519dce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_03b07ee3-dbb4-4b93-87a2-4d6c16ee9cba" xlink:href="mdt-20240426.xsd#mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_03b07ee3-dbb4-4b93-87a2-4d6c16ee9cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_8442b76d-7bc0-4642-82a3-8e65ab860657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_8442b76d-7bc0-4642-82a3-8e65ab860657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_8b8f1173-e215-4b24-a00a-24cc95f8c211" xlink:href="mdt-20240426.xsd#mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_0888c944-78e5-4e90-a7e1-abb33c50d62d" xlink:to="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_8b8f1173-e215-4b24-a00a-24cc95f8c211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ece0739e-6a29-4048-a4ae-ce7f42d1fe34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ece0739e-6a29-4048-a4ae-ce7f42d1fe34" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_854c7c9d-3337-4e04-8221-0f7f31af8ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_854c7c9d-3337-4e04-8221-0f7f31af8ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_84f18cf9-44a6-4017-b2b8-746218cf7809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_854c7c9d-3337-4e04-8221-0f7f31af8ee1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_84f18cf9-44a6-4017-b2b8-746218cf7809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_eb214279-d60d-491b-a5b8-9a8e3a8825cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_84f18cf9-44a6-4017-b2b8-746218cf7809" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_eb214279-d60d-491b-a5b8-9a8e3a8825cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb80256-64ee-4223-aa7e-d9ccdfe225bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb80256-64ee-4223-aa7e-d9ccdfe225bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_371d02d9-6456-4da7-b9e3-6253f68c96c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb80256-64ee-4223-aa7e-d9ccdfe225bb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_371d02d9-6456-4da7-b9e3-6253f68c96c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_8fdad39c-e71b-4dd4-b639-93c4cd88083c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_371d02d9-6456-4da7-b9e3-6253f68c96c6" xlink:to="loc_us-gaap_DomesticPlanMember_8fdad39c-e71b-4dd4-b639-93c4cd88083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_8bc77574-e537-423a-a17e-8a1ed14a083f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_8fdad39c-e71b-4dd4-b639-93c4cd88083c" xlink:to="loc_country_US_8bc77574-e537-423a-a17e-8a1ed14a083f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_26fa1c01-7c58-4697-9e62-c4f3f91c5634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_371d02d9-6456-4da7-b9e3-6253f68c96c6" xlink:to="loc_us-gaap_ForeignPlanMember_26fa1c01-7c58-4697-9e62-c4f3f91c5634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a5684a4-2706-4458-9f6b-6b5f27636714" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:to="loc_srt_RangeAxis_0a5684a4-2706-4458-9f6b-6b5f27636714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d8c200c-83aa-405e-9f2a-cb2045248dc3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0a5684a4-2706-4458-9f6b-6b5f27636714" xlink:to="loc_srt_RangeMember_0d8c200c-83aa-405e-9f2a-cb2045248dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0d22e148-8c6a-4af9-95f1-61584dc73c36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d8c200c-83aa-405e-9f2a-cb2045248dc3" xlink:to="loc_srt_MinimumMember_0d22e148-8c6a-4af9-95f1-61584dc73c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2759e471-7361-4a8f-b0ac-d5b1b58eded8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d8c200c-83aa-405e-9f2a-cb2045248dc3" xlink:to="loc_srt_MaximumMember_2759e471-7361-4a8f-b0ac-d5b1b58eded8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6c4171ff-a6c0-4560-9c60-67076570406c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6c4171ff-a6c0-4560-9c60-67076570406c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6c4171ff-a6c0-4560-9c60-67076570406c" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_e34221b5-ed04-4f72-bdce-9583456fed39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_e34221b5-ed04-4f72-bdce-9583456fed39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_7102d53a-33b5-460a-8c4c-3aca6a4ffb87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_7102d53a-33b5-460a-8c4c-3aca6a4ffb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember_429123fc-8522-4289-b5b9-f2d832ad6f68" xlink:href="mdt-20240426.xsd#mdt_OtherPlanAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a818da31-ef0a-4f64-9319-8354fe3f2d04" xlink:to="loc_mdt_OtherPlanAssetsMember_429123fc-8522-4289-b5b9-f2d832ad6f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ec3777d0-2f91-4b7f-8d8f-0179bdba5d5f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ea3274da-023c-4511-9f2d-15c80d027009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ea3274da-023c-4511-9f2d-15c80d027009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3e0b5a90-810c-4819-b863-6ec6167f04f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ea3274da-023c-4511-9f2d-15c80d027009" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3e0b5a90-810c-4819-b863-6ec6167f04f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_52dd77c4-e316-4e4a-9fc4-43254b85da94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ea3274da-023c-4511-9f2d-15c80d027009" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_52dd77c4-e316-4e4a-9fc4-43254b85da94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_703a05d0-a0e9-4249-a5e3-f4f0d2fb656c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_703a05d0-a0e9-4249-a5e3-f4f0d2fb656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_a0ab533c-ff13-4841-8b6d-72e7b7219eb4" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_a0ab533c-ff13-4841-8b6d-72e7b7219eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_e8775f4d-db7c-4c28-b1da-e9a64661296c" xlink:href="mdt-20240426.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_e8775f4d-db7c-4c28-b1da-e9a64661296c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_bdf3d32a-4831-4e3e-83df-7882e719a453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_bdf3d32a-4831-4e3e-83df-7882e719a453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_d5d8b383-9b39-4f2a-bd1d-0006ac45923e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2178e47e-ef0c-495f-ad2d-33a24f90be2d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_d5d8b383-9b39-4f2a-bd1d-0006ac45923e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_fd24c63f-c8ee-45e9-8c07-fe66a76f973e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2c6985a7-095a-45ca-bb42-5212ca38a45b" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_fd24c63f-c8ee-45e9-8c07-fe66a76f973e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_c8a45680-9976-4b9b-b244-7d60b54dfc61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_fd24c63f-c8ee-45e9-8c07-fe66a76f973e" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_c8a45680-9976-4b9b-b244-7d60b54dfc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_16ac26b9-0bce-4566-9438-b0bff8e0306e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_fd24c63f-c8ee-45e9-8c07-fe66a76f973e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_16ac26b9-0bce-4566-9438-b0bff8e0306e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_849a3ef3-f019-406e-b031-4a7475f4a554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_849a3ef3-f019-406e-b031-4a7475f4a554" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cd3f080d-191f-4f6a-9eeb-36c33ef81730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cd3f080d-191f-4f6a-9eeb-36c33ef81730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2055f775-dce8-4bae-8379-551aeb5cdd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cd3f080d-191f-4f6a-9eeb-36c33ef81730" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2055f775-dce8-4bae-8379-551aeb5cdd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_aa7379f8-8c60-4cf4-9f08-de2d5e965fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2055f775-dce8-4bae-8379-551aeb5cdd76" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_aa7379f8-8c60-4cf4-9f08-de2d5e965fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_1555b3f8-d265-424d-93c0-9c589458571a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_1555b3f8-d265-424d-93c0-9c589458571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3ca436b0-78aa-4c44-9e10-e69d096a596e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1555b3f8-d265-424d-93c0-9c589458571a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3ca436b0-78aa-4c44-9e10-e69d096a596e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_4ef091a6-3986-4639-8767-28dcfe96b4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3ca436b0-78aa-4c44-9e10-e69d096a596e" xlink:to="loc_us-gaap_DomesticPlanMember_4ef091a6-3986-4639-8767-28dcfe96b4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d96309e3-fc83-4e1e-b2c1-7cad9d7eacc0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_4ef091a6-3986-4639-8767-28dcfe96b4e4" xlink:to="loc_country_US_d96309e3-fc83-4e1e-b2c1-7cad9d7eacc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d50bf2dd-8857-4337-bf8d-601f54b3c440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3ca436b0-78aa-4c44-9e10-e69d096a596e" xlink:to="loc_us-gaap_ForeignPlanMember_d50bf2dd-8857-4337-bf8d-601f54b3c440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b2afdcc8-0476-4adb-9119-a0b9d468bd75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b2afdcc8-0476-4adb-9119-a0b9d468bd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b2afdcc8-0476-4adb-9119-a0b9d468bd75" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_996d4874-47d3-4a4b-8fd2-68a58a918371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_996d4874-47d3-4a4b-8fd2-68a58a918371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_cbb9bfdb-ae5f-4e64-b0ad-0af6e472daa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_us-gaap_MutualFundMember_cbb9bfdb-ae5f-4e64-b0ad-0af6e472daa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_1a05ebd4-ae3e-4cf6-b25e-0b4ba4fadf20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_us-gaap_EquityFundsMember_1a05ebd4-ae3e-4cf6-b25e-0b4ba4fadf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_5cfc5ed9-af15-447c-baa4-e0af5e027dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_us-gaap_FixedIncomeFundsMember_5cfc5ed9-af15-447c-baa4-e0af5e027dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember_b1d04b12-774f-4699-9293-c984a059be2e" xlink:href="mdt-20240426.xsd#mdt_PartnershipUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_mdt_PartnershipUnitsMember_b1d04b12-774f-4699-9293-c984a059be2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RegisteredInvestmentCompanyMember_17fca39c-7696-4fc7-9295-bdb04903e74c" xlink:href="mdt-20240426.xsd#mdt_RegisteredInvestmentCompanyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_mdt_RegisteredInvestmentCompanyMember_17fca39c-7696-4fc7-9295-bdb04903e74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_InsuranceContractMember_e6013d06-4934-483e-8ecb-c927d9150c53" xlink:href="mdt-20240426.xsd#mdt_InsuranceContractMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e47f0db5-f9bf-4f90-91b1-1f53c83e81c4" xlink:to="loc_mdt_InsuranceContractMember_e6013d06-4934-483e-8ecb-c927d9150c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_387a185a-a9e9-4433-a3d4-a59e9058adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_387a185a-a9e9-4433-a3d4-a59e9058adb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_387a185a-a9e9-4433-a3d4-a59e9058adb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8d2d4336-76a1-4aee-b379-5c9a0a070f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8d2d4336-76a1-4aee-b379-5c9a0a070f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e2a58461-ced7-4241-9573-d036f2e6e6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e2a58461-ced7-4241-9573-d036f2e6e6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4a0f31fa-f822-4531-92b2-538427d139c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4a0f31fa-f822-4531-92b2-538427d139c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_06a34d59-ff60-477e-ad55-3e4b56598890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f711fe07-efee-42cf-aedd-99509ff223cc" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_06a34d59-ff60-477e-ad55-3e4b56598890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0e0957c3-cca8-413a-86b2-307f5243e213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0e0957c3-cca8-413a-86b2-307f5243e213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81a6aab9-a3ea-4bf2-b7db-97accfa07824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0e0957c3-cca8-413a-86b2-307f5243e213" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81a6aab9-a3ea-4bf2-b7db-97accfa07824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember_213ff565-f58b-42ec-b4fd-08550d361dd7" xlink:href="mdt-20240426.xsd#mdt_PartnershipUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81a6aab9-a3ea-4bf2-b7db-97accfa07824" xlink:to="loc_mdt_PartnershipUnitsMember_213ff565-f58b-42ec-b4fd-08550d361dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a8b8eaf4-0333-41b2-a49c-b2af87479791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_596a0239-0a2d-4919-a5bb-f3be45a582f8" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a8b8eaf4-0333-41b2-a49c-b2af87479791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cf0745e7-b1ca-43c6-b6d3-0606b3a1b3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a8b8eaf4-0333-41b2-a49c-b2af87479791" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cf0745e7-b1ca-43c6-b6d3-0606b3a1b3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a8b8eaf4-0333-41b2-a49c-b2af87479791" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_784205de-b7ef-476f-90a9-759ea0525fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_784205de-b7ef-476f-90a9-759ea0525fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_f3cc774e-8d5a-4edb-babf-0c9a1f2b3e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_f3cc774e-8d5a-4edb-babf-0c9a1f2b3e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_f836ad99-0a2c-4597-9eb6-6d4809b7ae47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_f836ad99-0a2c-4597-9eb6-6d4809b7ae47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_b8b9805e-a44f-478b-be7c-4266aa9f56f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_b8b9805e-a44f-478b-be7c-4266aa9f56f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_e5132c7a-2216-4e0b-8e26-3a05d9f4e6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73d4cad1-e11f-4b22-bef5-47bd1fea7187" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_e5132c7a-2216-4e0b-8e26-3a05d9f4e6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#RetirementBenefitPlansFutureBenefitPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7c756b24-4820-4c76-a61a-29399ac6fb13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a597b48-2fac-45fb-8caa-a0dd392ab68c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7c756b24-4820-4c76-a61a-29399ac6fb13" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a597b48-2fac-45fb-8caa-a0dd392ab68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2440fab7-f208-47cd-8cda-d8769b7dc109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a597b48-2fac-45fb-8caa-a0dd392ab68c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2440fab7-f208-47cd-8cda-d8769b7dc109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_722d0bc0-6c27-48c8-8a95-1f7f2466e161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2440fab7-f208-47cd-8cda-d8769b7dc109" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_722d0bc0-6c27-48c8-8a95-1f7f2466e161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f3eb64a5-99b2-4196-bded-0299caeeff87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_722d0bc0-6c27-48c8-8a95-1f7f2466e161" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f3eb64a5-99b2-4196-bded-0299caeeff87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_579303ab-2767-4654-a43c-a07e819578b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a597b48-2fac-45fb-8caa-a0dd392ab68c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_579303ab-2767-4654-a43c-a07e819578b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ee17ec2b-5377-4889-8071-ee86db79b8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_579303ab-2767-4654-a43c-a07e819578b0" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ee17ec2b-5377-4889-8071-ee86db79b8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e90b7c37-85fc-4b68-ad07-ad47b45bfb40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ee17ec2b-5377-4889-8071-ee86db79b8d4" xlink:to="loc_us-gaap_DomesticPlanMember_e90b7c37-85fc-4b68-ad07-ad47b45bfb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1149fe5a-44f0-45e9-a5c3-21287f0f0f04" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_e90b7c37-85fc-4b68-ad07-ad47b45bfb40" xlink:to="loc_country_US_1149fe5a-44f0-45e9-a5c3-21287f0f0f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ec95ac24-4822-42a7-80a8-96d3817249c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ee17ec2b-5377-4889-8071-ee86db79b8d4" xlink:to="loc_us-gaap_ForeignPlanMember_ec95ac24-4822-42a7-80a8-96d3817249c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_01b51995-6128-4a8c-b75d-354452191f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a597b48-2fac-45fb-8caa-a0dd392ab68c" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_01b51995-6128-4a8c-b75d-354452191f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_01b51995-6128-4a8c-b75d-354452191f6c" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_540d8777-c26e-4d18-b0b6-d6605eb86bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_540d8777-c26e-4d18-b0b6-d6605eb86bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_dbf242d0-21a6-4daa-8abe-43a4b0718951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_dbf242d0-21a6-4daa-8abe-43a4b0718951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_fac1b8ba-36a3-40b2-99ee-da68a7b8acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_fac1b8ba-36a3-40b2-99ee-da68a7b8acb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_bf575b67-9940-441a-98f3-3db39d9b5cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_bf575b67-9940-441a-98f3-3db39d9b5cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_8b6b7055-bdf4-4af9-9b81-d23420b6fd35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_8b6b7055-bdf4-4af9-9b81-d23420b6fd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_50b5465c-f404-4cc0-9a15-0fe84c991607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b1eee9eb-d93d-447b-91f8-79d91cd28dee" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_50b5465c-f404-4cc0-9a15-0fe84c991607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b6bb5ab3-aca5-4edc-b383-47b402e9e546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b3bc2e0d-1c80-4ddc-ac70-ffa87863f3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bb5ab3-aca5-4edc-b383-47b402e9e546" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b3bc2e0d-1c80-4ddc-ac70-ffa87863f3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e93f83d7-6a11-4138-9dc7-652b3070cbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bb5ab3-aca5-4edc-b383-47b402e9e546" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e93f83d7-6a11-4138-9dc7-652b3070cbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_72f86e92-6383-41a6-a99b-baef888f83df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bb5ab3-aca5-4edc-b383-47b402e9e546" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_72f86e92-6383-41a6-a99b-baef888f83df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_63fec42e-ddc7-48e4-a32f-a84aba739344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bb5ab3-aca5-4edc-b383-47b402e9e546" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_63fec42e-ddc7-48e4-a32f-a84aba739344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2a89e9af-2e42-4618-b6fd-1ceae0955b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bb5ab3-aca5-4edc-b383-47b402e9e546" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2a89e9af-2e42-4618-b6fd-1ceae0955b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_94e51a0c-cd08-4f94-b751-e6a198aaf3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bb5ab3-aca5-4edc-b383-47b402e9e546" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_94e51a0c-cd08-4f94-b751-e6a198aaf3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6d6e958d-ae49-4b71-9d05-f09b4f7d5d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_689f5cbf-0460-4974-87eb-6609577caa76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6d6e958d-ae49-4b71-9d05-f09b4f7d5d5f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_689f5cbf-0460-4974-87eb-6609577caa76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1afd875c-6134-4050-a44d-1272fb66c55e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6d6e958d-ae49-4b71-9d05-f09b4f7d5d5f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1afd875c-6134-4050-a44d-1272fb66c55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#LeasesComponentsofTotalOperatingLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_993c036e-1f0b-482a-b3f0-3abca98c2847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c99b7245-6615-4053-9b57-67c873f9fc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_993c036e-1f0b-482a-b3f0-3abca98c2847" xlink:to="loc_us-gaap_OperatingLeaseCost_c99b7245-6615-4053-9b57-67c873f9fc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_4ee43bb5-de96-441e-a8d8-87514a430cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_993c036e-1f0b-482a-b3f0-3abca98c2847" xlink:to="loc_us-gaap_ShortTermLeaseCost_4ee43bb5-de96-441e-a8d8-87514a430cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_be7a9bf3-25d5-40ca-b001-fb9b66bf9062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_993c036e-1f0b-482a-b3f0-3abca98c2847" xlink:to="loc_us-gaap_LeaseCost_be7a9bf3-25d5-40ca-b001-fb9b66bf9062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3c6d926e-b240-453d-9715-4724680b33c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5c82aa7d-eb82-4b6a-9d16-417af3ee4e55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c6d926e-b240-453d-9715-4724680b33c8" xlink:to="loc_us-gaap_OperatingLeasePayments_5c82aa7d-eb82-4b6a-9d16-417af3ee4e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_09a0e796-0421-4a31-8e0b-89f88373e0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c6d926e-b240-453d-9715-4724680b33c8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_09a0e796-0421-4a31-8e0b-89f88373e0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#LeasesMaturitiesofOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ea955cf2-c6e5-40ca-9a12-8d05e354f6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ea955cf2-c6e5-40ca-9a12-8d05e354f6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_eaf3074b-2201-49d5-9b47-eb33ee8f4200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_eaf3074b-2201-49d5-9b47-eb33ee8f4200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b7a98734-a034-4839-b61c-76b501bfefcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b7a98734-a034-4839-b61c-76b501bfefcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16bf2ebc-0dbd-4d99-a657-7a2038e20b80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16bf2ebc-0dbd-4d99-a657-7a2038e20b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8905309f-2763-469a-9971-18e5879b7ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8905309f-2763-469a-9971-18e5879b7ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5c7ba036-9e64-40bc-8f92-c10fc499b74a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5c7ba036-9e64-40bc-8f92-c10fc499b74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2438fef7-b690-432a-b756-883b8b01900f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2438fef7-b690-432a-b756-883b8b01900f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ac058a21-24b1-4f7b-85ec-b02a1b36536a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ac058a21-24b1-4f7b-85ec-b02a1b36536a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dbf5802e-66a0-4383-a466-15218e57655f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2516e8fa-82a5-4902-b314-84c6b628accb" xlink:to="loc_us-gaap_OperatingLeaseLiability_dbf5802e-66a0-4383-a466-15218e57655f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bc5cf088-d19e-4141-a1a6-18b9a93223ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c51619f8-d2d4-4e7c-851d-db0bc49360f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bc5cf088-d19e-4141-a1a6-18b9a93223ae" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c51619f8-d2d4-4e7c-851d-db0bc49360f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9c286be8-a3a4-4dae-a6e7-f7d60eca3016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c51619f8-d2d4-4e7c-851d-db0bc49360f9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9c286be8-a3a4-4dae-a6e7-f7d60eca3016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b66dad6-f67e-4dea-8ef5-8181db9490db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c286be8-a3a4-4dae-a6e7-f7d60eca3016" xlink:to="loc_us-gaap_EquityComponentDomain_6b66dad6-f67e-4dea-8ef5-8181db9490db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b66dad6-f67e-4dea-8ef5-8181db9490db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cc8ce864-64f4-4ca3-9c59-afd03b3842fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cc8ce864-64f4-4ca3-9c59-afd03b3842fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_45ff56bf-10d3-474e-a716-7c434c2848fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_45ff56bf-10d3-474e-a716-7c434c2848fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_b3a360bf-a37f-4e8c-a193-1d84d1c3f652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_b3a360bf-a37f-4e8c-a193-1d84d1c3f652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_63b5ae6e-510a-4b49-9df0-6118fb71be73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_63b5ae6e-510a-4b49-9df0-6118fb71be73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_08c4838a-f859-422c-90ca-3c73157bcded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9df635d8-c781-4492-9c2c-7c7ce328c2be" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_08c4838a-f859-422c-90ca-3c73157bcded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c51619f8-d2d4-4e7c-851d-db0bc49360f9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e7dcb6c-59a2-4b10-ae8f-f0e54f9dc380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e7dcb6c-59a2-4b10-ae8f-f0e54f9dc380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6f0fccb8-89d1-45e1-b786-e8463ff25b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6f0fccb8-89d1-45e1-b786-e8463ff25b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5e33e328-f42f-48e7-b35c-a358be4c6171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5e33e328-f42f-48e7-b35c-a358be4c6171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_09c529fb-e6d7-4dce-ae62-15bb4fd70ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_09c529fb-e6d7-4dce-ae62-15bb4fd70ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a0311e0-1463-4a62-b957-990681d80f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_de5b212f-5071-48df-93bc-640538fccded" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a0311e0-1463-4a62-b957-990681d80f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_037c5d55-556f-4f6f-afc1-a4b1c03964e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_037c5d55-556f-4f6f-afc1-a4b1c03964e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_2ea16ecb-d7ff-4d2e-a2c4-dab89ddd08ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b445c095-c37f-4d71-b9ce-9149f10f41c0" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_2ea16ecb-d7ff-4d2e-a2c4-dab89ddd08ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_49f9d90d-0ba0-49e5-8f40-a19a29a09b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_49f9d90d-0ba0-49e5-8f40-a19a29a09b7c" xlink:to="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_775fa926-07b5-4b82-b7bc-6704d9886c5d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:to="loc_srt_LitigationCaseAxis_775fa926-07b5-4b82-b7bc-6704d9886c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_775fa926-07b5-4b82-b7bc-6704d9886c5d" xlink:to="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_HerniaMeshLitigationMember_425d66aa-0d1c-4603-8c1d-166dd4faaf12" xlink:href="mdt-20240426.xsd#mdt_HerniaMeshLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:to="loc_mdt_HerniaMeshLitigationMember_425d66aa-0d1c-4603-8c1d-166dd4faaf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ColibriMember_a86aaf5e-9fec-448a-8666-240b839589a2" xlink:href="mdt-20240426.xsd#mdt_ColibriMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:to="loc_mdt_ColibriMember_a86aaf5e-9fec-448a-8666-240b839589a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesPumpRetainerRingLitigationMember_94507204-2ef8-4777-a3c8-cfe2a576c701" xlink:href="mdt-20240426.xsd#mdt_DiabetesPumpRetainerRingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_49c22a9b-9ff1-44b7-90f2-5e42b09abff6" xlink:to="loc_mdt_DiabetesPumpRetainerRingLitigationMember_94507204-2ef8-4777-a3c8-cfe2a576c701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_51203797-b8e6-4f15-9eb9-ea0253e4f82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:to="loc_us-gaap_LitigationStatusAxis_51203797-b8e6-4f15-9eb9-ea0253e4f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_25311fc7-ea95-4c64-b0c0-5df4a164ced1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_51203797-b8e6-4f15-9eb9-ea0253e4f82d" xlink:to="loc_us-gaap_LitigationStatusDomain_25311fc7-ea95-4c64-b0c0-5df4a164ced1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_cd318884-fb0b-475c-8413-ee47975bb2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_25311fc7-ea95-4c64-b0c0-5df4a164ced1" xlink:to="loc_us-gaap_PendingLitigationMember_cd318884-fb0b-475c-8413-ee47975bb2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a2a2a21b-fd6b-45e3-bc3a-512bd219919b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:to="loc_srt_StatementGeographicalAxis_a2a2a21b-fd6b-45e3-bc3a-512bd219919b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a2a2a21b-fd6b-45e3-bc3a-512bd219919b" xlink:to="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_0b330aaf-3492-48e6-8514-f00619a51a07" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:to="loc_stpr_MA_0b330aaf-3492-48e6-8514-f00619a51a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN_96601eb4-c17e-46a2-a018-919808643144" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:to="loc_stpr_MN_96601eb4-c17e-46a2-a018-919808643144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_65da1990-2806-42c0-b6c7-bb4ec2de389e" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4963d4e7-8ec3-4566-9fc7-fb2d8168ca95" xlink:to="loc_stpr_CA_65da1990-2806-42c0-b6c7-bb4ec2de389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9d8b8a39-6f27-4266-96fe-9d397a131ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9d8b8a39-6f27-4266-96fe-9d397a131ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4bce0938-ad7e-4702-aebe-d3d717f2db8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9d8b8a39-6f27-4266-96fe-9d397a131ddf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4bce0938-ad7e-4702-aebe-d3d717f2db8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_781a5f5d-3550-4bd7-ac68-04ea73f358dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4bce0938-ad7e-4702-aebe-d3d717f2db8b" xlink:to="loc_us-gaap_SubsequentEventMember_781a5f5d-3550-4bd7-ac68-04ea73f358dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_050837d9-7ac8-4a26-8e5d-40d54bba6293" xlink:to="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_96a123fd-65c0-4589-ac1a-0312e01a6932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_96a123fd-65c0-4589-ac1a-0312e01a6932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e6640316-ba0a-4fb9-a552-224ddb9cbe55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e6640316-ba0a-4fb9-a552-224ddb9cbe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7accf7b0-8346-475e-9e4f-bf3c9c03c131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7accf7b0-8346-475e-9e4f-bf3c9c03c131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_702ec6fe-5ed1-4197-80ec-59a63a38ff33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_702ec6fe-5ed1-4197-80ec-59a63a38ff33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_155de917-eb3f-486d-86cb-9321bd7eee17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_155de917-eb3f-486d-86cb-9321bd7eee17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LossContingencyLawsuitsNumber_f4b67b98-f42f-4dcc-9f6d-109fdb916742" xlink:href="mdt-20240426.xsd#mdt_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5486c32e-d05e-4bf3-9764-ef0f12eed996" xlink:to="loc_mdt_LossContingencyLawsuitsNumber_f4b67b98-f42f-4dcc-9f6d-109fdb916742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_80c7af18-b130-4e5b-acff-9f9e76a2548c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4a2fb825-98ca-4159-9394-cbbe3bf7acf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_80c7af18-b130-4e5b-acff-9f9e76a2548c" xlink:to="loc_us-gaap_NumberOfReportableSegments_4a2fb825-98ca-4159-9394-cbbe3bf7acf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_342dc375-30ee-43fd-940a-abaad2f82011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_80c7af18-b130-4e5b-acff-9f9e76a2548c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_342dc375-30ee-43fd-940a-abaad2f82011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_509a379e-b22c-4828-b876-514292e43eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93514a0-066d-4dab-801f-da29e7445643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_509a379e-b22c-4828-b876-514292e43eee" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93514a0-066d-4dab-801f-da29e7445643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_605db78f-2bad-48ea-8fe1-8469d8b53cb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93514a0-066d-4dab-801f-da29e7445643" xlink:to="loc_srt_ConsolidationItemsAxis_605db78f-2bad-48ea-8fe1-8469d8b53cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_afff4b56-3058-4729-b631-917be874c748" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_605db78f-2bad-48ea-8fe1-8469d8b53cb2" xlink:to="loc_srt_ConsolidationItemsDomain_afff4b56-3058-4729-b631-917be874c748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_20a88ca3-e6ba-42fd-873a-0e90d4149817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_afff4b56-3058-4729-b631-917be874c748" xlink:to="loc_us-gaap_OperatingSegmentsMember_20a88ca3-e6ba-42fd-873a-0e90d4149817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_5210f520-8bba-4fec-857c-5b71f944d7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_afff4b56-3058-4729-b631-917be874c748" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_5210f520-8bba-4fec-857c-5b71f944d7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c7fdc189-0e3e-40bd-a2c9-8f4a6a45dc77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93514a0-066d-4dab-801f-da29e7445643" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c7fdc189-0e3e-40bd-a2c9-8f4a6a45dc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c7fdc189-0e3e-40bd-a2c9-8f4a6a45dc77" xlink:to="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_608df336-e5cc-4f95-87ac-5e2ddeea2601" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_mdt_CardiovascularMember_608df336-e5cc-4f95-87ac-5e2ddeea2601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_2d71becd-ac07-495a-9487-5c8612a4f294" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_mdt_NeuroscienceGroupMember_2d71becd-ac07-495a-9487-5c8612a4f294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_97825e76-cfa9-422a-a57d-5b11071f8f18" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_mdt_MedicalSurgicalMember_97825e76-cfa9-422a-a57d-5b11071f8f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_db89ed8e-4843-4428-98a1-2e755cd90b53" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_mdt_DiabetesGroupMember_db89ed8e-4843-4428-98a1-2e755cd90b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_cb121412-6fb9-4f67-975a-cffc6f37ed3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2f5656cf-16e1-4cf1-b39b-8ed7a8b0e4b0" xlink:to="loc_us-gaap_AllOtherSegmentsMember_cb121412-6fb9-4f67-975a-cffc6f37ed3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93514a0-066d-4dab-801f-da29e7445643" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_78539b78-b333-4df1-9f82-ef5765b538ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_OperatingIncomeLoss_78539b78-b333-4df1-9f82-ef5765b538ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CorporateOverhead_1c1b47b0-8821-4870-ac3c-2103b19d965f" xlink:href="mdt-20240426.xsd#mdt_CorporateOverhead"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_CorporateOverhead_1c1b47b0-8821-4870-ac3c-2103b19d965f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1bc3f9a0-94c3-4725-bf35-d4aaec2ab347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1bc3f9a0-94c3-4725-bf35-d4aaec2ab347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_aead40fb-06f1-4028-920e-917fc340a0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_aead40fb-06f1-4028-920e-917fc340a0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1ad24e3b-542c-4df6-92c7-f7a7fdf2eaba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1ad24e3b-542c-4df6-92c7-f7a7fdf2eaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e6853f76-3832-4e06-b3c3-b6e35fe7f235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_ShareBasedCompensation_e6853f76-3832-4e06-b3c3-b6e35fe7f235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CentralizedDistributionCosts_1ac99d7e-76c3-4ad2-b03f-e37987d2774b" xlink:href="mdt-20240426.xsd#mdt_CentralizedDistributionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_CentralizedDistributionCosts_1ac99d7e-76c3-4ad2-b03f-e37987d2774b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyCosts_ebab21b1-5bdf-4733-ab5e-9b23117a55af" xlink:href="mdt-20240426.xsd#mdt_ForeignCurrencyCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_ForeignCurrencyCosts_ebab21b1-5bdf-4733-ab5e-9b23117a55af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3a6bd0a1-e1e0-40af-bf89-a358ade4dc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_RestructuringCharges_3a6bd0a1-e1e0-40af-bf89-a358ade4dc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_299b58fa-8573-4dc6-9fb1-c5b188822f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_299b58fa-8573-4dc6-9fb1-c5b188822f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_97165ae5-5eb6-45a1-b82f-849a7a365d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_97165ae5-5eb6-45a1-b82f-849a7a365d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ImpairmentofInProcessResearchandDevelopment_e99df122-b9fb-4e60-8155-d15e6d30646d" xlink:href="mdt-20240426.xsd#mdt_ImpairmentofInProcessResearchandDevelopment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_ImpairmentofInProcessResearchandDevelopment_e99df122-b9fb-4e60-8155-d15e6d30646d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalDeviceRegulations_1e12d8c3-7c33-4173-b794-488916e37c26" xlink:href="mdt-20240426.xsd#mdt_MedicalDeviceRegulations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_MedicalDeviceRegulations_1e12d8c3-7c33-4173-b794-488916e37c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialChargesGains_4920da8e-6cb4-4995-8912-f112f355177e" xlink:href="mdt-20240426.xsd#mdt_SpecialChargesGains"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_mdt_SpecialChargesGains_4920da8e-6cb4-4995-8912-f112f355177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d31faaa9-7210-4606-bcb1-f3bf0c531f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c785686d-c8be-442d-9484-c712e9a9e93d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d31faaa9-7210-4606-bcb1-f3bf0c531f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bdd23513-f705-47de-b956-111474797522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_25795aaa-2ef7-44dc-bec6-f0b115ea7f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bdd23513-f705-47de-b956-111474797522" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_25795aaa-2ef7-44dc-bec6-f0b115ea7f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_46b9e770-190e-408e-9f23-73ca13e70951" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_25795aaa-2ef7-44dc-bec6-f0b115ea7f27" xlink:to="loc_srt_ConsolidationItemsAxis_46b9e770-190e-408e-9f23-73ca13e70951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c4457b57-ef5b-4e1f-8110-df31cbb70d0e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_46b9e770-190e-408e-9f23-73ca13e70951" xlink:to="loc_srt_ConsolidationItemsDomain_c4457b57-ef5b-4e1f-8110-df31cbb70d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_08a2c33d-81e8-4ac4-a89a-5c49adbc587b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c4457b57-ef5b-4e1f-8110-df31cbb70d0e" xlink:to="loc_us-gaap_OperatingSegmentsMember_08a2c33d-81e8-4ac4-a89a-5c49adbc587b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_1e02e3e9-a93a-4d85-9e08-c91a83c0d766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c4457b57-ef5b-4e1f-8110-df31cbb70d0e" xlink:to="loc_us-gaap_CorporateNonSegmentMember_1e02e3e9-a93a-4d85-9e08-c91a83c0d766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5ff0fd88-df33-4fb7-9c8f-e966bfda75d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_25795aaa-2ef7-44dc-bec6-f0b115ea7f27" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5ff0fd88-df33-4fb7-9c8f-e966bfda75d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5ff0fd88-df33-4fb7-9c8f-e966bfda75d5" xlink:to="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_50a2f695-39a5-4860-85cf-505b8cbf1708" xlink:href="mdt-20240426.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_mdt_CardiovascularMember_50a2f695-39a5-4860-85cf-505b8cbf1708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_6127eebd-eb8b-47a1-9c0c-d2e1571de96b" xlink:href="mdt-20240426.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_mdt_NeuroscienceGroupMember_6127eebd-eb8b-47a1-9c0c-d2e1571de96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_448dd5e5-6765-44e3-bb24-7c689ed1be29" xlink:href="mdt-20240426.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_mdt_MedicalSurgicalMember_448dd5e5-6765-44e3-bb24-7c689ed1be29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_25142f52-3cef-4cbc-9351-b848093afbf6" xlink:href="mdt-20240426.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_mdt_DiabetesGroupMember_25142f52-3cef-4cbc-9351-b848093afbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_6d8e9f7c-8cbd-415c-b66c-fb16b3c05078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25b42f76-4305-482f-950a-131172b7db91" xlink:to="loc_us-gaap_AllOtherSegmentsMember_6d8e9f7c-8cbd-415c-b66c-fb16b3c05078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_afbe4a64-995d-4dc8-9fb6-55ad139dd1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_25795aaa-2ef7-44dc-bec6-f0b115ea7f27" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_afbe4a64-995d-4dc8-9fb6-55ad139dd1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_45b17f15-7a85-4142-9256-abf1d4e51211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_afbe4a64-995d-4dc8-9fb6-55ad139dd1da" xlink:to="loc_us-gaap_Assets_45b17f15-7a85-4142-9256-abf1d4e51211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5c253191-d3f2-4c3a-aa61-fde5448118cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_afbe4a64-995d-4dc8-9fb6-55ad139dd1da" xlink:to="loc_us-gaap_Depreciation_5c253191-d3f2-4c3a-aa61-fde5448118cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0c11207e-36db-47a7-8865-7da55f23f5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c572f8ed-03af-4db8-86ac-8632467e4b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0c11207e-36db-47a7-8865-7da55f23f5db" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c572f8ed-03af-4db8-86ac-8632467e4b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_20a4d8d1-4626-422a-8273-39bc680e5795" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c572f8ed-03af-4db8-86ac-8632467e4b26" xlink:to="loc_srt_StatementGeographicalAxis_20a4d8d1-4626-422a-8273-39bc680e5795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_95b3024b-04c9-4960-bd42-86f4017834f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_20a4d8d1-4626-422a-8273-39bc680e5795" xlink:to="loc_srt_SegmentGeographicalDomain_95b3024b-04c9-4960-bd42-86f4017834f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_20fb0b0c-cd2f-4282-948b-d4c766839d9b" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_95b3024b-04c9-4960-bd42-86f4017834f6" xlink:to="loc_country_IE_20fb0b0c-cd2f-4282-948b-d4c766839d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingIrelandMember_0f92d7fc-ef1b-4f44-88d0-7a0c4594b011" xlink:href="mdt-20240426.xsd#mdt_TotalOtherCountriesExcludingIrelandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_95b3024b-04c9-4960-bd42-86f4017834f6" xlink:to="loc_mdt_TotalOtherCountriesExcludingIrelandMember_0f92d7fc-ef1b-4f44-88d0-7a0c4594b011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3127efe1-6204-425b-9d32-481c2286f748" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember_0f92d7fc-ef1b-4f44-88d0-7a0c4594b011" xlink:to="loc_country_US_3127efe1-6204-425b-9d32-481c2286f748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_c2f3df98-a7a4-43cb-a3d1-4608544515bb" xlink:href="mdt-20240426.xsd#mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember_0f92d7fc-ef1b-4f44-88d0-7a0c4594b011" xlink:to="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_c2f3df98-a7a4-43cb-a3d1-4608544515bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4f8a6fd-e9de-415e-a3e3-79748d900b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c572f8ed-03af-4db8-86ac-8632467e4b26" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4f8a6fd-e9de-415e-a3e3-79748d900b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c86e67c7-07df-4987-ac0e-94082215f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4f8a6fd-e9de-415e-a3e3-79748d900b85" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c86e67c7-07df-4987-ac0e-94082215f0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9c0df76a-6910-4ca7-abca-d6f9ec4f719f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4f8a6fd-e9de-415e-a3e3-79748d900b85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9c0df76a-6910-4ca7-abca-d6f9ec4f719f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="mdt-20240426.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_c225fe49-d2a8-464d-98b0-d5b894cdc092" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_04342f68-fa1a-447b-82f5-22c4c648e13f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_c225fe49-d2a8-464d-98b0-d5b894cdc092" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_04342f68-fa1a-447b-82f5-22c4c648e13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_977fbbba-6cde-42c4-96a7-206029ddbf01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_04342f68-fa1a-447b-82f5-22c4c648e13f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_977fbbba-6cde-42c4-96a7-206029ddbf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4379af19-e83c-4474-b2f7-7595f30b29b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_977fbbba-6cde-42c4-96a7-206029ddbf01" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_4379af19-e83c-4474-b2f7-7595f30b29b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_b480f9d6-ca54-44f9-84b8-d6858befe0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4379af19-e83c-4474-b2f7-7595f30b29b7" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_b480f9d6-ca54-44f9-84b8-d6858befe0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_a884f5fa-8e23-4ee1-9985-b66225cec227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4379af19-e83c-4474-b2f7-7595f30b29b7" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_a884f5fa-8e23-4ee1-9985-b66225cec227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_477d4b87-20b7-4799-a087-c17138c1f2c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_04342f68-fa1a-447b-82f5-22c4c648e13f" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_477d4b87-20b7-4799-a087-c17138c1f2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_477d4b87-20b7-4799-a087-c17138c1f2c9" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_cda92da5-083e-4959-999d-c27961c35326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_cda92da5-083e-4959-999d-c27961c35326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_fccc5ca6-5182-4bcd-b962-8125f7568f46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_fccc5ca6-5182-4bcd-b962-8125f7568f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_f39c2322-5b6f-4d06-a4de-6777c3aa3580" xlink:href="mdt-20240426.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_f39c2322-5b6f-4d06-a4de-6777c3aa3580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7b95400d-6a77-430b-898b-8757b12af0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7b95400d-6a77-430b-898b-8757b12af0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_6d2880bc-a05b-404b-97ba-658cdba28d33" xlink:href="mdt-20240426.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_6d2880bc-a05b-404b-97ba-658cdba28d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6912aa46-7bcc-4b45-a437-383d8975f22b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6912aa46-7bcc-4b45-a437-383d8975f22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_5f189fdb-7b5a-49a9-8b5f-9aa6fccf93c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_5f189fdb-7b5a-49a9-8b5f-9aa6fccf93c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_41b0b3c1-602a-4130-a30a-5fb8bf817c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b4ef6f6f-eb23-43a4-9dc1-05a45f3758ff" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_41b0b3c1-602a-4130-a30a-5fb8bf817c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_0.jpg
<DESCRIPTION>IMAGE 0
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@   K4   "J" 8   "SO[<F    "7!(67,  $SE
M  !,Y0%USO"5   I\DE$051XVNR=^U].V1['YY\X,PQ.QCB&82X.QG!RF3-G
M!M41(C1%E$P.HA1FE/MM7DC&)5(Q@UQ"*F%RJ<C]/HR9<*)()=+]JN_IN\_Q
M'(VA/,_:S]YK/Y_WZ_7]K9Z]]G==]GOOO=;:;Q        "2\P92
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MJ>7(N)F%E@H@M9!: $ CS)Z[@3[]V]B7AI.S/Y($J=4^/N[J :D% %(+J04
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MW1,1+1G48H0[$-02U%HZU X:/%MQDQX\^XN9NUE.J(47G^02" OS7Q%*4"L
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M:3QG!P  0*@%    "+4    @U (   "$6@   (!0"P   !!J 0  0*@%
M"+4     H18   "$6IH     A%H   " 4 L    0:@$  $"H!0    BU
M *$6    (-0"  " 4 L    0:@$   !"+0   $"H!0   *$6    (-0"
MA%H   " 4 L   !"+0   $"H!0    BU     *$6  "$I?\!  #__^W6,0$
M  S"L/DWS20@@$1"KR;0G 0  )A:   PM0  8&H! #"U  !@:@$ P-0" ("I
M!0# U ( @*D%  !3"P  IA8  %,+  "F%@  3"T  )A:  !,+0  F%H  #"U
M  !@:@$ ,+4  &!J 0# U ( @*D% ,#4 @" J04  %,+  "F%@" 00_(*',N
04L,^9P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mdt-20240426_g1.jpg
<DESCRIPTION>IMAGE 1
<TEXT>
begin 644 mdt-20240426_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>IZV5YY@\PYOJDK\MKZ-;W[^A-1117DGKA1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!L@R/QK\>?^#L$
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M+N#<QQN'CBJ/+RRVO*SWMV/E<PXQR_!XB6&K<W-'>RNMD^_F?T 45_/_ /\
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MW?%KQ"D_V>Y70)M.M9 <,D]WBTC88YR'G4\>E?R[=2>.Y)_'_P#4?PK]V_\
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MH?\ ;W_I$CY/C7_D35_^W?\ TN)^/5%%%?T$?@9[Q_P2[_Y2*_!7_L<-._\
M1Z5_4C']XU_+=_P2[_Y2*_!7_L<-._\ 1Z5_4C']XU^->)?^^T?\'_MQ^P>&
M_P#NE7_&O_21](_;ZTM(_0?45^<'Z0S\8/\ @ZQX^(/P7_[!^K?^C+6OR3R?
M4U^MG_!UE_R4#X+_ /8/U;_T9:U^2=?T)P7_ ,B:AZ/_ -*9_/O&/_(XK?+_
M -)09/J:^DO^"0!S_P %,_@U_P!C G_HN2OFVOI'_@C_ /\ *3/X-?\ 8P)_
MZ+DKU\X_W"M_@E^3/)RG_?J/^./YH_IY7[Q_SZTZD7[Q_P ^M+7\QH_I@***
M*8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !2%0PY -+10!Y'^W'^R/H/
M[;O[,_B/X=Z[B"/5X@]E>JFY].NTRT,ZXYX;A@"-R,ZY 8U_,S^U9^R7XW_8
MT^+E_P"#_'6D7.F:E:,?)N?*8V>I19(6X@DQAXF['@@Y4@%<#^L%E#8R <>M
M<=\;?@%X*_:(\'MH7CCPMH7BK268L+?4K-+A8V((W(2,HV#]Y2#[U];PSQ74
MRING-<U-ZVZI]U^J/DN)>%:>:)5(/EJ+KT:[/]&?R2[2000W8  ="/>O2_V4
M/V2/'7[9OQ9L/"'@;0[C5+V[D"W,Y4K9Z=$&&^:>7&U(U!Y/))("JS$ _OZ/
M^"#/[*1U7[:OPJC\PMO\L^(-5\K.<_<^T[<?[.,>U?2GP:^ W@K]G[PN-%\$
M>%=!\*Z7U:WTRQ2V65AQN?: 7;_:8DU]?CO$FA[)_4Z<N=_S627W-W/D,#X<
MUW57UNHN5?RW;?WI6.6_8F_91T3]BO\ 9N\,_#S0W^TQ:';?Z7?-%Y<FI73G
M=/<,.2-[DX7)VJ%7) %>LT@4 ]!2U^3UJTZM256H[RD[M^9^KT:,*5.-*FK1
MBK)>04445F:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?'7_!
M?+7!HO\ P2E^)P$WDRWK:5:Q'&=Q;5+3</Q0-7V+7P=_P<=ZZVD?\$R]7MUE
M6/\ M77]-M2",F3$IEVCT/[K.?:O8X?ASYGAX_WX_FCQ^()\N68A_P!R7Y'\
M\AP<$=&&1DY/XT4'!P0 "0,_E17])K8_F]G2?!K2?[>^,'A.Q,HA%[K-G!O(
MR$W3HN?PSG\*^Q?^#B?X/?\ "L/^"E&LZI%%Y5KXXT>QUR,*F$#!#:R?\"+V
MS,?=\]Z^6OV0]/BU;]K'X7VLT9EAN?%NDQ/&,_O U["NWCGG./QK]4?^#J/X
M,&X\'?"?X@6\#(EE>WGA^\E500?.1;B -W_Y8W)'^\?6OE<QQOL<\PM-[3C-
M?^DO\XGU&7X+VV2XJHMX2@__ $I?^W'XU4J=3QG(P1G&::!AAP00/F!.>:7&
M2/;FOJFKGS!^D?\ P;&_&0>"OVX/$OA6>8);>-O#DGE(#CS+JUD25/KB%KD_
MG7[S1M\Y7)/&:_EL_P""8_Q@/P'_ &_OA+XD,PM[>W\0V]E<R%MH2WN2;:8G
MV$<SU_4G&!G(K\2\1,(Z>8QK+:<5]Z=G^%C]H\/,7[3+Y46]82_!ZK\;CZ;+
MT'UIU,G^Y[YX^M? ,^_/PE_X.?OC'_PEW[87@_P;!*KVO@WPV+B1 ?\ 57-Y
M,[2 CL3%#;-]&%?FAG@#L.GM7T%_P56^,?\ PO;_ (*(_%OQ DJS6PU^;3+9
MU;*O#9!;.)E]F2W#?5J^?:_I3A["?5LMH4;6:BF_5ZO\6?S=G^*^LYC6K7NG
M)V]%HOP0#J!V/!K] _\ @@;\$H_B%X@^/7BBZMS-9^'_ (;WVF#Y<[9KY& *
MG^]Y5O,OT<U^?A;8I// S7[F_P#!M]\$)=!_X)\>//$;6I%]XZU>[M[8X"^?
M;VUOY4?/_7:2X'US[UYW&.-^K99/6SDTOO:_1,]'A#"?6,R@FKJ*;^Y/]6C\
M,%(8J1@@CJ!U'&*=0"22,8P ,?W>,X_,FBOJ4[JZ/F&K.P<@@@X(Z'TK^C3_
M (-[=9_M3_@ECX$M\H?[,O=5MOE[9U">7GW_ 'M?SF*I=L#&3TSSSV_6OZ O
M^#9_71JW_!.2:W#0G^S/%=_;_(<L,Q6\OS>_[W\B*^#\1(7RM2[37Y/_ #/N
M?#V=LT<>\7^:/T)HHHK\0/VX*9,^Q1UR3@8(S^M)<.8X\@,<'MUK\X?^"KO_
M  7>T;]DJ]U/X?\ PP^Q>*/B-;YAOK^5A)IOAV0@C8^#B:<=XQA4/WSD%:[L
MMRW$8ZNL/AHWE^"7=OHCS\RS/#X&BZ^)E9?B_)(^Y/CO^TMX$_9A\'2^(/'_
M (JTCPKI$1P)[Z?:TS<G;''R\C8!PJ*20#@8!K\[?VBO^#HCP#X2FN++X9^"
M-=\8S(65-0U:==*LR>S(@#RNO3AA&:_'+XV_'KQE^T?X\NO$_CGQ)K'BC7;I
MCNNK^7<8U[)&H 6-!V5 JCL.IKD 2#P37ZQE7AW@Z45/&2=279:1_P V?E.:
M>(.,JR<,)'DCW>LO^ ?H-\0O^#EG]HOQ>\@T:/P'X7B&-@L=)>Y<<]VGED!_
M[Y%>>W'_  7U_:RGN)'3XJK$C,2$3PUI!"#T&;0G\S7QV3N !Y Z>U!YKZNE
MPWE=-6CAX?.*?YW/EZG$>:3=Y8B?RDU^1]O>$_\ @X@_:D\-RAKSQAH?B )U
M2_\ #MHH?D'G[.D1]>C#K7T+\#_^#J#Q197D</Q'^&>B:G Q >Z\.W<MC*@[
MD03&4.<9XWK]1BOR=W'GD\]:3 QC'%88GA3*JZM.A%>BY?\ TFQMA^*<UHN\
M:\GZOF_.Y_33^R%_P5_^!?[9\]K8>'/%T>C>([D[4T/7E%C?.W]V/+&*8]?]
M5(YX/ Q7T]!('; SP/7.._\ 6OX^1(R2!]Q!4@YSR,=,?CBOT1_X)F?\%]_'
M'[,6H6'A+XHW6I>// (98%NYG,^L:&O &R1CF:)?^><GS8^ZP P?@L\\/94H
MNKETG+^Z]_D^OH_O/N\D\0(U)*EF$>7^\MOFNGJC]^J*YCX1_%;0/C;X"TSQ
M1X6UFQU_P]K,/VBRO[.42PW"9P2".X.00<$$$$ C Z>OS.47%N,E9H_2X3C*
M*E%W3"BBBD4%-E;8N0"3Z#O239\L[203TXKXW_X*G_\ !7[PK_P3M\,C2+&&
MV\4?$S5;<RZ?HWFX@LD/"W-V0=R1]=J#YI"" 5&7'5@L%6Q=98?#Q<I,Y,;C
MJ&$I.OB)<L4?3/QH^/'@_P#9Z\$3>(_&_B?1_"VB6WW[O4+E848XSM7)R[$
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M7#F:5EJUIOT:/9RWB#'8"#IX2?*F[O1/7;JF?L'_ ,18G_5!1_X7'_WOH/\
MP=@&3@? 49'/_(\?_<%?CY01D8[&O._U'R7_ )\_^33_ /DCT?\ 77.>M;_R
M6'_R)]:_\%5_^"HO_#S;7_!E^? __"$GPA!=V_E_VU_:?VOSWB;=GR(MN/+Q
M@@]:^2J.E%?0X'!4<'0CAJ"M&.RU?YGS^-QM;%UI8BN[REN]%^05Z3^Q]^T%
M_P ,I_M,^#?B+_9!UX^$M06^&GB[%K]KPI79YA1]O#9SM/2O-J*WK4H582I5
M%=233]&8T:LJ52-2&Z=UZH_8(?\ !U^R88_ 50K 8_XKGGW_ .8?2_\ $6)_
MU04?^%Q_][Z_'S.<^]%?+?ZC9*O^7/\ Y-/_ .2/IO\ 7;.?^?W_ )+#_P"1
M/V#/_!V TH(3X"@''7_A-_\ [W\5]_?\$R/V\V_X**_L]W'CX^%O^$0$&K3Z
M3]A_M/\ M#<8DB?S/,\J+KYN,;>W6OY?@,FOW^_X-EU _P""=-Z<#)\7WW/_
M &[VE?*<8\,Y=@<O]OA:?++F2O>3T^;9]3P?Q)F..S!4,54YH\K>T5^21];?
MMQ?M-G]C;]EGQ9\2QHO_  D0\+013G3OM?V0W6^:.+;YNQ]O,@.=IZ5^9Q_X
M.O'BP3\!A@]O^$XSZ=_L'UK[>_X+=C/_  2S^+G_ %X6G_I?;5_,[GYS_GO6
M'!/#N7YA@YU<73YI*5MY+2R?1HZ.->(,?@,9"EA:G+%QOM%ZW:ZIG["?\18G
M_5!1_P"%Q_\ >^KGA[_@ZJ/B+Q!86 ^!0MQ>7,<+2_\ ":^9Y89@N[;]@&<9
MSC(K\<*U_A_@^/=$!!8'4(,@=QYBY'Y9K["IP1DRBVJ/_DT__DCY&GQKG#DD
MZVG^&/\ \B?UUAV6)69B&.,X.1G/3_(KYY_;@_X*D?";]@334C\9:[+>>))X
MC+;>'M+C%QJ,ZXX+*2%B0G^.1E![$]*\^_X+%?\ !3^'_@GI\$(+70C:7GQ+
M\6JT>B6TJ[H[%%.)+V53U5#PBG[[D#D U_.WX\\<ZQ\3/&&I:_X@U2]UK6]5
MN&N;R^NW+RW,C$DL223W]>.G0"OSWA7@Z68Q^M8IN-+I;>7_  #[_BCC!9?+
MZMAK.IUOLOEW/TZ^+?\ P=-_$+5-4D'@7X:^$=$L0<(=<N;C4IG&?O$1- JG
MV&X#U/6N(T'_ (.=OV@--N6^V:%\+]11R,J^F7<;( 3D+LN\#.0/FSVK\Y1\
MHP.!2EB1U/7/XYK],APCE$(<OL$[=[M_?<_-9\5YM.?,Z\E?MHON/Z,?^"07
M_!6F^_X*7'Q;8:KX,M?"VI>$+>UGDFM=2-S!?"<R ;49%:/:8SU9NO6OMJOQ
MA_X-2O\ DH'QH_[!VE?^CKROV>K\:XJP-#!YG4P^'CRQ7+IZQ3_4_9.%<=6Q
M>64Z^(E>3OKZ-H*9.Q5..I/'.*R_'OCK1_AGX/U#7]?U.ST;1M*A:XO+V[E$
M4-O&HR69CP!7XI?\%*/^#B?Q)\3[R^\(_ N:[\,^&06AF\42(4U+4>H)MUR#
M;1]PQ E; /R#<M<V39#B\SJ<F'CHMY/9?\'R.C.,^PF6T^?$/5[);O\ X'F?
MJG^U3_P43^#W[&=DS>/_ !OINF:CMWQZ3 QNM2E&"01;QAG /3<P5<D9(R*_
M/7X\?\'3^G6,\MK\,OAE=WR*2(]0\2WXMQG_ *]H=Y8=_P#7#Z"OQWUK6KWQ
M)J=Q?:E=7%]>WKF6>XN)C--<.>KNQ))8GN>:K[CZFOU7+?#W+Z$4\3>I+ST7
MR2_5L_+,QX_S"NVL/:G'RU?WO]$?>GCK_@Y'_:7\6S,=.U'P7X74G(73="$F
M!_V\M-Z^W2N-_P"'^/[69))^+# <]/#.C\>G_+I7QYGC':C.3GO7TE/AW+(+
ME6'A\XI_FF_Q/G9\0YG-WE7G_P"!-?D?=7@G_@XP_:>\*31/?^(O#/B98P-R
MZCH%NBR<?Q?9A$1^!%?1/P-_X.H=4AG@@^)7POLKF)R/.OO#.H/"Z#_9MKC=
MO/UG7ZU^1@)!X)%&<Y]ZY<3PEE-=6E0BO\/N_D=&'XKS:B[QKR?K[WYG].W[
M)'_!67X&?MH7%M9>$_&EM9^(;D8&@ZP/L&HEL?<17.R8]_W+/T^M?24+;B.6
M/'4]*_CZAF:"=)$<I(C*RL&P00000?;KVK]!?^"<W_!?SXA_LN7FG^&OB1-J
M/Q$\!92(37,QDUC2(P<9AG;F>,+G$4O/ VR( <_"9UX=SIQ=7+I<W]UVO\GU
M]&?=9+X@PJ-4LPCR_P!Y;?-=/5'] E%<9\!/CSX3_:5^&>F^,/!6N6OB#P_J
MT>^"Z@;[K?Q1NO5)%/#(P!![5V=?FDX2A)PFK-;H_2J=2,XJ<'=/9A39<X')
M'/:G4C=*DI['YQ?\%!_^"_3_ +!G[4FM?#8_"D>+!HUO:S?VE_PE'V#S3/"D
MP'E_9),8#@9W5XI_Q%B?]4%'_A<?_>^OE7_@X3&/^"I/C;_KPTO_ -((*^)J
M_;,EX/RFO@*->K2O*44V^:6[7E)(_%,XXNS6ACJU&E5M&,FDK1VOYIG[!'_@
MZ_,N /@-CGMXYQG/'_/A[U]A_P#!)O\ X*NO_P %/)O'I/@3_A"4\$KI_P#S
M&_[3%Z;K[3G!\B'9L-L1T.=W7BOYNJ_73_@UL\3V'@KPW^T5K6JWEOI^G:7;
MZ#=7=W<.$BMX8UU5W=V/ 50"23T&:X^*.%,LPF65<1AJ5IKEMK)[RBMFWW.W
MACBG,L5F-*ABJMX/FOI%;1;Z)=C]C-?UFT\.Z-<W]_=V]A8V<;37%Q<2K%%!
M&HRS.[<*H ))/05^<7[8/_!R=\+_ ((ZE=Z1\-M+NOBEJUL6B>]BF^Q:.CC(
M.R5E:2;!QG8FQARKU^??_!6__@L+XD_;O\;W_A;PM?WVC?"*PF,=K8HQCDUX
MH2/M-U@Y*L>4B.5 "DC<":^(2[,<DDGZUS\/^'\'!5\RO=_86B7JUJWY:&^?
M\>U%4=#+=$OM=7Z)GWY\3?\ @Y(_:0\;74KZ)=>#O"$&?W2:;HXN&V_[371F
MR?<!>G2N&A_X+[?M9*ZNWQ4#J#DK_P (WH_/MQ:?UKX[/S=>: ,5]U3X<RN"
MY5AX6_PI_BU?\3XB?$.9R=WB)_\ @3_*]C]#OA;_ ,',/[0?@^[A'B"S\#>+
MK)#^^^UZ:UI<2+Z*]O(J*WN8V'7BON3]DC_@Y%^$7QSU"WTGX@6%]\*]7N#M
M6YN[@7NDLW& ;A55H\\G+QA  <N.,_@:!M?<.&]>]"L4<$ E@<C'7U/<5YF/
MX*RK$Q=J?(^\=/PV/2P/&6:X>2O4YUVEK^.Y_7WX8\16?BS1;74M-O;74=/O
M8A-;W5M,LT%PC8*LCJ2K CG(.#GC-:-?S3_\$S?^"M/CW_@GKXS@LENKKQ+\
M-KN<-JGAV:3<L(8C=-:,3^YE ZC.QR?F&<$?T2? #X[^&?VE_A1HOC;P=JD6
MK^'M>M_M%M.G!'."CKU212"K*>5((-?D?$/#6)RFI[_O0>TE^3[,_6>'^),/
MFE/W/=FMX_JNZ.THHHKYP^D/&O\ @H#^U:_[$/[)?BGXH1Z ?$[>&6L_^)8+
MW[$;KS[R"VQYNQ]F/.W?=/W<=Z_-K_B*]V'/_"B X['_ (3D88=C_P >'M[=
M:^QO^"^JAO\ @DO\5\@'!T<CZ_VS8U_-N223GUK]/X*X<R_'X&5;%T^:2FUO
M):6CV:[GYCQIQ#C\!C8T<+4Y8N">R>MY+JGV/V"_XBP1_P!$$7_PN/\ [WTC
M_P#!U^77"? 50W;/C<X/MQI_%?C]1_$/K7V'^HV2_P#/G_R:?_R1\?\ ZZYR
M]ZW_ )+#_P"1/ZUOV</BT_Q[^ ?@?QR;'^RQXS\/V&N_8O.\[[']JMHY_*W[
M5W[?,QNVKG'05VU>.?\ !.U0O[ 'P-P /^+?:!_Z;;>O8Z_!\5!0KSA'9-K\
M3]VPDW.A"<MVD_O04445@= 4V0X&>>/2LWQIXMTSP%X7O=9UG4;/2=)TR)KB
M\O+N988+>)02SN[$!0!W)K\7O^"E7_!QAKOCFYOO!_P$FN=!T(%HI?%TL.V_
MOQ\RDVD;C]Q&><.X$IQG"$$'V,GR/%YE4Y,-'1;R>R]7^AX^;YYA,NI\^(EJ
M]DMW\OU/U+_:C_X*!?"+]C6P5_B#XWTO1KQT+Q:<CFXU"<8)RMO&&?';<0%R
M0">17Y[?'O\ X.G=&L+F:V^&7PSU#5$!(34?$=Z+-,\X(MX@[,IX/,B'V]/Q
MRU_Q'?\ B_6;K4M3O[S4]0NY/-GN;J=YYYG/\3NY+$]>6))JGVK]5RWP]R^C
M%2Q+=27W+[EK][/RO,>/\?6;CATJ<?O?WO\ 0^_/'?\ P<E_M*^+)6.G7/@C
MPLA/RKIVB!R!];F2;/Y"N&E_X+[?M8RL2OQ6VC.<)X:T<X_\E37QX/E''%*S
M%NI)^M?2T^',L@K1P\/G%/\ %GS<^(<SF[RKS_\  FOR/N;P7_P<6_M0>&)X
MWO/$GASQ*B?>34/#UNH?'K]G$1_(BOH7X,_\'4FOV$T,7Q%^%NE:A"3^^N_#
MFHR6CQ+ZK!<"0.?;S5^M?DFQ+#DY^M"DJ<@X(]*Y\1PGE-96E0BO1<OY'3A^
M*LUHN\:TGZOF_.Y_2W^RK_P6C^ /[6U]::=I'B__ (1OQ#<X":1XBC_L^>1C
MT1'),,C=PJ.6(!., U]66TPF 8-N!&>#D8/0@U_'P ""IY4@J1V(QTK^GW_@
MD7?3ZG_P3:^#D]S-+<3/X=CW22N79L.X&2>>@ _"OR_B_A2AE<(5\/-M2=K.
MVFE]_D?I?"/%-?,ZDZ&(BDXJ]UUU2V^9]'T445\*?>!1110 4444 (_W?IS7
MYN_\'0FNG3?V O"]JDBJ]]XZLU9>Y1;&_<D?1@GYU^D,AP!UZ]J_*[_@Z?UG
M[/\ LX_##3LQ8N_$D]R0?OGR[5EX]OWO/N17T/"<.;.*"7?\DV?.\63Y<IKW
M[?JC\1AG:,C YQST]OY448Y)[GJ:*_HI*Q_/)[5_P3>TM]8_X*"_!"&,H&7Q
MUHLWS=,1WT,A_137[L_\%WO@U_PN3_@F=X[\F S7GA;[-XBM1M!V"WE F;VQ
M;//GVS7XF?\ !(/1?[?_ ."F'P;@\KS?+\0QW./3R4>7/X;,U_2O\6?AU9?%
MSX6^)/"NI*K6'B?2KG2;D, P,<\31."#UX:OR?CO&/#YOA:R^PD__)O\D?JO
M ^#6(RG$TG]MM?\ DO\ FS^1:,@C@8SC^5.J_P"*O#%YX*\4:EH^H1-!?Z3=
M2V5S&PP8Y8G*.I^A!JA7ZO!W5T?EDDU)IC[:ZDL;F.>)WBDA8.KHVUD(Y!!'
M0@]#7]9?[+OQ:C^//[.W@;QHC(3XJT&RU1PARJ/+"CNGU5RP_"OY,=I=@  3
MGH:_HE_X-W?C)_PM7_@FMH&GRR>;=^"=3O-"D8GYBH<7,7'8"*YC7_@%?G/B
M3A.?!TL0OLRM\I+_ #2/T/PYQ7)C*E!_:C?YI_Y-GW/7&?M%?%.#X&_ 7QEX
MTNMOV?PGHMYJ\@)QN$$#R;?J=N![D5V3?KVYKXG_ .#@?XPK\*?^"9/BZU2;
MR;SQE>V7A^W.?O>9,)IA^-O!,/QK\IRS"?6<72P_\TDOQU/U3-,5]7P=6O\
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M0]1]:6D/4?6OT%GY^C^JO_@G=_RC_P#@9_V3[0/_ $VV]>Q5X[_P3N_Y1_\
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M3SC_ .M_("OUSPWP"C1JXR6[?*O16_5GY'XCXYRK4\''9+F?J_\ @("<FE&
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MZII/\&?F?B/@H.C2Q:6J?*_1JZ_(^2J-N\A?[Q HI5.T],_@37[ ?D9^U/\
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M^_V6;;]G_P#8$T77;FT2/Q#\2W/B"^D9/G\ALI:QYZ[!" X'0&9R/O'/W*%
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MR>,O^_Z?_$4?\/@/VF?^BR>,O^_Z?_$5\UX'H*,#T%1_9."_Y\Q_\!7^1?\
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MQ]%%;55]-F2YMHI8V5TD0.K*00P/((JQ7\K2;;;EN?U'3244D%%%%(L****
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M97YMU^DO_!KE_P G_P#C#_LGU[_Z<M,K'BO_ )%%?_"='"O_ "-J'^(_>8*
M<@#-+117\YG]$A1110 C ,,$9K^>3_@XZ 7_ (*9ZI@8SX>TW/\ WPU?T.'I
M7\\?_!QW_P I,]4_[%[3?_0&K[KP\_Y&K_P2_.)\)XA?\BQ?XE^3/@^@C-%%
M?N1^)'Z2_P#!KD3_ ,-_>,.?^:?7G_IQTROWGK\&/^#7+_D__P 8?]D^O?\
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M@)QUP,X'>OVUL_%C[V\/_M5&V_X-Z/$7@-YD^U/\1X- BCW_ #K:2!=5#X[
MS02CZGWKX)!R"<=3US_GU_2KT7B>_B\-SZ,+N;^S+BZCO)+;.8VFC1T63Z[9
M&'XU1QS7!@,!##.I*'VY.7WG?C<=/$*FI?8BH_<%?77_  0P^#/_  N?_@IE
M\/4EA,MAX8>?Q%=D+N$8MHF:)CZ?Z0T SZD5\BD9!^]^'6OUT_X-5_@R+OQ;
M\5?B'/  ;*QL_#MG+M^\9G:XN%S[>5;?F*\_BG&?5LJK5%O:R_[>T_4]#A?!
M_6<THTWM>[]%K^A^RL8PV,=J64$KQV.:4* V<#)[TDAPM?SET/Z(/P&_X.;=
M'.F?\%#]&G(0#4?!-A<#:,$XNKV/YO4_N_RK\[J_3O\ X.E=#-O^U[\/M3\H
M 7GA 6V_N?*O;EL?AYWZFOS$K^B^$Y\^44'_ '?RT/YXXJAR9M77][\PKZW_
M ."%&K#1O^"J_P )Y&R4EGU&W(W8R9-,NT'_ (\P/X5\D5]$?\$E=;'A_P#X
M*3_!F<AOWGB:WMLJVTCS<Q?^S_K7H9S#GR^O'O"7Y,X,HGR8^A)=)Q_-']/[
M852<<8SBOY4OV]O 3?##]MSXN:"T+0)IOB_5$A5A@F$W4C0M_P "C9#^-?U6
MJNX =..]?SZ?\''7P E^$W_!0BY\416\BZ9\2-(M=527;A/M,*?99HQ_M 10
MN?>;/>OR;PWQ2IX^="7VXZ>JU_*Y^J>(F%<\#"M'[$M?1Z?G8^ Z#GL&)[
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M_P#$2,P_Y]P_\F_S/H?^(<X#_GY/_P E_P C^9W_ (<B_M4?]$AUC_P/L?\
MY(H_X<B_M4?]$AUC_P #['_Y(K^F+ ]!1@>@H_XB1F'_ #[A_P"3?YA_Q#G
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M +)]>_\ IRTRL>*_^117_P )T<*_\C:A_B/WGHHHK^<S^B0HHHH #TK^>/\
MX.._^4F>J?\ 8O:;_P"@-7]#AZ5_/'_P<=_\I,]4_P"Q>TW_ - :ONO#S_D:
MO_!+\XGPGB%_R+%_B7Y,^#Z***_<C\2/TE_X-<O^3_\ QA_V3Z]_].6F5^\]
M?@Q_P:Y?\G_^,/\ LGU[_P"G+3*_>>OPGC__ )&\O\,3]SX!_P"12O\ %(^/
M/^"^G_*)?XL?]PC_ -/-C7\VW<_6OZ2?^"^G_*)?XL?]PC_T\V-?S;=S]:^U
M\./^19/_ *^/_P!)@?&>(O\ R,H?]>U_Z5,*0]1]:6D/4?6OT%GY^C^JO_@G
M=_RC_P#@9_V3[0/_ $VV]>Q5X[_P3N_Y1_\ P,_[)]H'_IMMZ]BK^7<=_O-3
M_$_S/Z=P'^[4_P#"OR/A7_@XL^&1\>_\$R-?U".#SG\'ZSI^M!0N6 \PVK,/
M3"73$^P-?SN#.!Z'./S_ /UU_6E^T[\%K/\ :,_9[\9^!+XHEMXLT>ZTPR,H
M;R&DB94E ]4<JX]"H-?R>^*?"^H>"/$^HZ-JUK)9:II-S)9WEO(NUH)HW:-T
M(]F4C\,]Z_6?#?&J>$J89O6,K_)V_5'Y/XC8-QQ=/$I:2C;YK_@,H4$C(!SS
MZ?G_ "HI5X(.<8(./[W/3\:_2&?G:W/Z?_\ @DW\?(?VCO\ @GW\,-?6<3WM
MKHL6C:@=^YOM=F/LLI;N"QB#\]1(#7T97X3?\&Z?_!0NW^ WQ9U#X0>*;\6O
MAWQY<+<Z//(^(K/5 H4QY)P%N$ 4,?XXHUZ-7[JPOO8YR/3G(//^?SK^=.*,
MJG@,PJ4VO=DVXONGK^&Q_0_#&:PQ^ A43]Z*2DNS7^9)1117SY] %%%% !11
M10 4444 %%%% !1110 R<X3CKV]^*_EN_P""H.O_ /"2?\%%/C7<>:9?*\8Z
MC:YZ8\F=XL?ALQ^%?U(W'^K/8=Z_E _;/UT^*?VQ/BQJGF"4:GXQU>Z#8QN#
MWT[9_6OTKPTA?%5I=HK\S\V\29_[+1A_>?Y'FM(PR*6C./?GIZU^Q/S/R _;
M3_@U7T(6WP(^*VH^45>ZUVSMB^<AO+MB^/J/.Y^M?JQ7YG_\&MFE);_L.^-[
MP%O,N/'-Q"01A<)I]B<C\78?A7Z85_.W%L^;-Z[\U^"2/Z%X2ARY107D_P 6
MV(X)'&,^]?F/_P '07P4_P"$N_9$\&^-X8=]SX,\0_99&Q_JK6]B*N2>W[Z&
MV'XU^G) (YYKY^_X*I_!C_A?7_!/'XM>'DA,]W_8$VIV<:KEI+BSQ=Q*/=G@
M5?HQKCR#%_5<QHUV]%)7]'H_P.O/\)]9RZM12U<7;U6J/Y=,')SV/8<<_P#U
M\T=_I2 ?,2!CZ]?\_P"-+7]*+8_G!^0 8HHHIB '!^E?T4?\&\?P8'PH_P""
M:GAW4983#>^.=2O=?G#+@[6D^SQ?@8K>-A_O5_.]I>GSZOJ=M:6L+W%U=2+#
M#$HRTKL=JJ/<DXK^M']G/X46_P "/@+X+\%6N##X3T.RTA6 QYGD0)&7^K%2
M2>Y)-?FWB3C.3"T\,OM2N_2/_!?X'Z-X<X3GQ=3$/[,;?.7_  $=I39!D#ZT
MZF3 D#'K7XX?L1^+G_!U;HJP?$OX-:B%<-<Z9JEL6/W2(Y;9@/J/-.?J*_)F
MOV/_ .#K72A/X?\ @A?[FS!<ZU %V\$2+8MDGU_=_P Z_'"OZ!X)GS9-1\N9
M?=)GX!QI#ESBMY\K_P#)4%>L_L$:Q_PC_P"W-\&;XLZI:>.=%D?8<$J+^'</
MQ&1]#7DU=5\"M>_X1;XV^#M3W2)_9VN65SNC8JZ[+B-LJ1R",5]'BX<]"<.Z
M?Y'SN%GR5H2[-?F?UN !A@]#USUKX6_X. ?V+I?VI?V++CQ!HUF;OQ5\,9GU
MNUBC7=-<694"\A7O]Q4EP.6-LJ]Z^ZXE[G!.*2Z0-#@HKCIM/0]L?2OYFR['
M5,'B(8FEO%W_ .!]VA_2>88&GC,-/#U-I*W_  ?O/X]U'R]^,?RS2@D'(X-?
M=_\ P6[_ ."6MY^Q1\8)_&OA/3I3\+?&-TTMMY2?)X>NV)9[.3'2,G)B/3;E
M>JEF^#P-IQU!R<D'/^'%?TGEV84<;AXXF@[QE^'D_,_G3,<OK8/$2P]=6DOQ
M\T.0[> !C!&,9_+_ #QUK]8_^"4G_!P1#\+/#>F_#SX[SZC=:=8JL&F^+HPU
MS-!'P%2\C4;Y$4# EC#L, %<?,OY-TBJ%Z #Z5AF^387,J/L,5&ZZ-:-/R9M
ME.<8G+JWML,[/JMT_4_KD^%7QB\+?&WPI;:[X1\1:1XETB[4-'=Z;=I<Q'C.
MW*DX8=U.&]173H<GJ?7KUK^1KX7_ !E\7_!+7?[4\&>*?$/A34L8-SI&H2V<
MK#(X)C(R.!P>*^F_A[_P7E_:C\ Q1P#XDR:Q @XCU72K*Y/U,C1"0GZL>IK\
MQQ?AMBHR;PU527]ZZ?X)H_2L'XCX:45]9I-/^[9K\;,_I,HK^?33O^#EO]I*
MRLQ'+%\/;MUS^]ET616;Z[)POOT[5S_B/_@XE_:AUVW\NV\6:#I+8(+VGAZU
M+<_]=5<#%<$?#W-&]7!?-_\ R)Z$O$+*TM%/[E_F?T4R':!]>:\E_:%_;C^$
MG[*EC+/X]^(?AKP])"H8V<MV);UAZK;1[IF_!#7\X?Q9_P""FO[07QPAGA\2
M?%[QO=VMP-DUM::DUA:RCT:&V$<9'L0:\.FN)+F9I)'>21FW%F)))]<^M>S@
M_#23=\56LNT5^K_R/%QOB0K6PM'YR?Z+_,_8G]L;_@Y]MK>.YTCX)>%9992&
M0>(/$L9CC0X(#0VBG<_J#*ZXQS&1T[#_ (-M?VD?'G[3OC7X_P"O^/\ Q5K7
MBK5G.@,)+Z?,=ON_M+*Q1 !(E(5>$55^48SBOQ#!([GUK]AO^#3L8'Q['H/#
MW_N4KT^(N'\#E^25EAJ:3]W5ZOXH]7^AYO#V?X[,,ZH_69MKWM%HOAET7ZG[
M#$ ]1FN=^+?PXTKXO?#'7O"NN6PN]&\1V$VFWL/ ,D,J%' /9L,<'L<5T5-F
M^Y@'&>_>OQJ,G%J479H_8YQ4HN,E=,_DL_:3^ ^L?LP_'?Q3X U^-TU7PKJ$
MMA(Y4JMRBL?+F7/5)(RCJ?[K#OFN(K]P?^#B7_@FU<_&?P+%\;?!NG>=XD\)
M6@M_$-K"I+W^G(25G"C[SP%FW=VB/_3-17X?9VJ!G/ ZXR/8^XS@^N*_HSAS
M.J>98.-9/WEI)=G_ ,'<_G;B')JF78R5%KW7K%]U_P #8" PY&:]7_8P_;)\
M9?L+_'*P\<^"[M8[J(>1?64V3:ZK;,P+P3 =5) (/!5@"""!7E% .#7LUZ%.
MM3=*JKQ>C3/(H5ZE&HJM)VDM4S^GS]A/_@IY\+OV^?"$$_A;6XM.\3Q0AM0\
M,ZA,L>I6#CAL*3^^CSC$B9'S*&V-E1]&Q/O'0CZU_'[I>J76AWT%W8W-S9W5
MHPDAFMW9)(&'1E92"I'J.:^FOA7_ ,%H_P!IOX0Z='::7\6]?O;:%=NS6+>V
MU5L=AONHWD'X&ORK,O#>7/S8&HK/I+I\U>_W'ZAEGB+'DY<=3;:ZQZ_)VM]Y
M_32YQCKR>U<]\2/BCX?^#_@Z]U_Q3KFE^'M%T^,O<7NHW*V\$8QW=B!GT Y/
M:OYX?$/_  7Y_:K\169@'Q'@T]&&&:S\/Z<C'C^\T!*_48-?,WQF_:,\>?M&
M:^-3\=>,?$7BZ]0_NGU._>X6 >D:D[4'LH KEPOAOBI37UFK%+^[=O\ %(ZL
M7XC8:,/]FI2;_O62_!L^\?\ @LG_ ,%O)?VN--N_AG\+)[RP^'+/LU75'7RK
MCQ&5/$:J3F.VXZ-\TG!PH&#^;FXD<D9;D>_)/Y9- )!."1FKFA>'[_Q/J/V3
M3;*[U"Z:-Y?)MXFD<I&C.QP.<*JL<^U?J.697ALMPZHT%9+=OJ^[?<_,<RS/
M$YA7=:N[M[)=/)>13HI$8.BE3N7^]Z\"EKTT[JYYIW_[*?Q;C^ ?[37P_P#&
M\X<VOA/Q#8ZK<J@!9H8KA'D49[E P^IXYK^KCP;XMTWQYX9T_6M(O;?4=*U:
MVCO+*Z@</'<PNH9)%8=5*D$'WK^0CGJ%+$>F,CM7N?[-7_!2GXZ?LC>'O['^
M'WQ&UG1-&5B8]-EC@O[.V8DLWEQ7"2*F6)8A5&22>_/Q7%W"T\U<*E"24XW6
MNS7RN_P/L^$^*(95STZT6X2L]+73^=C^IFFRX*X/()K\4O\ @CQ_P5.^/W[6
MW_!0?P?X3\?_ !"N]<\.75IJ$TEFFEV-BDK1VDKJ6\B&,G!&1DD<9QD C]JX
M3OZYR /PK\?SO)JV65UAJ[3DTGI>VM^Z78_7<ESJCF=!XB@FDG;6U]+=F^Y^
M3?\ P=5> );[X2?"'Q4%D:WT?5K_ $N1QT#74,4B@C_MS:OQ:4$8R.W7/6OZ
M7O\ @M=^S)/^U)_P3L\;Z5IUL+G7/#B)XDTQ ,LTMKEI%4#DL]N9T '=Q7\T
M7&<!0,#.?KV_+'ZU^N>'V,C4RSV-]8-K[W=?K]Q^3\?8-TLR]K;2:3^[1_I]
MX5J>"/&FH_#CQGI'B#2)VM=5T*]AU&RF4X,,\+B2-@>Q#*#^%9='?Z<U]Q.*
ME%Q>S/B82<9*2W1_4Q^P1^W/X2_;S^!FE^+O#=W FH&)8M9TEI0;K1[O'SQ.
MN<[3@E'QAUP1W%>XIR^=Q/&,9X^M?R.?";XR>+O@5XOCU_P5XDUOPMK<2E5O
M-+O9+69E)!*,4(W*<#*ME3@9' KZE\._\%_?VJ/#FGBU;XB6^H*F K7>@Z>\
MH&, ;Q ,GW.:_(LQ\.,0JKG@IKD;T4KIKRT3/UK+?$2A[)1QL'SI:N-M?O:/
MZ0'.%SSQZ4V,Y8\DXXZU_-1XW_X+E_M2^/[2>WN/BQ?V$$HQMTS3;"RD0'TD
MB@60'KR&[U^M/_!N]\4_%'QB_80U'6O%WB+7/%&KOXLOHC?:M?RWMP4$-L0F
M^4E@H+-A<X&3ZU\_G'!^*R["?6J\XO5*RN]_5(]_*.+\-F.*^JT(26C=W;IZ
M-GHW_!;O_E%G\7/^O"T_]+[:OYG?^6A_SWK^F+_@MW_RBS^+G_7A:?\ I?;5
M_,[_ ,M#_GO7W?AO_P B^I_C_P#;8GPWB/\ [_3_ ,'ZL6CN/K11W'UK]$9^
M>,_K _8M_P"3/OA3_P!B=H__ *0PUZ97F?[%O_)GWPI_[$[1_P#TAAKTROY;
MQ?\ 'G_B?YG]08+_ '>G_A7Y!1117.=(R=-Z8YZ]CBOP!_X.)/V&Y?V>?VK3
M\1]&LA'X2^*#O=SNBD16>K YN4..GF\3 GJSS?W17] )&:\H_;3_ &2_#/[:
MO[.NO_#[Q/%LL]7CW6UY&@,VF72@^5<QY_B0]><,I93PQKW^&LY>68Z->7P/
M27I_P-SP.),F698)T8_$M8^O_!V/Y22,.1GN1CNI[BG!BO0D5Z%^U3^R_P"+
M?V._CAK'@+QI8FSUG2GW"1 3;7T+']W<0L?O1NH!'<<AL,"!YY7]$TJL*L%4
MINZ>J:/YZK4ITING45FMT6]!UR]\,:W::CIMW=6&H6,Z7%M=6S%9K>5&#)(A
M!!#*P##!'(ZCDU^W'_!+O_@X.\+_ !3T/3O!GQPU"V\*^+;>-;>W\12CR]-U
MGL#,P $$QZDD+&W)!7(6OP[(#=0#3MQ!)R<D8/N*\C.L@PF9TO9XA:K9K=?\
M#R/7R;/L5EM3GH/1[I[/U_S/Z_/#^OV?B;3+>^T^\M;^RNXQ+!<6\HEBF0XP
MRLI(8'U%7FZ=<5_)K\&/VLOB=^SFV? GC[QAX4B+!GM]+U2:"WE/^W$&V-_P
M)37LT7_!;/\ :G@A5/\ A;^N,%&!FQL6/XGR,GZYS7YM6\-L6I-4:L6O--/\
M$T?HM#Q(PKBO;4I)^5FOS3/Z8+B<0J&)P.O?IZU\)_\ !1K_ (+K?#7]C[0M
M1T3P=>6'Q#^(RAX(;*RN/,T_39>06NID.W*$C,*'>2-K&/.X?A]\:?V[OC/^
MT+936GC3XF>-M<T^XXEL)]4E2RD^MNA6/_QVO)1Q^6*]7*_#BG":GCZG,E]E
M*R^;>OW)'EYIXB5*D'# PY;]7J_DEI]]SJ?C5\9?$W[0GQ1UCQIXPU>XUSQ'
MKT_VB[O9CRY "J% X1%4!54  *HV@#@<MTHQS17Z93IQIP4(*R6Q^;5*DIR<
MYN[8'Z$GTKZL_P"".?[#LO[</[9FAZ=?6;S>#/"CKK/B)WCS%)!$RF.V)Z$S
M2!5(Z[#(>U?./PO^%VO?&KX@Z1X4\,:9=:SK^O726=C9VX^>:5F  ST51U9F
M(55!)( R/Z6?^"7?_!/G1_\ @GI^SC:^&8_LVH>*]5VWOB75(X\"^NB/N(2
M?)B!9$!QU9L N:^1XQX@CE^$=.F_WL]%Y+J_ET/J^$,@EF&+52:_=PU?GV1]
M'VQ&XX&,C./3\.W6ICTI%14)P ,]<#K2GI7X(?O/0_G,_P"#A/\ Y2D^-O\
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M'_!+K]HL'GX*_$=?<:'/_P#$U^H_VGA/^?T/_ D?F']G8O\ Y]2_\!9^QO\
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M_$FDV&M:%K,)M[VQNXA)#<1D=&!]."",$$ @@BO$X>SZKE6*]M!7B])+NO\
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MF_#.!Q,,TH2G3DDI=8L_9RBBBOY_/WX****  ]*_GC_X.._^4F>J?]B]IO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>mdt-20240426_g10.jpg
<DESCRIPTION>IMAGE 10
<TEXT>
begin 644 mdt-20240426_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%VEN+B:UFA1?W:J0GWS(J5\._P#![SXM\+?\,_\ P0\"?\)'8_VV?&.H7_\
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M^!W@_P 1Z[\7M7T73K7P7)X[N((K2:_NA;R1K=BP<RO9XGDN 8E"I:7!4ML
M:7XX_P#!3W7[']O[PQ_P2X_9F\ :%XB^+&H>%)?$?C?5M>U::'1?"5@D.]!)
MY,3374\K&,+$!&%6>)V8;MH^$/\ @UQ^ O[6?@?QK\1OV7_VD[;;X/\ V6_B
M9K-KX8BE1\2>)=0A%M-) QX\F&S6[D3^\->9\D$5X_\ \%&O^$-_X)X?\'.<
MW[7'[=/@S6I?@;\8=#M;>/Q39->+':(-)M;)SOM&5W:WNK-&DA4EQ!(KA&)4
M$ _1KX'_ /!>OX*>+OV%OC7^UC\;/AKJ'AKQ%^SMK]SH'Q2\#:->#4'&I1W
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MOBEXCMHVCL/#\T6IM)%>W+.3]GMI!>RKYKG:GV=0S LNZO\ LI_LY7'[7O\
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MQM'/!/&'21",%64\$$<$&HM%T/1?#>EPZ'X=T>UL+*W7;;V=E;K%%$,YPJ*
M%&23P.]6J* "H-3TO3-:T^;2=9TZ"[M;B,I<6UU"LD<JGJK*P(8>QJ>B@#-\
M,>#O"/@JQ;2_!OA;3=(MGD,CVVF6,=O&SD8+%4 !/ Y]JTJ** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-NN?%EI)HL-]J5SJD@^>[>WU!VF628LT<K, 1O8']D* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "F71N5MI&LDC:81GREE<JI;' ) ) SU(!^E/
MHH _-+XO?\$"OV&?"?P]\8_M1?M=?M$_&?7-9L]/U/Q9\1/$]G\2;K3K:64+
M+>7DL%K$0EO O[SRX@3L0*I9B-Q]R_X(5_L\ZW^SI_P3$^&VD^+6U3^V_%MC
M)XMU:'6-2EN[BU;4G-S!:O)*2Q:"U>V@.?XH6/4FE_X*^S7'Q7^&/P\_8'T2
M=_MO[0OQ+T_PWK"0,1+'X:M-VJ:Y,/\ 9-C9R6YSWO%'>OJO5]9\,>"/#\FK
MZ]JMAI&E:?"/.NKR=+>WMHQ@#+,0J*.!S@=* /&/VT/V*=-_;I?0?A3\8_&V
MLV_PFMH;JY\7^$/#FOW6F3^*;LF);6WNKBU*2BQC3[2[Q)(IEE: D@1$/\,_
MLI_LD/\ \$KO^"[/A[]D/]B7Q5XAB^!WQ0^#>I^*/%?PSU37+C4+3PQ<VEQY
M$5];M.[R1B28PQ!G9F8RRAF8",)^E7QO^.G@7X"> _\ A.O%\MS=&YN8[+0M
M%TF$3W^N7\N?(L;.+(\Z>0@X&0JJ&=V2-'=?+/V?OA)I_P %_'6N?M5_M4>)
M=%M?BS\7+VPTEXC?J\&C64;,-.\-Z<[8:98FEDDED4 W%Q+/,51/+2( _+[]
MIK7O$OB7]B[]OS]M+XDR26GQV^$W[5QTGX4>*F3_ (FOAG3+"\T5-$MM/<C?
M##/'=392/"W'VN4LK%S7ZD?M%_&WXLR^$O!O[.OPFD32_B_\4-,XN$A$J^$-
M/2.+^T];D1L@BV\U8H$;(ENY[:,_(9&6_P#M,?"7]B7X=1ZM^V9\??@WX=N;
M[PVMKJ=WK$FBK<75Y=VIV6!$('^F7J22+%:Y5Y5DE5(B&8"OE;]OGXK?M)_L
M#_\ !,SXQ_\ !1>^M;;3_CWX\71[19ID2[@\#V-UJ,-E8:9'D&-UL([R65VP
M8YKZ:>0@QR*B@'WC\&?A!X#^ 7PLT/X.?#/2FL]#\/V"VMC'+,TLLF"6>:61
MLM+-(Y:225B6DD=W8EF)KIZ^(/@Q\6/B?^SQ_P %C'_X)VCXF^)O&/@7Q'^S
M?!X\MI?&&L2ZGJ&EZS;:NVG7$BW,Q,@@NHRDC1$F..5,0K&C%*^WZ "BBB@#
MDOB+\ ?@3\8+ZWU3XM?!7PEXIN;2$Q6EQXB\-VM])#&3DHC31L57/.!QFM31
M?AS\/?#7@H?#7P[X$T:P\."VDMAH%EI<45D(9-QDC\A5$>QM[;EQ@[CGJ:V:
M* ,GP-X"\"_"_P (V'P_^&G@O2?#N@Z7!Y.F:)H6G16EG:1Y)V10Q*J1KDDX
M4 <FL'X>?LW?L[_"+Q'?>,?A/\!/!?A?5]4W?VGJOAWPM:65S=[FWMYLL,:M
M)EOF.XG)YZUVE% &-XW^'G@?XDV%GI/C[PQ9ZO:Z?J]IJEI;7T7F1QWEK*LU
MO/M/!>.5$D0G.UT5ARH(V:** //_ (<?LH_LR_![QS??$WX5? +PAX=\0ZE%
M+%>:SHWA^"WN'CEF,\J!T4%$DF)E=5P'D.]@6YKT"BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH XCQ!^SU\,O%7[0'AK]ICQ!IMS=>*?"
M'AW4M&\.2R7CFWL8+^2V>Z=(?N^<_P!DA3S/O!%*CACFA^UI^RA\#OVWOV?]
M?_9B_:.\*RZUX.\3+;C5=/@U":U=S!<1W$3++"RNA66*-N#@[<$$$@^C44 ?
M,W[57_!'K_@GA^VUX?\ !OA+]I[X%7WB?2?A]HR:5X/TG_A/=<LK33;9$5!M
MAM+V*-Y-B(IF=6D944%B% '-?LM_\$%_^"3?[%_QOT?]H_\ 9L_9,A\/>-/#
MXN!HVM2^,];O_LIF@>"0K%>7LL6XQ2.NXH2-Q((/-?7U% '&_$[X%^"OB_XK
M\'>)_',M]<Q>"-=.M:5HRSJ+*?45B:."YN(]N9F@WO)$"P5)2LNTO'$R3?'3
MX'?"K]I7X0>(?@-\</!EKXA\)^*M->PUS1[PL$N(6]&4AD8$!E=2&1E5E((!
M'644 >-_ ']A[X1? 'XHZQ\=K;7?$OBWQWK7AZR\/W/C/QKJRWM_#HUH2UOI
MT3(D:1PJ[-(Q";YI&\R5Y'PP]DHHH **** "BBB@ HHI RDE01D=10 M%<;K
MO[1/P"\,W,MCK_QK\*6EQ Y2:VFU^W$J,.""F_<"",8Q3?!?[17P-^(WB-?"
M7@3XH:1JVI/&\BVEC<B1BJ?>;CC H [2BO ?BI_P5._X)V? _P").J_!_P",
M'[87@?PWXGT2X2#5M%UC5Q!/:R/&DBAPPXRDB-GI@]>M3>&_^"I/_!-3Q=(L
M&@?M^_!N:5R D#_$C38Y&)[!'F#'IZ>GK71]4Q7*I>SE9^3%='O%%<UX'^-'
MP=^)V/\ A6WQ8\->(<C(_L/7;>[X]?W3M72U@XRB[-#"BBBD 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1535]=T?0;?[5K&HQ6Z=
MM[<M]!U/X5P_B+XZ1(6@\,:;O[?:+K@?@HY_,CZ4 >ADA068@ #DFL+6?B1X
M-T3*7.LQRR#_ )96W[PY]..!^)%>1ZYXP\2>(V/]KZM+(A/^J!VH/^ CBLR@
M#TC5/CU$,IHN@,?22ZEQ_P".K_C7/ZA\8/'%\2(M0CME/\-O !^K9/ZUR]%
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M6V[LMW07%K(%FMR>PD1<]LU\GC<IQ^7O]]!I=UJOO_S+4DSU2BBBO.&%%%%
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M%4'_  2]_P"3K+/_ + E[_Z *['_ (*\Z/Y'Q7\*:_M_X^?#TEON]?*G9O\
MVK^M<=_P2]_Y.LL_^P)>_P#H H _%;_@X/\ ^4QOQP_[#MA_Z:[.OC2OLO\
MX.#_ /E,;\</^P[8?^FNSKXTK]GRW_D74?\ !'\D<[W"BBBNT HHHH ****
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M"CMK\6?AE?\ _!.'XV:Z)M6\.6<MY\/9[R?Y[W2L[I[!2W)>W9O,C&2?)=@
MJ6]?SC]*/PS_ +5RN/%F7P_>T$HUTMY4ND_-TV[-_P CNW:!Z^28WDG[";T>
MWKV^?];GWM16CXJ\.W7A;7)M'NLG8<Q28^^AZ-_GOFLZOX'/J0HHHH ****
M"I+6X:UNH[I/O1R!Q]0<U'10!YQ_P6$T@2Z5X"\0(O\ JI]0MW8=]ZV[+_Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *X_X^_'OX4?LQ?"'7/CI\;?
M%]OH?AKP]9FXU&_N#VZ+&BCF21V(1$7+,S!0"36]XQ\8^%?A[X3U+QWXY\06
MFDZ-HUC+>ZKJ=_,(X;6WC4O)*['A55023[5_,I_P6B_X*Z^-/^"D_P 9&\+^
M"KR[TSX2^%KYQX3T5LQMJ,HRAU*Z7O*X)"(?]5&VT?,TC-^M>$7A5F?B?G_L
M8WAA*5G6J=D]H1Z.<M;=$KR=[6?!C\=#!4K[R>R_KH<S_P %8_\ @K)\8/\
M@IQ\7?MM]]IT'X=:%<O_ ,(;X,$V1$.5^UW6TXENG7J>5C4[$_B9_DJBBO\
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M ((\?\%9OBG_ ,$L/VA$\4V1NM8^'?B*:*#Q]X127BY@!PMW;ACM6ZB!)4G
M<%HV(#!E_J]^#7QB^&G[07PLT'XU_!WQ=:Z[X8\2Z='?:-JMD^4GA<>AY5@<
MJR, R,K*P!! _*\ZR>IE5?36#V?Z/S_,VC*YTU%%%>(4%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-&PRKHZDAE(Y!!P:?>WMEIMG+J&HW<5O;P1F2:>>0(D: 9+,QX  YR:^!O\
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M>"?V2OV<_&/[2'Q"E TKPAH<U_+#Y@5KJ4#;#;H3P'EE:.)?]J05Z!7XS_\
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M/$\5I#K_ (E\1>)+_6=3O8+6,QVUN]WJ$\TWDQ(2$B#A 69L;G9B >FT444
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M/X#^(6NW*6NE)JUA'<1WVCW%U(1%!<LUT\T22,OF1K\I9LK0!U?C/]J[0O\
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M'^LY55AY7^[7]!Q=F?U<4445^0&X4444 %%%% !1110 4444 %%%% !1110
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M._->A5^'SBX3<7T.@****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOJ&OQ;,&I8^J_P"]+\V;K8****Y!A1110 4444 %%%% !1110 4444 %%%%
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M#_X#6=^([SQO\0/MT\(;F6RT^V<R#'H)[JT.?51ZUZ63T7B,THP_O)_):O\
M!"D[(_G1HHHK]B, HHHH ***ZOX$_#>Z^,GQP\&_"&PC9Y_%7BO3M'A1/O,]
MS<QP@#WR]*4E&+;V0']D?[#G@8_#']BOX0?#=H?+;0/A?H&G.A&"&ATZ",Y]
M\J:]2IEM;P6=O':6L*QQ1($CC08"J!@ #T I]?A]2;J3<GU=SH"BBBH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /Y</^"_/P:?X,?\%6OBE9PVQ2S\27MKXBL7(QY@
MO+:.69O_  (\]?\ @-?&U?L1_P '<GP#DTOXL_"C]IRPM"8M9T"[\-:G*JX"
M26DWVFWW>I=;N<#VA]A7X[U_K3X.9XN(?#'*\7>[5*-.7^*E^[=_-N-_F?"9
MA2]CC9Q\[_?J%%%%?I9Q!1110!^F7_!K+^TA#\*/V_-4^!VL:AY5A\3O"<UK
M:Q%L*^I61-U 3V_U O%'J7 '7!_HFK^-O]G/XV>)_P!FWX]^#OC]X-.=2\'>
M)+/5K6+?M$Q@E5S$Q_NNH*-ZJQ%?V#?"WXD>$_C'\-/#WQ;\!ZB+O1/$^BVN
MJZ1<C_EK;7$2RQM[$JPR.QK_ #[^EEPM++^+<-GM./N8FGRR?_3REIKZP<$O
M\+/J\BK\^'E2>\7^#_X)O4445_)Y[H4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?S.?\'8/[2X^,?\ P4J@
M^"VDZCYNF_"SPC::;)$C[D&H78^VW#@],^7+:QD=C"0>17]'WQE^*WA'X$_"
M+Q1\:_'][]GT/PCX?O-8U:;(RMO;0O-)C/4[4( [G K^+/\ : ^-'B[]H[XY
M>+_C[X]G\S6?&7B2\UG4<,2J2W$S2E%ST1=VU1V50!TK[#@_".IBYXA[15EZ
MO_@7^\B;TL<A1117Z(9!1110 5]E_P#!OQ\%9?CC_P %=?@YHSVGF6N@:[+X
MCO9"N1$-/MY;J)C]9XX5'NXKXTK]F_\ @SB_9[?7_P!H+XL_M0ZA9DP^&?"M
MIX=TV1U^5I[^?SY2O^TD=D@/H)_>O,SFO]6RNK/R:^;T_4<5=G] M%%%?CQN
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!\-?\ !Q/^S7-^T3_P2_\ &&HZ38^?
MJOP]O+?Q;8*JY/EVV^.[.>H M)[A_<QCZC^8RO[1_%WA70?'?A35/!'BK3TN
M]+UG3I['4K23[LUO-&T<B'V*L1^-?Q]?M8_L^>)?V4OVE?''[.?BT.UYX/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI&4VU&$5>4F[1BENVWHDCV;_ (-=?VC?V@_B=^R#J7P9^*OP\UP^%O!-X(_
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MJ?$'7;9A:+@X>.U3AKR88/RH0BD .\>1G[__ ."<_P#P;<?#OX.^'[?]I?\
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MVOF^)LR6"P7LH/WYZ>BZO]/^&*@KL]XHHHK\O-@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\K^+OA7X8_ VX\5?M>^%/@%IFK>.I-$AMM4UFRL
MXH[^ZLX3\J23E2XB13N8+DE8UR"$7;ZI221I*C12H&5@0RL,@CT-=>"Q<L)6
MYM7!V4XIN//&Z;BVK.SLOG9]#DQ]"OB<%4I4*GLZCBU&=E)PDTTI)2NG9ZV>
MCV9^3/QQ_:*^*G[0FOC6OB)KYDAB8FRTNU!CM+0'^Y'D\\X+L2Q& 20!CAJ^
M@/V[OV3+GX#^-&\;>#[ GPEK5P3;"->-/G.6-N?13R4/H"O5<GY_K^M<@Q65
MXS*:57+TE2:T25K=TTNJ>_GJ?Y8\;Y;Q)E/%&)PV?2E/$J7O2DV^==))O>+5
MG'LM+*UD4445[!\H%%%% !7=_ +]HCXB_LZ^+1XF\#Z@&@FVKJ6E7!)M[R,=
MF Z,.=KCE<^A(/"45SXK"X;&X>5"O!2A)6:>S.[+<RS#)\=3QN"JNG5IN\91
M=FG_ %HULUH]#]6/V=OVH_AG^TAX>%_X4OQ:ZI!&#J.A74@^T6Q[D?\ /2//
M1UXY&=IX'I%?C;X;\3>(?!VN6WB7PKK5SI^H6DF^VO+28I)&WL1^1'<'!K[2
M_9K_ ."G.E:LMOX0_:'MULKG 2/Q+9P_N93TS/&O^K/JR97G[J 9K\&XJ\-,
M9@)2Q.5IU*>_)O./I_,O_)O)[G]M^&GTA\ISN$,OXD:H8C1*KM2G_B_Y]R?6
M_N/HXZ1/L"BJVC:UH_B+2X-;T#5;:^L[E ]O=VDZR1RKZJRD@CZ59K\IE&49
M--6:/Z9A.%2"G!W3U36S7D%%%%(H**** "BBB@ HHHH **** "BBB@ HHJMK
M.M:/X=TN?6]?U6VL;*VC+W%W=S+''$HZEF8@ ?6G&,I248J[9,YPIP<YNR6K
M;V2\RS7FO[1?[4WPR_9OT WGBJ_%UJT\1;3M!M9!Y]P>@)_YYQYZNW'!P&/%
M>$_M*_\ !3G2M*6?PC^SO$E[=<I+XDNX3Y,1Z?N(V'[P_P"TX"\<*P.:^+?$
MOB;Q#XQURY\3>*M9N=0U"\D,ES>7<I>21O<G\@.@ P*_5N%?#3&8^4<3FB=.
MGNH;3EZ_RK_R;R6Y_,OB7](?*LDA/+^&VJ^(V=7>E#_#_P _)+I;W%U<M8G5
M_'G]H3XC?M$>+3XG\=ZE^ZB++IVF6Y(M[*,_PHO<G RQRS8&3@ #AJ**_>L+
MA</@L/&A0@HPBK)+1(_B3,LRQ^;XZIC,;5=2K-WE*3NV_7\$MDM%H=%\+/BK
MXW^#/C2U\>> -8:TOK4X(ZQSQDC=%(O\:-CD?0C! (]__:\_8V_9'_X+S?LW
M_P!D>)8H?"OQ3\-V;?V'XB@A5[S1YCSL8<&[L)'^\A(P3D%'Y/R]6U\/OB%X
MP^%GBVS\<>!=:EL-2LI-T,T9X8=T8=&4C@J>"*^8XHX5HY]35>B_9XF'P3_]
MMEWB_P /2Z?Z?X5^+&:^'68>SG>K@JC_ 'E.^W]^%]%-=5M):.SM*/X<?MC_
M +&?[0/[!WQVU3]GG]I#P5)I&NZ<?,MYXR7M-3M6)$=Y:RX F@?:<-@$$,CJ
MCHZ+Y97]7/QW^ W[(O\ P71_9DE^#?QOTF+1/'6B0//HNLV4:F^T*Z8!3=6I
M8@S6KD()8&.& 4-M=8I1_-O^W_\ \$]_VC/^";_QWN_@9^T)X9\ISOF\/^(;
M-6:PURT#8%Q;2$#(Y 9#AXV.U@.,_FV$QM;ZQ+!XR'LZ\-XOKYQ[I[_\#4_T
M,R7.LJXBRNGF.6U54HU%=27XIK=-/1IZIZ,\.HHK[S_X(,_\$B-;_P""FG[1
MP\4?$?2KF#X0^!KN*X\97XW(-5GX>+2H7'.Z08:5E.8XLG*M)'GKQ6)HX.A*
MM5=HK^OQ/42NS] O^#5C_@DY/X#\-?\ #RWX\>&?+U;7;.2U^%6GWD6'M+!P
M4GU3!Y5IQF*(\'RO,;E9E(_:NJVC:/I/AW2+7P_H&F6]E86-LEO965I"L<5O
M"BA4C1% "JJ@  #   %6:_(<QQU7,<7*O/KLNRZ+^NINE9!1117",**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(\>^!/"_Q,\(7_@7QGI:
M7FFZE 8KF%^N.H93_"RD!@PY! /:OR__ &G/V;/%O[-?CY_#>LA[G2[HM)HF
MK!,)=1 ]#V61<@,O;((X()_5>N3^-/P9\%?'?P%=?#_QQ8[[><;[:YC \VTF
M .V6,GHPS]""0<@D5]KP7Q=7X9QO+.\J$W[T>W]Y>:Z]UIV:_'_%WPLP?B+E
M'/1M#&TD_9SZ26_LY_W6]G]F6JT<D_R+HKN_V@OV>_'?[.GCB3PAXQMO,@DW
M/I>JQ(1#?0@_>7T89 9#RI/<$$\)7]-X7%8?'8>->A)2A)736S7]?<?YTYEE
MN/R?'U,%C:;IU:;M*,E9IK^KI[-:K0****Z#A"BBB@ HHHH [CX-?M&?%_X"
MZD;WX<>+IK:!WW7.F3_O;6?_ 'HFXSVW##>A%?8'P6_X*C_#7Q1'%I/QET.7
MPY?'"MJ%FC7%FY]2!F2+GMAP.[5\#T5\QGG!^0\07EB:5I_SQTE\WL_^WDS]
M'X,\5^-N!FJ>7XCFHK_EU4]^G\E=./\ VXXWZG[&^$_&?A'QYI":_P""O$UC
MJME)]VYT^Z65,^A*DX/L>16G7XY>%?&?B[P-JBZWX+\3ZAI-XO2YTZ[>%\>A
M*$9'MTKW7X=_\%-/VC/!RQVGBB33/$MLF W]HVGE3[?:2':,^[*QK\HS3PFS
M2@W+ 5HU%VE[LOUB_O1_3?#?TH.',9%4\ZPLZ$^LH?O(>MM)KT2GZGZ,45\I
M^"O^"L'PIU39#X[^'>M:1(V TEC+'>1*?4DF-L?137I_AG]NW]E/Q3M6T^+E
MI:R'K'J=M-;;?JTB!?R)KX?&<(\38%OVN$GZI<R^^-T?LF5>*7AWG44\+F=&
M[Z2DJ<O_  &IRR_ ]=HKE](^-_P8\0 '0_BYX9O,CI;:];N?R#UN6OB/P]?#
M-EKMG,/^F5TC?R->)4PN)HNU2#7JFC[*AF.7XJ-Z-:,EY23_ "9<HJE<>(_#
MUIN%UKUE'M^]YET@Q]<FL;5OC5\'-!0R:W\6/#5FHZFYUVW3^;T4\-B:KM"#
M?HFPKYA@,-'FK5HQ7G)+\V=-17DOB;]N?]E3PLC&\^+]C=./NQZ9!+=%C[&)
M&7\R!7F'C;_@J[\(M)5HO G@#6]9E'1[QX[.)OH<R-^:"O;P?"7$N.:5'"3]
M6N5??*R_$^/S7Q0\/,EBWBLSHW72,U4E_P" T^:7X'U36=XI\8>%/!&DOKOC
M+Q)8Z591_?NM0NDA0>V6(!/MUK\_/B-_P4X_:'\7A[7PBNF>&;9L@&QMA-/C
MT,DVX9]U537@_B[QQXR\?:JVN>-_%.H:M>-G_2-1NWF8#T!8G ]AQ7W&5^$V
M:5VI8^K&FNT?>E^D5ZW?H?C7$GTH.&L%&5/)<+/$3Z2G^[AZ]9OT<8^I]S?&
MG_@J-\,?"B3:3\'M$F\27RY5;^Y5K>R0^O.)),>@"@]FKX^^,O[1_P 8?CUJ
M'VKXC>+IKBW23=;Z9;_NK6 _[,:\$]MS9;U-<-17ZMD?!V0\/VEAZ5Y_SRUE
M\GLO^W4C^9.,_%?C;CF]/'XCEHO_ )=4_<I_-7;E_P!ON5NE@HHHKZ@_-PHH
MHH **** -/P=XQ\3_#_Q+9^,/!NM3Z?J5A,)+6ZMVPR'T]"",@J<@@D$$&OK
MOQ5X8_9/_P""SW[-=[^S-^U+X3MX]?AA,]M+:LL=WI]T%VKJ.G2L"489^9#N
M&"4<.C<_&->K?LB? KXH_&?XJ6<WP[U.YT>+1[A+B^\1PY L!GC:?XI&P0J=
M^<_*":^-XSR/*\RRYXK$5%2J4E>-3^7R?5IOIO=Z:Z/]@\'..>*N%N):>#RR
MG+$4\1)*5!?:_O1Z1E%:N3M'E7OZ*Z_+_6O^#:7]O/1_^"@NG_L:)I!N?">I
M,^H6WQ=AL7_LH:+&ZB2X<9^2Z7>J&S+;S(ZX8Q,)J_I!_9&_9/\ @Q^Q)^S]
MX>_9M^ OAL:=X?\ #UH(T9\&>]G;F6ZN' 'F32/EF; '. %4*H]&@C>&!(I)
MVE94 :5P SD#J=H R>O  ]J?7\X9EG.,S.$(57I'MU?=G^D44DKA1117D%!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RGQD
M^#/@/XZ^";CP+X_TOS[:7Y[>XCP)K64#Y98FP=K#/T()!!!(K\UOVE_V6_'_
M .S5XI_LWQ!$;S2+J0_V3KD$9$5PO7:PY\N0#JA/N"1S7ZJ5E>-O _A+XC^&
M;KP=XXT&WU+3;Q-L]K<ID'T(/56!Y# @@\@@U]IPCQGC>&*_([SH2?O1[><>
MS\MGUZ-?D/BEX1Y/XBX/VT;4L;!6A4MHU_)42WCV?Q1W5U>+_'2BOHC]K3]@
M?Q?\#Y;CQM\/$N=;\*9+R$)NN=-7KB4 ?,@_YZ 8'\0'!/SO7])95FV7YUA%
MB<'-2B_O3[-='Y?H?Y\\2\+YYPAFL\OS6BZ=2/W27249;2B^Z]'9IH****](
M^?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***^D?V2/V /%?QCFMO'?Q3M[G1O"W$D,+#9<ZFO4! >8XS_P ]#R1]T'.X
M>9FV<9?DF#>)QDU&*^]OLEU?_#O0^BX8X5SWC'-8Y?E5%U*CW_EBNLIRVC%=
MWZ*[:1PO[+?[)WCC]I;Q-Y=BKZ?X?LY0-5UN2/*IW\J('[\I';HH.6QP#^D_
MPM^%?@?X-^#;7P+\/]%2SL+89..9)I"!NED;J[G')/L!@  :7A3PGX:\#>'K
M7PIX0T6WT[3K*(1VMI:Q[41?ZDGDD\DDDDDUH5_-?%O&..XGQ'+\%&+]V'ZR
M[O\ !;+JW_H5X7^$^3>'.!YU:KBYKWZMO_)(?RP_&3UET42BBBOCC]8"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $9592K*"",$$=:^7?VH_^"<'A3XC/<>-?@G]ET+6W)>XTIALLKQNY4 ?N
M'/L-A[A<EJ^HZ*]7*,[S+(L4L1@ZCB^JZ-=FMFORZ69\SQ5P?P]QIEKP.;4%
M4AT>TH/O"6\7^#V::T/QY\??#KQO\+O$<WA+X@>&;K2M0A^];W4>-R]F5A\K
MJ>S*2#V-8M?KU\4_@[\-OC3X=;PQ\2?"MOJ5MR87D&V6W8_Q1R+AD/T//0Y'
M%?%O[0/_  3%\>^#//\ $7P2U!_$6FKECI5P52^A7T7HL_X;6[!37[SPYXE9
M3FJC1QMJ-7S^!^DNGI+[V?Q-Q_\ 1ZXGX9E/%9/?%X9:V2_>Q7G!?';O"[>[
MC%'RO15C5M(U70=1FT?7-,N+*[MWV3VMW"T<D;>C*P!!]C5>OTE24DFG=,_G
MR<)TYN,E9K1I[H****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M3Z9I>IZWJ$.DZ-IT]W=7#A(+:UA:221CT554$D^PI-J*N]BHQE.2C%7;V1!6
MUX ^'7C?XI>)(?"/P_\ #5UJFH3_ '8+9,[5[LS'A%'=F( ]:^BOV??^"9/Q
M!\;/#XA^-=W)X;TLX8:;"5:_G7T/58!_O;F[%!UK[5^%GP;^&OP6\/CPW\-O
M"EMIMN<&>2-=TMPP_BDD;+.?J>.@P.*_-N(_$K*<I4J."M6J^7P+UEU](_>C
M^@O#_P"CWQ/Q/*&*SA/"89ZV:_>R7]V#^&_>=K;J,D>#_LN?\$Y/"7PREM_&
MWQE>VU[74Q);Z<J[K*R;J"0P_?./4@*#T!(#5]/@ # %%%?@V;YUF6>XIXC&
M5'*73LEV2V2_/K=G]M\+<(</\&98L#E-!4X=7O*3_FG)ZR?KHMDDM HHHKRC
MZ4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH XWXM_ #X1?'#3OL'Q)\%6E\ZIM@O@OEW,'
M^Y*N& SSMSM/<&OD_P",/_!*?Q)IOFZK\$?&L>HQ#)72=;Q%.!Z+,HV.?]Y4
M'O7W%17TF2\6Y]D-EA:SY/Y9:Q^Y[?*S/S_B[POX)XV3GF6%7M7_ ,O(>Y4_
M\"7Q6Z*:DO(_(/XA?!_XH?"B^.G_ !&\":EI#[MJ27=L1%(?]B091_JI(KFZ
M_9K4-.T_5[*33=5L(;JWF7;-;W$0=''H5(((^M>,?$?_ ()[_LQ_$-Y+N'P;
M)H%U)UN/#UQY"@^T1#1#\$%?J65^+>#J)1S"@X/^:&J^YV:^^1_-7$OT6\UH
M-U,BQL:D?Y*JY)>BE%.,GZJ"/S,HKZ]\??\ !)GQ=:.]Q\,?BE87L?)6VUNV
M>W=1Z;X]X8^^U:\?\:?L*?M3>""SW?PIN]0A7[LVBRI=[OHD9+_FHK[[ \8<
M,YBE['%0N^DGRO[I6_ _$LZ\*?$3(&_K>6U;+[4(^TCZWI\R2];'D5%:?B'P
M7XQ\)2^1XK\)ZGICYQLU"PDA.?3#@5F5]%"<*D>:#NO(^!K4:V'J.G5BXR71
MJS^YA1115&84444 %%%7M"\,>)/%%U]B\->'K[49L_ZFQM'F;\D!-3*<81YI
M.R+ITJE::A3BVWLDKO[BC17JO@_]B/\ :D\:R(-/^$&I6<;=9=7VV84>I$Q5
MOP )]J]A\"_\$F_B!J#1S_$;XFZ7ID9P7@TJW>ZDQZ%G\M5/N-P^M?/8[B[A
MK+D_;XJ%^R?,_NC=GW>3>%OB%G[7U/+:MG]J4?9Q_P# JG*G\F?)-;_@'X5_
M$?XI:C_97P\\$ZEK$P8!_L5JSI'[N_W4'NQ K]#/AQ_P3I_9E\ ^7<ZCX9N?
M$5VF#Y^O71D3/?\ =(%C(]F5OK7M>CZ)HWAW3HM'\/Z1:V-I"N(;6SMUBCC'
MHJJ !^%?!9IXMX&DG'+Z#F^\_=7W*[?_ )*?MW#7T7,YQ,E4SW&1I1_DI+GG
MZ.32C%^:4T?$'P:_X)6>,=:\K5OC=XLCT: X+:3I++/<D>C2G,<9_P!WS*^L
MO@_^SI\'?@58_9OAQX+MK2=TVSZC+^]NIAWW2MEL=]HPOH!7;T5^6YUQ?G^?
M7CB:KY']B/NQ^Y;_ /;S9_2O"'A9P1P2E/+L*G57_+V?OU/E)Z1OU4%%>044
M45\R?H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXO;C3O@E\:_"_BZ6TTRWU"Y'AO6X;U8K:>2>*&1FA9@ SVTZCG.8F&.*[>@
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M]%L_$6MPVDFH3.2$B@65@97)!PBY8^E=W87]GJEC#J>GW"RV]S"LL$J'AT8
MJP]B"#0!+1110 4444 %%%% !1110 45YQ\'?VN/V=?C_P#%/XA_!3X0?$VV
MUOQ1\*-5MM-^(&E0V=Q&VD74Z.\4;/)&J2[A')\T3.H*,I(92*]'H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH _&G_@\I_Y-G^#/_8]7_P#Z1"OY]:_H*_X/*?\ DV?X,_\
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M_MG?\FM^-O\ L"M_Z$M?E;7ZI?MG?\FM^-O^P*W_ *$M?E;7] ^$?_(DK_\
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M\/+_ $[Q/'K6C^)K6$2&XBBN!#!+#<QK#,QBDA&5B9@W*;_JNOA?]E;XX?\
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M<!U93@G!4CJ*_-3K-C3]*TS2=,AT72M-@MK.VA6&WM+>%4BBC485%4#"J ,
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MHX*L#Z$8K$\$_!;X.?#34)=6^''PF\,^'[J>'R9[G1-!M[222/(;8S1(I*Y
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M5X7N/'?ACP-^SIX<U633;QGM=,F2'4KVTM-MYK,\T@=YFEWV4*P,6B3RI)*
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M/!O[(7P1\1?%+Q+;P6UA\"Y_A/ISZQ+K[)C[%Y;63A85DW;KT@PQQ!I790K
M=3^V=^Q=\&OVS?VV/B?\4_V*OVR-9_9\_:O^#UAIUEKNM:7K"_8M?TN33+6^
MM)M3L6.)K,"8VYEY"_9CYD<H6)0 ?>W[,'QNG_:0^ 'A7XY77@'4?"LWB72U
MNYO#>KNK76F.696MYBO'F(5(8#@$$9.,UWE?,O\ P1V_:>^.?[8__!.7X;_M
M#_M'^$K/2?&&NV5VNIG3K?R;;41!>SV\6H0IT6.YCB2<;?D/F[D^1EKZ:H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \*_;I_P""=7[-?_!13PGH7@O]I/3-7NK'PYJ,E[IB
MZ1JS6C+*\?EL6*@[AM[5\T_\0PW_  2M_P"A3\;?^%E+_P#$U];_ +4_[4^@
M?LLZ!I6OZ_X5O-535;Q[>..SF1#&53=D[NM>*?\ #WSX<?\ 1'];_P# ^'_"
MOL<H\0N..'\!'!9;F-:C1C=J$)RC%7=W9)VU>K.>IA,-5ES3@F_0\S_XAAO^
M"5O_ $*?C;_PLI?_ (FOK?\ 8Y_8Y^"O["OP5@^ 7P"L=1M_#UOJ-Q>QQZIJ
M#7,OFS,&<[R <9 P.U>*?\/?/AQ_T1_6_P#P/A_PKZ#_ &<OCOI/[1GPSB^)
M>BZ#<:;!+>36XM;J57<&,@$Y7CG-9YWQYQIQ)@_JF:YA5KTKJ7+.<I*ZO9V;
MW5W]XZ6%PU&7-""3\D=!XX^&/PU^)MM!9?$GX>:'XAAM9"]K%KFDPW:PL1@L
MHE5@I(XR*=X<^''P\\'^''\'>$O >BZ7I$CL\FE:=I<,%LS-C<3$BA23@9..
M<5M5XO\ $'_@HC^Q-\+_ !;JG@7Q?^T;X>75M!<IXAL=-EDOVT9@,E;TVJ2"
MS..<3%#CGI7R1N>C>./@_P#"7XG3V]U\2?A=X<\0RVB,EK)KFB07;0JQ!8(9
M4;:"0,@=<5-X1^&/PV\ :+<>'/ ?P]T/1-.O)&>[L-(TF&VAG9E"LSI&H5B5
M 4DCD "D^&WQ/^&WQE\$V'Q*^$7C_1?%'AW58?-TS7?#VJ17EG=IG&Z.:)F1
MQD$<$\@BM/7-=T3PQHMWXD\2ZQ:Z=IUA;/<7U_?7"PPVT**6>21W(5%5026)
M  !)H YSX7? /X%? \7X^"OP6\)>#_[5E$NI_P#"+^'+73_MD@SAY?(C7S&&
M3RV3R?6CQO\  +X$_$SQ9I7CWXD?!7PEX@UW0F#:)K6N>'+6[N]/(;<#!-+&
MSQ$,2?E(Y.:P/V7/VQOV9_VU?">N^._V6OBW8>,]%\-^)Y_#VKZKI<,PMX]1
MAA@GDA1Y$43 1W,+>9&6C._ 8E6 ],H YB/X)?!B'PM?>!H?A'X831-3U"2_
MU+1UT"V%K=W<DGFR7$L6S9)*TGSEV!8M\Q.>:M>"?A;\,OAI:W-C\./AUH7A
M^&\8-=PZ)I$-HL[ $ N(E4,0"1SZUNT4 <E\-?@#\"/@S?ZEJOP?^"GA+PI=
M:S*)-8N?#7ANUL9+YP20TS01J93DGELGFKJ?";X5Q_$-_BZGPS\/KXLDM!:R
M>*!HT U%H ,"(W.SS2F.-N['M7044 <BW[/_ ,!W\'6_P[?X)^$3X?L[MKJT
MT(^&[7['!.VXM*D/E[%<[WRP&3N;GDUL>#? ?@;X=:0?#_P^\&:3H5@9FE-C
MHVG16L)D( +[(E5=Q &3C)P*UJ* ,GQ'X#\#^,8KB#Q=X,TG54N[)K.Z34M.
MBG$ULS!FA<.IW1E@"4/!(!QQ7/\ PD_9H_9Q^ ,U[<_ C]G_ ,$^"I-2_P"0
MC)X2\*6>FM=<Y_>&WC3?SS\V:[:B@#F/B-\$_@S\89-,F^+GPD\,>*7T6Z^T
MZ,_B/0+>^-A/Q^]A,R-Y3\#YEP>!SQ4DWP>^$ES-K]Q<?"WPY))XJDC?Q0[Z
M);DZPT:+'&UT2G^D%41$4R;L*B@< 5T=% ',>$?@W\*_AH;N]^%7PN\,>'+V
MZ@\N2XTC08+;S,<J)/)5"Z@\XS^5?FU\#O O[;?PTTBY^%O[=_\ P0W\.?'[
MQS/XBO[[4/C1H/B'PM>6GB=Y[AW2XD35WAN+)8XFCMTB882*"-(U555%_4RB
M@#YA_8U_8#^&7POT?QOXD\<_LN?#7P;'\1-;LM3G^%?A32K>XT31/LMMY$3D
M"".&:]<-(\TT<*+\R1KYGE>=+]!>%?AA\-? N@W/A7P1\/-#T;2[UW>\TW2M
M)AM[>=F0(S/'&H5B555)(.0 .@K<HH Y7X6_ OX(_ VSO-.^"GP<\*^#[?4)
M_/U"#PMX>MM/2YEY^>18$0.W)Y.3R:FM?@U\(++QAJOQ#LOA5X;AU_7;7[+K
M>N1:%;K>:A!@#RIY@F^5, #:Q(P!Q7244 <C>?L__ ;4/"VF>!K_ ."7A&?1
M-%##1]'F\-VK6M@&.6$,1CV19/7:!FMWPIX/\)>!-#B\,>!_"VG:-IL!8P:?
MI5C';P1EF+,5CC 498DG Y))K1HH **** "BBB@"OJVEVFM:=-I=\K&&=-L@
M5L''UKG/^%,>!_\ GWN?_ @UU=% '*?\*8\#_P#/O<_^!!K3\,^!= \)3RW&
MCQRJTR!7\R4MP#FMBB@"GX@\.^'_ !9HUQX<\5:%9ZGIUW'LN[#4+5)H9ESG
M:Z."K#@<$5QB_LH_LMHP=/V;/  (.01X.L<@_P#?JN_HH KZ5I.E:%IT.D:)
MIEO9VENFR"UM85CCC7T55  'L*YGQ9\ /@/X\UR7Q-XY^"?A'6M2G55FU#5O
M#=K<SR!5"J&DDC+$   9/  %==10!S^H?";X5ZMX^LOBMJOPS\/W/BG3K8V^
MG^);C1H'U"UA.<QQW!0R(AR<JK <GUJUX5\!>!? EI=Z?X(\%Z3HT&H7TM[?
MP:5IT5NES<RG,L\@C4!Y'/+.<LW<FM:B@#BOA_\ LV?LZ_";Q1?>./A7\ O!
M7AG6M4!&I:QX?\*VEE=78)!/FRPQJ\F2 3N)Z5N>/?AW\/\ XJ^%KGP/\4/
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MLI?#K]B;]EWP;^S7\--&M[6T\-Z-#%J%S$@\S4K\H#=7TS=9)IIM\CN>26[
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M*UZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .#^._[.7PS_:,TFPT7XEVMY+!IMPT]J+.[,)#LNTY('/%>9_\ #KW]E/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mdt-20240426_g11.jpg
<DESCRIPTION>IMAGE 11
<TEXT>
begin 644 mdt-20240426_g11.jpg
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF1 S#<,@'Y0?\$<OC1\ /^"K_P#P34_9T_8'\:_#;PUJ>J_#KQF&^(6D3:3
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M-(S2 "-(_DGXQ?\ !J[\3OC=^QE\)_V9/'G_  5#\0ZGJ?PBU*;_ (12\O\
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MPM\/_"FF^!? WAVSTC1=&L8K+2=*TZW6&WL[>) D<4:* $15  4#  K1HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)M+2RRV2+>&"V,<47W8U)"@9-?(?[/OQS^.W[0W_  1]_9HUSXG:_>:WX?\
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M?XP.O?M _$61M'M[@R:/X.T?=;Z3IO7'EP;CO?!(\V4O(0<;L8 _>_#+Z/\
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M%*_^"FWQZ_X*7?&9_'_Q-O&TSPWILDD?A#P7:7!:TTB GJ>GFW#@#S)B 6(
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M=8WD&/*U?4M-&HWZD=Q=7AEF7UX8#VK^>^)?I4>'N42E3RV%3%S76*]G3_\
M IVE\U!KS/6HY'BZFLVH_B_P_P S^7#X/?L9?M<?M!"*7X(?LS>._%4$V-EY
MHGA:ZN+< ]VF5/+4>Y8"OI+X=?\ !NQ_P5J^(4<=W-^S;;^'[:3[L_B/Q7IT
M!'UB69Y5_%!7]/2JJ*$10 !@ #@"EK\8S7Z77%]>3678"A27]]SJ-?-.FO\
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M:_A4Y+XFNDYKYQ@[;RDE\IG&8>UDZ%-^ZM_-_P"2"BBBOZR/""BBB@ HHHH
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M_P"04445^('I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9CAU_P O:24*Z7>5/X9^BL^KFS^F>%?&7@+BOEI5I_4L0_LU7>FW_=JZ)?\
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M-<\<NR_NYX$?]Q8D^MQ* A&0?*69ARM?U(P00VT*6UM"L<<:A8XT4!54#
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M_$WB*SN?*O;FS^P:>P.&$LY\O<ONJLS_ / *_+"OM3_@K1\1"EMX5^$]K/\
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MVG5-5\+0VOB*0MECJEH3:7C$=1NGAD< _P +J><YK^.2OZ!O^#.G]I23Q-\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X7_P#!XO\
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M#G@AU)35M<M;27'9'E56/X*2?PK]?E544(B@ #  ' %?F3_P3Y\.)XB_:O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@O2K/6]4^)WB6/5-6M-/CCN;U5TNVVB:15#2[0H W$X'3%>O?L1_"/PCX_\
M^"C_ ,=_^"B?P>MDC\!^/O"GAOPYI.LVL6RV\7W]@+AKO5X#P)K94DM+6*X&
M4F,$[(S(%=_(_P#@L9\0/ GA[_@JS_P3\L==\9:79S6OQ-\12745U?QQM"DF
MGVT<;.&(VAG954G&2<#)H _2FO.OBG^RU\'?CA\4_"WQ1^,'A*R\2MX+M;Q?
M#6CZU9QW-E9W=R8A)?"&0%6N5CB$4<A&Z-)9@I'FMD_:G_:O^ ?[%GP'UC]I
MC]I/QZGAWP5H/V?^T]8%C/=[#//'!"%BMTDDD+22HH"J?O9. "1XO^W_ /\
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MA/!MYX*N?#MM:_#V[TN32;%!9VD>C21M;VZQ ((4$?RJ$ "[1C;C&!7YX_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP0:YCX2? +X%? '3+O1?@3\%O"?@JSU"=9[^T\)^';;3H[F14"*\BVZ('8(
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M+?SMI^(TKL_J4  & , =!1117XL;A1110 4444 %%%% !1110 4444 %%%%
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MG5I4J]-TZD5*+T::NFNS1OAL3B,'B(U\/-PG%IQE%M--;--:IKNC]#OV8O\
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M#TWA*+]Y_$^R[>K_  7J7"-]33HHHK\[-0HHHH **** "BBB@ HHHH ****
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MV@BM81AI;B0\R7$[X!EFD?+NYZD]A@#T&BBOS&<Y5)N4G=O<V"BBBI ****
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MAUG#RUG'^\KM?)%%.EBDAD:&:-D=&*NC#!4CJ".U-K]:/Y=::84444 %%%%
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M.- %10!@ #%?'YUQ-3PZ='".\NLNB].[_!>9<87W.1_9=_99^!7[&GP7TGX
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M$<U&7]Y77WQO^*1_._$/T;_$#*&YX%0Q4%_))1G;SC.ROY1E(^*Z*]J\;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !3)X(+J%K>YA22-QATD4$,/0@]:?10FTQ-)JS.,\1_LZ_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /Y//\ @M=^T'\>_"__  57^./A_P ,_&_Q?IUA:^-I4M;*Q\2W4,,*^5'\
MJ(D@51[ 5\N?\-0_M,?]'$>.O_"NO?\ X[7NG_!<K_E+=\>/^QZE_P#145?*
M-?LV ITW@:7NKX8]/)&#W/</V:/VE_VCK[]H[X?V5[^T!XVFAF\;:4DT,OBN
M\974WD0*D&3!!'!!K^S"OXF?V7O^3F/AW_V/6D?^EL5?VS5\=QE&,:M&RMI+
M]#2&P5^?=I^W!^WA/_P7+N/^"9#^.OAU_P (+!\*1XZ_ML>!+K^U6A\Y;?['
MN_M'R0WFMN\WR\;!C9GFOT$K\P+<BT_X.WY_M)"?:OV0!]GW<>9C5ESCU^XW
M_?)KXHL^Z/VXO'?Q?^$W[)WQ!^,7P-\1:)8>(O!O@W5-=L5\0Z+)?6ET]I9R
MSK!(D<\+JKF,*75\KG.#TK6_97UOXL>*OV??"7C/XV^)M&U7Q)KGA^RU+49_
M#^BO86<<D]O'(T444D\S[59FP6<DC&<5S_\ P4.N(;3]@'XY7=S($CB^#WB9
MY'8X"J-*N22?PKK?V;[>:T_9W\!6MS&4DB\%Z6DB,,%6%I$"#0!X!^WA^VW\
M3/AQ^U=\$O\ @GU^SWK?ASP_XY^-4FKW;^,_%E@]Y:Z'IFFVWG3&"T66+[7>
M3$[(D,@1=C.X8 *:OB3Q7_P4M_9V_:>^#7P]\6_$WP1\2OA=X^\97.D>)_$H
M\%OI.O:-(FD7]W#&RQ7+VTT$LEJH\U8HFC("$/Y@95_X*Q?\$LO@+_P5.\(>
M'_!/B'XH:AX$^*7@>276OAKXZ\.W(&I:)(S1J\GE!T:6W:2. MM9&5XXRDB'
MK\@_L[?\%#?^"GW_  3"_:L^'/[!?_!9[PKI7Q!\&>/_ !%#H7PN_:%T$!F>
M^D80V\=X=J[FS(B,9$BG0.\A:X0%J /UZHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /YFO^"NO_  2*_P""E/QQ
M_P""E7QB^+7PE_8[\7Z]X;U[Q?)=:/K%C;1F&ZA,<8#H2X.,@]NU?.7_  XU
M_P""MW_1AWCK_P !(O\ XY7]>5%?5T>+<;0HQIJG&T4EUZ:=R.1'\GG[/G_!
M%'_@JOX7^/?@?Q+X@_8=\;6MAIWB_3+J]NI;6(+##'=1N[G]YT"@D_2OZPZ*
M*\K-<WKYM*#J12Y;[7Z^I2CRA7R!^W/_ ,$W?B1\7_VM?AQ_P48_8_\ BOHW
M@[XT_#;2I]$,?BO2Y;O1/%&AS&4OIUZL+K+#M:>9TFCW%6D.5)",GU_17DC/
MDSXC_L]_\%"/VR?"<OP*_:MU_P"%'@7X:ZS&(/'FG?#/4=3U?5?$U@<>=IJW
M-[;VD>GV\Z[HYF6*>5HF9$:,MO7TO]N7X=?MI_$'X'VGA?\ 8 ^._AKX:^-8
M?$=A+-KOB;PZFHVK:6CG[3;+"T;A6==N#MSA2H:,L)$]HHH ^:OVI_V7?VN?
M&_[6'@+]JS]E;]H+PSX6F\&>#]6T36/"GBSP[/?V/BB*]N;.;R)FAFB>T$9M
M Z3IYCJ^!L9"ZMQ'Q?\ V&?VI/V\_C'\*]?_ &Y;GX;^'? 'P@\=6WC72O!G
MP\U*^U6Y\0:]:QR)9RW5[>6MJ+>VB,LC&WCAD,A;:TF *^S** /&;KX?_ML/
M^W;;?$FU^/GAQ/@&G@!K*Z^'+>'D.IOX@^T%A>B[V;A'Y6%V^9MX(\HD^:/9
MJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^&'_  A-AX<\!:E<7\=Y$UV+B34+Z^GM;1IY=J1PQQ>0!&BG,DGR"/ZLHHH
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M[5? =KICZOX\U2ZO[&WN=,U*X>*"^DN#=0@/*VTI*K( H4C:,>!?\$ROV&_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\Y7_!5C_@E/
M_P %$OC1_P %$OBU\4_A9^R5XKUOP]K?BN2YTG5K*WC,5U$8T =27!QD'\J^
M?/\ ARQ_P52_Z,A\;?\ @+%_\<K^KBBOZ@RCZ5/&.3Y3A\!2P5!QHPA33?M+
MM0BHINT[7:6MCQ*F1X>I4<G)ZN_3_(_ES^ W_!'/_@IYX:^.7@SQ%KO[%_C*
MUL=/\6:=<WES+;1;8HDN8V=S\_0*"?PK^HRBBOS+Q/\ %?.?%.OA:N84*=)T
M%)+V?-KSN+=^:4MN56L=N"P-/ J2@V[]PKX#^-W_  3K_;O\??\ !6GPQ_P5
M"^'WC[X3:6?!_P .IO!FE^#=874[L7-G)+>2FXEN(TB*RE[LG:J;5"!<MRQ^
M_**_+#N/EGX@?!/_ (*3?'K6O#'@GXK?$[X1>'_AY%XEL[[Q[8>#]-U274]>
ML+>03?V:LMRXCA@G=$CG^4L\1= 0&8-SWPO_ &&?VH? _P#P5I^('_!135?$
M7@.Y\.^.? =EX27PG;WMZMY8V]I)')'=_:#;[)9&*/NBV( )  YV9?['HH ^
M,_V,?V'?VK_V9OVUOVC?VM/%VL?#W6;7X]WVEZA'X?T[5+Z"31)]-M)[>VA,
M[VK"X202J))/+0I@NJ-_JSPW[-/_  1P\=Z;^S_^U!^RM^V%XJ\*>(/"'[2O
MQ&UWQK>77A"2YAN]$O\ 4GA?RHUN(BL@@>"*6.4D$/$ T;!CM_06B@#\XOV4
M?^":W_!7WX;>%M._8_\ VD/^"C'@[Q5\ =%MUTT2Z5X0EC\6ZUHL8V+I,US)
M\EK"\0$3RJTTXC+*DBDK(OJ6K_L+?M577_!8VS_X*8Z?XH\ +X<M/A0?ARWA
M"6YO?MLVEG47OOMOV@0[$N/-<'RMA3:NSS,GS!]ET4 ?GE_P4T\-_'_]KK]N
MWP%^S+^QA^T;\/[+Q5\-_ ^I>*O&_@#XG^%UU;0;BWOWBL;*XFA!+R70 N@@
M",(HY'9FC\Y%FT?V:]?_ ."MO[(?QP^&WP5_:F\/_LQ:S\-_'FO7.BV5A\%]
M+U+1]6T>X6PN;W[4EK.OV>:U46Q$N,.OFHP/\)]Y_:X_X):_L-_MO>,],^*'
MQ^^#!N/&.B6WV?2/&WAW7K[1=8M8<L1&+NPFAED0%W(20LJEV( )-=%^S)^P
M9^RY^R)<W.L?!;X?W2:S>6OV6[\3>)/$5_K>JRV^X,8/MNHSSSI"6 ;RE=8]
MR@[<@4 >(?L?_L-_M;?LU_MR?M'_ +8GB/6/AWK%O\?IM&ND\-V>J7T#Z)-I
M5I/;VL9N&M6%PDBS8D?RT((W*I^X<;]@+_@GA^U]^Q3^R-\6_P!G/5O%WPX\
M2ZK\0_%VO^(M)UR"ZO[2"QN-61$DBFA,$C2)$0SJ5=2_"'9_K*^Z:* /RO\
M&O[,?QR_8,_X(Q^!?^"4>K?M3^%_#WQ%\7^,+3P5\,?%NB0RM#KDEYJTE_/;
M7=O<!/(M_LQGBF97D+QDJJ,\J027[SX>?\%S?V!/ _B7X_V$_P"Q#J'AWP]I
MLVJ^*K#2O!>J>'+W6;6!#(\:SVZ>6MPP!2(R!DWLN0<XK[V_:K_8Y_9C_;?^
M&#?!O]JSX.:3XS\._:ENH+/4@Z26MPH*K/;SQ,DUO*%9E\R)T;#,,X)%>9?
M?_@D/^PI^SSXIL/&?A+X=^(=:O\ 2+E+C1#XZ^(.L^(+?3)4.8I+>VU&[F@A
MDC."DJH)%(!# C- 'T5X9U:ZU[PWI^NWVC7&G3WMC%/-I]V!YMJ[H&,3X_B4
MG:?<&O /@G\"?VL/!7[;OQ*_:3\=O\/Y?#'Q%T30-+CT32M5O6OM'32EO=LO
MFR6RI=F5KV3*;80@5<,V#N^C:* /DS]D3_@D]\'OV,?VU?C[^VU\-!!<ZQ\8
M[V*YTO1IE,,.B;T6;4(TD4-@7=\JSN0AVB*( '9SQ'[)?_!._P#:_P#@%_P5
M$^-/_!0;QGXQ^'.IZ5\;K?3;35?"FFW-_%/HL-E'#!!)%</ 5N7$,1W*R1!V
M;(:,#%?=5% 'YJ_"?_@CK^W1\)O@O^T+^Q-X<_;%\$1?!KXQZEXHU+2M2F\&
M3W/BFUDUJW>*6TFF>86PARR^9+Y<LKJ)/+\AG1H:GQ7_ ."._P"W;\3O^"6?
MPG_X)Z:A^T5\-'U3X<ZSH5ZOB4Z)>Q6L%OHZ[+2TC@&Z2=GVJ\MR\B9.52%!
MS7Z:T4 ?,'_!2_\ 90_:*_;V_P""?OB;]D3P[JG@OPSKWCO38;/Q#K-Y?W=U
M::<L=S#,QMT6!'G+B(K\YCV;L_O,<^'_ !C_ ."4?[6.J_$[]G_]K+]FKXE?
M#[X>_&OX3>&HO#7C;Q&#?76F^-M$BAAB6PNK98HV>-BDCC<^^'< KNR1R1_H
M?10!\"?MZ_\ !+C]K;XU?M&^!O\ @H[^P]^T1X>^$?[0?AGPR?#OB2WOHIM1
M\.^)=*,K2BUN"85D(5F8[C"Q/[O&UH8Y![+^S_\ LA_M)ZM\,O&EY^WS^T)I
M?C;Q_P"//"\_AVXE\':&=/T;PWI<D<BM;V$,A,CN[R&66XE.^4I"F%6!!7TM
M10!^?_[,G_!-K_@HW^SC_P $Y;7]BS1_VP_A^FM>!M1T?_A5FN:9X,NXH%MK
M+Q!;:J[ZKON&>X:6&%[7R8/)01R.':8N'3T;_AA'XK_'C]OGX2?MZ_M->'_A
M_P"&-=^"^@:U8Z+!\/M4N]0N/$,^I6WV5I+RYN;2U:&V@C:=HK4+,1)<LQFQ
ME7^NJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>mdt-20240426_g12.jpg
<DESCRIPTION>IMAGE 12
<TEXT>
begin 644 mdt-20240426_g12.jpg
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M*R@MDML_;J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _*O_@\3_P"40B?]E5T3
M_P!%7E>8_P#!,;]GW]NS7/V._P!@/XR:3^TQ::G\&]"\3P3^(/AI:>$TLY[7
MS5U&"VNI+U9':\1)I OELL:@RJ^&* K]O?\ !9;_ ()=?$#_ (*U?L\V/[,E
ME^TQI/P[\.0^(;76;VX?X?2:Q>W$\"3HJ+)_:5LD<9\[)'ELV4'S8)%>C?\
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M7<Z*2"PCBC*XV5]@_P#!%O\ X)L_!']C;XF?M(?M!?!VV1M*^)_Q>OX?"1$
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M^!O#MGI&BZ-8Q66DZ5IUNL-O9V\2!(XHT4 (BJ  H& !6C110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+G4M@$ /S)8QQXVM=7"4 ?5-%,M[B"[@2ZM9TEBE0/')&P974C(((Z@CO3Z
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M=_S>2(\B+/'DB/;\FVON6HK*RLM,LH=.TZTBM[>WB6.""",(D:*,*JJ.
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M'^Q_)<:?\>/VGO#6FZI;9$OA_3[EM0U)6'16M;422QY/ +JH]Q@U\ _M"_\
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M(Q"(@Y9B/K6^%PN)QV)AA\/!SJ3:C&,5=R;=DDEJVWHD*4E%7>QE?M>_M>?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB_P#X+?\
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M* "BBB@ HHHH **** "BBB@ HHHH **** /F_P#X*/?\$LOV5/\ @IS\+_\
MA"?CSX5^S:[80./#'C?2HU34]'D/.$<C]["3RT#Y1NHVL%=?Y??^"E'_  3
M_:4_X)A?&A_AE\;M%^V:+?O(_A+QKI\+?V?KENI^\A.?*F4$>9 QW(2#\R,C
MM_8E7GG[4O[*OP(_;.^"VK? ']HOP#:>(?#>KQ_O()UQ+:S $)<6\@^:&9,D
MK(I!&2.02#[^39]7RR:A/WJ?;MYK_+9_B3**9_%%17UW_P %=?\ @D5\;/\
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MA04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0?"_^SO"/B'XNW]OB34KI=.T]F'(AB >1A[,[*/K%7PU7ZQ?LN_#_P#X5?\
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M_68G_P!EK[JK^9_$VHY\6U%VC!?^2W_4_P!$OHZT8TO"_#R7VYU7_P"3N/\
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MCX=^"?A%X T7X6_#;PY;:/X?\/:9#I^C:7:+B.UMHD"1QKGG 4 9.2>I))H
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MNK\.>'/#_@_P]8>$O"6A6>EZ5I=E%9Z9IFGVRPV]I;Q($CABC0!8T5%"JJ@
M   8% 'XT_"_X#?\%*]-_P"#D67PKXL_X* ^%M3\:6?[+UIJ>O>+8?@Y!!!J
M/AQ?$L"R:.EF+LK!,TGSB\#LRCY=AZU^LO[1_P 7?AW^SY\,[SXW>/-";49M
M'"0:%865HDNH:EJ%RZP6VGV8;DW%S.\4"*" 6D&XA02.@C^%GPQA^)<GQHB^
M'&@KXQET8:1+XL71X!J;Z?YHE^QFZV^:8/, ?RMVS< V,\T_Q5\-_ OCC6]
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M+:WB6..-0L:(,!0!@ #L*=117XJ;A1110 4444 %%%% !1110 4444 %%%%
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MC_TZ\7N/*@8H&'*RSPFNC"X:IB\3"C#>3M_P?EN)NR/Y^/\ @LU^VFW[>?\
MP44^(/QNTK53=>&[74?[#\%E7R@TFS)BAD3T69A)<X[-<-7RW117[/0HPP]&
M-*&T4DOD8/4****U **** "OWI_X,WOV;6T[P'\7OVN-7TX[M4U.S\*:%<,F
M"$@3[7> 'NK-/9\],Q$?3\%J_L _X(R_LJ2_L;?\$TOA3\&=5TS[+K3^'5UG
MQ+&R8D74+]C=S1OZM%YHA^D(':OF.+,4J&6>R6\W;Y+5_I]Y<%=GU!1117YD
M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%?A1_:04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ5"<;O)AC"!G(^\[8+,W5F9B>376T45^.RE*<G*3NV;A1112 **** "BBB@
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MP_Q3_P"#K;_@K-\04>/PCX@\ ^!MP(5O"_@Q9F7W_P")C)=#/X?A7RW\<?\
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M6X>YU"Y( >ZNI< S3/@98]  JA555'IU%%?G<YSJS<YN[>[-0HHHJ0"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'XT\(^--2N-0T^T6.&:RTVZOI[>UEE+2QRVSEE9/)DCQ@Q(%TOV>?C=\,/\
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MFUOQ+HNB^,[T0V(/A<3E;2"21H;*X,5S+";B%$D4L) 1(BN)_"_P&U7_ ()
M_P#!=_X)?!7]F7XC>,+CX._M.^'/$-OXB\!^)?%%WJT=AJ^EVC71OH9+J1Y-
MQ)MLL[,^'N 6*E50 _6ZBOR4_9T^'OQG_P""RW[$?C#]H[Q1\%O /B+7_B'X
MB\46W@_Q?K_QFU?3-3\!K:ZC=6>G0V%M:Z/.NG_9T@MYF\J8FY8F28DRE%U?
MBQ\0OVZO@QX1_8E_X)(_M@?'FVU#QY\8/%FK67Q9^(G@77KP2ZMX>T8?:$LD
MO9(K>Y2:[AEM8)YU"RMY<V'_ 'I8@'NO[?\ ^U7^UO\  '_@IC^R5\%/A_\
M%#1+7X;_ !@\7:SIWBG0H_"J-?RK96$<P5KR:20;'>7.(HH77RP"[ACC[=O(
M[J6SEBL;A89FC80S/'O"-CABN1N /.,C/K7Y3_\ !0?]DCX%?L[?\%C?V"/%
MGP*\%0>%+?6_''B.TU70-$+0:;-)!ID1CNA:J1$EP5D=7F50\HV;V;8N/U<H
M _,OX)?\%@?VHO!/_!:_Q#_P3-_;"T[P9-X$U/4;K0_ACX_T#P]<Z;)>ZY#I
MFFZM]BN/-O)T+?9-1BC.T+F5X<?ZS:/T9^)?Q%\&_!_X<Z_\6/B+KD6F>'_#
M&C76JZWJ,YPEK:6\32S2M[*B,?PK\G_^"DW[&GC#]J+X+_MA_%?X'F:V^*_P
M,_:>TSX@_#74K%,W*75AX%\)RSPQD<DO"K,J#[TT,''%>V^$OVS?"'_!93X&
M_LZ?"KX>^2=+^*>G1^-OCAIUN^Y-,T?1;B-;K29.X%WK*P6@!(,MK%>$ C-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO+FYM+5H;:"-IVBM0LQ$ERS&;&5?ZZHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>mdt-20240426_g13.jpg
<DESCRIPTION>IMAGE 13
<TEXT>
begin 644 mdt-20240426_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?"?QM^&">.]:O/".DZCXWNM!F\.7TMW<7_V>);2V</:+'<^2$,@5EA4/&P
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M/BC5;;XC>(=6\+7FG>&]!N,P&TT/1XEBCT^*"*""1@EDK;OO2MO(10#]UO\
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MM'8>'YHM3:2*]N6<G[/;2"]E7S7.U/LZAF!9=U?]E/\ 9RN/VO?^#JSXP?\
M!1/X>W4&K?"GX5:/:V=IXWL9EETW4-;?PS9Z9)9P3J2DS1++>-(4)$9B4-@N
MF0#L_P#@O1_P2D_X)M_!G_@DI\7/C7J/P=TN+X@:4D>LVWQ3OPK>(M7UZYOX
ME:2ZNP UQ]HEG=7AQY2B0^7'&$39[S_P1%\+^)?^">O_  0W^'.H?MF:_/H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6K?3/A?H7A6XMY)-?>6W-S]H2661(DM8[=3/).S;0F-H=G1&O?LB_MA?#O\
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MAHY$8%64C(((Z@U\3B\%BL#4Y*\7%_GZ/9EIICJ***Y1A1110 4444 %%%%
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MZ+UC2ZJ4UM*IV6T/.5G'Y;,LV=6]*B_=ZOO_ ,#\PHHHK^MCP0HHHH ****
M"BBB@ HHHH **** "BKOA_PUXC\6ZI'H?A70+W4[V7_56>GVKS2O]$0$G\J]
MN^'O_!+3_@H[\4HTG\&?L1_$N:&3'EW5[X2N;.%_=9+A40CW!KSL?G&495'F
MQN(A27]^<8_^E-%PIU*GPIOT/!*_0O\ X-AO^4J6D_\ 8DZS_P"BDKBO#/\
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M$:=OM2;1+9GH"95$98X5WKX[KZZAB*&*IJI2DI+NC-JP4445L 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK,%H?W,Z;J6G:SIUOK&D7\-U:7<"36MU;RAXYHV 975APRD$$$<$&IZ_*/\
MX-7?^"DLW[2O[+]Y^Q;\4-?\_P 8_":UC_L"2XDS+?\ AUF"0@9Y8VLA$!Z
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4C,JJ69@ !DDGI2U\H?\%M?VJI?V1/\ @FW\1/'VC:G]
MEUW7=/'AOPVZMM<7=]F$NA[/'!Y\P]X:];(,FQ?$.=X;*\-_$KSC3CY.4DKO
MR5[OR,ZM2-&DYRV2N?ST?\%;?VOY_P!M[]OOQ]\:K+5#<Z#%J;:/X0PV472K
M0F*!T]!*0\Y']Z=J^;:**_V+R;*<'D.48?+<(K4J,(PBO**27STU[L_/JE25
M6HYRW>H4445Z9 4444 %*JL[!$4DDX  Y)I*_0+_ (-U?^"?Z?MC?MKP?%/Q
MUHHN/ _PH,&LZJLT>Z*]U(L?L%J<\$>9&TS Y!6W*G[XKY[BOB7+^#^',3G.
M-?[NA%R:ZR>T8KSE)J*\VC6A1GB*T:<=V?KG_P $&O\ @FS;?L"?LB6OB'QY
MH(@^)/Q#A@U7Q>TT>)=/AVDVNG>J^4CEG'_/6209(5<?<=%%?Y$\3<19EQ9G
MV(S?'RYJM:3D^R[17:,5:,5T21]]1HPH4E3CL@HHHKPC4**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS>_X
M.3O^"7__  W-^R&_QT^%OA[[1\2_A3:SZAIT=M%F;5](QOO+'CEW4+Y\0Y.]
M'11F8FOTAHKIP>*JX+$QK4]XO^E\Q-71_"_17W9_P<*_\$[A^P)^WUJ]QX*T
M/[+X ^)/F^(O!ODQ[8;5GD_TRQ7' \F9LJH^[#-!7PG7[)A<13Q>'C6I[25_
MZ]#!JS"BBBMP"BBB@ KZ\_X(9?MIR_L-?\%)_ 'Q(U75?LOAKQ%>CPQXQ+R;
M8_[/OG2/S7/]V&<07!]H".]?(=%8XBA#$T)4I[237W@M#^Z"BOF#_@C7^UQ)
M^VQ_P3<^%_QLU;5?M>NKH2Z/XJD=\R-J=B3;32/Z-+Y:SX])UKZ?K\6KT9X>
MM*E/>+:?R.C<****R **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OPX_X.WOVE)=2^(/PO\ V1](U#_1]*TR
M?Q5KD"-D-/.[6MIN]&1(;HXZXG![C/[CU^>/[<O_  2,_P""</\ P4\^-6K?
M%+4OVA-:T/XCSJFGW+:/XB@96:U00*IL;I"2JA/^6)C#'+9.XD_KO@EGG#_"
M_'E+.<YC-T:$9-.$'/EG)<L7)+5))R=U=W2LNJ\;.<30A1CAY58QG4=HJ4E%
MRMNHI[O;;N?S:T5^K7[07_!IQ^UYX)\_4OV=OCIX0\=VD>3'9:M%+HU])Z*J
MGSH">V6F0?T^&_V@O^"8_P"W]^RWY]Q\;_V3_&6E65MGS]8M=+-]IZ >MW:F
M2 ?B]?Z.</>)WA_Q5999F5*<GM%RY)_^ 3Y9_P#DI\U5P6+H?'!K\OO1X311
M17W9RA1110 5_5%_P1+_ &)(?V&_V /"7@K6M(^S>+/%$(\1^,S(F)%O;I$*
MV[=P8(1#"1TWQN1]XU^!/_!%7]D9?VS/^"B_@'X=:QI8NO#VAWI\2>*T=-R&
MPLBLGEN.Z2S&" ^T]?U65_$WTM>,Y16#X7P\M_WU6WSC3B__ ">33_N/L?29
M#AOBKOT7ZA1117\2'T@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!\(?\ !Q3^PLG[:_\ P3>\
M37WAG1!<^,?AIN\5^&&CCS+*D"-]MMEQR1);>80@^])%#Z"OY3J_N>DCCFC:
M&:-71U(96&00>H(K^/;_ (*^?L?+^PS_ ,%$OB7\ ]*THVF@PZXVI^$D5<(-
M*O +FV1#_$(ED\@G^]"U?>\'XYRA/"2Z>\OU_1_-F<UU/FJBBBOMS,**** "
MBBB@#]TO^#-_]J$LGQ;_ &,M9U+[OV;QCX>M2_\ N6=^0/\ P7]/4U^YU?R5
M?\&__P"T6W[-G_!6/X3>(+N],.F^*-9;PKJJEL+(FI(;:$,>P6Y>VD_[9U_6
MK7YAQ5AO89HYK::3^>S_ "O\S6#N@HHHKYHL**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,;XB>++?P%X UOQ
MO=8\O2-)N+Q@W?RXV?'XXQ^-?CY=75Q?74E[=S-)+-(7ED8\LQ.23^-?IM_P
M4 \4_P#"+?LI>)FCDVRZ@MO8P\]?,G0./^_8>OS%K]\\(L&J>5XC%-:SFH_*
M*O\ G(_B#Z4V;2K\28#+4]*5)S^=25ORIK[_ #.X^'W[2?QY^%HBC\#?%76+
M."%-L5D]T9[9![0R[HQ_WS7MW@#_ (*L_&#0PEM\0? ^CZ_$D8!FMG>RG=O[
MS,-Z?@(UKY9HK[_,.&<@S6[Q6&A)OK:TO_ HV?XGX=D/B+QQPU99=F%6$5M%
MRYH?^ 3YH?\ DI]3_$75?^"/W[:'G?\ #3W[*VB6VIW*_P"D:S>^&Q%=2,>H
M6^T\BYQGNQ4=Z\'^)O\ P;(_\$Z_V@X+G6?V//VI-9\,71&[[$M_;Z]96^>0
M#$S1W"?\#F)]O7D*?;W%Q:3I=6D[Q2QL&CDC8JRL.001R#1EV"XFX<M_8&;X
MC#I;0<O:TE_W#G>/YGZ]D_TE.(J-HYQ@J6)7>-Z4WZM<T?N@CYE_:"_X-=O^
M"CGPH\_4?A--X1^)5BF3$FAZR+&]*CNT-Z(T!_V4E<GMSQ7Q#\<OV2?VH/V9
M[XV'[0'[/_B_P>?,V1SZ]H$]O!,?^F<S+Y<H]T8BOW)\ ?MK?M.?#DK'I'Q8
MU"\MPX+6NM$7J,!_#F8,Z+[(RU[3X/\ ^"J^HW]D="^-'P;TW5+2X!CO)-*F
M**T1'(,$^]9,]P74&ONLN\8_%?);+,,)0QT%UA)T:C];WA\HQ/U3)_'3PUS>
MT<3*KA)O^>//"_E*',[><E$^7O\ @TH_9EBT'X0_$G]KC6;#%UXAUB+PUH<L
MB89;6U19[AE/=9)9H5/O:U^PE<Q\&_#?PY\-_#C3%^%?PYT[PIHVH6XU&'1-
M-TJ"R2%[@><Y:* !!(6<ER,Y8DY/6NGK^0/$;BVOQSQIC,YJP</:25HMWY8Q
M2C&-UIHEK;=W?4_I++X4Z>"@J;NFKW[WUN%%%%?$G8%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %?AO\ \'CO[+-M)I7PG_;2T33,31SW'@[Q%<JOWT8/>6(..FTK?C)_OJ.U
M?N17R!_P7E_9UM_VEO\ @E%\7_"B6?FZAX?\.-XHTEPNYXYM,87C[!_>>&*:
M+Z2G%>IDN*^J9I2J=+V?H]/^"*2NC^1ZBBBOV P"BBB@ HHHH T?!_BK6_ G
MBW2_&_AF\-OJ6C:C!?:?<+UBGAD62-OP90?PK^VOX-_$K2/C/\(/"GQA\/@?
M8/%GANQUFQPV1Y-U;I.G/?Y7'-?Q!U_6K_P;[_%Z7XS?\$@_@QKEY=^9=:-H
M5QH%PI.3&-/O)[2)3_VPBA(]F%?&<94.;#4JW9M?>K_H73W/LNBBBOSXU"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#Y7_X*PZ\]G\&O#WAQ)-OV[Q'YS@?Q+%!(,?3,BG\!7P/7V1_P5RUD
MR:KX'\/*V!%;W]PX]=[0*OY;&_.OC>OZ>\-Z'L>$:#_F<W_Y,U^21_G']('&
MO%^*>,C?2FJ4%_X+C)_C)A1117W1^+A1110 5L?#WPP_C7Q]H?@V,$MJVKVU
MF O7][*J?^S5CUZU^POX?3Q)^U=X.LI8]R0WTMV<]C#!)*I_[Z05P9KBOJ66
M5\1_)"4ONBV>WPUERSCB/!X!_P#+ZK3A_P"!S4?U/U$@@AMH4MK>,)'&H5$4
M8"@#  IU%%?QMN?ZT))*R"BBB@84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G^+/#&C>-_"N
MI^#/$=J)]/U?3YK*_@/22&5#&Z_BK$5H44TVG= ?Q _%_P"'.K?![XL^*/A)
MKS9OO"WB*]TB].,9EMIWA?C_ 'D-<[7U;_P7'^&7_"I?^"M?QX\*BW\H77CJ
M;60N,?\ (1BCU#/X_:L_C7RE7[9AJOM\-"I_,D_O5SG>C"BBBMP"BBB@ K^D
M+_@T$^)#^)O^"=?C'X>7=SOF\,?%6[,$>?\ 5VUS8V<BC\95N#^-?S>U^ZO_
M  9A^-"UG^T%\/)YN$E\-ZC:QY_O#48I3_X[#7SW%%/GR:;[-/\ %+]2H?$?
MN71117Y8;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!\$?\ !62^\SXS>&]-S_JO# EQ_OW$P_\ 9*^5J^F?
M^"J[$_M&:4">G@ZV _\  JZKYFK^KN"(J'"F$2_E_-MG^8WC'4=7Q.S23_Y^
M6^Z,5^@4445]4?F@4444 %?0_P#P3$TQ+_\ :?CNG3)LM NYE/H3LCS^4A_.
MOGBOIW_@E)"C_M":S*PR4\'7&WVS=6M?,\93=/A;%M?R-??I^I^B>$M&-?Q*
MRJ+_ .?T7_X#[WZ'Z!T445_)I_J %%%% !1110 4444 %%%% !1110 4444
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M\??M(?\ "91?%TZ[9K:Z=X6EU.WU66"2V,HO'U-)(#;JB0&!]RR&=!E1^L%
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M%%?.'WX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M78QR!%;EE##E99X?6OY4J^]X/P+C">+DM_=7IU_&R^3,YOH%%%%?;F84444
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MV@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5%(CI(@DC<,K#*L#D$>M+7X@?V/N%%%% !1110 4444 %%%% !1110 4444
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MU4KJ?Q!U^!<_;M3= &C1B,^1"O[J,<9"ER TCY^&/^#8G_@C=/\  OPA:_\
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MT%_H.KVM[ WW9[2X61#^*DBK5?,RC*+LU9GZ'"<*D%*#NGU6P4444B@HHHH
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M7R'$>>K#1>%P[]][OLNWJ_P]2XQOJS31$C01QJ%51A5 P *6BBOSHU"BBB@
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MS/\ 5Y"6/YUF45V4Z%"C_#BEZ)(04445J 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2.13U5E8$$>QKYR^,_\ P3*^#'CYIM7^'%Y/X3U!\MY-NOG63-_UR8@I_P
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M6 ZCJH;NRW=T9)(LGDK&47T48%?1=%%?/U:U:O/GJ2<GW;N7L%%%%9@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSX&_MD_LF?M.:WJOAK]G3]I3P/XYU'0HDDUJP\*>)[6_FL$<E4:9(78QABI
M+ 9(- 'I5%%% !1110 4454\0:O'X?T&]UZ:%I$LK22X>-3@L$4L0/KBJC&4
MY**W9%2<*4'.3LDKOT1;HKY)_P"'M?P[_P"B1ZU_X'0T?\/:_AW_ -$CUK_P
M.AKZW_4+B[_H%?WQ_P#DC\M_XC=X6?\ 0SC_ . U/_D#ZVHKP+]GC]OGPA^T
M-\2(OAOHW@#4M.GEM);@7-U<QN@$8!(PO/.:]]KP,SRK,,GQ/L,93Y)VO9V>
MC]&^Q]QP]Q-D7%> >-RFLJM)2<>9)KWE9M>\D^JZ!117B'Q!_P""D_[!GPJ\
M>:E\-?B%^U7X.TO5]#N%M_$"7&J P:-,V,17MPH,-D^"#MG=" 0<8->>>Z>W
MT5P,'[5'[-MW\*;OXZVGQR\+R^"K&YGM[OQ;%K,3:;$\#,DV;D-Y>$9&#-NV
M@J>>*B^ _P"UK^R_^U):76H?LV?M ^#_ ![;63%;RY\(^((-0B@8;<JSP,RJ
MWS+P3GYA0!Z'17D&F?\ !0/]AS6OBF?@9I'[6OP^N?&PD\MO"$'BJU;5%;:&
MP;4/YH.T@\KT(/2O7Z "BL+X?_$WX??%;2;S7?AOXPL-:L]/UJ^TB^N-/N!(
ML%]9W,EM=6[X^[)'-$Z,#W7T(-;M !1110 4444 %%%>%?\ !17]NGPG_P $
MZ_V:[K]I/QIX$U'Q'8VNKVFGMIFEW,<4K-.Q4-NDXP,<UWY7EF/SK,:6 P4.
M>M5DHPBK*\F[)7;2U?=DSG&G!RD[)'NM%?D3_P 1=7[.?_1H?C;_ ,'EG_A1
M_P 1=7[.?_1H?C;_ ,'EG_A7ZC_Q /Q=_P"A5/\ \#I?_)G#_:F _P"?GY_Y
M'Z[45\M_\$N/^"HW@+_@J+X"\4^/? 7PMU?PM#X6U>'3[BWU>\BF:=I(O,#*
M8^  ..:^I*_-,[R3-.',TJY;F5)TZ]-I2BVFTVDUJFULT]&=M.I"M!3@[IA1
M17CGCK_@H)^QC\.?B!?_  I\2_M#: _B72<?VUH>D22:C<Z5G./M<=HDAM.F
M?WVSCGI7E%GL=%>=^"OVN/V7OB58ZAJGPY_: \(^(+72=)M]4U.ZT/7H+N*U
MLYY9HHIG>)F55:2WG7DYS$P.,5YY;_\ !7+_ ()97-P;6+_@HO\ !(.LHB</
M\3=,4(Y. K$S@*<@CG'2@#Z'HKA_B%^TQ^SO\)_A?!\;OB9\<?"FA>#+I(WM
MO%FIZ]!#ILJ2#*,MRS>658=#NP>U-^!/[3W[.G[4.@W/BG]G#XX^%?'>F6<H
MBNM2\):Y!?P12'.$,D+,H;Y3QG/% '=45YIX[_;,_9+^%WQ9L/@-\2/VDO!.
MA>-M5:-=+\):MXDMX-1O#( 4\JW=Q))G/&T&O2Z "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/Y#?^"Y7_*6[X\?]CU+_ .BHJ^4:^KO^"Y7_ "EN^/'_ &/4O_HJ*OE&OVG
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M$>.?&'B[X'?$BPAOK+QUKMG(]_H-ZYAN[* Q6\+%I"PC*Y;$<\S#;@D_J_\
M!7XT?#+]HCX4Z!\;/@WXPL]>\,^)M+AO]'U2QF#I+#(@9<X/RL,X9#\RL"I
M((H ZBBBB@ HHHH *_/3_@YY_P"45NK?]CMHW_HUZ_0NOST_X.>?^45NK?\
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MXEUFTO3\-/B-X6L25.O66H[UTY7V]Q<.Z!CUD^QKD!10!];_  HT/1_VF_\
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M>:Y+XF\<_!/PCK6I3JJS:AJWANUN9Y JA5#221EB   ,G@ "NNHH R++X?\
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>mdt-20240426_g14.jpg
<DESCRIPTION>IMAGE 14
<TEXT>
begin 644 mdt-20240426_g14.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%VEN+B:UFA1?W:J0GWS(J5\._P#![SXM\+?\,_\ P0\"?\)'8_VV?&.H7_\
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M^!W@_P 1Z[\7M7T73K7P7)X[N((K2:_NA;R1K=BP<RO9XGDN 8E"I:7!4ML
M:7XX_P#!3W7[']O[PQ_P2X_9F\ :%XB^+&H>%)?$?C?5M>U::'1?"5@D.]!)
MY,3374\K&,+$!&%6>)V8;MH^$/\ @UQ^ O[6?@?QK\1OV7_VD[;;X/\ V6_B
M9K-KX8BE1\2>)=0A%M-) QX\F&S6[D3^\->9\D$5X_\ \%&O^$-_X)X?\'.<
MW[7'[=/@S6I?@;\8=#M;>/Q39->+':(-)M;)SOM&5W:WNK-&DA4EQ!(KA&)4
M$ _1KX'_ /!>OX*>+OV%OC7^UC\;/AKJ'AKQ%^SMK]SH'Q2\#:->#4'&I1W
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MOBEXCMHVCL/#\T6IM)%>W+.3]GMI!>RKYKG:GV=0S LNZO\ LI_LY7'[7O\
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MQM'/!/&'21",%64\$$<$&HM%T/1?#>EPZ'X=T>UL+*W7;;V=E;K%%$,YPJ*
M%&23P.]6J* "H-3TO3-:T^;2=9TZ"[M;B,I<6UU"LD<JGJK*P(8>QJ>B@#-\
M,>#O"/@JQ;2_!OA;3=(MGD,CVVF6,=O&SD8+%4 !/ Y]JTJ** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HJIX@U[1_"N@WOB?Q%J$=II^FVDEU?7<QPD,
M,:EW=O8*"3]*_.#]J#_@I%_P6I^!/PQU/]N;1O\ @G7\.Y?@9HML=5U'P=JO
MB^[7QW%H2_.VH7"(OV6T80_O7MP)I(!N#@['( /TJHKY@^,O_!5O]GKX3?\
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MI:)N3\O^"?TT^(O$WAOPAI,FO>+/$-CI=C",S7NHW:01)]7<@#\37SY\6/\
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M\3>++S-_KNNZ[XGDN(+&-W-KIL'EQHD-I ';9&BC<[R2R%Y99)& .!_X+B_
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M#8& 96F5?[E?GW17/B<)AL7#EK04EY_IV!-H_J._82_X.8_^"=W[8,EEX/\
MB3XCG^$/B^YVI_97C:X0:=-*?X8-17$)&2 //$#,> IK]#K2\M-0M(K^PNHY
MX)XUDAFA<,DB,,AE(X(((((ZU_#'7U9^P!_P6<_;T_X)SW]OIOP7^*\NJ^$8
MY,W'@'Q67O=)D7.6$2%@]JQZEH'C).-VX<5\AF'"$))SPDK/^5[?)_YW]313
M[G]>E%?GE_P38_X./_V(OV[6T_X=?$C44^%'Q%NBL2^'_$U\IL-0F/&+.^(5
M'). (I1%(2=JJ^,U^AM?%8K"8G!U?9UHN+\_T[_(M-,****YQA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!( R3
M0 5\]?M]?\%.OV3O^"<_@C_A(OCSXX636[NW:30_!>D%9M5U,\@%(L@1QY!!
MFD*QC!&2V%/Q5_P5N_X./O O[.EQJ?[/?["UWIOBOQQ#OMM6\:OMN-*T.3HR
M0#E;RX7GUA1L ^80T:_A!\3_ (I_$?XU^/-2^*'Q;\;:EXB\0ZQ<&?4]8U>[
M::>=SQRS'H   HP%     %?U-X3?1MS7BJ-/-.(^;#X1V<:>U6HNCU_AP?=K
MF:V234CQ,=G%.A>%'67?HO\ ,^K?^"D'_!<#]L#_ (*'7=YX/OM;;P3\.I)"
M(/ OAV[8)<QYX^VS_*]XW3*D+%D B,'D_&=%%?WID'#N1\+9;' 93AXT:,=H
MQ5M>[>\I/K*3;?5GRU6M5KSYZCNPHHHKVC,**** "BBB@ HHHH **** "OT+
M_P"#8;_E*EI/_8DZS_Z*2OSTK]"_^#8;_E*EI/\ V).L_P#HI*_._%S_ )-A
MG'_8/5_])9UX#_?:?JCYW_X.#_\ E,;\</\ L.V'_IKLZ^-*^R_^#@__ )3&
M_'#_ +#MA_Z:[.OC2O\ /;+?^1=1_P $?R1]J]PHHHKM **** "BBB@ HHHH
M **** "OT6_X)<?\''/[77[!4VG?"_XQ7=W\4OA?!LA&B:Q>DZGI$(X_T&[?
M+;5&,02[H\*%0Q9+5^=-%<V*PF&QM+V=:*DOZV[#3:/[./V(O^"@7[*O_!0O
MX6I\5OV8/B9;ZQ!$$75]&N (=2TB5A_JKJW)W1'@@,,QOM)1W S7M%?Q-?LX
M_M,_'C]D?XJZ?\;/V<_B=JGA3Q+IK?N=0TR; EC)!:&:-LI/$V!NBD5D;'(-
M?T:?\$=/^#C#X)_M\G3/@%^TFFG> OB[*JPVB>;Y>D^)I.G^B.Y)AG8_\NSD
MDDCRVDR53\\SCAJO@4ZM#WJ?XKU[KS^\TC*^Y^F-%%%?+EA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !116%\3OB=\/O@O\/]7^*O
MQ5\766@^'=!LGN]7U?49MD-M"O5B>Y/ "C)8D* 20*TI4JM>K&E2BY2DTDDK
MMMZ))+5MO9";25V6_&'C#PI\/O"NH>./'7B.RT?1M)LY+K4]4U*Y6&WM8$4L
M\DCN0JJ "22:_ 7_ (++_P#!PCXR_:DFU3]FG]BS6[_P]\-\O;:UXICWV]_X
MF7D,B='MK-N?EXDE7[^U2T9\H_X+)_\ !;/XE?\ !1CQ9<?"?X6S7OASX.Z7
M>YL-'+E+C7Y$;Y+N]P>F0&C@Y5."=S@%?@JO[\\$OH]8;A^%+/>)J:GBM)4Z
M+UC2ZJ4UM*IV6L8><K./RV99LZMZ5%VCU??_ ('YA1117]:'@A1110 4444
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M^S7!X?-</4JSH5(QC&M3E)R<6DDHR>K?0]# X3%1Q<).#2371GYC_P#!P?\
M\IC?CA_V';#_ --=G7QI7[._\%?O^" /_!3#]K/_ (*)?$_]I+X&?"S0M5\,
M>*=6M)M(FG\7V5M,Z)86\+%HYI%*X>)A@\]#7Q]XT_X-S?\ @LGX(5YKS]C6
M\OX5/$NB^*](O-WT2*[,GYJ*_AO+LRRY8&E!UHIJ,5;F6]EYGU[3N?$=%>Z?
M$[_@F+_P44^#<#WOQ)_8A^*.F6L8)DOV\$WDMLOUFCC:,?\ ?5>(ZAI]_I-[
M+INJ6,UM<0N4FM[B(H\;#J&4\@^QKUJ=6E55X23]'<DAHHHK0 HHHH ****
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ME9H+J"10Z2QR(2KHRD$,"00015VO@&FF:!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 444V22.&-III%1$4EF8X  ZDF@#-\<>-_"'PT\'ZG\0?B
M!XDL]'T/1;&2\U75=0G$4%K!&I9Y'8\*H )K^:K_ (+4_P#!9/QK_P %'/B5
M)\-?AA?WND?![P]>DZ)I39BDUR="1_:%TO7)Y\J(_P"K4Y(WLV/2/^"__P#P
M69G_ &Q_&]S^R5^S=XF8?"OPY?XUG5;.4A?%5_$WW\C[UI$P_=CI(X\TY BV
M_F17^@GT?/!"'#>&I\2Y[2_VN:O2IR7\&+^TT_\ E[)?."T^)NWRF;9DZS=&
MD_=ZOO\ \#\PHHHK^L#P@HHHH **** "BBB@ HHK[:_8#_X()_MS?MTQ6/C6
M7PNOP]\"7>V1?%WB^W>-KJ(_QVEIQ+<9'*L?+B;M)7A\0<2Y!PKE[QN;XF%"
MDNLG:[[16\G_ '8IM]C6E1JUY\M-79\2U[[^RA_P2^_;N_;5>"[_ &?_ -G3
M7=1TB=L#Q-J,(L=+ SR1=7!2.3'=8RS>BG(K]^/V)_\ @WU_X)[?L?1VOB'6
M_ '_  LOQ9!M=O$'CN".YABD'.8++'D1 $ J66212.)*^X+>W@M($M;6!(HH
MD"1QQJ%5% P  .@ [5_)W&7TM<%AY2H<,8/VC_Y^UKQCZJG%J37G*4'WB>[A
M\AD]:TK>2_S/Q)_9H_X-']>NT@UC]K_]J2"S! ,V@_#RP,SX/./MMVJJI'3
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M4445\L6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU]%E>5*25:LM.B_5D5A86.EV,.F:99Q6UM;1+%;V\$81(D48554<*H   '
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MQ3<*=^E*#U:_QS6OE"+6Y\KGF*]I65%;1W]?^ OS"BBBOZS/!"BBB@ HHHH
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M4*,,/25.&R"BBBO!-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUU1OW!.W!!K].*XG]G"\\;:G\"O"VK_$;69+_6;[2(KN]NIHD1F\W]XBD(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4PB7\OYML_S&\8JCJ>)V:-_\_+?=%+] HHHKZH_- HHHH *]_P#^":.FB_\
MVJ+"ZVY^Q:1>S9],Q^7_ .U*\ KZ6_X)5Q"3]H[4G(SY?A&Y8>W^D6P_K7S?
M&$W3X7QC7_/N2^]6_4_0?"FC&OXD95%_\_H/_P !?-^A^A5%%%?R6?ZAA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2+,+L1_:O.!8RLI*']E*^=Q_P2Y_9%_X63;^/3X6U4Z=:?$5OB!:^!SK4O\
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M 4444 %?NQ_P9A>#)(]+_:"^(<\'RS7'AO3K63'=%U&64?\ C\-?A/7](O\
MP:$?#:3PO_P3G\7?$*[@VR^*/BI>&!\??MK:RLXE/_?TSBOGN**G)DTUW:7X
MI_H5#XC]6Z***_+#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,$AO@MH-S;%+G6/#\WB"X8C!D&H7<UY$Q_[8S1 >RBOY.O!?A+6_'_C'2?
MGAFU,^I:WJ<%AI\ _P"6D\TBQQK^+,!7]M?PB^'&B?!SX3^%_A%X:4#3?"OA
MVRT?3P%QB"V@2&/CM\J"OC.,J_+AJ5'NV_N5OU+AN=%1117Y\:A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^8O[?GP]_X5[^U!X@6"#9;:T4U:UXQN\X?O#_W^66OTZKX^_P""L?PTDO/#
MWAKXMV4&38W$FF7[ 9.R0>9$3Z ,L@^L@K]"\,\R6!XGC2D[1JQ</G\2_%67
MJ?A/TB>'WG7AU4Q,(WGA9QJKOR_!/Y)2YG_A/B"BBBOZ6/\ /$**** "BBB@
M#U+]C/XM)\&OVAM!\2WMQY>GWDQT[56)P!!-A=Q]D?8Y_P!ROU.K\7Z_4?\
M8K^-:?'#X":5K5[=>9JNEH-.UD%LL9HE $A_WT*/GU9AVK\4\6LF;5'-*:_N
M2_.+_-7]$?V#]%WBZ,7B^'*\M_WU/\(U$O\ R627^)]SUFBBBOQ(_L,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH @U/4].T73;C6=7OHK:TM('FNKF=PJ11JI9G9CP  "23T
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M7YAQ5BO;YHX+:"2^>[_.WR-8+0****^:+"BBB@ HHHH **** "BBB@ HHHH
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M**V **** "E569@JJ22<  =:2OLS_@@C^Q6?VW?^"EW@7P?KFD_:O"_A"?\
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF03P74"75K,DD4B!HY(V!5E(R"".H([T^OP[8_LI--704444#"BBB@ HHHH
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M>3^[LODC=*R"BBBN484444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_)?UT-81MJ%%%%?*EA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCP1Q/EC?M,-*2[P]]?\ DMVOFD?T+D'C%X<\1Q2P^/A";^S5_=ROV]^T6_\
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M,97Y:]8HH JZ9HFCZ)HMOX<T/3(+'3[2U2VL[*RB$,5O"BA4CC5,!%50  N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.\6FJ6C8>UPT_J,5^C.F:9INBZ=!H^CZ?!:6EK"L5M:VT0CCAC485%50 J@
M  < "OD<PXOIQO#"1N_YGM\EO]]O0T4.Y^=/_!-G_@VH_8I_8BET_P")7QEM
MT^+?Q"MMLL>I^(;!5TK3IASFUL264LIZ2S&1@5#((SQ7Z.@ # & .@%%%?%8
MK&8G&U?:5Y.3_K9=/D6DD%%%%<PPHHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/@;^V3^R9^TYK>J^&OV=/VE/ _CG4="B236K#PIXGM;^:P1R51IDA=C&&*D
ML!D@T >E4444 %%%% !1153Q!J\?A_0;W7IH6D2RM)+AXU."P12Q ^N*J,93
MDHK=D5)PI0<Y.R2N_1%NBODG_A[7\._^B1ZU_P"!T-'_  ]K^'?_ $2/6O\
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MF:G')#<O/-"(X@0<B4LP7RR X;*E0010 O\ P3#_ ."F'_!-?X=_\$V/V??
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M!_AWX.^&]GJ&G^"M$BL(-4UJ[U:]BAX62\NI3+/+CL7D9G..K,3WH VJ***
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MOP_/&\5R(EE^;[-(KHO'RF47!'S;S76?\&ZOBG7?V3O&/QU_X(G?%:_9M=^
MWC6XU;P)/< *^J^%=2E\^&X51U(DE25ST!U!%_A-?J';6UM96T=G9VZ10Q($
MBBB0*J*!@* .  .,5^5'_!=;PW\7OV$_VW/@/_P6:_9<^'$_B76;2]/PT^(W
MA:Q)4Z]9:CO73E?;W%P[H&/63[&N0%% 'UO\*-#T?]IO_@I'XU_:0OM,@NM%
M^!>C-\.O UW)$&_XG5XL%]K]U$QZ;(_[,L0PY#P7J9Y85]1UY;^Q;^S_ 'G[
M,?[,OA7X0Z_JZZGX@MK22_\ &.M*/^0KKU[,]YJ=Z>_[Z]GN) #T#@=J]2H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^$_VC_\ @W2_X)K?M4_'/Q-^T/\ %KPQXOF\2>+=
M2:^UB6Q\6200M,5"DI&%(484<5Q/_$*C_P $D?\ H3_'7_A;2_\ Q%?I%17H
M1S;,X148UI)+S8N5'YW^#/\ @U\_X)4> _&&E>./#_A+QLM_HVI07UDTOC*5
ME$T,BR(2-O(W*,CO7Z(445SXC%XK%M.M-RMM=W!)(*S?%W@WPA\0/#MUX/\
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MF2>"8*X(#QRQQR(W5716!! -7** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>mdt-20240426_g15.jpg
<DESCRIPTION>IMAGE 15
<TEXT>
begin 644 mdt-20240426_g15.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?"?QM^&">.]:O/".DZCXWNM!F\.7TMW<7_V>);2V</:+'<^2$,@5EA4/&P
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M/BC5;;XC>(=6\+7FG>&]!N,P&TT/1XEBCT^*"*""1@EDK;OO2MO(10#]UO\
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MM'8>'YHM3:2*]N6<G[/;2"]E7S7.U/LZAF!9=U?]E/\ 9RN/VO?^#JSXP?\
M!1/X>W4&K?"GX5:/:V=IXWL9EETW4-;?PS9Z9)9P3J2DS1++>-(4)$9B4-@N
MF0#L_P#@O1_P2D_X)M_!G_@DI\7/C7J/P=TN+X@:4D>LVWQ3OPK>(M7UZYOX
ME:2ZNP UQ]HEG=7AQY2B0^7'&$39[S_P1%\+^)?^">O_  0W^'.H?MF:_/H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUO'<6[.<XQ^\ '4ANA^8_P#@@9^U1\<_VUO^"5OPY_:8_:1\9C7_ !EXEO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO%$(HP%\QI)=PR(U^SZ** "BBB@ HIEQ<06L#W5U,D<4:%Y))& 55 R22>@
M[U^;G_!0W_@Y2_9/_97EO_AQ^S3;P_%CQK;[HGN-.O-FA6$HX_>7:Y-R0<'9
M "IP094(KZ;A;@[B;C3,%@LFPTJT^MOABN\Y.T8KSDUV6IC7Q%'#0YJDK(_1
MK7_$&@^%-%NO$OBG6[/3=.L8&FO=0U"Y2&"WC499W=R%10.I) %?G1^VS_P<
MU?L0?LYF[\)?L]077Q=\30[D$FBS_9M&A<<?->NI\X="/(216Y&]37XB_MI_
M\%-/VSOV^M=>_P#VB?C#>W>DB?S;+PEI9-II%F<Y79;(=KLO022EY,=7->"5
M_9? GT4,IP:AB>*<0ZT]_94FXTUY2GI.7_;O)ZM'SN*SVI+2@K+N]_N_X<^S
MOVPO^"]?_!1W]K]KG1KWXP/X$\-SDJ/#?P^WZ<C(>-LMP&-S-D<,K2;#S\@S
MBOC2XN)[J=[JZF>261R\DDC$LS$Y))/4D]Z917]49%PWD'#.#6%RG"PH4^T(
MJ-_-M:R?FVWYGAU:U6M+FJ2;?F%%%%>V9A1110 4444 %?H7_P &PW_*5+2?
M^Q)UG_T4E?GI7Z%_\&PW_*5+2?\ L2=9_P#125^=^+G_ ";#./\ L'J_^DLZ
M\!_OM/U1\[_\'!__ "F-^.'_ &';#_TUV=?&E?9?_!P?_P IC?CA_P!AVP_]
M-=G7QI7^>V6_\BZC_@C^2/M7N%%%%=H!1110 4444 3:=J.H:1?PZKI-]-:W
M5M*LEO<V\I22)U.0RLN"I!Y!'(K[N_8N_P"#CS_@IK^R ;3P_JOQ53XG>&+<
MJIT'XC![V5(QP1%>AEN4('"AI'1<#Y#TKX+HKGQ&$PV+AR5H*2\U_5@3:/Z>
M_P!A7_@Z!_X)\?M6R67@_P"-5_<_!OQ9<E8S;>+;E9-(ED/:/44"H@][A(!V
M&:_1[2M5TO7--M]:T34K>\L[N%9;6[M9EDBFC895T920RD$$$'!%?PS5],?L
M&?\ !73]NO\ X)T:Q#_PS[\8;F3PX)M]YX%\1;KW1KG)RW[AF!@9CUD@:-SC
MEB.*^2S#A"G*\\)*S_E>WR>Z^=_4T4^Y_8117YK_ /!-K_@YG_8N_;.:P^&_
MQ]FA^$'C^X*Q):Z]?AM&U&4\#[/?,%6-F/2*<(<L%5I3S7Z3HZ2()(W#*PRK
M Y!'K7Q.*P>)P57V=>+B_P"MGU+33%HHHKF&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/O[?/_  4S_92_
MX)S^!!XH^/GC8-K%Y SZ%X.TC;-JFJ$9&8XBP"1Y!!FD*QC&-Q;"GXN_X*W_
M /!QQ\/_ -FN75/V>_V'[K3O%GCV$O;:KXP;;/I.@R=&6+&5O+E>>/\ 4HV-
MQD(:,?@W\5/BQ\2_CAX^U+XI?%_QSJ?B3Q%J\YFU'6-7NVFGG;MEF/"@8"J,
M*H     K^I?";Z-V;<5QIYIQ%S8?".SC#:K57?7^'!]VN9K9)-2/$Q^<4Z%X
M4=9=^B_S/J__ (*2_P#!<7]KS_@H;>7G@V36'\#?#AW*P>!O#]XX6ZCSP;ZX
M 5KMNGRD+$" 1&"-Q^+Z**_O3A_AS(^%<MAE^4X>-&C':,5N^[>\I/K*3;?5
MGRU6M5KSYZCNPHHHKVS,**** "BBB@ HHHH **** "OT+_X-AO\ E*EI/_8D
MZS_Z*2OSTK]"_P#@V&_Y2I:3_P!B3K/_ **2OSOQ<_Y-AG'_ &#U?_26=> _
MWVGZH^=_^#@__E,;\</^P[8?^FNSKXTK[+_X.#_^4QOQP_[#MA_Z:[.OC2O\
M]LM_Y%U'_!'\D?:O<****[0"BBB@ HHHH **** "BBB@ K[W_P""7W_!P=^V
M3_P3MN-.^'?B35)OB1\+H"L;^#?$%ZWGZ=#_ -0^Z(9[? Z1,'AZX12V\?!%
M%<^)PN'QE)TZT5)>?]: FT?V1_L"_P#!3#]D?_@I)\.#X\_9J^(B75Y:1(VO
M>%-3"P:MH[-T6XM]Q^4G@2H7B8@A7)! ]]K^(OX(_'7XP_LV_$O3/C'\!_B-
MJOA7Q/I$OF6&L:/=&*5/5&[2(PX:-P4<$A@02*_H;_X(X_\ !RO\*OVP9-)_
M9T_;4FTWP1\3IREKI7B%2(='\2RG 506.+.Z8\>6Q\N1O]6REEB'Y[G'#-;!
MIU</[T.W5?YKS_X<UC-/<_5FBBBOE2PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHK$^(_Q'\!_"#P)JWQ/^)_BRQT+P_H=D]WJV
MK:C.(X;6%!DLS'\@!R20 "2!5TJ52O4C3IQ<I2:225VV]$DENWT0FTE=EOQ7
MXK\,>!?#-_XS\:>(;+2=(TJTDNM3U/4;E8;>U@12SR22.0J*H!)). !7X%_\
M%E_^#A?Q=^TM-JG[,W[$6O7V@?#PE[77?&$6Z"_\2KRK1Q='MK1N>.))1PVQ
M2T;>4_\ !9K_ (+<_$3_ (*'^*KKX.?!^ZOO#WP<TR\_T33B3'<^(Y$;Y;N\
M Z)D;H[?HO#-EP-GP#7]]>"7T><-D,*6>\3TU/%:2IT7K&EU4IK:53LMH><K
M./RV99LZMZ5%VCU??_@?F%%%%?UN>"%%%% !1110 4444 %%%% !1110 45?
M\.>%_$WC#5$T/PEX=O\ 5+V7_5V>G6CSRO\ 1$!)_*O;OA]_P2M_X*1?%!8Y
M?!_[$'Q,>&4 Q7.H>$[FRA<>JR7*QH1[@XKS<PSG*,JCS8W$4Z2_OSC'_P!*
M:+A3J5/A3?H>!5^A?_!L-_RE2TG_ +$G6?\ T4E<7X9_X-W_ /@KSXFC%Q_P
MRF-/B8\/J?C/1XC_ -\?:RX_[YK[D_X(>_\ !%G]O']B']N>P^/W[0O@K0M-
M\/6WAG4+.22S\26]U-YTZ*$ 2(GC(.3TK\;\5/$3@+%^'V:X/#YKAZE6="I&
M,8UJ<I.3BTDE&3NV^AZ&!PF*CBX2<&DFNC/S'_X.#_\ E,;\</\ L.V'_IKL
MZ^-*_9W_ (*^_P#! '_@I?\ M9_\%$OB?^TE\#?A9H6J>&/%&K6DVD33^+K*
MVF=$L;>%BT<KJ5P\;#!YZ&OD'QG_ ,&Y'_!93P4&FN?V.+G4(5SB;1O%VCW>
M[Z)'=F3\U%?PWEV99=' TH.M%-1BK<RWLO,^O:=SX@HKWKXE_P#!+;_@I!\(
M('O/B%^PU\4K&UC)\R^3P5>3VZ8]9H8W0?BW->&ZKI&JZ%?R:5K>F7%G=0MM
MFMKN%HY$/H58 C\:]:G6I55>$D_1W)*]%%%: %%%% !1110 4444 %%%% !1
M110!^P__  1&_P"#E'Q3\ IM)_95_P""@WB>]USP+\EIX<^(5R6GOO#R\*L-
MV>7N;0< /S+$./G3 C_H,\.>(_#_ (P\/V7BSPGKEGJ>EZG:1W6G:EI]RLT%
MU!(H9)8Y$)5T92"&!((((K^&ROTD_P""&_\ P7L^('_!.SQ/9?L__M!ZE?\
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MM*,E)>7]:&;304445N 4444 %%%% !1110!^CO\ P0=_X+D^+/\ @G%X^@^
MOQWU2\U7X)^(=0S=1?-+-X5N9&^:^ME&2823F:!>O,B#>&63^G3PMXI\-^./
M#6G^,_!NO6>JZ1JUE%>:9J>GW"RP7=O(H>.6-U)5T92"&!P00:_ANK]<?^#<
M'_@N!+^RUXOL/V%?VK/&!'PUU^^\OP9X@U&?Y/"]_*_^HD=C\EE,YY/W89&W
MG"/(R_'<1Y"L1%XK#KWU\2[^:\_S]=[A*VC/Z+Z* 01D&BOSPU"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$42!54 *JC  ]*6BBOXG/I HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *9<VUO>6\EI=P)+%*A26*10RNI&""#P01QBGT4 ?@[_P
M7G_X-QAX:BUC]M#_ ()W^!<Z<BO>>-?A=I-ODVH&6DO--C7K'U9[51\G)B&W
M]VGX@].M?W05^%7_  <8_P#! \6G]N?\%"OV)?!>(OWE_P#%#P-I=O\ <ZM+
MJUI&HZ=6GB4<<R@8\S'W?#W$+DUA<4_*,G^3_1_>9RCU1^&E%%%?<F84444
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MC]FHJ2<Z=.-FW**=X^TEW6JA%K<^8SZM4<XTK>ZM?5_\ HT445_8Y\\%%%%
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MXKU6*;?!97_]G6V#D!;=1$<>Q=7;_@5?H_A?ERQO$OMY+2E%R^;]U?FW\C\
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MB@ K\6?^#QC]F&#7/@Y\+/VP-&TL?:_#^N3^%]<N(TRSVMW&US;%SV2.6WG
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M%=-6?=X$T)'^7&H3R+ZG_1U4_P#H7YU\85_3GAK05'A&C+^=S?\ Y,U^2/\
M.?Z0N->+\4L73Z4HTH+_ ,%QG^<F%%%%?>'XF%%%% !6IX)\-S^,O&>D>$+7
M/FZKJ=O9Q[>NZ614'ZM677JW[#_A\>)/VJ_!E@8]PAU)[L\=/(ADF!_-!7#F
M>*^I9;6Q'\D)2^Y-_H>SP[ERSCB#"8!_\OJM.'_@<U']3]1K6V@LK6.SM8@D
M4,82-%Z*H& /RJ2BBOXU;;=V?ZU)**L@HHHH&%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5M
M:T;3/$6C7?A_6K-+BSOK:2WN[>0966)U*LI]B"1^-6:*-@/XBOCS\,+SX)?'
M+QG\&-1D9KCPCXKU'19V<8)>UN9(&)]\QFN4KZT_X+L_#4?"C_@KI\=O#"P>
M6+OQH=9  Z_VC;PZ@3^)N2?QKY+K]MPM7V^&A4_F2?WJYSO1A1116X!1110
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MHJOXE95%_P#/Z+_\!][]#]!****_DP_U!"BBB@ HHHH **** "BBB@ HHHH
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M04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ24BJJ*$10 !@ #I2U^.8S%5,;B95ZF\G_PR^2T-DK(****YAA1110 4444
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M;&$,P(@$3B1T<)*"GEL ?0OQ[^-?QO\ VC_V[OVH_P!GC3OC3XK\!:%^S_\
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M(-?F]^VC^QUK'[.WB-O$_A:":Z\(:C.19W!RS6,AY^SRG_T%C]X#!Y!S^_\
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M5\I+5?-/U/Z=X1^E#BZ$8T.(\+[1?\_*5E+U=-M1;[N,HKM$_6*BOBKX:?\
M!66[C$=G\7_ABL@Z2:AX>GVG_OQ*<$_]M!]*]U\!_MX_LN>/MD-O\3(-*N'Z
MV^NQ-:;?K(X\O\G-?FN8\%\396W[7#2:76/O+_R6]OG8_H;(/%SP[XCBOJN8
M0C-_9J/V<K]K3LF_\+9[!15/1/$?A[Q+:"_\.:[9ZA >DUE=)*GYJ2*N5\S*
M,H2Y9*S/T6G4IU8*<&FGLUJ@HHHJ2PHHHH ***Q?'7Q(^'?POT5O$GQ,\>Z+
MX=TY,[[_ %W5(;2%<=<O*RJ/SII.3L@-JBOB_P#:(_X."O\ @DQ^SE#-#J_[
M6.D>+-0C!\O2_A["^M/*1U GMP;93_ORK7Y^_M3?\'CSRVUQHO[%O[)QBD;(
M@\0_$N_!VCH#]ALWY/?/VG'L:]3#9)FF+?N4FEW>B_']"7)(_="66*")IYY%
M1$4L[N<!0.I)["OA;]N?_@XC_P"";O[%-O?>'[/XI)\2O&%L&1/"WP_E2\5)
M1QMGO ?LT #<,-[R+S^[)&*_G<_; _X*[?\ !1#]N:*YTC]H+]IC7+K0;ECO
M\*:*RZ;I17LCVUL$68#L9=[?[5?-M?48'@^$;2Q4[^4?\W_DO4ES['WK_P %
M#O\ @XF_;\_;SAU#P)I/BA/AEX O0T3^$O!ERZ37<)XV7=Z<37&02&1?*B8'
MF,U\%445]?AL+A\'3]G1BHKR_K7YF;;84445T %%%% !1110 4444 %?M+_P
M;3_\$09/B7K.D_\ !1C]K3P>1X<TZX6Y^%OAC4H/^0K<H<KJLR,/^/>-AF%3
M_K''F?<1/,\@_P"#?[_@A%K7[=7BRQ_:P_:C\.SV?P;T6^W:;IEPC1R>,;J)
MN8DZ$6:,,2R#[Y!B3GS&C_I3TS3--T33;?1M&T^"TL[2!(;2TM8ECBAB10JH
MBJ %4    8 &*^+XDSU4HO"8=^\_B?;R7GW[;;[:0CU9/1117Y^:!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 50\3^&/#_C/P_=^%?%6D07^G7T
M)BN[2X3<DB'L?Y@CD$ C!%7Z*J$Y4Y*479K5-="*M*G7IRIU(J49)IIJZ:>C
M33W3ZH_-7]L7]B_Q'^SMK$GBGPQ'/J'@^ZFQ;7A&Z2Q9CQ#-C\E?HW0X/!\)
MK]E]9T;2?$.E7&A:]IL%Y97<+175K<QAXY488*LIX((KX%_;&_8!UOX4277Q
M(^#]G/J/AGF6\T]<R7&ECJ3ZR0C^]RRC[V0"U?OW!/B#3S%1P.9RY:NT9O13
M\GVE^$O7?^'?&+P)Q&0SJ9UP[3<\+K*=):RI=W'K*GY;P\XZKYBHHHK]8/Y@
M"BBB@ HHHH **** "BBB@ HHHH L:;JNJ:-=K?Z/J5Q:3I]R:VF:-U^A4@BN
MWT']JG]I#PUM&E?&[Q+M7[L=SJLDZCV"REAC\*X"BN;$8+!XM6KTXS_Q)/\
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M"+8X>3_EIL3Y)/WSTS3--T33;?1M&T^"TL[2!(;2TM8ECBAB10JHBJ %4
M 8 &*^+S[B2-)/#X1WEUEV\EY^?3UVTC#JROX6\+>&O _AK3_!O@S0+/2M(T
MJSCM-,TS3K98;>T@C4*D4<: *B*H "@  #%7Z**_/VVW=F@4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4$ C!&0>HHHH ^4/VL_\
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M?9]T]4?Q/G61YOP[F$L#F5"5*K'>,E;YKHT^C3:?1A11178>4%%%% !1110
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M10 4444 %?R&_P#!<K_E+=\>/^QZE_\ 145?UY5_(;_P7*_Y2W?'C_L>I?\
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M)BZ_IE7SI^TI_P %#O@Q^RG^V-\,/V:OC[XST7PQHWQ3\+:Y/HVOZY.(+?\
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M6OB)XOF\3;=#\,VK(\TL,EI 5T[0EC*OB*18[HQ6SF5Y?)D< 'U[^W=#$O\
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MO_!6OXL_\$LOA)X:G3]G[]KA8/B)K>H6[M'%X=TV"Y4>([*(*-JF]RM@0/\
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M?$#P[=>#_'GA73=;TF^CV7NEZO8QW-M<+G.UXY 5<9[$&N7^$7[+W[,_[/\
M=75]\!OV=O O@F:^7;>S>$?"-EIK7 R#AS;Q(7&0#SGI7=44 9'B;X?> O&E
MO=VGC'P1H^K1:A9"SOXM3TV*=;FW#%A#('4AXPS$[#D9)..:POA'^S=^SM\
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MIT]E>+$^UC%+&T;@'L=K'FM&BJA.=.:G%V:U3\PW/ST_XAAO^"5O_0I^-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>mdt-20240426_g16.jpg
<DESCRIPTION>IMAGE 16
<TEXT>
begin 644 mdt-20240426_g16.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
MT *  P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BO'OVJ_V^OV2_V']/L];_ &KOBO\ \(5IFH3+#9ZSJF@W[6$LS!V6 744
M#0^:5C=O*W[]JD[<<UY])_P6?_X)I0^!(_BE+^TLB^&)H#/%XC;PCK L'B!P
M7%Q]D\LKD$9W8H ^HJ*^<_B=_P %;O\ @G-\&_V??!?[5'Q)_:HT/3? 'Q#U
M$V/@SQ&;2[ECU297='V1Q0M(J(T;!Y'143 +,H(S]$6EW:7]K%?V%S'/!/&L
MD,T+ADD0C(92.""#D$4 24444 %%%<_\5OBEX(^"7PZUCXL_$K5)K'P_H%DU
MYK%_!IT]T;6W7[\S1VZ/)L099V"D(BL[$*I( .@HKR_]E#]M#]EW]N3P#??%
M']D[XQZ9XVT#3-8?2K[4]+CE6.&\2**9H2)40[A'-$W QAQS7J% !1110 44
M44 %%%% !15/Q!X@T'PEH-[XJ\5:W::9IFFVDEUJ.HZA<K#!:P1J7DEDD<A4
M15!8LQ  !)-?-/[.O_!:?_@EM^UC\:_^&=OV?_VRO#'B#QB\DD=GHXANK7[>
MZ EEM9KB&.*[. 6Q"[DJI(R 30!]145PW[07[2OP+_97\"I\2/C_ /$BQ\-Z
M3<:C!I]B]RLDL]_>S-MAM+6WB5YKJX<YVPPH\C8.%.#5+]GK]K7]GS]J>WUP
M_!#X@C4[WPOJ(L/%&A:AI=UINJZ)=$;EAO=/O8H;JT9@"5$L2;@"1G!H ]&H
MKYB_:=_X+-?\$P?V-?B]'\!?VD?VPO#?ASQ<WE_:-$^SW=Y)9>8 R"Z:UAE2
MTRI5OWS)\K!NA!/T+I'Q#\ Z_P" K?XJ:'XWTB[\,76E+J=MXBMM1B>QELC'
MYHN5G#>683'\_F9V[><XH V**^6O@9_P6Q_X)6_M*_'J/]F7X(?MH^%=>\:7
M$[P6&EPQ74,5_*N<QVMU-"EO=,0"0L,CE@,KFOJ6@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%VEN+B:UFA1?W:J0GWS(J5\._P#![SXM\+?\,_\ P0\"?\)'8_VV?&.H7_\
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M^!W@_P 1Z[\7M7T73K7P7)X[N((K2:_NA;R1K=BP<RO9XGDN 8E"I:7!4ML
M:7XX_P#!3W7[']O[PQ_P2X_9F\ :%XB^+&H>%)?$?C?5M>U::'1?"5@D.]!)
MY,3374\K&,+$!&%6>)V8;MH^$/\ @UQ^ O[6?@?QK\1OV7_VD[;;X/\ V6_B
M9K-KX8BE1\2>)=0A%M-) QX\F&S6[D3^\->9\D$5X_\ \%&O^$-_X)X?\'.<
MW[7'[=/@S6I?@;\8=#M;>/Q39->+':(-)M;)SOM&5W:WNK-&DA4EQ!(KA&)4
M$ _1KX'_ /!>OX*>+OV%OC7^UC\;/AKJ'AKQ%^SMK]SH'Q2\#:->#4'&I1W
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MOBEXCMHVCL/#\T6IM)%>W+.3]GMI!>RKYKG:GV=0S LNZO\ LI_LY7'[7O\
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MQM'/!/&'21",%64\$$<$&HM%T/1?#>EPZ'X=T>UL+*W7;;V=E;K%%$,YPJ*
M%&23P.]6J* "H-3TO3-:T^;2=9TZ"[M;B,I<6UU"LD<JGJK*P(8>QJ>B@#-\
M,>#O"/@JQ;2_!OA;3=(MGD,CVVF6,=O&SD8+%4 !/ Y]JTJ** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>^%+ZXCG-J;JV6ZLKN":/Y9[:X@;?&Y"/\KJR(5P?8J "BBB@ HHHH ****
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M_!T1_P $NO!ID7PUJ/C[Q84SL.@^$?*#_3[;+;D#ZBO'/%__  =U_L\V6_\
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MK))!Y]P[O(8XY)5C4(-Y)8+];444 %%%% !12.Z1(9)'"JHRS,< #UK\ZO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $&JZIIFAZ9<ZWK>HP6=E9P/
M/=W=U,L<4$2*6=W9B JJ 223@ $FOYU/^"ZW_!;36_VX/%UY^S+^S=X@GL_A
M!HUYMO+Z M')XMN8VXGDZ$6BL,Q1'[Q E<9V+'ZQ_P '%/\ P6:?XH:SJG_!
M/_\ 9;\5$>&M-N3;_$GQ)83<:M<HWS:;$R];>-A^]8?ZQUV?<1O,_(&O[R^C
MQX(PRNC2XJSZE^_DE*A3DOX:>U22?VWO!?87O?$UR?+YMF7.W0I/3J^_D%%%
M%?V$?/A1110 4444 %%%% !117W+^P)_P0 _;F_;?BL?&VL^'5^&W@6ZVR+X
MH\7VKI/=1'G?:67$L^0059_*B8=)#TKPN(>)^'^$\O>-S?$PH4EUD[7?:*WD
M_**;\C6E1JUY\M.-V?#5?0?[)W_!+']O7]M5K>^^ G[.FN7FC7!&/$^JQ#3]
M+"]V6YN"B2XZE8B[?[)S7[]?L4_\$!/^">G['$=KX@N_AP/B-XL@VLWB3Q[%
M'=K'(.=T%IM^SPX/*L5>1>/WAZU]LQ1101+!!&J(BA41%P% Z #L*_DWC+Z6
MN$H2E0X8P?M'_P _:UU'U5.+4FNSE*+[Q/=P^0R>M:5O)?YGXF?LT_\ !H]J
MEQ%;ZQ^U]^U-%;$X-QH'P\T_S&QU(^VW:@ ]L?9V&>Y[_=WP'_X(&_\ !*[X
M")#<V/[,5CXKOX@-^H^/+R75C+CNT$I^S?\ ?,0K['HK^:^(O&CQ-XGDUB\R
MJ1@_L4G[*-NUJ?*Y+_$Y/S/9HY=@J/PP7SU_,Q/ GPT^''PMT<>'?AE\/]$\
M.:>N-MCH.E0V<(QT^2)57]*VZ**_,:M6K6J.=23E)[MN[?JV=B22L@HHHJ!A
M1110 5ROQ1^!?P2^.&DG0?C3\'O"WB^Q9-IL_$_A^VOXL>FV=&%=513C*47=
M.S ^#?VA_P#@VP_X))_'^">>R^ %SX"U.?/_ !-?A[K4MB4_W;:3S;4?A#7Y
M[_M4?\&=GQ@\.Q7&O?L;_M/Z1XFB7+Q^'O'5@VG704=$2Z@\R*5S_M1PK[BO
MWZHKU\-GV:X5^[5;79Z_GK]S)<8L_C+_ &LO^"<O[;O[#FI-9?M0_LX>(_#%
MMYOEPZW):BYTR=B>!'>VY>W=CQ\H?<,C(%>)U_<OK&C:1XATJXT+Q!I5M?6-
MW"T5W9WD"RQ31L,%'1@0RD<$$8-?G5^W;_P;%?\ !/3]K1;WQ9\'=$F^#GBZ
MX#.E]X.ME;2II3T,VFL1&%]K=H#W)-?48'C"C-J.*AR^:U7W;K\27#L?R^T5
M]@_\%"O^"'7[?'_!.A[OQ/\ $KX<#Q-X&@<[/'_@\/=V")G@W*[1+9GD ^:B
MIN.%=^M?'U?74,10Q5-5*4E)=T9M6"BBBM@"BBB@ HHHH **** /U1_X-_/^
M"\NK_L2>)-/_ &0_VKO$D]W\(-6O?+T76KIR[^#KF1^6R>38NQS(G_+(DR+U
M=7_I*L+^QU6QAU32[V&YMKF%9;>XMY \<L; %75APRD$$$<$&OX9*_:__@VG
M_P""X5UX*UC1?^"<'[6GBW?H=[*MI\*_%.HS\Z=.QPFD3.W6%R<0,3^[<B+E
M&C$?Q7$F0JI%XO#K7>2[^:\^_????2$NC/WQHHHKX T"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "OS1_X.%_^"N,O[&7PJ_X97^ ?B3ROB?XVTUC?ZC:
M2XD\-Z4^4,P(Y2YFPR1=T4/)\I$9;["_X*$?MN?#G_@GW^RUXA_:.^(31SR6
M,7V;P[HQEV/J^IR!OL]JO?!(+.P!V1I(^#MQ7\H'QX^./Q+_ &E/C#XA^.WQ
MA\1R:KXD\3ZD][JEY)P"[<*B+_!&BA41!PJ(JC@"OZ;^CEX31XRSEY[FE.^#
MPTO=BUI5JK5+SA#24NC?+'5<R7BYOC_J]/V4'[S_  7_  3DV9F8LS$DG))/
M6DHHK_1D^1"BBB@ HHHH **** "O:_V)/^"?/[4O_!03XC?\*\_9P^'LM^EN
MZ?VSXAOB8-,TF-NCW%P00IQDB-0TCX.U&P:^LO\ @D)_P0!^*O[<YT_X\_M&
MG4?!GPH9EFL@(_+U+Q*F<XM@X_<VY[W# [@<1JV2Z?T&? OX!_!O]F?X9Z=\
M'O@/\.]-\,>&]+CVVFF:9!L7=@;I'8Y:61L9:1RSL>6)-?S-XN?2*RC@J=3*
MLC4<1C5=2>]*D^TFOCFOY$TD_BDFN5^S@,HJ8E*=72/XL^./^";G_!OW^R+^
MPS%I_P 0_B+I\'Q+^(\ 64^(-=LE-CILW7_0K1LJA4XQ-)ODR,J8\E:^]J**
M_@/B3BGB#B_,I8_.,1*M5?63T2[1BO=C'RBDO(^JHT*6'AR4U9!1117@&H44
M44 %%%% !1110 4444 %%%% !1110 4444 1W5K:WUK)97MM'-#-&4FAE0,K
MJ1@J0>""."#7Y9_\%0O^#7S]F/\ :JM]0^*W[&0T[X4^/Y-\TFD0P%?#VK2'
MG#P1@FQ8G'[R!=G7,+$[A^J%%=>$QV*P-7VE"5G^#]5U$TF?Q5?M6?L@?M&_
ML2_%F[^"O[37PNU#POKML"\*72!H+V') GMID)CN(B0<.C$9!!PP('FE?VD?
MMC?L1?LS_MZ?".Y^"_[3GPSL]?TN0,]A=D>7>Z7.1@7%I./G@D''(X8#:X92
M5/\ -!_P5Y_X(6?M$_\ !+_Q#-X\TMKCQI\)+V\\O2?&UK;8DL"YPEMJ,:\0
M29PJRC]U*<;2K$QK^BY/Q%A\QM2J^[4[='Z?Y?F92BT?"U%%%?2$A1110 44
M44 %+'))#(LL4C*ZL"K*<$$="#244 ?TQ?\ !N+_ ,%D9?V[?A W[+'[0OB8
M2_%GP)IJFVU"[E_>^)])3"+=$GE[F+*I-W<,DO):3;^GU?Q*?LZ_M!?%3]E7
MXW>&OVA/@GXEDTGQ/X5U-+W2[M,E2PR&BD7(WQ2(6C=#PR.RG@U_7Q_P3D_;
ML^&G_!1C]DSPU^TY\.#';/J,)MO$>B";?)H^JQ!1<6CGJ=I(9&(!>.2-\#=B
MOS3B7)U@:WUBDO<E^#_R?3[NQK"5U8]SHHHKY8L**** "BBB@ HHHH ****
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M6Z6EI D442!(HHU"JB@8  '  ':GT45_$#;;/I0HHHH **** "BBB@ HHHH
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M^'89_P"R?!-I+D?9](MV80G:?NM*2\[#L\[#H!7[>?\ !R;^VW+^RY^P=/\
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MC@ >II:\?_;J^*W_  J?]F[7+VTN?+O]90:5IQ!P=\P(<@]BL0E8'U KMR[
MU<RQ]+"T_BG)17S=K_+<\C/\XPW#V28G,\1\%&$IOSY4W9>;V7FSY_\ VL_V
M7/\ @F+_ ,%AX["P^*/BN_M/%NCV\EEH&JV.L2:??VJ,Y8I%%-NM[@,P#']W
M(V,<K7YE?MB_\&M'[8WP;^U>)_V6O&.E?%318MSIIAVZ9K$:=<>5*YAFP.Z2
MAF(XCYQ7NM>K_"']M7]H?X,B*RT'QO)J.FQ !=)UP&Z@"@8"J20\:CT1E%?U
MIP]CO$'@"E&EP[C_ &F'CMA\0N>&]VHR5I0N[Z1Y5=W;9_)'#WTDL%C)*GQ)
M@N5O_E[0_6G)_>U)^4>A^"'Q.^$WQ1^"GB^X\ ?&#X=:WX6URT/^D:3X@TN6
MTN$&2 3'*JM@X.#C![5S]?T^ZS^UM^Q1^V/X17X9?MN?L^Z3=6K A)-6TM=2
MM8F( ,D3A?/MG/9D&1_?KY7_ &F/^#7C]ECX[:1/\1_^">O[0H\./,6:#0M8
MO#JVD,_:)+E";BW [E_M#>PK]CR+Z1>40G'#<58.I@:CTYTG5H-_XXKF5^W+
M)+K(_=\BSOAOBRC[7(\9"OU<;\M1>L)6DO5I)]#\*J*^D/VP?^"2W[?'[#SW
M.H?&_P" FI-H%N3_ ,5=X>']H:4R_P!]IX0?(!["81L<?=KYOK]^RG.<HS[!
MK%Y;B(5J3VE"2DO2Z;U[K==3TJE.I2ERS5GYA2HCR.(XT+,QPJ@9)/I25^@O
M_!N?^P#'^V%^VO#\6/'>B"Y\$?"?R-9U))X\Q7FIEC]@M3G@C>CSL.05M]IX
M<5P<6<2Y?P?PYB<YQK_=T(.3763VC%><I-17FT70HSQ%:-..[/UW_P""$G_!
M-RW_ ."?W[(%IJ/CC1!#\1_B!'!JWC-Y8\2V*;2;;3O;R4<EQ_SUDEY("X^W
M***_R(XEXAS+BO/L1F^/ES5:TG)]EVBNT8JT8KHDD?>T:,*%)4X;(****\,U
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K\N?\ @YZ_X)?0?M;?LMG]KSX4^&_-^(?PIL))K];6+,NK^'P3
M)<0D#EGMR6N$]%\]0"77'ZC4V:&&YA>WN(5DCD4K)&Z@JRD8((/45U8+%U<#
MBHUZ>Z_%=5\Q-71_##17V7_P77_X)WR?\$Z_V]O$'@GPMHS6_@/Q?N\0^ 71
M/W<5G,[>99@] ;>8/$%R3Y8B8_?%?&E?LF&Q%/%4(UJ;TDKF#T"BBBM@"BBB
M@ K[J_X-V/VUO^&-/^"F7A%/$.K?9O"WQ''_  B/B/S'Q&ANG3[),<\#9=K!
MES]V-Y>0":^%:?:W5S97,=Y9W#PS0N'BEB<JR,#D,".00><UABL/#%X:=&>T
MDT"=F?W.T5X3_P $S/VKK;]MS]@[X8_M+?:TEU#Q#X8A7Q!Y>,)JEN3;7JX'
M0?:(I2!_=*GO7NU?BU6G.C5E3ENFT_D= 4445F 4444 %%%% !1110 4444
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M+QAXC3_A(?&Z31[98[^Y12+9^X,$*Q0E>F^-R/O&O*_^"?/QA_:$UKXSZ/\
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MUK42TWAK7;?Q+H4,CY)MKR/R+E4'9$EMH6(_O71/<U^T=?RJ_P#!M1^T/+\
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MVW=G^M:2BK+8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFOC-\-M*^,OP?\5_"#70I
ML?%?AJ^T>\#KD>5<V[P/D=QM<UTM%.,G&2:W0'\-6OZ'JGAC7;WPUK=JT%[I
MUW);7D#=8Y8V*.I^C BJE?0'_!5KX;_\*E_X*6?';P)';^5#;?%/6I[.+&-E
MO/=R7$(_".5*^?Z_;Z-15J,9KJD_O.<****T **** "OZ=/^#4+XD_\ ";_\
M$GK7PJ;C<?!WQ"UG20F?N"0PW^/IF])_.OYBZ_H(_P"#-7Q<;W]FWXT> _-S
M_9OCC3K_ &9Z?:;-H\_C]D_2OF^*J?/E#?9I_I^I4/B/V8HHHK\O-@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH _/W_@JY=&3]H'1;4-D1>#X#CT)NKK^@%?,-?1_P#P5'F:7]I:!&'$?ABU
M5?IYDQ_K7SA7]8\%QY.%<(O[B_'4_P P?%VI[7Q+S1_]/9+[K+] HHHKZ<_.
M0HHHH *^@?\ @F=I::A^U+9W;#)L=&O)U]B4$?\ *0U\_5]+_P#!*JW6?]HW
M4Y3_ ,L?"%RX_P# FU7_ -FKYOC&;I\+XQK_ )]R7WZ?J?H/A115?Q(RJ+_Y
M_0?_ ("^;]#]":***_DL_P!0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y1/^
M#D7PD/"7_!9?XP)%&%AU%]%OXO?S=&LBY_[^!Z^&J_1?_@Z<TY;+_@KUXGN1
MC_3/"&AS''M:"/\ ]DK\Z*_9,IES990?]R/Y(P>X4445Z @HHHH *_<'_@S
MUN:+Q1^T+X;\W]W/8>&+D(?6-]37(_[^?RK\/J_9[_@S1O9(_P!H+XVZ< =D
MO@W2Y&/NEW*!_P"AFO$XC7-DM7Y?^E(J/Q'] 5%%<M\;OC/\._V=_A+K_P ;
M?BQKRZ;X>\-Z<]YJ5UL+N5& L<:#YI97<K''&H+.[JB@LP%?DQL>%_\ !3?_
M (*D?!S_ ()E>!O"FL^.O#UWXD\1>-_%%IH_ASPKIMT(II4DN(HI[V1RK"*W
MA\Z,%RIW22PQC!DR/2?VL/VM_A_^R7X6T&_\3:1J.N^(?&?B:V\.> _!VAB(
MW_B#5KC)CMXO-=(XT5%>62:1ECBCC9F/0-^7?_!9_P /KJ?[!UE^T[\;?$.C
M/\4?B%\<?!,EYHEOK$%R?"6A0WTCV6AQ,C$'R1(\MS(ORRW<\[@^6(53V[_@
MN3-\0_AS^T%^R#_P4G\#^%]3\7_#7X)?$75F^)B>%;5M0DLM.U.&VM3J8BA#
M&1+=8;D$@':TBCC<30!]/>#/V_WTC]K#0_V*_P!J7X-S?#CQMXST2YU7X=7<
M6OQZII'BB.U :[MK>Z6.%UO($8/)!)$OR$,CN*^C*_(#_@K!^V'\#OVN_P!M
M[_@GWIO[(?C2;Q1JQ_:(MM5M]=TW1[N.U.D1269U%$N)(DCE_<L#+&C%D51O
M"[ES^OY (P1D'J#0!^?OBO\ X+F?$8^.?$&C? __ ()&?M)?$KPQH^O7>FZ9
MX]\*^%4;2M=6WF:%KJSD<CSH&=&V2#(8#(KJ_AG_ ,%KOAGXQ_83UC]N#QS^
MSIXY\'QVOQ(?P)X?\":S]F.K:]KGVJ*R2VA"R>6F;MY86+L-GV69CPO/M_[=
M/Q_TS]B']AOQ]\</"^AV\<O@WPA)'X2T:TM56.7475;73+*.-1@![J2VA50,
M#> !VKYL^,?_  2:\<ZC_P $H?@W^R?\+=7L9?B!\%_$?AGQO:?VK>&.UU[Q
M#87)O-02:8*Q3[5-<7K"0A@))4+<9- 'T-^S1^VQ;_&KX\_$3]D[XE?#K_A#
M?B9\-(--OM9T2#6AJ-E?:;?Q&2VO;.Z\J%IDW+)%(K11M'(F,,K*S=AXC_:#
ML[+]H_0?V:/"'A>76]8N]'FUOQ9=170CA\-:4-\5O/.=K;Y;FY4Q0P_*76&Z
MDW 6[!OE'2O!WQ _9U_;%^-O_!6#X\?#F[TFZ\9>%?#WP_\ A-\*8-2M;G6M
M9GC?*12M;22VZ3W5[(D<:I*ZQ0QO+,R*&"=EX(_:'^!'[ W_  D6@?M(^-[[
MQ)\7=8T1_B-\<]6\)>&[S4HM%L3B 7$ODQLUMIMI'$+:VC.96@M'E\MF\^2@
M#[!HJAX5\4^&_''AC3?&O@W7;35-(UBPAO=*U.PG66"[MI4$D4T;J2'1D96#
M#@@@BK] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?GC_P5,B\
MO]I.T?'^L\*VK?\ D:<?TKYMKZB_X*O::T'QWT+5 /EN/"<4?_ DN;@G]'%?
M+M?UAP5)3X5PC7\B_"Z/\P_%^FZ7B9FD7_S];^])_J%%%%?4'YN%%%% !7TO
M_P $JI1'^T;J:9^_X0N5_P#)FU/]*^:*^@?^"9VI?8/VIK*UW8^VZ->0X]<(
M)/\ VG7S?&,'4X7QB7_/N3^[7]#]!\**T:'B1E4G_P _H+_P)\OZGZ/T445_
M)9_J&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!_+M_P=.WB7/_  5Y\3PHX)M_
M"&AQL!_"3:!\?DP/XU^=%?<W_!R3XHB\4?\ !9KXP/;3!X;!M$LHR#T,>BV(
M<?A(7%?#-?LF4Q<<KHK^['\D8/<****] 04444 %?M#_ ,&:%ON^/?QONL?<
M\(:2GYW4Q_\ 9:_%ZOW%_P"#+_P[YNN?M#>+7C_U%IX8M(F]?,;5'8?^0T_,
M5XG$;MDM7Y?^E(J/Q'[MUQ?[0W[.WP5_:N^$&K_ /]H?X?6?BGP?KIMSJ^A:
M@\BPW/D7$=Q%N,;*WRS11N,$<H.W%=I17Y,;'Y)?\%:/^#=C]D*\_9GT>+_@
MGU^P#H@\;CXC:&=2.CZA(DO]C"X/V[)N;D)L\OJ!\V.G-?HAX4\(_ C_ ()]
M_ 71/@O\ ?@5KUOX8TDW*>&?!O@3P_=ZB5DEG>YE0.<QP;YII'WW$L<>6/S@
M#CUVB@#X\_9N_8E^+7Q2_;@O?^"H/[;VE6FF^+['09/#OP=^&EI?1WD7@31I
M"QGGN+B,F*?5+G>XE>$M'%&YB629<,OKO@_]H+]H?7_VX_%_[-_B#]D75=)^
M&NA>#;35=!^,LNN1/::W?RO&)-/2U"!XV0/+\Q<X^SL2H$D9/LU% 'S)^WA\
M*/B-^T;\>OV>_@;I_@V^N/ %A\16\=?$C6TAS:QQZ)#Y^F6$I/RL9]2FM)0G
M.5L9">!S]-T44 ?/_P +_!GC#]HK]I:\_::^+/A34M(\-> ;R]T3X/\ AK6[
M"2VG>?YK?4/$<T$JADDFP]K:;@"MH)90<7Y5?E/]H3X1_&C]G/\ ;9_;)^,%
M[\$?&OCK1?VB_@;HVG_#=_!WA6[U=4U>PTVZTV31[C[-&_V'S7GBG$]QY=OM
M=R9048#]+** /"?^"8G[/GQ#_91_X)[?!W]G/XM7:2^)O"'@'3]/UU8IQ*D%
MRL0+P*X)#K$3Y08<$1@CC%>[444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?#_\
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MN^ >D:U=W7F:KI<8T[60S98SQ* )#_OH4?/JQ':OQ3Q:R9M4<TIK^Y+\XO\
M-7]$?V!]%WBV,7B^'*\M_P!]3_"-1+_R627^)]SUBBBBOQ(_L0**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH 9<W-M96TEY>7"10Q(7EEE<*J*!DL2>  .<U_'+_P %4/VO;C]N
MC]OOXE?M(0WKS:3JWB![7PP&) 32;4"WL\+_  EH8DD8#^.1SWS7]$'_  <A
M_MU1_L:?\$XM?\*^&=;%MXQ^*I?PMX>2.3$L5M*F=0N0.H"6Q:,,.5DN8C7\
MKE??<'X)QISQ4EO[J].OXV^XSF^@4445]L9A1110 4444 ?H)_P;)?LX_P#"
M_O\ @K%X0\07]AY^F?#G2;[Q5?AE^4/$@M[8Y[$75S X[_NSZ&OZG*_&G_@S
MR_9:D\(_L^?$K]KW7; K<>,M?A\/Z$\B\_8K%#)-(A_NR3W 0_[5I^?[+5^6
M\48GZQFTHK:"4?U?XNWR-H*T0HHHKYTH**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_P!L+X7'XN?L[>)/
M"]M;>9>PV9OM- &6\^#]XJK[L%9/^!UZ9175@<75P&,IXFE\4)*2]4[GFYQE
M>&SO*:^7XA7IUH2A+TDFG\]=/,_%^BO3OVPOA WP5_: UWPK;6OE:?<S_;](
M &%^S3$LJK[(V^/_ +9UYC7]B8'&4<PP=/$TG>,XJ2]&KG^3^<Y5B\BS:OEV
M*5JE&<H2]8MK3R>Z[H****ZCS0HHHH *^@/^"=OQ[B^$/QH7PIKU[Y>B^*PE
MG<,[86&Z!/D2'T&69"?23)^[7S_2@E2&4D$'@BO.S;+</G&6U<'6^&:MZ/HU
MYIV:]#WN%^(<=PIQ!A\VPC_>49*5NC6THORE%N+\F?L_17BO[#?[1L'Q]^$4
M-OK-]O\ $>@(EIK2.WSS#&([CWW@'/\ MJW;%>U5_(V99?B<JQ]3"8A6G!V?
MZ->36J\C_4WA_/<OXFR6AFF!ES4JL5)>7=/SB[Q:Z--!1117">R%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MARIF8QVZGLTZGH#7]?.G:=8:1I\&DZ5916UK:PK#;6T$82.*-0%5%4<*H
M'  KXGB_,.6G'"0>KUEZ=%]^OR1I!=2:BBBO@30**** "BBB@ HHHH ****
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M%%%%<PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***_-'_@J[^QW^USX-_9;^(?[?7AW_@I_P#&CPO\4_!NFRZ]H'A/P=XF^S>#
M@8G!@T5-*6(?;2X*0++.7DFF<.R!6$"@'Z745PG[/.L?&7Q?^S+X'U_XW:7!
MH7Q"U3P)IEQXNLHK?,>GZS)91M=1A,\K'<-(-N>BXSWKXT_X)4_$S]HS6?\
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M4-,\'_#?4+/5_BWXAT>]>WEN]0 2YT_PW%-&0PW Q7EYM/%N;:!@5O7V?0=
M!1110!YU^U#\ -&_:,^%5YX*O/+AU&+_ $C1+YQ_Q[W*@[<GKL895AZ'/4"O
MRR\2^&]<\'^(+WPKXETV2SU#3[EX+RVE&&CD4X(_^OT/45^R5?*O_!1;]DMO
M'^BR?'3X?:87UO3+?_B=VD*?-?6J#B4 =9(P/JR#'55!_4_#?BU97BO[-Q4K
M4JC]UO[,G^DOP>O5L_FKZ07A?+B3+?\ 6#+87Q-"/[R*WJ4UK?SE#==7&ZU:
MBCX)HHHK^A3^$ HHHH **** "BBB@#Z._9$_;Z\2_!/[/X!^)AN=8\*C"6\@
M.^YTP?\ 3/)^>,?\\R>/X2,;3]^>"?'/A#XC^&[?Q?X&\06VIZ;=+F&ZM7R#
MZJ1U5AT*D @\$"OQUKM_@C^T-\4OV??$!UWX=:^8HY6'VW3;@%[6[ [2)D<^
MC AADX(R:_,N+O#K"9U*6*P-J=9ZM?9F_/L_-:/JNI_17A;X]YIPC&&69TI5
M\&M(RWJ4EV5_C@OY6[I?"[)1?ZTT5X7^SC^WK\)/CI%!H.MW,?AOQ&V%.F7\
MX\JY?_IA*<!\_P!PX;T#8S7NE?@>8Y7F&48ET,93<)+H^OFGLUYJZ/[?R#B/
M(^*<OCCLJKQJTWUB]4^TEO%^4DGY!1117 >V%%%% !1110 4444 %%%% !11
M10 4444 %%%% !117YR_\%/_ /@Y$_8^_8334?AA\&+NV^*OQ,@#Q'2-$O0=
M+TF8<?Z;>)E2RG.8(=SY4JYBR&KIPN$Q.-J^SHQ<G_6_83:1]N?M*_M0? 7]
MC_X2ZC\</VCOB7IWA;PUIJ_O;Z_D.Z:0@E888U!>>9L';'&&9L' X-?S;?\
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M6Z?D[,_B//N'LZX8S"6!S2A*E5CTDMUWB]I)]'%M/N%%%%=QXP4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT&PD^^:^TP?B_AI)+%X5KSC)/\&H_F?D.;?15S"#;RS,H2[*I!Q_\FBYW_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=\&K\2_AY<:GH]YJ^H@6G]KP7,<4VFFZDV1MO28^675/,,+ ?,Z(?@3]N/\
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M67C7]@O]I7X2?\%LO@IX%U#73X.E'@+XU>&]%3_2-=\+ZE,%M6 Z-);WSQ[
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M^$/B!X=NO!_CSPKINMZ3?1[+W2]7L8[FVN%SG:\<@*N,]B#7+_"+]E[]F?\
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LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>mdt-20240426_g17.jpg
<DESCRIPTION>IMAGE 17
<TEXT>
begin 644 mdt-20240426_g17.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?"?QM^&">.]:O/".DZCXWNM!F\.7TMW<7_V>);2V</:+'<^2$,@5EA4/&P
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M/BC5;;XC>(=6\+7FG>&]!N,P&TT/1XEBCT^*"*""1@EDK;OO2MO(10#]UO\
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MM'8>'YHM3:2*]N6<G[/;2"]E7S7.U/LZAF!9=U?]E/\ 9RN/VO?^#JSXP?\
M!1/X>W4&K?"GX5:/:V=IXWL9EETW4-;?PS9Z9)9P3J2DS1++>-(4)$9B4-@N
MF0#L_P#@O1_P2D_X)M_!G_@DI\7/C7J/P=TN+X@:4D>LVWQ3OPK>(M7UZYOX
ME:2ZNP UQ]HEG=7AQY2B0^7'&$39[S_P1%\+^)?^">O_  0W^'.H?MF:_/H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU>XN/L[I=1^!=,N=2GO;[4Y,%HV-E'>PP1IEHY;Z:%,F(NZ_6O[-GQ0_8L\
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M:.X2ZBP\N%N/M,>POO7/[AT@CC$AE$:AV4!FQR0,X&?Q/YF@!:*** "BBB@
MKA/CK^T=\+?V>?#_ /;/C_7 +B5";'2;7#W5V1_<3(POJ[84>N< ^.?M9_\
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M';#_ --=G7QI7V7_ ,'!_P#RF-^.'_8=L/\ TUV=?&E?F&6_\BZC_@C^2/\
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M4 %%%% !1110 4444 %%%5=;UO2/#>D7.OZ_J4-G96<+375U<R!$B11DLQ/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 0ZCJ%AI%A/JNJWL5M;6T32W%Q/($2)%&69F/
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M@]XXO99/"=ZQ:0Z-<\O)I4[G)RHRT3,<R1 \LT<AKX$K^U3]L+]DWX0_MO\
M[.GB;]FCXWZ*+O0_$EB8O.11Y]A<+\T-W Q^[+%(%=3T.,$%68'^0+]MO]CW
MXL?L'?M->*/V8/C)8A=5\.WI6WOHHR(-3LW^:WO(<]8Y8RK =5.Y&PRL!^G\
M.9Q_:%#V55_O(_BN_KW^_J8RC9GE%%%%?2DA1110 4444 ?2O_!)+]O#6?\
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MV<LN <U\M>%/^#@W_@@Y\<V6+X@^)[?0[F?HGC+X97+,"?6:W@G1#[EP/>O
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M_JI))604444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>OQ+8W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR?D#+%HB6 65CD#XGK]!P^)H8NDJE&2E%]C)JP4445N 4444 %%%% !1110
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MEB)W,.#R!V-7K^_L=*L9M3U2]AMK:WB:2XN+B0(D2*,LS,>%  ))/ K\G_\
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MIT[X9>&]3A,<_ACPJSK*GFQMS%>W[I'=W((#(JVELW-J68 ^@:*** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^'7_  4#D7GY+76OAN&S]98K\?\ HNO2I\49-/>;7JG^B9/)(_"NBOV,U_\
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MW;N7:P4445D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSO[*4213+G&Y6'##CJ*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU:U53+:V4LT8<9!94+#/MD5^.FY^-?\ P1X_X*F_!_\ X)R>%6_X(]?\%8/
MLOPA^(N@:YJA;QKXH@+Z)XV%]>SSM?3WCC&Z7S67[1*3#*D:DRJW[L?IG^R3
M^RO\+?V2OV;=9^$7P<33?^$-O]=U[7O#UGI:@VEM9ZG=37JV\6"5,2>>53;\
MNP*!Q7@'@WXD?\$L/^"\7_!/C0?&7[1Z_#_Q%:3>&HKKQ38ZAJ<5IJ/@K4S
MOVH+*SK/8,D@;$FX+)&%;+QMSYA_P;DZ3XU^"O\ P3^^+^@>+/B?>ZU\&/"O
MQ8\36WP/\9>))O+6_P#"=N BWT3MA5LWD2616&%WM,1A<4 >6_\ !L/^WO\
ML9?L\?\ !(KPYX%^-_[2GA/PQK-EXIUVYNM,U?5%BGCB:Z9U<H><%>1ZU^D_
M[#_B[X$?&WX7ZC^US^S[I'V;1_C!KLOB"6Z5=HU-H433(;[854HTUM86SD,-
MPX!R037P)_P:E?M"_ +P/_P1]\->%?&OQO\ "&CZG:>,]=^TZ=JOB6UMYXMU
MUO7=')(&&596&1R"#7W3^Q_^T%^S5X_\7>+_ -G[]D.\TK6O"?PXE0ZQX@\/
MZHESIMOJVH7%S=R:7;M&&1VA5A)(%;;"+B", G>(P#WFBBB@ HHHH *Q?B1_
MR3O7_P#L"W7_ *):MJL7XD?\D[U__L"W7_HEJWPO^\P]5^9QYC_R+ZW^&7Y,
M_'FBBBO[1/\ (<^@O^"9?_)TEI_V!;S_ -!%?H]7YP_\$R_^3I+3_L"WG_H(
MK]'J_G'Q5_Y*=?\ 7N/YR/[^^C-_R;F?_7^I_P"DTPKXN_X*[?#;Q'^W3HFB
M_P#!*7X?^,Y]!F^*&BZGKOCW7;/E]*\/Z<B^2#QQ]IU6;3HMO\<$=X!G:<?9
M&L:SI'A[2KG7=?U6VL;&SA::[O;R=8HH(U&6=W8@*H )))P!7PE^QO\ "_2/
M^"B_B7Q[_P %+/"G[5GCO0++Q]XAG\.>!T^'VO6<,2>%=$N)[.S\T2VTS!Y[
MK^T+_;N7"W\:E04K\U/Z&'?\&ZG[6/B_]H'_ ()]6?P/^-/FV_Q.^ 6N7/PY
M\?:==OF>*73SY=M(X/)S;A(BYSNEMYCFO'?VQ?'%Q_P4*_X.$/AU_P $P_';
MFZ^$'P=\$GXA>.O",IS:^)=9V*]FEVGW9X(#<6+B)P58M,&!##'$6>H>"_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>mdt-20240426_g18.jpg
<DESCRIPTION>IMAGE 18
<TEXT>
begin 644 mdt-20240426_g18.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BO'OVJ_V^OV2_V']/L];_ &KOBO\ \(5IFH3+#9ZSJF@W[6$LS!V6 744
M#0^:5C=O*W[]JD[<<UY])_P6?_X)I0^!(_BE+^TLB^&)H#/%XC;PCK L'B!P
M7%Q]D\LKD$9W8H ^HJ*^<_B=_P %;O\ @G-\&_V??!?[5'Q)_:HT/3? 'Q#U
M$V/@SQ&;2[ECU297='V1Q0M(J(T;!Y'143 +,H(S]$6EW:7]K%?V%S'/!/&L
MD,T+ADD0C(92.""#D$4 24444 %%%<_\5OBEX(^"7PZUCXL_$K5)K'P_H%DU
MYK%_!IT]T;6W7[\S1VZ/)L099V"D(BL[$*I( .@HKR_]E#]M#]EW]N3P#??%
M']D[XQZ9XVT#3-8?2K[4]+CE6.&\2**9H2)40[A'-$W QAQS7J% !1110 44
M44 %%%% !15/Q!X@T'PEH-[XJ\5:W::9IFFVDEUJ.HZA<K#!:P1J7DEDD<A4
M15!8LQ  !)-?-/[.O_!:?_@EM^UC\:_^&=OV?_VRO#'B#QB\DD=GHXANK7[>
MZ EEM9KB&.*[. 6Q"[DJI(R 30!]145PW[07[2OP+_97\"I\2/C_ /$BQ\-Z
M3<:C!I]B]RLDL]_>S-MAM+6WB5YKJX<YVPPH\C8.%.#5+]GK]K7]GS]J>WUP
M_!#X@C4[WPOJ(L/%&A:AI=UINJZ)=$;EAO=/O8H;JT9@"5$L2;@"1G!H ]&H
MKYB_:=_X+-?\$P?V-?B]'\!?VD?VPO#?ASQ<WE_:-$^SW=Y)9>8 R"Z:UAE2
MTRI5OWS)\K!NA!/T+I'Q#\ Z_P" K?XJ:'XWTB[\,76E+J=MXBMM1B>QELC'
MYHN5G#>683'\_F9V[><XH V**^6O@9_P6Q_X)6_M*_'J/]F7X(?MH^%=>\:7
M$[P6&EPQ74,5_*N<QVMU-"EO=,0"0L,CE@,KFOJ6@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%VEN+B:UFA1?W:J0GWS(J5\._P#![SXM\+?\,_\ P0\"?\)'8_VV?&.H7_\
M9 ND^TBU^R"/S_+SN$>_Y=^,;LC.17I?_!93]G/_ ()D_P#!4;Q#X(^!7Q6_
M:"\/?#/XEQ?!JQ\1_![XR7>MP?V/KEK-<7<<VDW#LRQ2HC6RS*!()?W\K1@B
M.9) #[.U;_@IS>_L\?L7?%;]KC]OKX+CX;S?"KQ3=Z-J'AC1=:.JG4W5;86;
M6=Q)#;^>+QKJ)HB8XPJRKYFW8Y'@=E_P70_:'^'/QQ_9=\/?M+?L;:7I?@G]
MK2PLYO!&H>$O$MS?W_AV:\D@%M#?+):QQW#>7=VCR^44,8DD(#^7A_@'PI\&
MO^"C_P"WK_P:X>.O!'C:?6?'-]\-?BRMW\.KE7DN[KQ+X9TU8XYA:R$;[V"*
M26Z>%^2ZVQC3.Q%K[=_X(5?\%O\ ]D[X_?L8?!S]E?4Y-=O_ (V^$-!T_P *
M7'@+2_"US<W4RV<:6::DLX06\5O]F5999998Q%B13SLW@'L'Q*_X+"^*?''[
M;?Q<_P""?7[&7PW\+ZEXZ^#7@.7Q)XAU#XB:S>65IJ+QI SV=G':VTA?9]I@
M5YI)(\,^$CD4%QE?L0_\%9?"O_!7[_@DU\8?COI_PPG\':YX?\,^(-#\4>'W
MOQ=PQW"Z4TRRP3;$+Q/'*IPRJRLKJ=P =OC[]HK_ (**2?'S_@N'\6/V&OC/
MX \6>#_"/A[PC>Z7HGAWX8^#+M_$/Q.UB.&#[''JEY81&\;362669(M\5H4C
MB^T,4+9\R_X-C/B_\./AQ_P23_;"\"?$#Q-'HFHZ5%JNH:F-6ADMX;2&31EM
M8Q+.ZB*.1YPT:Q,PD9E;:IP< 'T7_P &4?\ RC-^(W_9=;__ -,VD5]F?\%E
MO^"CGQQ_X):?LTP?M6_#S]ES3OB;X8L-5ALO%\<OC"32[G2%G<1V]R%6SG66
M$RE8F)965Y8L!@S%?B/_ (,G_%GA>;_@GO\ $WP+%XBL6UJW^,MU?SZ2MTAN
M8[632=+CCG,>=PC9XI%#XP3&PSD&OU@_:;_9]\ _M7?L]>-/V;/BC9^=H'C?
MPW=Z/J6%!>))HR@E3/22-BLB'LZ*>U 'SAX5_P""E_Q>^+/_  3U^#/[:/P*
M^!W@_P 1Z[\7M7T73K7P7)X[N((K2:_NA;R1K=BP<RO9XGDN 8E"I:7!4ML
M:7XX_P#!3W7[']O[PQ_P2X_9F\ :%XB^+&H>%)?$?C?5M>U::'1?"5@D.]!)
MY,3374\K&,+$!&%6>)V8;MH^$/\ @UQ^ O[6?@?QK\1OV7_VD[;;X/\ V6_B
M9K-KX8BE1\2>)=0A%M-) QX\F&S6[D3^\->9\D$5X_\ \%&O^$-_X)X?\'.<
MW[7'[=/@S6I?@;\8=#M;>/Q39->+':(-)M;)SOM&5W:WNK-&DA4EQ!(KA&)4
M$ _1KX'_ /!>OX*>+OV%OC7^UC\;/AKJ'AKQ%^SMK]SH'Q2\#:->#4'&I1W
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MOBEXCMHVCL/#\T6IM)%>W+.3]GMI!>RKYKG:GV=0S LNZO\ LI_LY7'[7O\
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MQM'/!/&'21",%64\$$<$&HM%T/1?#>EPZ'X=T>UL+*W7;;V=E;K%%$,YPJ*
M%&23P.]6J* "H-3TO3-:T^;2=9TZ"[M;B,I<6UU"LD<JGJK*P(8>QJ>B@#-\
M,>#O"/@JQ;2_!OA;3=(MGD,CVVF6,=O&SD8+%4 !/ Y]JTJ** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHKAOBC^TG\#O@VKI\0?B-I]G<H/^0?%(9KD^G[F,,XSZD >
M];X;"XG&552P\'.3Z13;^Y'%F&99=E.&>(QM:-*FMY3DHQ7S;2.YHKY ^)/_
M  5C\+V7F6?PG^&EW?OR$OM;G$$8/J(H]S,/JR&O"_'O_!0K]J/QUOAB\<1:
M';OUM]!LUAQ])&W2C\'K[K+O#/B?')2J0C2C_?>OW1N_OL?C&?\ TB/#C)6X
M4*L\3-=*4=+_ .*;C%KSCS'Z6ZAJ.GZ3:/?ZK?PVT$8R\UQ*$11[DG KS[Q1
M^UY^S-X/+KK7QJT)F3[Z6%U]K8'TQ '.?:ORW\1>+_%GB^[^W^+?$^HZI/G/
MG:C>R3O^;DFLZOL\'X086*OB\5)^48J/XMR_(_(\U^E5F4VUEF6P@NCJ3E/_
M ,EBH6].9^I^C.O_ /!3O]F'1V9=.GU_5=O1K#2=H;Z>>\9_.N/U?_@K7\/8
M7(T'X1:S<KV-Y?Q0$_@HDKX6HKZ&AX8<*45[\)S]9O\ ]MY3X/&_2.\3<4W[
M*K2I?X*2?_I?.?95]_P5UU!VQIOP'AC7UG\1ER?RMQBNY_97_;\\2?M$?%J#
MX;ZE\.K'3(I;&>X-U!?/(P,8! P5 YS7Y^5]!?\ !,O_ ).DM/\ L"WG_H(K
MEXAX(X6R_(,37H8=*<(2:?--V:6^LF>EP)XQ^).><<9?@L;CW*E5K0C*/LZ4
M4XN237NP3^YW/#_^"CO_  <^_%[]A;]MKX@?LH:'^RCX;\167@[4K>WM=8N_
M$=Q;RW"R6<$Y+HL; $&4C@] *\ST'_@]!UN(JGB?_@G?:S@GYI+#XHM%CGJ%
M?37S],BO@3_@X/\ ^4QOQP_[#MA_Z:[.OC2O@\%D&45\#2G.E=N,6]9;M+LS
M^]'*5S^@_P &_P#!Y-^RW?%/^%A?L=>/]+R1YG]C:S8W^![>:;?/Z5[;\./^
M#K#_ ())^.#&/$WBSQYX.WXW?\)'X*DE\OZ_8'N?TS7\P=%.IPIE$]DX^C_S
MN'/(_L/^$?\ P6#_ ."7OQQ:*'X>_MT_#EYYR!!9ZQXACTNXD)[+#>^5(Q]@
MN:^B-'UK1_$.F0ZUX?U:VOK.X0/;W=G.LL4J^JLI(8>X-?PT5V'PE_:$^/?P
M#U0:W\#?C9XM\&W@</\ :?"_B*YL')'<F!US^->97X,IO^#5:]5?\5;\BE4/
M[<**_ED_9W_X.<?^"LOP'>WL_$7Q>T?XBZ9 0/L'CW0(IG*]\W-MY%PQ]WD;
MGL>E?H-^S!_P>'_L[^+9+;0_VMOV:/$7@V=R$EUSPC?)JUGGO(\,@AFB3V3S
MF^O;P\3POFV'UC%37]U_H[/[BE-,_96BO$_V6/\ @HY^PW^VM:QR?LR?M->%
MO%%W)%YAT2&^^SZG&N,EGLIPEP@'J8P.#S7ME>#4I5*,^6I%I]FK,H****@
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MA*481[127W]WYL_FG.<_SOB+%O$YGB)UI]YR;MY*^B7DK+R"BBBNT\@****
M"BBB@ KZ"_X)E_\ )TEI_P!@6\_]!%?/M?07_!,O_DZ2T_[ MY_Z"*^=XN_Y
M)C&?]>Y?D?>>%W_)QLI_Z_T__2D?B1_P<'_\IC?CA_V';#_TUV=?&E?9?_!P
M?_RF-^.'_8=L/_379U\:5^89;_R+J/\ @C^2/]0'N%%%%=H!1110 4444 3:
M=J.H:1?PZKI-]-:W5M*LMO<V\I22)U.5967!4@\@CD5]W_L6_P#!QY_P4U_9
M!FM-#UKXK#XG^%X-JMH'Q%+WLJQC@B*^#"Y0XX4,[HN!\AZ5\%45SXC"8;%P
MY:T%)>:_JP)M']/G["7_  <__P#!/K]K"6S\'_&F_N/@UXLN-J?9O%UTLFD3
M2'M%J*A40>]PD [#-?HYI6JZ7KNF6^M:)J5O>6=W"LMK=VLRR131L,JZ,I(9
M2"""#@U_#/7TS^P7_P %=_V[/^"<^JQ)^S]\8+B7PV)_,O/ OB(->Z-<Y.6Q
M S P,QZR0-&YP,L1Q7R68<(4I)RPDK/^5[?)[KYW]313[G]@]%?FS_P3:_X.
M8_V+?VT38?#CX\W$/PA^(%QMB6SUZ^#:/J,IX_T:^8*L;,>D4X0Y8*K2GFOT
ME1TD021L&5AE6!R"*^)Q6#Q."J^SKQ<7_6SZEIIBT445S#"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *^:/V\_^"CWP*_9)U71O@5J'[0/PX\)_$CQI;.^@O\
M$3Q7::;IVBV:G;)JUZ;B:+?%&<B.W1A)=2CRT*(LT\'TO7D/Q5_X)]_L%?';
MQQ=_$[XW_L1_"'QEXEU!8UO_ !#XJ^&NEZC?7(CC6.,23W$#R.%1%1<L<*H
MX % 'G7["7Q^_P""<WAN&Q_94_9%_:P\'?%#Q+>1:CXF\5:GX7\5V>N7VHW+
MRH]_K6J3V3-'%)-<3QC+[!F1(XD$<85(_P!M;PC_ ,$S/V]/V'_''C;XS>(O
MAIXW^'MOX=OEE\?Z=?V.HKH\D<; 36M["SF*XC<C:(W#%B%P=VT^O?!+]C/]
MC_\ 9HU>^U_]G']E+X:_#^_U.U%MJ5[X)\"Z?I4UW"&W"*5[6%&D0,,[6)&>
M:Y;X;_\ !,G_ ()W?!_X@_\ "U?A=^Q%\+=!\1K>?:X-7TSP19136\^<^;"1
M'^Y<'HR;2,G'4T >1_\ !+C7M2_8*_X(J?"/7_V__'</@UO!W@&W?Q-J7BVZ
M\C^R+::Y;[%:SE^4DCAFM;81'Y@X$8&>*\C_ ."OWA[3])_;(_8=_P""H?AO
M5+;4/A]X*^(KZ+XK\16<PEM+73/$44%O9:F\JG:MJKD@RYV_Z1%SR,_H+\7_
M (.?"K]H#X;ZK\'OC=\/=(\5^%M<A6+5] UVQ2YM;M5=9%#QN""5=$=3U5D5
MA@@&K5W\,_ASJ'P\/PBU#P#HMQX4;21I;>&9]+B?3VL1&(Q:FW93&8?+ 3R]
MNW:,8Q0!^?O_  5U^&VI?M9_\%//V)?V8? \9O+GP7\0;KXI^./)^8:1I&E/
M:M;RW&/N)<W"O;QG^)P1V)K[4_:9^(GPE^ ?@:;]H3Q[X&M]8U?1%2S\,6]I
MIT4VJZAJ%U(L%KIMBS#=YUS/)'"JA@N9,L0H8C2^#'[-7[/O[.MO?V_P*^#/
MAOPF-4:-M3?0M(BMY+ORUV1"5U4-($7Y4#$A%X7 XK7\6_"OP!X[\4>&_&7B
M_P -Q:AJ/A#4);_PW+<2N4L;N2WDMVN%CW;#+Y,LL:NRED65PI7>V0#X#_X*
M;I^TQ^PQ_P $9OCY^U%X<\3.GQY\96MA?^-O%6@.['2!<WUI9/;6#X#I:Z=8
MS210.-K H]T0)99&.O\ !=(?V8/^"W^C?LA?LY230?#'Q1^RJGB7Q)X<M[IY
M;2+5+76#:6^M8)(6XN(F,4LHP;@JKR%W7=7WMXJ\*^&?'/AG4/!?C3P]9:OH
M^K64MGJNE:E:I/;WEO(A22&6-P5D1E)5E8$$$@UPWP)_9%_9S_9IO]2UCX+?
M#&VTG4-6M+6TU#5)KRXO+N2TME*6UH)[F221;:%25BMU811 D(BY- 'I%%%%
M !111TZT %>?_'K]ICX5?L[:&-2\=ZSNO9D+6.CV>'NKGW"Y&U<]78A>V2>*
M\8_:T_X**Z%\.FN?A_\  ZXMM5UU28[O62!):V+="$[32#_OA3UW$%1\+>*/
M%7B3QMKUSXH\7:Y<ZCJ%W)ON;R[E+NY^I[#H!T &!Q7ZEPGX;XO-5'%9C>G2
M>JCM.7_R*\]WT2T9_-GB?]('+.&93RW(.6OBEI*>]*F_E\<EV3Y4]VVG$]4_
M:/\ VV?BW^T)/+I$MXVB>'2Q$>AZ?,<2+V\]^#,?8X7@84'FO&Z**_><!EV!
MRO#+#X2FH071?F^K?F]3^)<\S_.>)<PECLSKRJU9;RD_P2VBET222Z(****[
M3R HHHH **** "BBB@ HHHH *^@O^"9?_)TEI_V!;S_T$5\^U]!?\$R_^3I+
M3_L"WG_H(KYWB[_DF,9_U[E^1]YX7?\ )QLI_P"O]/\ ]*1^)'_!P?\ \IC?
MCA_V';#_ --=G7QI7V7_ ,'!_P#RF-^.'_8=L/\ TUV=?&E?F&6_\BZC_@C^
M2/\ 4![A1117: 4444 %%%% !1110 4444 %??7_  2^_P"#A/\ ;(_X)X3:
M=\./%.IR_$GX76[+$W@_Q!>M]HTV'I_Q+[HAF@P.D3!X>H"(6WCX%HKGQ.%P
M^,I.G6BI+S_K0:;1_9+^P5_P4J_9'_X*0?#C_A/_ -FCXCQ7EU:Q(VN^%M2"
MP:MH[M_#<6^XD+G@2H7B8@A7.#CWNOXC?@9\>OC)^S/\3M,^,WP$^(VJ>%?$
M^CR^98:OI%P8Y$_O(PY62-APT;AD<$A@02*_H>_X(X?\'*'PI_;+ETO]G?\
M;,ETOP-\4)BEMI6MJ_DZ/XFE. JJ6.+2Z8\>4QV2-_JV!98A^>YQPS6P2=7#
M^]#MU7^:\_\ AS2,T]S]5****^5+"BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOKL/B:&*I^THR4EY&;5@HHHK< HHHH **** "BBB@#])O^""_P#P7/\ $_\
MP3K\<V_[/7[06K7FJ?!37[_]YG=++X3N9&^:\MUY+6[$YF@7WD0;]RR_TV^&
M_$GA_P 8^'K#Q=X2UNTU/2M4LXKO3=1L+A98+J"10\<L;J2KHRD,&!((((K^
M&ROU[_X-NO\ @M_<?LW>+=._8)_:N\8X^'>N7GE>!?$6I3_+X:OI&XM9'8_+
M9S.>">(9&R<([LGQO$F1*O%XO#KWE\2[^:\_S]=[A*VC/Z):***_/34****
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M8I]%%?AC;;/[.225D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JOJ^D:5K^E7.A:]IEO>V-[;O!>6=W"LD4\3J5>-T8$,K*2"I!
M!!(-6**-@/Y[?^"\O_!NC=?L_P &L_MG?L%>%I[KP.A>\\8_#ZSC:2;P\O+/
M=V8&3)9CDO%RT ^89BSY/XXU_<^ZJZE'4%2,$$<$5_/M_P '%/\ P02@^!LF
MK_M\_L6>#BO@V>9KKXA^"=-M_ET!V.6U"U1>EFQ.9(P,0$[E_=$B'[[A[B%U
M6L+BGKM&3Z^3\^SZ^N^<H]4?C31117VQF%%%% !1110 5]J_\$*O^"G6J?\
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M+_@5\&O$WQY^)FG_  X\,(5>Z??>797*VENI'F3-[ '@<98JO>OU6^'7P_\
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MHHKSSW0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\%?LM_"@?&GX[^'O =S 9+*:]$^IC''V6(&20$]MP78#ZN*_5]55%"(H"@8
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M!FV^'VM2+GU(A3_V>O.S>3CE=9_W9?D-;G].]%%%?CAN%%%% !1110 4444
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MMS^JVBBBOQPW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK494WU37WH#^Y"BL#X4_$+1OBW\+O#?Q6\.L#I_B?0+/5K ALYAN8$F3GO\
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ML%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH *_KP_P""&7P>?X'?\$EO@9X,GMC%->>"TUR967#;M3FDU'YO<"Z
MYZ8QVK^2[X4?#K7?B_\ %+PU\)?"\>[4_%&OV>D:<NW.9[F=(8QCO\SBO[;/
M G@W1/AUX'T;X?>&H/*TW0M*M].T^(_P001+%&/P517Q7&=>U"E1[MO[E;]3
M2FM35HHHKX T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLIKXGC# N5.&*BMO=?IT_&_WFD'T/T#HHHKX$T"BBB@ HHHH **** "BBB@
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M\3:[JUOX5T"9UP5M[9!<W;+ZJ\DULN>FZV([&OVMK\NXIQ7UC-7%;027ZO\
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MAF.(]%:23/P37Z?PYD_]G4/:U5^\E^"[>O?[NAE*5PHHHKZ4@**** "BBB@
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M(>I-D['$<A_U9(C<\QL_Z!PWGRJI83$/WMHOOY/S[=]M]\IQZH_+&BBBOM"
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M[][1?TT>'] T+PIH5EX7\+Z-:Z=INFVD=KI^GV,"Q0VT$:A(XHT4!415 4*
M   !7QO$F>JA%X3#OWG\3[>2\^_;UVN$;ZLMT445^>FH4444 %%%% !1110
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MGK1C]P<TC]7M2_X/!_\ @I-<[DTWX'?!*V5EP&;P]J\CJ?4$ZF!^8KAO%_\
MP=9_\%:_$L31Z-XH\!>'RW232/!4;E?I]JDF'YBOS:HIQR3*8O2C'[K_ )AS
M2/KKXF?\%YO^"O'Q822+Q+^W/XNLDE!!7PS':Z,5'H&L(86'USGWKYK^)7QK
M^,OQGU+^V?C#\6O$WBR\#%A=^)=>N+^7)ZG=.['//K7,T5VTL+AJ'\*"CZ)+
M\A7;"BBBMP"BBB@ HHHH **** "BBB@ HHHH *_2K_@AA_P02\=_\%#?$]C^
MT/\ M%Z7?:#\$]-N]RDEH;KQ;+&V&MK4\,EN&!66X'H8XSOW-%ZM_P $/_\
M@VW\3?M&-I'[5_[??AR]T3P 2EWX;\ SAX+[Q&O#+-=='MK,\$+Q),#D;$*M
M)_0IX=\.^'_"&@67A3PIH=IIFEZ;:1VNG:=I]LL,%K!&H5(HXT 5$50 %
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M:_X*$_!7X/?%7]I?]G']ASP7\*/#5F/$GCYO'?CA].T*WC:/PYX;$=WY4FQ
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M$$9%?7X;%X;%PYZ,U)>7Z]B&FBO11170(**** "BBB@ HHHH **** "BBB@
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M?AO^V7X&_8+\4Z[J4?Q%^(GA^^UGPS8PZ-/);26MJDKRF2X5?+C;;!,0"?\
MEG@X+H&];LM/L--B:#3K&&W1I&D9((@@+L2S,0.Y)))[DYI9+"QEO(]1ELHF
MN(49(9VC!=%;&Y0W4 [5R!UP/2@#\X/V--.\&?\ !+7_ (*9_M5>!OVC_&>D
M>#? WQR\16_Q.^&GC#Q+J,5CINH32_:#K-C]IF98EN8)I4?R=V\P'S<;<XZ3
M_@C)\!O%>L?M%_M2_P#!2SQ7H%[ING?'WXDPI\.H=3M7@GNO#.E+-;VFI>6X
M#QI=^89$5P&,<4;XVNI/WSJ&F:;JT M=5T^"YB$BN([B)74,IRK8(Z@\@]JG
MH ^;_P!HN>;]L#XRM^PYX<F9O!6BPV^I?'C486(6XM) )+/PRK#^.\ $UTO5
M+$!& ^W1./%?VC9)/#O_  7N^"NH_&F:TL_AA#^SIXH@\#2:NR1Z=#XE%W$;
M]5+XC64Z4%X.#Y2R8^4-7W?I7A_0="DO)M$T2TLWU"[:[OWM;98S<SE54RR%
M0-[E412QR<*HSP*I>.?AW\/_ (GZ$?"_Q*\#:/XATPS+*=.US3(KN R+]U_+
ME5EW#L<9% 'QE_P;JOX\D_X)?>''\4)>+H+>+O$1^' OE8/_ ,(R=4G.G[0_
MS>3LSY6>/)\O;\FVON6F6UM;65M'9V=ND,,*!(HHD"JB@8"@#@ #C%/H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ?]JG_@G=^Q)^VS
M8-:?M/\ [-?ACQ5<&+RX]8N++R-2A3&-L=[ 4N(Q[+(!P..*]HHJZ=6I1GS0
MDT^ZT8'XU?M2_P#!GE^SUXOEN-=_9#_:4U_P9.V730?%]DFK61;LB31F*:%?
M=_/;\^/SS_:._P"#9O\ X*R? "6>[T/X,:;\1=+AR?[3^'^MQW+$=L6T_DW+
M''98F ]>F?ZH:*]_"\49KA])24U_>7ZJS^^Y+@F?Q#_%3X'_ !I^!>NGPQ\;
M/A%XG\'ZD"1]@\4:#<6$V1U^2=%/Z5R]?W)>(_#'AKQCH\WA[Q=X>L=5L+A<
M3V.I6B3PR#T9'!4_B*^:OC!_P11_X)2_'.6:Y\>_L+^ XII\F:X\.:<VBR.3
MU8OI[P$M[YS7N4.,Z+_C4FO1W_!V_,ETS^0*BOZ9OB5_P:7_ /!+#QM++/X0
MO_B7X.9N8HM#\613Q(?3%[;SL1_P+/O7AOC3_@S*^$%](Y^'?[=WB32U)/EK
MK7@>WOR![F*YM\_D*].GQ5D\]Y./JG^ER>21^!=%?M/K_P#P9F_&NV=AX7_;
MG\+7B_PF_P#!ES;$]>H2XEQVKEKO_@SC_;627;8?M3?"V1,?>F74D.?H+9OY
MUU+B')I;5E]S_P @Y9'Y T5^OD'_  9R_MNM,JW/[4?PK2,GYV0ZDQ ]@;49
M_,5OZ#_P9I_M%7!'_"3_ +:G@JS&?F^P>&KNYQ_WV\5#X@R=?\OE]S_R#ED?
MC)17[P>#/^#,3PK;[)?B'_P4 U"[SS)!HOPZ2WQ["26^DS]=@^E>U?#?_@T,
M_P"";OA;R[GQ]\4?BKXHG7'F12ZY96=LWT2&T$@_[^&N>IQ3D\-IM^B?ZV#D
MD?S:UH^%?!_BWQWK</AGP/X6U'6=2N#B#3]*L9+B>0_[,<8+'J.@K^LGX1_\
M$ ?^"0OP:\J;0?V*_#NKW$>"UQXNO+O6/,([M'>321?@$ ]J^I/AQ\(OA/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **QOB/XSM?AS\/=>^(5[927,.@Z-=:C-;Q, TJP0M*4!/ )"X&?6OR"_X
MC*?V9_\ HS/QU_X/[+_"N["9;C<>FZ$.:V^WZL3:6Y^RU%?C3_Q&4_LS_P#1
MF?CK_P ']E_A7O\ _P $T_\ @XL^"_\ P4K_ &H+7]E_P/\ LY^*/#-_=:->
M:BNJ:KJMM-"JVZABA6,;LG/!K>KD>:T*3J5*345JW=?YBYHL_1>BBBO**"BO
M$/B#_P %)_V#/A5X\U+X:_$+]JOP=I>KZ'<+;^($N-4!@T:9L8BO;A08;)\$
M';.Z$ @XP:[2P_:@_9UU3X777QOTOXV>&;GP;97-Q;W7BNWU>)].C>!F2;-P
MI,>$9&#-G:"IYXH [NBO!M)_X*E?\$VM?L1J>A?MW_":]MF) N+3Q[8R(2.H
MW+*1Q7HOP,_:/_9__:=\*W?CG]G+XU>%_'6C6&IOIM]JOA/7(+^WM[Q$CD>W
M>2%F59%26-BA.0)%..10!VE%%% !1110 4454\0:O'X?T&]UZ:%I$LK22X>-
M3@L$4L0/KBJC&4Y**W9%2<*4'.3LDKOT1;HKY)_X>U_#O_HD>M?^!T-'_#VO
MX=_]$CUK_P #H:^M_P!0N+O^@5_?'_Y(_+?^(W>%G_0SC_X#4_\ D#ZVHKP+
M]GC]OGPA^T-\2(OAOHW@#4M.GEM);@7-U<QN@$8!(PO/.:]]KP,SRK,,GQ/L
M,93Y)VO9V>C]&^Q]QP]Q-D7%> >-RFLJM)2<>9)KWE9M>\D^JZ!116-\1/B'
MX(^$G@'6OBE\2_$]IHOAWP[I<^I:YJ]_+LALK2&,R2S.W95123]*\\]TV:*C
MM;JUOK6.^L;F.:&:,/#-$X974C(8$<$$<@BJ?BSQ;X4\!^&K[QGXY\3:?HNC
MZ9;-<:EJVK7L=M;6D*C+22RR$+&H'5F( H T**\-\+?\%+/V#?&5Q:)H7[4?
MA4VNH3K#I>L7=VUMINH2,<(EM>S*MM<,Q^Z(Y&+=LUM>.?V[OV+_ (7_  _T
M?XK_ !+_ &I/ GAWPQX@7=H?B'7?$MO:65^-S+F*:5E23)1L8)R%)&1S0!ZQ
M15+PUXD\/>,O#FG^,/".N6FJ:3JME%>:9J6GW"S07=O*@>.:.125=&1E96!(
M(((ZURGQY_:8_9V_9:\+6OCC]I3XY>$_ .C7U^MC9:IXOU^WTZ">Y*/((4>=
MU5G*1NVT'.$8]C0!W%%9G@_QEX5^('ARU\7^"=?M=4TN]3?9W]E*)(IESC<K
M#AAQU%:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!PO[4/_)L_Q$_[$75__2*6OXF:_MF_:A_Y-G^(
MG_8BZO\ ^D4M?Q,U]]P7_"K>L?U,ZG0*_2+_ (-4?^4MVC_]B+K?_HI*_-VO
MTB_X-4?^4MVC_P#8BZW_ .BDKZ3.?^156_PO\B%N?T_54U^TU._T*]L=%U(6
M=Y-:21VEX8P_D2E2%DVGKM)!QWQ5NJ7B349](\.W^K6JJ9;6REFC#C(+*A89
M]LBOQTW/QK_X(\?\%3?@_P#\$Y/"K?\ !'K_ (*P>!9?A#\1= US5"WC7Q1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>mdt-20240426_g19.jpg
<DESCRIPTION>IMAGE 19
<TEXT>
begin 644 mdt-20240426_g19.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNKBTOO:"Z/=****Y!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_71OMQYC],9SSG KYC_X>%_M@?\ 17O_ "@:?_\ (]>T?\%>?^:>_P#<6_\
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M#3__ )'H_P"'A?[8'_17O_*!I_\ \CUXO11_JUPY_P! 5+_P7#_(/^(A\?\
M_0WQ7_A15_\ DSVC_AX7^V!_T5[_ ,H&G_\ R/1_P\+_ &P/^BO?^4#3_P#Y
M'KQ>BC_5KAS_ * J7_@N'^0?\1#X_P#^AOBO_"BK_P#)GM'_  \+_; _Z*]_
MY0-/_P#D>C_AX7^V!_T5[_R@:?\ _(]>+T4?ZM<.?] 5+_P7#_(/^(A\?_\
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M_P H&H?_ "/1_JUQ'_T!5?\ P7/_ "#_ (B'P!_T-\+_ .%%+_Y,]HHKQ?\
MX>%_L?\ _17O_*!J'_R/1_P\+_8__P"BO?\ E U#_P"1Z/\ 5KB/_H"J_P#@
MN?\ D'_$0^ /^AOA?_"BE_\ )GM%%>+_ /#PO]C_ /Z*]_Y0-0_^1Z/^'A?[
M'_\ T5[_ ,H&H?\ R/1_JUQ'_P! 57_P7/\ R#_B(? '_0WPO_A12_\ DSVB
MBO%_^'A?['__ $5[_P H&H?_ "/1_P /"_V/_P#HKW_E U#_ .1Z/]6N(_\
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MA1110 4444 %%%% !1110 5^Z'_!EM_S<I_W)W_N<K\+Z_=#_@RV_P";E/\
MN3O_ '.5X7$O_(DJ_P#;O_I2*A\1^Z%%%%?E!L?%_P#P5Y_YI[_W%O\ VRKX
MOK[0_P""O/\ S3W_ +BW_ME7Q?7]1>'7_)&X7_M__P!.3/\ -SQ\_P"3M9C_
M -P?_3%(****^V/QX**** "BBB@ HHHH **** /M#_@D-_S4+_N$_P#M[7VA
M7Q?_ ,$AO^:A?]PG_P!O:^T*_EWQ%_Y++%?]N?\ IN!_I'X!_P#)I<N_[C?^
MGZH4445\2?L(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYMK_ .YQ_P#<'7N\-?\ ([I?]O?^DLF?PGX7T445^KF(4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"^OW0_X,MO\ FY3_ +D[_P!SE>%Q+_R)*O\ V[_Z4BH?$?NA1117Y0;'Q?\
M\%>?^:>_]Q;_ -LJ^+Z^T/\ @KS_ ,T]_P"XM_[95\7U_47AU_R1N%_[?_\
M3DS_ #<\?/\ D[68_P#<'_TQ2"BBBOMC\>"BBB@ HHHH **** "BBB@#[0_X
M)#?\U"_[A/\ [>U]H5\7_P#!(;_FH7_<)_\ ;VOM"OY=\1?^2RQ7_;G_ *;@
M?Z1^ ?\ R:7+O^XW_I^J%%%%?$G["%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5^%_\ P>D_\VU_]SC_ .X.OW0K\+_^#TG_ )MK_P"YQ_\ <'7N\-?\
MCNE_V]_Z2R9_"?A?1117ZN8A1110 4444 %%%% !1110 5^Z'_!EM_S<I_W)
MW_N<K\+Z_=#_ (,MO^;E/^Y._P#<Y7A<2_\ (DJ_]N_^E(J'Q'[H4445^4&Q
M\7_\%>?^:>_]Q;_VRKXOK[0_X*\_\T]_[BW_ +95\7U_47AU_P D;A?^W_\
MTY,_S<\?/^3M9C_W!_\ 3%(****^V/QX**** "BBB@ HHHH **** /M#_@D-
M_P U"_[A/_M[7VA7Q?\ \$AO^:A?]PG_ -O:^T*_EWQ%_P"2RQ7_ &Y_Z;@?
MZ1^ ?_)I<N_[C?\ I^J%%%%?$G["%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?U%X=?\ )&X7_M__ -.3/\W/'S_D[68_]P?_ $Q2"BBBOMC\>"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY++%?]N?^FX'^D?@'_R:7+O^XW_I^J%%%%?$G["%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X7_P#!Z3_S;7_W./\
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MA/\ [>U]H5\7_P#!(;_FH7_<)_\ ;VOM"OY=\1?^2RQ7_;G_ *;@?Z1^ ?\
MR:7+O^XW_I^J%%%%?$G["%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7X7_\'I/_ #;7_P!SC_[@Z_="OPO_ .#TG_FV
MO_N<?_<'7N\-?\CNE_V]_P"DLF?PGX7T445^KF(4444 %%%% !1110 4444
M%?NA_P &6W_-RG_<G?\ N<K\+Z_=#_@RV_YN4_[D[_W.5X7$O_(DJ_\ ;O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#@D-_S4+_N$_\ M[7VA7\N^(O_ "66*_[<_P#3<#_2/P#_ .32Y=_W&_\
M3]4****^)/V$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\8/)H>._C;KGB31_#7@_PP;K2-%\(02)H4"WA:=999#)+.\JA<R,QXV@!0
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M!_H?X!_\FER[_N-_Z?JA1117Q)^PA1110 4444 %%%% !1110 4444 %%%%
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M4CR\1E66<2XAXG)\/"$I4-.>*A&T%RUL3R14DKMJE248MN?-4]V4#YNHKO\
M]I_X-V?P$^-FL?#33-4DO+.T,4ME//CS#%)&LBJ^ !N&[:2  <9P,X' 5]CA
M,51QV%IXBB[PFE)>C5T?D^:9;B\FS.M@,5&U6E.4)*][2BVGJM'JM^I]H?\
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M% !1110!]H?\$AO^:A?]PG_V]K[0KXO_ ."0W_-0O^X3_P"WM?:%?R[XB_\
M)98K_MS_ --P/](_ /\ Y-+EW_<;_P!/U0HHHKXD_80HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_"__@])_P";:_\
MN<?_ '!U^Z%?A?\ \'I/_-M?_<X_^X.O=X:_Y'=+_M[_ -)9,_A/QE_9N^*O
MA;X&_'KPE\7_ !O\)-&\>Z1X<UR"^U'P;X@ -EJ\*-EK>7*L-K#^\KKG&Y'&
M5/U3\2O^"@__  3T\-?M0:5^VI^QK^P/KO@3QQH]\NJ:3X:O?&\$GA73M50;
MHKQ+&&S69E23YQ;I/#%N1/E"!HV^(**_3JN%HUI\\K[6W:37FD[,RN?7/[&W
M_!0K]G7P1XH^+>L?\%#_ -C+3?CW-\77%SJ/B:_U!+36M)O#)/)-/:7!B8PF
M5Y@6,1B8&).2HV5S'B3]M[P'\*O@;\0?V8_V&_A[XG\'^%?BE>69\=:QXR\4
M0ZIJ^I65HTCV^GQM;6MM%;6X>5VD 5Y)C@-($S&?FVBE]2P_M'*SUMI=VTVT
MO;2RZ!<^TE_X*M_#X?\ !&X_\$M_^&1=#.NG7OMW_"R/M2>9_P A#[;]I\KR
M=_VK9_HF_P S'D<=/DKZ'_9O_P"#B7]CO]FG]G#PK^S'X<_X(T^'-;T+PK"[
M0W'B;XC6U[<7=Y*%^TWLK2Z(?WTS(I8C  5$4!$11^4U%85<IP%:+C.+LY.7
MQ27O/=Z/_A@YF?2'_!43]O\ TS_@HS^T+IWQD\,_ 73OAEH>B>$[;0=$\&:3
MJ*7-O90Q37$[LK1V]NHWRW,KD",8SU/6L?\ 9B_:M\&_LK? WXB7'P_\.ZF?
MC!XULO\ A'=&\6L(UMO#6@3H?[0DM6W&3[=<C%OOVKY4+2E7W28'@]%=,<+0
MC05%+W5;3T[]_.^_45SZE_X)#_\ !3+Q-_P2O_:O7X^Z?X)'B71-5T271/%>
M@BZ\B6XLI)(I=\,A#!)HY(8W7((8!D.W?N'4?M6?\%-? OB[_@G;X%_X)@_L
MR>#]>M/ GA?Q/>^(-;\3>+$@BU'5[F:[NIX;<6\$DL<,,(NB"WF.TK1(V(\%
M6^,J*SG@<-4Q"K2C[VC^:O9_*[_I(=V%?NA_P9;?\W*?]R=_[G*_"^OW0_X,
MMO\ FY3_ +D[_P!SE>=Q+_R)*O\ V[_Z4AP^(_="BBBOR@V/B_\ X*\_\T]_
M[BW_ +95\7U]H?\ !7G_ )I[_P!Q;_VRKXOK^HO#K_DC<+_V_P#^G)G^;GCY
M_P G:S'_ +@_^F*1Z#X)_:6^(_@CX;W/PBB@T?5/#MS<-.=,UK28[E(Y#C+H
M6&0<@$<\'D8)-8\/QF^(UMXVTKX@VGB#R=1T+RQHWDVT:0V2(25CCA"^6J<M
ME0N"68G)))Y:BOJ(Y9E\9SFJ4;SOS:+6ZL[^JW[]3\WGQ%GM2E1IRQ,^6ERJ
M'O/W5%WBEKHHO6/\KVL>A^//VF_B5X^U*]UR\M]%T[4=3M6M]4U/1M&BM[F[
MB8897E W?,.&P1N'RG(XJAX+_:!^*7P_^&NN_"7POKR0:)XBW?VE;M;(S'<@
M1]K$97<@"GV'&#S7%T4HY5EL:"HJC'D33M96O'X?NZ=BY\3<0U,;+%O%5/:M
M23ES--J:M-73^U?WN^[U-CP!X[\2_#+QC8>._!]XEOJ6FRF2TFDA60*Q4KDJ
MP(/!/6D\>>.?$?Q*\7W_ (Z\77:3ZEJ4WFW<R1+&&; &0J@ < =*R**Z?J]#
MZQ[?D7/;EYK:VO>U][7UMW/.^OXWZC]2]I+V/-S\EWR\]N7FY=N:VE][:&[J
MGQ"US4_ >F?#=8;:VTO3;J:Z\NUC96NKF3 ,TQ+'>X0!%Z!5& .6)WOAK^T-
MX\^&7AJ3P7I]OI^I:0^K0:I%IVJPN\<%Y"RLDR;'1@<HH*DE6 P5-<)1657
M8.M1=*<$XM\UO[U[W];]3JP^=YMA,6L31K2C-1Y+I_8Y>7EMLX\NEFK&OX[\
M=>*/B7XOO_'7C356O=3U*;S;JX=0-QP   .%4* H X  %9%%%=%.G3HTU""2
MBE9):));)>1Y]>O7Q5>5:M)RG)MR;=VVW=MMZMMZMO<^T/\ @D-_S4+_ +A/
M_M[7VA7Q?_P2&_YJ%_W"?_;VOM"OY@\1?^2RQ7_;G_IN!_H]X!_\FER[_N-_
MZ?JA1117Q)^PA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\FER[_N-_P"GZH4445\2?L(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?A?_P 'I/\ S;7_ -SC_P"X.OW0K\+_ /@]
M)_YMK_[G'_W!U[O#7_([I?\ ;W_I+)G\)^%]%%%?JYB%%%% !1110 4444 %
M%%% !7[H?\&6W_-RG_<G?^YROPOK]T/^#+;_ )N4_P"Y._\ <Y7A<2_\B2K_
M -N_^E(J'Q'[H4445^4&Q\7_ /!7G_FGO_<6_P#;*OB^OM#_ (*\_P#-/?\
MN+?^V5?%]?U%X=?\D;A?^W__ $Y,_P W/'S_ ).UF/\ W!_],4@HHHK[8_'@
MHHHH **** "BBB@ HHHH ^T/^"0W_-0O^X3_ .WM?:%?%_\ P2&_YJ%_W"?_
M &]K[0K^7?$7_DLL5_VY_P"FX'^D?@'_ ,FER[_N-_Z?JA1117Q)^PA1110
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MQ2"BBBOMC\>"BBB@ HHHH **** "BBB@#[0_X)#?\U"_[A/_ +>U]H5\7_\
M!(;_ )J%_P!PG_V]K[0K^7?$7_DLL5_VY_Z;@?Z1^ ?_ ":7+O\ N-_Z?JA1
M117Q)^PA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5^%_P#P>D_\VU_]SC_[@Z_="OPO_P"#TG_FVO\ [G'_ -P=>[PU
M_P CNE_V]_Z2R9_"?A?1117ZN8A1110 4444 %%%% !1110 5^Z'_!EM_P W
M*?\ <G?^YROPOK]T/^#+;_FY3_N3O_<Y7A<2_P#(DJ_]N_\ I2*A\1^Z%%%%
M?E!L?%__  5Y_P":>_\ <6_]LJ^+Z^T/^"O/_-/?^XM_[95\7U_47AU_R1N%
M_P"W_P#TY,_S<\?/^3M9C_W!_P#3%(****^V/QX**** "BBB@ HHHH ****
M/M#_ ()#?\U"_P"X3_[>U]H5\7_\$AO^:A?]PG_V]K[0K^7?$7_DLL5_VY_Z
M;@?Z1^ ?_)I<N_[C?^GZH4445\2?L(4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5^%_\ P>D_\VU_]SC_ .X.OW0K\+_^#TG_ )MK_P"Y
MQ_\ <'7N\-?\CNE_V]_Z2R9_"?A?1117ZN8A1110 4444 %%%% !1110 5^Z
M'_!EM_S<I_W)W_N<K\+Z_=#_ (,MO^;E/^Y._P#<Y7A<2_\ (DJ_]N_^E(J'
MQ'[H4445^4&Q\7_\%>?^:>_]Q;_VRKXOK[0_X*\_\T]_[BW_ +95\7U_47AU
M_P D;A?^W_\ TY,_S<\?/^3M9C_W!_\ 3%(****^V/QX**** "BBB@ HHHH
M**** /M#_@D-_P U"_[A/_M[7VA7Q?\ \$AO^:A?]PG_ -O:^T*_EWQ%_P"2
MRQ7_ &Y_Z;@?Z1^ ?_)I<N_[C?\ I^J%%%%?$G["%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X7_\ !Z3_ ,VU_P#<
MX_\ N#K]T*_"_P#X/2?^;:_^YQ_]P=>[PU_R.Z7_ &]_Z2R9_"?A?1117ZN8
MA1110 4444 %%%% !1110 5^Z'_!EM_S<I_W)W_N<K\+Z_=#_@RV_P";E/\
MN3O_ '.5X7$O_(DJ_P#;O_I2*A\1^Z%%%%?E!L?%_P#P5Y_YI[_W%O\ VRKX
MOK[0_P""O/\ S3W_ +BW_ME7Q?7]1>'7_)&X7_M__P!.3/\ -SQ\_P"3M9C_
M -P?_3%(****^V/QX**** "BBB@ HHHH **** /M#_@D-_S4+_N$_P#M[7VA
M7Q?_ ,$AO^:A?]PG_P!O:^T*_EWQ%_Y++%?]N?\ IN!_I'X!_P#)I<N_[C?^
MGZH4445\2?L(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^%__!Z3_P VU_\ <X_^X.OW0K\+_P#@])_YMK_[G'_W!U[O#7_([I?]O?\
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MYMK_ .YQ_P#<'7N\-?\ ([I?]O?^DLF?PGX7T445^KF(4444 %%%% !1110
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M)4J7L[.<:CD^:E";NXU8K>3M9+2W74_3C_AX7^Q__P!%>_\ *!J'_P CT?\
M#PO]C_\ Z*]_Y0-0_P#D>OS'HKZ+_B$O#G_/VK_X%#_Y6?!?\31<?_\ 0-A?
M_ *O_P N/TX_X>%_L?\ _17O_*!J'_R/1_P\+_8__P"BO?\ E U#_P"1Z_,>
MBC_B$O#G_/VK_P"!0_\ E8?\31<?_P#0-A?_  "K_P#+C]./^'A?['__ $5[
M_P H&H?_ "/1_P /"_V/_P#HKW_E U#_ .1Z_,>BC_B$O#G_ #]J_P#@4/\
MY6'_ !-%Q_\ ] V%_P# *O\ \N/TX_X>%_L?_P#17O\ R@:A_P#(]'_#PO\
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M****_*#8^+_^"O/_ #3W_N+?^V5?%]?:'_!7G_FGO_<6_P#;*OB^OZB\.O\
MDC<+_P!O_P#IR9_FYX^?\G:S'_N#_P"F*04445]L?CP4444 %%%% !1110 4
M444 ?:'_  2&_P":A?\ <)_]O:^T*^+_ /@D-_S4+_N$_P#M[7VA7\N^(O\
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MHH **** "BBB@ HHHH *_=#_ (,MO^;E/^Y._P#<Y7X7U^Z'_!EM_P W*?\
M<G?^YRO"XE_Y$E7_ +=_]*14/B/W0HHHK\H-CXO_ ."O/_-/?^XM_P"V5?%]
M?:'_  5Y_P":>_\ <6_]LJ^+Z_J+PZ_Y(W"_]O\ _IR9_FYX^?\ )VLQ_P"X
M/_IBD%%%%?;'X\%%%% !1110 4444 %%%% 'VA_P2&_YJ%_W"?\ V]K[0KXO
M_P""0W_-0O\ N$_^WM?:%?R[XB_\EEBO^W/_ $W _P!(_ /_ )-+EW_<;_T_
M5"BBBOB3]A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MPO\ ^#TG_FVO_N<?_<'7[H5^%_\ P>D_\VU_]SC_ .X.O=X:_P"1W2_[>_\
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MV/B__@KS_P T]_[BW_ME7Q?7VA_P5Y_YI[_W%O\ VRKXOK^HO#K_ )(W"_\
M;_\ Z<F?YN>/G_)VLQ_[@_\ IBD%%%%?;'X\%%%% !1110 4444 %%%% 'VA
M_P $AO\ FH7_ '"?_;VOM"OB_P#X)#?\U"_[A/\ [>U]H5_+OB+_ ,EEBO\
MMS_TW _TC\ _^32Y=_W&_P#3]4****^)/V$**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *_"__ (/2?^;:_P#N<?\ W!U^Z%?A?_P>D_\
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MQ?\ \$AO^:A?]PG_ -O:^T*_EWQ%_P"2RQ7_ &Y_Z;@?Z1^ ?_)I<N_[C?\
MI^J%%%%?$G["%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?A?_P 'I/\ S;7_ -SC_P"X.OW0K\+_ /@])_YMK_[G'_W!U[O#7_([I?\
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M^XM_[95\7U_47AU_R1N%_P"W_P#TY,_S<\?/^3M9C_W!_P#3%(*^W?A[\./
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M'_!(;_FH7_<)_P#;VOM"OB__ ()#?\U"_P"X3_[>U]H5_+OB+_R66*_[<_\
M3<#_ $C\ _\ DTN7?]QO_3]4****^)/V$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_"_P#X/2?^;:_^YQ_]P=?NA7X7_P#!Z3_S;7_W
M./\ [@Z]WAK_ )'=+_M[_P!)9,_A/POHHHK]7,0HHHH **** "BBB@ HHHH
M*_=#_@RV_P";E/\ N3O_ '.5^%]?NA_P9;?\W*?]R=_[G*\+B7_D25?^W?\
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M )-+EW_<;_T_5"BBBOB3]A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OPO\ ^#TG_FVO_N<?_<'7[H5^%_\ P>D_\VU_]SC_ .X.O=X:
M_P"1W2_[>_\ 263/X3\+Z***_5S$**** "BBB@ HHHH **** "OW0_X,MO\
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M -SC_P"X.O=X:_Y'=+_M[_TEDS^$_"^BBBOU<Q"BBB@ HHHH **** "BBB@
MK]T/^#+;_FY3_N3O_<Y7X7U^Z'_!EM_S<I_W)W_N<KPN)?\ D25?^W?_ $I%
M0^(_="BBBOR@V/B__@KS_P T]_[BW_ME7Q?7VA_P5Y_YI[_W%O\ VRKXOK^H
MO#K_ )(W"_\ ;_\ Z<F?YN>/G_)VLQ_[@_\ IBD%%%%?;'X\%%%% !1110 4
M444 %%%% 'VA_P $AO\ FH7_ '"?_;VOM"OB_P#X)#?\U"_[A/\ [>U]H5_+
MOB+_ ,EEBO\ MS_TW _TC\ _^32Y=_W&_P#3]4****^)/V$**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *_"__ (/2?^;:_P#N<?\ W!U^
MZ%?A?_P>D_\ -M?_ './_N#KW>&O^1W2_P"WO_263/X3\+Z***_5S$**** "
MBBB@ HHHH **** "OW0_X,MO^;E/^Y._]SE?A?7[H?\ !EM_S<I_W)W_ +G*
M\+B7_D25?^W?_2D5#XC]T****_*#8^+_ /@KS_S3W_N+?^V5?%]?:'_!7G_F
MGO\ W%O_ &RKXOK^HO#K_DC<+_V__P"G)G^;GCY_R=K,?^X/_IBD%%%%?;'X
M\%%%% !1110 4444 %%%% 'VA_P2&_YJ%_W"?_;VOM"OB_\ X)#?\U"_[A/_
M +>U]H5_+OB+_P EEBO^W/\ TW _TC\ _P#DTN7?]QO_ $_5"BBBOB3]A"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OPO_X/2?\ FVO_
M +G'_P!P=?NA7X7_ /!Z3_S;7_W./_N#KW>&O^1W2_[>_P#263/X3\+Z***_
M5S$**** "BBB@ HHHH **** "OW0_P"#+;_FY3_N3O\ W.5^%]?NA_P9;?\
M-RG_ ')W_N<KPN)?^1)5_P"W?_2D5#XC]T****_*#8^+_P#@KS_S3W_N+?\
MME7Q?7VA_P %>?\ FGO_ '%O_;*OB^OZB\.O^2-PO_;_ /Z<F?YN>/G_ "=K
M,?\ N#_Z8I!1117VQ^/!1110 4444 %%%% !1110!]H?\$AO^:A?]PG_ -O:
M^T*^+_\ @D-_S4+_ +A/_M[7VA7\N^(O_)98K_MS_P!-P/\ 2/P#_P"32Y=_
MW&_]/U0HHHKXD_80HHHH **** "BBB@ HHHH \MO_P!MC]E+2[Z?3-0^.6AQ
M7%M,T4\3RME'4D,I^7J""*B_X;G_ &1_^B]:#_W^?_XFN\E^&GPXGE:>?X?Z
M([NQ9W?2H26)ZDG;R:;_ ,*N^&?_ $3O0O\ P40__$T <+_PW/\ LC_]%ZT'
M_O\ /_\ $T?\-S_LC_\ 1>M!_P"_S_\ Q-=U_P *N^&?_1.]"_\ !1#_ /$T
M?\*N^&?_ $3O0O\ P40__$T <+_PW/\ LC_]%ZT'_O\ /_\ $T?\-S_LC_\
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M"B'_ .)KZ'_7',_Y(?=+_P"2)Y$?R&?\.D_V]/\ HE&@_P#AS/#W_P GT?\
M#I/]O3_HE&@_^',\/?\ R?7]>?\ PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1
M.]"_\%$/_P 31_KCF?\ )#[I?_)!R(_D,_X=)_MZ?]$HT'_PYGA[_P"3Z/\
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M=\,_^B=Z%_X*(?\ XFO4_P"(M<1_\^J7_@,__EA\U_Q*[P!_T$XK_P #I?\
MRD_(W_A&[C_H.:#_ .%+9?\ QZC_ (1NX_Z#F@_^%+9?_'J_7+_A5WPS_P"B
M=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\ B:/^(M<1_P#/JE_X#/\ ^6!_Q*[P
M!_T$XK_P.E_\I/R-_P"$;N/^@YH/_A2V7_QZC_A&[C_H.:#_ .%+9?\ QZOU
MR_X5=\,_^B=Z%_X*(?\ XFC_ (5=\,_^B=Z%_P""B'_XFC_B+7$?_/JE_P"
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M_HG>A?\ @HA_^)H X7_AN?\ 9'_Z+UH/_?Y__B:/^&Y_V1_^B]:#_P!_G_\
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M2_\ X1K_ (1W_BJ;#4/M?V3^U?M'_'E/-Y>W[3#]_;G?\N<-C]EO^%7?#/\
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M_P %$/\ \30!PO\ PW/^R/\ ]%ZT'_O\_P#\31_PW/\ LC_]%ZT'_O\ /_\
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M_1>M!_[_ #__ !-=U_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
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M (*(?_B:/^%7?#/_ *)WH7_@HA_^)H_UQS/^2'W2_P#D@Y$?R&?\.D_V]/\
MHE&@_P#AS/#W_P GT?\ #I/]O3_HE&@_^',\/?\ R?7]>?\ PJ[X9_\ 1.]"
M_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 31_KCF?\ )#[I?_)!R(_D,_X=)_MZ
M?]$HT'_PYGA[_P"3Z/\ ATG^WI_T2C0?_#F>'O\ Y/K^O/\ X5=\,_\ HG>A
M?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (FC_7',_P"2'W2_^2#D1_(9_P .D_V]
M/^B4:#_X<SP]_P#)]?J[_P &Q'P\U[_@GE_PN_\ X;"U'0?"'_"7_P#"-?\
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MX1NX_P"@YH/_ (4ME_\ 'J/^$;N/^@YH/_A2V7_QZOUR_P"%7?#/_HG>A?\
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M_P#HO6@_]_G_ /B:/^&Y_P!D?_HO6@_]_G_^)KNO^%7?#/\ Z)WH7_@HA_\
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M]%\.=<\+2>'O%-QH5WI7B-(TO%G@A@>0NL3.BC?*RKM=PRJ'!P^  >C4444
M%%<U\0?BWX#^%][H&E^,-<2WN_%&NPZ1H5H.9;NZDR=JKZ*JL['H OJ0#TM
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MSQ!IGB/4Q+:_:3!?G?;VZJL5J!):1L!&HP"RY(-=Q^U9_P $Q/B?^TW^RO\
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M_'O]H[2_%:>&M--IX=M=*T5[07!$1BCEOYBY>YVH=H0*HS\[F1PC+Y+^U?\
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M^%S'\3OB"?$NO7DYN-2OX;+[+:H^U5$5M;[W\F)0HP"S,S%F9B6X .GHHHH
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MK?AC^T=X:^+&F:=;?#!;4:?I.JZ=/=S:@8IA*QFN/.!RV N[#'JQ+$XKM?\
M@H3^R!K'[;_[.<WP0TCXDOX7N&U>VO\ [6+5IH;CRMW[B5 RED)8,.>'C0X.
M* /E/X5_M0^-=%_X*M_#GX6?"[XF^+K_ .'OC_P-]IU/2_$NN:EJ%G<W MKZ
M0W=@VINTRP&2V39( JR*&*@HZDW_ -F?_E8%^-G_ &(?_M/1J]%L/^"7_P 7
MK7]J;X7?M3:K^U?'JVL^!/#T6D:F+SP;#$EQ D<\06V2&15B!CN'&9/,*O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF7[5@_9%_90MO#-QX+MOV8?AY'HUU=I=76DIX*L!;33HI5)7B$6QG4,P#$9
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M+>&?"]SJ0VWUQHFCQ6\DRYR$+(H.P'D)]T'M0!W%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\
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MF[9=FEPD?\M'B82S'/R1/&A!\_Y0#[JHKSW]D;_DU'X8_P#9/-%_](8:]"H
M**** "BBB@#Q?]KW]KW_ (94_P"$>_XM[_;W]O?:_P#F+?9?(\CR?^F4F[=Y
MWMC;WSQXO_P]Y_ZM[_\ +L_^Y*/^"O/_ #3W_N+?^V5?%]?O7!?!?#6;<-4,
M7BZ'-4ES7?--7M.26BDELET/XE\7?%WQ#X7\0\;EF68WV="G[/EC[.C*W-1I
MR>LJ<I.\I-ZM[V6A]H?\/>?^K>__ "[/_N2O:/V0OVO?^&J_^$A_XM[_ &#_
M &#]D_YBWVKS_/\ ._Z91[=OD^^=W;'/YCU]H?\ !(;_ )J%_P!PG_V]HXTX
M+X:RGAJOB\)0Y:D>6SYINUYQ3T<FMF^@>$7B[XA\4>(>"RS,\;[2A4]IS1]G
M1C?EHU)+6-.,E:44]&MK/0^T***\1_X*/:-I6I?L/_$[4KVPCDN=+\&:A>:;
M=%?WMI<1PLR2QOU1@0.00:_!3^VCVZBOS(_X)?)^S#K_ .P[H^L?M(V>GZYX
MB\3?$H>'--_M#57&I7+W5S;6\:1,'$N$$K2$J1M5&.1UKJ_VY/A1^SW^SK\&
MOA!\"/CO\0_B?8:7HWQ U"_\*:UX3GBNC.)-0FGAM;AYY5E$T4,T2K-M.W#;
M2V2  ?H917D?C[]L?P'X/^-MS^SSX<\#^)O%_BK3O#O]NZUIOA>WM';3K$NJ
M!W%Q<0F1SN!$4(DD((.SYER>*OVU?@QX0^#_ ()^+^I_VJZ_$9["'P7X;@LU
M.J:G<W:JT5LL)<(L@W@.7=8T/WG&1D ]<HKQ'X4_M_\ P!^)W_"Q+34Y]4\)
M:A\*9)AXZTOQ5;Q1S:?''Y@:8-;RS131YC< QNQ.!Q\RYY^#_@I[\ HO$?P]
MT[Q)X5\5Z-HWQ4D9/ GB[4+6S;3=28/&@!\BZDGMR6EC7$T494O\VW#8 /HZ
MBOSS_:ZN[SP__P %R/@;IVA7T]G;:OX<AGU2VM9FCBNY1)J2"21%(#MLC1=Q
M!.$4=%%?>GQ!\8#X?>"-4\</X;U35TTJS>ZETW184DNID0981([H'8+D[=V3
MC"@D@$ V**\%^!/_  40^"W[1OP(\7?M$_#'POXGGT#P8TJZHEW;6D-S(8H5
MGF\N-KGHD3*Y+E V2$W,"!T7C7]L'X>^ [;P/INM>%/$3>*?B*V/"O@2&VM_
M[6G 3S)&D5IQ# L:89VDE4+T)W J #UBBO'/#?[=_P"SMK7P:\7?&[7/$=SX
M?T[P!JEQIGC;3]<M@E[HU]#((FMI8XFD#NSE53RF=7+ *2<@8GAS_@HK\&M3
M^,_A'X'^*_!WBGPOJ7C_ $>/4_!&HZW#8R6.LP2 F/RY;2ZGV,P'"RA#RHX+
M*" >_45X!\3O^"D?[/OP;_:-'[,/Q(TWQ+IWB"337OK6X&EQSVUU"())4\HQ
M2M([R&)HTC$>]Y"JA<L*[+]D[]JWX=_MC?"Z7XL_#+1->T_3X-9N=,DMO$5@
MMM<":';O.U'<%?F&#NSG((!!  /3:*^8_P!N?_@GW9?MG6FK:G\3?CUXFT73
MM*TL_P#"*:-HMTD.G6DRQ[WO+R-D8W+F3(X9 L2 +AF9J^;OV _VI?CY\(_^
M"-WQ"^._C?7+N_E\-7=[:_#Z_P!68S.J,MO!#R^?,BCNY6"@YQL9/NJ  #]+
M:*_(OQ[\3_$O[,W[!W[.G[</@N]G_P"$^U/QE=3>,/$$DQ:[\26\LMU)+;7T
MI^:YC*Q*BAR=@ V;2 :^T?VU/V#-(_;ET*^\4>/_ (_>)M(T>TT02^#M(T:Z
M2'3K63RO,-[>1LC&Y<N<<,@2)0%PS,U 'U'17PM_P10UK]H/XL?\$_=3T[QI
M\0M3M5/B.ZT_P=XANT^TW5M8".$2&$RDAMDAG6(N&5'7!5E0)7D7CO\ 9_\
M _P'_P""L_PE\.?LE_M':@VNZM>?:OB7;^(?&@NI&@BF4RPRO(VZ::YB\Y1;
MG<X8*X"@[@ ?J-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M":W_  ;$?\.\OVUO!?[87_#;O_"7_P#"(?VC_P 4[_PK7^S_ +7]KTVZLO\
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M\*>&KBYN_#GAC3M/EO9-]Y+964<33MS\SE0"QY/)SUJ9-#T2,W;)H]JIO_\
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M#>HK$FH>'K&<0($A$UHC>6O]U<C@>PJU:VMK96Z6EE;1PQ1KMCBB0*JCT '
MH \5_;U_;:^'_P"PY\$;CXB>)YXKG6K\M:^%M$+9>^NL?>*@@^5&"'D;C PH
M.YU!^=O^"8_[<W[,7CCQY;_ +X$>%O&.L>+_ !7>WWB+XD>-O%.F6UJU]/Y3
MO)<XAGE('G-#%'  $CC<_,6!W_=FIZ!H6M%&UG1;2[,8/EFYMEDVYZXW XZ"
MF:=X9\-Z1.;K2?#]C:RE2IDM[1$;'IE0#C@4 ?E'\(? P_9,_9T_;2_9Q^(U
MW%IFJQPH/#]M>2!'U6TN5NH;6:W4\RB3,8^7.&<*<'BO>/A-\9]'_P""2O\
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MYNM)\/V-K*5*F2WM$1L>F5 ..!5B_P!-T[5;8V>J6$-S"2"8KB(.I(Z'!&*
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MEVL]M:I&2.N"5 XX%&I>'/#VLS+<:OH-E=2*NU7N;5)"!G. 6!XY- 'YS?\
M!3OX.>!/&_QO\0_M+?LY_M%6_@7XQ?#7PS;:M>V5QJZ6RZ]I@MS)'<VLF[)<
M('A*_,CA45@H<,W"_ME?$SX\V7@7]D']OOXI^ )X[#PW-'=>*[+3['RH[>5K
MFWE67RQA83=01%E'"A@!Q\H/ZEZGX#\#ZU#%;ZSX,TF[C@=7@2ZTZ*01LH"J
MRAE."   1T  J]J.F:;K%A+I6KZ?!=6LZ%)[:YB#QR*>H96!!'L: /F#QO\
MM(_L/>)/V?/BS^T#\'OAOH?Q M9_"+7?CB31] \H:P!&4BM+VX,0)<*Q+*VY
MX8PS,JY7=^<7QB^+_A/XA?##]F?XCVFOQV5AI7CF[34/#NE:%+8Z%X0B6]M7
M2T@D=,32%$>:61Y99&+;B57:#^W&E:!H6@Z4FA:'HMI96,:E8[.TMECB4'J
MB@  Y/;O3/\ A&?#?]GV^D_\(_8_9+219+6V^R)Y<+J<JR+C"D$G!'3- 'YU
M_MD>,/"UW_P7#_9^U6'Q!:?9T\*6@DE>8*(S+-J1C5\XV,P=,*<'YAQR*_2*
MJ%UX4\+WUVVH7OANPFG8@M/+9HSDCH22,]A67\8-/^)FK?"OQ%IGP9U^RTKQ
M;<:-<1^'-2U*'S(+:],9$4DBE6!4/@G*L/56^Z0#\]O@_P# #XD_L^?\%/\
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>mdt-20240426_g2.jpg
<DESCRIPTION>IMAGE 2
<TEXT>
begin 644 mdt-20240426_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0,$17AI9@  34T *@    @ ! $[  (
M   3   !2H=I  0    !   !7IR=  $    F   "UNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36%R:6YE;&QA+"!!;G1H;VYY    !9 #  (    4   "K) $  (    4   "
MP)*1  (    #-C,  )*2  (    #-C,  .H<  <   $,   !H      <Z@
M  $
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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MAXSGR1=K*[=EU:."4I<[5RW_ ,+N^(7_ $,'_DE;_P#QNC_A=WQ"_P"A@_\
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M\B+/=28\R91C=L7^%!D=/;))KPS]I#_DJR_]@^'_ -">O"ISI5)\JBC4R/\
MA>_Q'_Z&/_R1M_\ XW1_PO?XC_\ 0Q_^2-O_ /&Z]>_9G)B^&VK3$94:F_?K
MB&,U!<?M+V5H5%UX3U* L,J))0N1[9%)R7,XQIIV] /*/^%[_$?_ *&/_P D
M;?\ ^-U=M_B]\6[NS:[M=1NYK9<[IH]*A9!CKEA%BH_AAX=M/B/\8IY=0A_X
MEXDFU*:W;G>N\;8R?3<ZY]0#7N7B?XO:5X,\?Z9X032]T,GE)/-$X1;4.<(
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M/!_*N)UZ6LXT4X)VOH:1P6*O&C/%R562NHWE;[[_ -=CB/\ A-?$'_/_ /\
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M$2 <'(__ %U=:I2A.4844U'?1?Y&.$P^)JT83K8J474^%7;O^)Q'_":^(/\
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M_ .7$8G,<-4=*K5DI+^\_P!&;W_":^(/^?\ _P#(,?\ \31_PFOB#_G_ /\
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MLS _\^8?^ K_ "#GEW.]_P"%W?$+_H8/_)*W_P#C='_"[OB%_P!#!_Y)6_\
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MU(!B;R?9;QDXVI]V->3@'&,]LY->N_$WXL>&KGX>'0/!-Z)FN MLZI;R1"&
M#D#>H'. N!V)KP2.1XI5DB8HZ,&5AU!'0UY.38>O4K5L?B(N,YNR3Z)?TON-
M*C22BCZPN-4L_@O\-+"/5+B\U9HV6WCY&6<@M@9^Z@ .!S@ #FH]9\GXP?"*
M2YT>XN[ S*[I$S;0\D9/[N3&<J2.WL>V*Q;'XD^ ?B/X5BTWQTT-K<C:\L%P
M6C42*/OQR#IU/&0<$CD=:_B;XI^#O!W@J3P_X"=+B?RFB@%N"8X=V<NSM]X\
MD]\GK7RD,'B?:1M2E]8Y[N5O=M^6_P#PYOS*V^A\YT445^IG"%%%% !1110
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MEY/%<-(JQV[R@H0#E1QU!XK+I*:<G'L.5*481J/9W_ ****LR"BBB@ HHHH
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M-73(;D(=0N#$)6VDL(B^P<DG[O>M[XS?\D0D_P"W7_T):9JO_)K\?_8#@_\
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M50@HHHH **** *E[_!^-5:M7O\'XUT_PIDTW_A9&F6FNVEM=V-^S6<B7,*R
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M_!H]YJ-AK&BZNMBGF74.G7AEDA3NQ!49 [D$UT7AK5[K4?%WQ#U.6"*QNY-
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MY9&W<&W*#D$<@@=Z9K/@V\T.SA:[O].DOI)5A;2[><R74+$$_.@&!TP1G()
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MC\UBN0@#8+=-W'3;]*\DJL%)O&5KS4K*&J_[>"7PH*S[G_CX;\/Y5H5GW/\
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M'KFNB^+/P_TGPQJ+3Z)J6E00+;P?\2U;J1[EF91N<*P/RGK][IV[4O:1NEW
M\RHKN8?A3J8CMUU;7- T6]N%5TT_4K[R[@!ON[E"D*3Z,0?7%<IK.C7_ (?U
MBYTK5[=K:\MFVRQ,0<'&1R.""""".H-4IQ;LF!1HHHJ@"BBB@ HHHH ****
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MY61E&[ ^11DG)_\ K'NQ5:K&=7WFIKX$EH]%Y:W=T^R[;DQ2T,GPEX0T+5_
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M,U'=:QJ=]"\-[J-W<1/,;ATFG9U:4C;O()Y;  SUP,5'LY.5VP/0?B+8W/\
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M !7T+^RO_P S5_VY_P#M:OGJOH7]E?\ YFK_ +<__:U<^)_A/^NH(XSXW?\
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M=U+X$%%%%>0:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'2_#W_D>]/\ ^VO_ **:O;:\2^'O_(]Z?_VU_P#135[;7I87X'ZGYWQ1_OD?
M\*_-A11176?+!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\@]C#L'_  S)_P!3;_Y3?_MM'_#,G_4V_P#E-_\ MM%%'^L>:?\ /W_R6/\
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M^IQ_\I?_ -NH_P"&5_\ J<?_ "E__;J**/K-7O\ D%@_X97_ .IQ_P#*7_\
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MW_V5%%']HXK^;\%_D']@9;_S[_&7^8?\*T_ZBW_DM_\ 94?\*T_ZBW_DM_\
M9444?VCBOYOP7^0?V!EO_/O\9?YA_P *T_ZBW_DM_P#95P'_  S)_P!3;_Y3
M?_MM%%=%'.L?0O[.I:_DO\CLPV6X3"W]C"U]]6]O5A_PS)_U-O\ Y3?_ +;1
M_P ,R?\ 4V_^4W_[;1171_K'FG_/W_R6/^1U^QAV#_AF3_J;?_*;_P#;:/\
MAF3_ *FW_P IO_VVBBC_ %CS3_G[_P"2Q_R#V,.P?\,R?]3;_P"4W_[;1_PS
M)_U-O_E-_P#MM%%'^L>:?\_?_)8_Y![&'8/^&9/^IM_\IO\ ]MH_X9D_ZFW_
M ,IO_P!MHHH_UCS3_G[_ .2Q_P @]C#L'_#,G_4V_P#E-_\ MM'_  S)_P!3
M;_Y3?_MM%%'^L>:?\_?_ "6/^0>QAV#_ (9D_P"IM_\ *;_]MH_X9D_ZFW_R
MF_\ VVBBC_6/-/\ G[_Y+'_(/8P[!_PS)_U-O_E-_P#MM'_#,G_4V_\ E-_^
MVT44?ZQYI_S]_P#)8_Y![&'8/^&9/^IM_P#*;_\ ;:/^&9/^IM_\IO\ ]MHH
MH_UCS3_G[_Y+'_(/8P[!_P ,R?\ 4V_^4W_[;1_PS)_U-O\ Y3?_ +;111_K
M'FG_ #]_\EC_ )![&'8/^&9/^IM_\IO_ -MH_P"&9/\ J;?_ "F__;:**/\
M6/-/^?O_ )+'_(/8P[!_PS)_U-O_ )3?_MM5Y?V6O,D+?\)AC/;^S/\ [;11
M7/B,ZQ^*AR5JEUOLOT14:<8NZ0W_ (97_P"IQ_\ *7_]NH_X97_ZG'_RE_\
MVZBBN#ZS5[_D58/^&5_^IQ_\I?\ ]NH_X97_ .IQ_P#*7_\ ;J**/K-7O^06
M#_AE?_J<?_*7_P#;J/\ AE?_ *G'_P I?_VZBBCZS5[_ )!8/^&5_P#J<?\
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6?)\OR]_^VV<[_;I114RKU)KEDQG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>mdt-20240426_g3.jpg
<DESCRIPTION>IMAGE 3
<TEXT>
begin 644 mdt-20240426_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0,$17AI9@  34T *@    @ ! $[  (
M   3   !2H=I  0    !   !7IR=  $    F   "UNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36%R:6YE;&QA+"!!;G1H;VYY    !9 #  (    4   "K) $  (    4   "
MP)*1  (    #-S@  )*2  (    #-S@  .H<  <   $,   !H      <Z@
M  $
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M_7/_ +QIE/E_US_[QIE?E%?^++U?YGI+8****Q&%%%% !1110 4444 %%%%
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M1T<:G"I( ^VR#RA$<=]V2?<U!\0UN!J_Q3G@OKBW2./2Q)!&$V3AE1</E2W
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M30_;6_X8#!\*?%-O"ZZ4%T<77]GZ=/8D-<;1*);GSB2-AP,97'.<YR.E8_Q
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MC:MHE@S-:VTB&+><D*\:N%SWQNQGVKEJOZYK5]XBUR[U;59?-N[N0R2-C ]
M .P   'H*H5T1NHI/< HHHJ@"BBB@#V[X>_\B)I__;7_ -&M725S?P]_Y$33
M_P#MK_Z-:NDKV:?P+T/R#,/]\K?XI?FPHHK2TK1)=5@N9DN;:VBMMOF/<.5'
MS$@<@'TISG&"YI;'+2I3JSY(*[_RU.JUO5M-T7Q9>7<<%U-J055&YP(1E ,\
M<GC'6G/HL8\6ZJ_]G1BQ%D6B/DCRPVQ>5XQG.?UKG;K20XN[B^UZTN)TB$BE
M)C*93TVY.#G 'K6<-6U%81$M_=",+M""9L >F,]*\V&'O%>SEK:SW\MOZZGT
M57'\M1^WAHY<R2MYIW];J_HCK5%MNT0WEJ]R@TTX"PF4(V>&91U J:#1K8ZO
M<RW<5HSI9I-;QQ69"D$D%C#G)88Z>XKF)_MMCIFF7\>HW&ZX2145793$JMC
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MY1[M[*V^SK.^X8:5B3P#\W&,8K:^*7B5#X0\+^#K?5[35VTJW#WMU9.)(FD
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MHX=47=?UJ_\ .QQXS'RQ<5&:U3O>]^B5OO5_F%%%%=1YIY#XX_Y'.^_[9_\
MHM:P*W_''_(YWW_;/_T6M8%?<87^!#T7Y'Z?@?\ =:7^%?D@HHHKH.L****
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M7_ 3[[77G9VYU=' 4445[QD%%%% !1110 4444 %%%% %*\_UP_W:KU8O/\
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M<!HVP&#/SS@Y_"O/JUC+F5P"BBBJ **** "BBB@ HHHH ^A?V5_^9J_[<_\
MVM11^RO_ ,S5_P!N?_M:BO&Q/\5_UT&CP^BBBOW8\L**** "BBB@ HHHH **
M** "BI([:>5"T4,CJ,9*H2!5J[T35+&U2YO-/NH('^[*\3!3^/2LW4@I<K:N
M.S*-%%%:""BBB@ HHHH **FCL[F90T5O*ZL=H*H2"?2IK_1]2TL(=1L+BU$G
MW&FB*AOH3UK/VD.;ENK]AV93HHHK004444 %%%% &;+_ *Y_]XTRGR_ZY_\
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M****T$%%%% &;+_KG_WC3*?+_KG_ -XTRORBO_%EZO\ ,]);!1116(PHHHH
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M$33_ /MK_P"C6KI*]FG\"]#\@S#_ 'RM_BE^;"BBBM#A"BBB@ HHHH ****
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M#OKG*KDMG':IX%69 ^\AQT7TJUH] W/%OBQ<P+X7T6RL+0Q>5-(+QG!WI*H
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MKF_A[_R(FG_]M?\ T:U=)7LT_@7H?D&8?[Y6_P 4OS84445H<(4444 %%%%
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M\E6HVO4%&*=TC5NF\^.29L;BO!]*S-#MMU\SACA%/(/K2S17$=JR!SG'>I-
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MK7>S%U/ Z***ZQA1110 45[I\*OA9X2UBW=O$<EQ>:BJ;S:G=%"J^JL.7QD
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M@8KHH8.-.*BMD)R&JN*=2T5Z,8J*T)"BBBJ$%%%% !1110 4444 9LO^N?\
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MP7WL****ZCP@HHHH **** "BBB@ HHHH **** "BBB@#R'QQ_P CG??]L_\
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MSJ"\BVG(ZCI7R)T%&?Y%WJ<$?K5FV"^4,?C5:(?:6W?P@X ]Z=+&\660X/\
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M .NU;XC:EK6ESV%_I^FO#-SD1."C?WE^?@_I[5R-%%3&$8*T0"BBBJ ****
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M ,31_P ()X1_Z%71/_!=#_\ $T44?6J_\[^]ARKL'_"">$?^A5T3_P %T/\
M\31_P@GA'_H5=$_\%T/_ ,3111]:K_SO[V'*NP?\()X1_P"A5T3_ ,%T/_Q-
M'_"">$?^A5T3_P %T/\ \3111]:K_P [^]ARKL'_  @GA'_H5=$_\%T/_P 3
M1_P@GA'_ *%71/\ P70__$T44?6J_P#._O8<J[!_P@GA'_H5=$_\%T/_ ,31
M_P ()X1_Z%71/_!=#_\ $T44?6J_\[^]ARKL'_"">$?^A5T3_P %T/\ \31_
MP@GA'_H5=$_\%T/_ ,3111]:K_SO[V'*NP?\()X1_P"A5T3_ ,%T/_Q-'_""
M>$?^A5T3_P %T/\ \3111]:K_P [^]ARKL'_  @GA'_H5=$_\%T/_P 31_P@
MGA'_ *%71/\ P70__$T44?6J_P#._O8<J[!_P@GA'_H5=$_\%T/_ ,31_P (
M)X1_Z%71/_!=#_\ $T44?6J_\[^]ARKL'_"">$?^A5T3_P %T/\ \31_P@GA
M'_H5=$_\%T/_ ,3111]:K_SO[V'*NP?\()X1_P"A5T3_ ,%T/_Q-'_"">$?^
MA5T3_P %T/\ \3111]:K_P [^]ARKL'_  @GA'_H5=$_\%T/_P 31_P@GA'_
M *%71/\ P70__$T44?6J_P#._O8<J[!_P@GA'_H5=$_\%T/_ ,31_P ()X1_
MZ%71/_!=#_\ $T44?6J_\[^]ARKL,/P_\&DY/A+0B?\ L&P__$T?\*_\&_\
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MT?\ "O\ P;_T*6A?^"V'_P")HHHYI=P#_A7_ (-_Z%+0O_!;#_\ $T?\*_\
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M'_0+LO\ P'3_  H_L+2/^@79?^ Z?X444>UJ?S,/J]'^1?<@_L+2/^@79?\
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MHHJUB:Z5E-_>S51BE9(/^$$\(_\ 0JZ)_P""Z'_XFC_A!/"/_0JZ)_X+H?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>mdt-20240426_g4.jpg
<DESCRIPTION>IMAGE 4
<TEXT>
begin 644 mdt-20240426_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0,$17AI9@  34T *@    @ ! $[  (
M   3   !2H=I  0    !   !7IR=  $    F   "UNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36%R:6YE;&QA+"!!;G1H;VYY    !9 #  (    4   "K) $  (    4   "
MP)*1  (    #-C   )*2  (    #-C   .H<  <   $,   !H      <Z@
M  $
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M?EY )VXR1QGO6257F5[_ -?@!K?$CPKHOA73[J#2O %S+9>6@M?$HU.25')
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M>5UYGOQQU"-&-)+[+U[.TK6TOK=)N[5C:D\(VL=]'8_VRGVV:,/%$;<@'(R
M6S@=ZBL/"$US:K-=RRP;Y6C18K9IN5.TEMO"C/'X5JZ]K5KI>O1R_P!F)->P
MVZ>5.92 ,KQE>AQDUDV?BQH[-;>_M6N=DK2(\=PT)RQR0=O49)K.$L5.FI1Z
MV[>>WX;F]6GEE*NX32TO_/;I:_6^_P .FQ9FLIM)\)ZC:S;3)!J"<CD'Y00?
MRI^IZ+_:.O:S/J.H1VXLQ$9)$@.U@5 X7<2.GJ<FLBXUYKG3;RU> !KJY$^\
M.<)@8VX/^-2WWB/[:VK'[+L_M+RO^6F?+V$'TYSCVJU2KIWZOKI_=_R9C+$X
M.4>5ZQ6RUZ*I:]K=7'[_ %)QX0EDU".*WNO-M9+;[4+A86SL]-@Y)]J9>:1)
MX;N=/U-2]Q )@P$D1A;<ISM*G)&<=:?#XND@:T"VN8X;3[+*GFD>8OJ"!\IX
M]ZH:QK"ZFL$<-NUO%"#P\[2LQ/<DU4%B7-*?P]=O/YW]#.K++XTG*C\>Z^+1
MZ;7TLM=]34T_QH;"S2 6(DVL[!C+@C<Q8X^7WQ^%5_#MO!JFGZCIC0QFZ:/S
MK:78-^Y>J[NN#QQ]:Y^K6F7\FF:G!>0C+0ONQG&X=Q^(R*UEAXQC+V:LWK\U
MJ<U/'U)U*:Q#O!:;+9JS_#;T-U=+1=!TRPCAC;4-4E\WS"@+11=L'J!W_.IO
M$EA83:4USI$"Q#39S:S;5 +C@!SZ\\9[YJJ?%K'7I]5^R RF#R;93)Q!QC/3
MGOZ=320>,K]H[B#53]OMYXC&8SMCP3W!"US>SQ/,IVVUW[[KY+3H>@Z^ <)4
MF]]$^7916C[J[U=D]-#4OM*LM0T>SL[2WCAU)=.BNT9%"F?(PZG'4\9_R:JW
M<\.EW>DQQ:=8RBZT^W,GG6X;YB6RWU/<^PK)N-?F>]TVZMH_)EL+>.!3NW;]
MN>>W!STI^MZ__;.KV]\+7R! BIY8?=G#$]<#'6G"A5349:QUZ[,57&89QE.G
MI-<J6FZ[[;K5/NK'07EO#?>+Y-'33[&"SMV6666* *X0*&(+#L2<?C56]T>T
MUK4M)O-/C6VL]0/ER)&H7RV7.>.@) _2JK^,)$N=1NK*U^SW5ZR8E\P-Y2J
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M8/(Y/!JI7+E^#E@J7L;W2V?7Y_/;RLN@YRYG<****]$@**** "BBB@#/N?\
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M@VWU!;B*Q*I'$N3L<>9R1N.7&!Q]T5E6_P (;;4M6\,)HWB47ND^(6GCCO\
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MLQC=Q3/"VA:9?>(=<O/^$):PO-/TDW.GZ!>M+,+B3+ R%9,,XZ#;TS[U\_\
MVG5A5J\Z7)!VTM?I;7GOUU]VWF;<B:5CRF]OKO4KM[K4;J:[N'QOFGD+NV
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M<^YP5?9JH_97Y>E][!1115F1Y#XX_P"1SOO^V?\ Z+6L"M_QQ_R.=]_VS_\
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M\"'HOR/,ENPHHHKH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG16]Q!&MN;.X2$$?*'W<D'DE>>E;>F7FGP(8UN$>5@-P0>@[#':O(_M;,/\
MG]+_ ,"9I[.'8XFR^"O@R>V21M/<EAG_ (^9!C]:MQ_ WP0Q+'3YN#C'VI\?
MSK8/BG3(;IA#Y@C3*D!21D'MBM"V\3V]XZQ:9&)G.2RN2F/IQS26:8[_ )_2
M_P# G_F')'L<1J?P$\(S1E+/[9:RL,ADFW ?@V:\K\<?!W6?"-F^I6LBZCIJ
M<O(B[7A'JZ^GN/TKZ2DN[N9PLVG@(#DXFR3CKZ?_ %ZQ_$TFHZAX;UF V;1Q
MFPF"H&#%VV'   R:]3+\_P =1K14I\T6U=/7\=S.5*+6Q\@T5<N-&U.T4-=:
M==P*3@&2!E!/XBJKQO&<2(R'T88K]:C*,MF<(VBBBJ$%%%% !1110 4444 9
M]S_Q\-^'\JBJ6Y_X^&_#^515^78[_>ZO^*7YL]"'PH****XRPHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /J;]F3_DF>H?]
MA>3_ -$PT4?LR?\ ),]0_P"PO)_Z)AHKQ*_\5E'AGCO_ )*-XD_["MU_Z.:L
M&M[QW_R4;Q)_V%;K_P!'-6#7[AA?X$/1?D>9+=A111702%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!FR_ZY_\ >-,I\O\
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MVD;_ );*.D;'U_NG_@/3&,IE9&*N"K*<$$8(-- )5BQL9]1O8[6U4-)(<#)
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M"X<G_58')^E4Z>&G-7I57>4>O=/9^7F@E;=!1117829LO^N?_>-,I\O^N?\
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MNSTJZ;*;/^K'3!Y%1FRER#Y8R.G(XH B+5GZO!;W6EW,5Y;Q7$1C8F.9 ZG
MXX-:9M)_[GZBJM[8W,EG,B1Y9HV &X<G% 'Q]>HL>H7*( JK*P4#L,U!76^+
M_ &O^&&>\U>V2..8B4!7#%5<G&<< ^U<E7T-.2E%-,R"BBBM "BBB@ HHHH
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M!K]PPO\  AZ+\CS);L*Z_6E:[\ :-+<;6ELT94E(^9HV<X0GT4YQ]37(J=K
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MJ4;[VQ4S6K]]R@E1^(ROXU\JGCK7V'X><Q:T!VE0J1^M?*_C33QI?CC6K)0
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MC!_ YKG9[KQQ"NG^,+T7$D:@?9=0F(P V1@;P0,Y-5]*^)-O;1*-3T.SNSL
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M4=I&'ZU]+_$B;9H=N,\M<@#GV-?-%R=UY,1WD8_K7H8'>1+(J***],04444
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M<?\ (YWW_;/_ -%K6!6_XX_Y'.^_[9_^BUK K[C"_P "'HOR/T_ _P"ZTO\
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M/<GM7RM<SM=7<UQ)]^5V=OJ3FOON#:,O:5:W2R7ZG+B7HD1T445^BG$%%%%
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M[9)/]:Z"OIX-N*;/R#$QC"O.,=DW^844459SA1110!Y#XX_Y'.^_[9_^BUK
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M,S/?1KYASNW%,YQUZ_IT]*U<X_PH>@#?*D);]X,,<X Q3DA"/N!/4\9XY_\
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MHWT]Y>S-/<W$C22R.<EV)R2?QK3\1>)[CQ$T EMK>TBA:200V^[:9)&W2/\
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M*/11PH_SZ5Y_4UY=S7]Y)=73[Y9&RQ_I4->Y1I^S@HDA1116H!1110 4444
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M 9]S_P ?#?A_*HJEN?\ CX;\/Y5%7Y=CO][J_P"*7YL]"'PH****XRPHHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ZF_9D_Y)GJ'_87D_\
M1,-%'[,G_),]0_["\G_HF&BO$K_Q64>&>._^2C>)/^PK=?\ HYJP:**_<,+_
M  (>B_(\R6["BBBN@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#-E_US_[QIE%%?E%?^++U?YGI+8****Q&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]C_ C_DBF@_]
MO'_I1+7H5%%>%5_B2]64%%%%9@%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>mdt-20240426_g5.jpg
<DESCRIPTION>IMAGE 5
<TEXT>
begin 644 mdt-20240426_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0,$17AI9@  34T *@    @ ! $[  (
M   3   !2H=I  0    !   !7IR=  $    F   "UNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36%R:6YE;&QA+"!!;G1H;VYY    !9 #  (    4   "K) $  (    4   "
MP)*1  (    #.3,  )*2  (    #.3,  .H<  <   $,   !H      <Z@
M  $
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
M   ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,082
M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3
ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C
MY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ \<HHHK]^/*"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^Y_X^
M&_#^515+<_\ 'PWX?RJ*OR['?[W5_P 4OS9Z$/A04445QEA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >M_"G_D5;G_ *_6
M_P#0$KMZXCX4_P#(JW/_ %^M_P"@)7;UZ]'^&C\GSC_?ZOJ%%%%;'E!1110
M4444 %%%% !15J'3;ZXA$T%E<2Q$X#I$Q4G.,9 ]>*CEM+F"/S)K>6--Y3<Z
M$#<.HSZCTJ>:-[7-'3FE=IV(:***HS"BBB@ HHHH **** "BBB@ HHHH ***
M* /(?''_ ".=]_VS_P#1:U@5O^./^1SOO^V?_HM:P*^XPO\  AZ+\C]/P/\
MNM+_  K\D%%%%=!UA1110 4444 %%%% !1110 45K6WA/Q'>6L-S9Z!JD]O/
M_JI8K*1DD_W2!@]#TJC<Z=?6=O!/=V=Q!#<;O)DEB95EVG#;21@X/!QTK-5:
M<G925_4=F5Z***T$%%%% !1110 4444 %%%% !1110!2O/\ 7#_=JO5B\_UP
M_P!VJ]?FF:?[[4]3OI_ @HHHKS30**** "BBB@ HHHH **** "BBB@ HHHH
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M(W@ KD''<CU-<3+\6&TY-%MO!FA0:%8Z3>&]$#SM<M/,5*$NY )&QF7'H>O
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M'N/$TMJ[2QR;5MQ Q*J%P=WRX'4=,\UQ5-0E+XP/JP^#O!J?$26\_L;2VBN
M^D)IZVD9BBN$CDN&E*8P"8UC&<9^;WKQWX$Z79:O\09[?4-/M-01=.F=(+N%
M9$+@K@X;C\:\UKJ/ /C+_A!]?GU/[!]N\ZSDM?+\[R\;\?-G:>F.F*CV4HP:
M3N![#/\ #J'Q;X5-GXHT_P /^%/$Z227%M'HT,99[=%^;S$1\$$_Q9X^7W!\
M]\#^#_LX\&>+OMV[[3XHMK'[)Y.-N) V_?NYZ=,?C7-^!?&$W@?Q1'J\-JEX
MGEO#-;NVT2QL,$;L''8YQVKI[CXJZ9'I>@:;H?A,:;9Z+K,6JK'_ &@TIF*$
MDH69,Y)/WN<#'%+EJ1]U:H#1O/AG%K]]XE\1ZAK$]E:KKMW;A+33)+UE*N6+
M2!#E%YZD']16=X6^$$GB#0;?5[C4[J"TOKB2&R-GI,UX7"-M,DFS B7/KSP?
M2CP[\5M/\/ZY?:S'X;N'U&ZOIKOS(]8EB0AV+!'C"[7"[CV&:=HWQA:UT5-.
MUW1&OXX+N6ZMC9ZC+9>69'+LC;,[TW$G!H_?)67Z <1XG\/7?A3Q-?:)J)1K
MBSDV,R'Y6& 0P^H(/XUE5?US5I==UZ]U2=!&]W,TIC5BP3)X4$DG ' ]A5"N
ME7MJ 4444P"BBB@#Z%_97_YFK_MS_P#:U%'[*_\ S-7_ &Y_^UJ*\;$_Q7_7
M0:/#Z***_=CRS3\.:#=>*/$5IHUA)#'<7;%4:=B$! )Y(!/;TK4U7X?ZUI/C
MJ#PG.(9;^X>-8I(2S1.'QA@=H.T<Y..-I]*N?"'_ )*UH/\ UW;_ -%M7J,V
MLV+:-?>-[AD_M?PL;W2H04R7D>3%N?HJNP_$GM7@8['U\/BO9P5XN*_\";:C
M\KJWS-HQ3C=GC?C/P;J'@?6H],U6>UGFD@6=7M79DVL2!RR@Y^4]JY^OHR;3
M;B]\?VMY9:E<V]Y:>%;5H[>S$1N+K<S9"&4%1@@9.,\CUJ^T"V_Q)\,:C-;L
M+^;1;O[49VC>21D48$AC 5F&2#@>W:N2&>RA!*<5*7*V];:I-[6VLMTV/V5W
MH?,E=!8>%OMW@/5O$GVS9_9UQ%#]F\K/F;SC.[/&/3!KTCP=J=S\7=)O?#_B
MJ[2:\M;V#48)7Q'^Y#!)D 4  !#Q[M[9IVH:TGC7PAXUO'N4M[2ZUJR@AEDS
MLA@#!%8CL HW$?6NNKF593]DX\KC*/-K=6;C:VFMTWVM8E05KGBM%?2WB;2K
MG_A!?%-CK,E_J%O:6'FVEQ>FV$;NHSOA2)0R@<<D]\46^M7EW\0M,\*W!CDT
M:Y\-*\]JT2D2L8SR3C/0 =:YXY\Y0<XTT[7;][HDGI[N^NSL5[+7<^;[*W^V
M7]O;;MGG2K'NQG&3C./QK6\9^&_^$1\7WVA?:OMGV1D'G^7Y>_<BM]W)Q]['
M7M7KOAW^W!X'\(-\.FM1IZNQU[<8A^\W+N,V_G;C=T[8Q_#7%_$[3'UGX[ZG
MIT5Q;VSW,\,:RW+[(U)A3&3@X]*ZJ&92K8MP=E%1E=7N_=DE=JVFE[*[NF2X
M6B<C_P (W>?\(7_PD_F0?8O[0_L_R]Q\SS/+\S.,8VX[YSGM617LX\(7GA_P
M)HOA;Q!?6NE:A>^+!<PN9%D B$.SS .XW 8S_>&<9KI_&;W^F> ]5U&_%_/>
M:-J-K/83ZDUN6R)@-Z+"H*(PR,$G(].:Q_ME*:C%*7-*RUMI=)6T:>N^N@_9
MZ'SC5K3+'^TM3M[,W5M9^<X3S[I]D4?NS8.!^%?15VFD1WD]C;^5L^(S22Q2
M@ &-/LH*9]S,Y/XUY)\6;V,^+(-"LWW6?A^SBTZ/#9!9%^<_7<2#_NUOA,TE
MC*BIQARW5[^6W;I*ZMY7%*'*KEB?X0W=MI<.HS>+?"JV=P66&<W[A)2O4*?+
MP2*YKQGX;_X1'Q9=Z)]J^U_9EB/G>7Y>[?&K_=R<8W8Z]JZGQ'_R0+P;_P!?
MEW_Z&U>EZCKMWK'Q'\5^%+[RI-&@T R?9S$OSR>3$PD+8W;AOP.>,#TKC6/Q
M5&7/-\\5SW6BTC*,;[.[UVT17+%_@?-]%?07AT:\=*\&?\(.;$>&?LL7]NY\
MK_79_P!(\[=SC'3'O[5C3^)5\,?#WQ#=>"9HK:VN/%C6]M/Y8=8HS#DE 0>,
M+@<9VFNJ.;2G-PA33=[?%MJU[VFCZVUT)]GYGBU%?2M_H]S;>#-?TO4+B^U7
M3+?0)9+:ZN#:BUED2(,C0QHN_*D?>)[<Y.#7-:NOBG_A"M('PR\@^&CI ^V^
M3Y&[SL'S?-W\[OISG.*SI9VJMDHI:VNY66U][:/RL-T['D_B/1K/19K!+#6+
M?5ENK*.YD>W  @=LYB/)Y&!UP>>@K'KWO3!;'Q-HNW[-_;0\#6O]C_:MNS[3
MM.,;N-WI^->9?$(>,_[3M3X_W?:_*/D[_*SLSW\OW]>:Z<%CY5IJE*U[=7J]
M]E;5=WH*4;*YR-%%%>R9&?<_\?#?A_*HJEN?^/AOP_E45?EV._WNK_BE^;/0
MA\*"BBBN,L*ZGPM\/]2\4Z7=ZI'>Z;I>F6D@BEO=3N?)B\P]$! )SR.W<5RU
M>K?"^V\67?A._M]&T;2?$NC2WB_:](O)D656V_ZU<L"HQ@;LGD<#@FLZDG&-
MT!YSKFD_V)JTMA]OL=0\L _:+";S86R,\-@9ZUI^!O"7_":>(SI7VW[%BVEG
M\WRO,^XN[&,CKZYKVKP]H'@_P_\ $[Q'I_AQF.I1Z;$UC!!<1O+!,=WG1PR3
M J7 V<MD\L/7&AYL;?%#0HKFTN(=631+XW<MY+ ]S(I'[L2^2 H8 -CCHPZG
M-8.N[678#Q(>![:W^&D7BS5=;6U>]DDCT^Q2U:0W!0X;<X("<YZ@]/>J_@[P
M'?>,[;4[FTU+3-.M]+2-[F;49FC0!R0#D*W]WOCM7HFM^*+F[^!/@Y?$=]?2
MZ=?7<T&H"UV"66&*3Y%7<,978N/IS1X$NO"=IX6^(%QH^G:CJ&BQV%H9;35)
MUCDE;?)D;XAP.G3FJ]I/E;\_UL!QDWP[T^RL]1EO/'/AV62VLWN8(K"Y\_[0
MZ_\ ++)VX8]L9/M7#5[#X3U/1=6T#QR_ASPXNA1KX?=7A6\DN?-;?UR_(],"
MNZ675_\ A78T\M9_\++_ +%.TX/VO['OSLW_ //39VZYY]Z/:N+LP/F2MB'P
MU>"'1+S4BECIFLSM%!>R.I4!'"2,5!R I8=<9[5]&?#K0[JWT7P]IMQ=7VKZ
M'?Z>6N,?94L$WJV860KYKN#QU!SUXR!RD.L^*=;^%W@6XANY+K3H]2\C6&!3
MY0MW"+=6'7C QCVSUH]NV[+^M_\ (#QKQ)I=KHGB.]T[3]3AU6VMY-D=[!C9
M,, Y&"1[=3TK+KZ(UG7]0\-:7\4-2T:807D>N0+',4#%-V 2 01G&>?>M*=;
M9OB/=WEA'9IXLOO"<-SIK2JJB2Z;>&89^7?@(!GL#VS0JS2U7]:?Y@?,M=?H
M'PTUKQ'X%U/Q5ITUG]BTUI%FAD=Q,VQ%=BH"D'Y6[D=#7H7Q.7Q*OP,TG_A-
MA'_;!ULF7&S>1Y3[?,V<;L8]\;<U#\-_$B^%?A/INHW!'V-O&7D788X4PR6>
MU\^H .['^S3=63A>/<#AO"/PQUSQGX?U+6=-FLH+33RP<W,C*9"J;R$"J<D#
M'7'45QM?3NGI9>%_$%WX!T:;S+73/#]_>7+9!+S3,I0-[K'M ]FJ?P6+2+P7
MX8DT*&ZGTG^SU_M1;>:T2T\[!\[[2)%,F<YZ'H!CWCV[5W;0#Y;KH_$7A+^P
M/#GAW5?MOVC^V[9Y_*\K;Y.U@N,Y.[KUP*]J\'B[U+P!)::7!?>%M*W7LT.J
M0R6DUM)$SNRBX5B6RH^08/8'/<)X;\2ZEI5K\*=(L94CL]4AD2]0Q*QF3?@*
M21D 9)XQUINL[Z+;_@@?.=%;'BZVAL_&VN6UK&L4$.HW$<<:# 11(P 'L *Q
MZZ4[JX!1113 ];^%/_(JW/\ U^M_Z E=O7$?"G_D5;G_ *_6_P#0$KMZ]>C_
M  T?D^<?[_5]0HHHK8\H**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#R'QQ_R.=]_P!L_P#T6M8%;_CC_D<[[_MG_P"BUK K
M[C"_P(>B_(_3\#_NM+_"OR04445T'6=+X2\#WOB^VU*XM=0T[3[?351[B;4)
MFC0!R0#D*?[O?':JOB3PT/#K6X77-'U;SPQSI=R9A'C'WLJ,9SQ]#7H/P5CO
M9O#?C2/2].MM3NVM[816ETBO%,=S\,&(!'U-;WA>T\0Z=\3--G\1^%=)T FP
MO/(33[>.-9]J MN",V<9'7UKYNMF52CBJL6TU#:-TF_=3]=^J-E!.*/!:Z/P
MMX3_ .$ET[7KK[;]F_L>P>]V^5O\[;_#G(V_7GZ5ZA9:M:^)_!O@[6O'CP7.
MSQ"UO)<2QJH$91B%;  V;@F>V!SQ6]<_\)B-'^( \5-"=-.G7)TO!BSY>&QL
MV<[-I3.>^.^:G$9O42Y%%1E>V_\ >L^6Z][3?:R'&FMSYNHKZ)T8:R4\)_\
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MVEHM16CO+WMM+V&Z:Z'SMI5E_:>L65AYGE?:KA(=^W.W<P&<=\9K0\7^'O\
MA%/%M_HGVK[7]C<)YWE[-^5!^[DXZ^M>S^'O[>'AKP2W@$V@T4(O]N<Q<2[A
MYGF[_FZ;L8_^)J7Q/I]SXDL?B'H.C(MSJAU6VN%MMZJS1[(\L-Q XVFJ_MF7
MUFS24%HU?5>^HWEII;>U]NH>S]T\5\,^&_\ A(UUD_:OLW]EZ7-J'^KW^;Y9
M4;.HQG=UYZ=*PZ^@_$L#6OBC6K>0J7B^'CHQ4Y!(<#@]Q6SX?-A%X:T231K>
MZG\/C3 ;Q4FM%LR^P^8+@.-^_/7G&<>]2\\E"/M>2Z=K*]K:7WMJWT#V?0^8
MZ*FO'MY+Z=[*-HK9I&,,;G)5,_*">Y Q4-?4)W5S$****8BE>?ZX?[M5ZL7G
M^N'^[5>OS3-/]]J>IWT_@04445YIH%36EI/?WD-I9Q/-<3N(XHT&6=B< #\:
MAKJOAEKEEX<^)6BZKJAQ:03D2MC.P,I7=^!;/X4I-I-H#>'P2UP7::?-KOAN
M'5W0,-*DU+%SG&=NT+C./>N!U/3+W1M4N-.U2V>VN[9S'+%(.5(_G]1P1R*]
M5U;X/^*]4\>W6K6%S:G1[N\>\CUU+U/+CC9BX?[V[< >W?OCFNVM_$VGZSX_
M\7ZQ>/;3> ([6.VU&>=2T=W.@ 5D'\3YX^7J I[K7-[9KS \&\/Z#8ZQIVLW
M%]KEMIDFGVAGMX)@-UXXS^[3+#GCW//2L.OH;6!K#:S\1Y]6:)[2;P[NTM[<
M_N3:;OW>S\.OOGL15[0/%6IP>-O 7A<-"^CWOA."2YMGA5A*PMI&!)(S_P L
MU&.F,^M'MGJ[?U8#YKHKW?2M?MO&O@?P[K/Q%:WN$MO%WV-IGB556%K<R!&P
M,;-^W/; YK?^)&I3Z3X0U6[OX-162&^ADT:YO9[,K#*LA97MA&H8K@<ALG:1
M_M57MG?EL!\]Z[X?U/PUJ7V#6[;[-<^6LOE^8K_*PRIRI(Y%9M?5DVIZ\?B3
M'J,SFZT$^')KBQ8E6BDE$2&3IR<\=?PKB/ ^IR_&+1IM)\87T<]_I&I0:HLL
MRHHDM1A)H]H & H].K"E&N^6[0'B%I:SWU[!:6D9EN+B18HHUZLS' 'XDUUW
MB/X:7?A>PN)=3\0^'C=VP7S=-AO]UTI./EV;>3SG@].:KZYXBO?%OQ6EUJQN
M([6XNM00V<TS!%A"L%B+%L@8 7/;@UZAXO\ #4E_X/\ $.L_$K0=-T?5[5 ;
M#5M.N !J,A. #&&.[.!R0#AN@P:J51IJX'@=%?5^I/I5IHEU):6=W>>#1I1,
M<:W%FM@5\OH 0)?-R.YSN/7TYSPYXEU/2[7X4:/93)'9:G#(EY&8E;SEWX"D
MD9 Y)XJ%7;5T@/G.BOI?P=:WWV/5M%TJSN_#]A'K%]Y>M6#6K0[5=@%GCD^8
M*NT 8Z@"L_PXFNKX2\*)\+);.6S6X<>(95\H%I-Z[C+OYV%<D8_AQCM3]OY
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M_P"$=UC_ *!MS_W[-'_".:Q_T#;G_OV:^8SXY\6?]#-JW_@;)_C33XY\6?\
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M2T8!1113 **** "BBB@ HHHH **** "BBB@#Z%_97_YFK_MS_P#:U%'[*_\
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MIJ2NCY^47&3B]T%%%%,D**** "BBB@ HHHH *3Q7&+CX1^+8V/ TZ.0$>J2
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MZ#\0(%-E#<  2([+NQSM.,BO/J]_*FW0U[GQ/$T81QJ<=VE<\A\<?\CG??\
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M-#BZA.IRU:;C'O>_WJW^9J\.[:,^5:*TO$.@7WAG7+C2M415N(#@E3E7!Y#
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M[*^6YY#XX_Y'.^_[9_\ HM:P*W_''_(YWW_;/_T6M8%?IV%_@0]%^1]/@?\
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M ':KU8O/]</]VJ]?FF:?[[4]3OI_ @HHHKS30**** "BBB@#O?AG"S?VA(C
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M^UY44EQX)FR!::U I'_/RKU\R?HASRHL=P1'@@=&QC-7K-?D)[^6O]:UH8_
M<TF)+O78!C&YU1OY5N:;X%TZXNH=0T'7EU6S1@9;69O+<KGICCI]/QI@=-X)
MM);?PW'YBX\Z1G0'J1Q_A6_7%>)Q%_PD&G6>L>8EI.IBLX8V**DI*JK-CL-Q
M/X>]=]J%C'IE_+90NTB0$(&?&3@=\=Z^DRS%.I^Y:V1^>\19;"@_K47\3U7G
MOH>,>./^1SOO^V?_ *+6L"M_QQ_R.=]_VS_]%K6!7ZEA?X$/1?D?0X'_ '6E
M_A7Y(****Z#K"BBB@!",U!-;K(I!%6**QJT858\LU=#3:)[;7]9M8O*,RW*]
MFN 68>V<Y/XU(WB36&Z&W3Z1D_S-4\45Y/\ 8F%OU^\R=&E)\SBKEDZ[K+$D
M72)_NQ+4$MYJ-S_Q\7]PX] ^T?D*;2UM#*<+'[-_4I4Z<=5%?<0"U3.2,GU/
M-2"-1T%/HKNAAZ5-6C%(TNQ-H%%+16]DA!1113$%%%% !1110 4444 %%%%
M%*\_UP_W:KU8O/\ 7#_=JO7YIFG^^U/4[Z?P(****\TT"BBB@ HHHH D@F>V
MN(YX3MDC<.I]"#D5]6>%/$</B30]-U.-P#-%Y,RY^Z_I^8(KY/KOOAAXO_L7
M47TJ\E*6=XPV,3_JI.Q_&N3%4N>%UNAH^A?$VB1>+O"-_I$Q"M<Q[58_\LYE
MY4_F!7R+J&GW6E:C/8:A"T%S;N8Y8V'*D5]=:;J/VA6G49< +=0J>>.DB^O%
M<Q\1_AC:^/+==3TJ6*#5T3"S'B.Z4=%?T8=C^'TY,-65-\LMF-H^8Z*T]<\-
MZQX;O6M=<T^>SE!P/,7Y6]U;H1]*S*]5--71(5T'@CPK<>,/%-MID 80YWW,
MH'$40^\?Z#W(J]X3^&7B7Q=,AL[%[:S)^:\N5*1@>HSRWX5]%>&/">E> -$7
M3M+7S[N<@RSN,/.P[GT4>G:N:OB(P5EN-(SO&OA:;Q+I=IH6G3)96]N1)([
ME44#"C KYXO8!8W-Q#/<1F.&0QLT+[O,(./E]?K7KOQ7^(::-I<N@:-<[M1N
M?^/J=#S&IZCV)Z#T%>!5CA:<G&[>@I),N'4IEF#VY\D+]T*>G^)JK)(\TC22
ML7=CEF8Y)--HKNC",=D 44450!1110 4444 ?0O[*_\ S-7_ &Y_^UJ*/V5_
M^9J_[<__ &M17C8G^*_ZZ#1X?1117[L>6%%%% !1110 4444 %%%% !1110
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M444 4KS_ %P_W:KU8O/]</\ =JO7YIFG^^U/4[Z?P(****\TT"BBB@ HHHH
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M\BK<_P#7ZW_H"5V]>O1_AH_)\X_W^KZA1116QY04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'D/CC_D<[[_ +9_^BUK K?\
M<?\ (YWW_;/_ -%K6!7W&%_@0]%^1^GX'_=:7^%?D@HHHKH.L**** "BBB@
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M%?+5_P"++U?YG0M@_P"%?^#?^A2T+_P6P_\ Q-'_  K_ ,&_]"EH7_@MA_\
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M_P# =/\ "C^PM(_Z!=E_X#I_A110 ?V%I'_0+LO_  '3_"C^PM(_Z!=E_P"
MZ?X444 ']A:1_P! NR_\!T_PH_L+2/\ H%V7_@.G^%%% !_86D?] NR_\!T_
MPH_L+2/^@79?^ Z?X444 ']A:1_T"[+_ ,!T_P */["TC_H%V7_@.G^%%% !
M_86D?] NR_\  =/\*/["TC_H%V7_ (#I_A110!4G\%^%KJ9IKGPWI$TK?>>2
MPB9CQCJ5J/\ X03PC_T*NB?^"Z'_ .)HHKW*7\./HCZ>A_"CZ+\@_P"$$\(_
M]"KHG_@NA_\ B:/^$$\(_P#0JZ)_X+H?_B:**T-@_P"$$\(_]"KHG_@NA_\
MB:/^$$\(_P#0JZ)_X+H?_B:** #_ (03PC_T*NB?^"Z'_P")H_X03PC_ -"K
MHG_@NA_^)HHH /\ A!/"/_0JZ)_X+H?_ (FC_A!/"/\ T*NB?^"Z'_XFBB@
M_P"$$\(_]"KHG_@NA_\ B:/^$$\(_P#0JZ)_X+H?_B:** #_ (03PC_T*NB?
M^"Z'_P")H_X03PC_ -"KHG_@NA_^)HHH /\ A!/"/_0JZ)_X+H?_ (FC_A!/
M"/\ T*NB?^"Z'_XFBB@ _P"$$\(_]"KHG_@NA_\ B:/^$$\(_P#0JZ)_X+H?
M_B:** #_ (03PC_T*NB?^"Z'_P")H_X03PC_ -"KHG_@NA_^)HHH /\ A!/"
M/_0JZ)_X+H?_ (FC_A!/"/\ T*NB?^"Z'_XFBB@ _P"$$\(_]"KHG_@NA_\
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M !_PK_P;_P!"EH7_ (+8?_B:/^%?^#?^A2T+_P %L/\ \3110 ?\*_\ !O\
MT*6A?^"V'_XFC_A7_@W_ *%+0O\ P6P__$T44 '_  K_ ,&_]"EH7_@MA_\
MB:/^%?\ @W_H4M"_\%L/_P 3110 ?\*_\&_]"EH7_@MA_P#B:/\ A7_@W_H4
MM"_\%L/_ ,3110 ?\*_\&_\ 0I:%_P""V'_XFC_A7_@W_H4M"_\ !;#_ /$T
M44 '_"O_  ;_ -"EH7_@MA_^)H_X5_X-_P"A2T+_ ,%L/_Q-%% &CI7A_1M"
B\W^Q-(L=-\['F_8[9(?,QG&[:!G&3C/J:***XJOQL9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>mdt-20240426_g6.jpg
<DESCRIPTION>IMAGE 6
<TEXT>
begin 644 mdt-20240426_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0,$17AI9@  34T *@    @ ! $[  (
M   3   !2H=I  0    !   !7IR=  $    F   "UNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36%R:6YE;&QA+"!!;G1H;VYY    !9 #  (    4   "K) $  (    4   "
MP)*1  (    #,S@  )*2  (    #,S@  .H<  <   $,   !H      <Z@
M  $
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
M   ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,082
M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3
ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C
MY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ \<HHHK]^/*"BBB@ HHHH
M **NZGHFJZ+)&FLZ9>:>\@)1;JW:(N!W 8#-7K3P9XDO;RQM8=$O4DU$_P"B
M&>$Q+/\ +N^5GPI&WG.>E8NM24>9R5N]^P[,Q**DN;>6SNI;:Y0QS0N8Y$/\
M+ X(_,5<M=!U.]T.^UFVM6?3]/9%N9]R@1ESM48)R<D]@<=ZMSA%)MZ/]=OO
M SZ*NZEHFJZ,8AK&F7EAYP)C^U6[Q;P.I&X#/4?G1=:)JMA807U]IEY;6ER
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M->C' 8I3YG4TO>UWTG%JRV7NIK3OV(YHVV/?/'F@I\0[QO#ZG;>Z/<V<ZN
MPM9U59<$^A7<?H*H^*X[/XBZ'X9LK>46VFW.ORVD+Q$'$$2.HV]N0F1_O"O&
M#\0?%!UZXUD:JRZA<6OV.6=88P6BX^7 7 Z#D#/'6J7_  E&LC1;'24OF2ST
M^X-S:HB*K12Y)W!P-V<GUK@HY)B:<8)37N;;Z-Q:ETU]ZS7S+=2+OH>I>(?
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M$!965E*ER-I#MGH><YJ"\^+.IW&EQZ=:Z)H6FVB7\6H".QM7C!E0Y!/SG.<
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MG?1);JW-'6^MTG?9HVBXVL-3X6;OB%H?A?\ MC']K6 O?M/V7_59C=]NW?\
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M'TKQL5F,J%?V:6FESZO+LBAB\$\1*34M;=M._P S:HHHKV3Y0**** "BBB@
MHHHH **** "BBB@#S'XE?\C);_\ 7HO_ *&]<A77_$K_ )&2W_Z]%_\ 0WKD
M*^TP/^[0]#]*RS_<Z?H%%%%=AZ 4444 %%%% !1110 44 $]!FEVMZ'\JER2
MW8Q*FLY((;Z"6[@^TVZ2*TL&\IYB@\KN'(R.,]JBVGT/Y4;6]#^5)RBU:X'0
M^,?%O_"4W-BEM8KINFZ=;+;6=DLID$2CJ2QQN8GJ<=A]:YVEVMZ'\J-K?W3^
M59THTJ,%3AHEYC=V[L2B@@CJ,45L2%%%%, HHHH **** "F2_P"I?_=-/IDO
M^I?_ '36-?\ A2]'^12W,VBBBOR@]$**** "BBB@ HHHH **** "NA\,^._$
MO@^.>/P[JLEI%<$&6(QI(C$=]K@C/OC-<]12:35F!T9^('BIO%?_  DAUJX_
MM;9Y?VCC[F/N;<;=O^SC&>>M.U#XA^*M4UNPU>]UB1KW33FT=(TC6'UPBJ%Y
M[\<]\US5%+DCV T==U[4?$NKRZGK,ZSWDH >184CW8&!P@ Z>U9U%%4DEH@"
MBBB@ HHHH **** "BBB@ HHHH _0FBBBOGBCX+HHHK]^/*"BBB@ HHHH ***
M* "BBB@ HHHH UO"\*3>(;=91E0&./?:<?K@UQE]?SP>)KJ\C8><MPY!90PZ
MD=#QTKO?!=N)]>9B^WR8'D _O=!C]:XI7LDUG4/M^S'G-MW9_O'T4U^7<62O
MCTNT5^;.ZA\!GWVI7.H^5]J*'R4V)MC5>/P'-5:?,5,[^7]S<=N/3-3Z=8/J
M-R88W5-J%V9NP%?)I-NR-924%S2V*N:,FNFM_#EJN/,,URV,X4;1C]33)_#<
M#*'@EEA#9QYB[E/XBMO83L<GUVC>VOW'.JVQU8 '!S@C(/X5JCQ+J9F60-#A
M&#A/LT>P$+M^[MQT_P :S[NV>SO);>4@O&Q4E>AJU:7$:6VP3>0PSGK\Q['@
M<X]*YIW6ECIE).-UJF=1X"OI-2\67AO]K+=0'S51%13RJ_= P.">E5JD^';I
M)XRF>)=J-&2H]!YBU$.E?H/!K=JR_P /ZF%?9"T445]^<H4444 9LO\ KG_W
MC3*?+_KG_P!XTRORBO\ Q9>K_,]);!1116(PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /;OA[_ ,B)I_\ VU_]&M725S?P
M]_Y$33_^VO\ Z-:NDKV:?P+T/R#,/]\K?XI?FPHHHK0X0HHHH **** "BBB@
M HHHH Y?QPV-/A!Z99OQ KA?"M[/=3VLEU(TSV\^(BYSL! R![5VWCLXLX/H
M_P#(5P'@XY=/^OC^@KPL53B\7&ZW3_(_1,GDUEL;/^N9GM=%%%>X?GCW"BBB
MF(**** "BBB@ HHHH **** /,?B5_P C);_]>B_^AO7(5U_Q*_Y&2W_Z]%_]
M#>N0K[3 _P"[0]#]*RS_ '.GZ!11178>@%%%% !1110 5:LK+[3'<3ROY<%M
M&9)'QG'M^A_*JM:ELQ7P;KVTXW1(#[]:\;/,14PV7U*E-V>BOZM(TII.:3,W
M3==\47>/[#D$$!D,<:+(J8.,X/([=ZJM\0?%,;LC:I-E3@_,:Q8=/$NF2W?F
ME3&<;-F<]._XU2K\;<G)W9Z)T_\ PL7Q1_T%)?S-2'XB>),<:O-GZ'_&N4HI
M =0WQ$\3<8U68\<]>*L6GC+QA?Y,&I2;0RJ6>8( 2<#DD>M<?10!VEQK'B'[
M#:W7B"19],NI6C63S4D;(."0 2PQCVSZU-J6GOIUWY+G<K*'1A_$I_\ K@C\
M*XV>T,,2NK;ACYNV#7H/B-V==,+G)^Q(,_B:^NX4Q518SV*?NR3T\UU.:MRR
MAS(Q:***_4#C"BBB@ HHHH *9+_J7_W33Z9+_J7_ -TUC7_A2]'^12W,VBBB
MOR@]$**** "BBB@ HHHH **** "BM&+0K^2)96@:*-L;6D!&[/H.IK0@\)R3
M2*OVI #][Y2,'TJX0E4=HF<ZD(*\F<]178R> )C&&@N@S8Z%:P-2T&_TO)N8
M3L'\:\BKE1G%7:)A7IS=DS-HHHK$V"BBB@ HHHH **** "BBB@ HHHH _0FB
MBBOGBCX+HHHK]^/*"BBB@ HHHH **** "BBB@ HHHH WO!T+2^(%92!Y<3N<
M]QT_K7GFI_\ (6O/^N[_ /H1KT7P7,L6OE6!)D@=!CUX/]*\ZU/_ )"]Y_UW
M?_T(U^6<6?\ (P7^%?FSNH? 5:TM E$>KQAC@2!H_P 2./UQ6;0"001P17RT
M7RM,TJ0YX./<]GTOQ3"EM90W,UW#-;0+&TT,89L),7\L#(^4K@?4<@BH=:U^
MSU'23:0Q21/(T.+=EQ':",,&*G/\>X$\#H?:N T_7HY0([]O+D'2<#AO]X#O
M[BJ^IZX)8VM['(1N'E;JP] .PKL]I32YCQU1KN7LVOF9E].+G4)YEZ/(Q'TS
M4%%:&EZ-/JV_[/-;1[&53Y\PC^]GGGMQSZ5Q-W=SVHI122.@^&?_ "-3?]<?
M_9TIM:/PWL)-/\?6\4TD,A>&.0&*0. #(G!([^U4[C_CZE_WS_.OO.#G[U9?
MX?U.;$=".BBBOT$Y HHHH S9?]<_^\:93Y?]<_\ O&F5^45_XLO5_F>DM@HH
MHK$84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'MWP]_Y$33_P#MK_Z-:NDKF_A[_P B)I__ &U_]&M725[-/X%Z'Y!F'^^5
MO\4OS84445H<(4444 %%%% !1110 4444 <CX].+2W^C_P A7 ^##\R?]?']
M!7?>/A_HD'^Z_P#(5Y_X+/[Q/^NX_D*\7$_[W'T?Y'Z'D_\ R+EZ_P#MS/;J
M***]D_/7N%%%%,04444 %%%% !1110 4444 >8_$K_D9+?\ Z]%_]#>N0KK_
M (E?\C);_P#7HO\ Z&]<A7VF!_W:'H?I66?[G3] HHHKL/0"BBB@ HHHH *V
M89(S\/M:B"?O00Q;'5<8 _,&L:MN&-?^%=:U+CYRP4GVVY_K7SG$UO[,GZK\
MT;4?C1YK1117Y(=XH5FQA2<G P.].\F4LRB-\K]X;3Q]:T+"["V9A>?8=Y\O
M).$)1AGVY(YJ];7<444<;RQR31E#(QF*@8+8((^]@$#'/3C-6HI]3EJ5IQ;2
MB<]16G<BVNH[>.)X8O)1E:0N?WA)+#(/3KCCBLPC!(]/0U+5C:$^9;6%+,5
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M3>?_ &:NL\21Z4]Q=R:E<O%=KIEJ;-0"0[[!D'@]OI6)?0^';-[N.VOYK_\
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M^C6KI*YOX>_\B)I__;7_ -&M725[-/X%Z'Y!F'^^5O\ %+\V%%%%:'"%%%%
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M/H_R,:WP&+1117ZP< 4444 %%%% !3)?]2_^Z:?3)?\ 4O\ [IK&O_"EZ/\
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M)7-_#W_D1-/_ .VO_HUJZ2O9I_ O0_(,P_WRM_BE^;"BBBM#A"BBB@ HHHH
M**** "BBB@#D_'7_ ![VW_ OZ5QVEPQIJMNR1JK;^H')YKL?'7_'O:_\"_I7
M(Z9_R$[?_KH*XJJ3;O\ UL?=95?ZK3M_6K/6J***[#X9[A1113$%%%% !111
M0 4444 %%%% 'F/Q*_Y&2W_Z]%_]#>N0KK_B5_R,EO\ ]>B_^AO7(5]I@?\
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M(V+T?B*291:^(;<:C"OR[I/EGB_W7Z_@<BH-1T9(K7^T-*G-WIY."Q&'A/\
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M,G^P[YF"PK#.Q[07,<A'Y,:IW$$MK,T-S&T4J\,CC!%1G!J[!J][;P"!91)
M./*E0.N/3D<#Z4:!H:47^I3_ '1575(I9].>*W5GE=E5%7J3NZ"M6..UNHD:
MW=;60J,PRL=F?]E_3V;IZFLJ_BN+O19Y;.&:0*^W<B'J&[&G%:HJ$7S)DGPZ
M@FM_%S)<QO&_V?(#C!QO2H!TJ?X=).GBYQ=+(LGV?I("#C>GK4 Z5^C\'?\
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M<)AOH3WZ5W_B+[NF?]>2?S-?2\+_ /(RCZ/\B*WP&+1117ZP< 4444 %%%%
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M7MX#/^$'U1V)1K8*>1F=>GYTX> ]5/\ RULQ_P!MUJS17J_ZG0_Y_?\ DO\
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M@ IDO^I?_=-/IDO^I?\ W36-?^%+T?Y%+<S:***_*#T0HHHH **** "BBB@
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M)_X+H?\ XFC_ (03PC_T*NB?^"Z'_P")HHH /^$$\(_]"KHG_@NA_P#B:/\
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M?^A5T3_P70__ !-%% !_P@GA'_H5=$_\%T/_ ,31_P ()X1_Z%71/_!=#_\
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FA2T+_P %L/\ \31_PK_P;_T*6A?^"V'_ .)HHH Z&BBBO.&?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>mdt-20240426_g7.jpg
<DESCRIPTION>IMAGE 7
<TEXT>
begin 644 mdt-20240426_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O)?VJ/VP_A[^RO)X/\,ZQX?UCQ+XQ^(OB Z)\/_ _AQ(3?ZW>
M+$TTNTSR10PPPQ(TLL\LBI&@ZEF56]:KXN_X+%_L!?M%?M7Z/\,OVD_V)?B3
M8^'/CA\!?$ESKWP^36@#I^KI<11QWFG3GHGG)%&H8_+C<C;1(9$ .E_9;_X*
M0^,?BIXG\"_#KX_?LK^)_!.I_$:\UJV\(^(K*ZM-1T*]GTYKMYK1YX9S-;7
M@M)'"RQ*DGEN8W;:0,;]KO\ X*W:C^S]X_\ $/@#X"?L%_&7XY'P057Q[KGP
M[T)&TW1IC"L[6:SR,#=W:1.CO#"K>6)$#,&)4>)_\$1/^"G7P/\ VH-&T7]B
MC]H[P%-\/_VA?AQK&KZLGA#7HBD5_/)-?K<7NDR[B+A%BN[J,IN9@A=E,B*9
M!^@WB?7OA+^S?\+_ !!\0O$EWI_AGPOHD>HZ_P"(+]QLAAWR2W=W<OCDLTCR
M2'&2S,<#) H X7]@O]N_]GS_ (*._LWZ5^T_^S9KEW<Z%J,\MI>6.IVXAO=*
MO8L>;9W,89@DJ;E/RLRLKHRLRLI/A/[1'_!;#1O@I\;?$GP;^&__  3B_:C^
M,-OX7U Z=J7C3X1_"E]7T1KY$4W%K'="90\L#L8I0!\DB.AY4U)_P1:_9%^(
M/[.O['WCOQAK>B/X)\4?'3XH>(_B1!X=O[ .?"B:HRBPLY8 R@O#;0V[R194
MJ[/&2-N:^3O&?AG_ (*\?\&]W@ZW^.=W^TC9?M-_LUZ5K3W/Q&\.:AX3BTOQ
M#X?AOKQI;G4[9XWD,Y\^=Y)&>5E+2,6B0,TT8!^E7[27[9WPS_9.^!&D_&SX
MS:#K=I=>(+_3=)\/>"+&"*XUG5=<OB%MM'MHED\N6Z9R5_U@C78[EPBEQB_"
MW]N*TUO]HBT_9*^/GPCU/X:?$+6?#<GB#PGI>IZK:WUIX@L(G"7(M;JV<JUS
M;ED,UNP5E5UD0R1Y<?&'_!3CXAV_QG_X+-?\$Z/ ^DZK]J\&:GJ7B'QC8LN1
M%>W$>GQ36DQ![HJ97N//;UK3_P""\/B+4/A[^W;_ ,$]OB1X7D:+6D_:2CT)
M)H3AS8:FUE:WL8(YVO$VTCH1UH _32BBB@ HKC/C-\3?%_PRTRRO_"'P=UKQ
MC)=3M'-;:+)&K6ZA<AVWD<$\<5YAXD_;5^)G@_0KKQ/XJ_8W\9:?IUE%YEW>
MW=_:I'"G]YF+8 H ^@J*I^'=8C\1>'['Q!#"8TOK.*X2-F!*AT# $C@XS5R@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *\,_:A^//Q\^ ?QJ^'>N^%?@%XJ\<?#'4M,UNS^(<_@O3X
M;V_T.^WZ>^F7GV3<+FYAVKJ,;K;J[ R(S*=J@^YT4 ?E#\%?V=_$O[>GQ[_9
M4^-'PX^"FO\ AK1?@/XQ\5:]XK^*/B?09=(FOXIM0N_L^A64-PJ75T'D8O,S
M1K#"H=0[2.T==G^U;^VI^V=XN_:PG\/W_P#P2 ^-WCSX2^ M3BG\+6FF_8;6
MW\3ZO!)N35+M)I2SV\#JKVEN0!Y@%S(#(L"0?I)IVFZ=I%HMAI-A!:P(S%8;
M>((@+,68@  <DDGU))J>@#Y7^ '[:7[;?QB^"_Q0^-OC+_@FWXD\$W7A33@/
M 'PU\0^(K9-;\67L<$DTW[T P6T3EK>&(D,=ZS$D\*.%\<?&KX[_ /!4S]DK
MQ!^RWIO["OQ6^$ES\1M!E\/^.];^*VD6MC9^&["Y3RKV2V_?--J-QY+2BW$<
M(0R%&F:$#!^XJ* /B3_@I3^P7XNUV;]G3]I_]E+P4VK>*_V6_&%O>:3X0@N8
MXY];\,R10VNI:;;R2LJ?:3;PQM$9&"EHF7JX-9OQ5^ _C3_@I/\ \%%?@/\
M'K4?A=XH\+?"7]G?^T_$*W/C70IM*O/$GB>Z2".UMX+.Y"W"0V?D^<]PZ*CN
MRI'Y@W.OW;10 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L
MO_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>
MKUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V
MK3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<__)H_
MCW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*
MW:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)
MGX=_[ 5I_P"B4K=K"^%W_),_#O\ V K3_P!$I6[0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?
M^P"__H:T =U\+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M -SE&;\-X'+\NG7IRDW&V[5M6ET2[A&;;L?NA1117Q)H%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/
M?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=
MK"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\ HE*W: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\
MZ&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQE>:-I'BCQ7:R7&G:':V=LL]S.T$<L37-P_F0PP0^9&K22@LV%V-]1U\[?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCU=!_L1?!NG6<XB-C_:7FB<W-U!L#?;(MI4/]U\XP-WZ#ZK_ ,'C/[#L)/\
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MM&>!+,J0&%UXOLH\$C('S2CMS7-:I_P4*_8%T,%M;_;A^#]F%!+&Z^)>E1X
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M6LTD[]=%T/H^&JW$M?+.?/*5.G7N_=I2<H\O35ZWWN>1>,/V[/V7O WB&_\
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MM6GNKF*%Y[B2*-(HXA"B0*&.Z5R'7ZAHH **** "O*/VY_\ DT?Q[_V 7_\
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M*DFTTVG9I]FGJ>D_\0M/_!('_HDOBO\ \+J]_P#BJ/\ B%I_X) _]$E\5_\
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MB#&TZV#S>M@91CR\D8Q<&[M\SC)6;UMOLCRWX)?\$X_^"1OQ(^*>B_"CQ/\
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MA<QK2P-+!5</S/D3E6A5Y;^ZI/X+VWMI<T_VCOV'/V$?^"B47AWQ9^T)\*M
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M?Q)W3>JVLW+>^A1117R)^DA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
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MHHHH **** "BBB@ HHHH **** "BBB@ HHHH " 1@C(/4&OF_P#:4_X)&?\
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M?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\ HE*W: "BBB@
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M &HK_P 8> _B%>WT]II,4%Q81QSV7V<[KFU$TD+OBZ78X.?E<X6OZ<*^(O\
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M'*^3; J%(V3+C%?KU^SW^S+^S_\ LH?#RW^%/[.'PBT/P=H%O@BPT2R6+SG
MQYDK\O/(1UDD9G/<FNZHIXW,\9CW:K+W5M%:17HOZ8))!1117 ,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_&OXJ>/?CC\7O$WQB^*6H-=>(_$VN7.I:U,RE?\ 2)9&=U523L52=JK_  J
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M^J[/X5_\&Q__  2N^'GEOXI\%>,/&\D>"6\4>+YHPQ]2M@+8'Z=/7-=E;_\
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M_F-)(****\T84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^B2W$B#\%K[+\ _#SP%\*O"-EX ^&/@K2O#NAZ;%Y6GZ/HFGQVMK;)UVI%&
MJC// ZFMBOQGC_QZXTXMXB^NY9B*N"HP7+"G3JRCI>[E/E:4I/TLDDELV_1P
MF5X:A1Y9I2?5M?D?E[XV_P"#3W_@GYKF^?P;\7?BIH4K9V1G5["Z@7_@+V8<
M_P#?=>3>)_\ @T6L]/N_[5^$G[?&HZ?/&<VZ:GX&#N/^VT-ZA7ZA*_9NBO)P
M7CSXMX%6AFLY+^_&G4_]+A(TEE> EO#\U^1^*)_X(&?\%JOA$=W[/W_!4$)#
M#_JX1\0/$&E%@.VR))4/T)Q1_P ,Y?\ !V/\%./!'QU;Q:L/0_\ "4Z)?[P/
M^PM&I/X\U^UU%>C_ ,1XXGQ'_(QP."Q7?VN%@[^O+RD?V717P2E'TDS\4?\
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M;L#   ^4?^(E/_@M;_T>C_YCGPW_ /*ZC_@Y3_Y36_&C_N7/_4;TNOA>OO\
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M%U:#5_"^CR((]2L)8Y!)$]EI<>V'3F!4#S9P)\JI:.3K7[M01O# D4D[2LJ
M-*X 9R!U. !D^P ]J?17P6.S"MCY1YDHQCLDK)&B5@HHHK@&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@&O<Z* ,GP1X8O/!_A6T\,ZAXPU77Y+2,H=5UQH6NIQDD>8T,<:,0"%SM!(
M+%F)8_/D?_!)[]E>/1S\,C/XH;X6'Q0WB+_A2;:TO_"*C4#<_:RWV81^<;?[
M5_I'V$S&S\SYO([5],T4 <)^T;^S9\'OVK?A5=_!OXV>%SJ6C7%S!=V[V]U)
M;76GWD$BRV]Y:W$162WN(I%5TE1@RD>A(/-_![]BWX:_"OXMW7[0OB'Q9XF\
M>?$*XT)=#A\:^.;^&XO+'2UD\S[%;1V\,-O;1M( \ACB629E4RO(57'K]% !
M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V 7_\
M0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'
M?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY
M_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M
M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6
M@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHJOJ>KZ3HELMYK.IV]I"]Q#;I+=3K&K2RR+%%&"Q +/(Z(J]69U49
M) H L4444 %%%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?
M^P"__H:T =U\+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V
M7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O
M*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[
M5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?_DT?
MQ[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\ 1*5N
MUA?"[_DF?AW_ + 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKY[N/^"J_
M_!/:S^*UY\(]0_:N\&VUY8P0-/K%QKL":5Y\MQ/;BT%\7\C[0);=T:(L"&(7
MELJ #Z$HK'\7_$+P%\/_  1>_$OQWXUTG1O#FFV)O=1U[5=1CM[.VM@-QFDF
M=@B(!SN) QWKF?@G^U)^SW^T;)J-M\$_BSI.OW.D+"^J6%K,4NK6.4$PRR02
M!9%CD"L8Y"NR0*2I;!H [ZBBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
MY-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K
M=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \O_;<^%?Q,^.7[&_Q4^#'P8\3C1O%OBOX
M>ZQI/AK5#.8A;WUQ9RQ0L9%YC&]E!<<KG<.0*_,/_@C]^U7\%/CIXQU'_@EI
M^VU\'8OA;\0O#O[.VA_"W7?AEXP@BMX_$9L)=36::Q#?+<"6VN(9]HY)=WC\
MR-?-/ZG?M2_'_P ._LJ_LZ^,OVD/%^FRW>D^"= GU?5((&(=K>%=\A7"L<A
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M 'NE%>%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\ X65S_C0![I17A?\
MP[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/^- 'NE%>%_\ #O?X)_\
M0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XT >Z45X7_P[W^"?_0V^._\
MPLKG_&C_ (=[_!/_ *&WQW_X65S_ (T >Z45X7_P[W^"?_0V^.__  LKG_&C
M_AWO\$_^AM\=_P#A97/^- 'NE%>%_P##O?X)_P#0V^.__"RN?\:/^'>_P3_Z
M&WQW_P"%E<_XT >Z45\;^$_V0_AQJG[7?B[X577BKQA_9>E>%;"]M2GBFX$W
MFRNP;=)G++QP.U>J?\.]_@G_ -#;X[_\+*Y_QH ]THKPO_AWO\$_^AM\=_\
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MKG_&@#W2BO"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X)_\ 0V^._P#PLKG_ !H
M]THKPO\ X=[_  3_ .AM\=_^%E<_XT?\.]_@G_T-OCO_ ,+*Y_QH ]THKPO_
M (=[_!/_ *&WQW_X65S_ (T?\.]_@G_T-OCO_P +*Y_QH ]THKPO_AWO\$_^
MAM\=_P#A97/^-'_#O?X)_P#0V^.__"RN?\: /=**\+_X=[_!/_H;?'?_ (65
MS_C1_P .]_@G_P!#;X[_ /"RN?\ &@#W2BO"_P#AWO\ !/\ Z&WQW_X65S_C
M1_P[W^"?_0V^._\ PLKG_&@#W2BO"_\ AWO\$_\ H;?'?_A97/\ C1_P[W^"
M?_0V^.__  LKG_&@#W2BO"_^'>_P3_Z&WQW_ .%E<_XT?\.]_@G_ -#;X[_\
M+*Y_QH ]THKPO_AWO\$_^AM\=_\ A97/^-'_  [W^"?_ $-OCO\ \+*Y_P :
M /=**\+_ .'>_P $_P#H;?'?_A97/^->5_'_ /9#^''@;XG?"_PYH?BKQ@;?
MQ)XJDLM2-QXIN)'$0@+C82?D;(ZB@#[(HKPO_AWO\$_^AM\=_P#A97/^-'_#
MO?X)_P#0V^.__"RN?\: /=**\+_X=[_!/_H;?'?_ (65S_C1_P .]_@G_P!#
M;X[_ /"RN?\ &@#W2BO"_P#AWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\
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MP[W^"?\ T-OCO_PLKG_&@#W2BO"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X)_\
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M !/% &[7'?M!?#.^^,OP7\1?"_3-3BLKC6].:VBNIT+)&20<D#DCBN&\2_\
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MOC'\&=3^)OCWP!XOL=:@M8_!WB%]1N89HV+7"F(IL4CH<G/-97Q@_;A_9-^
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MI >2A)D([)%-;+QD"O0/A-X<\)?\%//VR/B9^U/X!_:B\3:+X?\ A+=O\+O
MES\.-?LT:9U$%[KEY(TD$XV3W1M+9"NT,NDAQN60&OEG]OG1- _X(K?\%?/V
M?_\ @HCJG[0/B+7?#'Q=6Z^'OQEO/&^KVTMVEF1!]EO6,,,6Z& B*1V*$JMD
MJY_>   ^YOVV/^"KO@_]B#]I_P"%G[,WCC]G#Q]K4WQ7N-0B\/>(M#@M9[:Y
MDL[4326UO#',]S-=%Y+>%8GBB1FG!$A"MCC_ -G#_@LY-\0/VWQ_P3]_:O\
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M.N7,HCQG.XQHS[>NT$].: +GP#ABB_X.<OCT\<84R?LU>'6D('WC]MA&3^
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MNF213OX,N[J&*[U=("/,\KR[:WN5W*&$$OF.$VL  =#_ ,%YOB%?_LF_&/\
M8\_;8\#2_8M6T/\ :#L_!.K/;_*;WP_K5M*+ZS?'#H5LU90V0DBJX (S6O\
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M\9K"3PQ?>*?B]IGB33O#^L-Y5Q86-UKBW%O"R-R'^R1K.R=5#MN *MC]D/\
M@IGXD\/?\.P_C[XE_MVS.G3_  ,\4207XN5,,J2:/<^6ROG:P;<NT@\[AC.:
M /F;_@HI\<O"/[4__!M3XZ_:"\'?#N/PMHOB_P"!]OJVE>&4:-ETN%S \4 ,
M:(F$ 4#:H P, 5]@?L)?\F/_  :_[)3X=_\ 39;U^<GCKQ-X=/\ P9W0:@-<
MM/(/[..G60F^T+M^T[H8?)SG[_FC9MZ[N.M?HG_P3_U33=:_81^"VJ:1?PW5
MM/\ "?PZT-Q;R!T<?V;;\@C@T 7/'O['OP'^+GQUMOCW\8_ .E>+]2TGPXND
M>&;'Q+ID5[:Z(K32RW5Q;1RJRQSW&Z!)) -Q2TB4$#?N^)_^"?/[*WA+X&?\
M%Z/VH-?_ &5?#5OX;^%$7PY\/V?C/P_HD(@TM?&-RR7:K!$@$:O'9[I71!\A
MU#D#S *]T_X*2?\ !6#]FO\ 86U'1/@;XF^/G@[PQ\1?&D3'29?%-T39^'[+
MD/JU]'&=[1K@B*W&U[F4! T<8FGAQ_\ @GK^W?\ \$OM9UW1_P!CO]B3]HN#
MXF>*M7;4?$'B?4]+BDNKN\G/[Z^UO5;DQI&'FN'BCX_CGACCC6),1@'DG_!N
M9XVN/VN_A;^T1^W?\3((]2U[XN_'O5K9YKM!)Y>@6-K;0Z=IOS9S# DLZ*IX
MPYSDDD\M_P $4O">C?M.?LM?'[_@F?\ &:_NM4\#_ S]IC6O"EAI4LI9+_PS
M:ZA]HMM)F8G+6WG121O']U[?]P1L)%=+_P $.['PM_P3>\*?M(?L)?M"^*M.
M\*S?"WXLZIXMTJ^UR]2VAO?!FH0PR66JH\A :(&"=)64D12+Y;$-Q6+_ ,$A
M_%'@'_@GM^P1\</^"G7[;&N'P)HWQL^,FO?$2UAUN%HKL:5=S'^SH1 PWO<7
M'[R6.(#<RSQ\#F@"3_@MY^PC\$7\4_LLZO\ LE?"#P]X-^-8_:)T&Q\%:IX+
MT:&PN4TJ))[K4&F%NJ[[2WAMQ.Q8$1[<# E97W_VH_B'JGQZ_P"#D']GS]D;
M7)#<>$/A5\*-5^)3Z5)S!<:Y.;JPMIY$Z.]L@22)CRC3.1@FLSX/?\%E_P#@
MD[=^.[W]M?\ :1_;;\$W'CZ?19-/\)>#=(DGU)_!^CR.LC:=;+!$WVG4+ETB
M>ZFB!#O'%#&6B@1Y-;]J[P3?? #_ (+H?LZ_\%'_ !3I=QH_@3XB_#6\^%WB
MO4=2V(GA_5I#/>Z:EXP9DC-S+(+52&*>;$%W?,I8 ?\ M ?$74OV:?\ @Y/^
M!]CX1N#:Z5^T3\'-6\/^-[&(XBO+K1UNKZQO9%'#3H/]'60Y(C<KTK]':_.;
MQS\.)OVQ_P#@XM^'OQ8\!31ZCX._9>^%&H#Q3KMJXDM8_$NKBYMXM)WC@W"6
MDJ73J/N+LW8+*#^C- !1110 4444 %%%% !7S3_P4XUC7?'?PM\/_L1^ =<N
MK#Q'\?\ 7O\ A%);_3W"W&E^'A$UQKM^A(PC)IT<T,;GI<7EL.K 'Z4EEC@C
M:::141%+.[' 4#J2>U?"7PF\.>$O^"GG[9'Q,_:G\ _M1>)M%\/_  ENW^%W
M@2Y^'&OV:-,ZB"]UR\D:2"<;)[HVELA7:&720XW+(#0!Y_\ \&XGQ0\:_"7P
M-\6?^"1GQSUAY_&O[,7CNXTW2IKCY7U'PU>2R3V%T@/)0DR$=DBFMEXR!7T!
M^VQ_P5=\'_L0?M/_  L_9F\<?LX>/M:F^*]QJ$7A[Q%H<%K/;7,EG:B:2VMX
M8YGN9KHO);PK$\42,TX(D(5L?#/[?.B:!_P16_X*^?L__P#!1'5/V@?$6N^&
M/BZMU\/?C+>>-]7MI;M+,B#[+>L888MT,!$4CL4)5;)5S^\ 'LG_  5\^*/P
MZ\(_\%5_^"='Q'\1^-M+M/#\OC7QDD>M37R"U;[3IMA! ?-SLVO)+&H;.#N'
M- 'J7[.'_!9R;X@?MOC_ ()^_M7_ +%GCCX&?$+7-$FUCX>VGBC5K+4(/$]I
M$LDCK%/:.8DG\N*1O+5Y$'E2*9 RA6YFZ_X+H^-_$WC?XV?"7X&_\$Q?B[XS
M\:_!+6]/L=>\'V>H::+R2&<2&2Z8P33Q!5VIY44+SS3B0LJ*D4SQT_\ @H3\
M-H?VFO\ @M=^QOX6^%8CO-:^#O\ PDOC'XCW]D0W]A:/-!:Q64=RR_=-W<Q/
M'$AY(65@-H8UF_\ !(7QCX3U7_@KG_P4+T72_$MC<79^(7A:5;:&Z1G9(]/N
M89& !R0D@*,1]UN#@F@#W3PS_P %"_!OB7_@J#H_["OB']D7Q)X:\:7OPBN/
M%EMXU\2'3,MI?VI(OLT!M9IY2C3K('61HBKP9\M@58^,_ .&*+_@YR^/3QQA
M3)^S5X=:0@?>/VV$9/X #\*I_$?Q-X<B_P"#JCX>Z/)KEH+MOV/KVW%L;A=Y
ME.N7,HCQG.XQHS[>NT$].:/@#XF\.3_\'0GQXT2'7;1KQ?V;=!C-JMPID#I=
MV[NNW.<A9(V(Z@.I[T ?H-\2O!\_Q#^'6O\ @&U\3W^B2:YHUUIZ:SI4FRZL
M#-$T?GPL?NRINW*>S*#7YZ_\%QO^"=?[!/A'_@D!X[\,>#OV7?"&A:CX8TFS
MA^&$OAKPY##J<6N274%O8P6\L:^=++<3R)$X+,TOFL6W$YK]$?&WC?P=\-?!
M^I_$'XA>*+#1-"T6QEO=7UC5;M(+:SMXU+/++(Y"HBJ"22< "OS7T7_@M)_P
M27_:<^,VF_'KX^?MM^"=)\)^ =6EN/A;X$U*XE\Z:_0/%_PD5_$(SMFV-(MG
M;')@CD::0>?*D=J <_\ \%8-?^,&G_#']@'_ ()H?&;Q!+J%Y\7/B/X6T[XT
M2O<&3^WK;1X].;4;65N1)'/<3K(W]XQ+V)![[_@O-\0K_P#9-^,?['G[;'@:
M7[%JVA_M!V?@G5GM_E-[X?UJVE%]9OCAT*V:LH;(215< $9KGO\ @K;J>B_M
M%?##]DS_ (+"_!#3-5U3P/\ !CXQ6/BC6YY=,DBG?P9=W4,5WJZ0$>9Y7EVU
MO<KN4,()?,<)M8#=_P""POA/3/\ @H/^TY^R/^QC\&]<LO$,5I\6;3XI>.KO
M1[I+F'2O#6F0MMN9GC)6-;HW+0V['B1R=N0K8 /K^3]@W]EOQ#\0_&GQ9^*_
MP:\->./$?CJ=$UC5/%^@6VH/'81P)!!IT(G1Q%:HB%C$N%>66:5@6D8U\E?\
M&\/P&'P,\/?M+6?PO>X@^#-[^TEK\/P=TYYVDMUL+1_LMQ-:LQ.ZV,\9@1\G
M=]D8Y).X])_P4 _X*]?L5^"_C%>_L$:W^VMX:^'.H_9 ?B?XO;5=MUH-E)P=
M.L3&K$:I.N1OZ6<9,K?O3!&_LW[ G[:O_!/_ /:$TN;]G_\ X)Z^,=,U_P ,
M?#/P_86]P_A73Y4TG1H9-\=I9B615$DK)!*VU-Y C)D*ETW@'R_\>OAG\._
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MY^!%_P#M ?M)>.+;2=*MY%MM,LFGC6YU>]<'RK.V5V4/(Q!Y)"(H:21D1&8
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M1%& H%Q" !5+_@@9XI\-:S\=?V[DTC7[.Y*_M@>([EO(N5?$+D*LG!^X6CD
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M[MM/@MK^]^TSQPJLUR8PGFN  7VCA<G)P.!F@":BBB@ HHHH **** "BBB@
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MV<Y/6NA\1>&_#OB_1;CPWXLT"RU33KM-EU8:C:I/!,N0<.C@JPR <$=JNT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ K^?7_@M]_P %OO\ @J%^R!_P5"^)W[.W[.W[3O\ PCW@WP]_8O\
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MVK_AAI3^#/!NIV7B6]37O%FDRE;?0[+1+IIA+:0I/+:[(K8Q0B&:"Y=3^_D
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M*M7U;2;Z:73]-CNGWKI%C')CR(;8J(I/DC>6>*62558^6GU=0 4444 %%%%
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M61/E*L",\@U]I^ ]-\;Z3X5M+'XC>*K'6M92,?;M1TS2&L8)7[E(&FF,:YZ
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M_ MUHES8:G%<QI):7*S:C>)(KPRB2-EV$F.4$#:"WYW_ /!*_P %?M)^+O\
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M;^#?#-W_ &)XFN4LGMIIIYQ*^GL[6<\R2PQLLDL+G VG*$K6#\7_ (#>&O\
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MSU'XCZ!;:3\2_A_\6K&^?3;Q8(8(4F@FL@TJMMMH'"X4HZO\[)*8QA?M<_\
M!#G]I[]J[Q_HG[>LG[;&F>"OVJ_",ML?!WB7P3X0%IX;TZRA$V-.>&5I;N[#
M^?*'N9Y9-RN4%N(R8J_3"B@#YH_9/^&7_!3KPKX7U7Q_^VE\;?AQXS\=C34T
M[PWX6\#VU[H_ARV3S%::\N99(Y9KFZD"I@^2J1",I&%\^1Z\Y_X(S_\ !.K]
MIW_@FEX2^(?PS^+?C[P-XNTKX@?$O4/&TNJ>'_MEI<6%[=PP12P"&6-UEB/V
M>,AO,0K\W#Y&/MVB@ KP_P#;<\$_M^>*M#\+:M_P3_\ C;X$\*ZWH^O?:/$>
MD?$7P[+>Z;K]@8R/LSRP?O[8JV&W189NFY0,-[A10!X/\*?V:?C%XI^+V@?M
M*_ME^-O#&M^+?"6FW=IX+\/>"-)GM=&\/-=HL=W=![F62:\NY(U$(F;RECA9
MT2)3)*\G-?$C]B?XB^!/VX[S_@H-^R-J'AI/%'BOP;'X9^)?@[Q;<W%IIWB*
M&W</8:@MU;1326]Y;@&')AE26%MF(V4.?IVB@#YU_8R_8%T3]GF/XI_$/XO:
MWI_C/XA_'3Q')K'Q2UB/3##8SQ^48+;2K>&1G865M;LT*"1F=]\CL1OV+XUH
M'_!+S]I;X:_L;^(_^"7/PF^-OANQ^".NR:GIVF>+;Y;J7Q1H'AG4)I);O18H
M"IM[F0+/<017SS)Y<<BYMY#&-WW?10!S7P:^$7@#X _"7PU\#_A5H,>E^&O"
M.AVND:%I\9)$%K;Q+%&I)Y8[5&6/+'))))KY&_X+&?\ !.O]J#_@I%IOPS\&
M?"3Q]X%\):5\-OB7I_C:"_\ $'VR[N-1O;2.1(H&AAC188AYTF2)'9OE^Y@@
M_;U% 'Q=_P %#?V&_P!KG]M[Q-^SYXN\/ZU\.O#$_P %_BKIOC_4K6[U*_O4
MU6]LI6V6<;+;1F*%H^3(0S!I-H3$>Z27]IW]AS]JSXY_\%'_ -G_ /;M\-:S
M\/M,T_X&6&MPCPO>ZG?2S:RVKZ>+2[_TA;55@$0)\L^6^[8&8+NV+]F44 ?
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M4S1B-HI2!NM]J(F$V,-K>9]MT44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>mdt-20240426_g8.jpg
<DESCRIPTION>IMAGE 8
<TEXT>
begin 644 mdt-20240426_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^P?VE_PD?G^3PWS^7]D7=]WIN'7K0!^A]%?'7[;G_!0O_AC?QIX>T#_A /\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^8?VGO\
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MA6T_X0O_ (2S^W(;B7?_ &K]B\CRFC&,>3)NSYGMC'>OF[_A])_U1W_RY_\
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M1110 4444 %%%% !7Q!_P6%_Y,_?_L8+'^4M?;]?$'_!87_DS]_^Q@L?Y2T
M?*G_  2Q\(_ OQ)X!\<2?%JT\$W&HQZG"MB?%4ELL@B,1W>7YI!V[NN.]?.O
M_!0;2OA!HW[1%U;?!>73Y?#0T^%KU=(F\ZQ2^+/YBP."5*;/*)VDJ&+ =,"#
MX!_L7ZU^T)\!_B3\0?#^L?\ $T\'E2GAY;(R-J"B/S'V2AQM<(&PNQMQ &1F
MNI_X)E^&_A/XR_:/L-#^*&E?VG<72!_#Z7,V+)KU"6\J>/'[S<H^4,=I9-I5
MMXP ?HI\9(]9A_X)+.GB$2C65\#Z:+D3Y\P-BWP'SSOQC.><YK\[/^">NH_
M#3_$OC$_'M-)?3FM+<:7_:MO-*OF[W\S;Y2D@[=O6OUF_P""AW'[%OQ5 X']
MF)_Z/BK\C_V _P!C71OVQ/$?B_3=8\17WAY-$M(+B.2QA20R&1V4@[NF-M '
MWMX>OO\ @GOX@U_3-+TFS\(W.JWUU%;6D*:?>@R3.X5%!*  EB!SQ7FG_!:[
MX([X/!7Q9L+?YD)\/ZHZCL=TMLYQ[^>I8^J#TKT+P+_P1L\&^!?&WA[Q)!\1
M-=NI]'U&WU&."2SA"R-%*L@4D'@$KC\:^N_VHO@W!\?O@%XU\#2(C7.IV#_8
M7?@1W<>)+=L]@)43/MD=Z /F?_@C[\7QX\_9EG\)7,WF:EX-U%[4*QRWV2<F
M:%C_ ,",Z =A&*_/7_@H%X\U#]H[]M[7=(T(-J/V.^@\):/!&<[Y(W\ME7UW
M7+S$$=F%4OV#_P!J"3]DOXA^.9]3#00ZAX=OK86LR$ :E C2VJN.Q,BM%ST,
MO->B_P#!)7X-S_%S]IZZ\<ZNCWFG^$8&U*2:7YO-OYBR0;CZ_P"NESZQ"@#Z
MJ_X*/?#'3_@Q_P $Y_"_@?3-IM-"O],L_,5<>:ZI)YDI'J[EG/NQKY3_ ."?
M.K?LNZ?X!\3I\>4T-M<;4U.G_P!J6MQ*_P!G\I<[3$I &_/7FON#_@L+_P F
M?O\ ]C!8_P I:^$_V!_^"?WA_P#; \"^)=>UCQ7J7A^;2=26Q2&QMXY%D4Q*
M^XENAR<4 ?=/P;NOV&O$7Q0\-V?P\M/"\WC;[6L^DK:6-VDHGB!E5E9T"@KL
M+<GM7RQ_P6X_Y+1\//\ L7Y/_2EZ^H/@#_P2C\*? 'XP>&_'^G^.]9U6\T2:
M2:.SN;2)(Y"T3QX)'(X<G\*^7_\ @MQ_R6CX>?\ 8OR?^E+T ?)GP3^(WC+]
MC?XT>"_'(LY8EN+.#4#:[L1ZII=P/G0'H00& /.V2,'JM?I/_P %9?&FA_$[
M]A_P/XL\/W::AHNJ>)+"^LKA>Z/9W>,CLPR5*GD$$'D5RWQ-_9+_ .&BO^":
M_P )O$&@67G>._"?AR*[LEB7,E[:[<SVW').!O0<G<NT8WFOSP7]H35KK]F"
MX^#6H^9=:5;^(8->TJ4G/V3$4Z3P_P"Z[2HX Z,)#_%0!^H?_!$__DVWQE_V
M-LW_ *1VM?G7_P $\?\ D]+X5?\ 83;_ -$2U^BG_!$__DVWQE_V-LW_ *1V
MM?G!^Q7JEK\.?VSOAQ)KTRZ?%9:^+*XDG^412-OA&[/0;V&2>G>@#^BFOYX?
MV&?^3WOAG_V,']'K^A'6M:L?#NCWVJZG=1V.FV,#W-S<S-M2*)%+,['L  3^
M%?SW_L$1R:M^VU\,&MHGD+:TT^T#D(L<CL3]%!)^E 'TI_P6X_Y+1\//^Q?D
M_P#2EZZ_]G77OV%[?X&^"8OB!%X7/C5=,B&K&[L+QY?M&/GW%4*D_3BN0_X+
M<?\ ):/AY_V+\G_I2];O[/G_  2/\(_&;X)^#/'%[X^UK3KK7M-BOI+2"TA9
M(F8<JI/)'UH ^S_V2_\ AF#5O$FNZA\!K70QK-K:)!J4^EVMQ$ZP2/N56,J@
M$%HL\?W:^G:^8?V.?V$]"_8YU+Q1>:-XHU'Q"VO0V\,BWT$<8B$32$%=O7/F
M'KZ5]/4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'S=_P %&/\ DS'XD?\ 7&S_ /2ZWKX)_P""6?P7\$?&
M7Q=X]MO&WANR\1P6-C:R6T=ZI(B9I'#$8(Z@#\J^]O\ @HQ_R9C\2/\ KC9_
M^EUO7Q[_ ,$9_P#D>?B9_P!@ZS_]&R5]!AI..75'%V=_\B7N>U?M.?\ !,/X
M=>)? .JZG\-=);PIXML;=[BVMH+B22UO2N6,3HY;:S#(5D(P2,@BOD/_ ()=
M_&O4OAW^T78>$C<R-X>\7*]G<6I/R+<)&SP2@?WLJ4^DAZX%?JQ^T3\<O#_[
M/_PMUKQ/KFHPVD\5M(NGVK,#-=W)7$<<:9RQW%<]@,DX )K\=?\ @G7X&O\
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MTVV2STZP\*Q6MM;Q_=BB2>540>P4 ?A7Z$?L-?\ )I'PO_[!"?\ H;5\!_\
M!8S_ )+EX*_[%P?^E,U7@ZDY8YJ3NES">Q]<? +_ )1GVW_8EZG_ .@7%?C/
MX9\&ZOXPAUN32+-KS^Q]/?5+Q8^62V1T1W [A?,#'T4,>@-?LQ\ O^49]M_V
M)>I_^@7%?#'_  2AM[6^_:=O[*\ACN;:[\-7T$D$J!DD5GAW*P/!!7.0:Z<+
M4=%8BHNC_P P['TY_P $J?VHO^$U\'2_"7Q#=[M:T"$S:-),WS7%CGF$9ZM$
M2,#^XP &$-?&1!7_ (*8<C'_ !=S/_E9JW^TA\+/$7[!O[4MCK/A5Y+;3$N?
M[7\.7;Y97@W8>V<_Q;<F-AG)1E)^_7+^ ?'$'Q-_;P\*>+K:VDLX-=^(ECJ2
M6\A!:(2ZC&^PD=2-V,^U=-.C%2GB*7PSC^(O(^R?^"P7QFU'2=+\(_#/3KB2
MVM-31]7U0(2//C1]D$9QU7>)&(/=(SVKF?\ @F]^PSX1^)G@4_$[XA:>NO6M
MU<2V^D:1*Y%OLC8I)-*!C>=X954G:-I)!)&VA_P62\'7MO\ $;P!XKV%M.O-
M*ETO> <++#,TF#Z96?CUVMZ5]&_\$K_BMHWB[]FC3?"$-W&-?\+W%S#<V;$"
M0Q2SO-'*%[H?-VY]5.>V>"4I4LNBZ.EWK^/_  P^IE?&7X9_L6>-M/O/#M_K
M'@?P5JUE(UN;KP_=6UA=VTJ$JRN%&UR"""'5N_0\U]+_  #UKX8W'@.UT'X4
MZKH^H^&]!1;-8]'N%F2$D;OG8$Y=N6)/+$DG)-?FS^VY_P $^/\ A4OA7QO\
M7O\ A/O[5^TZN;O^QO[&\G;]JNON^=Y[9V^9UV<X[9KV'_@C7_R3/XB?]A>W
M_P#1)KGK482POM85'))]>X^I^A]%%%>$4%%%% !1110 4444 %%%% !1110
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M'V_0O!>NZ+?;#']JT[58()=IZKN28'!P./:OW1HK.GF52G*345[P6/Q5M_\
M@GW^U#\5K^!_$]A<1KNVK>^)_$$<WEYX)PLDD@'RCHO/&,U^@G[&O["/A_\
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M,9KZCHK@EBYRHJA;1.X['XWZA^PY\>_@#^T))KOPP\,7FLZ=H>J?:M%U5+J
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M1>./ VN:YXJT+Q%X>\06FB:AI5I=VGEW^F&]@G6X:!CO59HF&WR.-K Y(R<
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MQM;H..#GT^?/%W_!/WXYZE\,XO@_%XJ^&WB?X:V$C)HVM>)M*F.OZ3 SAV6
MI&45N ,[\D<95< 85N15)*G\-]!QO;4]"_;]_::^(?@;_A"?!GP4U:W/C?5K
M&\\275Y:V\%T/[,M;:20E4E61<2E6*MU)BV@_-7LMK^U9H,W['X^.>^$V"Z
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MO'K7]NSQ7\0M$_9QGT74O^$>UW5O&2>%O'6CM91%O/C$8ECVR(S1*VXL"I#
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MJ2E*W(.Y^[=%%%>:,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTE?+_P#P6;U*[B\(_"_3T=A83WU]/*@/RF2..%8R?<"63'U-<O\ LV_\%//
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M:]3$.4%=,$U8^"?VR/#^F^#?VJ/B1IV@JEM86^L22PI;C:L+.%D95 Z!79@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@_QN
M_8C^$/Q^U"75/$GAD6VO2_?UC293:W,G&,OM^60X &75B   :]XHK2%2=-\T
M'9@?&/AW_@DS\#=#U)+J\;Q-K\*OO^QZCJ:+$1_=)ABC;'_ L^]>T>/_ -D'
MX5?$?P+H7@W4_#2VGA?19FN+/2]*GDLX5E*[3(PB(WM@GYFR?F8]2:]FHK:6
M*KS:<IO05CS7X'_L[>!/V==%U'2_ NDOI=KJ%P+FY,MQ).\CA0H^9R3@ <#I
MR?6O2J**YY2E-\TG=C/F>X_X)T? R;Q9)XDC\-7MGJS7IU!9K75;F(13&3S
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M9M8U:X:ZNY8=3N(E>1OO-L5P!D\G ZDU]$6%C;Z78VUG:1+!:V\:PQ1+T1%
M"J/8 "K%%$ZLZB2G)M( HHHK( HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\NI9GB94:S:2BWI;NEU3[GP7&>?8KAW+X8O"1C*4IJ/O)M6<9/HUKIW/HO\
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M\:L?8L!FM'PKE\6HNI*[\X__ ")SQ\3,]G%SC0IM+=\L]/7WSZV_X:/\!_\
M04F_\!)?_B:/^&C_  '_ -!2;_P$E_\ B:^2D\,:S)IIU!=)OFL NXW2VSF+
M'KOQC'XUF41X5R^5^6I)V\X__(A/Q,SVE;VE"FKZJ\9JZ_\  S[(_P"&C_ ?
M_04F_P# 27_XFNW\+>*=/\9:/'JFER--92,RI(R%"=IP>#SU!_*O@"OLC]G#
M_DDNE_\ 76?_ -&M7@9YD>&RS#1K492;<DM6NS?1+L?<<&<9YAQ%F$\)BX0C
M&,'+W5).ZE%=9/35]#TZBBBOAS]E"BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RL_X*J?&3Q_\
M#O\ :$\/:;X5\<^)/#.G2^%K>XDM-'U>XM(GE-W=J7*1N 6*JHSC.% [5\:?
M\-0_&7_HK?CK_P *2]_^.U]-_P#!83_DYCPS_P!BC:_^EM[7PO7W>"IP>&@W
M%;&;W/3?^&H?C+_T5OQU_P"%)>__ !VC_AJ'XR_]%;\=?^%)>_\ QVO,J*[O
M94_Y5]PCTW_AJ'XR_P#16_'7_A27O_QVC_AJ'XR_]%;\=?\ A27O_P =KC?
M_AG_ (33QIH'A_[;#IO]JW\%C]LN?]7!YLBIYC?[*[LGZ5]P?M*?L?\ P;^
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M +C7_P $OR9]#P[_ ,CK!?\ 7VG_ .EH^V:***_ 3^X@HHHH **** "BBB@
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MBOY(/>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDNE_]=9__1K5\3Q;_N,/\:_*1^Q>%O\ R.:O_7J7_I<#TZBBBOR4_J$****
M"BBB@ HHHH **** "BBB@ KYX_X*#?\ )G/Q+_Z\X/\ TJAKZ'KYX_X*#?\
M)G/Q+_Z\X/\ TJAK?#_QH>J_,F7PL_!NBBBOT8@**** "O0-+_9_^)&N>!)?
M&6G^"=<O/#:2*GVZ"PE=7!5V\Q0%RT8"',@^4$J"<D5P"G:P.,X]:_7[P/\
M$>\_:D^'<-AH^J>-/@GXX8V]C!!#&38B1+&:12D9 (@>)RV["'*0E22 3PXK
M$3PZ3BM.OD-'Y,^%?!GB#QWJG]F>&M"U+Q#J7EM+]CTJSDNIM@QEMD8)P,C)
MQWK-OK&YTN^N+*]MY;.\MI&AGMYT*212*2&1E/*L"""#R"*_3']GG0_"7[,?
M[-:>(=>'B74O%/Q$U*YT.YU[P9:K=WEAMFDB"1R2#Y.8V?[I=G/"DH,?(W[3
MW[*.M?!/XK>(]!\.V^K>+/#^F6,.K2:E#9O*UG:RAL&[*+MC(,<GS' (7.!G
M 5+%QJ590V73SMN%CRSPY\(_'7C#19=7T'P7XAUO28=PDO\ 3=*GN($VC+9D
M1"HQWR>*Y1@5)!&"."#7Z^_ _P 10>"_AW^RWHGB2^\2:?J^J6TCZ;:^#U*:
M3<Q/&K1_VFI'SG;(C';_ !EF.!S7YH?M0:;JFE?M$?$2WUI;%-4_MNZEG73?
M^/?+N7&SOC##KSG.><TL/BG6J2@U:VWWV"QYA1117H""BBB@#^C'X#_\D.^'
M?_8N:=_Z31UW5<+\!_\ DAWP[_[%S3O_ $FCKNJ_-)?$RX[(****DH**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#\?/^"PG_)S'AG_L4;7_ -+;VOA>ONC_ (+"
M?\G,>&?^Q1M?_2V]KX7K[_ _[M#T,WN%%%%=P@HHHH **** "BBB@ HHHH *
M*** /IO_ ()J_P#)ZWPY_P"XE_Z;;JOW0K\+_P#@FK_R>M\.?^XE_P"FVZK]
MT*^/SC_>(^GZLN.P4445X11YO^TI_P FY_%3_L5-5_\ 2.6OP,K]\_VE/^3<
M_BI_V*FJ_P#I'+7X&5_4O@__ +CB_P#&OR/$S#XHA1117] 'E!1110 4444
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MET**** "BBB@ HHHH *^R/V</^22Z7_UUG_]&M7QO7V1^SA_R272_P#KK/\
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M<%JXK_(^7KM^UEZE[^W-2_Z"%U_W^;_&C^W-2_Z"%U_W^;_&J-%?8_V?@O\
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M_F_QJC11_9^"_P"?,?\ P%?Y!S/N?=?_  2<U"ZO/C?XL6XN9IU7PZY DD+
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M*_3_ "/H^BBBOY(/>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KS']H_P#Y)+JG_76#_P!&K7IU>8_M'_\ ))=4_P"NL'_HU:]+
M+/\ ?J'^./YH^?XB_P"1-C?^O53_ -(9\;T445^_'\.!1110 4444 %%%% !
M7>_ G_DK7A[_ *ZR?^BGK@J[WX$_\E:\/?\ 763_ -%/7FYG_N-?_!+\F?0\
M._\ (ZP7_7VG_P"EH^V:***_ 3^X@HHHH **** "BBB@ HHHH **** "BBB@
M KXF^.W_ "5KQ#_UUC_]%)7VS7Q-\=O^2M>(?^NL?_HI*^VX2_WZ?^!_G$_'
MO%'_ )$U+_K['_TB9P5%%%?K1_+H4444 %%%% !1110 5]D?LX?\DETO_KK/
M_P"C6KXWK[(_9P_Y)+I?_76?_P!&M7Q/%O\ N,/\:_*1^Q>%O_(YJ_\ 7J7_
M *7 ].HHHK\E/ZA"BBB@ HHHH **** "BBB@ HHHH *^>/\ @H-_R9S\2_\
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M^Z%?A?\ \$U?^3UOAS_W$O\ TVW5?NA7Q^<?[Q'T_5EQV"BBBO"*/-_VE/\
MDW/XJ?\ 8J:K_P"D<M?@97[Y_M*?\FY_%3_L5-5_](Y:_ ROZE\'_P#<<7_C
M7Y'B9A\40HHHK^@#R@HHHH **** "BBB@ HHHH **** "OVL_P""=O\ R9S\
M/_\ N(?^G"YK\4Z_:S_@G;_R9S\/_P#N(?\ IPN:_$?%S_D14?\ K['_ -(J
M'I8#^*_3_(^CZ***_D@]X**** "BBB@ HHHH **** "BBB@ HHK\R/\ @J=\
M<OB%\*_C#X3L?!_C/6O#5E<Z")YK?3;UX8WD^T2KO*J<9P ,^PKIP]"6(J*G
M%V;);L?IO17\^O\ PV)\</\ HJWBO_P:2_XT?\-B?'#_ **MXK_\&DO^->M_
M8U;^9?B3S/L?T%45_/K_ ,-B?'#_ **MXK_\&DO^-'_#8GQP_P"BK>*__!I+
M_C1_8U;^9?B',^Q_0517\^O_  V)\</^BK>*_P#P:2_XT?\ #8GQP_Z*MXK_
M /!I+_C1_8U;^9?B',^Q_0517\^O_#8GQP_Z*MXK_P#!I+_C1_PV)\</^BK>
M*_\ P:2_XT?V-6_F7XAS/L?T%5YC^T?_ ,DEU3_KK!_Z-6OQ#_X;$^.'_15O
M%?\ X-)?\:]V_9'^/7Q&^*7B;QGI7B_QKK?B338?#INH[74KUYHTE%_9*' 8
M_>"NXSZ,:[,%E=6CBJ-1R5E*/_I2/ XAD_[&QO\ UZJ?^D,]^HHHK]E/X?"B
MBB@ HHHH **** "N]^!/_)6O#W_763_T4]<%7>_ G_DK7A[_ *ZR?^BGKS<S
M_P!QK_X)?DSZ'AW_ )'6"_Z^T_\ TM'VS1117X"?W$%%%% %'7-:LO#>BZAJ
M^I3BVTZPMY+JYF*EA'$BEG; !)PH)P!GBO!O^'@W[/?_ $4NP_\  .Z_^-5Z
M;\>/^2'?$3_L7-1_])I*_G.KV,!@H8M2<FU8B3=[(_>3_AX-^SW_ -%+L/\
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M0*XS]G/X@?LY?"/X+)%IGQ1G\'_%'6[)%U;Q$WA^[O;NPW &2VMB(-B*"/O
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M%%% !1110 4444 %%%% 'X^?\%A/^3F/#/\ V*-K_P"EM[7PO7W1_P %A/\
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M HHHH **** "BBB@#[D_X))_\EQ\6_\ 8N/_ .E,%?JO7Y4?\$D_^2X^+?\
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M_P#KK/\ ^C6KXGBW_<8?XU^4C]B\+?\ D<U?^O4O_2X'IU%%%?DI_4(4444
M%%%% !1110 4444 %%%% !7SQ_P4&_Y,Y^)?_7G!_P"E4-?0]?/'_!0;_DSG
MXE_]><'_ *50UOA_XT/5?F3+X6?@W1117Z,0%%%% !1110 4444 %%%% !11
M10 4444 ?T8_ ?\ Y(=\._\ L7-._P#2:.NZKA?@/_R0[X=_]BYIW_I-'7=5
M^:2^)EQV04445)1^,'_!2+_D[KQ;_P!>]A_Z215\QU].?\%(O^3NO%O_ %[V
M'_I)%7S'7]X\%_\ ).X+_ CY;$?Q9>H4445]H8!1110 4444 %%%% !1110
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M )$5'_K['_TBH>E@/XK]/\CZ/HHHK^2#W@HHHH **** "BBB@ HHHH ****
M"OR0_P""QG_)<?!7_8N#_P!*9J_6^OR0_P""QG_)<?!7_8N#_P!*9J];*_\
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MY$'P-_V*VB_^FZWKU,K_ -Z_[=?YQ/R#Q0_Y$U+_ *^Q_P#2)FA1117UY_,
M4444 %%%% !1110 5]D?LX?\DETO_KK/_P"C6KXWK[(_9P_Y)+I?_76?_P!&
MM7Q/%O\ N,/\:_*1^Q>%O_(YJ_\ 7J7_ *7 ].HHHK\E/ZA"BBB@ HHHH **
M** "BBB@ HHHH *^>/\ @H-_R9S\2_\ KS@_]*H:^AZ^>/\ @H-_R9S\2_\
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M^K+CL%%%%>$4>;_M*?\ )N?Q4_[%35?_ $CEK\#*_?/]I3_DW/XJ?]BIJO\
MZ1RU^!E?U+X/_P"XXO\ QK\CQ,P^*(4445_0!Y04444 %%%% !1110 4444
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M]><'_I5#6^'_ (T/5?F3+X6?@W1117Z,0%%%% !1110 4444 %%%% !1110
M4444 ?T8_ ?_ )(=\._^Q<T[_P!)HZ[JN%^ _P#R0[X=_P#8N:=_Z31UW5?F
MDOB9<=D%%%%24?C!_P %(O\ D[KQ;_U[V'_I)%7S'7TY_P %(O\ D[KQ;_U[
MV'_I)%7S'7]X\%_\D[@O\"/EL1_%EZA1117VA@%%%% !1110 4444 %%%% !
M1110!]R?\$D_^2X^+?\ L7'_ /2F"OU7K\J/^"2?_)<?%O\ V+C_ /I3!7ZK
MU_$WB1_R5&*_[<_]-Q/HL'_!04445^9G<%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^/G_  6$_P"3F/#/_8HVO_I;>U\+U]T?\%A/^3F/#/\
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M1%1_Z^Q_](J'I8#^*_3_ "/H^BBBOY(/>"BBB@ HHHH **** "BBB@ HHHH
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M,=_'#_HE/BO_ ,%<O^%?T%44?VS6_E7XARON?SZ_\,=_'#_HE/BO_P %<O\
MA1_PQW\</^B4^*__  5R_P"%?T%44?VS6_E7XARON?SZ_P##'?QP_P"B4^*_
M_!7+_A7T-^Q3^S+\5O"OCOQ=)K?@#7M'BO/#CVT$M_9M!')+]NLY-@9\#.R-
MSC/\)K]A**:SJM&2DHJZ:?7H[]SDQF#ACL-5PM5VC4BXNV]I*SMOKKV/B;_A
M1/CS_H7IO^_T7_Q5'_"B?'G_ $+TW_?Z+_XJOMFBO6_UMQW\D/N?_P D?EO_
M !"[)O\ G[5_\"A_\@?$W_"B?'G_ $+TW_?Z+_XJC_A1/CS_ *%Z;_O]%_\
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MHHH *^>/^"@W_)G/Q+_Z\X/_ $JAKZ'JCK>@Z;XFTN?3=8TZUU73I]OFV=]
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M_KWL/_22*OF.OZ$-<^$O@?Q/JDVI:QX,\/ZMJ,VWS;R^TN":9]JA5W.R$G
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M@>&-3A\[780R;H?+C8S,K(FW;/N!R,E1D']%* "BBB@ HHHH **** "BBB@
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MCS&_\2W:$J<K;QLL,0*_Q?-]UB"V!%I?M4VOAR']L;7/$WQ>\9>-OA[X0L]
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M$#X?^-_%DDVK^%8_!1QX@TGQ%8&#4+#YF50T*%\EF4J I)SP0#Q6=\&_V_\
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MWQO\?CX_\?\ P%L_B#I^BSLWA;P]+XLL+33-+(;B?R?/8RRD*IW2=#S@80(
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M]C[Q3\.O _PN\,:]X?\ %7B*>.X\87^HQ02Z8Z/ 6,L+C?(5"@H\>XKD_*2
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MC[HG0G =N"2#GD5W%?SP_P##4/QE_P"BM^.O_"DO?_CM'_#4/QE_Z*WXZ_\
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M5A]?I=G_ %\S]K**_%/_ (>)?M"?]% _\HNG_P#R/1_P\2_:$_Z*!_Y1=/\
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MI?\ @4__ )6'U^EV?]?,_:RBOQ3_ .'B7[0G_10/_*+I_P#\CT?\/$OVA/\
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MG;G;G&3C/4UNU^*?_#Q+]H3_ **!_P"473__ )'H_P"'B7[0G_10/_*+I_\
M\CT?\0CSW_G]2_\  I__ "L/K]+L_P"OF?M917XI_P##Q+]H3_HH'_E%T_\
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ME_\ )%?3=%'UK$?\_']["Q\R?\.U?V</^B<_^5S4O_DBC_AVK^SA_P!$Y_\
M*YJ7_P D5]-T4?6L1_S\?WL+'S)_P[5_9P_Z)S_Y7-2_^2*/^':O[.'_ $3G
M_P KFI?_ "17TW11]:Q'_/Q_>PL?,G_#M7]G#_HG/_E<U+_Y(H_X=J_LX?\
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M;B/_ *#9_A_D'U:C_*?%/_#IGX1?]#'XV_\  ZS_ /D6C_ATS\(O^AC\;?\
M@=9__(M?2GQB^//@WX#V>@W7C+4)M/AUS4H])L6AMI)_,N'!*J0@.T8!Y/%>
MA4?Z[<1_]!L_P_R#ZM1_E/BG_ATS\(O^AC\;?^!UG_\ (M'_  Z9^$7_ $,?
MC;_P.L__ )%K[6HH_P!=N(_^@V?X?Y!]6H_RGQ3_ ,.F?A%_T,?C;_P.L_\
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M3Q,002C*&!P>G!%6:/[3QW_/^?\ X$_\P_U=R;_H"I?^"X?Y'G/_  SS\/\
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M;C_XY1_PSS\/_P#H ?\ D[<?_'*]&HH_M/'?\_Y_^!/_ ##_ %=R;_H"I?\
M@N'^1YS_ ,,\_#__ * '_D[<?_'*/^&>?A__ - #_P G;C_XY7HU%']IX[_G
M_/\ \"?^8?ZNY-_T!4O_  7#_(\Y_P"&>?A__P! #_R=N/\ XY1_PSS\/_\
MH ?^3MQ_\<KT:BC^T\=_S_G_ .!/_,/]7<F_Z J7_@N'^1YS_P ,\_#_ /Z
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MCJP^.GQL\(>&?B9XT\2ZGK.B^(/$0T;1[G4]28I]M.[+0P*=L,:E2,JJ@$$
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M'5A\=/C9X0\,_$SQIXEU/6=%\0>(AHVCW.IZDQ3[:=V6A@4[88U*D955 ((
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M"YMUD9U^3S$*NID?YLD$8! QD?0/[/'P/T?]G+X/^'OA_H=Q/>V6DQONO+D
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M\5_VQ-+;0S1W26UK!*JA@DK[68,P+$ +R$;D8KS7X$?\%8/A#XZ^'/\ :?Q
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MSE/+BC42*I)56D).,?.HSD''WM^U/_P3O^&/[4^L#Q#J?VWPSXNV+')K.CE
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M3 9S@%W8Y9V.!EF))P.: .JHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG^RW#\1_"?AC5M$^+OA?7M85M+GTR5+S5])N9&22$0E0T@VR.RX'*M)MY*T
M?I#^S3\:O^&B/@CX9^(7]C?\(_\ VU'+)_9OVK[3Y.R9X\>9L3=G9G[HZX]Z
M]/K\I9/@KX_C_9;_ &;;/Q7\/O&WB7X;Z+)J(\:> =#CGM]6F9[AS:N]J#'(
MZJ?FQD8!SE=VZL'6?@+\3M4^ +:9IO@;QUHW@.Z^*6FWWA;PI?+<7&KZ+I@B
MN5FE<+NDMHP6CQN/RD$Y).]P#]>*^??VD_VN[/X$^*/#7@G0O"6I?$7XD^)$
M>73/#.E2K"3&N<R32L#Y:?*^#M;_ %;DX"DUX'\'_P!G7Q]X!^//[07@_P"%
MNJZW\'?"-R=)O-"UNZTB35K%Y?+#77DB[8I*[$E68.2O _A %[XO?"WXJ_ G
M]H+X>_'6TTR_^.,FG^&O^$:\41Z/8QVVHRMN<_;(+5,CYMX_=IG&TC(#9 !]
M)_L__%[QU\4H]<B\=?"/5?A9J&F2I&B7FHPWUO=A@3F*5 N[:,9(7;SC<2"!
MYIX'_;XT#QM^UYK?P1BT%K:ULVN;2R\3M?9COKZW2-Y[983$,%-T@R)&SY8X
M^<8\+^ WBSXP^![KXY>.HO#OQKUGPU'H:?\ "+:#\1!<7FHR:DSXVQVJ\[ S
M Y1.(P<DXKQ:/]E']IKX:_!'P)XUMO#WAS4]1\-:\OC9+/2UU"3Q;<7-TT7G
MPW$938WRK&)(U&[$9Y;!! /O7]M3]LRQ_8_\,^'KP>&G\8ZSK5S*D.D17IM6
M6WBB+SW!<12<)\@(V_Q$Y 4U;_:&_:\M/@S\ _#7Q0\/^'E\<6?B"YL8+&S7
M419AUND9T;S?+D'& ,$=^HQ7RMXQ\%?'/]K/]I[7?'7ACP1IN@>&/#_A_P#X
M1_3+/XMZ;J>GP7$=Y!(MW)#$D8=I/GE0MP-I3()QCSS6/AG\8+S]B/\ X4KK
MW@CQ9/XA\$^/;6VM;W3=,NYDNM.9IF%Q:R^5AXXV+X8<*IBR%R!0!]Q? ?\
M:XU7XD?&#6_A5X]^&U[\,/'VG::-773Y-5AU.WN+4LJ[EGB51NRZ\ $<-SD8
MKZ/KPOX$_L?^$O@1XRUKQC!KWBOQOXSU:W6RG\1>,]6.H7HM@5(A5PB#;E$/
M()^4#..*]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\-_;8^.&I_L[?LU>,/&VB0I+K=K'%;6+2*&2*::5(EE8'A@F_=@\$J >":^5
M=%^R? _QA\+=5^+'[6OC^W\>^(TM=7N/#J)<7FCWT<Q ^SQ1)"\,2[_DWG'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBM^.O_"DO?\ X[1_PU#\9?\ HK?CK_PI+W_X[7Z;?\.>_@U_T,WCK_P/LO\
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M_#GOX-?]#-XZ_P# ^R_^1*/^'/?P:_Z&;QU_X'V7_P B4?VA@NWX!9GYD_\
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MC;_P.L__ )%H_P!:^ /^@.'_ ((C_D'L,5_-^)\4_P##Q+]H3_HH'_E%T_\
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MA%_T,?C;_P #K/\ ^1:/]:^ /^@.'_@B/^0>PQ7\WXGQ3_P\2_:$_P"B@?\
ME%T__P"1Z/\ AXE^T)_T4#_RBZ?_ /(]?:W_  Z9^$7_ $,?C;_P.L__ )%H
M_P"'3/PB_P"AC\;?^!UG_P#(M'^M? '_ $!P_P#!$?\ (/88K^;\3XI_X>)?
MM"?]% _\HNG_ /R/1_P\2_:$_P"B@?\ E%T__P"1Z^UO^'3/PB_Z&/QM_P"!
MUG_\BT?\.F?A%_T,?C;_ ,#K/_Y%H_UKX _Z X?^"(_Y![#%?S?B?%/_  \2
M_:$_Z*!_Y1=/_P#D>C_AXE^T)_T4#_RBZ?\ _(]?:W_#IGX1?]#'XV_\#K/_
M .1:/^'3/PB_Z&/QM_X'6?\ \BT?ZU\ ?] </_!$?\@]ABOYOQ/BG_AXE^T)
M_P!% _\ *+I__P CT?\ #Q+]H3_HH'_E%T__ .1Z^UO^'3/PB_Z&/QM_X'6?
M_P BT?\ #IGX1?\ 0Q^-O_ ZS_\ D6C_ %KX _Z X?\ @B/^0>PQ7\WXGQ3_
M ,/$OVA/^B@?^473_P#Y'H_X>)?M"?\ 10/_ "BZ?_\ (]?:W_#IGX1?]#'X
MV_\  ZS_ /D6C_ATS\(O^AC\;?\ @=9__(M'^M? '_0'#_P1'_(/88K^;\3X
MI_X>)?M"?]% _P#*+I__ ,CT?\/$OVA/^B@?^473_P#Y'K[6_P"'3/PB_P"A
MC\;?^!UG_P#(M'_#IGX1?]#'XV_\#K/_ .1:/]:^ /\ H#A_X(C_ )![#%?S
M?B?%/_#Q+]H3_HH'_E%T_P#^1Z/^'B7[0G_10/\ RBZ?_P#(]?:W_#IGX1?]
M#'XV_P# ZS_^1:/^'3/PB_Z&/QM_X'6?_P BT?ZU\ ?] </_  1'_(/88K^;
M\3XI_P"'B7[0G_10/_*+I_\ \CT?\/$OVA/^B@?^473_ /Y'K[6_X=,_"+_H
M8_&W_@=9_P#R+1_PZ9^$7_0Q^-O_  .L_P#Y%H_UKX _Z X?^"(_Y![#%?S?
MB?%/_#Q+]H3_ **!_P"473__ )'H_P"'B7[0G_10/_*+I_\ \CU]K?\ #IGX
M1?\ 0Q^-O_ ZS_\ D6C_ (=,_"+_ *&/QM_X'6?_ ,BT?ZU\ ?\ 0'#_ ,$1
M_P @]ABOYOQ/BG_AXE^T)_T4#_RBZ?\ _(]'_#Q+]H3_ **!_P"473__ )'K
M[6_X=,_"+_H8_&W_ ('6?_R+1_PZ9^$7_0Q^-O\ P.L__D6C_6O@#_H#A_X(
MC_D'L,5_-^)\4_\ #Q+]H3_HH'_E%T__ .1Z/^'B7[0G_10/_*+I_P#\CU]K
M?\.F?A%_T,?C;_P.L_\ Y%H_X=,_"+_H8_&W_@=9_P#R+1_K7P!_T!P_\$1_
MR#V&*_F_$^*?^'B7[0G_ $4#_P HNG__ "/1_P /$OVA/^B@?^473_\ Y'K[
M6_X=,_"+_H8_&W_@=9__ "+1_P .F?A%_P!#'XV_\#K/_P"1:/\ 6O@#_H#A
M_P""(_Y![#%?S?B?%/\ P\2_:$_Z*!_Y1=/_ /D>C_AXE^T)_P!% _\ *+I_
M_P CU]K?\.F?A%_T,?C;_P #K/\ ^1:/^'3/PB_Z&/QM_P"!UG_\BT?ZU\ ?
M] </_!$?\@]ABOYOQ/BG_AXE^T)_T4#_ ,HNG_\ R/1_P\2_:$_Z*!_Y1=/_
M /D>OM;_ (=,_"+_ *&/QM_X'6?_ ,BT?\.F?A%_T,?C;_P.L_\ Y%H_UKX
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M\HNG_P#R/7VM_P .F?A%_P!#'XV_\#K/_P"1:/\ ATS\(O\ H8_&W_@=9_\
MR+1_K7P!_P! </\ P1'_ "#V&*_F_$^*?^'B7[0G_10/_*+I_P#\CT?\/$OV
MA/\ HH'_ )1=/_\ D>OM;_ATS\(O^AC\;?\ @=9__(M'_#IGX1?]#'XV_P#
MZS_^1:/]:^ /^@.'_@B/^0>PQ7\WXGQ3_P /$OVA/^B@?^473_\ Y'H_X>)?
MM"?]% _\HNG_ /R/7VM_PZ9^$7_0Q^-O_ ZS_P#D6C_ATS\(O^AC\;?^!UG_
M /(M'^M? '_0'#_P1'_(/88K^;\3XI_X>)?M"?\ 10/_ "BZ?_\ (]'_  \2
M_:$_Z*!_Y1=/_P#D>OM;_ATS\(O^AC\;?^!UG_\ (M'_  Z9^$7_ $,?C;_P
M.L__ )%H_P!:^ /^@.'_ ((C_D'L,5_-^)\4_P##Q+]H3_HH'_E%T_\ ^1Z/
M^'B7[0G_ $4#_P HNG__ "/7VM_PZ9^$7_0Q^-O_  .L_P#Y%H_X=,_"+_H8
M_&W_ ('6?_R+1_K7P!_T!P_\$1_R#V&*_F_$^*?^'B7[0G_10/\ RBZ?_P#(
M]'_#Q+]H3_HH'_E%T_\ ^1Z^UO\ ATS\(O\ H8_&W_@=9_\ R+1_PZ9^$7_0
MQ^-O_ ZS_P#D6C_6O@#_ * X?^"(_P"0>PQ7\WXGQ3_P\2_:$_Z*!_Y1=/\
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M2M__ (W7M'_#*/A+_H(ZU_W_ (?_ (U1_P ,H^$O^@CK7_?^'_XU1_:N0?\
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M_A_^-4?VKD'_ #Y7_@"_R#_5GCC_ *"I?^#I?YGB_P#PT+\0/^@__P"25O\
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MU1_PRCX2_P"@CK7_ '_A_P#C5']JY!_SY7_@"_R#_5GCC_H*E_X.E_F>+_\
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M-%UG7=3OKZ^L+/0[". 7=PUG.\,[@R2I$D8:/[\DBCYT'#,%H ](HKE?A_\
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M*? 6L^+]8BNI]*TF#[3<K8QB27R\@$JI(W8SG .2!P"< ^>G]IEQXDC\-?\
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M0QVAOG\:0_9[BSN(8$@::&1;:X\R-TCC/D$1[65B'._Y>HN/AOXN\"^(]/\
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MT:QBM(2QZMLC4#)]<5O4 >4>&_A[XE\3>/+GQAX^M]'T^8:)+H-IH6AWLM]
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M+2;^ULM(ET/5(+Z\EMGBBDEMY#/ 5AD$K+Y!'EMY8.X'>,8K/\&_"'6?#O\
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MU\)O ^@3+HU]J_A2:QOH;76+;[5IMY-! T,D,JE<['220!]I*$J^UMNTXK?
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M^)6G>']&^%=KX?B3P]IVM00P>'(;T7$OVE7C<"V6;RS:^4'&<&;R_P".N:\
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M=@_=]% 'CMGXKTKP/\3/B[KNMW7V+2[*VTF2>;RWD('E2@ (@+,22 %4$DD
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M!=K:_#>S^'UQI\?C&Z\4:%_:4-H"VM2;;E"QUC(,X8'/S76#YA4 Y;!^UZ*
M/FSP?\-?#4 ^./C!M(M;CQ,^JZM!%J=Q$LD]K#]EC#10N1F)&.YF52 S,Q.:
MQ=8UB^^$>C>$_$NC12/=^-?!UGX<@15+*=9CC4Z:2 .-PGN@S'M%&.U?5M%
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MO/!_Y;_8\[MG_+MY6S'R8KZJHH ^$OA[XBT#5/C#\-/$&AR^#]'\5:WKDO\
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MASQWX3L?#=QKZS_V3=:1K#ZG \D2"1K>9FMX#%*8_,<!0Z$1/\^=H9GB_P"
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MWE$@1XEFA9E;&.)%-8-M\'_$_BGQ%H^J?$;QG9^([71;I+^PT30=%;2K W*
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M:;8M<1F2**XNKF*VBDD4$$HCS*Q&1D*1D9KSK7/V;?&5Y\/;SX=:7\2[;3/
M+1&WM;>3P\)]3MK<-N2U^U?:1&T*@"/_ % DV#'F;OGKVKQEX1TSQ[X6U/P]
MK,+3Z;J$+03+&YC< ]&1QRKJ0&5AR" 1R* .$T_]G^ULY+?4)?'/CRY\0HRR
M2:H_B:Z\N5P03FQW?8@IQ]T0  'C'6L7XZ?M('X(ZFYO;3PP-*M[,WLW]L>+
M8--U*[10S.MC:-$_VA@J-Q))""PP">M;-GX#^*EN(M.?XIZ?+HL>$^V'PNO]
MM,@/5KDW)MBY'!;[)C_9S6#X^_9Y\0^)+SX@1:!XXM_#^D^.X1'K GT3[9?Q
M$6JVV+6Y\]%B0H@.QXI,,TA4KNX .A\3?%GQ##\2]"\(>%O"5MKG]I:2=9EU
M34-5:QM[6!9DC96VV\K&0B12B@8;# E ,G*UCXL>)O$EOXMD\/\ @R&_\&Z2
M][IUUJ]QJIAO+F6!62<V=HL#B54E5XSYDL1+1OM##:6[C3_A_P#8/'%AXB^W
M^9]ET/\ L;[-Y.-W[U9/-W;N/NXVX[]:XC5O@KXQM%\2Z7X0^(5MX=\,>(+B
MYNY[2[T(7MY8RW!+3M9W'VA$C#2,\F)HIL,[8^7"@ H?!'7DM].^'6G):W\]
MTOPYLKQ1'J#B!P!"NP6S$1^82>)200/ES@U+\+/VEHO'GQ$/@^_B\+)J,MG<
M7L'_  B_BN+6FA6%XEDBNT6&(P2XGC("^8APWS\#=?;]G6VN_#$.A7FO7)M!
MX'/@J6:SA$,Q0JJFY1BS!&PO"D,!GDGH7^#?@WXITWQUX?\ $7B7QEINJP:#
MI=UI-AI.BZ =,MA%,8"9'!N)B9 +=1\I5,'A%YR 6_ ?Q4\6?$*;3=:T[P1;
M1_#_ %)B;35I]:"ZE)"<^7<FS\GRQ"^ R_Z1YFUE)C!RH]3KRKP+\*?%OP_F
MTS1--\=6[?#_ $Q_]$TJ;10VI) ,[+4WGG>684!"C_1_,V*H,A.6/JM !111
M0 4444 %%%% '/?$'4=<TGP7K%[X;L[*_P!:@MVDMX-1O&M8"1U+2+#*1A<D
M#RVR0 < Y'DG@7XU>.[CX;_#N'4?"VF:U\0O%&FK>VMO:ZTR6;VR00/+>W<Y
MM$,'S3(ICBAEPTJ!<KEE]TU"S34K"YM)"RQW$31,5Z@,"#CWYKQS2?@3XIT?
MPSX0CMO&]C%XI\(0/IND:M'H3"VET]HXHS;7ML;DF8GR(G+Q2P'?&A 4!E8
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M#;@#EM;_ &M+*UTOPC'9Q>%[#Q!KN@6WB*2T\6^*4T>TMH)Q\B"<P2/*Y82
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MZ6?Q;XPTW7XEB\J"VTG0CIR=0?,E+W$[/)P1\AC3YC\G3'9T %%%% !1110
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M:O-'\/>,- U[5[)!)=6&F:G!<SP*<89XT8LHY')'<5XGH6AV_C'4-7UVUO\
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MF?4H?A_H/Q1\,:[X \3:YXBU_5-2O8;C1]!N+V'78YBS6F;R-#%"T41BM_\
M2)(MGD9'R[6(![Q\,_$EUXS^&_A3Q!>QPQ7FK:3:7\\=N"(UDEA1V"@DD+EC
MC))QW-<?XL^/GAV.:VL?"?B7P[XAUF'7M-TK4]/M;^.YFLX[FZ2%S)'')NC;
M#-C=QD<@]*BT7PKKVH?LHZ?X;T\S:-XGF\%1Z? ;@-#):W9L1&N[(W(ROC/<
M$5YAKFO:;XD\/_"GPKX>^%WBS1;W0O$.CR364GANXM;70H8ID\W_ $DH()D
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M^,O'_A?X<Z6FI>+/$FD>&-.>00K>:S?16D+.<D*'D906.#QG/%5O%GQ4\%^
MK/3KSQ-XOT'P[::B=ME/JVIP6L=T< XB:1@'."#\N>HKS[]H".#3-:\->(8Y
M/%FF:Q8V][:VFK>'?#C:] %F\DO;W5K'%++LD,,;!T$>/*(,J;MK^=76M>+X
MK?PFGB'P_KW@.W?PK:QQKX"\(PZC/->,[B;3Y T%VEE J)"51]J?OF!F_=G
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ME%XHSM\Q2""*Z:\^,G@#3_$5OX?NO'/ANVUZXF:WATN;5[=+J253AD6(ON+
M\$ 9!KQ?PS:ZC/X+\/\ APZ%KD&K:#X^-S?)<:3<QQ""34KJ9)HYF01S1^6Z
ML7C9@NX!BIXJA\0_A2^J? _]H.S3PI/>:CXDURXN/L_V%Y)=054MEB=%P2X
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MR0*\P^+GQ<O_ (=>,KE;9OMMII_@C6O$<NDA5S/+;26OE'?C<.'E7 .#NZ'
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MZ_I>E_$?Q=H$JZCX:TH:3HNCQQQ0LDM]<RQ^?=;G9-RHMY; *TB)F*3)7E@
M?15%?/WAGQ9\0/ =]JVH^+I/$@\#6^D7=_?ZWXTCT7?IDT05D\J/2W#2PE/-
MW*ZEP43#G<153X4^.O'-I\7-&\/^(9_%E[I&O:1>ZA')XNL]'MF62![;!M4L
M'\Q(R+E@T=RI<83Y\Y# 'M^L>$+/6O$OA_7)Y9TN]$:=[=(V41N98_+;>""3
M@'C!'/K6[7C_ .S>_C#7_";>)_%OC&ZUZ:_GNHH--6SM8+2UBCNI(XF!CA65
MI2B+O+.4R3M5:]@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGDOAM@;:VT [?4/#>G:IK&E:K=6WFW^EM*UG-O8>49$V/P#@Y7CD'':J-_\
M#WPYJS>(3?Z1;Z@GB"!+;5(;Q3-#=Q(K(J/&Q*XVLPP!SGG-<5J_[2'AK2?
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MZ/5O$FFZ+K?@[Q-X)FU;>-)G\016HBU!D1I&1#;W$IBD$:,_ESB-R%; )5@
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M@'52?"[PQ-X6L?#CZ9G1K*]AU&WMOM$OR7$5R+J-]V[<<3*&P3@XP01Q7/\
MBO\ 9S\ >--6U/4-4TB[+ZM_R%+6SU>]M+/4SL"9N[6&9(;D[%5<RHV54#H*
MP=4_:BTC2]0\3A_"/BJ;0_"^H-IVN^(8K>U^Q:>ZA&+L#<":5-DB.3#%(5!^
M8*00/0/B9\0],^%/@+6?%^L174^E:3!]IN5L8Q)+Y>0"54D;L9S@') X!. 0
M"];^#=$M_!L7A/\ LV&;PY'8#2_[.N 9HFM1'Y?E/OR779\IW9R.N:Y?P?\
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MW<FJA&BMY+_4[J\CL8V^\EI%-*\=JI  *PJ@( &, "M _#?PX?!<GA+^SO\
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M"/P#\#^"-:.JZ7I5RUTMO):6ZZAJEW?064$A!>&UAGE>.VC;:H*0JBD*HQ@
M!_A'X$^"_ FK0:AHNG7ELUJ&%E9S:K>3V6G@@J1:6DDK06PVDKB%$&#CIQ7?
MT4 %%%% !1110 4444 %%%% !1110 4444 %<@WA"\;XN1>*?-@_L]=#?3#'
MN;S?--PL@.,8VX4\YSGM77T4 >&V?P-UZW^#OA;PFUWIQU'2_%4&N32B23R6
M@35S>E5.S)?RS@ @#=QG'-:DGPAUEO/Q<V/[SQS'XF'[Q_\ CV79E/N?ZSY3
MQT_VJ]>HH \AD^$.LMY^+FQ_>>.8_$P_>/\ \>R[,I]S_6?*>.G^U6=-\/\
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M / R2V<ED+KP+-,M_+OP&=;I+>UDMAC=\J%VR5(D&WGVNB@#R3Q1\)]6T%?
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ML/%VL>*M-LX;F.?PWJ2Z7=M.JA7E-M!< QX8DKLN$&2 <AN,8)Z.@#RGP_\
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ME_#IEMO!MK&&[G(>1@TR /* 2D,@6-0!M]HHHH **** "BBB@ HHHH ****
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M?MFNITSQI\+/AA\5O#FOZ9K?A/PS\-=2\)S:?HVH:?-!;:/)/'?>9)#%*F(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX2Z[0/)$@0*OF$+SM_$[X)Z_\3O$%H+WQ7I@\*V^HVFJ16=QX=CFU.RF@='
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>mdt-20240426_g9.jpg
<DESCRIPTION>IMAGE 9
<TEXT>
begin 644 mdt-20240426_g9.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
MT *  P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?"?QM^&">.]:O/".DZCXWNM!F\.7TMW<7_V>);2V</:+'<^2$,@5EA4/&P
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M/BC5;;XC>(=6\+7FG>&]!N,P&TT/1XEBCT^*"*""1@EDK;OO2MO(10#]UO\
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MM'8>'YHM3:2*]N6<G[/;2"]E7S7.U/LZAF!9=U?]E/\ 9RN/VO?^#JSXP?\
M!1/X>W4&K?"GX5:/:V=IXWL9EETW4-;?PS9Z9)9P3J2DS1++>-(4)$9B4-@N
MF0#L_P#@O1_P2D_X)M_!G_@DI\7/C7J/P=TN+X@:4D>LVWQ3OPK>(M7UZYOX
ME:2ZNP UQ]HEG=7AQY2B0^7'&$39[S_P1%\+^)?^">O_  0W^'.H?MF:_/H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@[V;(!XKW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOB1ID<C9]$>8,?RKH^J8KE4O9RL_)BNCW>BN<\#_ !C^$7Q-&[X;?%3PWXA
M&<Z'KEO=\=<_NG:NCK!Q<79H84444@"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>$XDMWQSLE56]J^3QN5X[+W^_@TN^Z^]%IIGH5%%%>>,**** "BBB@ HHHH
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M>-@&1E*L 017Y?FV3XC*JMI:P>TOT?9FL9)G7T445Y!04444 %%%% !1110
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M_P""SOB__@F1\9U^'_Q,U&\U+X,^+M00>*-*7=(VBW#80:I;(,G<H"B6-?\
M6QKT+I'C^I7PEXM\,>/?"VF^./!.OVFJZ/K%C%>Z5J=A.LL%W;RH'CEC=20R
M,I!!'!!K\HSC*:N58CE>L'\+_1^:-HRNC0HHHKR"@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "DDDCAC:65PJJ"69C@ #J2:6ORK_X.4?^
M"J$O[._PK/[#/P1\0&+QIXYTPOXOU"TE^?2-%DRI@!'W9KG#+ZK"'.!YD;#Z
MS@C@_->.^):&38!>_4>LND(+XIR\HK[W:*U:,,3B(86BZD^GXGPI_P %_?\
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MLGQ ^,7AG0;^WMI?$.CVDLPM--FEGEBCCM)+BTE\_+Y*^64#,JHX!]Z_ /\
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MDLKR?2KU9?LMU'C?;S*#NAE4,I,;A6 8$CD4 =/1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X5_P4F_;'T?
M]@[]C'QM^TA>F&34=+T[[-X9LIN1=ZK.?*M8R/XE$C"1P.?+C<]J]UK\&_\
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M;#R_?-/^)57V?.-)Z6ZU+W7NQ9]7DV!]E3]O-:O;R7_!_(****_DT]T****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XK_P""
MW7_!)SP?_P %0/V8[BR\/Z?:VGQ3\(6TUY\/M;?:GFR8W/IT[G_EA/M R?\
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M&WQG^,NO?$7Q/8:'<O/9:/+J$B"+3X9G1&G6&&*,&4HNYV? VA20#Z<HHHH
M_!K_ (.V?C]_PDG[1'PS_9KTZ]W0>%?"]QK>HQQMQ]IOYA$BN/[RQ688>@G]
MZ_(ROJ[_ (+@?&3_ (7?_P %4/C'XFAN_-MM*\3?V!:@'*HNG0QV3A?8R02-
M]6-?*-?ZW^$>11X<\-<KP5K/V,9R7]ZI^\E]TI-'P6/J^VQDY>?Y:!1117Z*
M<@4444 =)\'/A9XJ^./Q:\,?!CP/;";6?%FOVFD:7&<X,]Q,L29QT4,X)/8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK_%S.,1+%YMB*\MYSG+[Y-GZ+37+32\@HHHKSBPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\1_X*7>"?\
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M/KP#)'SV(8#NU? E%?+YYP=D/$%Y8FE:?\\=)?/H_P#MY,_2.#/%CC;@:U/
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M10 4444 %%%% !1110 4444 %%%% '(?&SX(^ _CYX(G\#>/=.\R)COM+N+
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M=6VR_DI_RQ[O>3U>EHHHHHKXP_6PHHHH **** "BBB@ HHHH **** "BBB@
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M\ET[4K.6WN(7*303QE'C8=0RGD'V-15^C)IJZ/P"491DXR5F@HHHIB"BBB@
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M:^<;=0L9(3GZ.!6;7T4)PJ1YH.Z\CX*K1K4*CA5BXR71JS^YA1115&84444
M%%%:WASP'XX\8RB#PCX-U7578X5-.TZ6<G\$4U$ZE.E'FFTEW>AK1H5\345.
ME%RD^B3;^Y&317L7A#]@G]JGQB4>'X73:="V,SZQ=16VWZHS>9^2FO8/ G_!
M);Q%<;+CXF?%BSM1U>UT2S:8GV\R78 ?^ &OG,=QEPQER?M<5!OM%\[^Z-[?
M,^_R7PF\1L^:^JY;42?6:]E'UO4Y4_E<^/:Z?X;_  7^*OQ=OOL'PW\!ZCJS
M!MKRV\!$,9_VY6PB?\"85^B'PU_8 _9D^&_EW!\#G7;N/'^E^(9?M.?^V6!%
M_P".9KV/3].T_2;./3M*L8;:WA7;%!;Q!$0>@4< 5\%FOBWA*:<<OH.3_FGH
MO_ 5=O[XG[;PU]%O,ZTHU,]QL:<>L*2YI>G/)*,7Z1FCXF^#G_!*?7[Z2+5?
MCCXTCL8>&.DZ&PDF/L\S#8A_W5?/J*^K_A1\ _A%\$K#[#\-? ]GI[LFV:\"
M>9<S#_;E?+L,\XS@=@*["BORW.N+,^SYM8JL^3^6.D?N6_SNS^E.$?##@K@E
M*66X5>U7_+R?OU/_  )_#?JH**\@HHHKYP^_"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BOF7]IG_ (+)?\$Q?V.OB\GP%_:/_;#\,>&_%Q$9N-$>.YNI++S
M&3[2UM%(EH2K*P$S)\K!OND&OH7P_P"._!/BOP5:?$GPQXOTO4?#M_IJ:A8Z
M[97\<MG<6C)YBW"3*2C1%#N#@[2.<XH U:*\1\$_\%&_V,OB%XX\/^ /#?QE
M N_&$KQ>"M0U+P_J%CI?B>1024TO4;FWCL]3; + 6LTI8<C(YKVZ@ HKA/VA
M_P!IW]GK]DOX=7/Q:_:6^,GA[P3X=MLAM3\0ZDENLCXR(HE)W32''$<89V[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX9M6L;NXM$>6W/\ :EDV8W(RGS*IX(^Z/2O6O'/PP^('QM_X)):M\&OA/?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;1(+>VB486..- %10.   !5ZBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHKS/]LG]IC0_P!C?]E_QK^U!XF\,W>LV'@O1FU&ZTNQF6.:Y565=B,_
MR@_-W]*J$)5)J$5=O1?,#TRBOQI_XC*?V9_^C,_'7_@_LO\ "C_B,I_9G_Z,
MS\=?^#^R_P *]C_5[.?^?+^]?YD\T3]EJ*^&_P#@D[_P7'^%7_!6'XA>+?A[
M\/?@9XA\)3>$]&@U&XN-9U&"=;A9)?*"*(N00>>:^Y*\S$X:OA*SI5HVDN@T
MTPHKSCXY?M=_LR_LUZAIFA_''XV:!X>U36MQT30[J\#ZCJ(7.XV]G'NGG P<
ME$8#OBJ?@']MW]D?XGZ[I_A/P-^T)X7OM;U/4_[/M/#W]I+'J7VK[/-<^2]G
M)MGB8P6\T@#HN5C8CBL!GJ=%%% !117E/[5_[</[)O[#?@VV\>?M7?'+1?!F
MGWUP(-/%^TDMS>R9 VP6T*O-.1D9\M&QD9QF@#U:BO./CG^UQ^SK^S5XO\ ^
M OC?\3;;0-7^*'BF/PYX$LI[.XE;5=3<#;;J8HW6+)91OD*)N=5W98 ^CT %
M%%% !1110 4444 %%%% !17EO[67[;'[*G["_P .O^%K?M9?&_1O!6B,S+;S
M:D[O-=,N-RP6\*O-<,-RY6-&(W#(Y%>G6MS!>VL=Y;/NCEC#QM@C*D9!Y]J
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M?^+TTBXN[ZUMC=7EMI=N;:;[4T$0^8S/;*[_ "QE^&-#]J?_ (+7_";]G?\
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M4M+2Y!:UDG9BJ"SL%5%ED$:PH[A2 ?<'C#_@I/XZO?!?Q?\ B_\ LY_LO_\
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MB]U=07%Z\D]]"N6D-R&>+RR'5_+VFO2_^#8[Q9X7\2_LB?&"#P]XALKY[?\
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MCLGB[X97=]+)-+X+U>+3=2%QHWF'.$D2=I%#?ZQ8@ZGS%N=W<_M;_%#]E/\
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M_P#!5/X.?#+Q19?\)!XEU>UTO27BO%!BN9M$O[17)!^4)/E2?X64@\BO+O\
M@EQ^VG_P0T@_8;\.?L]_M\?L^_"7PC\9?ACI4?A'Q_X(\=?"6UN-8U:^LL6R
M211FT>34)YPB%HU#3><74J<JS 'W)\?_ /@LY\*/@I\8O@-\.M!^ OCCQAH'
M[0MC)?\ @+QSX>CMIK+4+9;&.[ M[>.5[N29A/;+LEA@3]]N\S"/MU?V9O\
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M=*(L7#K( X:0,0P# YYKNZ\[_:<_:U_9M_8R^&5Q\8OVHOC'HO@OP[;'!O\
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MWH6@1BUL_&FE7,4TY%Y"F(Y),6TD1D(WDS1/G="C+]N?'W_@H5\.OAA^WU\
M?V2O$?[,6MZGJ/Q<DU67P+\2KPZ>+"T2VTW[3=FVQ+)="38\,3JT4 (F!#N
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M;^3;:B(+V>WBU"%.BQW,<23C;\A\W<GR,M?35 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<;^T)\
M"/ '[3GP6\1_ +XIV]U-X>\4Z<UEJT=E<F&5HB02%<<J<J.:[*N;^+WQ(LOA
M#\--9^)>I:;+>0:-9FXEM8'"O( 0, G@=:VPV)KX/$0Q%"3C.#4HM:--.Z:?
M1IZH32DK/8^&/^(8;_@E;_T*?C;_ ,+*7_XFC_B&&_X)6_\ 0I^-O_"RE_\
MB:],_P"'OGPX_P"B/ZW_ .!\/^%'_#WSX<?]$?UO_P #X?\ "OOO^(N>)_\
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MKZ*J@ #V%<SXL^ 'P'\>:Y+XF\<_!/PCK6I3JJS:AJWANUN9Y JA5#221EB
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M7QH++$8\4>&;R">>73[S'$Z*UIB/=DQM.70JRJ1T7_!N_P".M7_9#^ VH_\
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M3X3>'OC%X#T.U\)>._AUXM^#]K<Z[JVKV2K:9@MC9O)?3W,D:MY:AI!+(48
MC) /M?\ :*_X+*_#WX%?M'?!;X":!^SEXX\967QXTB[U+X>>,= GL#8ZW%%I
MRWD<=FAG,S22/-:PYN4M8D^TB1I?+1V'MO[%/[1?Q8_:>^#L_P 0_C3^RAXK
M^#6O6OB"]TR?P?XON8IYV2!P%NHY8L+)#(#\K@ $JVTLNUV^$_VV=>\%^"/^
M"NO_  3!T*^\(Z'\/%T_1?&]O_P@]K<6\4'AP3^'[*WMM.C6(+&J+*#;1!%5
M&,>U!Q@?J30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5B_$/P%X?^*'@G4OA_XKCE?3M5MS!=K!*4<H2#PPZ=*VJ* /G?\
MX=>_LI_] C6__!R_^%'_  Z]_93_ .@1K?\ X.7_ ,*^B** /,_@1^R5\'OV
M<]6O]:^&EE?Q3ZE;K!=&\OC,"BMN& 1QS7IE%% '*_%?X%_!+X\:-%X=^./P
M<\*^,]/@<O#8>*_#UMJ,,;$8)5+A'4$CN!5WX=_"_P"&GPA\-1^"_A-\.]"\
M+Z/"Y>'2?#ND0V5LC'J1%"JH"<#D#M6[10!D>*/A]X"\;W>FZAXT\$:1J\^C
M7@N]'GU338KA[&X'2:%I%)BD']Y<'WK''[/GP#'BD^.1\$/"']MF_-\=8_X1
MJU^U&Z+[S/YOE[_,W_-OSNSSG-=?10!R/A3]G_X#> ]<B\3^!_@EX1T;4H%8
M0:AI/ANUMYXPRE6"R1QAAE20<'D$BFS_ +/7P"N?BBGQQN?@=X/D\:Q(%C\8
M/X9M3JB+MVX%V8_- V\8W=.*["B@#D/%7[/OP$\=:[-XH\;_  1\(:SJ=R%%
MQJ.J^&K6XGEVJ%7=))&6;"J%&3P !VKKHXXX8UBBC5450%51@ #H *6B@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387297522304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Jun. 17, 2024</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 26,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-36820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Medtronic plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1183488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 On Hatch, Lower Hatch Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">438-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,282,269,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Portions of the registrant&#8217;s Proxy Statement for its 2024 Annual General Meeting are incorporated by reference into Part III hereof.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001613103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--04-26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D02 XH02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2025Member', window );">0.250% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.250% Senior Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2025Member', window );">0.000% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.000% Senior Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/25A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2025Member', window );">2.625% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.625% Senior Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/25B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2027Member', window );">1.125% Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Senior Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2028Member', window );">0.375% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.375% Senior Notes due 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2028Member', window );">3.000% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.000% Senior Notes due 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/28A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2029Member', window );">3.650% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.650% Senior Notes due 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.625PercentMember', window );">1.625% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Senior Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.00PercentMember', window );">1.000% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Senior Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/31A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2031Member', window );">3.125% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.125% Senior Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/31B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2032Member', window );">0.750% Senior Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.750% Senior Notes due 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2034Member', window );">3.375% Senior Notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.375% Senior Notes due 2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2036Member', window );">3.875% Senior Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.875% Senior Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20392.250PercentMember', window );">2.250% Senior Notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.250% Senior Notes due 2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/39A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20391.50PercentMember', window );">1.500% Senior Notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.500% Senior Notes due 2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/39B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2040Member', window );">1.375% Senior Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Senior Notes due 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/40A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2043Member', window );">4.150% Senior Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">4.150% Senior Notes due 2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/43A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2049Member', window );">1.750% Senior Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.750% Senior Notes due 2049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2050Member', window );">1.625% Senior Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Senior Notes due 2050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2053Member', window );">4.150% Senior Notes due 2053</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">4.150% Senior Notes due 2053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.625PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.625PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.00PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.00PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2022Due2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20392.250PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20392.250PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20391.50PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20391.50PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2053Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2053Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191094736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis, Minnesota<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185773568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 32,364<span></span>
</td>
<td class="nump">$ 31,227<span></span>
</td>
<td class="nump">$ 31,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="nump">11,216<span></span>
</td>
<td class="nump">10,719<span></span>
</td>
<td class="nump">10,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">2,735<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">2,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">10,736<span></span>
</td>
<td class="nump">10,415<span></span>
</td>
<td class="nump">10,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact', window );">Restructuring charges, net</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Certain litigation charges, net</a></td>
<td class="nump">149<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating expense (income), net</a></td>
<td class="nump">464<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="nump">862<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating profit</a></td>
<td class="nump">5,144<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
<td class="nump">5,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income, net</a></td>
<td class="num">(412)<span></span>
</td>
<td class="num">(515)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">4,837<span></span>
</td>
<td class="nump">5,364<span></span>
</td>
<td class="nump">5,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">3,784<span></span>
</td>
<td class="nump">5,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Medtronic</a></td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">$ 3,758<span></span>
</td>
<td class="nump">$ 5,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,327.7<span></span>
</td>
<td class="nump">1,329.8<span></span>
</td>
<td class="nump">1,342.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,330.2<span></span>
</td>
<td class="nump">1,332.8<span></span>
</td>
<td class="nump">1,351.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183602912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,705<span></span>
</td>
<td class="nump">$ 3,784<span></span>
</td>
<td class="nump">$ 5,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investment securities</a></td>
<td class="nump">46<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Translation adjustment</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
<td class="num">(2,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax', window );">Net investment hedge</a></td>
<td class="nump">633<span></span>
</td>
<td class="num">(596)<span></span>
</td>
<td class="nump">2,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change in retirement obligations</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gain (loss) on cash flow hedges</a></td>
<td class="nump">136<span></span>
</td>
<td class="num">(381)<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">178<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income including noncontrolling interests</a></td>
<td class="nump">3,883<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
<td class="nump">6,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Medtronic</a></td>
<td class="nump">$ 3,856<span></span>
</td>
<td class="nump">$ 2,524<span></span>
</td>
<td class="nump">$ 6,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183017280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,284<span></span>
</td>
<td class="nump">$ 1,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">6,721<span></span>
</td>
<td class="nump">6,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, less allowances and credit losses of $173 and $176, respectively</a></td>
<td class="nump">6,128<span></span>
</td>
<td class="nump">5,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">5,217<span></span>
</td>
<td class="nump">5,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,584<span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">21,935<span></span>
</td>
<td class="nump">21,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">6,131<span></span>
</td>
<td class="nump">5,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">40,986<span></span>
</td>
<td class="nump">41,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">13,225<span></span>
</td>
<td class="nump">14,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Tax assets</a></td>
<td class="nump">3,657<span></span>
</td>
<td class="nump">3,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,047<span></span>
</td>
<td class="nump">3,959<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">89,981<span></span>
</td>
<td class="nump">90,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current debt obligations</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,410<span></span>
</td>
<td class="nump">2,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">1,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income taxes</a></td>
<td class="nump">1,330<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">3,582<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,789<span></span>
</td>
<td class="nump">9,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">23,932<span></span>
</td>
<td class="nump">24,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued compensation and retirement benefits</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">1,859<span></span>
</td>
<td class="nump">2,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">39,561<span></span>
</td>
<td class="nump">39,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 3, 16, and 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares&#8212; par value $0.0001, 2.6 billion shares authorized, 1,311,337,531 and 1,330,809,036 shares issued and outstanding, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">23,129<span></span>
</td>
<td class="nump">24,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">30,403<span></span>
</td>
<td class="nump">30,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3,318)<span></span>
</td>
<td class="num">(3,499)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">50,214<span></span>
</td>
<td class="nump">51,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">50,420<span></span>
</td>
<td class="nump">51,665<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 89,981<span></span>
</td>
<td class="nump">$ 90,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387299823216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances and credit losses</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">2,600,000,000<span></span>
</td>
<td class="nump">2,600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,311,337,531<span></span>
</td>
<td class="nump">1,330,809,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,311,337,531<span></span>
</td>
<td class="nump">1,330,809,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387297412720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Shareholders&#8217; Equity</div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Apr. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,345,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Apr. 30, 2021</a></td>
<td class="nump">$ 51,602<span></span>
</td>
<td class="nump">$ 51,428<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26,319<span></span>
</td>
<td class="nump">$ 28,594<span></span>
</td>
<td class="num">$ (3,485)<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">5,062<span></span>
</td>
<td class="nump">5,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends to shareholders</a></td>
<td class="num">(3,383)<span></span>
</td>
<td class="num">(3,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of ordinary shares</a></td>
<td class="num">(2,442)<span></span>
</td>
<td class="num">(2,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Changes to noncontrolling ownership interests</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 29, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,331,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 29, 2022</a></td>
<td class="nump">52,722<span></span>
</td>
<td class="nump">52,551<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,566<span></span>
</td>
<td class="nump">30,250<span></span>
</td>
<td class="num">(2,265)<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,784<span></span>
</td>
<td class="nump">3,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,234)<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends to shareholders</a></td>
<td class="num">(3,616)<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of ordinary shares</a></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Changes to noncontrolling ownership interests</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 28, 2023</a></td>
<td class="nump">1,330,809,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,331,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 28, 2023</a></td>
<td class="nump">$ 51,665<span></span>
</td>
<td class="nump">51,483<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,590<span></span>
</td>
<td class="nump">30,392<span></span>
</td>
<td class="num">(3,499)<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends to shareholders</a></td>
<td class="num">(3,666)<span></span>
</td>
<td class="num">(3,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of ordinary shares</a></td>
<td class="num">(2,084)<span></span>
</td>
<td class="num">(2,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Changes to noncontrolling ownership interests</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 26, 2024</a></td>
<td class="nump">1,311,337,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 26, 2024</a></td>
<td class="nump">$ 50,420<span></span>
</td>
<td class="nump">$ 50,214<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,129<span></span>
</td>
<td class="nump">$ 30,403<span></span>
</td>
<td class="num">$ (3,318)<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191169456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends to shareholders (in dollars per share)</a></td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387184964592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,705<span></span>
</td>
<td class="nump">$ 3,784<span></span>
</td>
<td class="nump">$ 5,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,647<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(508)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments and related inventory write-downs</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(576)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(939)<span></span>
</td>
<td class="num">(560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other operating assets and liabilities</a></td>
<td class="num">(345)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">6,787<span></span>
</td>
<td class="nump">6,039<span></span>
</td>
<td class="nump">7,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(1,867)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant, and equipment</a></td>
<td class="num">(1,587)<span></span>
</td>
<td class="num">(1,459)<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(7,748)<span></span>
</td>
<td class="num">(7,514)<span></span>
</td>
<td class="num">(9,882)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales and maturities of investments</a></td>
<td class="nump">7,441<span></span>
</td>
<td class="nump">7,343<span></span>
</td>
<td class="nump">9,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="num">(261)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,366)<span></span>
</td>
<td class="num">(3,493)<span></span>
</td>
<td class="num">(1,659)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess', window );">Change in current debt obligations, net</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings (maturities greater than 90 days)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments from short-term borrowings (maturities greater than 90 days)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,279)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,409<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,012)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends to shareholders</a></td>
<td class="num">(3,666)<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
<td class="num">(3,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance of ordinary shares</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of ordinary shares</a></td>
<td class="num">(2,138)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
<td class="num">(2,544)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,450)<span></span>
</td>
<td class="num">(4,960)<span></span>
</td>
<td class="num">(5,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(230)<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="num">(231)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">3,714<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">3,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_IncomeTaxesandInterestPaidAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_IncomeTaxesandInterestPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes and Interest Paid [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_IncomeTaxesandInterestPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191178448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Operations   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc (Medtronic or the Company)&#160;is the leading global healthcare technology company&#8211; alleviating pain, restoring health, and extending life for millions of people around the world. The Company provides innovative products and therapies to serve healthcare systems, physicians, clinicians, and patients. Medtronic was founded in 1949 and is headquartered in Dublin, Ireland. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible asset, equity investment, and liability valuations. Actual results may or may not differ from those estimates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year-End</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;26, 2024 and April&#160;28, 2023 and for each of the three fiscal years ended April&#160;26, 2024 (fiscal year 2024), April&#160;28, 2023 (fiscal year 2023), and April&#160;29, 2022 (fiscal year 2022).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#8217;s investment and are adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant, and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of property, plant, and equipment asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Goodwill and Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#8217;s net assets exceeds the estimated fair value of the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from <span style="-sec-ix-hidden:f-494">three</span> to 20 years. Amortization is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable, the Company calculates the excess of an asset group's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group, which includes intangible assets, is estimated by utilizing a discounted cash flow analysis. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#8217;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;D with no alternative future use acquired outside of a business combination is expensed immediately. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain of the Company&#8217;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#8217;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#8217; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Assumptions  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. See Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a cash flow hedge or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs are unobservable for the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency forward contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, certificates of deposits, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#8217;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible assets, and IPR&amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general, and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and were $341 million, $351 million, and $354 million in fiscal years 2024, 2023, and 2022, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#8217;s tax return but has not yet been recognized as an expense in the consolidated statements of income.&#160;See Footnote 13 for more information on the Company's uncertain tax positions and tax policies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Expense (Income), Net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other operating expense (income), net primarily includes royalty expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in fair value of contingent consideration, certain </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition and divestiture-related items, income from funded research and development arrangements, and commitments to the Medtronic Foundation and Medtronic LABS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Non-Operating Income, Net   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency Translation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplier Finance Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#8212; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#8217;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023. The adoption of this standard did not have a material impact on the Company&#8217;s Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Yet Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387176470672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Prior period revenue has been recast to reflect the new reporting structure. The activity of the Company's Renal Care Solutions business and the ventilator product line were moved out of Medical Surgical and into the Other line, and the retained PMRI businesses were combined into one business unit called Acute Care &amp; Monitoring in Medical Surgical. Refer to Note 19 to the consolidated financial statements for additional information regarding the Company's reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below illustrates net sales by segment and division for fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Sales by Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac Rhythm &amp; Heart Failure</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Heart &amp; Aortic </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary &amp; Peripheral Vascular </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cranial &amp; Spinal Technologies </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Therapies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical &amp; Endoscopy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Care &amp; Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The table below illustrates net sales by market geography for each segment for fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Developed Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">U.S. includes the United States and U.S. territories.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At April&#160;26, 2024, $1.0&#160;billion of rebates were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$574&#160;million of rebates were classified as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheet. At April&#160;28, 2023, $1.1 billion of rebates were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $555 million of rebates were classified as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheet. During fiscal year 2024, adjustments to rebate and return reserves recognized in revenue that were included in the rebate and return reserves at the beginning of the period were not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue and Remaining Performance Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue at April&#160;26, 2024 and April&#160;28, 2023 was $453&#160;million and $405&#160;million, respectively. At April&#160;26, 2024 and April&#160;28, 2023, $352&#160;million and $314&#160;million was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, and $101&#160;million and $91&#160;million was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. During the fiscal year ended&#160;April&#160;26, 2024, the Company recognized&#160;$324 million&#160;of revenue that was included in deferred revenue as of&#160;April&#160;28, 2023. During the fiscal year ended April&#160;28, 2023, the Company recognized $240 million of revenue that was included in deferred revenue at April&#160;29, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At April&#160;26, 2024, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $0.5&#160;billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next two years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191297264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Dispositions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and Dispositions</a></td>
<td class="text">Acquisitions and Dispositions <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had acquisitions during fiscal years 2024 and 2023 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future, yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The results of operations of acquired businesses have been included in the Company&#8217;s consolidated statements of income since the date each business was acquired. The results of operations of acquired businesses and the pro forma impact of the acquisitions during fiscal years 2024 and 2023 was not significant, either individually or in the aggregate, to the consolidated results of the Company. Purchase price allocation adjustments for fiscal years 2024 and 2023 business combinations were not significant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2024</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of net assets acquired during the fiscal year ended April&#160;26, 2024 was $335&#160;million. Based on preliminary valuations, assets acquired were primarily comprised of $131&#160;million of goodwill, $150&#160;million of IPR&amp;D, and $29&#160;million of technology-based intangible assets with estimated useful lives of 10 years. For tax purposes, $51&#160;million of goodwill is deductible while $80&#160;million is not deductible. The Company recognized $30&#160;million of non-cash contingent consideration liabilities in connection with these business combinations during the fiscal year ended April&#160;26, 2024, which are comprised of revenue and product development milestone-based payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intersect ENT</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2022, the Company acquired Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader. The acquisition expands the Neuroscience segment portfolio of products used during ENT procedures, and combined with the Company's navigation, powered instruments, and existing tissue health products, offers a broader suite of solutions to assist surgeons treating patients who suffer from chronic rhinosinusitis (CRS). Total consideration, net of cash acquired, for the transaction, in which the Company acquired all outstanding shares of Intersect ENT for $28.25 per share, was $1.2&#160;billion consisting of $1.1&#160;billion of cash and $98&#160;million previously held investments in Intersect ENT. The Company acquired $615&#160;million of goodwill, $635&#160;million of technology-based intangible assets, $35&#160;million of customer-related intangible assets, and $13&#160;million of tradenames with estimated useful lives of 20 years. The goodwill is not deductible for tax purposes. Revenue and net loss attributable to Intersect ENT since the date of acquisition as well as costs incurred in connection with the acquisition included in the consolidated statements of income were not significant for fiscal year 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affera, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Company acquired Affera, Inc. (Affera) a privately-held company focused on the development of cardiac mapping and navigation systems and catheter-based cardiac ablation technologies. The acquisition expands the Cardiovascular segment suite of advanced cardiac ablation products and accessories, including its first cardiac mapping and navigation platform. Total consideration, net of cash acquired for the transaction, was $904&#160;million. The Company acquired $660 million of goodwill and $300 million of IPR&amp;D, which was capitalized into intangible assets during the fourth quarter of fiscal year 2023. The goodwill is not deductible for tax purposes. The Company recognized $201 million of non-cash contingent consideration liabilities in connection with the acquisition, which are comprised of product development milestone-based payments. Revenue and net loss attributable to Affera since the date of acquisition as well as costs incurred in connection with the acquisition included in the consolidated statements of income were not significant for fiscal year 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of the assets acquired and liabilities assumed were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intersect ENT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affera</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Acquisitions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquisitions, other than Intersect ENT and Affera, the acquisition date fair value of net assets acquired during fiscal year 2023 was $123 million. Assets acquired were primarily comprised of $66 million of goodwill and $57&#160;million of technology-based intangible assets with estimated useful lives of 16 years. The goodwill is deductible for tax purposes. The Company recognized $73&#160;million of non-cash contingent consideration liabilities in connection with these acquisitions during fiscal year 2023, which are comprised of revenue and product development milestone-based payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disposal Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ventilator Product Line Exit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2024, the Company announced the decision to exit its ventilator product line and retain and combine the remaining Patient Monitoring and Respiratory Interventions (PMRI) businesses into one business unit called Acute Care and Monitoring (ACM). In connection with this decision, the Company recorded pre-tax charges of $439&#160;million, including $369&#160;million recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$70&#160;million recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income in fiscal year 2024. The charges included $371&#160;million of non-cash impairments and write-downs primarily related to $295&#160;million of long-lived intangible asset impairments and $70&#160;million of inventory-write downs. The other charges primarily related to contract cancellation costs and severance. The Company will continue to honor existing ventilator contracts to serve the needs of its customers and their patients.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renal Care Solutions (RCS) Disposition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, the Company and DaVita Inc. (DaVita) entered into a definitive agreement for the Company to sell half of its RCS business, and on April 1, 2023, completed the transaction. This sale is part of an agreement between Medtronic and DaVita to form a new, independent kidney care-focused medical device company (&#8220;Mozarc Medical&#8221; or "Mozarc") with equal equity ownership. At closing, the Company received $45&#160;million cash consideration, recorded non-cash contingent consideration receivables valued at $195&#160;million, made an additional cash investment of $224&#160;million, and retained a 50% non-controlling equity interest in Mozarc valued at $307&#160;million. For the contingent consideration receivables, the maximum consideration the Company could receive in the future is $300&#160;million based on the achievement of certain milestones, as further described below. The Company recorded non-cash pre-tax charges of $136&#160;million in fiscal year 2023, primarily related to impairment of goodwill and changes in the carrying amount of the disposal group, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Refer to Note 9 to the consolidated financial statements for additional information on the goodwill impairment. Refer to Note 5 to the consolidated financial statements for additional information on the Company&#8217;s retained 50% equity investment in Mozarc as a result of this transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the sale of the RCS business did not meet the criteria to be classified as discontinued operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Mechanical Circulatory Support (MCS) Business Exit</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company announced the decision to stop the distribution and sale of the Medtronic HVAD System. In connection with this decision, the Company recorded pre-tax charges of $881&#160;million, including $58&#160;million recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> costs of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $823&#160;million recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statement of income in fiscal year 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charges included $515&#160;million of non-cash impairments and write-downs primarily related to $409&#160;million of <span style="-sec-ix-hidden:f-708">intangible asset impairments</span> and $58&#160;million of inventory write-downs. The Company also recorded charges of $366&#160;million for commitments and obligations associated with the decision, which included charges for patient support obligations, restructuring, and other associated costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration liabilities at April&#160;26, 2024 and April&#160;28, 2023 was $149 million and $206 million, respectively. At April&#160;26, 2024, $96 million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $53 million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. At April&#160;28, 2023, $34 million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $171 million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture-related and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:26.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue and other performance-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5% - 28.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product development and other milestone-based payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5% - 5.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of our RCS business as further discussed above, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2025 through 2029. The fair value of the contingent consideration receivable at April 26, 2024 and April 28, 2023 was $58&#160;million and $195&#160;million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, and was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387297789648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges</a></td>
<td class="text">Restructuring Charges <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2024, the Company incurred $389 million of restructuring and associated costs primarily related to employee termination benefits and facility consolidations to support cost reduction initiatives. In fiscal years 2023 and 2022, restructuring costs primarily related to Enterprise Excellence and Simplification restructuring programs, both of which were substantially completed as of the end fiscal year 2023. Enterprise Excellence was designed to leverage the Company&#8217;s global size and scale to focus on global operations, and functional and commercial optimization, and had total cumulative pre-tax charges of $1.8 billion. Simplification was designed to focus the organization on accelerating innovation, enhancing customer experience, driving revenue growth and winning market share, and had total cumulative pre-tax charges of $0.5 billion. In addition, in the fourth quarter of fiscal year 2023, the Company incurred $0.3 billion of restructuring charges primarily related to employee termination benefits to support cost reduction initiatives. These charges were incremental to charges incurred under our Enterprise Excellence and Simplification programs noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and voluntary early retirement benefits in fiscal year 2023. Associated costs primarily include salaries and wages of employees that are fully-dedicated to restructuring programs, consulting fees, and asset write-offs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of restructuring costs in the consolidated statements of income: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring and associated costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the activity related to restructuring programs for fiscal years 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Termination Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Associated and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled non-cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages. These costs are not included in the table summarizing restructuring charges above, as they are associated with costs that are accounted for under the pension and post-retirement rules.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span>Accrual adjustments relate to certain employees identified for termination finding other positions within the Company or contract terminations being settled for less than originally estimated.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387177801248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;26, 2024 and April&#160;28, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,185&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost of debt securities excludes accrued interest, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the gross unrealized losses and fair values of the Company&#8217;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;26, 2024 and April&#160;28, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the fiscal years ended April&#160;26, 2024 and April&#160;28, 2023. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to the Company&#8217;s available-for-sale debt securities portfolio is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 29, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of available-for-sale debt securities at April&#160;26, 2024 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the consolidated statements of income. For fiscal years 2024, 2023, and 2022 there was $597 million, $386&#160;million, and $186&#160;million of interest income, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities, Equity Method Investments, and Other Investments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in equity securities with readily determinable fair values, equity method investments for which the Company has elected the fair value option, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments for which the Company has elected the fair value option are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses a discounted cash flow methodology, taking into consideration various assumptions including discount rate, and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values, and that are not accounted for via the fair value option, are included within Level 3 of the fair value hierarchy, as they are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's equity and other investments at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;26, 2024 and April&#160;28, 2023, which are classified as primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments with readily determinable fair value (marketable equity securities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments for which the fair value option has been elected</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments without readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity and other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses on the Company's portfolio of equity and other investments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. During the fiscal year ended April&#160;26, 2024, there were $291&#160;million of net unrealized losses on equity securities and other investments still held at April&#160;26, 2024. During the fiscal year ended April&#160;28, 2023, there were $56&#160;million of net unrealized gains on equity securities and other investments still held at April&#160;28, 2023. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mozarc Medical Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described in Note 3, on April 1, 2023 the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50% equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. During the fiscal year ended April&#160;26, 2024, the Company recognized a loss of $220&#160;million, primarily driven by the timing of anticipated product launches, historical financial results, and projections of future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional cash investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191324000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financing Arrangements</a></td>
<td class="text">Financing Arrangements <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt obligations consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank borrowings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1022"><span style="-sec-ix-hidden:f-1023">Current debt obligations</span></span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Paper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   On January 26, 2015, Medtronic Global Holdings S.C.A. (Medtronic Luxco), an entity organized under the laws of Luxembourg, entered into various agreements pursuant to which Medtronic Luxco may issue United States Dollar-denominated unsecured commercial paper notes (the 2015 CP Program) on a private placement basis, and on January 31, 2020 Medtronic Luxco entered into various agreements pursuant to which Medtronic Luxco may issue Euro-denominated unsecured commercial paper notes (the 2020 CP Program) on a private placement basis. The maximum aggregate amount outstanding at any time under the 2015 CP Program and the 2020 CP Program together may not exceed the equivalent of $3.5&#160;billion. The Company and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the 2015 CP Program and the 2020 CP Program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $1.1&#160;billion commercial paper outstanding at April&#160;26, 2024. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately 20 days and the weighted average interest rate was 5.45 percent. There was no commercial paper outstanding at April&#160;28, 2023. During fiscal year 2023, the weighted average original maturity of the commercial paper outstanding was approximately 22 days and the weighted average interest rate was 4.34 percent. The issuance of commercial paper reduces the amount of credit available under the Company's existing credit facility, defined below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Line of Credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   On December 12, 2023, Medtronic Luxco, as borrower, entered into an amendment to its amended and restated credit agreement (Credit Facility), by and among Medtronic, Medtronic, Inc., Medtronic Luxco, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent and issuing bank, extending the maturity date of the Credit Facility to December 2028.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility provides for a $3.5 billion&#160;five-year unsecured revolving credit facility (Credit Facility). At each anniversary date of the Credit Facility, we can request a one-year extension of the maturity date. The Credit Facility provides the Company with the ability to increase its borrowing capacity by an additional $1.0 billion at any time during the term of the agreement. The Company and Medtronic, Inc. have guaranteed the obligations of the borrowers under the Credit Facility, and Medtronic Luxco will also guarantee the obligations of any designated borrower. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At April&#160;26, 2024 and April&#160;28, 2023, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rates on advances on the Credit Facility are determined by a pricing matrix based on the Company&#8217;s long-term debt ratings, assigned by Standard &amp; Poor&#8217;s Ratings Services and Moody&#8217;s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with all covenants related to the Credit Facility.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term debt obligations consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.238%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity by Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250 percent <span style="-sec-ix-hidden:f-1041">six</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625 percent <span style="-sec-ix-hidden:f-1047">three</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.000 percent <span style="-sec-ix-hidden:f-1053">five</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.125 percent <span style="-sec-ix-hidden:f-1059">eight</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.250 percent <span style="-sec-ix-hidden:f-1065">five</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.000 percent <span style="-sec-ix-hidden:f-1071">six</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.375 percent <span style="-sec-ix-hidden:f-1077">eight</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625 percent <span style="-sec-ix-hidden:f-1083">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.000 percent <span style="-sec-ix-hidden:f-1089">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125 percent <span style="-sec-ix-hidden:f-1095">nine</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750 percent <span style="-sec-ix-hidden:f-1101">twelve</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500 percent <span style="-sec-ix-hidden:f-1107">ten</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375 percent <span style="-sec-ix-hidden:f-1113">twelve</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375 percent <span style="-sec-ix-hidden:f-1119">twenty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.550 percent <span style="-sec-ix-hidden:f-1125">thirty</span>-year 2007 CIFSA senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250 percent <span style="-sec-ix-hidden:f-1131">twenty</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.500 percent <span style="-sec-ix-hidden:f-1137">thirty</span>-year 2009 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.500 percent <span style="-sec-ix-hidden:f-1143">twenty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.550 percent <span style="-sec-ix-hidden:f-1149">thirty</span>-year 2010 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375 percent <span style="-sec-ix-hidden:f-1155">twenty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500 percent <span style="-sec-ix-hidden:f-1161">thirty</span>-year 2012 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000 percent <span style="-sec-ix-hidden:f-1167">thirty</span>-year 2013 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625 percent <span style="-sec-ix-hidden:f-1173">thirty</span>-year 2014 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625 percent <span style="-sec-ix-hidden:f-1179">thirty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.750 percent <span style="-sec-ix-hidden:f-1185">thirty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625 percent <span style="-sec-ix-hidden:f-1191">thirty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1196"><span style="-sec-ix-hidden:f-1197">Finance lease obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-2051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Notes   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Medtronic Luxco issued four tranches of Euro-denominated Senior Notes with an aggregate principal of &#8364;3.5&#160;billion, with maturities ranging from fiscal year 2026 to 2035, resulting in cash proceeds of approximately $3.4&#160;billion, net of discounts and issuance costs. The Company used the net proceeds to repay at maturity &#8364;750&#160;million of Medtronic Luxco Senior Notes for $772&#160;million&#160;of total consideration in December 2022 and &#8364;2.8&#160;billion of Medtronic Luxco Senior Notes for $2.9&#160;billion of total consideration in March 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Medtronic Luxco issued two tranches of USD-denominated Senior Notes with an aggregate principal of $2.0&#160;billion, with maturities ranging from fiscal year 2028 to 2033, resulting in cash proceeds of approximately $2.0&#160;billion, net of discounts and issuance costs. The Company used the net proceeds supplemented by additional cash to repay the &#165;297&#160;billion Fiscal 2023 Loan Agreement discussed below for $2.3&#160;billion of total consideration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to year-end, on June 3, 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of &#8364;3.0&#160;billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately $3.2&#160;billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Euro-denominated debt issued in September 2022 is designated as a net investment hedge of certain of the Company's European operations. Refer to Note 7 for additional information regarding the net investment hedge.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Agreements   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Medtronic Luxco entered into a term loan agreement (Fiscal 2023 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2023 Loan Agreement provides an unsecured term loan in an aggregate principal amount of up to &#165;300&#160;billion with a term of 364 days. Borrowings under the Fiscal 2023 Loan Agreement bear interest at the TIBOR Rate (as defined in the Fiscal 2023 Loan Agreement) plus a margin of 0.40% per annum. Medtronic plc and Medtronic, Inc. guaranteed the obligations of Medtronic Luxco under the Fiscal 2023 Loan Agreement. In May and June 2022, Medtronic Luxco borrowed an aggregate of &#165;297&#160;billion, or approximately $2.3&#160;billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $1.9&#160;billion of Medtronic Inc.'s 3.500% Senior Notes due 2025 for $1.9&#160;billion of total consideration, and $368&#160;million of Medtronic Luxco's 3.350% Senior Notes due 2027 for $376&#160;million of total consideration. The Company recognized a total loss on debt extinguishment of $53&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income during fiscal year 2023, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. During the fourth quarter of fiscal year 2023, the Company repaid the term loan in full, including interest.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal years 2024, 2023, and 2022, there was $916 million, $743 million, and $553 million of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and charges recognized in connection with the early redemption of senior notes, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024, the estimated fair value of the Company&#8217;s Senior Notes was $21.2 billion compared to a principal value of $24.0 billion. At April&#160;28, 2023, the estimated fair value was $21.7 billion compared to a principal value of $24.5 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191107920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives and Currency Exchange Risk Management</a></td>
<td class="text">Derivatives and Currency Exchange Risk Management <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company uses derivative instruments and foreign currency denominated debt to manage the impact that currency exchange rate and interest rate changes have on reported financial statements. The Company does not enter into derivative contracts for speculative purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cash Flow Hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, foreign currency forward and option contracts are designated as a cash flow hedge. Changes in the fair value of these derivatives are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash flow hedges will mature within the subsequent three-year period. At April&#160;26, 2024 and April&#160;28, 2023, the Company had $229 million and $93 million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company expects that $158 million of after-tax net unrealized gains at April&#160;26, 2024 will be recognized in the consolidated statements of income over the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instruments that are designated as net investment hedges, the gains or losses are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on a straight-line basis over the term of the hedge. During the twelve months ended April&#160;26, 2024 and April&#160;28, 2023, the Company recognized $197 million and $107 million, respectively, of after-tax unrealized gains related to excluded components in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1257">interest expense</span>, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cash flows related to the Company&#8217;s derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Undesignated Derivatives</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency forward exchange contracts to offset the Company&#8217;s exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Company&#8217;s undesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of the Company's outstanding instruments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in billions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undesignated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;26, 2024, includes derivative contracts with a notional value of &#8364;5.0 billion, or $5.4 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#165;322 billion, or $2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;26, 2024, includes &#8364;16.0 billion, or $17.1 billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2051.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.704%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Reclassified into Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,234)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheet Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;26, 2024 and April&#160;28, 2023. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"><tr><td style="width:1.0%"></td><td style="width:47.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.220%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1328">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1329">Derivative Liabilities</span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1330">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1331">Derivative Liabilities</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist principally of interest-bearing investments, derivative contracts, and trade accounts receivable. Global concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash and cash equivalents, investments, and certain other financial instruments (including currency exchange rate and interest rate derivative contracts) with various major financial institutions. The Company performs periodic evaluations of the relative credit standings of these financial institutions and limits the amount of credit exposure with any one institution. In addition, the Company has collateral credit agreements with its primary derivatives counterparties. Under these agreements, either party is required to post eligible collateral when the market value of transactions covered by the agreement exceeds specific thresholds, thus limiting credit exposure for both parties. As of April&#160;26, 2024 and April&#160;28, 2023, the Company received net cash collateral of $101 million and $11 million, respectively, </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from its counterparties. Cash collateral posted is recorded as a reduction in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the offset recorded as an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. Cash collateral received is recorded as an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the offset recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span> in the consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178903920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178879328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text">Goodwill and Other Intangible Assets <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill by segment: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of RCS business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,873&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,425&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,644&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described in Note 19, the Company had changes to the operating segments during fiscal year 2024. As of the beginning of fiscal year 2024, the Medical Surgical portfolio was separated into two operating segments, and each new operating segment was considered a standalone reporting unit as of the beginning of fiscal year 2024. As a result of this change, the Company allocated all goodwill that was previously assigned to the Medical Surgical reporting unit to the Surgical/Endoscopy reporting unit and the Patient Monitoring/Respiratory Interventions (PMRI) reporting unit using a relative fair value allocation approach. The effected reporting units were tested for impairment before and after the alignment. No goodwill impairment was identified in either test as of the beginning of the fiscal year 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the fourth quarter of fiscal year 2024, the Company's operating segments changed again resulting in the two reporting units created in the first quarter to be combined into the Medical Surgical reporting unit. All goodwill that was previously assigned to the two reporting units was combined into the Medical Surgical reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not recognize any goodwill impairment charges during fiscal years 2024 or 2022. As a result of the agreement with DaVita, as disclosed in Note 3, the Company allocated $208&#160;million of goodwill to the RCS business that met the criteria to be classified as held for sale during the first quarter of fiscal year 2023 and was subsequently sold on April 1, 2023. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $61&#160;million of goodwill impairment charges during fiscal year 2023. The goodwill impairment charges are recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gross carrying amount and accumulated amortization of intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,605)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, the Company recognized $295&#160;million of <span style="-sec-ix-hidden:f-1461">definite-lived intangible asset impairment charges</span> in connection with the decision to exit its ventilator product line. The intangible asset impairment charges primarily related to purchased technology, customer-related intangibles, and trade names. During fiscal year 2022, the Company recognized $409&#160;million of definite-lived intangible asset impairment charges in connection with the Company's decision to stop the distribution and sale of the Medtronic HVAD System. The intangible asset impairment charge primarily related to purchased technology and patents. The intangible asset impairment charges are recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Refer to Note 3 for additional information on what led to the impairments in fiscal year 2024 and 2022. The Company did not recognize any definite-lived intangible asset impairment charges during fiscal year 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible asset impairment charges were not significant for fiscal year 2024, 2023, or 2022. Due to the nature of IPR&amp;D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization expense was $1.7 billion for fiscal years 2024, 2023 and 2022. Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;26, 2024, excluding any possible future amortization associated with acquired IPR&amp;D which has not met technological feasibility, is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191296704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text">Property, Plant, and Equipment <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment balances and corresponding estimated useful lives were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives <br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generally 2-10, up to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 20</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,062&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense of $954 million, $999 million, and $974 million was recognized in fiscal years 2024, 2023, and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178848752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Capital   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc is authorized to issue 2.6 billion Ordinary Shares, $0.0001 par value; 40 thousand Euro Deferred Shares, &#8364;1.00 par value; 127.5 million Preferred Shares, $0.20 par value; and 500 thousand A Preferred Shares, $1.00 par value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Euro Deferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes 40 thousand Euro Deferred Shares, with a par value of &#8364;1.00 per share. At April&#160;26, 2024, no&#160;Euro Deferred Shares were issued or outstanding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes 127.5 million of Preferred Shares, with a par value of $0.20 per share. At April&#160;26, 2024, no&#160;Preferred&#160;Shares were issued or outstanding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A Preferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes 500 thousand A Preferred Shares, with a par value of $1.00 per share. At April&#160;26, 2024, no A Preferred Shares were outstanding. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing, declaration, and payment of future dividends to holders of the Company's ordinary shares falls within the discretion of the Company's Board of Directors and depends upon many factors, including the statutory requirements of Irish law, the Company's earnings and financial condition, the capital requirements of the Company's businesses, industry practice and any other factors the Board of Directors deems relevant.&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ordinary Share Repurchase Program   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares are repurchased on occasion to support the Company&#8217;s stock-based compensation programs and to return capital to shareholders. During fiscal years 2024 and 2023, the Company repurchased approximately 25 million and 6 million shares, respectively, at an average price of $83.04 and $91.31, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company's Board of Directors authorized $6.0 billion for repurchase of the Company's ordinary shares. In March 2024, the Company's Board of Directors authorized an incremental $5.0&#160;billion for share repurchases. There is no specific time-period associated with these repurchase authorizations. At April&#160;26, 2024, the Company had used $5.7 billion of the $11.0&#160;billion authorized under the repurchase program, leaving approximately $5.3 billion available for future repurchases. The Company accounts for repurchases of ordinary shares using the par value method and shares repurchased are cancelled.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191226384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Purchase and Award Plans</a></td>
<td class="text">Stock Purchase and Award Plans <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2024, the Company granted stock awards under the 2021 Medtronic plc Long Term Incentive Plan (2021 Plan). The 2021 Plan provides for the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock and cash-based awards. At April&#160;26, 2024, there were approximately 88 million shares available for future grants under the 2021 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation Expense   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Options are granted at the exercise price, which is equal to the closing price of the Company&#8217;s ordinary shares on the grant date. The majority of the Company&#8217;s options are non-qualified options with a <span style="-sec-ix-hidden:f-1568">ten</span>-year life and a <span style="-sec-ix-hidden:f-1569">four</span>-year ratable vesting term. The Company uses the Black-Scholes option pricing model (Black-Scholes model) to determine the fair value of stock options at the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company&#8217;s stock price, and expected dividends. Expected volatility is based on a blend of historical volatility and an implied volatility of the Company&#8217;s ordinary shares. Implied volatility is based on market traded options of the Company&#8217;s ordinary shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions used:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during fiscal year 2024:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Remaining Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;28, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,914&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds from options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to outstanding stock options at April&#160;26, 2024 was $90 million and is expected to be recognized over a weighted average period of 2.4 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Restricted stock units are expensed over the vesting period and are subject to forfeiture if employment terminates prior to the lapse of the restrictions. The expense recognized for restricted stock units is equal to the grant date fair value, which is equal to the closing stock price on the date of grant. The majority of the Company's restricted stock units either have a four-year ratable vesting term or cliff vest after three years. Restricted stock units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on restricted stock units during the vesting period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity during fiscal year 2024:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;28, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,819)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2024, 2023, and 2022:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per restricted stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of restricted stock vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to restricted stock vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to restricted stock as of April&#160;26, 2024 was $361 million and is expected to be recognized over a weighted average period of 2.6 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Share Units  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Performance share units typically cliff vest after three years. The awards include three metrics: relative total shareholder return (rTSR), revenue growth, and return on investor capital (ROIC). rTSR is considered a market condition metric, and the expense is determined at the grant date and will not be adjusted even if the market condition is not met. Revenue growth and ROIC are considered performance metrics, and the expense is recorded over the performance period, which will be reassessed each reporting period based on the probability of achieving the various performance conditions. The number of shares earned at the end of the three-year period will vary, based on only actual performance, from 0% to 200% of the target number of performance share units granted. Performance share units are subject to forfeiture if employment terminates prior to the lapse of the restrictions. Performance share units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on performance share units for each component of the award during the vesting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value of the performance share units for each component individually. The fair value of the rTSR metric will be determined using the Monte Carlo valuation model. The fair value of the revenue growth and ROIC metrics are equal to the closing stock price on the grant date. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit activity during fiscal year 2024:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;28, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2024, 2023, and 2022: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per performance share units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of performance share units vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to performance share units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to performance share units as of April&#160;26, 2024 was $89 million and is expected to be recognized over a weighted average period of 1.6 years.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees Stock Purchase Plan (ESPP)  </span> The Company's shareholders approved the Medtronic plc 2024 Employee Stock Purchase Plan (2024 Plan) on October 19, 2023, which provides for a maximum of 30&#160;million ordinary shares to be purchased by participating employees. The 2024 Plan replaced the Medtronic plc Amended and Restated 2014 Employees Stock Purchase Plan (2014 Plan) starting January 1, 2024. The 2024 Plan allows participating employees to purchase the Company's ordinary shares at a discount through payroll deductions. The expense recognized for shares purchased under the Company&#8217;s 2014 Plan and 2024 Plan is equal to the 15 percent discount the employee receives. Employees purchased 3 million shares at an average price of $71.10 per share in fiscal year 2024. At April&#160;26, 2024, approximately 29 million ordinary shares were available for future purchase under the 2024 Plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178871088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision is based on income before income taxes reported for financial statement purposes. The components of income before income taxes, based on tax jurisdiction, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,517&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax (benefit) expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss, capital loss, and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease obligations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state benefit on uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities and derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,067&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,006</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis difference of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,076)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported as (after valuation allowance and jurisdictional netting):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No deferred taxes have been provided on the approximately $86.3 billion and $83.7 billion of undistributed earnings of the Company&#8217;s subsidiaries at April&#160;26, 2024 and April&#160;28, 2023, respectively, since these earnings have been, and under current plans will continue to be, permanently reinvested in these subsidiaries. Due to the number of legal entities and jurisdictions involved, the complexity of the legal entity structure of the Company, and the complexity of the tax laws in the relevant jurisdictions, the Company believes it is not practicable to estimate, within any reasonable range, the amount of additional taxes which may be payable upon distribution of these undistributed earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024, the Company had approximately $11.3 billion of tax effected net operating loss carryforwards in certain non-U.S. jurisdictions, of which</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.1 billion have no expiration, and the remaining $6.2 billion will expire during fiscal years 2025 through 2041. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in these net operating loss carryforwards are $4.0 billion of tax effected net operating losses generated in fiscal year 2008 as a result of the receipt of a favorable tax ruling from certain non-U.S. taxing authorities; and $5.1&#160;billion of tax effected net operating losses generated during fiscal year 2023 as a result of an intercompany reorganization. The Company has recorded a full valuation allowance against these net operating losses, as management does not believe that it is more likely than not that these net operating losses will be utilized. Certain of the remaining non-U.S. net operating loss carryforwards of $2.2 billion have a valuation allowance recorded against the carryforwards, as management does not believe that it is more likely than not that these net operating losses will be utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024, the Company had $81 million of tax effected U.S. federal net operating loss carryforwards, of which $56&#160;million have no expiration. The remaining loss carryforwards will expire during fiscal years 2025 through 2036. For U.S. state purposes, the Company had $90 million of tax effected net operating loss carryforwards at April&#160;26, 2024, $12&#160;million of which have no expiration. The remaining U.S. state loss carryforwards will expire during fiscal years 2025 through 2042.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024, the Company also had $292 million of tax credits available to reduce future income taxes payable, of which</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$122 million have no expiration. The remaining credits will expire during fiscal years 2025 through 2043. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established valuation allowances of $13.3 billion and $11.3 billion at April&#160;26, 2024 and April&#160;28, 2023, respectively, primarily related to the uncertainty of the utilization of certain deferred tax assets which are primarily comprised of tax loss and credit carryforwards in various jurisdictions. The increase in the valuation allowance during fiscal year 2024 is primarily related to the finalization of certain tax returns as well as an increase in the Swiss Cantonal tax rate applied to previously recorded deferred tax assets and associated valuation allowances. These valuation allowances would result in a reduction to the income tax provision in the consolidated statements of income if they are ultimately not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Base erosion anti-abuse tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign derived intangible income benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Israeli Central-Lod District Court issued its decision in Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office in June 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a $187&#160;million income tax charge during fiscal year 2024 and filed an appeal with the Supreme Court of Israel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, the net cost from certain tax adjustments of $299&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $187&#160;million associated with a reserve adjustment related to the Israeli Central-Lod District Court decision with respect to a deemed taxable transfer of intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $124&#160;million related to a change in valuation allowance on previously recorded net operating losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $95&#160;million related to a Swiss Cantonal tax rate change on previously recorded deferred tax assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $50&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $33&#160;million associated with a change in the Company&#8217;s permanent reinvestment assertion on certain historical earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the net benefit from certain tax adjustments of $910&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statement of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $764&#160;million associated with the August 18, 2022 U.S. Tax Court (Tax Court) Opinion on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006 (Opinion). While the Opinion rejected the IRS&#8217;s position and the Tax Court determined the methodology advanced by Medtronic was appropriate for purposes of determining the intercompany royalty rate between Puerto Rico and the U.S., it determined that the royalty rate should be higher, thereby increasing income allocated to the U.S. and consequently subject to U.S. tax. This case relates only to fiscal years 2005 and 2006. The Company has assumed the Tax Court findings will be applied for all years following fiscal year 2006. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $55&#160;million related to the disallowance of certain interest deductions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $30&#160;million related to the change in reporting currency for certain carryover attributes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $28&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $33&#160;million primarily associated with the sale of half of the Company&#8217;s RCS business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2022, the net benefit from certain tax adjustments of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$50&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $82&#160;million associated with a step up in tax basis for Swiss Cantonal purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $82&#160;million related to a change in tax rates on intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $47&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $41&#160;million associated with a change in the Company&#8217;s permanent reinvestment assertion on certain historical earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $26&#160;million primarily associated with an intercompany sale of assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the Company&#8217;s operations in Puerto Rico, Singapore, Dominican Republic, Costa Rica, and China have various tax holidays and tax incentive grants. The tax reductions as compared to the local statutory rate favorably impacted earnings by $229&#160;million, $115 million, and $248 million in fiscal years 2024, 2023, and 2022, respectively, and diluted earnings per share by $0.17, $0.09, and $0.18, in fiscal years 2024, 2023, and 2022, respectively. The tax holidays are conditional upon the Company meeting certain thresholds required under statutory law. The tax incentive grants, unless extended, will expire between fiscal years 2025 and 2049. The tax incentive grants which expired during fiscal year 2024 did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which will be effective for the Company in fiscal year 2025. The Company is continuing to evaluate the potential impacts of proposed and enacted legislative changes as new guidance becomes available. There are no impacts of this global minimum tax in the consolidated financial statements for the fiscal year ended April&#160;26, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $2.8 billion, $2.7 billion, and $1.7 billion of gross unrecognized tax benefits at April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022, respectively. A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2024, 2023, and 2022 is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of fiscal year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross increases:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross decreases:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation lapses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash advance paid to taxing authorities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If all of the Company&#8217;s unrecognized tax benefits at April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022 were recognized, $2.7 billion, $2.5 billion, and $1.6 billion would impact the Company&#8217;s effective tax rate, respectively. Although the Company believes that it has adequately reserved for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on the Company&#8217;s effective tax rate in future periods. The Company has recorded gross unrecognized tax benefits, net of cash advance, of $1.8 billion as a noncurrent liability. The Company estimates that within the next 12 months it is reasonably possible that its uncertain tax positions, excluding interest, could decrease by as much as $15&#160;million, net as a result of statute of limitation lapses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to income tax matters in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income and records the liability in the current or noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets, as appropriate. During fiscal years 2024, 2023, and 2022, the Company recognized gross interest expense of $134 million, $86 million, and $17 million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. The Company had $19 million, $61 million, and $117 million of accrued gross interest and penalties at April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. These reserves are subject to a high degree of estimation and management judgment. Resolution of these significant unresolved matters, or positions taken by the IRS or other tax authorities during future tax audits, could have a material impact on the Company&#8217;s financial results in future periods. The Company continues to believe that its reserves for uncertain tax positions are appropriate and that it has meritorious defenses for its tax filings and will vigorously defend them during the audit process, appellate process, and through litigation in courts, as necessary.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earliest Year Open</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - federal and state</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 for additional information regarding the status of current tax audits and proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191226384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the computation of basic and diluted earnings per share:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to ordinary shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of weighted average diluted shares outstanding excludes options to purchase approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 23 million, and 5 million ordinary shares in fiscal year 2024, 2023, and 2022, respectively because their effect would have been anti-dilutive on the Company&#8217;s earnings per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191368128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefit Plans</a></td>
<td class="text">Retirement Benefit Plans <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net expense related to these plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$451 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $494 million, and $459 million in fiscal years 2024, 2023, and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Company maintains qualified pension plans designed to provide guaranteed minimum retirement benefits to all eligible U.S. participants. Pension coverage for non-U.S. employees is provided, to the extent deemed appropriate, through separate plans. In addition to the benefits provided under the qualified pension plan, retirement benefits associated with wages in excess of the IRS allowable limits are provided to certain employees under a non-qualified plan. U.S. and Puerto Rico employees are also eligible to receive a medical benefit component, in addition to normal retirement benefits, through the Company&#8217;s post-retirement benefits. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;26, 2024 and April&#160;28, 2023, the funded status of the Company&#8217;s benefit plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$484 million overfunded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $103 million overfunded, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the Company offered certain eligible U.S. employees voluntary early retirement packages, resulting in charges of $94&#160;million, primarily related to U.S. pension benefits. The charges were recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">restructuring charges, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income. See Note 4 for additional information on restructuring charges. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The change in benefit obligation and funded status of the Company&#8217;s U.S. and Non-U.S. pension benefits are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated benefit obligation at end of year:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in projected benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments, settlements, and amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funded status at end of year:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over (under) funded status of the plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset (liability)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized on the consolidated<br/>balance sheets consist of:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other<br/>comprehensive loss:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service (credit) cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of April 24, 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This represents a portion of the total voluntary early retirement package charges for fiscal year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain countries outside the U.S., fully funding pension plans is not a common practice, as funding provides no income tax benefit. Consequently, certain pension plans were partially funded at April&#160;26, 2024 and April&#160;28, 2023. U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost of the plans includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss (gain)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement and curtailment (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit (credit) cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost other than the service component are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other changes in plan assets and projected benefit obligations recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for fiscal year 2024 are as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S.<br/>Pension<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and settlement recognition of actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; projected benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.54% - 5.75%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.99%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23% - 4.48%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; net periodic benefit cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.99%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23% - 4.48%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% - 3.46%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25% - 12.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68% - 5.07%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12% - 4.51%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50% - 3.51%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24% - 12.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.90%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% - 4.23%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08% - 2.87%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08% - 12.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% - 8.10% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.30% - 7.20%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.60% - 7.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% - 4.83%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a full yield curve approach methodology to estimate the service and interest cost components of net periodic pension cost and net periodic post-retirement benefit cost for the Company&#8217;s pension and other post-retirement benefits. The full yield curve approach applies specific spot rates along the yield curve to their underlying projected cash flows in estimation of the cost components. The current yield curves represent high quality, long-term fixed income instruments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets assumptions are determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Investment Strategy  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors trusts that hold the assets for U.S. pension plans and other U.S. post-retirement benefit plans, primarily retiree medical benefits. For investment purposes, the Medtronic U.S. pension and other U.S. post-retirement benefit plans employ similar investment strategies with different asset allocation targets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a Qualified Plan Committee (the Plan Committee) that sets investment guidelines for U.S. pension plans and other U.S. post-retirement benefit plans with the assistance of external consultants. These guidelines are established based on market conditions, risk tolerance, funding requirements, and expected benefit payments. The Plan Committee also oversees the investment allocation process, selects the investment managers, and monitors asset performance. As pension liabilities are long-term in nature, the Company employs a long-term total return approach to maximize the long-term rate of return on plan assets for a prudent level of risk. An annual analysis on the risk versus the return of the investment portfolio is conducted to justify the expected long-term rate of return assumption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment portfolios contain a diversified allocation of investment categories, including equities, fixed income securities, hedge funds, and private equity. Securities are also diversified in terms of domestic and international, short- and long-term, growth and value styles, large cap and small cap stocks, and active and passive management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., pension plan assets are typically managed by decentralized fiduciary committees. There is significant variation in policy asset allocation from country to country. Local regulations, funding rules, and financial and tax considerations are part of the funding and investment allocation process in each country. The weighted average target asset allocations at April&#160;26, 2024 for the plans are</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 42% equity securities, 34% debt securities, and 24% other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plans did not hold any investments in the Company&#8217;s ordinary shares at April&#160;26, 2024 or April&#160;28, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. plans target asset allocations at April&#160;26, 2024, compared to the U.S. plans actual asset allocations at April&#160;26, 2024 and April&#160;28, 2023 by asset category, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target Allocation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;26, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;26, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;28, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Category:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strong performance on equity securities during the fiscal year resulted in asset allocations different than targets. Management expects to move the allocations closer to target over the intermediate term. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Asset Fair Values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The following is a description of the valuation methodologies used for retirement benefit plan assets measured at fair value: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term investments include money market funds. These investments are valued at the closing price reported in the active markets in which the individual security is traded.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mutual funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Comprised of investments in equity and fixed income securities held in pooled investment vehicles. The valuations of mutual funds are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are publicly reported.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity commingled trusts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Comprised of investments in equity securities held in pooled investment vehicles. The valuations of equity commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed income commingled trusts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprised of investments in fixed income securities held in pooled investment vehicles. The valuations of fixed income commingled trusts are based on the respective net asset values which are determined by the fund, either daily or monthly depending on the investment, at market close. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the fund, less its liabilities.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Partnership units:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Partnership units include investment partnerships that provide exposure to long/short equity, absolute return strategies, private equity investments, and real estate investments. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the partnerships, less its liabilities. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered investment companies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Valued at net asset values which are not publicly reported. The net asset values are calculated based on the valuation of the underlying assets. The underlying assets are valued at the quoted market prices of shares held by the plan at year-end in the active market on which the individual securities are traded.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance contracts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Comprised of investments in collective (group) insurance contracts, consisting of individual insurance policies. The policyholder is the employer, and each member is the owner/beneficiary of their individual insurance policy. These policies are a part of the insurance company&#8217;s general portfolio and participate in the insurer&#8217;s profit-sharing policy on an excess yield basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement using net asset value as a practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported net asset value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The methods described above may produce fair values that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;26, 2024 and April&#160;28, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Pension Benefits</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a reconciliation of the beginning and ending balances of U.S. pension benefit assets measured at fair value that used significant unobservable inputs (Level 3):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partnership Units</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;29, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total realized gains, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;28, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-U.S. Pension Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. pension benefit assets that are valued using significant unobservable inputs (Level 3) was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $44&#160;million as of April&#160;26, 2024 and April&#160;28, 2023, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the fair value hierarchy classification on an annual basis. During the year, the Company reclassified certain investments in the U.S. pension plan from Level 3 to investments measured using net asset value as a practical expedient. Outside of the reclassification, there were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no transfers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into or out of Level 3 for both the U.S. and non-U.S. pension plans during the fiscal years ended April&#160;26, 2024 and April&#160;28, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Funding  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is the Company&#8217;s policy to fund retirement costs within the limits of allowable tax deductions. During fiscal year 2024, the Company made discretionary contributions of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$32 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the U.S. pension plan. Internationally, the Company contributed approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for pension benefits during fiscal year 2024. The Company anticipates that it will make contributions of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$45 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to its U.S. pension benefit plans and non-U.S. pension benefit plans, respectively, in fiscal year 2025. Based on the guidelines under the U.S. Employee Retirement Income Security Act of 1974 and the various guidelines which govern the plans outside the U.S., the majority of anticipated fiscal year 2025 contributions will be discretionary. The Company believes that pension assets, returns on invested pension assets, and Company contributions will be able to meet its pension and other post-retirement obligations in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 &#8211; 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post-retirement Benefit Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The net periodic benefit cost associated with the Company&#8217;s post-retirement benefit plans was income of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $11 million, and $20 million in fiscal years 2024, 2023, and 2022, respectively. The Company&#8217;s projected benefit obligation for all post-retirement benefit plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$235 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $261 million at April&#160;26, 2024 and April&#160;28, 2023, respectively. The Company&#8217;s fair value of plan assets for all post-retirement benefit plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$308 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $302 million at April&#160;26, 2024 and April&#160;28, 2023, respectively. The post-retirement benefit plan assets at both April&#160;26, 2024 and April&#160;28, 2023 primarily comprised of equity and fixed commingled trusts, consistent with the U.S. retirement benefit plan assets outlined in the fair value leveling tables above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Contribution Savings Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company has defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security during retirement by providing employees with an incentive to make regular savings. Company contributions to the plans are based on employee contributions </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Company performance. Expense recognized under these plans was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$471 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $390 million, and $403 million in fiscal years 2024, 2023, and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178895808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">typically do not provide an implicit rate, the Company&#8217;s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for fiscal year 2024, 2023, and 2022 were not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases were not material to the consolidated financial statements at April&#160;26, 2024 or April&#160;28, 2023 or for fiscal year 2024, 2023 and 2022. Finance lease right-of-use assets are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">property, plant, and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and finance lease liabilities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">current debt obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;26, 2024 and April&#160;28, 2023: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2346"><span style="-sec-ix-hidden:f-2347">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2350"><span style="-sec-ix-hidden:f-2351">Other accrued expenses</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2354"><span style="-sec-ix-hidden:f-2355">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;26, 2024 and April&#160;28, 2023: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 Years</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022: </span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company's operating leases at April&#160;26, 2024:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expected lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and the Company's net investments in sales-type leases are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. Lessor income and the related assets and lease maturities were not material to the consolidated financial statements at or for the fiscal year ended April&#160;26, 2024 and April&#160;28, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387176352480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">Accumulated Other Comprehensive Loss <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Loss) Gain on Investment Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in Retirement Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(519)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,458)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,347)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,485)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,080)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,265)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,234)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,686)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,318)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during fiscal years 2024, 2023, and 2022 was an expense of $4 million, a benefit of $21&#160;million, and a benefit of $51&#160;million, respectively. During fiscal years 2024, 2023, and 2022, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $5 million, $9&#160;million and $1&#160;million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Note 5 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2024, 2023, and 2022, the income tax on cumulative translation adjustment was an expense of $3 million, a benefit of $5&#160;million, and a benefit of $8&#160;million, respectively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2024, 2023, and 2022, there were no tax impacts on net investment hedges. Refer to Note 7 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. The income tax on the net change in retirement obligations in other comprehensive income before reclassifications during fiscal years 2024, 2023, and 2022 resulted in an expense of $79 million, $6&#160;million, and $134&#160;million, respectively. During fiscal years 2024, 2023, and 2022, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of&#160;$2 million, $9&#160;million, and $20&#160;million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Note 15 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during fiscal years 2024, 2023, and 2022 was&#160;an expense of $103 million,&#160;$56&#160;million, and $152&#160;million, respectively. Amounts reclassified from AOCI related to cash flow hedges included income taxes of $66 million, $133&#160;million, and $26&#160;million for fiscal years 2024, 2023, and 2022, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating expense (income), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7 for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//220/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178895808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#8217;s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">certain litigation charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income. During fiscal years 2024, 2023, and 2022, the Company recognized $149&#160;million of certain litigation charges, $30&#160;million of certain litigation income, and $95&#160;million of certain litigation charges, respectively. At April 26, 2024 and April 28, 2023, accrued litigation was approximately $0.2&#160;billion and $0.3&#160;billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages and/or royalty payments, and negatively impact the Company's ability to sell current or future products, which could have a material adverse impact on the Company's business, results of operations, financial condition, and cash flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Colibri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company&#8217;s Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately $106&#160;million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hernia Mesh Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of May 15, 2024, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately 8,350 individual plaintiffs, and certain plaintiffs&#8217; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">law firms have advised the Company that they may file additional cases in the future. Approximately 6,700 plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 500 plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately 1,150 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus six one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diabetes Pump Retainer Ring Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of May 14, 2024, 27 lawsuits have been filed on behalf of a total of 107 individual plaintiffs, and certain plaintiffs&#8217; law firms have notified the Company that they may file additional lawsuits in the future on behalf of thousands of additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In March 2021, the parties notified the court that they had agreed on a settlement in principle of all issues in this matter, and in September 2022 the parties filed a joint motion for final approval by the court. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of remedial activities. The final court order did not result in a change to the Company's previous accrual for this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accrued expenses for these various environmental proceedings are included within accrued litigation as discussed above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Corruption Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has regular and ongoing interactions with governmental agencies, and its practice is to cooperate with such inquiries. In addition, from time to time, the Company self-discloses potential concerns to governmental regulators. Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in China regarding certain activities, including in China. The Company is committed to regularly evaluating and, as appropriate, strengthening its anti-corruption compliance programs and practices. Any possible future determination that certain of our operations and activities, and/or those of our third-party distributors, are not in compliance with existing laws could result in the imposition of fines, penalties, and equitable remedies in the United States or in other jurisdictions. The Company has not recorded an expense in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court (Tax Court) reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS&#8217;s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic, Inc.&#8217;s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 13 for additional discussion of income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates&#8217; products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company&#8217;s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-20/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-30/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191015600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">Segment and Geographic Information <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the reportable segments during the fiscal year ended April&#160;26, 2024. We continue to have four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. However, there were changes to the operating segments during fiscal year 2024 as a result of how the Chief Operating Decision Maker (CODM) assesses business performance. During the first quarter of fiscal year 2024, the Medical Surgical Portfolio was separated into two operating segments as a result of the previously contemplated separation of the PMRI businesses, which were previously aggregated based upon similar economic and operating characteristics. In addition, during the first quarter of fiscal year 2024, there were certain Medical Surgical businesses that were moved to the Other line, which primarily related to wind-down activity of the Company's Renal Care Solutions business that was contributed to Mozarc Medical in April 2023. Subsequently, as a result of the February 2024 decision to exit the Company's ventilator product line and retain and combine the remaining PMRI businesses into one business unit as further discussed in Note 3, the two operating segments within the Medical Surgical Portfolio were combined into one operating segment, and the Company's ventilator product line, which was in the Medical Surgical Portfolio, was moved to the Other line during the fourth quarter of fiscal year 2024. Prior period amounts have been recast to reflect the new reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management has chosen to organize the entity based upon therapy solutions provided by each segment. The four principal segments are strategic businesses that are managed separately, as each one develops and manufactures products and provides services oriented toward targeted therapy solutions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Cardiovascular Portfolio segment derives its revenues include products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart and vascular-related disorders and diseases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Medical Surgical Portfolio segment derives its revenues include those focused on diseases of the respiratory system, gastrointestinal tract, lungs, pelvic region, obesity, and other preventable complications. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products from which the Diabetes Operating Unit segment derives its revenues include those focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment disclosures are on a performance basis, consistent with internal management reporting. Net sales of the Company's segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. Refer to Note 2 for discussion on net sales by segment. There are certain corporate and centralized expenses that are not allocated to the segments. The Company's management evaluates the performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest income or expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments. Prior period amounts have been recast to reallocate certain expenses from segment operating profit to centralized distribution costs to conform to classifications used in the current year as a result in a change to the segment operating profit metric used by the CODM to assess business performance and allocate resources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Operating Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(719)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments to the Medtronic Foundation and Medtronic LABS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Includes the net impact of remeasurement and the Company's hedging programs recorded in other operating expense (income), net.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets and Depreciation Expense </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. Geographic property, plant, and equipment are attributed to the country based on the physical location of the assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales for fiscal years 2024, 2023, and 2022, and property, plant, and equipment, net at April&#160;26, 2024 and April&#160;28, 2023 for the Company's country of domicile, countries with significant concentrations, and all other countries: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other countries, excluding Ireland</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,686&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No single customer represented over 10 percent of the Company&#8217;s consolidated net sales in fiscal years 2024, 2023, or 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178843040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDTRONIC PLC AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II &#8211; VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges to Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges to Other Accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Changes (Debit) Credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at End of<br/>Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for doubtful accounts and credit losses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 26, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 28, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 29, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax valuation allowance: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 26, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 28, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 29, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a) Primarily consists of uncollectible accounts written off, less recoveries.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b) Reflects the impact from acquisitions.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c) Primarily reflects carryover attribute utilization and expiration.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(d) Primarily reflects the effects of currency fluctuations.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(e) Primarily reflects the impacts from tax rate changes.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191075904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to ordinary shareholders</a></td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">$ 3,758<span></span>
</td>
<td class="nump">$ 5,039<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191276048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191170992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387186442064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation  </span> The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible asset, equity investment, and liability valuations. Actual results may or may not differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Year-End</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year-End</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;26, 2024 and April&#160;28, 2023 and for each of the three fiscal years ended April&#160;26, 2024 (fiscal year 2024), April&#160;28, 2023 (fiscal year 2023), and April&#160;29, 2022 (fiscal year 2022).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#8217;s investment and are adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories  </span> Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant, and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of property, plant, and equipment asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Goodwill and Intangible Assets </span>  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#8217;s net assets exceeds the estimated fair value of the reporting unit.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from <span style="-sec-ix-hidden:f-494">three</span> to 20 years. Amortization is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">amortization of intangible assets</span> in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable, the Company calculates the excess of an asset group's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group, which includes intangible assets, is estimated by utilizing a discounted cash flow analysis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">IPR&amp;D</a></td>
<td class="text">Acquired IPR&amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#8217;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;D with no alternative future use acquired outside of a business combination is expensed immediately.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain of the Company&#8217;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#8217;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReservePolicyTextBlock', window );">Self-Insurance</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance  </span> The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#8217; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Retirement Benefit Plan Assumptions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Assumptions  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. See Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a cash flow hedge or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs are unobservable for the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency forward contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, certificates of deposits, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#8217;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible assets, and IPR&amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Shipping and Handling</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general, and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and were $341 million, $351 million, and $354 million in fiscal years 2024, 2023, and 2022, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span>  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span>  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#8217;s tax return but has not yet been recognized as an expense in the consolidated statements of income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock', window );">Other Operating Expense (Income), Net</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Expense (Income), Net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other operating expense (income), net primarily includes royalty expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in fair value of contingent consideration, certain </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition and divestiture-related items, income from funded research and development arrangements, and commitments to the Medtronic Foundation and Medtronic LABS.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock', window );">Other Non-Operating Income, Net</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Non-Operating Income, Net   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Currency Translation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency Translation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplier Finance Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#8212; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#8217;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023. The adoption of this standard did not have a material impact on the Company&#8217;s Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Yet Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an entity's accounting policy for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Net [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income (Expense), Net [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481097/715-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 60<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 80<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480576/715-80-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReservePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReservePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191913392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below illustrates net sales by segment and division for fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Sales by Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac Rhythm &amp; Heart Failure</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Heart &amp; Aortic </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary &amp; Peripheral Vascular </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cranial &amp; Spinal Technologies </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Therapies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical &amp; Endoscopy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Care &amp; Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The table below illustrates net sales by market geography for each segment for fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Developed Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">U.S. includes the United States and U.S. territories.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191263856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Dispositions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Fair Value of the Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of the assets acquired and liabilities assumed were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intersect ENT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affera</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture-related and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Significant Unobservable Inputs</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:26.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue and other performance-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5% - 28.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product development and other milestone-based payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5% - 5.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191402656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring Reserve</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of restructuring costs in the consolidated statements of income: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring and associated costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the activity related to restructuring programs for fiscal years 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Termination Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Associated and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled non-cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages. These costs are not included in the table summarizing restructuring charges above, as they are associated with costs that are accounted for under the pension and post-retirement rules.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span>Accrual adjustments relate to certain employees identified for termination finding other positions within the Company or contract terminations being settled for less than originally estimated.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387315310832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments by Category and Related Balance Sheet Presentation</a></td>
<td class="text">The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;26, 2024 and April&#160;28, 2023:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,185&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the gross unrealized losses and fair values of the Company&#8217;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;26, 2024 and April&#160;28, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Schedule of Activity Related to the Company's Available for Sale Securities Portfolio</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to the Company&#8217;s available-for-sale debt securities portfolio is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 29, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Available-for-sale Debt Securities Contractual Maturities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of available-for-sale debt securities at April&#160;26, 2024 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock', window );">Schedule of Equity and Other Investments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's equity and other investments at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;26, 2024 and April&#160;28, 2023, which are classified as primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments with readily determinable fair value (marketable equity securities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments for which the fair value option has been elected</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments without readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity and other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-Sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional cash investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191198624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Current Debt Obligations</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt obligations consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank borrowings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1022"><span style="-sec-ix-hidden:f-1023">Current debt obligations</span></span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term debt obligations consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.238%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity by Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250 percent <span style="-sec-ix-hidden:f-1041">six</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625 percent <span style="-sec-ix-hidden:f-1047">three</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.000 percent <span style="-sec-ix-hidden:f-1053">five</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.125 percent <span style="-sec-ix-hidden:f-1059">eight</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.250 percent <span style="-sec-ix-hidden:f-1065">five</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.000 percent <span style="-sec-ix-hidden:f-1071">six</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.375 percent <span style="-sec-ix-hidden:f-1077">eight</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625 percent <span style="-sec-ix-hidden:f-1083">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.000 percent <span style="-sec-ix-hidden:f-1089">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125 percent <span style="-sec-ix-hidden:f-1095">nine</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750 percent <span style="-sec-ix-hidden:f-1101">twelve</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500 percent <span style="-sec-ix-hidden:f-1107">ten</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375 percent <span style="-sec-ix-hidden:f-1113">twelve</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375 percent <span style="-sec-ix-hidden:f-1119">twenty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.550 percent <span style="-sec-ix-hidden:f-1125">thirty</span>-year 2007 CIFSA senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250 percent <span style="-sec-ix-hidden:f-1131">twenty</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.500 percent <span style="-sec-ix-hidden:f-1137">thirty</span>-year 2009 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.500 percent <span style="-sec-ix-hidden:f-1143">twenty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.550 percent <span style="-sec-ix-hidden:f-1149">thirty</span>-year 2010 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375 percent <span style="-sec-ix-hidden:f-1155">twenty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500 percent <span style="-sec-ix-hidden:f-1161">thirty</span>-year 2012 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000 percent <span style="-sec-ix-hidden:f-1167">thirty</span>-year 2013 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625 percent <span style="-sec-ix-hidden:f-1173">thirty</span>-year 2014 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625 percent <span style="-sec-ix-hidden:f-1179">thirty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.750 percent <span style="-sec-ix-hidden:f-1185">thirty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625 percent <span style="-sec-ix-hidden:f-1191">thirty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1196"><span style="-sec-ix-hidden:f-1197">Finance lease obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-2051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191074448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of (Gain) Loss on Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of the Company's outstanding instruments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in billions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undesignated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;26, 2024, includes derivative contracts with a notional value of &#8364;5.0 billion, or $5.4 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#165;322 billion, or $2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;26, 2024, includes &#8364;16.0 billion, or $17.1 billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2051.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.704%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Reclassified into Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,234)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;26, 2024 and April&#160;28, 2023. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"><tr><td style="width:1.0%"></td><td style="width:47.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.220%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1328">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1329">Derivative Liabilities</span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1330">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1331">Derivative Liabilities</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsTableTextBlock', window );">Schedule of Offsetting Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingLiabilitiesTableTextBlock', window );">Schedule of Offsetting Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191257152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory Balances</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191365168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in the Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill by segment: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of RCS business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,873&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,425&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,644&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gross carrying amount and accumulated amortization of intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,605)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Gross Carrying Amount of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gross carrying amount and accumulated amortization of intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,605)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets</a></td>
<td class="text">Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;26, 2024, excluding any possible future amortization associated with acquired IPR&amp;D which has not met technological feasibility, is as follows:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178955856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment Balances and Corresponding Lives</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment balances and corresponding estimated useful lives were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives <br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generally 2-10, up to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 20</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,062&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387410891856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2024, 2023, and 2022:</span><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions used:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during fiscal year 2024:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Remaining Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;28, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,914&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds from options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity during fiscal year 2024:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;28, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,819)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2024, 2023, and 2022:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per restricted stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of restricted stock vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to restricted stock vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of Performance Share Unit Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit activity during fiscal year 2024:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;28, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2024, 2023, and 2022: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per performance share units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of performance share units vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to performance share units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387297016896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Income Before Income Taxes, Based on Jurisdiction</a></td>
<td class="text">The components of income before income taxes, based on tax jurisdiction, are as follows:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,517&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax (Benefit) Provision</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax (benefit) expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss, capital loss, and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease obligations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state benefit on uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities and derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,067&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,006</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis difference of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,076)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported as (after valuation allowance and jurisdictional netting):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Base erosion anti-abuse tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign derived intangible income benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits</a></td>
<td class="text">A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2024, 2023, and 2022 is as follows:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of fiscal year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross increases:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross decreases:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation lapses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash advance paid to taxing authorities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock', window );">Schedule of Major Tax Jurisdictions Which Remain Subject to Examination</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earliest Year Open</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - federal and state</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxExaminationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178893280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the computation of basic and diluted earnings per share:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to ordinary shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387184156704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Defined Benefit Plans</a></td>
<td class="text">The change in benefit obligation and funded status of the Company&#8217;s U.S. and Non-U.S. pension benefits are as follows:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated benefit obligation at end of year:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in projected benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments, settlements, and amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funded status at end of year:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over (under) funded status of the plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset (liability)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized on the consolidated<br/>balance sheets consist of:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other<br/>comprehensive loss:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service (credit) cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of April 24, 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This represents a portion of the total voluntary early retirement package charges for fiscal year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text">U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:<div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Benefit Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost of the plans includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss (gain)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement and curtailment (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit (credit) cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other changes in plan assets and projected benefit obligations recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for fiscal year 2024 are as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S.<br/>Pension<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and settlement recognition of actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; projected benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.54% - 5.75%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.99%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23% - 4.48%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; net periodic benefit cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.99%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23% - 4.48%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% - 3.46%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25% - 12.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68% - 5.07%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12% - 4.51%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50% - 3.51%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24% - 12.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.90%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% - 4.23%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08% - 2.87%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08% - 12.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% - 8.10% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.30% - 7.20%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.60% - 7.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% - 4.83%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. plans target asset allocations at April&#160;26, 2024, compared to the U.S. plans actual asset allocations at April&#160;26, 2024 and April&#160;28, 2023 by asset category, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target Allocation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;26, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;26, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;28, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Category:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock', window );">Schedule of Fair Value Measurements, Retirement Benefit Plan Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;26, 2024 and April&#160;28, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Pension Benefits</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-U.S. Pension Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock', window );">Schedule of Retirement Benefit Plan Assets, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a reconciliation of the beginning and ending balances of U.S. pension benefit assets measured at fair value that used significant unobservable inputs (Level 3):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partnership Units</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;29, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total realized gains, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;28, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Benefit Payments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 &#8211; 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure related to retirement benefit plan assets that are measured at fair value in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of retirement benefit plan assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (d)(5)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (f)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (h)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182432320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Balance Sheet Classification of Operating Leases and Amounts of Right-of-Use Assets and Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;26, 2024 and April&#160;28, 2023: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2346"><span style="-sec-ix-hidden:f-2347">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2350"><span style="-sec-ix-hidden:f-2351">Other accrued expenses</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2354"><span style="-sec-ix-hidden:f-2355">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;26, 2024 and April&#160;28, 2023: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 Years</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022: </span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2024, 2023, and 2022:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company's operating leases at April&#160;26, 2024:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expected lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185645088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Loss) Gain on Investment Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in Retirement Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(519)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,458)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,347)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,485)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,080)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,265)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,234)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,686)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,318)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183609360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 26, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Operating Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(719)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments to the Medtronic Foundation and Medtronic LABS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Includes the net impact of remeasurement and the Company's hedging programs recorded in other operating expense (income), net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Schedule of Reconciliation of Assets and Depreciation Expense from Segments to Consolidated</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets and Depreciation Expense </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographical Region</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales for fiscal years 2024, 2023, and 2022, and property, plant, and equipment, net at April&#160;26, 2024 and April&#160;28, 2023 for the Company's country of domicile, countries with significant concentrations, and all other countries: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other countries, excluding Ireland</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,686&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182529952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Shipping and Handling</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">$ 10,736<span></span>
</td>
<td class="nump">$ 10,415<span></span>
</td>
<td class="nump">$ 10,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Shipping and Handling</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185900704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregation of Net Sales by Segment and Division (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 32,364<span></span>
</td>
<td class="nump">$ 31,227<span></span>
</td>
<td class="nump">$ 31,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember', window );">Reportable segment net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">30,731<span></span>
</td>
<td class="nump">30,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">11,831<span></span>
</td>
<td class="nump">11,522<span></span>
</td>
<td class="nump">11,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Cardiac Rhythm &amp; Heart Failure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">5,995<span></span>
</td>
<td class="nump">5,783<span></span>
</td>
<td class="nump">5,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Structural Heart &amp; Aortic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,358<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Coronary &amp; Peripheral Vascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">2,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">9,406<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
<td class="nump">8,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Cranial &amp; Spinal Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">4,756<span></span>
</td>
<td class="nump">4,451<span></span>
</td>
<td class="nump">4,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Specialty Therapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Neuromodulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">7,989<span></span>
</td>
<td class="nump">8,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | Surgical &amp; Endoscopy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">6,508<span></span>
</td>
<td class="nump">6,152<span></span>
</td>
<td class="nump">6,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | Acute Care &amp; Monitoring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,908<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
<td class="nump">2,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">$ 727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_CardiacRhythmandHeartFailureDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_CardiacRhythmandHeartFailureDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_StructuralHeartAndAorticDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_StructuralHeartAndAorticDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_CoronaryAndPeripheralVascularDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_CoronaryAndPeripheralVascularDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_CranialAndSpinalTechnologiesDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_CranialAndSpinalTechnologiesDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_SpecialtyTherapiesDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_SpecialtyTherapiesDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_NeuromodulationDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_NeuromodulationDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_SurgicalInnovationsDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_SurgicalInnovationsDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_AcuteCareMonitoringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_AcuteCareMonitoringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387283277104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 32,364<span></span>
</td>
<td class="nump">$ 31,227<span></span>
</td>
<td class="nump">$ 31,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">16,562<span></span>
</td>
<td class="nump">16,373<span></span>
</td>
<td class="nump">16,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember', window );">Non-U.S. Developed Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">9,979<span></span>
</td>
<td class="nump">9,408<span></span>
</td>
<td class="nump">10,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember', window );">Emerging Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">5,823<span></span>
</td>
<td class="nump">5,446<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember', window );">Reportable segment net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">30,731<span></span>
</td>
<td class="nump">30,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember', window );">Reportable segment net sales | U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">16,471<span></span>
</td>
<td class="nump">16,212<span></span>
</td>
<td class="nump">15,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember', window );">Reportable segment net sales | Non-U.S. Developed Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">9,929<span></span>
</td>
<td class="nump">9,245<span></span>
</td>
<td class="nump">9,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember', window );">Reportable segment net sales | Emerging Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">5,742<span></span>
</td>
<td class="nump">5,273<span></span>
</td>
<td class="nump">5,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">11,831<span></span>
</td>
<td class="nump">11,522<span></span>
</td>
<td class="nump">11,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">5,597<span></span>
</td>
<td class="nump">5,796<span></span>
</td>
<td class="nump">5,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Non-U.S. Developed Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,857<span></span>
</td>
<td class="nump">3,564<span></span>
</td>
<td class="nump">3,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Emerging Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,377<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">9,406<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
<td class="nump">8,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">6,305<span></span>
</td>
<td class="nump">6,018<span></span>
</td>
<td class="nump">5,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Non-U.S. Developed Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,739<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Emerging Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">7,989<span></span>
</td>
<td class="nump">8,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,717<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
<td class="nump">3,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | Non-U.S. Developed Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,049<span></span>
</td>
<td class="nump">2,917<span></span>
</td>
<td class="nump">3,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | Emerging Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,650<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
<td class="nump">2,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes | U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes | Non-U.S. Developed Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes | Emerging Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other operating segment | U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other operating segment | Non-U.S. Developed Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other operating segment | Emerging Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387186209424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Rebate obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">453,000,000<span></span>
</td>
<td class="nump">$ 405,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized that was previously included in deferred revenue</a></td>
<td class="nump">324,000,000<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Period over which remaining performance obligations are expected to be recognized as revenue</a></td>
<td class="text">two years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember', window );">Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Rebate obligations</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">352,000,000<span></span>
</td>
<td class="nump">314,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Rebate obligations</a></td>
<td class="nump">574,000,000<span></span>
</td>
<td class="nump">555,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 101,000,000<span></span>
</td>
<td class="nump">$ 91,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183805616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Dispositions - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 20, 2024</div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Aug. 30, 2022</div></th>
<th class="th"><div>May 13, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,986<span></span>
</td>
<td class="nump">$ 41,425<span></span>
</td>
<td class="nump">$ 40,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionPriceContingentConsideration', window );">Purchase price contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Contingent consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments and related inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,216<span></span>
</td>
<td class="nump">10,719<span></span>
</td>
<td class="nump">10,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (464)<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="num">(862)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment of intangible asset indefinite lived excluding goodwill statement of income or comprehensive income extensible enumeration not disclosed flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other operating expense, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember', window );">Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=mdt_MozarcMember', window );">Mozarc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=mdt_MozarcMember', window );">Mozarc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareSolutionsMember', window );">Renal Care Solutions | Other operating expense (income), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments and related inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareSolutionsMember', window );">Renal Care Solutions | Mozarc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Contingent consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember', window );">Disposal Group, Not Discontinued Operations | Ventilator Product Line Exit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business exit costs</a></td>
<td class="nump">$ 439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet', window );">Discontinued operation, other operating expense, net</a></td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments', window );">Non-cash impairments</a></td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember', window );">Disposal Group, Not Discontinued Operations | Renal Care Solutions | Mozarc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Contingent consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Payments to acquire long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember', window );">Disposal Group, Not Discontinued Operations | Mechanical Circulatory Support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business exit costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments', window );">Non-cash impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration for the transaction, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLossNetOfTax', window );">Goodwill, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillNotAllocatedAmount', window );">Goodwill, non deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business combinations | Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business combinations | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_IntersectENTMember', window );">Intersect ENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration for the transaction, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Shares price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Previously held investments in Intersect ENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_IntersectENTMember', window );">Intersect ENT | Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_IntersectENTMember', window );">Intersect ENT | Customer-related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_IntersectENTMember', window );">Intersect ENT | Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_AfferaIncMember', window );">Affera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration for the transaction, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_AfferaIncMember', window );">Affera | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_OtherAcquisitionsMember', window );">Other Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionPriceContingentConsideration', window );">Purchase price contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_OtherAcquisitionsMember', window );">Other Acquisitions | Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Consideration, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionPriceContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Price Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionPriceContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Non-cash Impairments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of loss recognized that results from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillNotAllocatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of goodwill not yet allocated to reportable segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillNotAllocatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=mdt_MozarcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=mdt_MozarcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=mdt_MozarcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=mdt_MozarcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_MechanicalCirculatorySupportMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_MechanicalCirculatorySupportMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mdt_IntersectENTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mdt_IntersectENTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mdt_AfferaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mdt_AfferaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mdt_OtherAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mdt_OtherAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182646752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and Dispositions - Schedule of Fair Value of the Assets Acquired and Liabilities Assumed - Intersect ENT Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Aug. 30, 2022</div></th>
<th class="th"><div>May 13, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 40,986<span></span>
</td>
<td class="nump">$ 41,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_IntersectENTMember', window );">Intersect ENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdt_AfferaIncMember', window );">Affera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mdt_IntersectENTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mdt_IntersectENTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mdt_AfferaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mdt_AfferaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191035632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Dispositions - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward', window );"><strong>Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionPriceContingentConsideration', window );">Purchase price contingent consideration</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment', window );">Payments</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses', window );">Divestiture-related and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent milestone payments in business acquisition transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionContingentConsiderationMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionPriceContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Price Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionPriceContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bussiness Acquisition, Contingent Consideration, Divestiture Related and Other Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183126160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and Dispositions - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Revenue and other performance-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Revenue and other performance-based payments | Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Revenue and other performance-based payments | Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Revenue and other performance-based payments | Discount Rate | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Product development and other milestone-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Product development and other milestone-based payments | Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Product development and other milestone-based payments | Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Product development and other milestone-based payments | Discount Rate | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsQuantitativeInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsQuantitativeInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mdt_RevenueMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mdt_RevenueMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mdt_ProductDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mdt_ProductDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183266672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Dispositions - Reconciliation of Level 3 Measurement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionContingentConsiderationRollForward', window );"><strong>Beginning and Ending Balances of Contingent Payments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionPriceContingentConsideration', window );">Purchase price contingent consideration</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Ending balance</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionContingentConsiderationRollForward', window );"><strong>Beginning and Ending Balances of Contingent Payments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Beginning balance</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionPriceContingentConsideration', window );">Purchase price contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue', window );">Change in fair value</a></td>
<td class="num">(138)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Ending balance</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionContingentConsiderationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionContingentConsiderationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionPriceContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Price Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionPriceContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185654400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mdt_EnterpriseExcellenceMember', window );">Enterprise Excellence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Estimated expected restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mdt_SimplificationRestructuringProgramMember', window );">Simplification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Estimated expected restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=mdt_EnterpriseExcellenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=mdt_EnterpriseExcellenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=mdt_SimplificationRestructuringProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=mdt_SimplificationRestructuringProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182478944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Classification of Restructuring Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember', window );">Incremental defined benefit, defined contribution and post-retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185178928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Activity Related to Restructuring Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Changes in Restructuring Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_RestructuringChargesIncludingAccrualAdjustments', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(453)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accrual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Changes in Restructuring Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_RestructuringChargesIncludingAccrualAdjustments', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accrual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mdt_AssociatedAndOtherCostsMember', window );">Associated and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Changes in Restructuring Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_RestructuringChargesIncludingAccrualAdjustments', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accrual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember', window );">Incremental defined benefit, defined contribution and post-retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Changes in Restructuring Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_RestructuringChargesIncludingAccrualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Including Accrual Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_RestructuringChargesIncludingAccrualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mdt_AssociatedAndOtherCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mdt_AssociatedAndOtherCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387181758000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">$ 6,968<span></span>
</td>
<td class="nump">$ 6,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6,723<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6,690<span></span>
</td>
<td class="nump">6,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government and agency securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government and agency securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">6,438<span></span>
</td>
<td class="nump">6,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6,218<span></span>
</td>
<td class="nump">5,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6,218<span></span>
</td>
<td class="nump">5,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government and agency securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government and agency securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">3,953<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">3,832<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">3,832<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Mortgage-backed securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Mortgage-backed securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Non-U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Non-U.S. government and agency securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Non-U.S. government and agency securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of deposit | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of deposit | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Other asset-backed securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Other asset-backed securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Auction rate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Auction rate securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Auction rate securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185781712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">4,296<span></span>
</td>
<td class="nump">4,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">2,448<span></span>
</td>
<td class="nump">2,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">502<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember', window );">Auction rate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183793408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Fair value, option gain (loss)</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=mdt_MozarcMember', window );">Mozarc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mdt_EquityInvestmentsMember', window );">Equity and Other Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized (losses) and gains on equity and other investments still held</a></td>
<td class="num">$ (291)<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=mdt_MozarcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=mdt_MozarcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mdt_EquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mdt_EquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185657248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract', window );"><strong>Activities Related to Debt Securities Portfolio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales</a></td>
<td class="nump">$ 7,359<span></span>
</td>
<td class="nump">$ 7,321<span></span>
</td>
<td class="nump">$ 9,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized gains</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">3,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Total</a></td>
<td class="nump">6,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>AFS Debt Maturities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">3,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years</a></td>
<td class="nump">967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 6,723<span></span>
</td>
<td class="nump">$ 6,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182433744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Equity and Other Investments (Details) - Other Assets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments with readily determinable fair value (marketable equity securities)</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Investments for which the fair value option has been elected</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investments without readily determinable fair values</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method and other investments</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments', window );">Total equity and other investments</a></td>
<td class="nump">$ 1,282<span></span>
</td>
<td class="nump">$ 1,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191060704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Debt and Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Beginning Balance</a></td>
<td class="nump">$ 311<span></span>
</td>
<td class="nump">$ 531<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Initial valuation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_AdditionalCashInvestment', window );">Additional cash investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions', window );">Change in fair value</a></td>
<td class="num">(220)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Ending Balance</a></td>
<td class="nump">$ 311<span></span>
</td>
<td class="nump">$ 531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_AdditionalCashInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_AdditionalCashInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183025216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing Arrangements - Current Debt Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial Paper</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current debt obligations</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current debt obligations<span></span>
</td>
<td class="text">Current debt obligations<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Bank borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank borrowings</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387283069504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements - Narrative (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 03, 2024 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 12, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Jan. 26, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,092,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings (maturities greater than 90 days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,284,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest expense on outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916,000,000<span></span>
</td>
<td class="nump">743,000,000<span></span>
</td>
<td class="nump">$ 553,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000,000<span></span>
</td>
<td class="nump">24,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Estimated fair value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200,000,000<span></span>
</td>
<td class="nump">21,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | Medtronic Luxco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of debt | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 300,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings (maturities greater than 90 days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="nump">&#165; 297,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | Medtronic Luxco | TIBOR Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin added per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A2015CommercialPaperProgramMember', window );">2015 Commercial Paper Program | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CommercialPaperMaximumBorrowingCapacity', window );">Commercial paper, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_AmendedandRestatedRevolvingCreditAgreementMember', window );">$3.5 Billion Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_LineOfCreditFacilityLengthOfExtension', window );">Length of extension from maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Committed line of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_MedtronicLuxcoSeniorNotesMember', window );">Medtronic Luxco Senior Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Redemption of senior notes, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 772,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Redemption of senior notes, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="nump">$ 2,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_MedtronicLuxcoSeniorNotesMember', window );">Medtronic Luxco Senior Notes | Senior Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of debt</a></td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Proceeds from debt</a></td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_MedtronicLuxcoSeniorNotesMember', window );">Medtronic Luxco Senior Notes | Senior Notes | Medtronic Luxco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtInstrumentNumberofTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_MedtronicLuxcoSeniorNotesMember', window );">Medtronic Luxco Senior Notes | Senior Notes | Medtronic Luxco | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtInstrumentNumberofTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20253.500PercentMember', window );">Senior Notes 2015 Due 2025, 3.500 percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20253.500PercentMember', window );">Senior Notes 2015 Due 2025, 3.500 percent | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Redemption of senior notes, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2017Due20273.350PercentMember', window );">Senior Notes 2017 Due 2027, 3.350 Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2017Due20273.350PercentMember', window );">Senior Notes 2017 Due 2027, 3.350 Percent | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Redemption of senior notes, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CommercialPaperMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial Paper, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CommercialPaperMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DebtInstrumentNumberofTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DebtInstrumentNumberofTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_LineOfCreditFacilityLengthOfExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Length of Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_LineOfCreditFacilityLengthOfExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mdt_MedtronicLuxcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mdt_MedtronicLuxcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=mdt_TokyoInterBankOfferedRateTIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=mdt_TokyoInterBankOfferedRateTIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A2015CommercialPaperProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A2015CommercialPaperProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_AmendedandRestatedRevolvingCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_AmendedandRestatedRevolvingCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_MedtronicLuxcoSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_MedtronicLuxcoSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20253.500PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20253.500PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2017Due20273.350PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2017Due20273.350PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183052864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements - Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount, net</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">$ 23,932<span></span>
</td>
<td class="nump">$ 24,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">10.17%<span></span>
</td>
<td class="nump">9.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-term debt<span></span>
</td>
<td class="text">Long-term debt<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.250 percent six-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">0.44%<span></span>
</td>
<td class="nump">0.44%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.625 percent three-year 2022 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">2.86%<span></span>
</td>
<td class="nump">2.86%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.000 percent five-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">0.23%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.125 percent eight-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,606<span></span>
</td>
<td class="nump">$ 1,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.250 percent five-year 2023 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.42%<span></span>
</td>
<td class="nump">4.42%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.000 percent six-year 2022 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.09%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.375 percent eight-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">0.51%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625 percent twelve-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.000 percent twelve-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.06%<span></span>
</td>
<td class="nump">1.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.125 percent nine-year 2022 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.750 percent twelve-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">0.81%<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.500 percent ten-year 2023 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.62%<span></span>
</td>
<td class="nump">4.62%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.375 percent twelve-year 2022 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">3.44%<span></span>
</td>
<td class="nump">3.44%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375 percent twenty-year 2015 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,932<span></span>
</td>
<td class="nump">$ 1,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.47%<span></span>
</td>
<td class="nump">4.47%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.550 percent thirty-year 2007 CIFSA senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.67%<span></span>
</td>
<td class="nump">4.67%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250 percent twenty-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">2.34%<span></span>
</td>
<td class="nump">2.34%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.500 percent thirty-year 2009 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">6.56%<span></span>
</td>
<td class="nump">6.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.500 percent twenty-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.58%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.550 percent thirty-year 2010 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">5.58%<span></span>
</td>
<td class="nump">5.58%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.375 percent twenty-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.500 percent thirty-year 2012 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.54%<span></span>
</td>
<td class="nump">4.54%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.000 percent thirty-year 2013 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.09%<span></span>
</td>
<td class="nump">4.09%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625 percent thirty-year 2014 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.67%<span></span>
</td>
<td class="nump">4.67%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625 percent thirty-year 2015 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.69%<span></span>
</td>
<td class="nump">4.69%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.750 percent thirty-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.87%<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625 percent thirty-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A2625PercentThreeYear2022SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A2625PercentThreeYear2022SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A4250PercentFiveYear2023SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A4250PercentFiveYear2023SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A3000PercentSixYear2022SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A3000PercentSixYear2022SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A3125PercentNineYear2022SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A3125PercentNineYear2022SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A4500PercentTenYear2023SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A4500PercentTenYear2023SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A3375PercentTwelveYear2022SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A3375PercentTwelveYear2022SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotesCIFSA2007Due2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotesCIFSA2007Due2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2009Due2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2009Due2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2010Due2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2010Due2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2012Due2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2012Due2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2013Due2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2013Due2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2014Due2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2014Due2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387177268592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing Arrangements - Long-term Debt Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">2,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2028</a></td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2029</a></td>
<td class="nump">2,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">16,649<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 25,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387176489232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain on interest rate cash flow hedges</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Cash flow hedge unrealized gains to be reclassified over the next twelve months</a></td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Derivative, excluded component, gain (loss), recognized in earnings</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Interest expense, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash', window );">Net cash collateral received</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Derivatives designated as hedging instruments | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Maximum remaining maturity of foreign currency derivatives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss), net of tax as of the balance sheet date, related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480870/815-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -SubTopic 20<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480627/815-20-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) recognized in earnings from excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4D<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387176267184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management- Outsatnding instruments (Details)<br> &#8364; in Billions, &#165; in Billions, $ in Billions</strong></div></th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Derivatives designated as hedging instruments | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">&#8364; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Derivatives not designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Cash flow hedges | Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Net investment hedges | Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Net investment hedges | Derivatives designated as hedging instruments | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember', window );">Foreign currency denominated debt | Net investment hedges | Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">$ 17.1<span></span>
</td>
<td class="nump">&#8364; 16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185072768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</a></td>
<td class="num">$ (1,173)<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="num">$ (3,234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax', window );">(Gain) Loss Reclassified into Income</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(706)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Recognized in AOCI, net investment hedges</a></td>
<td class="num">(202)<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Reclassified into Income, net investment hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Other operating expense (income), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Recognized in AOCI, Cash flow hedges</a></td>
<td class="num">(416)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="num">(953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Recognized in income, cash flow hedges</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">(703)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Recognized in AOCI, Cash flow hedges</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Recognized in income, cash flow hedges</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember', window );">Foreign currency denominated debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Recognized in AOCI, net investment hedges</a></td>
<td class="num">(431)<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="num">(2,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Reclassified into Income, net investment hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before TaxeclassificationBeforeTax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480627/815-20-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387177616448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember', window );">Other operating expense (income), net | Currency exchange rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative instruments not designated as hedging instruments, (gain) loss, net</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182316368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments | Currency exchange rate contracts | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments | Currency exchange rate contracts | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments | Currency exchange rate contracts | Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387299821856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other accrued expenses<span></span>
</td>
<td class="text">Other accrued expenses<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183388096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Derivative assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetLiabilityAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="nump">593<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction', window );">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash', window );">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet', window );">Net Amount</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Derivative assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral', window );">Net Amount</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral', window );">Net Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset (Liability) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset (Liability), Fair Value, Gross Asset (Liability)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-13<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-13<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount as of the balance sheet date of the fair value of derivative assets and derivative liabilities that in accordance with the entity's accounting policy were offset against collateral under a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387186429040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 3,668<span></span>
</td>
<td class="nump">$ 3,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 5,217<span></span>
</td>
<td class="nump">$ 5,293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185204320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Changes in Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 41,425<span></span>
</td>
<td class="nump">$ 40,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Sale of RCS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="num">(565)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">40,986<span></span>
</td>
<td class="nump">41,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">7,873<span></span>
</td>
<td class="nump">7,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Sale of RCS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">7,966<span></span>
</td>
<td class="nump">7,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">11,718<span></span>
</td>
<td class="nump">11,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Sale of RCS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">11,644<span></span>
</td>
<td class="nump">11,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">19,579<span></span>
</td>
<td class="nump">19,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Sale of RCS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="num">(458)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">19,121<span></span>
</td>
<td class="nump">19,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">2,255<span></span>
</td>
<td class="nump">2,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Sale of RCS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="nump">$ 2,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182654672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 20, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>segment</div>
</th>
<th class="th">
<div>Jul. 28, 2023 </div>
<div>reportingUnit </div>
<div>segment</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 29, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment of intangible asset finite lived statement of income or comprehensive income extensible enumeration not disclosed flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other operating expense, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,693,000,000<span></span>
</td>
<td class="nump">1,698,000,000<span></span>
</td>
<td class="nump">1,733,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareBusinessRCSMember', window );">Renal Care Business (RCS) | Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Transfer to held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember', window );">Ventilator Product Line Exit | Disposal Group, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">$ 295,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_MechanicalCirculatorySupportMember', window );">Mechanical Circulatory Support | Disposal Group, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_IPRDMember', window );">IPR&amp;D | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareBusinessRCSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareBusinessRCSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_MechanicalCirculatorySupportMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_MechanicalCirculatorySupportMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_IPRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_IPRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185907696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 28,755<span></span>
</td>
<td class="nump">$ 29,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(15,915)<span></span>
</td>
<td class="num">(14,605)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember', window );">Customer-related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">16,518<span></span>
</td>
<td class="nump">16,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(8,689)<span></span>
</td>
<td class="num">(7,979)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mdt_PurchasedTechnologyAndPatentsMember', window );">Purchased technology and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">11,557<span></span>
</td>
<td class="nump">11,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,868)<span></span>
</td>
<td class="num">(6,277)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and tradenames</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(274)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (84)<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mdt_PurchasedTechnologyAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mdt_PurchasedTechnologyAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191130144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">1,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">1,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">$ 1,471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387186277776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 14,052<span></span>
</td>
<td class="nump">$ 14,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(7,922)<span></span>
</td>
<td class="num">(8,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, net</a></td>
<td class="nump">6,131<span></span>
</td>
<td class="nump">5,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 954<span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 6,396<span></span>
</td>
<td class="nump">6,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 2,872<span></span>
</td>
<td class="nump">2,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and land improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdt_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 2,506<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdt_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdt_BuildingsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdt_BuildingsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387297424656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br> $ / shares in Units, $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredStockSharesAuthorized', window );">Deferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredStockParorStatedValuePerShare', window );">Deferred stock, par value (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredStockSharesIssued', window );">Deferred stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredStockSharesOutstanding', window );">Deferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_StockRepurchaseProgramAveragePurchasePrice', window );">Average repurchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 83.04<span></span>
</td>
<td class="nump">$ 91.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount authorized for repurchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Amount repurchased | $</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available for future repurchases | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredStockParorStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Stock, Par or Stated Value Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredStockParorStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Stock, Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Stock, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Stock, Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_StockRepurchaseProgramAveragePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average purchase price of common shares under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_StockRepurchaseProgramAveragePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387176269312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Oct. 19, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to outstanding stock options</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to restricted stock awards</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to restricted stock awards</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mdt_A2024EmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares purchased by employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">The discount rate from market value on purchase date</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod', window );">Shares purchased by employees (in shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare', window );">Average purchase price (in dollars per share)</a></td>
<td class="nump">$ 71.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future purchase (in shares)</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mdt_A2024EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mdt_A2024EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387184318304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefits</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Total stock-based compensation expense, net of tax</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mdt_EmployeesStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mdt_EmployeesStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mdt_EmployeesStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191005936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Valuation Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 18.49<span></span>
</td>
<td class="nump">$ 17.76<span></span>
</td>
<td class="nump">$ 22.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.16%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">24.29%<span></span>
</td>
<td class="nump">24.05%<span></span>
</td>
<td class="nump">23.04%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">3.18%<span></span>
</td>
<td class="nump">2.92%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387193323856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Stock Options Activity (Details) - Stock options - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">30,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">4,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired/Forfeited (in shares)</a></td>
<td class="num">(1,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">32,339<span></span>
</td>
<td class="nump">30,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Expected to vest (in shares)</a></td>
<td class="nump">8,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable (in shares)</a></td>
<td class="nump">22,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Wtd. Avg. Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 93.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">86.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">65.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/Forfeited (in dollars per share)</a></td>
<td class="nump">98.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">93.32<span></span>
</td>
<td class="nump">$ 93.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expected to vest (in dollars per share)</a></td>
<td class="nump">95.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 92.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Expected to vest</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Expected to vest</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from options exercised</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit related to options exercised</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185705776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Restricted Stock Activity (Details) - Restricted stock - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares)</a></td>
<td class="nump">5,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares)</a></td>
<td class="nump">6,142<span></span>
</td>
<td class="nump">5,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Wtd. Avg. Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 102.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">82.80<span></span>
</td>
<td class="nump">$ 91.83<span></span>
</td>
<td class="nump">$ 127.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">102.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">99.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 92.57<span></span>
</td>
<td class="nump">$ 102.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock vested</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit related to restricted stock vested</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387178250512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Performance Share Unit Activity (Details) - Performance share units - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares)</a></td>
<td class="nump">2,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments', window );">Performance adjustments (in shares)</a></td>
<td class="num">(455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares)</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Wtd. Avg. Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 119.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">104.78<span></span>
</td>
<td class="nump">$ 98.17<span></span>
</td>
<td class="nump">$ 149.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">129.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments', window );">Performance adjustments (in dollar per share)</a></td>
<td class="nump">147.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">113.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 106.50<span></span>
</td>
<td class="nump">$ 119.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock vested</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit related to restricted stock vested</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182290304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 1,295<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
<td class="nump">5,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">$ 4,837<span></span>
</td>
<td class="nump">$ 5,364<span></span>
</td>
<td class="nump">$ 5,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387296978624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax (Benefit) Provision (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S.</a></td>
<td class="nump">$ 756<span></span>
</td>
<td class="nump">$ 1,303<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax (benefit) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S.</a></td>
<td class="num">(435)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="num">(402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International</a></td>
<td class="num">(93)<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Net deferred tax benefit</a></td>
<td class="num">(528)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="num">(611)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 1,133<span></span>
</td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="nump">$ 456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185798176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards', window );">Net operating loss, capital loss, and credit carryforwards</a></td>
<td class="nump">$ 11,775<span></span>
</td>
<td class="nump">$ 10,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">2,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization', window );">Capitalization of research and development</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions', window );">Pension and post-retirement benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsLeaseObligations', window );">Lease obligations</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions', window );">Federal and state benefit on uncertain tax positions</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsInterestLimitation', window );">Interest limitation</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives', window );">Unrealized gain on available-for-sale securities and derivative financial instruments</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">18,277<span></span>
</td>
<td class="nump">16,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(13,271)<span></span>
</td>
<td class="num">(11,311)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">5,006<span></span>
</td>
<td class="nump">4,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(1,406)<span></span>
</td>
<td class="num">(1,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Realized loss on derivative financial instruments</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use leases</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries', window );">Outside basis difference of subsidiaries</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits', window );">Pension and post-retirement benefits</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,960)<span></span>
</td>
<td class="num">(2,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income taxes</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income tax receivables</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Tax assets, net</a></td>
<td class="nump">3,972<span></span>
</td>
<td class="nump">3,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract', window );"><strong>Reported as (after valuation allowance and jurisdictional netting):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsNetofValuationAllowanceOther', window );">Other current assets</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Tax assets</a></td>
<td class="nump">3,657<span></span>
</td>
<td class="nump">3,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="num">$ (515)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsInterestLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsInterestLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsNetofValuationAllowanceOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net of Valuation Allowance, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsNetofValuationAllowanceOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss, capital loss and tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Research and Development Capitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from pension and postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of estimated future tax deductions arising from the federal and state benefit on uncertain tax positions, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Investment In Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Pension And Post-retirement Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387186216544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed earnings from non-U.S. subsidiaries</a></td>
<td class="nump">$ 86,300<span></span>
</td>
<td class="nump">$ 83,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration', window );">Tax credit carryforward, no expiration</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">13,271<span></span>
</td>
<td class="nump">11,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Income tax charge</a></td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Certain tax adjustments, provision (benefit)</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets', window );">Intercompany sale of assets</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount</a></td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization', window );">Tax expense associated with the amortization of the previously established deferred tax assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion', window );">Tax expense related to internal restructuring and intercompany sale of assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount', window );">Effective income tax rate reconciliation, tax adjustments for reserves, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount', window );">Effective income tax reconciliation, disallowance of interest deductions, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Deferred tax assets, unrealized currency losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlements', window );">Charge associated with tax basis for Swiss Cantonal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount', window );">Tax expense (benefit) related to tax basis adjustment, intercompany intellectual property transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Gross unrecognized tax benefits, net of cash advance, noncurrent liability</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated reasonably possible decrease in uncertain tax positions excluding interest over the next 12 months</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_IncomeTaxExaminationInterestIncomeExpenseGross', window );">Gross interest expense</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued income tax penalties and interest</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-U.S. Tax Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, no expiration</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards, expiring in future years</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Net operating loss carryforwards, valuation allowance</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxHolidays', window );">Tax reductions from tax holiday</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare', window );">Impact on diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-U.S. Tax Authorities | Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, no expiration</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Tax Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, no expiration</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Basis Adjustment of Intangible Assets, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_IncomeTaxExaminationInterestIncomeExpenseGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Interest Income (Expense), Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_IncomeTaxExaminationInterestIncomeExpenseGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxHolidays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxHolidays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482620/740-10-25-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 740<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481141/942-740-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 740<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480135/944-740-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387183634192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_IncreaseDecreaseInTaxRateAbstract', window );"><strong>Increase (decrease) in tax rate resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">U.S. state taxes, net of federal tax benefit</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax', window );">Puerto Rico excise tax</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">International</a></td>
<td class="num">(6.70%)<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="num">(10.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent', window );">Uncertain tax positions and interest</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent', window );">Base erosion anti-abuse tax</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent', window );">Foreign derived intangible income benefit</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Certain tax adjustments</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">U.S. tax on foreign earnings</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">23.40%<span></span>
</td>
<td class="nump">29.50%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to Puerto Rico excise tax from intercompany purchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_IncreaseDecreaseInTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_IncreaseDecreaseInTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182102832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at beginning of fiscal year</a></td>
<td class="nump">$ 2,682<span></span>
</td>
<td class="nump">$ 1,661<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract', window );"><strong>Gross increases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Prior year tax positions</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">980<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Current year tax positions</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract', window );"><strong>Gross decreases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Prior year tax positions</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute of limitation lapses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at end of fiscal year</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CashAdvancePaidinConnectionWithProposedSettlements', window );">Cash advance paid to taxing authorities</a></td>
<td class="num">(934)<span></span>
</td>
<td class="num">(918)<span></span>
</td>
<td class="num">(859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid', window );">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</a></td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="nump">$ 1,764<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CashAdvancePaidinConnectionWithProposedSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Advance Paid in Connection With Proposed Settlements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CashAdvancePaidinConnectionWithProposedSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net of Cash Advance Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185705648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to ordinary shareholders</a></td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">$ 3,758<span></span>
</td>
<td class="nump">$ 5,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic - weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,327.7<span></span>
</td>
<td class="nump">1,329.8<span></span>
</td>
<td class="nump">1,342.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted &#8211; weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,330.2<span></span>
</td>
<td class="nump">1,332.8<span></span>
</td>
<td class="nump">1,351.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Share based payments (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Employee restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends', window );">Employee restricted stock units (in shares)</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Employee performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Share based payments (in shares)</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares included in diluted EPS for potentially dilutive effect of nonvested equity-based payment award containing forfeitable rights to dividends or dividend equivalents, whether paid or unpaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 68B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-68B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191192064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387180595152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans - Narative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Cost of retirement benefit plans</a></td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Net underfunded status of the plans</a></td>
<td class="num">(484)<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits', window );">Incremental expense related to acceptance of voluntary early retirement packages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense under defined contribution plans</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Net underfunded status of the plans</a></td>
<td class="num">$ (357)<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated future employer contributions in next fiscal year</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Post-retirement benefit plans, net periodic benefit cost, income</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Post-retirement benefit plans, benefit obligations</a></td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">3,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits | Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits | Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Net underfunded status of the plans</a></td>
<td class="num">$ (54)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated future employer contributions in next fiscal year</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Post-retirement benefit plans, net periodic benefit cost, income</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Post-retirement benefit plans, benefit obligations</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S. | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S. | Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S. | Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S. | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other post-retirement benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Post-retirement benefit plans, net periodic benefit cost, income</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Post-retirement benefit plans, benefit obligations</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_OtherPlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_OtherPlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387311581584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract', window );"><strong>Funded status at end of year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Over (under) funded status of the plans</a></td>
<td class="nump">$ 484<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized on the consolidated balance sheets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(1,101)<span></span>
</td>
<td class="num">(1,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Plans with accumulated benefit obligations in excess of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Plans with projected benefit obligations in excess of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">UNITED STATES | Pension benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation at end of year</a></td>
<td class="nump">3,144<span></span>
</td>
<td class="nump">3,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at beginning of year</a></td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">3,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation', window );">Plan curtailments, settlements, and amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) loss</a></td>
<td class="num">(245)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency exchange rate changes and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at end of year</a></td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">3,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">356<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Plan settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency exchange rate changes and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract', window );"><strong>Funded status at end of year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligations</a></td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">3,526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Over (under) funded status of the plans</a></td>
<td class="nump">357<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Recognized asset (liability)</a></td>
<td class="nump">357<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized on the consolidated balance sheets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Recognized asset (liability)</a></td>
<td class="nump">357<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract', window );"><strong>Amounts recognized in accumulated other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service (credit) cost</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Ending balance</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Pension Benefits | Pension benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation at end of year</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at beginning of year</a></td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation', window );">Plan curtailments, settlements, and amendments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) loss</a></td>
<td class="nump">116<span></span>
</td>
<td class="num">(303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency exchange rate changes and other</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at end of year</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">103<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Plan settlements</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency exchange rate changes and other</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract', window );"><strong>Funded status at end of year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligations</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">$ 1,740<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Over (under) funded status of the plans</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Recognized asset (liability)</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized on the consolidated balance sheets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Recognized asset (liability)</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract', window );"><strong>Amounts recognized in accumulated other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service (credit) cost</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Ending balance</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSpecialTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387186009904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans - Net Periodic Cost and AOCI (Details) - Pension benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(261)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net actuarial loss (gain)</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement and curtailment (gain) loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit (credit) cost</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Amounts Recognized in AOCI</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax', window );">Amortization and settlement recognition of actuarial (gain) loss</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment', window );">Effect of exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total recognized in other comprehensive income</a></td>
<td class="num">(355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive income</a></td>
<td class="num">(378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net actuarial loss (gain)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement and curtailment (gain) loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit (credit) cost</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Amounts Recognized in AOCI</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax', window );">Amortization and settlement recognition of actuarial (gain) loss</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment', window );">Effect of exchange rates</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total recognized in other comprehensive income</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive income</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Before tax amount, net of reclassifications, of pension and other postretirement benefit plans (gain) loss included in comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange adjustment to pension and other postretirement benefit plans (gain) loss included in accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2012 Element. Before tax amount of the income statement impact of the reclassification adjustment for actuarial gain (loss) recognized as a component of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185565568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details) - Pension benefits<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Actual Allocation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Actual Allocation</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Actual Allocation</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Actual Allocation</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.54%<span></span>
</td>
<td class="nump">4.73%<span></span>
</td>
<td class="nump">4.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate &#8211; benefit obligation</a></td>
<td class="nump">4.73%<span></span>
</td>
<td class="nump">4.23%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate', window );">Discount rate &#8211; service cost</a></td>
<td class="nump">4.68%<span></span>
</td>
<td class="nump">4.12%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Discount rate &#8211; interest cost</a></td>
<td class="nump">4.73%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate &#8211; benefit obligation</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.48%<span></span>
</td>
<td class="nump">3.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate', window );">Discount rate &#8211; service cost</a></td>
<td class="nump">5.07%<span></span>
</td>
<td class="nump">4.51%<span></span>
</td>
<td class="nump">3.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Discount rate &#8211; interest cost</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">4.23%<span></span>
</td>
<td class="nump">2.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.83%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">2.85%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets</a></td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate &#8211; benefit obligation</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate', window );">Discount rate &#8211; service cost</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.24%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Discount rate &#8211; interest cost</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">26.40%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate &#8211; benefit obligation</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate', window );">Discount rate &#8211; service cost</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Discount rate &#8211; interest cost</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_OtherPlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_OtherPlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387186528160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans - Fair Value Measurement (Details) - Pension benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 3,398<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 3,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Level 3 | Partnership units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Reconciliation of Retirement Benefit Plan Assets Measured at Fair Value Using Significant Unobservable Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Total realized gains, net</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Total unrealized gains, net</a></td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,179<span></span>
</td>
<td class="nump">3,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">$ 1,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=mdt_PartnershipUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=mdt_PartnershipUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_PartnershipUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_PartnershipUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_RegisteredInvestmentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_RegisteredInvestmentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_InsuranceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_InsuranceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387179581056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefit Plans - Future Benefit Payments (Details) - Pension benefits<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Estimated Future Benefit Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2026</a></td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2027</a></td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2028</a></td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2029</a></td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2030 &#8211; 2034</a></td>
<td class="nump">1,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Estimated Future Benefit Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2025</a></td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2026</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2027</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2028</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2029</a></td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2030 &#8211; 2034</a></td>
<td class="nump">$ 417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387413668448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="nump">$ 1,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Balance Sheet Classification, Other assets</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current liability</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Balance Sheet Classification, Other accrued expenses</a></td>
<td class="text">Other accrued expenses<span></span>
</td>
<td class="text">Other accrued expenses<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current liability</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Balance Sheet Classification, Other liabilities</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387179155792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185642768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Total Operating Lease Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387177618288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182848544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total expected lease payments</a></td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 1,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182250320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 51,665,000,000<span></span>
</td>
<td class="nump">$ 52,722,000,000<span></span>
</td>
<td class="nump">$ 51,602,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">178,000,000<span></span>
</td>
<td class="num">(1,234,000,000)<span></span>
</td>
<td class="nump">1,213,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">50,420,000,000<span></span>
</td>
<td class="nump">51,665,000,000<span></span>
</td>
<td class="nump">52,722,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(3,499,000,000)<span></span>
</td>
<td class="num">(2,265,000,000)<span></span>
</td>
<td class="num">(3,485,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">457,000,000<span></span>
</td>
<td class="num">(704,000,000)<span></span>
</td>
<td class="nump">1,210,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="num">(278,000,000)<span></span>
</td>
<td class="num">(530,000,000)<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">180,000,000<span></span>
</td>
<td class="num">(1,234,000,000)<span></span>
</td>
<td class="nump">1,219,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(3,318,000,000)<span></span>
</td>
<td class="num">(3,499,000,000)<span></span>
</td>
<td class="num">(2,265,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized (Loss) Gain on Investment Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(258,000,000)<span></span>
</td>
<td class="num">(209,000,000)<span></span>
</td>
<td class="nump">92,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">29,000,000<span></span>
</td>
<td class="num">(78,000,000)<span></span>
</td>
<td class="num">(304,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="nump">17,000,000<span></span>
</td>
<td class="nump">29,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">46,000,000<span></span>
</td>
<td class="num">(49,000,000)<span></span>
</td>
<td class="num">(301,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(212,000,000)<span></span>
</td>
<td class="num">(258,000,000)<span></span>
</td>
<td class="num">(209,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="num">(21,000,000)<span></span>
</td>
<td class="num">(51,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassifications from AOCI, tax expense (benefit)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Cumulative Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(2,839,000,000)<span></span>
</td>
<td class="num">(2,599,000,000)<span></span>
</td>
<td class="num">(519,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(846,000,000)<span></span>
</td>
<td class="num">(240,000,000)<span></span>
</td>
<td class="num">(2,080,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(846,000,000)<span></span>
</td>
<td class="num">(240,000,000)<span></span>
</td>
<td class="num">(2,080,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(3,686,000,000)<span></span>
</td>
<td class="num">(2,839,000,000)<span></span>
</td>
<td class="num">(2,599,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="num">(8,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember', window );">Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">245,000,000<span></span>
</td>
<td class="nump">841,000,000<span></span>
</td>
<td class="num">(1,458,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">633,000,000<span></span>
</td>
<td class="num">(596,000,000)<span></span>
</td>
<td class="nump">2,299,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">633,000,000<span></span>
</td>
<td class="num">(596,000,000)<span></span>
</td>
<td class="nump">2,299,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">878,000,000<span></span>
</td>
<td class="nump">245,000,000<span></span>
</td>
<td class="nump">841,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Net Change in Retirement Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(741,000,000)<span></span>
</td>
<td class="num">(773,000,000)<span></span>
</td>
<td class="num">(1,347,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">205,000,000<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="nump">514,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">212,000,000<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
<td class="nump">574,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(529,000,000)<span></span>
</td>
<td class="num">(741,000,000)<span></span>
</td>
<td class="num">(773,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="nump">79,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">134,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassifications from AOCI, tax expense (benefit)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gain (Loss) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">93,000,000<span></span>
</td>
<td class="nump">474,000,000<span></span>
</td>
<td class="num">(253,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">438,000,000<span></span>
</td>
<td class="nump">184,000,000<span></span>
</td>
<td class="nump">781,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="num">(302,000,000)<span></span>
</td>
<td class="num">(565,000,000)<span></span>
</td>
<td class="num">(54,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">136,000,000<span></span>
</td>
<td class="num">(381,000,000)<span></span>
</td>
<td class="nump">727,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">229,000,000<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
<td class="nump">474,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="nump">103,000,000<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
<td class="nump">152,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassifications from AOCI, tax expense (benefit)</a></td>
<td class="nump">$ 66,000,000<span></span>
</td>
<td class="nump">$ 133,000,000<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387297423456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 15, 2024 </div>
<div>lawsuit </div>
<div>plantiff </div>
<div>claim</div>
</th>
<th class="th">
<div>May 14, 2024 </div>
<div>plantiff </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Feb. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Certain litigation charges, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued litigations charges | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember', window );">Hernia Mesh Litigation | Pending Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs (in plaintiffs)</a></td>
<td class="nump">8,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claimants (in claimants) | claim</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_LossContingencyLawsuitsNumber', window );">Loss contingency, lawsuits, number | lawsuit</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember', window );">Hernia Mesh Litigation | Pending Litigation | Massachusetts | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs (in plaintiffs)</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember', window );">Hernia Mesh Litigation | Pending Litigation | Minnesota | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs (in plaintiffs)</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_ColibriMember', window );">Colibri</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Amount of settlement paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_DiabetesPumpRetainerRingLitigationMember', window );">Diabetes Pump Retainer Ring Litigation | California | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs (in plaintiffs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_LossContingencyLawsuitsNumber', window );">Loss contingency, lawsuits, number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mdt_ColibriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mdt_ColibriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mdt_DiabetesPumpRetainerRingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mdt_DiabetesPumpRetainerRingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387191366720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Jul. 28, 2023</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reporting segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387186111744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,144<span></span>
</td>
<td class="nump">$ 5,485<span></span>
</td>
<td class="nump">$ 5,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,693)<span></span>
</td>
<td class="num">(1,698)<span></span>
</td>
<td class="num">(1,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(393)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and associated costs</a></td>
<td class="num">$ (300)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
<td class="num">(335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Certain litigation charges, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,837<span></span>
</td>
<td class="nump">5,364<span></span>
</td>
<td class="nump">5,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,979<span></span>
</td>
<td class="nump">11,664<span></span>
</td>
<td class="nump">12,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,474<span></span>
</td>
<td class="nump">4,522<span></span>
</td>
<td class="nump">4,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
<td class="nump">3,712<span></span>
</td>
<td class="nump">3,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
<td class="nump">3,048<span></span>
</td>
<td class="nump">3,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Other operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment reconciling items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CorporateOverhead', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,784)<span></span>
</td>
<td class="num">(1,763)<span></span>
</td>
<td class="num">(1,724)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(719)<span></span>
</td>
<td class="num">(636)<span></span>
</td>
<td class="num">(553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,693)<span></span>
</td>
<td class="num">(1,698)<span></span>
</td>
<td class="num">(1,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(393)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
<td class="num">(358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CentralizedDistributionCosts', window );">Centralized distribution costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,609)<span></span>
</td>
<td class="num">(1,558)<span></span>
</td>
<td class="num">(1,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ForeignCurrencyCosts', window );">Currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">465<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and associated costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
<td class="num">(335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition and divestiture-related items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(777)<span></span>
</td>
<td class="num">(345)<span></span>
</td>
<td class="num">(838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Certain litigation charges, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ImpairmentofInProcessResearchandDevelopment', window );">IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_MedicalDeviceRegulations', window );">Medical device regulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_SpecialChargesGains', window );">Commitments to the Medtronic Foundation and Medtronic LABS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CentralizedDistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Centralized Distribution Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CentralizedDistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CorporateOverhead">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate overhead expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CorporateOverhead</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ForeignCurrencyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ForeignCurrencyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ImpairmentofInProcessResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of In Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ImpairmentofInProcessResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_MedicalDeviceRegulations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Device Regulations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_MedicalDeviceRegulations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_SpecialChargesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Charges (Gains)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_SpecialChargesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387182122656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">$ 89,981<span></span>
</td>
<td class="nump">$ 90,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">954<span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">71,980<span></span>
</td>
<td class="nump">73,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">16,128<span></span>
</td>
<td class="nump">16,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">18,270<span></span>
</td>
<td class="nump">18,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">33,586<span></span>
</td>
<td class="nump">34,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">3,996<span></span>
</td>
<td class="nump">3,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Other operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">17,455<span></span>
</td>
<td class="nump">16,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387180444784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 32,364<span></span>
</td>
<td class="nump">$ 31,227<span></span>
</td>
<td class="nump">$ 31,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">6,131<span></span>
</td>
<td class="nump">5,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingIrelandMember', window );">Total other countries, excluding Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">32,251<span></span>
</td>
<td class="nump">31,129<span></span>
</td>
<td class="nump">31,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">5,879<span></span>
</td>
<td class="nump">5,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">16,562<span></span>
</td>
<td class="nump">16,373<span></span>
</td>
<td class="nump">16,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">4,593<span></span>
</td>
<td class="nump">4,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">15,689<span></span>
</td>
<td class="nump">14,756<span></span>
</td>
<td class="nump">$ 15,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140387185012576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Allowance for Doubtful Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Fiscal Year</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charges to Income</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charges to Other Accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other Changes (Debit) Credit</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Fiscal Year</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Deferred Tax Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Fiscal Year</a></td>
<td class="nump">11,311<span></span>
</td>
<td class="nump">6,583<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charges to Income</a></td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">4,779<span></span>
</td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments', window );">Charge to adjustments</a></td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charges to Other Accounts</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet', window );">Charges to Other Accounts, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other Changes (Debit) Credit</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Other Changes (Debit) Credit, Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Fiscal Year</a></td>
<td class="nump">$ 13,271<span></span>
</td>
<td class="nump">$ 11,311<span></span>
</td>
<td class="nump">$ 6,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>156
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MNEI;J:>5&1".0F5(4"] T>20N!GXY@U]?^1=U#33ET\SP%=&!+4 %$V.B'N
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M#FV(O7_ ]_[!GI<%KO(R*V<YV^7V)]7ZK[VNZ_[<&BL-_=5K98AFOG[J0?4
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M=@C9&'/9&,-E8PR5#2@M1='D-+ELC&&R82$Y3O'$C'..<0C9F'#9F!PJ&Q9
M5S74.9D'NN:$HLDY<=>8H%S# M)5#?,PY[2&<(T)=XV)V35\K;^KJX89Y[K.
M06DIBB9'R5UC G>-"=0UH+0419/3Y*XQ@;F&A>0XQ1,SSCG&(5QCPEUC<JAK
M6 ";JJ$\164>Z1S4$+(QX;(Q0<F&!:0M&U#90-'DM+AL3&Q7-G2WF&C*!E0V
MH+0419.C%)I?P&5C I4-*"U%T>0TN6Q,8+)A(3E.\<2,<XYQ"-F8<MF8'BH;
M%L"F;"AOOC6/= T*19.#XK8Q1=F&!:0K&^9ASFD-81M3;AM3VVU48\UIWU#U
MABN79ISK0@>EI2B:'"6WC2G<-J90VX#24A1-3I/;QA1F&Q:2XQ1/S#CG&(>P
MC2FWC>FAMF$!]&5#G1-4-E T.2<N&U.4;%A VJH!E0T434Z+R\;4)ANZ.Q-#
MU3N<79IQSNL<5#90-#E*+AM3N&Q,H;(!I:4HFIRFT(\/)AL6DN,43\PXYQB'
MZ=$G-ND[5#=LA+YP**.RC'3-"H;;"4MHR.>AE,-&TE4/RSCWR 9IPN<%0F2V
M.ZHFNL-+]7:UEQ:>ZZ*'Q:4PW$Z>0@L^#RX?STA8I-C>?"C<3J1"=SX/9B V
ME.-L3RP\]RR'D!#?$YKW>8=JB(W0EQ--6-@6?BC<3EA"$S\/Y2(VDKZ<8%OZ
MH7 [D0E-_3RSD 3:-X$+E3?H6GCN:Q^VZ1\*MY.GT/;/@UO),Q(6*;8?( JW
M$ZG0$="#J8D-Y3C;$PO//<M![$1L(6[I\KU'.;$0^G(R55Y$MPQU3FN@=N%B
MOW"8GEA(VGJ";A$^B)Z(3<(M+;W]DY'N#A5U/8$V]$ZPN!2&V\E3T!,?KR?0
M7M\)%I?"<#N1"GIBZ?GM4D\L*,?9GEAX[ED.HB=B;W%+;_!]ZLD>>C)57EVW
M#'5/:Q _$9N,6YJ$N]23;_03<,OQ87J.BTW'+0W#?>W9Y$C51/S2PG-?_+!^
M,DQ7<K$MN8_W$VB#\02+2V&XG4@%/[$T&G>J)[97A3C-]L3"<\]R$#\1&IK[
MEO[C>]03"Z&K)Y&G]A-L&W,8;B<MP4\L?<<=ZHF%I*TGV![F,-Q.9(*?6-J/
M1R>^Y@Q I&J2>&GA.2]^V)[F,-Q.GH*?!'@_@78J3["X%(;;B53P$TNK<I=Z
M8D$YSO;$PG//<A _$?JA^Y8&YOO4$[N?1*&FGF#]9) ^Z+[0"-VW="IWJ2??
MZ"?8GN<PW$YD@I]8^I7[VGLD(_7Y+F@?\P2+2V&XG3P%/PGP?H)MDX[%I3#<
M3J2"GUBZJ#O5$YN?.,WVQ,)SSW(0/Q&:J_N6/NA[U!,+H:\GZK"P;<QAN)VP
M!#VQM!]W*"<6DK:<8'N8PW [D0EZ8ND[KG];B)'Z=!>T&WF"Q:4PW$Z>@IZ$
M>#V!=BY/L+@4AMN)5- 32_-REW)B03G.]L3"<\]R$#T1FJ3[EL;F^Y03NY[H
MPL+:R2#MT7VA/[IO:6?N4DZ^T4ZP7=%AN)W(!#NQ-$;7^_](?;8+VPD=BTMA
MN)T\!3O!=T/WL>W0L;@4AMN)5+ 37$MT&\IQMB<6GGN6@]B)T ;=/[@/NHW0
MEQ-U6-AFZ##<3EB"G<#ZH=M(VG*"[8@.PVTB.VT6E+9IUF;G9TM:/]"$%D5#
M9M6Z9/@NQ^U724WONT1?7@1'IVPD__'SLU7V0-]F]4->-J2@]VQH][+A(U+G
M#XOM)VVUZI#DKFK;:ME_N*#9G-;=#[#OWU?L8'WZI/L%CU7]J7]XY_\'4$L#
M!!0    ( !."U%AN%SK!/ (  ,0%   8    >&PO=V]R:W-H965T<R]S:&5E
M=#(N>&ULC91M;]HP$,>_BI5)>U61$"#M6!()VE5#@@FUVO9BV@N3',2J'S+;
M:=IO/S^$C$D0\2;VV7=__\[.7=H*^:(J (W>&.4J"RJMZWD8JJ("AM5(U,#-
MSEY(AK4QY2%4M01<NB!&PSB*DI!APH,\=6M;F:>BT91PV$JD&L:P?%\"%6T6
MC(/CPA,Y5-HNA'E:XP,\@_Y>;Z6QPEZE) RX(H(C"?LL6(SGR\3Z.X<?!%IU
M,D<VDYT0+]98E5D062"@4&BK@,WP"O= J14R&'\ZS: _T@:>SH_JCRYWD\L.
M*[@7]"<I=94%=P$J88\;JI]$^Q6Z?&96KQ!4N2]JO6_\*4!%H[1@7; A8(3[
M$;]U]W :<'LA(.X"8L?M#W*4#UCC/)6B1=)Z&S4[<:FZ: -'N'V49RW-+C%Q
M.E\T)=%HQ?WSFGM*0VUD[698=!)++Q%?D!C':".XKA3ZPDLH_Q<(#4\/%1^A
MEO&@XJ*6(Q0G-RB.XNF WJ1/<N+T)M<FB7XM=DI+\TO\/I>O5YN>5[-E,E<U
M+B +3!THD*\0Y!\_C)/H\P#KM&>=#JE[5B'1(Y$,K1[.X0T+Q).[ 8Q9CS&[
M"N,;9G".83AZ*TD!+=8@*]'8DC%-1"JT7F\'T)(>+;D*;2V*BW_LL,*&< ZX
M%I2H&^0,)30^AQ:>5!8#>7#]0Z%"-%S[(NM7^Q:U\)7YS]WWMPV6!\(5HK W
MH='HUERA]#W#&UK4KDYW0INJ=]/*M%F0UL'L[X701\,>T#?N_"]02P,$%
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M[V^DH?7=C?UVM?]6.?\/4$L#!!0    ( !."U%B/?5V8V0(  !,(   8
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M1TV4!.WGF?*C0O?$)YWXY WBF=;KUX4G_Z@)XS",XW04/T]Y7V@<7 0?@_A
MVZ2=\/0-PO$^TP:[G(G5:^K3X]7WA1Y0[^\<V?:ZO*5JQ80F')8(#@8IEE U
M5U S,;)VI_A"&KP3W+#$6QN4#<#W2RG-T\1>#-W_@.PO4$L#!!0    ( !."
MU%B&AJ/?@0D  *95   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULO5QM
MDYNV%OXKC-OI36:N8R3QYG37,XE9I,S<MIG=MO?#G?N!V-HU$PPNX-WVWU=@
MUAA):"$Y:3YD_7+TG /GX2 ]1^;J*2\^ESO.*^O/?9J5U[-=51W>+A;E9L?W
M<?DF/_!,?'.?%_NX$F^+AT5Y*'B\;0;MTP6V;6^QCY-LMKIJ/OM8K*[R8Y4F
M&?]86.5QOX^+O][S-'^ZGJ'9\P>WR<.NJC]8K*X.\0._X]5OAX^%>+<XHVR3
M/<_*),^L@M]?S]ZAMXPLZP&-Q>\)?RHO7EOUH7S*\\_UFP_;ZYE=1\13OJEJ
MB%C\>>1KGJ8UDHCCCQ9T=O99#[Q\_8P>-0<O#N937/)UGOXWV5:[ZUDPL[;\
M/CZFU6W^Q'A[0&Z-M\G3LOG?>CK9>L)X<RRK?-\.%A'LD^ST-_ZS/1$7 Q 9
M&(#; 5@:@/V! :0=0&0/WL  IQW@C/7@M@-<V</007OM $\:0(8\^.T 7P[)
M'1@0M .")KNG=#2Y#.,J7ET5^9-5U-8"K7[1$*(9+5*89#5W[ZI"?)N(<=5J
MG6=EGB;;N.);ZZX2?P0QJ]+*[ZV;/XY)]9<UMWZ["ZU7W[^VOK>2S/HI25-!
MNO)J40GW-<ABT[IZ?W*%!US]FE=QJAFV'C',NMO%!=_EZ987Y0_?!1CY/[8!
M:A!#,^(OQ3;)Q(5Z M4=R8T9X-UVF]17GHCK8YQLY^*TK.-#HC^\R(QURRM1
M8<3)OXF++,D>=.'0%\+9;([[8]JD\)=JQPMKG>]%)=O5)>:16__)2QTJ,Z/^
MG&>;/*N*7.0[>[ ^9!47)ZN2D!:";V?2X3/I< /M#$"_YP])5A^L*#MIG&VX
M]4J<PK+)QFLKKJQWA^*-1>Q_6]C&2,<T(WY=[]^6AWC#KV?B-)2\>.2SU0_?
M(<_^4<<_2+#P!.8U8/6-XW&%B./:S;^KQ>,ER2#]1I!@%!*, 8'UF$;.3",3
MF3:&72=,_R*'KH@']].WUEDY..A;A:J53 /5 GL$+?M6D<8J<)=.WXJJ5G/B
M!&[?BJE6R.^0>B?:.9]HIQE$!D[TAVPCIDZEN))#?GKUNKY;W%7YYG-;MO_U
M?$?YWZVH*9:8>CS%Q?;_N@0XD)<W)%@("78#"19!@E%(, 8$UN.E>^:E:RP
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MGMR;6&-5*G21HVQLU: I9-"(CHZ[M.52H-%#;;*46CY48S8GSE+>.ZPQ0\'
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M3I4UE6!83ODI^HH^(H)T::TZ)<;FX)A(WL2;A'C1D7B#"-U(RZ;1E2B@>$Y
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M^]G2#3UQR__,G5C6>S*_'B3H:[<K*_/="8F(,_VU.?G^KW]Y_/FC;VZ!]DF
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M2IS\5_+P^2W-"9#?-W;5!F]1I(6<!'R=N+4ZI1KW]_97HZ$G+;<:65<$M+A
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M6$\LM01I/U)"3O)FW\:2SW.> !FX3(I"1DBS9LRP S\EA?>D9K34!=A4I5S
M7CH0Y!_0245]D, =SI)U/-/HU_YM1FJS'%DD7'G-N55]AO5U[*CD2&[;@;GT
M :8H8,'XS5#ZLC3ZGWB4P% P9??&^.(H'35^Y/UAH)*?OC*F^)E\TN+Q4XT"
M#Y/2WAZ+K9$#,^--3NN1$LMG"8'/BY<$M@Q5N0-?D6V*XT/4X;&LBPM%R=#+
M>,\6^FD3X8&_,))ST/M^N_78R'?04PFLS-NF1@+5"YRF>7QDF)_T@)7O/!''
MT^L>FD+BZ/M.;%",!?\XKI^N&JQ&;9!^$N^WJZ7'<(62FC]6^II$V8=?%%OR
M8J CTM6XU3D$:GB)#1O_P8I9S'QH:%NH;QFB%R_AM+ ,]-&+=<*57\@@G^7:
M<6SDRWW3S]PQ%"2D@YI<]^76:5SZ#V:*G]**2LJ4*]MR^H;-[%$V.5:;\7FA
M5M47LP']L>,9'7N,<0+%@J>7LS#MN+2<6._1#\9: &MTMHL?:.]+'GQ[S1,B
M>^@NU&P7ONU+DP1)@5-2SF+=>=R1B\2:$T)'%%P >"(::!%8<48'TC;;^Q<J
MU]*42ZOTTE@I N6]A]33C]WC1RA1MHZM"EF8QFVXD9:"XAX)5LF3B3,<%)HL
MS@61B"4^^;;\V&Q9%6FS >!)NAMU(=:LI! /'AV[PX>7>S6SDB%40\9QU,S#
MV7R5[U<]+WXYA*$/?\ZA4FBH?>XXH<]/!OH%8BUBQ*<KL4V/[@*J1LZ.O>:9
M#)IQDO9,E1FTF\V@*H+)9^_-JO63:M/8,C4^Y1*-7!(M<?_3'SVE3X6$&D10
M0DM4F.?[A+TB3E-MVG"#:)9X,5;0HH).Q#M^F IZ&- T2:@:63;,-P00T27G
MM E  J/=&'M\TCZ>6T-, 3W?J+<?B-5J>]-)&[:4!WFG3&^H1ORZ +DN/O]&
M(\W'Q1FYFX'4OXU6DM&-,(O>P*#$T^:ZT/7K&T#ZW%/(=[B(._@Z;K[+*FD>
MGEWQ$([%S!*SS<A'U_,'"CH;D9ULX@O##/*#I%LVV_,TOII(C0^^YZ34-+Q4
M3?Y6-;0\Z(BLK_QKBK7+G"Z98CJ^":8B)UP<H,RC94_]=))"J9./[JWAKW;B
M(%IT-"OSL_N9?,G1)09$\QFX[<@#GJN1YY$=J?]!AX!2MV)V@"XIABGFO0H1
MHG.)/:K8U\C52/?BI+[J#^['D2JV*C=E7X?XR&4X:6"5:(G]X53$+"2'<B)@
M<X'C3G%YEZD1<9C0,]-\Y(UX4/)@U&:.FA>?2OZ+0'-RK-$(/AP,<2WN0>-D
MD.@,65;$]\G72#S+R)B?4"*GL?%D1U5J38L>OHG;"IQ)G:!)W2&U2Q,Y5.VL
M9-*18O9^>W:(=.";0R_8QX4$RWUOEXP&Q-"+=,'4LOH1:5#?=X)YA9,>7-*L
MW'-,GW+B)QFB6*1#-;:&NF8_<]^8%IWA_;5/5%)@5FT 0++ZE-]Y6I^"N;&G
MD/2FW!TV;'J2EWFK%><"%)/'=-W=JDZXV&]QS)W/JN&96,$VURR06L8*/<B*
M&H9@='&$Y@AMY'1-'_SH ZN>E&=H>Z]M?;L3O3F=QSG@.T]W 6UQUYR4R$AD
M$6Y!(N7JR5O",< (NNU,Y@OP^HE757A76#KV(P8^5>XOH]QK42B9D)E5P& ,
M%D(TQ"8*4--\>Y&)X!UG4Z7L7$5_)C3\I4?]=:S7OISFR_C@:_-GS[DIRK5!
MFC5>*E3O-N8(+E@VCYW^P$QP#?D,ONX^L(MWP<7MZZ+*3<,KPAQ9M'@-@S=0
M?"T'X91[BL0D+'2\+<WL<HN#+Z3-U,-HQ1L.!.>\]3#U*K,I,B<3+5-:"5GN
MY_SYV;:>>50?-._D.NFV 41(1=(>Y-&8,]1,)"?0W?%0ULHY[X4?JQP?.RF8
M0ZYKD MEQ/#XOJM]*/'@7A5/@!UMU8S;(AD#\.>LO9\_J;^=<TY$*\Y!Q6C\
M'.5FPJ;'1D%3RX&G3I)K$4YP.GER24>0+%;L-Q8K,M.OQ2WJL:/C=H2'IN05
MLHKJ='KUY9LRXN,Q*-)+9)*H_BZ29RW!:0?$BP/M.-4[JRQ-,S.Y.6WNWV'Z
MF\<)'UAIN8A76)P2V:$&? J^;MCIXN8HI4:80I@[^HP9^-.@G8/,&Q%5TA(O
M?V1J<F$1?4^T<LN.S\C%%FB+SO1HRY6>:M^MO,;0OO3&!>T;1MY1'9!VYK>2
M; ZW8R6E(5*:0&?HE:- V([KC<9;!:Z <+')+TD.IRD1DBA)[?/$5GZA45EP
MQ=9.6T<^<Z';.O3)A(D1=C76G9:\94IM'\87)45(;B[WW_D[DO9EJ^A$B8G'
M\J#^?0F*.()K\II"/I*+]R"Q8Z/W=G%W5NRK\&+BNZ9%D ,"G6WK/X[%1;9Y
M:&E.P> T"5C">P#\ 6GY!OIQ<= TP@91K*'D8,VZ#(,$26)]%O>+8\@(#>^^
M(->H;I)N,4P;(;?]1GL%9/MKS,[*P7G0W,-(2EDNY@/"%CBWM)8HIK5.I)_J
MAMQ?5\8#X@\><>7\.7OE\!#3_AV[;)MU&4/>U).0F9Z&JS*V\G5G/^X\LT3$
MLW3/7QMURUMV3(U<^\;+GA=71*Z=3V 3:#5_R2@UL;BP&ML5V00)'KVS1-(1
MPHP2A]\VC@.__IHSVI-+RT*78?#9RR,'(%G '2Y^V(C=BC*)7Z$6-0.]CPXR
MI^2)P%8.+_O3;OYR$9@>"'\8T?62)61CU9F@7=YNU0>=.#:B$L*H,S?YF(\E
M^B<7(EL+\-S"V\"Z]KV$#@J5S$#C]$ZNTY"U2DVUPA;X7Y,;?%C?;ADJ^_48
M;U$#B7FN2J]?6DP<,N/[KF8,5"@/<YT!CFN25D$IQ1JAH7B01SC5QY/<+!3O
M_B# ]EH]"!ZNIT#2SJ)Y:1<TU#)<MB91L0L7/_5I?VO@>7E/7>QCM7!P9F^X
MS3DT-79IW['N>VQ(G'/!Y5K.F,X [FPC1^.;BL($H.\Q](,R2[T?J-GJ97XR
M$:Q?)+U-XH.1')OKLLNRX_.-?I,NIQGT%7HWJM/.(1)S, 77+\,_5I$!9W=!
M0EJTK2=A4G):I;/I='27-^&$4E<:ZS%:T/X'J-&DR1IDR:HC>]AK>L<:P;)6
M5XUS: 9?3J&,68MD2H!L#6J<Q*&-7FBJ"[K)+&PRX;Q(/+*9%C$MUVD4S?=F
M,*N4$UP$8:D-GP!JQ&\7G:6DW>CWP#II& O-X1YMVK<&*@!&VFS'<Y^9:?B[
M-PWS!F,R'H  23MO"-=;&R]PC9YO]+HX2'+&30F8?N6O)8JSLVK(%GD73EFC
M(,A=CC!\ON/MOCUNTN^-',E_73YY[._(7-"_GB;_PD/TR1/_";?SI??YX;8^
MN:)/'L:=>PM?>2:X4"?XA47;W1.=T&/$=4!EZ'[8B4.O;AYG+[WS=8@N/YF>
MNX7W[_U[FX[*O$S:F=\>FZ&)\^:ALUONL@A3(7>\&I/:;E"E),_CUD<R?88;
M<'RO#B)ESL['CC4."'E5TA:=N0E,F"@-SBE_R/,)R7T)W": GKK&Z0VC805R
M6T841:6$K=.'=QZ*B^1A$+(W9V'"))TZ@?/!-Q8C7=0W:K\Z9WRW0L5L'?H9
M68_$NRQ@I/=FT.D5\5_"\FF#)%\J/:_BLR:">[7!< --ET^Q22/-RE^JD]T_
MFBHV\?W]O412=@]S:Q\ZE$5])"#.H_0()T8V'Z^ );.XEVD?G80P^!*^C!Z$
MC":$C<+J'H22AS=5]C#Q(+LE%63IK^9'R2- $VE86UQDPBZ;<S'YW+<P;J?3
MN&&1JNI'!;E,!OC"J<C/=9R5H?",Z7T N]9ECN-# (D^E%R V"L0!)'?5GMH
M&!Q1D^*@OYM8\> 5L&?K77.XNAQ%:#.V'M5?IS!(J!$<I.G]5.%B7@U/_76V
MR;6W"ST\3%BX"2E>UW!D*(*=5%K'R)V] A;<\KDEBLGQTN:"[/-)K]WA&W$
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M>F"+)E5M+L2U6$VAAT*WUU3>GU>_(HJ\OJZ*OS>'#2=J?V"E-32YA;O0T.Z
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M&/=:O_N!EI%?I9^G>9ZN^<\5OX]%#^#^(H7W^Q^T0?6_%6_^"U!+ P04
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M<8?9> V.+]Y4X>J)0S#.7^%G(3@XD #6YP;#O7DA ^O_B[C\%U!+ P04
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M8-?^^Z=NN/^*[*VT2X+R3"TP=7@Q'9_XQDUS49HU?PTU-V5I<OZY0J*@+ W
M\X4!$M<7M$#[>=S+?P%02P,$%     @ $X+46)[OZSH]#@  .2L  !D   !X
M;"]W;W)K<VAE971S+W-H965T,34N>&ULM5KI<]LV%O]7,*[;M6<46B*IP[EF
MG+C99B=I,W'2G9V=_0"1D(0-13( Z:-__?[> PF2LN0<[7ZQ0>KAX=T7^/2F
M,)_L1JE*W&ZSW#X[VE15^?CLS"8;M94V*$J5XY=58;:RPJ-9G]G2*)GRIFUV
M%H['L[.MU/G1\Z?\[IUY_K2HJTSGZIT1MMYNI;E[H;+BYMG1Y*A]\5ZO-Q6]
M.'O^M)1K=:6JC^4[@Z<SCR756Y5;7>3"J-6SHXO)XQ<QP3/ [UK=V-Y:$"?+
MHOA$#Z_39T=C(DAE*JD(@\2_:_5291DA AF?&YQ'_DC:V%^WV%\Q[^!E*:UZ
M663_U&FU>7:T.!*I6LDZJ]X7-[^HAI\IX4N*S/)?<>-@P_F12&I;%=MF,RC8
MZMS]E[>-''H;%N,#&\)F0\ATNX.8RDM9R>=/37$C#$$#&RV85=X-XG1.2KFJ
M#'[5V%<]?Z5SF2<Z7XL+8V2^5A!X99^>5<!-$&=)@^>%PQ,>P#,)Q=LBKS96
M_)RG*ATB. -1GK*PI>Q%^"#&B]($(IR-1#@.XP?P19[3B/%%!_!=JF4E+K5-
MLL+61HE_7RQM96 5_]G'K<,5[\=%GO+8EC)1SX[@"E:9:W7T_*<?)K/QDP<H
MC3VE\4/8OT$GWX-'O*R-P0*V"X$4RTRO)3F(%0G^:%NI5!0K46V46!49G!8(
M'HL3G</\LHP 3P5THS.OG/9QP8^1>"'S3V)9&,-[K3@6D\C]<10ID2DXTN#L
MF9B+E\5VJTRB92;>R5(9,1F-YY'XZ8=%. F?'*;[F #/0_P/Q_>1_):+?\B\
M1L1I")Y,1^*M2BM3Y#H1?\^*)6!_*;*4B;T*7@87@3CI(-[4MTEQ.A(R%SA>
M5W<",5#F^@\(JH:Q&Y95)F\LR0W0:KLL:K,>$;@R@-)Y58AK:7116R'71C6:
M*&MC:PF6\//-1B<;L7,J//U.:&MK)3[FFC1S5<E*67$)S4CS*%5Y@: @*R;%
MJJ2FXY).!"6+("]HSPF12>R+E^_$.U.LC=R>"HJ, OJ[!A)19K!IHHTBG;;$
M<TH0K0"C":MX?(_.OY+3GVM3?!=GI/VOY"P0'[ %<51OZRT(!:5K I/;H@8,
MLI>MP#OYCJP@A3M1(17UU+TC1Q;4'BK [UKAO6'^0*U0MXE2#E9]KD%<1D3!
M<(ZC8"J6SL4<>3#EDHXFW%Y<(_$Z3P*QD==*K*$4"+7%U_<)(-R5\#<3SU0@
M4MY(^-@DF+34W5?#CKR&X2$0E[6A7U8(OMARIZ3A'T9\Z TG3K  C@SJ 'B7
M7D/S&41682/YFPM'#QY+1,JR- 54"DUF=Q0,4GEG/7?W#M)LM+82AE1/"*9!
M/!7 G$ G?>[SXFMY;F+@(9ZC_S?/X3?S' =1/."9W9##-&BX=S[<L$[@<X2]
M]1: X;6&HUQ+G<EEUO>4QHK_9F'ZR"Y$=P.]DHG.P.N(RBCDKE0LJ4@,Q!L\
M$-:7#@X1_%+!>Y>4$L)1(\<=\T:LLDW2468G]")R2_A^ROZ/9XV(Q"](,) 4
M"80C3<M&&[C$24/"JX94I(&E<TCP#DYZ;KGCH7L(Y#1!IQHK5J;8NI@">OA_
M*0W43K%"586+O)Q((8<+J$ G<B1^16IB1F6*X*BI?J&B%@03L;2%=$<B7F(K
MI'!;*6<J%8>[QK92TGUC8#L,$CE>V!#TH@E%.U"PN6N=P@S0%B#*]F,73/Y:
M/6*#[P*W4==%=KU']_<E'(@+1$F)%"'S'*B,I<SS ,DC6+E()/4(GVLR;8G0
MWU#  N &HMD[D,$7>.M9+ZKR:N-L?NGEI',P0X4,V9.O=T **D,"84N!JH =
M%,"#$$3'7DS]O)*Z8$'X8;;;EEAOAW])/J!7K8/8OH/NBG. OTD>-Z!:R,P6
MW2'[SB#R(#J]=IF[/6Z_H"&_K"9!2[%%$Z4?)5SA)7<]8:X4*4RQG27*5&@S
MA2U5HE<:^/$6 0X)R6W4RK+U[)2GQ,\P/(\HHKOH96$]P-\/JP=%$T#6O?!I
MN<1(KRE6\GJ?/TD@3Q5IU46X.U>4<%D.8S3ZEKO*U.]W2N:B=_[$B@QAYA$;
M!=>]Y/ H4RD(D)0=QBNB7)I4_"2WY1/QKBB,W__>;1!7:%(TT<G:+8JT.^)U
M?@V6"N.!@H[\E:(MAL+3'0?V0VQ22!RRJAVD1:0%IWD.F4KG5(,D9(?&K2UM
M1-HI,\U)B#U/POJ2XEJA?8#&C,K8O"AT[M/2AT':V9'@UW8\#_<X_7YHQ$5=
M6>WP=2K>ML$&.GKE"H%_452Z<'GSY]5*\5"B,ZOW%.:^\/,X"*?C-F,+"P,"
M13-NEL;X,8ZY'9J[91C,0E_2@$4$% <^C:;X<8%%?.X6XV \[O!2%!\B!M<M
M8EH&DQYB+C.$5;DNVJ(<>^?8,!L# RBF9=PLXP$'[4D+0@\*XB .^\MH0%?#
M[WE#5A1,Q@U9@#L';=%\EZP>^#B83CP7M!R*YT9E3$LT:> GP7S:P+OE@)8.
M/O3PXYF'QS(:2"FGNJ8''3FY..*Q'..(?=@C3_VBHQ[+.)CVJ5&Y!V;9S<+^
M,AI(ID,^]<1XR^%EO N?5W<M_#E8@&[F_>4LF/:)WVCCX!<BG$9$PKRW&!A
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MJBJVO-PH";8) +^O"LB\>: #_->RS_\'4$L#!!0    ( !."U%ADK9.]N@T
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M$.M-9Q<L HP=3^$'<)E LE"&/&RC55K@4+!_V@GMYI2T,!K"HL:@I%[<CV?
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M,\@.=*G<_;!J0Q>YP<\ ;NGK2D"BT#@ WB\4Y$C_ QE4-_MO_PM02P,$%
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MH-'IZ"P W75R9UC5^.Y9*DN]Z)<5?7ZH70#MKY2R.\,=T'^G^3]02P,$%
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M:*N\G"LT-TL$>#\UJ+[U PEHOHQ?_0]02P,$%     @ $X+46/R&S;E9 P
M>P<  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULI55M;]LV$/XK!S4H
M$D"+)%I^K6W 3M-M0 H8+;)]&/:!ELXV48I422J.]^MWI&S9'=)TV#Y(Y)%W
MSSUW/!ZG>VV^V!VB@^=**CN+=L[5DR2QQ0XK;F]UC8IV-MI4W)%HMHFM#?(R
M&%4R86DZ2"HN5#2?AK65F4]UXZ10N#)@FZKBYK!$J?>S*(M."Y_$=N?\0C*?
MUGR+G]$]UBM#4M*AE*)"98568' SBQ;99)E[_:#PF\"]O9B#CV2M]1<O_%K.
MHM030HF%\PB<AB>\0RD]$-'X>L2,.I?>\')^0O\08J=8UMSBG9:_B]+M9M$H
M@A(WO)'ND][_@L=X^AZOT-*&/^Q;W9P\%HUUNCH:DUP)U8[\^9B'"X-1^AT#
M=C1@@7?K*+!\SQV?3XW>@_':A.8G(=1@3>2$\H?RV1G:%63GYBM#YVO<(8:5
MY,K%P%4)]U\;45/FW31QY,-K)L41;]GBL>_@90P^:N5V%NY5B>6W  F1ZQBR
M$\,E>Q5Q49M;8(,86,KR5_!Z7<2]@-?[=Q%_&S#\L5A;9ZA6_GPI]A8Y?QG9
MWY^)K7F!LX@NB$7SA-'\[9MLD+Y[A7?>\<Y?0_\/)_5_\."\79^WL=M><UHM
MT(;E0AN*M]:J%&H+:)V@ZX(E-!8WC01)]\["'@T"M[#1DCJ!G<"U4%314M+E
MM#= QRQD=\XG<13$'MQWF(\MYD/ /-.]@D'<&P_".$R'\#,J-%S* ["?LC2&
MI@:G(>O#G:[JQB'U);UQ>TZ<6#P:,OJ/^PP>6[44'GQ<_I/^)ZK:Z"?TGBR!
MC"$;G'19"LM&2!]YFPR)U"1V6O[#BL7]=$#_?#0\6N8ID5%4;4W;H"@=I+^E
M3'KM+",O\;"?P]LW(Y:Q=S\ZD2R/4XK #T3N@5 FL"B*IFID2%R)5)2%X,'7
M]3 >,W8#UZ,X'_=N?H =@\(VQ5DOH[$?]P=C>'\)B,_T3%@$O8&K,9$^'FQ,
MTGA\ECSLU7C8[<.>*H)0]%:)OX@DY6 C;,$E') ;&VJA+8'6EF8L!E]L&-JY
M/-R^=+62BX98H=F&MF^I3AOEVM[8K78ORZ)MJ&?U]EGZR,U6*$O'NB'3]';8
MC\"TK;X5G*Y#>UUK1\TZ3'?T.J+Q"K2_T=J=!.^@>V_G?P-02P,$%     @
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MR497"*NH% K"U/9 L3>H2DMLF-"0T;<(\!*CI;;B5F8U&]/*;5T#H]MZ=.A
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M),#94>)PD!Z WCJ297GVC-.V W8"IJ'N?#P,FI-8$[.<,KZDD#85MZ*#_P-
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MT</WK_01T60HWN6%P==DZ76+H8?@N7^2X*?=RC%#SU&Z./ ,!YZFVL'U7V?
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M-)2B=@)TOE;4#O<;9Z ;<Q?_ E!+ P04    "  3@M18'+K569P8  !S5
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MDILJ*H ^$GX%<JI=M1O@L<8>2#R9JHU:I88N^Z@H5:Q@=' !XLZ,1;0'TRW
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M5B6!(F;@D%)YDV#@75=UOJO()C@JYZ!EU2A?KV6!]L<RKB7R#2\>\K0"?2O
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M?DNMPO%LP92?S'%DS^>1IQZ./#4CX].3(X=/CJQ:WM.9](39P$\X>7\\(;0
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MFJ:E"8')CM7&'+1\%WT!2?S*[NI<RT>+P3#;*J$*N7R0*34&\@/JJ! 9KO[
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M$T[:M5B?UCQP >-OM[=W8_'.3-VU4CAH8P.=*2HGHV6-&O1 P#,RO^(*5UL
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MV=!K5)"["BQQ?19 1ZD]@'KE!XN>Y#*U3^R'^_/MX1-)DCE/-7]"DVRK@<1
M#-BZT&_WI'-;0U!#OP;];V!PSJ'5=.Z=02ML-4BKOOUQ?FH.) [2*JQ!'SLR
MW(N<3%K)8<W9JF=.K/OUH72^^J$YP!ZYAZM.G9AOGY=Q-W[@,1[YJ(\&0[Q=
MB-"U![:C>I'>Y$+?-:LWF/ZV=Q2 <3,0G./P VN O9TBO/9J9:+,6YTZD>*Y
MN5>SVFR,;(,=SX]P+R2?G,ERS,0S#>$XH@DH0-B75Y2&6KPP$ESE9I/*4Z=$
MAI>YM."(\8QP[]@2U >S;/RQM+EW_\X%2FAA#I1$.B$_[I+3;DQL[J# ;=?U
MO12X= TX5G3?D3YV"4+8O4LDX9-C.%J>\:J\>_X6A\ L[0OM>DP/XC)HA+VU
M]NJ0<<S'-NR6!3S]Y Y:CR"3+O!P4@-'MO5.%2;#DVHK#%X#PZ4$H]^JY)1\
M%WWNGB_&.QJ"24=]I^X,<=A!"]+LE>K)4F=GFJO;H\YE,(C_="S>N@4R9W]4
M<[$)#5"?DG;$["/'4O=V?>Z6=]I[RSE+*)?<^%H?!S)G>!M<3LV<707]<W+X
M;1?]DA-PE(>:O$EO(AWJ$M57'0EK,ZLN%G#%V.ZY(^L\:O9'6H,DDUX;G&-/
MM%K#1^8&E1W><T;GP9_<,-LY%L:E':R$6 V7O;UE(T-24S]I-C"9$HK9+6SV
M$SA$-+4D/*-^_#3(WPH\3W%GQFJ=&7CNV0-B%.8UZ";!1\(S9&_+  ]BX;%9
M^.,)2&SPN*[ F'V&AY;\)7Q?X/DA?P(:8[>8PP,>'O=F4Q%";'+7H6/_RJD3
M1S,ZU_$,&\F3>Q$C;5,+5&QOYE[1Y'F=&YK\R>^ZH&EH-\NI,QA<_4O3,^9P
MZ0?3MDWR9\UU4^?4'<Y!]GAEXQF8!I-%&]-@XO]N3$^-ZUY<@5[]Z2T]S<;@
MV"W,][8D]++14:\B61OB)Y S%R#6:PP.J:FPYR295,)M+M-YYUZ'9@^5]R]L
MVSH5O>,WJ+%1I8NZSKLAS49__>N\F#%U\9XW3IL8K;X936GWRC'G0J&FLEIO
M(S&NW"7DP72E'9?.$7S:UXB*#:T4GSD@5\Y[^PH[Y_$1-V#"E&;77+T:)8<O
M'7$]2FO?[OOZ8KCZL%GMH#O7P\U;U\,%RTGW>CCG)JO?8'V&KAB\<2Z"W,EB
M0]==:MY^R'="UK_6-VK>\D6237.^CO/[J-C@I0"I7$/7R7@^O1 %7W')#V6^
MIVLE007+?$=?MQ*"R0(;P/MUGI?V 0>H[QE]\[]02P,$%     @ $X+46.+J
M<TCH!P  LA<  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULK5AM;^,V
M$OXKA-OK"^#8EN+$WC0)D*0M;H'M=;&[;7$X] ,MTQ:QDJB25)S<K[]GAI(L
M^>W<NWY(+%$SPV?>A[S=&/O9I4IY\9)GA;L;I-Z7-^.Q2U*52S<RI2KP965L
M+CU>[7KL2JODDIGR;!Q/)M?C7.IB<'_+:^_M_:VI?*8+]=X*5^6YM*^/*C.;
MNT$T:!8^Z'7J:6%\?UO*M?JH_"_E>XNW<2MEJ7-5.&T*8=7J;O 0W3Q.B9X)
M?M5JXSK/@C19&/.97MXN[P83 J0RE7B2(/'SK)Y4EI$@P/BCECEHMR3&[G,C
M_4?6';HLI%-/)OM-+WUZ-Y@/Q%*M9)7Y#V;S=U7K<T7R$I,Y_B\V@38"<5(Y
M;_*:&0AR781?^5+;H<,PGQQAB&N&F'&'C1CE]]++^UMK-L(2-:31 ZO*W "G
M"W+*1V_Q58//W[]34,G=CCUDT<HXJ?D> U]\A"^*Q4^F\*D3/Q1+M>P+& -$
MBR1ND#S&)R4^E'8DXNNAB"?Q](2\RU:S2Y9W>5(S\:^'A?,6SO_]D))!Q/2P
M"$J(&U?*1-T-$/%.V6<UN/_JB^AZ\MT)@-,6X/24]!.F/X=/?$J5>#)Y*8M7
MD84ELUKI1 T1'T6U@LJ5U<5Z*&2Q% 1?VB056->9]AKDM+Z15J6F C?HG-@@
M/>@7%BM<::R7E#M#L41LB=*:1#G7RC0^55:H/RI=(DW]J =IJ;RR"%CLLTD5
M4TJ1(&3(%T)C]X!:&,O+J!_;-0F*(E$E)R[V5B/Q2XG'Q.38*5&TW5#XSG96
M)69=Z'^36L)2*EZ8U45%LIQ#;2.\07:FY8(L\#H2'_;H' 2QJPO?%?^U"S*%
M-X)HZ5.%N+?9*ZQ1;X$*R1_"-J3]2+SK;<E&MVI'LEED>LUV)O&Y_*PZ8DKY
M2LH2GR;+BY4U>6.GD7AP76%??3&/H]EWKHD'_UKJ1&89O&%$83QY\%DOH6LA
M=%YF.M%>6)AW>%S*'O@<JY55<#]JJEAJEYBJ\'A'<81;*T;9UQ"^M.PSF8F%
ML<@3HK'LUW>MM8@78G3!W+5#V2QF=<"E[H!/"2,VRRKH: KH;3B$'!E6O7@%
MAHZ'4H09:81FYDPA%Z!/E*5()/J% HNRB08H&'JY9"QDS6''Q:X;!XS[;*"(
M>@=G6!$21=9(ST&55)Y ?>I9N4Z=M54JA$QCB28:2'(JGQ5\X-.&'-" TB1:
MD@\+6(W7D6E(.!+33^L4Q8%;*H@!1R;L?8[]74:6328Y+9_*C104-9G:E1'V
M)D.93"]EB+),H@((;GFN">Q&U;8,+!O;$[".T5N@P1Y#*C6>]]A6%JXXPV J
MR=ZA"/2HC5C(0]=C,2[HN(,!R17"C@Q45BBZ\EC)8)=H=U8$?CI<[5R5I(U&
M=>KT[.50PNMX@!+ :'(54I?:(@<K-9@Z>\VSVB]B_=@_4G6?4:"@P%[=ZEB&
M<UO[0X6E1EXJJPV3;5(-O6BM4QY#A35=\9K#O+*63/3K$0S$MT*A0OEY11?D
M"8/GC,O0R/ 4H_4AZ0@M1CW D-F?S:\Z%Z F[8>HQN2,&D?>;B@X(0C_'NT*
M!8#".E"&K0^4DN&^[89MTCCZGDB')H]9VPT[=0<Z81@(-7R;C1OMTYU2W<>Q
M;Q2*R[T8"TSTM1-MB&R,=#IK9SK*F7IE'JQ/*\=]T[IF)'[LHCI<8H&S&V;H
M=+"^1[R6J!<^V*(=58:B0/:%Q9[&>]VN*Y/#C,J#6OA.6-;UW13K"ZX5X?.!
M5.R7KN#CE<FRT X]1VXX''%&$7^/1209M-68\633%G<FB4,!)W.*--=0G]^?
M]AU(='T/WHAO8)A<9QD9XEOQ6./]R'B?^GAWI.W$PJ%A[.<P-X:7+T4TG.#<
MP;_32#S5[F@'NH8\26P%<ZL7G%S)"M'\$G\3\0]37"1'F+J*SZ<3,;]^<XY_
M-GSJ4\L+] J+0RPJ(IV$6Q>$[L&#]BYE,SGQ'-0.CZ><>98_3AOYM[/PSD=S
M\4\DHQ-O1E']M,?9QW\YFOY-Q/3O#*MUFC]%I:&Y<$==+F=G%>X;5 >F()P[
MX<@F8,6YQ/]\:(\O17Q)015'$876FRL$+PX^(9<[=(BXZUA<7XE/Q_%"RNQR
M^_]Z<I8UJ&*74M>]H$[7;N$AJGKLYOD$1MO=OI>X=-X[D$UF09-%$*E>,)84
MZQ!XIX3]Q2YX^JN5W;IO0NZ;30\6DO])]3B>P.LS,9N?X\9.BSVC,._F\FXA
MW89J?=P'T16I.6%#7D/3.3W,1'05T<-<1!%_>B/FC!<SY0HQ+*;3:1VR5!!Y
M<-\9CZ)A-)MA'^=NQ-N\I+,%[ 1>A9#^)KJ:?EL+V#E ATH,]W9'4SJ_NG:*
M11M>5@FUF&>I,S8;!HAPKZ5L?7AJ)BMKR2V,:5B'!(_*G76Z2[!J\;IMY30!
MHL4GS3BSE;U)>50IMC,X=>,J9Q0ML/H0$\#SD$YW$L&!G:N-MV%P[I_"]X#U
MAF/MZDD: Y<-4WY[."&H, ]-(4YF?V9T;PY5V^ B(;IXAK.:L33(O,#Q?SN<
M[LPRX>ZFZ8:=.<!T6^XA5+M3S+M:OSX\JS*FWILP.FGR_PV7]>Q(]-WZI.@Z
M\K\WRM&A"[QQYQX5(;3FVV(ZJ*-(A2O5=K6]D'X(][!;\G";_9.T:[K1RM0*
MK)/1[&H0:G+SXDW)M[(XBR->^3%5$ME !/B^,L8W+[1!>TU__Q]02P,$%
M  @ $X+46#;XZ.#_!0   1,  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&ULQ5C;;MLX$/T5PFL4#N"-)4JRI#0QX+CM-L#V@EZV#XM]H"7:XE8B79*.
MDW[]SE"R[,27IDV ?=&-Y)DS9X9#BN<KI;^:@G-+;JI2FHM.8>WB;# P6<$K
M9D[5@DMHF2E=,0NO>CXP"\U9[@95Y8!ZWG!0,2$[HW/W[;T>G:NE+87D[S4Q
MRZIB^O:2EVIUT?$[ZP\?Q+RP^&$P.E^P.?_([>?%>PUO@Q8E%Q671BA)-)]=
M=,;^V66(_5V'OP1?F:UG@IY,E?J*+U?Y1<=#0KSDF44$!K=K/N%EB4! XUN#
MV6E-XL#MYS7Z*^<[^#)EAD]4^47DMKCH)!V2\QE;EO:#6KWFC3\1XF6J-.Y*
M5G7?(.Z0;&FLJIK!P* 2LKZSFT:'K0&)=V  ;090Q[LVY%B^8):-SK5:$8V]
M 0T?G*MN-) 3$H/RT6IH%3#.CL99MJR6);,\)^]LP369J K"6Z#NUYS\J8PY
M'UBPA/T'68-Z6:/2 Z@^)6^4M(4A+V7.\[L  Z#8\J1KGI?T*.)XH4\)'?8)
M]6AX!"]H_0X<7G  [^6WI;"WY._QU%@-J?'//B=KB' _!$Z7,[-@&;_H@&"&
MZVO>&3W[S1]ZSX\0#%N"X3'T7P[,XU')IX*3F2IAO@HY)Y9-2TX66EV+G!N2
M%4S.X2YP1FW E /+[H"5"-8;OYM<G?2)A *C9H!VTR=,YF1ZZWHKR:4](SV
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M<$F^7"*902E54%I 5ZI<32#H5C&^KO#4Q/5SXQ"Q#'(>R1X@=@B6<C!:B@[
M\O<]X_<2T@;U+?3F.2OGW/RQ^ D^G4T3#X)"</8/D/WF],E+>&Q=T_H@?#=7
ML^*;Q_///"ILR;+?O'SZI81CR@7UU5ND%Z% A8%(EDH,)A<OO1AV)C"2T]M
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MEH1GCFJLRCTT335%;K)LC]M)@&ULJX-RVY0!)#=Q=HML84O/-V+ G.AJ6H.
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MZB&"9C5=*G:.*2)QY?YAJ+Q3:/I1DV44EQK&_&$TS$^!RA3N5N3)+8EICJ(
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M.]1$C)L9Y44QG>9S*[H5W68LYF0JL=^YC]V;H: .,F9:*5<-PXK;H+.!2YQ
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MKJG:)<?+B2W0Z;N.3MSSC@@/UVP7^1X7/MX2?)L#:\(QO =J@4K :\G":EU
M5RYD/LA:M6K:9@.).21"/;=W*'Z#]WN7LXNWUI3 :@7*._#=/0H"RAZ!%G<M
M];JJX\Z5]1-R@WPD%D-&YS"<?)GCSI-JZ>M</Q]^#H2/@F<J:V3]'<X\P97?
MY] NL)VB2+A*6V+-SG^!V("7K '[*GB>ZAXWYH'(FW(#)+?VHT/@RFY6RH%E
MO*&&V;)B/7P7"3:O<JA^*B./C'ZB.?QNBUMI0\H%[6B2K$N47!2&JBDJ&-=V
MQ02(3=ZD)*L ;N ?YN,683YD)3+&>;M=08G5RU)D:M?D4ZG,C6-N(V:DO?"X
ME21^UGYIG&N:PCBC %AR_X@K^M)P@3R#1V0^A'*H#CU-=T[!)N"YW\PJ.[B,
MW<YHAQB2T@>$?^R][8DZ.&#IH*.)MM^!O1_5&M+!0-P.1)R&;9O +2AE<Z<R
MBLVXSL K<M3KI<;"3-"2SRZ,LC)'4<O0^)!OQW6F-#CGN4F[=FZDNSM1-M6]
MS!M9*V_L.!P=!?2U#CIT*Q#@'&HBI:HOJP=F>5QXOPU-"]RZIKW-W1-/**JT
M;VTCAB"A0X ZJKNKY1?RN/HR@!;00'9V ^#IUC,!=1I R)]]WX^QV#YIRD7:
MT=2$M)%'^Q#2<."=GS?6@K[W0L-Q*=,G>D7P1F-5OV_=JFP#78CFRN>#20\T
M0IHB98)'@DL[A@T9!F"FGYY[?Q)?8)KTVX:!4UC*UZ+]7[1<G91>KQY:G!9/
M19$FGW8?CS"\D^?+'%[7ZXX!1=/VS*2X]W/MF\;Q!H":]7;;>V3D0X4*!052
M+Q=IQ4R _2O-\SO81_>O!Z@>0.T31J8IN8X70:U)]4 R!QV@YXZ"@-7R+CJU
M%.X8;0O""W'=>C@CF*=:#E!$0J(]I?53:C[8 &H.^S8?12'WZW23V=$]M-PA
M&F3IP7+0P[8CVG1X2DZ?S7Y';9AGAYUSJV_GY<-.N4OLH5[=^MB\]YN"?U)\
MS^$!;*!S0L$SOZ6C?2 =HN.^\P<Q#:;S*9\3/.;S<G;86\7!<CK!<1Y&."Z2
MQ<-N(0[".0V93!<XSI:+H;;&RZF(%[%(%HOV-=SXI<]#F(5AL)POZ32;3448
M!7,L[C='#[9GXCQ\)L*).%\LGXGS&#?7?=*?A\%\,7W&YUGLSQ'N;SI*ZV)R
M/@]I]BR>X9@D&.I7>XQN N;@*1R1A(F(PX6X^AH+TL*SI5< CO&*Q+B_>X*,
M8 @/CY.$CYAR?9H(2/)DR9*3I%UA2L[HZ/4\>B9F"S&=)0)A^JBZ[1X9QOGI
MG"&HLB8L,6:/SJ9S4B&&(E?IYT8[[=^P<T6^IZZ-:G3?VGOJ/)_/>=:4U%_$
MK+[/RQS3-][&GI+)G^?A%*O%B.,2<VYN/_XHB^KENVZ0^/$OBRB,7O;G\W "
MZSH0HF] 1TMM8MN[DT,XI&$RH>,D(EP4A:X]H[1$A_FU;]7?@X0RV9LV//C[
MU=N[8=4YI'4W-T^63\ZA13S'.0GBV93/23AGK-[X/LGW EM$$NT>V=#BC'3G
M2E1N#+\!L++L?+ZQ2GG]N6X<;(7[UH,WZ?32ABC&MD%2V</74GJLR+>]W*&1
M)U]/73#.#DRDZ)ZJ[8>KMY6>EMY86;B!K@$><T0!??IZYS]C*(&(30T-KWSJ
M\1O@,0__U$XZ&/7HB$,6/7RMW=TN@IY93W)L. O":.$O)O&,+I9+'*,)'T%@
M!WP;+H((:8I3/)V)*(FP\!S_DT=X-PZ2Q4S$TV 9S2"5U(@Q<S;BWV )0L<1
M^87GBXF ,&__8V_WYZ!?C)G'010O<%J*>8+_4/\4!R?3N0B#&*CO$B2"%B,V
M#N?!-$G( ?$<;@)YDO@(8KTJ/XC%$@N'N%A.4&_(6\N$DF?)KEJB2/T?)- 3
M?Z,9MF T4=;C=[_<WU$79?>'O<6X&?%-8+LOJ^4GWW%QUS8:T6_+H#W@/VR4
M^[<&M+REO_18E1UH2XT,6!Z[\RJ7W;LGA9)1^5S_=K6K[=YQ2(_U]^6T>UV(
M7FO'$6;X]MN:88M$N\+1NU+7OO&G-/7:4:X&W;N_$\K[&H5=X!$)T* C(NA>
M" UXZ$RDAI#^EH$N,VA_I&:7]]].;TINW.$H-/2^ZV=D!%WWW+)?/_'%"!*W
MWZ#]R9[P-+G=4'6'1)!6&%,F,I%-*%.)FG"]F/)K$X3PKN:M*[(\F45=LA/[
MQ0DWEC&.$_2"U(&02W;&YID(DV"V0,<W#>;)C.ZF"=@OB,!BX)1)U%+$D0O&
MV]1.QS@*HB1$7P:^7=(I622HO@OTDZC%N.[(!@-]:<:8*)K[B]F"J)FT#7W1
MGBVQM4!XRDT^2I]^$TV8O<</X&\$(&W?_XWBSUPX?\E_KG'8WV3<)0T015">
M1*CAM_O1Q6-_6+X<?08 C3;\L4.+-?]%0/]K_SW%E?^,8!CN/\;X@ Y+@X)R
MM<;4R<4\.1/6?^#@;VI3\4<%*U/#?+[<*@D"H %XOC;8?+4WM$#_E<F;_P!0
M2P,$%     @ $X+46-M)'!@.!   !@D  !D   !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&ULK5;;;N,V$/V5@7:Q< "O;4F^)K8!^9*N@=PVCE,411]H:103
M2XE>DHKC?GV'E"\I$'O[T ?3O)TS9X9#COH;J7[H%:*!MTSD>N"MC%E?UNLZ
M7F'&=$VN,:>55*J,&1JJE[I>*V2) V6B'C0:[7K&>.X-^V[N00W[LC""Y_B@
M0!=9QM1VA$)N!I[O[2<>^<O*V(GZL+]F+SA'LU@_*!K5#RP)SS#77.:@,!UX
MD7\Y:MK];L,SQXU^UP?KR5+*'W8P2P9>PPI"@;&Q#(S^7G&,0E@BDO%SQ^D=
M3%K@^_Z>_=KY3KXLF<:Q%+_SQ*P&7M>#!%-6"/,H-]]PYT_+\L52:-?"IMS;
M;GL0%]K(; <F!1G/RW_VMHO#.T"W<0(0[ "!TUT:<BHGS+!A7\D-*+N;V&S'
MN>K0)([G]E#F1M$J)YP9SNF4DT(@S&;P%9Z9*%@9K3R![P43/-WR_ 6B.)9%
M;G2_;LBHA=;CG8%1:2 X8< /X%;F9J5AFB>8_)N@3FH/DH.]Y%%PEC%:JQH$
M[2H$C:!YAB\\A"!T?.&I$$S'L ]#%?S@:Z-7_74DX,]HJ8VBK/KKHZ"4)IL?
MF[0W[5*O68P#CZZ21O6*WO#+)[_=N#KC4//@4/,<^_]QIN<-W$XG3X_W=[,Q
M/-R,(;J;P'PQFL\FL^AQ-IW#?/QM.EG<3*W]+Y^Z@>]?P7-TLXB>9O=W;OOW
M170SN_YC=O<;1./Q_>+N:0X5GE.""T%*]05$2<*M: T3\B4NNR,F6!XC, /C
M%5,OJ,%(F.6QS/#]S+U9H3J>5#FD]=RN5R:XY.8"Q@K)Q($S$O0^N1Z]=)#(
M8FG20M"KL2.QP8M+B)!:H[Z$:ZYC)F"+3 ':Y 9*32X.N0F?P>^TJ>TUJ'&1
M"*ZH5^F%%U!A%VX]/$W3=30A!&$#:-^>H.('G1)OV4^B>PX=0-#TH=4]HMN]
M$FQ9)YBB(J? L#=X/2;*/A;_S4>_&OJ^[51;9.\SA%!96N<J?J-+MF+G:%@-
M.B2DV8(*TF1 O^3BU[ZWJZUN",UJI].#L.>(*^VP9-T9]AU3Q04%SU#N ]*J
M=JGM=ILDL%?*(*4[SM*>C<^#XE2FN-A"3+G'->6 3*&@9!.NI"SI@AVR8Z.X
M,9C3CK0* K6F@A7+5U0<=<VI?L34PB@_5P@\H\MO(%4R(XZ?!==ELM><AJ-E
MM0?%3*FMY:/<-XHO"X-0&"[XW\>KC6]KKMRPYISZ@,;:QC1U?7(F+NCP\W@+
MJ: K5AZ^U8 GP:5P72JW24,&$>+R:M4^>KOJ[VI3AG1#;04FAVS<RC)UF#T4
M^:BL;<?MY1?"+5UP3L^ P)2@C5JGY8$JJVXY,'+M*MU2&JJ;KKNB#Q54=@.M
MIU*:_< :.'SZ#/\!4$L#!!0    ( !."U%A8VQJM=P(  * &   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;*U576^;,!3]*U>LFC9I*P3(1SN"U)15
MVT.GJ%6W9P=N@E5C,]LD[;^?;0A+.UI%4U_ ]_J><S^,#\E.R'M5(FIXJ!A7
M<Z_4NC[W?9676!%U*FKD9F<M9$6T,>7&5[5$4CA0Q?PP""9^12CWTL3YEC)-
M1*,9Y;B4H)JJ(O)Q@4SLYM[(VSMNZ*;4UN&G24TV>(OZKEY*8_D]2T$KY(H*
M#A+7<^]B=)[%-MX%_*2X4P=KL)VLA+BWQO=B[@6V(&28:\M S&N+E\B8)3)E
M_.XXO3ZE!1ZN]^Q7KG?3RXHHO!3L%RUT.?=F'A2X)@W3-V+W#;M^QI8O%TRY
M)^S:V''L0=XH+:H.;"JH*&_?Y*&;PP%@-'D!$': \#G@I0Q1!XB.!<0=P(W:
M;UMQ<\B()FDBQ0ZDC39L=N&&Z="F?<KML=]J:7:IP>ET21YAJV")TGU"/$?(
MJ,J94(U$^ QWMQE\./D()T Y7%/&S&&IQ-<FM27P\R[-HDT3OI!F%,*UX+I4
M\)476#PE\$W-?>'AOO!%^"KC12U/(9Q\@C (XX&"+H^!SQP\&H!GQ\#/'#Q\
MI9NH/X;(\47_<PQ#XV[IXF$ZJQ7GJB8YSCTC!@KE%KWT_;O1)/@R-*JW),O>
MB.S)&.-^C/%K[.D/HY.4YZ)"(%I+NFHT63$$+4#(@G(C;*!*(K$4K$ Y^"&W
M&:8N@Q7-;1I-II/$WQY.;"!H.IX]#<K^#1H'T5D?U';H']S="N7&::""7#1<
MM[>A]_8R>^'4Y9E_8>2W5<N_-*UV7Q.YH5P!P[6A#$ZG8P]DJX>MH47M%&(E
MM-$;MRS-+P2E#3#[:R'TWK )^I]2^@=02P,$%     @ $X+46 JEV;]# @
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M\ 6%7""S,YO6-5(6*(Q[35ZE;3B72"BJ3H_.)2R;J&38YNH:H@/Q3U3B$$5
MG$5O@:JM0-C!]>V:Y0;?@I@;CL&BNY>6EM" ;2B\\R].#1)[K#K2%9$L(1[)
M'[+7= I;4P8 KN> ^Y"/6*AK>+<1'F.7"E-]7<A8"^B 6X83VM4=>73\!$M8
MD*U1^(5.GEM@&H>0 56Q-/$Y%"40: \H@UYJ0BD4( O;%'#<2%:@%?P[ *UK
M<)4SEE6-7H(ELL (QD<RY9KC/BZ)*#QX@R+D7-.DT/5N)1U58EG]JPNX)DDW
MRW2,>H;OATV9[),R6P:=XE4R<8&U?&6OD395*.!$0%RO'K);;ZZMN8$'0:M
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M.IDU20URY]/];1]27NT5^'PKVU(N&E,H6DD>1?\/0^V9^[##L\GJ(EFZ;R$
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M9$>'OM?:E]M)49BGDOM\NNQ-P?/?B;%^SARR,;%X&*2>B*Q<31DK,N$'F?:
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MJG.A>/HZ,:H*)]\XIW!A!?,9/J6D4M:S/,M[V%V%ZIK\S%MK:FQD]->:!(5
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M;5G+D6.' DVZH(G23G/@6NI)D*3[@>J%HD3.%UDZ5U/37.HK45'6WF%6-I&
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M<15Y0S@?<L^VV/RVQQ%.TO2/YPZ<.XUI:@Z?3S>'OU;6_@U=XOK@?-D#P.A
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MBR>^V>>)!*MXDYV2,,;S)W<PAM!R<,#]W[Y(DX74Y(*V$;97\PU>*;2CIVG
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M!)"1ZXQQ@=QI8!(IW*$*T./( I32#54KP:LEZ)1M;(^NMD-?EQ\^%!/=C-Z
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MRJ.6.%NBG5Y\*3GE6<E7<"4EY2N& =<*SI[HLF+J?#[1N(A1G60MX'4#2(X
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M6AO$X^=1&+:-#8'H7VGL3QS9BTQO&-MGJ >,'+07VXBC"ZQ<@CQ@\+W@VKC
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MNQ"\%)H$<'ZFE-T\T +]9^.+_P!02P,$%     @ $X+46%1_]FYZ"0  :A@
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M>@C<N VX<<\&-\,89L(^9_D<@0C"#A!L6VK:BFK6O5Z8,SC_'X YR?YB:S>
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M[PSQ_%'E-;Z<&)F[J_-"&KR(N^$:OWRHL@*XOI32["9V@_I;:OHO4$L#!!0
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M+_0>4K3G^_9&\<:>>.^XTN=G>[D#7( P ?I]R;EZO#$-]%]9TI]02P,$%
M  @ $X+46*U&6,@#!P  %#8  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N
M>&ULM5M=;]LV%/TKA%<4+;#5$DE].$T,I&&+%EBV(&F[AV$/BLS80B71H^BD
M ?;C1\F*:4J4TC37+XDDWWO$>\1C'5-7QW="?JM6G"OTO<C+ZF2R4FI]-)U6
MZ8H72?5&K'FI/[D1LDB4WI7+:;66/%DT244^Q9X73HLD*R?SX^;8A9P?BXW*
MLY)?2%1MBB*1]^]X+NY.)O[DX<!EMERI^L!T?KQ.EOR*JR_K"ZGWICN415;P
MLLI$B22_.9F<^D>,AG5"$_$UXW?5WC:J2[D6XEN]\VEQ,O'J$?&<IZJ&2/2_
M6W[&\[Q&TN/XMP6=[,Y9)^YO/Z!_:(K7Q5PG%3\3^5_90JU.)O$$+?A-LLG5
MI;C[R-N"@AHO%7G5_$5W;:PW0>FF4J)HD_4(BJS<_D^^MT3L)?CA0 )N$W W
M@0XDD#:!_&@";1-HP\RVE(8'EJAD?BS%'9)UM$:K-QHRFVQ=?E;6U_U*2?UI
MIO/4_)+?\G+#T6^(956R7$J^3)H+(F[0'WK:724YK]#U/;KB2WVY%4K*A0Z]
MS9H+_XIQE61Y]5KG?[EBZ-6+U^@%RDITGN6Y#JB.ITH/LC[5-&T']&X[(#PP
M(!^C<U&J587>EPN^L &FNKI=B?BAQ'=X%/%T+=\@'/Z*L(>I8T!G/Y(>-^G$
MD<Y^)'W6I..1:LCN@I$&CPS@]2_3PR7\^W<=BCXI7E3_N'C?XE(W;OW]<E2M
MDY2?3/072,7E+9_,7_[BA]Y;%V>08 P(S.*3[OBD8^CS>I)7]21W4;9-C9K4
M^AOT=DXP"?4DNMWGPA'E8QS94<P5%<;A+LH:?; ;?3 Z^DN^%E(EUSE'52O0
M<JR@4;2GS@%(, 8$9K$8[E@,#Z2I$))/2# &!&;Q&>WXC'Y>4]O4T-*43W%'
M4XXH+R)^1U.NJ%DP<VLJWHT^'AW]62(7F;A-JG23)])5PFC^4Z\Z)!@# K-X
MF^UXFQU(13-(/B'!&!"8Q:?O&6_F_;R.VMS]R>_[<5<B9\ZP '?TQIQA)(S=
M4O+W[*7_!#&A_U!S($G1Y>I>K0KT,BG6;]%'GDB%/F@KN9'<6>SH69XZ14#1
M&!2:S3 V#.,#R:X%AB(5$HU!H=FD&I/MCWK.1Y1'>EH)9K.@*SQ'5!23KNX<
M47& !V1G3*T_[FI[LM,?;E*UD4G>BFTKO%/M'K/46>3H"9X\.2#1&!2:3:[Q
MW'YP*,6!^F]0- :%9I-J++@_ZD@?45S8-WHDB+N*<T6%/<4YHKP@&%"<L;S^
MN.?MW^B$%&4B[UNE77"9K5>\%N#7$6LY?I8GSQ!(- :%9C-L;+D?'TIVH(8=
M%(U!H=FD&L_NCUK81V0WZTD%TZ@G.T<4B8*N[%Q8H>>6'386&3]FD3=25&G&
MR]1I',?3GWKI0=$8%)I-G;'FV#^0GC"H&P=%8U!H-JG&C>-18SJNIS9W7P,S
MZH4=/3FBXOU%C;9.1U04TP$]&>.+'S.^1D_U34PF9:9O6=M[V-4Z*_7.9YZN
M2I&+9390)NA*,R@:@T*SZ36^'--#:0[4CX.B,2@TFU3CQ_'X(OBXYH*>3F@4
M]#3GB*)!=[G1'36PA(^-]<6/65]+<U=KGFK-J7OTN?:+ZR&5@:X]@Z(Q*#2;
M4./%<70HE8':;U T!H5FDVKL-QY?%A]76=QW=S.ONR3BBHK]KE-T106S@241
M;)PN?LSI6BIK=@NQT#_$ZDGB+ IT71H4C4&AV<^@C>TFWJ&>0H,:<E T!H5F
MDVH,.1E?*Q]56)MK+=!'M'L?<T6%L^X2B!.+#"R!$.-]R;CW/>>++-7^\&HC
ME_6&LPS0-6=0- :%9M.WU]AQL,X.V-8.V-Z.0QAN8@PW>49[1YMK_8:B?M35
M5#\JFL7=WV-.K'#@430QWI:,>]NNIFI_^+"Y_5'VOESHVYI8WSLK!%UP!D5C
M4&@VL\9UDT,U?1!0YPV*QJ#0;%*-\R;/Z/P@_7:-,/"ZRXFN*#_H/J]V8E$R
M(#=C<LFXR77([33=*%X_MN:MX,Y%F2DALW+I+!)TK1D4C4&AV>0:!TX.U2!"
M0)TX*!J#0K.[%XT3I\_H$:&.KHY93W&NJ)CT^A==6'A@\8,:TTO'32_+DFNN
M!H8/NLX,BL:@T&S:C->FA^KZH* .'!2-0:'9I!H'3I_1]4'[G1J8QCTM.:)P
MV+U[N:((&6BVHGNMS.-F]T^UXA*)-9=Z5I3+AY9@9S6@R\F@: P*S6;16&YZ
MJ/8."NJV0=$8%)I-JG';]!GM'6UN9(FFV\CH"*+=IBOF"(KV.O&W@Y_NO2Y3
M<+EL7CNJ4"HVI=J^5K([NGNUZ;1YH:=S_)U_Q+8O*!F8[?M2YXGVCV6%<GZC
M(;TWD69?;E]!VNXHL6Y>RKD62HFBV5SQ9,%E': _OQ%"/>S4)]B]"#;_'U!+
M P04    "  3@M18'("\:@L*  !+8@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U,BYX;6RUG6%OXS82AO^*X!9%"UQCD11)>9L$V(3;NP*W=XL-]N[#X3XH
M-F,+:UNNI"1=X'[\2;)BFM2(MNK1EUW;&3X6QWSME^.1?/V:Y5^+E=9E\,=F
MO2UN)JNRW+V;3HOY2F^2XBK;Z6WUEZ<LWR1E=3=?3HM=KI-%,VBSGM(P%---
MDFXGM]?-8Y_RV^OLN5RG6_TI#XKGS2;)O]WI=?9Z,R&3MP<^I\M563\PO;W>
M)4O]H,LONT]Y=6]ZH"S2C=X6:;8-<OUT,WE/WJF8UP.:B'^E^K4XNAW44WG,
MLJ_UG=\6-Y.P/B*]UO.R1B35?R_Z7J_7-:DZCM];Z.3PG/7 X]MO]%^;R5>3
M>4P*?9^M_YTNRM7-))X$"_V4/*_+S]GKWW0[H>8 Y]FZ:/X-7MO8<!+,GXLR
MV[2#JR/8I-O]_\D?;2*.!A#1,X"V Z@[(.H9P-H![-P!43L@:C*SGTJ3!Y64
MR>UUGKT&>1U=T>H;33*;T=7TTVW]NC^4>?77M!I7WG[6+WK[K(.? Y46R7*9
MZV72O"#94_"/:MD])&M=!(_?@H])_K6Z_U>=+?-DM_H65&LN^)#,5\&#7E8+
MH0Q^5+I,TG7Q4P7[\J""'[__*?@^2+?!QW2]KI#%];2LCKA^WNF\/;J[_='1
MGJ,C-/B8;<M5$7S8+O3"!DRKJ1[F2]_F>T>]Q/>[_"J@XB\!#6D$'-#].</C
M9C@#AJMSAL^:X=0S&W9X]5C#8SV\[FOV]GK^Y^]5:/!;J3?%?Z&\[[D1S*W?
M;-X5NV2N;R;5NTFA\Q<]N?WA.R+"7Z"<8<(4$LS*9W3(9^2CW]8KOJA7/)2R
M_5#9#*W?3E]N&66B6D0OQ[D H@BETHY24)2(Q2'*.GI^.'KN/?HO5P]7P:?V
M/?E.;_536H(S\6*&OOB8,(4$L](G#ND3(XE)8.83$Z:08%8^Y2&?\L^+:3]4
M' F ""ZH(R8HBDGFB F*(HS#8HH/1Q_[CS[;_MP(2E6+8%WYK$7[$0A.Q\L:
MN@(P80H)9N5P=LCA;"1%S3#SB0E32# KGR0T;BW\\YIJQQX+83:3,T=34%04
MQHZF@"@2$MKS"46.[";Q3N##1N?+=+OTB<F/&/KJH](4%LU.'S7IHR,IJ@5C
M)163IK!H=E*-B29>3WE"5*PC!!Y3YHH*B(HBX8H*BNK5E#&MQ.]:/^M=EI?)
MXUH'1;L7VWJGY,4-7@J8-(5%LU-I'#3A8^D+U52CTA06S4ZJ\=7$:S-/Z$MT
M-,$HB5PG"(6%DA%785#8C,]Z)&:L+/%[69_$@O\%9^^\_$\S>)5@TA06S4ZQ
M\=LD'DMZJ.X;E::P:'92C0$G7C]Z0GHS8.,42>)*#PJCA+K2 \)X+'L^W:BQ
MO-1O>4](;]@^S?]<0Y<**DUAT>P\&V=.R4CZHZA^'96FL&AV4HU?IU[KZM=?
M.];>KU%WOP9%T8@[Z@-9H>P1G['&U&^-3XCOG-V<_QD&KP[46C,6S<ZN,>XT
M&DMRJ!8>E::P:'92C86G_BJX7W*\NP.3';,)1=%.V1&*(KV?=\8M4[];OD_R
M19J]),7\>9WDX"10Z\VH-(5%LY-G?#J58RD*U9FCTA06S4ZJ<>;T1"G<JZBX
M:_M([&[,[L$P3ET3"88Q$?>(ROA@ZO?!MJB&[-C\X,'K K46C46SOWLVSIR%
M8WW[C&K#46D*BV8GU=APYB^0>\76CK4^<OC,^7+Y'HJ2,[<8"45%LQ!6&C..
ME_D=;T=IPS9H?OK@E8%:IL:BV9D]ZO48K=D#M]L#M]UC# O.C 5G%W1\M&.M
M:F+,.W(#HKC;%Z) ENAQB\RX7>9WNQVYG;,E\S,'KP?46C46S<ZG<=]LK"80
MANK*46D*BV8GU;AR=D$G".NV;U F.R(#HHAPR_]05'A4J;2/WQA@=LH /^=9
M,4_U=J[!*: 6H%%I"HMFI\X8;S96"PA#-=ZH-(5%LYL4C?&.+N@"B<#^#L?]
MW0-1\?'W9/MY0E$RCF ]1<;C1J<\KM'3D+V8'SMT2:#2%!;-3JFQW=%8C2$1
MJN-&I2DLFIU4X[BC"QI#HFXSAV A=W4&1(7$[;8"HKCDK$=G1]W,I\RMI;-A
M.S$_>_"Z0"TQ8]'LO!K3'8W5)1*A.F]4FL*BV4DUSCNZH$LDZO9U$,G<K\J@
M*,$[8@.BXI#TB,V8W.B4R;7$=LX^S$\<O!I0:\Y8-#N;QG)'8W6#1*AF')6F
ML&AV4HT9CR[H!HF _@W6Z<B'HFCL?C4&1M&>+BQN?"_W^]Z/>I'.DW7P\%Q)
MJ[H!3<./&'QR"VII&8MFI\_8;CY6AP='-=ZH-(5%LY-JC#>_H,.#=[LRXHBX
MM0T@2LYB=R\&LD2?IHS'Y7Z/ZVIJR'[,CQZ\+%#KRE@T.ZW&>O.Q6CLXJN]&
MI2DLFIW4H_,;+VCMX-UV#":[6@.B>-31&A E^KJ(N;&XW&]Q :T-VY/Y^8/7
M!FJ-&8MFY];8;SY6YP='=>&H-(5%LY-J7#B_H/.#=WLU6.A*Z1Z(HC-7E@IB
M$=YS"B<WAI?[#2\@N'/V97[JX!6!6GK&HMFG2!L++L;J^1"HQAR5IK!H=E*-
M,1<7]'R(;I\&$3QT9 9%==NK8%:/S(3QP,+O@56:/.JRY_!1R\NH-(5%L]-F
MK+<8JZ%#H!IO5)K"HME)-<9;7-#0(;I-&#2*8U=+0!1U*R$*BF*LIU-1&(\K
M_![W34M#]F%^Y.#E@%I5QJ+9Z3RZIL=H%_7 O:H'[F4]QO#:PGAM<4$_A^CV
M8,3<+2-"09U=&! TDSU?/@OC:87?TQX);-CFR\\=O"!0"\M8-#NGQF>+L;H\
M!*K51J4I+)I]]1QCM>4%71X2N#X'C=V+44%1Q.T%45!4&/>X0FE<K?2[VB.A
MG;/I\M.&K@14FL*BV9DT_EJ.U=PA4=TW*DUAT>RD&O<M+VCND-V&#-;Y$(."
M0K>R 011V5-)E,;E2K_+_6>YTGE0?6+EU9*H=-6>G E.!;6>C$I36#0[B\9K
MR['Z."2JXT:E*2R:G53CN.4%?1RRVWM!J7NN&! 4S=P3GH$@27O.=Y9'EZSS
M.]L>70W9C/F?8?#20"TG8]'L[!KK+<=JZI"HWAN5IK!H=E*-]Y87-'7(;B/&
MK",WZ/H>H2NW;A#M^T(L-A8W]EO<?KD-O/PB:FT9E::P:':*C0N/QVKZB%$-
M.2I-8='LI!I#'E_0]!%W&S4ZY7H@A@BWBPH(HJ2GP!@;WQO[?6^_YL[9I?GA
M@Q<%:N49BV8GUGCR>*R6CQC5HJ/2%!;-3JJQZ/$%+1_MV./+:,?NIQL00Z1;
MRP>"*'=/A9X>766_5DKS:P5%,,^>M^7^ O2'1P^_B/"^^1T Y_$[\D[M?]?
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MCQV&9QP&E</ $"TC,[161)+%C+,=XMI:H>F&T<9X*S8TT]/X*+EZ2I6?7#S
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MES5R&JZ@6C1EU:(6;)7U-9,T+F0A6F0FG=:LG-[6(&D^*"TH:'5K>.1,F]Z
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MY),;1E>,ZQ74Y^LLD\\S^K64\LVHQ7]02P,$%     @ $X+46%G?A<@P P
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M]*Z'NA!$>9&7'<5S>Q>NN=(WJVVF^NT#PACH[QO.U:%C)JA?4]$?4$L#!!0
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M9WU=RT71<A83Q3/;M=UQI7M .TQTFP["!.CG"\[59F(VJ!K_\2]02P,$%
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M 3LD<U(>B3H$@9*P0H$O3W23'9_KIKOO'S_.;HO5]]Y5X:@.9VNZ,[:XL4H
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MW]ZH$#3-+[= (F#*0/Z^IE2<;E2 ZLQW\2]02P,$%     @ $X+46-W0._4
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M\XZ'F!]9O6K51(O"/@QSH?&9L<,4KP9(8X#["R'T\\2\-<U?B^@/4$L#!!0
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MG_=V.-<W,A0F0+^?<J[6$W/HEW>\\"]02P,$%     @ $X+46-JE7A[H%
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MY2[/D5U>QSYVQA3RM[]A/>/R%YYK]OF_!%W@DB[PC!;\B'A W_P2K"*0K")
M[HE,!+]^&)/\,38@?_"$K@U)1A+ C 2$0"0W'8= .-.U*\E< IBYC$-@GZB!
M6^R;G,H:%8X0JD 1*> ;!C,@L!_)1#;+\8,'ZM7*C3Y -GH= D/M_I]&_P(4
M >&I9@LN2]"&0-*&(*(5FXCX0-_\$NPBD.PB0.Z*3$7 V'I<AL,#>(E[&8&D
M)0%,2V  A',!#@AGNG8EZ4L TQ<  %,+N_--#HA%Z65)[A# MPOF &!F/WY"
M4]6:$*@KJW*S#V<)((%V_:L((!-N_\$SS84 JM'T=9&<(:050$)2 81J-+UY
M22U"&@&D'T:__#WSS2L8>#;7;B0C"4^0/Y!<0/Z ,UV[4IZ)<)4_PDGRAS5J
M[ HXE+PA)),_0KNJ$3"STI$X?^1692CW^7"6^N&?!<G(!?"$NW_P7+,18 G&
M$$K&$-*J'R&I^D$UFMZ\)!8AC?H1VM4/OSV*S$-XB=L9H:0DX0GJ!Y(+7 ##
MF8Y=19*Z1*[J1S04-BP(:(T:0\!(,H>(3/^([+*&'YD0."%0KU9N]=$L_8/I
M O"3V,I+X DW >')YL( U6CZTDC>$-$J(!&I D(UFMZ\I!<1C0+2#S.X"3A4
M@.$)71M2GM \00=!<AD?!T$XU;4M26$B5R$DFB2$6*-&05#RAXA,"(GL^@8;
M;*(3 O5JY88?S11"U(O@^2!(JH10C:8OC:0.$:T2$I$J(52CZ<]-2X81TR@A
M_3#F=;"YB\.SN78CB4E\@@R"Y$(("*>ZMB493.RJ@\06A6.(@-:H,02,)7N(
MR720>$3>&$@V$P+U:N5V'\_200)-"B[:X!GW >&IYD( U6CZPDC:$-/J(#&I
M#D(UFMZ\\N((C0[2#V.2P&"HY,$3NC8D:4E\@A""Y&8  BYQOR*6]"5V%4)B
MF\0Q1$!;U"@"2NH0DPDAL5W?"(;'#QZHOWXD]_IDYIL@233& 2?<#(0GFPL#
M5*/I2R.)0T*KA22D6@C5:'KSDEXD-%I(,O(RR. R!I[/M1_)2Y(3U! D%V*!
M<*IK6Y+ )*YR2#))#K%&C6%@(NE#0B:')",O>:3F9<2$0+U:N=\GL_20\"Q2
MKX-%,>-A&'BFV1BP!&U(E'=3:=60A%0-H1I-;UZRBX1&#4GLK[2& _Q;XH9&
M(EE)<H(6@N0R'\"_)6Y5I)*^I*YB2&J3.08/PV!1>EF2.J1D8DAJUSC"V'P8
M9D*@7JW<Z]-98DB@Z<$&!\2O@^')YJ( U6CZTDC:D-**(2FI&$(UFMZ\)!<I
MC1B2VL608"@(PQ.Z-B1I27J"&(+D0B003G5M2_*7U%4,22>)(=:H,1*82OJ0
MDHDAJ5WC" :O!$\(U*M5O"YFB2&A"8)%\_,HAD0X")**(52CZ4LCN4-**X:D
MI&((U6BZEXAD&!F-&)+97PL)AR (3^C:D.0FV0EZ")++ 28(I[JV)4E,YJJ'
M9!:E8^B@@T7I94D"D9'I(9E=Y@A#TT1G0J!>K=SQLUEZ2'P6J7<#[S>5!$$_
M\2X_O/_Z!H5">,JY:$ UFKY DD%DM+I(1JJ+4(VF-R]Y1D:CBV3V]T/B@>L7
M/)]K/Y*@9"?((DAN "'A$G<N,LED,E==)!LJ'CPR'UM'@O2B%$\N,E4D&WGK
M(Q[@(!YH^&.I!EFS=!&NO2%GT,$I)EG$+EF+V&3YBD^63VR4Y=,Z95$-9RP
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M3^<\:+0+*\-G':=$&A4KE !S_IP!C?B[+\AL\Y%A$7ZAV(BRD%B"H7((/2S
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M?COMM;IC=ULL\7X,+@TJ#_%KLVE:."!8J7"]K' ]2+\R%?ZQ9U75O3:+IO<
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MN?'\@T%^(ME2OT)_9%*R5!_&&$689P'J_IPQN3G)&B@_VTQ_ 5!+ P04
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M#<[3^J!%&#1[G]6JK<=4\@%VSN[O-;_PE.;7-(*MKU(U]>&H+QT*.P7$NQM
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MYB8;K;*)DO3/N)9<W8W4.+G\C;'P%,4Q($D(_I0[RL'G1))D&VUB"FZ%H%*
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MLJ187-,@I#POH/8O&9,O*WD%]=M>YO\!4$L#!!0    ( !."U%AJ7HY=/@0
M . 5   9    >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;+58;8_:.!#^*U:N
MJEKIV,2&O&TA$F75WDJMBG;;NP^G^^!-#$1-8LXV2_=^_=DFFQ P%DCA"\1A
MYN&9R4SFL<=;RG[R%2$"_"J+BD^<E1#K6]?EZ8J4F-_0-:GD+PO*2BSDDBU=
MOF8$9]JI+%SD>8%;XKQRDK&^-V?)F&Y$D5=DS@#?E"5F+Q])0;<3!SJO-Q[R
MY4JH&VXR7N,E>23BQWK.Y,IM4+*\)!7/:04864R<*;R=H:%RT!9_YF3+]ZZ!
M"N6)TI]J<9]-'$\Q(@5)A8+ \NN9S$A1*"3)X]\:U&G^4SGN7[^B?]+!RV">
M,"<S6OR59V(U<2('9&2!-X5XH-L_2!V0K_!26G#]";:UK>> =,,%+6MGR:#,
MJ]TW_E4G8L\!CDXXH-H!G>LPK!UTYMP=,QW6'18X&3.Z!4Q92S1UH7.CO64T
M>:4>XZ-@\M=<^HGD,Z79-B\*@*L,?!,KPL!])7"US)\* J:<$\'! ,PP8R]Y
MM033DFXJH:VG:;HI-P46)%.WF<C_P_K1T(4!X]T=$3@O^'N)]N/Q#KQ[\QZ\
M 7D%OLI_EUY\[ H9CV+EIC7WCSONZ 3WZ9K= !3\#I"'1@;WV3GND78?=MU=
MF<4FE:A))=)XPQ-XG_(J%V3P199E9DC WU^D/;@7I.3_F&+=@8_,X*J;;_D:
MIV3BR';EA#T3)WG[&PR\#Z;(>P+KY&'8Y&%H0T\^,\KY8<68(M[!A!I&O6Z>
M$Q2%OC]VG_=#,5C%"(:-58?CJ.$XLG(\5;LFFCND8(_  /HQ/.1I,AL%GF\F
MZC=$?2O1^_G#6URN/]R9F%E=+RV9GL Z409-E,$U6R?H,P\]@77R$#9Y".U/
MNY(3:)>+PIP+4_CA4>4-H\/J/+9!0V0NS:@A&UG)SO1T(FS B&XD$S4KPJ5/
MIB>P3K!Q$VQ\S0J-^\Q#3V"=/$"O%0Q>/Z_W&F>_YF#@P^B@,HUFL1^8BQ/N
M"1O8VRN^ANJ\O*,@B@^I&LS".(Q/4&V% [3.XV2^8>E*:M$,")*N*EK0Y8N6
M6&O)OC(WO1WRTI+J"ZV;@%8QP.$UNPM:!<G%N>@)K9N+5IE NS0YO[^.%0>$
MOA\>%JW)+/!/%6TK3*!=F5S47_YQXP2RP0ZIFLQ0>$+KP59=0.O03KXSG,G=
MK]P9ZZX2:EGADI@;JU<UT1=:-_)63\#PJHUEE2L7YZ(GM&XN6KD"[7KE_,:*
MCLIPI#:8W5HU&$6GAE:K,J!U>%_65/%QMZ#PB*?)*O+,1%&K I!=!>BC N,V
MUNIW\3ZV)[1NE*V&0/"J6WJK0KDX%SVA=7.Q=[IA%REGMT^-T]EK[,FY.IAC
M(SF53E1EJR.0_>CADO9!QP<+@^BP>TQ&P>'H=/>.W]39YU?,EGG%04$6TLN[
M">588[OCQ-U"T+4^D7NB0NZ@].6*R)G$E('\?4&I>%VH0[[F4#?Y'U!+ P04
M    "  3@M18]GS0.UH"  #X!0  &0   'AL+W=O<FMS:&5E=',O<VAE970X
M,RYX;6R-5%MOFS 4_BL6JZ96V@HA ;HN04J:=>M#M:I1MX=I#PZ<!*O&9K83
MLOWZ'1N"TI4V>P%?SG<S^(QKJ1YU 6#(KN1"3[S"F.K2]W560$GUN:Q X,Y*
MJI(:G*JUKRL%-'>@DOMA$,1^29GPTK%;NU/I6&X,9P+N%-&;LJ3J]PRXK"?>
MP-LOW+-U8>R"GXXKNH8%F(?J3N',[UAR5H+03 JB8#7QIH/+66+K7<$W!K4^
M&!.;9"GEHYW<Y!,OL(: 0V8L \77%JZ <TN$-GZUG%XG:8&'XSW[M<N.6994
MPY7DWUENBHEWX9$<5G3#S;VLOT";)[)\F>3:/4G=U@8>R3;:R+(%HX.2B>9-
M=^TY' #"\ 5 V )"Y[L1<B[GU-!TK&1-E*U&-CMP41T:S3%A/\K"*-QEB#/I
M9RGSFG%.J,C)5U. (C?"4+%F2PYDJC483=Z3:2F587^H.\E/._PE-)#3.1C*
MN#XC)X0)<HLTN*W'OD%CEM[/6A.SQD3X@HEII<Y)&+\C81".R,-B3DY/SI[2
M^)BK"Q=VX4+'._R?<,]CS9G.N-0;!>3'=*F-PE_D9Y_[1F74KV*OS:6N: 83
M#^^%!K4%+WW[9A ''U_),.PR#%]C3_%(HCY/#2IQ*'OSMND@'F+EMD=KU&F-
MCFG%?5H-*GZB%0[[M:).*SJFE?1I13U:0="O%7=:\3&MBSZM^+E6%+V@E71:
MR3&M#WU:R?/O-4H&_VCY!Q?9]L1;JM9,:,)AA;#@/,'344V?:29&5NYN+Z7!
M3N&&!;9F4+8 ]U=2FOW$MHNNV:=_ 5!+ P04    "  3@M183]OO9?8%  !L
M,   &0   'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6RU6UUOVS84_2N$5PPM
MD-8F)4M6EAA(S!8KT )!BVX/PQY4F[:%ZL,EJ3@%]N-'?404986)[:N'));-
M>\1S*/+>8S)7^XS_$%O&)'I(XE1<C[92[B['8['<LB04[[(=2]4GZXPGH527
M?#,6.\["51F4Q&,RF7CC)(S2T?RJ?.^.SZ^R7,91RNXX$GF2A/S7+8NS_?4(
MCQ[?^!)MMK)X8SR_VH4;]I7);[L[KJ[&#<HJ2E@JHBQ%G*VO1S?XDCJS(J!L
M\5?$]J+U&A54OF?9C^+BX^IZ-"EZQ&*VE 5$J/[<LP6+XP))]>-G#3IJ[ED$
MME\_HG\HR2LRWT/!%EG\=[22V^O1;(16;!WFL?R2[?]D-:%I@;?,8E'^1ONJ
MK3<=H64N9);4P:H'2916?\.'6HA6 /:>""!U .D&N$\$.'6 \]( MPYP2V4J
M*J4.-)3A_(IG>\2+U@JM>%&*648K^E%:C/M7R=6GD8J3\SNN'B$N?UV@NSA,
MY04*TQ5Z_S./=FIP)7I-F0RC6+Q!;]&WKQ2]?O4&O4)1BCY'<:S&35R-I>I%
M@35>UG>\K>Y(GK@C)NASELJM0._3%5N9 &/5_88#>>1P2ZR(-SO^#A'O I$)
M<7LZM'A)^*P,=WK"Z4O"@S*<6-@XS8@X)9[SLA'I#,@_GU1S]%&R1/S;IWV%
M[?9C%XO(I=B%2W8]4JN$8/R>C>:__X:]R1]]ND&"42 P0U.WT=2UH;<TW>FG
MG#V*VJ=CA>>7>,7:>3_'[F2JQO>^+5!O*Z_3BEK[=B+S:<-\:F7^B0EQB6Z6
MRSS)XU"RE5H4U6V645@LNWW,*SROQ>FM'Y N\YY6,S=P.LRM?3N1N=<P]\X8
M\PN4LMZ!]PZ(>=C!'?:'C:93+^B0MW;O1/)^0]ZWDJ>M04;L054)@O6Q]0\>
MX&#J=LCZ!V2#H,NU!\?7. :%64-A9J7PWC8]K:''+G.08!0(S) L:"0+!DP=
M :2FD& 4",S0%$]TA30Y:R')!5OG,8JC=>\4>P8=3]$O%O*^0FIA#SU612@T
M4\96H8F!<W -V%Y5/"?P.LM3W<I8L?V)WUF@[)T[E3S1Y,G+%C/TGRJ=TRC)
MDU[&5I1CYR H&H5",Q7453$>LBS&H'4Q*!J%0C.%U:4Q/J<V?GYYLZ,3R^H&
M5!?7*@Y196-=9F-[G6U,\/#AR0D.5!'7"D*B42@T4T%=KF-OR D.5&W7PD*B
M42@T4UAM!;#="YP[P>WHUOK%&GJTC$!HIHS:CF"['UEDR2Z7C".1K>4^Y/UB
M@1H34#0*A6;JI[T)'M*<8%!W HI&H=#,+S^U/R'G^),^,6O =F%-9G[W*YZZ
M5;NP)D'W*S!J[]RIY+6K('97<3 K[?G7CG;L8P2*1J'03"6U12%DP/E)0)T+
M*!J%0C.%U<Z%6 OX<_/O,^AX\G3^M8<>+>,0/H5HGT+L3N)3(5OQ$Q>_HF3'
MLWM6*-B[!V4'._IY!+4J4&BFD-JJD.F0$QW4P8"B42@T4UCM8,@Y.PZ]8GJ'
M&TC3H)N'#W<;\,$>D[UKIU+7'H/87<#3D_.9? SI$!:@:!0*S914^PTR&W*:
M@AH14#0*A68*JXT(L=;C9^=C.SJQY6-0VP&%9IY2T+;#L=N.VSR*5U&Z$=6\
M9Z%@VRQ^/C/;88\^H@"Z10*%9DJJS8R#ASSZ >IM0-$H%)HIK/8VCGW[Y?C,
M7 ,:%GDZZ>X]U:T,B^S.NGM/]LZ=2KYUGLCN$%XR4>U9VGZ#HY\LV&-%0[@2
M1[L2QQURRH*Z%% T"H5F"JM=BF/?4#DS2S^#[EJRM#WT:!F'\"2.]B2.W9,L
MLE1(GE>';*,4J2F_4??IS\R@>RB@:!0*S911^QO''W*:@[H<4#0*A68*JUV.
M8]]5.2$SSPXS,\9=T]S3"OO=HVW4WKECR8];Q[ 3QC?E<7:!EEF>RNHT<_-N
M<V3^ICPHWGG_%E_2ZN"[AJG.X7\.^29*A<KB:P4Y>>>KU8571]NK"YGMRL/>
MWS,ILZ1\N67ABO&B@?I\G67R\:*X0?,/!O/_ 5!+ P04    "  3@M182IZL
M=?H%  #9,0  &0   'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6RUFVMOVS84
MAO\*X19="P36S9:=U#$06[)68 6"&MT^#/O V+0M5!)=DG+:83]^U"62J,B,
MM9SY0ZP+SW.HG)>4]%J:/5+VC1\($>A''"7\=G 0XGAC&'QS(#'F0WHDB=RS
MHRS&0JZRO<&/C.!M'A1'AFV:KA'C,!G,9_FV>S:?T51$84+N&>)I'&/V<T$B
M^G@[L 9/&[Z$^X/(-ACSV1'OR9J(K\=[)M>,BK(-8Y+PD":(D=WMX,ZZ"6PG
M"\A;_!Z21]Y81MFA/%#Z+5OYM+T=F%F/2$0V(D-@^74B2Q)%&4GVXWL)'50Y
ML\#F\A-]E1^\/)@'S,F21G^$6W&X'4P':$MV.(W$%_KX*RD/:)SQ-C3B^5_T
M6+1UW0':I%S0N R6/8C#I/C&/\I_1"-@9)X)L,L NQ7@V&<"G#+ :078XS,!
MHS)@=&F7QF7 N)WA7)?<,L"]-&!2!DSR8A7_W;PT'A9X/F/T$;&LM:1E"WE]
M\VA9D3#)I+@63.X-99R8KP^8D0.-MH3Q7Y#_/0W%3_3>(P*'$?^ WB(#\:P)
M1V&"OB:AX%=RHUQ>A%$DM<1GAI#=R&#&IDRY*%+:9U):-OI,$W'@R$^V9*L"
M#-G_ZB#LIX-8V%KBW9$-D>U>(=NT1^CKVD/OWRI]+[XZNKJ\!#S-P<Y%0*]/
M3]^]F3KNZ&.%[>#Y_]>1K_3@SUB"'4L%=V""BS'6=3=&J;A3R=;)N<X9[C+"
MG".Z0VM!-]_0G[_)_>B3(#'_JTN0!6S4#<MF^QM^Q!MR.Y#3.2?L1 ;S=V\L
MU_S8)1E(F <)\R%A*TA8  13M#*JM#+2T>=+&L?RI,<SI5PAG(H#9>'?9(O>
MRVFL&!]=REYHJ7U%4\#<')9='ISFMFN6GYEQ:DH",J]_>=X59-X "*84?%P5
M?-RCX$?,T E'*<GKO:51A!E'1\**VG] _S3FRRX=:)/UU4$!L\Q&0<RAK(75
M$@%D4O_"I"O(I $03%& 6RG U2K (SO"F!SBI0;*D^'E8U^+[UMS2)@'"?/=
M9[/#J&-B@$P9 ,$464PJ64QZR4*=&DC*:&MBN. ";:%-V5<JD#"O@,F[L+J\
MK1'O0^9;0<("()BBDVFEDZE6)_>L)93+)PXMN*\:(&$>),R?/ILX+'LR[KJJ
M@$P; ,$445Q7HKCN)XI77UAH\_75"B3,@X3Y!6RJ7'S8+95 )@R 8(I*++,V
M5,Q>)YF0\_3E>4,/[2L&4)H'2O-+6G/N:,\9H D#*)JJAX;!9O72 TT%%SC9
MALG^15%HR;U% 4GS0&E^2=.* C)A $5316'7HK#[G4SZJ$*+[JT*2)H'2O-+
MFE85D D#*)JJBMK4M+0^V'-57'CN +4W06D>*,TO:5I!@/J64#15$+5S:>FM
MRW7A6S!R3-GF@/D%6N@P_,9==M^RHZ7;Z4?J^]B[A)"T%2@M@**IU:YM2TOO
M6]Z=",-[TB@W.K)P\Y_O+\ITS2OOJ3,T1V;]L=JB>!YR;0V=MCNI/Y#>DH"D
MK4!I 11-E43M8UIZ(_,NIFDBFO[#CK*F0*0&.DL/:F""TCQ0FE_2)DTKHNUK
M=[09JTV"CB9NU40M7NTV6GJ[L2Q><_8^5ZX"U'3JQL-)>VR"FH.@-!^4M@*E
M!5 T506UEVCIS<2G(7S"880?(I*/X%TJ4M:<Z?E9:8 ZBJ T#Y3FES1U$#CM
MH0SJ)T+15&G4CJ*EMQ37A(6R\G>HOO!?GS^;@]J%H#0/E.:#TE:@M "*IC[G
M5)N+M@GYW(L-ZBJ"TCQ0F@]*6X'2 BB:JIG:@+3U!N0K?LW2DWOK!]2 !*7Y
M]G,#LO/G+-"L 11-54;M0MH]7<A7_Z2E3]A;,*#>)"C-+VG*?4=;*Z#>)!1-
MU4KM3=H]O<D>CK4>W5L5H 8E*,VW7S8H01,&4+1"%4;C0?*8L'W^C@!'F^P.
MIG@XM]I:O8=PES]]W]J^L&Z65L=VS[KQB[<,:GSQTL-GS/9APE%$=C*5.9S(
M^P!6O$=0K AZS!]C?Z!"T#A?/!"\)2QK(/?O*!5/*UF"ZFV.^;]02P,$%
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MA[)RRL ]E)#'UKX">CHP9:,Z92,PSL^Z! 2SHFWKMRD%/7SK4.;)V8;8L.M
MHWOB<;\*P%.V?'G;3%>#R\+_3T'MB65=48-U1?5W%A3LZ="L89<U[&_\%5L%
MB(CI9NUTBI\,OU$_W!I_X=@.U>X(,H01<GL\07]KX,Y9MLA:%7D%2E_>-J4[
MI Q/S92A5ZCTY6TS70XK0Q@*]\/7'@?1;OJ"+0^5YK RA+FPK0C(P\XB\,2*
ME?1CD&?HT#,<G+H(/!%FE:YC\&KH@#6$,?$910 [ 'Z"P):'2G-@&<)D.:7"
M+O#E,2T78S0J,-4^L7DE3%_>-E=T'&+B4R,F]HJ8OKQMILLA)H:Q;G\%['$
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M"0E% 8'EOV>R($E2(,EQ_%N!.O4UB\3VYS?T7Q5Y2>81<[*@R5]Q)#8S9^R
MB*SP-A'W=/<;J0A=%G@A3;CZ"W95K.N <,L%3:MD.8(TSLK_^*42HI7@^0<2
M8)4 ^PFC PG#*F'XWH11E3!2RI14E X("SR?,KH#K(B6:,4'):;*EO3CK)CW
M!\'DM[',$_,'0<,GL-RR<"/5 SB+P/4.LP@L$YQQ< Y4P'DA;006-)7KC6,U
M8]]?BL\$?$5$X#CAWV3PCP<$OG[Y!KZ . -W<9+(0#X="#G0XG*#L!K433DH
M>&!0'@1W-!,;#KYG$8FZ  /)L*8)WVC>0"/B=<XN /3/ '3A2#.@Q7O2QRI]
MJ$E'[TF?J'1H8#.L)VVH\(:')FV#&='-R35C.%L3Z4L!'E]!.VZ)7]7I<G;_
M_EU"@EM!4OZ/;G[*ZX_TUR_N15<\QR&9.?)FPPE[)L[\YY\\W_U%IZU-,&0)
MK*/[J-9]9$*?_T$%3@!O.2)LJT]*1^CT+'$#A5O<BI_GPXE<2,]MF30QEY?=
M&*2+F=0Q'5*7-:E+(ZG;3)(@0. 7\$@RLHJ%UK$EB-^Z\KD_ZC'0Q;@]!KH8
MJ&?@UPQ\"]-R!C+Y,TI7!5,=07]O8$,XZ1'<CX&3_A3I8@(]P: F&!@)+BA7
M(\\9C;:AX(#3)-)Q,,(<:UN;8,@26$>^<2W?^,2WR[%-W6V"(4M@'=TGM>Z3
M3[I=3O:]V+/90A/B]YQH#.DP\MRF7'*-G.ZE2E@62ZI2BLBS+)QSM5 ,;,R0
MQRX/JVC(%EI7SE;UZ9W8FM4 ;(EO$PW90NN*#QOQX2?YLP)N6VL4] RJB1GV
M?D^1#L<]8-&F./:,->#\03:1<;8^ VM9SC"<G"FOXDAV3S$7#!>-II&<U>+7
M*AJRA=:5MJE_O=&I[6JLP(\6WR8:LH76%;^ITSUSH?X!N^X7W4//[?MU/PB.
M^]6[-FAXP+%-_>Z9"_CR(03-Q<''!<;\HU>%331D"ZVK7=,:>,&I+6FUJ["*
MAFRA=<5O&@O/6#]_Q)+C/2,%?M^1FIB@;TA-S*%?T*9N]\R%NRQR!8M#(?DH
M;EH"1HBC5X5--&0+K?NHL>D1H'MB2T*K'855-&0+K2M^TU% 8]'\ 4M6P&TK
M>>/^(RY=D-]O//\'J<NL*=>AN5Q?$J;V>;*0 %XL';#-#CRL,R,=O3YLHB%;
M:%T5F^X GOK9.;3:/UA%0[;0NN(W_0/\K ?H%7#;4I-^QZF)"49]:^['^ <>
M"L&F,H?FROQ[FB?TE9"2&<C?=M/R!&=:,D:XHU>(331D"ZTK9=,*0/_4]K3:
M2UA%0[;0NN(WO00T[S-\P)[!_L94OYS5Q8S[]M3$]/>W!JW=[I2PM7IK@,NA
M;C-1[@C79^LW$Z[5?GSO_(UWA<KW"QJ8\G6'.\S6<<9!0E82TKT(I"E8^09!
M>2!HKO;4'ZD0-%4?-P1'A!4!\OL5I>+MH+A _1['_#]02P,$%     @ $X+4
M6+@/S@Z# P  EPL  !D   !X;"]W;W)K<VAE971S+W-H965T.#@N>&ULK59=
MC^(V%/TK5K9:S4H=DC@!PBP@\;%5^[ 2FE%G'ZH^>,@%K''BK&U@^/>]=I@4
MJ(E&%3P0V[GGV.?XVKG#O52O>@-@R%LA2CT*-L94#V&HEQLHF.[("DI\LY*J
M8 :[:AWJ2@'+':@0(8VB7E@P7@;CH1M;J/%0;HW@)2P4T=NB8.HP!2'WHR .
MW@<>^7IC[$ X'E9L#4]@_JP6"GMAPY+S DK-94D4K$;!)'Z8#VR\"WCFL-<G
M;6*5O$CY:CM_Y*,@L@L" 4MC&1@^=C #(2P1+N/GD3-HIK3 T_8[^V]..VIY
M81IF4OS@N=F,@BP@.:S85IA'N?\=CGJZEF\IA7;_9%_']C%XN=5&%D<PKJ#@
M9?UD;T<?3@ TN0*@1P"] ,3I%4!R!"0?!:1'0.J<J:4X'^;,L/%0R3U1-AK9
M;,.9Z= HGY=VVY^,PK<<<6;\9.3RE2RV:KE!]P@K<S+9,Y63A6"E)O?DF8DM
M<ULTT9@;E6UJ<C<'P[C07S#B%Q(2O6$*]# TN"1+'"Z/TT_KZ>F5Z6-*OLO2
M;#3Y5N:0GQ.$J*411-\%36DKXZ12'4)[OQ(:T=2SH-E'X)F#)Q[X_"/P@8/3
M%C5)LSV)XTNN;8_U]7Z*6X,[P@YXW@R9*,7*-;CV7Y,7;10>GK]]WM?<J9_;
M7B@/NF)+& 5X8VA0.PC&GS_%O>BKS[=;DLUO1';F:=IXFK:QCW^XNP -93M0
M>+61%>.*[##/@<@5D<<47Z/+-NJ.ER270C"E206J3O4O/KOK:3,WK;UN=^,X
MZZ2#8;@[]=$3U>_T>^=1\_]&4=K)DB;J3'FW4=YMS:;3$[S%E'KPJ>C>,FEN
M23:_$=F9=;W&NEYKTGQ[J_!+A>D@^ K(W0$P';Q)T$[3(PY)8E+8:X_T2,X.
MOGMS]B$>GTO_ WCF2+]QI-_*],CUZ_U* 1".YP0=-T0Q SY/:J(X.<GFJ!.E
M\472S_QQM']Q-OQA438X__G/2M;(RUKE/4N!GSW!S<&G*/,M@:;T\K!?B8NZ
M%Y+\<4F4^D4,&A&#5A%SON,YX#?]P$'D/B$#KY=)G%T(\<?1 ;T0XH^+!]T+
M(>%)R5* 6KO23Y.EW):F_M@WHTUU.7%%U<7X%*O.NDC\EZ8N6;\SM>9XTPE8
M(674Z>/]H>HRL.X86;G"Z$4:++-<<X.5,R@;@.]74IKWCIV@J<7'_P!02P,$
M%     @ $X+46!KPC3'S!0  ,R,  !D   !X;"]W;W)K<VAE971S+W-H965T
M.#DN>&ULM9I=<YLX%(;_BL;;V6EG4@,RQCCK>,:)N[N]Z#33].-:@6.;*2"O
M)-O)OU\)")B/R-!1>]$8K/-*YY$0[S$L3I3]Y#L @9Z2..4WHYT0^VO+XL$.
M$L+'= ^I_&9#64*$/&1;B^\9D# +2F(+V[9G)21*1\M%=NZ>+1?T(.(HA7N&
M^"%)"'N^A9B>;D;.Z.7$EVB[$^J$M5SLR18>0'S;WS-Y9)4J891 RB.:(@:;
MF]'*N5YC7P5D+;Y'<.)GGY%*Y9'2G^K@8W@SLM6(((9 * DB_QSA#N)8*<EQ
M_%>(CLH^5>#YYQ?UO[/D93*/A,,=C7]$H=C=C/P1"F%##K'X0D__0I'05.D%
M-.;9_^A4M+5'*#AP09,B6(X@B=+\+WDJ0)P%8.^5 %P$X$: X[X2,"D")GT#
MW"+ S<CDJ60<UD20Y8+1$V*JM513'S*86;1,/TK5O#\()K^-9)Q8/@@:_$3W
M!Q;L)#U$TA"M3H2%Z#XF*4?O4=[@\U[-$D<K-4V1>$9OUR!(%/-W91-:-'F/
MOCVLT=LW[] ;9"&^(PPXBE+T+8T$OSH[\75'#UQV*$^^4<>?HCA6"@M+R,34
M\*R@2.(V3P*_DH2#T2>:BAU''](0PKJ )8F46/ +EENL55SMV1AA[PIA&[L=
M [KK$^YGX9..\'6?\'D6CC793,I)GF1ZDU?TBMGK IL'NMV!:M.YYGL2P,U(
M[BH<V!%&RS__<#S[KRXH)L76AL1JP-P2F*M37WX^""[DTHS2+2("/<(V2E-U
M0#=H#RRB(7HK5VR^EM]U<<WUO4Q?[;W'Y<3V/6]A'<^!:4<Q%)@AL1JP:0EL
MJ@7V#R.I@(M4IBTJKJ\ND!H4;4]#H1@2JT'Q2BB>%LJ')V!!Q"]C\5I8WCNN
M.VUPT78VE(LAL1J76<EE=H'+/F(06O+&O8&HQ[*9=?"9VTT^VDZ'\C$D5N/C
MEWS\(;L/R'MR[WW';^\[>#*9-U!UM&KO3FOM*'^1P;QD,-<SR&]95T@N%FD1
MY1H1%!V!BTL YJW4_+GC-O+7]CUTJ1@2JV%R[,J_V7U!9;L->8SA$J-"\AP2
MQC.W>7?2]SP4DRFU.J<SG^MH/= /$8[1ZK@=OX "=,^B #KY."9=D5&UM2FU
M.D9<8<0FG%%(XY@PKD[E"[%['>9]^6?K<#X9-_V ?D2#^1E2J_.KG+BC]:TU
MH]034B[HS,ZW-&_LMZY6H^[;E%H=4^6_';T!KUNGGJ#<-BAO.K:]^=F_)C2C
M#MR46AU:Y<$=O0GO]E4]X4W;\.;^V,%-8$;=N2FU.K#*GSMZ@W[1:/5DYW6P
MD_N8HUMX7H^M;ZT?_Z_RJ7RZHS?J/[)?S>0Z6AV!D2TT;IVOF+.>T&8=T*9C
MK[7@C-IZ4VIUH)6Q=_3.O@?0NHGKR=)O+R8\=J>Z]6?(W!=8?T>IX%2U@C/7
M>KM5&$;*!9,8K2,>Q)0?9#>=I$PZ_SNC:FM3:O4?/*M" NL+B=;:_ +JN8':
M&^]H*A@)Q$$"_@HLN4)G.V<7Y@M=N>@9U*IV;)3DO]MB%X7DN6O*[O1:0R&;
M4JM#KJH0K+7GPR W=]=.TOK^_(*TVP>TT3K%E%H==%6G8'V=,A!TN>MV,M9W
M-1G"V&@M8TJMSKBJ9;"^EEEMMPRV1 #Z*(E&*8\"])W$![B\/^3"Y_?^B=VX
M0^D['XSJ=]0SN*IGL+Z>T:#J=96W'R<T?9)^ (-Q_8Y*!E>5#-97,EI<^FNU
M_8@!^TU41FL84VIU5%4-@_4US!WA.[1G-  (.=HPFI1/8N&EB.X$U7[H,&N!
M\EJ7Z6S6*%$ZVF"[<IOUK*K* ^LKCVK:CVK:55G6+ZOVHX+V]+?;N+B95;N-
M,W-?R:JR_UAO_[^2)_0(*6PB@1C$I+CJ^V7FMS@W?P'J:#)OYM5NXMJ-M*RS
MMPD28-OLK0R. GI(1?X$O3Q;OOFQRMYW:)R_=:[7^?L;E4S^.LDGPK9R>E$,
M&REICV?R&F+Y&QKY@:#[[)V%1RH$3;*/.R A,-5 ?K^A5+P<J [*]V26_P-0
M2P,$%     @ $X+46$U$G:1)!   ^1,  !D   !X;"]W;W)K<VAE971S+W-H
M965T.3 N>&ULK9A=<]HX%(;_BL:;Z20S#;:%,786F"%AV^Y%=IBD::\56X F
MMD0E >F_KR0[!G_$-5WG(ECBG%<ZCV2=@R8'QE_$!F,)7M.$BJFUD7)[8]LB
MVN 4B0';8JJ^63&>(JF:?&V++<<H-DYI8D/'\>T4$6K-)J9OR6<3MI,)H7C)
M@=BE*>(_;W'"#E/+M=XZ'LAZ(W6'/9MLT1H_8OFT77+5L@N5F*28"L(HX'@U
MM>;NS<+UM8.Q^$;P09P\ QW*,V,ONO%O/+4</2.<X$AJ":0^]O@.)XE64O/X
MD8M:Q9C:\?3Y3?V3"5X%\XP$OF/)=Q++S=0*+!#C%=HE\H$=ON \H)'6BU@B
MS']PR&T="T0[(5F:.ZL9I(1FG^@U!W'BH )M=H"Y ZPZ>.\X#'.'85<'+W?P
M#)DL%,-A@22:33@[ *ZME9I^,#"-MPJ?4+WNCY*K;XGRD[-'R:(7L-SQ:*/H
M 41C,#\@'H-E@J@ U^ !"\E))'$,,MNY7BDB?X++!9:().*J;"6,U35X>ER
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M'0;/./0#=,N96DKTF150[ NX.MPVYF ;\R0XJ3BN1 \%R04*O"#J,'3]&OK
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M/IBH9-.HFH46E2O=#T*;1N"FI>GM(*V#V2^$T+N%/:#[MY#^ U!+ P04
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M@'^_(H0=#L0%RC<QI_\!4$L#!!0    ( !."U%B+-I2!Y0@  -Y/   :
M>&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6R]G&%SHS83Q[\*X\YTGF>FC4$(
MV4Z3S"16.NV+:S.7NSZOB:TD/,7@@GRYSO3#%S!!EI VX%OG7EQL9_4WNZS$
MCV6CBY>\^+-\%D)Z7S=I5EY.GJ7<GD^GY>I9;.+R+-^*K/K-8UYL8EF]+9ZF
MY;80\;H9M$FGQ/?9=!,GV>3JHOGLKKBZR'<R33)Q5WCE;K.)B[]O1)J_7$Z"
MR>L''Y.G9UE_,+VZV,9/XE[(S]N[HGHW[536R49D99)G7B$>+R?7P3EGBWI
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MGJKTO$[3?!7O3?[#A8R3M/QO)7+7ILC#7KR\F,KJJ.OOGJ[:([S9'R%Q'&%
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M A]'A6$\W%JCQS4U;R$< COA<'U?U>VKEM=K+Q<UK"4!JAF@: R%II(J-$-
M:X87URETR0]%8R@TE5JQY _H);]=G6J6_GXT+--QT'*H[NE!34U:K.<#>CU_
M6I'29U3T+:SG%%00H-!4>H4@"%*WY0H]=X"B,12:VIH@I$1(2PFK<@W'6F)<
MKIJ@4;G2@YJ:M! ((2T0+,M5>Y1%W\*Z:P.J-5!H*KU":X2!TW(-H0(#BL90
M:"JU4BL1W4MD5ZZA\33+',+H$4W-6*S[0WK=;UFKVF,N^A;6$PK:#(1"4^D5
M\B)<N*U5J,B HC$4FDJM$!DAW9]D5ZNQN5:-(8P>T=2,Q=H_I-?^)]?J"W:?
MZ"%83SCHJ0(*3:5?J)!PZ;:6H0H$BL90:"JU0H&$])&$72V/#R1&M6P,8?2(
MIC;?"F$0T<)@6,N?-^TF*[S;37FC39J&L^ZWA9Y'H-!4*H7<B'RG=1E!I084
MC:'05&J%U(CH8PVKNMQAT?)5%S0?[@G3HYJ:M5 !D<43!8/:I#>9:&#KJ00]
M8$"AJ:1*CQM$;JL4*C*@: R%IE(K1$8$?.A@AV6H4DW0N$I=K/\CL?Z/[)Y/
MT%:I=F^)!K:>2M#C!12:2JJ0&)';9Q8BJ'R HC$4FDJMD \1\,&%:-R4-%SC
MFD,8/:*I&8M5?63WY(*V0K4[2C2P]32"GBB@T-3GRX1P6+A]EF$!%1)0-(9"
M4ZD50F(!?)9A87Z6P1S"Z!%-S5BL[Q=V;4N#"GW!/A)]8^MI!CUD0*&II MY
ML7#;Q;2 B@PH&D.AJ=0*D;$ =C$MQOU)HPHVAC!Z1%,SEIXWMNM?^O#')F__
M\E;5>IV7=T4WS=IZTQPA 'JX $5C*#255B$N%FX[F!90B0%%8R@TE5HA,1;
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MZD^!ZP7J_9(Q^3'0+5/1\8:_ 5!+ P04    "  3@M18EE4EG<\"  !?"0
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MN:Q8@14H&G1[&/:@V$PL5)8\24ZZOQ\E.UYN#3I@+[8D\QSQD#0Y6$OUK',
M0UX*+O30RXTI;WQ?ISD45%_)$@1^64A54(-;M?1UJ8!F#E1P/PJ"GE]0)KQD
MX,X>5#*0E>%,P(,BNBH*JGZ/@<OUT N]S<$C6^;&'OC)H*1+F(%Y*A\4[OR6
M)6,%",VD( H60V\4WDR[UMX9?&.PUEMK8I7,I7RVF[MLZ 76(>"0&LM \;6"
M"7!NB="-7PVGUUYI@=OK#?NMTXY:YE3#1/+O+#/YT+OV2 8+6G'S*-=?H-'C
M'$PEU^Y)UHUMX)&TTD86#1@]*)BHW_2EB<,6(.R] H@:0+0/B%\!=!I YZV
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M@U;I0VD!BJ:_%]8XO([9X74YG3.INH[';;PA3_D;;(F:B#P=+8=F-.++M%A
M7;8>,E?<5C50F@NE>5":#Z4%*)HNK\8F=FST&.5 ?5\HS872/"C-A]("%$W7
M3>/[.D9_\*?70V9L:_$XQX\UNR-]<'&A57I0F@^E!2B:KHG&TW7,GN[_?1AI
MQK?6QK%3[!Q) ^KL0FD^E!:@:*4T.GNOZ,<L6Q6[+_+<JWEK^=)[?;;>X7%7
M[&LX.._9-T&Y3Z/!E-M&'FBVXHD@$5LJ9/=J-+!(5N[$* ]DNBDV LQ3*=.X
M^+IF=,&RO(#Z?9FF\O4@KZ#>#S/]%U!+ P04    "  3@M18+\:OZ)0"  #J
M!P  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,3,N>&ULK55M;],P$/XK5I 0
M2+"T2=I-I8W4-KP,:=.T"?B ^. FU\0BL8/MM./?<[;3T(TL [0OC5_N>>[N
M.?=NOA?RNRH -+FM2JX67J%U/?-]E190474B:N!XLQ6RHAJW,O=5+8%F%E25
M?C :3?V*,N[%<WMV)>.Y:'3).%Q)HIJJHO+G"DJQ7WAC[W!PS?)"FP,_GM<T
MAQO0G^HKB3N_8\E8!5PQP8F$[<);CF?)Q-A;@\\,]NIH34PF&R&^F\UYMO!&
M)B H(=6&@>)G!VLH2T.$8?QH.;W.I0$>KP_L[VSNF,N&*EB+\@O+=+'PSCR2
MP98VI;X6^P_0YF,#3$6I["_9.]OIJ4?21FE1M6",H&+<?>EMJ\,1 'GZ 4$+
M".X#H@< 80L([P.F#P"B%A!995PJ5H>$:AK/I=@3::R1S2RLF!:-Z3-NRGZC
M)=XRQ.GX!G(LHB:49^0]B%S2NF I.>?N19G2O":75$IJZD->)* I*]5+/%4.
M.O<UQF'8_+3UN7(^@P=\AN1"<%TH\I9GD/7@DV'\.!@@\%& 3H7@H,(J&&1<
MUO*$!--7)!@%44] ZV'XQZ9$^)F%AWWY_+?W.]F$74U#RQ<^4M-KJ(74C.?D
MZW*CM,3_V+>^:CFVJ)_-])V9JFD*"P\;BP*Y R]^_FP\';WI4^HIR9(G(KNC
M8M2I& VQQY=-M0%)Q!:[VT'']LFK/A4'V?Y5Q:<D2QS9U)*9,;"+\97M>J29
M=-),_E(:'#^F,SPBS>2/ ((N )?OHQ;)D(5+PC_J@A7(W$X315+1<.U:07?:
M#:RE[=/WSE?CV=K-G=\T;@I>4)DSKD@)6Z0<G9QB5-)-%K?1HK:]=B,T=FZ[
M+' 8@S0&>+\50A\VQD$WWN-?4$L#!!0    ( !."U%AF4'D"3P@  $L[   :
M    >&PO=V]R:W-H965T<R]S:&5E=#$Q-"YX;6RU6^]SH[86_5<T;J?3SM1K
M0/SR-O%,8MCW,M-M=Y+VO0^=?B"@V)H%Y HYV>V\/_X)L"T#%^WB*E\28Q\=
MHW/%]3WH<O7"^,=J2XA GXJ\K*YG6R%V;Q>+*MV2(JG>L!TIY2=/C!>)D(=\
MLZAVG"19,ZC(%XYE^8LBH>5L==6\]X&OKMA>Y+0D'SBJ]D61\,^W)&<OUS-[
M=GSCGFZVHGYCL;K:)1OR0,3ONP]<'BU.+!DM2%E15B).GJYG-_;;V,7U@ ;Q
M'TI>JK/7J)[*(V,?ZX.[['IFU6=$<I**FB*1_Y[)FN1YS23/XZ\#Z>STG?7
M\]=']G?-Y.5D'I.*K%G^7YJ)[?4LG*&,/"7[7-RSEW^3PX2\FB]E>=7\12\'
MK#5#Z;X2K#@,EF=0T++]GWPZ"'$V0/+  YS# *<_P!\9@ \#<'^ .S+ /0QP
MOW: =QC03'W1SKT1+DI$LKKB[ 7Q&BW9ZA>-^LUHJ1<MZX7R(+C\E,IQ8O5
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M&2#?KRD53S?E![0GQ9;_ U!+ P04    "  3@M18 >0NJK<$  #5&0  &@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,38N>&ULQ5E=;Z,X%/TK%CM:S4B9@DWX
M2#>)U);N;J5V5#73W8?5/M!PDZ !G+&=IOWW:SX*@3AL&[GJ2P+DGN-[C^W+
M"8RWE/W@*P"!GM(DXQ-C)<3ZU#3Y? 5IR$_H&C+YRX*R-!3RE"U-OF801@4H
M34QB6:Z9AG%F3,?%M5LV'=.-2.(,;AGBFS0-V?,Y)'0[,;#Q<N$N7JY$?L&<
MCM?A$F8@[M>W3)Z9-4L4IY#QF&:(P6)BG.'3@!2 (N*O&+9\YQCEI3Q0^B,_
MN8HFAI5G! G,14X1RJ]'N( DR9ED'C\K4J,>,P?N'K^P_UX4+XMY"#E<T.3O
M.!*KB>$;*()%N$G$'=W^"55!3LXWIPDO/M&VBK4,--]P0=,*+#-(XZS\#I\J
M(78 V#T (!6 = '# P"[ MBO!0PKP+!0IBRET"$(13@=,[I%+(^6;/E!(6:!
MEN7'63[O,\'DK['$B>D,EG(6!0JS"/T!=,G"]2J>HZNL7%+YU'Q%,[G:HDT"
MB"[0-[D69V$"' F*+I\$L"Q,T$61*3!>$-TRN2Z9>!Z@VR3,Q*"X>/ES$Z_S
ML08YQP ]/.\.> ?+?*S/ 8@P3O@7.>K]+$"?/WU!GU"<H9LX260 'YM"5IWG
M;LZK"L_+"LF!"C%!-S03*XXNLPBB-H$IY:HU(R^:G9->QK,U.T'$'2!BD:$B
MH8O7P/T";BO@P6O@HP).>JJQZQ5@%WSV ;X[>(1L(^=SP6AZ:$:O:;;\>BUW
M:(3.. ?!T3_7D@=="4CYOZI)*0<=J@?-N]DI7X=SF!BR77%@CV!,?_T%N]9O
M*D%UD@6:R%IB#VNQAWWL+V*K!"N!7@',N_7CU":V*]?7XZX2BBA,B->."E11
MKN_64:W<G3IWIS?W9E>OFUT-S:[.0*CJ*DG=G5Q<;.-.6?M!CN...E7UIG?D
MQ+EU\6YO\5<,9-&1JL!>X%M7NDZR0!-92S"O%LS[B+;BZ11;)UF@B:PEME^+
M[1_;5OR]G86QW=E]^S$CO[/W%#065O>349WTZ#WZR6@O$^*03D'[,=CO=-*@
M-[DCYPM;C>VR>HO_3H7<#52L@*$YW62"Q< '")[FR2:*LR7J:3C]U&_=!%K9
M EUL;5EWW"S^B*Y3C:I+<9UL@2ZVMN*D49P<VWHJI-NR-,3IWOM581B3[MU?
M&>;XCKH)X<;^XE[#=VP;JEA;EL7W1MW:%%'V3LY5:>]A27'C27&_*;W/8B'W
MPDR$ M1_L'KQ;U[^.MD"76QM[1I/C)T/:3B:O&ZEN$ZV0!=;6_'&B.-^)][7
M<-S]^[[KN%UWH RS/;N[*U5AV#[4<!ICC'NMX-$-Q]M+9^B,NE9.%67Y>Z6]
MAUG%C5O%_V=7N<B?)6TI2]0.IQ?_YN6ODRW0Q=;6KC'->/0A#4>3':X4U\D6
MZ&)K/^QKK#KIM^H]#:="MEJ$X_I=%Z *&WJ.V]F559C78ALZEKKAD,84DUX+
M>&S#J5A;Z1#?[=:FB+(MTBU-JTDU=YYWRS6_+-X;\/)_5/D8M[Y:OYLX*Y[(
M=ZZ?X].@?,/0T)0O/&Y"MHPSCA)82$KKQ),W/5:^0RA/!%T73]4?J) ;KSA<
M01@!RP/D[PM*Q<M)/D#])F?Z'U!+ P04    "  3@M18QQN??Y($  !G%0
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
M$X+46 @PMWC]!P  ZDP   \   !X;"]W;W)K8F]O:RYX;6S%G%UOVS84AO\*
MX9ME0+W(DO7AHBG@YJ,+T+5>''27!2/1-E%)]"@J:?KK1\E)2B;RB]V<^"J1
M;,N/*9'/.?QZ=Z?T]QNEOK,?55DW)Z.-,=NWQ\=-OA$5;_Y06U';5U9*5]S8
M0[T^;K9:\*+9"&&J\C@,@N2XXK(>O7_W>*V%/G8/E!&YD:JV)[L37Z6X:WZ]
MWAVR6]G(&UE*<W\RZO\OQ8A5LI:5_"F*DU$P8LU&W?VIM/RI:L/+9:Y569Z,
M)KL7O@IM9/[B]+*#O.8W37_&\)LK;D%.1DE@+[B2NC']._KK<\MX*^R;=T>M
M41>R-$*?<2,^:M5N9;WN+F-_Q;'S,_IR>/R[*\2W^O\4HUJM9"[.5-Y6HC:[
M<M2B[ #K9B.WS8C5O!(GHU-U*W3W>^P77!:[WV8LE%-2^JVT+^C+HL>C0YFW
MA33LLMY]V+[J8(4 *Z3%.K7'JI2%_?:"+3N([@,-4RO+FBL',@*0T<$@3U6U
M=2"G '+ZBI ?>,GK7+"^CC0.8 P XX,!LJ,%=R 3 )D<[%:?_]M*!S(%D.D!
M(;^%#F0&(+/#51K>;!S(&8"<T4(NVZKB^KZ#6LIU+>W'>&W8/,]56QOW=D\"
MU'8'M)A7XE;4K7!QH$JH79+;JM#(_CSC=<'.9+-5#R=<2"26";%9KD1C=)N;
M5EO[L],-UVOAP2&A3(B-<B%KV_Q)7EK+=9A]U7#AD$@FQ"9Y@+.E-M>:UVOQ
M@@Y99$*LD3.AY2WO K[=LW?::BWJ_)Z=_\@WW UK)L@C$V*17-:VRAH;]/H/
M';+&A%@;'Y4J[F19]L7VQ6R$MD^?L3>XXV!S%Q-Y8T(L#IMU;&U.</^&+6R,
M8-[TN)U\M]T'74HDC@FU.6R#(C:J+(1N?NOQS+T;4B-=A,2Z6!J5?V>+5ML*
MT8B^_.9W7!=]@;J/8X@L$A);I(OO*\&N^0^OBH0P&R&6QCG7M6WX&K:PE:._
MQ2X9,D9(;(PK8:3N6V+V0=1B99.Y%W<322,DEL8G81\UCP9)(B26A W@VJHM
M^]ASU])UB9JML*)NK#E<3"2)D#S;J"II=G%Q[S)E@TXK7&M?ORR1-D)B;2S%
MNG_L.L"/0JTUWVYD_M25X&(B;83$VEC::Q2M%=GE)1NSK[QL^_?TV'^W;GH9
M(F^$Q-Y8\'MVV[<O_<>['-A&SWFIFM9K;"(DD(A8(#8HE59L[%KS L2!$=)'
M1*X/GW%AD\VNVO0W?.'VND7(*!&Q46"&Z>7J$>SA(M=+GV&RHVMNO[CYW>5"
M6HF(M0)337;D8B+?1,2^&4PV!PL3Z28BULU@UCE(B7P3$?MF./T<Q$2^B8A]
M _-0OV(CWT3$OG'RT*$BG"+-3(DU Q-2KPBGR#138M/@A)2YF,@T4VK3P*S/
MPT2FF1*;QDW[!I](.(9"K)N7^=\@(E+-E%PUPXG@ ZB+B5PS)7;-+A\<+#TD
MERFQ7&!BZ#<Y2"Y3ZF0&Y5P^)I++])##)]\B=]P1>29^G>$3FQ;:Z)&OUUJL
M=[FAY?XLW PV1IZ)B3T#,;V;'B//Q.0#*X^8G[D-T+H(B!V="<-EZ=7S&%DF
M)K8,SAO&+B;R37S(],:_Y7#DGKP[#6%Z]1PY)R9V#L:<NIC(03&Y@Q!F[&(B
M!\7$#AK.:9]JO8N)'!03.V@?YFG)FT:NW&DER$$)N8.&,>?=W#7I.BA!#DJ(
M'33<13!F71K9F,K%1 Y*B!VT#W-^:RW$;UQ,9*'D$,/\@U4H019*7F? _V5I
MOGPVD8428@OMPWR(0EU,.(/L(+UL-J@3-UU [V(B"R6'Z68;/W1DN9C(0@FQ
MA?9B[NJ0BXDLE!!;:"_F)U6OQRYFBBR4$EL(8GKQ9HHLE!);"/>MNO%FBBR4
M$EL(8[KQ9HHLE!);"&.Z\6:*+)026PAC)BXFLE!ZR/EGWU(7$UDH);80QLQ<
M3#B3F=A"&'/F8B(+I<06\D91!OHZ4N2>E-@]>!C%;2TSY)[LH*,];FN9(?=D
MQ.[!F&YKF2'W9,3NP9AN:YDA]V3$[H%C9_Y2!>2>C-@]0[,Y!RMZAM23$:L'
MCO#YA8G4DQ&K!V-Z[1%23T8]KPUB>NT17$9#/10$,;WV"$DHHQX*@IAN>S1#
M$IH=<FJT%[W-D(1FKS@WNDO)5;55]:^%D2XFDM",6$+/,'\=LJ-N;-K%1!*:
MO>:4@S%[FBEJR_),K#Q,)*$9L82>83X?77,QD85FQ!9ZAGF^6HE^_?7#[7<Q
MD85FY MP/,PKD:LZEZ5\&%)U,9&%9L06&IAQXCZA+B:RT(S80H.8OYY0%Q,N
MYR0?#-HS.::'=2>!3P*\H)-\.&@OZ.FS56P!7.H9D$]*V%^BPIO\-@G@<L^
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M?FN/.<UOVW'Z7/1Q;09\I][S^;WCY^>_7WX\:1%ZYWKX.F.Z^0M02P,$%
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MI[*^C^/^'\<OU[BOVN$U/UG^Y>'F)U!+ 0(4 Q0    ( !."U%@'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ $X+46 /XQ/'N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ $X+46)E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  3
M@M18 QI6X,\/   8L0  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ $X+46&X7.L$\ @  Q 4  !@
M         ("!$A@  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( !."U%@C7)5=S 4  /X7   8              " @80:  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  3@M18UIDH,BD$  "M#P
M&               @(&&(   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ $X+46 2WD7VY!@  MQP  !@              ("!Y20  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !."U%B/?5V8V0(
M !,(   8              " @=0K  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    "  3@M18AH:CWX$)  "F50  &               @('C
M+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ $X+46-FL
M 8Z+ @  N 8  !@              ("!FC@  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( !."U%B]'!J$BP@  *\I   8
M  " @5L[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  3
M@M183(6M5\TB  !G<P  &0              @($<1   >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !."U%BU9<I,3 H  )@:   9
M          " @2!G  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#
M%     @ $X+46.UV!G1^#P  9S$  !D              ("!HW$  'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  3@M18^4F[FTH&  "7
M$   &0              @(%8@0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+ 0(4 Q0    ( !."U%B:<]=76@P  "HG   9              " @=F'
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ $X+46)[O
MZSH]#@  .2L  !D              ("!:I0  'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6Q02P$"% ,4    "  3@M189*V3O;H-  #E+P  &0
M    @('>H@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M !."U%BQ9R3;; (  %H%   9              " @<^P  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ $X+46-UL+@>Q"   )1<  !D
M             ("!<K,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    "  3@M18_(;-N5D#  ![!P  &0              @(%:O   >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !."U%C0;K(8&04
M *T-   9              " @>J_  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ $X+46,IQE_6N"@  T"   !D              ("!
M.L4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  3@M18
M$YKC[U@4   Q/P  &0              @($?T   >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( !."U%CFUGU-<00  /(*   9
M      " @:[D  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ $X+46!RZU5F<&   <U0  !D              ("!5ND  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  3@M18XNIS2.@'  "R%P
M&0              @($I @$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( !."U%@V^.C@_P4   $3   9              " @4@* 0!X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ $X+46/SC5?RT
M$P  Q3H  !D              ("!?A ! 'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    "  3@M18C9P*K(<,  !Q(@  &0
M@(%I) $ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !."
MU%C;21P8#@0   8)   9              " @2<Q 0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ $X+46%C;&JUW @  H 8  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( !."U%BZW;F=5 4  /4-   9
M  " @7AC 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M$X+46( ;K&1=!   DPH  !D              ("! VD! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    "  3@M18>WC#0X\(  "G&P  &0
M            @(&7;0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( !."U%@O:$IA.P4  &P.   9              " @5UV 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ $X+46$I3/T1+"
M&"   !D              ("!SWL! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    "  3@M18@1';P7X"  !J!0  &0              @(%1
MA $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !."U%CR
MLO<A?04  'T0   9              " @0:' 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ $X+46&Z,_4DQ P  'P<  !D
M     ("!NHP! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !."U%@_&04A=@0  %<-   9              "
M@3JR 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ $X+4
M6&:OT-H#!   B0D  !D              ("!Y[8! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    "  3@M18*!O2EAT'   6$0  &0
M        @($ANP$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( !."U%@S)8]@A0,  '$1   9              " @77" 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ $X+46*U&6,@#!P  %#8
M !D              ("!,<8! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    "  3@M18'("\:@L*  !+8@  &0              @(%KS0$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !."U%A)3Z7]
M'P0  #L2   9              " @:W7 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ $X+46/]@M,S/$P  N1P! !D
M ("! ]P! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  3
M@M18^6%W0PP&   E-0  &0              @($)\ $ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !."U%A9WX7(, ,  %D)   9
M          " @4SV 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#
M%     @ $X+46)<WRX$$!0  W28  !D              ("!L_D! 'AL+W=O
M<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  3@M1866%A U<#   $
M#   &0              @('N_@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;%!+ 0(4 Q0    ( !."U%C@4'778 ,   01   9              " @7P"
M @!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ $X+46%C'
M*PXX!   G!D  !D              ("!$P8" 'AL+W=O<FMS:&5E=',O<VAE
M970V,"YX;6Q02P$"% ,4    "  3@M18+2@%E-P%  !P*   &0
M    @(&""@( >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M !."U%C0;(S#" L  -5E   9              " @940 @!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ $X+46!2>X65<!0  PR(  !D
M             ("!U!L" 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    "  3@M18C;Y)O, #   &$@  &0              @(%G(0( >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( !."U%B#ZFD': 0
M /\5   9              " @5XE @!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ $X+46-W0._4  P  9@@  !D              ("!
M_2D" 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    "  3@M18
M*.]1$10#   \"@  &0              @($T+0( >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( !."U%@GJ>69[P(  .\)   9
M      " @7\P @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ $X+46-JE7A[H%   \'T! !D              ("!I3," 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    "  3@M18CG2K0N@.  "ZC
M&0              @('$2 ( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( !."U%A&(+\R?0(  , &   9              " @>-7 @!X
M;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ $X+46()T=-,B
M!   /0T  !D              ("!EUH" 'AL+W=O<FMS:&5E=',O<VAE970W
M,BYX;6Q02P$"% ,4    "  3@M18P 8B>)T$   [(0  &0
M@('P7@( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( !."
MU%@# ZV0^P0  ,(9   9              " @<1C @!X;"]W;W)K<VAE971S
M+W-H965T-S0N>&UL4$L! A0#%     @ $X+46+QY_- " P  I0@  !D
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M=#<Y+GAM;%!+ 0(4 Q0    ( !."U%@OK'HWL 4  'HA   9
M  " @5A[ @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @
M$X+46/P,>_H7!P  ^44  !D              ("!/X$" 'AL+W=O<FMS:&5E
M=',O<VAE970X,2YX;6Q02P$"% ,4    "  3@M18:EZ.73X$  #@%0  &0
M            @(&-B ( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4
M Q0    ( !."U%CV?- [6@(  /@%   9              " @0*- @!X;"]W
M;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ $X+46$_;[V7V!0
M;#   !D              ("!DX\" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX
M;6Q02P$"% ,4    "  3@M182IZL=?H%  #9,0  &0              @('
ME0( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( !."U%A%
MF9'1+08  &@I   9              " @?&; @!X;"]W;W)K<VAE971S+W-H
M965T.#8N>&UL4$L! A0#%     @ $X+46(B7I?<F!0  TR$  !D
M     ("!5:(" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !."U%C?-!*ZW (  #L(   9              "
M@=NZ @!X;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ $X+4
M6& %0QED P  7PP  !D              ("![KT" 'AL+W=O<FMS:&5E=',O
M<VAE970Y,RYX;6Q02P$"% ,4    "  3@M18=FAJZ&(&   G&P  &0
M        @(&)P0( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0
M   ( !."U%CHG?9@G@D  -!#   9              " @2+( @!X;"]W;W)K
M<VAE971S+W-H965T.34N>&UL4$L! A0#%     @ $X+46#@)UF>I!   %1,
M !D              ("!]]$" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q0
M2P$"% ,4    "  3@M18[Q!C_S4$  !@$   &0              @('7U@(
M>&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( !."U%AQ*T%D
MM@0  &L7   9              " @4/; @!X;"]W;W)K<VAE971S+W-H965T
M.3@N>&UL4$L! A0#%     @ $X+46+Y-5(JZ @  .0@  !D
M ("!,. " 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    "  3
M@M186[RSO1P(  !U0@  &@              @($AXP( >&PO=V]R:W-H965T
M<R]S:&5E=#$P,"YX;6Q02P$"% ,4    "  3@M18[_^('@@,  !470  &@
M            @(%UZP( >&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"
M% ,4    "  3@M18E,O"MXH&  "5*0  &@              @(&U]P( >&PO
M=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"% ,4    "  3@M18BS:4@>4(
M  #>3P  &@              @(%W_@( >&PO=V]R:W-H965T<R]S:&5E=#$P
M,RYX;6Q02P$"% ,4    "  3@M18_M]_ ]H.  "=LP  &@
M@(&4!P, >&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    "  3
M@M18YU%L@ D#  #]"@  &@              @(&F%@, >&PO=V]R:W-H965T
M<R]S:&5E=#$P-2YX;6Q02P$"% ,4    "  3@M18EE4EG<\"  !?"0  &@
M            @('G&0, >&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"
M% ,4    "  3@M180QFXWV@"   T!@  &@              @('N' , >&PO
M=V]R:W-H965T<R]S:&5E=#$P-RYX;6Q02P$"% ,4    "  3@M18[J=1F;@"
M   ="   &@              @(&.'P, >&PO=V]R:W-H965T<R]S:&5E=#$P
M."YX;6Q02P$"% ,4    "  3@M184$KW'-8"  "_!P  &@
M@(%^(@, >&PO=V]R:W-H965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4    "  3
M@M189N_F^+$"  "S!P  &@              @(&,)0, >&PO=V]R:W-H965T
M<R]S:&5E=#$Q,"YX;6Q02P$"% ,4    "  3@M18.;@=%'H(  #>.@  &@
M            @(%U* , >&PO=V]R:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"
M% ,4    "  3@M18*WW*(.8%   ;,P  &@              @($G,0, >&PO
M=V]R:W-H965T<R]S:&5E=#$Q,BYX;6Q02P$"% ,4    "  3@M18+\:OZ)0"
M  #J!P  &@              @(%%-P, >&PO=V]R:W-H965T<R]S:&5E=#$Q
M,RYX;6Q02P$"% ,4    "  3@M189E!Y D\(  !+.P  &@
M@($1.@, >&PO=V]R:W-H965T<R]S:&5E=#$Q-"YX;6Q02P$"% ,4    "  3
M@M181<EH6*D%   U)@  &@              @(&80@, >&PO=V]R:W-H965T
M<R]S:&5E=#$Q-2YX;6Q02P$"% ,4    "  3@M18 >0NJK<$  #5&0  &@
M            @(%Y2 , >&PO=V]R:W-H965T<R]S:&5E=#$Q-BYX;6Q02P$"
M% ,4    "  3@M18QQN??Y($  !G%0  &@              @(%H30, >&PO
M=V]R:W-H965T<R]S:&5E=#$Q-RYX;6Q02P$"% ,4    "  3@M18L4>#ZX,#
M  "-&   #0              @ $R4@, >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( !."U%B7BKL<P    !,"   +              "  >!5 P!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( !."U%@(,+=X_0<  .I,   /              "
M <E6 P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  3@M18(7'WLCL#  "L
M1   &@              @ 'S7@, >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  3@M181K1.*H\"  #M00  $P              @ %F
L8@, 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ?0!] '0B   F90,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>812</ContextCount>
  <ElementCount>692</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>201</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Acquisitions and Dispositions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsandDispositions</Role>
      <ShortName>Acquisitions and Dispositions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringCharges</Role>
      <ShortName>Restructuring Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Financing Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangements</Role>
      <ShortName>Financing Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Derivatives and Currency Exchange Risk Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Property, Plant, and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant, and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stock Purchase and Award Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlans</Role>
      <ShortName>Stock Purchase and Award Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Retirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlans</Role>
      <ShortName>Retirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Accumulated Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss</Role>
      <ShortName>Accumulated Other Comprehensive Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformation</Role>
      <ShortName>Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/Revenue</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Acquisitions and Dispositions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsandDispositionsTables</Role>
      <ShortName>Acquisitions and Dispositions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/AcquisitionsandDispositions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Restructuring Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringChargesTables</Role>
      <ShortName>Restructuring Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/RestructuringCharges</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/FinancialInstruments</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Financing Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsTables</Role>
      <ShortName>Financing Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/FinancingArrangements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Derivatives and Currency Exchange Risk Management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/Inventories</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Property, Plant, and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant, and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Stock Purchase and Award Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansTables</Role>
      <ShortName>Stock Purchase and Award Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/StockPurchaseandAwardPlans</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/IncomeTaxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/EarningsPerShare</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Retirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansTables</Role>
      <ShortName>Retirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/RetirementBenefitPlans</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/Leases</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationTables</Role>
      <ShortName>Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/SegmentandGeographicInformation</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Revenue - Disaggregation of Net Sales by Segment and Division (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails</Role>
      <ShortName>Revenue - Disaggregation of Net Sales by Segment and Division (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails</Role>
      <ShortName>Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Acquisitions and Dispositions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails</Role>
      <ShortName>Acquisitions and Dispositions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Acquisitions and Dispositions - Schedule of Fair Value of the Assets Acquired and Liabilities Assumed - Intersect ENT Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails</Role>
      <ShortName>Acquisitions and Dispositions - Schedule of Fair Value of the Assets Acquired and Liabilities Assumed - Intersect ENT Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Acquisitions and Dispositions - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails</Role>
      <ShortName>Acquisitions and Dispositions - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Acquisitions and Dispositions - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails</Role>
      <ShortName>Acquisitions and Dispositions - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Acquisitions and Dispositions - Reconciliation of Level 3 Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails</Role>
      <ShortName>Acquisitions and Dispositions - Reconciliation of Level 3 Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Restructuring Charges - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringChargesNarrativeDetails</Role>
      <ShortName>Restructuring Charges - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Restructuring Charges - Classification of Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails</Role>
      <ShortName>Restructuring Charges - Classification of Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Restructuring Charges - Activity Related to Restructuring Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails</Role>
      <ShortName>Restructuring Charges - Activity Related to Restructuring Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails</Role>
      <ShortName>Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails</Role>
      <ShortName>Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Financial Instruments - Summary of Equity and Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Summary of Equity and Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Financial Instruments - Debt and Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Debt and Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Financing Arrangements - Current Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails</Role>
      <ShortName>Financing Arrangements - Current Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Financing Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails</Role>
      <ShortName>Financing Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Financing Arrangements - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails</Role>
      <ShortName>Financing Arrangements - Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Financing Arrangements - Long-term Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails</Role>
      <ShortName>Financing Arrangements - Long-term Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Derivatives and Currency Exchange Risk Management - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Derivatives and Currency Exchange Risk Management- Outsatnding instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management- Outsatnding instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/InventoriesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Goodwill and Other Intangible Assets - Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/ShareholdersEquity</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Stock Purchase and Award Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Stock Purchase and Award Plans - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Stock Purchase and Award Plans - Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Stock Purchase and Award Plans - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Stock Purchase and Award Plans - Performance Share Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Performance Share Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails</Role>
      <ShortName>Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails</Role>
      <ShortName>Income Taxes - Income Tax (Benefit) Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails</Role>
      <ShortName>Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Retirement Benefit Plans - Narative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails</Role>
      <ShortName>Retirement Benefit Plans - Narative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails</Role>
      <ShortName>Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails</Role>
      <ShortName>Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails</Role>
      <ShortName>Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Retirement Benefit Plans - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails</Role>
      <ShortName>Retirement Benefit Plans - Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - Retirement Benefit Plans - Future Benefit Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails</Role>
      <ShortName>Retirement Benefit Plans - Future Benefit Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9954545 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails</Role>
      <ShortName>Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9954546 - Disclosure - Leases - Components of Total Operating Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails</Role>
      <ShortName>Leases - Components of Total Operating Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9954547 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9954548 - Disclosure - Leases - Maturities of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails</Role>
      <ShortName>Leases - Maturities of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9954549 - Disclosure - Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9954550 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/CommitmentsandContingencies</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9954551 - Disclosure - Segment and Geographic Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails</Role>
      <ShortName>Segment and Geographic Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9954552 - Disclosure - Segment and Geographic Information - Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails</Role>
      <ShortName>Segment and Geographic Information - Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9954553 - Disclosure - Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9954554 - Disclosure - Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails</Role>
      <ShortName>Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="mdt-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>9954555 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts</ParentRole>
      <Position>117</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 31 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityAddressPostalZipCode, us-gaap:DebtInstrumentTerm, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod -  mdt-20240426.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="mdt-20240426.htm">mdt-20240426.htm</File>
    <File>mdt-20240426.xsd</File>
    <File>mdt-20240426_cal.xml</File>
    <File>mdt-20240426_def.xml</File>
    <File>mdt-20240426_lab.xml</File>
    <File>mdt-20240426_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mdt-20240426_g1.jpg</File>
    <File>mdt-20240426_g10.jpg</File>
    <File>mdt-20240426_g11.jpg</File>
    <File>mdt-20240426_g12.jpg</File>
    <File>mdt-20240426_g13.jpg</File>
    <File>mdt-20240426_g14.jpg</File>
    <File>mdt-20240426_g15.jpg</File>
    <File>mdt-20240426_g16.jpg</File>
    <File>mdt-20240426_g17.jpg</File>
    <File>mdt-20240426_g18.jpg</File>
    <File>mdt-20240426_g19.jpg</File>
    <File>mdt-20240426_g2.jpg</File>
    <File>mdt-20240426_g3.jpg</File>
    <File>mdt-20240426_g4.jpg</File>
    <File>mdt-20240426_g5.jpg</File>
    <File>mdt-20240426_g6.jpg</File>
    <File>mdt-20240426_g7.jpg</File>
    <File>mdt-20240426_g8.jpg</File>
    <File>mdt-20240426_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="2387">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="100">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>163
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mdt-20240426.htm": {
   "nsprefix": "mdt",
   "nsuri": "http://www.medtronic.com/20240426",
   "dts": {
    "inline": {
     "local": [
      "mdt-20240426.htm"
     ]
    },
    "schema": {
     "local": [
      "mdt-20240426.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mdt-20240426_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mdt-20240426_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mdt-20240426_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdt-20240426_pre.xml"
     ]
    }
   },
   "keyStandard": 616,
   "keyCustom": 76,
   "axisStandard": 46,
   "axisCustom": 0,
   "memberStandard": 95,
   "memberCustom": 99,
   "hidden": {
    "total": 52,
    "http://fasb.org/us-gaap/2023": 46,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "contextCount": 812,
   "entityCount": 1,
   "segmentCount": 201,
   "elementCount": 1219,
   "unitCount": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 2387,
    "http://xbrl.sec.gov/dei/2023": 100,
    "http://xbrl.sec.gov/ecd/2023": 5,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://www.medtronic.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.medtronic.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
     "longName": "0000003 - Statement - Consolidated Statements of Income",
     "shortName": "Consolidated Statements of Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
     "longName": "0000005 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofEquity",
     "longName": "0000007 - Statement - Consolidated Statements of Equity",
     "shortName": "Consolidated Statements of Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical",
     "longName": "0000008 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.medtronic.com/role/Revenue",
     "longName": "0000011 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.medtronic.com/role/AcquisitionsandDispositions",
     "longName": "0000012 - Disclosure - Acquisitions and Dispositions",
     "shortName": "Acquisitions and Dispositions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.medtronic.com/role/RestructuringCharges",
     "longName": "0000013 - Disclosure - Restructuring Charges",
     "shortName": "Restructuring Charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.medtronic.com/role/FinancialInstruments",
     "longName": "0000014 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.medtronic.com/role/FinancingArrangements",
     "longName": "0000015 - Disclosure - Financing Arrangements",
     "shortName": "Financing Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement",
     "longName": "0000016 - Disclosure - Derivatives and Currency Exchange Risk Management",
     "shortName": "Derivatives and Currency Exchange Risk Management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.medtronic.com/role/Inventories",
     "longName": "0000017 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets",
     "longName": "0000018 - Disclosure - Goodwill and Other Intangible Assets",
     "shortName": "Goodwill and Other Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.medtronic.com/role/PropertyPlantandEquipment",
     "longName": "0000019 - Disclosure - Property, Plant, and Equipment",
     "shortName": "Property, Plant, and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.medtronic.com/role/ShareholdersEquity",
     "longName": "0000020 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlans",
     "longName": "0000021 - Disclosure - Stock Purchase and Award Plans",
     "shortName": "Stock Purchase and Award Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.medtronic.com/role/IncomeTaxes",
     "longName": "0000022 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.medtronic.com/role/EarningsPerShare",
     "longName": "0000023 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlans",
     "longName": "0000024 - Disclosure - Retirement Benefit Plans",
     "shortName": "Retirement Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.medtronic.com/role/Leases",
     "longName": "0000025 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss",
     "longName": "0000026 - Disclosure - Accumulated Other Comprehensive Loss",
     "shortName": "Accumulated Other Comprehensive Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.medtronic.com/role/CommitmentsandContingencies",
     "longName": "0000027 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformation",
     "longName": "0000028 - Disclosure - Segment and Geographic Information",
     "shortName": "Segment and Geographic Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts",
     "longName": "0000029 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-485",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-485",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.medtronic.com/role/RevenueTables",
     "longName": "9954472 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsTables",
     "longName": "9954473 - Disclosure - Acquisitions and Dispositions (Tables)",
     "shortName": "Acquisitions and Dispositions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.medtronic.com/role/RestructuringChargesTables",
     "longName": "9954474 - Disclosure - Restructuring Charges (Tables)",
     "shortName": "Restructuring Charges (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsTables",
     "longName": "9954475 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsTables",
     "longName": "9954476 - Disclosure - Financing Arrangements (Tables)",
     "shortName": "Financing Arrangements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables",
     "longName": "9954477 - Disclosure - Derivatives and Currency Exchange Risk Management (Tables)",
     "shortName": "Derivatives and Currency Exchange Risk Management (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.medtronic.com/role/InventoriesTables",
     "longName": "9954478 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables",
     "longName": "9954479 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.medtronic.com/role/PropertyPlantandEquipmentTables",
     "longName": "9954480 - Disclosure - Property, Plant, and Equipment (Tables)",
     "shortName": "Property, Plant, and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables",
     "longName": "9954481 - Disclosure - Stock Purchase and Award Plans (Tables)",
     "shortName": "Stock Purchase and Award Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.medtronic.com/role/IncomeTaxesTables",
     "longName": "9954482 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.medtronic.com/role/EarningsPerShareTables",
     "longName": "9954483 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansTables",
     "longName": "9954484 - Disclosure - Retirement Benefit Plans (Tables)",
     "shortName": "Retirement Benefit Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.medtronic.com/role/LeasesTables",
     "longName": "9954485 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mdt:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mdt:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables",
     "longName": "9954486 - Disclosure - Accumulated Other Comprehensive Loss (Tables)",
     "shortName": "Accumulated Other Comprehensive Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationTables",
     "longName": "9954487 - Disclosure - Segment and Geographic Information (Tables)",
     "shortName": "Segment and Geographic Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954488 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
     "longName": "9954489 - Disclosure - Revenue - Disaggregation of Net Sales by Segment and Division (Details)",
     "shortName": "Revenue - Disaggregation of Net Sales by Segment and Division (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
     "longName": "9954490 - Disclosure - Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)",
     "shortName": "Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-177",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.medtronic.com/role/RevenueNarrativeDetails",
     "longName": "9954491 - Disclosure - Revenue - Narrative (Details)",
     "shortName": "Revenue - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:ContractWithCustomerRefundLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:ContractWithCustomerRefundLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
     "longName": "9954492 - Disclosure - Acquisitions and Dispositions - Narrative (Details)",
     "shortName": "Acquisitions and Dispositions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails",
     "longName": "9954493 - Disclosure - Acquisitions and Dispositions - Schedule of Fair Value of the Assets Acquired and Liabilities Assumed - Intersect ENT Acquisition (Details)",
     "shortName": "Acquisitions and Dispositions - Schedule of Fair Value of the Assets Acquired and Liabilities Assumed - Intersect ENT Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails",
     "longName": "9954494 - Disclosure - Acquisitions and Dispositions - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)",
     "shortName": "Acquisitions and Dispositions - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mdt:BusinessAcquisitionContingentConsiderationMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
     "longName": "9954495 - Disclosure - Acquisitions and Dispositions - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)",
     "shortName": "Acquisitions and Dispositions - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails",
     "longName": "9954496 - Disclosure - Acquisitions and Dispositions - Reconciliation of Level 3 Measurement (Details)",
     "shortName": "Acquisitions and Dispositions - Reconciliation of Level 3 Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-224",
      "name": "mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails",
     "longName": "9954497 - Disclosure - Restructuring Charges - Narrative (Details)",
     "shortName": "Restructuring Charges - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-230",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-228",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
     "longName": "9954498 - Disclosure - Restructuring Charges - Classification of Restructuring Costs (Details)",
     "shortName": "Restructuring Charges - Classification of Restructuring Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-230",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-231",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
     "longName": "9954499 - Disclosure - Restructuring Charges - Activity Related to Restructuring Programs (Details)",
     "shortName": "Restructuring Charges - Activity Related to Restructuring Programs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mdt:RestructuringChargesIncludingAccrualAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
     "longName": "9954500 - Disclosure - Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)",
     "shortName": "Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
     "longName": "9954501 - Disclosure - Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)",
     "shortName": "Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails",
     "longName": "9954502 - Disclosure - Financial Instruments - Narrative (Details)",
     "shortName": "Financial Instruments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails",
     "longName": "9954503 - Disclosure - Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)",
     "shortName": "Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails",
     "longName": "9954504 - Disclosure - Financial Instruments - Summary of Equity and Other Investments (Details)",
     "shortName": "Financial Instruments - Summary of Equity and Other Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-276",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-276",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails",
     "longName": "9954505 - Disclosure - Financial Instruments - Debt and Equity Securities (Details)",
     "shortName": "Financial Instruments - Debt and Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
     "longName": "9954506 - Disclosure - Financing Arrangements - Current Debt Obligations (Details)",
     "shortName": "Financing Arrangements - Current Debt Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:FinanceLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:FinanceLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
     "longName": "9954507 - Disclosure - Financing Arrangements - Narrative (Details)",
     "shortName": "Financing Arrangements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
     "longName": "9954508 - Disclosure - Financing Arrangements - Long-term Debt (Details)",
     "shortName": "Financing Arrangements - Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:FinanceLeaseLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:FinanceLeaseLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails",
     "longName": "9954509 - Disclosure - Financing Arrangements - Long-term Debt Maturities (Details)",
     "shortName": "Financing Arrangements - Long-term Debt Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
     "longName": "9954510 - Disclosure - Derivatives and Currency Exchange Risk Management - Narrative (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails",
     "longName": "9954511 - Disclosure - Derivatives and Currency Exchange Risk Management- Outsatnding instruments (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management- Outsatnding instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-440",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-440",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
     "longName": "9954512 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
     "longName": "9954513 - Disclosure - Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-442",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-442",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
     "longName": "9954514 - Disclosure - Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-462",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9954515 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-468",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-468",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails",
     "longName": "9954516 - Disclosure - Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OffsettingAssetsTableTextBlock",
       "us-gaap:OffsettingLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.medtronic.com/role/InventoriesDetails",
     "longName": "9954517 - Disclosure - Inventories (Details)",
     "shortName": "Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
     "longName": "9954518 - Disclosure - Goodwill and Other Intangible Assets - Changes in Goodwill (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Changes in Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "longName": "9954519 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-485",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
     "longName": "9954520 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails",
     "longName": "9954521 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
     "longName": "9954522 - Disclosure - Property, Plant, and Equipment (Details)",
     "shortName": "Property, Plant, and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.medtronic.com/role/ShareholdersEquityDetails",
     "longName": "9954523 - Disclosure - Shareholders' Equity (Details)",
     "shortName": "Shareholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "mdt:DeferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
     "longName": "9954524 - Disclosure - Stock Purchase and Award Plans - Narrative (Details)",
     "shortName": "Stock Purchase and Award Plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-536",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-536",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails",
     "longName": "9954525 - Disclosure - Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)",
     "shortName": "Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails",
     "longName": "9954526 - Disclosure - Stock Purchase and Award Plans - Valuation Assumptions (Details)",
     "shortName": "Stock Purchase and Award Plans - Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
     "longName": "9954527 - Disclosure - Stock Purchase and Award Plans - Stock Options Activity (Details)",
     "shortName": "Stock Purchase and Award Plans - Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-535",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-520",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
     "longName": "9954528 - Disclosure - Stock Purchase and Award Plans - Restricted Stock Activity (Details)",
     "shortName": "Stock Purchase and Award Plans - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-539",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-540",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
     "longName": "9954529 - Disclosure - Stock Purchase and Award Plans - Performance Share Unit Activity (Details)",
     "shortName": "Stock Purchase and Award Plans - Performance Share Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-546",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-526",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails",
     "longName": "9954530 - Disclosure - Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)",
     "shortName": "Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails",
     "longName": "9954531 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)",
     "shortName": "Income Taxes - Income Tax (Benefit) Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954532 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954533 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9954534 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails",
     "longName": "9954535 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
     "longName": "9954536 - Disclosure - Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)",
     "shortName": "Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-520",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails",
     "longName": "9954537 - Disclosure - Earnings Per Share - Narrative (Details)",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-558",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-558",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
     "longName": "9954538 - Disclosure - Retirement Benefit Plans - Narative (Details)",
     "shortName": "Retirement Benefit Plans - Narative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
     "longName": "9954539 - Disclosure - Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)",
     "shortName": "Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:DefinedBenefitPlanFundedStatusOfPlan",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-571",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails",
     "longName": "9954540 - Disclosure - Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)",
     "shortName": "Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-567",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-567",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
     "longName": "9954541 - Disclosure - Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)",
     "shortName": "Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-561",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-561",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
     "longName": "9954542 - Disclosure - Retirement Benefit Plans - Fair Value Measurement (Details)",
     "shortName": "Retirement Benefit Plans - Fair Value Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-562",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-662",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
     "longName": "9954543 - Disclosure - Retirement Benefit Plans - Future Benefit Payments (Details)",
     "shortName": "Retirement Benefit Plans - Future Benefit Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-561",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-561",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails",
     "longName": "9954544 - Disclosure - Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)",
     "shortName": "Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails",
     "longName": "9954545 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)",
     "shortName": "Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails",
     "longName": "9954546 - Disclosure - Leases - Components of Total Operating Lease Cost (Details)",
     "shortName": "Leases - Components of Total Operating Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails",
     "longName": "9954547 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails",
     "longName": "9954548 - Disclosure - Leases - Maturities of Operating Leases (Details)",
     "shortName": "Leases - Maturities of Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
     "longName": "9954549 - Disclosure - Accumulated Other Comprehensive Loss (Details)",
     "shortName": "Accumulated Other Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-64",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954550 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails",
     "longName": "9954551 - Disclosure - Segment and Geographic Information - Narrative (Details)",
     "shortName": "Segment and Geographic Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true,
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
     "longName": "9954552 - Disclosure - Segment and Geographic Information - Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated (Details)",
     "shortName": "Segment and Geographic Information - Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-756",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
     "longName": "9954553 - Disclosure - Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)",
     "shortName": "Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-773",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails",
     "longName": "9954554 - Disclosure - Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)",
     "shortName": "Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-782",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    },
    "R117": {
     "role": "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails",
     "longName": "9954555 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "c-799",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-804",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20240426.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "mdt_A2015CommercialPaperProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "A2015CommercialPaperProgramMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Commercial Paper Program",
        "label": "2015 Commercial Paper Program [Member]",
        "documentation": "2015 Commercial Paper Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A2024EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "A2024EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Employee Stock Purchase Plan",
        "label": "2024 Employee Stock Purchase Plan [Member]",
        "documentation": "2024 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A2625PercentThreeYear2022SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "A2625PercentThreeYear2022SeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.625 percent three-year 2022 senior notes",
        "label": "2..625 Percent Three-Year 2022 Senior Notes [Member]",
        "documentation": "2..625 Percent Three-Year 2022 Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A3000PercentSixYear2022SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "A3000PercentSixYear2022SeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.000 percent six-year 2022 senior notes",
        "label": "3.000 Percent Six-year 2022 Senior Notes [Member]",
        "documentation": "3.000 Percent Six-year 2022 Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A3125PercentNineYear2022SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "A3125PercentNineYear2022SeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.125 percent nine-year 2022 senior notes",
        "label": "3.125 Percent Nine-year 2022 Senior Notes [Member]",
        "documentation": "3.125 Percent Nine-year 2022 Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A3375PercentTwelveYear2022SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "A3375PercentTwelveYear2022SeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.375 percent twelve-year 2022 senior notes",
        "label": "3.375 Percent Twelve-year 2022 Senior Notes [Member]",
        "documentation": "3.375 Percent Twelve-year 2022 Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A4250PercentFiveYear2023SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "A4250PercentFiveYear2023SeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.250 percent five-year 2023 senior notes",
        "label": "4.250 Percent Five-year 2023 Senior Notes [Member]",
        "documentation": "4.250 Percent Five-year 2023 Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A4500PercentTenYear2023SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "A4500PercentTenYear2023SeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.500 percent ten-year 2023 senior notes",
        "label": "4.500 Percent Ten-year 2023 Senior Notes [Member]",
        "documentation": "4.500 Percent Ten-year 2023 Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r1301"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of accounts receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r1230"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, less allowances and credit losses of $173 and $176, respectively",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r255"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r255"
     ]
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Change in Retirement Obligations",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r31",
      "r65",
      "r1425",
      "r1426",
      "r1427"
     ]
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain (Loss) on Cash Flow Hedges",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r360",
      "r361",
      "r850",
      "r1258",
      "r1425"
     ]
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (Loss) Gain on Investment Securities",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r350",
      "r360",
      "r361",
      "r1425"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r911",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r203",
      "r334",
      "r1003",
      "r1046",
      "r1050"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r911",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Total Accumulated Other Comprehensive (Loss) Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31",
      "r65",
      "r866",
      "r869",
      "r944",
      "r1041",
      "r1042",
      "r1425",
      "r1426",
      "r1427",
      "r1449",
      "r1450",
      "r1451"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Translation Adjustments",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r31",
      "r65",
      "r360",
      "r361",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r1425"
     ]
    },
    "mdt_AcuteCareMonitoringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "AcuteCareMonitoringMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acute Care &amp; Monitoring",
        "label": "Acute Care &amp; Monitoring [Member]",
        "documentation": "Acute Care &amp; Monitoring"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "mdt_AdditionalCashInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "AdditionalCashInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional cash investment",
        "label": "Additional Cash Investment",
        "documentation": "Additional Cash Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r1301",
      "r1596"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r788",
      "r789",
      "r1065",
      "r1449",
      "r1450",
      "r1451",
      "r1570",
      "r1598"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r749"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_AfferaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "AfferaIncMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affera",
        "label": "Affera Inc [Member]",
        "documentation": "Affera Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1325",
      "r1337",
      "r1347",
      "r1373"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1328",
      "r1340",
      "r1350",
      "r1376"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1332",
      "r1341",
      "r1351",
      "r1368",
      "r1377",
      "r1381",
      "r1389"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating segment",
        "label": "Other Segments [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1387"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r794"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stock-based compensation expense, net of tax",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForCreditLossMember",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for Doubtful Accounts",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r1443",
      "r1444",
      "r1445",
      "r1446",
      "r1447"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowances and credit losses",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r467",
      "r519"
     ]
    },
    "mdt_AmendedandRestatedRevolvingCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "AmendedandRestatedRevolvingCreditAgreementMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3.5 Billion Revolving Credit Facility",
        "label": "Amended and Restated Revolving Credit Agreement [Member]",
        "documentation": "Amended and Restated Revolving Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "negatedTerseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r92",
      "r97"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Hedges",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r350",
      "r360",
      "r361",
      "r1425"
     ]
    },
    "us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value",
        "label": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions",
        "documentation": "Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other asset-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1467",
      "r1473",
      "r1474"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairments and related inventory write-downs",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r98"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r327",
      "r380",
      "r433",
      "r448",
      "r454",
      "r508",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r590",
      "r592",
      "r594",
      "r595",
      "r846",
      "r851",
      "r901",
      "r998",
      "r1109",
      "r1301",
      "r1314",
      "r1509",
      "r1510",
      "r1580"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet Classification of Operating Leases and Amounts of Right-of-Use Assets and Lease Liabilities",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r339",
      "r380",
      "r508",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r590",
      "r592",
      "r594",
      "r595",
      "r846",
      "r851",
      "r901",
      "r1301",
      "r1509",
      "r1510",
      "r1580"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_AssociatedAndOtherCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "AssociatedAndOtherCostsMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associated and Other Costs",
        "label": "Associated and Other Costs [Member]",
        "documentation": "Associated and Other Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AuctionRateSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AuctionRateSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auction rate securities",
        "label": "Auction Rate Securities [Member]",
        "documentation": "Debt instrument securities (for example, but not limited to, corporate or municipal bonds) that typically have long-term nominal maturities for which the interest rate is reset through an auction process."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.medtronic.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1319",
      "r1320",
      "r1333"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.medtronic.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1319",
      "r1320",
      "r1333"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.medtronic.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1319",
      "r1320",
      "r1333"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1470"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r994"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1469"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r993"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1471"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r995"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AFS Debt Maturities",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1468"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r992"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Activities Related to Debt Securities Portfolio",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1384"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1385"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1380"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1380"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1380"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1380"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1380"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1380"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r755",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1383"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1382"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1381"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1381"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r159"
     ]
    },
    "mdt_BuildingsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "BuildingsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and leasehold improvements",
        "label": "Buildings and Leasehold Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r1286",
      "r1289"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r837",
      "r1286",
      "r1289"
     ]
    },
    "mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "BusinessAcquisitionContingentConsiderationAtFairValueRollForward",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments [Roll Forward]",
        "label": "Business Acquisition, Contingent Consideration, at Fair Value [Roll Forward]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_BusinessAcquisitionContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "BusinessAcquisitionContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liabilities",
        "label": "Business Acquisition, Contingent Consideration, Liability",
        "documentation": "Business Acquisition, Contingent Consideration, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_BusinessAcquisitionContingentConsiderationMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "BusinessAcquisitionContingentConsiderationMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Business Acquisition, Contingent Consideration, Milestone Payment",
        "documentation": "Contingent milestone payments in business acquisition transactions."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_BusinessAcquisitionContingentConsiderationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "BusinessAcquisitionContingentConsiderationRollForward",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beginning and Ending Balances of Contingent Payments [Roll Forward]",
        "label": "Business Acquisition, Contingent Consideration [Roll Forward]",
        "documentation": "Business Acquisition, Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "mdt_BusinessAcquisitionPriceContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "BusinessAcquisitionPriceContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price contingent consideration",
        "label": "Business Acquisition, Price Contingent Consideration",
        "documentation": "Business Acquisition, Price Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares price (in dollars per share)",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition and divestiture-related items",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration for the transaction, net of cash acquired",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r27"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously held investments in Intersect ENT",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r1435"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r140",
      "r843"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, significant unobservable inputs",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and Dispositions",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r838"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangible assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessExitCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessExitCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business exit costs",
        "label": "Business Exit Costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "mdt_BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestiture-related and other",
        "label": "Bussiness Acquisition, Contingent Consideration, Divestiture Related and Other Expenses",
        "documentation": "Bussiness Acquisition, Contingent Consideration, Divestiture Related and Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CardiacRhythmandHeartFailureDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "CardiacRhythmandHeartFailureDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardiac Rhythm &amp; Heart Failure",
        "label": "Cardiac Rhythm and Heart Failure Division [Member]",
        "documentation": "Cardiac Rhythm and Heart Failure Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CardiovascularMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "CardiovascularMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardiovascular",
        "verboseLabel": "Cardiovascular",
        "label": "Cardiovascular [Member]",
        "documentation": "Cardiovascular"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CashAdvancePaidinConnectionWithProposedSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "CashAdvancePaidinConnectionWithProposedSettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash advance paid to taxing authorities",
        "label": "Cash Advance Paid in Connection With Proposed Settlements",
        "documentation": "Cash Advance Paid in Connection With Proposed Settlements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r323",
      "r1249"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r213",
      "r376"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r213"
     ]
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedge unrealized gains to be reclassified over the next twelve months",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months",
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedges",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "mdt_CentralizedDistributionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "CentralizedDistributionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Centralized distribution costs",
        "label": "Centralized Distribution Costs",
        "documentation": "Centralized Distribution Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r1308",
      "r1309",
      "r1310",
      "r1311"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1359"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.medtronic.com/role/Cover",
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r331",
      "r332",
      "r333",
      "r380",
      "r413",
      "r417",
      "r419",
      "r421",
      "r427",
      "r428",
      "r508",
      "r583",
      "r586",
      "r587",
      "r588",
      "r594",
      "r595",
      "r626",
      "r627",
      "r630",
      "r633",
      "r640",
      "r901",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1096",
      "r1118",
      "r1137",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1396",
      "r1438",
      "r1455"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r427",
      "r626",
      "r627",
      "r628",
      "r630",
      "r633",
      "r638",
      "r640",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1274",
      "r1396",
      "r1438"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1360"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1360"
     ]
    },
    "mdt_ColibriMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ColibriMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Colibri",
        "label": "Colibri [Member]",
        "documentation": "Colibri"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaper": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaper",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper",
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r253",
      "r1590"
     ]
    },
    "mdt_CommercialPaperMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "CommercialPaperMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper, maximum borrowing capacity",
        "label": "Commercial Paper, Maximum Borrowing Capacity",
        "documentation": "Commercial Paper, Maximum Borrowing Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r1308",
      "r1309",
      "r1310",
      "r1311"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Notes 3, 16, and 18)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r178",
      "r1001",
      "r1095"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r1231"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future purchase (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends to shareholders (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity",
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ordinary shares, par value $0.0001 per share",
        "terseLabel": "Ordinary Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1304",
      "r1305",
      "r1306",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1449",
      "r1450",
      "r1570",
      "r1594",
      "r1598"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r1096"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r191",
      "r1096",
      "r1115",
      "r1598",
      "r1599"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares\u2014 par value $0.0001, 2.6 billion shares authorized, 1,311,337,531 and 1,330,809,036 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r1002",
      "r1301"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1365"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1364"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1366"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1363"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of deferred tax assets/(Liabilities):",
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total recognized in net periodic benefit cost and other comprehensive income",
        "label": "Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax",
        "documentation": "Before tax amount, net of reclassifications, of pension and other postretirement benefit plans (gain) loss included in comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income attributable to Medtronic",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r355",
      "r357",
      "r366",
      "r989",
      "r1017"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Comprehensive income attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r144",
      "r148",
      "r355",
      "r357",
      "r365",
      "r988",
      "r1016"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income including noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r248",
      "r355",
      "r357",
      "r364",
      "r987",
      "r1015"
     ]
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r363",
      "r986",
      "r1013"
     ]
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r1247",
      "r1495",
      "r1496"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r384",
      "r846",
      "r847",
      "r851",
      "r852",
      "r945",
      "r1241",
      "r1413",
      "r1416",
      "r1417",
      "r1508",
      "r1511",
      "r1512"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r384",
      "r846",
      "r847",
      "r851",
      "r852",
      "r945",
      "r1241",
      "r1413",
      "r1416",
      "r1417",
      "r1508",
      "r1511",
      "r1512"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r384",
      "r435",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r456",
      "r583",
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r591",
      "r593",
      "r594",
      "r1414",
      "r1415",
      "r1509",
      "r1510"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r384",
      "r435",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r456",
      "r583",
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r591",
      "r593",
      "r594",
      "r1414",
      "r1415",
      "r1509",
      "r1510"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r1259"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_ContingentConsiderationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ContingentConsiderationPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Contingent Consideration [Policy Text Block]",
        "documentation": "Describes an entity's accounting policy for contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type [Domain]",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r643",
      "r662"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized that was previously included in deferred revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rebate obligations",
        "label": "Contract with Customer, Refund Liability, Current",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "mdt_CoronaryAndPeripheralVascularDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "CoronaryAndPeripheralVascularDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coronary &amp; Peripheral Vascular",
        "label": "Coronary And Peripheral Vascular Division [Member]",
        "documentation": "Coronary And Peripheral Vascular Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1284",
      "r1593"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate",
        "label": "Corporate, Non-Segment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r447",
      "r448",
      "r449",
      "r450",
      "r456",
      "r1458"
     ]
    },
    "mdt_CorporateOverhead": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "CorporateOverhead",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Corporate",
        "label": "Corporate Overhead",
        "documentation": "Corporate overhead expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold, excluding amortization of intangible assets",
        "verboseLabel": "Cost of products sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r979"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold",
        "verboseLabel": "Cost of products sold",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Country Region",
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CranialAndSpinalTechnologiesDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "CranialAndSpinalTechnologiesDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cranial &amp; Spinal Technologies",
        "label": "Cranial And Spinal Technologies Division [Member]",
        "documentation": "Cranial And Spinal Technologies Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1405",
      "r1441",
      "r1564"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1405",
      "r1441"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax expense",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r822",
      "r830",
      "r1441"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax expense:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelatedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelatedIntangibleAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer-related",
        "label": "Customer-Related Intangible Assets [Member]",
        "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current debt obligations",
        "totalLabel": "Current debt obligations",
        "label": "Debt, Current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Arrangements",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r378",
      "r596",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r612",
      "r619",
      "r620",
      "r622"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r185",
      "r186",
      "r254",
      "r257",
      "r384",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r922",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1439"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Margin added per annum",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r257",
      "r623"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Face value of debt",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r177",
      "r597",
      "r922",
      "r1270",
      "r1271"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Interest Rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r174",
      "r624",
      "r922"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r598"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r621",
      "r922",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1439"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r384",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r922",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1439"
     ]
    },
    "mdt_DebtInstrumentNumberofTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DebtInstrumentNumberofTranches",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Debt Instrument, Number of Tranches",
        "documentation": "Debt Instrument, Number of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of senior notes, face amount",
        "label": "Debt Instrument, Repurchased Face Amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r110",
      "r113",
      "r173",
      "r174",
      "r177",
      "r179",
      "r231",
      "r232",
      "r384",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r621",
      "r922",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1439"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt discount, net",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r1514"
     ]
    },
    "mdt_DebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DebtLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt [Line Items]",
        "label": "Debt [Line Items]",
        "documentation": "Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1481"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r528",
      "r1266"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "More than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r528"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r528",
      "r1266"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r528"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1481"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross realized gains",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross realized losses",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments by Category and Related Balance Sheet Presentation",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1475"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r1266",
      "r1482"
     ]
    },
    "mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]",
        "documentation": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, weighted average interest rate",
        "label": "Debt, Weighted Average Interest Rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated reasonably possible decrease in uncertain tax positions excluding interest over the next 12 months",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Compensation Liability, Current",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r234"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1441",
      "r1563",
      "r1564"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred financing costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r1514"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r1441",
      "r1563"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax assets",
        "verboseLabel": "Tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r802"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r245",
      "r287",
      "r829",
      "r830",
      "r1441"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax (benefit) expense:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r256",
      "r816"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "negatedTerseLabel": "Deferred tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r802",
      "r999"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "mdt_DeferredStockParorStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredStockParorStatedValuePerShare",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock, par value (in euros per share)",
        "label": "Deferred Stock, Par or Stated Value Per Share",
        "documentation": "Deferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredStockSharesAuthorized",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock, shares authorized (in shares)",
        "label": "Deferred Stock, Shares Authorized",
        "documentation": "Deferred Stock, Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredStockSharesIssued",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock, issued (in shares)",
        "label": "Deferred Stock, Shares Issued",
        "documentation": "Deferred Stock, Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredStockSharesOutstanding",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock, outstanding (in shares)",
        "label": "Deferred Stock, Shares Outstanding",
        "documentation": "Deferred Stock, Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reported as (after valuation allowance and jurisdictional netting):",
        "label": "Deferred Tax Assets and Liabilities, Balance Sheet, Reported Amount [Abstract]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "mdt_DeferredTaxAssetsInterestLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsInterestLimitation",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest limitation",
        "label": "Deferred Tax Assets, Interest Limitation",
        "documentation": "Deferred Tax Assets, Interest Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "mdt_DeferredTaxAssetsLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsLeaseObligations",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligations",
        "label": "Deferred Tax Assets, Lease Obligations",
        "documentation": "Deferred Tax Assets, Lease Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1561"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1561"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredTaxAssetsNetofValuationAllowanceOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsNetofValuationAllowanceOther",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance, Other",
        "documentation": "Deferred Tax Assets, Net of Valuation Allowance, Other"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss, capital loss, and credit carryforwards",
        "label": "Deferred Tax Assets, Operating and Capital Losses, and Tax Credit Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss, capital loss and tax credit carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, no expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, expiring in future years",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsResearchAndDevelopmentCapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalization of research and development",
        "label": "Deferred Tax Assets, Research and Development Capitalization",
        "documentation": "Deferred Tax Assets, Research and Development Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, no expiration",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration",
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "mdt_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension and post-retirement benefits",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits and Pensions",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from pension and postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state benefit on uncertain tax positions",
        "label": "Deferred Tax Assets Tax Deferred Expense Federal And State Benefit On Uncertain Tax Positions",
        "documentation": "The tax effect as of the balance sheet date of the amount of estimated future tax deductions arising from the federal and state benefit on uncertain tax positions, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, unrealized currency losses",
        "label": "Deferred Tax Assets, Unrealized Currency Losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized gain on available-for-sale securities and derivative financial instruments",
        "label": "Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives",
        "documentation": "Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails",
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized loss on derivative financial instruments",
        "label": "Deferred Tax Liabilities, Derivatives",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxLiabilitiesInvestmentInSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Outside basis difference of subsidiaries",
        "label": "Deferred Tax Liabilities, Investment In Subsidiaries",
        "documentation": "Deferred Tax Liabilities, Investment In Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use leases",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DeferredTaxLiabilitiesPensionAndPostRetirementBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Pension and post-retirement benefits",
        "label": "Deferred Tax Liabilities, Pension And Post-retirement Benefits",
        "documentation": "Deferred Tax Liabilities, Pension And Post-retirement Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1562"
     ]
    },
    "mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental expense related to acceptance of voluntary early retirement packages",
        "label": "Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits",
        "documentation": "Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated benefit obligation at end of year",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Ending balance",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r65",
      "r1523"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts recognized in accumulated other comprehensive loss:",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net actuarial loss",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r712"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior service (credit) cost",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r712"
     ]
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual return on plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Actuarial (gain) loss",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of net actuarial loss (gain)",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r707",
      "r733",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of prior service cost",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r708",
      "r734",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Recognized asset (liability)",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts recognized on the consolidated balance sheets consist of:",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts Recognized in AOCI",
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r666",
      "r667",
      "r690",
      "r1108",
      "r1284",
      "r1589"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssetsTargetAllocationsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Assets Target Allocations",
        "label": "Defined Benefit Plan, Plan Assets, Allocations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate of compensation increase",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate \u2013 benefit obligation",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected return on plan assets",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r738"
     ]
    },
    "mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate \u2013 interest cost",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate",
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate of compensation increase",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate \u2013 service cost",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate",
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Post-retirement benefit plans, benefit obligations",
        "periodStartLabel": "Projected benefit obligation at beginning of year",
        "periodEndLabel": "Projected benefit obligation at end of year",
        "terseLabel": "Benefit obligations",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefits paid",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r741"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee contributions",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "documentation": "Information by defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r719",
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in projected benefit obligation:",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in plan assets:",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r694",
      "r737",
      "r1282",
      "r1283",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Special termination benefits",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Plan curtailments, settlements, and amendments",
        "label": "Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation",
        "documentation": "Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDebtSecurityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDebtSecurityMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt",
        "terseLabel": "Debt securities",
        "label": "Defined Benefit Plan, Debt Security [Member]",
        "documentation": "Debt instrument issued by corporation, government and governmental agency, municipality, and other institution; in which defined benefit plan asset is invested."
       }
      }
     },
     "auth_ref": [
      "r1521"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity",
        "terseLabel": "Equity securities",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Future Benefit Payments",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 \u2013 2034",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated future employer contributions in next fiscal year",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r1285"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expected return on plan assets",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r706",
      "r732",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Post-retirement benefit plans, fair value of plan assets",
        "periodStartLabel": "Fair value of plan assets at beginning of year",
        "periodEndLabel": "Fair value of plan assets at end of year",
        "terseLabel": "Fair value of plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r692",
      "r694",
      "r695",
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rate changes and other",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net underfunded status of the plans",
        "totalLabel": "Over (under) funded status of the plans",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r690",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFundedStatusOfPlanAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funded status at end of year:",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanInterestCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest cost",
        "label": "Defined Benefit Plan, Interest Cost",
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r673",
      "r705",
      "r731",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Post-retirement benefit plans, net periodic benefit cost, income",
        "totalLabel": "Net periodic benefit (credit) cost",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r729",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Periodic Benefit Cost",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets at fair value",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projected benefit obligation",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plans with accumulated benefit obligations in excess of plan assets",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated benefit obligation",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r727",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets at fair value",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r727",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projected benefit obligation",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r1525"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefits paid",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r1527"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rate changes and other",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Target allocations",
        "terseLabel": "Target Allocation",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r1284"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plans with projected benefit obligations in excess of plan assets",
        "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement and curtailment (gain) loss",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r710",
      "r736"
     ]
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanServiceCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service cost",
        "label": "Defined Benefit Plan, Service Cost",
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r704",
      "r730",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Plan settlements",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_DefinedBenefitPlanSpecialTerminationBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanSpecialTerminationBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Special termination benefits",
        "label": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits",
        "documentation": "Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual Allocation",
        "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage",
        "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan."
       }
      }
     },
     "auth_ref": [
      "r1520"
     ]
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Critical assumptions \u2013 projected benefit obligation:",
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Critical assumptions \u2013 net periodic benefit cost:",
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r117",
      "r118",
      "r119",
      "r120"
     ]
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense under defined contribution plans",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation Expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r99"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r438"
     ]
    },
    "mdt_DerivativeAssetLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DerivativeAssetLiabilityAbstract",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Derivative Asset (Liability) [Abstract]",
        "documentation": "Derivative Asset (Liability) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DerivativeAssetLiabilityFairValueGrossAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Amount of Recognized Assets (Liabilities)",
        "label": "Derivative Asset (Liability), Fair Value, Gross Asset (Liability)",
        "documentation": "Derivative Asset (Liability), Fair Value, Gross Asset (Liability)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Amount Not Offset on the Balance Sheet, Financial Instruments",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r45",
      "r283"
     ]
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative asset."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Assets",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r344",
      "r900",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1102",
      "r1103",
      "r1192",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1257",
      "r1306",
      "r1595"
     ]
    },
    "us-gaap_DerivativeAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative assets:",
        "label": "Derivative Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash collateral received",
        "negatedTotalLabel": "Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted",
        "label": "Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash",
        "documentation": "Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross Amount Not Offset on the Balance Sheet, Financial Instruments",
        "label": "Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction",
        "documentation": "Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeCollateralObligationToReturnCash",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset",
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r165",
      "r342",
      "r1256"
     ]
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeCollateralRightToReclaimCash",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset",
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r165",
      "r342",
      "r1256"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1087",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1192",
      "r1193",
      "r1196",
      "r1198",
      "r1304",
      "r1306"
     ]
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, excluded component, gain (loss), recognized in earnings",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r1568"
     ]
    },
    "us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) recognized in earnings from excluded component of derivative hedge."
       }
      }
     },
     "auth_ref": [
      "r1568",
      "r1569"
     ]
    },
    "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueAmountOffsetAgainstCollateralNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Amount",
        "label": "Derivative, Fair Value, Amount Offset Against Collateral, Net",
        "documentation": "The net amount as of the balance sheet date of the fair value of derivative assets and derivative liabilities that in accordance with the entity's accounting policy were offset against collateral under a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value - Assets",
        "verboseLabel": "Gross Amount of Recognized Assets (Liabilities)",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r157",
      "r201",
      "r340",
      "r1257"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Amount",
        "label": "Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction",
        "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r164"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value - Liabilities",
        "negatedTerseLabel": "Gross Amount of Recognized Assets (Liabilities)",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r157",
      "r201",
      "r340",
      "r1257"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net Amount",
        "label": "Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction",
        "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r164"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r158",
      "r160",
      "r162",
      "r1085",
      "r1087",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1192",
      "r1193",
      "r1196",
      "r1198",
      "r1257",
      "r1304",
      "r1306"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives and Currency Exchange Risk Management",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r859",
      "r872"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "documentation": "Disclosure of information about derivatives and hedging activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r155",
      "r160"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, (Gain) Loss [Table]",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r155",
      "r160",
      "r162",
      "r166",
      "r167",
      "r858"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, (Gain) Loss [Line Items]",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Derivative instruments not designated as hedging instruments, (gain) loss, net",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r1403"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liabilities",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r344",
      "r900",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1110",
      "r1112",
      "r1113",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1257",
      "r1595"
     ]
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities:",
        "label": "Derivative Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Amount Not Offset on the Balance Sheet, Financial Instruments",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r45",
      "r283"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross notional amount",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1566",
      "r1567"
     ]
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives, Fair Value [Line Items]",
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r149",
      "r150",
      "r153",
      "r163",
      "r383"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives designated as hedging instruments",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "mdt_DiabetesGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DiabetesGroupMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diabetes",
        "verboseLabel": "Diabetes",
        "label": "Diabetes Group [Member]",
        "documentation": "Diabetes Group"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DiabetesPumpRetainerRingLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DiabetesPumpRetainerRingLitigationMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diabetes Pump Retainer Ring Litigation",
        "label": "Diabetes Pump Retainer Ring Litigation [Member]",
        "documentation": "Diabetes Pump Retainer Ring Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1517"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase and Award Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r752",
      "r783",
      "r784",
      "r786",
      "r1293"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration receivable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable",
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value",
        "documentation": "Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold, excluding amortization of intangible assets",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r319"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer to held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r180",
      "r182",
      "r225"
     ]
    },
    "mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNonCashImpairments",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash impairments",
        "label": "Disposal Group, Including Discontinued Operation, Non-cash Impairments",
        "documentation": "Disposal Group, Including Discontinued Operation, Non-cash Impairments"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operation, other operating expense, net",
        "label": "Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net",
        "documentation": "Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Not Discontinued Operations",
        "label": "Disposal Group, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is not classified as discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1289"
     ]
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends to shareholders",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1319",
      "r1320",
      "r1333"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1319",
      "r1320",
      "r1333",
      "r1369"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1354"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticPlanMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic plan",
        "label": "Domestic Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1528",
      "r1529",
      "r1530"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r411",
      "r413",
      "r419",
      "r420",
      "r421",
      "r425",
      "r883",
      "r884",
      "r990",
      "r1018",
      "r1262"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r417",
      "r419"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r413",
      "r419",
      "r420",
      "r421",
      "r425",
      "r883",
      "r884",
      "r990",
      "r1018",
      "r1262"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r422",
      "r423",
      "r424"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r804",
      "r832"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base erosion anti-abuse tax",
        "label": "Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign derived intangible income benefit",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Percent",
        "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r1559",
      "r1565"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions and interest",
        "label": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain tax adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1559",
      "r1565"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expense related to internal restructuring and intercompany sale of assets",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1559",
      "r1565"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1559",
      "r1565"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Puerto Rico excise tax",
        "label": "Effective Income Tax Rate Reconciliation, Puerto Rico Excise Tax",
        "documentation": "The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to Puerto Rico excise tax from intercompany purchases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. tax on foreign earnings",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings."
       }
      }
     },
     "auth_ref": [
      "r1559",
      "r1565"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. state taxes, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1559",
      "r1565"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation, tax adjustments for reserves, amount",
        "label": "Effective Income Tax Rate Reconciliation, Tax Adjustments For Reserves, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expense (benefit) related to tax basis adjustment, intercompany intellectual property transactions",
        "label": "Effective Income Tax Rate Reconciliation, Tax Basis Adjustment of Intangible Assets, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Basis Adjustment of Intangible Assets, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1559",
      "r1565"
     ]
    },
    "mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax reconciliation, disallowance of interest deductions, amount",
        "label": "Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount",
        "documentation": "Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period over which unrecognized compensation is expected to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to restricted stock awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1557"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to outstanding stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1557"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefits",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit related to options exercised",
        "verboseLabel": "Tax benefit related to restricted stock vested",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Termination Benefits",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "verboseLabel": "Employee stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_EmployeesStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EmployeesStockPurchasePlanMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan",
        "label": "Employees Stock Purchase Plan [Member]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_EnterpriseExcellenceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EnterpriseExcellenceMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise Excellence",
        "label": "Enterprise Excellence [Member]",
        "documentation": "Enterprise Excellence [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1394"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1395"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r314",
      "r359",
      "r360",
      "r361",
      "r393",
      "r394",
      "r395",
      "r398",
      "r406",
      "r408",
      "r426",
      "r512",
      "r518",
      "r641",
      "r787",
      "r788",
      "r789",
      "r825",
      "r826",
      "r864",
      "r866",
      "r867",
      "r868",
      "r869",
      "r871",
      "r882",
      "r911",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r944",
      "r1041",
      "r1042",
      "r1043",
      "r1065",
      "r1137"
     ]
    },
    "us-gaap_EquityFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityFundsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity commingled trusts",
        "label": "Equity Funds [Member]",
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments."
       }
      }
     },
     "auth_ref": [
      "r1521"
     ]
    },
    "mdt_EquityInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EquityInvestmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity and Other Investments",
        "label": "Equity Investments [Member]",
        "documentation": "Equity Investments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method and other investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r504",
      "r1419",
      "r1479"
     ]
    },
    "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and other investments",
        "label": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments",
        "documentation": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity and Other Investments",
        "label": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]",
        "documentation": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFVNINoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments for which the fair value option has been elected",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments with readily determinable fair value (marketable equity securities)",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r899",
      "r1251"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r899",
      "r997"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments without readily determinable fair values",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1362"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1325",
      "r1337",
      "r1347",
      "r1373"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1322",
      "r1334",
      "r1344",
      "r1370"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r1600",
      "r1601",
      "r1602",
      "r1603"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of debt",
        "label": "Extinguishment of Debt, Amount",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r895"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r895"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Unobservable Inputs",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Retirement Benefit Plan Assets Measured at Fair Value Using Significant Unobservable Inputs",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r171"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r889",
      "r950",
      "r951",
      "r952",
      "r1270",
      "r1271",
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r891",
      "r892",
      "r896"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r694",
      "r699",
      "r889",
      "r950",
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r694",
      "r699",
      "r889",
      "r951",
      "r1270",
      "r1271",
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r889",
      "r952",
      "r1270",
      "r1271",
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Inputs",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments measured at net asset value",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "documentation": "Fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r886",
      "r896"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total realized gains, net",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrealized gains, net",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases and sales, net",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)",
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r950",
      "r951",
      "r952",
      "r1270",
      "r1271",
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r896"
     ]
    },
    "mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurements, Retirement Benefit Plan Assets",
        "label": "Fair Value Measurements, Retirement Benefit Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure related to retirement benefit plan assets that are measured at fair value in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fair value, option gain (loss)",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "mdt_FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Retirement Benefit Plan Assets, Unobservable Input Reconciliation",
        "label": "Fair Value, Retirement Benefit Plan Assets, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of retirement benefit plan assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r156",
      "r166"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease obligations",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease obligations",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r527",
      "r529",
      "r530",
      "r621",
      "r638",
      "r872",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r1014",
      "r1266",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1475",
      "r1476",
      "r1477",
      "r1478"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, estimated useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r552"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r551",
      "r552",
      "r554",
      "r980",
      "r984"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r984"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96"
     ]
    },
    "us-gaap_FiscalPeriod": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiscalPeriod",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Year-End",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_FixedIncomeFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FixedIncomeFundsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed income commingled trusts",
        "label": "Fixed Income Funds [Member]",
        "documentation": "Investment that pools funds from investors to invest in a combination of underlying investments, primarily fixed income investments."
       }
      }
     },
     "auth_ref": [
      "r1521"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-U.S. Tax Authorities",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_ForeignCurrencyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ForeignCurrencyCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Currency",
        "label": "Foreign Currency Costs",
        "documentation": "Foreign Currency Costs"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_ForeignCurrencyDenominatedDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency denominated debt",
        "label": "Foreign Currency Denominated Debt [Member]",
        "documentation": "Foreign Currency Denominated Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_ForeignExchangeContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignExchangeContractMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rate contracts",
        "label": "Foreign Exchange Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r1257",
      "r1282",
      "r1299"
     ]
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-U.S. government and agency securities",
        "label": "Debt Security, Government, Non-US [Member]",
        "documentation": "Debt security issued by government not domiciled in United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1521",
      "r1593"
     ]
    },
    "us-gaap_ForeignPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignPlanMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-U.S.",
        "terseLabel": "Non-U.S. Pension Benefits",
        "label": "Foreign Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1528",
      "r1529",
      "r1530"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1329",
      "r1341",
      "r1351",
      "r1377"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1329",
      "r1341",
      "r1351",
      "r1377"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1329",
      "r1341",
      "r1351",
      "r1377"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1329",
      "r1341",
      "r1351",
      "r1377"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1329",
      "r1341",
      "r1351",
      "r1377"
     ]
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity Related to the Company's Available for Sale Securities Portfolio",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r1428",
      "r1429"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on debt extinguishment",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r105",
      "r106"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails",
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, beginning balance",
        "periodEndLabel": "Goodwill, ending balance",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r536",
      "r985",
      "r1268",
      "r1301",
      "r1485",
      "r1492"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill as a result of acquisitions",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r1268"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Other Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r548",
      "r1268"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation and other",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r537",
      "r543",
      "r548",
      "r1268"
     ]
    },
    "us-gaap_GoodwillImpairmentLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLossNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, net of tax",
        "label": "Goodwill, Impairment Loss, Net of Tax",
        "documentation": "Amount after tax of loss recognized that results from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r1268"
     ]
    },
    "us-gaap_GoodwillNotAllocatedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillNotAllocatedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, non deductible amount",
        "label": "Goodwill, Not Allocated, Amount",
        "documentation": "Portion of goodwill not yet allocated to reportable segments."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase accounting adjustments",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r1491"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sale of RCS business",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r1268"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r858"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "mdt_HerniaMeshLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "HerniaMeshLitigationMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hernia Mesh Litigation",
        "label": "Hernia Mesh Litigation [Member]",
        "documentation": "Hernia Mesh Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "country_IE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "IE",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ireland",
        "label": "IRELAND"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_IPRDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "IPRDMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D",
        "label": "IPR&amp;D [Member]",
        "documentation": "IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1319",
      "r1320",
      "r1333"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible asset finite lived statement of income or comprehensive income extensible enumeration not disclosed flag",
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible asset indefinite lived excluding goodwill statement of income or comprehensive income extensible enumeration not disclosed flag",
        "label": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of finite-lived intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r1436",
      "r1497"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of indefinite-lived intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r1436",
      "r1497"
     ]
    },
    "mdt_ImpairmentofInProcessResearchandDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ImpairmentofInProcessResearchandDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "IPR&amp;D charges",
        "label": "Impairment of In Process Research and Development",
        "documentation": "Impairment of In Process Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r831"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r205",
      "r262",
      "r433",
      "r447",
      "r453",
      "r456",
      "r991",
      "r1009",
      "r1264"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r831"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1289"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r563",
      "r1121"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r1121"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r796",
      "r805",
      "r813",
      "r820",
      "r827",
      "r833",
      "r834",
      "r835",
      "r1062"
     ]
    },
    "mdt_IncomeTaxExaminationInterestIncomeExpenseGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "IncomeTaxExaminationInterestIncomeExpenseGross",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross interest expense",
        "label": "Income Tax Examination, Interest Income (Expense), Gross",
        "documentation": "Income Tax Examination, Interest Income (Expense), Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "totalLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r288",
      "r407",
      "r408",
      "r441",
      "r803",
      "r828",
      "r1020"
     ]
    },
    "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact on diluted earnings per share (in dollars per share)",
        "label": "Income Tax Holiday, Income Tax Benefits Per Share",
        "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r799",
      "r800",
      "r813",
      "r814",
      "r819",
      "r821",
      "r1056"
     ]
    },
    "us-gaap_IncomeTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivables",
        "label": "Income Taxes Receivable",
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable."
       }
      }
     },
     "auth_ref": [
      "r1423"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationDispositionOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intercompany sale of assets",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expense associated with the amortization of the previously established deferred tax assets",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible amortization."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain tax adjustments, provision (benefit)",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax charge",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxHolidays": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxHolidays",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax reductions from tax holiday",
        "label": "Effective Income Tax Rate Reconciliation, Tax Holiday, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxSettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Charge associated with tax basis for Swiss Cantonal",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "mdt_IncomeTaxesandInterestPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "IncomeTaxesandInterestPaidAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for:",
        "label": "Income Taxes and Interest Paid [Abstract]",
        "documentation": "Income Taxes and Interest Paid [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts and Notes Receivable",
        "documentation": "The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities, net of acquisitions and divestitures:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating assets and liabilities",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_IncreaseDecreaseInTaxRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "IncreaseDecreaseInTaxRateAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in tax rate resulting from:",
        "label": "Increase Decrease In Tax Rate [Abstract]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends",
     "calculation": {
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee restricted stock units (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends",
        "documentation": "Number of additional shares included in diluted EPS for potentially dilutive effect of nonvested equity-based payment award containing forfeitable rights to dividends or dividend equivalents, whether paid or unpaid."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r1452",
      "r1453",
      "r1454",
      "r1456"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payments (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r421",
      "r751"
     ]
    },
    "mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental defined benefit, defined contribution and post-retirement",
        "label": "Incremental Defined Benefit, Defined Contribution, And Post-Retirement Charges [Member]",
        "documentation": "Incremental Defined Benefit, Defined Contribution, And Post-Retirement Charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r553"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r222"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1332",
      "r1341",
      "r1351",
      "r1368",
      "r1377",
      "r1381",
      "r1389"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1387"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1321",
      "r1393"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1321",
      "r1393"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1321",
      "r1393"
     ]
    },
    "mdt_InsuranceContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "InsuranceContractMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance contracts",
        "label": "Insurance Contract [Member]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r95"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r266",
      "r362",
      "r437",
      "r921",
      "r1122",
      "r1312",
      "r1597"
     ]
    },
    "us-gaap_InterestExpenseBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on outstanding borrowings",
        "label": "Interest Expense, Borrowings",
        "documentation": "Aggregate amount of interest expense on all borrowings."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income (Expense), Net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r374",
      "r375"
     ]
    },
    "mdt_IntersectENTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "IntersectENTMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersect ENT",
        "label": "Intersect ENT [Member]",
        "documentation": "Intersect ENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r1253"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.medtronic.com/role/InventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "totalLabel": "Total",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r1250",
      "r1301"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r322",
      "r336",
      "r531",
      "r532",
      "r534",
      "r978",
      "r1260"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r1255"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r1254"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-down",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1162",
      "r1164"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Abstract]",
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Debt Securities Contractual Maturities",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Member]",
        "documentation": "Assets held for their financial return, rather than for the entity's operations."
       }
      }
     },
     "auth_ref": []
    },
    "country_JP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "JP",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Japan",
        "label": "JAPAN"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-U.S. Developed Markets",
        "label": "Japan, Australia, New Zealand, Korea, Canada, and Western Europe [Member]",
        "documentation": "Japan, Australia, New Zealand, Korea, Canada, and Western Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandAndLandImprovementsMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and land improvements",
        "label": "Land and Land Improvements [Member]",
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r1300"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1575"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1576"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expected lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r380",
      "r508",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r590",
      "r592",
      "r594",
      "r595",
      "r847",
      "r851",
      "r852",
      "r901",
      "r1094",
      "r1263",
      "r1314",
      "r1509",
      "r1580",
      "r1581"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r259",
      "r1006",
      "r1301",
      "r1440",
      "r1480",
      "r1572"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r321",
      "r380",
      "r508",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r590",
      "r592",
      "r594",
      "r595",
      "r847",
      "r851",
      "r852",
      "r901",
      "r1301",
      "r1509",
      "r1580",
      "r1581"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits, net of cash advance, noncurrent liability",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Committed line of credit outstanding",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r257",
      "r1591"
     ]
    },
    "mdt_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional borrowing capacity",
        "label": "Line of Credit Facility, Additional Borrowing Capacity",
        "documentation": "Additional borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_LineOfCreditFacilityLengthOfExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "LineOfCreditFacilityLengthOfExtension",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Length of extension from maturity date",
        "label": "Line of Credit Facility, Length of Extension",
        "documentation": "Line of Credit Facility, Length of Extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case Type [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of settlement paid",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Axis]",
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1503"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Domain]",
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1503"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans Payable",
        "label": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r1000"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Fiscal Year Maturity",
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of senior notes",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r384",
      "r1515"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r384",
      "r614"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r384",
      "r614"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r384",
      "r614"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r384",
      "r614"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r384",
      "r614"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amount",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r104"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r575",
      "r577",
      "r582",
      "r1504",
      "r1505"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r575",
      "r577",
      "r582",
      "r1504",
      "r1505"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued litigations charges",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r1397"
     ]
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain litigation charges, net",
        "negatedTerseLabel": "Certain litigation charges, net",
        "label": "Loss Contingency Accrual, Provision",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r1503"
     ]
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r574",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581"
     ]
    },
    "mdt_LossContingencyLawsuitsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "LossContingencyLawsuitsNumber",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, lawsuits, number",
        "label": "Loss Contingency, Lawsuits, Number",
        "documentation": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNumberOfPlaintiffs",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plaintiffs (in plaintiffs)",
        "label": "Loss Contingency, Number of Plaintiffs",
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1504",
      "r1505"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of claimants (in claimants)",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1504",
      "r1505"
     ]
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MA",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Massachusetts",
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MN",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minnesota",
        "label": "MINNESOTA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reconciling items",
        "label": "Segment Reconciling Items [Member]",
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r577",
      "r578",
      "r579",
      "r745",
      "r977",
      "r1038",
      "r1086",
      "r1087",
      "r1145",
      "r1166",
      "r1171",
      "r1172",
      "r1209",
      "r1242",
      "r1243",
      "r1265",
      "r1274",
      "r1292",
      "r1303",
      "r1513",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587"
     ]
    },
    "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum remaining maturity of foreign currency derivatives",
        "label": "Maximum Remaining Maturity of Foreign Currency Derivatives",
        "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1360"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1360"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1571"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MechanicalCirculatorySupportMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "MechanicalCirculatorySupportMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mechanical Circulatory Support",
        "label": "Mechanical Circulatory Support [Member]",
        "documentation": "Mechanical Circulatory Support"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MedicalDeviceRegulations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "MedicalDeviceRegulations",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Medical device regulations",
        "label": "Medical Device Regulations",
        "documentation": "Medical Device Regulations"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MedicalSurgicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "MedicalSurgicalMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Surgical",
        "verboseLabel": "Medical Surgical",
        "label": "Medical Surgical [Member]",
        "documentation": "Medical Surgical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MedtronicLuxcoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "MedtronicLuxcoMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medtronic Luxco",
        "label": "Medtronic Luxco [Member]",
        "documentation": "Medtronic Luxco [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MedtronicLuxcoSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "MedtronicLuxcoSeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medtronic Luxco Senior Notes",
        "label": "Medtronic Luxco Senior Notes [Member]",
        "documentation": "Medtronic Luxco Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Emerging Markets",
        "label": "Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea [Member]",
        "documentation": "Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r577",
      "r578",
      "r579",
      "r745",
      "r977",
      "r1038",
      "r1086",
      "r1087",
      "r1145",
      "r1166",
      "r1171",
      "r1172",
      "r1209",
      "r1242",
      "r1243",
      "r1265",
      "r1274",
      "r1292",
      "r1303",
      "r1513",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r258",
      "r380",
      "r508",
      "r583",
      "r586",
      "r587",
      "r588",
      "r594",
      "r595",
      "r901",
      "r1005",
      "r1098"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes to noncontrolling ownership interests",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1380"
     ]
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MortgageBackedSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage-backed securities",
        "label": "Collateralized Mortgage-Backed Securities [Member]",
        "documentation": "Securities collateralized by mortgage loans."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1283",
      "r1284",
      "r1460",
      "r1467",
      "r1472",
      "r1473",
      "r1474",
      "r1593"
     ]
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MozarcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "MozarcMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mozarc",
        "label": "Mozarc [Member]",
        "documentation": "Mozarc"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1388"
     ]
    },
    "us-gaap_MutualFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MutualFundMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual funds",
        "label": "Mutual Fund [Member]",
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective."
       }
      }
     },
     "auth_ref": [
      "r1521"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income attributable to Medtronic",
        "terseLabel": "Net income attributable to ordinary shareholders",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r215",
      "r263",
      "r319",
      "r353",
      "r356",
      "r361",
      "r380",
      "r397",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r408",
      "r418",
      "r433",
      "r447",
      "r453",
      "r456",
      "r508",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r590",
      "r592",
      "r594",
      "r595",
      "r884",
      "r901",
      "r1012",
      "r1117",
      "r1135",
      "r1136",
      "r1264",
      "r1312",
      "r1509"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net income attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r249",
      "r353",
      "r356",
      "r407",
      "r408",
      "r1011",
      "r1427"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetInvestmentHedgingMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment hedges",
        "label": "Net Investment Hedging [Member]",
        "documentation": "Hedges of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "mdt_NeuromodulationDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "NeuromodulationDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neuromodulation",
        "label": "Neuromodulation Division [Member]",
        "documentation": "Neuromodulation Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_NeuroscienceGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "NeuroscienceGroupMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neuroscience",
        "verboseLabel": "Neuroscience",
        "label": "Neuroscience Group [Member]",
        "documentation": "Neuroscience Group"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r409",
      "r425",
      "r469",
      "r470",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r558",
      "r787",
      "r788",
      "r789",
      "r823",
      "r824",
      "r825",
      "r826",
      "r839",
      "r840",
      "r841",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r897",
      "r898",
      "r902",
      "r903",
      "r904",
      "r905",
      "r919",
      "r920",
      "r923",
      "r924",
      "r925",
      "r926",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r981",
      "r982",
      "r983",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r409",
      "r425",
      "r469",
      "r470",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r558",
      "r787",
      "r788",
      "r789",
      "r823",
      "r824",
      "r825",
      "r826",
      "r839",
      "r840",
      "r841",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r897",
      "r898",
      "r902",
      "r903",
      "r904",
      "r905",
      "r919",
      "r920",
      "r923",
      "r924",
      "r925",
      "r926",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r981",
      "r982",
      "r983",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1360"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1329",
      "r1341",
      "r1351",
      "r1368",
      "r1377"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1358"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1357"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1388"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1388"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r641",
      "r1449",
      "r1450",
      "r1451",
      "r1598"
     ]
    },
    "us-gaap_NondesignatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NondesignatedMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives not designated as hedging instruments",
        "label": "Not Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_NotesPayableToBanksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableToBanksMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank borrowings",
        "label": "Notes Payable to Banks [Member]",
        "documentation": "A written promise to pay a note to a bank."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1457"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1457"
     ]
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting units",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffsettingAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Offsetting Assets",
        "label": "Offsetting Assets [Table Text Block]",
        "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r343"
     ]
    },
    "mdt_OffsettingAssetsandLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OffsettingAssetsandLiabilitiesLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offsetting Assets and Liabilities [Line Items]",
        "label": "Offsetting Assets and Liabilities [Line Items]",
        "documentation": "[Line Items] for Offsetting Assets and Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_OffsettingAssetsandLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OffsettingAssetsandLiabilitiesTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offsetting Assets and Liabilities [Table]",
        "label": "Offsetting Assets and Liabilities [Table]",
        "documentation": "Offsetting Assets and Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffsettingLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Offsetting Liabilities",
        "label": "Offsetting Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r343"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating profit",
        "terseLabel": "Reportable segment operating profit",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r447",
      "r453",
      "r456",
      "r1264"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1300"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Classification, Other accrued expenses",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Classification, Other liabilities",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r935"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Classification, Other assets",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1300"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1300"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, valuation allowance",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r456"
     ]
    },
    "mdt_OtherAccruedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherAccruedExpensesMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Expenses [Member]",
        "documentation": "Other Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_OtherAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherAcquisitionsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Acquisitions",
        "label": "Other Acquisitions [Member]",
        "documentation": "Other Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r1301"
     ]
    },
    "us-gaap_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "verboseLabel": "Other assets",
        "label": "Other Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other assets."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r166"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other commitment",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior service cost",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r203",
      "r711"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r203",
      "r907",
      "r908",
      "r910"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of prior service cost",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r203",
      "r352",
      "r711"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) before reclassifications",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r65",
      "r360",
      "r911",
      "r914",
      "r917",
      "r1425"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), tax expense (benefit)",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r359",
      "r1013"
     ]
    },
    "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "(Gain)\u00a0Loss\u00a0Recognized in Accumulated Other Comprehensive Income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "(Gain) Loss Reclassified into Income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before TaxeclassificationBeforeTax",
        "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before TaxeclassificationBeforeTax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on cash flow hedges",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r349"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Recognized in AOCI, Cash flow hedges",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r349",
      "r854",
      "r855",
      "r860"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Recognized in income, cash flow hedges",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r349",
      "r351"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized in AOCI, net investment hedges",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified into Income, net investment hedges",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r47",
      "r354",
      "r357",
      "r363",
      "r911",
      "r912",
      "r917",
      "r986",
      "r1013",
      "r1425",
      "r1426"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total recognized in other comprehensive income",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r203",
      "r1284",
      "r1522"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net change in retirement obligations",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r203"
     ]
    },
    "mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Foreign Exchange Adjustment",
        "documentation": "Foreign exchange adjustment to pension and other postretirement benefit plans (gain) loss included in accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net actuarial (gain) loss",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r203",
      "r235"
     ]
    },
    "mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization and settlement recognition of actuarial (gain) loss",
        "label": "Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Gain (Loss) Recognized in Net Periodic Benefit Cost, before Tax",
        "documentation": "2012 Element. Before tax amount of the income statement impact of the reclassification adjustment for actuarial gain (loss) recognized as a component of net periodic benefit cost."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment hedge",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax",
        "documentation": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investment securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r349",
      "r502"
     ]
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r1301"
     ]
    },
    "us-gaap_OtherLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Liabilities",
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other liabilities."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r166"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other, net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-operating income, net",
        "terseLabel": "Other non-operating income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherNonoperatingIncomeExpenseNetPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-Operating Income, Net",
        "label": "Other Nonoperating Income (Expense), Net [Policy Text Block]",
        "documentation": "Other Nonoperating Income (Expense), Net [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeExpenseMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating expense (income), net",
        "label": "Other Operating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other operating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating expense (income), net",
        "terseLabel": "Other operating expense, net",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherOperatingIncomeExpenseNetPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Expense (Income), Net",
        "label": "Other Operating Income (Expense), Net [Policy Text Block]",
        "documentation": "Other Operating Income (Expense), Net [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1360"
     ]
    },
    "mdt_OtherPlanAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "OtherPlanAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Plan Assets [Member]",
        "documentation": "Other categories of plan assets not specified in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other post-retirement benefits",
        "label": "Other Postretirement Benefits Plan [Member]",
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r716",
      "r717",
      "r719",
      "r722",
      "r725",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r742",
      "r743",
      "r744",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1327",
      "r1339",
      "r1349",
      "r1375"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1330",
      "r1342",
      "r1352",
      "r1378"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1330",
      "r1342",
      "r1352",
      "r1378"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholders\u2019 Equity",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_PartnershipUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "PartnershipUnitsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partnership units",
        "label": "Partnership Units [Member]",
        "documentation": "Partnership units include partnerships, private equity investments, and real asset investments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other investing activities, net",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1399",
      "r1430"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of ordinary shares",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r1434"
     ]
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends to shareholders",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r842"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial valuation",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireLongtermInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire long-term investments",
        "label": "Payments to Acquire Long-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term."
       }
      }
     },
     "auth_ref": [
      "r1430"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to property, plant, and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1359"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1359"
     ]
    },
    "us-gaap_PendingLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PendingLitigationMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pending Litigation",
        "label": "Pending Litigation [Member]",
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process."
       }
      }
     },
     "auth_ref": [
      "r1503"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of retirement benefit plans",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r691",
      "r693",
      "r699",
      "r718",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r739",
      "r740",
      "r742",
      "r1284"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current liabilities",
        "label": "Liability, Defined Benefit Plan, Current",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r666",
      "r667",
      "r690",
      "r1284"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and retirement benefits",
        "negatedLabel": "Non-current liabilities",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r666",
      "r667",
      "r690",
      "r1284"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefit Plan Assumptions",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r24",
      "r26",
      "r34",
      "r121"
     ]
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionPlansDefinedBenefitMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension benefits",
        "label": "Pension Plan [Member]",
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r716",
      "r717",
      "r719",
      "r722",
      "r725",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r742",
      "r743",
      "r746",
      "r1284",
      "r1285",
      "r1289",
      "r1290",
      "r1291"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1358"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1357"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance share units",
        "netLabel": "Employee performance share units",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanAssetCategoriesDomain",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "documentation": "Defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r719",
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1531",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1531",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r626"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r1096"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r626"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r1096",
      "r1115",
      "r1598",
      "r1599"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid income taxes",
        "label": "Prepaid Taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1252",
      "r1267",
      "r1483"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1418"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of businesses",
        "label": "Proceeds from Divestiture of Businesses",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of long-term debt",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r1057"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares",
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r1057"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financing activities",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1400",
      "r1431"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt",
        "label": "Proceeds from (Repayments of) Debt",
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in current debt obligations, net",
        "label": "Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less",
        "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months."
       }
      }
     },
     "auth_ref": [
      "r1432",
      "r1433",
      "r1437"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r1459"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and maturities of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from short-term borrowings (maturities greater than 90 days)",
        "label": "Proceeds from Short-Term Debt",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from options exercised",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r39"
     ]
    },
    "mdt_ProductDevelopmentMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ProductDevelopmentMilestoneMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product development and other milestone-based payments",
        "label": "Product Development Milestone [Member]",
        "documentation": "A milestone in achieving certain product development target."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r979",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1245",
      "r1275",
      "r1302",
      "r1404",
      "r1506",
      "r1507",
      "r1517",
      "r1592"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r979",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1245",
      "r1275",
      "r1302",
      "r1404",
      "r1506",
      "r1507",
      "r1517",
      "r1592"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity",
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "verboseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r353",
      "r356",
      "r372",
      "r380",
      "r397",
      "r407",
      "r408",
      "r433",
      "r447",
      "r453",
      "r456",
      "r508",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r590",
      "r592",
      "r594",
      "r595",
      "r845",
      "r848",
      "r849",
      "r884",
      "r901",
      "r991",
      "r1010",
      "r1064",
      "r1117",
      "r1135",
      "r1136",
      "r1264",
      "r1297",
      "r1298",
      "r1313",
      "r1427",
      "r1509"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Accumulated depreciation",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1401",
      "r1402",
      "r1500"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant, and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1402",
      "r1498"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1398",
      "r1420",
      "r1499"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r277",
      "r285",
      "r286"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r996",
      "r1008",
      "r1301"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r277",
      "r285",
      "r1007"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment Balances and Corresponding Lives",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for credit losses",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r522"
     ]
    },
    "mdt_PurchasedTechnologyAndPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "PurchasedTechnologyAndPatentsMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased technology and patents",
        "label": "Purchased Technology and Patents [Member]",
        "documentation": "Purchased technology and patents."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r577",
      "r578",
      "r579",
      "r691",
      "r745",
      "r778",
      "r779",
      "r780",
      "r953",
      "r977",
      "r1038",
      "r1086",
      "r1087",
      "r1145",
      "r1166",
      "r1171",
      "r1172",
      "r1209",
      "r1242",
      "r1243",
      "r1265",
      "r1274",
      "r1292",
      "r1303",
      "r1306",
      "r1501",
      "r1513",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r577",
      "r578",
      "r579",
      "r691",
      "r745",
      "r778",
      "r779",
      "r780",
      "r953",
      "r977",
      "r1038",
      "r1086",
      "r1087",
      "r1145",
      "r1166",
      "r1171",
      "r1172",
      "r1209",
      "r1242",
      "r1243",
      "r1265",
      "r1274",
      "r1292",
      "r1303",
      "r1306",
      "r1501",
      "r1513",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassifications",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r65",
      "r360",
      "r911",
      "r916",
      "r917",
      "r1425"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications from AOCI, tax expense (benefit)",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r352",
      "r359",
      "r1013"
     ]
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Assets and Depreciation Expense from Segments to Consolidated",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1322",
      "r1334",
      "r1344",
      "r1370"
     ]
    },
    "mdt_RegisteredInvestmentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "RegisteredInvestmentCompanyMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registered investment companies",
        "label": "Registered Investment Company [Member]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_RenalCareBusinessRCSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "RenalCareBusinessRCSMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renal Care Business (RCS)",
        "label": "Renal Care Business (RCS) [Member]",
        "documentation": "Renal Care Business (RCS)"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_RenalCareSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "RenalCareSolutionsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renal Care Solutions",
        "label": "Renal Care Solutions [Member]",
        "documentation": "Renal Care Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1433"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r1060"
     ]
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfSeniorDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of senior notes, consideration",
        "label": "Repayments of Senior Debt",
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments from short-term borrowings (maturities greater than 90 days)",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r1558"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1323",
      "r1335",
      "r1345",
      "r1371"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1324",
      "r1336",
      "r1346",
      "r1372"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1331",
      "r1343",
      "r1353",
      "r1379"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock",
        "verboseLabel": "Restricted stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock",
        "terseLabel": "Employee restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Activities [Abstract]",
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringCharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r560",
      "r562",
      "r565",
      "r571"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated expected restructuring costs",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r564",
      "r568",
      "r570"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "negatedLabel": "Restructuring and associated costs",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r566",
      "r568",
      "r1502"
     ]
    },
    "mdt_RestructuringChargesIncludingAccrualAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "RestructuringChargesIncludingAccrualAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges",
        "label": "Restructuring Charges, Including Accrual Adjustments",
        "documentation": "Restructuring Charges, Including Accrual Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringChargesMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges, net",
        "label": "Restructuring Charges [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227"
     ]
    },
    "mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges, net",
        "label": "Restructuring Charges, Net of Restructuring Reversals Including Cost of Product Sold Impact",
        "documentation": "Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r568",
      "r569"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r569",
      "r570"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r567"
     ]
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveAccrualAdjustment1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual adjustments",
        "label": "Restructuring Reserve, Accrual Adjustment",
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r569"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Restructuring Reserves",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveSettledWithoutCash2",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled non-cash",
        "label": "Restructuring Reserve, Settled without Cash",
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r569"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r233",
      "r1004",
      "r1045",
      "r1050",
      "r1061",
      "r1097",
      "r1301"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r393",
      "r394",
      "r395",
      "r398",
      "r406",
      "r408",
      "r512",
      "r518",
      "r787",
      "r788",
      "r789",
      "r825",
      "r826",
      "r864",
      "r867",
      "r868",
      "r871",
      "r882",
      "r1041",
      "r1043",
      "r1065",
      "r1598"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanSponsorLocationAxis",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Axis]",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r722",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r1528",
      "r1529",
      "r1530"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanSponsorLocationDomain",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Domain]",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r722",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r1528",
      "r1529",
      "r1530"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r716",
      "r717",
      "r719",
      "r722",
      "r725",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r742",
      "r743",
      "r744",
      "r746",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r716",
      "r717",
      "r719",
      "r722",
      "r725",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r742",
      "r743",
      "r744",
      "r746",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling",
        "verboseLabel": "Shipping and Handling",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r446",
      "r451",
      "r452",
      "r458",
      "r460",
      "r462",
      "r660",
      "r661",
      "r979"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition and Shipping and Handling",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r1244"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r664"
     ]
    },
    "mdt_RevenueMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "RevenueMilestoneMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue and other performance-based payments",
        "label": "Revenue Milestone [Member]",
        "documentation": "Revenue Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period over which remaining performance obligations are expected to be recognized as revenue",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1300"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1388"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1388"
     ]
    },
    "mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charge to adjustments",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments",
        "documentation": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Charges to Other Accounts, net",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net",
        "documentation": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r1284",
      "r1525",
      "r1526"
     ]
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive Loss",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1573",
      "r1574"
     ]
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allocation of Plan Assets",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Securities Reconciliation",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r1284",
      "r1525"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofFairValueoftheAssetsAcquiredandLiabilitiesAssumedIntersectENTAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r837"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax (Benefit) Provision",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r110",
      "r113",
      "r173",
      "r174",
      "r177",
      "r179",
      "r231",
      "r232",
      "r1270",
      "r1272",
      "r1442"
     ]
    },
    "mdt_ScheduleOfDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ScheduleOfDebtTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Debt [Table]",
        "label": "Schedule Of Debt [Table]",
        "documentation": "Schedule Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)",
        "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r117",
      "r118",
      "r119",
      "r120"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plans",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r117",
      "r118",
      "r119",
      "r120"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of (Gain) Loss on Derivative Instruments",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r160",
      "r858"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1456"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r505",
      "r506",
      "r507",
      "r508",
      "r901"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Table]",
        "label": "Schedule of Equity Method Investments [Table]",
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r380",
      "r505",
      "r506",
      "r507",
      "r508",
      "r901"
     ]
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expected Benefit Payments",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r980"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r1268"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Carrying Amount of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r1268",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Before Income Taxes, Based on Jurisdiction",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1441"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Carrying Amount of Indefinite-Lived Intangible Assets",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r222"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory Balances",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r197",
      "r198",
      "r199"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Line Items]",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1163",
      "r1165",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1163",
      "r1165",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1200",
      "r1201",
      "r1202",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Benefit Costs",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r569",
      "r570"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographical Region",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r207"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r204"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r90"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r750",
      "r753",
      "r754",
      "r755",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r123"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Current Debt Obligations",
        "label": "Schedule of Short-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r231",
      "r232",
      "r233",
      "r331",
      "r332",
      "r333",
      "r427",
      "r626",
      "r627",
      "r628",
      "r630",
      "r633",
      "r638",
      "r640",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1274",
      "r1396",
      "r1438"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r1296",
      "r1560"
     ]
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r392"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1315"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r462",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r564",
      "r570",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1268",
      "r1404",
      "r1592"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r460",
      "r461",
      "r1079",
      "r1082",
      "r1084",
      "r1151",
      "r1167",
      "r1188",
      "r1215",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1246",
      "r1276",
      "r1306",
      "r1517",
      "r1592"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment and Geographic Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r445",
      "r450",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SelfInsuranceReservePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SelfInsuranceReservePolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Self-Insurance",
        "label": "Self Insurance Reserve [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative expense",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative expense",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2009Due2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2009Due2039Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.500 percent thirty-year 2009 senior notes",
        "label": "Senior Notes 2009 Due 2039 [Member]",
        "documentation": "2039 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2010Due2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2010Due2040Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.550 percent thirty-year 2010 senior notes",
        "label": "Senior Notes 2010 Due 2040 [Member]",
        "documentation": "2040 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2012Due2042Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2012Due2042Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.500 percent thirty-year 2012 senior notes",
        "label": "Senior Notes 2012 Due 2042 [Member]",
        "documentation": "2042 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2013Due2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2013Due2043Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.000 percent thirty-year 2013 senior notes",
        "label": "Senior Notes 2013 Due 2043 [Member]",
        "documentation": "2043 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2014Due2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2014Due2044Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.625 percent thirty-year 2014 senior notes",
        "label": "Senior Notes 2014 Due 2044 [Member]",
        "documentation": "2044 Senior Notes - unsecured debt not collateralized by pledge, mortgage or other lien in the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2015Due20253.500PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2015Due20253.500PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes 2015 Due 2025, 3.500 percent",
        "label": "Senior Notes 2015 Due 2025, 3.500 percent [Member]",
        "documentation": "Senior Notes 2015 Due 2025, 3.500 percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2015Due2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2015Due2035Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.375 percent twenty-year 2015 senior notes",
        "label": "Senior Notes 2015 Due 2035 [Member]",
        "documentation": "Senior Notes 2015 Due 2035 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2015Due2045Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2015Due2045Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.625 percent thirty-year 2015 senior notes",
        "label": "Senior Notes 2015 Due 2045 [Member]",
        "documentation": "Senior Notes 2015 Due 2045 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2017Due20273.350PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2017Due20273.350PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes 2017 Due 2027, 3.350 Percent",
        "label": "Senior Notes 2017 Due 2027, 3.350 Percent [Member]",
        "documentation": "Senior Notes 2017 Due 2027, 3.350 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due2025Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.250% Senior Notes due 2025",
        "label": "Senior Notes 2019 Due 2025 [Member]",
        "documentation": "Senior Notes 2019 Due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due2026Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.250 percent six-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2026 [Member]",
        "documentation": "Senior Notes 2019 Due 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due2027Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "1.125% Senior Notes due 2027",
        "terseLabel": "1.125 percent eight-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2027 [Member]",
        "documentation": "Senior Notes 2019 Due 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20311.00PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due20311.00PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.000% Senior Notes due 2031",
        "label": "Senior Notes 2019 Due 2031, 1.00 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2031, 1.00 Percent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20311.625PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due20311.625PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625% Senior Notes due 2031",
        "label": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due2031Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625 percent twelve-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2031 [Member]",
        "documentation": "Senior Notes 2019 Due 2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due2032Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.000 percent twelve-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2032 [Member]",
        "documentation": "Senior Notes 2019 Due 2032 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20391.50PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due20391.50PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.500% Senior Notes due 2039",
        "label": "Senior Notes 2019 Due 2039, 1.50 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2039, 1.50 Percent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20392.250PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due20392.250PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.250% Senior Notes due 2039",
        "label": "Senior Notes 2019 Due 2039, 2.250 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2039, 2.250 Percent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due2039Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.250 percent twenty-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2039 [Member]",
        "documentation": "Senior Notes 2019 Due 2039 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due2040Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.500 percent twenty-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2040 [Member]",
        "documentation": "Senior Notes 2019 Due 2040 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2049Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due2049Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.750% Senior Notes due 2049",
        "label": "Senior Notes 2019 Due 2049 [Member]",
        "documentation": "Senior Notes 2019 Due 2049 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2050Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2019Due2050Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.750 percent thirty-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2050 [Member]",
        "documentation": "Senior Notes 2019 Due 2050 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2025Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.000% Senior Notes due 2025",
        "label": "Senior Notes 2020 Due 2025 [Member]",
        "documentation": "Senior Notes 2020 Due 2025"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2026Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.000 percent five-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2026 [Member]",
        "documentation": "Senior Notes 2020 Due 2026"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2028Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.375% Senior Notes due 2028",
        "label": "Senior Notes 2020 Due 2028 [Member]",
        "documentation": "Senior Notes 2020 Due 2028"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2029Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.375 percent eight-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2029 [Member]",
        "documentation": "Senior Notes 2020 Due 2029"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2032Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.750% Senior Notes due 2032",
        "label": "Senior Notes 2020 Due 2032 [Member]",
        "documentation": "Senior Notes 2020 Due 2032"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2033Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.750 percent twelve-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2033 [Member]",
        "documentation": "Senior Notes 2020 Due 2033"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2040Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.375% Senior Notes due 2040",
        "label": "Senior Notes 2020 Due 2040 [Member]",
        "documentation": "Senior Notes 2020 Due 2040"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2041Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.375 percent twenty-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2041 [Member]",
        "documentation": "Senior Notes 2020 Due 2041"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2050Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2050Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625% Senior Notes due 2050",
        "label": "Senior Notes 2020 Due 2050 [Member]",
        "documentation": "Senior Notes 2020 Due 2050"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2051Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2020Due2051Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625 percent thirty-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2051 [Member]",
        "documentation": "Senior Notes 2020 Due 2051"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2022Due2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2022Due2025Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.625% Senior Notes due 2025",
        "label": "Senior Notes 2022 Due 2025 [Member]",
        "documentation": "Senior Notes 2022 Due 2025"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2022Due2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2022Due2028Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.000% Senior Notes due 2028",
        "label": "Senior Notes 2022 Due 2028 [Member]",
        "documentation": "Senior Notes 2022 Due 2028"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2022Due2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2022Due2031Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.125% Senior Notes due 2031",
        "label": "Senior Notes 2022 Due 2031 [Member]",
        "documentation": "Senior Notes 2022 Due 2031"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2022Due2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotes2022Due2034Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.375% Senior Notes due 2034",
        "label": "Senior Notes 2022 Due 2034 [Member]",
        "documentation": "Senior Notes 2022 Due 2034"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotesCIFSA2007Due2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotesCIFSA2007Due2038Member",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.550 percent thirty-year 2007 CIFSA senior notes",
        "label": "Senior Notes CIFSA 2007 Due 2038 [Member]",
        "documentation": "Senior Notes CIFSA 2007 Due 2038 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotesDue2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotesDue2029Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.650% Senior Notes due 2029",
        "label": "Senior Notes Due 2029 [Member]",
        "documentation": "Senior Notes Due 2029"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotesDue2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotesDue2036Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.875% Senior Notes due 2036",
        "label": "Senior Notes Due 2036 [Member]",
        "documentation": "Senior Notes Due 2036"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotesDue2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotesDue2043Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.150% Senior Notes due 2043",
        "label": "Senior Notes Due 2043 [Member]",
        "documentation": "Senior Notes Due 2043"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotesDue2053Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SeniorNotesDue2053Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.150% Senior Notes due 2053",
        "label": "Senior Notes Due 2053 [Member]",
        "documentation": "Senior Notes Due 2053"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Shares",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1421",
      "r1422",
      "r1516"
     ]
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combinations",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "negatedTerseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average purchase price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The discount rate from market value on purchase date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares purchased by employees (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wtd. Avg. Grant Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance adjustments (in dollar per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested at beginning of period (in shares)",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested at beginning of period (in dollars per share)",
        "periodEndLabel": "Nonvested at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766"
     ]
    },
    "mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Performance adjustments (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of restricted stock vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions used:",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r750",
      "r753",
      "r754",
      "r755",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares purchased by employees (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for future grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired/Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1537"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired/Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1537"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value of options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wtd. Avg. Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r755",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r756",
      "r775",
      "r776",
      "r777",
      "r778",
      "r781",
      "r790",
      "r791",
      "r792",
      "r793"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Performance Share Unit Activity",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1531"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1294"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_ShippingAndHandlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShippingAndHandlingMember",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling",
        "label": "Shipping and Handling [Member]",
        "documentation": "Packing and transport of product."
       }
      }
     },
     "auth_ref": [
      "r1519"
     ]
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank borrowings",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r254",
      "r1301",
      "r1590"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Axis]",
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Domain]",
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average interest rate",
        "label": "Short-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r1424"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221",
      "r1248"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r1300"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r377"
     ]
    },
    "mdt_SimplificationRestructuringProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SimplificationRestructuringProgramMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Simplification",
        "label": "Simplification Restructuring Program [Member]",
        "documentation": "Simplification Restructuring Program"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SpecialChargesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SpecialChargesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Commitments to the Medtronic Foundation and Medtronic LABS",
        "label": "Special Charges (Gains)",
        "documentation": "Special Charges (Gains)"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SpecialtyTherapiesDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SpecialtyTherapiesDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specialty Therapies",
        "label": "Specialty Therapies Division [Member]",
        "documentation": "Specialty Therapies Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Tax Authorities",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationIncomeFromOperationsBeforeIncomeTaxesbyReportableSegmentandReconciliationtoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r462",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r557",
      "r564",
      "r570",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1268",
      "r1404",
      "r1592"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.medtronic.com/role/Cover",
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r331",
      "r332",
      "r333",
      "r380",
      "r413",
      "r417",
      "r419",
      "r421",
      "r427",
      "r428",
      "r508",
      "r583",
      "r586",
      "r587",
      "r588",
      "r594",
      "r595",
      "r626",
      "r627",
      "r630",
      "r633",
      "r640",
      "r901",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1096",
      "r1118",
      "r1137",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1396",
      "r1438",
      "r1455"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r62",
      "r314",
      "r359",
      "r360",
      "r361",
      "r393",
      "r394",
      "r395",
      "r398",
      "r406",
      "r408",
      "r426",
      "r512",
      "r518",
      "r641",
      "r787",
      "r788",
      "r789",
      "r825",
      "r826",
      "r864",
      "r866",
      "r867",
      "r868",
      "r869",
      "r871",
      "r882",
      "r911",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r944",
      "r1041",
      "r1042",
      "r1043",
      "r1065",
      "r1137"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutsatndinginstrumentsDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r302",
      "r460",
      "r461",
      "r1079",
      "r1082",
      "r1084",
      "r1151",
      "r1167",
      "r1188",
      "r1215",
      "r1229",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1246",
      "r1276",
      "r1306",
      "r1517",
      "r1592"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r426",
      "r979",
      "r1052",
      "r1076",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1096",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1116",
      "r1119",
      "r1120",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1137",
      "r1307"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r426",
      "r979",
      "r1052",
      "r1076",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1096",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1116",
      "r1119",
      "r1120",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1137",
      "r1307"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1326",
      "r1338",
      "r1348",
      "r1374"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares under stock purchase and award plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r190",
      "r191",
      "r233"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r190",
      "r191",
      "r233",
      "r762"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares under stock purchase and award plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r190",
      "r191",
      "r233"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount authorized for repurchase",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_StockRepurchaseProgramAveragePurchasePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "StockRepurchaseProgramAveragePurchasePrice",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average repurchase price (in dollars per share)",
        "label": "Stock Repurchase Program, Average Purchase Price",
        "documentation": "Average purchase price of common shares under a stock repurchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount available for future repurchases",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of ordinary shares (in shares)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r190",
      "r191",
      "r233"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of ordinary shares",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r190",
      "r191",
      "r233"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchased (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r190",
      "r191",
      "r233",
      "r1060",
      "r1137",
      "r1225"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount repurchased",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r190",
      "r191",
      "r233",
      "r1065",
      "r1137",
      "r1225",
      "r1313"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r194",
      "r195",
      "r217",
      "r1098",
      "r1115",
      "r1138",
      "r1139",
      "r1301",
      "r1314",
      "r1440",
      "r1480",
      "r1572",
      "r1598"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r146",
      "r314",
      "r315",
      "r360",
      "r393",
      "r394",
      "r395",
      "r398",
      "r406",
      "r512",
      "r518",
      "r641",
      "r787",
      "r788",
      "r789",
      "r825",
      "r826",
      "r864",
      "r866",
      "r867",
      "r868",
      "r869",
      "r871",
      "r882",
      "r911",
      "r913",
      "r917",
      "r944",
      "r1042",
      "r1043",
      "r1063",
      "r1098",
      "r1115",
      "r1138",
      "r1139",
      "r1227",
      "r1313",
      "r1440",
      "r1480",
      "r1572",
      "r1598"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r379",
      "r625",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r641",
      "r873",
      "r1140",
      "r1141",
      "r1228"
     ]
    },
    "mdt_StructuralHeartAndAorticDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "StructuralHeartAndAorticDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Structural Heart &amp; Aortic",
        "label": "Structural Heart And Aortic Division [Member]",
        "documentation": "Structural Heart And Aortic Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Axis]",
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Domain]",
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r946"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r946"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r946"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries",
        "label": "Subsidiaries [Member]",
        "documentation": "Entity in which controlling financial interest is held. Includes, but is not limited to, variable interest entity (VIE) consolidated by primary beneficiary. Excludes entity in which broker-dealer holds controlling financial interest but control is likely to be temporary."
       }
      }
     },
     "auth_ref": [
      "r1524",
      "r1577",
      "r1578",
      "r1579"
     ]
    },
    "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxExaminationsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Major Tax Jurisdictions Which Remain Subject to Examination",
        "label": "Summary of Income Tax Examinations [Table Text Block]",
        "documentation": "Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r244"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SurgicalInnovationsDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "SurgicalInnovationsDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surgical &amp; Endoscopy",
        "label": "Surgical Innovations Division [Member]",
        "documentation": "Surgical Innovations Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1367"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology-Based Intangible Assets",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "mdt_TokyoInterBankOfferedRateTIBORMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "TokyoInterBankOfferedRateTIBORMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TIBOR Rate",
        "label": "Tokyo Inter-bank Offered Rate (TIBOR) [Member]",
        "documentation": "Tokyo Inter-bank Offered Rate (TIBOR)"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_TotalOtherCountriesExcludingIrelandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "TotalOtherCountriesExcludingIrelandMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total other countries, excluding Ireland",
        "label": "Total Other Countries, Excluding Ireland [Member]",
        "documentation": "Total Other Countries, Excluding Ireland [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "TotalOtherCountriesExcludingUnitedStatesandIrelandMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of world",
        "label": "Total Other Countries, Excluding United States and Ireland [Member]",
        "documentation": "Total Other Countries, Excluding United States and Ireland [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_TotalReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "TotalReportableSegmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segment net sales",
        "label": "Total Reportable Segments [Member]",
        "documentation": "Total Reportable Segments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1359"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1366"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r465",
      "r466",
      "r468"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Names",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks and tradenames",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1387"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1389"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r621",
      "r638",
      "r872",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r1014",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1475",
      "r1476",
      "r1477",
      "r1478"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1391"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1389"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1389"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1392"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "TwoThousandTwentyOneStockAwardAndIncentivePlanMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousand Twenty One Stock Award and Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty One Stock Award and Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r568",
      "r569"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. Pension Benefits",
        "terseLabel": "UNITED STATES",
        "netLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government and agency securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r1261",
      "r1282",
      "r1588"
     ]
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undistributed earnings from non-U.S. subsidiaries",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r797",
      "r836"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1386"
     ]
    },
    "mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on interest rate cash flow hedges",
        "label": "Unrealized Gain (Loss) on Interest Rate Cash Flow Hedges, Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount of unrealized gain (loss), net of tax as of the balance sheet date, related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized (losses) and gains on equity and other investments still held",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails",
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits",
        "periodStartLabel": "Gross unrecognized tax benefits at beginning of fiscal year",
        "periodEndLabel": "Gross unrecognized tax benefits at end of fiscal year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r807"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "UnrecognizedTaxBenefitsGrossDecreasesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross decreases:",
        "label": "Unrecognized Tax Benefits Gross Decreases [Abstract]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "UnrecognizedTaxBenefitsGrossIncreasesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increases:",
        "label": "Unrecognized Tax Benefits Gross Increases [Abstract]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income tax penalties and interest",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "UnrecognizedTaxBenefitsNetofCashAdvancePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits at end of fiscal year, net of cash advance",
        "label": "Unrecognized Tax Benefits, Net of Cash Advance Paid",
        "documentation": "Unrecognized Tax Benefits, Net of Cash Advance Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Statute of limitation lapses",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r275",
      "r276",
      "r278",
      "r279"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Valuation Allowance",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward."
       }
      }
     },
     "auth_ref": [
      "r1443",
      "r1444",
      "r1445",
      "r1446",
      "r1447"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other Changes (Debit) Credit, Adjustments",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment."
       }
      }
     },
     "auth_ref": [
      "r1448"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at Beginning of Fiscal Year",
        "periodEndLabel": "Balance at End of Fiscal Year",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r391"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges to Income",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges to Other Accounts",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other Changes (Debit) Credit",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r390",
      "r391"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r390",
      "r391"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_VentilatorProductLineExitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240426",
     "localname": "VentilatorProductLineExitMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ventilator Product Line Exit",
        "label": "Ventilator Product Line Exit [Member]",
        "documentation": "Ventilator Product Line Exit"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsandDispositionsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r1242",
      "r1243",
      "r1582",
      "r1584",
      "r1587"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted weighted average shares outstanding (in shares)",
        "totalLabel": "Diluted \u2013 weighted average shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r421"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic weighted average shares outstanding (in shares)",
        "verboseLabel": "Basic - weighted average shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r421"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a),(b),(c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a-c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i),(j),(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i-k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481097/715-30-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "60",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "740",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481141/942-740-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "740",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480135/944-740-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "80",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "SubTopic": "20",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "68B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-68B"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-12"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a),(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//220/tableOfContent"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r242": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r243": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r244": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r245": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r246": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r247": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r248": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r249": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r250": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815/tableOfContent"
  },
  "r251": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r252": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r253": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r254": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r255": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r256": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r257": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r258": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r259": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r260": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r261": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r262": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r263": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r264": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r265": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r266": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r267": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r268": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r269": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r270": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r271": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "30",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "SubTopic": "20",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-20/tableOfContent"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-30/tableOfContent"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-20"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>164
<FILENAME>0001613103-24-000072-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001613103-24-000072-xbrl.zip
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MH8BF%_=9V).M@"_G+L*GN,]US@\CYML\N7[NRH>&O*[6Z70^/N*0I0^-P\J
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MBGH;BP'^6TY'TB)'YAI8$' C+9),K(%%T4Z$')^Z@812>K6TD451+H0<S6E
M4;P#(<=R&E 4[SYV@N34U8R3XQHI"J<H<TJ.[Z,HG*+,&CG.C7*R-%WXX'GR
M7*MR6]6VH=WH8Z,@H]XVW!M];!3D4]I:$G#?H+_"9=X-A^[8K@<HD5>5U+:3
M8\,(RZ@H&TN.G"(LHZ)L'3FNB+(??(_:IRVM#&[O!/^CJ:#SW*FN38Y+,E4H
M6U-J<M24D?76]-HP7=3* K:DU8>&MR(LZ3QU^I <"[7C,[7;TFARC)*1\U;T
M64M62F.]TI)ATAC?ABTB.6NR+?4RG!%U<>>JW>28HW7$?1*(<0 "YY>!GPRY
M/@I&CK^A..*Y8EQ+%N5=1IS"M.Z1EM3'^XNGH!G=(W)\!4WQ%#29>T2.9GAA
M\R$[B/U(3(XOSDIGR$@R <6*HBBC19(D*%8411DHDOS!NXMB2]G$$<ETO<C1
MS3-S."*9':\QNM]O=< NR4RXR-'-%;LDL]YG1A?GG>Z"B"DF[42.M<M#=8:-
MZP^^^V[$'?F D/G.A> >_%/.G+A#,B?637@%!9\=DAFS;L(K*%SMZ)9/4Q'>
MEH*$CFY)-4%YY!E6='3+K%^21[GC"-V2;QK2*BIPT"V9IR&MHB(%W<B!PJ2U
MK=! -_Z @@!RC07(40SI]-]OS(O5H<2>%SPPW^9AUW=N>,C%/0^7S]^87G8>
MB!/!'3?:^HG2.0KBJ$J.+J N" +!V5&5'$] 76K;<21'57(YOT:"6 BIWB8(
M<LD^=4$02%N.JN0H >I2RZA/;5YF;U,?<MD^=4$0R"./JN2R_M=*;?GZJ_XI
M[W,!$KQCC]TPY/J4QA]5R>7WFLF%1(Q-CB/03(C;"KE+0QT4+Y<\(_!::9@$
M"D:OH("\5AIBH7CERC,^KY6&9Z"@7-L/US^ZC\>"AT$L8#S4QR%GCFR\X]Y_
M_AG^(V7KLG:O;[=;G+%VJVDW>*_?ZC1ZC/6:O-EN'[7^C1HYNR>,)A[(>.3Z
ME2%W!\/HN%$[:(VC3P^N$PV/:]7J_]F35W[^.1PS__///?$1[E=_J\<L/6S,
M')Q#J'B\'QW7CN!AZ3="OD%^A?VJ,,\=^,<V##07ZAO71PP=-]KC"-X;L9['
MT\?V @$=KMB!Y[%QR(_3/SXY;CCVV 0TPG-]7I$W?1HQ,8!.]8(H"D;'V*-[
M+B*< 4G>*E^G?IYU]J"J.AS!P$9.^N;DYP/XZ>/R]YVC@TYU]4_5@YK\_J-\
MGDA_3$=:]=&QH"<XH'_=:^PM=#9I?FT<67*1D?6GJOS?I^3W*!@?UY=^3(;[
MN&K!C=/W?Y0#LTKX:JCP6>U5DME3LD\OA]8&XCA]5Q\@6NFSD>M-CO]R!_H<
M6I?\P;H)1LS_RW[(_+ "JNOVU86A^Q]^W(&7R$\/:AP.X3%2<LFXU.HH@^^7
M%W=GI];M7??N['8><9FV$VGL[=G)]YN+NXNS6ZM[>6J=_?/DU^[E+V?6R=6W
M;Q>WMQ=7E]1[\ \6#@$S4>#O6Z<')P=6O=IJ=IYL];QZ(6S>&T6UP[7Z=7YU
M\\WZ&>RE'_B7\0@>8EN)6;WA?72&M3W+9^CH'.X>GP9VC$X '<V>M*A]N.!S
MK5KYN[2ZLZ=\MO(=G/>U=1VP9NWVIJ:N==!HUI^U=&L;S?I!LW6TCM%\RD*F
M1JX^?D0SEQU3=#Q+0Q",UT?@/^#!^/#PM2JEO,C&J.OZ?HQ[_XX#$>U9_4",
M6 0^_3$Z[KN/W*E$(IZB$B*X/_^I<]AL?UH$YA27D9/3X"GH9 .!][-.<BC5
MP%A"CHPUCD480^QK18$%(2E&?U:M807"JK4^.#]90=^*AMRZY78LW,B%5IP]
MVD/F#[C5M2/\N=9I- ^6]+>0KIU#L[&U?3>$ ;<FG D+PD+NO,)J7<OP\4P%
ME?, <N";R@@>,<3;*@Z;5/!5%>ZG@&IN@MB3& )L/SJ7C?X7/&C=E\[>UP"Q
MCH7K_?E/M7;U$[(Y\S#>MY#I6?QV06H2XP5:BM<AH;D2"6H@\M=>2AW:0:-^
M)^!M+AJIIPU[GWGAU+*W$LO>?$_+7H#EFPW,*L-^^P;#CDEJ:E>CV5M4=FWU
M13"R_CW]'[YL]FD9K>OD30TZ>=-),!JY(9(JUKD+$>5E<+"!)SF3G ?>"!?W
MH \))ML0 U<:[:-Z]4E,/A\%/S5"[FA@A<*&RYVH@@:_VJRW_SVH'?P^'NQ9
MS(OD+UXP".J]:DM].Y]&UZJU\>-K8N!F\VC\B)%FOGE)]27;6$]LXV'STTN#
M1PQ;F^+HA@_<$!4PNH1?4BP=[GW^QIU(!#X\8^S9FR*JL$%9+<D/9X\,C _V
M'2V0F/;98J$5CKF-C*ACN;[E1J$%YDI 4W]*.ZE#VM<X.J@?M7+)^VJ=@Z/&
M82Z/@E:U#K>50B:<Y/M'4F^-.I3B7?AVLNT0^ %9!ZYJO"<G@3,?HT.#[&/N
M#)@8B^ ^65<^"]*/]CXGM>#YQB*2":8<J.X:8N[8XT4R?6-+U,S[_\[>Y\Y1
MI58[:C2/CIZ%@H8ZMQH4'Z3>8/ 9X"()ZW>(.4/'55$I&'HWJV/R,C%@OOL?
M^?DGHQZTA7MQ<'-P>V"=C<9>, 'ISH,?H^:?-D@%-(W/NHXC>!@F_WR%Y]6F
MI'=U[W.]:EWYUJ\LLH?[UM?@ 89)?K!N(\%YM';<IO?HG,"?5^(N>)@Z1:QJ
M.(U[\ :KOLQ:O?8URO4N.^?$)^-M,[^,$_@O.>;"Q?!$O)QT&&WH6( 5=<?,
ML_@C)/61>X\Q-&@A#W]Z>GZ%")[^9P.Z5,D0\Z%@)L/&WN=&J[$\K[3^8Q$^
M@C,5U25/;4*J_H9G?@W /%\/ W^! :BU]CXW&Q #P&!H![E9(OJ7T(JXQ\?8
M0<N7/=Q'5Z[6/5H,1A-&Q^$_;=RG5;41]$";X<Y4ILH%)*<KB;?ZA]Z4<NO:
MT?%&7=.B=*/9.#A\H71C[<3V,+='-5H'C?4*2G2*PY[@@-W(D[0)9Q!7V!X+
M0TWCS"<Y;FE7;B>C7N"5JFN7">$E)<=3'AX,Q\/0A6]FUF63]#!3U[1<]*3/
MV#SK;NM9=YO8XTFMWI.Z,'6W[;W/5P*ZR\3$"H?@E\)]:\R$=<^\F%O_+>U=
M#:<TU*^OH&=V;JP3952Z.!UHI*-/[\SXK8_5=-)-D?I+9"+\NI"L'(&U@+;^
M*Q _('<,[!_3>;NR44FO&.+&6N:@L_>Y>E!O5?\/Q&>^&PCK,HB@?0[8@GJU
MWLJ7G=5V^%9J>+TJ-?RC&:4WZG&]9O3XZ2%NKJ/']3KJ,:8J1H^?&;[5>MQ(
M];AKANEMBMPTBOST$+?64N36WN?Z0;O>,HK\W/"M5N1VJLA?S#"]39$/C2(_
M/<3MM109DI/:0>TI13[<782V7U;D3J+(9I3>IL>-JM'CIX?X<!T];M0PLFX<
M/J''SQ>M[,[PK=3C1CW18S-*;]3CAM'CIX?X:"T]AMRD\72&O,,(/7I9CUNI
M'N]PAKP291LK<MLH\M-#W%E+D0]1D=M/4=:=W45HYV5%/DH4V8S2&_6X8_3X
MF<*OZCJ*W*QBAOP4U=58*C;;'8C.C]]*36[6E":;87JK*C?K1I6?&>/:6JK<
M0%5^*KC>:8S67E;E9JK*.QQ=K\;9QKK<,KK\S!BO52'6;&-\_11QO=.Z_'+5
M5_,PU>4=GH):C;.-==E4=STWQFN5=S5E>=?A$[ER8VF5T0YA].7ZKE92WV6&
MZ:VJW#(%7L^-\5H57JTZNN6GYJ$:2QM:[1!&7R[Q:B4E7F:8WJS*IL3KN3%>
MJ\:KU4)5/GI*E9=VK-LAC+Y<Y-5*BKS,,+U9E4V1UW-CO%:55^L(RS6?6C_1
MV.%IEMK+95ZMI,RKT=EEXBN70J^V*?1Z;HS7JO1JXX;<!ZVG2.Q=UN672[W:
M]527=YGXRJ78JVV*O9X;X[6JO=JX6\F3V7+SZ9U&RH_1E\N]VDFY5[.ZRWXY
MEWJOMJGW>FZ,URKX:D.>TCRH/1%C-Y<V.MHAC+Y<\=5.*KZ:C5W6Y5QJOMJF
MYNNY'1W6JODZE#5?3TU(-7<XQJZ_7/-UF-1\F6%ZJRH?FIJOY\9XK9JOP\9S
MY9NM'0ZQZR_7?!TF-5]FF-ZLRJ;DZ[DQ7JODZ[#]7(2]O)7H#F'TY9*OPZ3D
MRPS3FU7Y+15?&^^A799]5</9OJJ#U^^K6D#7+@.?KWG*#Y[LFSFE9>&@W]_C
M,'+[DVWW8O4>P!>^@YN[<ZLWL>PA!\Q"0W]8KI)#YM06-[28]< ]K_+##QZ@
MF9R%, (._!#&N%LP X/+^ZZO#G6YB3UN-:NM%8=3@7 W/WOI'_#FO^.+;Y/W
M7LC73G4/DMM_\7!1S^:WZ%]S>#<]$>VIDXSD*936AB_/4[:70=']?^8HI_1B
M>1!VH(XB.\:MVW&W\Z5SMM.[$H6JSFYAO3#PXFCYEI>.YE;_'8J9+QOP2D]P
M]J/"^F!5CIGWP"8A[BN\K2/!2VDE_""";_Z(7;3T8.#[>-R:.LDN?.8HN^FG
M[)%VTE2 7M/!<0&#GW1^0X/Y&VB%'S$A3ZT3X?3D(IQI#^C9R=)ZTH<AE^?D
M+"C*A]I/UA!<)FJ'8S'/FZI(5G=Z/+D GKF&NKQP B0D1 )WW<9+QX+;7.[!
M7:M;\BS:T/H SX4PUPIC>VB%PP!/9$M/AXR&+%KLPP,+ES5=WISTY2>("GS'
M^E!7?>U!L R_]WZ'MLO0#R^%F[ 5R7/P9-!0-D(VDH61U:E:#MCAS4.&Y#!>
M=;PHYCT1B^*9(M2(1@R%6QK284-)S0&J!VC&R(TBT"7N@8;(@R#!,$PL#DGT
MQ+K 5(?9\C"84Q8Q=8[I@K68/2/K:;/!^ T?Q)XZS>FV<F=]0%D??JHWZ@?3
M:-V5YS&.\3S&;9L,U=ZI)>#A3YOK>69@<%P2M9_J>=WHN=%S*GHNLV@/>L(M
M9MN@YX*ALB+T,87V5WX+(;5?6?E#. (# 6\1J8\#;1G!&$SV,4: QX%#Q5$;
M6 ,1/$3#].<#"!6X;)M,V64F)4^>^O.?CNIUZ.83+90_USZEE[UXP=/M2R_$
M^&#OB5;N38F$6KU7J:=13C:T.<@%0 4=S]/I'+0W/YVG]O(!K^M^7S^H'N9S
M@&VK>=#I;/;R=^K?MH["+>[8^-5'-[[F,'-Q JH["%8=K\?E15*I[>2BS/&W
MC;W/7U>;B'PG$:@-\F*R^G*GJMBE!(%Z][V[+.K2B;;Y*:=)5FJ]NUP5091?
M@+NBF[=/Q5GE$O&F/DX.RY<XA >%X9R/.^Z[C]R!1GKAM(S@J)D!T=M++]9$
M5[Z7:2#$L]7!_FXC-1V47^28G*3YSTN(;6V V"<K#/1)M?N*L&"^^C=-&]4G
M!2?U]RS+Q$]NDJ*K3[U)<@TFZ^I/S-B32Y-70)ZI_ICE[NKSD"6349*CXX[Z
MX ?)SU'"J<0A7W@0C"'WG?0&?**:P$S9,F31L-G>!'7CP07-@!Y8/HQ<@(;]
MW@VEW_:9;[O,P\@;3T_&B\,(LF@FG- :B^#>=5:?7*M>7&M\8#^I/X/%OJ:)
MM?HDY]X2=#U]Z+0^X-F8C_WSG]K->NOPDYR@25PK'N2)E 6+(@[#+@4(0^Q&
M(3S.9P,Y@8'<1NWP4VBQ, 3'@U^EW 7O][ED*OWDJ&^\TT7VP0>9HID0@6<%
M8,DRHIYY]1@0-)O[:5:;F;.(;YGH,7ALY>K1XQ,Y[_.AUK*^']P>G!Q8A_4V
M'ES\$W9_UM>D&J?G@8W* "KMN1@I$G<,+6!X*2!1EGLXLMTL=MPH:=U!@5SB
M^L;VPNZ++K8Z$-V9!,\]-EAE:R,1STQM.Y/]/6%J]=6-/I9AI5.'(.E-#\'&
ML\)?5*\9H''<DZF^8+F$0)XZKJJ(U&W)!&'?D_.&\)4=")&T!.Y'FE,(G#(,
M$*GW;A"'WB0%ZJJWZ@'6T\".L;GGKG\;C:(S[./)M.=/@78^0#A\.4#8%+4D
MS3>Z2@FE(.0)&F8@22&=@9TT:].)*+3N=B!GV<"(>Y/05;;91V(8C'6EQ]#Y
MHGOF?JBL/DZ&P4]R:G[Z]BR0IUZ /X)NR6F[H-]W;2["[*R:@$#B'G$_;4(2
M$&3U+IFD:U8/:M732@V4[V#3PC(S;?/6:9MPR#TO35>L#ROJ'>>F*< L%B6E
MC?-D[-G:2<=1_C:%#"RZ@P&('7&!<.!1<JXXB/0^D*$1!G\X'9=\!#2,P!B@
M(8FD#?C&'35S;XT]VX)QE09"3N#UT9,Q7)BP[/28_/+*CH(>H*]^N(]G033V
M+65X N4);2\(\:5C&&O9IO]N=PZ:#4O.J6,0-KOTB3KT8XN-(4=X=$' ''SD
M?R=(.9?SYW!O[+L*)W'H["U6R4,F[G ;[O7"O^[-'RBB<'0M(\ES+V#1/(S\
M>%1Q@JB2W X9/:3I<&MG"JK.WN=._6"ZOUW:H,]6S_4\^./  I#AV. PI0?
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M]O,#I<,T]]%:JSPOP-/I,I&TV*.G9K6S3%6>2W&+E-,IQ$_"':-_,.):[)/
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M),^ I-G:^WP9X '542"AHFTO++V;;XRWT<L%2+1,<:B6PJM7(6?K&+[8X)
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M(&WXL##2<T-\-^0ASW;<]>\##Z3YPP\>U&;FL:_^%F[X YX8^[:JL8LD]&;
M=T<XN S[P.3Z9K7/$(K>9C&\!4<2?D%!3-L'792;W\%#)4:9/73Y?=(6@$^/
MPP/ W,'0>A/+<?M]+@=!8@QPN-3A9Q\(0P<7AAPU -OKN? GX!Z!_=PH7<7B
MF=_GT#V'(55Q"-W K@]$\ "ZA0.6_)D 0XZC XWT@G$J!-FDD3QT.Y28P">
M0CJQC;W$ 6=C-ZG3"),ZC?T,#F<#HF[*O@"L#4AQF-S-84PE%!&L^W@C9\)6
M#<W>E,(8+QG$T+5 3*96 FZT<<%>Y$I; -=R?Q -55-!*= 18K-0(O 7UIS@
MT#BR]%)*PT_^!K&@#@.6Q^K0P2%G'@R6#?A+6CS@P1@LH0S(4=G[<)G:5A]'
M*=6[_:?U]2.JS72HX E.HK-P1R1@M&*1[LQO!R&X"G:/GUT?+I.Q88AF(^*>
MQQ6>81#@!='$DI$__(JM&\@7RJ=$[!%Q',D5_@.YIE^>(2OOM#E'2Z/Z!OH'
M;4CNA8M'7 S2Q1[,_B-VE7E!Q+CR2ID2[2=8@4ML/HX0_;+7:X&&S4I_\(&H
M;S,HX3 @.ERE[H$_"/ [-+$B4>8 Q#1M[T,@I'K8\";L'WB6/V)F VH )?&T
M5:J;$NW[\HLI"N58(=*2[Z6U Z@(#CWUI5$(9ZM;$@L4,@^Z!<] EWM@78"'
M",#_@%G$1H>Q/5S45S L+IYRZ?8S-D!:*?!S7$"T#*$%V&QY+PM3KS4#[W[J
ML9)?>MQ#0[/X-0RMYRQ^F0[STO>RLXO?I@9^\7M$H+_T[-0^,=";I1^AYXM?
MH4-:^BX(0Q>BV.7O$SU>^D$$OZ]H>3A<U?L'UYL]0$K/A9"-"<2.(UU:8J<1
M40?HJI\RO*O=>V**T0-'T@'Z 9@\>(<RQOLK_?QVSC&MKQ5='A=TB*I\N7++
M/=?#E6>@7(Y )?1 T2NH!UEE4RI<Y$A]*G2DLMY01GTJ]IAZ4_19B;5-? =:
MU5B%&\G%\P;Z)>.,"$?YA'P@\?II9@_!@J V8&R GM?CTMG ,Z<./(P@K.5)
M'(+7)H%(^M)/TH<-E%_$.WT8IXC;0VGZ7.7DTMB8"325TE\JS^<.<)F$]:%[
M\9,*%5C$X _F3<!"*O\8K.6 /J6^*PV=4]>;">66G=E<U([H_<^T&TE\.HU\
MDC#JTYS'5&YY+C;IR166&'=".WG0_R1_QP! 73W]'=XQ'3EH -BJ>S>(PSG_
M_&DNSLD(Z[LO[9"<*0^M#]\/;@]^ AL7.&HMBH@'5M>!JUT9;V&7Y#76^6E7
M#;0?^!7YS8HP+)5B5L2VX Q#7C2I4F0P-'A-,BS9H4P#SB".(+ODLO_XJD^6
M/3O@:!:9JN ?Q))\E*;BTZ)!&7'X"2->?(/#1U)SDHB6/T(WU1BF#<X.8B8B
MDDJW$("ES<86)2,L\;\<G:('?P#0XK\+H)?OPS.N;9G9NK*3"71G4:/" HP@
M\GS)G9F@3OT\%TFGD)TS&M-("@<27AK+  LPXN+/-CJK&=Z&0:AB*$#XQ/)4
M0)T,+W8,4AL87_2-H;PKS7OQ59\RP5,2]\Y26A51S]Z6'<N9.J0BA[$0W!WU
M8A&J%!5C;SO5XC'DW8D2A+CY;/CLFS//3#L-G?,=V0=4W54 2N(TE3^/,/-$
M[8; #(Q'V(^]6:8]!BN5+)U.18)^WU\V#4&*,&D^P_EL;3X+R( .FQ8!3F:&
M.1/G)U!0&<KZ(?XG2&>@S7 =!_D%(W5ZN>-F8)?&T!*N]PQB)608ER+M1!D7
MO_?AW8E4QFPB)0C/ 5N(X^JH)@$4^6B<CI+4XS U?ZD/2W.Z%-@]YDG3' YY
M8@H\%U0)6CY)1*CR"AQ:F[OWLM& "[E'L;IB&(,UF#8TPX)(%@K:@"":YL]>
M *^4W0/S8?-/*TSX+'G$.Z1?=&4CY0/GI)*8B:F9R61! ^@%WG50 N;R']P:
M,@CH>M('1)+N>8;*@#!\P+U)FDNOY)R4VLN 7WWN@5:D\8W<5'J1%$/D. D?
M] !M4:F2S,.8M)GK).[[JU/V))V'!&EH];W@84IJ/=-+P!7[ 7V$CK(P93:1
M6%5_/TL8*K! 3\-8<G@(3V;Y\:@' 3*ZGQ4TF;H'[*/2L1"<0F@+MY<RE%-2
M] 9NMLX5?39E1-4X*Z[&"_D#1B=K,)L'UA>NB+=G1H+)1PTEJ>9-LGV2_4@(
MP#G&3V;6T-&'H0L.R&8^IE>03H,'P!W&5;0+]BK)K?>M21!;*A.4F9A(\/4B
M%D$TR3.5I>[/8^S NO(!0W&H'"<X G@NDN0NIBK//==/F'?I>A0J99I?\#@E
MOD'2KPQR+>'R:#*%U*I7+)&T&4\.SQL%&!%A-"N#[P"&VW%#.Y8,: *\,-5B
MM*"1!S\D4/QE:BQQ/_G$5*:81',*#T@NO8!1LFJ MT2!L[G]W"7= VL5PM=A
MZ3,!G.K)S%\?/VFFY\XS;[17VF7UE8NKOJ/C2NWHN4//%RUU%WGIMV6T<@S:
M!>:UG^8/?6\<R!&8DKD@A33F1]B">""@=646X<  BLF^&?W<1]\!;$^2'&$%
MU6Y&//<17S778,8Y_W&6.:_*,X3,Q(6(QZF5D4Q7/!Y[QJAL8>C[D#AB] 0Q
M2T(8\LP$J33Q:D:!SU-=<X0,W# W[V3DE+N<F .!EPQP9J9?JHP9[/P'6];=
M+#$V&6[ #/H6!GU&FJ5E"F:4<Q]E2"TE@PI18\_C(S/&6QCC#),N6?%)RG";
MP=Y"3CKIH6-,-DE-)A_ND1?'36P<64MBACWW89=1NII"P0G&#!\[/P,WX]Z9
M&,GYM*0PZVFAO$<)_BMV -DJ(5][>AV *>DO44F_,3BO-3@A]_HP*&$L9!6O
M,>G;8'='7"3%/&:<MS?.LZH9-AZ#,Y1V)"UP-='*-HC<:65'Q'YP7U;VLD=9
M4A9'PT"H.F8S\%N8LY"%9G+>%,L#94V0K&%<529D)+ -6B4IO\'9=A'UF6?F
MBK9"I'M8&Y84PX!I5T4RD(;R1V7PC77?7B[:5[PLKNTRXYN_$7?#=#XNK:%+
M*L#DND558SAE ,I0'P<97<C_B&59S[[E!T\7 :7+A@8Q@X YXFG)SOR21GG5
M/1.3[+I%M2)6EJTDA7.S ISGUAW^(YV2DRMI(9ZQF',/[V:#Z7K<6];GUJ],
M] )9'7_OAFFQ%/YZC019!%<IU@Q+T;[.R/<;CO7U5E>Q-K5.I[6X[O7Y(BI5
M%#7C@-P07#^VUY;=4@6X:BF/-8[%.%#+J[@/83#>$<M"8*Q0DU6<(HCXK-9+
M%B=AYX:J<XLEH3"PSX_=T,4B655ER+WDKG@LR_Q>KCV+5/W6.'!EW;D2E2P_
MV[<>AFII-H/K$KE+VLN?R,)Z,%*X;$&9J;F2-;4,&^]]<$-\4%*<";!+]4S*
M.U5 1ZZU"P/T+'PL.Z#&%*^!-R>5Z[U)-KWPV,,V%)/ ;AK4J+QZ+EMZ-,R6
M'F7D_[39TD-MW[RLV&O"M[VGB?]?W?O%VM5<+.=4GNX(S+>PX6XGJM2K]6:U
M66__>U _^'T\V ,7%OUU[P*\Q4"P\="UU;?S!K76JH\?/\V_'!5]84,J^7+U
M<V(##EO5\2,:#"V$L]K +FR<@BN:_X#H"\96Q4^G6+4'3C;9-67?<D.UFPI<
M*!=RJ"4CF5G:Z?+&2;+>:W*0V9[E@>%F"[$L@8+'USK-CEID$C@01.""1>A;
MYFGA)(QP9MT:#R<A+H[$63$;FI3^+:D/M=!)IHJC -N .YC46E5++CC!'5QP
M48OG@-RXC/D$QU5.V, 1[B7CJ"4&(U>NB)YN,(/[M<@83>TB(]O;KJIR=K67
M0H@15E* +:N^\&V].)(U8&KMS0/W^MB39 %\$D:D\4?/#=*J7^X#0CA/5D2E
MJ^'D0E/<O"($L. F!'Z,FW_(*"E=ES^W+%8%;OS>Q2ALS-QDSP4<%C6NZCX9
MX>""HCX_2*K$2Y!KX#8BWQ(IR@UTZI]>,2#36_EH'#S@BC/7#_$M%;ETVU?+
M"-6"55R1-ENSEJZZE&A[$FD]CC(&_ 0#M4N1#',3;9%1J82$"F^' 1C-:+*?
MK*IT\<_,XEZTJZZG\HFDR#]$71LHV"8/@3 8F\Q'/<'L-/<0 4!'OGJU^J*.
M8PR.@X-K)M+[EK?=@0[V\9<??(+O8>'3"P;FL=3$0';+7$*N */&*C0/6C@6
M7R'[$6R02FCLCCG>*+%OVY";H:  <0#>F">;XQSC*BY$72^S?%.N+)6+0).E
MR[BR$,F)9*7WW+XV(NCAVJ#IV]PPLW@^F"YLG#4A;5^R.P\6!%J !+4=E@^F
MKB(7.:8[(T@%8NY(ZDQB%S'+P^T3Y(+XA$NYGX,M7"S7V&51'8QQP4OLJP1=
MK1>223(/DQPYT62YE#I=."O7=1Y8UZE[80)52C96*CA:9?18LH-AF"ZC1!.2
M;F@S6TZ/#4[4,+$B268N;PELN8PU63\N]=M&RXZ+<Y/UY<E"U6"./)K;#2&[
MIT&ZT#S39O35:Z^X-)J9CV;*$[YPX3_ZFVF@@GQ"5BE<WP_NE1(FX,CL9>6
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M6I,?9K8DF,<M]F1I!P>#U_?%ZYE*!-+X)9F@08+==V?;***)]]T1,EER(XU
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M#OJ\]Y.+[E5QU518<WGVW9O3%V]?__ [_5\*<GZ\=%R/!5F:CML@'(ZAWS7
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MVU?9$X<=K+,M[K;-UGBS#?DVY>((X[\!Z@&F_J:X+@4_971+UV5$7@926CW
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MAT$3F=>5X,.V0G%!0=V<D<NNNY6COVH>DSEAGRN)3=\KV>4H9R>8_[U4CC$
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MQC=)9_XHNIRT6'SUV&+Q.3S*KZO%XM8E>>9RFT+JJ"P,P-!Z6@=+!_/^T2X
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M&QTM^XH%)QU/;,9\HHM#T3)_FIO2 X]*2BLT,C,ZJ+02JF:4=Q'^P*+7TSZ
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M<Q<;);(_DMM9%_5R:)39V]$X2FM9%BC?48AHYVT=?49:AYTXAHKG:6-WN#J
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M.]3)/\ZB1FOJ.VPS%X1PNMA"C@?@!VD9,NF_3ZJ0?;M9@=![OM<].+'@#BP
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MP!W2K-J!F5>T;,NXY.VZ[3>\A_4\ZDU$K]6*A!"V,7.G)#!\F\U/I8"&_-?
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MN;5HB$1.D9R!GSVG.!)< NJ.1MX-#!TD9@83,*Q8#3.219XHI$ ?_$_J#F5
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M267B)_]#@P*Y<8<;3KA;\@]-51A!A9P^52]2I74\"GV>*C?);H3K("T1W'O
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M6^57FOZ+&F L*<6V5&;)I7Y?141%<-@!XN?(GHSV0!CGB_Z&>"K0=H";1'(
MNI..4ZZ"EY-*#;$#(B=)HP UE/FJT]E*2CU;?,D5\5'0G (7=<F_V./)>^MK
M&$9Z_:-;^O#KL=5M-$ ?=<5W/7Q2?D7?_$/8/KSY$@4/5K%.:*0W/Z](W;>!
MT@>X(X/&96L8OA-0,-.QJ@/X 4P9Z\%&K>]>4&TH%0=0"2[V2A"X_XM)Y/E2
M4/1JI*-;WA(759L[ >VUMO+A^'G8&;;0R=@;:5B14%M_&8U2UX![XZ$51P[\
MVDU.4#@V.JW>_PU/Z_^9#-_ 3I*_O6GVFIFE+Y&QW6Y,OJ]3N@EK3;Z3(V 7
M*D8[W7J[4?S5JC6'K7KCA6H.>_7S%]K3R]5!5GNJ]O32>SJ4LEII#+PE*7"@
ME7TD?$GF'O@%M!J'?@'-0[^ UJ%?0/O0+R"?H?E4;LR^5!YG77$G_C(CNAZ+
M+1Y((=>^U&N1=?9X<''S0>UU8M>'@GC//W_),1(;^ZQ9E;#K^1<5#N\)#G=[
M]>YIA<,5#N\P#K=.ZRL/M:]PN,+A$AV\V>S45YZ@6^%PA<,E.GBST:DWUZQU
MWV8KC5WR?\R%D)_K!FL57L.NI,D_[1/8G-F_2D'##M[U^5F]4S6R*"EPFIW3
M>G=+#1(JZ"P#G;->!9V20J?;K)]5'6#*"IVSL[4=5)7>6*@W/I)?6&F3E3:Y
M(7]'NWZV9G%KQ71?7R0VZBNW8JF@LS%ULE$_/8S"_YV$SOG6%)8*.D]SMG:]
M5\K)Y <YK_)T\;S*:O3D@8Z>W&[M'/80,.?BR:*UK ^"X*&)6$\G@I@?FOCP
M1FXR\(8G2+?J:JSBU/KR$(@H'GD3NC3@#K876#^)0 P\:B7 WU-IUR<[ &0G
M>PS_?&2JXYN7:"RPY<'$D1>/8-]Q$GD.SY&'W5^/Z1QX_*OO?"2X-7OB857A
MD@<J#SI=?7<$B HJ*W1!*B T^\(/'U1O!![0C>/F<[<0A,$)?(;E?0DU KA&
M.0!WXH+QCE6= 'V^/S>$[8+  >Q38SQK<IBX%SA^BH,>9\LV:3W\,56%!AZV
M#GADIUF=(>X@$JX83QCO>20X?.['H9P"GF(%*$Y3&D1"^%,KB>#Z!B(BK@'?
MF">SC$X'<0H[SL[ =9I9OXT[N0S@NY/4K.;Y>2L;9$D5D4BF?*I/7H#3/2,J
M!>4EA.4 \,?V-SG^,E:-2;AIBKY\+@E7+TWT2_LB>1 BT&#(!J [6"$>T8X_
MRO4F:02RF.^9212W+%N)%*R>M0HA>%%M9_9JAN5#F/H($&L<WLN^(["Z(^D"
MY\S;4_X8:W(]YEIC < %9)'M(Q*0H7BW<L:\*G*_JO]:MSQZ9&J-;'R+P+MR
MA3[V)T&3R:CI2:R6H]_=A19V4*D]=?TC.];WG.NW\O@=VU:@AZ+!L2(WNV]=
M.XNC7+&/3)SV_R,<JM8''!N&>#Z>X[HL(RP/W[@(,LJ!L]<,""/IPTU.\*CX
MC2T;<)#@@FL7,3VB/O:"^]"_5[!FR-,R<*/87H+O<\HT!+<(!!C!USZ/?%5W
M"@__&G@(N<^V9%(1(P"<DME6C9:; "21C"*K'[I3X@E1Z/L\1!8?D,@#N"$(
M1'0T^9W\L0T+(M8&@!(CVQ\4_ :GMO6%"?(<!P4*C%.;.S<P8U&[) 8WEKUZ
M8%=P9:'$6]]^V F)>6=_AR4O)A,?V+3DJK_6;^O6/R0WW3EL_Z %#/6F 6S(
MZCP>/."&0]"6(F"+LT"7(E#^G%@?BA3"=ON[=90A,Y;,6Q$. P1D:G41U=#T
M.;;2P!<Q,A-+?%=RS<:[!8Z^![T@9JY6H4JF6]#]!F&RVLU*T<O-"-ZM?T_2
MIC[!@,F[=J_PYO@CT$I@O^].FML;IDURNJ?]!IO?0OZZFIUZ%^]""GM'-GVS
M 9+:M@C1ML!/,X*2.N!(^*XE?_I!D.\@!#%P%\&EZ]Y#1Q_N+H]9ML.;(R04
MR8OGWB&7XH95]!AJ/L#;44GJ1^$W?"96CTEA(A4*EN1>?B(Y_*FQ3 X@E\O(
M!FZSW;#^"V80H MKQR (Q\+U0.E]#YNH$+14"*JZFB'BU RTD:B$NF+&8(J!
MK94CL)?16K;N;4P9).:&-C9V$[251G_#W [4T",RCGO-7N\8<9-_Q+SN,RB-
M-\HPH<=^:^V>XLAG 4L"S$+BU*@ID7EFPS>"._8H]1'NULW+AV6Z_M2MB[P0
M 1,E!%M#H$T2",4AM#B-P10,QXME"5AP3N3UL>-.']13X@:XHAN*F"03/CS/
MP))1%*;#$?([P 70\4)&!F?*QC$;$>HIMJ)LQ!N7NDXZ=@16!)TXTRZT,!S9
MM)&I-7>?OF?W/1_].J@H9*>:TURHGZ9J1UE# \OF:S-;(^7-%KRV1=?$=&)^
MJ.P![',)2PZ)D3ZVXYHIMD5N'X,4[,%XA-<:&J;<C;@7:-'+3IMD/*+74O:^
M5*!>"%K0M,$0?KH?4>G(Z/>1AXHU2BH V5N%31^XBS)HX" HP9AF \?V@CAS
M*Z"=.[0CN@/C/FJ6RZX1!B,@8>R$D]6IQ;ZW/9_4?O+?SGJ!P(@!7$NDOR"G
M-Z=!(!P0X4C):)K;,U1LX@,95/Y4N3\3/FQVQ@*(>N[?WCSM0.XTWI02#188
M7.C,[=51@(CH7K@+\?@@HS=GBZ,W*R!$^TT5\CG D,\V*?JT;D1:M)KS0?>+
M)A7D(K#]:>R1*9/YH>$&6*++ $V<^NR*_3(1?,GQVJRQ]PAK+)6KH?AJ?_W\
MX>KF]N[B\X?KSS];7WZ]L3Y>?[[X?'E]\8MU_?GCEYM/%W?77S[O@5,EWV#3
MS>.-K?!&AR=,JW:<1?CZPO= OXIEO 1$A;B7/DNBTQ@;92K';>8P=W(8&&48
M&&H,G.D772]G]]H[TASY[K;9Q)8B0; +09&W,(V,RU;7F_4/SMH%@W8&FO1<
M2]!6QSJ:[9A]K(,5CR]P1@NTYQ9H'Z/192":W&@Q]'&SLPN@WUOV@-4V]8)-
MG-,F6G.;:!VS X>"5.0[^FI'B75]7;,45WV#;+64R,8T]^/+<?DW=.D @\7Q
M=XTUQD5O$]$+,*V4L*H!]OK&U ?K]NH2+Q8G#&SU ELMOC7NVXO$4,K[ ],_
MFJ#*QYY34/1$1-XO"G:1HU7CZ#:OLV[].TS!["13%91]Z01>)$]M/Y0F-='=
MT_,[6#YR"DT0)MS\.A)P!W92R+>)(12P8_Q\AJG&<L)%A@[((57F!09>)\"<
M.<8H(_)OUI@BLE2:CW5!;>K1\8!?,F\>\_05(Q\ KY 7X>=HER@34D(4.V9O
M6-;W7GKKPQ2 [,:Z637@4QC)B'^<CI6R@2N% 9T%?8[H11/HDF<' C4%E^WT
M"[<IO2-$-Z#TP*'T)!=_6K,<F3<%N)F. PG;\"$['IHHV9MQ7[,K[I3B6:QB
MF_DPZ+3=J2,MT@+)01NF":/H\H89$)NF,HT?&2,8"SM.(Y4=-+ =](%B #A3
MP7]$DKGWX" 2A[42!;^?&),!\OHTLR7TA +1>*QOQ0GRVR$U)@0J WQ[;XW"
M!]#OHQJG(!3LC)._$H-5>+,*J,'.X"E6WS"[P\%X">V-&"+^G0:4-@'\"WXZ
M06K(W'_PO9C(%\S'WX[0$7C,_[%^OKCX>DSI5[%8M&GDO6#:X&;>8$(7_J;@
MV3=\4Y2%DK#^0PD9BLLQ2Y$"0,:@C:5M=([3,"AT2-:*-I.[N=E+T<>I6[\+
M96XQ.CRR:66WY<PVL X&J8^[YQ[[./X*WCAOIV6)HNQKH7#D(K0BAAKIS#ID
M7@:>LKKNQ8J)<VY9'BM5#II,X[-TXA>F\,%^A3,*@)"'_)T+E!Y-=XL1+E!E
M9T"/AR9X H0^*]C>"$ FO$YI%\7",7-Z,PL>W8W 3I#R'D,,\9WS\_#''MPX
MYT6!4(L2.80,_P94MX.AAQXS.XZ%%.U:?LE(#28]40@]D0R*,J6\/LAB2F!#
MV\Y- <B@:R W44%R&DH!]#P88,S(3*/3:*32")]\)5N/'&^@>*KMZ-PN#/RH
MYQXRXL%WP[=*S$:8K\G(&7L 9AN_2@"D-D?((G5/>"1XTC!2D5>G21H12GLA
M[/U( ^["1>PBKG?\C,$RY4'7:\8XNE29^(O:F%5P8@J%#P.:JB>E@;PU0%1I
M[[/NA=$@)XP3 ["@V#(2J;PPSNI#O1,CC2@_:/Z:!<S!25DS9BV9-;*Z]9-P
M;&!VO%U",IR@0HE3F$&+24)PG11=I[PJAF^6HE$$0YF?2\FWO@TX[::1XI<,
M?!+EX0!D!%LK"E_PB/3NE$8R :1'13M3SA5-O$$X]I#9ZM]GN/59?H4QO!OX
MBD6=M?![CA5GM\43=(SPJ@Z*@32C,PM7&_X9ERBZEQHK$3(5#7@0LP]:N4]*
MMO$>9%#,@/ FBI;;![[^,1*"9W<-@#<SD2QFR29@ /_BM ]LS)%:$%(-Q;Q!
M'Y.:AM#5[BHN+Z.M&87I=^_%==XH8D)DE GH3XG)VANP5!GM*-.TQEK<&P+-
M)5[/1[B>-TJ:LOH;S8A:J3 _)DUY5QY(#.1A+DT5]:=2ZR'^5:SO+=2!,W6O
M"M.:3JOS%PG3GE=AVD,,TY;']W'UKZO+7^^N?[NR?KGZ[>H7Z\MO5S>_75_]
M7MZY@W.P;G;G@H<DX>)T/$:/'PU\I8PK++KRR2^G]7\]:I%E628D"SV3RB79
M7C\Y>_'DMS-C\MO5=[ !2!7[!;;N6U_N140NE6LPGVG.GN=8_]NQ/OX;-G7?
MX5_.LN/F>H/B3KL-'A17/MC/X3#!_DD3=9<2Y30V2]\K50MJAUR!1H :_><G
M-8*7UP>>H)"G+<Q';WTWAA2VZJUV^T7&KIW73TLW"J[:TV[OZ7',W*,^;,6=
M1[*F*Z>[.97J8W%6BZ4BJZO,JBH%.)<[]I$1P"3O#%;0:ST-"Z/MXR5:ZJT[
MG:M\>"#]!C^Q\\KT(KS4-3PQRVWOKA+=D%]UQX(C;AN2O!A6'<QU?A:)PL>+
M&1^YKMBI+G7%2_T@;=2KK[?5W:UX=U<ZA*$B#2L-=)S+,7,<(>:;E#TE/<>>
MZ_IB\]8P70':9DLW89/G>_EA(1NZ@N<."UGY_$]VIMOJP3NUL_:J71)7O8+E
MF_3)JUBAA>(,N2TU[^;54'A'YMV\/ IOMY=DK=ENEP:%5^\"6J'PP:-PN]8[
M774P187"E2)1HH.WZB7"X!?5(Y9JQ?PBV%Q"J+;KJPZ;>G6H;N<F_OP\L["X
M=W6I65E1;MN[9?P+:_4YKWY_>+]_(><*L])6O=4M.45=/)6BOC@@M=JE[(AT
M:=9ZYVM:;CNF%^P@<%K=5><S5*#9&-UTVJM.F:R LRG@U!L5X905-MUZ:SNP
MV;3!8"3/Y7N!-DE-VM+]TY")U$FX[HC+=^/0\:AR!&NHM ;THKOK8?_3)[=7
M4(: UNM)NUZ0$8AE^IRD;ATUCV>2NU?1WIXUPVFKQ-0^V^CPL]7YW%;':VT5
M-+V-3CFN(+,"T;16-7@JT&P(-(UZ:U5?9P6;32ENI_6-C@9_AN+VS 2@<BIN
M%\Y_4R_.6K'!+K'/,?8-.%&MG;"\/7Z=OF"OJL =M9ZCO^VN,71ZNF;B3V6G
MOCJ[:U9NT9*"IM=;,R!:@>;U%;CNJDI"!9M-<;1.?4L>ZQ?RO.U,D%%-MO5!
M%1IRJ%%VGJI9@4C6"C'NL.'0J9Q4)05-NUE!IIR0:397C6!5H-F8CM.H&%I)
M8=-JU+=$-Y63BLK ?P:]Y_BM'\8T06+L!3@K;2I;Q7(+Q!UT3[4/TSW5KM(H
MR@J:+>505(!YFF:JM+"2@J917SGR6\%F8[!9LW2I)+ZI'=?;/LDN^:ZX]QP<
MP#;$7L*Y/GP[I*YU#C,;K-FL[-*2@J:UJKY6069#D#E?-0)?069S?K8*-B6%
M3?-LY5CB9OQLJKEL$ :/@+)ZZGE/5<Y.,\R+HT]L<Y9)())=5)N[A^GEI.%Z
MK?>59Z"<X#EJG9_/-?FLP+)ML !4*HHI)V@:]97-S0HVAR!L]JMESH+NQK)E
MSJIVB6R6) =0M.%VW3#%MB"XY<6ME/:Z/]I+7DVYR?*LUCI=LRKP)6YG2TZ*
MBB8JFGC$QU-KM]9TP%4T4='$7M)$KW:^;F)N11,53>PE373KK34+PW>8)/8]
MOM/;2K%_:?K*OJ61.-78Y!:G-"X>FUQ-0#[0"<@:(ZNAG^48'%GM:7?W5 W]
ME,K4O@W]/*.AG^UJZ&<U]/-EKN%@A@)60S^KH9]EO]1JZ&<U]+,:^EG-ZEK'
M:5IKK]O%K.S#NBH4/@P4;M:Z9VLV>ZM0N%20/%@4;M=.UQVQ4Z%PJ1Q+!SNW
MME4_6S/9M^QC:U?)!-Z[H9_GZ_;JK(9^[DX&<S7TL_I]-?2S&OJY><NM=UYU
M=BLI<%K=JH%824'3K'4Z50>QL@*G&OI97MAT5TXGW=&2QW)VJJB&?NY1;G:O
M4[5%*BEHFNVJ U])0=.MFHF5%32->KL:=E%2V+2:)6WT=B ]QO9ZZF?O,!N.
MM3N5AZ>DH&E53:U*"IEV<TL-XBO0/*V_K3RUO8+-AF!S5M\2:"K'V^.30'=1
M7SL]3(?;4;NQ? /2RC+=%%3.*J"4#RBM=@65\D&E46^T*KB4#BZM7GU+3NG*
MN59-*]TW4^>HO8+LJ0S03?&XRC-03L <M:JQ"B6$RFJJ6@673<&E5V]N'"R5
M#ZV:3;HGIDZSNXU^HI45NDQDK8),22'37+>Q<@6:UX]Y-JI4SY+"IM782O/J
MRJVFVJ*)?@)JFBO&$XIX3B(Q]M(QY:^%R4A$NQP#/3M,YUJWJGLK*62:S0HR
MY81,I_)]EA0RH"!4_*RDL 'M;4MUO)6[[:FIYKNGKUE'YX?I<%MOT&QEHVXJ
MGG#>K)(*RP<6@$I%,>4$3:/>JZI$2PJ;K0J;0V@5O_)4\WPWR&HRYRM=3;G)
M\JS6/']>D_G2CN9\?N?CBB8.DB::M6;K>2V_*YJH:&*_:.*TUEBW)4%%$Q5-
M["5-=.OK]H+889+8\]!"L[V5T$)I&N<OG&J>'\3<@O7S 8F9V<\8%/ &4_[(
M"UP1).].\*&7/NHR [/?_-UH!+GQM^<OZK3>;>$M7,QTU[2\P/%35V1_I5$D
ML NG95NN%PD'$V;BU$^P/7DRPBQGLV/G) J'D3VN67'JC/!7L>W;D0=G&(21
M)<83/YP*^"M.)Q-L=0X_P47TSYPPP,7Q<_%](H)8Q#75!E0DUD/D)>(D' SB
MNI4/ENP/CK3*AB-W ""5!S4!9 C'7F 'B3_5R/)#IWVNYNLB7JBG5=^O)"0H
M?Q3]*+6CJ=5JT+3ACN4*A^>EPA/BNY?08Y?A& X^_3&V[@$6'BP!J ,8X@*6
M6;CEFO4P\@"])I$'L/:RC<26'^+NO7ML-C;3.]_R8%DOXF))1"DLG@Q@[:E$
M*S=\" "OK@,+;P$C>+69++#LA8BG7IS(PP;XI1=8 UC?NK?]E.;9PS.(R/ .
M?ARDJ:W;H\VVM9V]*[CH>R],8WY7@I1#7\=B8D=Z/@ ^^?73S;753V.X&#CF
M'A-&NVR$\;O 4=)$ 6D0";BU/Y!5 G3U'T/;"QC;L'974/5NF$;%%;S +A\$
MZ&!6$"967_B>N!< 8IO((D:>/)Z$ 3U*LR%H2"ZR5>:4ULB&YS6;=L*( ]!,
M7OA6((X062O\9I!B9SZ--U8XD=@9UQ?BSTYA2Z=LV&*RT4@ ?<?(&0"*D4#P
MV[YD!,0Y@-RG"*D'+QD1E0>PKZLT C#!87X-$*CCQ>5& ^*8FH/ 5\"L! IR
MR4<9)^<8J-X@+H!\)[(=X)!%\OH_B&-9HJQ$NF3D1>X)L"A ;27 Z];O0G-
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M_ RTYII5):1H")M;OK+D1IO4'.LQID;C@$(.HZXQ9P=])W8**&$3OF)&F8O
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M F\H(K79V\E"]$!#0P>4%*:AR5X0:S(6F[584$,0&S >^\6?@9$&'K23,LW
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M;EU<'+W[>,BJFG6)<H\;:;?LWRA0*E J4"I0*E J4"I05AN4^RZ;3>7 ,F6
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ME9\I/S:UL8W!9X9]$/A;&<P3OB.0C<D#X7$VJZY=.Z"<,&8]:WW$I?P6.,V
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MMB8,*"OJ44H.9<V+'8XE9_.IY2 K["E6JR4)!OB>35-Q_]]<XB!25OQ5)_#
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MV]H[J4)1&YJ]/YN!/=28Z;MPXD";,E\+QJ:?2U25Z)0U -26%Z'Q? ZBHCP
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MIJCM)*EMT^#$#JBM#79K=UMS<53884LE#T,S&&LCQWOAL0A5[;#U:@=DI1N
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M>)(DMVS*YT%(3N=5KR>V-^4H5,#&J4ME7.TF=;D!.U'VLE>9J0F*D@Z;O=R
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MUFILG!!3IG,5"6J)C-X!076(H(S*S*T_-X,ZP:#F46DC=G;Z;(S=7,],<[Q
MU8^7 ^G[S41X "\ ?RMHSI"(HG*UFS2:>,'P-\#5'0N_CQ[-U])\V,691T8S
M7TJ<2Z$KL_NX*"PGTP]$83U:BM[/>W=[I[!MFN3'4Q49S*T2.*2)OME&T>KQ
MYC;M=XI1"HQ](4R59KK^Q56[4=.;VYJ148D%MHKT=F[I;TYZG08VLM5:F]=.
M[H/T3JM,K)@^L*T!+O(]![Y[TFR@!Y\%AYW3<M8\N$3\_VJ[G@^<=RL05<1D
MN!>BD4]N5W"%LB*LR@CW50@+!ZML/D9Y'X1UGM:\LMRK++KSYA,XT$Z$(+GW
M?+S]=1CZ]B *<>W6HY=5S0E?EC2Y#++V6UM;CE@)A:#(]0#6_E[(M44>0F=K
M7=?54C,+@E7'HV92K;14$;F!VEE@V*UH/W!X?#0 BI87 27&R-V,N2OGJ:V^
M)WC[ #HAJ;=Z&_*U:VTAXM&^N.KU:_W-%T=L':L'<M@47RN^/FC#]W;XNG-Q
MU6_4^JUMS5DZ+%^3(?,367*R@2'53C<Q_2?;I4?OM)F.[O@1*_SLX6+ZT,D:
M&3-<U^5-X#1O&+UTJ=G;].%CET*93SX5!?NAYHVT<,P"AF1#H*/JAI'MFN[0
MQD08-J51 W$]V\>1 H-X>$OG)1Q3+Z#BQ(\^<TQL ?GT8EOA6!)OZH<"J8WD
M)^8 #A&%\W^20MV0H2V]?QXD&+=;,VTMJ?_B<9$=;+,S& T[;6::G79K:+#!
MJ-TW!J8Y:+%6I]-K_V\39Y*)7XW]I$OSB5T.?&;^>6F.X!4_FLZ+^18@/::)
M#RAO!O*S0)L+FM%H'=#T5X ,YRV0#YY/\\X_ D<S'Z^"(YE5.8HV]E$\_FTY
MAKK 3LC]R"C8/X^<\(^?S*LB["^"^*[<#R+&7YD%_J5K#[6I,\RQZ6'.=).6
M)P^Q%$$X?LGX121<$XE PAP.Z9C3@'V4?_EDV<'4,=\^VBX]BG[T2<A?(4:0
M V8$.5$ _SIA#FR>1081_JEXLOBZ#E_]E/]<;]?;G4[A5XUZL^3GK9)WFG>H
M=KUE&!4[4Z>N5^Y,W0KBKE,W*G>F?KW;*/[FD&=J5(Z>^A6DIW;=:/07WDG$
MY&:,-MT@P[78?UUQ3L?"R_JYRPJ<3V[*'69NQYS1I7)$!>^N7B&(MPQ8OO<R
M&W\_*HBDV@GO13OAS<KMA*<.'%GL_X^!_]/5E]6[>4X=+JDZ60(-%<O2WS(5
ML_3)M]7*YT\=9)1+((#P@$G!P*K4MU]6S3&<.MAF"K9N2Q1LG3IH>':J@%**
M38*FOH))4*G16\6O_1XTU(3/Y@EJ&GL=LFFH39G/B[LU\$S-548>KCJLK$08
MLMKD<A=-!B"D5TA;KO+*9P.V>]/7:$;&]FCJJ"X[ZJ&J*UHS4]]V-*-1T_2&
MWE3U9%N;DEAV.E9_Y:DU:P['2B6T^+:#UE'4W6R!"G=+>54;S[EZDKGTZQ\G
MPQ6ED)=PVRX*XA9.ENKTMCU92C%EE8A3,>5RIC0:E:Q2Q=WUG9K1W-923,68
M52)0Q9@K,&:SBHS9;0!C]FKM_KGT-BO&/ ?&+#7<P]!7'.YQ(!9MTLR/7M[1
M7'WFAV).Q9R5>>]2O&E44FOJ?"R#OG$QLV),Q9B5>>]2C-G:#V/F><^XN&IV
ME;FJ&.],&:]=28THVI ;VQI!>@QMR%5FI3L6:C;-&U231\OM9:/\@1J6K["C
ML*.P<T+8*65D=!8;&?>^-[)#+,PM;2BTP5"H-0RUG^1(R$8Q=96Q4XJIEXSR
MV("I.XJI3Y=LEDR*2)--GC*Z%U?ZMB8@*K*H$%GHNS,1>B1-.E4AFY,J8)ZS
M>+M@:PF/'FCO<7O)*OT09[$O:)<VD]KFI+"CL*.PH["CL+,'LWY)]?XNUA=U
M^]@SHV^M"E@15)4(:DEX81<$U6LH@CHJ@BI7F+GJUK752"M//<V+J_S:C])5
ME8IH*B2%EH4E=B*%="Z%JK+/=]_E#=N?);@:77RVGVV+N5:@A5YF,Y_V_MTB
MFKEG/K7_+J:=V[NO"_J'XV?+FWUF0P?^L&+Z:"3T85Q<Z?5V/IY%4R<\.5&*
MWB"1/GR I"K:4#DJA1V%'86=L\1..7MYB>T3ZZR4'KLQ@W%I>Z=%>ZX+EE*J
M/==5(R#%WE7&3CGV7A)@V1I[MQ5['PL!*?:N,G9*L?>RR,76V+M3&?8^@\J*
MVR"(3'=(>R+XT#*-UDW ,0!_VC3RAV,S8+07SGPQ?4N;.O T56^QPS%QK55F
MY"#BF/4Y\K%Q"D[E67QD'/WW9T"9A5%$Y@:T0Z2(S[H75]V*1 05!:F\]A%C
MIXP:;:TR9R?/W#2A=77>[H$.U576\4CH1W&WPH["SN%+0+8C>_M*]AX1_2CN
MKC)VMAF@V IW]QM5XNXS&!3Q@\4Q"&\T4XRP7AA"A?NV&8=(\&-=N]8/%MI^
M45BBB)6:%U=Z?HVZ"N)7C6Y4$+_*V"D5Q%\I^K"4I4EEEHWK]W5@]UJKE2\S
M4QQ?-9I2'*^PH[!3@9J)7<IC0\GC8Z$IQ?%5QLY6RRAVR?&MRG#\&516$"(O
M!XA#FEPA@TJJ=$*%9Q5V%':J%3Q?%ABXMOZ(@G#"W#!X]*X!$GA'T[DW;>O6
MO3&G=F@Z%.D;S ;1?["_(CNP0_; _&=[R+@"^\&&WI-+=Q&Z+*^NL,ZW7950
MNZ(V)0L4=A1V#BZIEX4,#B&I.TI2'Q&U*5E09>QL,YAP"%G0K9(L.(,"B9NQ
MZ3XQFC'A9G:E:-Z+R_Q@;$\U6ZQ-4043*NRJL*.P4S$UMBSX\*OM>CYMBN)B
MC"NC6W?H,]!;GQG_LT@9]2ZN\A5&BF(J23&*GQ5V%'8.'T!87]KVE;0]&HK9
MS:3+=6G':."DU+S7J$I1CIIN\O&)K=--$^@FO^:Z:@4-EAU,'?,-S\CFDYFZ
M2EVUG:M.JKZF6RB(KJ>^[6AZOZ;I#5SA=+BJFKF[@(]0O)=M$=(7VY*I64"\
M#^A[% :AZ2)42I:O&0T:8VP8&YN8I=!VH!S'#FFN:@'L[6U5S[[[<?)947AL
M"9/M8J7ZR'YEUN6_F>\5<:(1QP,4+RI>/"M>-/;/BRNH1JSL;M7:G?RZ",6/
MBA]/F1];E>1'+%UMU/1V0_&CXL=CY\=R'>;M%4-^!^+,#O9 Z9WVYGN5%$]6
M@SS/DB=+L>0J+8?[Y\3NQ55;K[7;*IZC^/&\^'&5IO\M\&.>Y; <JJOX3?';
M>?%;KGJA$OJO3_JOJ^?;\:O&CV=017_'0LVF39NJ1%Z5!2KL*.PH[)PW=DI9
M&/W%%L:][XWL$'<XE[42FCAON-9MYTO<%-E4DFP44U<9.V68NKUD_/$&3-U4
M3'VZ9+.DF2U--GG*P"&Y&R?Q%5E4CRST7%YL:]+$(&G2:U6$;$ZJ]K@8\=_#
M,?-IJI_/QLP-[&>F.8 Z-=M/S2%1V%'84=A1V%'8J2IV2M4SM7/%]W/JF<@F
MN$F;!+>43T"3[HZ%WT>/YFMITZZ%+2^ZD3?M2E<K*:JJ%%7E8@O[I*JVHJIC
MH2JE2:J,G7+-\*M6QNZ$YSN5X?E]5Q-8]O-!B..S_6Q;S+5H-!^USXH:$^W]
MNT5T<\]\ZI5=3#^W=U\7--O&SY8W^\R&#OQAQ:312$BC>W&EU[OY,A1MROR9
MC8L)L1!458V$2@DI["CL*.R<)W;*=08M*9*(=59*C]V8P;BTJ=/#?$BGF4^C
MJ6E252,@Q=Y5QLZ&(8T=L7=?L?>Q$)!B[RIC9\/HQ6[86V]4AKW/H)#A-@@B
MTQTRS1MQ!S\ (K# [0\0?YK<0JF9KJ69+Z9O:5,'GJ;J''8X4ZV]RH@91%QV
M)2B?KT;__7EVFT<1GS4OKK8U+4;%F2NI1Q5VJE<&V%YE7DV>N6G;SNJ\C56D
MAN+N(Z$?Q=T*.PH[AV_HV([L-93L/2+Z4=Q=9>QL,T"Q'>YN58F[SV NPP\6
MQR"\T4PQ@MIFN*5PWP9QB 0_UK5K_6"A[1>%)8I8J5T4@% Q_*J1C8KA5QD[
MY5)TJP0?EG+TG,V_AMZYN&H73!=3+%TUHE$LK;"CL%.!FH@-!6Y7"=SC(!K%
MTE7&SE;K(#9DZ5Y%6/H,:A\(4Y<#1!*-<I!A'U7<H *H"CL*.]4*;R_SW:^M
M/Z(@G# W#!Z]:X $WM%T[DW;NG5OS*D=F@[%X@:S8>X?[*_(#NR0/3#_V1XR
MKJ%^L*'WY-)=YBHKK,1MYS=I*&JK)+4I6:"PH[!S^#*# TAJHZ$D]1%1FY(%
M5<;.-J,%AY %S2K)@C,H8;@9F^X3HRD0;F9SB.:]N,P/QO94L\42$572H.*J
M"CL*.Q538\N"#[_:KN?3WB0NQK@RNG6'/@.]]9GQ/XN4D7YQM;$J4A2C^%EA
M1V&GRMC99@!A?6EK*&E[-!13KM DMW1BSFS!]6D'1]%NLC5;T4T%Z6;EF93K
MTPT.FVT<GFZ6!!HL.Y@ZYAN>D<TG,W65NFH[5YU4?4VW4!!=3WW;T?1>3=,;
MNG'(JIH-ECU73KR7;>)9$H!.3>OAG3K?HS (31>A4G9TCT$SA@U#+1C?C.:J
M%L!6"\:76=^KU(1N><'XR'YEUN6_F>\5<6(WC@<H7E2\>%:\V-D_+ZZ@&GL7
M5WJKUN[G/2'%CXH?3YD?NY7D1RQ=;=2,?G[K@>)'Q8]'QH_E0L6]%4-^A^',
M%LU_;?7[FR^J43Q9#?(\2YXLQ9)+-B,<B!.;%U?M9JW5,Y2.5/QX3OS86:5M
M?PO\F&<Y_>*JV5,VJ>*WL^(W/6>25D+_&:3_.IUMU<KOCA_/H(K^CH6:36LP
M58F\*@M4V%'84=@Y;^R4LNAS]9%9"^/>]T9VB N62UL)+=I7U-UX)K B&\74
M"CNEF%K?&5.W%5.?+MDLF6N=)IL\970NKO2>(HO3(XO=60A=%";=1E4Z;TZJ
M]+@8[]_#,?-IJ)_/QLP-[&<F@@?:>P=0F$LE[K,:^?C82,TC4=A1V%'84=A1
MV*FJ^=99,J*"3(*;M$5P2P8!6G1W+/P^>C1?BXRW'F9DMU6UJRBF2A2S)'RP
M+L7T%<4<$<64JIW,AP[FU$ZN23OMQL55OOJC=.&C(IH*B9DE<85U*:4)4J:[
M<2#J2*?X6?;S0?#^V7ZV+>9:-,R/&FY%58KV_MTBFKAG/G77+J2-V[NO"[IS
MXT?+>WUF0P?^L&+B:"3$@?N_ZP71:VW*_)DEBHEP(:"JH@J50U+84=A1V#E/
M[)0SAY?8-K'.2NFQ&S,8E\V@M U*QW;4NMCJ$Y!B[RICIQQ[+PF0;(V]6XJ]
MCX6 %'M7&3NEV'M?RKM=&>X^@\J'VR"(3'?(-&_$_?L :, "KS] _&ER+:5F
MNI9FOIB^I4T=>)JJA]CA#+;.*N.A$''9':%\'AO]]^?9[1]%?-:YN-JX7E$%
MD*NL1A5VJA?>[ZPR;RK/W+2=9W7>[EY<Z5N;JZCH1W&WPH["3B6QL\T Q79D
M;T_)WB.B'\7=5<;.%N,3VV'N?I68^PS&./Q@<0C"&\V4(JCEAUL*]FT0ADCP
M8UV[U@\6VGY15** E3I8NZ86Q%2?;E0(O\K8*9>A6R7XL)2EQ:;@<F']3A/8
MO=;HM13'5YZF%,<K["CL5*!B8I?R6%?R^%AH2G%\E;&SS2**73+\_V?O79O4
M1K*$X;^B8"]C1U TB+N]#Q'5OLSZ>=IMA^V>C7F_; B4%)H6$J-+E9E?_YYS
M,E-*(0E0(4H"M!';4P:1RCQY[M=^;0C^!O(JZ"+OYGB'U%="^I2:Q(G&.=O<
M3G,[]7*='_(+W)O_"/U@S9S _^'> R1P1</^:ECF)^>=L;$"PR9'WWS7A_Z-
M_3.T?"M@WYGW:"T8%V#?V,)]<&@5(<O2X@J3?*=EC1)HL*WA!<WM-+=3R]LI
MTV-0!:<>-ISZ@K"MX05UOIT2?0E5L()1G5C!#:1'O%L9S@.C]A).8HB)YCXY
MS/-7UD:SQ#R3)EVB<;HVM]/<3G,[S>TTM]/<3G,[S>U<V>V<ISGC9\MQ/1HB
MR!5I;@Y]<A8> \OI/>/_FV4.C4]KS]B@30W1)F5UEXXUDUI@S54%Z<>9]WZ_
M\2Q;TT=M3>_J@RI#\V+4)P?&FSY<E^F&<YOQ<9\GS+:M':T5+4(8[W=R*<U&
M>*7!ES#P \-!J!3.D,%.S.U^KZSRGC(NM2(G:V7X6C<'VW-G,9\&F<NDX"P=
MZP#YGF-2\]+ZR<R[?S'/S:#Q<3?2X1LJ;ZB\H?)2J+R6\]C'6''4;_?T:4/I
M#:4WE%X*I4]K2>EZ:];OM@?=LB+/#:4WE'Z%E%[(SP6:\G&.KHIHGGI\]WOI
MD2:%Q]\TU-Y0^Q52>R%B/Z8N[>5I?-":#;MMO9>N66OD>D/I#:4_A]*/*3DO
M@=+3Q#P$<[Q;5L?AAI(;2KYQ2M8K\*T?(;-')+,'>ED33:NB=(I__T*PD</N
MX#]RNVO#>[ <N2N\7/$)[41/$A[FX5O+;=DHU>M*G*(5WV!"O[78CV4Z8MF/
M%=.,!9:E&\X6D\4=-X#W&1[V^:=\\0?/L+6-X078=2]8,9\A\A%TC8"9VM)R
M#&=AP4-^ !]0D4$G.1E0 99X^4#OC(>PY8WK4Q7!&X_91F ]LK=/EAFL) DH
M/Q3@[<8_,>:PB3#(_XD"]@5#'#X?U/?">#C<&92H_!>WB^1B&:/Y<C$:,L,8
M#0>+/ILOA]/^W##F S88C2;#_^WUIRWYJY4GS[ Q'MC=W&/&GW?&$H[XQK"?
MC*V/6*NB*&"CA#R"?1=BN7!9+I\#E^D18.%$ <S#]:C0Y$V(LR;P*=B249>M
M:"L/.>R_';Z>,= 2,@BDDG?(G!VLLC!F65=?_@S2%":FLEP($S\S$YBZ8RVT
MC;U(T6@U>WJG,I/O$0LA.!K^2OMHNT]1O0KQX)@E$,.'C=K&QF=OY!]O3<O?
MV,;VC>70Z^A';Y-L&JE@A]\3%O"O8P+I=#F1B.PG\6;Q=0>^^B7]^:C?&8Y&
MF5]U.[W,S_.6ZG4[>K]?:*G\SP=7OZG]2QU(8ZMEMEI>ZG&6^A2=J3<\YE!<
M)M8I">^CA3JD]G=F>(FS7>+%99_PE>5HL*H-4L9/.:>SK,D\G39#K:WWW1Z;
M5GG,@3-3*Z\4:/T&:,6!IA=A'_5.7SZL1=&AOVP8*J]@P-V#A?T(%A+SWYR2
MQOQ<?*@0,L^2E:=F=#>@;$!9#BA+ZE% WJTQ=Z_4&0*_LT"SG(6[9J>4LU3L
MW3[RK,>[M[..6)&;^LBSE=BFY*OG+JW@-]?W"[N:QY@",NZFATA<;'EF0P77
M2@7Z@6DJ)Y#!A,@@H[%O0P:U096&# 09'.@T>@(93%NS8;L[2I?.5D,&)1F@
MEZ+9*=W&L!N5Q^#>%Y;--"=2^:A+%?QK@1[^C>?BO'A3FV\U-[)CC7+LV LW
M"E[8OFJ@=4/0*M/@[.D=O>Y\Z3W; "^R*,:K&8ZI&6M,?OG7_F[\%];FXN6M
M-A6L\+?-*)_(,>\5Z!:5X!.<"-@>#<8UD> WW#>E @/H+!A%0^=&TP:CKA*C
M#M@29\$H&ILU[M8%H\JT,BY!G']%L\%'S(![TQ8>,ZU L\%<W#,-^,(:15?B
M@N5 _>AZ[]UP'BQ#^WZQ #@%69-[)_W6;%I6>F\-$O(;1"GBI2R$*8/6;%R7
M=N -IKRP(Z\0I@Q;LV&ZEO>B&\=?C%!]SY;, U$:^>F,G\\4IY>K>)ZE!Z0$
M[">"ZP\$*^B?\+_O2'')) 2JGSFEJKVQ5>J(,FG)6B+.8)]9/5U:V>#,A>-,
M2L:6B#.3UFS4O9YAL!<C; M/AFUTS4/-*;#QZZ^[0XRR<'Y:I_%$C3WRDI;K
MT4@R[0*2#$_.*6N0I(Y(<L!H/1Y)>H@D9366;.S58E>.Z4$:7+7)YH$&^X0S
MA):_PN23&[-:2Y2B?S4LQ_^-/.E?G \)H'Y9O@=(%^BR/-5+Z[+<6"8U1*6C
MC=DCD"J-//W6;'BRDM;@31WQYH#\+94'#>K&@PZ(:=G  #;*\E'O4IZZ-;/^
M'I VT*SUQK \G@6+R6;4X88<ZX_PF>MMM2?/"MB=Z3XY3<#Z^:.-$=B?(EB_
M [7]@65YN:8XFWQ<UD"7QIBK$XX<LOCSD.1X"3(J>U9(@T"U0J #VLCQ7&8,
M&FNO+BZC1LVX8M?'EV#%O#:6T32>CI/#\P1,;'MI^"L>.OOP$[U^65,9IQ.@
M\=-SF1JSM(;X<K0[HQ#"3%LS?7QRFF2#,'5$F&,#\P40!G;5FO7Z)^? -6'Y
M9UT_:'?. P-#7:U&1060&_*V9<PMFRI32?IBITIC\<_0XGUI^4.F]<C\P I"
MKZE?;2HR&VC5O7Y5'UY 7;W(F<:*>F8]8E?;6U3_3TO/30KEW1GLGQP)Y'O'
M_!U;H7^+8)TEIS'V/TW[%)MLR\O&FD/^Q%/11D<#LDG2O3JT.>!%/!5M^JW9
M8)PN-[WH/-U+$+R?1,A.:OPW%JT[K\!5@)N%\P.TA-/9=84G.S;QEEJA27$)
M>P!/AJW9M,&3Z\.3PB+U )Y@3=TH[8I]<3RY6>-U8VQIB LU8%HLO) E7&HW
M9LR^B"W[E8,<^YUP@/\6PSN+1L;95FT3KKA\''J^95L4B;"H<'KRC,\&B>J(
M1,^V<XLB$09.>W6)M-^:V4L1RX,QL,88+E%B$\BC62[OC T.\OR=9=1&#'I8
MG#A(9YHU%L]EXTQQ"5T$:7JM66]P2DN1!FEJB32%)7(1I-%!E:L!HRG)9*Z)
MS,V>X_7[L4W13[&3CYZB="&D4J)(!OCCU-FO OJ_;O_PL9=*1"CQ=+6"[4('
MO3Y047L\*:M=:)%16'6WEVX9(0_)^S-BY  QLIOA-6\P\J8Q\H R<4:,'+9F
MXW9_4);;Z*P8>0MC13&8XI<Y5K2>AV\2-!MH50ZM&YO_>:^DS$=Y]&3Z4#*]
MQ\P;"P66Z5G\:FRI\\ /]YX#\]?0AQ=B-PV0WE^6*+_%-V:6'!ZAW[W):[TV
MK#G8T[T0VA34[<:M6:\]&=4@?['!JA=U/I[*C":M61UR[)MB^FL>66F*XKW
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MM(B'>39A7!ZJEH#N#1WRK2=?Y+E_ JJ9[I/#&[SQSM_TI@3?$!SQS?/3-\5
MU3N<Z_VF/\H42/PCB_#KS5WO)6;N98L#1$I]]+8ZB90$5V^  U);,QZV[6EW
MVJ>8OOX9NCPKS^(4RD-!3%",:+P2-7&3M7S>'@.PN=8JKE6/KU66Z"2O=JDT
MX,N\QO3EMS.6R&SHE[N>Q*)(.\&(+'^)K/FA+;]2.LXEWODZ_JDB'V3Z0)8\
M8A8M95J@@ 0V#7_!G$/^KP95:X"J_20'2N@]^3=[#=VC/^Z*^0BYD\D1DE.K
M[7P%42<G<3R@R]#A/CH7FTD*[8 \@,J7E$R LY:2 Q+6(<U*6H8T@<T'_3@0
M7<55>SISNH*2P2\(5NI8G%=0T5VL@W[")"7>&62GKD8>7/8W7Y#:_61X9A1F
M\!,PL5!MAR6VZ8:TF3M)RS2^;<K*/I]HJPW2_4AHBMS7@<76UD\"%4UN276L
MSL)'O:,50V ]PMJ%ZV$7T2#5U[Y]!)8JO<#O,$$2$U*4KS%GE'?19Z+E.>6&
M",3%8H 'RJG8_24.N_29:N?NI'NKIL>. !(*N$ T,5^,'%<>V;QB^AOY[]$$
M:O.HF>>Y<P(#!M/:ZH*J\23GI2'^RA8"4M*J!^<9DM3]#CZE3"6E V];[<CL
MFJB1DRMA:S$;&U-ZCS+'< X07^$&E-5W*98F+'H,D 7P]\G8I-NYR"LWDC7Z
M%!04D,P3\H=E/#<^Y"OR/'&)(J0$8T#SRR26(JH'H@Y% C2T@]"/^R_GW T_
M'=A'W%5R!>PA1=*&DAL. )0R6U;ZP]EWVU&G*$=B+@=N^U";<$[E,9)383@(
M.(F@!EJO.*S-=5C"8*7U%=-?D_X:WO(TOL.BG*L?<RZ1D:XTB,X4@HC:Q$:P
MX8\BA$1FW993=>3"28P*(0] ;'1'O2[4H_XC-!]D+K^L_T+*9&6W>1<@%PV@
MB&>K;.''BN7 @KA+WNE3HIJ*C^[0(;.-T$7ZB;AOPHF%ANH#!,B!5A%/E91*
M @V#!9A2/2\7:FW1W5U-IJ3:.)G%GY&,#RL^D;<RRZ44C3+AS7UYH^%8MJII
MV/-MEM,ILZ0V&]2IPMDD5]W7?Q^I0BG-E6!,(E2&NY'O[L!#B2XFV:ZBO+*5
MO),B<O!QAGR,,1>=LN9Y&^67XS1?>0$;>)45KC6ES9D\IRF=43O)_QT*&XAR
MEXC%""=O3#<[:)HW"4&5??A42YF:UL+3\2?G< 0>0HM;[7 YV.3.%LB=G3:Y
MLY5OI<F=O=G<V4%F[NPP-\^2QYLO5"/.:&)!+?[B&NW]DC!JE+;$7!/AD9%Z
MI2RSCA^/0RIBIKP2$SPDBQ-MRG+'GE[D+;Q+*=Z[*NTR$:;.F(FSVQ=S@[/6
M:%#+*Y>7@<<#9U^#1H$:IDQ4-2WR2%##!B'HHP:>69>786&4MMNLG4G[1.C_
M/%[XD_"1"N:P%P.L;)-7(*249%1$'>9A'R[>J4[V@'O (7^\7T>DV$<#YC)R
M69)Z2:%LEF^\#O(C@/*=4-S_!PCDG6@6EIO2HE]'\HHX/DYZP7PT7FE>FRPY
M3-/PB2ZB1BS!RG/#AY4(IV@X!=6/.\@HV6MJ;!^T;IX%ZU)[,>%%0F<88)Q&
M):7N;FW[7_RH&6'4A"'JFDONB ='U.2*>2'1C!B>Z[)R?6KN(OI3NEO#%G2!
M&?4T^P1-1)EQ#Z1-1<,BQRTG65!NB9P?9&FZO$EJ7/@M.;;L=\>5_0B (*[-
MTZ'83KP\:D:G;H/B_4C;TDM 'X E:*$-U4Y5M1/M<8N9)Q.Q!R/JLZED_F7"
MOIT'C*@?I*P_L(28Y*U(L.,R)M]]%<7,_/6/.%Z*'YQFL<D]@N'F414& JR-
MY^:U[P+2(J5:?"I>> VB[].2!@B+*\(_:!(2I2B2]Q3]8&J+!'<.NS;BX(KJ
M+^%->RU*?'47LJ!5SC3+6"+&%&E1"O>I3>XW("7IX@/#]CL@W$;FDL'63/J2
MD(+%^9O+T%Z"Y<N=_-(E!/0=N8,-O+ZUY9.#WGNDY#)A]8/- >=NQTUX(L^D
MD7, H&8<Q"R["9/SQ%#B#"BA13+8-G8#4G8<H*C+#\_?#V^3<W%1CT/V%4UR
MDKR!(QY)<07L_->V\+3MN&\X4XLF8E$?!?;3P/9";<X=VD@U;:E0FJ9LM>.C
M; >-!$#%QTV_CL+JJD-"["VB8!%&H\/*;D11R; 9>I$;$J^8&B=C'(Q&ZJ2<
M^9RZ,W2EJ)Z'4O[0/:<$\#"KT67\#KF?+ =3I=^?^C'$HTYA8U<1 OX1YTO"
ML20.*3T/1)*;'TF).;GNN*:&\1=?NO9(.8T]A))J^>^$*S2O_ IIRV/4QRSJ
M6N2HC<7$>_.FH5%BF?' ;TGM1;]Q+7XT&I@>=:*7C6AD+]^Y&,YMK?D;Q&0*
M\872 (/[RH 3L4?#2:3:97>#V6F%D0$^:FKGD<0EMR$P*D1K2G*/_A%=S;7@
M7 I.F)_'9;9$0B4#=ZF.D8/+\Y,=%J+,7S6J0!>+;T6X8R\BXN)S8M^)AZ6^
MX!-7=DDW$%P_K4R]W]UE'.%3&AF"QH*I_, E+$1WC"7P!?V=J1+*K)"V8J!E
M=$(1V<LB7D,#2@G9C1U81 S+9'0"9.7R=1WM6T3@42^)Y^QUIR]*U+].@DVT
M9\%;P#W"RS;^ONR%VAA$"?WAOZ7^4*U)E*W3[#1XQ$B%J.8%5%R[C['*&_D)
M8M.&HA4^\W?Q6_U*#@J/AW34J\6-T/S:R3ICP\1D=NJ\A)JBZ'MS$9UN>.]"
M#-O^NW!B?/2$*H+N$7)AA+[9VFW2/6RAI  N9/O_IW4WRJCO1SC]E4/IWC'O
M$R#ZP"&4:-K]Q@G7=Z9+?G=<MZ5A$T98<Q1[0/JM67_0DW$BN=,9MD>SB247
M.\2HDD,,X!##?8? *REVD'$E!QGB00:Y!Z$>6'$G35_3N_J@C?_M\S/"7WI;
MEO7 /NQM1Z.B<C+AC^$^J->!#$/.$Y4,;KBW4+@>*&](.@3JSEWD_*JDXZ1*
M/G)TPZP2B_VRNSP+)$TV%QAV4\V>ZZZ=YOE$E1[3RJDK[BCP+:_U=3S-+&K(
MRD<Q1\V<#_PT3HKT V%J\.?;&L/A$HRZ ,B& 9BG0/FI<8LNBOK0JJ!!.W!>
MJ7DHBC3E)/Z9S.90IO%1)2$V$;-X$S9E!0!=B'53O,I-3.0X>"BJHXN&@WCL
M+FH,K3:+1J<(P)H.%'B6L$H=G\F"Q@5US8L:N)%N'4_E1>?!E@6BZ33WJT3+
M%YAE]@)=?MYA_(7;H4#,4:NZA;6GL\$XHVYW7)-F/XD37$*K'PZZG=+<V/I-
ME)L>50A/)?1.<HP#+Z5'+*6./HL$D!2;CSO716:N*-",!C?\Z6 !G72U<]\F
M[Q*J>%"2S;'13>$Z\, V]@!%;<NC+V/W$&\L';TH6EUNP:"Y-D*1P'[5_&U*
MK2'OL$J/SEF S1.CM;D'%Z!+OAKNSZ$*UW"].PTJ6F2Q %3F6S:4"1;1J3;P
M$47@YV% 9)_:NTCOSH<'WTCL(*.W8(\CV@3L2+Y65%L?TR[H97G()](O?A@_
M<SE&NCT8?%83CL%W+WSQ%\$P)FF&@8ZMR%%&#G<9,4 // 4W1!M>@>)R5F?
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M47Q 7D6I>QIUAD=LZNW&]2W$BC<>LV%7C^PMWO!=GWZ]"T'#9[A :_9J\/K
M>/8FTM<;O42D;]0=@:;>M*R[3@PZ1^0KC4$4W#JYP+!!H5JBT$O4N(RZ..CE
M]%XA#0K5$H5>HL9EU)V"OMHPH>O$H)<H<1GUNBC'FLZ75XE"XW-$:M(HU ,Y
MU@SBN%(4.D=8)8U">FLV:>RQZ\2@<X1 TAB$92CCIH+@.E'H)8I01KT!VF-U
MT:9+3?_NC(<USP#_X0:&G9_T?:2CG1_A31_.;;HAII/+G9\05JD=K)X[0O1D
MZ%P32ZD^V-0;4B+R\/3)%N5><T5!TH;$&Q(OE\0K;Q,WZHV(Q/MEISDT)-Z0
M>$/B0.*55[F->KS*K=<O.1>Y(?&&Q!L2!Q*OO&)PU)M07O?IE>$-A3<4WE!X
MBL(K+[X<]:9(X8/NR4&LAL(;"F\H/$7AU=>QZICGT&WW]))3NQL2;TB\(?&[
MWJ3ZHF"]A\4;$[WQM344WE!X^11>?8&UKB.%#P:-#&\HO*'P\BF\^F)UG8K5
M!]>@I5,"SR_4U% 6_,%_Y([7AO=@.?3>"=RD>-D=TM4;7>_LI.O\ T!L+;?\
M(\LQF1.\N>./E8U8TT-XI2->O>J]/DL!YC%O3P*KIW>Z.H+AC\[WCF8YB(/P
MHF#%M#\ V9FI?0^, #XQ'%.C9P+F>5;@>A;S.\F"3.5^+NY"]-I=R.^N<T<
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M[YF_\*P-_OEE"40'>XB//VG-@B>7[M'?3;,XRI&)"QWV(_6&8",4YR\5^1I
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M\=-:A^N=QU0&N'!#VY1L4-H@RQ"Y%?+]8G#JY<RNK)CVQ]WNOD9FDGERQ[J
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M6P&!T,TH18YO!3B K#QHRXS:I8NU#-H_0\,#4L+3[E)9&;Q9[W<+ *40=U8
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M@LOD,1Z,'#D^RY\*T-1;Z/V<NKFBM(%)-]VR<NAJD O7X(B"(P>&&1Z+(U/
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M$I8YI\_LY])]%BJ5WW'NRF;*J#?5^ZHRKL@MF&_=6^"2%@ ^^XYYW)M654!
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M8YQ252-KV/..E-Y4T\69\%6B[=Q[WE%U?6$%X)JYYZT)<<?VO"/,W4P:F^+
MN'%X.J.Z++);T3'D7L2Q=!-%Y\IF&HT$BKJ+HIK2?_);3]6=&(@CWY/P\LEU
M;L2Q;UD^*I4Q5,<6>-*;2J6S[82CLHU@._<.>%Q=MIH W#4!;F\#G!]PD@#<
M50.NLLW-6!9JLJL@FM04F)\$D2) U%D0G2'P_K"NJ^YX01P*GY9&C&-A?17@
MF>X"X, ZKHD3X0-<4RJ3H(;M\%@#$2T.A*\2;&??#C<NBT4 KA6 .WD[/!*
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M#4)9TJ)/PDKN34=*%YO8=A-=31)BQ6U/&5,!*BAJ+RJ('$?*1]<+'L"B%'V
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M@Q5'O>FDKTNM8,5KJ$OPF^?Z/HG.-\F#83FB',')MN7A$^4O(971RYK&&UC
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MWIUJV,K(!PT*,W4<T%^&'[:4BE-QUQ"S6"LJ$_ZR+>:^84:N 9:2Z3Y10"Z
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MM0IUJ?)./H^\"Q-N2U=6$<AK(_*RY)U<M[S36B+OSET'K3U[&Z7FO8T.UO9
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MD_Y84=@Z[)3*N<06+C)IS?BYH;\]+018P.;%?:3 -1[SC.T>F"A]\KRT3'2
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M+*TY6"^WC#JC)&>',[@X@W,9'G-,[W6]W \SRS"1<BCDA.[E5Y3Q>.WXTX+
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M"8P=I@!@M9"K8V-Y7E+.(_#:[S0@2%+&(K!:CL^5,0X!5!\\:?;"B1.]%1%
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M'/TX<@W3]$#JXIZ+.C[=YH<D3,Q+D/.0TM#S@3TYDQ2'#C[VN.4BZ9->2]Q
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M2/^:,TWW/-.$S4%\UNYFY&E'L(LI[OPW6MA^7FTKI4U :D RM>"/.NTM5WN
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MV41.2IF0]$8<Z:^E9NMF MDWRWSE56AH7#K,BHS^_=9RW&^6^R\*KPTVOPG
M+)4P471B?YLX.H-$!);PI#N,I$$_@2E2-J2\!5B3B/3F9YI+A*>:2RMF!F-
M)F_^>V6$XI;YG67['^'WLJ2^]X8X9CB6^L[3PSHY,L%./]@S.3OR"2@).\+C
M8V"2I&!3IV!L*;(<SJO(=\"I-@U8VX<=9O$A"I"K?;PA7O&+CC?]$Q"+>)V'
M'1,E?2Y1AB[TWR27VDO=))@9"A+ LO'+^$B6>X?(Y5F"?#'(71T)LQS7XB5D
M GA%^,6M52/S_ >'OOD/?\'&^A+FGTISHML\;MF6WA;Z;!'[\LRPG+7(6F$U
MD&29[$_L";!&]CR^L"7YT[)QYJJ_=.0'8K[_CY.V-J#* LBX )X%%M[-I_UA
M:3XS^\<_^+EQGDSFPC<+.)N:$48<M29SR[.OWED6V!8[VH0G50:(P..5X&!F
MACZ?^UU0,*E]WT9'-=CHN#5Q%S:E7,9L;[6SBT5,R\4M.;I&;:JQO%KD%WM#
M!\(+ ?GV>Y!FNXF8CA0,H48XZ@!19)?U*\ALYBT]KEP!CBGH\G-IXTRZ)3)+
M'<Z\)@R39'_@2OA9[)[4K*(>.KN1S+&3*3R6>2<%&I'4/%0ZW7[_S/.'=[]<
M3!JNSZZ2\Q29W!)SAI/G#+/91"E#AB^FU47H (GQL)7TL!A7U,/B"QA4[ON]
M"8K98P5G#VB#?U\0TW?APX,]L+>%W&M-E'9O5'F.2AVBG!5BN'8W5V)J;/;&
M'>-J&G=D9]ZMS@M,97T&A^D.?/[-V^!(5P\9;X.[<J=?^$*X<MZ]L!D]8CYJ
M%J4YJ&H<SUZ^VQQ7F5]G]EN3?EL>%\Z7%MD_IX;F+K4PJ&@T3TYX'J8;!JW)
M2.Z,"M\DUBM7J"D*@/>&O+"DH-SSV$ZG /CY'*X %!S+-NK%G28QA;1VL&R6
M[-]$YF&R7^5^0:\N$THOS/H7DSD;I G"PUHK@P1Y/VQ-%#F>1BJ&<-8.>LV2
M]I'QG(>)^E%K,AZ7$ &JEYG?X/N4DS0.O\AAE8->8^]<QJV)VNX5KQXK'2K"
M ZF/3NHU\E*BWV6MQI5:^1Z;*>S-3]3")+D@A?HJ2*%.3!7%5+U86M<+OYYH
M^WTP]WP[T'.F5FT/S.;GBHD&F*(!9EURH"ZK 69;HC]G%-3#BMH\21D%(1%]
M,0_=\"6U>!1],0\@VN7UQ?QGHL%UM6UPH03:MJ%$NTS1@*S^P<@2T@[ZO9+2
M#D0G0<'(-=KX88PL-YB1Y=9DW.N,^H*1!2-?/"/W&\S(_=:D)P\[@T8T][V$
M)J1W6<*M%Y8PDJMURJ"J+J0YD[-8%Y$X\T7:I?0'P'RCPNW'1/)(+6%859/(
M\F&HM":R(F!XGC#L-P:&F)<ZOM14I5, *:5[:9DVQWEF9>2V.2KM"=C'CF*B
MV>1Y NN4S2;[H]9DH A@G26P]M@%U0)KC GS-0%6ANGO->_#6$)+TWAO+];&
MK9QFIH,R.C$?U,PT?!+_T;:)FKO!*>CY25_MG;##Z:#^'4[AN"=R1SW?#J=
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MYZ;_)-:NY42-WT;REA,4^>?"#E:S(B_T:FI3\N.*S&&QU\1X(^\.8B1Z*G
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MR%4<X,WB>+QFU@]^"Y9$ZK(4:6$C-_Y%)^IT/E,52@CX;;,^G<Z5<7]*R'1
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M(@B=Q"OVS:<X"\LS8(T4%/D+*PUAM_!3M&EG-B4.)S([+?\(U]<*#"OX3A2
M]#\>8!G  .?TIW]W$!20XJV_[D@S;$C)0UZP61.^"]])/RZ>*Q!<XR^0<H[C
M+>GV(<Q!Q*'= : V#-P*$-C0X6M(7%BT_^Q0[&ZI?7R1$,0-M,YS"N'M^[KP
MIN!A'G2X_<RM=4#SH7)X!"YICJ O EF++ 5I$%B;03-V20M7)8#:3*".=MO]
ML>N'/TP0O08:X;<>_,&<O7]E]U3Y\3@&]W!?B&0+CVO?T*8K#)2 Q)SYRV B
M-0#HC-CVN_5*0<BZKJU//5?<I#44H(<YIJ5'] :8Q!2??R(B>@+I1W#>CI#B
M,^AE"->!:P"  3(F0AV,!68F+(@Q#Z"^'<![NGV6IA[8[M1I;C1.SAV-VX'1
M^;SB>[63QJ'RP5\]811R(.^_LVE>$%)DJ0H]=O3<IS@?YTM^@@^>J>L:U*\
MS\O).! YK7-%^LV3X]*5Y*TD7X!/B:,[S*O8RGX*@F+"S#I7>.:(E?^**%D'
MS%G QF]NSPVQ \,U@T$&#*>DG ;I>1C)C#;;3TS!$[!MAA]\F&E4OA^LM":#
MO(4 P@\62"^,]!JEM@Q48()>4U);!-AK'O0Y3+27$O3![A;JP4$?8FZ*Y"
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MS9)6$KX^6GP;KL*F*\^>+=@FPL8?OB7D\!Z>^!;6=,QOO)NX/OZ6CO289?%
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MG6JN;9GZ#$S064W6A&*%^96W43%T!QK'1%TD/:\%TH?;(,[Z,0>U]P9PY>0
M;K_^ =QDBOI:?QW?]I4GBW.?U!Z6<MX+K =ZQ^W=R'V DW AT!\DG&I_$+\0
M\ T)\X6BW1"X:-84#I(C!8WX3.Y=Z+1_"X(=VV8+=]QQ%#>&"[#E[B%W#GP7
M29LKY<ZA$:.YE?RCJYLW!5LL*NNBFC\O?*_]DJ5W]'A[W*_/B;G&:N[<\S'M
MYVSC@)F@#51<X*!6HN64CIQA10E."XK;*[DSBLO#*7$H-X4_]+9LFAV-P7?6
M0Y:"@?I-?0YU:MI1-V; ?#6<?@:#O>]XY.U?E-@9NN/G8X(S)D\3,)]MAQ_
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M@!-U:%!6<-:KSPQ!ZR!H0950Y@;J$5P:E[+@_:H5T1LO!0P1FL+F!0"P"ZJ
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M&NBS'7$7@,>X?'_<!58UD<7F541]MEON_/@8M<OWSEU@59TRG'02]>4XZ2Z
M#VJWT"VF@]\67]T%5M4KU657^[RX*KCL+IH79V Z)W.]4WUV-Q^-*-5G]U[L
MTF$RH<AVCJ4Z[?(MB_=VE$&X:L&^3*]=/GP,MW2MJ)S;+M^R1MLR "7L:^JW
MRX</*G1N%Q.B*=5QEV]95-,Z+C9&(V%?9<]=+GR,B^P-6:KK+M^R2FD4*7%?
M9=]=/H 4V36R5.==OF7E:B$I<5\'[UT^@/01]T6I.94Q:L>#"Z3<74OKU-]^
MK/AU?@[S?,=28&=7L"'8\X(==+FY],>?OW(SV+0/MO7\Q)SE5]J[SS@.;%HV
M$X#EGMWZO8JUG,<L$&SX<:N3M4 9FZJ<[^JR4!EC;F)1=DW9!9_'+! ,^U&K
M*\.TE6*%TDM CT *H!=8H2A3I^RBT&,6V$%6N$#&PJX.?AFL4-<.?A44_Q-*
MN,](3<_9RF^'XG]-K?PDZ(L&_:B"*L&D1^7R:=M>@EZ"OA#0EUTJ?PSHZ4*1
MH93T\E8@>2M0/KVM;!=6SO;+$WE=BFPU7BK@RW9IY@7\MDRKD@!?O1TL#_$R
M''E)+U5>1A@5F7)8MH<J[^+&6VY&*CLB+X7^6;Q3>>$PD1>J2"WGFCU3^0#?
M;;?EK2H2\-?LE<H+>*R@E79LPB/UDZ?.3!:J.IPPG_PEO$!+:-1+U7DVK#ON
M5**;"\0GGKVB?\86_H?O>L9\??Y5=G&53PNF("94:ZWXGF'"HZZB*G/?-)6U
MP4S@4]]Y88JZ6CFVJBV4)?,6M@ZS>UXKGJTPF/P2W5<>#!1T_%(M/5E*2)XM
MVV*6YZ*?*W$E$<(1&81^AT\FOX5/[QSF&0Y;PN.)"XR4N>W0>\4"J()R]+,;
M#HFCV? #9]LP;DM! FQ?+?S%-( B[@I8<P[S<5<VKQ4%*IFV]4SOCS\*-(&/
M# <87F>.N0;0*S#8'SQW35/=A3(W[5<7"!00#Z<*5,&1-HC%IP<#.SCIV&M<
MQ6$K("]^O(#M5/[C YJ\=5/!2=T!Z9?*W/C!<!]@. ;_<3W'7_)!DRK[U>*6
M!1F!T9H=X4G-S!%,7(^E.@SD+3Z$<E7Q7=PH59GYAHF"2IF9MO8]!$(3Q;5K
MP([B=PO#]6R'W[@%(DM]1C18F)D(G_!7$\X900C?K6@F_+>EO ><@XQ3#<2[
M;WD.@*NIO )$67S48 R<I 6 6S+5@A<#3J.)""^QJSP;+\Q"W,&,X5G8L>_P
M0DX<E2\6YA*C$1^\=54H2!5-$PJ^1APM3CH%CT8@,["(1Y]_\Q 3(*PNU0N1
M)JK$Y2S($,NU'5<!CG0!EMY"!2ZV@;=1! BLHFS[O?6M%0HS!+(;$VG\RRWB
MD7[<!,$#\L6!Y2C\-PR0I!/"(@'X#EYD1/1:^0X,BJC$R7QDNN?8%@B^Q%SR
MS$)ARY5IPZH-H*N:>)?+]P8%[*OA+13=F,\9B3K.-*J)D":<>X! (,MU@7;_
MD;M0\;3]?RB\YP:((4(O?+DT/ ]VZPWN0?*SMQPNA)$8*9]]D GXKD*0P[=#
MH!'$DFII)%:!A,RQ #XHA'P3/A=GE,OB,T"Q!1,#9<EP%["J&2B9.@IC(9O@
M:=T@R=14',/]#L++!($&+VG"66R1_'78?WPQ-_@53CX4]^%4U?4R.B4W2 =J
MM*W8()U=QEQ:2HQ:,6"!?->8"Z]PF0G#IWX*VPWRW1%S6 (O>,BZ'*"@I@"U
MESCSEO(0*1ZFH<Y E_(,08Q(^(+@MU20OZP9UUP$CR 6HI]ZMA<>!9%& G)^
MJ?X 7OJ3ZUR'GGV("A56Z^NX*I.],)-^#.2'J2-+6SZ>9["[:]AR?!R'I^U!
M*OJ<,L'@\TTZK6S'F]NF8>.1A!OLTU[!= 6WT0/[C^SHC*X+KV<1B4A$:H *
M4@_IR_D_!DP@2>Q)#06ES=4%4.E,GY@$><2CSQ+*GLM 211? /\],^(J 6$X
M$UZ0Y/3LNJ5\"W],4"6^B4\)YHC[1$J$#J,#.;5(P[=HLBKH)>X"%G='WX2;
MVU3 &'P%48*?OJBFS_@&P%1,%.BPK!5]YX+9:]*_0 ?2OHNIHL7YPLV)%0HB
M^#MG1R1)'>#QV?=0ER/60*G<3,CL4&V%;?'6*SRWX23G%  IN$9_ 1#"4=%J
MTP$"P'.&ZJS1@.!2D(M&>!QXTH7EH@D#,ANVPC&"+ , I6EHZ_21.W?LI=!2
MR=03?VTI'VRNHSZ3OX&D>"BU?=I<W+&Y88%<-$BF@!Q0?R0U5[ZLE>IX@3 )
MQN#8VB&KR71"61C."-F,$QIYB*OD0F5(K0M>["D/P 4F]V1TATVEV^[V0VM2
M')=.9CN@K2DW9],D<T>2$J&#[G['DG N ?*>B((/(>F^, <!!\3-=AEANFI6
MHUPN:A)B*><JANWVV5:!^8=9C<%T-O,2:T"@YEY'YVSKP%N4LM9!2F#KHM90
M#43W4R@I=$,G(YTL.%3F(N%%HBK+0V4[(.I05+L+$#1;11)(I/C'8_JXMW'R
MX0XCR@Q0X&B+BR'H].\SYZ?IUIT2Q.AC;AW8$J3.WSL,3X07]O.KH7N+P!,>
M>TK,HQT]HLY<V_2][8_$)LBOF[W0AD\Z&V2/_;EPHLYVS^QNYC#U^YTZA\G>
MJ^:KNG8QYA'?%=@ ,?BH"V_?7/O6%<[GQZQP<L ".1! --G\?+[G_DOX%4Q)
MK<I4E(6#@O0OACJ<S;7A@*GJ<-#7>FPV'TQZ,U6=]5E_.!P/_CT"%D5O/6H7
MCRB#+2P25M. WHGVR[BU(J_+RM0J,J=/-OJ\00U\1.>5:>@JZEKO0B7OFP<?
M<)GWYI%+(Z:_S4%M_N>&+!.G66?2'=T-^&%* S]XX<?#,-8F(C$;1VYG\XS]
MIH%-!'KJYWETEGZ>Q\]9@,T3#/ +NH!C!RI,@,%!NT*AY/@;2537=7)MGD?<
M)43'64ZUN4GA"CC$=!'ZB(\%.@<Y%0Y5P5&CRCCPT-81;G1N!J^;W%9%MX:)
MT93[@C4*"O1%AY8#\@?U?5-=N>P^^,O/NN'".M?WAD54IH=^3KX0C\>-J":]
MD'\="?Y6FPM_D?0NWBR^;L%7/Z4_'W9;H^$P\ZMVJY/Y^;:A.NW6H)W]U;:A
MMG_>K_VDNCN'VE.]<&S_W))D!8UX;WCP-FWW.4 ()>Y&87E(RXT=2^6ZW'D6
M.SZH R^WKY3H4,BQP,S$ELEUTN&!"^TM=#@>W)=<:7:*1W8J2U9B$S\!\,C
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M@ ]A1H%L?H45@1SZSM*2IPX(RFTE_?8#=6>FO_,]T,P" "5P]0E>\(X(_7]
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M)/_1QMD;HPQ))VQ,F"5VN.>5,@3P7[Q3'GZV$7?W%G9\>(-@[CL.DNB?6^:
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M,A5EX> 9]9?]VP,JWQ/FM2$+/^+Q!LK.WW]2IRDSB--Z^O>9\].V+\]8S$X
M_<ATS[$M0U-6IE:1.:'(<5'V #$I Y'4PW>&I5H:NJ^_>? !^II=Y<TC%S5,
M?YN#VMOL4B%HT#2]O*6:39O.N!4$X$3>Y(9&U=G4H- "X%1Z1I7C5U!G0!'Q
M06>)*4-=KI@1)1^\X$,<C('VLT*)ZOC GF!A+ V/TQY5FFA@S#1)970FJ+YQ
M,,1>CN_)>GVW<:6[]($] TX_JAZ(97>?-Z12Z]GN'T'C4K76M.T&;O]\;IB&
MBJR*:JEAO=CFBPC%**" SU +G"LFD8)KURY793T#+3F;_Y<_AXJBT'X4&'0&
M(WOKIL*6*]->(]R:\$./F2;#():)OP4%T^.S ;42\$:B03?<%>@%;E-Q%S K
MGJP=6IA+OB$PKO5B@-3#@?E@&F.8W0Q?H?\G&@6'?[9?F)/Q6TX)BE,& :^F
M,%AQ.=["!JU7!_YQC!FY+,&N!>L =/; 8$ BY!K=-+ZSF)])M8*\8M^!_^B
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M<>K_#;:&RQN.!8N$T,QW00JZ(=+5U0IL.=+R$LC>Z^N^,NF.W@5'1^8+Q7!
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M'S.9X:]'Z"F]S&6<IJ8,T-F<L9ZCO!4;"C1(59XM?+@&'=>"(B4Z241O8?O
M?+PN)JY]!W4N+>5C+(6$;X-@'(=M*A-1J"2N5,G#J#Z'44[W_&^)^L$O4<W!
M=:PV7ZS2]36-N:[M\(#\"QT0B<I$SO(@VRU_%=6[><J+ZAC AT%=1(P-D@68
MO(0LF<N 3NI8&:EK4#UFO,1,^4R%91X&Y3_B@4(,Z5)V !XCH<Z*B9TT%^91
M:!)G^&+PTHAH0)B$_<+EKHOY.)2NL(2C2B1L<M5TH?ZI.CHMBI=I:$Q4M;JV
MP0OV^,T[KYB%D)6"*A83T0LM,ZRE>\:OA#"+$@QX_4VZ1D5D%(5)'J+5_[/J
MZ&%9S@^/Q4J+1*U-\.*@=3M,<X4G<I!I$ZMT0TDK9$I0+2KDNVK"8Y8:'NJX
M$*#5PM:OA>-S\8#IVIN,H%*-T%J$+,CB% =39%;E,R]A%L%#O+*H"XO$-!4>
M<?^D>E1D]!6L>]]!V/V*01(79PHH$.##7_*AOC![93)X_L$T#4JXC&=N8<$T
M*G*H/ZA4622V'P< D]V>N1J<,5]A@QT:^!>5!W+LE:CDQO2>@&]A3,H?2HQ&
M\>>/J@.?<YV5BCI1J>7AW>C<I^,T=NHO5)UGG)%J!(0/0^B4+@%<KQDK[B6&
M\PQVR/4#GUH84&X&Y<C?V,IC)$:HD5Y\$GRC5.4/VZ D)B_J^83* GE)4"2(
M'1"G/JSJL^;9P8C-V!)H)C@B'X NTQ+#A"6PT5J"_0JF@YH'&/7?\:>D$:!G
M"[A>%;65!M:3D<@,-DML@!D3:5SD\/?S2?%9Z(8N])-4G5<R*?YO&%MG+R2X
M1<:Z &Q(VQHD/25X_&]N*JL\X%%@K^ 4V]HT0-0#BDYUHB0T(Z%>C6<GJS/[
MA5T+(7.J1P]P&MT]@NWFD["H3>Y"\F! C9\?C%Q"BMX#\6X%[HYV!<VP_\'N
M=@0D6&-=!MY;H4'33/?32.KV+C/G=T'UKANS(T"R@-Y@N:D.%%'S@Y;R ;M-
M+$52 =6_HN:!9:N4M!5VG$#'G:AY%5H!V5KQ3,KXI)CU')A 8<=YP1<1R<*C
M\UMTD1'2Z[>@81YUHJ$GFN*,92A'@XRU_T68:*+,+>!@U0<-);J-[Q'X5(WI
M3('1FJT?!@]L%-!0UX:EX0G%5@ "[2<X.7Q^-L(<J)5"E-7,L-,&6&_/L$XJ
MHR;+$]E&B]B&"HCYT0W//3OJDM,@P NF7EBQ2G"A.T;%P@:EO*I>//L"6X5$
M.R/JDJ+UBL1=GN8A?@[RS-'ON+K#'>DSGZ=,!STMC,1D:0/9#_AEX)%*U1B3
MZKD,\@E(\<54W&:\:AFGACHKW1D9M9G(;#U"5=)9G4<.-]*E15Y%,9P=U^:]
M;94G[ 9[5<O95@,3ZLGM"<?"^Z_? FV21 /(((3MRG8HD3U,-FC">:"ULAJ5
MM@?"1]H>ME*_I_H)ID=U'9'4Q3?;O(=,,VPN@6IVP <Q,YX#*_YBSF_ K"IO
M#X%]M%U1WH++V3-3,;@;Z*3P7EL+U=VPF[;WBL[3S44%Y^GKP@:>NK-?+7+J
MB4RSM1+OJJY\\4$FVF#@:'9014#]@]A&0AWHAM_)$6GYV+R!U\^3-X(OE<X>
M *(P[=Z$?WV+?6<,]DHV#F^B@4VE0KOD?WUX5[?=&39#LP$6N0*R!>(G5IBZ
MEQ8)LV8WB2F(CC<_> JH(NC-,5%<H,M$V&, @3"Q.RI(0RR0);S$6J/@2%G"
M^1WU,Q=3W=P9;*K%$[.IJ0/97:3)B-KK=F<4P3ZPRC[9I!2%6<C!X+LSE']#
MOEH$"<H;'I%HGP2A8WN8&C'&?L&VP'H?_&>0%3CEL1#N  T],&158 >\?3F8
M:_3"C0:JA"7\KT%Q5@&FZ.>QE[L,JT\RYQ!8G]EDDXF!.Q(#)S(Q\.)3D8F!
MMYL8>+49@"<<1IO>2-%P)P((*BM@\G ;(A#H5&5Z)^ITC(3SL7==ROQVGPH>
M8&B<;5%YW4-UWA&0G6KG2+-*Z[V!RY6_CVK1-A5A=-2!MALO;Q4.9O9#@]T+
M-_<LNFGXMJ!8E>UNFKBACHKBJCWF00U M$'O4'W=6#7JF:BZ!9VN.A-.L2#O
M)78)4*BO.BQ1B$8.'<0FTX/  *"I#C1\M%\ C0#>#U^4-ZJ JI*&ZEQ)'&EO
M>7&F0<Z7?88E!S-F4?B\Z2(U!!#6 XYCJBN7QWV07?9M3L#MFT55==B.!Q.S
M6&!QQ[=&B5$LW1^%(A Y^J.$3?QD=Y2S7+K1Z6T:C9&7/';BT)5(U[7Z;)WT
M'[[JP&G+ZN+20X1;F+;- ['<GQ[UG-BHD$0T;S3##J(CY* A8QDC+':\&0LQ
M9M"D@YQ7* "<32?6EA=0^VJ=+4'16<,9YP)1D87AAZZ/62#X#X1@T*E$<0P7
M.\]02 ID=:P5J<@+Y>UG>9,9GNH&YZ?ATID9=?3>G%UJ9D&R8-3G@XC)GF%G
MF:5E^.AX@JK%3-[25+1Z"=)7PX8G\1BWR%0/>AUPH11%.D3/G2@K/;.53C*^
M0.XQ&YO#@::G.@AG@]_X%(2@@M=F=RA?JC^H*3#[L:(K&A2RE86$?0[Y(QDA
MF+%XB^/_,6 ;'0Z:),B"X <&/!P#R:@G>Z^&UU/Q]WGK%2\OCEY\76)F?P@W
M/.^\>)H6>:S]>$(,'94;&Q"04A.^\,TCC\WG["Q'7;9C[[";A;I869-_-R]U
M^<DD[^4GWQCUFOY*5B20.+K]Y F>^@4,N.^Q1.=ANE@1/DS?@B)&)1OB'PPC
MLZL%S.5]="G6<5>AB)=ES>$*KD+9RFZ8UL0H4BPRCL(X ;?N29"YG*;AE:@\
M+3O2ZADYV2E>P+N<!#U<6\J_6$BRD!&WILZ+]^QL59S*FP\2Y;^&\Q40<'-7
M9HT:TSEH ^EL^@Q:W"N/&+RP7U27>I$K7^ 7<Q ;=A.VQW=LZBP.QV'L\X\B
M1^.;#WC O\2^0[R&M2"?0X\#AM+AX+!?,;>W*<H$:<<VMBMR4FSNUH;]U=\\
M[1?V*Q>#"X/-8Z_^%6CN\A2A[W#0O7G\_.O'M]0 B,ZBJ/TX<XC.EA8UL>8(
M<<#:^0\(9H_G"6].I!G$H[80A5K[NI@Z(I+]8:EYL8,7>!^"GG#91X-GW)AZ
MKW9&65]Z8S+4K2"MS^1IGWBY#F]$QY<?3P#]^/5]S.,4!$@)$[%1U.=GC*^)
M>Q[@3W^%D6.PZ!&L&+:RER 7>=IH,$,T(V'>($TP0V<SH4G/N[<A5$4\,K75
MFXXS^O72?@DCV HU8E)0= 4+!2D#\M2@N&@8['X%7?E.QTL61,+,.JV&?L7T
M%>1:IGP3.D0,Q?S]*K\&@[)H^,@?[3]51PNG;D1QT6ZO!2N)G,+-K'T->V$1
MY^D!2]%]/ZF[3C"QW: ,K]B%2U:0J,+SG_B=2C/\V$M$\S=PP=D%S8YPB517
MAB%>WR&J1NX&&)C,6M&)*C^3#<[$9)/#F2QV_<<N$4/XY 35(YJEQ@NKM/=O
M5\B1:I@0M4OPX\^V0#[!<>@S7NQBN9;R!>P81YBFHNMUO* -*WM=4>,[-YGP
M3UF@2SB!#H:9;[Y&C0_J94[\#0TX2Q5M\]#<TC"-CCC1=IY5;(G&T_NQ%>@Z
M+C-Q.]356G%#H4$YXSKW,5.S4P$2;CA65;WIM+>I-R)K'V])"8\H+/GT\. %
MP&8&.#@YPQ.*"0'(F[\B=D%C,>V5*VZZ"5)T6,R\YPF31$L\Z!UJ-PC;@5>R
M$#]@.S[%0]>F2']);L2UI&CO!2D_T]9)RH0$H3S!V!5M6_3.8/. \H[!'<5N
M>+]6D ,?O2((7NF&^FR!04N=BIGJ1=(NQC!XE0.^5M449['V%DL\/*AX073,
M3\X)OF3 0(D[RL+E8*4E?R<3KXR_3EE0,TV>&LR'NPL.^N0[Q4MN% 79-L9A
M&. 9Q',;3G\>SK%H,,]8!O<.<E8+$KMUQW^&$4TL. +V6[N@GT8 "E%#*%F(
MV!/U-HYM?YCGC4FS@7;DK@+U9N;P!_#F/!ZZ6#$3%HYP,+%BG?0>T>@W?!Z@
MTE0XD/CQ[-BJ=YMXV*'C'(>)@+VB&D78+8=W_. 0:"K/H$\X6*"%3D[4KCT\
M4YJ*Z9/'3&PAV"%D/]@SYM+5H5')YHKFP2UKGJ4NLA4W-U%FR"6<;=B92*;(
MR10YF2)W@10Y[O/-= 5?;>9<YGFS<<1L<4\>?;Z(T2(U,UG2%>M:TPR(C1K$
ML^EK.-820(GA-+1:A4K"#TB A"-JE-PE*I/A6*PF-D,0Y-"C"^/))J.*[)@_
MEE_QFKXM0Q0#FG$5/_0!M&"6'ET'O-G ^&]N9" &^\HL_2X(3T>['I0V9=TJ
MS&* X29B,V$?-@/M7KCA8,N2R1==?L%F+.$"-=A@RK-UPAP77?4"%R2(\97M
M!"V5--Y[G]JAA]7%H84KBFLPD3#RS@0$2 2)D]X%45TH0I?Q[0C4WM#*IG8-
M_ UTE:KH'L"]#XEE<6ASND7>*2#K' ,$W[9\@[L*PP8[QK,@J0MC/$.EB>F3
M(=\!-$"="WX E!:4::)+"1#R9RROTE.M9\I"PK  Y@+$*1IN(2^8=.E[RM;3
MPMM%1*&\BA@.XW8+IF-J *KVUET\^W)C1B!I@.N;&9L;7C((P-2^WW%ZTHTR
MEJM&=X6(Y &2'7MV.X=O+1@EG%=4N$[-2+;M%=87[R2?N 0;X41_%3>\!@4^
MOANUM@CN92'O8-POG=%<8.N$E@Q;8/!Q@[LE/O_ZD5IL4!@H,PB40'4$ZEH(
M7N1Y5:,+M(E.H'MHL4;O"?<9%W]XV[LK3C^=N1KL:,SAWFDICP(D.G(J:"\1
M-T7W0XN*6-@#]*R%+NG7\ :BX&'"2L@=;A+0JL7QGO!6)C.EMXT3"B0>J[+I
MJ(CE8/#Y!D!)^D13X?7#4P2^8IQ*H\0C>%LL@/"% (HMT]X!2P4>T2<[K@]F
M9!%T4ND"58=AMOX;B/M($>,$*9C#1,0[,)?1]78'2Z0TX/O@+S]C\:2IKN\-
MBR9*#_V<?"$:YB\,KYE13?$6>B'_^O^W]^W=:6-9OE]%RS6W.YF%L=Y(2;?O
M<NPDG:I4XK93/7?^FB70P6@"$B4)/_K3W[W/D80  1(((V#73#LVZ'$>>__.
M?N^IQMF6A=89A_ _-WUS\G4;OKI8_-Q4VQW3+/Q*;BN%GR][E"*W#;GXJV6/
M6OZY?O2#4E<^ZH)OHMA(H!4DS+^?:6=3VX2+\L8[=?PL*;,$.&3]!7(1E%(W
MNUGK0)^3HXAIR7@K=F?GI!AE)B7L1?N9U@*(\&E]$O[#_P8)869N:S8.4VA%
M&;7S9*!]_M_[1NYH\=3?8'*TZ,04O5VZL27FG( BHBA,6>)GCY0._Z"H 3W(
M.U\)&=<A 8V376:-EODUEEG=#M1Z/<:: FKKE1,^Z5G'\#R5K9MIZ<V7I4-8
MC/_8W?SS\^:=;!LU\4JM$G5]=:O$3,$057U0X:K:$-%0U+-+O:5W]"4M$7>V
M4?AMI0VK@)AS\)!'7&(T8K1%1C->@=$T9#0#3SYB-&*T$V4T\Q483>>,9B]K
M\MLH1CMH=;XDA>2#X99J5VJU.1>"PJ$SQYK.V+4PAW%VJ;5L?;$?6$7F**;#
MG1TT<Z\KU*&)A#JZ]0HD9"()=92M!1DBH4:2D/T*)-1!$K(,JR$D= KVI_D0
MY(U.XH)Y'R,/&/(K\("%/*!TMCZ)BVEQ'RH?D5".A)17("$;24C6MX91(J%&
MDI"Z>Q)2920ATVX*"9V"/IQ&:I,NO(+VM0UHOX"\%2!O>VO?!FDJC:213=QC
M!32B HU8&M'(4=+()IZ= AK1SBX-Z\C45?[>3KMC-/R\O%NH[[00#+^-,KO4
MOG_\S/$*WAA5/[M4E);=L7?MCCDT]>6$Z>X5'!VJP>G.-'<>V$)T=S!T]PK>
M$=4$NE-;G>T];#NGN]?6M7,9+\DCSO'Z=S(70?9$0**>UT)%L2POJM8QF6VC
MQ* *JF3@[I]K[8),'<S]$J47WBAS.?1D5RB @$V\6P5<WL$R'PU1!TAE7$<B
M;RK1B+G@_<%BW_#;IL1BG5U:B^+O0FH+T<F!T<F"BV=+.D%WCK)_.CD%;_AU
M6HS@Q-S@%2E\B0=JY,;OLA7\#O,;,,>M+"IK,ARBK8ZUJ*&5)WGR7#:3<):X
M;VHB'(43CKEHLR?".73"6>+3J8EP5$XX:@,0YQ0<W5_2:D5)K9(3<WC7<]:F
M0F2ZF$*&_"A6]%O@9Z:+;RPNI'GM[+*CD/IQ? 2S)D1B8X+1SRY-;3%[A@CF
MT EF3;S$Q@1CG%T:QC;"&"FN%>W51:7W6EB/\,34V5I/6+ZT>7J?881"RC?/
M+O7M$V%(%VDDN:P+0:Q.+AT 2L4@<CE*<ED7C5B=7#!#1*'([-?;\*MU)71)
M@]WB?,VO[O?^EVQMK_C25C?FV&C,,>T&")ZDJ;RN:ELS)>FRH*1%J"5*.G1*
M6G,JUTU)PC.A-0"33D$9OE]2/_[$M.!ZC^G[@1.R#[BFU[DE+:1VS)S9ZOPE
M5::9)++F_*U (AJ0B+&H\A*)'#J)K#E8*Y"(CB2RC>Q%&F[YN*>5+4Q(O=TT
M&&JZK#>Y5;W&1:TN1!I<'9')9WM\-+0J+JI6&L(TE):Q%:P2#363AE:%2-5*
M0QVNS.HG&)+\"KTSEYS/:0>V \P_4K?)/SI<N7E+(6(N9P"Y^%,0P@O\E!82
M[BU@4.OLTFR*?X@4K!U[G[<A%/OL4C?)\7R<E+(@#VQ!*89\=MF8DH2GH)#?
M,1#3)MA;%R.Y>'/.* JPR2.W:9-2OITQ>V9YKT7?V4*ZQT)AE*1YA 2RQI1=
MFD!4D+7T#A'(T1'(&D-V:0)!3X>VC:?C0'7EO01J]?Z<>$))3?K1/\(V>=BA
M_IPKK=C%&1N'DR=XB\/S0](__#H8=3V?.W!R"W\GUGFY**F#*-G9!C%)WV@F
MV:PY4K<D&^Q0HI/'^/C(9LU!NR79F&>7ED9>Y%?R(H>QX_G2$+;F041+]X1D
MM'D2TLG(FVL.7:P.<PVWP"*@I>:JUPLGSO V#!Z!$XHC* QTU.BDO!X K=1K
M ]Z&9C"YA"J8'0K=U'O4;D(O]MFE3=KMZ]3-N+W[BS,:O[])3]43TV)K"\OZ
M,AH[7HCU/(/^%Q_HNP?RY1V+F!/"ROKN#7MDPV",%\Q&1_2]9^:>_YN%01$O
MF/(9 *6E*NK[AGA*2%=YE=3?7=*40C1U:#157]Q6):(J(!ZL:R5O$Z=%RF_E
M1HHN>_1Z3 K9PV3(=6#RU&YZ3B=+>L-7]&ZZH(6TKF%A?U)VCX] 5ARZE0@$
M.XX8BZHM$<BA$\B* [02@6!^A;Q8M8=TV9T46AZ-O!@%ETB* RD>, GV*@X#
MW^M)GW!R3N;%G7[Q]>K#/2F]FQVF]V/XPADFH0J?'<^/*BDB)BDBAT8[]1VT
MA<130"2=PC!1\M$VCC1J.V&WA16K:;!2DZYZ*%T41;DQJ<M@SUA2,E**G>=%
MZ_*Z!4@Z4HG9O--@"=Q@@C6R>%>J+=J+-6[-_F,O2W,\@++0(&6^X&S:#N53
M&(R$0VH"RY#T2P'Q_0.G5G'=#Z35C\]QZ, R>KX3OGS!"+]O@8\O#8/AD!?5
M$S5L*R<[FI@BT[*TQ7BUS5RB=5#"GI1.XG_B_WKX7UW3?;E) -"1SRZ-EK9]
MOU "  (  H $ -9TF&X4 "@( (9RZ!( UVLN>+_T-!,_UWEU!.J;YZ>CLF#'
MDT]P)-8L._[O)(J]_DO==&:O(S.5VS24MQ)L^W#BPB/1;#CPHC@(N>LMR,B#
MVPT#_R' [$D@##]-"GD(&1-6QSY0EM1-@HN39V%-*L=_D09.)+%G#]-%@C#)
M(F%N2WH:>+V!- Z!5D*8&:I+TX$D-_\UDA[A!=[0@6%A'WIWTHLEG @?%%YY
MQWP8[;4#"M=],)R($:=#:<]62SC(/5+G]LAGL>3!ZL!"!'TIA!UPHDG(-R);
ME.GR#9C[@/L&:_<0.J,(;N@A6[BPWE(PUY@WZ2$DO1&JZUL>:3RWA@GC?IN,
M8#H]\7=/@ HGEYE53F:BH^*^6/'BR7/C08IXN;N239&GMSC="/=V^2VYW>HQ
M1*?7!VZ^6SQ"8&:Y<C\'83J<L?/ SKLA<WZ>.WT8[3MG^.2\1 @M>1H%<DR>
MWE'A]?.37SK%?G]7]"C8PD4:XKO]#C"9A:(XR=^<I@Q%&H1X-O[B.6:WWS,-
MYCBFH?<TUNT;MM9UG*[.=-.TC/_IG%W^0!1'5L*C$='L;Q?.Y0)NB+6^_%LW
MO%CVY>YHK5-(:U-7SGC8:\B8O@4QXTXH6$Q^WO(TP4\@2/AHV93N8_A G!EO
M$E&$N6\KK+;X.8<YF7PAF^=:)CTE$+5H+YE//H4+>M[02PH4B[+$*"O=BS[E
M/X+\9'[ HSX,@][/G%2CGDD,A)TQ E$X8:]3W*AX WX$,2RSF ,_#F[8.$2K
M,E^GI!-"5OF(2S!3V.7B$HQTZ(PC]B[]Y;WK1>.A\_+.\_G[^$WO9P_0@JI%
MG#W%UU/D:LL"O1*;</+FY.LV?'6Q^+EFM55-*_Q*;BN%GR][E"*W#;GXJV6/
M6OXY( @-B@;%![6:/->X05:ZS.R%RPJ4>B'SO(X*:ZW#(7D>AY9&&91< L4X
MS#4H@MZ9M2A)%WNUXI2;*F@,$CQUB-K7@H>ZR%:V3#4OT,Z;O<E7H,$.)=5L
M2:J,36_KF7HA'QSQ\EE\^;1MD>(85XC(:K-%*T-,M&ASBZ96.9^.(WC2"5TO
M>'2BWF3HA%4#9$IO_K'Y8BK/_W@<+AUSC<MUP\9&'<RZ,%N*6E>YV2K(M(^P
M0&(N8JY%YEKCSMR4N73.7')!TW5B+F*N$V$N?4W1BKS%HI"+,*W'7DP,)!8B
M%CH5%EHC_*UE(1,5+6(A8J'39:$U(MY:%NH "REU5=#?*0N=0K&&;VP2!E'/
M8WZ/+;6Y'6=R=37-IK,;S<8"F<QJJ=NWE*"<_$:2C;4;LK$YV6CZU@HQD4T3
MR49?@S;K#EE+AD/66*S@0,1Q#,2Q!E/6$H<"Q&'6%<5/Q-$LXK"W) X5B6/K
M3FA4 *9RN;3[2?B OU!9EQ7BU!KJWE"<LGAKFI9AU>5?:(#QALAF2C8=>3=D
MHV,GCI:M$MD<)=D8:\AF[5G*'2Y;YTL3<322.-;4[EA+'-R5H!%Q'"5QK.EA
MLI8XL&%)8Z214["#WWA.E\4;=A(X$=VRLP;R-A6CL--*R[;)EGF<5+,&"S>E
M&IM3#;7H.4ZJ,=;T4%QW@MKRV>7VHC?11B-I8\M .%LYN[0(-XZ3-K:,\+*Q
MC7E3?",UF;\/I0*K2#L.V3@(D]H&HH;#5NV]MJBV=N"LT%ESA&XH>-G:V65'
M:=G;(VBE'3H J\8)D]J:$WE34L,.Z5I++6A;3*1VHJ1F;!E_:AM(4SL/X2:"
M.AB"VC+6RC:!H PB*"*HE*"VC,^RL7?([O.(#\XMD"NNF#SB'*]_)W/-9D^4
M\7VN"F>BLJ2[5.N0S+918DP%M3IQ\\^U=D&=MZX3,5$ 4GJCS)7RV\0%<KI<
MWRE95Z" WZVS2T.ON:IR,PNG$RF5(J7=9-';F#30TNKNX$&4=KB49E2*%B[=
MS,J4ZVL 3\1V+,1F;A=.9\J8MT#D1.24D--V 7BFC#WAM]:R=DY/IY "<1V$
M8RP$OUD&\HG$%'9VDH%LREBXK-/2C:US?B@4M9%DLY,,9%,6);FT#D4P'R?9
M;)=':,H&EOD@3#E*XK"VE>0Q]Z$VIRX11[.(8UNY' L$U>;^:(B3XZ!"L&IM
MY(?C/=E"8?4OT/$ A;HC?<8ZN[3LEFTIK]&FLM+F[<F<1.Q+[+L#]MV17FF?
M7=IRR]9KMLP1^Q+[$OM.V7=+(5W!]"KC55K!$X\2CYXFCZK;Y3*9B@),NGW!
M=V)28E)BTJ5,NET^@JFHP*2=XSA)N;'L@N?NY?I!IX.>;3J,7<V23W PUBRS
M_.\DBKW^2]W[7Z8U^=GE&^6M],7O#2<NML,>,&G@17$0\BI]2:1OX(L&S8'_
M$&#8;QS"ZWC4K>0\A"SIDMT/@Y'4G43P!M"&Q+.N@Q',Z$4:.)'$GCWLL!V$
M$BP3B^#WEO0T\'H#:1P"084P,\G+#R2Y^:^1] @O\(8.# NN#=Q)+Y9P(GQ0
M>.4=\V&TUT[(I/M@.!$C3H?2G@OTG6FY76G/=LZ@Q8VR/[/@(73&L%2P44+#
MA DN=")O$.6M1Q[1@IT!3P)$ '7!SCEQ''K="=)('/!M[0'/Q^&+A'';2'W\
MPV'0$VUJ@[ZX"*80P%Y*L?,3B7,<(/5%N2L2DHF0]#P_H3G\ H;]Z/62UX?,
M!ZQ@;EO*K3?<"BP0O[2D\=#QXQ:G./;GQ!LCS5<9]GCP$G&>FA^_PTT';6EV
M/ROUA;_O#9@[&;+O_3L&K#)AO"?\Q^>8A< 7U\D"15>^^Q58^"MPGRL,%A]>
MIG-UAE<A<Z(?B&<_V'SG>%/1BCK''Q[-_8 E[P?#8?#$D8QG7L.9%7$(\S."
M!#:3^AX>8-(+<\*(M\P5G5\%$6 '2O';:AII\8<ZL<3;QXIS+FW!RZ_,?Y[T
MEN5OGT7 E*: :-Q@Y/6\(6LE'WHPW"<O'D@1K*[7AYT$R@2*P:Z="7J+,3E#
M0'2>P9'=^$ZJ&4:25/;DX!;'+VSMT!E'[%WZRWO7BV"M7MYY/M\@?M/[V1<6
MI&_P%XJOWZ<-S>6V+(28Q&N5O'EU'W3-:G>.O,^[JJWN\TZ#:O3V&;*^\E$E
MV[$?58_Z3%K8MO6V?9CSOUU_SE1IB=R(D-ER,W\#4AL\=8A'V=L2NW]4?:ZI
MH_H&BT8=U3=8-'5;8#W&=>'BN91*[$16FRU?HMA4.9^.(M?C"V:E^^[N>BT>
MF>W]E'M-6FM*QR:V'33M7 >HVO?B_P*U/S7O?'Q&TRDLS!6W?S'WA_-<:(+'
M7 :EKD2&1KC!J*LK<5HE3EM3*[ N3C/.+NV=5[8A1B-&:RRCK:F46!>CF7"D
MR5N'0!.G$:<U:.+5.&U-]%1J/+Q%T^&5[WY,[8;?6%S(4IU:>JH22Q%+-6CB
MU5AJ3:Q399;BW<_K:I"V^]"F.$P'D:RAJ#M89\D7NI_NKWK_*9@-__!YJ-Q]
M[&S:I.LTTJ^5=:78-U(P*B9Q*38O#F*8=4E+#1"(B,9R-+9&M'X-&E-E*D!S
MU#2V1M9\%1I3.(TI&M6Q.48:ZUAK2A"LUF>J$I-Z=JFW#)OPZCAI:4T^?+VT
MI"$MR593:.D4.@3?L2C&8/.G(!PNA"^4XH2"21\E)ZPI'?<J)S>Z](V6:=65
M_=J _%6BL2F-V6LJT+T*C1E 8WJK8U#CZN.DL34U,EZ%QDR.8[I![6J/D\;6
M1+C5*S5VL &(:A%>'2<MK8GAJI>6+-Y,1JZK(0.5R5]/#:(_\ER^:DMBZ4$C
M+8FMKJ*F;^?7/W0.:H#O1+7/+C6UI1JG$KQ%U%F6.AO@==%DH$ZEI:@[[W=*
MU'E@U-D ?XVF<.HTK+K\-42=QT*=K^GIT=2S2Z-E=0@CB0IGJ? U?42:AE2H
M'0864IL%JD])]2GW4.CY5<0RG:NTFGD<52ZI%"VQ>B-9?5V]Z%?A=8.K8*I:
M<Y=QXG7B=>+U\F6G7X773<[K9FT.1>)UXG7B]<J=TNHU&W3.+C'DG=JG$4\3
M3^^M?5J]/&VA*= PCZ,53$&7B2TZ&#2G#ONW0(I@78:Y OXA2PJQ8]5\6!!)
MD24@"RQJF!;+3PJB_^472U4Z[[$LNL^7V\%[IM7;/7]Y\?8@Y+7;"[I"(,UZ
M_H273)]9U63@.AI:QX'H?/$.HT]B[Y%-2Y'_G]F:^,DFR--;G&Z$W2F6W[)0
MRG%/FZ/(ZMSRY'[B>)'7/,?L]GNFP1S'-/2>QKI]P]:ZCM/5F6Z:EO$_*K8G
M3>X:9-4$QLX#.^^&S/EY[O1ACN^<X9/S$B&QYRD9B#9==U78N.=7;>G:]/N;
MK$V9=BF"?P!\ E%9_]T$FT;@53 DIRE#D08AXNXOZW<(Q!_>\ 'Y"S4G[(+P
MMPOGLFCWF]\HY4O,1I+=EJX'CO\@8 !K9-]X4:Y-#6^5<-7C(64.?@!G5_(G
M1I7A#9\\W_%['L 'W-H;!M$D9!OW2=@;OL:2,QX/X5"!_6TO#K\D"V-;M09.
M>A4!7+4Y+8<@"O/M!.FBQUS8PZBYFU@\GRGYU3ZCYD@"WR>A! ^!4T'4L><,
MREOF."@3>>.L74X 5UX//-:7/CZSW@1/7^E[O^_U0%; 91'?3;DW^:XEVD\]
M.L,)EQ/PV:S?9SU\ ':(2J4+EV$+%='J*NU\E;[7G6Y%+[\5XVPKI#?P%I?U
M88(N0L_=!'!5T9QSQ7C#WDH<GOEK[F'L(4@$<,O'YQ['*D @+N,HM@:""CP'
MQ&.XWI7>X WYJ]Z^Y:_M32&N2"[R?-'[)QVKD*?ZV<J J!6$'.]6#+J?'_3,
M&'"$R9HQ7*RDSQ+L?X JZ"/V49*Z+_"I%R7O:DL?>#NDR9@W1'+B=$-@C5MB
M#M5W%C;VD>\'[QKF\N>V*@W.\4'@2]>C5<].)V^<6[$P1W0%<-QL(/H]X\^,
MQ*[$RMWQE<-#]$M*<PE42=^1YJ9[=I?2W!%@UG0])$[A$5!UY*$@A:V;6(3Z
MFA<-4H%BY !#PO_XWR[[$W&H H_.M8.:)[\9$)EEX+=M*3=4>!$V0H.[8,6F
M[)=QRSPFEA_A3*NS?@CH]12$/W%PZ6;O:)?X$]]Y,1!%K\2^+= H)V?E/2?>
MAY ?#Y^RX;]1945[N^,9K!PO4%<T2>&*$\#(BV/&Y?5[I+D@Q.7_'CXXOO?O
MI%5CLIT_0,5R0;,2=XF.>&^NO]]_?YMB,=\O+YI!XM$,N>1P=<MSY@F/X)3
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M$C&/&^G2%>7C76VX30RB^LP"8Y,1&#36QX9A)XK*TR"8;OAL+GBR8<"!.A]
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M,IL'0CB?R_2X_A  -8$\BQ3.J]4*46OJY<U,H/-!ERUAGDU\F,XR>^FOH(,
M<'/*O&?C. DLL&U#E.)./\'UV+S4K+I1I=F]EIZ#<W-&;P1I+3J@CAUK2]O,
MEC-*JDEW7Z1D]EF%M7PK(ZQ;4U3$#;FX0A&W7$^: >/%JZ)2Q><RNL]O1RLM
M-U=7^;K%!TY?QBL-3T3++;SG"L#C)?(6[BFFG%9AM;W<TZ?F"5&K:^8&T59J
M=<4Z+D#-[U#MQ23+,KUY<$P/BFGF=/[^Y">2)>J:2=7_#T#9 *?<],*_3W U
MLS7AGW=)^?X<S<,E,18G;X3_::5^LAX;U#UA [\LMRVY+DH9@Z.4S\\[>/M,
MW<@Y!BWSK(6]3FAANMM%#%W,^M,BG;":\<OL=[=#Q\^/H ELOR/=H&V4(L(M
M0,<^.-#1VAF\W,W6\LMAR8\0WN/T<J4CL]/P2]:^\&C*WJX&(*W1PDE^.ZJ6
MUTUW&VM1O\SLN6B?QNN3)D=)$U!B<S[5U(/C4YUKSSXV+A]*5].NH)_2\K%I
M$.I),*'>1":L4IXZQY-7V"HVJ8OMGXN_<%<;RF(G'0=BU-)N0S.HW<:I1X\T
MH-W&OS8_/ZT5YV<33DNCG586%X=C0=]KZ;XW8"X61T^7X75+%MMVVS+-JA6+
MM;:EV;64]+6UMFVNKB=\1"5]WSAO*Y2U/809*87=W#.J+LJMGCN[-<ZDM13X
MS2X[!)*Q2F73"D%HAT33,/N;J."24(_TY4M;^I<SG @!/'%.#V%@O'&V4#^F
M[5UR'0^C54WG\Q]:_$--F!/R7]@M$:4S=]CN@8YG$Z!+-2^)POA=NHC?^]D*
M7OGN=/W2Y9LV#OP!3_HP#'H_<^U+]#.)P:J.D3RPL<F>)>+BT_;WCS<_[KY_
M^W(MW7Z]EJZ^W4CW?WRX_W+SY>KNR\?[,O;FO0[__OH?'V_^^/H1R%W0,FA;
M_[KZ^L?5CR_?O_'I_/./JZ]?/OWWEV^?I:OKZ^]_?/O1_%F] <40'CM$R\W;
M_0@W&_9C4*TVQZ$:Q!NT]M;T*)4&18,J.:B2\D_5XVB#R^RF-:"8%[N6])](
MPOFB"I+7833@*#?_&Q =>CM:@*I2^C&MZP=GR(VU3LS;"'_(0JR#/O_@DQ!A
M_QM$V/H6?FE7!7EU8X7F+=_U (0 [-L>\+R84OUQ2LW^%%=0>-)2-8#(;7&Q
MQ K!DOFX9&]N6->+WTK7(7/G"AR?'(!QL')BZ2-/]%\)7<=5XG*)N( M\CBP
MHZ//#2;=N#\92DYJH4#C0H^3C02J=L1R?>XV*.RX*8.%..*#-&Z]?L,A6LJ=
M+.6VM4AIGVO;YV,R?I_DOM=4JE;"?SO"B=^,,[9X!3Y-K?MYX[XT'ZV9DDF5
M99"E9DD9Q2OP'UM-<4_D77)NB5_C4RAB_:2)[PFOQB1RS^;<'!W;/I-<UO-&
MSC#Z^]FYF;H])M'Y@^.,WTT='JE<%EWY[AWC^5%1(L("H\#<X2XSY^XPSBZ5
MCIEV:D]'LP2(-F&TTMNP>9'@_!E)3'"L3&#)\C9,(.P [H_@.HAB^/SC,\;B
M%S.%>79IR\03Q!.GPA/<[I,:QLXD$0+\]S/O.7[7]YZ9>_YO%@:%K-)!28U'
M(Q"_$+_L8VYO7I%AIEZB0F:PX-S0%OA@(0*NH2QP"(1<$$](W'I(W%J-695=
MJ3TVJCV+K+J?(ZLFA\'!VS62T,2EYB^UVI(4,ONA<X2Z(XXPY+-+5=M:Z5E!
MF;LXP<H8RXEJ+%E[)<W94,XNMX=5(J(C)J*-54U#K4W5) )KIFZV%86MULT,
M#20^M;.%<K9?HCD$O655LM=QTG<SG#B&7HL3IR8")R^MT&:2?*J-.**LZ>*P
M.<*2]5UQA ':C*XT1+^OLW<J48TE&Z^ES9AGEX9%1$1$M -MYA@=9T=.8!6U
MF:TH;(TV8YU=FC9YFAJHS!PN>3?$$&W78HBNUS63OB==+WU%Z8.=A733_71_
ME732 X/A97FY?19B#<+8>98>IY514E1Y)VT4+5]&B*'[3^]^<L5OEF)0UH3;
MN!4H'VM3-,5C$NC,6@2ZO ;L3T;G;L"K0N)CBZ0]4SZ[5)26IFQMJVN.3X^8
MY'B9I+,3TV-5IE& :5H&^A:(9XAG3H-GYBRM!5RAGET>>.C1(=#UF^Y6(1/$
MO/N>6T4K]E;<N]J*;6),CKSH8*.8G!IWNT?L>M#L6HU;K;TH<1A_I+743E.4
MN&T-HXTQ1]5GV#UTPEYR#(W<^-W]Q^NT]+.BRO9J&L_J7 K!\D=PY6+I;ZSA
M7GQ&&6>7AFXL$'8=5N=#@-8W[-3<H/7(1Y4),ZE3.*?H?&-Q(56:9Y>+VC^Y
M_VND K=,XXK&GP3DV* <P\IG;3UQZE6%R,[9I=DRK ,WX9Q0<D\EHE)V4[RG
M*I%99Y=ZJ]-9#)TC(B,B*V]JML\NM0.GH8,0PA9MS4=.[M64C^WH?;5QMB/#
M>;Q-,1LB[PULLT=.W@<0D=)1&A:1<F+YE%N40&ZJ[DU6X!W+=[LUMG540(33
M-0"O,(21 7A;&6R-]Z&CG5UN5;2"#+W;.#C(T+JYH76;\@<G(N J]90WK"K@
MZF>71LLZINA1(JH<46V5F%FA.D+'.+NT+)VHZ$"HJ*)8LT!&$<P ?MN53;5C
M@I2]34H[V9MV)<J?+LW7:$[M8*PKV5/)GGIB?OV.U2R_/M?/+F*G.V3PK^L]
M7OZ-_^"?9&\77=3@S4-G'+%WZ2_O72\:#YV7=Y[/-X/?]'X$9YSGGXMWO$.-
M;>[M?'3BZ_>B;[FMM&73Q!U,5,7DQ:L;H1MM35=K::ENJVW=L*JW5#<S-EH!
M#&C2\/HO"ZL0C.MF$[ML*1?I-@0"!<7T!;DB\J(XDH(^\ ON+ -ZQ,W/NI<^
MA5X<,Q^NZ+>D(8LB*62] *;CL:B]OB7=82Y2]ZT$2(&+$4D@K$G>: R,*O7#
M8 0K\^?$BT3@[-$N0"]/)6&Z%#TG#%]P[R4GCD.O.XF9-(F]H??OI!*%[TKL
M>>R%_,^C71RW<'&03@"4^>_ 3KU)&#*_]R+UAR *B</D>.F%+5T2P3J1X!TL
M7 +$P:2>:*M=L!ZSQU%R3GZ;C&!</7X\\=/4<\QNOV<:S'%,0^]IK-LW;*WK
M.%V=Z:9I&?^CZLI9[E!+%P0FV#N'A<2#]UTT&<&07^8.+>S)F7R"K4,M4=_H
M=8]$HVT*H:;*D:C#.5K\3=4C4>FT+;-#CRK[J,YJ262-'7RE 48QM@"$O0KD
M(#I+ 9HZ0!(6SLA(<D(F!2.4*%RIRWK.)&*($B_\"S^()6<\'L($D-F"D -(
MR."\Q:I'GB_$;3QIO$B*!L$3_.+SB_J>#Q*YYPQADH OW(F$#X!',HY#(8N#
M0O1-5R49NK:BFEE)9_1!7;9!4;=F#'PGR[!##FU<-3&U+7U\'GA=+X[6G<)[
M4 IAC&VY^A&HM2U-JP76K;8M5SM,EWT.ZB6JMW6,26EK\MJ7%]!ONBL@2K%M
MR7WQL@)J[P$ L_ 5Y-.2Q)Y0NO1M[A#8U?Q?3T O73LPZH7>& _/$@MP0O12
M++MH;>55Z*3H5!"SSNDLBW2U?%7Z_9VMBABWRWJ!T._?37PX _ J&(Y3J& Q
MP7;O]SY :1"BY7<0Q^-W%Q=/3T]M&&;[(7B\N I[ ^^111?,?7#""]>)G0O%
M5#1%UBY@N(IB:XIJ*(:LRJ:E7+B68<-_+GO6E/8@AL/[&G>O#_L':BWH_5]\
M>/TX&0%^\#MSXS#PO9XT'O:D-U[V/8K 7%EF:"@ .3A(#V0)R __G+F55TCO
MO(^D:VY9B*4[!H^))7C+)Y"+)>O\MQ;(P4-X+'STJ^-/0+65U [&GBA&2_H$
M7R'^23"I<\VT5/DM8*$S#=X3"G=E4#@2 9H@K[T\0(D@[]@AS]3-CIP'O(ZL
MR;:E7;B:9G44&0%/%8!W-1+!;6CMO6-<WW8!JD8P!-^=C/CG5[B]J/ # %Y%
M40"J^79XJ"['PSOVX$5Q KCWJ?J?X>+]N9;#Q4^L&W)@Y%5=E4X.%S5-.U<5
MP[(- D8"QBDPZB0+$C#"?[8A*UI'M@$C356[Z.FV)9OL^5%_2B1!#C=<!'2!
MA"<AD[HL?F+,GP)7"^7#-H?(_V+#821]<L*'0/K@^#];TC<^4F<X@Y@A@Z$@
MR0!<R3:Z86$YX*]RP*G/"9+B_9M!Y^\.+(_$8YEE>PXW%:,#_Q%N$F[F<9,$
M2L+-&=SLF,I%SX!?M!G<],(HENXGX_&0XP\@8 :A+<D5\B4''T5-T:<&9$4$
M'4XXM*(+"1&/RZO?ICZCH/^V'J MI;//SW%&8Y<['9D E@!V!F"7UVXB@#TM
M@%4U>#BH[3((IH9I6TH>8._A;8"+I1!6Z,7R42-L-D="V.H(N^ :GINLKHI,
MS7$@@B3?A6P(Y/#(II[=_S,+'8E?6)[>XG2C8#B)E]]2&,:U -6OC\LJ#E21
MS3D"ROT<A--->&#GW9 Y/\^=/HSVG3-\<EXB7.C<3$>>?SZWLE46I6X07AL/
MJ.X7@[<<7P+!OZR/+^R<7?X084I]Z1J3"WR,HUB #HJ?H/B)HQ U%_J?D:AY
MNJ*F J*FI9@7/5,S9"LO:OX8>&%)2=/@4IARL))F6%K25$C2)%U^'< :!+ $
ML*GW7064U>7.A:LIEJ6K+GO6U=3)- GC03F$Y;X:M"<V#V'5FG1Y54[G2 A+
M"+L:84U"6$+8%&'AAREWE L7!%BSTT&$S=Q1_9( *UI#*UH3 ;8N8^ETC@2P
M!+"K ;9# $L FP(LB*^JJ6@7KFGIFF+G1-A[[WDMP&9QFDD N[XKC$6(_3P,
MNG E(NT^)-F"N1+6$M:NQEJ+L/9DL;8X/TFQM [/3]+,3AYMV2,0[SJ\=;BL
MF64-F6G6$. >XJLS"@ S9^+O6_.@E_L@1=1_!$.DK$BZ;U^WKRI#=77X+9DH
MI:@?*%>*X'<+^+4)?D\6?A=%75VS9=T"\-4,4[=SMH0%G+UA/3;JLE!2Y)KE
MVAT:!1*H?/+@&$&Y^3H8C;PHX@E=?M&42'PE_%R34B43@!* K@!0M7QNP.XP
M-;$5I':"3\, OH,/[C#9_Y[Y7A F]EEWPK#' \:4)A<K;0/6K.@JQ9I>I2Z]
M*O\LK0T"?O%5:OZJI<\RIE?I;:UC%%ZE&7Q]IA>::O&%NE'%/)+/^:4CAXZ<
MO1TYE,9[ND=..9.)5B%?HKK%9!<2O4;F#\+2/6 II?82EJ[&4KU\0'!%*'T]
MX[).Z$KHN@=TI;S>(T77: /KB*K)IBP;]H6KZ[9F8RDNW2X1#%Q@ZTV5^24(
MG 4B2"HO0J!JK77@VTK0=\$;R.%X4?P%/7X\ 7:+!ECQ^T<(),4_<_P7P&J$
M\3<PEFC2ZS' ZQ#G4(#I<-W;%@XZQ@<P5A+0 ='MFNJ(B> X3:S26X)O@N\<
M?%.NW G#]Z)TK.H*@+BF@W2L*(JFE8PUKH[?OTY\)B6@I"] ]V*4QFP4QQ*Y
MNK4>L_-0W.(P_W'H/")P9FT9[EGXZ &F2S=7URWIC]^D#R%\,]C0<SF#VT75
M;W$ADG4@<"9PSH,SY=D=*3B7P6;-,A2KD\-FN:.JJM4Q+C@H.TNB-@2\?N_%
M 3J=A' L=^8,%-?!H^=ZS >8!9KW4[N#P$ &:"JP-+GH:^P*&?F&36)LD,-E
MVUETE:YXVRMX>VF8Q/Y^\$GVFG(FBRER+LYQUERAJ89-Y@J"U!E(I<0Z@M1E
MD,HJI"T?$,PR@EF"V5>&64JO(YC-P:P-/SJR>5$Q=3EG*M"S:KK; 6QK!@AW
M +<;8*VB?M;F# )&86%=PEK"VD6LI?0ZPMI<?(.LZ)8N&WFL+9/%G,-:U4J+
MSAX3RLXA['22!+$$L6L@EE+H"&+S)<]40S,Z(,YJAJT;:AYI*V0P_^Z\2%I6
M$^PXH79VCH2TA+2KD5:E7#M"VGSI,U75-=.^< U=5COY<(2/^/[R0*MDM<&.
M%VB5XOIGM0$MM5-8P0A).X7.W!)3.P5JIT#M%(ZNG0))G$<C<5*J[0E+G*72
MPPPA<7[S=ER;;$54:RH53KI#N&[HC3Q\6R^-;&U"H(%!"6B$WWO ;TKO)?S.
MX7='MFW+,B]<U98-RYZQS:Y*2$A*B NOT'P@5V7$7LAD6)+QR[/(R@#L7WY1
M3/G]RN2"*I72LVD2P!+ K@%8RO E@%T-L!4*H!T4V&Y4L)? EL!V<["E?%P"
MVQS8VK)IJK9QX784N6/H,])LZ<)? H:$3CT?0;L]V!8#[2YR:^N5@;/U(%0F
M5%Z#RI2(>Z2HO%F5!,56K$['[@ LFZJE63E8KE!#;#)\D=04A,H5#BM1NF8%
M(%<I?+!%M8._ED#AV<D7(' >@/?!]&U"?T+_!/TI9_B$T1]1?[%,CJP:'4M1
M+ES%-BTEG]96/GGXGHUC41I<Y=V/5;EYQP"_?.R\P,LEYP$Q?:XO73_M_8E_
M8($Q47V]E?YMS/UMS?ZMJ;-_ZW)2O1U')CXRDH\V[2=:]D@JVHXF'DP2G4QT
M,B4G$Z59G\C)Y#W_7S?H_;W"":6J.AQ0ZH6KRZ:EV:[ULVK>=0X0E5;2OZ/&
M\ZE<J;82Y35W?:2M.\*4A2-+T[<_LBI%?Q=M%9FUZ/A8<WQ0YOB)'!\EBW\6
M5&^NT =[KC!SZ;K,50Z-4G69-SDXZFCBNGE5YAQ::YIVKG9DM:,27!-<S\ U
M9:&?"%Q7E_8UV3),':5]6S9D+9/VJ^6C<T22#PZV5\CNUJ)LKE65S3>* EH
M>GD!Z4DN)Z O /I?]+9&6?!'B/0C-S['*N^*_/,9&_C) J)O6-0+O3$7&@&X
M,BG2C_\*&,MZD]"+/1;MW>Y,^$3X)'+<VY0R>83PM'F0HJ7IEF7)%Z[9437%
M=-FS(B?NT"L0.5V4,$'^NF-1S$6MZY"Y(%E=/82,BZ2S8NBT8;*(#['*-M=K
M2??75RVI!Q3C>+#_DV[DN9X3 GA*OC-B7 (,F><7!#%.'WK[]5I8=H<X\C"2
M^F$PDF+8"10#^;]C)XQ?Q,/B0 BW/($2!I]D32;!YC"A*W?D^5.KP%5F<%XO
M>2*C;1GI.%U++5U+$C\)WM? .V54'BF\5S4+BU]507.=BV1* .Z.@'5 OI#E
M@)Z;.Q%;%.&&>XZ9'PG82Z">8RB :PWGPN9!DX5P_S6!^QEP7X[MK7EP?V2[
M!W=%/O]G#MVGIG9K1< *H3NA>Q[=*9US9ED4H^'HOGJ -:&[8D[175: 9$?#
MP/&=AS"):H</I*_PR3)PYN7GU"VC&"OB\N_>OR>#U##\]<?-?C!Y/K4HOPZ$
MQH3&:]"8\CU/1-;>(()/T0R YPM7TSN69F8^O5)@K*9A8.5L)V4@.?/DS0(O
M+XT*+W9F@5>$UO%71XDMY75A6*5 .$+ADBA,^9U'BL)UU0#,#-H<;+@U I&F
MSV,I1K[7ARWE!M[=0AR5RZL?ZJBJ]0I&2ZI:6W,$1%6MJ:HU5;4^NJK6)R7S
M458WR7QK9#YU5N:;E_6F7JW24M]&L:0D]9&"NPW8_2<0'F4*$]K-HIULVC*B
M'?Q?HN'J NZN!X[_D,F!88#IL["GO)+\[1"VZ1S#4CD"*N8'Z7L? !$]-&_0
M")CSZX>I7[^X*'[9 'S4E?4M[8&$F829U3&3TF,),W.8:1H=4]/,"U>Q=,LR
M\E;!KRP&ZLT)A(G7I<OB)\;\PA2IWQS +>G6"7\.O.$P<>!DC@O%W-24V-K,
M7:*+MQ(R$C*N1T;*1#U29-S":YV$$_%X(MV\2+*=5+FCVIN#Y)='V,C?V@!:
M_D,"D=^"QR0.5)3I4NH!RG^"@ C#&[ZL";J<EEI)*JT0.A(ZSJ*C0NF;)P*/
MY4(L%1L';Y@7 5>5@WYOX'@A#!@0#NX7Z"C4:*YU)]^*K/F!Q_J 8:PWX6$U
MB;8M+8!I'8[GLAB8A>)KKUQ#W2!8/&!8I+31(X7%S5#1X$1GH:0(('2.=KD_
MM6?N=S%F'2\ >CG(RS*-RGM=5O2F7(EY6$^$1Z'_*:Z2A'4S,R=JJ3FQ(">'
M3(V$C>6QD7(N3Q<;3=WLR!<<#.V.(BNRA2IT!Y Q12SXQ-;4_T%L/-<$-BJV
M;4G?)W'DN4RZ\4+6BP&K[N.@]Y.756)^)+S4W&6SU#?# %I[(F![QDO#E5O9
MJN"DT>:4:]3AZT%90XQEBK(+9?3T](H9K)4[';E#6$M8.X>UE %YNEB[)/+'
MECLSOG!U/JL]R5NOB+H[#0LB_S8!X79 2,F'IPN$U83.)#0(A"Q-^AKX#^<\
M"1%$/"!K%![+"IF;BY?ZSL1+:UZ\)*&2L+0REE(*X>EB:4FA4ELB5*Y!U<T4
M<!(B"?A>!?@HC^9T@2\3(A5%UDT#:\_+MJ48%XYLG.NZIO^/@L#G:K/^'*SX
M%GH]Q#.A.E\].:&;<V;S\>P&%^N7'(WBUN+R/("2Y$@ 6@2@E)I# +H.0.>J
M3WP+_'- KJ'7]S(,_3Z>2THL!:+]8!)*+\P))1A9#+13)2V'@)6 M<' 2OD[
M!*SK@%7=%;!ZHQ%S/8#0#8!5)6 E8&TPL%+Z#P%KYC<"8%5T6T:_D6RH'=,4
M'B-57J/S_^%[<;1;S5^55P'IE0^@."Q T=\R%.6"L8#0JW'H#2757@#07R<^
MRWU. $H N@Y 54H0(@!="Z!S.O\M"[&[)2_#<<][:.X6.U=J]X2=A)U[PD[*
M(B+LS+#3!*305#,7M&2JNB9'2H*AVH[4^UQ$$X<P7K-#KE"S0UWIE=H(7H5N
M;R[ :_8YP2O!ZUIXI40D@M?2\*KOP*^_/;2N#!4E:"5HW1.T4MX106MI:#5*
MF$_WA*\&X2OA:P/QE=*9"%]+XZNYW+JZ'U0U"54/ 56I7= *CD[:!=ES!$3M
M@JA=$+4+HG9!ARU>4H8GB9>9>-F19=6PU)QXV='MCCE3HNE(TIV^]^( BWV*
MQAURIZ@0J)Y^12(E*>IKD9121@E)RR'I.@?3QE;0_=4=(3@E.*T73BF!E. T
M7\9)T>P\G%JJ*>NIW5.S=Y;P5%8^M6LW="X4"$T,G53!B6"T/(Q2NBC!:%D8
MU<MD-^U8,*T_N8EPE'!T>QRE[%#"T=(XJNP?1^M/="(<)1S=&D<U2A(E'"U7
MG3F)%?T2A0X;>KD.2?46&%T9]UEOAP\JP4R 61DP*3.4 #,#3!O=2FH>,&W#
ME+4D^C,K9V_-N.1YR^'*1>VO)@^PQTG=9-G>9Z&GU+FDR6(L1<XE._V*0)5
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M1P'0(6 5"[,A<[$<0'IQ2W+YYTZ$N5<9="D"NY060BH^P!D%_D,./S\/@RY
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M( 3-(F912_H211/L\("1P9\G#N82!V%$B@:A1 XE*"OL^%$BJ71X'?@1VBH
M*+[ '6.,(^6FBP> #Q8R5[J==$'/P-8&P<3G10P^>>&($(,0(X<8E-1T_(B1
M5/6[#9Y8R,/=8Q =?/9"4$!0,(4"36F3$>+HP4!3$BO$-6Y '[: NYVQI/S
M8WWIXS/K3;AC^7L?O@7 &$_":.*(%,5[;%($EVNRFE8UNG?"KN.SZ/S[\Y"]
M@+3!11)5EE6"%X*7&7@A&\8)P(NZ$EX^>;[C]SQG2/!"\%(KO*@DO9P O*AU
M2"^V;!*\$+Q4A!>27DX 7NJ07@A>"%XJPHM-V:A'#RYVIRA$3,2"89RI] ,
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M\[\&*=TVVI!/4;,VI'0;MJ%V3C;)@HI2_!UNVHQL@ALW(Z$T:D;]@J&)14H
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MMUY4@FG(Q"97Q?0V9)*&K$)C@US6^U[E+FSCX)'73#R"&-'+0J/%QM+#UEH
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MDWJJ;!I .,V(\^S3HEM-_[N?EC=D9Y*)_W$:9UBWU]5R$DT24@8$Z:4 Q=&
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MSG."C$DW/V3<_L#CN''),7&JN4P/=X3Y:YC56B3O3[#>"=SOP/+Z9S4_GGP
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MV>YMD ^0Z11+5BEX 8['FG$5%1EXV8'5D>>LO>2V=<K;8YE.8\L*&IQCMQJ
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M=#F=([GOZYH/O?36O\D3)U'+K K4CJ3$'!'!F>(AF&B=R4[XV/I4>AM\6[H
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MTFWSP_]E-NT]A7I0 O978)[-\V_T:9?M(G$YX5FYP+V!H MY8+ZF,C/MP(3
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M]. ]CH>3[LUDAE/!N/_Y'(D!O<"EG"LZ)#)T)+G-I,X6(D,.UBINI%1:>_6
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M;,WJK3&.A]5]A+>"U5:!J M0RP6$8S',&0G<.$$;O-807,Y0=$#DB2>5=CE
MT,>XZNXDM!79%3L'GVHJ[_*&UP?Z[,!+:1)J!C'1RE_S>B%Z7Z?'>$852;7N
MRVU\.+']^FB'X[*G#/>=1=<PE^TZCA?C\7D8O<./DVXVT(PQEY(&H6KHJY"1
M'1VG+4!H5\,G.L4V5%X?]6@HW5F4#3/:KN,A+VHXR:_&^><P0UJ DK>B+O7"
MINH\.XA&&3+5F-68BZ.UI0FW-X8]&G)W%V;#U+8;"T@7QM.Y+!<:ASYQS"Y
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M_,(%3F>7RY:R*6@/$N<-6X2#P%1MVVX%S3ZH<&_H?Q?EN _/,9A_S>3=@[%
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M16N.82!1ILR"L+0H;4#CFL<? Y,M)-?P/+U"^AWS,(71^_/NI/YWF>YA<RU
MZR$+,AR5B@IBO:CG<^ 8-3-9E0VH7/GP8R!R?ZDU+%13 ?T\I.]G.+VN5=X6
M[[-B0+,D1]**!,XP"_/H4W0:F=[D?5SQZ&.@<%^)]5 KYL5H-"]I<VN&@86L
M; F@M29;CF94[U4I$"Y8:6)B],O&YNUJ),_1&FHHVS[\F/,XO6ZV!^2JW@L#
M3!II!<D2/"?=1B,\(X31A^:>S$T(QQ?"V$/$/52/NP9GH=6; .HK<'$;S",%
M+_:A:#W=>\BWWU=] <PKQF1(''+.M:Y=('-!*@XQ.1^DEBDU#_@?B/"'0A>]
M\KV-6!M[1G-/+:1WIU]FIV=AG/\=0S?[)0Q'YQTNSY@6&X\J11=5$N14RT(Y
M@>"%]\!H$\O,DU&C^0;&V>8C/L+FO1\UMSW@]G)M'-MX/^O.T^R\"Z,YOGHN
M7&];IUL(R2054L0 4A$X)40 %W($:Y.*'HN7MTNGKV1^L]&>,^L]R+/U^S[I
M)N/0?2%HM6##Q].:#_#W1:#F%DS'$SJA,AFOY%$HJVK[)R^!"VN5#MG;VY>L
M5[_PFP_YG+GO2[*-HR<ONS >SE- WG\<CL/H Z;3\60T.:EW_F^BQ)P8<YX<
M4^^JG\II85)" P;#1!"U/ C;A/^-1WS6]/<CU\9!E_<?,1'*V9</53T_WL46
MI?;>L=K2AQ I<BDAR,0@<UZ80N%8EILL]0^,\YR9;BK#AC&9RW#MV237;BTU
M.^@F,(:!<^,9^"P3*%,OQP5N 6-QID8C5,D;D'OO(,^9V7;2:UA\=ZYRBZCM
MZ_%X\FF.[;;.*>.3D^2!*%5HRE%ZTCEO:Z-N94D9K4X;F6@/#?2<Z6TKQ89%
M;RNX%^E\AN0UX.\3DNBDNW:9)7LM; Z0'<U9Q9#)6L0"OC 7R$G@26]R:KQV
M@.=,:1NI]5!7]H&DWLN+!_5: /T_U[KO)FN'C$L0+M>[4)D@>ZRIOIYG+F40
MIG5.] XP#Z\NO>8?]DW46H_]P&G2OX?NGSC[%2<G9+.<?BF3[E5(I\O3BOXR
MIC<:]R#)T]M+X%!YU(4%Z4((D P/9##*>M-=TF)HO(@RV&1TZ]YCCYI'G7W,
M5M=3,>X<K<WHP8=$7E#.*;# L[.M+Q4]BSSJ;?1@JSSJ;03^//*HA<K*!2=!
M,5M+LS@!/KI(5H..2@E5@FI^?^C9Y5%O1?M6>=3;B+_W9-I-P'RM>=1;$75O
M5NTN4NZ=>L]LM#)[X$S5[J5.DX8;#MIXEPH/D3<O6O[4\ZC;,;Z-< ^:1RVL
M\DIP#EYQ E84>8NN%."\9,2":#$\]SSJK82_<1[U-I([1!YUT5$8XP+(6!LC
M"BTAT$_ ^N0S)\:"LALP^=3SJ+<2^T-YU-O([%!YU-S8F). I ,YQ*'4;"<3
MP!B56;$YQ(UH? 9YU+LRV4)R!\FC3L8$&8HFIR/%VNVKQKLC:5<69#I&CDEL
MDH+[Y/.H=R5R?ZD=((\Z2V&+(,/_HB>RTV3SVYIE4,.I)6@N^":G 4\\CWI7
M"O>5V"'SJ&4VHF0H4M;P8B%;3F,&G;,M,B?%<*-RN\\^CWH7:ZBA;!O7!+PT
MX)?!R+J2S(UWGY/.-D801=#>[FS-%P\&BB*-#LP[XUH4>ET+X&C"&.W$W+@:
MZ$(+KT-:ZO@&H!I6 UT+Y/#50!L1->E+RJU?_[7@R-Y3QF0-ADD-Y*T3.-J!
M0&C$'&66?K/U_FE1?T])T$,ROXUP&S(^+P?6?1G\[?V !6VLU 6LL@(4RQQH
M,?. O@1)%J+4Z;Z@]133#R>33S\NGGC!\.*;*X*OQCMLC<]&@I_L);7&,8O_
M%3Z&\8OS6B9K- QO\,__BV$4QOD_)AV&EV$<<J#O_H'3&7;C5^3A?5S6,-<8
MI%;% B9+<\[DGSNK$@AA&8],2W^[J^=*"WQG ,^9^\-)OG%XY/=ASB-\%::S
M%Z4C(?Q&ULSXQ1G6K^M/+Z$2]!?38;A,+IC/=CF[99@GT3H7/0%/.=9<I Q.
MU*N#R2CAN'<!-W+$&V)Z[DKU:/ST<"MOE[P5R16G)=-"++YV<O<(#DLD3S=%
MA9QL;+^1=_'5)1CM<S#?-U&'33!Z$[J+DI%[IPS=>5+#)*#[41XLK4=$94(R
MD'4FK4&5R645!82U)6E'>H.M;\$_:EJ/*%K4?#L(QI#6:D=?%26!2QVU$E(8
MW[K%X/-(Z]E"#[9*Z]E&X$\EK>>G:L8E?'^*./NM?KHR4AV^8B(W0CNPF.JF
M7J<5M09-CIYGPOF K3>G=5B>9!1L*[(G/0B]AV2.5;@6-MXFR'I*ZEF/ZG$R
M?-JPMX%*["'Z RM'0!_11'").7H7LB?[*'+@NBB'.4?3/.WGT$KQ0 [0P75B
M"XDW]JKGAS<O4J+-*2\*E2_/<"07Y&AQ"T;47"?M-%G,:"'3BHC%1<?%)E&6
M]2,<WA=IQ<&DN0![:&"R:)8P?8<)AY_J-K? Q2.IJ9,1K./5 3((0=(FRATS
MF;9!*6^'S_8_^%R#Y=FK0%-A][#.S]7SMV&(PQ$)]E(U161.),Q04'-"E3+$
M(&N+,,>S-]4S;EUK9C62HU& !H+N(9"U*BCR#LOY."^A?GEYWG7D>@Q*R=Q+
M[B#EA*!J;,23?H((S%B9YDUY&ZO$YNB>8MAJ#\>S)UIZV$16(;W$.!"665ES
MZX+!"LXQ"+3/0=0\\11""3P<0&<N 7T%:K*;\'O86>X%MQ #[8:3D_'POS$/
M/.>$DTDH1M?N-R0"'VJ%SD#+8T'!M,!#JLH=A%^3[NQ'3W\'+N^P"JZV]\*N
M3+JSNE&_C:/AA80&9E[84SCPJ>2%0<U4#=H(+[CA]L[5A%9'+/<#.S+5:4]&
MPZS<6R!78OL9IZD;?KP0S8?A&<UAH$LHJ9 -AK)6=L4DP<<LH%C&<LG*Q=B3
M[FP*\3BUJ!>"UB8)MSV6>Y'^ZWPXG3]G.F\+-OTX67S;X*ANFZ>W.+[;>3:-
MCO26%^JNX;BF:5$XEI0G-]G7/*3 (6 @_RLD3N1CX:EUI>/[\.Q]D3*=8CX?
MX=NR8I3I3U^N?7=Q ,&#CC1-#2'5MBQ(%ITCEY,DD3#J8DP,K<VC;3$>ZLBO
MF9[<N8#9)RE/Y@CP[M3FH6LM?&#.!1!:U="UJP6V1 (6?8DRTR+;O#?:&BB/
M=0#8+_VWH_T-:.CCV&<%K/IEA[B(@6T"L*^CP8? /=()80LJ-U"/_7EX%(5Q
M.4IA*K):6$QA*!"YLA!T8)(L.I_Y 7;N0RC*0Z>&CZ(GVXB_EXH1W1"G;\OK
M<1Y^&N9SVMF_O#X["S/Z>1BM6FB7F<0J"Y) !JMKPZI4$CAA!;D66D01HJ6E
MMK7!LR/61SBC:$O[G4(4!^"L\66!UV0L=5-,LU=O/BSK/&<O8\D:O-*,WBN&
M$'/Q$"W+7">GB][D'N[=)Q\+WPWDUCC;X$4IV(77X[2$(HW-DGQ^88I==,CR
MH@ Z+PW70DEC-J#PUF./B;]])-:XI,$BT^'.JF!$X88;!]YY3L:Q4Q=MF%AV
MD3LCM4YJ Q+7//Z8R&PAP1Y"J;]4D>)OPT^8:;D(XY,A>3\U8WY&7M'OX3\G
MW<M1F%X40(JL.N#D< 5+%HVR2% +.4;6D!9F5@QKOFUO >^K<"W[HJN'8YU[
MH%X!?1/.EB_6)G![<CZWA/HXKFAOU&^N8LUXZ\$9V1:VXMXG+B2P>J518:()
M"(7  H\*LS1%M$YY>1)J]H C^U2U;!NZ>M"NRZ8C7WX*TQ60%_TIF!2Z9%51
M(9 Y%LA 4PRT\IHIS35O7F=\(V"'MZ-ZI7?2-S=]Y%)=9GJ-R-=>!S(0",XD
M!QN0C,%"1D)49&':VKBJB.*Y;9XHLPFPXU:@]MSTL0)U(6.=\!(/4^3+.T-K
M;E)D/";&@;[':E5Z(W-))NG6B\TM#,>M%GM)O >#^O7XCVZ2R+]XAU.D)Y^^
M&.>?\1..)A_KX>'2GS3*V1H5$*5&>+S@X,C'!*FT4BBXT:QUKLM&P(Y;5]IS
MTX.O?Y'U$4;S\GSSV0_+\-H-)\88#[7JJ?#U,KZVN9;J0]!.>N0%BVVN.@]
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M;"U;K^SG I$9)EB,ANO6%[N>6@? PQ8 ;4'$707Q/39^VP39U]X5<"OV-N\
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M>Q+0T!:==F0=!S+&YNIO,;L4O0!IM*1=,M$NR9&#<%:0_65I^G$3+:"G7M,
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MZ/_\\44BIVPX^[(PVV:354D9C<\@MQNSKW/(/69^R+-(M 6#R6252S&O)A3
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MLJDE!D'X0A/3,H.WO);235$I8T64>I/5A9Y\;66A[ZY6E3N#'HG9M)\P&QY
MW "R[/&V 91M[)Q-^7T,\V1/(E;1N8<4&R[7JR )FV@/$Q9LJ.=M25OPP@A2
M7&^80Y99V.@:WE,@=,TNWA^?VPBO\;;[^^2_Z5G+@DDZFER;K!>A:Y-U8\#I
MFC"9!>J"+K <-MAKKS_S<!OLWH*=-)!*#[DURPOHK\=I<H:O/G\D-<4W.!LX
MTK!43P>%8!%4ILTA,*-(#Y-AEADI4^M@_3HL3ZX^P#[QJB8"[^/^PXU:+#4"
M_W9\;?(#(:S+*4A@ DE/%:E]S(41VEJ 503ZWT8VTS;7'NZ'=%1JT5+\?5Q;
M&(XGW=RHO]#>RZ7P#[)$"6!-D__R9C*N45&2Z*AZ'?./#)+3WBER'9BL!TS%
M"W"H+#B?JC]J?6E^_KTSV*/2J,-0UD=OB&6ZU=N/5?@O3\/X!*>OK]*PEF\(
MIQV8"6L3!Q:%!^6U@Q#(@]'&2.6]E#8V[S^X,;JCTJ:>2'G$4C;OS\_.0O=E
M4B["%6&<YS4?KTFN[8GNYN/U==2[XXR;GP%?#/\[SDXG>:6BJL(9.A:@Q%H,
M*9D,T9(I1.N.,ZS4H%1_9Z0/H6MW-KQFI(O@C%+(F;>VEANK/:-K\5*'"$)J
MGJ6U@KO6+;DV0W;X,^.F^K+^_+@9'4_E+'EM!6P7?$I6&K",UU*V3$)(F,!$
MBYQ6;LMMZSZ63[>-0#O:-VTIL(WX#UPU?@-D7WM+@:W8VZ)\_ ZB/ZQR))12
M:FF!9?(-R)(K$(,KD'R)1:'VZ%OORL^EI4!/.K&-Q'O0A;LUT$O*(A5O@=?.
MDRHE1H 4 Z:,=MD&ZUGK<GA/N\3\5@P]6&)^&_'V$ *\V FO,GI_^?1F.% Y
M,\=ENCBJ5<)S"&@5Q-K,UB)SKGFENE4X'M.9[M7^W%OHAU"$O[]Y72-%YUU'
M$Q]X5)(7Y< :'0F=$."28Z!9\"'X@CFT3LZY']'7HQR[$]'#_G ;W3^&)(3S
MV?_/WK<MMY4CV7Y1SN!^>72Y7'WJ1+7M<+E[XCPI<$G8G)9%#RFYR_/U)T&)
MDBR1%#<);%*4>V)<LB1S+V2N#60F\O(!0YZ<?_\5+W'V97*Q* FXK:#\,KTB
MX&A]O=0,H'U)H+2)Q'17>Q<@0^%,EJYUW&YGL"^&7'W4UR% O$8J9XHGPZ-&
M\-(Y4($+VC4S[9H1>;3*9WI9NK#J$903Y\Q^HF_8S.8NV^S'/7(':H>+O&YQ
M4GGCDQ2 4A'=D3MP&&F%T5O#G%0B/[C"VI DV!'HR;'N^-2[MI%.E_N*BT^O
M9K-ZT;( ^OKZU*]5=^_B^>33P@_9_Y)BR$,:WDSLO+8]KR.632#N78M)<M4*
MN>S%UHKX5&_$;-1UY$PNBHO,<)N\I!\^=)\-[>ZEJA]Y'8>T9-QIVD;!<4^6
M7HH!G.6$D2P\AAZCXG$+C"L^NG<X?S]YW]\)]I7+L83E__P\G5U^I"UJL0SZ
M1XL0$L8DR:0*(&HUKM(ETEE*?_!<6(ZT'P71VB1>"63L@'P3S3Z\T]E;PAV\
MI4>@;D)(V\#J%'-? ^DP ?<&2GN*!GM(?$1"$#@E0S&0M*3]T84,@9,MC46@
M3-GP(%H'64<EPA-!]O%X,$30'?3_=GJ)\_?A>]WN/DY_"1?_NFWMJ")GM""P
M@1$P&Q7XD!-Y4YG;Z I7I76 ;2V8 S@5+=0U[2'K#J'6VOOB\B'9R6OVGLXX
M$+80IJ )3N8<@N3T?_0FR, :ZW\5CE,P!?:6;X?XU4-,RZ'R6Z#J9 BL1G08
M.V!_C3U!@3W$W>$46(-.ZRR,Q 1$_CJ"4$GP!34D9F3P$IWCK=LZCDF")VR
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M=\=K3WL:.>4%,&I+3GKQX HS8*62*C"MLF]_].P!>/^#>?C#KYN312Z-MM*
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MARVYCA,GL](P#6A=%KQ8S42_^_,?L1Q))4FO-.4]!+_V13Y<-<C=[U9YS:O
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MR6H1&)2<R,1EF8$WN6YX$8779/+:UD[M!CCCNQ/[:NO19.PVHNZ37_IE>K$
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M_SB]#.?W?_YZ.K]\.[W\?WCY =/TTT4M&;IW"38_4\&@B-P!)D_2=AS!&\Y
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M=-KY:/MSJ<Z\#9ZQE!3RAP-(]]YB-L!YV2&)5GKJ4*ZR!MK-B[,-N$Z1AHW
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MHS='D"OCK77@N8C>)LPJ')N/O-^*G]%^>!SQI1$)=H0;W+VX\\9E"JZMR\X
M4\K7QJ,"/"8':#&@TL&G<&PIMULN[><+<P24Z34E>8]EOLIYP8-P7J<KGD_G
M"PLHUI8RZ?(L\L*4+1*BD!)4IC^"]PH*;0-"6?I?.;8<F8T+^OD6'(P>O:8G
MQZ<7%P?;AA^P*I>^_WIZL5CJ53C_B+,OXLRF4 PO'$I."I139.ES3SX*(]^;
M)XTQ'<W\\-V7^8S>D_9$;35X?"26];J0V&/)@XW-=9+@9W2V*E&[M11O,B@4
MNO9_#I!09"?18)9=2D2.8O4_7\-GS\E>%QM[2&*]9;M^R<%&EKRPD%/6M.00
MP0N9 )-)7.=D9/-2V ,L\^?[]GQ8=H17&O?VDM]I99.+^23],YQ?X9E7W&LM
M8NT&INO$ 07.B@(NZL C3YR+H^GE]-1B?KXDQ\:8(PRX/7W:OOKT:8:?PB4^
M6#@F8:VW&?2B<9Y$"Y&C@NS1*YF\C?G80G [+_;GJ_3<&-<K@M?FH/UQ8;PV
M$A?<!5I9R8'<2!$@2NV!>Z&%BIR[/DUSNJSFY\MR=)SI$--[/YLFQ#RO;7Q7
M%Z8JI@RF6 '22ZHR&@A&(Y H31W7D8QN'1%X$M0SXF:;N');-3WFD3VT ?,H
M%^OC]#*</S@Y"LM>"N,@FSJLT$@#'HV I%&)VKY"RV,KY=AF72^.S4='EL<O
MA#M W_SELMZ5^Z_XF73(# NJ9@!X4(II<DVR EXT!FU%T+)ULDDS\"^.VH=1
M^V/^^G$[FC^8+]NSJ?D3C^K;UWS(.H^GM7E(F!0G&].'VJJ71U43B3RP%"22
M:8#L>#K;_7%\K<T9<QA*8.0Y8 *%V9-I)5@]3AP72@C3/AC_ EN;#V%IO];F
M0Y1]G*W-G9:I,&&!!U<GKR97Q^TR2#$H+E 7Y5MWXC^QUN:#.+"QM?D071Q5
MI>.&GK+;K.EG:_-!K<T'T62,'M&[Z/BY\%=K'F.V!6R69-[S4L"5.EHM2FV"
M#=Z-?SEX-+P=U-K\Z&@[1+4=Z/K .UC.H8T6$W<()F8&2B-9..@+8# !M572
M!M.8;RN!'*$OWEW'CZ?![JF@8^KS_.9_KLCW_/V"UG2UD.:[R\\X^_@Y7-S$
M$-Y.+[XMKNGNM_KSKA@,-H'Y_^R]ZW*;1Y(F?$6Y6^?#3UFV>_2%6_9*]G3L
M+T362<(L!6@ 4&W-U7]9X%$D0.(EJEX )*,G-!(E T]E/E65F94'4P2MMDZ[
M58[,;.L8%AY$R:WI..X*CY#GG9V?XR70:6Z7RUY93CEE'0J0$B5=;W7,@?4,
M7/0ZVD1_=SQ%ST,7=T*;9 26CK^AGD"Q8VHS^.A"?^Q;,O'9)L,C&8E>DC8$
MUE)SC2!JWQ^5,!1]- EY ]?VNI,.LI/V(-@Q]35\=)T7>5;7Z^3%^1Q$ !=D
M!E4L@M,Q0,VH,MZXG-7H;6\:K>UU(QUD(^U!L&/*"7]TG9<=1VXM-:/RFCP\
MD.0[DO_(/"W:"@B*JR"TE,X<S;/8\.6];J>#;*?]:'9,J>6#C5F6% L^1]#)
MD \KA 4?M2)OUDCD4DM5CF:\U'[^TC%IX>&L5Z^S3M+64E94M6M9!I]IDWB1
MM;)&I:".)F5NOZ6>T'EW[&&?=I0Z*9_U>LO?*:!;NQH_XRK_BM/%90V#M<&[
M4, 7IT%9+. D9B OP]"U%*(]GF[Z#==]0GML3)*/'SYJR]"3VJ4/=L3=( C'
M7,!@#%B=R4P,V4-PRH&*)5GFF1/F:'JUM5[\ZWX]['[MR=43CF(]+@BF8[*)
M)TCH:\L'ER!8+T%&PSWRHHPY'5=BX.)?-^UA-VU/KIYBQ*RJ['$I!(?<6LL@
MHB%[PR4#CJ,'GFH!O67:.7\R.W;(RE^WZV&W:S>6GF8L[G$9H$BHDS<019VF
MB9Y\!*')YA!)"F-C8OYHFDQV\UV/27<_7CCK6L9;VLHH98D!3 X<E.89T$D+
MF,C#4UPPY4_G7'UHI2=TCAY[_*X9H3KX&.T*)%4.!G.PH.O\7"59@&"R!5:B
MS4+6+MFO=;''0O;#J'VKN3U672SMP#)??,'9Y9+_HF_K61R[R_?UK9 =O.+C
M*9,-$0//K,[.RG4(>M#@/7$LA\24M<Z;<#1):K\=89ELR%[9Z@]P5:M!.-+&
M%!&,YEADX%RWC]F\P#+9(2SM6"8[0-G'62;+O)=6%/)[BJW3CX0 C)$<(I$2
M64:.+KO6V3_/K4QV" <>+),=HHM3*3/<94VO9;*#RF0'T62,>L.GZ/A4^.L4
MHDN2 ]>6=G<IM+L9CX Y2Q-5]$F/7B=V-+P=5"9[=+0=HMH.=+WK(BPOZS!)
M2C$6YT"+ZE\*Y."LE:"8M.B4Y9RWOI&W0#E"][R[GN]V'&R@I-.L_KN=8QQJ
M6U"5%(FLT&IU#39@<N!*=((QYY@]G7?H9U,LNY<+=+P$.LWM<I7\K1G*R"SD
MY$DG$04$+B0(@UDE-)&[UV+9(WCBW9^E!RN6'4*Q$TYIG+BB=2(E />1[$5T
MDOSJ.HW*:6%=2(7,R)/92B^L6/8X=](>!#OA-,-)HI6EHCD($6B=DC/P11G0
M40FIM(K)GDZKDQ=6+'N<&VD/@C5,_?N25AW7>,OS>Y/^ZWRY6O^K24XY\>04
MD.2QEEL:0*8-".=E+JFPDNYLIGOOEH? _;I1-FR4HR?02>7>W2_Y-4)[E1D#
M'6J:H1(10G 9G.?&&H8BG]#%\_(JRX_S[MF/9L<T"WVPYV<85U)E"1AD'50H
M+7BI$**-S.0L4L1G$EPX)BT\G V>3)9"J9IX%6J-/QWGQ,("&+7D27+AU-%D
MR[S RO+CC)&VH]1)!7@&9.=[+@U7+(/DM<@"R4%WCDX^%X1 3#KE>#H-&UXK
MR_<D^3%6E@]AZ$GMTJ'5ND86RTT@N]"SF@]=PVA>D7VB$9E,TI@3ZA_U6EE^
M4ONU)U=/..3[N"!D8.3&%0T2JRLAO*GN4H&23'67A';^=#;M:V7Y26W:GEP]
MF?#R@R?7MM!A#.A"B:3.:G($[L&)(,!GEH1-2)HN!XT]/V%1KYOQH<UX=.H:
MQ,%3#%_O6$!/UG^4T8)5(8$R0D!(@HZDDC [JWTHI]--Z;7-P^G<G=U8>IJ!
M\1W:/$C.&3<1HD5W.5B^. 4"E0G22QU.J._9LV_S8#$657( $[@!98T$+U@
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M<"H]EN;CZU$0?](_7O?.8@(M%SY"<;[0Q2,BU(<#*%EKNGDX"W=-O;U)^0.
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MK.>?OM=?UR/0WN(J?YHOKA)/A(R(#,GYXG4T$=U5=;I# 2M%*=F&4IJ/&1L
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M<T.>+N^&A?O7(*ZNFAU@#'$G=E%_^_W\N-.PA_#OJF\/R34\A._"B=:%@CZ
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MP2\;_.G"B+0@B-:@'$KP.6HH/DDKE.16MP[E'=>0@4-Y#T_20/>>J[?[VN^
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M-(0:$1Q]."B)*M"EX+SN/X9W%Z2O+&REQ@[QF:>@)C;E2<'(@PL(TJ $Q8(
M[W.&A,:A#0YC$$= OXKUE8#M5-DA8? )N'^=GR\FH6BK@[$$5I'?HCB"=T6"
M3$&2N(*.V#]C9">HKP1LIL@.J79/@3W]EB<NF&"9KMU4"_E06#R0 \8A":D$
MV0\ER?Z3;G:"^LJ_9HKLT'MC(.P*^5=RZ?"L+F#YY^>\R%A6M44W"UH9':$H
M1NN(=50@<@VL9*>B]]RPUL^SK;"_,K2?JK?V FZ;2?LFQO,O->4[I_OE";4P
MX>GYLSM_=(NLV:>MHU&N[(-??E/C<1/("4KIR+R&*&TA]\%R"#YFHJ3RA;.B
M^(-3%)^RYX=BW/=\W/'[+A[3H^:&^_7,U$0;HV;L.\T3)/+HH_+2L-(Z=CP$
MWUCYLUUY=/=4ZZ:@8\FD_;BBM=4/NAB*4M<WGZTOA?J@ZJ-P)F0'2"Y[]> S
MH,D6BDV&Y8B2\=:]&Q\$=*BLEWXTN)NZW4P=W:8276.Z?+C9!52G%)>-@ Z3
MU-)0<1NG%;60^FB4,,&8A,E ,;9&G3."JZ5PCCN>@E>>I7"Z5'@D365L)@P1
M=@<&[' T7LW/2\5(G1Q$2QZH4EX 22."C39F*5P4H?7;YL[@QG?2&BASN*WR
M!$UT>*V\!?1]7OTU(\_O;/H_MT?]7)6%7TWCBRYF9Q085:,8M$L(KZ[SNA*3
MH78P+MB/.3MA')] G=2]G53M==7W./IS@;/E19WVF_1?YQ=HK]IAZ]KJ+A3@
MK,[RK,T[T')#(E%2T1&M7&E]0^V&[ 7PJ)5>.CP9OIG'Z<]Y,?U&Z+[E_W-.
M7"_?I[-/;Y;_D=.G_,O?%UTJKD_M/W!Q@SU()-N>L./:S\PN G(O@2>G$H^R
M&-WZV7 ?O,^6:6/IL,-[X2T);2BON+=;C P:L\F@.:L-0)4'DAP#PSGM$\M#
MMJW3=H8A?+8<ZZ>G#J^ M]!>7=;OZU"_Y>=?S^;_7N^*'S8!<U$YZ>JL"+JX
ME2"A>!819+22:QMB#09WH]4N$%\ KYIKJL/SWIO?W[Y[LUHMIN%\54-??\XO
MT!'FW\N?^/?M]C@IZR"X**!K5J]RJ8"7(9*9R+1T)?8@U>[PCI)0#</8G135
MP3G\N)K'__=Y?D:?MKSPD2]Z@]$-_L=\L=;)#PMY/Y_5T#B)GC[QT[M9'1J[
M7$U$MBD&$T%[%'3D<@:878'"LE;%IRA=Z\>C-L@/P,1>Y+@7VQY=LQT<S(<V
MZT^YS!?Y0XZU2?NT3"\*')97@IR8PDA$P8'SB==R%-K"UAG(3AE9BM#!M/80
M]H#[?)DXE@Z[%!W_".Q7$N(.5\G;\T45Y!_D%\W3]5ITEK*:)% 4"5*YVKY=
M:G)YI'8AJVBX;=\ HQW^YTO0@VFY@T_[T&:[QLA\U,*7 -G4^86)[!IRF 1P
M'>H,"LLPM\YMV 77\V58<ZUT\%L;&0P>F>0\,^!T0H-"6D#PNJ;D,N-X<JS(
MUN]./4S!44R5M=:EC;I.\-/:T'E1Z!<LD0.2K169]$;E([!2#K,[QW3:1E!?
MEZ86&ZZN>9S^<#=5G"(C-SD&2+94T0@Z7$14D#"0:942<]@Z(+ KMF=.K"XJ
MVFKKMDW%)<%\F:YCJTN<I;=T:-*!F6=QFO=(PMWA0UNDWP[%WBCQMA+GAR^[
M89%6SD1):DVU';0*18*W1D$F)X>+G)/WK?/[MJ/9]^2Y]\D7Z7A,,R=M\F Q
MUGIP8<!EG4"QI%4(9 [XUH\DFY&,E2#;2-]W3XT&XCUTTNMRL9K\1C+_=-G'
M?7G1\-!:7= 3<&:#)JFX.D>OVM&6J>0=B4SO=!/1Q]]B!_WIAAF;O_E0Z:PM
M5#EO)M*&1LA]-+>;&.Z :4BBZB!U'ZKO:PO];%7UGL(=2_'*1R'0!_"EU!>Y
M0+X?*P)T5B(PCZ&4G6ZYHU+XEBS4L?0]1*:-I\;^1U[,IOC/O/Q\@^XJ?4CH
M5&=8 $L\@C),@HL\ 3<F)540Z99[Q!9\^!O&\PS:27_>7'0-G_TJJK?SLVE8
M3"^!H",4A<P37S(!4:X.238&2$?!2:^=QUUT^,.'GKC:GBZ@QEOOYRG]>967
M?YQ_^?JANBRSO/A 5L0]-GFEF15,@<BE]I"V%E"241%+%JBMB9;Q'92XZ_>=
MN'Z[B+7#X],-GEKD<'Y1T:"Y8-)Z"\%E ZIP76=R><C(A)99%2=:QW$VX7@&
MMG0S,8^@^JM.NCN@ZE3\M1G18:J_]M?8(Q380]P=8KQ;T!$$SDNT!,>3D1F-
M@L B YV*0FY4S*GU<_*8)'BD[FLL#@R1<I])"FG3U123Y,XY!26P0%>3CN 4
MEY!SG=RM0Q"I]36P!<KXT?L6FKH_-6%O,3<TTZO9<UW8^(\\_[3 KY^G$<_6
M+$=1_\<#E&1"S8F1$*)$(/:')+CWW.]43?.(@[T5P#.X^]L)N&$*QQK41<CU
M-J1+>N\"JF$\;2N0\0-JC10U[R7EQH&U[>"4-S*I;(G?41(X\D)]/? *'4..
M&Q?IX#L]U3\06AM3\T.$VU+CJZ^+R3_?3%B0DB$6D+6$057[Q6E.%P]CAGO4
M'!]LN775;KY^W(5NZ^]NZ?7B:\;UW!L)>_YT2;6\D]=?_W[BC6$\!P61UYIQ
M@P*0<0?$.,><49*K7>8"/*RH]Z>OJ&&2:KVCWKZ9&)V0#@(&PC%R!@29@L$0
M]!!4CB)EZ?Q#B6@[*>KMZ>^H@9+J$.SX>!Z6^;_/:P^/;_3+]60\GUQP*#V8
M4L>@B;HD4S+X)+U%+GE*I74FX68HS\#B;2GL'LFG]V%=M=[9 5BGF-=64 =J
M>M1"=8_380^Y=PB ; >H0LS,RSJBIEXOEM'UDNN^DLER6T0*KG53B9$)\5CK
MHU'Y,$3<_7EP&9^QCJ,NZW$CFH$*R0)&XX"IC%86J5WS,-A&(.,'P1HIZF'U
M/T'*'6I4?[P%O[^)<7&.9W\LYM^F=9^0G8E<R)+ Z%C'3CE/\#@"DUQDQM%X
MV3J#_A%(!XB)CI&%N)_H1V/&F]5;7"QJ$Y+_Q+/S/,G&* )D(&#M!U%"'4NF
M!0BA4@H^AJQ;MU??"=@S9\D^:NC[BI97JXL4US=?ZO"Z-[6\*Z<_Y^M:@#]P
ML?H^(<LZ%AL8.*E,#?S3]9E5 9)+])')2-=HO\>UQP$^'^YT4TN/9_D?B?[^
MO(KL]_+'&0EP-2UE.:';-L=J;.E<ZY6YKY/P\KIZWDB4KA39-_U] ZCGPY6F
MXN]0?'L'X.6KXEO"]V5Y@7;"M4[9<PLYR%H>;!*00 +01<G)L,IU,&-?@FQ
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ML2$$5.+0!J0*M\2D"3%=G"".[R:(3$@UD$\!S=BI3!>-8S &J"JV+J3 .F2
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M]=C<>N [3_-NXSMFK#O(#1@8(H)J ZD[AI\? S\K?4>-=6L/^.,_F"VYEOX
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MSH+KH8?[=F?_D%TW(+F5QV\#?7$>*"Y>5BTJ+'^YHP+RD4R6^#GAP<SIYWL
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MBDYQ!)\/&&_?07_(?)*\M;2=01>U=VBNG9%8WX1N6,08+_LG*VTK**'(<J5
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M('RKPWD\CQ$;')5O\B:S<I9T?6G6UROZC;MEYC\L&/LO,+'II$QR-(9V 3M
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M!T4S66'(U<!"C@?)_G2?-E3=1Z"PQ79]I.H;2O"&_#Z]TR)N]UJ6^QO@Z:%
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M2-36;EC9M4<#IT?(?:1, D,U&TS'4IO8/S#K:[;8]G+/#6(I;0(R@+4F$88
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M&U,R$!^3=F PP'TI*@Q3&3AH,N8E5<]H8)XK6>GE52CWRT]"AIY;]$*MK !
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MK_K(J904YK?\9XCY_^,'>#[S/P!02P,$%     @ $X+46$W?(E^]O   6M,
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MM+;U]/;U#PQ^^CPT.37]=69V;AZ#6UW[MO[]Q\^-3>+>_J\#TB'P^\]?O9A
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M;2KU&]9/53X022Z.^[YJU/JJ<'GO$@^;Y>7AQO9[6M;$*6Q$#PKC@.-(@K/
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M&YWZ!+VD[? T,<?W*8>67QN'2PJ6]S W^(]-6#RI+E;F%1?DE$WY;?6WLWB
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MT,#TDD8A5+N!9G0K>SM4Z.%0+CG[E^M3,\=B!W"Z%E:;I ;3_O;8)R@X!&4
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M$Q2,@D=H[!C1Q-"4!@8GJV\[ Q'.U1A+ Q4J.JP*)";6-ER2P;+7Z;N^A*0
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M? T<Q4D)9'"ZD8W:/+3?C/O+\HA,Z*T.?MA<!^/W-(+TX2EPLCNT?8O2MZQ
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M2"%EO]#(EODCS03)/L@J?."/:1E)?SW2X"1):)BS/=DQ*EM>A8B%LY_G5_-
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MKN]7W7ISZ_^E<G0'NI".@/HT-*Z1\PM9%;.)-QB'9TR1]#A+G=C^),LVC;=
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MP@8B0.7,=7Z:-%O@%P/^RVU>&812<43N_B)9UBNV3)#Q8+%-4S/-Z&]37FV
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M3G7 WJ*\'*>;L")JCPZW3#0R0GXII6H7%A__XK+DO7#[JE#-[X=Q;>]9B?!
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MO/X*Q)-K6AD:RWB!@0RT+>7LY)]U[MXV%\*@7U2VNI"#QO%_\4E'[H:W"R5
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M[$($+66[HT. 54IM\A^^6CJK[:2X3?QDF'&\]&=1C>0N__X[Z0-3;0+'N+/
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MU?]XYO)_MR"$0<C= IU_!QW;1[T#$OA'Y.H;CE@5Q(7ZG,'6OOWHQOZ5R(G
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M4SY*_>S:,^+R,DKG2GQ0>"F[MD -S$"5&E0'H_G M=I.:YHZ/Z4 KSY?27M
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MTOZI5=J5M(1%VD;)[WGGZ$#;TX^,8BO_;N*G4F;'5O.HG*3@/#;;>< ?SY(
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MK6"/_,)3[82I\I*I3>ZW_NPI(IZJ)?"-NG9X?#;ZIR=H(S9V9^P7A"$$IID
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M_FG_JF3KT^Q?4?<>9INWI!R<-%PV?G>;T$G KT.:!Q+)2%RJKQ'(92_W8+5
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M1-8QU1S/F$-$8YN1'Y8BD7$_KYN"WD;YH]L.TQ71;=H,R"UH,K9:[C'LCFY
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M@!K!$DLU!X_-T!)6>W@!MUKG7%TY%JNLX<0RA*+WM8_6+<_;W-]!_4N6A6+
MY!X:G&8S&]Y LI>!N1+0$A:!HP2G3&RU7P4D?HOJ)D(N/# \,>FD87RE6$L
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M?+4<5<2+8@"8.J^C:]$$UHKP=L+=WS]?"=2YJ'9J!T? !W+L&!!?9#H-=0"
M[9"E#823AZBOOYBI(K1G5('BV1F(Y'B%1C06>R5,R 'EV4&G5*Q^D#ZP"W^8
MT3O:KS#>U1N20 :;W><2WX=CT]OZ?N<E5(NK_6")5-A7NK/!,507MG:OI\&M
M&5"AJ &4+L'1;7%R_()2<^+M^R^RSHJDWOOL, +E!E%B-A50<N@4#6[-)@<\
MOE"?OMF_J";@2R8 G=4:9<#KBE\;D->*D1 Q)B.4=@Y-M:&]):?_([^"VE;C
M&/I^\"3=XK<^1\1A<9#AC_13!U=3V^%$/R$JOX63$:9SGK^5W^=M8)-"R,S^
M,O1)J!&,=$ Y3F?G UUFI;W&XEY!:W=3"7*DLWC$XY!FT8!#]';+LQ=3M@;4
M=*+MN91-3Y\90+VW@;\*Y!D1[?P@TU>V_+VI9EQD^&Z&AY72;%JU67-MB?./
M]:(,W,\!*X79"$S"//':/*!UB5Q :X#=@<9!:Q$=F&FASSKVN7AQ\^G%2?,)
M?*LC843WG.3):7D7,Q4^O5!]_V6X"(CB^6CBM51NJ8$%3!R,7>]BI)=4)4EE
M0QWCKJK\S) !>91#S_A9T?\V4,L_MD0DT&_83.E#W$[$*;3</#\6]P,+**NU
M-X=AFVAIJB$SUUE>4%46]75H*?HG4]"@5)YOVD?CV3;>4*[2!V]WX'LVEO$5
MAQ5;!\]V21QO^7CQ@5MQLEWU]RA# GR&RR3"R_OMM)G;6R<CO>,GS=[DG/ZR
M9LSQ-%SR0&3'AY2E"NLJ$?H50O>D:* Y@QUV:10C=)L@%I>-J>745D=:T9);
MH CT/?:'WNUD.>.6.?1R@86[N_II$*]S'_TT%'-8U2: :'\X*%SWJG-Y&%F)
M]DY-8^KN &(!&S=Q:E'0XXO-0Y]WI+<_SR).]MB?6_W13KKEZ#)=A*/NPN_3
M;(\_-L&-"^RD$D )R9(*)FX4JBW]IBM]"%-=7(EX_;F31^AG/.U-H<YJC/;I
M.S>"IF[]GJ?E[#>UIF3Z:2X,6IE;-(5)@EUAZ+\L3;W%XK(P1#O,-)@> :1*
MO3#BR(&E<[O.^^&*9#WVL'OVHPZ1@9_N[VO+L_]>89:DOA<^>I+^#N8!G8'A
MA CK1"%S6C[,&RZD6I*_=JF_J2Z#I7ED<XQ9)F_L D;1\X>Z^J5#'XJ>9::2
M_.%6?]8Y8;BW\V)@S* UG#!^ [$?9N_"X=?#7Y-ZHE8:E!#OIY5"Q"^'\45U
M*T3VI1G^2/DYK_UJ26/[A$Y-YKL*:F[O/ADMMVR3F;K!G; ]..5 +@:4*-Y4
M]B&T3T6DA$KJ#>)\G KRB_0)QW(O,;, '<_GQ<E5'V+?"+-$L>_H4+OOYIUO
MZ'4L'_YH8R0@R6]C!/F?-6Q(L'BJ+JZ":TWB# E5[U_LZV2747\_J^"A3@_7
M>[XW$3+/9ICLKA\SPS'!OZ92!>OI'..+J8""6@_S I;9=?8&59:8O!2_(*ZP
M=W*L2-AX;).7 >DW$>8K0[]+PC.]NCA_ ]W6#R/:AY&RXU1!^,B#5:_&#Y*-
MT^^5+*:4>VD+9?M<DLUXK]-S'#)ZOT_P;*I"!^K\Y-[D<'W;3\\&^4#70&M:
M_KM/1VJIYS2IQMA7_@OT&P:_?9%U@<\?F.GPSR6BM6>6]\'&")\TB?P?GKEF
M4A117[ U4$(9R7T4!Y8/<7.K4V2@6V*A0%3EO>07KL"@L\BGG6?WGO\VM>/L
M5%CIQM^-"#T6_M[.=+2$Y4>1;(9[%J$^W[7(6/UEAON'J97:/1/J\0[Z$2Z*
M#WW6O:?'56IX9J&B8SVOBH<?>-5+'W[ 1U?2U7N?'G7DY(\>/K:3WY,<UN:I
MQWGH7'.T7)A[URA="35DX4%26[Q^TBOE0;_+M$&R_"I-<,Z0,L6_\\JM65'X
MF-1+>L(DJ20>;AXW_)(H!F65K0F/+X=MBFMC,XK+:=WO!]^T+875D'B6L YT
M>,1OGHVS8%%=H#UB0-P,O1>MV9%GX8) ]Z0_ ]+NBS>RZ'];)+99G^H3,\EV
MSF?(['$48:*U-3^!KCUX+E9O\690]ZV&%Y/OZ&-+,SL.PZJ]CJIQ!R+72VU2
ME06>@IF&S_EGVVA<KX[<<7O@_]S>=,FVRGB-H^I9U!%]PXI!],P>G>LC6-](
MU#0\@)0:J:>.X@.F5X,8D#N XH!@]^(UJH-.J+W04MH58^$3+ZMS:!SY3:>_
MMUAQE^@+-V#5)K%?+6714FBB#0;LL020/;),8QLG4;( #_V8]:'W,P$&)P%[
M[891<GJTD)2$5^[+1_$7;'N._/;0_"V.#G**R2M9(Q__Y52>I&U??[K&06N2
MCRWEQG>W9QE+ZD]-)8F&%5\& <5)JL@H,0Q/'&O5 NO:8,:2R)8$#]Y[Q8K9
M<Q)\1S.MG^8A(TL^7OU+COFVHW=%0Q]0E6=?BA=2HGO5#P3OS@P-=%12-VQ<
M$#UJD0S(">RMU/B#DK;45!CW+NQH>($QIF\L^*'3O&<\;?):7Z\HSPO/BU_6
M+BE(/KZ9^?"EEW"7N>JOIV".GOZ'OC4 56*4%+H-WH( ':ZGO6;%QJ^VC!L<
M#Z];.]<2M/ S/K1.3W'-OG\Z/';.IK,R*O:9J-RN,\Y:/%QW$1U5@XEC0'CT
MS'S?_W3:S..BI[[[?D4Z9G/Z.H_8VXYW54]-)K"Q3K3$/Q(:AJN\ACQ.6L90
MCY>1DTF.$MPD?1*4J];_5ZN+J%UFU>VCVK-1R]^N55E][]EZ7O$E4,N\DG].
M-6%OLK/Y [V,Y!K=;C]$C_;)3Z#^'/N?MGBR"#(J%0:$RM\]2F<?I,@/:$>%
MR*,7/($?EL6 Q/>%G*%H"51^W_WW'.LUO(99IH]8PSS6MX3#.SJ@/$BI=^%[
MW=.SK2\*?'*")P_J"D(I[K5UT9QIYJM5[TKEOCO\_G.T^Q*M!0DV,%8^6D6+
M$6G=+FM1G%5:)RRJYL4@]?'.\Q<MF4I#IDLU(R&TI?=,GR&H;1Q;C$4GM\J-
MI-MJ4>W3(6HURV0%!F1F0%MML[CFGDEV#AY5>G$8**I?&\34BIM<G=!DWWWH
M=.!?UER:XU^6&V_1JY%D<;9:PC%>.BU">DS#!OYKQ%SQ"_ Q/T$A\C_TZ\,_
M)[2]P*D_0P6Y0M2S<)J!%-(H9L\0,'SC&CU16V.;[G]6@>7[5-KY.Z\\6^+:
M-I=4PO4L.AO5CGC6!MV<>%=BG#/^:>;7B?)EV1VS._[&R5>,C(XHU04R($1S
M+" MUP/2ZI).:(WOF8$%;*R(Y7?KX\#*RO<,V].6Y?DOCR:F%=[E_M[&N>0E
MP( 4HK]OD^5I+[%N:D_J0&V+]N:!&!;ZKM?NBNZ?D=DL.W="6^C:4Q%''H.$
MUP0C.R83!+%BP:$C-0K*$XR)AAZA"KLM,"#</J&) 46^(IZ'S@7@Q2/%S:2K
MS_2?/?;53'K2$+X2EBAQ-I MOF'5:C.%0^U'_BORM)T(4,* I/7XK$=8;'P\
M'Z+,CVAIPOX&JP(KHL_[WSDUO@(FC_P>]5@_^3H8Q)=4-0;DB1Q^,!HU\.'[
M!7R'A/9(P?6QG0B><R92>Q_3^R_L&Z]I?72 +^_1.?XL\WRF%<%PS^$BT(7L
M;H(0(4>%\H5^C/0!<Q3MO9ZUAOI]'*/HQ1+Q],R/)X^WI:3JR3*N$11;>A_V
M$.SV5M1T_6?HM-IGK5<GB7,5T"W)O$"5]Y]YLP5_\^0(ITN_3S 4EGIJ:D"W
MQ#CTR[Z!W<?<F?.GUJ'CU1.\249&#T')S!H"VFR$O T^VE-OZW"WJ&INQ>;L
M=B;CT&(RK<<(; -DY^06HS 1VM)/',)*76C)G ;CB2M(R'\W$I8X];SV+U"F
M_/4WC@2?M42HWW3N&_Z2)"PNRFJZQ&MRR3(_$E::"FCGTCF:L$0;^-1-I"Y0
M4<&.4J)JUT7U=Q+T,)\F;L?-($HC4=NGX:JW@S/#Q/.O"QSPP;MCJ<<Q9#P0
M#\9HD_8!J42Q1AKX>ELJKF_03PV/N)25_;)]JAH@6O^UX-[QIVG2B*BK#F0A
MXH/%R4B4/E*1N->-B<ZA.I7$ZETKF%F[KTEUD:U_P?Q&ZMU'-LZ2S+\,VU@<
MEG^89"ICA0@*%??N5\B-H\KH3#7BPR-@U]F._O</>]A;I^KYOJ&>)[J6XK''
M;D:$ZEAF9&NK_'CW(3357@["O?3(P>KEVMC5J.8[O6$(#\7=GPL^YK6.\NT*
M=7.],J'S:29?0,%?\0A65T]0HG#Z00^C/;B.]=LVC(?(8[IU(L99:W<W7PAZ
M4O0_$*7NC;SWZC!]DL]_E?*E8D6WYP\>/R"6=$VV0H \W">'CNF5W#.)5X=W
MR]A5[@3,4RK$(M5?45,R:2)(S3]9B_0CEB14J+4$> 54_)RL'[&FY<F>RAH0
M[X^XV\<V>_4N<PP.<J3"!<@EXNGL?[[4X$>\CN($!G"6:G;C^'HESZ:HHRI!
M5^2D<_V?G.Q[O"U@'/[M\*Z^TL%Z!XPO"'M8G0'9^#JJ:G?7-CVWS 1XEO$^
M-^>^F72:PU*5D]D&ZGS'G.Q=6)S=_NES%=YQ4[9E/HVAR^.E\ =&C6$)L$P_
MI5T3,@WL'ZYHGZTH6 #PB"(8GDR7#?=3&<%PS<7A)LMY@Z*9;SLT,+^+N'?L
MPHW<<I0K@&F?DR5:QR'T9/ P;O@OD0\8W4OH8K\L!"(P0'XMS422,TDWBJEB
MX\,Q_ =^_$NAB:J;U_V*2$:^Y_;-N4=2!QQW J#6\*-P+E6G9Y47$^0KRL&&
M66%)2T5[;B7"ZN8)7 M;4QVX;UFRX[OK[RW"%#%25K6NMYI?IC;S^V;I][:_
M5>[C4=45?=)_-^1,>.E;VQ(A!;-F^2ZENGG/A"2O\_)=+M4_8+BG,*(Y.@Y&
MO 9/Z;!N%KIOTH'@LA9K/4?2,'M<\[M.JS-)\^MKB0B^#RZ/]D' *!F,1A\U
M@"+Y@* "I#1P;<'"DJ?C%?1C2K_IR'N/&?$6^=.03;.E+!#XE#O3+ /AE8B-
M1\1TLB M+YAGJ@<WE[?\JTE#M"*$W>,0_OJGNYR3Z<\FS$YX#U]75!7@Y[E>
M\7NU&RY HLN2F(-G4C@2_9*TL":V_OO+?U!R%N[;3[BWP7GW>BWP:FOG#TJ*
M_K=0\C_1<A#MAY@*P]43,HEJKK2\5EBXL8I'!TJRYLS-RY_9 XK$>H*8GUZY
M9OP].' H!?<4G0X#%+6IQTWPVM1C# @YO050(9U2T.0Z3/G:3#1)+(@L%)F-
MV3@L?M'JA5V6<EJ2H;")"6)#IS44S&H,2*YTZ&!O:;O"@'BYP,DH(++2T6]X
M9:_ME>SO,(O\M81"D].;PUI7[I60N@>23MO#T2>_>6<Y+.=^.G^G.:)BLFG_
MN/PLM,=(8 HUA(;0%5']6!$]$PJ,>IO8T@1+T%,I_915[J$FJ?.[2BHX?):C
MZ=S"\'@LBX,HO+3;YN7U_,T7<2":7/BC!P0HS:!^?8IN,Q&U&=F=!V1[.FD/
MU*?8=QF0F( @M;DG>9-D=LQF)<56?BFV42Y: #!RF=_HHEP$0+>M::^I4(HI
M4K7E=\C\X?4A/WO)1G:#[GT<\IY'ECKIW&;:Z2W74/_(%(]'>4*MZ[WEV/XA
MWRG,C(I %^H;5 +)1K%!LA)C"7S$/N+@F_#^"W7CP8N=0LE>%[KE>LRD H8;
M-KYTU(;6 CL%\F;=Y@.B__8J'QRDDW:M9[12%\1%<:\R0^T#7*T)7(Y\C12-
M@+BGJ<9/!0_:E=;3+@C+04)DL?(P/WBB.M(/("SRB!6UI0UL<;5F?[M0F[B4
ME&KY&6&PZ;^#X*SR>A'(-B%;P7$TESYWWV0WF]:$8MU)6.SIH'(0^;W\&GHV
MJ+2<ZK=TOR'4-;T##,OV]+=LK5&]>\9M!6E:)S,??9%,B7EAA#:[@\8HU&RF
MYM.9T6VFK6>HIW\'P^+.D^X\?7YS;J".#";,K=OB](:G9_2U5>[7=Z=.S=/9
M7X"8AR2^':'+ UK=JYV5TQDU8_DS)4"B)03=?SY;UO/FJMNV6^]R$)SG>E9V
MF+V0S=SW'[V<P^?"B^/[JDZ?9^'[(C71"A-N V[@[=TRQK-X!,3MS"U[X!HY
M\^7EJ'H8 E<A$=X1C1=3/4\+XJQ9>DO;P39?<_A96)A].?4E X*8![2\R76T
M7(,9_/R4'X&N#!B+CXB**KD)?O(^L<KEQRYT W<G,MLC?5F^8B#@FOG8CKXY
MWGAB9VIC2T76YTZYZAN?Y1BC<YXA?W%\E(PZ\N44MM Z<IYHBTU$<^OE'5U$
MFG3EF+LA]Y>F'AX[B+]OL1[+@ME*V&R%T;O1Q"L\@++@(YFM1*JF/UM2ZT <
M]5+A[=&62]Z/'K7@$@MMNJ4="X3/M:U@31?F)<*;G[R\^\,K^J"+M63"I^AK
M]OVGPS"M1KV,*9IE.Q+=)A8A(%;-MU')0[\Y7N.%WFRN5:.$].Z9TEW+#L!*
M?7P?U.C/E2B\J $I?&H7@B<.)4LUJTI8H>O&5:HF%XF9(3P&Y0F=H]S<O^,Z
M3D>A?&G/P3LF4X61QVE8ZED\/'[^F 9,A"I.W.WP5S@97;Z%N/.7E]:$ME9Y
M8^@+CN:JYH)"U<*3(0(4([C<3ARI3''Q)H;G&7'EY/4W=HJ9):)E992,'%^-
MT9NCEG)$U9\T785^;^.",D?'<J&_97Z/]]"_P@F@:5AB,)QZ+)<N<@UWE]9B
MP!&.&" -=N2=KD@,4#E%6ZE\?5)U!/?P5X"9+].:FZ^AG*<__)LE.JA>:V*R
M;L1QSKGP8U^T3,)US@^%?Y6R11W!"U"S0'0+1N->:L.(5CPS!4Y$>'1-;"S(
MA).TU^=YBCF0#>7202M3WI2)D14]S_KLI4;*[AY5+D?G:;A.JMW[ASH56>O]
M0]_\2TE%H&-^M_ZQ?(&^@";ZF!#:U));N<-'R1RDK,K6O;8PMDX45X)#O[CZ
MRH7ZNZ\W*EW4S381N2-8;W^ ](=)TK^KTSN@Q*N#,1AH18AQ[1!N\IHER5?M
MB8[EZH%^_VGZ21&S50@ZA5^_C,)E8L9K)GK87MB>33*!VI%PU^+H<XIIN:+_
M]CH=??:&[AM0Y>WG_SN'S'C4:%5T>71[,>UEB]FBDG^J*GEME *SDEQH^<6
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M2?T%5($TW2S\U^_?KVX<&>4:/U-V3_0B"/1;/@.!?P2F6 L<1.YC5C'0]-L
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M8GR.(4:)ZQ,X//E])@"G1<%A*A=H$X\NC5P("Y;I]B=9'NW\N*]#[A@QEU'
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MG7.\DM>['O&R8O7 I81#8NH9GG]H\/[%E3%0FRI2);DJC02^;AKQ]0F!_49
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M.$[4J_%5A+4.SW]L$8AAHVS[=3[*#9U-A?92$K)V&YBFIJI;*BR.(Y+=U7#
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M@J7=2T&?P*BI?H3G7>DWZS>$D)LL.?=TZBN/ORT>NTM0JEU"-&+#^M"+?2<
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M=YZ9]-#,Z/=J]=5V1Y\_GY0SH'??-M[_AE5Q,3X&*.1!MD?R(,DQ2&4.%JG
M.H=TX%0>/&K^!BJY+A,P,RCUQ.EUP)>]'K%)#WI$[%]D*0L^&'+9+V*<;+)F
M4S95QJGV8"H<&!1@5-__()+F()F9YGIH]ZW[-A '&]DS?#9R@VQWH&P&DPP7
M;\+<A4DW.50C8<^\3'_4H7<4'AUJ:H$33.PB,7N[%8,OE*KK'9&LM(?\TL$9
M<1["(B0FXIG?Z&(;/=")([-JCV<C^$^.0AWQG]=:OWM2.^R+'S]7/V?=:G?P
MU)M>E1B_Y\>VR[K\=Y%S[E;;_0FI]6P:J.KQGBI_7![:G.T;9G'O^=5:8KA
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M'Z71@RWKZHS!TL_#[D)KQWK1$$0#D2M%WTB)BNV4(1%$D8K7N'N PFH[46@
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M]5B^I,WNY>WW+&^_.:1[WD']07?NAFIG9V=9F[?WL0<VT@(9.I]UBV_>@*A
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MQX[(3*&X0$TYL)_LJ!ZR?8,V@-/A&$ C$@?BZ_$_-YR(^,PP,3$P(DZ9THY
M76ES7A 9R4\R##Y\Y)CHIR-7&2]=O8JOP8IR.:^X7[ -$EU1DWK,)(;=P@2C
MQ5IA6I5QNF!T['BT5G/.GN+7J;>/:&4<R]:X0+U_2>H^^K[SY ASW]^W=[$X
M+SJ<6/O9%YH,$HN_+@^O>]+T=N J7N^=9JK\_/; 3D,[H.KYYH-45"'I\<![
MG40EW,8#M@?:;6S9^.%EQ)_>=?+8/Z)Z$>PJIYTGK7L(=&<>9%*/"&U22"U(
MN/"IR<99,O23%:PQ]B4Z/O[R\9F\.X_*$5YRRI49W%ZVX"Q&&'F*;HMA:+RY
M_M6B*)TF9DAQ'5I7#GH?[][06]^CB[6U=8=Z<U7#MZQ!SNF,CAP%5EG*<Y1Z
MB2S3&*/;>*EI(Z9=X5Z_).'%*2J_94O._@*-"9=G<$=@VG" 4R9$HS7=PPPM
M;L#>MQZ]C'HU9".W^?O%/YN_KB:Z+X,N0!0UBQXVK:2SY<>8E?G,O\!HCF#_
MQ6!FO>3D^X[%,J@$L;;F,87XB90VM4$5-21I6FF]7O2)0O?A:64]$EJZ8_:T
MU6E7Q^5W?LMO/];8#Y7^-,A^S5Y#$WW0X9L\2,3RY'(?1:FZR3KF6<_+9@Q5
MU,PEMNJ$_\V13X[6'^TV*L(VFS/T.'??U3]5LWYX<>6K>I/N_DSUCN)L^%'3
MI<'!RG.YWO>N3LV!N.CZI;]1I&[5$0$;S9P;D&\%CIQMX#3&H6>POUD!*#(=
M>98QFF%H*4%_1JR>JSJ86-SY^2ZTUOLIW>ZQ\LDWW^1:=%$ KHB&UQH 8.D'
M#G\TY2ZEG"^8UV[T[_B^M[B#;/K<%I$Q5*$ZL?43C"BE/S1D$O4&6Z^%NXU,
M>';;2I-MG2;FT;-X$)'OG!YJUA9?N6G__2EZT$M3<8\'] J880\L3W5[Y<L'
MCV=2H(9A3:7?6(9#OB5R(3VQ#M DVTP=UW.S]6!.=6B<^6=VD> ^+ .'CW!W
MHGD0L0^L/80^YU2\&LNNFY!JUC"G%'MM*"@";M_+&E [''\&C[3.Z525#?(/
M7TO+^$VD5<[4':AQ1A!^([N_#+&-AN#7T,0N OTTE;4-1?'N[$MNA-4#_#3G
M)S2C'9L'%M.^%#FO#<CU\;][7%]IM6!R'+YS;.'1>1M+/S73EXM:Z/E/Q*H_
M)33Z[PJQM<H5"F2%#K#$T$0'-A]#P^T+:H"*D_+#B"*Z.YX$< ?QL9@/,9SQ
M8,GST!"A9?@>L//I6,N<.%?1F -'&$@L)6=LWN(*C;'..[ NHXGF5@KLRU^:
MX$WS5<\-,;27JJL:8=<T)T]I;!W$>P]B'$;Q6%Q/U5"16N-+9T0S]NVOKV G
M>_M/+?,1Q&$SB\MD5U\GFD07#S(!M?\,&UJK,4;+A=_7N'1PM=V;'+EVR3[R
MG@4M.C&3.SOV$[,X $9')A@=T6"3<K8R#:/(-AF19;P_<34^OJSXVHRAZ2AZ
MU9PY5GDY\GYVI0S7\Q%)I?DTS7D>OS/X*:R+G>!T^&. N6W*I9$4E<U@K0$%
MS28';>VX^-CJ-ISRX>Y/J;NHW]T/%-J%O'2PZ9]\4=$^&?ES-=P&58/Z!*>'
M]BTFS&!AKIQ"O 7"NN_:@V]]@54VAEE)VL656(MMB8'EQSE6RIQGA)E'/$C+
MQD++SZ_(*$X..[#,RR=X<-0@MB&IXIE:R[5R>T':.O=>],:=:2C#+<_KL>O3
MHJ&KW[!</BLO'N1;Q0<WHO\O9'3X"FN(>M#%)FFB_V]BSW%!$T%^[F^/OD@8
MY^_R$QYMQ#0@&GHD,5+ ^[>/'D1%/A">;(F^D&*]4]6\]UO2+/PFC&X#GU!$
M7QX$= @W4*KA2IYM=&;Z=:0#K3'V:UK7V^HBGWN_]7N%)!K7.>X>#//AL<SO
M<K>H2,L6SKH/<O:T$0^BG>/,PM2M/197IKWB*/PI!FAIJ/U_9(4"N>?/16]N
MUSM6..A$\XY32=1"R?- '[5\60ZX6((Q[K^OD=0\<>6=M$]"RF[6L(W$,]QW
M"\+KWQKW0LB*)1YVKHJ>ER2O)^L!3# 0\*B^ =:?*QQ_X;78_,.-):'/2*_,
M*JB:;EUBNG21)Y>LV2>T<MYJLSXU)2T+SCY];JG9ECBPSH%^>/PASBH,S*/%
M]_^X+B8Q9028H)G/];'R/$B 0; KBQ#$P*37./$@KX-1Q\"3H)W/PE]_8>>B
MB00>I-$']0%+=X>E3.]N[]S_&Z\SZM/55IG7];8@6SG$6HT8Z4=V9@7#1VM0
M%WL\HRX6'*XIS]E<X$'TV!\N@%FG@RO0_P>(_?=(+W"'-H#F0_#[,#I'+3LU
M'%H[+DRQ6R<8P"PT"V7EZWL>[NN0&&_BH#^LD&=KV2"3[3P++Z?0STC(\B!=
M!JQ]B,<E.9?;DB?'28-PXUAQV/+X=78/CF*I3JQ,\-.0'6THP/3K\B!/,32)
M,K,(7;;#C8&SP[G:L$('GY5R/ ]BT@HDL1S8"8"W.N8-12[N[J$]I^J\C@X5
M30@V&B]EHBFFB],0T#75[ N?NGR0Q^E6&%SW@QM!S?'UA9.L]Z3KJ&VFN+P0
M'.']H>#='R(9GB$.^.9& EUG@JM-G9"XW7&%Y.YU[:*[E(_-0 $4$-A\SH-D
M8\^R;;Z@9S"4YO1"L 8?9>F%Y)$+^WF0TG!SO+*4KWW?"Y]%R[M/@]OE5.>)
MW#^;INIA]-,$LKA(83#3DO/2%"OJ*]6^X(2.PGGY_+PO>G+HJS9;W#^I,T$X
MJ;.GI_1W7.B1'OW+2H<U_*NK#PM(O3T8.&ZXESJ OA $9%KX'!\@#\,WQ.,Q
M/U"=.1RM0QE9)4\OO/3W0$P_I%2='V(]PSQ&AQ@!II-<X</TDL'/*)E35.@=
M]WTYTB'7W]9UZAYI-"\^*,AYF/MN<5".(=%G-*'-?,9YO)R5OLC'@@$$XL_W
M$RI;S)M'.V2@6\$F1ODZ&[;JA*M(/E8X:@0K[MA7BO3\;&1 2AYM&U)X\08M
M'B3Z"_]VP&]DA@<!=/$EZ$NQ1EG0'6M3KL,SNY8UA\MU:J14;@FP1D]N;/^L
MQ*IN[X7)K?CHDW9:JVX?E8X-@_E,0W6Z.6>U&2.D\]-#W?VOI*,V9P=%-AU5
M/DY?=;'R ]N[(RS(LQ&: I-&AV<%D13\]HRJTT?3]>^D^?B<\UI2=([+]GI^
M=CD<7IO['JE,IY"P8NQ#(PI4.*GP2%>!V?-(TUVQI\P=D]_M2;SY\W#(,SZ!
MU*?Y&H?]3SM[_Y[?Y.^.-,#U689F?@PCDL@.W@:4O ..![)&"[1J6N*3G'_K
MXV5_SSQ[V5Z.0VV,_ME4TUUX\W_>8?#O$7@:""T1RPL-$7MSZ5CF\-#!]Z=4
M-M3$&7+].(JM1(*_N$6$'LH8C2]I0GWS> NE^\$G1BG,/#"079!P>K'79EMZ
M.OO0M,[P><.?]R(.I,XN0*<1_@5&I15R<Y=:<95!#RMC.[$E(URATE>8;]?!
M_!X7_4>O$X,* E4^=.V[L01E((@^.>=M5K*=B8WN]"]2E+>?I <*TG&+N!E*
M=XW&+*Q+0AAYD0Y +S""TQ;BGJB8V>7$1>94'.5ZJ(PQ!.&C.+;R,N,Z/)-"
MMX?=4OK^G?(XKB3$0VE[5T[.KI%E[<8[SIS:#.FCCSQZK^2*7S;5G7H"OT[X
MY7MTL/Y7<08;^/S/%)U-.%>8A#N*)>(D$%<T)YG+4IL?!1GZ9^P/K+W/0//!
M^<<FH'0/@TOO*@$HJ7]<RH?R]=#Z]"==KH_R*BYK?BN1=%VM+R4$]B,&O6D"
MS[;;[%N[V=L!ST"\I3B&/53@BF1B9_>"W2%I"&C]@Y#=^T@445@6,NDY8+;?
M*8S<V?1(9&RCOA*]\ 7CU\02 9(L'5@>"(M^SPU-\^&II\S]1,U*]'*I'+&
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MF42UJ:>@R"(#U)*E?=F])QP="5(4Y$]NG=9-S(^E&\R&@*,L&<@$&C^U9X@
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M7VR=Z@O#CN7N"9BY!\T"#SA<&\P?1QIEJH$1_XO:X/_/SZ.S/O$W4$L#!!0
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M9ME_S+"H?\JR?QCV+W9-00ZR[0,GCTT  H<PZ(4)QR'_GY3F<&HEHP7GAIM
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M1>@*83QRGJ(8%P2-R^V?SRPMI!0?I 8'3$V;(CRF;MGFFLFU&PCJ"HL>0=1
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MED^!:,'Z;-M;G.]H?]5]:#ZSF6&*?#=W(.]<._- &8W79\^#+@ EZJPVT+R
MX/5=+=X301$>;>)U;R^X!E18E#LL-UD7.*NI$+=\,?.ZH6Y7\YXQT>A68SCA
M)WP"1DI9VRX#-$@>[0@1Y&7@-!EA[[C!MRPMEC;B-:M*N6243;N\5I:*I)V]
M;#.EP*&06N"A'*6)?8>2!JWN1',009\*+:,+;\WA/Z/%/1&'](TH;H!%VV$#
MJ6'7$7]"O9V( Y.>4Q0OM'9E]LV5%_L.>M?JRD>BPM"MYEI80![3"0/4=E8W
MR!N$@;CF<V3O<? _QJE(D&(3'Z"Y^HOM9[R#Q[\/E"W_BC_HG7X'KHQ7CTM5
MY<\1NRB,-M("VD%O&07.TF1 ;8(,Q.G0)E"?AP"M#<&/4OXU>Z8^2@7=ELT=
M$% (7+53]%E)NJFXH;SV,N-\J^I%4P4586]GDVLTM9()U>Q2Q^5X_;3J>F[^
MK#L_UD7.]TK_G$L_+S1H) RQ_M\L-_@"VUI$*>>*]]#Q^CHNY1<>Q&6?0M@7
M5Z@7'3:Z18CAZ>M@^YYFXH S@ICX^/BX^DAE9M;?:S_H<C1&GJ?\Y:WC;)$0
MPK[K]>@#H5;MXSNY;QX1D_2Z5JZD]XVHWETM2K#(7EQ(S=B_F-XSX#!8&"GK
MR"O\R=?R;J&H&G_2.KMKN(Q\M,I(I-F9'4V'B4F[7<SMN@28WC7EV>LN(>]_
M=4N9??ZYU6EA!!'9'* +_T"W7KLK1/1(0!-R$HDS%\\I=C_[@;Q&;JS3RA!:
MR969<)B22.QP>V0JR.6F=$KMB&'T+51I8:3^--41,"+!HYTA(UIJ<3ZWD!YS
M</X9(+MK:#FM_AG?Q9^OJYOOJQ=92#74VS0&?/E:19DR[GMMQO:! HNF:\SQ
MG:Y'' :"VZ_7>1P:RTTJM!)P^9YQS]C$-0$<%".II P;0\N$;PI-=D\L_&HB
M'YU.^OC05=*U]*3VX._8FI1+$:H3TQ>O]32=4NV8NG!3]=2I\UUZMZL&_U&O
M"B#L)KV#KRY/9;ZP/;S5-0@6U+%@,2WBKL]OPBZ>:/3]-X)O^=X22@H,=.7J
M<=]/^9D?.H4-==L*(X7=TC]OV)2_W/]RY/<G#8?AA:&@?#W>CXYQ7V\Z.EVL
M-3E9\/KKYQCIKK+"2 WD:<+& >!D9SV.$W"T'%(I,)2;]LHZ/=WUS9A7Y/P^
M_4,1E>;_;S<^_H_\'_G_F[P.?>P\2%=Z.0M@.AR>!.>B\KP41K=_=',?/%T1
M$DSEX8:;TPF,<CBA&$%VP#R"'PR"3^<9@YDGB'XVFW G\6Z0DTGK%#9Q?;P[
MP--BJ_'5O3B<>[T+=,/Y!W=QI-^A0]TR;+]?)^P^GE.CB_A3'P*68/J?' *)
M:TGC!U19)1#8,2LU[(^4(+Z[X3JB%<XPO#WE]=K@5MT1A&OJ.V.Y5.:M%P2@
MFSK+*(&[;L3A#M2S(-/C%\B2*%%@@.2)5/*I"A7G?6?R&&D6(&3A7N;4$ZA9
M="4J4'*0=\31-TUV_;'KQA4HUK.P)8Q1C?-/TB!8=6*YF3TXCA88O .1U*+?
ME+;17L#1-!*=WX(I[3+OK_S5%"Y/XWOB)C(KEV9V,RS >"W_)<S0&J&%&L<U
M*G;  46U52D*+[6'45%&'D_P:Y8K-0QP?P5HF+P?OIWUB^19[5O5UR2JPR?C
MDT,R/&-*CL[[.N?KBA1D-*#.+L&:&G!TH15JXY#^4<6X9B-RC)HT8-LAS?WV
M0WV#M--D/6ZH-&&!%!SF$I&FT%:K7)/59UU+B(QP,@K3Z4A)*3@)JP^)1M]!
M/!:WP92O"+9]V.DXR[@@12!OQ#[6#Z@1^) >$J:GJ?WELG9[D ;78>;-@KI_
MW9_\F]A&,T=PY*L;$XY4=3-?%L33?\JD_8-VB>!/ #5%Q 9I=,.6LMK,,J0?
MY5RD)?O@5+YNZ<\)OYW@$:JV7A,S^FHU+SRI\>)$=^[EWKX=<R7*'#439*2-
M+2*>]ZV*4#WH.M5J$C>GS;F0KIUE%X@<D#4%U3839D$:Y$TF;%O!VH>++FD"
M$AI+8'/+81(9T$A6S==&DQP)4K)G57 6\?K3KX!+2CL&DGL:P*N"\I$.ZYC#
MT&I[VACH/<(_,1D95JJ-@5$EA7Y6O4QNAB:0V#$K08Y)/_:)-, _L1Q\ZFE_
M>/E,L8#BZ(](N!#" &D'>NQGD#B=1O$T/P-6J!-D)0L!6<<(KNMZS>4F5WIN
MU9TRZ+B#RQR(1X@Q5>EWQM!$6:"58M6!4AI1MYIN-JO^@; <0!1XW&'XY&&G
MU-&%G#?8"WQR+_N_+CG0OI[Q8V/EZR>H7AF_)9T?H<."'$2;(@3@A*440&$\
M*G^X73PVA8ZH)R+:F0*;F0P69+BD22;"*'3Q*9JPCIM<Z'R!-&"DT#TJ'F&4
M5_08)3$1&O/577 'NDPASO!SA"C]>)O\ZZ%*1WJ0&^XW_FB/\HJ42BY";>L]
M[1P)"G+"CG0_! ^SU49[YJ+!*XK4XL!-P0H7Z;,!!=T%H3MH0$&'+LE+T6#R
MJ-&<)IC]* 7&BWJU@_8_EFRGGN26)+_7ZGOY^5$41^C(K?2>?O2Y&WM_VB+M
MZ*_7ZS$TP2 ,0SAS'H@EH*.;X9^/%)S=EWW\1HEQ\2LU+P=+,Z-ZQJ^DLP;+
MA>2<++TW)P4R?OL^0/R,B #G5@+T" SJ%*H-W[C1 9TT,6)D-&N1E&!<WC94
M:NZG\;@W*@OO[)4)+[*-DC+XW>4>?^?9LN1B0L^/S:7:=H!EOI6$V;/%P GD
M%<^XQ7)H:2,J1X2L2)>$L2 GD@"0.[M,0QE:D^-=F72?J"_J"<#):_DJ-V_/
MULZ43&*NSBMAOL=&@3BSZ3]Y>\\()@!W'8@3ORJTU9A898=_=NY)*1[^'.L/
M>+$@7#:@9\@C@Y<*%"DIR<U'FI\VQ2-%E%\9X"8W@O;NX)[SG!@A7BH,5X29
M,$,.A<$FLD$/!I3&Z4)"<W5&T';T=#:Q;USHF4SM:+.A=$[@T7-9$OB3Q@:M
M@0A#+[V63*S7VQ5QZ3+_<*][>6OKU<?LY3(C;F0\:_]A2QYP*FN#3AE2HQF8
MH*-5R / ,EA?<SIQZ^0TJY L*O=W,[ *XR'O=-GO^?1A6S/P9.^&7UB@$F44
M;DB[6XC+&I@<9QY"@<Z-I?.DS?9V8H1^J\6+NXDAW@(K[93FO+,L2/%4F%#=
M0\UD.E4N@<'-R(83R"F3*5U#TTOHAK+5%9+5_A\M@I;^[:)>579LLR9)64=(
M"*KU';@#F7+S=)[+]M/KXSN(I=6OURXQ$@J;0ZA_NH2/4)VXQM)<+>CD8VH:
M&9?HOMG<H_E1B051NO+H=/[09)\@Z>@ZY5'K;^QM+&>)7D99K^;PZF]W$'NN
M[/O;ZLQ_G^S7DT^P'E%_V\KN)H#00;=:T2U(F,.H;P[=J[[DV[,2&_%P24T+
M%H0'\!NZ\.&<=M>"FISUV)N ON#&X*WZZ!2HQO3G]V&#5M^E3W^D.,4^:;#
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MA4 W$=\=/A'$@HB$JM,Z8)/94UP)<K;V6%\G4FA9X\=#SNYW[.52+YQ?V81
MV1FY6AN)&+(]8M*"6@T:<0$$AK\:>A4H?YI>PIW$"%>2:,R#C*;$&TEEX=6*
MMH<CGYBQC^VWB3=7DKFP>?ANN&@BDR]TAQK&*$(P>:)I#BL?X G-$45TM3K
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MO_?]T'XU669X6><+=].GV'/R2;M=Y]U5DS8_LM&CF..(VJ9.[$09-9YBLCI
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MLZ#12Q8DQC;BKQ]>G?3=G^,91WZ''1)?OX$O9%P$52*Q+5_\5^W;_YQ O\$
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M_A-U@*CBE324W $F2.7H+WIG0'L/8H6 D_@P&FN+RFZI*U&<?!R]Q;"?]MU
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MMM60IYK=97$_=2OO-M=$]/ASB3RO2JYTY!_6Y/DHQ\#0A(%1TB E'K#)A_L
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MJM&+"=I2.1AEI3=JUQ$P85)D8E.3<B"M Z3J7SX>%%[S(S%OCM'-.$K$@Q4
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M^Q;$!U5B9W[P>==F4V0I3<=V5PDT'"A,OF\#BS0UO3E;([.F1=6E.U,/8"P
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MN#9_9C"TD#?3R5]J>5:'"]%;9VFLSC7"E ^MHM&[,Z:S/JW_6>?37MK37(O
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M&,*N.\^"/(L0F,"Y*/'^FT@YP_5B5]H]?@:)S@W%2@0N"#5MIZ6K@":>0\6
MO U3*Q01F<OOFYJ@?)6J3.W3?AG%ZR=H^_:X<U#&W"T92>H6WU4EPV,=[3$&
M8T@GAMF!W^F_$X,_CJ7P3R3\'DZ9I$9&BC$T<&W[$<'$Z8NN_B@.HN]I_TCQ
M[U&M^\<\Y;%9U4V5G6V.SX0I.FMK*.)L%9(I:@_R+3'DS/T(G=0V#([2=+-B
M1I.V>FNFYK9PN/$-!]>VZ-ZW)LHT!BEY?.IPUY.]B:K\KV&.MO=YBG#JM*RA
M:2$SNU<D62/<3H3+3Z/7+U!Z5UZ4R,QH-,5]]-JLU(4@B![-A.X/66O^QON1
M$(K>RBH;4[[I.X!5]&/$;W:N4>9/5]$]-PE-1IQ04',1YZ!(A@T)I)RDNP\W
MV^-X%3;ABM^LR^7B?PV<[YK ??!P88@G@C<HNG),&\I=2X^- T^B&9*S[U*:
M#)!9SW$)U9,%65=+F8=0IW%Z,A]FA5H5F8<&QTFS0J<X\X%PI%M@U4!-:> ^
MV>6'"8XXJZG\1&9OD4O&Z^,CZ;<CZG[-?EJU5/."7'>F_6]P-J0F$+E (4S
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M.8GA;@^[?LD572K<#41F_7FC693_E:,=H6G[O'\G=;*^@)['!#U4/@;@*04
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MS9?N^E</:YPH6= [:O7P:FJZ92.7T(,/\5?<=RM9CV7=W-B$%H?,9J5>"F_
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MSWXWZ/:K/X\/#9[[W*@.NY#;PGM"^E9'\R>V1V(^_]PY/K0PUA=ZAIM7Q$M
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MBIZ+_OV+AMX_<[" "<IY-O;"F@F2D@//Q3/>1F(:^N>>L8 ;Y1WM-WT_[/D
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M^CZ Q=Z&]$5ID'5>3"^:UHGSZ'<(3;BBG$]R$!Y/?JCV_0KZ@Y9,Z1*&].F
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MGW"9N?:-!P<_S>CB\A=T'DMW?[NEEZD^@B7$HX51OOC)4A;O4;HFW(QDP^U
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M<2VH>!G)RZS4T%B@F+\F:HM-X_% 1&#O :EO>(WLZIY;LU=GBOKG)722E _
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M?\@]PM*D?HTE0!,FT9U8Z9F8/.NA,/_ZT_;AIK,.+3KZ-<<XLN(<3RA0X?M
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M]P\;^159!0>K0'8<:;],>"^5SF'_+#SM_PV+ SFIB02KS\,$&").A4QLTV(
M7"C5R')45;>G8G;*;7HV0.KN5>H3GH.-#;F;-[*7++O]7J<BRDQNO,>Z,,M!
M=./_I,3B.TM=[9 ;8+(AG2A19\1IYG,3A7-\78@?DR]7#N9GWTD*"B_75X_4
M^^RT1G/\07VB;)5]1KB><5H1*_3 2SAYX^9Z^%^UB0%.<C&UN!#-MK,+QG8?
M/YK'U3BX3-\_H]'I/8W9S\S!WDSG80V;& *IE!NK'=L%LL #2I9'PS#C'M%Z
M-7'Q>,G*1/"[]X1<6/:]P$1Y1+ IK&_E<]RMF.3_9N42(\HL0Q'>P*HVUOP5
MJEA#\+J<^*W]ID>V\_<9%4665_7(U#8*FPC?."(]^[%F#:/[5<=:\'[1J>^*
M0X_<WS E+GM_O54JWSL173!CAC1!#J,H$3T=PL+]MPM9?=!:DUJ2E?11H0]S
MI\_JK]ZRH%:VF-S,+-_R3?IT9AG.C8@!VY=D+*$<OU_QWE787!#Z@?YR[]=\
MPFDY(]/8AJDDQ-2SGKI";"AQL,@B67;%04?B>ESLJBOR-[:=ZZ3JO(KXE\J7
MA'(_M-XFR(%1-G(@CVZ!$6W4KM[K.D4NR//:NUZP?:G9TO/QW=H/$.3AUGM
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M?N9$_\Q2Q^Z ,NH\O3EX#,R!9=Z_1X-)-NA82^3LY!A#/(>V0$D@\^7HH85
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M<.KF&:[A\+;@5WS[]I8K&P><%GWJ]+M4V*OE+('/KAC7!#8""6GC"-/%^.T
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MRY"C#9$W=6^&!?:.C3\%V^ZC@@@FW!H,9K7*'ZA)P\M/V9!^*(\[V/^TY3F
M36S% M =C.:?DV-#T'?@2'3YKG"<A -*3+<,N\/D!DM7:\@W)B_X33L:;,BE
MCO^"*S["\^(L(3/*$TH.0PH^M]=,QCE<>BB$M/TK+/#0(HO%C8FOV(*SA%Z.
M9/>S^'Z3[F6D;PWR^(4JW',%O44[SUC"3.B^"/5Y"MU6VE'B;@*A?(GG;]5N
MFYLET/9C(:4+6J<=S\#/#%XGICQ)^&$X.J;$8J'4&":8B0U SYQF":*7=FKS
M+6[O5L'AGU[K.7= X[W.I9Y(#?6N1\)W[=5@HLP]=F9W\/*M>@PC9CY+;)4-
MD4=J!/:7 /=P=T-G YS<^#_8W:_NCEW(=KI3W2/W\.MZV:O:/? L>45IL"08
M@LYX@U  'WVBY#MR!]-:3D>2;$6C\%U2N; $8_62&9Z29\I-R4<WO.^\.]28
M\/6QM%JDE8;.8UG=TZJT*F8E"\KJ14I]"V'8O DXM9&(\"4%A@A%";=/RB3B
M@5C'IMZT66V#X1-#=AXNAS.R3Q2EOD@_@\]!45S8$.'WI71N%^0(5AYQK@C6
M!4V$*X MR$)2R+NS=Q JK\_%*/T?[+UY.)3A_R\^%0E9LB21J2C94B2599(0
MTEAB+#')GI 0:LR4?9\0BAA9*S1D7YK)7H3L(6:1[)FQC(?9?N/SO;[+.>=[
MG=\YG^\Y_YT_[FNN:\;C>>[[N=_O]^OUOM_+N*>_VGF>;R+:=6JJ/2J_UNMU
M;:.L)O'$!G6$/A! UT-^A5 L4?L N!45U08/AQ\*<@=>Y8K7^%PS5=&RBIX8
M7KQW1E]29,JY@>O9X^KX2[_,0&$ZQ/Y)Y@9ZHDV?&<\&W8='!" N4>L2-TQS
M8*217_:,)\4IY-B5J]Y-WD^+DB4<OAZ*^,:5HOI57[8>6Z"TMH_%UT)W9@@R
M/[)!/JN _'0V_00PZ"=VOXL66SOBLSFE:=24/+QPR-@]2,PT[N2-66;//F7/
MCI3;?OP- 3NLJ[)<KC)Y/WCF=DML$1LPA]#)"+T"A!!G_0V1@W"1YO,%2V-/
M?%_/$/@ :RF3,9MI]ZB/9;\?:<]+#M3>4#MR,'Z1)<D1$6^<)-!%$QV%^ I)
ML_IR+U,0C_$BX"^Y8,KI*II+J??$W$3^)U//:]]FBWVG;6V;!#!NK]'\_76L
M*0AXH_]G#$V*NM4EQ#__F-I#)!PP!D=6>YM:V\X..]J,W?R4K'%DS]_"VJC;
M!P6(>R9P#X!=")]%[2O@?+P%-.GR#)6193?@.07>CI2D?BZAE9.2QYRH E'?
MFH=%O,(KH35F_D]:KQWA/77ME^L/GA^$*J.52C]JZ4Q_.W1<BPQKPP+ZR-.(
M"Q%FN-' &QIOWXW#O>JHDBK8!W^;W]F[_OID<++:HOK1Z7/=W;T_0]"TB*I/
MS((-\'A!JXQ$IL/HV8W0&OQA1X- V9@V>W.">/-Z3CG.(3O]O+Y0MZ-S8]K#
MP\M2L\>46@C"$ _XI,2,'T,\8J:K+?OSZ:5.)W'*5AL;%$G@NSM<[AM4[AY"
M4! K]Y&K7= 968Z3OI_:V''03_E[_!%Y-R)Z DPT6A;@J.;#S^DW@&EZ.T8B
M*.D02Q81,-)\BM34:Z)RN)V\QU\U34JC-MM+^MK$A/IK>WZCS![W]=]Y0A6>
M'V3$J=!HAC\I2;,3)S#FHV$F:UL1O64RO"QO=[>I-ITKA8.F3PRDI$<('C@>
MC___M_2Y$,KMK\WXB5L#5%95:VTY&Y12 A[$^6#?X8FE$]YZ5,*U$="VK[:\
M&(HBUU OO^$//SNV&<-M#(UZF(0ZR3B+7A?JV/'-C'M="&<P_5:-66\YL&,8
MG/T/$!FFRGF_'UX:T0T7O3!X$G\Z&_0MVXJI]"=^AX?%F_,^+()6_*EF"ET[
M/_9B9NR '!LT$;2.<.&QBJ+&H?H;($WP'TR>UOB!MV1#:WDV")*'I\CW[& *
M-BP,4*<PBT?^#Y0/V,-H0K4,U<4%<#17*%7[##$;=<#3OP+<:I:'0-X4FH'G
MB&]I,J33R+'-%IP_R0*^T(9XHENJ3<]\U3GX1"76'[AQ!]:F03]M)2'],9ZU
MC)*[N\4Q>)_W_$MP[ ^.9&4=IN-T&'Z-7;\HT:F8G&'.WG?#=BPR.SCV5Y6A
M]6<)4ZV9X 39/)Q[I#KN,Z)SY%@,2Q_Z'1;7[CNN L]DO8Q'MR-7QB3H^L@^
M C?J_FKD4?P7R 28M(F)1X _9@>4SMM'?*WXM2UQZ)=!?6<W07G <(;K442=
M^(0%1RF#4^$4&S2@Z4*[ULQ\O1&")V+@%8*QVKZZLIX>EE=TWYXT92:>%9K\
MY.M[[<':SO-UEQ*-G1,DZ '&@=UB3@SN 5U^QAY '.L N!AK*I P^P'1MJTG
M<7:G<OZZ79T[WX+S*@S;$NF2L640!74>QX. =9HO,PZI@K!DUJNBB.\@M;1T
MKV( UZ67UH;G01ZUAQN%2CR_X,4O.5=?G_BJ9.1L<'TZ247:HB'.]?7#GB6<
M$#,/[QF&HLU04<L$LM"XA/4@\NB\DT#U2" X\=-2BDYQ'4JI4VYH</AXR/B^
MGG6)2W0MD3QC2=U> Q#B&ST$<09(HALRGC!S6?L76 *X>@IW3+L-=:P]R>=$
M;YG__(OM';?(0D:9QW!Q]4OYRPZ2O,2 C2D.]^KGL'"&Y(S0A!(MHYE9C%,&
MK"P'M36(4CU3HD0V*+JFB5>E))3E':;?'J"G&&U\NFUBPA=4GI=A[H^T1EHQ
MW^H>8G@R.83*!S,I/\.]V@(^"BP9,/-9^^<G4&W!E. HW\T@,Z<VL\8AUX&_
MNKU2S)C>4/(;J/_LY$KP:7.+9TSE_&?:\BS>.+HN0I_Y$D7,)?"@/" ),"_5
MN.83Q&,0Z)B-0OM[[NYV_B\?>04K16?W2Q\Z(IL(:_I?\!4AC#@;V'\PT>DX
MQ;!6-&YY-4\%_5=;F8=U78,Z%;;*^=&9LCJ)% P)[N"5L6]K=](7UETTXXK$
M%-^S .*!D_@2QJ5V18:L7E#"2SB+B_![@.4?=OR<6@M0DI1I$O]FC,6?"&>9
M'>;<*^P;\.4?X=@?D.VX$QSMZ$%[3W'*@WMFW[X8DXM#0 4AE[E#'>^'R+97
M >J=64:)*GKK@3F6TVO:05-B\3.;]N3O%()C3ZDS&Y0K@I[.8D)=8@+ R\G'
M6UW8H+E>>XZX?CE=M .N?'G[<:;-UFBETX2)C$(!+&ZL0$&29^V]$C!2G/.:
M55-<^+&6(XXO_FO832D7J*%*&  02FD[X3##A!2XRA_R9 LV?*3V/'>UD/H;
MVK;YD/&W\3T,#IAJL<7)ZE-=6'QN5$+7X4S=H&8V2*PF^ZEQ58K<X2VHGZC0
MO10%F9'U64>J?*P&]' (QVYWV,^V9&U9?<[XNV;%>/1U=@I_6&Y$D=F8I&&8
MZ/4Q3K5^%]_7_ N^G]=D'?Q)N9X!KN+IA,9Q"_8Z=-5>N5][Z?1@3Z\L&R1O
M- ?O3T=!X93[\+:X9@X.X,H80IBIU+;,@,'>]NT^Z,UXM'CT:E\[&A! $,2'
M?W<?9;EG+NV("\4R3W.P[MKZW7^F!$ GA)CG)((ZC.S.E1,V:O2YH(<2[M*3
M[K[#!A$^;6XGP2N=="G-,IJ4BU7$GK+0)[7I_N[TQCW*#S!T#:3VE,,=NSO?
M/()%C90MQ3(N2I?N"^?H7ER(02+MM9,LWU;D,,[2AD%&"3,5/F7JQU(D4^VM
MB\Y [!_A9RW"V@,M#)#U*.5_<UQ\P%<2T# R9'F$I"I\H>E/@HF#4CY4UZ?A
M7&I8WQ<"17&C$6"#6+Q:5!55;74R/#(XC47K7M P%9=/DWYF=$:F^YODSC?X
M7=@:[/!LOR)9^Y;,Z)U>+*5G&O[H\39X43-JG!&2^4R-$;2JZOY6E3JT=0H%
MD]JYL.OU(6VU_!>.D/? A?Y1*:A:&5(UQA Q)0=2G$+MT4DJ*PSYHN+ET.(=
M\TQ^#C'Q#ORY6HLC8EOZ >T 6K&9?@>*#W*/*<(0'RKWU8:3SXA_TAXWG;"-
M2$Y\EUD8T7?:ZHOVSKB,)+G*WGP^AY _QMJC]MB(+"YF <<>^;<8&I0SAF+D
M%]E+,67Q^E.4OHC:'SD-%@QD&O[=6W^^'X'Q3;_!HJ22GF_UHN3@5:NM8="9
ML2X,%T-P()A9U>FD,E1MZG+DFU!0@#0(_39-@UDU_^1L)NGSX?ZVQE-9#N.V
M]ET^'GY'MN_%B2F>H?&!&$KDD+[/[RT+INJV//$7O:"/1CC/L_>?BC@6WW:C
MWV= V* H?[I92*EAM$#&6"8'3QQ^=<0R$V1RE2;8AZ<<99IAXR'$,KR *]J"
MTM6Q=$/7^%[8:>:7^6Y[6Y3(43_Z;]@\2^*/*7=[;BO4I-)_&QN*-$/TS[%!
MA3%"S9-M<XF1?MHJ-_K[,YQ^XYPV7-F@5H0/!_!LQ+'"_G4598KHD@Q[-)&P
M(I0'9.W,=0_]_7,%^:ZC(I^WHBE['.P:P^QFWL)V[#!O,!-T-8RH3429E'+'
MJ="LCYE'AFI>]&:HM^?Q"M'G+=87VQ]C.[3MOV7?#C#QIJ<RR&R0!NHZZFZ8
M1$CM^1"<-%:%#0J#4I*NX]?L3K'D?VWN$G012.5_A:'NO_-KTL[!.#3T88J^
MB$2&W1W%_.>I[;F@?6_&J+LI4N9,K"_$%SVY2H:MG!!8ZBU<G#[^%'YPOQS7
MH,_5NJI6#KCUO&=\1&@FI1\QMJ''!O&<8$U9L#HQE%LJJ%:<Y&A'72)2,9-2
M%Y-Z^;RRS6!Q$/^+*\\R.@H.7K8[>T^#\1%&>(CD[7Q#M72@EPYA9_SJ^_SR
M.#R7UOFOH1D\\_(,J5/T2YS%9W$02F6(?KL$30;YFC)GC*-: V[;^NWATS_G
M*B5@YRZMTJOFO7?>8#LQ@'H/S3ZM%5(UUXZ=V'*L4/*?44&"A>:A)]=I2F)J
M9B?!?[_I?-%GC93,T57@&51#^27)ZOS:< LFG+RR=C&\^EK\&6S.F7_*%?F=
M#7J@&M5%GEM>(4/Y)QU",RO&LU<N[,E8)S+)'^@5-E#@V!,W\9'G'2-?7!3(
M7@CSU-3-6W/9;]Q"'JPJ8#/)X@NCD6]5C4]C^AVU^SMVE(;P#U0C!2@PVK,Q
MA)*/]ZS7ECH3?P/DC.P]K_P!]W5RA@VJ#?JCP8Q[WFGQ_5P@]4+.S*7WJH8?
M46G;?=8)7ZON;S]6L"^2[!;93/"&RC?^#8\_\[&@]Q_.FIU]+-Y)ZE_52,A1
MB=:LS=7,?*#L5$Z;EK-S(]>V"%@OPU5^\":F"0X9#+\=;:G'$Z[4U_OIEZY_
MQDC+*.!>/K^C\2<G:T/GKP19.IC/?S_X8BMDVB(UO5&C.I]1=)C,>$V'&(1@
MES7IABW4+9+8Q9U>&AMT:/Y 1M:@%F+]X#TM=!A1FO/XY9/B*]:,I-=NP)M2
ML!5OK,V;8YCYL31[K"S3C,384B4_R(CV>IZIH5AIZ>0XM)[0;#\_I,<11=[E
M?RI9D"N*^Q51L'  G@VG/,IDB+%4?Z)HUS.)0FW'$ 94>7+'RYVP!+VSIP8#
M'VDW-4U?-KK;>0#-$]#T_KL<[)80/TPJ+NGHTV_,*<)7LW%PXFXZJ2I#S% (
M.*.ZLED&#Y&ZHXD$ 0@TB<!]P=)=J2CI6R/NSD/$]G-%0H?80X\4N"#'A'V+
M;AMJ=9XQS!VP.?>$,PN'?Z2WW=YQSW[G?24=ARX<-PT(#KZB[^VS]W"HZSUQ
MBZN_4V^ ! N'Q;?P#*DPNH09W7$WM12AA%W*@DQHJU*:4:T.6.VX5]]'E[D3
MK^?R:TQ>HT.G;[AM:/0GM.OS1N=XK8@1-A=Y'3$#JPQ1-,VFEAG'!CGCH^%5
M(OHB4P"\E6)4?N&2PNFBB[ZJ=PX-:WRO.K1L\-1-#$8>N7^KQOAVQDHMR^,J
M1SS_Z700Q&>.4KD*G)E6!^P\J'Z&U5-AI% 3IV4GIV[+/;ITL!?MX!\<"#ON
M^%1_L-DLWRDDP+'*-%N);J?R=^4W6#GE2KH;Q/P&]AL6C3JPZ?<<?S@($SU1
M3'.02GWP\9@_+<%].S]M*%WVTOR7Y!'Z7)3=8CO1(WT$N0EYHNOO9[V6QJ&D
MF2Y Q()&BV7/^@=MHQCT7^KA**ABBM,2:B:\KDQJT7_C'_!"Y5_WRK&Y90)U
MS)&9BU2T95P=M/Y3:_7[_JCB3PF;,L,--BCDKEKN]X): ^0[0+-3YACPG.0@
M=#3$U-*T5].RUF[EK.Q\]]-#/R->Z/T6UOL-FTD/DZ>#6&/O*2[M^TA^[<>N
M8J,VO5_X_"U"9=YL\-7$W, \FWI)JM^NVD;'-LLJS_!O,N3\[+-&5.; HQ93
MP3#[>90AP$-^>0FJQFK_/O?@5.C33T\MWVTTA9W0$6N4]_)L>+TC97#R4V.,
M(?>-K\<I!BJH*YAITO\V-A&'PT8VRO>9-([53-V:[N[LGOJKJGKVCRTY7,ZR
M7[9)6-Q:[U3<%U":(?$A&U2CN:)!R:1= ;C)?A/Z,ZA8B5N4N:B-/XU-#_4R
M2*QE&\I[6<3@5YL+=];Z+N^30QV'U]6ME%(=6'R\=,N0;!H&:'ADL^[0.%ZT
M8*P0$IBDJV;P^:5=U[>C,K?V;WD\TM2"C4(H#S49ATW667SZU$9(!($[*"$6
M)QARE*67_\P$U:J/5$.__UH"/CWX;6^=8F+?X^JRA.TQ>#%E^B9%3*?&FOX-
MR5]7NK0E:0+CJ#W<FW^/4USD80G$,*/@M)L<XQ(Z@8!3D;$^S0[4^#\087CH
MP$J&BL+MXFQ>-LBU?? .>H=Q? /;P@8!LOAE\7<<Z3- ^4%X& >:*K*@_/90
M9M5,SZLUKBLZ54HWHV(4W5V.->;V7LE]-K:Y7N(U>M00LS^MR,[ Q]N;K\W'
MA\M9-EYCC[6X$5\>""0-XJ C_+G9$FDY&:S=DT X$B_GQ3V<Q;%"SR_\E\XJ
MMA-8?(YT'4@[).8\XBYE*IGIT$K5G!S5V"ZID%?97'N52;-)F\#E%-]QF)QV
M^.85O-=4[)VE[6]SZ^%$8;W% RM.'XVS[ZEI#V9<3*8\#7;06+='RO?ZQQR\
M&](3<U[24)54*B4_JF;?:=JG9KR]4@4Y\@Y[AUD%\3#%C!/(*YWI)0YXVO[R
MQM6KKWX_EX1<X&*#GJ@]WDD_ YW&RF*7$/ACT=\IMZFVP2%FCJBT=0>- <SL
MQ]#4/]):V6,]_@.SI2:WU)QR8($C66%6-SGV=5D[[U])R#+^IQ!MVO34)T"
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M8[<2HJMD2<W.<,PBLE_I6-N-BW/Y,SI+,U#@%+2]?T+=;O<XA?4+OP]YB37
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MTF];3C+S_[+LW'.FY?F/QI)M6RQS2SDO^PVS6MN?[H?LJ9N^ &"+;?5FP-S
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M__3V=[.Z8'K@<6Z0?]F(GYKWW+,,^%7U,R("8YE%&37T>-U[K[:@]IT#\5+
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M$UC6_OK?'CC]GP<FY_\-4$L#!!0    ( !."U%B%-TWBOW4  '"-   4
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M)+\P8(-V&2AW)%0&_$=__LL%OW4J&SP$ZC-@MZ0(.@)6;O_F ,H?0X?^.3J
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M%UKA.:MXEP&KD%#:4-I=B=[Y,D;Q? EX5-9>PEQ"$^\Z]LZI4J R)^01.,&
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M6[$G, -!,A;LY .;D55Y+;UCF>+/^&_TH:YO 7XYG2JYDY\GQS+:-X^PEA3
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ME7#J"AZVNK$ED1@NKQ(GG?DPW>=.[8/U?8D[=:?X17E<(_-$V\L3$ZFI= ?
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MNX%6^D?*[1H)#8[=-XZ_G"]W"<AM(N&UUS$?]B"T8\6SXYU!GF94I0B5H"N
M=^?G]5J5D?+(L/?>]!['C4?<],?ER[6XL%U&#880BJE[@*C#TOBPK0SE\:WR
M&F1W*RF! SFA+^<8V'_;/'[^3^^YJ5=.BK&> <>"1A"<74("WY2]$-.8=+KE
M#Q>6+]338%.>_TNL[R^1:FZN&G&?_^;+7D"H"Y%+"OCUN%#D1/\YOD^0@_H:
M\OMEAD)R&>/)Z&EH77='^>0M]H^R7VNP1]4EA*W/JKI8]"F6,!"SBAQZ*RSD
M1HG<=$8$AO 3/U4#O^\)P#1K" GLRU+X+KA N@G'0WVQ5ZGR%VXL79#T;9NJ
MB'D\_Z A<GRC&Q'4"@B*>'?J>ZZ5:^/F/.L_>X**P$_I^LN@6'Y@28\\5Q9A
MJR!69'8%W,0'T[+R  G#!$'7N#K-FQ4)JD-[D. D&P[J[OA6 ")R/U,-76G8
M=0YFR#.^VXP&<Q?AIP##]C]G"9%OS!N;I4>MYZN$Q9P$Q!*[5SO1B,Z+6,_T
M>L4W23MK>Q U5-R=:G!H6MP__$N'"C-PA#)<I25-=9S&5TY,^*0!OT&UJ/&=
M'?^&4A+)LUM*?6!O\R[[3:_,52E=4E][<Y"TMIM.R8)%G)ZG0/H.TS>&D+"U
M5?')0V)'=0T,J/(,]G&J8"^5%W3M-]0#"*M07=46(;+O.$T6S?,=)(=9RXV]
MO%S!]SX*'@VF3[S<+H]SHV1J(.\]U"E133)9OS03K'W,XM/?5R%/@IQ@%--Z
M?8X>A7LTY1F6K3G.7/Z,<7I'1*#R3V^MO*+>)<90XR7" 9DX)KYGO/.OZ*V(
M+)^B@5AQH1 N+987;AF"8?EQ[09A1KD@&V69KQ^I@G_<E2=@@0O=#+8 3W!V
MCM)C/=35R$P(/IHQX,$AHAL[%N"M^I;KJZ(*W.)/(MO'/4CVL,%CIM-H2GFW
MLI5KO?KU@F\VG5.[6ZK&^RMIOX7^%1]P2RW7U7[B5$&O#.& (>(UEN0-H_$?
MADZT4XPPWS-FG:/4$Z*@ @J.U1:U:7PN(L(#_I8!8CG]@TVZH7]N+'ES^M[Y
MD.(U4? EOPD[/4U[/IVX7UR%>0/4_2@8[=@%"C"V!?Z^+/?[DR:S)6D]N.GC
M.?X!93WT,*HY85+N1]\//MXV;GD$+T@[N\/;1]KNSNED#UN<>1IVS-3VV=\:
M^$X]7CJ._9S8J> DD_>R05C0Q[/18Q)6J\#WGB4IA:D,PE8=A$CNOSNS%;@R
M<MQL83K1,'&V?I^QX3-K29=6K8AN[>P1*2ZKQ_ _6.VQ7R_0>)TI>M *;AK?
MT&S$RG90?DS0?1/2$@*9Q4;#3]8]F+8OAA*_*Y0>A0'W3;N4$=I@V^1M2I9'
M4_37Y:9VLD1!.FG][%\N+'@?G'\;=-L3QC"T0C9BU920)3A$AK4NCW_\QJ'\
M2W]3/BG*Y^)\4Z$ Z\ZLM/60-V+0 ^/%4")APVE!LQIFGUK.#A.^^<2Y&6>W
MFX^LF?GX6XSH#/?SQ2_U#.0^%6%<QA'R$!70:!PA&U>;%@=W4CJJL#&Q:!/\
MD=3R_NP>I.>:'O:LC4EV6%-5!?E3ZB5!P&U3@F> WX"W37]9W#('OX9Y_7*L
M3ET =)!5DG^M$&^#&%O.<Y5*EF:PUE!M@4!*$HDG?:EKFM%)G&:6G4S_G"RM
MA'4//+QCH3=!JNP6%7NFQ6AB,*&\@;M40YH8:;V[/%3B1(0UJ3O:IWY],^XJ
MW_;<W;[*+7V>4.FW.XG#+Y]I\=-TQI=8:*+@##._ 6$.+Y"'J\Q?%2:&8(\T
M.1<>KO[VZ.>.NGR1?IC@);C?F-VI@<O'IY0@^KAY9)H<<@EN]:X96&LL_V.O
MN=;99N$'SV,[^<*$^1NKM\=9?;%(D4O2=\Q?QH8<63JR;E(^:'3U?YL"G,)&
MJFN]19IH-9--HE4R[-5NC'C(-(#^?W'LA,>;.,->A?B.4U(%"E8O((?2>3V"
M6]'CF!KG-J4)+,6??&%5D8RS%7C*'5XBXAPG%#!>A4T5U3N6V.+RX%3T9<=*
MO9MZC"N81] I42)N=9EJC,RA8(%.)%<^471@<I&L9\-YNE?3-O"B]]>+<P>\
M8RM^K*8ZP9:P@%("34#> C2W5S2D2026344^PS.TY7!+BKJ2N[^.;V.+Z9;U
M"P*M79[M0]]U_>,VU@(XN-OFFECO'J1J(="U>#N))NCIL ?QOR9LL +.].Z]
M_X V[Q& "IQR#%Y5OJ(10+V%'-+>0!F1H\F/5F*'B7KGU>XM/LQ13U"9#-BX
MZ)/$1)/"L>((KZ$5T"@<X2V\MBX$XV3$)?]\9,OHNCVR^&:=V.*N^B%]?\VG
M\@'W[SF'*B26DRTI)V=!XN?]*9M_1)V'0)?@5-,;K@;<?9HU1U4[W3S8CA"C
M6!QOF]_48$8Y"SI)?'[^./%IO^5"+17_TTZ@[OQ^E@;X]F^=I]L88G E@N/G
MUDN]C>X[BA['<OA(P^-:>&SZ5?/%FP*234E_Q+=/=BMX3%U@GX!-GF&]BRA,
MX5]-R7[O?#JK8%+;R].+3U>=3T=\/TGCJ'Y42S*T]7 #Z6+#*[';;NU(7+,O
MXOQ^TC$IFNK,8&\$W5=G,_@]5\;WNDG=T.HHL]GR^!N3W>W+);RI9$$)=*;5
M5J#SXQR99+ZVCOEX3;GRB0\3T58-/*5&,V<MS[@._"/MN ^AIM:!"S &^XC'
M+++:!(!A5XOGM&.,115:! '\;2R[6X_59L9'(3)4.\0"#N/AJ^N?HG8BVNAH
MD"BV,L,)<WI-ESQRT)UPTLTA,8\/<?<K2? .N@4&H)B&Q???2L3-OYJ]M=BR
M?M"L;CN&].-:^V<CXH?BSZ:(=+IIKN,PMG'3[&ZZZ*M;Q!GSI$O'SEY6O<;4
M(QG_+@MQY.%_?1'L-DV+R,G2]I3_=[2Z6>FD2X-3EIOLY[<%^!\E9VRO1EO_
M3-(];LJO)1L%@>B_E9L0>'1:<67U9V-CEE2TC))"Y1ES;2:9)"2$:XNV!/:J
M TIRT*):+#U-6(%3)8!2W*R-RS@:$=MD>5^9J=.2IXX6V-9>&GWQ\UIR0PC<
MK^@!G-"$(SUFO*=:GBZGBJ,[-"4;1A@B+($(?F3?P2\_D 5,X2$2<?Q1ZYGJ
M<R$"ZB78Q)1=%N['?]Z-R1]K7J^2F/$<JEQ<KGV2=GU_ \7;5__A[(/V2Z[N
M+[W=<X63;F&GSK8;D-&)TB@5TKGV$I16PRD_N^MBK\X3,+@G"WT!AZXGG[ET
MDTLH4UM!EM6B8%6H..0;';4'";7%$3+,T'WX2H_N54\RO'T/XDRNZYQ"YH](
MUR?P+C(DS%J^7YHW:L?DJEX\24$]NSF^9*_KXNR2/ZE]]ZZ;V%$MD6Z.,V]N
MQQV[<RKX$P0"$3]E0/,7CRF,[S1NVDZFIFEOZ"Q:@S'-+O3?7032W*_]7+1?
M/:2)"73BRO07-?COU Z\<]7X.Q93$CQ2+@%F,)ICL9'Y@G4C4R#:7'C@B3+3
MDT)H3UHG[OD>Y&@+,\IXO(4+945J_AQ#-.%T37;9'4OSJP\,F+M7TO2X/39<
MV.*6$.\1%3K.\J<_36R_&.>C>GJ!)M2(^A0].,/_IT42N':C.\XG4 @32!27
MDNW),D?3!RM#@[=SG_,?>I5S;2M3.5-!UK/8'/TS.P&<(-@.K2?3LY"V  +G
M7:T7_QRJ=^/ U]N!,Q"G"4.W7S.D9^Q!W%QJE(1H,K&E+6D%Q\^Y9O,;1Q]7
M\/9ZV$R /5':S0G;R-@] YPDM\\*KHJ2A@R!;I(242"-F,#A=I/59_J^WD=>
M[1-K^0V7,XMU/ET^<^K346T,C\KF!1K?'(,MF&J':3W/D-J#M+E0+R.WT@R:
MLA =$IRC=4:YRVQGX$%<L[4W.%ASY*7BF3QD3?I^JZL8BDR[PQLUBW/ COS>
MWCY]KO8W144;I;A?]Q><"QJC"THR;32$'ORQ;$I3!S+.%AD2$+P(2<%*["[+
MCQ>%?MP/VHQ:Z3.'Y[:-T %1;<0S*?:7A[W0F+&\J/U#RW?._"]1>\@581C$
M5PZG@B$48$E/ZE;2J#R=A2@%>M::0HL\ZL8S=46W/(='PSY1$=!%?Z],@Z6G
MK0<44TZML[:69<IQ\\45KRQT]C(<RM]DZ%%C* 5T$!P[8R>*9\6WN_8@D[;$
M1]C9K(,]_/J/\#[CR7=2ZNK"GFSSJ7))7S$^ (/PPM/+ 04$3;!_#D<[UF[^
M$3 B+8GBF6CBM0V#=>'WZSMGZDTKDY=.1W#V<-0NW7CX6#\QQ0Y5075D3$-K
M6%:WR#:(6/"'#NH@QE0TV:AR#V)^__T58U2,K>_.<>/#CR\HBV:]KNSN6=ZT
MPT:<<*04V\X4 DHF<'A#UZUDD&-9CO#^LROS0;!J'D-I 8MD-2W@$BF_75!D
M*$K=J*@]_V&#8]'\VFG9.T5-I!R8;/S!9U8O#JC0_3"MI^"$+/0!<*H<&3U/
M82OTV;20;0<L0T[S(OF0?FC1TE>I*#O> SR2YM&R%]MT<N,&.FAJ(!?IQ[2*
MXBE.0( G%87^*L&GC-(B^Z7KAIP/!)1A$=6O+3/"+:AI%TY@9N)Y!27[I1+&
M#6CXJ#]A,:5;KB8_XM?!,"2[0XN[*^JZ?Z3R];^]5?@?J][Y(+H]#GJ H^_I
MKU"V!>@9>&7=\Q[ JQR_DZU*VGH.50I7FL< 0-QM5*VWFL\B1USU70D51$\#
MXR?*?!;!B?S=?CDBA.;\QGJI0:?443&[,,]58/F\H-_&27VI1"%^'T<9?NE#
M?(@!$YI@,N.(/Q$'P 0[]!EJJ"/#Z[XF(6BIECW(M<Q'Z0AV>[T?5C\J>L\D
M>7$,;H=+/[$[G+RI*3ID(27/'HG>!1 8)<30."I?U#7A\_YVB(YG_Z3:!X8-
M%7A+OO3T++0F?B,4BA_1B$.#**$51->_AJ8B**KQ[;/KW9>&NJ 'IYBC%&BZ
MJ-X2JXZ+!]EIYRXR 3!K'8CYPVZ5G1IM[WL?D'8>F@:D6XBQ(=\-$0_H.'P%
M!CI'L)DA2#2>9+V 9V\Y;PM@.NML;P."727IZ+P'\-8C3LKVV-U9F0CQJYOE
M96X XE A1_XA'ZF6'GK<?OU-#,D,,U&HZ ,_A,)\)",B%*\6(<V(O*JE3@67
M91ZMG9:\<EGAUCNJ9??]>HWI?E;X2]P@NOB7#=9[=^(=3@3N6 ZHJU&"R+<M
M)F&KP5159$3;A=+G&78DQZ^NJ0K3/Q\Z*ANQ;>W<_HRW(^]R4C7 KB,PA-?X
M&MYK@JU[D*D+K8*":9  &YV:PCW( _PEQM(4XHCC$_CW6_+S%9=T')]CFG-7
MIUU;MGQLDIR_GC=37)-L##Y=ZJQ_+Y%)5\9=V%H/Q EO=D>6/_\3:[T]MK7*
MW7[9;O)WE$J&D6;?M+^= \).P?1Z2\G*%=.M\X^8&^1_)DR">*<8]&_Y]-<Y
M]:%=^%I8N&_658Z$E81#?9,_5^9*'GQGE8[#+>>\80G11@>@1^$DY*\P]S01
MV(HY]:2=O7Z()%FPHWB6]^0B]L/W1D&6 KEY[J+=IZ_LTLYU[D&XDNO\W]$\
M -9>Z6TVZ_OAJNDN_#S'JAK%F)D*834H:2H2TPKB)6/$1)+:$,<BCD>W8UW8
M-MR<U/T,%K]T\;V8Q\?FH>^$ _6.G#)@,]4',>JX6CB-?YO!)D[U8\]2FMM>
M/5[2_\:N8NBYCX#(HR2^2HWFEN&+XNGWI3$UB//CWPA(31Y7JX_X/OAOAO[3
M%[\GJ%@&FQ)H5\SH&1SIYL/R)G:EZ.19?/MR<\\,&\EC()%>QD<3K'/FG?9J
M-4D2(.Q<^8/@ .%'.)0]HLV,XG/O71.N],:4^S\CQ[\C?#"X$:;P@)1X]ZK&
MG*(:99U>A#J.#9]D7L\@E#*9ALZ3-=_R[4'*?>[^^=ZV_(56I=<8<#W1MA=#
M",63KI7S[Q]6:)'L) _-96<$OD<=(ZTRE!X=7GA/UO[F+-?V/?Q(I(3<:_3"
MSM%UV1Q&MOK)600'(-@NXA_2)/S&>M%&)]&1/SLMSX6R?$P@E?Q&CQAW#!)9
M!&$[##G8HA9U;C0BIFT6W\* 3?4&,!P:[:2#K#'YH*GBU%7^3Z2L_B%=0!1I
M_1-.@,9>C#H+9,RJB?NW[Z[&IMIT)11.1=UI#.X2N6#6>@AMKRM5^S O(Z:!
M:>?IWVLU'V;L^[J+ZF;^Y"F">=8>)+*%S34-][%)LM]WUN6!N^+[V:5AWJN=
MCY&/>$CS-["9*?0>H+@M6X@\'EY.$YY#<%N[[NH4.\N6Y;]?LBC4:/[!>](R
M6N_'W]R<9 @G1AU#LL4#JG] Q:R2[2H%*4IKMBANG"&&WECOT&0-#0+_$"Z8
MZG)G:5OU?M+3WB/"'@O"XYL*,9%SD8;<T7Y8??\-- ;[]_WUB;=!I8CZG_IM
M#"F"4D8OP#AO6P#\5!U@N?4M]+$).U"YT<JZ;?7@IM;:D=9UA 'J(HB&(C"$
M"BA'DEJ0$F5PU/?BT3OM1 T6HV\Q"0&G%=--.BZJD!WYARQ9GI?3#+S2BF[X
M/Z2KDG T<1 \,5M_D;+:>H@66G[N&V36NO'6L_Q[V3WHB[*6(08W%SBD,;G7
M7:$0338#:OU#'R,'Y80;XOH?ES^[;;A&$U-U7_8NZ\ ?>^O1[X[""20L<((^
MX."00I(GE!9*AB=NBMM<U3BR!XEZP82[Z19!QM#$O<!/.I-/52Y,KK>O<R=G
MBDNWNE*]%RF%3HOKN^._:H[-)3DJ/S5-F,8,7,H-"B2?8[!/@8\$ N5B'Y#)
ME'FR?9+A"\MV54KZ)=.%TOL<"IH?AYI1XV2UN;0N7-S^[I=SJ#MDDYBRT3K%
M\2B:EC=&4K,QW^]2F4WTZONP]IN,8\>">!$ORB9 ;%G_/SU_CX[#M'+A0&LZ
MNE^T;^9T-?";/&7R35V-9&+8-+#]1N@1RE3!([RZ2L-"4LOZ$0M[2*3AFO+N
M.(V'C\'92,:L:L@E4,T9TY/\E&#2CU=K-#CA=:@6AN@SFZ3?H%*3X16?--!4
MUB$OC;G6(D"J"V_BGFWD/@R<:Z?8&">^M^YVR7-)]ZUL]W0YY,HO%7_^@"G_
ME0-7( <0XMEDF<>+LZ3XC>73,]F8M+)Q(;S%;<"+-/<)<T2=)9>F!"!FY3E9
MVB?Y8_V>:B;DV4:^J0X^S,^C"T'G)AGKR]46O,-I>/1.IX<=,]7[WTVU_I?2
ML3WK@$($3529](>"S;"@YV+N]&M<:(,>S5/R+4$JUDXM2AQ/2QIB%;*53[WT
MFWXC+J3MK(,9;0=E"1B2+Q 0'>)FL[I=\(.NV2)DN9@G=T;/VSL-OLF>[B[Z
M\),G1,C1:I_((Z:V4-/[!;)!W31']V!)9G (IDV9>@4I=JW<VK8:+4'NBBWF
M*GW/EW300(NW,TD__,IP9A+$_<SN #9J^2[O^ZBFM\-;B%\X:$_452JT.XR?
MTDT[]H=Q1)_J!&+]]3+:_9*%B&XHIX49!1&I*5;ES=_ %R;XQ3&[=X=)P4;*
MBCDE_@J0C=-J)SZ\MWCJY8/W@A.]Q<Q_+8[^UR6H?'_A >P&+^,[CG0KRV"H
MLT$W O]I#\(I84K!13I(5_F&^[!P*-R1==C:C2VT"CYT/OHQEU"L$8<L[%;U
MRWN-(498610,T"7#Y^HZ%)5FX:VX TO9<F2YFB>27S?M10;SLV>'8&PYSPX;
M*K<5A70\8RU?.,<X AK4X0&:!OT5WI .LA3/.+4;9/^.$]%V"PPVYD<^"=SZ
MK9:O-NKJ#+M+E&L-HHY8L_R DHR' %GX2BC8Y '2<=+O%2H!HX9HJ;.B:<W%
MN;E/UA;HL%J\A$C%2/)P:-V\PRM<V;UXBD:]2'PZ4;UXMWG"-PBQH]2]H1*K
M6 ^!?/H[PM4;*'@__0SR( EY,+4>,VE&F.Y>Y29)@RSI8 ZY=#NBE&:?IYI<
MM#1I!76-,<F,7!<XK*Y];NK\<&Z]IFU#R]A4]3-?*"D5:<D(]X#O09C,:*Z=
M7>6YDY.R]+%\3S'>N?YT_6_2/Q_<20Y-'$1K8%J-<829/0@@O;XR1Y4<8OF$
MF-B#] $Y<PE'%R58 .<"!]05\J&5AE^%_N(EED9\8(M_ZHQ,GZT4ZIM2G9=/
M1+@QAK$D'<_O[)1Z$JQMZ!FV^G1BX3*"K84;Z:IXH0W#[5X3F'5Y)O 5(7Y,
MK;&P5";>6D3^H<7%%.&#.R.I^.:KD" S3Z()UXQQ[5CZULO*2VVZXE_/*5,@
M?RS=-G((W#2>/PS6(1(3@SV0T'R!HDS/O$>J1C"W"#H@Z[IV(VBR(F4%5:X-
M3>7Y"Y38NG$SA1LOM(KL:&^4-?57E'<+'U>I<Z5N1/X\<57/\K%9/)<:_023
MYEQ7-E<U64:3HX'L]%J@PHLG"6^0Q%#YF'))+57*_PQA@^6^9?GZBD^Q<(W&
M+8JHFQLRW3 F)NJ@C%Z.PD!W&.2@OCH;#0MJZ3 85D&4?&]__UL4$1$^-OP=
M_:WE!+DL0;"=.ZH!&S,SU9%]G'R]CC([GS0_?_/V=:>4E*N='B),O%W2<;K5
MF-8['BVRWQ>PE2SM2I$V;T9IPB6,KPZ\7QE*T^</>*@XW?;VX/^!>3PYB$JL
MB.MJ(_)K7)&$(A<D)+^H6^9, 1%MN_/9[_.G\ZBVR^POTX73+OZ(?U[,$=JC
M4;AM\SG!L6!R4;"AIOJ"_Q2CTTUAJ=+.711[+SEM\M+%SRQR+4Q@#SR!;F/@
M&A7)P(^9NJ8^%?RTS@PLMT^6I?D,?'"QL2B6>W8:I7.3+&;K:"7SBH/924''
M:OP+MA+Q7-V4G R._^HL.>)*X\@6G,\EWQAPG&TVYA-C")&*+_=ENWL,6-:M
M)4[_"&&2*GU?Y>UJ_4PS^-_?LO$/.2@_):]A\-E#S;0ZFCA#E(M'PF(OZ\6>
MZ>O[VQ;T$$ZT#3@]!AC"V-!W,TI>ZAZ$B%G!8%Q(,5TCJ:GVIV:^X")JA$TN
MNOGLE$1=W'G##!E:L\H<7PKB'W_>?>^#RJ4%_4X&]ZA[Q]= ;%?=:@UHYM_H
M56  S)Y1T!2EYS/8ET2T,ZM>;>+Y;)0F?;)T1WH;$TY8Q:-JIZ1"+DB-/[?<
M%I_C/HR$$Z'AGBC^N3T(FTO#K[B"3W>_G<^ZUZ66X58P=#OIY %=LP4M_IV
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M^?^E-(3LE5 ;L4[8<919Q2@=XK$92X<0(]S?O.CARJHH=M-:OZ?8*YG.X"_
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M%#7 [V.H#IRU"@KY72,EX"7C[H7/W*E%FWGRBL3;O@VP$(WJ8=#Y5A\0[RC
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M/D2@;;#,WWIO]G&5G7=KST7\*X/103HV6T</%[TX/)\Y/T\>^W2"UK)!AS2
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MA!'>Y6C7T'.Q[L4"FQ: $I'*D X>-)M;K9W.,A&Z%>-Z.RH/'IBX.3N(,I>
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M//>$FWJJDUTB]RUF58$(I?$P,UC925Z]61?HT32=PAGCT'$)U<:&,=TVG<J
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MY_O<S_/\GN_?U*=7+C.?.>=SSGF?]SGSN3[#[&$. ]OT=?1T )8-+, 5^ _
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MYZKWBP8=^V55-VFLZ4#DIM;E/,-TV^Q"#X\Q)P4SHZG<E44O<\T4+8UQ%9=
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M"RZ!DR@Z$H8ED'KM6$8T_?/:50'P%7J1"3 !"1C9_/ON( 8W"=*4VG17XYB
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M-<]YMK$AV5KPU? <FU="/4,TJ.HK7P?WX%)5J;BE@\YS$\[2_!*.T-?I80<
M0$_U<:-)*-_!K5NWZH[+N9]-2O)S?'*IL*N%XK&07YRF;L'1EIJE7J'39]32
MG'4HMK?@19*%(NX]7ZATUL'U NY_2P&WWC;[GVZ;848A*<H!*)?LR=@<1)(B
MNM!XS]6>Z?$:.=FY#P^5V!*RC>2.H2P[#P6\"YUTO9"^O<.GR5[YCHOS9&-V
M<+4/S-W8-TSA\Q1+8?8C1];"U"<Z1[ EV+[LZ_.JI!VVV]N10>:RT2[WOGU&
MR&4UW36-6U9_(%X>TU4 -9.%&5MP5!%&#19>EN'8%+;8&C.IJ <Q-*>HX^V,
M(:50VB]M%^6^>\Z^;A6(+GO_X*9N])B@A%M!?#-LGO>,#RFP@GXOP$H/'-X6
MV9-4Q^!HU]!CKX*6D"&KV3,="JF371T-NT._GCAJX#YJ<"7G]<']M6]-ID;W
MJS[E<GMU@8HMLU\RC7F/32\?0K__FKF @PY54Y3IJ1INCN2CE!:(DQ1+: US
MQW-+% =JJ+ZD77C_+D@_WCQJ,>S[F4JN-\[[0H^>/W,BI[];(A#06*8)Q5("
MZ44:>L2Y#8QF9+':]+GA.?\CFDDY>EF2:</"QQ7PP=>JJFQ"OQO(IYQV49JM
MY'IYJ_S\C. ("""'D_ DTZ-H5A\=*)>*<$@<^X+>C-F+]G*K\1CBUG#]GAFA
MTV&7XFW@>(?/_$%=<TY8Q?'E"T5%0S O]8O%#.%W@G9(2!Q;!?;.42;>EKA$
M)B)KS4NI]DOER.D^/$ULF_V, $HM5Q 5,BOU_L KZW,'[8EG=SR<Z2*T)KTF
MW\I,*DH8#RJMH!2CW+N/^R8AGN,+>/R1-G8:MZC'?93(ID]3JZE*<'&:6Q'T
M"MK.Z9NA7?#>'L>H];X"=M*+]-2FXY15<@3XZC?@]X(VP:ET/[Q-,;V,IL57
M3U:JY_UJA\]G8&7'#0_MY]H5%:J?DF)DUO4YI5A!_ADBG_6RU+0)R?8\/5W#
M6#. #!*-"M-\A" W*ZD0AK@#I]<,VY,,'<)ICS;E.Z#3^[CVODVL;@;JZK*X
MJ!+\</30-@P?8PA=+%6'BQ@2I+$^5\P=QMTOGAAFKV[*Y",V57=13(+?#!<$
M_F)Z2>%JS_$^ XU\XV+,)=L>T*8M,SF9^&9LWM0@)^^K\8KO.<Y![*.#30HU
MV1KS^:6YMIXWXJ5>296\[/Z&IVUW) Q59AGWN%$.09.K3@'8VJ$]/@IJ(AHI
M7U4-RIW;]A52)=/N"K"*MYB=441,)(TWJ<4?8MQ&E3ZHD;^PR43.H7N@CUKP
MV?#BGV#*2O_.E!\2_KIF9\4@Y$T:@>N%(OQT% '!JD"O#RS$<2![;SA+%F@:
M=J02SXG<E.1ZINQT-+I>C'T<"JV():_=:>YC -F2 L% D$]ECM/1DL5_NB\N
M)4VN/^F.QP?-[IT<)U_7;;?A,'@*[8UQ=%:H(I*1%U;S;R;;]&7&?=GU(+M9
M^.@KI&<C7/HT$#RLXJU;#ZS2K,P>?=?A>RZ9)MO0F8'1*RJQ-K1,+<(EI">G
M-6&&OBITTU#44Y-Z1!YVX]2B!%ONB#=JI[,E:F1*XCVL&XOHH^'\]^\G^UL,
M34L-*W%!YPA*<.)Q 'DU9#R?52O$^[L?PZ44*0=?2!S6I3D]N<::(5RG,_T
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ML<4US;J28E0/#Q^*-EX;7S.\)>T4M*US?7SH;.[Z3>4AVU7A58PR]"94%#6
MHSLVIJN)OF:8%C,[&[ZT55&"45XW)(EKGOX7#]F+1H8](U]L.N9[A_UE+WSU
M%TL.Z<]IW0$MEH"%4%)!.)4M;QWR#!'=&L[?1F<GN>O)CWW@Y/AL]A38CHYJ
M'50^-YKT)2+F*@\U<E$3.!5T*]0'GHP1X.H!67U)E%<#!YH#7@;F<HIR+[QT
ME(JZN^#UF'7UV;?=BS'XF,-MENW#A'_99:\9H6]E:#(;@!1HO/4%\OF(ZE*8
MEV*$^:J!^$")?8YUM[E?>L./<N]:/0$16^,H.*V&AX;?&3JT(Q1,? 1)@JOQ
M@RL_@9+ZH#V^]:M>S:L\U(Z8GU'DX]ST:G:H7!EJ<F^BJI<3B]59X,7S*L^(
MYQE.MA=;)^V?(DTX64<,=K4&/8"@2[:Y=ZG?AD&W>D&("+;L+V8ST$TG0X/V
M\5'<\3 I!-41, J/CB*W,^QKM9?(F;._Y0^W;,BL[O6T&PJM"@/=GC;J(V3@
MVF8&LV;OD;=I7O0 E : HQS?QJN6X!16?CW\16;URH<8/LL=TG-_XF4O?S,N
M2$/X4M''C<C&:$X^;K$$H@YH,A2I%BDH'>2I<;9S.3*(=9ZQ)\>OPBDP&+\Q
MWSV4.8']IA=QZ&D,XD)9*X:EP?-@= !A5BL0)MBCQ_*:<Z$W;%_*W;"2!!S.
M_#I<3D6ZSO\I"1Z)X3O]_+4-8MHB^"W?1^X1Q PUI'X')/!R'.J+%N-^6C"C
M\W0#TH;LUSMU?\S$,^(4^K6WU1]=\ZWX]L<=AW#JVGE!(!N>T?N!<D8A)14U
M"6ZNPJ,SN$;3=4CIAM:JI'":W=5<;\]IG4+7!.97[-6]GB=MP/<+]-JMHXQ2
M<-<;DXDDMES4:4YO,$K7OZFO?&7X7-* L?]&8>X7XEC(8)7,HB.+>2-^&'3O
M_4ON (GNLJ[*_0"5AQQ"[( &T7*F&"E/]D6L8E="?D&.0>WLAP-=V8=,SK"R
MTSH%]X/SSSW\)!C+<Z0>["X5PMLL&>3E;@8N16"L/6L]&',ZRS,[8$:[3O]]
ML1>Z6ZOSWF89ZM)6XP.>S_:AIG= 4M#;T%E31 G9F?Z&(9EB;;,GY=:K)W&E
MQZ_IOLP-O\RO*"Q\Z=U10U4@<)TM2V *,4BKX!L429 G.Z1E!KFO.F@SL"L\
M%HAXU[MY._%HF/6RN]NK')T1%5U#BQ#1)X1[K'#N,$2:TPD!>;/E&/:=AGF6
M"X/5_L5X5V'GC&\W/M\^DFM1XZAE?S7VTD>A_2J@#4R" J8E*7$'=,?;HH\K
M_XE[(!"ZQ]IQ$=R,2+O P':&F?Y%-:M\/#4EZQPZ.; \E%TC??C$9HAKI0T8
MZD"5)#HL&K'E-+TYB9 CJ$\+)EV\L<7CVV!)$),I]@U$7H#Y>MAREE8M+2I1
M>L1?5,+7X[V:5U?[%^B;]K=H(HD,B]\B2;*C..4M./FJQ);) /*<M]ZI*)O0
MD_8'EW!/.J-*JQ_$BY1#K8KV:AKE<C_SE)\3(874^C+K!@6LP+Y%YQ8Q^%P8
M\<7U51DM7R46C]<GG_(P!6Z9+!^E^CB(X]9K(19.ZOOW)K$53(;1"C@_/T#W
M%EV3ZI+&/G:@OM&Y,E#6@>+5R9V1Z>VT+_5Y_&=4+*L 7A07K!7SS A/2MD!
M*>V ;A* 0_ !<,)#^#!4&='<AY.KV]\^O053##) JO<41 :S6:$GO*[OM65I
M7(+]3HNIM-V TKVB32CB5?$X/V=%"CCU3J.U SCM ,_.5R;JD$]>/HG.06XE
MVI*%CP;'9TONT_OQ#GT=EP*5A0;#Q+DSN!;<H('@98C Q"E,_!98[,<%3SO]
M9Q_ZUQ;'3"NOFM:1I7+RLY;[I1;5I'U89]AP3@/W"'?BKV!">%;RX06V=<:6
M2X*EPR,S9=K^5EQ&H[3ANG7-K2NCS<1A/.N39A=M=Q-ZL1S<(DG+6P3/FBQ"
M\5 IH!N/DX1H_%*I*(:EUVWUGJ=-1&0M;6HE*FZDW(T]GQGKW<D'BLH@L663
MJ!']L#E9/*;5:#6:9;L"46QG3&7II/4<HT E>CG=3EIEM]\,R5Q<.)M0X7I&
MWO=&3ZU\/70.QQ7^S!!E#M+!CY#"?@RBZ@%Z8KEA961=T$.GK_.![O#M)W5W
M[7,..$FEFE>K7SQ4+;=KB;L/2&)T+\+9"E4\C=,<A?JD=H3ADL#V65R!FP5;
M#:HT$M6='OE$0(OX#]7*MZ\;7'PD<W#7[,/KDL<8A;0$*F8/Z@M:E@OB6536
M.HJ^[?Z9??8[.2)]:UUFP>M'%PJS+-^2&G1T_L3TQ(L&UK,,C6;LLFU"X<H.
M2 ;5!Y6S=N;!EC1]F+9RC^%BDPQ$.7H?ZS$M-L4[RWJZP/6$T^?-0V[[_ DU
MKS[V[2E/ #IPA;\R3)A5]'Q"/RP-+<,VJ@8>NNS[^NNA/98++F1%V+XN9CK%
M57E]\-'=?Z0C^72?;8-@ 4OJDZ !HY#Y@N&'AP.'A#E9:W V#+Y($$$<:=UG
M=Y:N_7NPDME8/2;FIFG-G#AU./'HFER\ ZA+9NX1* K,EBV\PGD%A_#- Q',
M+CJS-I@B+HE7-/>\7%FO-#9=^U+ OKWC\1!>><_W]+Q8Y.MSCEIT4LL,6Q8]
MK&;(J4*:L&YR/\"4@Y&25&]1ES07;-RE294U@FM[IHG,^JZXV_W(EX+J^:ZQ
MZ=U9XSL@X1X=*DX8N#K,L*((,PQ[(X]U3#62W[ ,7D$^GY=OQ6YOW'0M!S6;
M'/'UU>X K?SX/W:X 3A7!,828/L OQA)3IQ7N)OK*;\JD:YTWR+Y_+5\M4KF
ME1#UT5S;\0^HB]DIMVUS;QZ36LQI21S^MV+ PUI'K"&P3DT@K7:S[K$/<H>
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M7"GN!+C-@A;&.HP89A8!T C&;A8E'2IS@2MMH&.+S4%";U39!CL%;,PI7UZ
MSX_I69W)T,3HKWW46R'%D%[K9$&DN5^O03BO6PDI788U?E267HD526+PQ8BJ
MU\D-VY6VR_EQ.=\TVB[N$</?>G2UZC];3#S+X&[M@%+4M"=V0+X$XHL!1R"
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MAJ:"$U'6=,EA%\"N53+)<S/P<NV]<E%6I(^QC8;SDK*TYVGBKIC9RQ(VP\=
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MFB,UR]BQ'($9O )&SOKXRRQ%_[_+]3B7HN^ZLJ:77_&'26GQFXL5G;CRI<"
M))F&4VB! 8;AN+?=T-0R3?B>!<#3V18N=O77A;';.L$01U']<_B#"\]CTP^5
MQ4CHU0*5O/[, ZT,':I.'S1=API.JO<%CE6N3(][[("N?QQYY1BL874,;JV4
MWW^03\Q=:ZG+W2:*)8!TX$UBL=E>J(4:AM,IKZ @HU4R.:]\K+=>O-DK[_N?
MCLW#@]SE^9@C"S$0;\".=0-!,2*6P#BEN#LN*0L\5,<_ ##P</+7.T !PU2U
M1* G(<\Q%P_-D>\9M[]L%6^W+/PH$D0H0E-P \>0?CP?8DSTR%8CSS(26MRQ
MLL4_]6A6>&.OKQYQ-^[IY 1KW'J?I*DJ=SWQSK<FG85_"_%'_RW_/XR([5%D
M;%*@";\SH'T+![W/D ;-N_C'@PA5M=WB!S],O#'>]^[EO=B39X8,J&$D8(0%
M0A!X^L@O"1UB%(]37F5#7P7\U0MXV%#Z"D"2M'*>^,:/",LZM+D8WHJ9=7U7
M9Y?^'$3'96&M.>5;.$#?+P[JZQ*/:Q%,V8H6Q:.DC!>(\S_??.T3554E&WRP
M,U%B?S[-GRSR6/90D[VRX">L,?(@IXD752ZS!PBVX] [_CWVUX$8,[ R,$>1
M:/E[A_[#T/X.I3- "_''5=2> EN0CY=0Z,(I<?O ,D@'GE'DZ=]II  &S.$T
MVX(WDKYSP .J0WX9Y6M]P_Z(R )7_B2:X8!PB_SY=-\VW&(Y^O5,"CH$MAMQ
M:P"B +Q%:H>3,=(--:K.+SD-"TNQ\@*4A<[[[P^=<]"O0,Z"U(19/!MB(85<
MD5YJUNQ</TZJ)RB2/N=&CW]8EE(!4%U[N[K>Y*VVW:VCM[T@A,ET%EP6^N9S
M^VIU/S69YQUWD <A.O_VW%&?IKLP@Y(JB71<JL?P/<&4EX[A9DGGBV2LAO?.
M'_CR^<Q3L=MB(G^-R-_9LH64I$<XN!:G];<+T2=\KI:SVPHL,P=#7#[HVQ.>
M>/1TTOOP3*%WB=8^WODV_,W@P_[_TJ3$HA#410M:*94W$;N324-S1[? R>V8
MX!E348)D9&' D:<?QT^%+:^>)MJ'>@R-+76Z\B4\!B%F5H6IX+0=D.J_4SW$
M$F8D(VL8K3+RXH?*Y^E"LB,)WVYT[X7&3\6<4UHRS>L2M7N1N1'Q R'\<6.H
M?E(+;*A[?1<[E),)L4:Z,<QV0$/[C/#"E< ]MUZ&]BSF_H;!8[>YG/VW4Q>H
MBL;&MY#&2^V'&%ONJW!>])SD/.&)E10>*@LF0W3]B5-0.;-CZ[_%#0D.!5_K
M?*)J&N3L:7KKKKX^WW:?$#R>Y>['$F8?YTF5-71(]8(1331+J*&4@_FV-07]
M;,9<7U=U?7UK,FS]A)HVZQSWT[7#="AMF.['W#V.O$0]9GW$*.GV9[9[5/G/
M=O&&H+KL!:7K%DX:H^71+_^(A53&Q]\6$+W6_(\-3^$"K?R M$4H472@3#/+
M=KP'9H(TFV:['RW@;ML7.*:?=U9_D.N0<MYX(_?[1U!>)H]#A_"8%R89%P!+
MY8IR*K&"[*LP?J0#_=CI+8[;\@!-8?OR+[TS.>^>Q9HWC\SF%[A?=A/2G,.*
M("PH,XFFQ^!<"_:Y=H9%<F/\S:6M>M/9@.GJ&%KFPNXU!_W!"E_#;UE=KY*?
M[:O_GTD9]5]+Y'HZV@<\.T>1Q",@1@"!?*ZD&O'RD[T^VP:R VJ=XW]O(_<H
M[J1<[@FWPQYE%3//_U\\^_^CLG<'A"<EH"51QL 9^"[D>7I]6_N+^:[>CT4/
MA1-O5NGUVNQZ>_3H,640=?\%B");"PBCN_>/ V"R>SRMY;B:HF_[I'Z:D+J^
MDSE>*YX_]_35W8[''1LR_^]/O"QRC;BC8! $&FBNTCZ4E>#IGN(W\:FA^&^=
M_?E X?FAP^>D<O=XB)76YKT=#GZYPNQRCK?TR0X3DTZFR)R9..QZV'C4R6(J
M-S#P?WP#>,,]BE&_9 )&T:#> '6 #9T([ZL:]9W$N#4YWFY^G*ZL?M?B)* T
M'P]^^./',PE8'TP (HNT^NP[PU9=%#<><>N(>X>YZ!6Z[7;JZ9]@DV7;(N79
M[I#(P?N?; 3JA(.#11SV^BL<'3]QR?4PB._9[M)3H'L8:9044A_H# X(8EB0
MN7D-XI!;YD__YJ<Z:3^MN/Y>-*=+Y^W0M_VLJ6O"@"X=0YZNMTBV5EX4-Q_F
M-?;^OVT,1/O:;DWI^N_Z5.%SV:UN%__UN(4>S!"F77!U[-^VBV=[4H\S0[H<
M)AFH,*UVX'/P5FW-%DWA)[EM0/SK?%B+^=JH;?::N8P%[=T(UI@[AVO66651
M@_7(__E*JMF?V-8E]>,U-*E5.'<'%'7HD=CKMXQW$<:Q\BD"B6$Y)]1JQ0[/
M]1<P&?IA0\_/2X?*28! ]^5^+LXP\X&3(Y05Q8N?/R!D$8RSY?W%!2/&377I
MS[&$E"?V*^H>::7IJJJ1C<8E7)%6EJ!./)FQ5#7TWG#KBM%@Y5"-'SGCS.D[
M%5H\\B.*W@K%DYUHI,2YTOH8R1?^#5"*X/ .* XMRE6VX9%1G)2^08_%@VQS
M3$W_6*A1^J*2PM<;8MN2^_>_L%=^<G=7'4$(-442Z F^0:G-T,0K-GT%P(*#
M708+21$*Y2_YP,49VN6GOAOWH"W?: HJ$\])@(Y+I/[YL,D5(;! <X@CD/TV
MC*60K;R:-.&&.K95]7MFP&DWL0\&VR?C#Q-707<;Y)KL^:9X$_DD= ]$Z0=*
M=8:GO^5;)X /"#(]_V7*+3/.QS<$</'+!;WPB!SDF[T=JI=.:Z6GQT2TN N3
MH42OQ<9T)%\CVW62[:N_921ZS26 HD<+&8JV8EGZW\QT=+O==7K!.$WCFW'Z
MWLQR>0<RG!9,UZ-*IEVG&\7UG(]0:XQ^/EP?<%EE*"VBZGU-0.:9RJ77G1G6
M0,H^=ZW0TZ#8$\</_,]<ZO[_MY)5*><J^ W.EJT:P.X"ANGN5/1J-,N=.]Z^
M(#35@/0S+Z=P#)>C+8E.$RI&EG#+#<7H<4+0)NVZG''N'HK+))1^'C-[KP^J
MA+O>*("4H^_M:NNE&H"=W\ 3&B.DO-UV0*MM:=^5X_1]^#R?!P@+\6-=AS:2
M444,H]5RE@EBA'(2JF3M3I?L]\Q*W9^CE>7=\^EZ[K=W3[ZL+MW]V*%ZY8T[
M'__URVM-] @R.!EY0Q%O@";[)1FU @;$A7UW-^W:"S:.%CUH"3)1#ZU$')(0
MHL1 ''DDXR%W$J+&*8<N%I4=>%0A2FD4 Z+<WS">WATE'!^C]IGB0K([]<="
ME;J/_-J?[R *.\S]\)#PB,*K*<CVF?P=;#OPT45J/H4V6K.LOW9'H,GG5^[/
M[GLS\'UZ6_ A=#.L#Y.($V$'W*-+,D/HV*+&GUS%WJ84:VURMZIH[73!@4O)
M[VJ5]G?RKU_?8P*SX$ET Y[D*?L+BT?['5F$S5U@GAO'X(D.J6OPED[VJ5LW
MJOG@6J&KPEKP Q<MCQUI!VUFWCL!-D0^Z "JZ+5,)4XJ$DU=^6WE+#C U>Z8
M"B]Y0L,G?G7>LK"\MYISY4I"[N@MWES-P[U45M);F"!VURE&VC"I5?(1-*#7
M:?C:04;6@/"+SR\2?PYY2;ZN"*U3%&L+U1@\H"Y2\D5Q]YT]7P91^8SV@480
MTI'^F+L;B%NLU_,:-RR_V#$1[B7TO3W\JOQHB C]A&:F$/\M^91%V"QA$3Q@
MM'N!;4R7[&L4#[BF-M6.#O@Q76RJ!X_JN-'S;2[ES=$_FV_YGCV3?(>..^^9
M!>S7&:R)#TOQHBR]:EX,.1H,YH.\Q8S.3&#DT;ZJC40,4Y=3V())!"ON@,CR
M0!-Y/9'^$R?QK8#V+',']+YIDCNY>S3I_@7)K0A[Y;>99S.ZBU"?XYBG.(\-
M>DS"%KOALTGD;P_-/A.]O0-T%VMW!9O^J'1S3S[55&IW6,S^Q,U=R_6!_W#]
M5STBPHF>6$XWZ0^N] _:_VEKZ]/UT_=)1W)*Z\<O"BF]49\O.7>19_PG)%7L
M4=0$K,6(+>-%N8J69<OHLR^1)=,4BF'X8)=S;3S-U9KPQDYVY&C:-^-A#<]A
M=9<\:?MY]TE2,SP6Y^="E!U$\Z&#A-"!I;>N,*ZED$E-B*B!!W<#WG];:P[O
M:NF(7?AR1F'_[<N^^\6,1B,,U^NMC]#+R5FQ;#&4,L*%S,RH L(I!<=,G;S-
M35MS;A.>J!TVQ[)+YQY]S7OZ;1K:#YO%,!\"XE%1-6Q%P(",$9W_:1?\>RBE
M?!"N-?(T7C]5XFVD\+8-[<2^P?_%E.E_E_]=_E<5-1Y@".AR6G#D!5B32P;T
MCA%P&?>?&[C4.:4[(+EU)H&))G)G:CQGT</#>?\N,X7X_6W[.-;C%\HNY_&[
M"?0O5?"?)SL@%@%V']WW ;V18)0!WC9$_W2LG-G(@@4/1-I[/[GNX]9SK#C/
MJ[4R[\?,O6/OJY[_2RXB7;$#FC:';O*TU799[R17N'X')&BU QH80 ?#!;C#
M.#H>1D]&]\,XO);D%=GZC33)-]%YSEV].Z L].H7Y!C)=X/W"$.+M>^J+IL1
M_UZ@%;-13(KE/9#WT)\6K]SKL\BK+S+WU)]V:TZ_/=-K,!$<+O.X >TN=]XU
MT#.DM,YCI/(G4\K;ZUR"3GMGLO5=W9_*'E(.38VC8XX_&M_# 9V]8*%P\%P$
M,V8<YV_@XH(61G@&.[?\L':JD0ZH<E"H_B$2F=6Z>\B<\>4F-AM(HN<QT< ]
MUGZD$\ JQZ6WH!-Q"ERU'XJ%7>C$QK'!Y93>D'UK&DXU%_7/%5[^P-#<2T,_
MUEWDHQ7K+4G.$I@8SM,=D"_I2^'B5TQ\:Y82HGAXL%#X.4)BV#5U-CS#D]R@
MY5;A9&PCHG=;?..51F10QU.^U6M[.;78O3  /%0&82SDUP$'".3?FYY @Y$"
M<5BL(+WM]7P![(#CY=NZE@+^L_$9_2$?<G>MM+C'("'_N1Y?ED$8) BQ5?X=
M52.)!T*EK"%=,X_6V*>JO"K;6OW[9E7,$RGN*46:?L+&0U_FWNH_FP)X+B)@
M"HC2-T\RLM)-"6*(\D&(&A#=X%"!F,%#E&,_.$4?H'WS:+-T"9?;J(ZX9"07
M4O1.[$$;")+Z @=!+W;"I*TMJ.@ODF])^R!RB)2R?5Y#EL@N\^ZJ[@&]V:L>
MUTY?""7^K']C_"YL4^.;#X)53KZ:ZTP?&,C]L%34HFH\.JR5M_MVW@G5*?=X
MMB:O&[%(+6"0=38(]N9:UF*68@#J"'U5EE W%U2@\.D4?.^I7==_A0ZY#GFT
M_;G1KI?(ZKS1&LWR1^K0"?UH1>0=H.CE+X@,?3TN/"W#R+5GYEF<A;OKF1NY
M5C[MQ1<LUI,*A(:6WRD3OX!^?]![SU7D?H%*8C61[CN@!-4ZP 5_38IQ9T$E
M":_R((G2'>2_A)N\?1.+-(!;OWOP^M!XLWZJS8?K,M:L(2C]$F:VN1\BDD=9
M55%,#<> ;"CEY%\XL']!P;T5YO9;GSC[D(+59WM3%';7"1WR,/[&MU*LAX<&
M8N8V%[-6$\B2XFQ;(+\J:.:O9.K3 SFUB(<3HLFEQ5"S7>+&A[^"1X7<.O;=
M&[P"J+/"V;*<9UQK1,D_?_2A*(>#15=2JEUJ%P+4SF&B0]:J&X-U@R=J]$4Z
M3SDJ+F>41CZ3]'W1,\+SP#*C'5  2=B3;3B%TOVUH$0?W; NTU13Z/**HCF>
MV*T'/YX?'RISI6)7!&3J:H(!)A6Z6 @5QQY C9+H;K"T'= ;OUCN_I]$7B"[
MB/ZHM1X^7X(,]3X;7-FV>,.->KMY:- V:>-IONK%@X(KVO)_'!?1*=OH-F@?
MCKC.?,&8VO#^R542(8FW[LE.Z3$)OF/H$^/1L3S[\=UHEMJD.G_3,;.M]E42
M.)U'":M@=!="TB;; >AM]#>?>7V5"&R@1><-VI[7C069S TEWJS33/4NN__<
MW?!,=7\!/]^JI]XFG"M\CSY'\5L=X[FP-H!C'4 8423J&]FF=&QJ\VBX<ONP
MP-00T2MDC[RAN9/UG8L'T;KOS[?:;L/HGG"B$>5 /NLP,/ 6+;#.':E:V9P-
MX$)FRF^*E+1Y%U_50H\XI,0W[V7G6/O;;')=);NJ&X]S<G#?IE!*.Z!9ZW'T
M5J+*UJ'_<\&"@29N,WEHEGAQ!Q0?Q3589VXSMWF&6S9@PC3?;:!7'I>T1RY\
MF2-9(W#LX]^Y]>L[($,"]UOY?Y>Z:OVJ8A_2K"3TL]@UPR0SQWO>F\[7)G,]
M=;7?>$M28(I(;X9D MMN:*G(UV+V4]7JGUNK/S[,3P6\_W7H;EY/Q4+]NL]S
M9M+_M8%&?TXV+H@$!.* TVC*P@[H.N_'R>/>) 5NLG= 5MPBAW9XWGKIUR;"
M\O'_/N55><91H\0W92J-:?VN2S5J7I" [FMA+@X'VN#/$*<HZ\G(\Q0U4?U1
M!G8BP25@#.QG;[%4[N;D,9F>7RFW%11T7++EX(L>!Z[(\?( S\)5*,/*K?=U
MIE.I45]QPG+)???MMD+I_M'<(<[Y1WS9-HU]+K3RN>K&T2Q >P,U:LF33%;E
MO\ M&668!D0:GB23E&1*HHE?&JJ\N^UN/LVH.+O7*5ZF);Y&]9+2M_"&1N8W
MX#SK./<C;@]6"BD$K#,D*=&)A>7($U-&;-UZQ#E$0SK%V3: W-H1N73EY+B=
MZ9GF8*O0.:?;,;O^*I^*!&?A[J!W 5!J,&%UDTS@ TH&N8<F>ZPXW?4!6,7V
ME@>3=4ZO!,/"PH1S/BZ>=$W1VA_7O'RU[!"G%26&L%O\MZ)K]!--;,!)E_6#
M!8 043/+EU7W'KP:]]+7[M>/0TAX3YM"(X?L3QR_F\H )T#;=T!OP2DD>I.!
MV;'?+L*!8)';3Q"_G!B7>LZ/50V#G_R7]JX\&NHWW$]4MAC['K(4(;+O0XLE
MV<N>$<HR(2E&EK%D"4,(19:R$V,;2V$RA!*R9\8VHY EWVD9PXQQI]^]]]Q[
M[CWW[WON.?>/]]_W?<YSGL_S?#[O^Y[G$?6<^3G"/[ZJ#1K8LF:15%LK2:"S
M1P+L*CPTP\DN"P)48!VG_=Y"Q("-N'UA9J1UP2)A(%92>L-B^X._M[L5_RU+
M&O[N%]"^7BKMUT%#PXX!A(&2(8I8E9_3Y!P^@"Z>%&V/F[F=H=AYJ2";3?:R
ME/X=I%#(40+_?3OHPR@34BPE>AGI, @F=#LX69T=^5$Q>=_9WK(FZ[CSI8SU
MD_%?MQ=RTN5E8XVUY%''*'Q_FZE2E*FF-%92^#8?,(BEGRDQ!KROO'EU ^]Z
M,?14JD!Q\#FMSO4LM<YSMEKF5I]83PHA$7<DDWN8VP"CPGJX0[\5L22E/I.=
MPBL&0VS[O[-1,\UR#3G!(7JSJ#SWPN\S=\^"#+U226.<?^?GM;2A =C[)3'T
M&,\\!6$-'*\)J83C;6:5XSW69S\/2</\O1^7<VU]NVY0^>#>.X4S4E[P4#J[
M(@!SH(P1)./HBD!X:I1*#?P09);I )B6U?=YRV6T'(U]1NL,/%?UY1,+A_S%
MCQD<\E(2!Y?A+/T[% 7)+2H03$9*MH#[D=K];\)39"<]]F>6_4/& A^PQELX
M?#Q_94)_R,MOXKS$[I/:Q&'V+8S/#JZ=L+2-!-Y TR G6JTB;2:79X+N?U#N
MNNS9-LOD%[:C;S<OL)?$M;4F%6L"8I[T0S'H5Q""<F8A?[O(ORX P1=C""^\
M/-E:K\3@<0IE?NT67$7^:H/=.RHR/M[W5J]FB##UQYX3>5ZWNO,%3*Z@[ &9
M=-8%$L<*!OEG^.U>E&9X) S8/P0Y>JO7JN%[P2HE:O(_OGF6KHF)&&W$@B"6
M?J@AC 3-AJ2R-4)EB1DM:0?'[_@R,AC5@90[M:A*.IHC^)8DU]6\8*&,_EVU
MVIG^^DJJ>%$L9Z'Y\9[Q S3$<T2&_.TSJLMNA4'D%D]/:$1:<5LN;\N8OC&_
MO^EB@%)=7#0=&O@V_.+N$*_<D;N?1HPE[<:A'(A>?DT4#DP<I/'M.DQV^9,X
M'- .1/UZ2._BJ;<VK0MNSJP$7N&KY4ESIXJ\SHG8S1YSL96+$&(H8(9QS#06
M!MA::'+ VE8^U2R LV%CMB2 DA],E!3EJ!%EK7104NM"OO%O\/KUU*UH5%@Q
MMO0'2+)ZZK\V-/L_LJ(819Q%X1#TD;]' S'?>0BJ.9T/_6B(N%4"V)=\::=+
MB%'Y*9-D0P:#R?UG,)@<HSXMD>P0W@B_Z)RM@MSZ'5KDWN>]PIZ1;X>@U^[!
M"Z-:)1\AE'@\O=GF$/0L]!"$$2#/:Q=^FXLY?FUS++=3N^6AR[G'9/47;@\E
M$__LFM'$7 Y!"O44AB&ADO2RAQ71XX<@;C?$C,4AZ!<78I?X;XS_>#^BKPOS
ME_!_@0+X?Q<?97_%!TT1NG4(0A^@K-XT,R(E<UNAJQOC_PLRW186N**?7)])
M%'_5=KQ>Y_K;IS[Y;Y5Q_O=YTQMB&JZ%AX?E"8Y%1(>*JPZ\+<]S8J\UM#!@
MSRY[TXKN:8^TQ/NMIIH\ELYE5@1? !_'J&M"9#'+SWI8*2RD,3H[,_4"'$*<
MB2.@>/WU%D9K<;?:ZL75E=]%NV B@MR>X-VY24_ZI.)U-,F0;>KRP9GE*AJO
M=_\AB./T3)E?%P0@]UU"=Q9AQ9)BW;#/COX<:='9A%YUHVAC!4,KIJL2[W^I
M0":8R8:=KU,XR2KE(]I>_=W5HPF$GF[%1U8G!/',8QM*]PEQ:SE[GUE6P8ET
M, -?K8<@&N_2LE#OSF.&$ JDR:!N]-06LY%\<JKFZC6=&T[?;NX8/L%F^_5$
M7=!CU7L7>I@&J;=H#_]YC0^AJ*_4)9&"*H#- <<VK46921]M>Q@Y3[W,?: E
MKK 7A)1UNM-IS_^SU&GC:3$G\*@-7&%)L-*LOW5"M@TF_"E([$B<N^=:P-JL
MW^\Z/=/,<CC".LWL\_TZF**YT!W!MB=*(0/J+\Y6@\ 5H*AH!A$@']0=@GS
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ME%RE__FK^(JTJXT9Q\+^G.)G\F.V_M_^BO+_ZU\YTN'<OP!02P,$%     @
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MZ^MH[&C04(=UQLEE%S \$1F,AF)]AQB*4E7EC*C7)#95<N1X*DU;\ $7N5<
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M-#QW4-R]DF5_'N6A@:]+I[JN(11=R27!8ZLG(FN7DHU=VTF%9PM9L,Q3)+@
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M?XU1_P:%"P;@9:M2 *.\(!<QFGZ>$Z_A"VT5P^Z+Q4IYLP^YPFA4Y\T+D&4
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M+?01NZRZW=/:?] ?\T;V3;)$H;E=(@3YX()L&K1LZ?>X*ITD"IUI\&FNCCX
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M/#/._LC;OK>MDO 01*=&OGW+5C)2S7'O801>^(;%M*5)4@DS;,M@=%T[Y2
M \ 77'H,INH?Z*^I&CCJ+'CEU->/CE;)L49P%;;U8"NW-X1P[K-I./<%\5>T
ML5^3Y@[$"6V, 6::<H]S=N<P "M3%@8PN8<MH-0G$H(::>WFZ1#Y%Q-IR[K5
MY4X/WW.]C_OHZ4SO14/;W;P-DEJ8JD,_E59!MZIB@/2,',BCUM0[[AB F6C/
M2C_N&"PIQWYGH?QR:'^:\L5CB9FM*YY5@9'8CI7;N30+&?/Z]O6#M; V1E*Q
M#I^0A$@,8-W/-V)G\'GO=2R/F)Y<"]MBV3Z:RM@@.NR-[T1.1Q/9+^NF6U*4
MO G3B0;OBSEBUP_M0E^7=I1;*I@"LQ"FBBK$]5WZE<' ";('"WD8('/OLD4L
M8)<9!3WZ@0$80*N^<.:K #%T5&A=\<ELWA(;42=?4GF3!6^ 9PVO#;^&VK0:
M^ND>)[H)&T"_ZB1TP<[9[3  ^"&43:^I/!45/JUV!<7&6M$"?ACSX;-)=.-K
MM$*U,Q@?%^6*&M:85WRTW$1HH[-0YE"8=7O>/\W^08ZV[_D\AS<=[RXKWTLK
M7W=CH0YSU$.D=-9V"AT&>)O:65KZJCN*711M$O[43")683&P4^'&2E+2<BT&
MH(7VY!E@@%\\+S# 4%J>OGP.BG.A+)/N19A[R>Q7FCTEWJC2=EVN7YOTCC)1
M1N2=RW>#8K49M/+$:SQUP,XUFO%SQ*/PG*74*.&ZF,6\\J!U)JD=NYS/;&Y1
MF[L0F5\#XB+=?AQ()RPK]Q%,L!5IL3TA&]];7(E/"6<^WR:,ZV:Y)C1=VQ2(
M 4C]Y)9XS=2QB9_ZE\XSF4'&JL2B=<:6]\F9@5'5C&@SY +2+D]_!TKCYP'-
MJ8Z=^GDCNH'Y-=<KGR"M#_[</U9XAG/",Q3JDMAH*GCFLJ='O_BA#UZJJW94
MF/#*4*%X8.U>D@R-1@/?5WLK%2X>#]T3I ":X=4@ <XF941J1./-]\V-@G9$
MG#&[CG>IJ=9?*.>R4W(V$J8V1^SS8H#5?;4K?Q Z-A%V^@D#Q&0H8( B+(8<
MZO=:&Q<0=B,4WM#1U+Z?^Z@AI<Z_7943?Z],RCB"JZA2(N@__L+R[S=6^I2I
M;EC?)4%"N<\'6#& .PR9L-J_Z:>8@2+%[I[0SGS*;X0!=N.8 _T$LN>1V$EC
M)Y+^Y7Z%>91!Y1>2T<[7;[JJ52M!R:7M13D$0^-D(<:L(RBQ0CMJNO')J?2:
MX4)>4R?>5/>H*EO4MQ5QJ13NJI"[\+ZM>8_)B"*40$&; (]SL=(#C:>*.'Y%
MR:\8-J2@:H/FR0O=NZ+"3F1(S?8FRO(K7O<K.=GR6%;'\IF:X@5K;<X>1:?/
M/+?JJ_I[.L5_- I4#-N7?]G;K\?] ='44=+2[W;DB*=M!HD[B0VY$GH,YA@Q
M4T)@K3)<"*IPJWQ;GY"UK- D!T>1S<49WO;9.$^%\R_4"^L2H,A$6+B[ ^=2
M9]FWG$@^/Z-[&:L%F8+3_0R>C^A=_'HAXBM$2(3*?*T/&C0Y3\"[$D77IAC<
M1I+S9/7K%3Y176KR5[_\0WQ'I2Y"<1H&]P(U<HAL-P3:S"9?^<J#Q(=*;]7F
M53B[X(_[$NQ<&\64CNMGK3+"\(2PE0D/#(!4K#"B&_K56V3"T3K;GL/5VS-*
M*\6T>LRH1H?L>AH[VJ+8,JJ\MW3B4KK-2B.HG$5;QSCC9:+4Z:(J8<0/'B/-
M/ECJSP[T$?XN0VO;R!%Q[;:#W@%[8([3LO4*^!/77M(&<Y3;)/C&ROOE1?A2
M7>+",]'4:56I7JG- MFU0$:Q($)T]9[&]D7.VWJ#/*5"&,.V#+U=YY%C>0VO
M55+'W4NT0=JT5E),D@<*_QYLQ5^L#7R'?;S\5P71%<F*G1)KTR?AP\<[81O?
M),[?7%SS2?Q\J>(]<X'^0(:>0GI\GX=:D=TTW-*);8I/_+&MH20E)ZY')W3(
MU/Y]+XE.+0H#'.I58("S96P %AA-D$>ZY"R0/$76[FB51:$Z1D:?QTJLT2Z+
MQA0'#Q7O)1$.(',*;=#LR*]YV].\7=/VCL9"%'6T8J;LFFV (LL)I0MR5'>F
M %472!9D,LI976NP0&1KS%E/V&196A8S# S^'%P+0KE$NO0,VFY*N2SQ/(+B
M3$,2%]JHT135Z&'1.S:3#CP/WG0:6<AQS<$^!<^ E*5(EAVX%Y9.<Y;ZBLAG
MD?H7R^=\H5EX9"R)#[_ZQ0N@%JU2U282.NC.P@9;FY"*[@NWYG9\(NR4?'D[
MQ@19XOP2-%Z*.G^+8Q;HX8@64*IQV[K  &TX3D8E</[@8Q#QG!'$XR1*3GN$
MI39EZF M5/Q0XB.W%Y5E=_/=QR^2QLG(D:0#9^WSE$QWHO8>^&GC:<CAC= &
M]*Y5=M=%$W&?G$A=ZBC"*OI!!K#6E>?51_UA87OYA0$*8#YSJP?U@4F.#)$P
MGU]C*#<KJQP_J9IA*VIJ-%-XU,\'D6D&/TF*8Q\^ 2(CAS[%JCI]QR_QAQ^U
M78QWAC"_=11YMILE>F3K:NLJ+YR?0[K]_I#T23/+1N0(RC)Z@%&NU67+3>I4
M9>FKNM.#]Q4ITH=[[)[BG=83#P*8(,'Z-9-F"(_..,;5[&4'/E5!)<OPSVO#
M1@%R/>+LD2Z):0@5\%#%E<H3)Z+ZT-ZNIT$_N[B+(7I,:C'AN"XX">SFMR'"
MBLL&@6W#?__K+; LNA<#'(E 9U+1$T4I>9O@*3#:LN@2&[RFQP?#T7?0M4'B
M@U$+AZ].!B^],, (9"<!OA%^ KVYK?H=$G"PFZ!*_JYGC6U-"2_R(=MWRC$_
M1PP0VU4(G6E"?^PRM$S.LI7LZ*D:><!7M$%HV&%'I-RBB+?T1'S5[0#\?='L
MA9X#AS8GT[/Y2_LJ<8X +].]C8@*;+ZE)+MM9)PP/O%LC9I5V% 0H-@#^'$4
M:38:0.V-#R?]3-RN=[T[F#Y4<;]/?CA\+<@5\IA@93)+'KH$OK7EV;FA.53Q
M2)PZOXK*52$#P4+86UCK#C]T219A]GHZ7FZ4X"1KX/\B1P\9MSQX:]-*<4+$
MJ?P58TW8[C#GG(2Q]I.]'27^=ACEX)++TI2'T?3+0(>.IJETYCK#UXXS=<4;
M$H7&$7%!K9GIN9T]<]95!SOK#"/[[A-@<C_-'*1VO9C5#V\?%7GV>PN["(;,
MD/=1'5YN-76(E/O39-A-D6;/T'U#)^#2J7VKP\;^.X=SWA:<)X4!ER\:1OED
M!G/U9O7ZRT$)+G<49M3D@H2"M3<OLJDRP?O+8\GS[W47^L_#A!,T,^"3[61W
MD+(#=F#2;:A9J(U4#_4N0BF^4RA!PX>PY[W>F,-)6[[!7 _I-TN;QF'R7RV_
M8M48A3YVO7#1^EY Q13Q*?-;$>]<?&-#AZ?/$^312D;.U=>]RG35ZLMG%6"A
MG:M9-&4;U'';JOUFH?1J[+;+0!61&Q]C?0=+KD2W.(LS9(52-J(WFH@(ZSR)
MNO,]MF+WI:<:EJ'TR+!.L 46CGQ\>6DU)78.JHF6_EI2M\\UX!G=&&>GA8Q9
M;K!K:_JEGY*W85.G+@4K>UI_]WK Z[3JY@/#!DJ[FV'* EHKUMOE^B"^!99U
M_ZXVX<I)\D$GM@[AYTP2;*;YD:1/\-Q9SO+T4\I^V&EDUG9F>7]7HMM3K$W.
MXI;&,77FCJ.LBS2L21Q[(D^A?>/O]QJY?UT=YNDVM2 GU>#9JF)H*H4O-H73
M!D:_%LKTNA,>YK^AQ=%B8UD,FQETM#N*1,PPJE] M[CVL^!LT>FU#00MAW,H
MW4IX<O,1K8B0@\NX%[OC[W\.\<NCVT0+;5VP5^F#PJ4X[.SL,K==5*]UV=R(
M!@G2ZND5?R-] BX4ZH<T#KMQG8E(=4:<Y*G*]#T90=/H^4>,V=:FY#+EN+G>
M\FYE$\SGJ2L<J1'?BC&<C)(2*+*5D4*HGJ:FVXIYVN7-.U8'C2A&FEH-_L07
M3]-2#>Q0-Y@GKZTK']LW[FJ;N+C\*J&]M\]+MV1JZ,:E/E3$+&:?6F"N]VMN
M6\S&+F>ZW\.%<S;T1E^=/[ ZOO"2);UH.Y&T**V4KR(+;--_SY.HSNI=I;08
M3N(QV7MCAHF3IO<^JXFBL.^VY.WQZ8KE%=ZRS*4=8]_%<S=TGY$]3$]F=R(N
M8/C>PRJ@HT##K?A2T<SH(/2XC]=W\2#BK@$-:5Z&&FD:97?4TP(BO]A[N^8_
MWAC0=JI*J,09DEZ+..$/FG:,^+@]SX+0CJ2N=4B=VIW@^4[U[.?'GWEUQ )Q
M0.IKN\]C4K3"S%3L\+>VFP::5#$?Q,CI0=@@==9"HKE'+01[+:',4XS\>/H(
M T309:6&'F]^JPQ=U)N9T9L)F=6\X?Q#@B-08MOME61JZ$G_;8H$O>$*$AD)
MTC'?.MUW CMO7A$?_]!0O8?O0*&N]3]_[TJAJW?8@OTF?BCL!]1\3D7LX_KY
M!ZE7<U7T=<<BJ?*4W/>5>AS[.30T@H)]>&;6*=3EU3_KE-K=,K 1U/_UZUQH
MD";:-_Y3B<<^T-67V).>_C(2S:;OD:.\S^@^%<#8^-M_O_QU=_4?&X32=P]"
MZ8^/+9#X9<"Y)_5BV YT;V%LRT\,0=;!1%X<W]<VG?IK;RVAW_U22L.B&-]U
M6^TQCXY:%/@61V0&).0-:*X\4&W]CDC?5B/]I,A7SU3%X0HBI'JE<'QE$7>>
MF3C'DPT\EX/G8^6\8(6IJY*L^5_>J6Y[.@=4!]F+0D9'K8O<VG[PX-1$+ M?
M3AE&55PFYEG&'?R>,-4P'A?D=K'$.5JP*BQL>UF!HJQW4F00_.'\N_PB!2I[
M8G1N!Q505N'#&98-PF],6AZ#RAO6A3EA&??O5_,4W"FM-?I0. !KQQ9E:LN7
MX@Y^\KE7I33F1VS@L@XF>IH!]2>;MD:^RXH1*+5,J,5.8M%T_AG/.=@R7,(X
MZ4?PQ22__%-GB/7A]]&(M7'K\N/=WR%YL@D;DK]#M/W$O']X)RIW,+!B0S(Q
MNX4R28N72X7O4;1M50C*I@@BN;4.1W\[;7WN'7.+3D+F!V2P">S3FIXZ[HR*
M3F5=\ZFPL+PL7O=J&#AH!]'Z62P_HBJM;HH>F9;G8=7K6CL/GJMQ:KXE;8?;
M)B,T6<_(VY["T'1)/_LC/Z<G6K79BMG_A61*7)C\TX>O]-V3:48-BSPLK'9F
M)3+G]AV*(CW&$%XH]AW_*#,7:/GY_;'"GWLS5?N(D8_MC?R34B8>)%WOBAJG
M'MPPBZK_!+/=$&_E.GA5D>:49BNF3S)?<;UQ3V;@:81WU?=?_6<*(ZYNN]QS
M#-(2"AD1JO^CO>^.:O+IUHV"HM)$!:0C71"0WHFH]-YK!$5J"+VW" @H54!
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M+VM;5EZU<93:&7Q52:)8F?O-:N=AP,?24L\J@XFY4P__B.V#6#*LD-&>;%%
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M)%\MLJ#*ISH(P@97MKSWGD:7PTQL2"CF*^ >5S<[D4=NFZ]5#1!1MB.6[W'
MV5_[5+9KUE &W=KCBVO<"^[G-=>M;Z@>9TN1*E)FMP[]E>64_%(<X!(T0SG
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M(9S\S*A GV6\#9E?DHR[S>L(9)1#T-4AJ\<<V8V6[,Q.U.Y;F0F&)++6$1W
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MA=DT('71^FWK%#%B']X4B[GR*.8[R>O@^9>/;MX7ERES&?1Q3"X%T]))V3;
M,&FO>P[L7/<<>TM&A+3GP+1?#OE)=[*\7.[^<&3@^/+%1$=TESG=%$!RU-:M
M6)F0.$/P,Y!EZM+/[*8L:LEP<<EI1S2+:TIVF/ )WDHZ^[I__>:.#+@<&Q*P
MBJU1/>,/JPEDKQC3D8!Y&"7Y!(Z$ FBXG&_TS#6YTQN^PP.<MIBF>I5PXRVX
M'YP< RC^Y:.Y8Z':4AG)L12O]T<HQFE85;233EG0>UY*V&S<0]GLAU>3*WQ]
MKFR^S[<7 S+ZT]D4KR?Y\O:DE9GF5!?CK+_7OS987GPSU;Z&[G:9&%4)E'TF
MX"G(=*> -]T-D[+\8(P?4DW96MN8SM,-?6S6R_,HZ')_J:-?FT_AYTLZ?P'[
MT;&MND8<]." 8$WJV&,NW6U21.5+R]:5+=]KC;/^)M@,*SN:>+O#"^O[+-I)
MGH(67 R#;BTW0[I3'DDN:WF;;<+=.F]M-H!F2>M_UEA:A-RY>H--,)A(]Z<A
M-6-1?F?A%QVZL_PC E85QPGK.\D..Y"3(0T-#9]!(SS@;2J(MGP<6%/-A*("
MY1Z@G-8H-EHE>@F:^:TQ!*5[O6'"J=!K=NEL9;^<_$7</#PQ\79BKE6IXX9>
M7VB<F9P>:/CA;(;M5_.*[7W'VS*,QAR/;B9ZON?+LS,B5ROGI-2HBK S_BL+
MP9-_RKWV3X7RD'^[% \0,KRXW"%1]B>;?\9^S+ 9".!6/FO4WR6FY]X-_)WH
M6G*K57\ .&O[-\ZJ],FYVJ4/='CC/X*]N/^):V<_OHL.%#%HE1AJ7=CT;V7S
MTL'^E?MZF3;T[]GY_Z P\/\=$KST"__\)ZLDZL7 O#5_;=P)$[IT\+)-D,W
M_ZG5?_\L %?)VK-?PC*<;9S=+6QER89G\AL5567*/P26^5;CY@*=M "]6STO
M6O.QJCHC+ G/?^Y40=2M.KMJ%?R\8AE<\8#'#IB-B68EY,=-\:>DV:@ 7F@+
M'A!T=%ZC*")_S_#E_R:2@[TU[I?XVV7*N="JDC2\O<GFRF7E(<C%'#)& <_>
MR[X-QQZ;UU:_?Q#,H+'"&B%R*S_3   0!Y )&/E9H9H3&\SWRE Y W";]\7;
M+;3@0,:DAX/SWSP(?TGF[X]K'=2M29P2F#7?T]?-H774 -K-G4[S_Z2KNQSZ
M_/^K [?/];3E_1]._:Y9_U;Y'XW[?].X36G^I=18LHV##4-?CZ3RK-E^]I2>
M/4&Q);I?X=Q3 )N4\4EA)C*P[+74[G2*FKH17+=STC$<TC5O7[*W7^7HPRK]
MLOG4,JV9O+O!*CWD(AI)3@*WQ[P72'FHHPMQCO*6B)-[)+ZNN'_?LWG)R*E)
M.IT)C8EE?)_MLV";1/DE-]Y'X,T+A9XG#->!N9*<"J43]PKDNA<,/?HG38MV
M)H_= S3+&VJ*M\XMEV"FG0:RE-7HO8@.-\069\K12X,4+4N$V&-Q[;ZV'74K
M;-@:[BY3* 4V3S>"<*+80\!29(3YF0^=8ITC &#F@K6N]K=!\K(,:Z+3,Y!,
M9/+%3UH8*E)H[JS <J,^,I<<$?'LAP2+2QR5\'3A!'&S(]N' 4+JX8J_'#[U
MD:;IT! K*1 WIALW' 1%39*1DZW0NN:I)N9Y\8J8;+0*M4S8#RQ')LQO'T6[
M*+X5X=]F(L&N*:('8?$LS96F5"F&W#?C#;B\[J:=6E+^L.]]6H=M7IQ!W3KM
MV$2N[H^>*6Y3?'PWQ&%6IW-=S$;\B/"X^/K>3F*QR0RTPP;Q>J(4E74;=F@X
M#&%[)[N>8/O@^]'BQ.MY?F5ICSSO8 :6D2$&66^VB)Z?/O8Z'(0/'>X8!05W
MW3UYE4>>/!EZDK"Z8M?J.0+Q>G'0.#E?'33(T-1*49WJ%+%O6V-]0QB(LK3A
M2&%^1I]O-;52(6A<813OFQ*NB)Y/S3I_OE<]5N,\UXFH<^0K+EZFB:K9G=MA
MZ @9J;OIL2O4,XQDJK3TS'1J&5YUOUB]2"W'VC"%7BIN1T=S"/+2O8IP@+!$
MF5>^W\Z5=7!]CIVCHR<)"9IR+WEOP?U4NHH5W#&< P=#14M*U^KJ$V;GT*67
M:)S"?EYXY-&YG+0)++'[4. BW9;UJJ@@:4FH'J65."OCIQ+57NB^=I/R)6XW
M+;V@'_]IAY-%KX86RA6L,Q*%36 >$O@D; IJ% H=..C4&; R"\Q%'98\>S&&
M!]2<*Q;8MVC&8;;J'?UA,S5.KC-N06DV-&TE47Q,"7<VGR97QO(V. 7^@OCW
M)1Q#_#[^];R-Y.^?M_V/Q?K/MUB7'3PEV%*%YU9"BU.?%6BNT4D9;2^>4'H^
M3^-&7W=)S\OPS9*G%(BRJ']5''8YT%K!_R Q[7_BA.;OM;:U8M6:K )*H1WR
M&&#U";3NC/QSI8-]AM\/FJ'9PUTC(/I'QI$H'K!RV>>:7_*@1WB 8(Z&,$*G
MCRTI;MK_O?O7.3@YUEKS-!6ZGXH'S%S.?MAK/*"@%@]XV'I1$\&-!TQ(C^("
M\8#E<CS@@=]]SW_O;BX\P.A \^3LKQC.><A49QFT4Q Z-H,'?%S S2B>"W%>
MJ+>>7$X#JDI;\;0W!3J\<)X$7&;L80C!T23@<A?.<_$ #!R(^ S<A. !_4YX
M "0S OB; ,R8Q]M,?W0)#R#IPP-TG7"ZT#/(/6U<^6K&P?%?:GY"5!YN\:=\
ML;^+GAE[%"N,!V2TGCR"?I>)DB+Z7;S?Y9:_!RWVR3N_P /Z+'%RVR^G_I O
MZW?)N;(N+ >!:[LX5:9]<DNR]C^$^U-N>:8M1CL\  C=OT36'_XOQ[7\'AY0
ML?NE%L=];HG[EG%1DWE9P?"R0N]E!>A%0P3/$.S3*_"8![<*ZH1_GU>>_343
MNA\/.!*__'G^2R72OI3L4L%T8W$ZERO.XYX!T+AH8?^O:3#'Y3&=7_KXF$T@
MXE+E-ETN^VF.!SAF1LA6&K8N4Y%CK:"G:=#]Y$LQ\__N5[E.!R\MP0>C/VMF
M_=XH5]:6B!].SN+/FK&_-YH96SR^>W+MOYDLPDTR9V)0BZV)T^1S]A?0A,9C
MZ/2,EY7*T8%F:8XG'H"& 3=Y+^=OX2+QGD%9[RMF&$T@\7FL%&4B0L!-GZ<#
MQ>,XD<'!]-MMOU_?TX?:(EM3T>;+E]#<PJKU8'<O^23\G$?S-!*Z?*DE5HJ_
M75\J[#_?S#1%XW1^=FZ%>XD'W!K%92Z<7+8WK?W'&WDFN'CIZCGU"1'FNBD>
M(/M7HJ!/T(XJ/""_%J<*Q>C]?JVMB(GA.6F]AI.["$K" X9;>\Q7_TV9M2^R
M(G!.[= /T/__)#:\\J=A,I2GWV)ZBAO**5UN_;[=:56GQGL1Q1MPY.1D\._9
M,\/?S*3'V?\8W_\*QO>/<=5?N4AJZB.&=KR,PN!^_&UPS;!16TP1X>SVR:;;
MK<_U['KX-DC_/1-3]S<#HO_?S-[]5Y6EZ&<+Y?E?"9AM+HKP@+L9*""*B1,'
M\L_@'[B<+ANIBP9M>;6BL925!!K\]/\"4$L#!!0    ( !."U%@6V#-A.70
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MD2%,@IXSHWH(7X$1LO1Y:>)TS[OPLFH*QO%MSCMDU3C39N5 5:,J2KNJ99)
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MB%F6HTYCAT36IUJANFQ@,@F]_G@E\5S:*G?W)B+J3H'X\WU2"96$IH%L X%
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M;C'6)X_J!LKSWJ%^\5NXK4#H 56 5Y7$O3K=*H+X6[Q(\++9G+_G)HEG@O!
MY./3?E0%>^0F<XZKB.\EE$(!(C06.P?&+JN+CI<_C-G3NW3&&CEIS(-^2O!4
MM'4_&=C=RC&?-*]=CVQ)^PN>'?B7&2@W*>>+A-PT N[-_OQPI/F&"W[%YK%H
M'5:W]9KQ ^;]G99BRGH5-T.J@,DOTR4&2(H%.I[C6R/ZRG_D]CN"_A+-N(>R
M]'N"GERCA;FN,P6!7HSK];2=-FH_L<83\>/&9FKE4&;WQ%?K-.LF4COD+U&%
MP'R__-))O=7B6@^!9\./@$_"E6&=XB(# 4KG-D9L)O9RV=Z2W4U*"XQ9WZUO
M/BAZ1E@TNCW R&B2/1]$C^4NQH(/GW>]63#\LD1GM4@T&.L2^_$&?_D,'(=_
M1:,"<U\K(?\!BKHM2R9EN!$L?M#JO.+MT0%I;<+"*A5PB;<^/7\H+[E.W5D(
M/-];S6.5553SM-'>'B5!KQX*Q2:,#C,;O DYQ)%;58,IG&#J;IU<%!\?S&UA
M.P!PFW@GEQJ;[ML1U#V<OVQK>!$NCU!;)J=+R1#JV+WX[[^IJV]YD=/^N47/
MK(#)12Q'F.J+J^JFHK*,4= O20P)G/:H-WL!+Y918V-NZW[!&$ @KE9_+((^
M.\<TU0B.M3H(])HLX56U+\*=\H.RP#O=6;@=N?HGYV"6X%BZ&#F.!]^$]T!0
M3VI("X=$'A^ODH-U'G>GH/Q&%=480Y*QN&)L7C.';8P2D,7!M1]K<!EDAV/4
M3K,S4?X\;?W@@>%7$M!+WR]<W@):&WETH#JHL.70R4+&V.:Q@G.G 6G_!!?(
MS%7U*6K>?5Y0EXJ!_;[?,XPQT#=LV,*9_0RAGQ]19.%,:3X+T@V_4X0T)&KZ
MDV@IH.S4?'Z+Q-,0-RQ&(+!B0_N;5'Q7M/+SA?9%PH) 4C%ZA07!+"^RFG>6
M>:_BW9RQD>I(=$@:)YHWJ76J<Z50RU7BC%<M_^*7BX,B\(31' 9^5W^6RMB2
M1=%1A!C"*$@'6+!@_UPW8CJW+GS;95!?Q>JU4-_PZ^WC'!08N<"D6&.>'8%"
MWILR6"KE Q60IGN2#ZKM6=QWF82#-E-WKL?+'TKW)EPI'F3CK/52#JHXT(BX
MW7/A<C[KI5ES0PO[>3WAJPBX(]09:2=Y32T>CS,S;G-:6> 1N(3J=+0@3!..
MXM=SHF(BN$9UA8Q/WIOA2UN1P7R"GM W+D.TF_CW@(.O5]?R-3[?TXH.? 3D
MZ3<I;CW\A[A'K>J*<<0&6<3MIM.)TIF9#*%V!/K?\DK^ IHJ@O(H2FHAG\/X
M&YT7LM"#&HPCFQLEDG]>A1].O128\=47LN@]I_'.@JC*3O;F>5 UF(:=G>%G
M>)6"TDB'*@)VV U=(8H[$A$_N])BG]6U,3LUC"X,;U0JMCNXTIM\JS_89E@G
M4E#\O]I[R["XEFUMM E)""Y!$Z )A #!+00G)'B X.Y.!PCN= C!I7$"P:WQ
MAN#N%MR=X-ZXTW1_K+//NG>MM>]SSMYG[^>YWX_S8_R!KEFCJL9\YSNJQAB5
M[6X,0(\&"5R_J$OE)^:)[()>F(0EGQ7OJH9<Z.\MM:KD:V=Y2MA>TU6/\TI,
ML,(OTD]6=7G2;X]F2V%B:TG-R\\#'I70U4\7'(D,; KBI_,F>DCC)K7CU)HO
M5S:K#/>SOGY9W;C?M)_-21D2G?YY UI2ODF?=8?!7W[?U<%_=M2-B'#]=3Z$
M D@4&ZJC '_:JVE:Q48\\F#ON15%1^[*(9B/?WOSWDR2P):9: *[DGBJ(X@>
M'62X4]0]P,,4S3%5#_!E\NO0]@HECPS]VD;T<#6J2Q&8XK@"VV.PV4,!:+/J
M>!KD\ZMRC* )XD\HV-ZP<$B[O_=# =Z*IIA9J<A0M6<K])B&?W[YZ0TZ#<0K
M9!^AF#4GXRV2!G9_::VBT^Y*GD2OAF&.A=O8A14%65X=K=$!N7ZY9I QB@'Y
M=:1;I'EI!/MWB%?A.2U&EUO?@ Z811F@/:,R^;J1(&6YKBP;.P]\]:A7=P3+
MN^2IJ.[DKY"/1N.L%3IPJEFS!$7I?G8(YWO37-'9);2H[62<D$UG08;2YF@R
M()LKG8N9,*ZU7BL]\OOR K>B9.IV5@QA^J;CSVE@Y,-Z\^UJV4H*+<%KG;C&
M)KDR@9U$%>DQ._/QAD*0E?X>0=0[XGTN/G1(/Y+D8)'L,.Z7OY,<R!-74A.V
MJC<F75S'9]*K#/V2!87YG$4M*V+K73IL/],3&\J;F[.MB9OJEU[HF2/:C+X7
MP! U_F3;UFR"S59#KO:-RQA[RNLQ-)EW@*4PSE7[5;]DVTX?@PZ*\;(SO2?R
M#@S-GCY)U2>GPE@\M22+*_INCN*7OO>J0[^6ZI4#?_1'QS[P\-E+BPMX\YJ?
MM_42LE0Y&?2SU( M*Y?;G)?.YB=UC=K6U0&DA'G:]$@RE"JXO*:LUJ\/\M%%
M@U0>^ T#C8!C5O'-9^NJ[QG6A\WG(3D5>$L%5B=$*XM<CI6F0*?4I7N-@;+'
MI;5-W-AXLHX7ZKVGWE-V\;>N/'&O>Q>R-I@J%B1G_+ORC7@$O(>/1^TICF,M
MPHO'_"[/BB'W,D9@E<+B9[EJ98']TBMW!'T_ A9V;>2@:"L,FCM[:NKW(8Z%
M-77Q>/MS_<@&I/_+E:(&^=6;%M'7W8K?--) 2@)N):U%QM)[F^$5,\OQ)!I5
M>#GO'=![:*KVU@(H_5IAA>U'][J8E/(?4)N5U+VJJC8?K9YWE(6PY16[$V,O
M#\C8K./;.)KEN6-]9@$1J[29S&9!Q65VY-WI/5Y4>Y5?ONC8(0QE#A5DLLF(
MX =/[<?><UG]S+D;<E)W0PFY5#F.49R";3F,S]]]>B[ZO_RS90+(*HP?EG_$
ME_2&'JU>3TX,9.EY\848<LTJ9-&7IYT_1PM$"D%/2EQ&#6C/*13?16DB'];+
M4[R[!H>=NJPUUC0$>7R;?B6U! JH7R_&1&N[@\5Y- D23ZD1V!E<F554MMIJ
MGUZ(<0O#0=%06)Y)1D)?YYY\/6VXDX=H.PI  BICJ3,/='XN/ZIAP(H_\ATP
M5>PFV/H$Z$^QUBC-?B;]\*JD!'!<W,4=BQ$&KG"_5N$=BIC5BPW'"S<3*:1-
MIEB/^1ETYRER:$)^UDPR32"QZO9Q>?:&7C5>RJ^"R!MZG2C6 *9!5/2BT=&@
MJ"1,FUPW6UJWG+<!,L2%3*<TIS#;D28A>GA/Y?@>N/Q=-F-MB/%6PYTW1$?C
MZ:<MPG]XFD;D]#U%?/(GXQDN/V;$LLC93]_HP*GQ)WV[SL^T5 IQ@<KC&NR\
M0VEWOOQIT+],.R,J !IOE].PYD$)C(-88G@RW8LD=NT^C^K'Z65@J\>TK,?=
M-(*_@'MGG1X3X94EX2"JR@KP-@O@D4;&!?S2XO0^)&3(L?/^X;0%3+W.G5U4
M)+7>3B'ES'PH,*G]?6FH9'FP#0#P\TV?-#BM29AYU*F'=:7\K?7/G?8#=H^C
M[[T&BG/6-OW5RHSN6D,_=Y[N1W.)-"OU'CB^.?HX2[7F0NTI1S)"B-N=14T,
M46AK%HSUR/JQ66 MD!;]CK3=ZZ#E7I//Y41)2>B*-ZT<4?G.?<)/2RA (5;+
MZFYOR6:W"'_5H63"RZ)"-AC7<A#_<?FTY]2 0$FA8[&ULMY"/3?G*L-KF,K+
MGYL1^>Y6#^IOR<XRN--> CW!KW*\Z2?Z2*/?QL _J!"H!D%80J(*!<O:"L*B
MO0&PJ;PVGOP\":WGGX0UXZ;<I%I_[$PQ":^4?B9P,3E0@V&[D:YL2._SDLRD
M)1KN7)[15:^&G#&:! R2E(YI<$=5^UZXG?50(-P0Y4=:Y^X#7FP4VQ/(T#/S
MT_PSB[=9NM/DQJ/P.!9X<0OND^2U"X;:"YAX10"Y3:R8:@8%#O[#!I%S\XBW
M)K9EA[[K5NCH]?=M-S'\QBA=#X[WW>PZIV2\Z@@2!OC>7;%T?+KLO4;O[?0B
MSLH9F7 <X<65257\,>,U2@TMI:X\<>T$$I6$'[$_X=32*F[7'<17;W^!L<9<
M?PDY(IIKJW-*TD_@2+HV"MY0&037X>=X[3JZ\MZNSNMR6CA&RWMJB:BPV$@(
MI-U#>#7WA\3QJ\6O_1B\X!8:N_MW;?"^5<4$I4KA69V]4DC(#"7.G:D-O_E'
MF2SSK*A%"HYBX:]=(G8"F@#NK6[8MCZ[@:(7<>D3@W;I_9_+)3@)]WW'\=)^
MUMHK5[#.@QR'/XJ"[1W=W.<W&$]N.U$ TEY$@3!80L]31H?BQ7$,G*"_V];U
M?I0N;+6:Q.1]:.\H/":#\,N\23076$5IEZ]:7?W9Z8UY;:TK&AUV*@:+(ATE
M^F64OI&B8XC?TD8:5?*GO@)=H2@RTUA)M-XH+>YH!V(:75?JN,PT'*>URFCB
M<3L:,G6XG>>Y811V-HOFO7LI-2SNE,DG25/>'N<RY-I6W"1J+ .,SEU/ 6C5
M,9#OZ-545H<['OT)I/6GE=)FL2R)@VH<7(L+"FC -L^1]*"B!@JHEC7(ZT5#
MDEH:G$:.D7GC2E]%!$#YXPR>VI9HLP3$:Z%0[UQ[#PAFV=_%"B1Z$/;XF&T)
M#R,]<U+8&[Y\DFH6M6&YR?7C<Y#"VUS!SX^Z;_0GA#OCR]@*-^1O=H5PWCSH
M#<2->"K\B;_G8NAU.C:7F\;;I&.YQ--"=_-X&7I7IWFM%'%^_C,U0$0R5IE1
MSK05J9Q5CO9;D&UV:0C];'IJ;GG%+=%:.0I@;4OXH]2,C UI<O!<U*9&)0Q_
MB]DJ"--W+L30?*',VV$"G8 V0(;\(3E_6QADL*S""O<7A(T<$KU(*W-1N.CF
MK:%<(^I"(HVV=/H44K/N;W;)7]T*LY9B8%W/%VE>&_\QX['>,,?L*D0J&0-4
M!JWC/]'#'GIJ?<+4PZ> =HX!'&TJG5SX6&01=:D#LD\S+(Q!%*YZ!LMW]I?S
ML=+%BP8/N"Q-%D?1"C!F-A+]/VS0]M+SCJ:]2$,!;,"G( T9W5]_8=+G5@CL
M880?!PK@58QD\OGXF_DN_PEI84PO6R#:94JRM<2TF7L#WJ1(.?[X%1H^!CHZ
MVH*=A#=AS5P'-_V*$D-7VUK@V6(BXSER]5F=FPYG[%MYI^NU)SZ5N'&'>C'D
M1SP D]09V*MBQ5^>J0DBW;B!*("9(N&/";9->B/@')>9A9L?$1^P\4!CGY)%
M-NNS(D!M#%11U0+X $"O)E'W%%=SM:"MRB(_@?IL4G/VCL7%)=1#[]C$6Y#D
MV #"EK#M4187)]UHZ1D_)]O(_.1Z1N-H$=+L.'J#Q:L]'CA::A>8R$%;D>6J
MKKP]O-DY2^ZFXKF/-#'4Q4I*)&\;VTT_S-[_[1PB\E_=2@7$&:HN^45*6=]-
MO]21>19^Z+X79\GWV HCRS)K/H#O6IVTP_1^-_WG@[1BQZ;7HZQ.<%-=JU!:
MK87P7<K"RA6O>S^E/GXI$OZF'NCGTUIX"58>@<'?G8CG[B^8O(Z[ZTV3^.1G
MWD*8 [HW<_8$ZVE^ Z>58_&,WB/MUWNSV[9$\H75M]1+! !#,<OI-9.^UHVF
M-^JI^(^?6+,-V]#GEMGN+() [L^K+21BLQP'<^H:]00&EW6_(2U_B!G5?K+W
MV^O3'SN\:(<]3+V>+ 39F=A#WQG%+=)]&[-T7>) :S(Y7=.@7S; $ENDK1C9
MEU^#&.5AUX?RTRA]:Z%,)GH(SRHT_"(LX1$X:U([_+&H1+=@A^_ V34H[?89
M'T\V8Y<T"J".7R55[-5,L$&PIFF--5NU.*6HVLAR-]6Y7WDW3),^CLUJOLIZ
ME8)#.F9^#N9:#BNLL;!=2([D2+<H)8$NWYR.+$7+P8'J.O4!)VRV\K!OY&G.
M#.OHGP71%&.?WFJWRL:5ACU-;.A@U!>3BO>7Q@"L-R\Q:Y_LB.GP?"BEKZOR
MP+I4'VP++C<@,^B9;6,XER^/J_YAT@\/<X?!>V>;@^%?ZT?9G'BUG(1M-\C'
M(:?,Y>=!WURQ=#;U16<1+^MER,F5XN$AH7VNAD-T1 *FI[DE,K:XH@K-_74-
MT7U>.@[]^ZJ=6W1T^\X(SXU2(;F,/F=W' =X_"K&7E)D&!'6R;I"(X6BR37>
M]>;+6M9DE_PEM43T@V?=$J>%VL+HCIU-++HM360C'XM8<?151[&[/KEF%P#>
M>9T*RAA-^W6ZRWM+K0P]U+S,_6F6F#2[O7*,6-<-[&9N<&W=DJ)+[0BY:N^@
MIAIOX"[@C2A$"^]F7(V- S= :V"3-2J<&3K89S;0I]L+PG;7W(,=;_(=G;BV
M,D-NN&/_R3U6@$:A%_-81:/UZ:*^'$UM!)V5_9,J=,F?JGQ-4D E?14=$=(C
MG$6**>.F(#+(OCSYZ\7 O.L+ZI52F-RL>-\GNB,V/^?E-,)%*[Z"=_''!,41
M5!Z%^,8<H)=-L1->@LO-04D/PA?SZ3J%(E>&/@0"_(5)?)<_"T/H4D%M#7I+
M R:M'OGEDS1M5>_),/L=805IV^.J2AUM=E'-GJ5:LQM8A8)?)5CZ/P$HGD\U
MNJE(!K:(D"3)M5/R<=$D?*AU[  O!'FL"F.H7&JD>+&-$EUT0/+F:=R<>A!+
M^)*QR32(XU^'3\J/Y#JX%G:4MLJDO;XKIGH!F[EQ3DXQ[F"918TW^+9]+F^5
M#Y/AL6B7CV!:APIO<1#(6X@Z\&!@OWMLQ,,;=(<A.UF2Q#3Y8^K2#C'?Z[&N
M%9?N5SM<8FT?Z%80+E1\(MO+(*/;PH3A':;Y.O^B6" _!8D;O0VV-1,TANPL
M#)7VPER/V/*A7BR7ZDGJW]EV?;%U6CQXROE^14*,91#^1L'1T1]THKU^Y<4*
MY(R$/L49JJ;^'O&RDEC#\*]'XT!QY$\4X(07/)>&G,R$_.%$5B,\&,F,K,.E
M!DH0:^QWQQ,K::^;C9X6,L_IV"-CBY&QV_5XY.&AJ6@ ]-T3#6&/P6C=LGK;
M7IO-:UP"G:TIKJX7-4Q6:&LR_'-IZ3L@Z"$>Q!5Z^?W]!,Q)[ON<>6SH^[;W
MB@SOS(5CB?"\[=40:-G=*W:DF^JLCB0-DJ[A@UYMC] 4JQ2W]5O!*UE&N0M6
MA_+6=J:<W^A.Q/=F??8%C[9#+I,O^#N6O[=M#] 7US&,WE3=S&@YU8[)AD1O
M %VYK39T^I8L&FN\1SE5$I_>-*!7&!((VH=D7F3V#=36N0T@ HT9[C-04 !,
M*=%\![E3-TJT+@/AG+=I*A)D#]XLA"U%+%T IK@+\/?FH*DKZDD6ZQ1SSV&O
M^7=_D1R6Y>5D"N20$;.NWVC/IE4,;/1&O^6@ )R$3:6 ]%_8YW4_?^\J1=N,
MD8L'SI%?T7/=.%XV-F,>R@Q9R8GM4?1*CMD!3?8=/NY2K% _.#WCSZ%%UI;H
M[5['+"SRFYL_O^<8-L$X'LW!91546Q*P.32\6D4:Z8YM;QM=/*);41](KWD*
M6'<[W6@6RY W6GWB9.339]>( K274PCN]#R62*'A6FQP 56_?/':XIK=8+"^
M.4! /RO#+5ZP/IQH$YY "C_'S*T6T;U_%AF#T'G34M",7:'I[*U_H#JN 9<W
MJ^BD#*3IF7D&&;."R8TW&'!-2QE!%6UXCW6O B^FKV27PIQ7ITYAR4/E2:?)
MI=H&<!UH],'&*=S$0U4U@6,[1X]>_?E;UOY^&19,MH[CCM6G/]ZT=I/('$@D
MXQ7L7']=N_)_)"@MRG$?+6#MV,.$HH4DB[J6.L/V4.&^J]Q08L0;(8NK$T1A
M9#-X+Y%>Z[D5&V5*/SR^BX/_H-OG["@J*;7K.#1B+2F^P(:5Y$7R &V$[J'.
M8L/Q:N?8S&Z4_IR@G6_?/2CE$F17_HBM=N/]D4XMP^7T>8G\?.TYR=[ZC%.9
M0T/%EU]#O93'\=D7U_Y=4(\+/@6M::1JSV26Q("F4L@M T9@&&VL6C1'3$U%
MA9)^_K<[2&OY1R/AO'V7Z]^57FJ8H-$36^U&-THNHP!3L$@3BBBI?))SR$S/
M(26G)/\-L2%^BP8>=\:'^1ETX_NGY 5UR7PGW;9)IBN+$M^X>]KI+-7O["]9
MK>H^9Z?P4[I4_)Q/OOW;UQI!M(T!.KMCSZU[&]]G[V-7/X](7CI%SQ]TZXBT
MJD,0-*A?*'65K 5&B^\W\C^',<"@*Z"<APG$: /SE@)Q[7RS[-&&,461/+4B
MFA04S&&/_<*<7@\]S(X1&\]UJ]XYII&_^4G6_]V7@M]6( (#G5+]BM@"/0F0
M89&C,RVS>6_HTUOV;X,=<8-BK0SI+4.5<BP%05I!  <9N$1'@[\^YNYI4;C'
M<N8HO>9E](=G[YT?1(@6,\?&S82Z@\\-L(;<UC:6&I!0' 7!U.E")%'5*^2C
M,;I(8WGQU0$[^V040';3RUK.\M#J?(;5_J789P^GDD7RK,KFBE*_6_7OIF3(
M^Y(86[C2POMWM(OTC!/JAJ'VC5)HR]B@,*6Y)^E*H7'SW'^BH9%/?C3K(T4.
M]^NAP[R66TVDVM+$CI&)I4'M;Y[7+L'OR83P7W\^X/_^%R*L/R#JZP&,- <>
MQ#5WL@_<K:TVY;,_UJ%4VY]W5WYH+CW"U[\[H9&+<?/>#1@,5\?$RH[YS/\B
MT=-P('>.)0MH&2E/L^_V$W*)17C9 PJE4%<*^2K"9 D!,;:+%VNI%Q^J:( S
MN4YKM-+@U8\(J)\%>4]/58D.-3HIS0>V,#1K9W^P:2%'SY$XR?@Y>;HE3CR.
MLV.N!M)P_GYZ?/SJ;0D>OGYN*JQ*PH$ 3K,4ME%&ZHZA'0-GD?)0Q*OCMMS
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MI>IUBE\>@V02LMK6%5=WA M'V7PXO*$MH[,\KDJ[)U+KO.,22@(G--TT45V
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M$4'V%@7H&$$!'C%\!6^IC8@>ZN&C (\EB+VMFT^:&P-?[@$/O[A)(?WU'J,
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M_S\S^<>4MW*ZF>?>-Q,:,P4\!W#OW,&Y<QL7YP[.75S<NWC$^#<ZQB,G>D!
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M<^9UNB7QEG(>ZA'BA$M2Q/":&7FE ;]2RTQV]ZW87)0B*2X(E7E[7T#>J/'
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MF9&.)LIZ@V2)Z).<%O_#W*0XX2,QZ>[8W9"8:W\=I4;"0+#) 4],S>+=XZU
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MIYENF831%Z_A\0U'W[UQ4Z]9Z^E/N1:]SLZE)USPVE&GO+KJ .=47_RZMX!
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MP^QGKZ1I%(GK7=.Y%(FH!ER;C@-LS"QQVC,_HI)^PL,0")\\MT\^1O(#8$K
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M!&G75O.OHS8'E%TX2SLNID2V3Y)B<@3@%QYA-P(OI[X,--[.!C-2X7UM*S^
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MD[LW.@7/Y>$S\5*FFV7W2\I8IKQ0Y(F<VW9X7@V7\"C+%#9*+M04%1H7W@^
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M7Y>=27C<)M._FB/V_WHA/OSZ7U!+ P04    "  3@M18(!R&6*%P  !/AP
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MU[W[O'R\C.R"(H(/A'D>\#[XHQ(\XNO7;]ZX24U"0OV F9[YP;^=+IL BNO
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MQM09.I3&;/&J.:\8V<Q6Q?YL*N&PGQB*UF8/O*4RV<6#,WNS*JN9#?'7V%-
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MD1,FX2!=9^J"U\SB3LQ,GN/>_OI5$5)K^Q((CE%W_[VIUK7^8_:H<>M%9=)
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MS&N_#<L/K?@]M9JH8CWIA=Z,;VZ\.W0N!"/5N@2>FAG;/SQZNWU+X]:W)2F
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MY@C$NM*P/^O9[J$>4E?78'=U"Y3/R!@J6H!59*(>!N,F=?& 3+?!$CC#$9'
M]B,GB[IDIR]IU)0-YMQ;*4,LMA*ZO1&[5%'[5<R%W=8B]Q$E. [D3@FNSZW$
MI.?Z4_4\9X6LX_([^BH&\K9J"/'L=1$)N1R3 4ZAM-#J(8J.J(2PQX$;"LBC
M#]R+5:DO:U4BPRPB<R]!U\21H=BGO0XT(Y[J=X(EW<&8<;5%"9Q+Y.B5>V9&
M%,>"O5_5??)E,(9'@B>0B</,BWS92V.[T3JE5Q)N*L^P2/W,ZRFSIYBNUG1
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M)4'I.7C )<.2NP\N$NEL]!1W0?V;5?*.D8E=J?D7QLW$QSVX&GVL81%L)H%
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M_NSJ?K8$7&WQ%)-L)J;RZ+S#T4-'.N_^T_GQF %_VCZJI:4T(T&:/FMV=A5
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M),4UDNH^?K,!;1+!SF61]27Y,EJ!F%<\'GV>JMR'<N-LHS4B]+,;,R=*][Q
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MVY61P@-DL&11<W'$'&A&$($'.* ?EUU_7\A^;J*E8>3#^NJM?>FS'/!0;TM
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M;Z::C3,[_6PF&:]W8GV9E'U.?<9*QJ02BT7_EKN2Y'J2NG';;Q.II4(ODO&
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M2@4 M\'V7"Y(#&AP-\U_5>7ONI8# /?*L?<(ZJ>$$M3_^0?U3='"N%"NFWC
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M-#ZZ%K'TDT7\9>K>"KQY7UM^?AV","UF)A;M\?7^4/K6U-1$-(0C/DK99YB
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M2'GCR5GZ-D!^C4Q8:%V/7-IV;;)B8V?1C=M7M-_;UPE^.CE[0[MET9<0F]%
MV!7,(KA.2,0SONNXZWS-M[K@_[AM\I!E$XSR7J 0E^2SK#8R=I/R6=9J+[;<
MJ8U8&&0S.8+'S^WMMX3]ETF07DOY^=>%UW($(X)71W[6YW" \*)1*C+62H<U
MG9AU&W3(>FB7R3_U36H<^;2=0[11Q%I?,$;ZSA+U*.3DLJ\[=;K6K0*T?Q8\
M;1[HL-)04Q_6YDM@PL97YRSS,D9)+@:&GQSLRJQ$L'!==?LFB1U[6=*!XM(I
M2L<M]EXC5B':IV7DS-H@$["+3G4U[\1N*F]VF!_M765K+2>)K'[]$XHACK/'
M4BYO:BO"='J;+2IT]>>U<FSJ.?06/N<ZJN0"#*\KOZ^G;Y4FE4'?38#],[/0
MH2I.=JN[49O1M3E&F'M;,JOI;[>MD!U!CD[1WL01JM==:_IJ+QK&RN/Z#CP(
M.J<2C=^JW^M&Q3K*'>P?\?IT)R5PC(\8:<_5M(=.N@98)"/=727"S>S^$WYZ
MFK.!40?KKC)JE/&M!6SU:\VU,G;ID[;B_*XRB=4*G$6]7-V]L[FPV)[ VYQ9
M(=27&Y&^4[D4G<<XGEE]J9.9(JU\JK,@2<?C0F&&F2\=6M ZQZ+<#=LDY$)%
M%SV*X!8_C]56<CN6'1!=A1G+VOK@%,O'>9K>Q>_OL14%1@/4-*5[*A[7A[/7
MEE94+L(!2]T(W33T4#Z=%NJCPN3,#^DNF4K"J2/*65Q.R-6&'XB?0NF\11*N
MFH+JLHJU]89IL(4?ZX%:*$FY^AH)<;Y'8D]7I:UN?[@0X>I*G8[YNL=+K)A;
MPIOE#BF.<#5E?#OXYK[>89] A]&.2R!%CXC.<G<2J#4S)1=$HBO DEU37\O1
M1>J0L8"ZH*B5J75JG92U/G^+C;D+>6(%,MN,"CHSI-+_;GI&^D6U'/UM.6'Z
M6]+U5 'K*U@M''B'YN9V8M_I0+P+$DD77$HQ!P\[N7CYG[R.DR 7",I9J1R5
MVC E=?^JW8*[JN_0664#PVJ>BEOJ4PX>O\14^L$VP'Q?,RKVK;,W3H"BI3S8
MI1O=*T\A;]ZJB5M0HO_R,M6O449KX.JJE*.?.KKUNF,K>PI&;]V4F86595-H
M)2@2Z2'O05N>8FTD'_82A3N+@YZ0U-3_P[TH?;;O:6LA(<+,JQ0X\E^NW?UT
MUB#CK_5E/4TXWA:]?6*)\BE3=JW58Q7[HWT+ 8OJNDQCO.KTH5E#<\NM$.'!
MRB/?(KYUI+EOW1;"2-'!;?Y@OE![J.::_+"#2C3AD0.I<-B]V'=!R.]D15IM
M;+H"\'PU5\M4V)]-L;%W2HU%^-R&F87>X\AH[J.NSQ>82"\^7<#2.1K?ZCR2
MU]WWLBNGLJN2X,1S%0U2HISD81V>O*I7U5M2HNT^K=M.TF09\9,5CE?1_"WR
M(U_\QSBZL3VD_93*"@Y<SL !J5K7Q(.)ZZ=?;E"-8#>Z4%7HK(HD_I=.1/0+
M_)5<D:7>KW<)ZM6!2Y;TEP@Q(OO0: (_S=>_5+8F)VR>.-ANL(G0GE[L?/U-
M3CN79L7T[9O+IL,:8HUX6_"0P>"YGLP+0N9F?M(+: G=M-UP9BO!@(<U%W6W
MX_-L&:VC[9^7PX[2\\5>AB?M-^0+TX^4-9>3"U*+#+<6:@2]A/D*VKZQ/!%/
M806Q]MY9^#Z;SX22VWQN/*E=;'%96QO7+IL82EJD'0IO'2 \%ZVEJU_39J\U
M:ZA,6F7]^0RG?U;UQU[V>IF5-3E7\-[T2A<M1(';!X6F,)%(1(9_P3]DYG2[
MD%1=5+/UJA4.Z&;4%B9INB@I:AR,R^T/3H- !L>&S;QB#PSE4;"2><WE0U'
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M,]-%'3E^95UG;(!F=<OP'T875*FMH7:#$5F=N07L<<KK+# 8#I"WMWCT+=[
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MML]>,^ ?F#M? V%\F3#XR[C05<M;MQ>EI",K"/RGL+)S., )'B>O]J0V-#V
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M;']A_H^>:LO?-7& SZF.K=2NJ9DJ*P==28P& +!UR1+ *F9NIU>ZBG'6G@T
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MSG"]>6Y2,%C-.V&0V%.TP0Z"[!'",>0@C+)$!VH/!]PP5!U:@Q^'S9Z1B..
M-"B>>5$? P^6^6*ZIUC>P8H(\3O?L%U>% +EQ(H83G=^UA+>Y,3!'>[M+@][
MJEI*H<(Q'HX503)LD+XC1J-P=]+A_6*W(KMEN2,'>PU @Y0$!OPK#[RHM<,R
M0SV3=9;*RLRW.]+NQ0G*@1ZK'#8>>,R:90SB?1O"?S@7/HR/$!M;.+M:'3U@
MX2+HPRJJ[,RP[4T[#<N?P.A_0W-<7#0Q4I/.Y-GV#X*;P,('#48RR9,"T/[@
MXY0L1537HR%T>D-CG&S-74)-0Y!G[#!;L.<3^@=9=R7BHBYH.+K)?4Q]4K"K
MA .^1W2G]>KJZG^PU9JW=Y^'"/M987_!;IC4@OK+R03;2KE3/QY]S(A1?_;S
M'NO_V'G[/'B 2^4[%L8WLPB^7TL4Q]+RS-9<F%S/WG.X?)GT=,Q9M2UDH NR
M9F3*SYZV5O'UF2=BGZTLOM>DLW*B9RAK7*1!UR%T5J=VXW/>/B:?.6S>T(',
M7@5R3 Y.-.VOZYEG.\C*4SHLZ650NXXP]W<)U'5H>)+39\L1>,FM-^#-[961
M?0PX+:,T!/HBZ&3T.CQMJ<1%C8P[YI[ZNA:]MEGI;Y-"_O+Y.^Y6_^/G3\&R
MOUE;\P\7L#$TSSG2*J+,F<;M&/7;E\'N]IW9RT"N"<(I>>P"0YRM=N$]W>R*
M6.BRQ";:S_031G];/YNYS"YJ2A1+4="FB ,"*/TK\YJDMG-U6MN\#;5'SLL@
M.\4(?E%S)GGJ#[.U>EFK:2=L$ ,_[8/1E;;9"VN#\6EM^M" E!+UY5(,G20J
M[5*3X'H3]]CUP#N-B0.JH7L.I<4)7#LO>U7E!IC6S)PTS"+-6PTT6<\_-AZM
MV/FUW:OX6*#AXN'B)?+>PTFH%0=XPP3AXMK:RGZ"CS(*&2P?X6=U_[<QXK^[
MFO:/GG^+/=V HXBW$>?D=;Q8BO2?E9PX((BN!;(OL)IV+/P*!X1FA)WMO87\
M(1'P3Y+_SR06Q_"Y(6??Z^ET..#A./PX$8(R/[Z)#1:BP $72O!:1T+;G/_!
M@K72^.]>P%N:MQW/R8T8L106/T?/^(!OR/$V9O,^_U/S8Z&?7\C$,N" 0/BJ
MSK?F;6,:'$"'=^9_VP\'!,/G9D_I*T0P5_!RW3:H#("VBS$L.$ I/A@'O/SK
M7"F08, XX")>)V:EP^>J0%@>Q#$,2X5' 0T\=G]Y!L%HX1'M?S5#C(48\0^3
MQ@57$GE2B,$II5]MF'.ZNCX3C7W$M@Q!5AF?X( 7:U@\)$8?:^\<(Q:@HUB+
M\^"/\&_"/3B 8!C#]U_)=!^!QHU4SPDWF[?9("V(32$N;("[^3%U&NHGRQ8V
MH'V*,ASPV14_14A)!>+TP@1\3AH>C)_TWQA4@>3P2C0.4*@7P9! MS//*-3P
M1KUI I8H^QB/TO\C/LC@X M")4T0)Z2R#3FP4J5GE4:\9G\/WM*&MY"A0*<,
MKE ,XYU?_U4?74@(XF,+7HHX<0 I;Q!\56\0LFWZ4RI4,1RIM'A9@OV"%Q_7
MG[*DWZ'VVP%^V^E74?HGR9]#,@0B.%8(!Y&O!L''I?&[.TQ P)?RR@+\#V&Q
MZ?X:S6^1X'?;E^\#T6^!0/6W>(*W>7Z'!+_#DU]A_X]8>O%/AOZ((6EFOHP&
M5!INXE\ 4$L#!!0    ( !."U%AIRLH!#Q(! (=/ 0 3    ;61T+3(P,C0P
M-#(V7V<W+FIP9^R[!U134;<N&@1$:9$B* A1 0%!8Z$I)2K2!0242(T*2!,B
M(! @)BH"4@0! 0$A*B(B)=*E2*1&NH"T4). 2$\H(9!VX__.?>6_9]QQ[KOO
MO#+>OQ@S(^SLO3/GFG-^\YMK[7!&.3.  ^;&9L8 GCT\@-O</P!G%2!ZV1U^
MUP/@ > .'LXXP!"PA^?O^/NZY^_@X_W[RL_'Q\NWEW_OWG^(P/Y]7!'8NW>?
MT+[]@G\']YVPD*#PWW_^WN1_N70//R\OOZ# 7@'!_^'!^0X0V[?G%5\G+\]Q
MP!XQ'EXQ'DXK ,35D?\?ZO$ _FWP[.'EX]\KP%5#B'M"U0&N^KR\7*7YN1IS
M/WW$_1S )\8O?NSLY;T2-G<$C@=(GGN2_&Z?PI6RIH.V_13%\W<#G^X7E)(^
M=%A&Z82RBNI)#4TM;9T+%PVO&AF;F)J9V]VX:0^]Y>#HYNYQS]/+VR?H87!(
M*"(L//)95'3,\]BXE-17:>D9KS.SWN=]R/]8\*GP<WE%955US=?:NN:6UK9V
M_(^.SH'!7T/#(Z-C!"*)/#OW>_[/PB)U?6-SB[9-W]G]:Q</@)?GOXY_URXQ
MKEU[_OI X*]=/'M"_YX@QL=_[.Q>\<LV G<")(Z?>[)/\DKRN[*F_0KG;2D'
M[P;V"THI:A"5J']-^X=E_S'#GOZ?LNQ_->Q_LXL $.;EX3J/5PP  ;"8[^-4
M /^2_W'!*K$^0^Y#8G#E#;E 2F\9D>76VGB6'D_B?8^$4" QXA+HDBEU2XWZ
M:^M&PF=:Q#7*^]3CDM\N.J0Y#1>1UNCJL&5^AA%J:!?2 B98TY3HJ6[$OD00
M#](L"(LTL/3B+5A<") ,F/(>S(V=5[3YY+9.#M3J/Y8,N @;@[,%#<F@N%QE
M"K@%FS1=CHME2A0RC1N&2QH42&IJ198F5[YAK'QKLOKGHX,TJ[X_'3 14C=/
M"?-W"R%<:F>5<@ S)82D91:9 SA YYU17I:F9I"3*9=O4E=K*6M7C <?>B>H
MZ3H4KY_1#O66R&LX4Q1V]ZIP4ZP-"4VY:DU7'?G. 1 BC?O1=Y,(NM_MD!#6
M.]017YG&XMP#(^]5#S+7+5$UTG77ZI]_-8I;73R7G?E4VN/<\4R!/]JQ6VO/
M<!7H9NX7(Z]0E:8P1(S0G^3%BQS <_#$_6BY=8O0T$#Z;(7INFE 2C>>5U$0
M0$3?QHWC:$@.X&DBNV<7N@)A:/EFA%Z4RM.KSDB_F/,U>MO\6[R\7T[WG=>*
MA;76G=W%I0G%G9W6S]C]((J3B.Q,0?NT.%*6#N< ^$BL3^PSXW38]8LA^63K
M9VA!&+1?9D?,LJTX](H'4%VT7?422/'YGS [6W23%,X=]AQ2@5U^1,8=\@U7
MH"NW@>0,5!!)I*OR<K@OHDB5K#R5+Q7I@$ZA%C^1^@ZI&T45[:;C63NZ[:C#
M7&T;T$W?ID1KZ/.A#-,QU""ZPC6M1+^O%2[J(R\1;T$%QA ;&[S]@W4]7\R>
MQQB$IAB'.5B8MKV_U*-Q&Y0/J\Q8R:'TT:SH8A^8]^D];Y=",ER/X@8?8H"(
MX^W[2C5SH,Z-Q_PJ([S2K4\[?0R$LFZ_"-'-V)??#FZ>'H\;=&*]/P5QQR9A
M]FU!HC$'JC B'23@_H7PW"+?1]XDH7UOE'Y4U54'E@3Y.P@/+Q],<W$W5 P+
MH,8P)<DD.5P[FJX^PI3(^[YK543#[O4)SWB.=+O;E7QPI34<:>=X[?)J7*8K
MN0_N.,BUDT*/OTZ/8(1P $WZC8H(5^-X1VN"N?[^$\^(/=$?A^UKRIY>(%"U
M!BZ*#3^&6*J\CP.HE)XG:[=.2S//#:ICF<<HH8[4A R[RB GKW+C$O]W@7(U
MR4UZ :YW2-;C4))GY*8:5H)>1-.FIF,*'(Q^NTQ-3A,^/"C8SHR_+0C8%8PK
M($[>A8@A4/C6 \UN%DLZI>):M\UC+GT7U]'I<7Z[)T[E7_+O2<-YVCOZ!G5C
M!M2.C0E?BT+Q((KP(.'@4^>=*N@QD*>;=#A\4W=E-V(A ^,^<=K_#J$NP;]Z
M<5GX>7>!3^3JP^L"<\ FV-AT*ZZF (\;LR.;M"0]S>( HBMAC]EGJ?;?2+@X
M ^6?'@,G<'%^5]:6=P^^TA;,@%Z>O;MQWOA+\[M?NJ8K<B'H*OA*(<,344_[
M@FG9Y@ HIL 74WITBYE35JK,4]X?6='#TZV[#>+^EK8K)UY5C']?Q'K[7Y*_
M+7V.]_CWEZ@4;X)_S@?'4]&I=_B+]W7;RR*>'E5O>_T8<"3%;$LQ*_>Q 93.
MP_!&C:,/-0HQK]/'R6#ZB>E8/8E@HJ4.$(#4I *?EZ0Z43V6'YAI3'\#-/E)
MI-=$'S>46SJK2,F+HN+;L8E<I6[TC:FU@LJGLAF"3'NZ61!5]G)&"UMWF*WF
M+56MA9+]4FM]DF8!G]8@O,"G#,0''#DF'"5S[YDPZ.NGM\!8R$P^Y LLOFH,
MYVE-0--L*78^4VJL=.8=>-@'^A6AUV2,$Z4[V="WT+MZW;P3XZU%:>\_?$C5
M*S/\JV8V%3H#>0&9^<#5P@;VF .0KP)%3:E0:IJY4\^P;E4+(KL(^IW<:,U5
MKC-5J*IYVCM[JMG0<W:G[\&?3ZN=R3N10=C)RNL\1I+7>5QM&$$<0$<>?9O]
M'<P!O"L)_Q9FLM+' 9Q((D\S #AV="7/)/(T!Y#B29QF\#BB_[PJ(33373@
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M&TUU]VKR$3%-C1I?:K7D%<M^P:Q303XU=VEVAB=R9!6?'BY7##[)<^Q;;QR
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M<CNNYP/H)5G0SFL.@-$'^XI2H"K'($'O7!!Y;016>L;'6\T>WWX%RWYX*H3
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MFV+46B+<J#  3+<Y'RV^!#5_7OHMA% <F'" ]R'V%BL--S.<M+</"XR;IMC
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M9#!3B8JPM;@Q,LX6FS2Q9J@YQUY3D*ZF9$P<S5CU;Y\*2'Y=]!AO$YEC;IL
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M4>^-GJG$4?Z Z?8XZ@LTY0OW]#L< )<J=I-9J2P,#<@],IB#S\:MX);]UCF
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M+]"R*%1RBS1/LT>VWFZVW ("J#XT<>]=:4F^%G%DB]I;Z*+#/FA]B(2:FN^
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MF5+KHS'6',ZSYZS[$#A4F*B:O>W]L\_3F^J*M2HFC*YX3C?;ACGV!:!$=7D
M@WE,.PT=(ZDNQ.4<I&3^;#2Y3 TJ%GTB\><WR>-_=53+]T$L[EICT,H;X7\>
MKDL^FEDW6"EFD0=?^[C#6%M\H1M_G5KY)YYN*Y+U"'J,_+I,VK#IZ\=![PF/
MQG6,[BJ:=R%HVSG7LOWF@RA!0;-.S4\?)PWK@LK"'LA5*LX3-B3(YZEV0%@
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ML.LL.W!/X32-0S;STKCTBY@Z8QM!@@?\)Y0$-Z G^EU5LD9Z1D7BT"KRX(E
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M0=X<_K;DK?)QSUL[;8B,;/&9A5)(;%5[O:+JY13(6B#!&!QE^W('$#4-21H
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M3:='+)Q?PN(Y@L\N'? <VAGDX?8VV*P;KFD1WG;\07.%,J1;_ZS@1P1@A<C
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M$QV4^PV%IA]7GS8Y'M)@&RPK7DF]?4!*-KU+^&+UQ:$UB/I66CT,6 (LM\.
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M7*^4Q_6[9(7<29K1'U6D6?<8[DO_^>L*#])_\[J!(^V#46OF6;B-E\U1EH0
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MK1...+FICFB#NORKEUN<2K[NS3.]+5AQ<]>"=:3$5DGNI^,FAN0H.F4E 'C
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M.WA9_+KY'9;+RD_V0%H\[W1N@Z!=Z>HOV(Z\H1ZRU 9OT"?%>Q*) 9*3&W[
MJ_Q=[\+)7ZJT[C^@/+<0]NC_/#7/?GEP;*Y5@?F%""AP)2Z ,6QCT,C]KKD5
M^)-]=!+=_YNLV&$;2C=72:[80W0;&FBI#+X$@S;KJ=/#4UHB@"4&B\=)8M/W
MXP*'5 Y-@CJL/T#C0K61NN4$X5!HJG%/W=ZRWODYVYSNL6:KI$.OPXX[*!.
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M>SS]\&=V-\+8EABIF3WY'NZQ@+&F$25 HO4;@))J+&IP_DR34ZZ+<MI+N,!
MYO4%:KE8]'7;H"9KR'4HT+<)J1[:4''MV(1P]ES#@1_#Q\TLLYXA=X(XIY'*
MRA6#U9S9V7XAN5TI<E[ERD4J%[=%;XN)WK%O4)9O$&,*F@ XZLS3N<1V:+RE
M,E"AG#9$-A&R,"WV_/3T'>7[B-4VW0@>2G\>*SP*V@/E]"A/6"<QP5N=*>,N
M*!_@-7RYZ8#@%#$@+ZTA_./[@P4EQ_2*GT0?-(8GX,0Y)K2CG.VTH<3?VOAB
M+\T784\^+1[H0A[J/=RK+'?VOJ*THE3O<AX<@CD(H@#\J5!QC $850RBG)!D
M_U$.K+0C@"^K]?L?M(M>/6^[G4+^-FQ3M2>M59BC!#YZT5.)L0%M:1D[O4]"
M[JFTA!YO:'JT6\Q- ^F<=*E&E?]^U;%E_^4.=>56@ &:K7>,&R&EW3>RG?9Y
MGD+Y-TS5]!V4JGU&R0TYF'XPI<4:$LG!"V*%."KU^718!WZR[&2PSYGXM%)O
M:6 P3CFN*:';SJOYJ4#YS@B[$J4^0A(/[6*A #QJC;<R%1*P2MP9Q.MG:248
M!P">]!-5:>K.=,EZLE1C*SY>;#)M@(P0J&F.PLS:G$WH@\R;_#YJ#;G5>A2T
M!O#TV_6C' ?P"HVRLR6OFFSY]@DI_+)X&DGL^915VWLSZIWS(5QQC 81\")V
M1*W%>ZOD=]1G_\II%"/+-;F?^.4_G2G[J6Q_CT;8U:B\1=TB"6/N>US-)+
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MM>BJV<M'DV$_OO7_^$T):3-Q#/T_.V)Y8L8A>?B0H^Q[^ 7K'' QC3 ]>*+
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MPK%V_:*L3_)3>;F:)$V=:YK6'TRF;-M47^;GWO-.2QT^?*E,?3RL8#ZN%NL
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MR+:P%P#_^F6\$"N(NOS00%O,]7-577QSI4V@ITL U6F_T3F'<^[\X"(%SI*
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M,V( 8@9R!X\RSN@VC/\N(18EA-N#YHCEV8+Y0&K/-DST3X"#X)RMW;W&":T
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ML,>P^6)C,2JW$+B]%LNR#* 19@3[.WG!Q@6XT"_GD=4@"EEH;AMV Y/[7:N
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M("@D),3%*W)"6/ $OZ"0X#\W86(&KV%A96=E91?DYN06_+</QG> []B1/E:
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M;OX258AHU\94P !\DWF&G!F )ZUX@XYTN2EUOW/R;^6[XD)D* -HW<6MQ3.
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M;A(-%H1SZO;+AMMJ#DU2E5/]ON@HR0T\2UX)];BM^&#"G"6U)I8J;-$\6L,
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M.RNGKTFROVH-W*]T[RRRI-?*I06:+TKM&JN8&-7(&*;U/[X(A[P!P4Q]'+6
M[N1-HHN/('CGQ3''O3*;("D#\#C/F#-IB:^GRB6':*,W!R7^P6H>Y DRQI@6
M:?IT^]%K::(?]61MG1_)[9$Z*3;RMMG?HY-I#B9!*4]&!P1O68CHV40K9.0)
M0SD;H!0>^F".P)#)^_=D1>=^[/!5SC+HK4CV2SGY@==X> M#D$*T=R!A@L,$
M'^S"+B^B*DS#./'+H2\U#MR:P;H+!.N.Y)BPF>ECZ]0"#:'R!6)R&$#M-E4
M;T_&+22BXQ@ MWMU%BQ'2*P\5BY2X,GJD4]]]9)YEW*/VI[FZ;O8+4U]C.-
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M*B]X;@PN;"=E&4E^[7^$YTD<R;*BF'W-M/;CZ/%O%CPR6?,L17]E< 5]C.I
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M3_^!AX6RD)Q'W3V[RE&\_LI&1<BG=<>8]PR G>L,[>.".17W)7/R6Z*[04Q
M]E^-K[]WWN*JY 9J,IM <8Q/67!\O:FO-6/,JN2R"\N">Q&UAU90<^]G3U C
M"%$DY$#U;$S=ZWZJ-:I\W(MH5M/G+.*0:34=_5I4[T[#HM%"PY-1T@81UJ8J
M0 K & _AYJ5&@_U$%:,;@O.K7QHWD-ONVI.ZDOJ5?54X7GS7F?IM:91"*VMB
M(D<MCK;".$/#6_]F^[S;RE@X;V"7??VJ [].S%1%L$WJ-[6@[]*\-LKM1NJH
MYO/!L./(<20?N7,N^>;5@3UY4 =@^/[H#OY$:P_Q!VD=2_VBJ>]Y,H$ZF8(,
M0G-1!*807I1 ! <YC,C>P+< B3N\CUFX\O*B]K<4+YG:%V\?9C^Z+'A%ZOWT
MX[_MBFVHR?0Y5(N5@#==B@A#2P]4OY/WF=D:W! )TOBT*J5P4^*:G,VG@I<J
M(O[3D<:([46K,=V%J0"$#4$]"G%S+H!0OV!4,S%2'(;]LVM1-F:8QI8J?:SI
MUK.KR85=LA\W_%[MGZ&W&BGT@]7>M')]^%%8%4:$S#/8(B:8E24@_F$IID/9
MY^^YY]$V=UE>JCU!-'Y@7J<IMC\Q:9P/A_']R7ZN'Q,;[*U^IZG&3T//3?FK
M?NJ0T#+.J$&3R  6:S>%YB7]%F9>$]'-.  I5E2B\V:>8G7<WE%_S4#\MZZN
MB.C.CSO8KJ ,A *@N J)1'W&/T.(Y%.U1PUA\Y3S3@NHYU5.$<H4;_R->AT&
M4)\\R,EWS]39;'$%K6@X&@^?_6S5CF<A>X*,E,=( H[AH1H3$AWKLP]'3<C1
MQ=>U>Q-5<DO@]U-T65\*5(]%'NL"TLS8"I##T"K/1*H 062^]PUAI5U?/<[H
M-/F0CC?KWV\4.IG9$Z91M+ F&'3Z1.7S[BF17VR&=@$4&?J %Q%.<OU"[$Q4
MSZ\=J3JAIFIX4Z7GQ8&(;>[KZ6'_DF]'NI\"XF3 [MD#'.$Z5G0]YPP9Q9;8
M)#NU.L-'X(U)M^C#(G@_6'B4<H[X[%I>>_&EK:QQ]%1[0D&$GM#KCZAF(Z1F
M**1U5@3!2ECL=#S/ )[2I2W@6G6QB=46Z:4M<\N;;UN];6S?J!36JMF)BG;G
M<D/'LD@_R<E$@\7HWG3BZ;G+\SB(UU_'E:>;,Q/'D'@6D9L=(\W]0@5^:AJ!
MOU-DN*FWYTBH6M..9.;Y_<XV):0>&04;WD3<.M2GJC3TJPCOK(V=.W*#P(KQ
M8DG:9$8W6#(=<K9A"-=H?M]'<=Q4<T+I BH.Y .ARC=B+%2AG8?=6==B?O+.
M7O0]6:,*($[/*=D41/5R/\G:\*,(_YEEHJH'09,;].:FX9VHR=HG[XKC5!YF
M+BS,B.H</*CE;TDK@6&>?9]N7NIC&\K<T1HAFA&K5-9.=$S?2NVC)*3])[CI
MA_+RN8K:M(7E!YN;BRYXE4]"MW@*TK\++6.JLCK+9$E^9/-2\J@=>M/'KX93
MF=4_.>S1 5\;^Y^^2BG_#YUL)[#MM/!.B#C4%Q__HR@^F%?0VXYKH#G?H2+1
MZG/<<4X6Q7MF&KE=*XI)%7*> RUS'O&6/COMP0*/H<&/,.+D$-=ZX;K[N,(U
M72>+,)VLU!ZRI.7PW0"G8#)J$4M6F.U$Q1B)H_C+4[U*5;/CEV(O-&I.M[ 1
M628^M:$JOO[%#J+&/%MPPE1U@DT_4@T>Y/VD\(?*B+#=]\;-Z&^NLE]?O:W/
MJ7>2UQ>&!KO*<EY]>;Y0_^.%UWO7A8B=5"'QQ:=D&,708OZ-,EK9B?BRV-+8
MME4U^^FHZMYI&]G-L]@?V^.ZBW(,H'*[DP$<(]?<3^-6]12>2)M[)O]R5JX8
MTEXEN4C[,(+ES;+B,QZVG,X*<*9'*ND'>E5<3>](,UF7\V56+NFZ\^1X> +U
MGR>H,NC#,VI$6 >WYWQ,?(G+@QF!OM</MWPVEA],VKQ+=?@Y)ANH9'";%Z+D
MGF:BY__5Z^['0.,QGS&:1U1'DU3=4)9EK.N@_-").4?3,/&KEII_F3V+JWWL
M%G7^^<XFASSX/E0+GEEK!!D./C6_N]2O@I6CV)_K;5,]D3SUA(U9]K=J.S*:
MW@+C0LI3SY*5X7Y$@[:LB9J24-MP%X6#-GS!172F@-*/2BEVFZM%1SZ<T)OD
MB\FWE-A;*PECQ>=_P#:KCUO1K9R^HTA:ZO0D;]KFAPXW9(F\%'S:6>"K-2S2
M$4;%5!?37E8Q@,%<[,S$V5#8QQW*:-U71?^\IA#0?7 +NM]2+1@ ]AQT[Z,8
M-8#,3-$BCY(R1[1=-)MO.%@%%UVHU3U"6KIP1-/GA%Q@D).;_]DVFV /HUL8
M/[+T.(W3&I8BQ0;>R94:V(?PRO4.>2PF75TYI+KEH?Q1Z22_\?WOG8K " .@
M"FO2+;(B<1O.D,.;VL[^6BNV6B7#C=N#<$1[T'Y+ @$RIDB_SC:/ID4Y,0!3
M<Q>_327BNCGM31.?-UU[6);BG$GQV7C(O '_4=R5(AW.PWEVXU_)KG.K<-/E
MU-KV7?2UNOK(CAF+Q-?YM;7)(89?/M^^H9]F!=B:9"UBN=>S$KV*R%$60VJO
M^#\[SK0KO]!_\;%M=#ZE> $+,OG:VC9BT:?1&7E<1E+_G\=;;H-58U^8? HV
MDH]>F&FK]-?X:?)D&\( FK6,]*C:A+8<6;'[F')3+\B$0FV?GQC\*W#^BH?@
M-TE4R-?1"MH;2^%DQQ+S/?IKP\[-WT('BA1F\-*+AM?GL>(/&  OR&D$X$TB
MP_(6!I(W;[QL['BG>;PB)B/%D=^_X*R!QC'I([R2#(#5B>P))CEL4PMQD<5)
MA7J[J!7A8"*"3PKCQX[R=732ZVS/_O#8I#W_#2\M;FPYA%16V<4A>U!"J@TP
MBCQ9O$,_>2!N\Y%TUE^N)]H?JVX:A"\+N^]C6ZSB7#7JR-&+VWSDHEV9;<<A
M7VW1HT'5A:EOT;G3Z)9BSJP??'K-/5--%\9I\M:NY@3WQ?.81-Q]"#?UZI#"
M]#$"84A;E.F/'!^D:G>#V 7EH*)H*0BE8,H%Y/B,:-W0(N5"EGU6VY/T8-BT
MIK/DS"]I8P;P;.21O^_'$J6K4U'?*+6@?L_^_ZK?_U<8S+NQ=$[MCRZ7YWFC
M#P,-.)43U]?C;T!>=DOX?Q388OGBO@:WHQ^;GW]W&A(MI4?D,!6 9XE-C%DH
M0$-KB,WB'9IC(IF6[Q[O]MG5H)HO03T-MB=DYPQ'#KD@#XB6S_RUK^NS,@?W
M"F7:,VTX\)B6RO <8'^JCZV3&L&*O <1]TZ=^A/HW20^]-IMN"K$7;#?\-XS
ME;#Y>\Z?3[=RG3LGS;=7)4/4"R^T6+#:_R:N^=<[@;I)3@0S,X[P'"GP-E2\
M^7"Z,U[^>9QEW8M6N-_)Q:"PP'HS-I=\WU!1B<6/@PQ@+M_658V63'5?_%V1
M?H78E"[FI3#M[E>I\UX_(\9,SBT&\'W98?G[V,6NT[]^&QX]*3?E$W*W')V$
M YN78^RF'L45%X,P[#@<M:Q/;)DP-!LW]]Q];+8H@1C4Y&[]F&=7@&JV@MYW
MXGV.%"?;8<G(2=\LCR+3>7CW[8 ZLQL-_+JE74V/K2A'FA[2LG'W&( X?42_
MMQ$^;U&F-DA1.+72T#A2G'FNUJQ-YFB*'OOCB974)-F@]2VQ%2J_[N)_8>\]
MPYKJMK7A94$45$1 BD)4$%045$10D=@ $3$"(DJ+BH" %$&:ABP;THF@@J(8
M 1&0$I4J+=)!4'I' @'I):$F)%EY)\_>YYRM\'S[.>?;[WO>Z_O.CUP7F5EE
MKKG&N,=]CSGFY$! ])#$W:;<C?$;=3P5>&(C1]MUU4MV?]K3]&;#C<M+CU:(
M2R=[[8_<*10G<#U<[NSL9A8)655$ST%$Y4;J8TPZ,?UVKT4!O7E)J*J0>."
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M<PDY4V6$)5!0+=12T4WT"9<2HYVTS0BQ"\7FM3:D\(U9X:H0(\C;+/[LIJY
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M,1S@ZD@-S2@>?U.-56QPO&E15?#%%*)]C4#12A7KYRF_EPH^QBIHU$%>HW)
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MG^\UZD&34!K,O8[.;6R5)^211K4@[X/EM;455813UO!@R?NV>P^E5!_IA[2
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M6348_O*HB()>G5GE"KY-S,<G/3Z9M]GP]W/DGPKMNUDY$;J$DNDS PT66D>
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M5WH.($#&@$IG[T9L,&_V^MQ167$KNYKABXF,?N_J(];E>MUWE.3?1DPD*G!
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M3KQI=@FP]O UT^OO>N>OPST1,Z N<'W_F_T%GMX1N+-FNIJI8YG'\W)3[^\
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MX"#78FV13.3^6S5$]JCGVLG?_VAL-KUPT7@8Y7J??@NR-T(J.4TK.F1SZN7
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M$VM\<:9$Z&@_SZT^1:<(6-67M^%M\>%=! ?RM:C^G4LA4YUUQ245A#_HC1.
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ME392[^9@+C65O&KNP!#5>WU9"&J]W[D$G3<+'_*=\2M,->FN0I??5?6? JG
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M] X22DBH4A-0"!)@^>WLSLX[6V;?]Z_[UYU[YSRG?+[/N?<Y 2MCJ23AE0,
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M[UYO:6OEHGM2Q0G+HZIDCMR?]G$_A:)W3*1!K,3RGG]]K3@,G^UO37SZHEL
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MD6A'>&%(K"_=GD.;9)38<^9\'2@=$"R'' =:S(B\ASTPO%4W&$5]O?O=2U[
M&N(^%AIGQ_JG@U6.Q6V9![_>]QYGI&2J,Z6RDZPC'D&+&+CO6A=6O@(HHN _
M'$H)ENL5L8)<.[I@:9J:L[K.4'W\I=U*Z1JMV2]M@*XN-K<XLK&V886(Z<_&
M1,L51#XF^N&@/-JB(8Y+;IF\UMX];W3[N )J5'?I2=]UF:P)UB[Q9T86L*)N
M) ]J DZ'6S)[/E?8WAZK':/.T18SNVQ/G\FJOB0M:.%OE"/F\GK;1'\4($U4
M^X%4F ')2J22[.VQ&,9%]-:46ZW[A0 JYZD:6'3"<&/1VA#JI:_-0LN=M'?D
MI'[A:58UQX>]!"2@)1*J$9J08KKVC5E?S)ZO<UA!8]-MFA.RGVY#M9+?=7$_
M2?;<*8/_MP,!->;ZEZ\1>(E]4WT75&U3#@1^?[OYS#;_^@[/O^KWA=.5W1WI
M\0-\#=&BUU=HG2CYA*J>PZC[,*QP"^R(%>ZZFZ5X*G9A;$]*DPD6<@S1LE[^
MKJBC<?*\DVR>V]\YW@$(FI7UCZZVNX*+8#P8KIUPA%.V96S$K_]1LY5&Z.98
M(_+F&X[6'] GI&E+H/4(@<Z%:RP;]C&+R=K'1L;T(UB^);;N919B'%HN!H*0
M V6MQO7<O*4U3%C2>=UT0L6U)-I>=!CW>N=(MK,=LXMFD.MA^SW[EKZI9DD7
M'?7O,\N#C,DG%B_+L<U9<=U.I31V'7E2'F$:9=V7 %JOAF!M[/DT+S3F#[?O
M'>AFQQ1)TQ-2&6G,=B/NJ=RPKNX&I+W&BEQ=[S/\]7D.W(@@94H83]7%ZR4X
M$@1J8PUG2=:30W[8=Y"'5.I6T/J?*24]Z0<6]L*ED,[CI'-U'4!@2N%*/MMO
M# N"!W=/4$;\8G9(/U-[1@B)R)C')1A UI1^F/)05"#O"UH%OMJGAO5):7:B
M:/SR&2\!7:UG1B.)5]<[WM\- ];U-V&M1W"4G*2B+N'S*E+)-C?X^XAKN7N3
M>ZFM32_,B=7V_OJI:H[9:\7]UQB%4]U>K[<K/A::#"3W2P ==6>3Y<FOB\[C
MS"S0V,9I#KPU3V/_QZB_:QE/+R!0(CZ$;?N?;&LU,8$AZ,&42CN*?X$8VSWP
M;;AK&8NJP]8$&;10:,3)/OAT\G%0E8_RUEAD(Y0%C&GH<>Q1_7<OKZR$J.N+
MF&J0.D'%](\AHCHWGA >])98!9K?C'\M<GMIMB._1U!@$FY1;/W;<B/3M>)W
M@%1=D,"#)8D(DS].KTUBI\VX@J'8U# 0WV0E_.;*N83NE!^#Q] 3U;LJ#:;,
M1=:+HN*0VE):F[/:\,^.(I4 9P];5F+X"H8?EF^.?PCBGVVX!+"-,"PME:*"
M[B7^LM&#"K1FJR70(OZX86-/'C[4%@'*'W2=-O<9SU?WHEBJ2&[O?]M2$'R7
M;]0QF^]<2%HD7?!!ZZ09,_QC>#X4OC.0M%=^S.O8/HQ6"[X3_.;87XV+%B*S
MVLNGWX2''(D)L;($,+>GWD^G,A9]X3O4/ZV\8/A-1J(F'99NVMBVL-%E<5_R
MS"+S]2@C+0\UQ=\")OK_Z3UOV[-N$-F,<B@[K/LYHJ.Y@[?W8S+B>5)%LJA\
MF_Y^2]>^"P7 ^.W!UP)&-BPP'$JBQ.MU@1BGQ9MR7DPJ\]G(!D*RLCDS;G.J
M.DD7)JSQLQ:L-KXBOL#*5A?^1E%75GE)YR* I2H9!0YI/S^.I'=^JHL4>3TV
MTIPRC^MP:<UEZLM?L%4C:,8B^]<N 0YB1>=E(TN;@5M[R2U\_KO]+SX?%S )
MAD9@F+U W-5=M%4:ZE>2A-6JOR255<_O]@QC=D71[M5]\MQ1R"MPNP0TL.0O
M!]IU6H8HGN<>:)C\-TE6$7SFN-+ID(_^QU^2N(2Q*NGQ?T.67'+-=JQ=5&!"
MN[-/K^V9EJ#*F2*<?3:$#@:VJB<PED,KM\T"L#)5*[*/W)OP_1!'N@S @;G#
M\U^K0:T4F^*A_'#AV?\&D=/)[3:K*EQ%CA%5+D=^KDBJ=&?NA0OS"C\AZ0S7
M\38!<)B:H$FY0<Q9=:NJ\OH2J97?=7<NIOK:'2[AZKPI<)_JW@]ST0%1_H\K
M:UCE)0E<4_F796)03RU,1UHW2R7_&)GK]^9H6[%!AU7;<_P[FCYW^(H3EX#+
MU?K_/QI:A- X%)D+8:X+2K[%)IL<7$Y\#N;;@O@E0AO=F]_?)]<65?QFO>N;
MK@5TEWR$G%UHP#7_R/6X!&!/XG8]-:16-&/:1@MF"V40$AO<^X4)?NE603D-
MS<WO>N_>C(N.8V?L/\GJ#:;4 <!/\*B5)QTKEP!6XIQ-;-<E@ G.W#8;2Y7E
M7D#TIVZM-RA*7Q]NEA9J4HI52@J+TZ+P.4EA0.TV5L$RNT*4Q_VDY.B)= ]G
M*J59N[LM*9=&JXL[ \#>Q]&M\L8<".\BQ;YD*+L'S\O]-_H+?SG8R59L@>?Y
M?;7%Q/>/YT($2.IX:=[2-+^B1DRDB-*R?GU9QB&MY2QFP*8$%1"OJ']*[/2O
M7$$E(>6OM)9N"_)Z\Y3O/=<GT]!&L-1"<_[+%+3S&]:9RAF(^4>&U+OV?8MA
M :E!7\+D-=R6)5(-+. 2G._]OND)N33,.F5P>XET#M(6F<DW^>=>6(<!=+L_
MI^:"@"%#%Q+32)YM/#&M 44)>_]RO $"DK+AN5CB:%S^O*?,U<SX7$&Y3YO;
MF?SZNVA6-7I0-H&J7#6^:'&YL]06K-A%9B6@.72T/D!.MW%7CF=,^C;U;TMV
MLM6W=A$7(CO+*E>$WM]#@-D9S?C:<!X8C?N.*!YN',[ONRHT9)JQ(N3KOAW>
M>,9:Q/%"^(B[IJ\L"4&-RX\7!.+%TZH'OE16F/FWQ2;>:'"'EY>%/RRGK*M;
MZYDSY ,JA!^.?V-H69V6++B&4#+"I_8Q4>PLJ]I<TZ3:1NO%^67Y2:DG/[G8
M1@??=$I15O]B&,BY\T&N'G[/_Z"3,G@T 4"P(5\1F(ORW&T84;W@RZ&3HS3
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MG@QT^[W=NIOT 5YM6LN>X,CWD2-7;LD9_AUN3W3',3#:46]=W)K].Q#:["O
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ME;8&A#^(#V<C113W5T'+^[!:L4=M=DZI9Y9=B6C:%_(W@<DW,RFZQT)H!VK
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MO59\:*'R&RC/YQ#^6. ]GPJ[K18M2*:1=35Z:ML]>I.H[*1-$<>ZIV[@07+
M&7S*J2>$?9XZUXDHV\(B&ZNK"X3@*>(->="RN[OI7XP KMG?!9_-(QB_&DY0
M+$'G_X/I,C\C*=1A!NCU^1_ :>?/XWE(2_UV,]*T&\*N\H&WY!K1T%8QN63O
M5MYF0%?\J7U1I>W!C")+B<F)8-D2>(?E.R;%KV3@FB/UTF!N;(3LK60G-ES>
M4ER@%XU6@DH5[N+9T8A/0OO#CEO*:@&-)DI?],HT1@GZB?:O>%W%1QA $I%7
MJ2V-ZJ#LO_%>@_U.;I"0%Z>EL1EAGQ>WV?WF7W9&J>0MFC;<_>:^;I4D"*CD
M=%1[1-MJ4KOU;?N&E6:11^X$.*G-RR:0=9!"5+^Z;>A!%>-@<N51=2'-^0-"
M7)]+I\]54I4^46UV2*A=3;F8<;;%_Z-D 5AYNF=YI11V5@=5Z5]B1S*=&Q!=
MD&\J+VT64;_Y#DU"4 ;JM>(\5[&4ZY-E3M3]<*SVNY?/_3H:RMJ7HD_M<A/"
M16Q(V4IF\=B4D]S2\?*_!7<(1VI*3;Y#1+G(NMF: C\&C^_#ZX8=8 :5YY$:
MH?V:*H2#-]7A<WC3"!#AH@ =T>21FS%O!#>TV@^B OB%W0'*K-0QDN91*W:$
M@WC%F@A]T>Z?31VSM5ZIXUUG?2\0CAL%$J.::O2<X;=A0ET_%:V5A@)V]G1W
M#:ZT8%UC<L:Z\U0C)7?;1*BOG.Y=^<;\$7K0JRE,@KL1W?HTKTT<IX@_0#?M
ML2_RJ%]HG<G_MBZ8VK?VX03;"^W)@QO L:W)DOG:CDZ =.8O0 6B4P^?4OV,
M#%!CA9]Y!_W:(J))6G'L"?W[7<)534_A##Z ^/H@ ),/>W%1!61>[J(%!1;!
M= D*.ZP>0>T/O"H\98'L#2!%B$CFE_O5O;=7Y1N\]> A+K2O-A2EF)8&U&+K
M:K%+YR9H)3 SH\-6PJ6GD(D3FA*@OUMT)JOCXB6*\DZY_^XW2U SIS<J@,.>
M-M_@XA.9DQ1J/"G>3!Y%$'[LJ2TNM,R76 ;5W'$>L'2T=!4OXRPXHEBTA5D1
MZJ+.M7##0+>5@VO6"]L3@R>>6S)"TWMP\;OE85]!"IDUK=>_&.'B1E^C,8E(
M0:AE=[/<$C2K#ZL55UUBF"&M!";5%+O8>CO^Z+ZN(FUVIH=&?#&]OX1+ZS_@
MWPX7)92U51GAG=P5.YV,)O:5'$_JYT5,GXO/K61\II?-<UB,CK\H2>^+&]0@
M'. T*TOG8-1PS-%5MB:>&HM3=<.Q7O<$$?.PS(42VPK9_KO:]^Y>>VX"X :<
MF/JON*&Z&,:\F.I7EA@@"G:<:+H#>!+4QEPH+EG C2=)0H(AD)H%70>-^"\1
M6.,903H3Y]9%.VKK'PI;('GAI0Q_E-][E8\E<#;X#X[2 BWSMC4IP..\,.\9
MT0D^O)<#ZN3U2Q56FUR.C)K.@></DE49Q>\JC#"<U$;TDJF["/M)9[*#Y:37
M^.$CD#(<F2+%I=G/LSD59X)T6*#Y)$0;I/FJN 80:I%%U.IIOXPS!^<R9= 6
MO9\P4'F4CZ*GZ7TN'ZEOVIK.=_NGJ5,_![+9[*QP1+Z$@;QP\VD\)+^E/@YS
MI2;N!^WP]H61NY]JN/4=_&6!;%0"F%'RC4M[F#2P=-7AT33BN4\UI'UE82>/
MDU"M%O[V,T<CPOI*)V;NV8:YR-?\E;9LL'H^%^!84Y'D^>H?@"H"0MU(F!EM
M7^\,JUP$&_'F=_8?)7A>;X9BN-)C4X*\:+-7/D[0(DC_C63(?&//.1)AUD4D
M#[O_-9+A].)>.Z29[4M6*3"BTC"XY(&;,"X"&=_+?!/:H4OXA=EKF-)P>!([
M4\NCVO?"D.>'V4M,5G,Q,\HL@0S\>?YL^2+8UN'&H*OBGKGQ1/E,=/.P1X9R
MH< ;WDLH%#@L45]"X=,<<ZJE_62@&?WY4^*GDWKQU",I^KX<]-6209P#HXTG
M"]V3F1>9O:^:+4TI3*A3?C=TZZ]6N85\9BX^=ZHSQ74Q+&X'#3^7G+C;4%L*
MDZSY8<5<\"+MFR,AZ#\IK:Z[<?Z"P!$52/V-R)%R?N^S Z+J&G8[#][95",,
M^/[&KN>7#C53"8NM3#*07CGI3#+MVB:Z?>8,"[%H;D:W1X)3]#P4H2; S\\^
M/77<&_H;>EQEXQ.YW$Z"$WTL.B=&WUI,!>S=\RYK$?4NLG);NE;/Z<BMEZ[^
M;=P#<&QG]JQA,J"C!O08T?)MND;0,REII-)"]7G"TT;UCNMLVM29#P%L^),E
M^"5:G^/L%!P(;O%-&@_'S\)Y)9XNA3'4N%"92GI)%CPM,>1Z 6%YOUS$F/:P
MX\2_\6?34B0_8_5QOF>^ALT2*@^F$H3)4/0WN#O_V3G \=HW@2BZ(2&$WSA*
MO#^"*4#KRC:2?:966M$GGCZX NNP^4?BY41SE:__K6$)\6P@^(&WC;*+;21)
M_";%D5$T68 $'LSCV;'G(DIGX*6XE9W#C$RZ$K<7K VMN(1??'Z#*;@K\[\C
M&U#Q@?&X2Z4P2@B7 Y-\'B"HGDP [TEZ^3 \3C%91G:$5@5DNL@B:KPK^>;D
M6S-E5R"U^3C-7!>\0P([4M34'*]<'%:ZY;]%=DN$:3"E>-WR SYPE#B1</OX
MEKNA(22C%HUBG'5D#OD__Z,O1!*-IV&FHBGS6SE89S6G[1MVIA5?;8W@O9F.
M$GTZ?@]*"70#ZC,.#.<6!+.4P*HQ?M2B[(32GOTP=:X%MVOYE5'"G0&N%4/)
MXHQAWGY?>ZV)8XGQ!+6%&61AH$93 0VBR:0XY@-WT'NV^.NRMJFZQTJC5N>:
M^:@<_D:IYBS<WUW\A.N9$A;ECMIEW_NR(%&-"-][T"NJ7I^+919Y1-M(&ADD
M<Y#\2\M*\>.L$#[.Z0*=:XN>*I,VNC_\_G-A[*I -^ S'W;84X)#9/71SO@-
M:)<.8:_L2]"<697'*YO!@%=,0A!.6E6!\[9MB?$N=[KE::4Z1FCL/:!UF2>[
M\I_FYKR6.)@J]HC"]1 TOV S>+-A-QW%0ZO#!_S"4-GA^7<&#<>3:L[%"@0)
MY,YE]6!"3;5O721"F*D8B$G>%YM>9;R"M=:N2,\VPA8B'5TOYKIID:2L@6 ;
MLU0$2S&V%(%6VUE(6'.T[NVGR+AVW7=X)QUZ5/7H_V6DCG##\<<$7JCT1C26
M(HN*M]DM;1YF ;FC@Z\_KW;85:<$P76+?BFG H:Z>25B29[+/,>$C5@8U0JC
M$?X%-.W!C&!'&[R></%YFALO470;:6KZ4O=F$*4%S<:XX)PUB/T)Q3%O5U_:
M53OH=Q\Z%#Z%W8<-Q?%).H:OB-[!B(]B<8)FD8/:S_ >VR1F])3> 1J\(E98
M#/4W)O(NYLLDR!PS@D!$\1BS.<6N>VXA/M6!+D^3F$4^S#H7Z#8VO)"E,X,2
M.%)>DH6@3T;ZU ([9SICMM+GD_J>A@A;<[%K4_%G]\;9?MQS&:(5 +CJ$:MP
M:X.)4C 5CC2@@DQ\[3_ RI*QZ8M?"V.8?5W^T##TIE;TZ;,E%I@9P2?ZLB2Z
M&!BX:+-]L4R[?CJ0]SZGM/?AO%$VSS>W$=_#M^-LA^NY)U)Z)W8S9+Y-,MU,
MV64K,55=%)S82(X[_\FT&U]S ,$J5[4GD7-7<PS2.9'/?+(""[&L6NP>.1$W
MSC4T"I-8#W^;G+&GN.%DKJ%"??!*9W17#GQ<FCX("05G4RJFRU=[6(;XIC.7
M Q\3)7KY:-NCYOO"[TXJTB=%17$&FAKRN*5WL&D7S=YH>_,XM>2ZQ-N)?P /
M&4KH(:;?%RK11^;"P".8Q]:&(<I=7@Q//A\VJF8JW+'RE]41?,#Q!!%8OH6\
M'EJ7ILE#9-S/4LRT@LJ#5(^YBEX(YH#B'V0<"%,,Z61@ "=CKPINPW^"]4@X
M7. $?%C)2\_2SJ9OL.17)WRA4<^)T[V6C>'!67$ZY]N_;Y^+^HX!0G/CD>(D
ME5XU<GZ1)U)JXLC.QUS :JL]M92!0R7$J_A[RJS"6NM?G8W$'J)/GRE(AUA6
M7@+N\3A!(SG:T),EAM)NJ=I?2V*I7)F%N?[47;THZ<*)H]/ZO1BV%B6;<_X!
M3#U-Z1\2<F.*.EN(#*XC!_9+((B\OH5;QO^LV?W+FA6:$IG>5ME!F[>7(9A&
MX7/-UL;?^DP]M0R)^M:#\GP/%Y$_*387 <1/7<G >Z4__@295IN4S2TY6(.-
MZ<$?\$QM#W(,7BHO+.@6/&3T@N2A"VL@K[9?!U[ R?GR(1GV-J,-NCL7:X$B
M+/N,L/&5>686F!:A*_+8CO*'9YAG'YD73M!8]602:VG/%$ '2S/1L>]ZMU R
M49=\O**TI<6NR:D8T3A',(M5S/IJM=5\&M;N'J6O%^'DI2CF"6Q[.CIA(.(@
M=RT8%T^=!]A!J!-#NPO^.V8C@)^;% QNG-)3+O(M]_AF:^1ZDW7 U4A(%B"R
M/R#GH&YRY@D97_[DWY<!,R8]YVS'8/0F7XH@G[QT.O-M]NRHU$1K3I3=LMW5
MCZ8FRS,1%[%+=?W,R1',2G7T)$_;B=US)<;SU[6EU9LM-H92JV\>*QZ9K*24
M,\ID2S]2!)W8[@\_@J!P8<XPSNGJAQDP&4L\7:>G3Z/6>ZE_ )P(!(%O_3$N
M\2>_W>MO8ZH[U4_%PD1-KL9\U&NFQI4N^@52HV53:B@X%-1:DV_.T/:[QBL/
M<FM@5N3Y_^#L/8.:C+YV[RA-I7>IH8K2I0M(E28B4J3W#B$@/4 H@O0. @+2
MFW2!T)&6A-Y+D ZA2"<1A2@!7_[/>>>9,V?FO/.>\V%_W_>LM>[K=^V]9ZW"
M%/1SMYL&K$9_ 1"KDQ+MI\OH8N89)S+,D/M\KYS,.)OIOP^= A!./9@-)%C[
MACJ$&Y$;754'DG5<.XWY@C/<V,^-[B=T^BFD3"54EH:D.9?8!IE'?*7IZQ7Z
M GETP](0>T.%C?J!>">O6[=AH>RY54AI9F7JYN_3:J/H(246DK^=6&M]0#LX
M;$MTSS(Z_/F9TG5Q#SLN#YW<@+E\C;5*\T+7B7*D#SQ77RO/4MW[DZ;!/&PQ
MPIB^;G=")"T<A+6Z_9?XQVT!'^(ZIP;-;B*W+$FUKNZ:;1PNQCDU:<E[RW%K
M"43Q[6R2L3K7O<',Z6R%+1,@I ):S>:GC\P>9;-%5UT7RE_,MK0MX[<DQUWL
MHOI\9=(RO+S:G@MD=V&%VN"%R\"AY<FNS09:RX._R=D5_?8-!^S KH52[QJ1
M?'>:Y6=LLH/(UF.9.WG\)>'/44 JUP#C:1-XE>E8\/.V%=M6K9FR] V.P.JB
MG0I3]:U!$Y^)%^N",]RS?D)Z+?G/?2<DQML6*PX(I2I8_PP83\XO179YL;SS
MB?^3^<L2M-DPD$^*YMJG6;;<9QZLE+!B?F'<'J,^+UPX]M6R+GSTQ%D8R?,D
M8>S-.X$-!0H<YPT;7GI&0CM._EJ-&Y2O$O;G)% <MB@6UE>1KHYW(?B,T3UA
MVZ*,7V:KK]P,\5%>I+TR]5T9YD%M:H$_3O H8YFR?7H_6CV>W'BJR1%_T* @
M!B'0Q=+WQIQV^VQU@8/03FTQVGG&;=I5O ;1:K$]Z#Z,$A-QMS5<JC/QAA3S
M#Q!#$56O7..BH" M/>)5MCI$%:'S\M A]UD.H8_&;F<C9"GB]$Y\ 7\,0C%*
MI!I*>5UT/#>0L>ZFP+,H+*PP=<&8;JG\5BB+3ZU?&*#[L0'XA/L_ .X21H_G
MV[8$FG_#A-T2#[JTG)LTY?C:BLDV0JGL0Z[FV!_396_-S;OOO-[^5DPLH, D
M1U5:X^#('B8,+-LH=4WT&VI34RGUG7V62H$=P[!Q'WER9/F[,*INOF @<LZK
MW.42N/03^GS!=S$7M9"HKE;P?44Y]6D7N13B* +'YMI+V4W)?XMUQ,U?7#+*
M_EK#=^9F?Z+78I8J CG..4<>&G,I&.*_&YPIL;?4X+;A!4!,!U:X"DTNHH/Y
M\3$C#+1N-41?F?7]^XV/J$XE-XG,,WK@!WS85@K0+*^0#))QJ[>=)2^=9CU+
M.I423;B=I+@)2\.#CSU5K24ABO"@F/ 3/$G]40'5PAE>>FLB&.F5I##U,FMO
M6T?\4#^/9?^$^E5]!%&6I$O:)Z%I_@?I&B$8=4N^-[@#K+/1K(0KS*3%_#G-
MA6-G<[!<0MP#RX9\00H&S=5JCA6NFBUE#J?PY]:#8?]U"*:MH_M?3Y1$_L<A
M6$,)[$,'X7^>*(WT;S]#MU.F*,*(8S -6Z?YM2N0RH'.$%1; ,BUW J4C:W+
MJVT>8LWFN$\UP:K%F1DAB^ENBFPWP+8,X$BW8:%2*+Q<S9$9:P\P1?OK/,SR
M48@1F'_3XN5Y55N;%I_>NQ3/*X1*[WZ[=Z]P(+E O^R.-87?$[MI$=@8FS%:
M+;FCPB54FZFV]G6IVZPF%@!-/6.]?%78]TBNM743H!"%^39_N<XR>^KA)T#N
M%%A7FMG")DQ+7X?:)9F((TL'JT\JG0,C%.Q1+?_+9/;__6I@P1[BIA ;++_.
M2%UZI&^S+B8EQG'>HU"[J3GWI)YAESME#/2)5TV_]NJ]07Y-F^M($:5#28\^
M1C>YA\<,!^P/HY+<8-.N#7.!%(A06NU3'V2ENIYY7)[9- M_[YENWN$I^[,G
MGW575)2HEQ5O@74J1,=UZVQ-&".6VZ+JH&J@DI<)E0>B."A!"'T^0JW<;YXG
MTW+GKDE<RO@K0@XJ)862VBER7,9KK'\*<4W9:DC]@)-?,C@QY_%Q$AP <;2=
M:PG,^G@CBN4[(4)W&6&34/E;Y'?)94TDS.7D]#W*<Y^1U4@TJ4SM0F.5DC(O
M&?XT1M737H"P+;?&7-@=^A14W19S(B_1)MUF!LTZNLCW<NQH?^LKQGD7)34L
M0KWN:%E64L\+^#7%@"</>VAQF+H*5<9F5L;XJ:"OX*UM60/+CEXQ:CDGRX=T
MMGC1R7"?-B;)C8,>X.RO0.@*FRQJTKH9Z>(00:\NBNP:34P5>RO=L[ OS>HG
M>0Z$3\4I,BIPNMYRT7I:!:3Z=-&H/=I50BYJVFZ&NRDP8JP%,8C3836/=?+,
M?0%_471BBJ?=L@;BG(:V)7]$=SO^IWN:*]K6DRWJ%_-+\:KH_LH"0?.^0C<J
M)H:GW+'2_)[6W0B"0[,]O"=69 !(=EQW)F^+KJ,=R,H6"WQC <I-E/(:W71V
M@]46)]^1845WA+VWXFU'P<!.@_\ ".:]KJJ#@!NU 4BA5HSN?)WTB^3&48YD
M&2?@4\<LNGNC2F/T3O*]0U<-5*9X0YRX2+3$A+3QPF!IU;T3/["Z-JF_]?&?
M %J)=Z_[WJ>39'E#AH^4V+]MA3'LA\K,V*#DG]4>W'#,\DUEAI6O:?@0?I*1
M<U QW,3VUTAU[N6'5&VXMBY>M#$GQ2:N+:N)P5K12J^<7I \:;^KKC1,0G^N
MMAAQP[/?2_L+E8*X8"?JQKVOF?"J-<,YW6O01[& Y?D?.G6V(;+)9JI<S>@M
M*UU5]$Q^6XGC,M$BA*M0M?C1G^NG9[JRQ/F5:V[^([MPR9V2M7KGGQ\<%\R4
MN1_SBY8)]T$ E]4"R*)>K/7 1MP-R;2?-;,5[D@':[]N_K+S6_EG1BD#N(<'
M@XG"&*%2?^P:DP-%WPC3N0QG[<W$V39YV  8'<: &SRRRKT)_E(T9S2)(M4V
M*>U,E_GT<,O43#^V:^S9JXP6H_#G$?$8Q5@@;??;S:.4V!ZF"+P%I.#7TLCF
MDD.+TI>V<K">PNF2PM2[])=73= .6G\U!US>;72HY VP L@>%LRO'M'6-DR>
MZ?)U*=SH+VE(JRM8WX=WZN+#^U:@J/!W?<5V7 ;?O3N_,NG/&^+E/;<WJ&X=
MN%JR->V^E6RD>HS>(DR$T.R D1BE95IJG+NMYT.9;O6D=8CZ7%-=[BL_:1@0
M<H;.C@HEG"C'Y=U0_<%;N_).=OA4FJ[H/%IH/@^;08R(<0>&V\O-"TAO_-$!
MA'"K!;8-)8$0"J0X(/JY*CRW*!*19>1ZH:/R\^$.,7B_>$>I6-,=WV_X[O5:
MMWT4+@D-9($POL%HA-?Z_0/00?),L'</&=MD?T?5)^8FNGI\O=DCS+=MT<OI
M)YHU)F4A>\H[3[ O*_ C7W$02(OGKG URXZWGQ?R?2Z'0%U(BX.>5.:=:+_J
M3++1JF1P+$G6]-A5%V)'NJ2FEZ89=AM@,P:-ELERLW(OI=] :@8KX9UW#S!F
M3,>UZ&BU=(<K50W:$<'6;"*R>L/[I7WN[C84?\\WR8*0J^^.V.6PH1U;GTY+
MNZS)K-?,)7-\4U\F\)2L6KY\/P\4UEK2?&AC'/_;[$^*!=9XD)($_Q07)9A4
M9_X\,^K;8"2:DG&H[/F/Y67])KB$6:!H-T?@"^FLI.A4;Y46$*B $SLTL$'G
M5L#>CLV_3)@LWIPPMX)US-<*;N<.7LP4O6DDA=@;Q?7,WM-B4"<BF53F"E>(
M+ND.Z>%VFQG"2 +? %VP<K<%BY0OFYA-X@^.O@%F7%:Q0-M_[7M9.6/.T,;(
MJ5@SXVA\0-E! 7]7RT(]9Z[.@RW?AS#-XP*;IBBOISTT0PQHIKP<6G*:R!8E
MA<(%R0DY589*O=Z6.>3"@)EY7E66HJRSC&:&%TM^BAIKP8)_NV*"V>^+2,H/
M28DUU-U8WJC/*R4::[0=9*7O9/BNX(3^7-WFR!Y^7$8YQ'J;)*4$^QLA5?!@
M_LQ:&_,K")QA9FFV F>MHY^3(';BR:$W>V+/ >9IG "$:)MF*?#,M0CY&,Z<
MU,M/:+RB:EF5>QAH]U8(.*Y.H5+P89L5W?UE#=*+KDS!V]J60];/^I:MH_E:
MFB,V7C;""H*7REKB=\O;09_*V5_SF2QP4;?:I^90*%F9#Q4\6I2G#<3F&<]Z
M$IJME?>\3_A2MY#-DYGVP;,=\#8O\C/!8N(TR:QD-IJ2UK6'L0U6:-!Q)6AL
MG&JBLFZN<+"7JD$#+=H6[G/ B(_<[8:C?R#';OG/2JS#W.D*7%&X>9OTW@><
MQN)C8-Z&CP';[[9V+0@BNXK[AMBV4RAP\)>8L_"6Y\%HP@(AL#92EL#23,L1
MY.E(RM*^(J5@J&+9,42K_51@<E.# _A2SUK0$JJ.:]C^IHK\VQMYW/W&8?IW
MWK6 SJS@]G1TBO]%T\/P[N"XJ#T>QU4S;H8%O^6&Q-XPV^!M8#R06MX Y(E>
MF;I[4,!8,#GM&@0NST<L!M"8(?VX+4;D]?=87S<2Q8RY(SG/G[$H/3> ASZ:
M@UJ6U9>7K5[7CU3DWA')&CE'"B Y;J45LNK\4&9XN+\^S (WMRE"ACO2Q3C5
M;;/1ZF"MBIFR%C4[>Y+EX@SI"1[H&G3MDF3!P20@^\_7V0X%NI',/JLP$>_E
MK%I'D-TKM5Y8?9.!_,FD5\'"MI7"K)_(^S &22%G_>E?O2RXNW_AUEB*<D;J
M0]&^GZXG?GL:CY]:WOO@^M4C\8^]T_VD@/ 0(?14W TYAGPWJC(.;UZ,\SYZ
M \YZY[;\4:K!>VF0V_0AXS,.&^<ZL-LR,CJRW-(M*/^D)[]B^<7<JI7E:*,J
MF9O8Y"F"Z,T=GHQP@9%0;ITBDPTWHW4FS%IAW T';D,W>75ES<-%)_V)6N[)
M)^D,5^"G(1>@G!R148#D *2T+^BB(W@SY?TZ$$M1Z&F[N4;P&B4I-Q$ZJ+V[
M *UB)M4LBWA6+ 3, ?/4R_>?\RB=ZH_VL5]O4\:QT^ "R\P/>_BQKQ.V\H71
MRG32RX/%Y&4T'?K];W=LRC()-]G#<_/Z>^0QBP@=UL-U.BQ#!CI$9-PE=*W4
M"AE \JE=,&_;KBM:7=UGN('SEE@^C&U7QD"%ZEV#LJ*V=.EP&HB@I):CM8,Y
MMRSQB;MK)IIV:@5K%PH_MT4^7E5Z$2Z",?9#RS\2ZZ Z%9""R4%**IR],9CY
MXL=+8<&SA\ID!_+\.]TV9?MD[N-ZD>3C +L[^[#_=2R+D49"MYKC%N6#(^:]
M\A"&'-N*I;$ KT!Y,)<R,Z>3OQKG)X XS-OKO14]IG+(ZAD,UU$*"4.(XYHN
M-1=A"6LJS^0MG4M7Q$8(5FR6RR/_Q#$Q"C++90J+%BIX/R38'XT_/!1@,:U_
M!$X=2.)NO3_P/OW=\YK=*4I<+UH]85.1%*^"D@_VJB4]HUW9OV1G!\N.RC$T
M%QI>T<@XO'=F?%"?;#[Q<^P)NY5 =5L7MA!AR3>D\"1E<-:E,S0[I/H@2X$I
M^M9C=IK)IS)\R](L\)Z5 ',\U:(R]-WZJ@T(#HVL-X44JLZU)(F%P0XZHV !
M_LWN#N=<::JE8)M[HZGOE!1:0KN[MBIC:[LYKYY"="WF&TKF!"4V[IFNK5KI
MLFBFJF>YC!_'JXH"G%UVMN^VZT8IR&(G*I$3+/ ;SD)D=J?ZMS*K0^H1]-%S
M]J4L3?85X@5!X+CF<(?-S&J5UX<_YZE]0/6W0@86<["G;GXL5Y;REA:\Y1V=
M.?;G%3X?XJ2I.[[_TALYL1:#A"'_ 6@DK._@K-$,C=LK23;6D((-C7;,N2M*
M[WO+Y[^5W]/@/*0RM^CJO>Z99:KY$VNUA 59]4S;8M(:,^VD"WB^-N?Y:EZ5
M!'!^]" A_ > V"0CWI $JD%;T!OT4*W9;A%LY- ,Y"^:19?(+:"A'!?T7&JD
M3K@.O)5L%'^02R!.\RJ^CJXQ52K=9*]KS@]]B\\%BMBHZ,SMX%X"U]"'!:A)
MTA#^P=G ,Z=TE$!6UE:]W<= F7Q[PUCUI605AV=WE)Z7Q&/KR+O!:,H4=CY8
M![8<61B%?PZJ&,U5+[1W*_D9:)<ZSAO(E:Y,_;VV.KF>5'HJ\<%Y2DP838\P
M5&6V6WK[&]\K[-NU^CHOLED78](B9(F&PSG11X&X)$R63!O5^.KP)Y>/;-5W
M?CO2_SQ+#A6&-.MB7ZP_PNS5H,'F Z@>KI897K6Y7Y^@"G=ZXB?17+.=AS0O
MZW_>$7PQM/?H+M6]YQK)W<;;0%*\D;39>DL#Q*<_X8NI<L54Q0%#]M_G\_JQ
MZ9IGPT;=$0;B+TO>/E6*M^5II'A,L%Z=U5+ONLXRQS?? KJR%'D=3B"T=CQ&
MIA>A1)0?2\#S?N10#3KFAV5!]R;_IF0\O*%LPBIGJ*(\?]5):S:GJ# _7UD>
MMKN+/7W$^"DMV\LET?SMHEN/V,T8MA21FQUS0W%DABQ)4C2(7W]R5S-M:E=<
M\_W':")S)NYBMGV"Z2\-)(LEN/?_B48OE;M$;VQ #_V,! LITZ\K2\77C3D%
M>YKESK0PC*89,(UBGO^/,_Q]N.S9 ZC*/-3UZIFKE32+Q+6Y 086U .>IH\.
M:*'9I;\D(Y8GGE+^/$U2KF<M@^-#W!IF 3^,CQY6).E4WE#>M]=Q_M<([$I3
MR'U/UGTQ_L+IL?X; J4W<046,=NN])&8<[3N?Y!#]S_(X?K?R$'QW\AQ<HL<
MM!K_08Z]--&9QW*&!(>CXXW81_E5H-R*%+#7GINL353]UG?X&$V5RXV=J#?=
M+[Z'/^BWPYI3(G^#26X+@>Y4I-NK 9),CQ5LW9LSB-357+H9<EH/E+IH5,R)
M;+X3 2;86<N2@#IN/]?N"^7'=52[_ ,X6NIK8$X+09(_Q5=61GSXEK)<WYIJ
M\SB!CXNS.>\-3[H0[)L)((M[L<ZWR+]^;]I/D=D*<O3Z%OE7-/\+^1G^!_*'
M_B_(W^%)!.E"6WY#U96#@GIJ&!&@B0<_]^#P HY9(4:UX/V(J&"6%:7[;13P
MIQ8OSS_ZV7'S_P'\?1G_QV-[VSA.@0U",IAA[5;P> %JZI3KFJ"&#4VR]?2S
M60Q069E(!EGSS^X1.4\2QK@FQGPB80D"4JQ#7>8\?N<%@X!4;M.K+HOIRY:X
MLRN:IZ"JZH8E>^4*35*EG78OKBS+FAB.SX#@"52V<XB7LY>/*Q$2^3D:Y.H8
M9UKDG1B5FI9IESR6-ODP^<-"-7;CO=7CA0;)I( 76(9OZ(1O'O>$SH :V- T
M9Y"?4[V#OEU[DUIK^X?,ON\.#OP!SU:+@NEOY<$J^$H94FB"\>QOH =9 7LB
M=5!U0@'+EFLO>..?D'XA.X0(3''/M=]:ORC#ECJ?UYCU'(7R&NOE@R!? )/'
MF9.)72(-0/!8B8F'0E=?8&@O;U#Q/CY@4SM$=R@H)AGV#T!_Z.W*:!14'O61
M>%+9V<N[V2S/Q<XF?"73X>.H_U>Y?H.NM&F\ZO91V-(EPDIV41[L57/H YM9
M-F%3&'$_X4K^4Y(4$4O07<><M+M:H;6<@ I7R"OI]M;J-L?*H34281/2@XL%
M]V>A CY@>_J>-$=G2>2O63.D]^RJY+Q8"A^MH%N:(/C3SB/55,;XN1MNR"6Z
M(@:3+"2'P.)>'IE_6W#W6U/5@$5XR333##K!&*E'JWHT"80W-WD2*7[>*:*L
M>%Q/@MXK1E/>QXMWH"3D5A(2KBF'YX6SCV?&A(M!!#5KJK#'=W:B' !%A$\M
M[,L#"Y-O9(_^6F5C@<AEPIHO.-!+YM<)I4.L;YJT0WP$0T-0/QQ6O[1E]0EH
MQGTJ&[$R 830JT&OMPH9H$H8MHNZ+[A.71I* O,#QH#+OQM)W#,!!QDOZ#-&
M4[3?S0X83*S6E_>_@.<CWOY?R!3[1BU$9<H,*Q+S>V0W7_B7>O[)K)0>2X[]
MSQ4(1T8XI)_U+^H$\@]PO'XCNHA_M,Z']4ST:#EH^-$93R[I?F(#:XF7J^*.
M>Y],GUG^.*&[^>.(W%O0]\?_<P>T_^_5[3,T"^E%;+!(]-[;[Y'IP'C$K@/S
M##K_TT,Y>,G1_-.VKM"I72;UNQ_^]N[X]N77H,P,=':LNZ\U'4[J"M&9.17W
M:X,&OC4A;C(#&].2?&X<DBC]77.'U)5M /&3)&U>A5"M55@EG++4I2&G6PXK
M@*;!R^.B>,>7ARZ&WOLEF*X_=YI[G6'P;0[YK64-"1NSF_)P="G+H2Z^%[:
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MR-^+T,%$Q W0>VMO]2T3*1)#5; !0QWRW*Z.Z,!N J*IB%]3=&Z,S$+EL+8
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M$MH89A<^P#_Y GFPV!\@*T@+<9M]:-O69+?106V#.'@44!O[UM2!O%N4C"5
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M$HC<D&R36U!FU YS2FIK^IJK;,MZ'N_\ RT3#^9EDPF$3;/=LX#'ZZO0(=D
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M5%J*Y-'7,_E QGB\+2;2<-J/):/H:&9]C9!HRSQVH@"''YZD4'ZV#.</(??
MO\+=ULKD.?R"LA@4RK7@=[#;.@>[IKBWDV5JGS@Z.L$3FY94/13<5#0D^)@@
MH&^=:#J4&6<V! ]EFK.;E1!@0R\/T@S*J';)$8WPD$]^9R-^)PJ@AX,VFBG#
MY;6V7?#:P?9?F*16 _^^,FN9#[)<>87M3I%,'^9,;58GO=OEP"=&PE]N&GBE
MN1\$C.PVKSOZ2]&[M;+QH)]^O:[(6IDP&[,RC- 0"Q37HONRPL,QQ.W#TK!!
MY/;[<HAH3L*2'=1+!"F@I#HRT&+(V;(6GOG-4IZD*M%A'DGX-(HC*]?D(KWZ
MN]-;#G+4/X SD.AH77 !K\4-R7N-DG2*:RB?@5K7'%0]2W[*ZH $^[&&\3\F
M(,5/N. R-@,^=!M3Q(ML+F2=:[1>L174.398+[N![I!V2G^+]FO/-*ENOL]C
M,UZ<)RAN:A ZPPZ<@]*B-ZC<.IV:2U=QKSA1,)8\R,8;V'K\O@J2>^BQHWO-
MB]/:MQ]I1OM,,!N#^[\]:5P[A=LVSV@AC\#FD%EG+*%1B9!R&K/Z"ZE+FD]E
MU*6*V3))PT9]O"8 4K.8OC""#9SSBVG[V4>SM1)JCG,.,WZD^5*'T])_)[*E
M?FJ(K@>&%?Z0;]7Q#7V 48C!G"DEJ&$N"CK]\UFZRPE@*3S)R+)T+=;LM*4X
MP5/MI\]X%BDI3^Z7CP4ZO[MAP1+U?O#TV&YLQ7Z<62$7<RW[J$I%^N.ZB'OX
MK9'!O<13@RY7PMGNZQ+>;YW8NL+H&R"D!F& ,W*M;1"N0WZ0VG!5TZ"N*CCE
M^J/%\.I+GT6$JJT+P?<O#=PX:>SR#S1Q]N8P5'5+QWQ@^4>LKVJ-RJ+=4IV'
M/V]'*F)Z]96A]#(!EZ;JL1'/W8JNPCNX0SCZ49Q473G2.^M)B)\]:_:]FA]Y
M@>LD::)#3[.36C,BU"F>%5$D_T^=@1[D]F0XHLD?7;Z:/^'LG6NP#0;EF7^@
MI)N1S?3UDZ?G2%4^)/=BI[S%H(:[N&3RL%=?>[/-VMK2)TE/#$R_S3M&K(UF
M14AUY.JD.=+%+CZXM_G@5-)2?TYU]DR2304MITTJ8X5&HPT^Q$OHCX\' ^XH
M1@761UXIN_ZM+RUY5+QE30NQUURLU 8S6J!.BN(7WZ3-%$C<:Y; B%?GE^P]
MCN,UA([3A?OI0X4QB'6&1LSV0<Y,;8/M//BD9T9DQ(M^N#/ITF/52RRZ7T:F
MG_"_6L_<IJHB #)G-/^;W$"S2Z0F;%@?-67\#=8\/]F7T]42[1"]<_S68C0I
M\XWL@_X%13<A;NUY^=?  07^/%5,3]&R?Q?Z8=U)*+*R\X/=,7E?KN$2US-1
M).>;4)LRJN<$:&?$<_$MW?"60L8C:DO=<E?1D(I==WL:[=V=NV^U6!H_;[*F
MRA!N4I&B;LAGA/ LC!_^ 9IM\^!IW\E%KF0WF4I >L#L705\MF7AD[7/R1WU
MUOW_ '>@])O6U/T-!UF,/X^,+GZ:]H=4@Z0[$[^:=^A/JR^*:S4)EJ0Q;RFS
MWK'HN*ZP@*0KDH<-U&)_X'D9&2KU8#/C9N_2]X:EACIH668(W6KU7GF/IN\N
M7CI_]CQ0I)>88K:"RLW[YFN\;6U:O%EJ&CK^&I56$M<]7!\0@86]KE7T#W3D
M2(?=F1[!=,'_0V+PE IG]:9O,7IMK5<O>GD1QER'TFM=7HA1%L+-;4)J).BH
M@&6N6[-5H,H\I,QD#1GB>=YTG"O^,>QCXN;%,Y+V!G[,U(E6*2X'UM6X)4)W
MT,,R[R=> D?+'06_;;X**$"A[U:]FTL<KWC*E[E+HS$U"=*VNBZ&G;!?6H 4
M'^#RK*=]2=*%G!&R;VO)G>VPP@?&H/&,53I@\/&,=F3FU>@H0'9-8RLENL63
M')('OPSRS"N#9%:"C3:F/H:4C;_G_1/IH3,*^'-OR-W(^?](DI_=<.!.*@Y"
MQ6_M2[1$$H$9-K2TWK5WA2%]7V6A;N)3FEZE:T6!Q(,>!^=Z$YGO#W<HY(:
M;'X;!$L34I%;)V%#GGR)V],_1EVGZ])AK?LV*7X(HK;[FG$K7FN%$M7AFB1-
M+CV4,]UR7ZS6#[*HERRLU AI ]4B'F[II_%7^']YRP,H,A;Z/T"O-R/8.8U&
M3$J2WYJY]@),=8MHLK)B78/4TOEX9O5QHH9 6=Z'8KJ:S<ZF'XFH7L0&3=B
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M<E*W/^/R9[.HFN^O.D\; JO12]C.>Q/SLX%ZG\E*P%8DK ]^/7A,D(!AO!5
M4KSDMV_?9L -._,BW,GW&WZ'F)T9=C[EM$N[7U^>AI(41*C7TC'P,4DNZZD!
MZ ?P7IAO_P!)"G2X&+79$[7?OW<TTU::JV,0L9J\L5;AOR77])18=6-"R7"Z
M S>//:F63-9&JC^XU.WTSI\V<#<F]?PT4Y-H8*M.!0@\*.*XDP@04,)+8[8P
M%@4T-Y.W"!&JLU*+__-LC?,C_JHMY*>NM<=G8QTUP+MU49S E@CK44+MH5$
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M,@(15C58-O?']H?7@U:B2 1BM\@IU7?,3/W>'71MN)^UDN."4W#BCX?DN:P
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MA<12IY4 64G*K@$4&FCGW^'CM:Q;4YF/H#$BTICA:@[%X#Z:L\ZZR9#:B(&
M#S\6(3Z^OHA4KWEUV:4<&ZAR4HGNW;>U=9)LEO'4BM$ [%^3U=%8N+?=VC<H
M2C1G._ ACCK#)G<!TN2Z."MG[#,S.2@AZH[M.6JN.:*'?R:_741Z)\$5)]S1
MRH?$:8<3WJ+ORO37[M-S--^?]$[C#Y^YF%GOG-!RB.-WY%1!BO#3]4F4Y@>Z
M#O[^_()T.(@!28JA (8',2'!&.<8"C ]+'JB<\ZE)HT=,_N\OA[^)$8DJ6>R
M+4UFQ"KI%N4/1M=!7Q/KN[BV>*0?.F.4^:;BI-6P99<[/G&YRP9>7L6+')"R
MZ3S=>W&NAL9^'.^0Z]]R8>2^'\+S\^=VC:7FG)@3P68#D@(M0\[\;K?Z!G[R
M'-TB"$T#X,/8A5-P"GHQ73OBQDV#"9+3?_3%W,=@=0>#BLWM56Y/_*'5KM)"
MZ,#QTTPSWW/X?@48F_"QXKT%#<?\TJ)ZG+]Q<^LGM,BRI6=/9,XGHLT[S]7Z
MMH=]7[T@';)6QF[%*C-=JN 59W8O@<]PUX"PBC_[@EV^BJY[9R^L!W80Y+94
ME/K #,X)1 *]T!NYTX6D/S2?"()VJZJDCJV<D[.NB%0(4Q[<LX.1JG<J^:Y@
MX_V\5JS/IV)8RG,<U69$P=+NA9,N$Z)$)0_J[10OL<N8YZ;6%<P8>U86#7CP
M_;^C$[<2Z@H/6$V@A;T[U;U7/5-S&:<(X;W<2>X9KP2[L\ZF]J\"HZP5H92.
MR[)!E N.'Z@+(<6C/QQ3C5IF*@5*_!)#7/F%ZMX,5"K=DB$(\_#YH/=K7I#&
MP4I61VK+X;SX#K2C6"G#"UQH^@U[\L?S1EJJ51:F/Z:74!\96WP_[*/*B&0)
M6 L*5ZR($+&KCS[=85W3%6-#2+P>C]=Y^>'AOE4^XZTN_57G<] C,UB?'O1O
M&DV$PP0[_? 66^8FF\:M>K>ERI\C>^OQ2K/ FUZV6E>/UE5FG/4UAX<\F3[9
MO4RXKZVTUI*)T7EL1V)Z-]7'_1;IG>8+T:SXTMHR[EZCL7VH[*YPR>GDO-ZC
M:>7@%&6I/HRQ1B6W''&Y;L\KB?+DC\K&NZOEC:H="=1X3;<:7#%DF??G=/[G
MOBL]#9+2U/@?/K:5<3J C_+N.IQ31G!5?!K:V8 1YMSIB;=?ZVK:W_A[4E?Q
M8W&4:3/^+%FYFJ::7RSUDSU"VW*8E))VRVWS-\$"EW%%!\4;J&(,3BOPFCE5
MJ5>@NH#"?;:U ZX,CZN9@)+)!T3#2!;L9SQ+MS57BL$WV['W!N3:Z#YFW_L;
ML9Y:AAGDC''%_7WK?[J]KGCP&A@S9>F*@E2Q+Z *P=ALG'XHBR]]-U1(4X:>
MS"[)QC[R9U3XAJ[<.J?\T]/T>(QW;3W"GKC4R3)L]Z.T&E %_A@;MQ(=J SC
M,$B<M] M@T05P>J?AIL)AN5,.L0[OXPW)**I6?3SLWVYG4DR1&..;T13C +A
MBC,U5"#3>\B6.'KY1GO3#GIASB_$?XSFD;E=0#KQ_?=<#-WI-)T5E-N9#_"I
M00QFI>8_/U7P7'*F/@3E>R+L$*^CY:TBZUGY 7C^A.PUL?&<I->V[8L_%CZJ
MM#]B W[,II9^BM4_28A7]BKM%VVLG77=P]1IVB^'/\C36I9;O6UI0WRV;6W@
M?2F'_]+*2)#$+A64%,P[-:E&K&&S(AUH'D:O/4M^P+RG]OBV[9);IID[4MK!
MS?GWSN X7+\ '[UF'&+0>/FDZ37Z)Q(LFCKPCU8RX_G'T7XASMB$C'+U;!HN
M?#7V#E(=QS[:,P\.)7"LF:7JZ-,'D/;H;JA5]@H/,HY94OB',#Q$:-H>1=XH
M9K$1,\QH\$5^[R>":CYDA2:0?<=^1G<K]:DH*(XJ]BB@?Z\\.]@D;EK7V"Z.
M[<R-BEL.:(0UB%-%2Z:@]$Y5JX)LG8XA?L>^YZWFN7[?2!8/+Y%K7,X%-QH<
M.]H%Y(*IFN.AQ5P:SW!6-XZ_'_W7<^ME:T-]VI>-^L3%SDV%=%\P3_F<F=ZZ
MM ZU)QH+M@!2P>G0A[60:X#K&$'?M72Q?U,5@>W]<$99Y&/;V@.X#1B%>UGW
M>GLSQ97.,LCUO=5*6B!&J_4_XI[NK>^F$"XS:O> ) 4Y0EI%PRUB+/:'F?L0
M*Z/:OP93&G56]_F4+UZ0$N&43GV:\-]^P)]>OCX)JXV(>C_,3,$@0_);T^NM
METJ[='N'L4X,4JW@,$TCI#[8J*/MSF&9ZTE/PPVA37:PI&S[,C.?@9BTTOWR
MDN0.(7%Y)*P7FQ)5#$G'N)"#&VKX8@5_.%V8L-I9UIT(HF@V.Z%LOCK12O6"
M1 :"OYZG/#RO(V1G-I BP*%7TO5X_R*8UG'G\FU<8"JT;!$\M[!;7\\A2V;?
ME+G*ICH.WO-"3?363EFZ_0J:3B:_/&&\A;GARO=!7'"E:T"H1J?)(-7?VJ&F
M@MQBR_/95.PV8J&CKC+\P)-;BTH*</3QJ0:/Z=2M^OE_.Z3N?P[EP^XVZA-1
M_Y[TS JHR@\+*YCUUA/-I%^/,G6)A&D9X[YR_K,U7UW>RK@SV8M]:XSI ]Y9
M*KT(M[H&?,C5:ZQ!J8H/P?L_$Q8"7QA8$NW<].!OA*=8:.3AC3=M8X4]UI=R
M]7\2?M!?LV2O>Z^VM;91HB8I;4V7G90&2G&7V)-2^"$XPQ.G2@=BQ9]A9*PY
MIFK_TG2 !"]9D7HKMW=\SXBT4H>/0J5JNRQT'!!TG!^A=:]Y?=H?-T(_?/\(
M\AL#$<%"NL#$-TS)D-H51$,P5'*>3:]IHOHC90X!O9J5&F57VZ4,7\*(A8'[
M@QH\:NHVYO >6*]N$!<W48;Y5)D84*-U6BR_UN(R8[2JR[/\7FTXQF/S>24)
M1:O^/]1,:N0J==$ -(@3SWP-Z 0]Q"<46^N[BG#SSZ:\JC%EB^%_W#FQ6)KV
M@@A:[_51I\/:*U%YK:,,1RT\&CD.4YSM2AU;@E7AV%T]C_SM)T>_D$D):5)F
M08#=&XB(1.VT<([ X!]UBE:9Z6[ZW_*8PS?M&[+ZXHR&/W^DJ",=ZB7B/V[/
MIOE'UF NXM7X&VQ=6N$V-R,^*=OQBJMZK*SF&L"ERZM1:*DV8G[UP/CNA)G
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M?^]BS[)P!CX58T5JB(_RKE"[HL4>HCC K'._"C[/V\Y:2\CA=EZTNX&F3[_
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M'QIC#^-(FC&OIY1-,-VU\9?&]3\E+-296I6+7/=C2U]*/"L+__*K9D2/K@9
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M/'+>7S>Y>J.9"\*0!]>D?403G9" ;/N..PE%$UXB(ZE-7>H$3J&N7#/OBI3
MAIB5+1;/UF*"$*'S[/$W;.\4*S-BK2#1)B9W5UL$=Y2(:F0'HB+"'#B"D*2&
M^R.MABH8R]P.E&2:5U<^+-UN:6U/=?6O2SZW=$+AAS8''VY6;?$[N95:!O.+
MBKY+X0+BM?16V;Y)]0^*"+RH6O;M:$P--?V2=&#=G29:9WJ+Y9JRQ=MCIG=]
MZ"=?HIZ@?5<!Y7D*+Q-9"^B&]L*Q9N0^XFJR_LT5.%;3NGEYQ<)S _)>M7A.
MV&9:T0Z-&/GQ.O A[W[0PRYG?! T GZ%A([KLKA=[X/M?NQ0;-]0M5Q)GB_X
MH1"QD791UL/41D@CEUDR#?*IO&N)G$A%'4&\]A9M;8BFF:1#0DE9,BI&&AB:
M[EMA?E. ?; YV^I<R,+'/<P0.-I99'P)XY8=N1?V^<Q73<@U$[[_S$KWV^X(
MPI2F ".:FX^(&RCY/(R*V?CQ&HW+AA'MU!;S\//;\H=B-(R$**DDJ9.D-#Q:
MK%V%+WL])CD=^BMJ<=>[)"UER%XKTR%8MIK)U^Z.!=C:(X09@*PY@F!4MPV$
M5X!5B_2!R.2!<8F-,</H"^I1FBSLNU\+Q/;4,V[U:"?$/<MQ!:.)01.(.C2@
MS<*(%M:+?G_4>'QT4:D&7)8<*'^5QY\^K_@4C@0_8'AMSM^^]/MUUTMC=\DD
M#%:!OO\(@D/K[FTG@BT,4/-HG!0)H!E\_958-K2:Q++6[?>S3_=*Q5I4 V,0
M!]PR/!A)CBB86NS'*H<;F!M+VM^XKG\'HO5+;>=O0,=,H;VRE\QP$Q3>=GQ-
M,H6["F@GA"<ZW!0Y&+"*<=$QGE(1G4C[.'Z"J],R.%BK_E,Y;>?ZP\,-DTM
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M>*OGHH/;ZYNF=?K.Y/=N^6SEZHH0/1&%\EA6"A;DP],4H]D8*23&"'G["++
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MQ)RXN?T5QX86]_^&UC<;B)Q_6O55W5R7*6U4Q2EL5W_K_;;9Q[(6Z+;9H3W
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MHM8@IKE0GS8$:C7HX,:3!P(4EV3W>D2_E04]SEIHR9'J"-G.T3X?Z8T/$HB
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M\=:"40\N1-_=H3U"*@+!Q-@W>*X7X C4,9Q2=6]H>8&=A=X/%KI9=VW!92-
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M\8U:N9DN_>V*.QZ%1#U9'_:57%9/F7-;Y[7.Z(G[B]^.N7CZ'2X%4^[7@.9
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MK=J'Y5,;.MKYFQLK'8'*F3^O"3>,Q)O5__C!L0G&N#53U&N-DCSDD EKW,J
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M]%3Z+??4>M,GDQ.-(TXW<V(53D%Z6*"^06PEPUN2\1@"-VDHGV'XHU3  /'
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M)+G@;V0J9;89(^+6IV)TV/*V8ORU4)]K-WU$<S)J+_2VV^]!G.; \3:VX84
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M7UY\T=(<;!4]K*V6<9PCMT[!E?=X*P1FV7T<O<@6I!8,8"$@WDN1XF@29.C
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MV>?CH?/K1+&V00F A*":]-* 6<MC;%T'?D*FXZ/Z28'/V6/*"&ATI=AGET?
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M^*B5 ^*99(PT\R1U*),TG;;#*3-'?57NGW,77Q"F'[ &2,6>-'B/Z37 A.H
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M6,@WR,O_NPT&___K?^^"[<W_#U!+ P04    "  3@M18H..KA-M' @"?.Q8
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MZE7$TRAEH:?L# HABA&%)(H8)")*A>_YG/G<QLZ8BY[9RES=J=\$R')0]
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MEEFEW\5-'KN^58Z8G!?@ZUW&[@ CN;IJ_:ANZ61HN4797KTIU0UJS?WU3N2
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M2<Y!L].QSQF;L58P(7CU5BGTKJHV^JCSNBF#<"W?_'VC&P!S/TI")B(8LB2
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M6P>-2-OZ:0=\&+YU)VEI^:I]HN <K]>CRCBKCW8@8.&Z:,<4/*R'=O1*!SL
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MAFT2FIE-G,(&=J+!4W1 S\,&GW:JGES601Q7N7K:\)B9O<5(MS.  Q(_JVG
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MZZR]&SP0]C=BM1L_VZB>W[;_'L9JVDKM4E=P&(#NEFX:MQZH+7+006]+/NS
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MN^VS0Q%+[WT=5?*9C:OCU]I'N_U9E'E&?A/5W?NLSFZ;<>RK,@2(!(1A&*)
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M'FY%-_UT'WKAS<SNW2_S_I4.1^.T>7PYCN=:7O9(P74.=H.B+]^B/;_:G'-
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M(B2PM*O29R!S9F,\"$TI=%.:(88)&V,F9)K92\<4V1G!Z>S81V2;Z^LJQ-I
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M$2$$4R$2P2-!.;6B>[558.+]XEX=N%3Z@+U"[8[$MA;)$E^SX_J4J-EMY7J
M?3P-F"*![FZ'.WT\7FFX0N&MALE2_,P536[@'-<W.8YCYY4X98OKV]O-^ZI2
MS74^K3?_Q3?ON)S']^IHOM]D&S@8T[&FOM6X;?9X'$A%UBN^WNI _JYQ$)"*
M :D9V*MFYF&,L1KV*%/ 9.=!'!#R?.=AB\% $8<<JO4:E.V=A;& 69R#K;F=
M,[!^SFU+\D>Y6JMZDBY)X_./E9QV=^7#%RZ_0-+SW/+?GE1FWWJUD>;*D6Z;
MCRSR),UX@!+%9,T@XFD <1!CF-!4I&%:4)1978LZ:S)USG6GASICMHK8;4O<
M,3;;G\R"G)V;^;8E=<E*K"JJ]P#N]6GRG/?Z-!_RMT\9#8FG#8N['K/N7$;#
M=;B%&3^@8\L;.4=UB.<;O]5QB98<-:,!CD)Y?$*9X!"E82@/4J& 489)SDB.
MXL2J%>D9.1.[HJ\ZC*-C9'4KU[+3S1EXS/R,!Z/MO,A.(.@D3D!W?<$J7PUN
MSDB9M[W-L*E'S6TN?-R157;7L+._[^RU=_WMZ:BGIVZD^_Y_MMJC=+PO36W!
M]SN\^JP#I[7T)X_2UW#V#U[>WLG_7C]* V[Y[W+HS3NYY]W%@Q9A4B0H#2*(
M<4$A"I(,$I;'D.&@"+%@* KPHHDI?]O@:F/F%5Z#:3:S\=! XXFY4P?@3>\J
M8"UV<?AR!9CTZ[BJU8] K<P^'X=XO5^4@F813@H$>1SE$,4YAR2(.60B0RC%
MJ5P]@O:+\G[%_B]_33KSW+XD?,7^+WX]S!;.UZ#JA'O]7K?N9Z&$?LMN\@1.
M=O565EZ!QLX>;5K=YAAMI*F@M56?&1IKKT!G+V@-!MIBH$P&^PMOC_34K^@5
M^N*_?@TFS4NP_1HL/K/9>E6Z.;,7K^_Y=_QSGW2[(X;"2< 88C$4*"$017$*
MBR B,(U%AF/.$X&MF+,&9$U^::6ORU6[\'Y>^&4V*6O,3&^GO"!A>Q'E"((+
M5? E\_SQ 9^5-#?I[R633S#[7GS$_G;H@[1@O>+J1ERZC*=W6_Y]W;)W?1;O
M5V(MOQS:#]UO3"^)+(:<>!ZWFH!.E2ZKI-5&[59[^N@JW.U '[Y1X%V^-9H(
M-[M9[QDRJRLC!P"<;HYLY,QV@>1@?/\>R>5QAUSJ=24W&*NFNR%]>L=7ZWM5
MA<.9*A[N K&!8+B0JW]0%(D*O*3R/,T+&-*484(Y(I%1JP)3@=,[$:4"H*T.
M@.V5D'\GAO["&+YA1S$%*-8>0N/1B0<]^4"3'=CW/#,"QB(1V#- ;KF]%X'R
ME)5H8>Q0HJ'),//E#EH8]2P=T.8YQ^+ W?;KL^B?X[[RI9*C*5#U,8[TCG%[
M^EP6$I$D00Y)&'"(5 4)02151<<"99BRG%I=4XU39V+?V<2#R/-X4"]DY'JD
M&OD.S$Y=\R'K'HQS!-6^",\+%K[*[L8I,V^AG1?@CDKK_(QJS\;\?K4I-T_R
M$-H1AU$MM^G/L!!I@#$/&<RS7.[\A/1M&&&Y$:0,\R)#498:Y0M=E#2QVVID
MZ]#'<^EMIP]SPN9AO(;]D%<4[%R,,P!6G,Y&QCD1/ ^//!O;LY&!?>IGLP?<
M]BU=*O'!%DFU5*F76LR. 0BS H=1RB%/L-RC1(1"$@48!C$N,A$2BI%1@:N]
MZ(DG]FXKOMF+UO5)ZT'JS;%XFNTWID');N)W.ER!H]-+3X]IN)3L[?>TG[ 0
M/.O>P1Z0PWV"PPCV0:%O?%6NJT_K#:^C($S>;7D4Q$E[:(\13=.0%#!'62ZW
M!#B"1<A#F!,F6"%_)7(C]I-+@B9V'.C7.$NZ[&"P^2'_?()/'%= :0)JK1E8
M*=7,HQZ#P%T. _F"P_+TT9BJQ3;&2\% 27:(^PPB8![O\86$6YQG#")6D1X3
M,P<B/(./SQ;9,3&B']$Q^KS;CNBC:I"ISDH+B@/&$YK#),Q2B J5 A8& J:$
MI"*G>8Y(:,,/O!O9RBW94_E^UP7SZUT.[5*W?J76!+][),RV*D[VV?D9+>(*
M#)(56V\QCO3VM(/8CSOK!N'(G,/U__@#SH1H7&X=F#R9- 6*N_YL"X)QD11A
M()?U)%0]X@G,J9Q).0I1$+!$4+O.,>=%39[TT<JQYA8[!XUAF-&+P7:3JY.I
M3_@=,<QE %RXNR[8YH^)ZYR@N7FU+AA\@B7KTA-V<[:N-HNO*ABLFM4OXH+A
M(N4QC"@*($I8"G$F5S;!\C@K2*3:QYM,SV>C3GUKH#9@]::D<FW[H\=]\Z>2
M;;B[?(["\$QTMLURY^QFEO&D.VG&T/R2#_3FEOS7?EX]'VN6*712_6ZVG/ZE
M(R=P0V'T[8[SS<=U$V%[M[Z7!^%%@HLP+A"'B8CD8L8%;JI'8LZ*3##*TSRV
MX@$^*VKB*=0*!EHRZ$2#/QOAEK=M X"9+7%^8+";;:X(V!/[7C3.%YGO>4'S
M$OA>-/B(M/?R$ZY74;KZ5'-:\7=X@YL(UV;!:1ZJO&-(DD!.9))2B'F2P0(%
M."I0D5$D[&ZB3@N:YR*J)UN5/^ V*&MXR+L(UO D]@F!W11VM=[A$FK8M!%W
M4&<&GOD*:MB\XQNH"Y]W3IS!+36)G/^JD[?<Z&ZYIM]:H)#%!&4$)E&N&/AY
M @G+&(P(88AB+O]OFQ9S5MC$D_:YZ(8H50MOB37M<UW.PV9XQ/0$AN4ATQD'
ME_24BP;Z2SXY+VKNU)*+1I]('+G\S!0MW)JO:Y;'H0C4Q7(8$8@R6L \DYOL
M+ C3/$)9D#(KLCL#F5-/]N'N7HI1TW':&\!I&F#R"I)MI.EB][,)W(&YQ;-T
M'WL)YV .@5T?L#&N8K_!^ =?+O_?U?K'ZAO']7K%V8WBG*T6 0J2 E,**<XB
M>0"/Y39 $ P#3*A -&0L-@I7790TS\9="8?_5-)!)QXT\FVW[N< ,]V[>X#!
M:?/N@(##]OV"=2/V[^=&GGD#?\' XQW\I0<<N9=4FE03IFXOZ<,XR7(4%A#K
M%3WB 20JTDR90 7/0I$2HV*?LQ(FGJ@-!X$+$^TQ%H@)G$<%@WG *$24I_)O
MJ(!%%@F<9FF(HGCQR"NRG@6-OB1+/+ 7/,RV)Z-LM/-)_9<]!<W4.4M\$4P=
MC3\OM=0Y\XY(I<Y^<&8ZJ8^[IDTY3^* 106,4:X.'AF#A8CEP2.G68Q8F)/$
M*![H3Z6I[]!ZE3>7&5L.*G24HB/:;7EX7V:N8]ZW8.=K1E/F3-1.RQ]F+\U1
M\_%E6F?Y ] ;/\SQR/99O"=ZL<H=XWW#+_,WI1->TNU2YYE]XILOFN6KI.WG
M58Y11P2J_JX*E!0QP%>\X8LH)DQD>0J#E'&(&,H@QI3 B 0!BAFF(39*$9I6
MS>FCPEH44,U2P+__6QZ%X5]!V2ICD;,W\<L:]KROYQ78AJ%.-8SNZ0W^IAWU
M7G,@50>=[KOGE,97H-.__>?NU2H;7L5+-$^=?ATOTRWQ^A6\5*O\[>FQ'LC^
MGE#X;+GCTP/8SSR?09H]7U.;.*:SV@SYF'J/3+S&M9+^8LZ@U#=G>.4988G=
M4M$*\9:6=T9Q)^:B_CBS,1.=4+[//'3JUV[G?+GKO2\W3:GZ2NZ!=4=!OJ(E
MKT]0YXF0Y2PK!*14=6$-D@(6(>40AYR'01@$.4$V1WHKZ1-/I)XNNCSUF38^
M. GMH#8[C4\&H-W\]8F=]>G:"0-/!VD[V;.>F9U@.3P>NPUBO\1^WF[J#=;M
M3CLZM9L5^X3OC6X>AT>8V&\H$>:+[X"AE]=B/S9:QN_W,G<$A6KCSLK'DFWQ
M$@S:;[5B7S;/:0$?&':V]?RR:?WEW>#3;JM]FWKT0>JFYK*:M/\H-W=OM_5F
M?:]:Q"]+^M1KNHY$'*""P823 B+$(DA$D<*4\SA7EY )L6(7MA,_\;SM$N.^
M-JV%=[04W^[*AX>N _-_R#_D<+=V*[TES&9+_73@V3F$#C?U!0>=)N"'5 5T
MNH _&VV,VIE;K_=N0'A:\"V%S[KBNP%SN.0[CF(?_7XO!-?ISCN6975.?]XG
M^--ZQ3C;RH^1)6^Y5>6A_QZOY);D*R\U!;N.R=<UKW3D+4-Y2"*5#L%S 1&5
MIQ5, @I)FA4%1ED><:,SRG0J3NS85'TI;ZF#JX:<3+$)Z[#W2B[8*CI227V;
M;O'*R^E?J7;J>/6D&Y+ONGA;,&M,]#HOQ\9?_B79.="=OJ!']ZY4!L]UUHTY
M]EIW=-!78*<XZ&L.=JJ_^#LS#X6__+MS"X._W#NTBGY/"^] Y'LBP;-%O:<%
MKA_QGEB2:UU!53YBI95.*?JTWGP60OZE6?S?+Y7&Z]6[1B<UX=,LRUB0P##
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M@ YQ/U,2-%J"-TJE7ZZ:XX_2%6AEKX!2=_?;0YVO -%:J_V-QXX#WJ'TU:7
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MQB*-(&)40!SE(<P(#TFFNIE3NV7!4/#$7GY7LX#;FH7=[55E' :QQM+0]4Z
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M/V>7)#B/9"0@PU) A'(!"8HYS() *'L B0Q'=@<<)S0F/];84;3.0!E#QO0
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MQ;T@RI%C>^DJ-_OKL]"!*J;MO/6#^D54W\3G<K52]J!N]+@4*""!R#G,$AI
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MF*<(012@&.8BI9#F*"!13J.8";MP_BB]&4+WO%\A&[5":$O636U<PLQ.67A
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M0)R0B&8T1&EP:X!AA/S4487!F)5.%8%R1QR0#1!J?2EO5L\XNSF", :S<]C
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ME &,<\PA"KB$E,D0\A")*,WB+#,[FADG,['R:<T)TE+6\8.&M+E3.X+/]="
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M9#[JM>O=]_:V[]^[-7^K%L(R0R3+6,Z@#'52<DZ(6K1Y"JD( QHE.<JE46>
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M(+G<E!NR,O3(_/)GI09W7)I[*@=#&8J&7?V?ED^P/N!)_:%ERM:S\_S*#'W
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M!T$PO5FJZ]4?[K:;Q[*=L+>,4IJJ_P]@EE*D-JP@A#FC#"81#EE(1!I);->
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MD#UQ\%.Q!G63 /4W\]R1V5_S^.[SP[XUIZVH81,V?(+#"39[80!] </K.H%
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M4Y2&F./(KN'5Y#P[1+KMM%=#4_#_J^-$*3#K\/9\+]!,[?T8+^6U MF[D.1
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M*$KC3&U*WWCU\G['[S:2PK]V>+7?Y;2SH]V?ZNNGK6E-7I>Q9U;4+4M!QU/
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MY1&-BH0 B"B3A[4,@RS+"A(6D!*([[_QBFS,N\.,D[59B'WBQNM1D;1M#6.
M5B:MWIA*FY<F"0:0\Q00A!E@3(1ID5 1Q58;A6^L'#:$]U."TXQ ,]/KOJ&P
MT]\M]: EKXNP7AV%K;W,$+1F([.W-CP&)!?NR6,.PNL&/1;OVA^"?^=L6VW6
M)?UM]YUN>M9K^V47:9%A5"0@B3)I-T:% )A*70I)B.(B(E&:&Y=1'J$ULQ;8
M4P\T^:!__#$_^8WA-7[\]8B"G0(8 L#A##R&A/DQV",B;B=AIT_#ZBQL*.+
M<7ALA,5.Q(:B] _%IJ\XUF6ACYSM5ORSZ*S*.Y4$?Y_ .,0\@R#,(A6#"Q-
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MN-+-6K=-%@3OQ+!L"+7 #)K9@C_8O-CI],.4W!ZF9"^!_E<K0U..)=!2@(T
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M!5F<FLN>CK588]D+0O2;REYZ9&(0R']N5B7#AR8:76KW_F:,4\%CD3,0\IP
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M:._.!"LFWLBUX +494>#TVA.I8]51;7W_%M)^1?^L&M'OJ<\HHPC"!@*(ZF
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M#M*X3,@^[D)E5)>5HK 1-^O;:D-Y77_AM30!555\]EX==C;/3?'./"H8*0A
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M7( ;;ZCB-*IC'HFRU;[PYYVJ7US+ ]^N*M</33F)IF0!9E'$,EX %(<80%1
MJ0*3"&"6QB%#HD@*J_/7*,69M5Q3A"NH#AQ8YG",(F:FLKSB8*>5-.F@1SMH
MB.\+Y?BN@V,JJJ],B%%ZRV8XF(K_*G/!^$7[]@U?^!JOWJG2,FT?Z2_OOK9-
M#K,\ICQ'*<#*SP*)-'H0H@)(6RB2%D^(DR0R6?'#9&9>YIIPH"@'^P;F/TGB
MAO6^1B :7N+^!+=;UQ=E'F\ :2.\>5,%/R"X]5"P_P"L>B6,BS;0&F'@Y<4Z
M(8P+T&]\8/#TU.STFW6]K?1$UYUQ\\O+?W+V('7>%]XF+#R6SZH'KBI*\55^
M$+I&UF]M$^I?7LX-]J6L_[MIGQP1G*)(*C(:$7F8$T1J.$Q#D.84TP(G>1@;
MZ;7E69\[-/.0-MZ3Y"KX20GSMT"),]K'^:TGU_2<^"-.F>V9\OQL]<Z*_KIN
MOQUPWBL(S,[X&]4C6&I"+E<W6(P#/S'\)ZT<#K>=OU:2\S_6%<<K%7:JY>!"
M'L'O\/=[R 415& 0"74/&86Y"A'%(!2,0D:CO*#8HH>95^:,E,WD#F<'XGI+
ML TQ]3,-9GI^.51GC,[O!8QH-H.3";@*B&8UD+S.%W$_";J9(NW=>'K3"/M)
M,(Y%UD\;?(+G\*:N=\=^"5VNMM:_;&O4?OBN(A-KSNX%SY2R1*! , .01 2@
M#%-I@&<Q+HHHD0]T*M3"F6C%A(.JM-.2>TH36N_:0VOA<_0/UYN7^N[8[57[
M]NR]= +-ISO3CH'E_9M. )UU>+J-Y*;$/JO[3/7U5?Q1?H#:_.P*7K[#]>/'
MU>8O9<CRO5VKM><73E>XKDM1TBXT3MDF:8Y(+G48P(EJOIBFN?P;PJ ($R82
M+!"*B8.)Z)7)94Q%27OSL-:6BER1UY_?W5P%BM5 2%Z#1\6LI?7H=Z;,U.7R
MP#MI4LUF<,3G<9'<%GO%;J#Y/7(6[,W(4[Z;XC$^;<M9 /6D9?WRMJ@"G@76
M4]T\#Q$WM7V@_%&"H8HKENN=W"[:)#.Y033$F^<D/5Z_EW^IMR6]IUD1<U1(
MJ[.(,8!250,$4PHPA#Q%6987=O'$$WB9V:W[Q\]??[93LE-P-5.I"Z%EIT"/
M*XJK]14<. L.K'6*LGU><W<5=/SY4Y,>0/*D%*=PLJ@*] #9J<+S,:1K4FN]
M_2Q^W6R8#J?FU;>22OMWLV+W*<192+,$Y#F4V@L*(:U+C@%+!4.DR&/(K?I[
M7R8U=["A)*RJ=CY7&[:CVSJH)<TK%7K8=E#&O5P3]6!YB.K%#J57!S!%65H4
M:0X!4<!"2@I 5!<; ;,XA)BF5!3WWWA%-LNBVB<Y#5=O4)DI>3_BV^GP3FY-
MM:E:TM(-O@XAX)!L/":<M[SCBX063D$>$_AU-O+H&[ZBN9MHOOIPWKQ9_X)7
M*KWMZR/GVWN$(Q'E10S"%"$ (R0/YP@3D$5))B),L[BPRC.VYL!*C=JG#?<.
MVEHK!C]U;2A>+)V.]MB:7KG/B)CMM<NY:.R6G4#NY4U0MC0$]Q@&QYZ,_<VE
M+@JN\RAU/8--7?I-W75&;;:P[#'Z;QR);0C/>/"UZ4".MR:[IR=<O7P6>ZOQ
MPW?\)#\D;5#V2CZG.,HIS0 *51T3PB* T@("',:80 )Y 4.KJ&LSNC,;??V:
M^[_C?\H%)QD)_L^N*FM6MA6+_^NQI(]RV:DF"<'7'5'5WU5CIQZ_EK<IAI ;
M7J'X!]+RWJ1A0$%X.(?VT9FY^KV=_+ZN0 RI+GOO80?%J\L.R]<7[EBM__B[
M.LYVUS#1/>)AED.4 IH4TIK*I5:2!Z4<Q!S# F%."8P7:4=]AKF955=+3#6.
M'KI=G'\.#-74&R&[^!VP_E_0S8[WN]\98'SK]LSG6/OWZ+T\ *JWQLI#-%PK
MG6S;=B/J]+"KVSYB)(Q2#GD*XCPNI"[-D;3U<@;B),QIB!-$XMRNKLDY,C-K
MQ0/1H*'JV''M D9FNFZZY'9:RT%HA_(D0S)Y*T9RELC"I4>&!'U=:&3P:?LT
MN*^ZP?<GU=_[W<W'K]=2A/S]CL=A4K393FF:T;3($* Y)0"F,0$%813$6<R*
M4.1I08TZ)!I1FWFY9C^G::A,&*IVT.UC66U?@"[%K3@)-$\./<_-@!Q>S-[A
ML;1$&J$U[18'#8FJ6J[H.V30C2-BGDCG%1FW?+KI"%GEUQE+/)!F-S[&8MEV
MQN+TD^[,7YK:1/)FS90C[%(UEI/F@V'&2)HE&) DT865$H 0A"#"6 C.BC1!
M5DUC'?E8T%G5Q-^_PU7UHHX9;0T![8+I&+Y4?,BU0Z3=E!B>"N<'VE+M]C >
MAW*AMHY.V'AOXFC'Q1NU;'2"ZG*#1K?AW)3?)_[7-:5J':N37K59R[]2?32L
M/U=-<Z:;=?^)<DW+YY7DK"N,EN51&F5Y 4B$I67(LP@4A3S&13R/0Y0A'.'$
M1@U.YFAFA2CY"P[D@V,.)?9!PZ..^.T_UK(YH4[=]+DRTX^+SH"=IEP$?&NE
MZ0TP3^IS.C^+*E)O\)VJ5'\#3^IU^Z$M)->U/V_//1%'&<92<8I8GJMA&#.
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M_K7:U'6K2)6S,/@L1*V2"->!W.>.U?)5<Y-\X%:U6J=<"L#^%J@4T8$NAE.
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MOVGEU%,AQBJGOGK>L5389OT@-<"3"OV\DT.T6:F"1 @SPD&:000@807 19*
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M_W88PH./GF7 VAC7#4^K:_WF[\]R2PT-QUNZ,9%WGU'!L$?S<KO(,4U(+#%
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M2NX;G=*?=7_4/OV(Z&GZI"&KV"M[$U&'9B@!W]BP*WR>]^#F&@^OH,<4>\P
M\^;H%>R[*[_IO0*7?C0!7X%]/=S\K\*O@FZV5^)4@Q<6O8&JO4""9JOS"PM,
MOS(P\),#)%JKX61)]8$^R/94948S4D =<D.49P"EJ00DAA (4>"8Y2))LMP[
MUVJOQ]3%3$_2AY&1Z\D6X8NS1])U&O3&Y%TM@1N7674W>XKDJH,6SY=?=8=J
M,,7J\3A?[IF-CNB-+Q0ZNA?U5M3[AP>J1W9)EUUGPKKE8%76HKNJ>H*02J@
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M'+<(99H78A?+/#O,;JYLW\*@I^]-GUBGKW)7RMLIW53Z'M2.6KUOHNLOSCE
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M7[O>;]CJZ?QAO:KK<.L*L@5&K. )(H#F"0)(9A3@C%&0(XD$PHPH[-1K]UC
MQ,/TXT:4*[IYC"H#4O6?_X%A O\2?:.;Z+L1'_T_\6]Q'"<W$?PMCUBY7)KB
MIN;BB.ZV]^N-.:UU$R4W::+_GQ8W69K499;FM_@&Q^0F3O/NEK*J=BV;U/K0
M5NY&3_/5MZ91U-*1 >SDC=AYA3$XNWF#1E)3<-\<G]:KB/<U#N%\P25S OF
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MT6U-#D^-2DU(Y^9O'0&V<ZK3P>;F.0].,?JC!UA]?JL&K/E;;QD7O-K-#XI
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MD^?/>ZSXDGDGYXDO7NA9/6(J&SZL5^MNK[3)77:L.GI=+J >8\#L2NKU)2:
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M8W(]3AYMIYM[/#;0([0];ZE]W#K:8K^@U-URIU!ST*J!./+\?;,%B8-J]R/
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MY^W#M^7Z4<HO<O.]-/M8Y\C8#N[OG;;U[4^YX66E=:L301^_-6Q?*N<(0Z@
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M.=( S6H8,T/%*9M_QH^<O?O)Z5J9RR]"E%12>+_<^AL:%D=K(,_VI:4/-@R
M@8.97 #52K55T;,C>DHY;S6<Z\/,1EQ6A6,L82-YCYB!AM/?[JL?_Y\<I[<
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M,FC;L!$O $MKQ>_+Y5+]0T'4=&='OY1+P*K% M>-^A5HE&R_3K3'&$XX%DE
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M(A(8,D10*(H@C(T@& \H>%Y#BIXZ&'^J*[:FJP8TU<*PO\ZA4@3+\IPR#(.
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M[[.N(B!62F9KK@Y;"5_]Q?FR_37?3$=7CZV^VQ;CILU38?(WS:JD0'!UM[$
MTJ:LUM+^/Q\^OEK5)5FOVHA!3MOQ)=$U%RQ5'2#M0C+P)&5XP UO?G.38G?E
MI)S)OK,=>;+$O"M%'^?L73N4V5[#*9N_EQ)7RY:$W->>W_U4QX1]P_D/CT^J
M-V%)^Y/<;6BM$658#^[[:JKC"0Q,J8R.#5MJV>XSIF?Z['5Y?C>91(V&MT>F
M&@1_.CW+N%HE9T MY=B]OTO9ULVUISB)$;I:(8,)NGX@NY.0;WQ5UNW-D#J*
M_?Y4+9NJ_J@^ (7\HO#'>9Z@B#(.,TH#B$3(88XXA3DI1)0E..58"T56FZ)G
M*[2EW]TY]!R @06K9E>7U:@75#M5CIEMN58O%IV/-65UUN?X$KV)NQIKBG_8
MPUCW1=LKW+K\@94KU+>#Z!O>ST.<\TRA7P99G$-$> )QB$.(<(Y)DF5(1$:Y
M>*<(^3[NW)#M[V3_P_12]H1^=*]@KY?:],)U(W!+4J[DGJ;#U7Q)+&=7I2?(
M3'PQ>E[8PVO0"\^;GU0-/5U&99$GDO-N5IN,^C%*89%B)I(BAB3(*$0T4M"1
M.(=I'@G,LT)AVNI6.5[+C/<M?QS%*3_Y#;\OETMUJJZB_G?= ?L;O.AP#>4#
MHX343^6"-ROE=G_%S^TUE!6BI)-)NWS^->54F)FA37NM$6NSL:)WN)L!O!J5
M%KV<RO5/QZ94O=TQ&80JS9#_)O\7[(P N/0;Y(>M4@16#V4#^*+U,'X#$+HY
MI7*EG#/'55>3F.S<RI4RQ@=8SL9T">-9+:L!8DZAY8DD)D5:1)!E,8(HH0+B
MF&%(LR1D- NS(LB&:Q(]'U*'K,65B-G^LD'=XQU]%QB?>YK3\RV=:<,Y]N>(
MATF00(_+[!45=(_D*T (/:X$/;30$^]:9N?U?1S^7I>K%5]^$:)/5[NK5$+:
M%S$8KS^6Y6H>)7%41)Q"GD8JVT;&F23."<0!BB,:)5'&N,%EJA43TURCMMEX
MTMO\=OL=D)ZZ82*>D6;UK(A[1=FEZ?5LS$#/B-24&.<Y#MK;.):*'X<)>S9J
M<)6_9T1[VG0^&[4<9/=9#>*HE]0?RYIW4+A='3%]5HF&O)EGE'&,HA@F4:%R
M@U5%0H$+F*<YIZ10]61:<(7&E+V?>/7=DM2%-.YS[-<;7@#MF0&+EILK>TR=
M5*_N^9@'I9D>F!WI+K5E PQ\@(_G]75]9ZE+LOMJ*W62[LOVE+JDCHL-I2X.
M8&MBR&J;1KZ/>O&M)ZE(S:-,X")$(40%*R#B*(5YP"C$#(N0T"S#"38+@?2)
M>P^$?J\E%;!9)W;F1%N5NO;$J7K\X>@,K+16Q:5-,97?F5'1)CRQ53%5R*%9
M,1[!SJX,!\YW5=^3_6NMHK+5L[KY6]TLV3OYVR?UR%SP@$>,<\BB0MJ5A!%(
MDBR'-(BR)$Y2EI+"S*[H$_=N5VX8ZU%#I=O_U+,Q:^LJ5[/V")\/O)A9&P,%
MZUD;QTJSLC:;:PJIK)X+\'6CM*];I;V[J#1C:V,NOR-K8T!X4FMCKI!]:V,Q
M@GDRXFWUG2\XE2OS$\?-NN8WCRO=7,-C[WJ.:/KR1C 0!CUE8 **=5+N\TO=
MA<AF"]I66J.\OG,B6:7M'1UPLJR\<^*,D^[./N<* T$=JBH2[]<K26'X0[^N
M6\P[.?5SEG 5!00PC5IDNB2'.2.J94(D2,+3, ^-&IY9\N%YZ<IO)+\6!4%/
MG]KG#;ZU9'SZ< 0?86 *=%QM_]KQU8-I*LY\ B(8J<8;.H(>%R\,E6"DJLNX
M"6;#68(+=U B 499@!""41CE$(D,0:(ZO.4LR7#$4\IY;%)Z:P&Z8EY1>Z=>
ML0)9&>!H& T+%J20(1Q %*$<DI1PF#$6A0$2B":9$33R%% SG=07&MR?DUK/
M1OJ&A+D@@#D,L ^4EI= 8#F/KG(5<HIR?FY4XD=SNZ@:?E=]6CZ5JJOUAR7[
MC!^YKO=_;@S/7[\BH>_JGQ7VLLOO2D[#E=%2!2U9!69^5SZVU8:?/G_]T':9
MEW^0^T&+F<3*'R53^$AG]6(4%.@(;14<G!UXLB!!1[QQL*#UO*MN)&W_CKZU
M?-]>(LL33F,:P3"CN<J[CR N1 'C-,AH%I,HB;0B!!.BGM=P2_!HT\<XO+8I
MQQ$-GE_GOO1BMN9/-^>8@:ZI2\^(L^XE1Q1U;2>3ZQ3FNJN)L>(<-#DYK0'C
MAB='AGKAYB>GA;O<".7,NW9QR^8 =&@[*4A XS3K:I00"B-88![!J*!IAC")
M*35J3+TWOF>+>/E47DL)>I[]%:*9&;4-(8=K[X(0COS^_=$G#0!.B+8?"9QZ
MS/(<@/UC/2"N5</=&UZH+M8?EGTG\19UA^"&,W4ZS9=-:ZJ_\2[YG'_G]8^2
M<KG*RXJI^IO[93M*UQ6G2-(TB",*"W6^B4A1P*+(8YA1EE""12*=&:-8VS/#
MGE?\]U5%_PE;W@ =,6<8T?N>-<VS@E<T%X:QUM</M[,.,PR^:2>C/U\#-W4M
M'^3=0>L&G%85R]Q6S0J,6'1XAC&1'EV=COAF=]ISEXF4?W"B,Q7=ZULJ;7OO
M?.-/_3GT%_&U+I>T?,*+#\OV4+K\P><13F*<J+IQE!.(>,!AH6 D<!+Q-(X$
M2FAA8NVMN/!_JU78MV+2UZ6>#?:N(3/#NM_(:=LEKKNTDL3]]&\REMU#>R=]
M'EZL^Y.QFLXUAS(?S,X623K2Q"DH\;ZX>WG_8<4?AZ;0G(5<1GIM%EP*I>$)
M89$+#%G&TB1$F(O"* 8\3\ZW@\CO6S^DWA('I:)N9G(NJ$S/MKA3A.FI6*>#
M$5W0$O804.K)Z,A87" VJ570$WQ_^6N^98M0U:SJ-55&97E_LV1]H5 /?*_R
M;P?\E9QD/$[S%"8DY1 AAF$NBA3F2905&<T2(K00+8PI>U[].WRTB9M#$=R6
M%1U,ERO5JV<>O"C-S%*XTI<%HI6A[,Z0K73I3HQP9:B.0Z0KTP'L3(P,F=1@
M7^N^7*@]CQG\B$#$C.$(8D*H#%X*!K&@ <1%5N 4Q2PS.ZHZ0\N[$Z$H@QNP
MH=WCHYL9C'/*TC,1CE1@ZCX<2J_H>O >-.1SM/#/49ITJ6N(O+^X=5ZQ7,[J
MJWZS?T R.L-[\[Q]I#_B:V_VU2GZZOG#4EF=+FY9/?#Z[@$OOSRUY2=_DP:)
MLP_+[G!E#Y;^=SG^2C4VWW9_#Y.<D3P6,,P#Z9&$60QSE"*8J<YGE,8B,RLH
M?C62>395'3=MQPM6+1:X;L 3K[ON%X;-+UZ-RG2-XVOAUZ,I'IVPCX4<'[,#
M\GS\)%Z).@.=L& D+6C%!2LI+^@%GH'^.Y*?42?T#!PT"VD%!TKR$=J8P[W@
MM4VGJYWGU<@U[3[W:L0^M:N^.@;-LU(_5\O/O!I.I3334'=>\IUW6BWAYW=?
M-!WG0Y'.[P1726-FB0=!'#K!)[FW2A/='6FRO-"C HP308\_8.>N*FR^-LR5
MJTPNK[JZES,V?"H41XQC&6\&F>H\5V0(YH'\9Q(CD0I"N=#+^-0AYGG5C$FK
M+?FI)V[FSYW5EIZ+Y4H'9FMM7_R!KH< 5$= 1W[ 65*3;LTZ0N_OEEKOF.=S
MOQV'M-T9RX>F67,V%R$6+(I4!!A%$*6%# ACP6%,XE"$ 0U3HG6:=):*YW6\
M04=J%.$9*%NBYNT)SVOJ_%)V)K_9&GZ[<W0T&_H+=F1=2*V?=>U$>KLT:SLM
M&&547Y3N3 KUZ7<GRYF^R/XX2?KRPY;@,4-O[5OIE]]7ZK3M;?6(R^6<H3!(
M,YS#)(U3B$*40E($ K(@P)0S09+8Z*+L)"7_ENA2)_F>HV?P9\>1X>W8:1WJ
MN1I.-&-LH]PIQ1S_Y9+ KN!>3M*9%MWEDK@'8"X77[!;[ ->IHSZ2;GL,P+;
MW+__D4$[DS:^%*4"J>H;4'1(,NQFR3Z674LI=1@OS<[C (VW&OUAGHLP+%@8
MPQ3'*H4/%[!@10%C5691X( 1;%0<[9==WX%,1Q LMA3-K(KGR=(S3:]G"LSL
MVP;M=\3X#&Q9!V/>>Y,WP&"Q-AM@Q";H!9B!85(_:DRJL56<1M>.3*MG9B>U
MS],H?M_(3T35TBWDRT;U,I6+JMF%&>D/41)"\HAG,BAE:0@1RB@D(9+>(2UD
ME)J&(N>YD7=X@:!G:]V3!Z2C:6BJ+VI+TP]TJ ,S<SF(WSJ [H^:= 5SY?9=
M(C>M]Z<I_($3J/N>W0K?W,%TYJ7'-6-?E!&2UJ1<WK_!3=G\L:Q(P^L?RA!]
M6#ZM5[MMLF[Q@JX7G?$:M4-*,Y3C- AA@G$"41!$L" JI2$-XDR!$Q3,R!/T
MR:SWO,S]MF*C'IKC\&OP0@;A]EI;_=&H/,7OI=P?1$G5=?186M"*:VBVO'X"
M>B;OM4RLF;G<3LOL8-;D'&]X!RWSLR,S!78%4-'V1@3=+F;&9G@*93LRX5Y9
MG=3\3Z'T_:UC$IIVV\YG=:C1/'RMJQ\EDSO:\Q^-RA=X+SU@27EY?R2EG!<H
M03R)(>8BA8CA&.8"1S E!0N+#&4\^O^KN[[?MG$D_+Y_!=]N#S 7(B5*Y,L"
MW31[6& O*=#@#H<^&!1%)KYSK<!RTN:_/U*2;?F73%*4TGT)TE3FS'PT1T/R
MFQFG)!UW%49^1>PD=ZCGCNUF/6"U<]#C@N7F=K4NP"@#MMH8_M?/1B&P6/T=
MG(-Q% :_/R:!O*.' I/Z/'^ CCW9@)&\*$6?9'DG2V=24?=C$]"*/MW>@[O;
M>R=FT8%E_6M_H%&.BWIO3WB"T3D3?"E&!V--23(Z9\01S>CL(Z'J4N]N(ZH'
MOGZ4FP_+9=M'OBW/Q!_EG$H4%8G,($9<P4051._X"@IEC+*(Q3S1[_#YJUSG
MI7]A:AM%7+ZH776LOZ^-:,!WLMT[8?G@6Z2")#E%,*.&XE7H'QQ'!<PTYBG6
M(9)43N=MXZ/K4ZBVP78O>1)H[0*A\0$+?H-[ N<,[#4;LP"X"S*CU?^V4N*=
MRW^[ '6]^K?3:!YU@(O_/I2&,/[A^Z*R+OS;_=#([F-?%\<4O^U2VRUW4Z=6
M7@^4O UT6^Z7;=-;'"TY4,QTUAJ_VKT'(TU7K/>< 0?5><\^$(Q/<=!#_6'-
M5U7#V]IF3C1=E%ONUH=587XQYR_S-,$\CS"%.6413#*"8<Z9@CGA1<Q215)B
M56U[!-W&OGM;R]=%^5(MW\"37)J]_*MLRUL9"G2ME_Z^;<#MW<-@"H7W_-A%
M">^$NILO.4^..- 3=!3M)-*UNK8LSIHGL55W5![$4 S'(SUX:_;>#(>AD%K0
M&0:+"-3*^7[;H]XT6[SAZ_6;:LZRJSFA15KHW91VN$K_H#2"E.<II((2G%#"
M6>KD=1UDC^Q5=X+K!JM =$4/[-W<@Z?U7FH,E)PW4*?]F_>H&4W C15JPSLX
M7[=_K![./9+?MXOS=4BN]G&V&,*_D_,^"?9/[??J2E9S@O,DIC&"0F(!D[P0
MD#',H(Q4AJ3*LR)QHLQ?D#.RYZC[$._%@B]&<%-%S9$8?PDG6R\QV'I7C^!A
MN%>KY1ZS O95/B=E\B;*/::>ZYC<][C?8CU*0K][,8?D]ZK)H;E_V50;'<:V
M5^)BSA#ADI!(;[Z0WH:EBC;;L!1G>G<F$$VBPF4).TD?>6'7,L"W;7$+WA:W
M:/+Q0+E7QCU-SP]LDA4*,R:AE(IIL(L"YAD74")%21SAB%/N=FDP&MQ>=P4-
MX/!'@MS.]8X&HYM#/JG#TBAB2'1M.F%'EUG-MA+A'+47"('<MYOL29VZ%RS'
MKMYOD,'[P0Y!_G(/]Y0(I1!"4!$1:Z_$]7:01QF,18HR$6>IB/F\VZ'>9;]C
MHX'5@F+-@NKJ87^8+,3+UY>FVF4AG]=2+/RNVYQP==X;!L-J^/ZPH\H,;)5I
MKMLV]3'8]7X\0W:)+DB$WRE:27^OW:(+-#T[1J=A/'-JUHMRO>NXL.1553.Y
MZ])+N]N=C[(2Z\5SD]DO<9;%VOVPV' JLC2#%*$<$IZS+",Y5PEWRK%Q5&#D
M</18!]>D&U<X[?S/F""Y.:!C\;/ZVH^OFR_J&^A<"7[Y5"X7X@T\R.\;\)M>
M*?\+F;WCB4BH;!Y7\=-F]WB"<Y+MXSN.1R/1VYO/XDD6+TN)<,0,4;R1LUR6
MW[BVNJJK*!MFN*QNG@R5H'HHZTIO.G H7U:;ZDYNYE2F@A F((YE @U%&])"
M[YDCG&.N9%J@6&S#I ?+;J-!-/,(GQX\\KL;\>8VOBDJN=5@!E;2LBM?P-GH
M=VX3@^M7\//V!FP5G &$8<1F8*<EV*O9%FMO%-5.L9V(A].)N'N'B7!HB3KY
MA'@V3)UV8MR:J@;%L*_E:AA!TS5D#0K,0;O6L".[O[^V-\UU1GRU:&^:S3V/
M_FH?W#EW\Q$90:D2+(8YQ1%,%"<P1SR!.)%ZI@E'F%H1:+TU&/MP5SXN5JMM
M+XO;YE#Q-[YL5F:IP%[#;9WDRC;3,- 47']'C0ZLVRMI1Y3IZ#/K GG(F9D6
M3?L7S>BH^KU7W- -\[X8!$7/Z\%OW,G>!H/,[CK_80,%RTCIE$;X]V+SU#G/
M;)^ZSY>+Q^94X8_5[7?M DU[N1T_>M\-BJA8)8C!&)LB=P(3R+(BAAE+$(JS
M1.]QG(Y81M1U;!:F41!\TQH"WCD>;@NB@'*OI"%EREI-\UIY-AD'O-9T<+9&
ML&FU/FK^$2;+^5CZ4MY'/7G=L_WM,WNES=S=[N:N6W9BC$39"0 >+WTDF*;O
MG6,2&G*+1)3@(CU.N>1J4:[ORHVL<(3BCR\21TG<YK_25$:8$@9Y3!.8Q"F%
M3%$$*8MPI+*L*+ 5R^.:H)%]=O)+%$6FZ8VH\T*>%NO-&WPSW7*-)J"J-0,K
MHYK#.4@?<!;'3('@<#P\:DRMQ3;&:\' 2+Z>5.R&@,/Y3B D_*+KVO8#6"!X
M656F $A]ZYMOS!<#"-,Y27_U^+(NBYB_Z1>Z+![E#'PMUYM'0[K0 Y3U^<UR
M(>L7B/X',.7I-F]_J]I7_R^!CG,L(.L[I.G[^'1'+Q9&'!RHV#SO[@!ORN4B
M7R_:KVTJA1 )*J!*< X3@A+((AWW"ARS1"F.5!39>KR#D4=V<:TL^\5[:/9U
M?^5MC)N#:L5X>*-#@^S=C[=A?O[FVD0Y^8&SNO<L_,/G)UOI9]7L+NWS#[BG
MWGYZ?7ZHL] LLVZWSX^]9^1OX+4R2>6J7'\U)XW@XZ(2R]*4F[)/N=U9U[]:
M?0US6ZB]-H$OM?1 R;;'QGCEV>X&F2S%]ECM;G;MR?]Y-N?4SD<>Y5846:J$
M2F$N<QVR"Z9_BP2%."]2G"1IE!"G ABG(D9>+#N! Q(JSN!B=]0QS%K'6-S-
M4/=NB1=M"=6V\%3 M/T#+QIXTLCO\I/N >._3$R_-.!_6I?%BZ@'O?V^*V),
M,T+TWEC )"$13*3^01G-89X*1!@NN&)69Z46LD9>BGOIH!4/ZF^J4< ^,+N&
MU_78,R *;DNT#P"/$/4:$O9!:T!$_,)8KZ^&4VQK:6)/M'MMA,GB7TM3NA&Q
M[4<F;NI]T+[4<'Z_/TMAB&&E^5,G(:')5)@+E)/"=&?+<2Q-\CB!G+,(LB2+
M4<2+2.!I>G8[*CZR8]WU5-ZJ8>AQIIJ'?WK39%-J&4C]@!/E&)X-;ZQ]W#J[
M9IQT9MS\>7:8F]58]0.TS/:<A_?NB.VJ]E^CX;7G9 3K9^TK/V0BVC_*LOBV
M6"Y- 10=K:P>%[N>+\?_GM-$))2+'!)E:I:07$&:DAPF*LU0RA'E/ Z1FN:@
MDY6C&I*LMA?H2S,8"+K=BV$:( -GLG6P_="/;:#L-0\\1LUG<]'G!\AP\X#/
M+N?-9V#_VBF?S2UD4[7[E>O=@![[]W+]F2]E?7AHLICJ)*8Y1B*+2(2TE\L+
MF*0$P3RF!52Q3"B+N:!$N!94L14^]G%@RZ$V/)P_.A7O=.2UZ[S9\.E;+D]#
MY=5AF90;O3>5U79OZUZ3Q1I_6]<W#JJN7B[?@+T:,[!3!*IR#8TJ[?'].&ER
M/B@$+/9B+7KR"C"NH)PK"^,\QE#"$*NOX6/<GF!E/(Y0)#.]U1=FO\\+F"L6
M0X8*@K @C'/KL\\^02,['71(&/HFEZ]R1QAB00A#1\!=/P0-!8?C+OB(,,1:
MPE",!Q.&CA#P)0SY(^&9YC4 D0$DG_-F6I-\CC[^3B2?\T9<)OE<>-XOHCKV
MB'M?:3SG/_EFZSD-H\NPO&[*:K-GP'-9%(424*4F+RJ3&/(T-=V5<I(JQ+!0
MS"7$&J3-R.YO)Q,8H6YQTS"4[0*IR; +'EGIOQU@.P._+RK!E^ _YN72:OXV
M"LD\"&B! K%ANDP:F06![3A4"S.H9V<Y;7>YVF@,]$./V^K"V_B-T#B.!(>(
MZ=UDPB.N-Y)8P8RF(B,%SA3%3CWD>H2-[,0.1>^+<CLVC.M#R\Y;A<+ S1E=
M,'^$KL4V]H5JZ-8G:MK6;19&GS1IL_G,I47=G:\_]6^__K3]B_Z1\TK^^M/_
M 5!+ P04    "  3@M18'BP=F55> 0#QE1  %    &UD="TR,#(T,#0R-E]P
M<F4N>&ULW+U9DUM'DB;Z/K]"M^[K]5+L2UOWC%&D6$T;2>0E6=US[PLL%H\D
MII  &T!29/_Z\<"2B41N6.+D.=EF59)()D_X\H6'NX>'^S__C^^7DY^^X7PQ
MGDW_Y2_\K^PO/^$TS?)X>O$O?_G[Y[?@_O(__OM_^V___'\!_*]?/O[VTYM9
MNKK$Z?*GUW,,2\P__3E>?OEI^05_^O?9_!_C;^&G#Y.P++/Y)<!_7_VUU[.O
M/^;CBR_+GP03:OMCVS^=_Y/D66BN)41C&"A,#$)4"BPR'H)FDHOX_US\D\R"
M9^\S^& 4_5BA'V.Z #-1J"*TM$ZO/CH93__Q3_4?,2SP)V)ONEC]\E_^\F6Y
M_/I//__\YY]__O5[G$_^.IM?_"P8DS]O?_HOFQ__?N?G_Y2KG^;>^Y]7?WK]
MHXOQ?3](G^4__Z_??_N4ON!E@/%TL0S35!=8C/]IL?K-WV8I+%=2?Y*NGQ[\
MB?HKV/X8U-\"+D#ROWY?Y+_\]__VTT]K<<QG$_R(Y:?Z[[]_?'=KR4O,R_EL
M.DY_3;/+G^M/_/QZ1H@@6E=_=_GC*_[+7Q;CRZ\3W/[>ESF6?_G+95Y"U2E3
MPM0%_^_UW_OY9MVO<UP06%9\_D:_L?GK=9$3:,#O2YQF7#.V76(R2[=^:%+%
M.KO^FY,0<;+ZW5'&\6CUU5=QL9R'M!RE8-%AR""#]!53"9PL''36JL1BB:]T
MF^5*\X*(7FEA@>FO%[-O/].'21M"UO^H I$K8=Q9;BV8T^C^=;H<+\>X^!SB
M!$?*\IBMBN (_:!2Y."9"2"R5-GZ&'7Q9]%]:[G;=.^J]-4\_32;9YR3Y=BN
M%^;ICGIO8W;S$S]_#7/Z$*0OXTG>_NTRGUVVT-9RUD)V:\T0O7_YB=@N.)]C
M_FVMF >Y6[&V)(.*JY\\5>E7"[@(X>OH$TD:J\%]/0F+Q?OR:3E+_WCU?;P8
M,?293*>"0)R#8IE,8]8>LB[:)<:8X>81$)2PB"NJ-RNMD8"3Y6+[.S>0>)*8
M_B!RAG)G74AZ )#9I?_-[#*,IR,665;)20@R(JA22$*:)]#,FBRD9"F(QEBY
M2T4_(&FLWEE360\!+;/+R]ETQ<#O>!EQ/N(I"\-Y $S!@>+T#Q>2!>V31$>R
MLBFW!LL^$?UBY5RM[H/D+!&?C!$Z.^/L3)20BS?ZA-/Q;/[';(D+P;A_<X6D
M/[WA1#E7=$B9CF+R/6GS6(@,.5BKN)%2:>W5$U[C4VL<A 4Q<"PT%62/9N,.
M'X+=YL/9))(0&6S,'%1$#TZQ BD$3%I$+E0Z%A![:QP$"/G2 '&.( <%"'&;
M#T.:14W.NLRN$+"Y)I_,6BAHBO=1QL+XT8 0QP-"O3A G"'((0%B:^GLAH\L
M@Z/?M 1G2W%<20RB,!ER9,9%F;AAY=0CPQX!"/W2 '&.((?E16QMG=L>?L(R
MBN M<&49*%<$1$0!1@N#'F5(1IQZ:+@C(&%>&B3.$>20;,36UFWY*#Y:G2@F
M0Q$H)E-1@1?,0*)3,7#F5/#'>Q'B>$#8%P>(,P0Y'$"L>? ;'H*CL$@E#JX4
MBI9*UA"CBJ!16(7248!^I'6X]?V#@.!>%A!.%^!P0'!]X$G._VJ$_H#S1 +=
MNL<R>5V"A^H3 =D]"<XK 8%$%ZTAGSF<ZD7<M]Y!(/$O"R3M!#Q0T#!VFR7)
MD45)/#AK-2B,&ESR'A+SGGQKIK0\!S-[RQV6PV(O&#/GR'=(D-D<FI)O^$A6
M*X.R)H,UJW(B>ZE3!&E$+#HJYO"IJ]"GUC@,'$//<#:5Y* 0L?:KI=CPX8OF
MP=@$C$4+BH .+@0#PI5D OU7-/IH1-Q>XS!$O+@\YSF2'!0B-LA6V^,Q%:$Y
M)LA<2*  G,+PFIS1P4F?(WE4S)YJ(]0QB'AYB<XS)#D<1*QY,-L+'1^]L,&"
M]S4W1T@&(IV!SO2?+"55U)%HN/7]PY#PPC*<ITMP."BX<8>\^*O0>_Z0M\YE
M'1.XJ&O%BD@0C*$CL#!;6% YB:/]B$?6.PPE+S7M>;:$!XD:_M<[+#%O@U,.
MBI D,PK#((;(@<Y&VB-,>5OBR:"YL]QAF'EQ>=%&\AT29#:.E&+;5*]UW"D5
M(!L?"?J9#&;"4G^ILDN"&YE/=$FW:QP&CI>7(SU#DL-!Q)H'N>&!156,C $4
M!=I @;:%&*VB,U1QCR)J'?P)#LCV^X<AX24F24^2X'!0<&WJU#;9JS(O*GL-
MR:L$BL)M(/])$*0ISEJ%W(R=>'ZH8S+F_*5F0T^2Y) 0L;%O>FO?K%<Z%"8@
MDX,-A&X/,0<-*I#S5*R4KAR-B+TU#JO1>G&YSG,D.1Q$K'G8VCF.Q3!G)'#C
M!/D_6D-P.4/1 9$GGE0ZY39-'W-2B!>6V#Q=@CVBX+H\_L>[:7V0M7V%@^^6
M>+D8&>M#2=&""=S49'T&EW0$#-83F(4W<2\X/>41R;UK]U/1V>:Y0$.I]HR-
M[5.^S_2S(R^E2:@9Q$2.3Q4,1._K3F$\HXIDX1Y[(? T&G97Z_FY2 /-S1J(
M<2#J?S6=7H7)1_PZFR]'FC'F4M(@5,W.%]H1T7'R@(1V-4NK4VP#@]U5>S8'
MW<#A9+$.!!8?<#Z>Y5^G^4U8(IVAR5M1/1UA4\VS.8A&&8J0F-68BZ/CL0DN
M;BW;3Z%WQ\ X7; #0<;G>9@NQE4H&W2C3QRS"Q"TX&3TH@?/%?E;/ =BPIGB
M69NS8V_E?NJ^NSY'SA'O(-S-M^,)_G&UK4?5PF8)2C(/2I<"7NI:?F:E9K5Z
M.;5P,F]6[*?RNR-(G"7.04#A(UZ,Z_/MZ?*/<(DCXI5GGA-$QDHM3R;/*+J*
M9Y-4Y$4H/.\8N6_5?BJ_.X7$&6(=!"S>3=-L3L9M)935R]S7LZOI<O[C]2SC
MB$N>8V84H4>3R5NJ33\<DNF3VC.1$[H4FD2FCQ#13W5XIZ!I)_1!8.AS^/XN
MDRS'9;QNI+*QD>0Q,46[ :(,Y&MG[B'4,E:9@Z?#,@2I8@/T/+!\/\7DG>*F
MA: '@9A7.9,^%IM_5?'P4<(@O.4"DLQD.G4L=)AJ#MQ$Q4(,0F,+M-RS=#\5
MY9TBY5P!#PDEK^D_W\\_S_Z<CGQD46H".BL.07DAR/=.%EB2*7AE+)<MO)8[
M"_=40/X<$#E1NH,"R/KP).?+)T5D0Q;DB2M-MC!X7<!F<L:=38:0WA =ZU5[
M*A]_%FB<(->><;$AN7KEL^D(969>.@F2U;R.)VA[U F,$=RARY;K\V+>6\OU
M5#;>$1).EV3?$*@ GF-8^=*>1XYTKD%MX0#*2N(^<P5.*)T,QF+.1<#.:CU5
MB7<%@%/EV+/^?Z,_G7SX,IMN4S719F8(O)!,+1X)(=.Q1MZQ$]8ZZ:WEX;$N
M2D]C8'_%GFK$.\+!6?+L&0N?,%W-22!<Q,_CY03)CAE54I @DB([EI.'F$@2
MRFEC:LY&[;\>.A(+^ROV5 G>$1;.DF?/6/@\#[67[J<?EW$V&:'V.@N%@%9$
M4+&0+8N%O%ZKM>'*9*?E64"XM5Q/M=T=H>!T20[$'/SZ/7T)TPM<I6Q]M@&Y
M*"!]I;J*PKMDH*B 7CC&SW41[ENUIWKNCLW"R7(=1#3Y[SB9_,\I!<*?,"SH
MN,OO%HNKU56/B44CG7*U\Y?*Y/L$;R2X6DA@/1DY_UA[UT/#R@>6[ZG>N]/X
MLH6D!P&9?YM-*$H*\]7-X'PQ(F"7J&($'E2I-01(K' --A29G? H]RLZ3X+*
MWK(]%8%W"I%S)#L(:+R^FE?AK2L'ZFE)&KE:C"1:'A$EA!Q7]\842(N404KM
MDF,A%W=>,/+8ZCW5AG<*E 9R'@1>WDWI:R$MQ]_P35B&#5NC6*))R6A(]>Q4
MEM6V#5B?/X02K31%Y#8WL/>MWE,%><=WKV?+>1!X6=G%UV&)%[/YCU$BTV@P
M.2BKNQTK/=2!'> #&FNC3<;Q!C"YM>AAZ'@I^<YSI3H(4'RZ#)/)+U<+DL9B
M,=(^2^_(^8XA!% I._"Y5!NHD&4F#$5N#4!Q:]'#0/%2<J#G2G40H/CU$N<7
M=#+^;3[[<_GE]>SR:Y@2MAT6[H0 5T@0-8L+08H )2D?LK/<QA8'R[V+'P:2
MEY(@;27EGL'R+I7YJZL\II]XM5SB8JV0MY-P,0I8*!A+%I I"8IG 5ZF A24
MZ5Q*B3*=5U;\\-J'0>6EY$\;R7@@Y>=OQ]-/R\OEK_/Y;/YZ1D2D:VZRDPX%
MM^1TZTS<%#*2A'60Q? H'?>LE+,0\S0-AR'GI>1<&\M\$ ?3IR\XF6PM9=$Z
M\&P8<,5KNM ZB'6F5!(Z*.&4ROZ\A/S=-0]#R$M)PIXITT$@XL-5G(S3V\DL
M+$?>>:=MR(#""SHZL49D:I7V459+;S&>9T+N+'D8'EY6JO54B0X"#COC>CY]
M(1DNWE\MZ_C&>OLTTHE%HV0&7^=-*J?HP S,0^'1%,GIT,RV 3X>H^$PP+RL
MQ&LSF0_$25G<%-MC_N7'QTH)3A-^QN_+7^B'_S&RD=8.4=&.J/-,Z:0$GW0"
MYEBV3(A$;GH37^5)4@Y[9?E2\K/=:& 8AHG8FH?)NVG&[_\3?XRT<MEE74!'
MHEUA[7N7<R#S:K*G'9)U;I%IV5OV,+B\K/3L.9+MN_!PG4I^.UZD,/G_,,RW
M+XMU3#)IED#J1/!V@EQT[2(0Y-%DP^GH/:\N^:&5#P/(2\G0-I%OSQAY108Q
MK^*X&K$A\XS\\PPL2P;*> TA"0,.@_8*+5/VO.OB6\L=AH:7DIH]79(#<4S6
M.%[W('A+O[<8)9>BDZI2G1/4(<K@=!(@T)*GA2I(U<81N;/T8=!X*0G9-A(>
M%$RJN5NS4)2VDJ&$B(E88,F!BX%#+L&GC-Y@..\P>6#APR#R4A*Q+:0["$]T
M\U3GPXQBM,G_/_ZZJM:WJ*)A40/*@.1/>P0?*6#+)A24,6AL<O%WW]J'P>2E
M9%T;R;@94O[YYSMB)2;_L?JCU9_4OT4!UD_UWW__^.[6]R\Q+^>SZ3C]-<TN
MU]]?W47L2.PVP8OQY=?)4VW1[WSBYQMJ]NG<?.F.QH^FC")'.OTQ_^7TKHS[
M"[R*M8U#6HX"2S+86,#;VH-8FP A%CHH:D/!B%Z1;_F$3![[_EG>X_KJZ.UX
M?ODNCZSA3)92(,KL05D4!&HIP.90'^S)X-EYA<NWENNG4UPS3=UR'4\68]_1
MPYKP57DUF1Y%EH;"85G?6_@2P3/&(&C-HV;%17'>?<G.8OVTA>M2]T>+<!B:
M_VVV[OLPXH6AETR!5Q6T260(: BT(B5#TO Z^A;:WR[83_^W+A%PDB@'>Y"_
MGDT7L\DXUQ3KJJ',*O$Z*S7U>HDG'.M/?+#-(7\,U6<>^=NNQ.M/7R]VC2;.
MO$LY(SBA:^^#F, C*Y"SBEEZ(RE"?&1#E;"(*Y5OUEGO*IPL%]O?N=E>3Y!R
MJIG8?O8C?L/I%;ZE743R77WRW\?++Z^O%DM:;O[K]S2YJI<YKQ8+<FHQ?P[?
M1XX1P\Y+D,*Y=18^I!@A6N-X1JMR3HVY/X',?ER0ELC9VJ'GTE6/I]9U&W"*
MFA:OIOG7[U]Q2ESLR(W.W^00Q*H9.,FP%M?6(SBFI+.403YVA)V"N8=HZ<>_
MZ1)83:0^$/2\+W^;S7+EYA/.OXT3+C[-)GD4L\Z*2P<EA#JL+EB(@E$ KG22
MS&2'^V/_FN#G?FKZ-4UMM'T/A!J(?@ @^DC:( *^$!MOR.!.9E_K/ML(Z\;&
MIO^X&A-Q[Z8?YK.T:G^S( F6B-H+ \J08ZBT51!-SB BE[G6TS"CFI^,)Y/;
MKR'K!(;/I;P!X/033B:U@ARG. \38OA5OAQ/5^U%ZW.E#<\C3AX B[[F*A0#
MA8&X\H;B($R>7/B ]M%B@U,@>1AE_02)G:*O Y4, &BO+NM;R?]<J>8]15O+
M,+T8QPE6-W.Y&(5@LZM!-7<43ZN,FH)JFT%S%^LE2!"Z-< >IZB?[N*= JNA
M"GH>;T0&>CF_2LNK.6V4UU_"_ (7?R"Y#K?^H$8Z\T68U&*PM<E>^Q=DKC/]
M3'4KWEU^7>5U"J*F?0,\(<4W)3#P7@<(S)=8$OJL]]HMW)M_;TQ6/]W,.X%@
MWTH;@ '\;58]A&E]+X[3].-52O.K,"&VOHT7-2=H4:>@G *K%3D.J.6JX(QX
M\E$9IX*(K;V^)TCJIW5ZIR:PI1(&@*GWRR\X?_\5JV<PO5@']1MYT<X:U1FX
MT98 20H-2G(.(>4"VDI>@DQ2R\=JO4Z!U.,4]=-7O5-$-53!\8#R:T!-\:*F
ML]M ZC8K=<.,,)$_&0J#(.O(.Q\".$.!#9=,\>"3*[FU:;J'C'Y=_2XR9N?*
M^G0+-%N&23L+],=L.KMW!XR$#(YC9L!M+;7WAH(4L7H-5"@6MMQ8_UAYX<D6
MZ$&*^G7K.P%1.PV<:X ^-SO85AU3R"W<<J$S]RH'26:4!U#:*W!%D56U)NGH
M5(FZ]4FV1T*_SG@7P#E'Q@/P?6YLYO8J:SR](OAOC.ILNO@%RVR.ZY_['+[C
MXM?O)#52U7@:YC]657JT;U*]!)NM4BY;B8P"'<\D5HI]Z\0"E>H@\% L6)FY
MDIHGAJT/O [9Z=>/[P:ZP]#]  [@:Q8WV_@7G&(9+T<L\.A8K3<57-7F=9K8
M, 629LZ%S+-@CW60/!W"=TCIU^GO#G[GR7P %I3"7J)ZY75J$;22+D&-<BE,
MR:86J-6!R,5%.A848X\]?#\%+3>K]S,UJ4N G"C9 9@3BEEOC.NKY7(^CE?+
M.B[[\^P!>\DU09Q% RS;.GXNV3JJDF+IZ$QF4M1!/XVA<S21_4Q;ZA)AW>II
M.(' +3Y'B7OO'9*<(J/-%"(%Q[Z.A@DV)[3!2M&Z?N<6 3W-9'HV(!TEX %8
MJU_#?$H87WS ^:IQQ"]A,4ZC^AJ72SJ!4ZQMK= R""EQB%'$J-%&V;S*ZUY"
M>AK3U"5:SA?X /R>?2;>C"=79+1&D0RCJ85%1CMB0P5RWSC2+[DI4:0L4O.Z
MFP=(Z6FLTW,BYQ2A#P [_X[CBR]$]ZMO%&E>;,;3O"]WVM:L-P9'K0.J"+[4
MT;R9D_/'G(7L),]!1&.:6Z*C".QI>E27..M.0<-%WV8OW>V=I.J38J$8A1RU
M&9MQC.(.'<#$'"V3JI DGP=_#Y'8T]RJ'A#81$DO[C%0;0LXQR\X78R_8?.7
M0?=]O=MG0D_RT^C-T/6:[S<ODUY-\SUK7P.6%!U+(JQ*AX$ BXY<>.N@9.\-
M[5$52FO?Y4@2&V:KA+7<1R$@JER?UNMZ52]B[<!CK6!>,VR=VSPR6]694]\E
M+A[)8ATC\0&<DZL[T7O$4GE9E9Q]#M_7/5KH]^<8%O@&U_^^%ERQ5F+B9)7I
M/ZI5+N!L\/7Y@4]<FJ3E8V^=3[ZY/HOJ?FOQGQ.;SZSA 6/Z[U-B:S+^3\S_
M.IM4A^)O83RM8G@_W<Q(&^/BU7R\H#]ZLRJQ7,ME*Z5122H:BM0AZD(^<)"N
MUOUZ(-DDQS()1K<.4KKBI5_;_-R8/'!+/"M !KQ1WL[FY)E/URW]TH_/\S!=
MA%4K<[)3JU]-5E#9BN<QD5B7&;?.@4C&@K*U5L+2H6C1L]H1W>GF3[>?@:U^
MCX^!;I^^8-/S$XO'M'%C46Y,R1OB]-OJ@=(#$G@WI3]:5O?@7S%?X+5,DN5&
M*E?%47@=0A' U<@;12Q9,J[)VSS@[<5ST=MO%6I/>V2P@!CP<5.E\*'^QLI0
MK'ZJ=G.;XW(\7WG)FZJ1#Q,R(:_R_[Y:R^+&5G#EO8T6M)$1E*JO$%*1("W3
M$J,243[6:JMU '(&*_W6W [T6'E.> SC8<$C@G@=%E_>3F9_K@S!]4%::)-^
MQ#0)B\6XC->MD^J92]S[G$SF5I-EJ,4,LI"-<'5^8G;TOY283:T3VRWI[[>8
M>, [HE,@#/RPN-[:Y 3&)(VB  OI &2:XJU$C(5B@A$F&ZN:/[<Y@*Y^RX@'
M#-J3%#> ZIE[V-FR<OWX]D-],DX:/J3"K$B-@5,X(W.H>U'6HL?54W*;;2+!
M)-^ZHU=C%OIU[I\S?]JG[H<-_8/8359RZZ,"C5E6=@5X9@W)7SHC*6XQX;'I
ME(VAW@S:G3GA X%V<]T.PK-^A.%1*%)F907((&O;+"_!Y\S &<;1,9%YR<\'
MU'[]WH& \"B=-+.5719\_!(H2$WXZ0O6QCGGE7?<_E;[8HY':&U?NO%V/*7%
MQF%"H?WX5B=A+F/TEA#E@C+KIT+.&@%(+FH41CC>OJ'6 72=W>5IU4KHFDN#
M4F5A.+G85H&J8_N"DPA8/&VI)+UPK0LU;E,PF&*--DBXT]'I='$/(!A>4[\9
ML77-A$]!4^"N(8=0@RB*I&)B')![[C%Z$U3KJ[5[">D7.N=H]EZ0G"/F 6"E
M)H;J<4W_^O4_KL;?PJ36X[U:O@[S^0_RWOXM3*YPY-$(Y;@"^@"=V('7#NO,
M0#%T>HOD=<#FWLXAA T!2V<!8-^[::Z- 4#LTQ>*=S_C_/+F8FHQ<J)V]A<*
M4-<I/IE"6F^* BLRDUGDK$+K6YC[Z.CW9KX]@,Z6]0#P\BJEV171_1$3TA:@
MD)(\_(V01L4Y%T)M*<5K+UAN(H3*BTM>^,0$M[GUJ]C'Z.DWL=4>/\UD/P <
MU2TPI1_Y4?N%25^P6)? >O(!%?<)0@KT#VF-=#$K;-XP:7?]?K-$[7%RLFP'
M@(O5E<,MD8PX=UP(4T<1>^* D2\85&(@"F$:!=KL.RG5O$5%OTF<]A@Y4\X#
M0,IMXF4,66*RD$4J%% B ^>U!BT$LR8)H9N#Y'A\='9/V,%9<[)T!W#1\6%>
M^\(M?]0RDF7M?4GN^M=-(<E(VEJ'*#B$8.HXJR A9#*(0A:3F ^1EPZZOCQ(
MSQ"<W"81=S.A#\"VU&$<?XXGDY$2L?"D3=TS#%2]1R<GRX 0'+W56OG2.F.Y
M77L(WFL38)PDS & 8+]7/.'X>@S&-4\ENBR]+2 Y&445K0''LP%9IUQ'56RQ
MK5],'4+7$%S:)N!IKH0! .O-9MGKCFK7K(VBE[&@#2"]5+5QEH7@HX# 6/!!
M,)E$ZRJHAZD9@L_;!$2-!#X Z.RX[?4B?^.>U1$6J&P"I>J$3E:KK[P28+6P
M*'CRF77R,&>?D"$XP4T <[Z8!X"5S803GRB4D[6G_VHDNW1TZD8"?$AH6(Z!
MT!\[B8SZ;8'9_"[I*$$.( CZ;1SB>+)^YSC-GY:S](\OLPD)?5$]\^6/FPI1
M83 5"A-MKA6B=09 9+(^<U<N:AD=BM85C(?2-IBGW=W<9'>BH@%8GAV^]G,2
MTAA?#.U#X80%90(G3FP$*Z-.B0G%8VMK]# U_=Y0=J/]AR%VCBH& *HW&*\O
M.Y(L*G">(=$>HY,XD$0"1G")SF@?R4Z+UCF<G>4' YNS-'K'1SY-O - QO9>
M[$/X42_%MEPP;UVL[XYM2O4FWC@(1B<(7"FN++*26I<KWT])OZ=81WAI(/0!
M0&<;&=;*59PN-G66:X']V/*$+"597[@H$ZN8G*?#WFD04I9 ?A_7N75!WR%T
M]9L@[,P,-5;( $"V&KBVDWVXEMC(*.%RL!YJ&KQF'R1X^B?HG#FS7L@DFY?]
M/41,ORG#[JQ4 ]$/ $.KC,1=(8TD4NAJ9)T+KB*HJ )$7\?9,!3!U/ CM;Z@
M>("4?K.%'>&GA=@'@)[[.."Z.%TR8&(45 2;P3'T8)!8D]I@^_%V)V*FLX1A
M1Y@Y4]A#2!W-IA>U3K'&!*N*UZ_C^NGZKOA]G(POUM.&1J)X*WQ <'5DJ I*
M$%<4H9+>@W6HE$JMRT0/HVPP#G>'<7U[%0W 3CW:&X1<P_$4\VZ+D!U1[^3I
MG0C%*#20A:7-RQRQGP1"*C8I,MLL\^85'BT('XQ#WQULGU_! T#U72=TAQ=>
M)U4F.AIX3G7X,NU0GT0&SW)R&)U/S2=@/T;/8** [C#83!T#@-:=F^W=#5/K
MKN@ 2$9Z((?%@'**@T=K0-B5TR%C%*V/Z"=(&DR8T!W 6BIE !C;CX%V#;'&
M%%U,8+@.Q(DP$,AO!FU-"MD7C3?S6CJ*/H=2?? LR&JDB@& :H>)44&>2TJU
M0:ACH#RO@P(=F6!A8F(E<EM:]S7;6;[?,H7GO@0\2M@#"$5?SRXOQ^NG<JO&
M%77H[05.4V6%F]I2HM:3AD0B$<J2&QBQWE59#"H$%UL_-WN$G'X'>CX+CEHI
M8P#VYQ$)1:ZS2D71><PING E0<!:VV%5$5P$(5G[J2)G5<!T-L3S65#52!4#
M %7='[/IBI_U8W"RIHKYK$'EI&A3: E>^E [ES)>1"[!=M <[A8-?3<#::/;
M>PS1R8(> %!>Y;RJ(@N3#V%,<<(F?3<*F1O.'#EQ6.<"(GER3C'Z):DY\B30
MZ-:W.0^0TG?E72>P:2'V :#G(RY#391MITN^2NGJ\FI2&SW5%%H:UU)EJXR*
M!31*DDU]]1=%H?W 8GT3X921K4L6GJ:J[T:3G6"JL3(& *\=#@YJ .L33T&R
M H5[8B\D#\%$!4PF#)$9Y=OWNSJ.Q+[;0'9CS#I4TP!0>%=J(\=9Y$QG\BIK
M"T$1#$1O')10G)+>*M6\UN$N%7UW<^P$2V<*>P!Y@M_'T]F<Z+YN:$I!AQ8E
M&9"\/NQ"QR!2" HZ<L-T;8K1O$1XGX9^$Y(=0>4L00_2KIS4^IF.]!B9\F"\
M=J",]N0RJ@S1!*EL*#+YUDW7VE#>;[KSV>Q7YTH=@,U[*CLSTEKFF.MKZ)@Y
M.9[!@O<\05(^YL*DP=C:!CY%TV'I"-85_IX[W7Z^7EY>+^0/*TU\P>4XA<EM
M-LYKC'S[PQUW27Z$B^=LF9RS"$EF!:9.[E"8R2K6YX4E:(8J6Y]*ZQO69VF9
M/)G,_JS"?CN;OYE=Q66YFMQM;[<MGXPV"X;>@S!.D!!, N^0 RLEL2(-YZEY
MA'D,@7WG6!OCZ$ZDV9FR!N /[J22:<N_GZ^DF5=9Y0\X__2%5##2 ;V,20+9
M;?(+M.<0!!T+HN1@K#)DO5H'G@>0U7>*MF/4M5;,L+"VHG_QZFKYA:*I_\0\
M\DQD52)MFQ08N;_:U,8"&1AR3+ID1^%4=QC;)Z?O5.WS8>LL10P14^\6BRMB
M@_NDA4!?7ZA06)YI?_A$!MDF"LE-=,XU?VC_ "E]9U^?&TLG*&"(.'I_M5PL
MP[3&T"-O<PC).7#>4, B4$/T4D#RTF=O(R^FPP/P#CU]YV"?&U&GJJ(9K+J,
M':_%N9B538[@O)CQG@^VCQ6?HKI]C/A(LL(Q9W*V&G(2@4R-H2.+$29X9B%+
MJU+BK0OA#B+L_%SM9I'/-< 8&2NT9M)"B06!E(_@I+.T$Y)VH0@G4NO7TK<I
M&$R<UP@+=].H)\M[ "?8-?5KB=3[T-ET5:OX?;P85?*CY XR!@U*Z@S1&099
M62.KK$SS&.Y1@@:"I1,T_1!HSA;[ #"TQ\.;V6483T<E&Z&=Y$ \K*XF H3:
M1DXJQ:WE'(UK7<9W+R$#P<SYBIZUEOH H+-.&/^.EQ'G(\&D=)X58+H.118)
M(1+!(#GGEFOZ5W-KL[M^OT!IH,[]9Z.GRG8 N-CQYC<,H/3*,#*O0O%$UC87
M"&@=),F5\@J%B:W?N]PAHE^$G*[/AT.E$X0[ '0\4)*Z82:);),+="X7F4'%
M&" *%*!-%+(4;XMK?8'[*$']IIR;H::=T > H/T"U"T7=. Z:P/XHOFZ6VUT
MSM1W7IQ'=(PUGZET/R7]II*;8::!F < E@.*1C>,9:Z(D<Q!B_J>*UH&040Z
MO7.13DH3B=7GK^H] E*=993;F:%.E#$ E-U?7G5M7I5-07N06#.C23@(3-7^
MR5:0M.I3P=87$X_1T^^1UMY5;B;[ >#H.N+\C2SO._K/Q4C+((@)A/5KKQ)J
M_W4RO\D59KER030?=GN7BH'<O#?,W9PFX % A,SDO#:]>H/K?[^;WLV-?J2]
M\'8V_S/,\RADZY12K+Z"H!U@) ,O8B1&*6PHPFB66^>0CR1Q($F>$Q%Q9WQ/
M=^H9 /H>O:D+MBA/42B($.NA78=N1N:AJ. Q<R\XMNZ]<_:E:6>XZA0(Q]R?
M'J.5DQ'V%>?C6;TCG"^']&@A>!9DP0"X*DE(7H/3Y%>02\&T%.A<:3TD\QD?
M+71VX#XG=GO0]&!0_F$^*^-E?;0XPDI]S@F$2H;"*DEA564B9I]YO6'0I?58
MO9O5^\U8/"?:3I3XR8CYAO,X:]F6[*E'K]R*(FMW9E$".<?.$5=DY<&2U\R8
M<3$W+UP:_H/DYT18<RT-P.M[,_XVSCC-BQU'XW58?!E)[87SJ"#'VEM+5#X*
MDY"R0H<R9@KB&Z/M(5KZ+9%[3H0UT<;QJ/)K5$WQHN;OVGEYZ^K1-U?S>N*O
M#]B5#[OZYR\DRUNC,49:R1!8;55J?:HS=0T%_D771V7""K2IJ$[>H1Y'9K\O
MH9_=?^M0AP,P?P^PN'J9\1"'/&*TGOS/XHA-7P<"2>E!>R:%1QXEMBZ@.9[*
M?E]&#P"DK30X%(Q^Q*]7\_2E\O)JFC^N^HS?LRM'+"CB060(K$A0G)S@&&6"
M5%@-FJ3QW83%!]+7;V/)9\=E%UH;SO'^)'?K?G:2>Y-#(=GQVL^NYEQ]*J%.
M#5%:!>NE;WW[>@1Y_3:E'!XBC]?9( #Y*O_OJ\6ZG>OGV0,U,:O-%O>/@X](
M4EZ,E_@)Y]_&"==B^(AI=C%=?64M$5MO&#%%,+Q.2>+:@=?90')>"_)Z;&@^
M8ZAKGGKN7_&<V!\4/ ;@4^QW/EISM:^1418E:VD88)VVH[B5X'VI>36T@B6)
MKGEGH,,H.PRZ_R5N@#I0U0  ^.B]EL+$."\(6<=:]TK_""Q'R$QQ4U(PTG?8
M:OC$V\;_$E<VS=1RYD7,K].&?NKY5U R%!,M&M!,D$B9UN"1&6#<)"E$CIEW
MXL(^SV4C_R]Q_].#JIN"_'G?);=L;/74UY_CQ?*SMKAZY,EJ" S1, ;"4?RN
MG)<0HC(41VGCK!4!5?O\RS,\7]XY&*XO*;:M:VAW3^A?M'U-4@ZC@!31UIMZ
M#\X4#8Z\X)(C:CHFNCNW'Z1K(%5HS7#SR*'=1C<OKM="O2-[.YG]N6AHR6Z^
MV:W]>H#V]E;K>J&;-J6^%CPF"RES"<H[.FX9#R"$)E>/V3K.K3MC=8>>LTOU
M<5F_^6$^JYL@__+C[XLZN.X]G;:A3O=YE9:T/5:M++<2\(;G@DB[H@@/*D</
MT?@ =.RS0B+PI?G0M^.I'(S].@]!=ZK[NU77 (+<G9*DI+2DJ(D#:E5JJ68M
M/"8>&%&L+>?"L=8%M$<6@74&H*[U_' =V#%"'P!<;B4I:X9QFL83)/'=E!E]
MGATK2HQ2Q*)<'=>>007A**3R!I)"QK,C>7:;MV[$1[]5L\\,X=Z!,(#-\ 9I
MY31>J9C^>X++]:SM5Y<UF/_/]4T^^:V8)%/@<_+U>;.#:'TAGHQ*2G*%H7F1
MV@%T]6MO^T?/G1G"C54Y 'BN9%?'O]_31WA4(@5;47D(W 7RBF0&%SFKW1.M
M#KKPDEO[U8_1TZ_M'!P<FZEN #"\,YY[U::?_OV:?G-,_ 1;=)!)0S*H25#$
M3RPF0>3)RV2CYZEU?Y:G:.KW2<+@X-A4A0. Y -%=P6YL\ISX%B;2WCRQ<F^
MUYXDAH3'D&%HWK/N]-+(SMXK# Y^#=0U -#]+8RGBRH\7+R?_OJ]RNEJO/BR
M3EN\P;@<\:)RCC)"](6!2G6J:@P*BA!!1U/08.N^HD\2U>_#AL%!L:T2SRU+
M^]PNKB>.EN\NOX;QO/+RFG;<!2Y&,F)ASD=(MD3:8I93A&@R^!(#%TG3_YIW
MI;F7DGY?- P.A@W4-0"+N'JL5N^X27)K2?[ZO9IW'&F1K=->@>$4;JFZG;Q5
M";PL3.DB,,76J<@'B>GWG<+@H-=&:<.Q?'?K/ZXEMRFZO!9;,I%+9EUM/B9
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MW/O[3=?)$1I!+""Y!";4>":17^!X!%2Z<,NB0NQ@MM\35/7[J&H(Q^?I2AK
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MJD)@Z%0TW?FDSX'WSI+BSX_WY]3UH$#^!VZ]P/48V/W)UL'$)#@4YP.=8%*
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M!)L])#YQE/!N3L_YMIRM\KN_8CX[R_-X5=9;LG"2R032Y%2+$#:-DP64Y*-
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MM#T 0GN(O@,0;7R'S<B]JTYB%->(6+P%;FE!J1@9,: 8,&6T2Q:M9X,:,.V
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M"*Z<L%\6R^7BG[/YZ>I$)FW1JP"R4J^<]811X2!;ICUC.4K3W!0\)&.Z4/@
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MSL3F8PJ?HJ4GS.RNXV<ALZ? I\Y(%XSK>U'DG\O%Z1+/MZ?4#)U6TEG @'6
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M%;-AZMFJNT/WO.'FZ2B.H9N(N0.8W)7)+[B:K3X3+9@^SF_7'O"3>L*918S
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MH6I_G?>#H)M'^ZMY?AV^S<["Z7IW?A]/9Y_7IB*%)5.9\RRX.L!.2:? )U7
M,J>PN"*2:ST)9[N5]=3-VC[8:F21W<_)1?WTN-<*;TK!=#;[CC?R5SK_C44G
M@6F6R9<X@V!EA&*D%/0'E)2,P0"\]0)[:I8=^W)A7_MT$*0]$W.NKT\N!IIM
MZ+##Z8?%:CV)?#/./I[2?[BBZ#0IB\8KP"!KS2LES2[[#-PJ%J)/3)36!VNS
MQ??4RGN07&(DNQXO*_UOX>Q\2>+C:D1^^OL?.1!3_3/2C<M9KVGKJX,.0?I
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MP.F7Q1)GG^>7L=*E0)M^39F\2R0#9"4S:<E+< $5&(JVT5J#)K=.2IY<4"^
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M_AU79]77;DNBO77<>%L;.S6%GU42$3S(Y!E#)S1O_N[X^&JF/4G' 5 CW7>
MHD<:^ZS32IE" L0:%?#DP2LMR2M*1*DB^47K.&V/IMK#5A#U%X<U,&*74+S,
MNYSFQAD+2/\'R@L/E&D%R"DP]*IR+(S4+70<7;B#[+QU%^X I7< GFT:/R46
MG:7Q8%.E'++1T]D>$W#.24U&R91;#\HZXB[<(?;?H0MWB#$ZP->[Q3Q?2;41
M@3XC;# 9<F%UZ#RMWFDK('E>HN N,]6:4.V!97017[7%S[[*GA OJ^79R=79
M_P]<?%Z&;U]F*9RN=VJ3HTBJ.& \9#KD4X20,9!FN'+9I^+X5CL0?>4&6NC?
MKI'RY (Z+&?M)YIJ9[JI\8>?[XJP<4HO2R[%%]"J\G4PH<$[Y""5Y-[&J+/9
M*JQ_#G^/+6":LZZA81>MM3PQ5-Z<+Q??<+/%NJ2EYY0"I_JVJKB5X'7*4(PQ
M,@<CM<8&Z+CYS0D!T<9\BP:ZG! #ZU'+RQ\G_^_#B7?:.)8L2)MDK>STM?<$
M(3*9$D=AU9-\^BM,_^?SXOO_W?S$"P!L_N7:_M??FR9L:6_Y'37804C[Y''\
M]JK66 DZ,FT@I5AA*:<4E0L]<H@YT"%*D9>+!WVR>SNHL_VPS0C]!#,C&KDK
MZ+Y;5 W247[!LQY<0)$EN:PM=)@G3EF"81K0NBQXL9J)\<!Z>RT=/\CM:/='
MH;6'$5Y$C\#UWZT:7E45UT&GEQELN'\)<J &@CT6=OCN@E9:[(!J/R0M1)!(
MD#>T8PND2* V=-D<N.:>E\);SR;JC6I_G*/0*K1*R @YECH+VC/P++HZX5QY
M1T<CLP?AYG^!;0N'PON$30U#T--5E/-0-;0S-2QD$%&FFJMP(%UGX()%RF(B
M\N8$/G\W-0S%T*"FA@$&[0J<#U3*AJR2L=& %RF0DI*BC,4)R,D)$2TW+K:?
MN'Z<30U#K#ZDJ6&("3J T]/U]"%ZPWPL8&RJCTF*05#&0HB&%R64"6ZKF\F_
M0%/#(+L/:FH88H1C:&I0G(0AW8#0-??EM)T'76@[#]9&[5R6V3Z3B[V IH9=
M\#**BCO8A!X)"=8;=3;<D*(XY!(HQ$5E(*9@(3),A5%4@*%U2O?$<GH!5-?A
M5BMS]HO,C0\+70N7DP6GI0=E ZN_HHV:&V:"UBJ(UH4H3RYHVN.QF=FW@],.
M-N@ 4&L^Q???U@Q$]4KM@ISH&\Y7ER^84:LZ!;=>#;-*IA@#.&411$)TUK/"
M7>L-[]E%=0FL70"P&-,:'<#K]6)U]K[\'DYQM1& %^953!(TCZ*661API3X/
M\&PR9]*JYO.P[RUBVE-S//CLI^T.X++E:Q5/CF&M<2Y%Q2I+!N<%@L["6@R!
M6SD>;^3>3]$OH4NA]>W7GD;N +I/$1,_2 /[$Q9*G:Z)8#?1R3Q7!N/B@R3Y
M%$4EM2$RD<M6L@!(3B;G96"N>2375(!>+D;:(>RADWH2<P_'NK_ ^AP_U[3\
MTT$@?Z\S;CM%9$GQ.%8R%UN)Z^FP@Q@X@N2:2=IJ4FK>[=I>BHZ3\O'!?P##
M3WRIN+7KDV@[:L-85"*H!,C1D#:$@YB-AJ"R\2DX+'>9RAZ\DAQ_I1T'//M!
MO4-#[[WQ+\["Z32QSEWI+W12%8"HG1,L0>:>%,#H#/0Q:XC6)V2R<.5;O^BT
M6WW';30313EM#'WL(<[C6A#,2)DCK_Y.>5-V";SE!K@VPJJ40PBM,]?&(G1<
M;3UE<-/&Y"\BLGE4%8^JB*$)(4<!1O+:;Q$8Q!(T,(&1>^U-0G>P<&?P\CLD
MD.\M!AH7$JT#HRE+R-<ESY6.?UWUO)C?^&_?+<YZJ"5OL<+#%Y4WUVL'U>7:
MLZ"%H4-%)_H'G2K@K+0@O8N\1*ZQ.1_*7Z.Z/!7MA#8(@J.OW$VY<E($$#$H
MYWD*J.0A%/MW=?G.>)^PNGP(>CIXN'BJ3"(ASZZH BD:BAJ"HJ2M#GBFB):+
M%#S%L*V)+?<M=GH)M>6#$#2@V&F(.?M%YN:A/*4HI68)F//K"-&!0PIK45GT
MK@@ABS\,-GLO=AID]D'%3D-LT &@GB^OL488IB2"#)5].T=;!VIYB%Y&QVU,
M.8_R_G2LQ4Z# #"XV&F(-3J UY,-'BG4M#5;T,$CJ.02[>F.D53"!,91ZX-T
M+ [JTWH)A</[G*7-#-H5.!\H_K<L^A15!F&D 44^#<$6 Y@D=XD')>7?PV>&
M6WU(G]80$W0 IZ=;A'2R)7-E(+/"*O-#'<">-.@8N7?:*Y?_'CZS@]T']6D-
M,4('B-KR(KLPID11CH*-2/HJ08)W/@"7O#:F!2?R0>]FWO[E:C];GZA[&KE7
MZ-ZZ5GZ __9*['=X=E**P"RUA.ATKCJE8\4'VA3J]"BDM,WK]I3$>RZZETVU
M'9*V >MH9FU=]##E*];K6Z]Z]-=_";/EO\+I.5Y00ZT6Y4'ESN8_A=,P3_C[
M%\1#/6@U7NSAW[;&U'8'SUP4!4G/% )W(5&@701X2_^:4RY&6:6,;%TB-N$S
MUY7M5C<@<--.#QW3-^/*J\/^!A?WQ<%=0M319X3B,@6$U@6(+!<H1L8H@S8Y
MM Z=QI.FP]-G!#S?B_C[0$<',=<C,S!HF5EP88"E>B$950#/Z%<8Z;R77B.[
M2^8PY<":T?#9"TZV&U SQ&A=0N]RE)3-: QE1D6F DKY"+[0KRR:[(SQFJO6
MKP='-:!FD)VW'5 S1.D=@&>;F2@J^9BL2*!=H1-"Y00ADHN9Z(PH+JEDVW.Z
M'>N FD'VWV% S1!C=("OAV:FY&PBYUP#);RE#H9B$$6JW(P8F"W%)M::PN%X
M!M3L@Y]]E=T!7IY\[5!&<TP^0*H3=U3*"J*T!H*.UM>77U'T 5*O/AXM.XVI
MFAFP*S ^\%*2HE,140$*6UM$:QE+%I;\MB /(2?)6T=71_I(.<CJ0QXIAYB@
M S@]PV-H8\[<26"A3IYS5D$(A8,L7C%M??+B;S+)'>P^C$QR@!$Z0-1#V_T%
M?VMR+!KR,8H/ZZ6.8N!B(%V9$"SZJ'-HO3D]MI9I'R([/26;&*Y3 &Z<U*&A
MT!(Y,$>:4;+>*TJTH 574CF'L;2N,'M\-=-N9FVLO06$=E!]!R#ZL,1O898W
MQ9;UWOJBS6_]RG3V:K7"LTL",4LYD%/60PY(H40EI_9H*NF<<LP%C?1;C4&U
M_>KZ ]DN>%@<Q#@=P&XMQRT!T$N?-/>4;%=>8,<1(@H-O+Z$!)E2+J/07 T&
MT6A)Y4@@VD_5.V/E.R[CHE4C^JN4EN=XY0B7 Q6]#SY@ I;KF$[:T.MU7(;H
MA159^ZCTG=+"QWO%'_S"M.%38SPT5&8O&\C;68BST_7CZB4G:I%UH)@ 0K@"
M%;V&J*6@G%=S;I GDUJ_^3V\DFGY8,;<2O93>@?0N9&,7&4H;Z_9$;S7P:<(
MW ?*+)#QRL"4( :EC&>^>#O>G*X'%C0MD#I-X=J9L"L\7LGR_D:5UOKH/J&U
MZVRK4^4Z:2-I#8Y;DDE*$;2@S"6ZT6#Y^+IZN:C:&P:/ JR13?K'V>6^_N.D
MH%/2YLI$)^M%7,G@/2L037)>V:C+B&023Z^MEUZU ^-M-]N\L$&J%SE,)6ZY
M&8&$6E"7P]F5WA;S\!$3_4PZ='X*J]G!YZKNN\XIQZPVU7$/!<,V^RQ+J9,1
M*-6MC7JQ4E\%-#EYYXT^3(O0@0N&+\SXZD$SOI]?F:X2=2WFRUN6O C.N!5T
MB&$ H>K<^E(L.*,]<)>Y94D;EUJ_]C=;?"\QR;AH?;0<^*"V[R"LN1+\IQ]7
MO_R/&2YI45]^O,7O>+J^[@]2H9&)@?$N@ZJSR$-@)%^RE)XFD55H_22RW<HZ
MJ0X^+&P> V\[&_:$S(T>UUO!??DV%S/9.\TM.HC::7+^FE=XV@L*Y\'GF")C
MS6L0ABRP$YPV1,AC(&QNKIZP^.O\V_G9:JTQOKF_2XJAY#Z!B93"*D,Y111.
M4(H17(I&%Q%:WRT\L9Q.<-8>!(_!;4^+] 2N/0Z1ZSP:M=3:^@*&!*U14 $?
M(@?K#7-*V!+<:'!L(4 GI:E]'.@'1T0'[G WG3Y!RW))]8$D,UXO;2SXB)K^
M-3H9D4G;?++!W35TLJL>'@Z/7K3M8)NNL'5#@R<,B\>UJSJM2(@0P/&20#JC
MG+,A.#,>9\2-A1S_UM<:9;M:J2NHK?5Y10[SOOPRFX=YFH73#XO5K%KW3;WI
M6\WHU'@S/_^ZIO%;S$^$,MR[F('S]8#2G,!+;RE8RCPJ;X)7X_'<[;;F3@IF
M.P+P 6S?%=:OGEJ&R\Q$2E%I"SDQ5^>U&O!%*4A:(R9!?X3CE0[LONY.*@PZ
MPOR!,/ BWN?>ET)VJ[2M#[T='>;M;;LU'/Y=;0?==/!FEB6+45L!:+VN7<X,
MG(H1 D^4^)4@I7H!LR36Y9!/VN<B"\Z((:%TP$JNS0%9@==H@;%*2)Q9-FFK
M(M/G/W6\[U9#$'.K'+6Q_KL*)!YHQF1<:,,YTFE 1X(*F8/+6(!+PX2/7O/0
MFJ=^[Q[JYH ;Q?!#&J&'6*$K1#W0C:E<%$9I ZF0^ZE0:52XYD"JX]R7B%[\
MW0@]W.I#&J&'F* #.#W=@RN+UK$HK"R5E8)8ASJ5TX)0KCA>#/.L>=W'D39"
M#[+[H$;H(4:8>DSDDQOY=5Z6@RJ\JDB87(=#&$?"T;9.\D3F4K3:^+VCJ(E?
M8,8\V,;2=0<;TMT;^>NH,M.F+(6L;(@)%)>\,N8R0)&85:EZ2.L!N8^MI==(
M:4>C/_,FLI,%ND+2$T7[=-@G9K*&7+@E13D)L0@/Y'2)RQ*-M'_E1HI]$+!+
M#\40<TS:B_J(JMXM-K<\'Q:GL_3CS2FF=;,=YO/U+TZ4%-8927&G9!0F6%7
M.R:!>R--,BRE$9LIMEIB+ST5HT"OO9'V)6=OGA2>GM*/78;3]_%T]OFBP6[Q
M$<_.E_,ZE?E$YJ1$*@6RK$R;+I"'H8O @R7G\TEE.=Z&]]SJ>IF4,0KVFIJF
M,]@]OJ5?$,U?^-NKSW76\MFU(DX"4U8F<K+ =02E>*RYC0*MG4,C.:81F=MV
M7/2T#V23G<WM#+E[;'AG''OCNIDK519O4$5*L6VIPB19(-01@[5<V ?,&5U[
MEMTG%M1K MLZW]C7%OTG'=>=FR*ZXD3V8"/YBC)14Z1K)0B?I0E*1._&:T5K
MT%5[@.1C;SCLVE4[Q#:MA_,T+5IY-M*5RAIA3;T!]QQ43!3IJA# 1X<Q2:FU
M&:\4=>ME]I*2C ?(<2S6U7YX'2Q\G'W^<E8CWW0:9E_7H6\049C$%%02$ I]
M'0.7Z23Q,@@7;"AX]UE]E*SD_LIZR4C&@UXSNW2%MJ=W^*=C6>E*<$PEVN\-
MHUA6"'!!!#!.EF QHN7CS;S=8^&])"93G=OMK+KWH;YWHE*#[SL)V+6<ETIE
MP?D<@@0>+5:1+#@=)1CILT"#*/2=/.7!9[3GOC/-'CAV^M%<PQ._O3XFRY7/
M_&.Y6*UN_]F)S+F0YS'(GI-\D2+=$,DI!+HBG(R%H=@#04]]>[I'M+96WP).
MS4PPX<W) _+=<<=W6]RL&RN%RH4#"W7LJ1$>@JE\1<$RVG]]PKMDZ-O@;?A"
MIKM1.13X1C9.ER?D?9D?NG,_NWGG'KC.4:H,B+4QA5L+46 &)[Q%3VZIQ0X;
MX/"%3'?&3@?(IL:9'I!/A*M/1J9U'+1FQ<:B++!47<_1(> K&29:&;A"QHP9
MK[AEZV5.DV",!M)#&:S9J=VZL>?7^7?Z.8OE7ITY#_R0-JTUSZVN46_,Y6=^
M/-3)X+-W+%M(QI?*>9#!<S*U2!2:)993QM8L]$\L9]^-Z>I'_S*;SU9?,/]C
ML<AU(WY?/I*5EM]Q=5(S<61HP&*-1M%S\#H@Z& Y5UZ;TOQ!=HME3?LBT0HA
M=_>=UO;HX +N2J3_7"S__>O\PW*1<'5')$<2H:X4"Y+R=*5IJPZE1(@E2AZ%
MI!2^=0G4%LN:]HUA=(@ULD=/$/L8_OBM'LBS<'I'HE"<$B(BF.(3J#H"Q7G4
ME:I&.[2L!-VZL>KY54W[DC ZP-I8HR=\U3 O"1&,*8Q28A2@I$,@99%^%*K$
MR4-R;MW#?_/[T][HCXZ9H1KN-I"N!_<?,\H/-B.9?J4?.O]<R0 N4M_7Z[Z>
MU6Q^^1=W#[=W_E2;H+R-I(U"]\MOO)KGN^MX +*2:\[J_.;$10"5,$!@5A#<
M5"@6DW6N-?_,H 7NNW']GBB$/#_%]^7RLY?$;<EI<B4(,5HZWU'2K^A\1ZVC
M*NBT*ZV?,Q]9RK1A_'AHN;O!M;!$!R?A%=W)3^?DT!0W_HZ?+W@ :@<MYJ(E
M"X8V_UJM;'6I$:,"EY34@FD7FE]9/;F@:<'5Q.1W8=1,_SV Z6+MFVY98PS*
MK!D4KC@HKQAXA@EX2KZD;(IJ'E?=6L#$8&EGV+N0V5G+$[]>OP[+/%M\#ZMT
M?AJ6F\[GHF)BB7E( K$6O$F@G($\R$<1"LM*,?-,N/38SYX8 +N;:=%09Q/;
M_!V>+Q>K-,-YJB_CY]\N9P\JXS [#5H*75F[6;WSRI!+HN31JB"W*FMYY,=/
M>]'3QO(M-#>Q\7_#/$OA]/?SY>?ZOQL!A#1($E@P2E1.S$C9H%(2M+-%>*LU
MI89;F/[!'S[M!4P;P^^OM:FKE&;T[V>XNHE:H8I(HF@P&&CY5M*!ET(!EH7E
MH?"0K=W"Z _\Z&GO3]J8?%^-=1#[78;$;Z^)&9/W3M3WTN0S*)X91",CB(#1
M)><%UZW? .XM8N*#8(2$83\]=P24CXO3TU\6RS\HP#DQ%,)(1 N6U;&*D1=P
M05I@,FK&N,O&MVZ4>F 9?5Q=[&C81V"RJY8[ LI)B2[D'"2D7'=5D11$[@($
MATG%(&/$UA.>+[_=!R1V-N(CH!BDT9V1\ V7LT6F/'AYUA0/K]+_G,]H$3^?
M5S;@#^NOG.BH/0\&@=0022W*@?>> \7$C!1EK8RMJSB>6L^TY\Y8N-E;\QWM
M*A_.E^E+6.&KE&H96&T_R/]]OCI;W]&<6*^SH4@+BI6RGM"!HNUDP6%PA2=N
MC1[K'>')A4V;WXR%JW:VZ A@_[F<G9WA_'TI'_'THOKT]U!CP<L+P7_.9V<G
MRAL4'ADD%6KYJ^;@K$]0)Y&PK#-/KG5S[J %3IM=C06X]K;IIT7\4L8-X>0E
M7?FG99BO3M>6^P>EJF\7J]6)3H[G0 HL.CI0ILX=+9P!SSS2_U+JG<8Z-)]?
MW5;(T\>&O,96Z6B_.U$J,5]G,+*B BB?-3A7''#C8LAU-IX:"TU;8<4<&U8&
M:73/,/W-_"9=U*%K9]Z%Y7)=G#]>S<R]3QRF5N9IR2:ID>$E9&XIVW->$JJP
M9'#:2Y!>>"?K'&HSUKW<I#4R!:,,C/)=Q[BJ#R<1R(DHK/3HC6*TK:;6<K^
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MA=FRBK N..69!:\D U:K[&FGK PX-H+$8C7F'&)I??'W\$KZZ)II YH&NNX
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M__>E4BCB?+66XB.N.X1>+U9GJW6 '^NF]R'\6#.6795Z2Y^MMZZ BKY>2<0
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MGI5TKG$M0^+;$0,=WZR?G0V_L_XZB#Z?/1,?.Q+?7A5.6AV$0L/ <Q);69?
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MDH9$"RLF;R(J(:-M_=+SD!R]@68?#\\;F[L#R) 9<+F:IMM*R,B$%BQ ]MR
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M"T564-(R<(5Y^B6B"%J6^&1:>_+D4#MY[#XYU"[FZV"CN$]3I*3 (M"!%U:
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M-PM)KKS 6%&ZUM5)5T=N!&_!!^V@,%LXJN)X.$(+3RMU>BOV'3XQ& <)7<9
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M_.#:2;)=P2R'I^1\6+9Q(=<("L\STQWNER[Q]CO&U4:K7QN=+&<B:QG6T^1
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M$DW0\"("J<N)87_,9U_JG(3+R6&;J6$Q%YFEH%C75>9PE A.Y@+6.=HEN*>
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MS:EU,<##DHS;I3 ,:!K8?.0^M ]AL9K13_HZ_?[7;'IUG$:>F8I<@+6JU&D
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M%EJWX?["?'\3IB&VB_D8JO#B!WNI0U6W%4/D6I=*@!F;F.F&X0_7WU)?!EB
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M9K^T\T7&J^[]5'O!65,ZZT4!E0;PN649F@G90[)7M4)-R:S#HBF>^=\:__P
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MK87R0JL+>1T++U"1N@1[#+<PSJWS#7=N8?GO,)2%=#,Q .,4&IO+"5WLRSO
M"_S),CZ9=+/FN:9QK W""F'2XW&B*Y<WDAE"CFSIJ%VR/8&A%8-=PATS2WOK
M!)Q4HEMBB"XGOR+!<N@E[ZF\5/4\X=A?>J9+7FPI6\KGE;7,LG&?Z)&T_KKB
M'(B.UB7<Y1KAPS1E,2D=7?"G4,#,AC6&3'7$;DYY?K30R@OP?*-U[UPD=:F4
M$[J >]HZ$.?^<M@A'M=Q]N,09O^S%!?^(@VZUD^=2#-&)^F2OZB\0%Y+B(&Z
M0V- (2CQ\?K:YMJ@2+J$&_@)#D%I7JL/I_L777'PTW/25O=\GMPU,!3[I0Q;
MD7G%93:UO1XI9T8XC3O#>F9^=BG];]2]F2S]U:?^J].&P=XWEGC/8"I'=4QU
MQ$M&ZF-X19, AOAB,<,L-^& /R'PB)%?$<L+LC8C%-V$,%EM;H"7K^,CVN#J
M0)GF#!+\=BOK##,W]0!2>>V_Q^P1I"&/91T_O3:OVKU.?QQ>:.8%.I>%G$S\
M.RSUEKPBE1=B7=O1R:0C?A*ZHRDCUNRLZ#G=10U@3_FV$R&3$+H*V;AJ5&<
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M"0D3P?.GTPHOQ4F$Q!G^5MN!'E[&8BR(S>Y-O/<C#8E7U-\)ZO'1^? $CM[
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M97H6 94D5;9LLK*(REETD!U&#?RVK-*L4-4JJJ]5I>LX6JHJNE5YJZ-_.Y[
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MT\#+O&5,=5[>,1.W,YQ$OXZ]4/;=\T'MPTO;$%Z2F"/>&[1>8O&O5T[![;@
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M--37D>_D%#7* [F9Q\CF2\L\1]=Y6?F(J[9"QKG:&7I?@S),292R51 @(^"
MB8R'/$#PMT,8\,_@<!S"0'[GYQ;ACK+RB*B"TG=P[R0"9>"*.NX1X.\"FYSX
MNT/[B)NUX]C&.*:E;/]"=\2N%W,8PH?V<94@KLBK%4>5*FY Y%+RJIR&YU;N
M #[P#AE IJ4/AS3^RS?G3U\@(C\,!\.TLP6&?RGV1"%ANQ:'OV$FBGFL8'_!
MX_FJ_ZNZB\0+)VA].SM .F]S33Y";66XF=AGFLUHTMGP_%Z-9(I& [4&3DY?
M]%+MY/.QW+7/O-BU2S/Z$#GYQ8F R:X%R@9ED*H=^MXN%_^P\XIW^)TV'FBX
MWN]T*I$<%FTO";B->:'U=BSH@;F0O\#L4='>A2N^3L$,0M6D4(2QJFX0!(T]
M-:^T!'[9XK<F% 8#M-4"_30 P=YXGB]6ZR2GH'80ZPX\#"]'#X!@5%B!*%:6
MTG!Y76$1>"-0-C8ZN2X$AX$B8C8#P<DY%#SGA9>LX&&S52UYZYA:PFXNCC(]
M!L;YL#LK#WD_IU_X3_C;_B6Y[,2PV3?K4]O3+"7'AN2.FD0/N!XUI]WGN4=H
M';(R$#0_@+.@ZR0P%;4PT1R^:0:%X,8+X^A]&@XJ:^P0'0JIO/4W[LI?B[_P
M+TDHL2$4EX+101@-1IK[AV$\GGXXVO'7XFBAJAO=>$?O,R%"Z%AOBF!JTTYX
MVM+TZP_HF!' B&6A2,<8]+,.-9.+PF\D]1NTXW9%^!Z%V)$.O07$2,.X*)O/
M']?R6N=N&.7-P7LX<]J0QJH#Y,T$Q9W@4",>LU$W"IQ(7XCT^?FV:.P/5$8V
M9<-;LKJ'Q1*'<KR[BH7)+R4P A#"PIAQ(\YH0YD>7E<1@LT"PF18=IFIQB@<
MDXXJ00',L3EE@@S>.$M8(&<FU&:&DT\<&/+$ 9 &!V]*+IIS3R(R:%HDT[KS
M)O^L2>4D)^(1NJ FT7=<!*$PF\>BT28-C0E6>\?4M+S5\3!')142ESFUC%/R
M7.A0N\&FT9OZ9:M6F%U#_WQ!H#-GUQGGIGAEN/00U<P*$.T><(=RMNX*RRR-
MZ#!1 -8Z&G5CY(<Y&U(W!"Y4=/42^P/0='ARI-JB2@)*L7C8AO4<5ZW"%^ ;
M\=%]$'?+&.V(:[WGCR629A;7+Z5!9"AN:KZI>,V[N=L26>MI!A[A?T3*]=YS
MM>6>JYW,DG>Z5.HI%;W*"PDJG@2P@2V@_#:,DF.9H-9JM^P3[TOH\%?\= B9
M8%.!8*0DC"GYDT-1)T/@8U-(P<(S'&C/X#@D7S3EL ?CI\TX>5XV)F^R#^MH
MRCE'_JV:'<! ;"QF! #259EX+8(!Q(<EE=BEIWC3\P8?W^3.?O9.J&N45/K(
MZ$9.*AKHHQ.*.T&N&_OV>H<0"]//5PPO,W_%GL%6L:\O4$J\(_&#*Y1KS$$[
M 3134ML4E!Z.VN-[[A#_Q]DDJN!$(/AMXF7\"C$LR[MN;B;R&O<L_E;L:*9$
MI% -#V1!(I_+INM.Q(5O9;8XOE.QF[O2E%'R?):]G5E(@H!3V6HO^HTA;2]-
MHEMFB>[>;)81R[SEQ":S#UXD+=3]5:^HF-"RXN!5W2B6HD,6=N_ RBH@C!NR
MI#BGB(HV*WPU@F$8B\A;;6L_$Y =_6+>;-UK*8';H,L%2R[H\,XS 0Y=?DG5
M7%R%("^A(RS]@K#P[;BG#S3:-W.(;<G:'FBR%_*7X!KX#\^S@T?HTA.&")4U
M1N<LHZR$F?PUP?*?X[XB=K[>Z$%?VSHW:WQ/2B')8L-5.^:<@/U<"H=9GH,/
M#]94^SMPNEN\;2#:<LP-5I)"V3<7,?9"O$R*P!'@6-+,PCQL]XPD$%$LO\6<
ML/Z>K/6[]4/OM37/Y1@*[V0V&S0V#@1TJ:3N&72](ZK,(L0\)#]ZP/OY:4-9
MH%["HATP(V&E*ZE5*"6LK)BJ@VP[#E]-RQ93_,@]"KH$<F%BF7[F+KU[(&NN
ML)E ",SP-#1;K8,%F,@&6ZB/':R==%CCB/87(_6.9 ?C4#CUMI&B&_4R5R3J
M[>8&P+"L(*4+7SL-80S&GO.J>9>,RMLYG,P;RLE!8.9&_ -)NW]=!C&5AH'X
M14W,1CN#XF'._?>2]$-E$#Q1., OD6QS/)TTIC0BEWO*,<V15XE_$YXPF$ X
M^X%T[QTX6C*UNCENQK2B;1L5L;ZY16Y(PK@.V!JDOIA8MR0NI":O-U%Y(AF&
MUAZSB?3A0/ EC(;7BY*U/M*BN\>0^_1VW#^O,RSHYU\;7$,]1)$QEAL5MKFQ
MM>='VZ4&JLOB#GC]/9$CBS!N":=Y3S!@%M+'MJ$HA]7''S--3I8K83POX?!K
M]P'1"XCG&6A26' <%BE?;-7:/IE12[@4L"@K#%T06+02P&XN&\7%)_@*$?N'
M:YSJJ4!M\TQ-L]PVMN@"3,5M+DS1E0J4,C&($6RUI$;$%H(:4K<3#1/4]WUW
MO%\2-*O</8X[J$[$K/#D87YMP544!?<ZZCAQM1$Y.Q<L9(.5EL@2XJ5C_W*)
MB35C^I',V]J+^4C55;0U*0D:>2%_;HK/#7<OX*EU10RF98J*Q^\WE1W"+"+B
MO!1Q8XRY%ZX88@JN8 .'E;!I 2'BI9H8G(+6[-[>2O^Q^'_?@[)?SPCDG(:Y
M$?9.;X,K^&/BY_N8T!<0'"]M[H]!1F#20DW%;;"] +"F5#[8!5GQJVW0-"(Q
MXM#U&2.;&;#$X\A+BI*T91(TU/Q(DBUF+E[K>M.$M>_!QI[KJN/U)\\==9T)
M2NRPOXOW.]5N;/%^U0M,X:TLA^=1:I!R'YA;X@->UYB0U>Z$%O/.Y4W.=KFI
MR%K"DJQI/"W?H=%BD9)!D(98%,!S_. )22KSHF&O0Q#0* MQ+;-)[S(*_PY+
MB%Z6;=78N5$J%,9+:);K)B75PIUI$PP=)"ON! 5*9Z&?V!536SHTSH^M6L)]
M9.@YYY $R,*D$AZ#E9L0;(1.,>!1$FCP BPG%U)I*#8J=VI C&/C96)P.Z1>
MKE$_I$!*.'J!Q?"EDA'7?O7+4\VR&IZEQXY@A$ETB?E=PR\5595+C+8-U@?#
MM4@&:'?R!/V&8YDC_-O4CJBT]ZLRTH4#0_FHG# ?RO??F43*7"ORULG+)]$N
M4,_/UB4Y?K+&GF98DP1PQA(Y"UNQDI*DNZ"2]5T7_%*O*@(92OU-Q&WJZF"=
MGD0I:&0&")5Q>,[\?+B X2YYLLC*X5XX%F4#9\ U?=8WR8%C:M!D4)S3L.["
M(N6;GJ]A;3WC$['E^P8SV1D?@:5-K1?%V:N40RX$X/5@Q2(*L$\B-4![F7IU
MQV4A_XY, 7/9ZTX'33#ZL)4-N[@HD!]\,@NISN"P05^2"*SWM?7<5GK1%K:F
M()9LT3GZX$RQ)K70AU2DL2A]:9O5G&;<]\*!W1!."DOU&;U/WK[V7*3N=O>1
M?I(-&;?H[<^*EAV1[)C?,C(?ZZ$,9&KUI1]D"W99#H<KZASJ ++.!+$%BV!N
MXE"+&;H^Y*2^*SN?F_M[C0V=]0>=M 0F8$JH\">W_B_<17:_@!]@A44][&LU
M)V *@HYBD4V5]C55#A-5591U$+J!@;H/;K.A60S4;)'K/8GNV6^<A*L310I"
MIP(">Z=LD,UW^+F;3OA6"W$4Y:I7Y@]T%(XBZ'63BIFQDWMKBIW:<1O-O4;D
M46L2T3"(HQN<<'-MU V1@@;I@D&[.HBB>L5!1XN*$.8];1UFWDMDH8HG;7-O
MVZ0=N(N!5K/V3#ZQ<M,M$&V$T*AWPE=< CV'*5@T'2%_\PLX(:Q!1.7).0:_
M?HVFABE5C1FQ'4_.-WJ3J3FQ]H4[02-OF,P3">K>NXD^LQX%B?2Q#117[43\
M;1WH\,;YS(_W'PAJ25PQT=G2>?:1@8#9EJ4#CVQ06Q^C)4)8XBK A85HM9$;
M8)%C!H/'.NH&"Z&VS=T-(+:,S"ECS)W8A%:5LLL>&U6R.@<6::O6F>5U33:3
MY'EZ<I0B((EN7=Q]4[>@=NQY RG5*&@6X$S<$M[H.A>8I)R.W)MYO=47,6<G
MP[]J33G1O7,Q]L[:7;Q&Q*;;Q[X$W6!7=^'VCAX\=X( ]GG'L7;!KZPKM8AD
M,J=ZCQ6?GG]RKF?D6)7%HZ[6,]"KM ,CLV=[']<9OXJDB+DIGS[C"QT"C\SR
M5^B=J$2S0R>RLFY"LOM O;LC,9&FE8&[ E&T8R)_'[OY C;3_[1E!6H""N*>
MP;0#5W;CN#Z8VE8]%M6[Z]/H7Q3!::OH=]XE4HZ),6-_*_)Q$W<.B]_S+ZB>
M#\,!N9,OUGM?F3>-8;B'+:*'(K1[H&SA5]:M6L"*=$V[)/"D OYJ6ORI6:S%
MG6ZG C9,SO]@8;A5,_U72ZCDN30H<>Z:A#S+W'JCA _9))!3%OE5B8FN,&13
M2"$TOVNLQ%TR'PE(HUDT*.:!%M;>&/H]3\Q!7 GGMCT ^O7.%0??$1,]"Z\.
MZEN<A((]8/O]W@0/0GR@E@R+6MHNB*Z)]2Y):!H_@;U,_PC4-F%)!M?6-P@\
MJ*S?_#1$B[H>9!M-PK08C](6JSJRBY'+XWY8&<60V5:!B6*22ZW\F2&&#RM%
M4-@'6 K!=3SDL\%+*HY?8^9/Q<J*X)Y(=?#S\2VVCV9OM5JB;)MQXW(]3-$W
M:>K%W02RBN?-^>C4:<-#S[J5FJB+1" KEW.\MAB_MS=^5YZ^B;1@(V"1-3V3
M!_7B69!&-O-G[CNF@2JQ=1S]##U/.W&[^L4Q;#^GOK=@N/G28*LES^]@$NS$
M8D3WG5HLY;B,&<EO)>$X\%J!W/[EFXMG+QZZJPSZM.HGHL"/$JREN:SUM^8?
M+P0F_VU6T![10R\6JIJ#PB@ZZP5L*/6<AM,] A-\7GS;@ 8O7XLJ^>SIY.SL
M.6J3#<RF2<V+1=&<D*+YUR;M?W<V>79Q/OKM\>1D]+L_?M1GSR;/GY]N-.Q?
M:1]X+V"W:Z"S__C3V9^<UIZB2O3M<72R;+SQUOST=/D!?_R"-I_/(=>S_MF4
MRS]]F3MUH XM'3Z"Y5 K$9.+4A+,A!SWHP"DCL%\\?Q%L!U"$1T[\N24SO^3
M4<G'_O1KI-?IXZ77$=5@3Y5;?XP'R>.B2AMM5)'D8"'R"LOQ;, N_TH*R99H
MDB,VO:H<^^?.K]%ETX ]9O3!Z*5)];ZR#<9V)S?E7KRQM< 'VS=0"I2_19SW
M;FI7^QOE>8Z&TAL\^\CV3!WO.3:4V"SU![CNH,V_MY%B=#.):\Q$ /O%"=@@
M&W1W^94 P#B0%YC<O)TPB]Y?!SDOY?I"9^SUYL/KHQ%,Q<\A7$AG4[UZ"#:5
M47.E1R^:@<V@\*"=N]-ZC*3*B]=.)<R<&SA$>M] [=VAZ?I3]7/+.W..G7N2
MH@PU^P;*C_/%?AIGJ[_:AWA>]YDMVQ\=N73)HCLA2BY-(ISTLS%Y<+Y_;:I=
M-BYUFG(YSG<$@+7%:G? *P(D-#EF,GJX6^3T],EG<(M\CE&?'T].SY_MW2)?
MAUL$HRA5<V35L#JYUJS-4W/3N=^.>#11YG+D,5+&.J$%\<O*BTU!"Q/T[Z;X
MN/Y[7I]73VH"4Q&6$N!8GE[\&;^RU0$XH2.0[Q*&,5(;WR/HEO%@JL-2<7=*
MSS],&@IMPMXJWWJJ?V2^HN:ZPFH_0)^-IHN*H3=UHX$NJ>Z4EM!;<YU55%O
M5%:RX*WAUE$<;>MHV\\0,2WZ[R"FR*]=YSKO25DV$Q;,*J\94@=]6.F%RGK
MM:! L<GL@+T,4L8:DVWNO\*A[+(4=\<BZVST#[,&)8F^!I59_Y]&Y=ODAI-U
M2U,S0.;BB!?6FR/-CU?N99_0 %P-FAN.>)/QVI $V](KA4RK&+*D[[2-B',-
M'?,L\](K*IGSVI3,(?0?0V"EIWR_K(Y$*E^WV.H13N[7PD)]QW?)%86QW21
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M/&]<A[(H774^6QZ-G%2X!,+5FPIL8Y4J_N@='J."+W_;O\=.\Q4SL$M&=>P
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MO@JJF;KPO;24*4QG1^HUCR:<NN74="S ,J;T["_0X[E C^L&A0H^.JW(#X(
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MWH\9:%FIVI4\E[ZP3&6MR&' YLH6&5%(KWAF2KMP*Z55[\H6:6X99!UX?IZ
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M1>5@1-9-U8**5A'!]O8&:#)X*TY#WKS^,EBZ#>CB@&D%6&71(R70HE3+3MM
M? <2Z' 7-)^.T-F$E>A-#,:XSV$<YZ"-W9QC#=FC(-F<N.G)SD 1V(S-N8D]
ME&_=.]F_?'/Q_ 6*Y<]SM9?Y\!9]W%WGR8H^^; +)S/&L3QF.[93]M8-[MC
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M,_ZP)YLGT:4W0^_+!2:]B<V EDBEC?&[T1:$>.^RH)M),[.X_%I2G4&W",*
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M,^N$.7N8Y3#$YQIT^%F,(1+:P*Z"]$G^L.@$.:F(M0<!XU!M%\F'H)6A*-A
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M#D?8(V;OM?R*4K_7C7HR>7[^65*_+\[VJ=]?#XH4XWGB3F&C@%L(6 \7^]A
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M!LN6BC62MDO#"2CM.OLE%[,:E 7+9UT1@8D?L$443@LBDL_')]%M? 8Y$ZN
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M[#W$F=E44CHXBY?)D<P.)#F,'+I(!N]J$R!Y\T4)XDU;^0,/<,HW311"V%X
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MLW/W),$>XV^,PA^3*DM?_C]02P,$%     @ $X+46 0Z!5*)(P  4@T! !,
M  !M9'0M,C R-#$P>&5X,3DN:'1M[5WK4]Q&MO]^_PK=I#8+53,$,'[$]J:*
M $ZH.-@!LKGWTU:/U#/3:XU:44O@V;]^SZ-;:CT&9G!@!J+=JAB0U&IUGS[/
MWSGG[32?Q=^_G4H1??\_;_]W. R.=5C,9)('829%+J.@,"J9!+]'TGP*AD-[
MUY%.YYF:3/-@?W?_(/A=9Y_4E>#KN<IC^;T;Y^VW_/O;;^DE;T<ZFG__-E)7
M@8K^\97:VP]W912-Q<MH?+#_72@.GNWN?;<[.A#1^,6N?/:OO?U77\'#\  _
M9?)Y+/_QU4PEPZG$&;Q^]B+-WURK*)^^WMO=_=M7M?MR^3D?BEA-DM<T7[@Z
MUO!U]G*H8YV]_GJ7_O<&KPS'8J;B^>N_'V9*Q'\?&)&8H9&9&O-EH_XCX3WP
M2OKUFN?P$IZ.52+=G'@B)Y^G:J3R8.^[M]_BW>X[RJ_Y_JV:30(1Y[ 2,S&1
M_]K=^7<Z^2HP6=C\"\_7??)^^OG-3&036(61SG,]>_T<9G0ELUR%(K8?3-_.
ME]WZX(.=RUD;ZQF,9?^2Z_0UK&_WLNWM[NW*46/9KF2BLN ,WAV\OPP^9GK!
M&NX?++6&/\9Z).+@-#$JDEEPF8D(Z?&CCE4XKR\K_8?_,,J^7^G:&M=A;[EU
M^%ADJ39RX<P]0O]W87(UGJ] ZDO/M4GW!\VY[N-<+Z<R^&WG8B>XD&&1J5Q)
M$X@D"DX^AU.13"2PC]E,&:-T$FQ=G!QMTU6=3V&#)QJH."$.!*P"GW2,*"MB
M^"W709K)*[Q>)#*?(KT#CY*!'@>)3M)B!(01J&2LLYG(X0T[P>54F2 E@@ET
MD>-\81R88R;_*%0F\64FD+,TUG,)EV:P?L%8Q[&^QM>%&J[,@VN53_$I>!7/
M!.<LTA2&%:-8!K&X-CMW(ZR]_351%NW61:C3QT)7U4;2RC,]B#@.?I%1GND$
MMK[:1]R@F9R-9&:0.G#'?] BB_"78]CW,-?9X]PRYG[!10X'@X[*UK',A8K-
M]L*O246$C',8RS&,\@I>0SNKD@B>?SW$O]S'QNXM]3U[Y2ZL90)O:HOS:N?@
M&2[&#X='/_]X_N&WL^,E2>1%2UR\6<_I:7WCB_V_\50B&>J,V.+K G8^P[N
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M4858.H%*AM6"@SIS+EN'+$: 6V#T-B+?X'0(=SJH#/7-)9F[P>M]2'H-Y.(
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M"AZ0X-31E<*#1YF)=,(:"3CDJY;RD]7=]'5B*WZ%%F+<@XA!XWVVN2#B1W/
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M &UD="TR,#(T,#0R-BYX<V102P$"% ,4    "  3@M18>>.VU,]"  #9Q0(
M%               @ $^ 00 ;61T+3(P,C0P-#(V7V-A;"YX;6Q02P$"% ,4
M    "  3@M18S-G"S[3P  !G(@L %               @ $_1 0 ;61T+3(P
M,C0P-#(V7V1E9BYX;6Q02P$"% ,4    "  3@M18!5$_AN^Q  "TW   $P
M            @ $E-04 ;61T+3(P,C0P-#(V7V<Q+FIP9U!+ 0(4 Q0    (
M !."U%A-WR)?O;P  %K3   4              "  47G!0!M9'0M,C R-# T
M,C9?9S$P+FIP9U!+ 0(4 Q0    ( !."U%BL!,T2MZ   !*X   4
M      "  32D!@!M9'0M,C R-# T,C9?9S$Q+FIP9U!+ 0(4 Q0    ( !."
MU%AA:&VTZ)\  '&W   4              "  1U%!P!M9'0M,C R-# T,C9?
M9S$R+FIP9U!+ 0(4 Q0    ( !."U%C-S@]GGXL  (BB   4
M  "  3?E!P!M9'0M,C R-# T,C9?9S$S+FIP9U!+ 0(4 Q0    ( !."U%C2
MD(M7S8H  ,BA   4              "  0AQ" !M9'0M,C R-# T,C9?9S$T
M+FIP9U!+ 0(4 Q0    ( !."U%CL_SRG4HL  )6B   4              "
M 0?\" !M9'0M,C R-# T,C9?9S$U+FIP9U!+ 0(4 Q0    ( !."U%@A#^U
MS8D   .A   4              "  8N'"0!M9'0M,C R-# T,C9?9S$V+FIP
M9U!+ 0(4 Q0    ( !."U%B%-TWBOW4  '"-   4              "  8H1
M"@!M9'0M,C R-# T,C9?9S$W+FIP9U!+ 0(4 Q0    ( !."U%C2_5$3_78
M '&.   4              "  7N'"@!M9'0M,C R-# T,C9?9S$X+FIP9U!+
M 0(4 Q0    ( !."U%@?V00U2I@  (?[   4              "  :K^"@!M
M9'0M,C R-# T,C9?9S$Y+FIP9U!+ 0(4 Q0    ( !."U%@O%*3=,'4  "^,
M   3              "  2:7"P!M9'0M,C R-# T,C9?9S(N:G!G4$L! A0#
M%     @ $X+46!;8,V$Y=   #(L  !,              ( !APP, &UD="TR
M,#(T,#0R-E]G,RYJ<&=02P$"% ,4    "  3@M18L@2PT]YU  #ZA@  $P
M            @ 'Q@ P ;61T+3(P,C0P-#(V7V<T+FIP9U!+ 0(4 Q0    (
M !."U%@@'(98H7   $^'   3              "  0#W# !M9'0M,C R-# T
M,C9?9S4N:G!G4$L! A0#%     @ $X+46/,@I@XA70  _7,  !,
M     ( !TF<- &UD="TR,#(T,#0R-E]G-BYJ<&=02P$"% ,4    "  3@M18
M:<K* 0\2 0"'3P$ $P              @ $DQ0T ;61T+3(P,C0P-#(V7V<W
M+FIP9U!+ 0(4 Q0    ( !."U%ATD;U;B0\" -=W @ 3              "
M 637#@!M9'0M,C R-# T,C9?9S@N:G!G4$L! A0#%     @ $X+46 *^&H3S
MN0  ]-   !,              ( !'N<0 &UD="TR,#(T,#0R-E]G.2YJ<&=0
M2P$"% ,4    "  3@M18H..KA-M' @"?.Q8 %               @ %"H1$
M;61T+3(P,C0P-#(V7VQA8BYX;6Q02P$"% ,4    "  3@M18'BP=F55> 0#Q
ME1  %               @ %/Z1, ;61T+3(P,C0P-#(V7W!R92YX;6Q02P$"
M% ,4    "  3@M18YJE.CS\:  "CQ@( %               @ '61Q4 ;61T
M+3(P,C0Q,&MX97@R,2YH=&U02P$"% ,4    "  3@M18:#GUAPX#  " &0
M%               @ %'8A4 ;61T+3(P,C0Q,&MX97@R,BYH=&U02P$"% ,4
M    "  3@M186%,<O)X#   H#@  %               @ &'914 ;61T+3(P
M,C0Q,&MX97@R,RYH=&U02P$"% ,4    "  3@M18C%["( 0&   ;*@  %
M            @ %7:14 ;61T+3(P,C0Q,&MX97@R-"YH=&U02P$"% ,4
M"  3@M18/T-56[8'  ##)P  %0              @ &-;Q4 ;61T+3(P,C0Q
M,&MX97@S,3$N:'1M4$L! A0#%     @ $X+46'*D_9S!!P   2D  !4
M         ( !=G<5 &UD="TR,#(T,3!K>&5X,S$R+FAT;5!+ 0(4 Q0    (
M !."U%BZ1T9[#00  #,2   5              "  6I_%0!M9'0M,C R-#$P
M:WAE>#,R,2YH=&U02P$"% ,4    "  3@M18155\+"0$  !M$@  %0
M        @ &J@Q4 ;61T+3(P,C0Q,&MX97@S,C(N:'1M4$L! A0#%     @
M$X+46'82)%3X>P  +4P# !4              ( ! 8@5 &UD="TR,#(T,3!K
M>&5X-#,P+FAT;5!+ 0(4 Q0    ( !."U%A;20W>1A8  #.'   4
M      "  2P$%@!M9'0M,C R-#$P:WAE>#DW+FAT;5!+ 0(4 Q0    ( !."
MU%@$.@52B2,  %(- 0 3              "  :0:%@!M9'0M,C R-#$P>&5X
<,3DN:'1M4$L%!@     D "0 .PD  %X^%@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>mdt-20240426_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mdt="http://www.medtronic.com/20240426"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mdt-20240426.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2022Due2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2022Due2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20311.625PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20311.00PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2022Due2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2022Due2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20392.250PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20391.50PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2053Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2024-06-17</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:JapanAustraliaNewZealandKoreaCanadaandWesternEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:MiddleEastAfricaLatinAmericaEasternEuropeandAsiaExcludingJapanandKoreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-13</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-13</startDate>
            <endDate>2022-05-13</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-13</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-13</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:IntersectENTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-13</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:AfferaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-30</startDate>
            <endDate>2022-08-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:AfferaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:AfferaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:OtherAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:OtherAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdt:OtherAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-20</startDate>
            <endDate>2024-02-20</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mdt:MozarcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mdt:MozarcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:MechanicalCirculatorySupportMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:MechanicalCirculatorySupportMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mdt:EnterpriseExcellenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mdt:SimplificationRestructuringProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2023-01-28</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdt:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdt:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2015CommercialPaperProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-26</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-12</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2625PercentThreeYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2625PercentThreeYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2625PercentThreeYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4250PercentFiveYear2023SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4250PercentFiveYear2023SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4250PercentFiveYear2023SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3000PercentSixYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3000PercentSixYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3000PercentSixYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2032Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2032Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2032Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3125PercentNineYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3125PercentNineYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3125PercentNineYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4500PercentTenYear2023SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4500PercentTenYear2023SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4500PercentTenYear2023SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3375PercentTwelveYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3375PercentTwelveYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3375PercentTwelveYear2022SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotesCIFSA2007Due2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotesCIFSA2007Due2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotesCIFSA2007Due2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">mdt:TokyoInterBankOfferedRateTIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2024-01-27</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareBusinessRCSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareBusinessRCSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mdt:PurchasedTechnologyAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mdt:PurchasedTechnologyAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:IPRDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:IPRDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:IPRDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:TwoThousandTwentyOneStockAwardAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-19</instant>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:ColibriMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-08</startDate>
            <endDate>2023-02-08</endDate>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-15</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-15</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-15</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-15</instant>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:DiabetesPumpRetainerRingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-14</instant>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:DiabetesPumpRetainerRingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-14</startDate>
            <endDate>2024-05-14</endDate>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="c-806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>mdt:tranche</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="segment">
        <measure>mdt:segment</measure>
    </unit>
    <unit id="reportingunit">
        <measure>mdt:reportingUnit</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="plantiff">
        <measure>mdt:plantiff</measure>
    </unit>
    <unit id="claim">
        <measure>mdt:claim</measure>
    </unit>
    <unit id="lawsuit">
        <measure>mdt:lawsuit</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-92">0001613103</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-93">--04-26</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-94">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-95">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-96">2024</dei:DocumentFiscalYearFocus>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-97">D02 XH02</dei:EntityAddressPostalZipCode>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-73" id="f-494">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-708">http://fasb.org/us-gaap/2023#OtherOperatingIncomeExpenseNet</us-gaap:ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-28" id="f-1022">http://fasb.org/us-gaap/2023#DebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-1023">http://fasb.org/us-gaap/2023#DebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentTerm contextRef="c-331" id="f-1041">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-334" id="f-1047">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-337" id="f-1053">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-340" id="f-1059">P8Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-343" id="f-1065">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-346" id="f-1071">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-349" id="f-1077">P8Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-352" id="f-1083">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-355" id="f-1089">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-358" id="f-1095">P9Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-361" id="f-1101">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-364" id="f-1107">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-367" id="f-1113">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-370" id="f-1119">P20Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-373" id="f-1125">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-376" id="f-1131">P20Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-379" id="f-1137">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-382" id="f-1143">P20Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-385" id="f-1149">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-388" id="f-1155">P20Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-391" id="f-1161">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-394" id="f-1167">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-397" id="f-1173">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-400" id="f-1179">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-403" id="f-1185">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-406" id="f-1191">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-1196">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-28" id="f-1197">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-1257">http://fasb.org/us-gaap/2023#InterestExpense</us-gaap:DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="c-27" id="f-1328">http://fasb.org/us-gaap/2023#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-27" id="f-1329">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="c-28" id="f-1330">http://fasb.org/us-gaap/2023#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-28" id="f-1331">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-1461">http://fasb.org/us-gaap/2023#OtherOperatingIncomeExpenseNet</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-520" id="f-1568">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-520" id="f-1569">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-2346">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-28" id="f-2347">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-2350">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-28" id="f-2351">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-2354">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-28" id="f-2355">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-04-26</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--04-26</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">1-36820</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Medtronic plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">L2</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">98-1183488</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">20 On Hatch, Lower Hatch Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Dublin 2</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-12">IE</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="c-1" id="f-13">353</dei:CountryRegion>
    <dei:CityAreaCode contextRef="c-1" id="f-14">1</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">438-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-2" id="f-16">Ordinary shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-17">MDT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-18">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-19">0.250% Senior Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-20">MDT/25</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-21">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-22">0.000% Senior Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-23">MDT/25A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-24">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-5" id="f-25">2.625% Senior Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-5" id="f-26">MDT/25B</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-5" id="f-27">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-6" id="f-28">1.125% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-6" id="f-29">MDT/27</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-6" id="f-30">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-7" id="f-31">0.375% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-7" id="f-32">MDT/28</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-7" id="f-33">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-8" id="f-34">3.000% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-8" id="f-35">MDT/28A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-8" id="f-36">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-9" id="f-37">3.650% Senior Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-9" id="f-38">MDT/29</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-9" id="f-39">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-10" id="f-40">1.625% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-10" id="f-41">MDT/31</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-10" id="f-42">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-11" id="f-43">1.000% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-11" id="f-44">MDT/31A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-11" id="f-45">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-12" id="f-46">3.125% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-12" id="f-47">MDT/31B</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-12" id="f-48">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-13" id="f-49">0.750% Senior Notes due 2032</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-13" id="f-50">MDT/32</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-13" id="f-51">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-14" id="f-52">3.375% Senior Notes due 2034</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-14" id="f-53">MDT/34</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-14" id="f-54">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-15" id="f-55">3.875% Senior Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-15" id="f-56">MDT/36</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-15" id="f-57">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-16" id="f-58">2.250% Senior Notes due 2039</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-16" id="f-59">MDT/39A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-16" id="f-60">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-17" id="f-61">1.500% Senior Notes due 2039</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-17" id="f-62">MDT/39B</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-17" id="f-63">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-18" id="f-64">1.375% Senior Notes due 2040</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-18" id="f-65">MDT/40A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-18" id="f-66">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-19" id="f-67">4.150% Senior Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-19" id="f-68">MDT/43A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-19" id="f-69">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-20" id="f-70">1.750% Senior Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-20" id="f-71">MDT/49</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-20" id="f-72">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-21" id="f-73">1.625% Senior Notes due 2050</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-21" id="f-74">MDT/50</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-21" id="f-75">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-22" id="f-76">4.150% Senior Notes due 2053</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-22" id="f-77">MDT/53</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-22" id="f-78">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-79">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-80">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-81">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-82">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-83">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-84">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-85">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-86">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-87">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-88">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-23" decimals="-8" id="f-89" unitRef="usd">92400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-24" decimals="INF" id="f-90" unitRef="shares">1282269783</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-91">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Portions of the registrant&#x2019;s Proxy Statement for its 2024 Annual General Meeting are incorporated by reference into Part III hereof.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-98">238</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-99">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-100">Minneapolis, Minnesota</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-101" unitRef="usd">32364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-6" id="f-102" unitRef="usd">31227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-6" id="f-103" unitRef="usd">31686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-6" id="f-104" unitRef="usd">11216000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-25" decimals="-6" id="f-105" unitRef="usd">10719000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-26" decimals="-6" id="f-106" unitRef="usd">10145000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-6" id="f-107" unitRef="usd">2735000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-25" decimals="-6" id="f-108" unitRef="usd">2696000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-26" decimals="-6" id="f-109" unitRef="usd">2746000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-110" unitRef="usd">10736000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-25" decimals="-6" id="f-111" unitRef="usd">10415000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-26" decimals="-6" id="f-112" unitRef="usd">10292000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-6" id="f-113" unitRef="usd">1693000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-25" decimals="-6" id="f-114" unitRef="usd">1698000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-26" decimals="-6" id="f-115" unitRef="usd">1733000000</us-gaap:AmortizationOfIntangibleAssets>
    <mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact contextRef="c-1" decimals="-6" id="f-116" unitRef="usd">226000000</mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact>
    <mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact contextRef="c-25" decimals="-6" id="f-117" unitRef="usd">375000000</mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact>
    <mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact contextRef="c-26" decimals="-6" id="f-118" unitRef="usd">60000000</mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-1" decimals="-6" id="f-119" unitRef="usd">149000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-25" decimals="-6" id="f-120" unitRef="usd">-30000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-26" decimals="-6" id="f-121" unitRef="usd">95000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-6" id="f-122" unitRef="usd">-464000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-25" decimals="-6" id="f-123" unitRef="usd">131000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-26" decimals="-6" id="f-124" unitRef="usd">-862000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-125" unitRef="usd">5144000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-25" decimals="-6" id="f-126" unitRef="usd">5485000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-26" decimals="-6" id="f-127" unitRef="usd">5752000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-128" unitRef="usd">412000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-25" decimals="-6" id="f-129" unitRef="usd">515000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-26" decimals="-6" id="f-130" unitRef="usd">318000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-6" id="f-131" unitRef="usd">719000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-25" decimals="-6" id="f-132" unitRef="usd">636000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-26" decimals="-6" id="f-133" unitRef="usd">553000000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-134" unitRef="usd">4837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-135" unitRef="usd">5364000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-136" unitRef="usd">5517000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-137" unitRef="usd">1133000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-138" unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-139" unitRef="usd">456000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-140" unitRef="usd">3705000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-25" decimals="-6" id="f-141" unitRef="usd">3784000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-26" decimals="-6" id="f-142" unitRef="usd">5062000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-143" unitRef="usd">28000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-144" unitRef="usd">26000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-145" unitRef="usd">22000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-146" unitRef="usd">3676000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-6" id="f-147" unitRef="usd">3758000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-6" id="f-148" unitRef="usd">5039000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">3.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">2.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">2.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-154"
      unitRef="usdPerShare">3.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-155" unitRef="shares">1327700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-25" decimals="-5" id="f-156" unitRef="shares">1329800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="-5" id="f-157" unitRef="shares">1342400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-158" unitRef="shares">1330200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-25" decimals="-5" id="f-159" unitRef="shares">1332800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="-5" id="f-160" unitRef="shares">1351400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-161" unitRef="usd">3705000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-25" decimals="-6" id="f-162" unitRef="usd">3784000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-26" decimals="-6" id="f-163" unitRef="usd">5062000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-6" id="f-164" unitRef="usd">46000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-25" decimals="-6" id="f-165" unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-26" decimals="-6" id="f-166" unitRef="usd">-301000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-6" id="f-167" unitRef="usd">-848000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-25" decimals="-6" id="f-168" unitRef="usd">-240000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-26" decimals="-6" id="f-169" unitRef="usd">-2086000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax contextRef="c-1" decimals="-6" id="f-170" unitRef="usd">633000000</mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax>
    <mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax contextRef="c-25" decimals="-6" id="f-171" unitRef="usd">-596000000</mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax>
    <mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax contextRef="c-26" decimals="-6" id="f-172" unitRef="usd">2299000000</mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-173" unitRef="usd">-212000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-25" decimals="-6" id="f-174" unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-26" decimals="-6" id="f-175" unitRef="usd">-574000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-6" id="f-176" unitRef="usd">136000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-25" decimals="-6" id="f-177" unitRef="usd">-381000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-26" decimals="-6" id="f-178" unitRef="usd">727000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-179" unitRef="usd">178000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-25" decimals="-6" id="f-180" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-26" decimals="-6" id="f-181" unitRef="usd">1213000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-182" unitRef="usd">3883000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-183" unitRef="usd">2549000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-184" unitRef="usd">6274000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-185" unitRef="usd">27000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-186" unitRef="usd">26000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-187" unitRef="usd">16000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-188" unitRef="usd">3856000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-25" decimals="-6" id="f-189" unitRef="usd">2524000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-26" decimals="-6" id="f-190" unitRef="usd">6258000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-27" decimals="-6" id="f-191" unitRef="usd">1284000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-28" decimals="-6" id="f-192" unitRef="usd">1543000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-27" decimals="-6" id="f-193" unitRef="usd">6721000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-28" decimals="-6" id="f-194" unitRef="usd">6416000000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-27" decimals="-6" id="f-195" unitRef="usd">173000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-28" decimals="-6" id="f-196" unitRef="usd">176000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-27" decimals="-6" id="f-197" unitRef="usd">6128000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-28" decimals="-6" id="f-198" unitRef="usd">5998000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-27" decimals="-6" id="f-199" unitRef="usd">5217000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-28" decimals="-6" id="f-200" unitRef="usd">5293000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-27" decimals="-6" id="f-201" unitRef="usd">2584000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-28" decimals="-6" id="f-202" unitRef="usd">2425000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-27" decimals="-6" id="f-203" unitRef="usd">21935000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-28" decimals="-6" id="f-204" unitRef="usd">21675000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-27" decimals="-6" id="f-205" unitRef="usd">6131000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-28" decimals="-6" id="f-206" unitRef="usd">5569000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="c-27" decimals="-6" id="f-207" unitRef="usd">40986000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-28" decimals="-6" id="f-208" unitRef="usd">41425000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-27" decimals="-6" id="f-209" unitRef="usd">13225000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-28" decimals="-6" id="f-210" unitRef="usd">14844000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-27" decimals="-6" id="f-211" unitRef="usd">3657000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-28" decimals="-6" id="f-212" unitRef="usd">3477000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-27" decimals="-6" id="f-213" unitRef="usd">4047000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-28" decimals="-6" id="f-214" unitRef="usd">3959000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-27" decimals="-6" id="f-215" unitRef="usd">89981000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-28" decimals="-6" id="f-216" unitRef="usd">90948000000</us-gaap:Assets>
    <us-gaap:DebtCurrent contextRef="c-27" decimals="-6" id="f-217" unitRef="usd">1092000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-28" decimals="-6" id="f-218" unitRef="usd">20000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-27" decimals="-6" id="f-219" unitRef="usd">2410000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-28" decimals="-6" id="f-220" unitRef="usd">2662000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent contextRef="c-27" decimals="-6" id="f-221" unitRef="usd">2375000000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent contextRef="c-28" decimals="-6" id="f-222" unitRef="usd">1949000000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-27" decimals="-6" id="f-223" unitRef="usd">1330000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-28" decimals="-6" id="f-224" unitRef="usd">840000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-27" decimals="-6" id="f-225" unitRef="usd">3582000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-28" decimals="-6" id="f-226" unitRef="usd">3581000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-27" decimals="-6" id="f-227" unitRef="usd">10789000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-28" decimals="-6" id="f-228" unitRef="usd">9051000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-27" decimals="-6" id="f-229" unitRef="usd">23932000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-28" decimals="-6" id="f-230" unitRef="usd">24344000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-27" decimals="-6" id="f-231" unitRef="usd">1101000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-28" decimals="-6" id="f-232" unitRef="usd">1093000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-27" decimals="-6" id="f-233" unitRef="usd">1859000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-28" decimals="-6" id="f-234" unitRef="usd">2360000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-27" decimals="-6" id="f-235" unitRef="usd">515000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-28" decimals="-6" id="f-236" unitRef="usd">708000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-27" decimals="-6" id="f-237" unitRef="usd">1365000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-28" decimals="-6" id="f-238" unitRef="usd">1727000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-27" decimals="-6" id="f-239" unitRef="usd">39561000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-28" decimals="-6" id="f-240" unitRef="usd">39283000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-27" id="f-241" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-28" id="f-242" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-28"
      decimals="INF"
      id="f-243"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-244"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-28"
      decimals="INF"
      id="f-245"
      unitRef="shares">2600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-27"
      decimals="INF"
      id="f-246"
      unitRef="shares">2600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-247"
      unitRef="shares">1311337531</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-248"
      unitRef="shares">1311337531</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-28"
      decimals="INF"
      id="f-249"
      unitRef="shares">1330809036</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-28"
      decimals="INF"
      id="f-250"
      unitRef="shares">1330809036</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-27" decimals="-6" id="f-251" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-28" decimals="-6" id="f-252" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-27" decimals="-6" id="f-253" unitRef="usd">23129000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-28" decimals="-6" id="f-254" unitRef="usd">24590000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-27" decimals="-6" id="f-255" unitRef="usd">30403000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-28" decimals="-6" id="f-256" unitRef="usd">30392000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-27" decimals="-6" id="f-257" unitRef="usd">-3318000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-28" decimals="-6" id="f-258" unitRef="usd">-3499000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-6" id="f-259" unitRef="usd">50214000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-6" id="f-260" unitRef="usd">51483000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-27" decimals="-6" id="f-261" unitRef="usd">206000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-28" decimals="-6" id="f-262" unitRef="usd">182000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-6" id="f-263" unitRef="usd">50420000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-6" id="f-264" unitRef="usd">51665000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-27" decimals="-6" id="f-265" unitRef="usd">89981000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-28" decimals="-6" id="f-266" unitRef="usd">90948000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-29" decimals="-6" id="f-267" unitRef="shares">1345000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-6" id="f-268" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-6" id="f-269" unitRef="usd">26319000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-6" id="f-270" unitRef="usd">28594000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-6" id="f-271" unitRef="usd">-3485000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-6" id="f-272" unitRef="usd">51428000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-6" id="f-273" unitRef="usd">174000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-6" id="f-274" unitRef="usd">51602000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-36" decimals="-6" id="f-275" unitRef="usd">5039000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-37" decimals="-6" id="f-276" unitRef="usd">5039000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-38" decimals="-6" id="f-277" unitRef="usd">22000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-26" decimals="-6" id="f-278" unitRef="usd">5062000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-39" decimals="-6" id="f-279" unitRef="usd">1219000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-37" decimals="-6" id="f-280" unitRef="usd">1219000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-6" id="f-281" unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-26" decimals="-6" id="f-282" unitRef="usd">1213000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-26"
      decimals="INF"
      id="f-283"
      unitRef="usdPerShare">2.52</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-36" decimals="-6" id="f-284" unitRef="usd">3383000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-37" decimals="-6" id="f-285" unitRef="usd">3383000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-26" decimals="-6" id="f-286" unitRef="usd">3383000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-40" decimals="-6" id="f-287" unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-41" decimals="-6" id="f-288" unitRef="usd">329000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-37" decimals="-6" id="f-289" unitRef="usd">329000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-26" decimals="-6" id="f-290" unitRef="usd">329000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-40" decimals="-6" id="f-291" unitRef="shares">21000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-41" decimals="-6" id="f-292" unitRef="usd">2442000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-37" decimals="-6" id="f-293" unitRef="usd">2442000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-26" decimals="-6" id="f-294" unitRef="usd">2442000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-6" id="f-295" unitRef="usd">359000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-6" id="f-296" unitRef="usd">359000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-6" id="f-297" unitRef="usd">359000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-41" decimals="-6" id="f-298" unitRef="usd">1000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-37" decimals="-6" id="f-299" unitRef="usd">1000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-38" decimals="-6" id="f-300" unitRef="usd">-19000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-26" decimals="-6" id="f-301" unitRef="usd">-18000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-6" id="f-302" unitRef="shares">1331000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-6" id="f-303" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-6" id="f-304" unitRef="usd">24566000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-6" id="f-305" unitRef="usd">30250000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-6" id="f-306" unitRef="usd">-2265000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-6" id="f-307" unitRef="usd">52551000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-6" id="f-308" unitRef="usd">171000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-6" id="f-309" unitRef="usd">52722000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-49" decimals="-6" id="f-310" unitRef="usd">3758000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-50" decimals="-6" id="f-311" unitRef="usd">3758000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-51" decimals="-6" id="f-312" unitRef="usd">26000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-25" decimals="-6" id="f-313" unitRef="usd">3784000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-52" decimals="-6" id="f-314" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-50" decimals="-6" id="f-315" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-25" decimals="-6" id="f-316" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-25"
      decimals="INF"
      id="f-317"
      unitRef="usdPerShare">2.72</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-49" decimals="-6" id="f-318" unitRef="usd">3616000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-50" decimals="-6" id="f-319" unitRef="usd">3616000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-25" decimals="-6" id="f-320" unitRef="usd">3616000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-53" decimals="-6" id="f-321" unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-54" decimals="-6" id="f-322" unitRef="usd">236000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-50" decimals="-6" id="f-323" unitRef="usd">236000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-25" decimals="-6" id="f-324" unitRef="usd">236000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-53" decimals="-6" id="f-325" unitRef="shares">6000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-54" decimals="-6" id="f-326" unitRef="usd">571000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-50" decimals="-6" id="f-327" unitRef="usd">571000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-25" decimals="-6" id="f-328" unitRef="usd">571000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-54" decimals="-6" id="f-329" unitRef="usd">355000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-50" decimals="-6" id="f-330" unitRef="usd">355000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-6" id="f-331" unitRef="usd">355000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-54" decimals="-6" id="f-332" unitRef="usd">5000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-50" decimals="-6" id="f-333" unitRef="usd">5000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-51" decimals="-6" id="f-334" unitRef="usd">-15000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-25" decimals="-6" id="f-335" unitRef="usd">-10000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-55" decimals="-6" id="f-336" unitRef="shares">1331000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-6" id="f-337" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-6" id="f-338" unitRef="usd">24590000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-6" id="f-339" unitRef="usd">30392000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-6" id="f-340" unitRef="usd">-3499000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-6" id="f-341" unitRef="usd">51483000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-6" id="f-342" unitRef="usd">182000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-6" id="f-343" unitRef="usd">51665000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-61" decimals="-6" id="f-344" unitRef="usd">3676000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-62" decimals="-6" id="f-345" unitRef="usd">3676000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-63" decimals="-6" id="f-346" unitRef="usd">28000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-347" unitRef="usd">3705000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-64" decimals="-6" id="f-348" unitRef="usd">180000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-62" decimals="-6" id="f-349" unitRef="usd">180000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-63" decimals="-6" id="f-350" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-351" unitRef="usd">178000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-352"
      unitRef="usdPerShare">2.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-61" decimals="-6" id="f-353" unitRef="usd">3666000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-62" decimals="-6" id="f-354" unitRef="usd">3666000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-1" decimals="-6" id="f-355" unitRef="usd">3666000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-65" decimals="-6" id="f-356" unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-66" decimals="-6" id="f-357" unitRef="usd">231000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-62" decimals="-6" id="f-358" unitRef="usd">231000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-6" id="f-359" unitRef="usd">231000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-65" decimals="-6" id="f-360" unitRef="shares">25000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-66" decimals="-6" id="f-361" unitRef="usd">2084000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-62" decimals="-6" id="f-362" unitRef="usd">2084000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-1" decimals="-6" id="f-363" unitRef="usd">2084000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-66" decimals="-6" id="f-364" unitRef="usd">393000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-62" decimals="-6" id="f-365" unitRef="usd">393000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-6" id="f-366" unitRef="usd">393000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-63" decimals="-6" id="f-367" unitRef="usd">-2000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-1" decimals="-6" id="f-368" unitRef="usd">-2000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-67" decimals="-6" id="f-369" unitRef="shares">1311000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-6" id="f-370" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="-6" id="f-371" unitRef="usd">23129000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="-6" id="f-372" unitRef="usd">30403000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-70" decimals="-6" id="f-373" unitRef="usd">-3318000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-71" decimals="-6" id="f-374" unitRef="usd">50214000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-6" id="f-375" unitRef="usd">206000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-6" id="f-376" unitRef="usd">50420000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-377" unitRef="usd">3705000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-25" decimals="-6" id="f-378" unitRef="usd">3784000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-26" decimals="-6" id="f-379" unitRef="usd">5062000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-380" unitRef="usd">2647000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-25" decimals="-6" id="f-381" unitRef="usd">2697000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-26" decimals="-6" id="f-382" unitRef="usd">2707000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-6" id="f-383" unitRef="usd">90000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-25" decimals="-6" id="f-384" unitRef="usd">73000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-26" decimals="-6" id="f-385" unitRef="usd">58000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-6" id="f-386" unitRef="usd">-508000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-25" decimals="-6" id="f-387" unitRef="usd">-226000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-26" decimals="-6" id="f-388" unitRef="usd">-604000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-6" id="f-389" unitRef="usd">393000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-25" decimals="-6" id="f-390" unitRef="usd">355000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-26" decimals="-6" id="f-391" unitRef="usd">359000000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-6" id="f-392" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-25" decimals="-6" id="f-393" unitRef="usd">-53000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-26" decimals="-6" id="f-394" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-6" id="f-395" unitRef="usd">371000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-25" decimals="-6" id="f-396" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-26" decimals="-6" id="f-397" unitRef="usd">515000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-6" id="f-398" unitRef="usd">-573000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-25" decimals="-6" id="f-399" unitRef="usd">-270000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-26" decimals="-6" id="f-400" unitRef="usd">-138000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable contextRef="c-1" decimals="-6" id="f-401" unitRef="usd">391000000</us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable contextRef="c-25" decimals="-6" id="f-402" unitRef="usd">576000000</us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable contextRef="c-26" decimals="-6" id="f-403" unitRef="usd">477000000</us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-6" id="f-404" unitRef="usd">139000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-25" decimals="-6" id="f-405" unitRef="usd">939000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-26" decimals="-6" id="f-406" unitRef="usd">560000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-6" id="f-407" unitRef="usd">391000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-25" decimals="-6" id="f-408" unitRef="usd">696000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-26" decimals="-6" id="f-409" unitRef="usd">213000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-6" id="f-410" unitRef="usd">345000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-25" decimals="-6" id="f-411" unitRef="usd">148000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-26" decimals="-6" id="f-412" unitRef="usd">65000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-413" unitRef="usd">6787000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-25" decimals="-6" id="f-414" unitRef="usd">6039000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-26" decimals="-6" id="f-415" unitRef="usd">7346000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-6" id="f-416" unitRef="usd">211000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-25" decimals="-6" id="f-417" unitRef="usd">1867000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-26" decimals="-6" id="f-418" unitRef="usd">91000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-419" unitRef="usd">1587000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-25" decimals="-6" id="f-420" unitRef="usd">1459000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-26" decimals="-6" id="f-421" unitRef="usd">1368000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-6" id="f-422" unitRef="usd">7748000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-25" decimals="-6" id="f-423" unitRef="usd">7514000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-26" decimals="-6" id="f-424" unitRef="usd">9882000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-6" id="f-425" unitRef="usd">7441000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-25" decimals="-6" id="f-426" unitRef="usd">7343000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-26" decimals="-6" id="f-427" unitRef="usd">9692000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-6" id="f-428" unitRef="usd">261000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-25" decimals="-6" id="f-429" unitRef="usd">-4000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-26" decimals="-6" id="f-430" unitRef="usd">10000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-431" unitRef="usd">-2366000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-25" decimals="-6" id="f-432" unitRef="usd">-3493000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-26" decimals="-6" id="f-433" unitRef="usd">-1659000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess contextRef="c-1" decimals="-6" id="f-434" unitRef="usd">1073000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess contextRef="c-25" decimals="-6" id="f-435" unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess contextRef="c-26" decimals="-6" id="f-436" unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-1" decimals="-6" id="f-437" unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-25" decimals="-6" id="f-438" unitRef="usd">2284000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-26" decimals="-6" id="f-439" unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-1" decimals="-6" id="f-440" unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-25" decimals="-6" id="f-441" unitRef="usd">2279000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-26" decimals="-6" id="f-442" unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-6" id="f-443" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-25" decimals="-6" id="f-444" unitRef="usd">5409000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-26" decimals="-6" id="f-445" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-6" id="f-446" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-25" decimals="-6" id="f-447" unitRef="usd">6012000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-26" decimals="-6" id="f-448" unitRef="usd">1000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="-6" id="f-449" unitRef="usd">3666000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-25" decimals="-6" id="f-450" unitRef="usd">3616000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-26" decimals="-6" id="f-451" unitRef="usd">3383000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-1" decimals="-6" id="f-452" unitRef="usd">284000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-25" decimals="-6" id="f-453" unitRef="usd">308000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-26" decimals="-6" id="f-454" unitRef="usd">429000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-6" id="f-455" unitRef="usd">2138000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-25" decimals="-6" id="f-456" unitRef="usd">645000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-26" decimals="-6" id="f-457" unitRef="usd">2544000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-6" id="f-458" unitRef="usd">-3000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-25" decimals="-6" id="f-459" unitRef="usd">-409000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-26" decimals="-6" id="f-460" unitRef="usd">163000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-461" unitRef="usd">-4450000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-25" decimals="-6" id="f-462" unitRef="usd">-4960000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-26" decimals="-6" id="f-463" unitRef="usd">-5336000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-6" id="f-464" unitRef="usd">-230000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-25" decimals="-6" id="f-465" unitRef="usd">243000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-6" id="f-466" unitRef="usd">-231000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-467" unitRef="usd">-259000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-25" decimals="-6" id="f-468" unitRef="usd">-2171000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-26" decimals="-6" id="f-469" unitRef="usd">121000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-6" id="f-470" unitRef="usd">1543000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-48" decimals="-6" id="f-471" unitRef="usd">3714000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-35" decimals="-6" id="f-472" unitRef="usd">3593000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-6" id="f-473" unitRef="usd">1284000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-6" id="f-474" unitRef="usd">1543000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-48" decimals="-6" id="f-475" unitRef="usd">3714000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-6" id="f-476" unitRef="usd">1622000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-25" decimals="-6" id="f-477" unitRef="usd">1548000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-26" decimals="-6" id="f-478" unitRef="usd">996000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-6" id="f-479" unitRef="usd">826000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-25" decimals="-6" id="f-480" unitRef="usd">606000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-26" decimals="-6" id="f-481" unitRef="usd">540000000</us-gaap:InterestPaidNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-482">Summary of Significant Accounting Policies &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of Operations   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medtronic plc (Medtronic or the Company)&#160;is the leading global healthcare technology company&#x2013; alleviating pain, restoring health, and extending life for millions of people around the world. The Company provides innovative products and therapies to serve healthcare systems, physicians, clinicians, and patients. Medtronic was founded in 1949 and is headquartered in Dublin, Ireland. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible asset, equity investment, and liability valuations. Actual results may or may not differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal Year-End&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;26, 2024 and April&#160;28, 2023 and for each of the three fiscal years ended April&#160;26, 2024 (fiscal year 2024), April&#160;28, 2023 (fiscal year 2023), and April&#160;29, 2022 (fiscal year 2022).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#x2019;s investment and are adjusted each period for the Company&#x2019;s share of the investee&#x2019;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of property, plant, and equipment asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Goodwill and Intangible Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#x2019;s net assets exceeds the estimated fair value of the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from &lt;span style="-sec-ix-hidden:f-494"&gt;three&lt;/span&gt; to 20 years. Amortization is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;amortization of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable, the Company calculates the excess of an asset group's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group, which includes intangible assets, is estimated by utilizing a discounted cash flow analysis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#x2019;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;amp;D with no alternative future use acquired outside of a business combination is expensed immediately. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain of the Company&#x2019;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#x2019;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating expense (income), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Self-Insurance  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#x2019; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Assumptions  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. See Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a cash flow hedge or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Inputs are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency forward contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, certificates of deposits, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#x2019;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;intangible assets, and IPR&amp;amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general, and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income and were $341 million, $351 million, and $354 million in fiscal years 2024, 2023, and 2022, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cost of products sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#x2019;s tax return but has not yet been recognized as an expense in the consolidated statements of income.&#160;See Footnote 13 for more information on the Company's uncertain tax positions and tax policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Operating Expense (Income), Net  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other operating expense (income), net primarily includes royalty expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in fair value of contingent consideration, certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquisition and divestiture-related items, income from funded research and development arrangements, and commitments to the Medtronic Foundation and Medtronic LABS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Non-Operating Income, Net   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Currency Translation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating expense (income), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplier Finance Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#x2014; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#x2019;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023. The adoption of this standard did not have a material impact on the Company&#x2019;s Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-483">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation  &lt;/span&gt; The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c-1" id="f-484">Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-485">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible asset, equity investment, and liability valuations. Actual results may or may not differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FiscalPeriod contextRef="c-1" id="f-486">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal Year-End&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;26, 2024 and April&#160;28, 2023 and for each of the three fiscal years ended April&#160;26, 2024 (fiscal year 2024), April&#160;28, 2023 (fiscal year 2023), and April&#160;29, 2022 (fiscal year 2022).&lt;/span&gt;&lt;/div&gt;</us-gaap:FiscalPeriod>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-487">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-488">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#x2019;s investment and are adjusted each period for the Company&#x2019;s share of the investee&#x2019;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-489">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-490">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories  &lt;/span&gt; Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-491">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of property, plant, and equipment asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-492">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Goodwill and Intangible Assets &lt;/span&gt;  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#x2019;s net assets exceeds the estimated fair value of the reporting unit.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-493">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from &lt;span style="-sec-ix-hidden:f-494"&gt;three&lt;/span&gt; to 20 years. Amortization is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;amortization of intangible assets&lt;/span&gt; in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable, the Company calculates the excess of an asset group's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group, which includes intangible assets, is estimated by utilizing a discounted cash flow analysis.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-74" id="f-495">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c-1" id="f-496">Acquired IPR&amp;amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#x2019;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;amp;D with no alternative future use acquired outside of a business combination is expensed immediately.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <mdt:ContingentConsiderationPolicyTextBlock contextRef="c-1" id="f-497">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain of the Company&#x2019;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#x2019;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating expense (income), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</mdt:ContingentConsiderationPolicyTextBlock>
    <us-gaap:SelfInsuranceReservePolicyTextBlock contextRef="c-1" id="f-498">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Self-Insurance  &lt;/span&gt; The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#x2019; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured.</us-gaap:SelfInsuranceReservePolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy contextRef="c-1" id="f-499">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Assumptions  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. See Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-500">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a cash flow hedge or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-501">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Inputs are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency forward contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, certificates of deposits, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#x2019;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;intangible assets, and IPR&amp;amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-502">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general, and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income and were $341 million, $351 million, and $354 million in fiscal years 2024, 2023, and 2022, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cost of products sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-75" decimals="-6" id="f-503" unitRef="usd">341000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-76" decimals="-6" id="f-504" unitRef="usd">351000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-77" decimals="-6" id="f-505" unitRef="usd">354000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-506">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-507">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-508">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#x2019;s tax return but has not yet been recognized as an expense in the consolidated statements of income.</us-gaap:IncomeTaxPolicyTextBlock>
    <mdt:OtherOperatingIncomeExpenseNetPolicyTextBlock contextRef="c-1" id="f-509">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Operating Expense (Income), Net  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other operating expense (income), net primarily includes royalty expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in fair value of contingent consideration, certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquisition and divestiture-related items, income from funded research and development arrangements, and commitments to the Medtronic Foundation and Medtronic LABS.&lt;/span&gt;&lt;/div&gt;</mdt:OtherOperatingIncomeExpenseNetPolicyTextBlock>
    <mdt:OtherNonoperatingIncomeExpenseNetPolicyTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Non-Operating Income, Net   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income.&lt;/span&gt;&lt;/div&gt;</mdt:OtherNonoperatingIncomeExpenseNetPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-511">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Currency Translation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating expense (income), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-512">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-513">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplier Finance Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#x2014; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#x2019;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023. The adoption of this standard did not have a material impact on the Company&#x2019;s Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-514">Revenue &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Prior period revenue has been recast to reflect the new reporting structure. The activity of the Company's Renal Care Solutions business and the ventilator product line were moved out of Medical Surgical and into the Other line, and the retained PMRI businesses were combined into one business unit called Acute Care &amp;amp; Monitoring in Medical Surgical. Refer to Note 19 to the consolidated financial statements for additional information regarding the Company's reporting structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below illustrates net sales by segment and division for fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Sales by Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiac Rhythm &amp;amp; Heart Failure&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Structural Heart &amp;amp; Aortic &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coronary &amp;amp; Peripheral Vascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cranial &amp;amp; Spinal Technologies &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surgical &amp;amp; Endoscopy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acute Care &amp;amp; Monitoring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The table below illustrates net sales by market geography for each segment for fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Developed Markets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;U.S. includes the United States and U.S. territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At April&#160;26, 2024, $1.0&#160;billion of rebates were classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$574&#160;million of rebates were classified as a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accounts receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated balance sheet. At April&#160;28, 2023, $1.1 billion of rebates were classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $555 million of rebates were classified as a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accounts receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated balance sheet. During fiscal year 2024, adjustments to rebate and return reserves recognized in revenue that were included in the rebate and return reserves at the beginning of the period were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Revenue and Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue at April&#160;26, 2024 and April&#160;28, 2023 was $453&#160;million and $405&#160;million, respectively. At April&#160;26, 2024 and April&#160;28, 2023, $352&#160;million and $314&#160;million was included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, and $101&#160;million and $91&#160;million was included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively. During the fiscal year ended&#160;April&#160;26, 2024, the Company recognized&#160;$324 million&#160;of revenue that was included in deferred revenue as of&#160;April&#160;28, 2023. During the fiscal year ended April&#160;28, 2023, the Company recognized $240 million of revenue that was included in deferred revenue at April&#160;29, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At April&#160;26, 2024, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $0.5&#160;billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next two years.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-515">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below illustrates net sales by segment and division for fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Sales by Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiac Rhythm &amp;amp; Heart Failure&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Structural Heart &amp;amp; Aortic &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coronary &amp;amp; Peripheral Vascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cranial &amp;amp; Spinal Technologies &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surgical &amp;amp; Endoscopy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acute Care &amp;amp; Monitoring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The table below illustrates net sales by market geography for each segment for fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Developed Markets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;U.S. includes the United States and U.S. territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-6" id="f-516" unitRef="usd">5995000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="-6" id="f-517" unitRef="usd">5783000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-6" id="f-518" unitRef="usd">5852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-6" id="f-519" unitRef="usd">3358000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-6" id="f-520" unitRef="usd">3363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-6" id="f-521" unitRef="usd">3055000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-6" id="f-522" unitRef="usd">2478000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-6" id="f-523" unitRef="usd">2375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-6" id="f-524" unitRef="usd">2460000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-6" id="f-525" unitRef="usd">11831000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-6" id="f-526" unitRef="usd">11522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-6" id="f-527" unitRef="usd">11368000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-90" decimals="-6" id="f-528" unitRef="usd">4756000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-91" decimals="-6" id="f-529" unitRef="usd">4451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="-6" id="f-530" unitRef="usd">4456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-6" id="f-531" unitRef="usd">2905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-6" id="f-532" unitRef="usd">2815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-6" id="f-533" unitRef="usd">2592000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-6" id="f-534" unitRef="usd">1746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-6" id="f-535" unitRef="usd">1693000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-6" id="f-536" unitRef="usd">1735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-6" id="f-537" unitRef="usd">9406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-6" id="f-538" unitRef="usd">8959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-6" id="f-539" unitRef="usd">8784000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-6" id="f-540" unitRef="usd">6508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-6" id="f-541" unitRef="usd">6152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-6" id="f-542" unitRef="usd">6543000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-6" id="f-543" unitRef="usd">1908000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-106" decimals="-6" id="f-544" unitRef="usd">1837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-6" id="f-545" unitRef="usd">1926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-6" id="f-546" unitRef="usd">8417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-6" id="f-547" unitRef="usd">7989000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-6" id="f-548" unitRef="usd">8469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-6" id="f-549" unitRef="usd">2488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-112" decimals="-6" id="f-550" unitRef="usd">2262000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-113" decimals="-6" id="f-551" unitRef="usd">2338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-114" decimals="-6" id="f-552" unitRef="usd">32142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-115" decimals="-6" id="f-553" unitRef="usd">30731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-116" decimals="-6" id="f-554" unitRef="usd">30959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-117" decimals="-6" id="f-555" unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-118" decimals="-6" id="f-556" unitRef="usd">495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-119" decimals="-6" id="f-557" unitRef="usd">727000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-558" unitRef="usd">32364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-6" id="f-559" unitRef="usd">31227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-6" id="f-560" unitRef="usd">31686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-120" decimals="-6" id="f-561" unitRef="usd">5597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-121" decimals="-6" id="f-562" unitRef="usd">5796000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-122" decimals="-6" id="f-563" unitRef="usd">5490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-123" decimals="-6" id="f-564" unitRef="usd">3857000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-124" decimals="-6" id="f-565" unitRef="usd">3564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-125" decimals="-6" id="f-566" unitRef="usd">3866000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-126" decimals="-6" id="f-567" unitRef="usd">2377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-127" decimals="-6" id="f-568" unitRef="usd">2161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-128" decimals="-6" id="f-569" unitRef="usd">2012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-129" decimals="-6" id="f-570" unitRef="usd">6305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-130" decimals="-6" id="f-571" unitRef="usd">6018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-131" decimals="-6" id="f-572" unitRef="usd">5753000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-132" decimals="-6" id="f-573" unitRef="usd">1739000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-133" decimals="-6" id="f-574" unitRef="usd">1658000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-134" decimals="-6" id="f-575" unitRef="usd">1801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-135" decimals="-6" id="f-576" unitRef="usd">1362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-136" decimals="-6" id="f-577" unitRef="usd">1283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-137" decimals="-6" id="f-578" unitRef="usd">1229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-138" decimals="-6" id="f-579" unitRef="usd">3717000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-139" decimals="-6" id="f-580" unitRef="usd">3549000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-140" decimals="-6" id="f-581" unitRef="usd">3659000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-141" decimals="-6" id="f-582" unitRef="usd">3049000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-142" decimals="-6" id="f-583" unitRef="usd">2917000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-143" decimals="-6" id="f-584" unitRef="usd">3155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-144" decimals="-6" id="f-585" unitRef="usd">1650000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-145" decimals="-6" id="f-586" unitRef="usd">1522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-146" decimals="-6" id="f-587" unitRef="usd">1655000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-147" decimals="-6" id="f-588" unitRef="usd">852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-148" decimals="-6" id="f-589" unitRef="usd">849000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-149" decimals="-6" id="f-590" unitRef="usd">974000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-150" decimals="-6" id="f-591" unitRef="usd">1284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-151" decimals="-6" id="f-592" unitRef="usd">1106000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-152" decimals="-6" id="f-593" unitRef="usd">1085000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-153" decimals="-6" id="f-594" unitRef="usd">352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-154" decimals="-6" id="f-595" unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-155" decimals="-6" id="f-596" unitRef="usd">279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-156" decimals="-6" id="f-597" unitRef="usd">16471000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-157" decimals="-6" id="f-598" unitRef="usd">16212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-158" decimals="-6" id="f-599" unitRef="usd">15876000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-159" decimals="-6" id="f-600" unitRef="usd">9929000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-160" decimals="-6" id="f-601" unitRef="usd">9245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-161" decimals="-6" id="f-602" unitRef="usd">9907000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-162" decimals="-6" id="f-603" unitRef="usd">5742000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-163" decimals="-6" id="f-604" unitRef="usd">5273000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-164" decimals="-6" id="f-605" unitRef="usd">5176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-165" decimals="-6" id="f-606" unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-166" decimals="-6" id="f-607" unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-167" decimals="-6" id="f-608" unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-168" decimals="-6" id="f-609" unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-169" decimals="-6" id="f-610" unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-170" decimals="-6" id="f-611" unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-171" decimals="-6" id="f-612" unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-172" decimals="-6" id="f-613" unitRef="usd">172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-173" decimals="-6" id="f-614" unitRef="usd">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-174" decimals="-6" id="f-615" unitRef="usd">16562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-175" decimals="-6" id="f-616" unitRef="usd">16373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-176" decimals="-6" id="f-617" unitRef="usd">16135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-177" decimals="-6" id="f-618" unitRef="usd">9979000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-178" decimals="-6" id="f-619" unitRef="usd">9408000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-179" decimals="-6" id="f-620" unitRef="usd">10126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-180" decimals="-6" id="f-621" unitRef="usd">5823000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-181" decimals="-6" id="f-622" unitRef="usd">5446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-182" decimals="-6" id="f-623" unitRef="usd">5426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-183" decimals="-8" id="f-624" unitRef="usd">1000000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-184" decimals="-6" id="f-625" unitRef="usd">574000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-185" decimals="-8" id="f-626" unitRef="usd">1100000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-186" decimals="-6" id="f-627" unitRef="usd">555000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-27" decimals="0" id="f-628" unitRef="usd">0</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-27" decimals="-6" id="f-629" unitRef="usd">453000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-28" decimals="-6" id="f-630" unitRef="usd">405000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-183" decimals="-6" id="f-631" unitRef="usd">352000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-185" decimals="-6" id="f-632" unitRef="usd">314000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-187" decimals="-6" id="f-633" unitRef="usd">101000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-188" decimals="-6" id="f-634" unitRef="usd">91000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-6" id="f-635" unitRef="usd">324000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-25" decimals="-6" id="f-636" unitRef="usd">240000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-27" decimals="-8" id="f-637" unitRef="usd">500000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming contextRef="c-1" id="f-638">two years</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-639">Acquisitions and Dispositions &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had acquisitions during fiscal years 2024 and 2023 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future, yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The results of operations of acquired businesses have been included in the Company&#x2019;s consolidated statements of income since the date each business was acquired. The results of operations of acquired businesses and the pro forma impact of the acquisitions during fiscal years 2024 and 2023 was not significant, either individually or in the aggregate, to the consolidated results of the Company. Purchase price allocation adjustments for fiscal years 2024 and 2023 business combinations were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair value of net assets acquired during the fiscal year ended April&#160;26, 2024 was $335&#160;million. Based on preliminary valuations, assets acquired were primarily comprised of $131&#160;million of goodwill, $150&#160;million of IPR&amp;amp;D, and $29&#160;million of technology-based intangible assets with estimated useful lives of 10 years. For tax purposes, $51&#160;million of goodwill is deductible while $80&#160;million is not deductible. The Company recognized $30&#160;million of non-cash contingent consideration liabilities in connection with these business combinations during the fiscal year ended April&#160;26, 2024, which are comprised of revenue and product development milestone-based payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal Year 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intersect ENT&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 13, 2022, the Company acquired Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader. The acquisition expands the Neuroscience segment portfolio of products used during ENT procedures, and combined with the Company's navigation, powered instruments, and existing tissue health products, offers a broader suite of solutions to assist surgeons treating patients who suffer from chronic rhinosinusitis (CRS). Total consideration, net of cash acquired, for the transaction, in which the Company acquired all outstanding shares of Intersect ENT for $28.25 per share, was $1.2&#160;billion consisting of $1.1&#160;billion of cash and $98&#160;million previously held investments in Intersect ENT. The Company acquired $615&#160;million of goodwill, $635&#160;million of technology-based intangible assets, $35&#160;million of customer-related intangible assets, and $13&#160;million of tradenames with estimated useful lives of 20 years. The goodwill is not deductible for tax purposes. Revenue and net loss attributable to Intersect ENT since the date of acquisition as well as costs incurred in connection with the acquisition included in the consolidated statements of income were not significant for fiscal year 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Affera, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2022, the Company acquired Affera, Inc. (Affera) a privately-held company focused on the development of cardiac mapping and navigation systems and catheter-based cardiac ablation technologies. The acquisition expands the Cardiovascular segment suite of advanced cardiac ablation products and accessories, including its first cardiac mapping and navigation platform. Total consideration, net of cash acquired for the transaction, was $904&#160;million. The Company acquired $660 million of goodwill and $300 million of IPR&amp;amp;D, which was capitalized into intangible assets during the fourth quarter of fiscal year 2023. The goodwill is not deductible for tax purposes. The Company recognized $201 million of non-cash contingent consideration liabilities in connection with the acquisition, which are comprised of product development milestone-based payments. Revenue and net loss attributable to Affera since the date of acquisition as well as costs incurred in connection with the acquisition included in the consolidated statements of income were not significant for fiscal year 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of the assets acquired and liabilities assumed were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intersect ENT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affera&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For acquisitions, other than Intersect ENT and Affera, the acquisition date fair value of net assets acquired during fiscal year 2023 was $123 million. Assets acquired were primarily comprised of $66 million of goodwill and $57&#160;million of technology-based intangible assets with estimated useful lives of 16 years. The goodwill is deductible for tax purposes. The Company recognized $73&#160;million of non-cash contingent consideration liabilities in connection with these acquisitions during fiscal year 2023, which are comprised of revenue and product development milestone-based payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Disposal Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ventilator Product Line Exit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 20, 2024, the Company announced the decision to exit its ventilator product line and retain and combine the remaining Patient Monitoring and Respiratory Interventions (PMRI) businesses into one business unit called Acute Care and Monitoring (ACM). In connection with this decision, the Company recorded pre-tax charges of $439&#160;million, including $369&#160;million recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating expense (income), net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$70&#160;million recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cost of products sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income in fiscal year 2024. The charges included $371&#160;million of non-cash impairments and write-downs primarily related to $295&#160;million of long-lived intangible asset impairments and $70&#160;million of inventory-write downs. The other charges primarily related to contract cancellation costs and severance. The Company will continue to honor existing ventilator contracts to serve the needs of its customers and their patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Renal Care Solutions (RCS) Disposition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 25, 2022, the Company and DaVita Inc. (DaVita) entered into a definitive agreement for the Company to sell half of its RCS business, and on April 1, 2023, completed the transaction. This sale is part of an agreement between Medtronic and DaVita to form a new, independent kidney care-focused medical device company (&#x201c;Mozarc Medical&#x201d; or "Mozarc") with equal equity ownership. At closing, the Company received $45&#160;million cash consideration, recorded non-cash contingent consideration receivables valued at $195&#160;million, made an additional cash investment of $224&#160;million, and retained a 50% non-controlling equity interest in Mozarc valued at $307&#160;million. For the contingent consideration receivables, the maximum consideration the Company could receive in the future is $300&#160;million based on the achievement of certain milestones, as further described below. The Company recorded non-cash pre-tax charges of $136&#160;million in fiscal year 2023, primarily related to impairment of goodwill and changes in the carrying amount of the disposal group, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating expense (income), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Refer to Note 9 to the consolidated financial statements for additional information on the goodwill impairment. Refer to Note 5 to the consolidated financial statements for additional information on the Company&#x2019;s retained 50% equity investment in Mozarc as a result of this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the sale of the RCS business did not meet the criteria to be classified as discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Mechanical Circulatory Support (MCS) Business Exit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company announced the decision to stop the distribution and sale of the Medtronic HVAD System. In connection with this decision, the Company recorded pre-tax charges of $881&#160;million, including $58&#160;million recognized in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; costs of products sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $823&#160;million recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating expense (income), net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statement of income in fiscal year 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The charges included $515&#160;million of non-cash impairments and write-downs primarily related to $409&#160;million of &lt;span style="-sec-ix-hidden:f-708"&gt;intangible asset impairments&lt;/span&gt; and $58&#160;million of inventory write-downs. The Company also recorded charges of $366&#160;million for commitments and obligations associated with the decision, which included charges for patient support obligations, restructuring, and other associated costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating expense (income), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of contingent consideration liabilities at April&#160;26, 2024 and April&#160;28, 2023 was $149 million and $206 million, respectively. At April&#160;26, 2024, $96 million was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $53 million was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. At April&#160;28, 2023, $34 million was reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $171 million was reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase price contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestiture-related and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue and other performance-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5% - 28.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 - 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product development and other milestone-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5% - 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 - 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the sale of our RCS business as further discussed above, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2025 through 2029. The fair value of the contingent consideration receivable at April 26, 2024 and April 28, 2023 was $58&#160;million and $195&#160;million,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, and was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase price contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-189" decimals="-6" id="f-640" unitRef="usd">335000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Goodwill contextRef="c-190" decimals="-6" id="f-641" unitRef="usd">131000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-191" decimals="-6" id="f-642" unitRef="usd">150000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-192" decimals="-6" id="f-643" unitRef="usd">29000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-192" id="f-644">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillImpairmentLossNetOfTax contextRef="c-189" decimals="-6" id="f-645" unitRef="usd">51000000</us-gaap:GoodwillImpairmentLossNetOfTax>
    <us-gaap:GoodwillNotAllocatedAmount contextRef="c-190" decimals="-6" id="f-646" unitRef="usd">80000000</us-gaap:GoodwillNotAllocatedAmount>
    <mdt:BusinessAcquisitionPriceContingentConsideration contextRef="c-1" decimals="-6" id="f-647" unitRef="usd">30000000</mdt:BusinessAcquisitionPriceContingentConsideration>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-193"
      decimals="2"
      id="f-648"
      unitRef="usdPerShare">28.25</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-194" decimals="-8" id="f-649" unitRef="usd">1200000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-194" decimals="-8" id="f-650" unitRef="usd">1100000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-194" decimals="-6" id="f-651" unitRef="usd">98000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:Goodwill contextRef="c-193" decimals="-6" id="f-652" unitRef="usd">615000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-195" decimals="-6" id="f-653" unitRef="usd">635000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-196" decimals="-6" id="f-654" unitRef="usd">35000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-197" decimals="-6" id="f-655" unitRef="usd">13000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-193" id="f-656">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-198" decimals="-6" id="f-657" unitRef="usd">904000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Goodwill contextRef="c-199" decimals="-6" id="f-658" unitRef="usd">660000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-200" decimals="-6" id="f-659" unitRef="usd">300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <mdt:BusinessAcquisitionContingentConsiderationLiability contextRef="c-199" decimals="-6" id="f-660" unitRef="usd">201000000</mdt:BusinessAcquisitionContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-661">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of the assets acquired and liabilities assumed were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intersect ENT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affera&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-193" decimals="-6" id="f-662" unitRef="usd">39000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-199" decimals="-6" id="f-663" unitRef="usd">66000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-193" decimals="-6" id="f-664" unitRef="usd">32000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-199" decimals="-6" id="f-665" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:Goodwill contextRef="c-193" decimals="-6" id="f-666" unitRef="usd">615000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-199" decimals="-6" id="f-667" unitRef="usd">660000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-193" decimals="-6" id="f-668" unitRef="usd">683000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-199" decimals="-6" id="f-669" unitRef="usd">300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-193" decimals="-6" id="f-670" unitRef="usd">40000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-199" decimals="-6" id="f-671" unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-193" decimals="-6" id="f-672" unitRef="usd">1408000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-199" decimals="-6" id="f-673" unitRef="usd">1027000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="c-193" decimals="-6" id="f-674" unitRef="usd">63000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="c-199" decimals="-6" id="f-675" unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-193" decimals="-6" id="f-676" unitRef="usd">51000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-199" decimals="-6" id="f-677" unitRef="usd">53000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="c-193" decimals="-6" id="f-678" unitRef="usd">18000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="c-199" decimals="-6" id="f-679" unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-193" decimals="-6" id="f-680" unitRef="usd">131000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-199" decimals="-6" id="f-681" unitRef="usd">56000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-193" decimals="-6" id="f-682" unitRef="usd">1277000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-199" decimals="-6" id="f-683" unitRef="usd">970000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-201" decimals="-6" id="f-684" unitRef="usd">123000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-201" decimals="-6" id="f-685" unitRef="usd">66000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-202" decimals="-6" id="f-686" unitRef="usd">57000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-202" id="f-687">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <mdt:BusinessAcquisitionPriceContingentConsideration contextRef="c-203" decimals="-6" id="f-688" unitRef="usd">73000000</mdt:BusinessAcquisitionPriceContingentConsideration>
    <us-gaap:BusinessExitCosts1 contextRef="c-204" decimals="-6" id="f-689" unitRef="usd">439000000</us-gaap:BusinessExitCosts1>
    <mdt:DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet contextRef="c-204" decimals="-6" id="f-690" unitRef="usd">369000000</mdt:DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c-204" decimals="-6" id="f-691" unitRef="usd">70000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <mdt:DisposalGroupIncludingDiscontinuedOperationNonCashImpairments contextRef="c-205" decimals="-6" id="f-692" unitRef="usd">371000000</mdt:DisposalGroupIncludingDiscontinuedOperationNonCashImpairments>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-204" decimals="-6" id="f-693" unitRef="usd">295000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown contextRef="c-204" decimals="-6" id="f-694" unitRef="usd">70000000</us-gaap:InventoryWriteDown>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-206" decimals="-6" id="f-695" unitRef="usd">45000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-207" decimals="-6" id="f-696" unitRef="usd">195000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-206" decimals="-6" id="f-697" unitRef="usd">224000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-208" decimals="2" id="f-698" unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterest contextRef="c-209" decimals="-6" id="f-699" unitRef="usd">307000000</us-gaap:MinorityInterest>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-210" decimals="-6" id="f-700" unitRef="usd">300000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <us-gaap:AssetImpairmentCharges contextRef="c-211" decimals="-6" id="f-701" unitRef="usd">136000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-212" decimals="2" id="f-702" unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:BusinessExitCosts1 contextRef="c-213" decimals="-6" id="f-703" unitRef="usd">881000000</us-gaap:BusinessExitCosts1>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-213" decimals="-6" id="f-704" unitRef="usd">58000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-213" decimals="-6" id="f-705" unitRef="usd">823000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <mdt:DisposalGroupIncludingDiscontinuedOperationNonCashImpairments contextRef="c-214" decimals="-6" id="f-706" unitRef="usd">515000000</mdt:DisposalGroupIncludingDiscontinuedOperationNonCashImpairments>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-213" decimals="-6" id="f-707" unitRef="usd">409000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown contextRef="c-213" decimals="-6" id="f-709" unitRef="usd">58000000</us-gaap:InventoryWriteDown>
    <us-gaap:OtherCommitment contextRef="c-214" decimals="-6" id="f-710" unitRef="usd">366000000</us-gaap:OtherCommitment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-27" decimals="-6" id="f-711" unitRef="usd">149000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-28" decimals="-6" id="f-712" unitRef="usd">206000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-183" decimals="-6" id="f-713" unitRef="usd">96000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-187" decimals="-6" id="f-714" unitRef="usd">53000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-185" decimals="-6" id="f-715" unitRef="usd">34000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-188" decimals="-6" id="f-716" unitRef="usd">171000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="c-1" id="f-717">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase price contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestiture-related and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase price contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-28" decimals="-6" id="f-718" unitRef="usd">206000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-48" decimals="-6" id="f-719" unitRef="usd">119000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <mdt:BusinessAcquisitionPriceContingentConsideration contextRef="c-1" decimals="-6" id="f-720" unitRef="usd">30000000</mdt:BusinessAcquisitionPriceContingentConsideration>
    <mdt:BusinessAcquisitionPriceContingentConsideration contextRef="c-25" decimals="-6" id="f-721" unitRef="usd">274000000</mdt:BusinessAcquisitionPriceContingentConsideration>
    <mdt:BusinessAcquisitionContingentConsiderationMilestonePayment contextRef="c-1" decimals="-6" id="f-722" unitRef="usd">104000000</mdt:BusinessAcquisitionContingentConsiderationMilestonePayment>
    <mdt:BusinessAcquisitionContingentConsiderationMilestonePayment contextRef="c-25" decimals="-6" id="f-723" unitRef="usd">154000000</mdt:BusinessAcquisitionContingentConsiderationMilestonePayment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-6" id="f-724" unitRef="usd">18000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-25" decimals="-6" id="f-725" unitRef="usd">-24000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <mdt:BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses contextRef="c-1" decimals="-6" id="f-726" unitRef="usd">0</mdt:BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses>
    <mdt:BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses contextRef="c-25" decimals="-6" id="f-727" unitRef="usd">-8000000</mdt:BussinessAcquisitionContingentConsiderationDivestitureRelatedAndOtherExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-27" decimals="-6" id="f-728" unitRef="usd">149000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-28" decimals="-6" id="f-729" unitRef="usd">206000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-730">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue and other performance-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5% - 28.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 - 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product development and other milestone-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5% - 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 - 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-215" decimals="-6" id="f-731" unitRef="usd">80000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-216" decimals="3" id="f-732" unitRef="number">0.165</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-217" decimals="3" id="f-733" unitRef="number">0.282</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-218" decimals="3" id="f-734" unitRef="number">0.203</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-219" decimals="-6" id="f-735" unitRef="usd">69000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-220" decimals="3" id="f-736" unitRef="number">0.055</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-221" decimals="3" id="f-737" unitRef="number">0.055</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-222" decimals="3" id="f-738" unitRef="number">0.055</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-27" decimals="-6" id="f-739" unitRef="usd">58000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-28" decimals="-6" id="f-740" unitRef="usd">195000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-223" decimals="-6" id="f-741" unitRef="usd">195000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-224" decimals="-6" id="f-742" unitRef="usd">0</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:BusinessAcquisitionPriceContingentConsideration contextRef="c-225" decimals="-6" id="f-743" unitRef="usd">0</mdt:BusinessAcquisitionPriceContingentConsideration>
    <mdt:BusinessAcquisitionPriceContingentConsideration contextRef="c-226" decimals="-6" id="f-744" unitRef="usd">195000000</mdt:BusinessAcquisitionPriceContingentConsideration>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue contextRef="c-225" decimals="-6" id="f-745" unitRef="usd">-138000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue contextRef="c-226" decimals="-6" id="f-746" unitRef="usd">0</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-227" decimals="-6" id="f-747" unitRef="usd">58000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-223" decimals="-6" id="f-748" unitRef="usd">195000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-749">Restructuring Charges &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In fiscal year 2024, the Company incurred $389 million of restructuring and associated costs primarily related to employee termination benefits and facility consolidations to support cost reduction initiatives. In fiscal years 2023 and 2022, restructuring costs primarily related to Enterprise Excellence and Simplification restructuring programs, both of which were substantially completed as of the end fiscal year 2023. Enterprise Excellence was designed to leverage the Company&#x2019;s global size and scale to focus on global operations, and functional and commercial optimization, and had total cumulative pre-tax charges of $1.8 billion. Simplification was designed to focus the organization on accelerating innovation, enhancing customer experience, driving revenue growth and winning market share, and had total cumulative pre-tax charges of $0.5 billion. In addition, in the fourth quarter of fiscal year 2023, the Company incurred $0.3 billion of restructuring charges primarily related to employee termination benefits to support cost reduction initiatives. These charges were incremental to charges incurred under our Enterprise Excellence and Simplification programs noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and voluntary early retirement benefits in fiscal year 2023. Associated costs primarily include salaries and wages of employees that are fully-dedicated to restructuring programs, consulting fees, and asset write-offs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of restructuring costs in the consolidated statements of income: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the activity related to restructuring programs for fiscal years 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Associated and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages. These costs are not included in the table summarizing restructuring charges above, as they are associated with costs that are accounted for under the pension and post-retirement rules.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;Accrual adjustments relate to certain employees identified for termination finding other positions within the Company or contract terminations being settled for less than originally estimated.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-6" id="f-750" unitRef="usd">389000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-228" decimals="-8" id="f-751" unitRef="usd">1800000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-229" decimals="-8" id="f-752" unitRef="usd">500000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges contextRef="c-230" decimals="-8" id="f-753" unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-754">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of restructuring costs in the consolidated statements of income: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the activity related to restructuring programs for fiscal years 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Associated and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages. These costs are not included in the table summarizing restructuring charges above, as they are associated with costs that are accounted for under the pension and post-retirement rules.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;Accrual adjustments relate to certain employees identified for termination finding other positions within the Company or contract terminations being settled for less than originally estimated.</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-231" decimals="-6" id="f-755" unitRef="usd">55000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-232" decimals="-6" id="f-756" unitRef="usd">97000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-233" decimals="-6" id="f-757" unitRef="usd">117000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-234" decimals="-6" id="f-758" unitRef="usd">108000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-235" decimals="-6" id="f-759" unitRef="usd">173000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-236" decimals="-6" id="f-760" unitRef="usd">158000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-237" decimals="-6" id="f-761" unitRef="usd">226000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-238" decimals="-6" id="f-762" unitRef="usd">375000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-239" decimals="-6" id="f-763" unitRef="usd">60000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-6" id="f-764" unitRef="usd">389000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-25" decimals="-6" id="f-765" unitRef="usd">647000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-26" decimals="-6" id="f-766" unitRef="usd">335000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-240" decimals="-6" id="f-767" unitRef="usd">94000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserve contextRef="c-241" decimals="-6" id="f-768" unitRef="usd">81000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-242" decimals="-6" id="f-769" unitRef="usd">28000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-48" decimals="-6" id="f-770" unitRef="usd">110000000</us-gaap:RestructuringReserve>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-243" decimals="-6" id="f-771" unitRef="usd">285000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-244" decimals="-6" id="f-772" unitRef="usd">279000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-25" decimals="-6" id="f-773" unitRef="usd">564000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <us-gaap:PaymentsForRestructuring contextRef="c-243" decimals="-6" id="f-774" unitRef="usd">150000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-244" decimals="-6" id="f-775" unitRef="usd">281000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-25" decimals="-6" id="f-776" unitRef="usd">433000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-243" decimals="-6" id="f-777" unitRef="usd">-11000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-244" decimals="-6" id="f-778" unitRef="usd">-1000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-25" decimals="-6" id="f-779" unitRef="usd">-12000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve contextRef="c-245" decimals="-6" id="f-780" unitRef="usd">204000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-246" decimals="-6" id="f-781" unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-28" decimals="-6" id="f-782" unitRef="usd">230000000</us-gaap:RestructuringReserve>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-247" decimals="-6" id="f-783" unitRef="usd">233000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-248" decimals="-6" id="f-784" unitRef="usd">163000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-1" decimals="-6" id="f-785" unitRef="usd">396000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <us-gaap:PaymentsForRestructuring contextRef="c-247" decimals="-6" id="f-786" unitRef="usd">292000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-248" decimals="-6" id="f-787" unitRef="usd">161000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-1" decimals="-6" id="f-788" unitRef="usd">453000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-247" decimals="-6" id="f-789" unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-248" decimals="-6" id="f-790" unitRef="usd">16000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-1" decimals="-6" id="f-791" unitRef="usd">16000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-247" decimals="-6" id="f-792" unitRef="usd">-8000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-248" decimals="-6" id="f-793" unitRef="usd">0</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-1" decimals="-6" id="f-794" unitRef="usd">-8000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve contextRef="c-249" decimals="-6" id="f-795" unitRef="usd">136000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-250" decimals="-6" id="f-796" unitRef="usd">11000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-27" decimals="-6" id="f-797" unitRef="usd">147000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-240" decimals="-6" id="f-798" unitRef="usd">94000000</us-gaap:RestructuringCharges>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-799">Financial Instruments &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;26, 2024 and April&#160;28, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost of debt securities excludes accrued interest, which is reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the gross unrealized losses and fair values of the Company&#x2019;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;26, 2024 and April&#160;28, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the fiscal years ended April&#160;26, 2024 and April&#160;28, 2023. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to the Company&#x2019;s available-for-sale debt securities portfolio is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of available-for-sale debt securities at April&#160;26, 2024 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the consolidated statements of income. For fiscal years 2024, 2023, and 2022 there was $597 million, $386&#160;million, and $186&#160;million of interest income, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Securities, Equity Method Investments, and Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds investments in equity securities with readily determinable fair values, equity method investments for which the Company has elected the fair value option, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments for which the Company has elected the fair value option are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses a discounted cash flow methodology, taking into consideration various assumptions including discount rate, and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values, and that are not accounted for via the fair value option, are included within Level 3 of the fair value hierarchy, as they are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's equity and other investments at&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April&#160;26, 2024 and April&#160;28, 2023, which are classified as primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments with readily determinable fair value (marketable equity securities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments for which the fair value option has been elected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments without readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses on the Company's portfolio of equity and other investments are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. During the fiscal year ended April&#160;26, 2024, there were $291&#160;million of net unrealized losses on equity securities and other investments still held at April&#160;26, 2024. During the fiscal year ended April&#160;28, 2023, there were $56&#160;million of net unrealized gains on equity securities and other investments still held at April&#160;28, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mozarc Medical Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As further described in Note 3, on April 1, 2023 the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50% equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. During the fiscal year ended April&#160;26, 2024, the Company recognized a loss of $220&#160;million, primarily driven by the timing of anticipated product launches, historical financial results, and projections of future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Initial valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional cash investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-800">The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;26, 2024 and April&#160;28, 2023:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-251" decimals="-6" id="f-801" unitRef="usd">494000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-251" decimals="-6" id="f-802" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-251" decimals="-6" id="f-803" unitRef="usd">22000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-251" decimals="-6" id="f-804" unitRef="usd">472000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-252" decimals="-6" id="f-805" unitRef="usd">472000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-253" decimals="-6" id="f-806" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-254" decimals="-6" id="f-807" unitRef="usd">3953000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-254" decimals="-6" id="f-808" unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-254" decimals="-6" id="f-809" unitRef="usd">125000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-254" decimals="-6" id="f-810" unitRef="usd">3832000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-255" decimals="-6" id="f-811" unitRef="usd">3832000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-256" decimals="-6" id="f-812" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-257" decimals="-6" id="f-813" unitRef="usd">847000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-257" decimals="-6" id="f-814" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-257" decimals="-6" id="f-815" unitRef="usd">43000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-257" decimals="-6" id="f-816" unitRef="usd">804000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-258" decimals="-6" id="f-817" unitRef="usd">804000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-259" decimals="-6" id="f-818" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-260" decimals="-6" id="f-819" unitRef="usd">692000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-260" decimals="-6" id="f-820" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-260" decimals="-6" id="f-821" unitRef="usd">50000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-260" decimals="-6" id="f-822" unitRef="usd">643000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-261" decimals="-6" id="f-823" unitRef="usd">643000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-262" decimals="-6" id="f-824" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-263" decimals="-6" id="f-825" unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-263" decimals="-6" id="f-826" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-263" decimals="-6" id="f-827" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-263" decimals="-6" id="f-828" unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-264" decimals="-6" id="f-829" unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-265" decimals="-6" id="f-830" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-266" decimals="-6" id="f-831" unitRef="usd">941000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-266" decimals="-6" id="f-832" unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-266" decimals="-6" id="f-833" unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-266" decimals="-6" id="f-834" unitRef="usd">934000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-267" decimals="-6" id="f-835" unitRef="usd">934000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-268" decimals="-6" id="f-836" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-269" decimals="-6" id="f-837" unitRef="usd">6438000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-269" decimals="-6" id="f-838" unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-269" decimals="-6" id="f-839" unitRef="usd">227000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-269" decimals="-6" id="f-840" unitRef="usd">6218000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-270" decimals="-6" id="f-841" unitRef="usd">6218000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-271" decimals="-6" id="f-842" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-272" decimals="-6" id="f-843" unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-272" decimals="-6" id="f-844" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-272" decimals="-6" id="f-845" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-272" decimals="-6" id="f-846" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-273" decimals="-6" id="f-847" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-274" decimals="-6" id="f-848" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-27" decimals="-6" id="f-849" unitRef="usd">6968000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-27" decimals="-6" id="f-850" unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-27" decimals="-6" id="f-851" unitRef="usd">252000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-27" decimals="-6" id="f-852" unitRef="usd">6723000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-275" decimals="-6" id="f-853" unitRef="usd">6690000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-276" decimals="-6" id="f-854" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-277" decimals="-6" id="f-855" unitRef="usd">527000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-277" decimals="-6" id="f-856" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-277" decimals="-6" id="f-857" unitRef="usd">22000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-277" decimals="-6" id="f-858" unitRef="usd">505000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-278" decimals="-6" id="f-859" unitRef="usd">505000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-279" decimals="-6" id="f-860" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-280" decimals="-6" id="f-861" unitRef="usd">4140000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-280" decimals="-6" id="f-862" unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-280" decimals="-6" id="f-863" unitRef="usd">162000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-280" decimals="-6" id="f-864" unitRef="usd">3984000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-281" decimals="-6" id="f-865" unitRef="usd">3984000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-282" decimals="-6" id="f-866" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-283" decimals="-6" id="f-867" unitRef="usd">879000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-283" decimals="-6" id="f-868" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-283" decimals="-6" id="f-869" unitRef="usd">45000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-283" decimals="-6" id="f-870" unitRef="usd">834000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-284" decimals="-6" id="f-871" unitRef="usd">834000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-285" decimals="-6" id="f-872" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-286" decimals="-6" id="f-873" unitRef="usd">560000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-286" decimals="-6" id="f-874" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-286" decimals="-6" id="f-875" unitRef="usd">54000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-286" decimals="-6" id="f-876" unitRef="usd">506000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-287" decimals="-6" id="f-877" unitRef="usd">506000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-288" decimals="-6" id="f-878" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-289" decimals="-6" id="f-879" unitRef="usd">15000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-289" decimals="-6" id="f-880" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-289" decimals="-6" id="f-881" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-289" decimals="-6" id="f-882" unitRef="usd">15000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-290" decimals="-6" id="f-883" unitRef="usd">15000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-291" decimals="-6" id="f-884" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-292" decimals="-6" id="f-885" unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-292" decimals="-6" id="f-886" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-292" decimals="-6" id="f-887" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-292" decimals="-6" id="f-888" unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-293" decimals="-6" id="f-889" unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-294" id="f-890" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-295" decimals="-6" id="f-891" unitRef="usd">580000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-295" decimals="-6" id="f-892" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-295" decimals="-6" id="f-893" unitRef="usd">19000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-295" decimals="-6" id="f-894" unitRef="usd">561000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-296" decimals="-6" id="f-895" unitRef="usd">561000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-297" decimals="-6" id="f-896" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-298" decimals="-6" id="f-897" unitRef="usd">6185000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-298" decimals="-6" id="f-898" unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-298" decimals="-6" id="f-899" unitRef="usd">281000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-298" decimals="-6" id="f-900" unitRef="usd">5911000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-299" decimals="-6" id="f-901" unitRef="usd">5911000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-300" decimals="-6" id="f-902" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-301" decimals="-6" id="f-903" unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-301" decimals="-6" id="f-904" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-301" decimals="-6" id="f-905" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-301" decimals="-6" id="f-906" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-302" decimals="-6" id="f-907" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-303" decimals="-6" id="f-908" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-28" decimals="-6" id="f-909" unitRef="usd">6748000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-28" decimals="-6" id="f-910" unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-28" decimals="-6" id="f-911" unitRef="usd">305000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-28" decimals="-6" id="f-912" unitRef="usd">6449000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-304" decimals="-6" id="f-913" unitRef="usd">6416000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-305" decimals="-6" id="f-914" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-915">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the gross unrealized losses and fair values of the Company&#x2019;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;26, 2024 and April&#160;28, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-306" decimals="-6" id="f-916" unitRef="usd">661000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-306" decimals="-6" id="f-917" unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-306" decimals="-6" id="f-918" unitRef="usd">2448000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-306" decimals="-6" id="f-919" unitRef="usd">116000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-307" decimals="-6" id="f-920" unitRef="usd">177000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-307" decimals="-6" id="f-921" unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-307" decimals="-6" id="f-922" unitRef="usd">730000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-307" decimals="-6" id="f-923" unitRef="usd">61000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-308" decimals="-6" id="f-924" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-308" decimals="-6" id="f-925" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-308" decimals="-6" id="f-926" unitRef="usd">582000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-308" decimals="-6" id="f-927" unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-309" decimals="-6" id="f-928" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-309" decimals="-6" id="f-929" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-309" decimals="-6" id="f-930" unitRef="usd">502000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-309" decimals="-6" id="f-931" unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-310" decimals="-6" id="f-932" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-310" decimals="-6" id="f-933" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-310" decimals="-6" id="f-934" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-310" decimals="-6" id="f-935" unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-27" decimals="-6" id="f-936" unitRef="usd">838000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-27" decimals="-6" id="f-937" unitRef="usd">14000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-27" decimals="-6" id="f-938" unitRef="usd">4296000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-27" decimals="-6" id="f-939" unitRef="usd">238000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-311" decimals="-6" id="f-940" unitRef="usd">286000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-311" decimals="-6" id="f-941" unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-311" decimals="-6" id="f-942" unitRef="usd">2901000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-311" decimals="-6" id="f-943" unitRef="usd">158000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-312" decimals="-6" id="f-944" unitRef="usd">89000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-312" decimals="-6" id="f-945" unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-312" decimals="-6" id="f-946" unitRef="usd">821000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-312" decimals="-6" id="f-947" unitRef="usd">64000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-313" decimals="-6" id="f-948" unitRef="usd">26000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-313" decimals="-6" id="f-949" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-313" decimals="-6" id="f-950" unitRef="usd">460000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-313" decimals="-6" id="f-951" unitRef="usd">53000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-314" decimals="-6" id="f-952" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-314" decimals="-6" id="f-953" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-314" decimals="-6" id="f-954" unitRef="usd">545000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-314" decimals="-6" id="f-955" unitRef="usd">19000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-315" decimals="-6" id="f-956" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-315" decimals="-6" id="f-957" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-315" decimals="-6" id="f-958" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-315" decimals="-6" id="f-959" unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-28" decimals="-6" id="f-960" unitRef="usd">401000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-28" decimals="-6" id="f-961" unitRef="usd">8000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-28" decimals="-6" id="f-962" unitRef="usd">4760000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-28" decimals="-6" id="f-963" unitRef="usd">297000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="c-1" id="f-964">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to the Company&#x2019;s available-for-sale debt securities portfolio is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-6" id="f-965" unitRef="usd">7359000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-25" decimals="-6" id="f-966" unitRef="usd">7321000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-26" decimals="-6" id="f-967" unitRef="usd">9611000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-1" decimals="-6" id="f-968" unitRef="usd">24000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-25" decimals="-6" id="f-969" unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-26" decimals="-6" id="f-970" unitRef="usd">15000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-1" decimals="-6" id="f-971" unitRef="usd">26000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-25" decimals="-6" id="f-972" unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-26" decimals="-6" id="f-973" unitRef="usd">18000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-974">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of available-for-sale debt securities at April&#160;26, 2024 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-27" decimals="-6" id="f-975" unitRef="usd">1548000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-27" decimals="-6" id="f-976" unitRef="usd">1534000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-27" decimals="-6" id="f-977" unitRef="usd">3644000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-27" decimals="-6" id="f-978" unitRef="usd">3479000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost contextRef="c-27" decimals="-6" id="f-979" unitRef="usd">758000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c-27" decimals="-6" id="f-980" unitRef="usd">744000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost contextRef="c-27" decimals="-6" id="f-981" unitRef="usd">1019000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue contextRef="c-27" decimals="-6" id="f-982" unitRef="usd">967000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-27" decimals="-6" id="f-983" unitRef="usd">6968000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-27" decimals="-6" id="f-984" unitRef="usd">6723000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-1" decimals="-6" id="f-985" unitRef="usd">597000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-25" decimals="-6" id="f-986" unitRef="usd">386000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-26" decimals="-6" id="f-987" unitRef="usd">186000000</us-gaap:InterestIncomeExpenseNet>
    <mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock contextRef="c-1" id="f-988">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's equity and other investments at&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April&#160;26, 2024 and April&#160;28, 2023, which are classified as primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments with readily determinable fair value (marketable equity securities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments for which the fair value option has been elected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments without readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-276" decimals="-6" id="f-989" unitRef="usd">28000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-305" decimals="-6" id="f-990" unitRef="usd">115000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFVNINoncurrent contextRef="c-276" decimals="-6" id="f-991" unitRef="usd">311000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent contextRef="c-305" decimals="-6" id="f-992" unitRef="usd">531000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-276" decimals="-6" id="f-993" unitRef="usd">859000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-305" decimals="-6" id="f-994" unitRef="usd">872000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-276" decimals="-6" id="f-995" unitRef="usd">84000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-305" decimals="-6" id="f-996" unitRef="usd">89000000</us-gaap:EquityMethodInvestments>
    <mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments contextRef="c-276" decimals="-6" id="f-997" unitRef="usd">1282000000</mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments>
    <mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments contextRef="c-305" decimals="-6" id="f-998" unitRef="usd">1607000000</mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-316" decimals="-6" id="f-999" unitRef="usd">-291000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-317" decimals="-6" id="f-1000" unitRef="usd">56000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c-208"
      decimals="2"
      id="f-1001"
      unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-1" decimals="-6" id="f-1002" unitRef="usd">-220000000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-1003">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Initial valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional cash investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-28" decimals="-6" id="f-1004" unitRef="usd">531000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-48" decimals="-6" id="f-1005" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1006" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-25" decimals="-6" id="f-1007" unitRef="usd">307000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <mdt:AdditionalCashInvestment contextRef="c-1" decimals="-6" id="f-1008" unitRef="usd">0</mdt:AdditionalCashInvestment>
    <mdt:AdditionalCashInvestment contextRef="c-25" decimals="-6" id="f-1009" unitRef="usd">224000000</mdt:AdditionalCashInvestment>
    <us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions contextRef="c-1" decimals="-6" id="f-1010" unitRef="usd">220000000</us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions>
    <us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions contextRef="c-25" decimals="-6" id="f-1011" unitRef="usd">0</us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-27" decimals="-6" id="f-1012" unitRef="usd">311000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-28" decimals="-6" id="f-1013" unitRef="usd">531000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1014">Financing Arrangements &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current debt obligations consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1022"&gt;&lt;span style="-sec-ix-hidden:f-1023"&gt;Current debt obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial Paper&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   On January 26, 2015, Medtronic Global Holdings S.C.A. (Medtronic Luxco), an entity organized under the laws of Luxembourg, entered into various agreements pursuant to which Medtronic Luxco may issue United States Dollar-denominated unsecured commercial paper notes (the 2015 CP Program) on a private placement basis, and on January 31, 2020 Medtronic Luxco entered into various agreements pursuant to which Medtronic Luxco may issue Euro-denominated unsecured commercial paper notes (the 2020 CP Program) on a private placement basis. The maximum aggregate amount outstanding at any time under the 2015 CP Program and the 2020 CP Program together may not exceed the equivalent of $3.5&#160;billion. The Company and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the 2015 CP Program and the 2020 CP Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $1.1&#160;billion commercial paper outstanding at April&#160;26, 2024. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately 20 days and the weighted average interest rate was 5.45 percent. There was no commercial paper outstanding at April&#160;28, 2023. During fiscal year 2023, the weighted average original maturity of the commercial paper outstanding was approximately 22 days and the weighted average interest rate was 4.34 percent. The issuance of commercial paper reduces the amount of credit available under the Company's existing credit facility, defined below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Line of Credit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   On December 12, 2023, Medtronic Luxco, as borrower, entered into an amendment to its amended and restated credit agreement (Credit Facility), by and among Medtronic, Medtronic, Inc., Medtronic Luxco, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent and issuing bank, extending the maturity date of the Credit Facility to December 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facility provides for a $3.5 billion&#160;five-year unsecured revolving credit facility (Credit Facility). At each anniversary date of the Credit Facility, we can request a one-year extension of the maturity date. The Credit Facility provides the Company with the ability to increase its borrowing capacity by an additional $1.0 billion at any time during the term of the agreement. The Company and Medtronic, Inc. have guaranteed the obligations of the borrowers under the Credit Facility, and Medtronic Luxco will also guarantee the obligations of any designated borrower. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At April&#160;26, 2024 and April&#160;28, 2023, no amounts were outstanding under the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rates on advances on the Credit Facility are determined by a pricing matrix based on the Company&#x2019;s long-term debt ratings, assigned by Standard &amp;amp; Poor&#x2019;s Ratings Services and Moody&#x2019;s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with all covenants related to the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's long-term debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except interest rates)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity by Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250 percent &lt;span style="-sec-ix-hidden:f-1041"&gt;six&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625 percent &lt;span style="-sec-ix-hidden:f-1047"&gt;three&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.000 percent &lt;span style="-sec-ix-hidden:f-1053"&gt;five&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.125 percent &lt;span style="-sec-ix-hidden:f-1059"&gt;eight&lt;/span&gt;-year 2019&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.250 percent &lt;span style="-sec-ix-hidden:f-1065"&gt;five&lt;/span&gt;-year 2023 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.000 percent &lt;span style="-sec-ix-hidden:f-1071"&gt;six&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.375 percent &lt;span style="-sec-ix-hidden:f-1077"&gt;eight&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625 percent &lt;span style="-sec-ix-hidden:f-1083"&gt;twelve&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.000 percent &lt;span style="-sec-ix-hidden:f-1089"&gt;twelve&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125 percent &lt;span style="-sec-ix-hidden:f-1095"&gt;nine&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750 percent &lt;span style="-sec-ix-hidden:f-1101"&gt;twelve&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.500 percent &lt;span style="-sec-ix-hidden:f-1107"&gt;ten&lt;/span&gt;-year 2023 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375 percent &lt;span style="-sec-ix-hidden:f-1113"&gt;twelve&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375 percent &lt;span style="-sec-ix-hidden:f-1119"&gt;twenty&lt;/span&gt;-year 2015 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.550 percent &lt;span style="-sec-ix-hidden:f-1125"&gt;thirty&lt;/span&gt;-year 2007 CIFSA senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250 percent &lt;span style="-sec-ix-hidden:f-1131"&gt;twenty&lt;/span&gt;-year 2019&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.500 percent &lt;span style="-sec-ix-hidden:f-1137"&gt;thirty&lt;/span&gt;-year 2009 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.500 percent &lt;span style="-sec-ix-hidden:f-1143"&gt;twenty&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.550 percent &lt;span style="-sec-ix-hidden:f-1149"&gt;thirty&lt;/span&gt;-year 2010 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375 percent &lt;span style="-sec-ix-hidden:f-1155"&gt;twenty&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.500 percent &lt;span style="-sec-ix-hidden:f-1161"&gt;thirty&lt;/span&gt;-year 2012 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.000 percent &lt;span style="-sec-ix-hidden:f-1167"&gt;thirty&lt;/span&gt;-year 2013 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625 percent &lt;span style="-sec-ix-hidden:f-1173"&gt;thirty&lt;/span&gt;-year 2014 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625 percent &lt;span style="-sec-ix-hidden:f-1179"&gt;thirty&lt;/span&gt;-year 2015 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.750 percent &lt;span style="-sec-ix-hidden:f-1185"&gt;thirty&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625 percent &lt;span style="-sec-ix-hidden:f-1191"&gt;thirty&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1196"&gt;&lt;span style="-sec-ix-hidden:f-1197"&gt;Finance lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026-2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026-2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026-2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Notes   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, Medtronic Luxco issued four tranches of Euro-denominated Senior Notes with an aggregate principal of &#x20ac;3.5&#160;billion, with maturities ranging from fiscal year 2026 to 2035, resulting in cash proceeds of approximately $3.4&#160;billion, net of discounts and issuance costs. The Company used the net proceeds to repay at maturity &#x20ac;750&#160;million of Medtronic Luxco Senior Notes for $772&#160;million&#160;of total consideration in December 2022 and &#x20ac;2.8&#160;billion of Medtronic Luxco Senior Notes for $2.9&#160;billion of total consideration in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, Medtronic Luxco issued two tranches of USD-denominated Senior Notes with an aggregate principal of $2.0&#160;billion, with maturities ranging from fiscal year 2028 to 2033, resulting in cash proceeds of approximately $2.0&#160;billion, net of discounts and issuance costs. The Company used the net proceeds supplemented by additional cash to repay the &#xa5;297&#160;billion Fiscal 2023 Loan Agreement discussed below for $2.3&#160;billion of total consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to year-end, on June 3, 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of &#x20ac;3.0&#160;billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately $3.2&#160;billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Euro-denominated debt issued in September 2022 is designated as a net investment hedge of certain of the Company's European operations. Refer to Note 7 for additional information regarding the net investment hedge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term Loan Agreements   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Medtronic Luxco entered into a term loan agreement (Fiscal 2023 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2023 Loan Agreement provides an unsecured term loan in an aggregate principal amount of up to &#xa5;300&#160;billion with a term of 364 days. Borrowings under the Fiscal 2023 Loan Agreement bear interest at the TIBOR Rate (as defined in the Fiscal 2023 Loan Agreement) plus a margin of 0.40% per annum. Medtronic plc and Medtronic, Inc. guaranteed the obligations of Medtronic Luxco under the Fiscal 2023 Loan Agreement. In May and June 2022, Medtronic Luxco borrowed an aggregate of &#xa5;297&#160;billion, or approximately $2.3&#160;billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $1.9&#160;billion of Medtronic Inc.'s 3.500% Senior Notes due 2025 for $1.9&#160;billion of total consideration, and $368&#160;million of Medtronic Luxco's 3.350% Senior Notes due 2027 for $376&#160;million of total consideration. The Company recognized a total loss on debt extinguishment of $53&#160;million within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income during fiscal year 2023, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. During the fourth quarter of fiscal year 2023, the Company repaid the term loan in full, including interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For fiscal years 2024, 2023, and 2022, there was $916 million, $743 million, and $553 million of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and charges recognized in connection with the early redemption of senior notes, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments Not Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;26, 2024, the estimated fair value of the Company&#x2019;s Senior Notes was $21.2 billion compared to a principal value of $24.0 billion. At April&#160;28, 2023, the estimated fair value was $21.7 billion compared to a principal value of $24.5 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c-1" id="f-1015">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current debt obligations consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1022"&gt;&lt;span style="-sec-ix-hidden:f-1023"&gt;Current debt obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c-318" decimals="-6" id="f-1016" unitRef="usd">13000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-319" decimals="-6" id="f-1017" unitRef="usd">13000000</us-gaap:ShortTermBorrowings>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-27" decimals="-6" id="f-1018" unitRef="usd">6000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-28" decimals="-6" id="f-1019" unitRef="usd">7000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:CommercialPaper contextRef="c-27" decimals="-6" id="f-1020" unitRef="usd">1073000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper contextRef="c-28" decimals="-6" id="f-1021" unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:DebtCurrent contextRef="c-27" decimals="-6" id="f-1024" unitRef="usd">1092000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-28" decimals="-6" id="f-1025" unitRef="usd">20000000</us-gaap:DebtCurrent>
    <mdt:CommercialPaperMaximumBorrowingCapacity contextRef="c-320" decimals="-8" id="f-1026" unitRef="usd">3500000000</mdt:CommercialPaperMaximumBorrowingCapacity>
    <us-gaap:DebtCurrent contextRef="c-321" decimals="-8" id="f-1027" unitRef="usd">1100000000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c-322" id="f-1028">P20D</us-gaap:DebtInstrumentTerm>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="c-321"
      decimals="4"
      id="f-1029"
      unitRef="number">0.0545</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:DebtCurrent contextRef="c-323" decimals="0" id="f-1030" unitRef="usd">0</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c-324" id="f-1031">P22D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="c-325"
      decimals="4"
      id="f-1032"
      unitRef="number">0.0434</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-326" decimals="INF" id="f-1033" unitRef="usd">3500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-327" id="f-1034">P5Y</us-gaap:DebtInstrumentTerm>
    <mdt:LineOfCreditFacilityLengthOfExtension contextRef="c-327" id="f-1035">P1Y</mdt:LineOfCreditFacilityLengthOfExtension>
    <mdt:LineOfCreditFacilityAdditionalBorrowingCapacity contextRef="c-326" decimals="INF" id="f-1036" unitRef="usd">1000000000</mdt:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCredit contextRef="c-328" decimals="INF" id="f-1037" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c-329" decimals="INF" id="f-1038" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-1039">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's long-term debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except interest rates)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity by Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250 percent &lt;span style="-sec-ix-hidden:f-1041"&gt;six&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625 percent &lt;span style="-sec-ix-hidden:f-1047"&gt;three&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.000 percent &lt;span style="-sec-ix-hidden:f-1053"&gt;five&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.125 percent &lt;span style="-sec-ix-hidden:f-1059"&gt;eight&lt;/span&gt;-year 2019&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.250 percent &lt;span style="-sec-ix-hidden:f-1065"&gt;five&lt;/span&gt;-year 2023 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.000 percent &lt;span style="-sec-ix-hidden:f-1071"&gt;six&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.375 percent &lt;span style="-sec-ix-hidden:f-1077"&gt;eight&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625 percent &lt;span style="-sec-ix-hidden:f-1083"&gt;twelve&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.000 percent &lt;span style="-sec-ix-hidden:f-1089"&gt;twelve&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125 percent &lt;span style="-sec-ix-hidden:f-1095"&gt;nine&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750 percent &lt;span style="-sec-ix-hidden:f-1101"&gt;twelve&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.500 percent &lt;span style="-sec-ix-hidden:f-1107"&gt;ten&lt;/span&gt;-year 2023 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375 percent &lt;span style="-sec-ix-hidden:f-1113"&gt;twelve&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375 percent &lt;span style="-sec-ix-hidden:f-1119"&gt;twenty&lt;/span&gt;-year 2015 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.550 percent &lt;span style="-sec-ix-hidden:f-1125"&gt;thirty&lt;/span&gt;-year 2007 CIFSA senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250 percent &lt;span style="-sec-ix-hidden:f-1131"&gt;twenty&lt;/span&gt;-year 2019&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.500 percent &lt;span style="-sec-ix-hidden:f-1137"&gt;thirty&lt;/span&gt;-year 2009 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.500 percent &lt;span style="-sec-ix-hidden:f-1143"&gt;twenty&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.550 percent &lt;span style="-sec-ix-hidden:f-1149"&gt;thirty&lt;/span&gt;-year 2010 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375 percent &lt;span style="-sec-ix-hidden:f-1155"&gt;twenty&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.500 percent &lt;span style="-sec-ix-hidden:f-1161"&gt;thirty&lt;/span&gt;-year 2012 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.000 percent &lt;span style="-sec-ix-hidden:f-1167"&gt;thirty&lt;/span&gt;-year 2013 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625 percent &lt;span style="-sec-ix-hidden:f-1173"&gt;thirty&lt;/span&gt;-year 2014 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625 percent &lt;span style="-sec-ix-hidden:f-1179"&gt;thirty&lt;/span&gt;-year 2015 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.750 percent &lt;span style="-sec-ix-hidden:f-1185"&gt;thirty&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625 percent &lt;span style="-sec-ix-hidden:f-1191"&gt;thirty&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1196"&gt;&lt;span style="-sec-ix-hidden:f-1197"&gt;Finance lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026-2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026-2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026-2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-330"
      decimals="INF"
      id="f-1040"
      unitRef="number">0.00250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-330" decimals="-6" id="f-1042" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-330"
      decimals="4"
      id="f-1043"
      unitRef="number">0.0044</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-332" decimals="-6" id="f-1044" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-332"
      decimals="4"
      id="f-1045"
      unitRef="number">0.0044</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-333"
      decimals="INF"
      id="f-1046"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-333" decimals="-6" id="f-1048" unitRef="usd">535000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-333"
      decimals="4"
      id="f-1049"
      unitRef="number">0.0286</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-335" decimals="-6" id="f-1050" unitRef="usd">549000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-335"
      decimals="4"
      id="f-1051"
      unitRef="number">0.0286</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-336"
      decimals="INF"
      id="f-1052"
      unitRef="number">0.00000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-336" decimals="-6" id="f-1054" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-336"
      decimals="4"
      id="f-1055"
      unitRef="number">0.0023</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-338" decimals="-6" id="f-1056" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-338"
      decimals="4"
      id="f-1057"
      unitRef="number">0.0023</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-339"
      decimals="INF"
      id="f-1058"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-339" decimals="-6" id="f-1060" unitRef="usd">1606000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-339"
      decimals="4"
      id="f-1061"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-341" decimals="-6" id="f-1062" unitRef="usd">1646000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-341"
      decimals="4"
      id="f-1063"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-342"
      decimals="INF"
      id="f-1064"
      unitRef="number">0.04250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-342" decimals="-6" id="f-1066" unitRef="usd">1000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-342"
      decimals="4"
      id="f-1067"
      unitRef="number">0.0442</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-344" decimals="-6" id="f-1068" unitRef="usd">1000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-344"
      decimals="4"
      id="f-1069"
      unitRef="number">0.0442</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-345"
      decimals="INF"
      id="f-1070"
      unitRef="number">0.03000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-345" decimals="-6" id="f-1072" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-345"
      decimals="4"
      id="f-1073"
      unitRef="number">0.0310</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-347" decimals="-6" id="f-1074" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-347"
      decimals="4"
      id="f-1075"
      unitRef="number">0.0309</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-348"
      decimals="INF"
      id="f-1076"
      unitRef="number">0.00375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-348" decimals="-6" id="f-1078" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-348"
      decimals="4"
      id="f-1079"
      unitRef="number">0.0051</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-350" decimals="-6" id="f-1080" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-350"
      decimals="4"
      id="f-1081"
      unitRef="number">0.0051</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-351"
      decimals="INF"
      id="f-1082"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-351" decimals="-6" id="f-1084" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-351"
      decimals="4"
      id="f-1085"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-353" decimals="-6" id="f-1086" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-353"
      decimals="4"
      id="f-1087"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-354"
      decimals="INF"
      id="f-1088"
      unitRef="number">0.01000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-354" decimals="-6" id="f-1090" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-354"
      decimals="4"
      id="f-1091"
      unitRef="number">0.0106</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-356" decimals="-6" id="f-1092" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-356"
      decimals="4"
      id="f-1093"
      unitRef="number">0.0106</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-357"
      decimals="INF"
      id="f-1094"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-357" decimals="-6" id="f-1096" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-357"
      decimals="4"
      id="f-1097"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-359" decimals="-6" id="f-1098" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-359"
      decimals="4"
      id="f-1099"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-360"
      decimals="INF"
      id="f-1100"
      unitRef="number">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-360" decimals="-6" id="f-1102" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-360"
      decimals="4"
      id="f-1103"
      unitRef="number">0.0081</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-362" decimals="-6" id="f-1104" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-362"
      decimals="4"
      id="f-1105"
      unitRef="number">0.0081</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-363"
      decimals="INF"
      id="f-1106"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-363" decimals="-6" id="f-1108" unitRef="usd">1000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-363"
      decimals="4"
      id="f-1109"
      unitRef="number">0.0462</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-365" decimals="-6" id="f-1110" unitRef="usd">1000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-365"
      decimals="4"
      id="f-1111"
      unitRef="number">0.0462</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-366"
      decimals="INF"
      id="f-1112"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-366" decimals="-6" id="f-1114" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-366"
      decimals="4"
      id="f-1115"
      unitRef="number">0.0344</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-368" decimals="-6" id="f-1116" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-368"
      decimals="4"
      id="f-1117"
      unitRef="number">0.0344</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-369"
      decimals="INF"
      id="f-1118"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-369" decimals="-6" id="f-1120" unitRef="usd">1932000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-369"
      decimals="4"
      id="f-1121"
      unitRef="number">0.0447</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-371" decimals="-6" id="f-1122" unitRef="usd">1932000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-371"
      decimals="4"
      id="f-1123"
      unitRef="number">0.0447</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-372"
      decimals="INF"
      id="f-1124"
      unitRef="number">0.06550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-372" decimals="-6" id="f-1126" unitRef="usd">253000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-372"
      decimals="4"
      id="f-1127"
      unitRef="number">0.0467</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-374" decimals="-6" id="f-1128" unitRef="usd">253000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-374"
      decimals="4"
      id="f-1129"
      unitRef="number">0.0467</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-375"
      decimals="INF"
      id="f-1130"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-375" decimals="-6" id="f-1132" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-375"
      decimals="4"
      id="f-1133"
      unitRef="number">0.0234</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-377" decimals="-6" id="f-1134" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-377"
      decimals="4"
      id="f-1135"
      unitRef="number">0.0234</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-378"
      decimals="INF"
      id="f-1136"
      unitRef="number">0.06500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-378" decimals="-6" id="f-1138" unitRef="usd">158000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-378"
      decimals="4"
      id="f-1139"
      unitRef="number">0.0656</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-380" decimals="-6" id="f-1140" unitRef="usd">158000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-380"
      decimals="4"
      id="f-1141"
      unitRef="number">0.0656</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-381"
      decimals="INF"
      id="f-1142"
      unitRef="number">0.01500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-381" decimals="-6" id="f-1144" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-381"
      decimals="4"
      id="f-1145"
      unitRef="number">0.0158</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-383" decimals="-6" id="f-1146" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-383"
      decimals="4"
      id="f-1147"
      unitRef="number">0.0158</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-384"
      decimals="INF"
      id="f-1148"
      unitRef="number">0.05550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-384" decimals="-6" id="f-1150" unitRef="usd">224000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-384"
      decimals="4"
      id="f-1151"
      unitRef="number">0.0558</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-386" decimals="-6" id="f-1152" unitRef="usd">224000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-386"
      decimals="4"
      id="f-1153"
      unitRef="number">0.0558</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-387"
      decimals="INF"
      id="f-1154"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-387" decimals="-6" id="f-1156" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-387"
      decimals="4"
      id="f-1157"
      unitRef="number">0.0146</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-389" decimals="-6" id="f-1158" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-389"
      decimals="4"
      id="f-1159"
      unitRef="number">0.0146</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-390"
      decimals="INF"
      id="f-1160"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-390" decimals="-6" id="f-1162" unitRef="usd">105000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-390"
      decimals="4"
      id="f-1163"
      unitRef="number">0.0454</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-392" decimals="-6" id="f-1164" unitRef="usd">105000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-392"
      decimals="4"
      id="f-1165"
      unitRef="number">0.0454</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-393"
      decimals="INF"
      id="f-1166"
      unitRef="number">0.04000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-393" decimals="-6" id="f-1168" unitRef="usd">305000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-393"
      decimals="4"
      id="f-1169"
      unitRef="number">0.0409</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-395" decimals="-6" id="f-1170" unitRef="usd">305000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-395"
      decimals="4"
      id="f-1171"
      unitRef="number">0.0409</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-396"
      decimals="INF"
      id="f-1172"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-396" decimals="-6" id="f-1174" unitRef="usd">127000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-396"
      decimals="4"
      id="f-1175"
      unitRef="number">0.0467</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-398" decimals="-6" id="f-1176" unitRef="usd">127000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-398"
      decimals="4"
      id="f-1177"
      unitRef="number">0.0467</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-399"
      decimals="INF"
      id="f-1178"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-399" decimals="-6" id="f-1180" unitRef="usd">1813000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-399"
      decimals="4"
      id="f-1181"
      unitRef="number">0.0469</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-401" decimals="-6" id="f-1182" unitRef="usd">1813000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-401"
      decimals="4"
      id="f-1183"
      unitRef="number">0.0469</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-402"
      decimals="INF"
      id="f-1184"
      unitRef="number">0.01750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-402" decimals="-6" id="f-1186" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-402"
      decimals="4"
      id="f-1187"
      unitRef="number">0.0187</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-404" decimals="-6" id="f-1188" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-404"
      decimals="4"
      id="f-1189"
      unitRef="number">0.0187</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-405"
      decimals="INF"
      id="f-1190"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-405" decimals="-6" id="f-1192" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-405"
      decimals="4"
      id="f-1193"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-407" decimals="-6" id="f-1194" unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-407"
      decimals="4"
      id="f-1195"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-27" decimals="-6" id="f-1198" unitRef="usd">55000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-27" decimals="4" id="f-1199" unitRef="number">0.1017</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-28" decimals="-6" id="f-1200" unitRef="usd">57000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-28" decimals="4" id="f-1201" unitRef="number">0.0991</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="c-27" decimals="-6" id="f-1202" unitRef="usd">55000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="c-28" decimals="-6" id="f-1203" unitRef="usd">64000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-27" decimals="-6" id="f-1204" unitRef="usd">110000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-28" decimals="-6" id="f-1205" unitRef="usd">124000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-27" decimals="-6" id="f-1206" unitRef="usd">23932000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-28" decimals="-6" id="f-1207" unitRef="usd">24344000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <mdt:DebtInstrumentNumberofTranches
      contextRef="c-408"
      decimals="INF"
      id="f-1208"
      unitRef="tranche">4</mdt:DebtInstrumentNumberofTranches>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-409" decimals="-8" id="f-1209" unitRef="eur">3500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="c-410" decimals="-8" id="f-1210" unitRef="usd">3400000000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="c-411" decimals="-6" id="f-1211" unitRef="eur">750000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-411" decimals="-6" id="f-1212" unitRef="usd">772000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-412" decimals="-8" id="f-1213" unitRef="eur">2800000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt contextRef="c-413" decimals="-8" id="f-1214" unitRef="usd">2900000000</us-gaap:RepaymentsOfDebt>
    <mdt:DebtInstrumentNumberofTranches
      contextRef="c-414"
      decimals="INF"
      id="f-1215"
      unitRef="tranche">2</mdt:DebtInstrumentNumberofTranches>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-412" decimals="-8" id="f-1216" unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="c-413" decimals="-8" id="f-1217" unitRef="usd">2000000000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="c-413" decimals="-9" id="f-1218" unitRef="eur">297000000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:RepaymentsOfDebt contextRef="c-415" decimals="-8" id="f-1219" unitRef="usd">2300000000</us-gaap:RepaymentsOfDebt>
    <mdt:DebtInstrumentNumberofTranches
      contextRef="c-416"
      decimals="INF"
      id="f-1220"
      unitRef="tranche">4</mdt:DebtInstrumentNumberofTranches>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-417" decimals="-8" id="f-1221" unitRef="usd">3000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="c-418" decimals="-8" id="f-1222" unitRef="usd">3200000000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-419" decimals="INF" id="f-1223" unitRef="jpy">300000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c-420" id="f-1224">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-421"
      decimals="INF"
      id="f-1225"
      unitRef="number">0.0040</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-420" decimals="-6" id="f-1226" unitRef="jpy">297000000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-420" decimals="-8" id="f-1227" unitRef="usd">2300000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-422" decimals="-8" id="f-1228" unitRef="usd">1900000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-423"
      decimals="INF"
      id="f-1229"
      unitRef="number">0.03500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt contextRef="c-424" decimals="-8" id="f-1230" unitRef="usd">1900000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-425" decimals="-6" id="f-1231" unitRef="usd">368000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-426"
      decimals="INF"
      id="f-1232"
      unitRef="number">0.03350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt contextRef="c-427" decimals="-6" id="f-1233" unitRef="usd">376000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-428" decimals="-6" id="f-1234" unitRef="usd">-53000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-1235">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-27" decimals="-6" id="f-1236" unitRef="usd">1092000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-27" decimals="-6" id="f-1237" unitRef="usd">2684000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-27" decimals="-6" id="f-1238" unitRef="usd">1612000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-27" decimals="-6" id="f-1239" unitRef="usd">1006000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-27" decimals="-6" id="f-1240" unitRef="usd">2146000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-27" decimals="-6" id="f-1241" unitRef="usd">16649000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-27" decimals="-6" id="f-1242" unitRef="usd">25189000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestExpenseBorrowings contextRef="c-1" decimals="-6" id="f-1243" unitRef="usd">916000000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings contextRef="c-25" decimals="-6" id="f-1244" unitRef="usd">743000000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings contextRef="c-26" decimals="-6" id="f-1245" unitRef="usd">553000000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:LongTermDebtFairValue contextRef="c-429" decimals="-8" id="f-1246" unitRef="usd">21200000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-429" decimals="-8" id="f-1247" unitRef="usd">24000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtFairValue contextRef="c-430" decimals="-8" id="f-1248" unitRef="usd">21700000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-430" decimals="-8" id="f-1249" unitRef="usd">24500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-1250">Derivatives and Currency Exchange Risk Management &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company uses derivative instruments and foreign currency denominated debt to manage the impact that currency exchange rate and interest rate changes have on reported financial statements. The Company does not enter into derivative contracts for speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception, foreign currency forward and option contracts are designated as a cash flow hedge. Changes in the fair value of these derivatives are reported as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash flow hedges will mature within the subsequent three-year period. At April&#160;26, 2024 and April&#160;28, 2023, the Company had $229 million and $93 million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company expects that $158 million of after-tax net unrealized gains at April&#160;26, 2024 will be recognized in the consolidated statements of income over the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For instruments that are designated as net investment hedges, the gains or losses are reported as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on a straight-line basis over the term of the hedge. During the twelve months ended April&#160;26, 2024 and April&#160;28, 2023, the Company recognized $197 million and $107 million, respectively, of after-tax unrealized gains related to excluded components in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1257"&gt;interest expense&lt;/span&gt;, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The cash flows related to the Company&#x2019;s derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Undesignated Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency forward exchange contracts to offset the Company&#x2019;s exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Company&#x2019;s undesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the contractual amounts of the Company's outstanding instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Designation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undesignated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;26, 2024, includes derivative contracts with a notional value of &#x20ac;5.0 billion, or $5.4 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#xa5;322 billion, or $2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;26, 2024, includes &#x20ac;16.0 billion, or $17.1 billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2051.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.704%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Reclassified into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of (Gain) Loss in Income Statement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of (Gain) Loss in Income Statement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance Sheet Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;26, 2024 and April&#160;28, 2023. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1328"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1329"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1330"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1331"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist principally of interest-bearing investments, derivative contracts, and trade accounts receivable. Global concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains cash and cash equivalents, investments, and certain other financial instruments (including currency exchange rate and interest rate derivative contracts) with various major financial institutions. The Company performs periodic evaluations of the relative credit standings of these financial institutions and limits the amount of credit exposure with any one institution. In addition, the Company has collateral credit agreements with its primary derivatives counterparties. Under these agreements, either party is required to post eligible collateral when the market value of transactions covered by the agreement exceeds specific thresholds, thus limiting credit exposure for both parties. As of April&#160;26, 2024 and April&#160;28, 2023, the Company received net cash collateral of $101 million and $11 million, respectively, &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from its counterparties. Cash collateral posted is recorded as a reduction in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with the offset recorded as an increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets. Cash collateral received is recorded as an increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the offset recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt; in the consolidated balance sheets.</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1 contextRef="c-431" id="f-1251">P3Y</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
    <mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-27" decimals="-6" id="f-1252" unitRef="usd">229000000</mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-28" decimals="-6" id="f-1253" unitRef="usd">93000000</mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths contextRef="c-1" decimals="-6" id="f-1254" unitRef="usd">158000000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-1" decimals="-6" id="f-1255" unitRef="usd">197000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-25" decimals="-6" id="f-1256" unitRef="usd">107000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-1258">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the contractual amounts of the Company's outstanding instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Designation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undesignated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;26, 2024, includes derivative contracts with a notional value of &#x20ac;5.0 billion, or $5.4 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#xa5;322 billion, or $2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;26, 2024, includes &#x20ac;16.0 billion, or $17.1 billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2051.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.704%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Reclassified into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of (Gain) Loss in Income Statement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2024, 2023, and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of (Gain) Loss in Income Statement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-432" decimals="-8" id="f-1259" unitRef="usd">10400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-433" decimals="-8" id="f-1260" unitRef="usd">9100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-434" decimals="-8" id="f-1261" unitRef="usd">7400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-435" decimals="-8" id="f-1262" unitRef="usd">7200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-436" decimals="-8" id="f-1263" unitRef="usd">17100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-437" decimals="-8" id="f-1264" unitRef="usd">17600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-438" decimals="-8" id="f-1265" unitRef="usd">5900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-439" decimals="-8" id="f-1266" unitRef="usd">5800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-440" decimals="-8" id="f-1267" unitRef="eur">5000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-440" decimals="-8" id="f-1268" unitRef="usd">5400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-441" decimals="-9" id="f-1269" unitRef="jpy">322000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-441" decimals="-8" id="f-1270" unitRef="usd">2100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-436" decimals="-8" id="f-1271" unitRef="eur">16000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-436" decimals="-8" id="f-1272" unitRef="usd">17100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-442" decimals="-6" id="f-1273" unitRef="usd">416000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-443" decimals="-6" id="f-1274" unitRef="usd">161000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-444" decimals="-6" id="f-1275" unitRef="usd">953000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-442" decimals="-6" id="f-1276" unitRef="usd">312000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-443" decimals="-6" id="f-1277" unitRef="usd">703000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-444" decimals="-6" id="f-1278" unitRef="usd">144000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-445" decimals="-6" id="f-1279" unitRef="usd">124000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-446" decimals="-6" id="f-1280" unitRef="usd">79000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-447" decimals="-6" id="f-1281" unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-445" decimals="-6" id="f-1282" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-446" decimals="-6" id="f-1283" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-447" decimals="-6" id="f-1284" unitRef="usd">-61000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-448" decimals="-6" id="f-1285" unitRef="usd">-431000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-449" decimals="-6" id="f-1286" unitRef="usd">524000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-450" decimals="-6" id="f-1287" unitRef="usd">-2299000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-448" decimals="-6" id="f-1288" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-449" decimals="-6" id="f-1289" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-450" decimals="-6" id="f-1290" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-451" decimals="-6" id="f-1291" unitRef="usd">-202000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-452" decimals="-6" id="f-1292" unitRef="usd">73000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-453" decimals="-6" id="f-1293" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-451" decimals="-6" id="f-1294" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-452" decimals="-6" id="f-1295" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-453" decimals="-6" id="f-1296" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-1" decimals="-6" id="f-1297" unitRef="usd">1173000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-25" decimals="-6" id="f-1298" unitRef="usd">-356000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-26" decimals="-6" id="f-1299" unitRef="usd">3234000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax contextRef="c-1" decimals="-6" id="f-1300" unitRef="usd">369000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax contextRef="c-25" decimals="-6" id="f-1301" unitRef="usd">706000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax contextRef="c-26" decimals="-6" id="f-1302" unitRef="usd">83000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTaxeclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-442" decimals="-6" id="f-1303" unitRef="usd">-136000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-443" decimals="-6" id="f-1304" unitRef="usd">-31000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-444" decimals="-6" id="f-1305" unitRef="usd">54000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-1306">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;26, 2024 and April&#160;28, 2023. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-454" decimals="-6" id="f-1307" unitRef="usd">368000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-455" decimals="-6" id="f-1308" unitRef="usd">318000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-456" decimals="-6" id="f-1309" unitRef="usd">37000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-457" decimals="-6" id="f-1310" unitRef="usd">109000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-458" decimals="-6" id="f-1311" unitRef="usd">276000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-459" decimals="-6" id="f-1312" unitRef="usd">33000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-460" decimals="-6" id="f-1313" unitRef="usd">17000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-461" decimals="-6" id="f-1314" unitRef="usd">117000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-462" decimals="-6" id="f-1315" unitRef="usd">644000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-463" decimals="-6" id="f-1316" unitRef="usd">351000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-462" decimals="-6" id="f-1317" unitRef="usd">54000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-463" decimals="-6" id="f-1318" unitRef="usd">226000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-464" decimals="-6" id="f-1319" unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-465" decimals="-6" id="f-1320" unitRef="usd">17000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-466" decimals="-6" id="f-1321" unitRef="usd">12000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-467" decimals="-6" id="f-1322" unitRef="usd">10000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-27" decimals="-6" id="f-1323" unitRef="usd">659000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-28" decimals="-6" id="f-1324" unitRef="usd">368000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-27" decimals="-6" id="f-1325" unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-28" decimals="-6" id="f-1326" unitRef="usd">236000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-1327">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1328"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1329"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1330"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1331"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeAssets contextRef="c-468" decimals="-6" id="f-1332" unitRef="usd">659000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-468" decimals="-6" id="f-1333" unitRef="usd">66000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets contextRef="c-469" decimals="-6" id="f-1334" unitRef="usd">368000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-469" decimals="-6" id="f-1335" unitRef="usd">236000000</us-gaap:DerivativeLiabilities>
    <us-gaap:OffsettingLiabilitiesTableTextBlock contextRef="c-1" id="f-1337">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OffsettingLiabilitiesTableTextBlock>
    <us-gaap:OffsettingAssetsTableTextBlock contextRef="c-1" id="f-1336">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OffsettingAssetsTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-470" decimals="-6" id="f-1338" unitRef="usd">659000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction contextRef="c-470" decimals="-6" id="f-1339" unitRef="usd">66000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash contextRef="c-470" decimals="-6" id="f-1340" unitRef="usd">101000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral contextRef="c-470" decimals="-6" id="f-1341" unitRef="usd">492000000</us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-470" decimals="-6" id="f-1342" unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction contextRef="c-470" decimals="-6" id="f-1343" unitRef="usd">66000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash contextRef="c-470" decimals="-6" id="f-1344" unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral contextRef="c-470" decimals="-6" id="f-1345" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral>
    <mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability contextRef="c-27" decimals="-6" id="f-1346" unitRef="usd">593000000</mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability>
    <mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction contextRef="c-27" decimals="-6" id="f-1347" unitRef="usd">0</mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-27" decimals="-6" id="f-1348" unitRef="usd">101000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-27" decimals="-6" id="f-1349" unitRef="usd">101000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet contextRef="c-27" decimals="-6" id="f-1350" unitRef="usd">492000000</us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-471" decimals="-6" id="f-1351" unitRef="usd">368000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction contextRef="c-471" decimals="-6" id="f-1352" unitRef="usd">189000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash contextRef="c-471" decimals="-6" id="f-1353" unitRef="usd">11000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral contextRef="c-471" decimals="-6" id="f-1354" unitRef="usd">168000000</us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-471" decimals="-6" id="f-1355" unitRef="usd">236000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction contextRef="c-471" decimals="-6" id="f-1356" unitRef="usd">189000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash contextRef="c-471" decimals="-6" id="f-1357" unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral contextRef="c-471" decimals="-6" id="f-1358" unitRef="usd">48000000</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral>
    <mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability contextRef="c-28" decimals="-6" id="f-1359" unitRef="usd">132000000</mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability>
    <mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction contextRef="c-28" decimals="-6" id="f-1360" unitRef="usd">0</mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-28" decimals="-6" id="f-1361" unitRef="usd">11000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet contextRef="c-28" decimals="-6" id="f-1362" unitRef="usd">121000000</us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-27" decimals="-6" id="f-1363" unitRef="usd">101000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-27" decimals="-6" id="f-1364" unitRef="usd">101000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-28" decimals="-6" id="f-1365" unitRef="usd">11000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-1366">Inventories &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory balances were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-1367">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory balances were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-27" decimals="-6" id="f-1368" unitRef="usd">3668000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-28" decimals="-6" id="f-1369" unitRef="usd">3440000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-27" decimals="-6" id="f-1370" unitRef="usd">642000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-28" decimals="-6" id="f-1371" unitRef="usd">789000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-27" decimals="-6" id="f-1372" unitRef="usd">907000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-28" decimals="-6" id="f-1373" unitRef="usd">1063000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-27" decimals="-6" id="f-1374" unitRef="usd">5217000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-28" decimals="-6" id="f-1375" unitRef="usd">5293000000</us-gaap:InventoryNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-1376">Goodwill and Other Intangible Assets &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amount of goodwill by segment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill as a result of acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of RCS business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill as a result of acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As further described in Note 19, the Company had changes to the operating segments during fiscal year 2024. As of the beginning of fiscal year 2024, the Medical Surgical portfolio was separated into two operating segments, and each new operating segment was considered a standalone reporting unit as of the beginning of fiscal year 2024. As a result of this change, the Company allocated all goodwill that was previously assigned to the Medical Surgical reporting unit to the Surgical/Endoscopy reporting unit and the Patient Monitoring/Respiratory Interventions (PMRI) reporting unit using a relative fair value allocation approach. The effected reporting units were tested for impairment before and after the alignment. No goodwill impairment was identified in either test as of the beginning of the fiscal year 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, during the fourth quarter of fiscal year 2024, the Company's operating segments changed again resulting in the two reporting units created in the first quarter to be combined into the Medical Surgical reporting unit. All goodwill that was previously assigned to the two reporting units was combined into the Medical Surgical reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not recognize any goodwill impairment charges during fiscal years 2024 or 2022. As a result of the agreement with DaVita, as disclosed in Note 3, the Company allocated $208&#160;million of goodwill to the RCS business that met the criteria to be classified as held for sale during the first quarter of fiscal year 2023 and was subsequently sold on April 1, 2023. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $61&#160;million of goodwill impairment charges during fiscal year 2023. The goodwill impairment charges are recognized in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other operating expense (income), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the gross carrying amount and accumulated amortization of intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Definite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased technology and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2024, the Company recognized $295&#160;million of &lt;span style="-sec-ix-hidden:f-1461"&gt;definite-lived intangible asset impairment charges&lt;/span&gt; in connection with the decision to exit its ventilator product line. The intangible asset impairment charges primarily related to purchased technology, customer-related intangibles, and trade names. During fiscal year 2022, the Company recognized $409&#160;million of definite-lived intangible asset impairment charges in connection with the Company's decision to stop the distribution and sale of the Medtronic HVAD System. The intangible asset impairment charge primarily related to purchased technology and patents. The intangible asset impairment charges are recognized in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other operating expense (income), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Refer to Note 3 for additional information on what led to the impairments in fiscal year 2024 and 2022. The Company did not recognize any definite-lived intangible asset impairment charges during fiscal year 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible asset impairment charges were not significant for fiscal year 2024, 2023, or 2022. Due to the nature of IPR&amp;amp;D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible asset amortization expense was $1.7 billion for fiscal years 2024, 2023 and 2022. Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;26, 2024, excluding any possible future amortization associated with acquired IPR&amp;amp;D which has not met technological feasibility, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-1377">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amount of goodwill by segment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill as a result of acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of RCS business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill as a result of acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-472" decimals="-6" id="f-1378" unitRef="usd">7160000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-473" decimals="-6" id="f-1379" unitRef="usd">11132000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-474" decimals="-6" id="f-1380" unitRef="usd">19957000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-475" decimals="-6" id="f-1381" unitRef="usd">2254000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-48" decimals="-6" id="f-1382" unitRef="usd">40502000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-88" decimals="-6" id="f-1383" unitRef="usd">726000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-100" decimals="-6" id="f-1384" unitRef="usd">615000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-109" decimals="-6" id="f-1385" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-112" decimals="-6" id="f-1386" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-25" decimals="-6" id="f-1387" unitRef="usd">1340000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-88" decimals="-6" id="f-1388" unitRef="usd">-6000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-100" decimals="-6" id="f-1389" unitRef="usd">2000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-109" decimals="-6" id="f-1390" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-112" decimals="-6" id="f-1391" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-25" decimals="-6" id="f-1392" unitRef="usd">-5000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-88" decimals="-6" id="f-1393" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-100" decimals="-6" id="f-1394" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-109" decimals="-6" id="f-1395" unitRef="usd">208000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-112" decimals="-6" id="f-1396" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-25" decimals="-6" id="f-1397" unitRef="usd">208000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-88" decimals="-6" id="f-1398" unitRef="usd">-6000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-100" decimals="-6" id="f-1399" unitRef="usd">-30000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-109" decimals="-6" id="f-1400" unitRef="usd">-170000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-112" decimals="-6" id="f-1401" unitRef="usd">1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-25" decimals="-6" id="f-1402" unitRef="usd">-204000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-476" decimals="-6" id="f-1403" unitRef="usd">7873000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-477" decimals="-6" id="f-1404" unitRef="usd">11718000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-478" decimals="-6" id="f-1405" unitRef="usd">19579000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-479" decimals="-6" id="f-1406" unitRef="usd">2255000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-28" decimals="-6" id="f-1407" unitRef="usd">41425000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-87" decimals="-6" id="f-1408" unitRef="usd">131000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-99" decimals="-6" id="f-1409" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-108" decimals="-6" id="f-1410" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-111" decimals="-6" id="f-1411" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-6" id="f-1412" unitRef="usd">131000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-87" decimals="-6" id="f-1413" unitRef="usd">-5000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-99" decimals="-6" id="f-1414" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-108" decimals="-6" id="f-1415" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-111" decimals="-6" id="f-1416" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-1" decimals="-6" id="f-1417" unitRef="usd">-5000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-87" decimals="-6" id="f-1418" unitRef="usd">-33000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-99" decimals="-6" id="f-1419" unitRef="usd">-74000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-108" decimals="-6" id="f-1420" unitRef="usd">-458000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-111" decimals="-6" id="f-1421" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-6" id="f-1422" unitRef="usd">-565000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-480" decimals="-6" id="f-1423" unitRef="usd">7966000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-481" decimals="-6" id="f-1424" unitRef="usd">11644000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-482" decimals="-6" id="f-1425" unitRef="usd">19121000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-483" decimals="-6" id="f-1426" unitRef="usd">2255000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-27" decimals="-6" id="f-1427" unitRef="usd">40986000000</us-gaap:Goodwill>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1428"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-108" decimals="0" id="f-1429" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-484"
      decimals="INF"
      id="f-1430"
      unitRef="reportingunit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-485"
      decimals="INF"
      id="f-1431"
      unitRef="segment">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="0" id="f-1432" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-26" decimals="0" id="f-1433" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="c-486" decimals="-6" id="f-1434" unitRef="usd">208000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-487" decimals="-6" id="f-1435" unitRef="usd">61000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-1437">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the gross carrying amount and accumulated amortization of intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Definite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased technology and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-1436">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the gross carrying amount and accumulated amortization of intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Definite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased technology and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-488" decimals="-6" id="f-1438" unitRef="usd">16518000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-488" decimals="-6" id="f-1439" unitRef="usd">8689000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-489" decimals="-6" id="f-1440" unitRef="usd">16956000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-489" decimals="-6" id="f-1441" unitRef="usd">7979000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-490" decimals="-6" id="f-1442" unitRef="usd">11557000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-490" decimals="-6" id="f-1443" unitRef="usd">6868000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-491" decimals="-6" id="f-1444" unitRef="usd">11659000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-491" decimals="-6" id="f-1445" unitRef="usd">6277000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-492" decimals="-6" id="f-1446" unitRef="usd">424000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-492" decimals="-6" id="f-1447" unitRef="usd">274000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-493" decimals="-6" id="f-1448" unitRef="usd">486000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-493" decimals="-6" id="f-1449" unitRef="usd">280000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-494" decimals="-6" id="f-1450" unitRef="usd">256000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-494" decimals="-6" id="f-1451" unitRef="usd">84000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-495" decimals="-6" id="f-1452" unitRef="usd">116000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-495" decimals="-6" id="f-1453" unitRef="usd">69000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-27" decimals="-6" id="f-1454" unitRef="usd">28755000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-27" decimals="-6" id="f-1455" unitRef="usd">15915000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-28" decimals="-6" id="f-1456" unitRef="usd">29217000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-28" decimals="-6" id="f-1457" unitRef="usd">14605000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-496" decimals="-6" id="f-1458" unitRef="usd">385000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-497" decimals="-6" id="f-1459" unitRef="usd">232000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-204" decimals="-6" id="f-1460" unitRef="usd">295000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-213" decimals="-6" id="f-1462" unitRef="usd">409000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-25" decimals="-6" id="f-1463" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-498" decimals="-6" id="f-1464" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-499" decimals="-6" id="f-1465" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-500" decimals="-6" id="f-1466" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-8" id="f-1467" unitRef="usd">1700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-25" decimals="-8" id="f-1468" unitRef="usd">1700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-26" decimals="-8" id="f-1469" unitRef="usd">1700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-1470">Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;26, 2024, excluding any possible future amortization associated with acquired IPR&amp;amp;D which has not met technological feasibility, is as follows:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-27" decimals="-6" id="f-1471" unitRef="usd">1635000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-27" decimals="-6" id="f-1472" unitRef="usd">1623000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-27" decimals="-6" id="f-1473" unitRef="usd">1600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-27" decimals="-6" id="f-1474" unitRef="usd">1550000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-27" decimals="-6" id="f-1475" unitRef="usd">1471000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-1476">Property, Plant, and Equipment &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment balances and corresponding estimated useful lives were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.702%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives &lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Generally 2-10, up to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense of $954 million, $999 million, and $974 million was recognized in fiscal years 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-1477">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment balances and corresponding estimated useful lives were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.702%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives &lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Generally 2-10, up to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-501" decimals="-6" id="f-1478" unitRef="usd">6396000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-502" decimals="-6" id="f-1479" unitRef="usd">6707000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-503" id="f-1480">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-504" id="f-1481">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-501" id="f-1482">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-505" decimals="-6" id="f-1483" unitRef="usd">2872000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-506" decimals="-6" id="f-1484" unitRef="usd">2952000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-507" id="f-1485">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-508" decimals="-6" id="f-1486" unitRef="usd">159000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-509" decimals="-6" id="f-1487" unitRef="usd">162000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-510" id="f-1488">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-511" decimals="-6" id="f-1489" unitRef="usd">2506000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-512" decimals="-6" id="f-1490" unitRef="usd">2487000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-513" id="f-1491">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-514" decimals="-6" id="f-1492" unitRef="usd">2119000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-515" decimals="-6" id="f-1493" unitRef="usd">1754000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-27" decimals="-6" id="f-1494" unitRef="usd">14052000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-28" decimals="-6" id="f-1495" unitRef="usd">14062000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-27" decimals="-6" id="f-1496" unitRef="usd">7922000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-28" decimals="-6" id="f-1497" unitRef="usd">8493000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-27" decimals="-6" id="f-1498" unitRef="usd">6131000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-28" decimals="-6" id="f-1499" unitRef="usd">5569000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Depreciation contextRef="c-1" decimals="-6" id="f-1500" unitRef="usd">954000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-25" decimals="-6" id="f-1501" unitRef="usd">999000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-26" decimals="-6" id="f-1502" unitRef="usd">974000000</us-gaap:Depreciation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1503">Shareholders&#x2019; Equity &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share Capital   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medtronic plc is authorized to issue 2.6 billion Ordinary Shares, $0.0001 par value; 40 thousand Euro Deferred Shares, &#x20ac;1.00 par value; 127.5 million Preferred Shares, $0.20 par value; and 500 thousand A Preferred Shares, $1.00 par value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Euro Deferred Shares   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authorized share capital of the Company includes 40 thousand Euro Deferred Shares, with a par value of &#x20ac;1.00 per share. At April&#160;26, 2024, no&#160;Euro Deferred Shares were issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Shares   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authorized share capital of the Company includes 127.5 million of Preferred Shares, with a par value of $0.20 per share. At April&#160;26, 2024, no&#160;Preferred&#160;Shares were issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;A Preferred Shares   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authorized share capital of the Company includes 500 thousand A Preferred Shares, with a par value of $1.00 per share. At April&#160;26, 2024, no A Preferred Shares were outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Dividends   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing, declaration, and payment of future dividends to holders of the Company's ordinary shares falls within the discretion of the Company's Board of Directors and depends upon many factors, including the statutory requirements of Irish law, the Company's earnings and financial condition, the capital requirements of the Company's businesses, industry practice and any other factors the Board of Directors deems relevant.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ordinary Share Repurchase Program   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares are repurchased on occasion to support the Company&#x2019;s stock-based compensation programs and to return capital to shareholders. During fiscal years 2024 and 2023, the Company repurchased approximately 25 million and 6 million shares, respectively, at an average price of $83.04 and $91.31, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, the Company's Board of Directors authorized $6.0 billion for repurchase of the Company's ordinary shares. In March 2024, the Company's Board of Directors authorized an incremental $5.0&#160;billion for share repurchases. There is no specific time-period associated with these repurchase authorizations. At April&#160;26, 2024, the Company had used $5.7 billion of the $11.0&#160;billion authorized under the repurchase program, leaving approximately $5.3 billion available for future repurchases. The Company accounts for repurchases of ordinary shares using the par value method and shares repurchased are cancelled.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-27"
      decimals="INF"
      id="f-1504"
      unitRef="shares">2600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-1505"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <mdt:DeferredStockSharesAuthorized
      contextRef="c-27"
      decimals="INF"
      id="f-1506"
      unitRef="shares">40000</mdt:DeferredStockSharesAuthorized>
    <mdt:DeferredStockParorStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-1507"
      unitRef="eurPerShare">1.00</mdt:DeferredStockParorStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-27"
      decimals="INF"
      id="f-1508"
      unitRef="shares">127500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-1509"
      unitRef="usdPerShare">0.20</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-516"
      decimals="INF"
      id="f-1510"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-516"
      decimals="INF"
      id="f-1511"
      unitRef="usdPerShare">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <mdt:DeferredStockSharesAuthorized
      contextRef="c-27"
      decimals="INF"
      id="f-1512"
      unitRef="shares">40000</mdt:DeferredStockSharesAuthorized>
    <mdt:DeferredStockParorStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-1513"
      unitRef="eurPerShare">1.00</mdt:DeferredStockParorStatedValuePerShare>
    <mdt:DeferredStockSharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-1514"
      unitRef="shares">0</mdt:DeferredStockSharesIssued>
    <mdt:DeferredStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-1515"
      unitRef="shares">0</mdt:DeferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-27"
      decimals="INF"
      id="f-1516"
      unitRef="shares">127500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-1517"
      unitRef="usdPerShare">0.20</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-1518"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-1519"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-516"
      decimals="INF"
      id="f-1520"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-516"
      decimals="INF"
      id="f-1521"
      unitRef="usdPerShare">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-516"
      decimals="INF"
      id="f-1522"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-1" decimals="-6" id="f-1523" unitRef="shares">25000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-25"
      decimals="-6"
      id="f-1524"
      unitRef="shares">6000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <mdt:StockRepurchaseProgramAveragePurchasePrice
      contextRef="c-1"
      decimals="2"
      id="f-1525"
      unitRef="usdPerShare">83.04</mdt:StockRepurchaseProgramAveragePurchasePrice>
    <mdt:StockRepurchaseProgramAveragePurchasePrice
      contextRef="c-25"
      decimals="2"
      id="f-1526"
      unitRef="usdPerShare">91.31</mdt:StockRepurchaseProgramAveragePurchasePrice>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-517" decimals="-8" id="f-1527" unitRef="usd">6000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-518" decimals="-8" id="f-1528" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-1" decimals="-8" id="f-1529" unitRef="usd">5700000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-27" decimals="-8" id="f-1530" unitRef="usd">11000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-27" decimals="-8" id="f-1531" unitRef="usd">5300000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1532">Stock Purchase and Award Plans &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In fiscal year 2024, the Company granted stock awards under the 2021 Medtronic plc Long Term Incentive Plan (2021 Plan). The 2021 Plan provides for the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock and cash-based awards. At April&#160;26, 2024, there were approximately 88 million shares available for future grants under the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   Options are granted at the exercise price, which is equal to the closing price of the Company&#x2019;s ordinary shares on the grant date. The majority of the Company&#x2019;s options are non-qualified options with a &lt;span style="-sec-ix-hidden:f-1568"&gt;ten&lt;/span&gt;-year life and a &lt;span style="-sec-ix-hidden:f-1569"&gt;four&lt;/span&gt;-year ratable vesting term. The Company uses the Black-Scholes option pricing model (Black-Scholes model) to determine the fair value of stock options at the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company&#x2019;s stock price, and expected dividends. Expected volatility is based on a blend of historical volatility and an implied volatility of the Company&#x2019;s ordinary shares. Implied volatility is based on market traded options of the Company&#x2019;s ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions used:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during fiscal year 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg. Remaining Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash proceeds from options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to outstanding stock options at April&#160;26, 2024 was $90 million and is expected to be recognized over a weighted average period of 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Restricted stock units are expensed over the vesting period and are subject to forfeiture if employment terminates prior to the lapse of the restrictions. The expense recognized for restricted stock units is equal to the grant date fair value, which is equal to the closing stock price on the date of grant. The majority of the Company's restricted stock units either have a four-year ratable vesting term or cliff vest after three years. Restricted stock units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on restricted stock units during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock activity during fiscal year 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Grant&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to restricted stock as of April&#160;26, 2024 was $361 million and is expected to be recognized over a weighted average period of 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Performance Share Units  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Performance share units typically cliff vest after three years. The awards include three metrics: relative total shareholder return (rTSR), revenue growth, and return on investor capital (ROIC). rTSR is considered a market condition metric, and the expense is determined at the grant date and will not be adjusted even if the market condition is not met. Revenue growth and ROIC are considered performance metrics, and the expense is recorded over the performance period, which will be reassessed each reporting period based on the probability of achieving the various performance conditions. The number of shares earned at the end of the three-year period will vary, based on only actual performance, from 0% to 200% of the target number of performance share units granted. Performance share units are subject to forfeiture if employment terminates prior to the lapse of the restrictions. Performance share units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on performance share units for each component of the award during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates the fair value of the performance share units for each component individually. The fair value of the rTSR metric will be determined using the Monte Carlo valuation model. The fair value of the revenue growth and ROIC metrics are equal to the closing stock price on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes performance share unit activity during fiscal year 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Grant&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2024, 2023, and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per performance share units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of performance share units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to performance share units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to performance share units as of April&#160;26, 2024 was $89 million and is expected to be recognized over a weighted average period of 1.6 years.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employees Stock Purchase Plan (ESPP)  &lt;/span&gt; The Company's shareholders approved the Medtronic plc 2024 Employee Stock Purchase Plan (2024 Plan) on October 19, 2023, which provides for a maximum of 30&#160;million ordinary shares to be purchased by participating employees. The 2024 Plan replaced the Medtronic plc Amended and Restated 2014 Employees Stock Purchase Plan (2014 Plan) starting January 1, 2024. The 2024 Plan allows participating employees to purchase the Company's ordinary shares at a discount through payroll deductions. The expense recognized for shares purchased under the Company&#x2019;s 2014 Plan and 2024 Plan is equal to the 15 percent discount the employee receives. Employees purchased 3 million shares at an average price of $71.10 per share in fiscal year 2024. At April&#160;26, 2024, approximately 29 million ordinary shares were available for future purchase under the 2024 Plan.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-519"
      decimals="-6"
      id="f-1533"
      unitRef="shares">88000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-1534">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-520" decimals="-6" id="f-1535" unitRef="usd">76000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-521" decimals="-6" id="f-1536" unitRef="usd">77000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-522" decimals="-6" id="f-1537" unitRef="usd">70000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-523" decimals="-6" id="f-1538" unitRef="usd">184000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-524" decimals="-6" id="f-1539" unitRef="usd">166000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-525" decimals="-6" id="f-1540" unitRef="usd">184000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-526" decimals="-6" id="f-1541" unitRef="usd">97000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-527" decimals="-6" id="f-1542" unitRef="usd">74000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-528" decimals="-6" id="f-1543" unitRef="usd">66000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-529" decimals="-6" id="f-1544" unitRef="usd">36000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-530" decimals="-6" id="f-1545" unitRef="usd">38000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-531" decimals="-6" id="f-1546" unitRef="usd">39000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-1547" unitRef="usd">393000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-25" decimals="-6" id="f-1548" unitRef="usd">355000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-26" decimals="-6" id="f-1549" unitRef="usd">359000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-231" decimals="-6" id="f-1550" unitRef="usd">35000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-232" decimals="-6" id="f-1551" unitRef="usd">36000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-233" decimals="-6" id="f-1552" unitRef="usd">36000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-532" decimals="-6" id="f-1553" unitRef="usd">47000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-533" decimals="-6" id="f-1554" unitRef="usd">39000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-534" decimals="-6" id="f-1555" unitRef="usd">40000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-234" decimals="-6" id="f-1556" unitRef="usd">310000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-235" decimals="-6" id="f-1557" unitRef="usd">280000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-236" decimals="-6" id="f-1558" unitRef="usd">283000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-1559" unitRef="usd">393000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-25" decimals="-6" id="f-1560" unitRef="usd">355000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-26" decimals="-6" id="f-1561" unitRef="usd">359000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-6" id="f-1562" unitRef="usd">64000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-25" decimals="-6" id="f-1563" unitRef="usd">60000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-26" decimals="-6" id="f-1564" unitRef="usd">62000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-6" id="f-1565" unitRef="usd">329000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-25" decimals="-6" id="f-1566" unitRef="usd">295000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-26" decimals="-6" id="f-1567" unitRef="usd">297000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1570">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions used:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-1571"
      unitRef="usdPerShare">18.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-25"
      decimals="2"
      id="f-1572"
      unitRef="usdPerShare">17.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-26"
      decimals="2"
      id="f-1573"
      unitRef="usdPerShare">22.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-1574">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-25" id="f-1575">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-26" id="f-1576">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-1577" unitRef="number">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-25" decimals="4" id="f-1578" unitRef="number">0.0270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-26" decimals="4" id="f-1579" unitRef="number">0.0090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="4" id="f-1580" unitRef="number">0.2429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-25" decimals="4" id="f-1581" unitRef="number">0.2405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-26" decimals="4" id="f-1582" unitRef="number">0.2304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="4" id="f-1583" unitRef="number">0.0318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-25" decimals="4" id="f-1584" unitRef="number">0.0292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-26" decimals="4" id="f-1585" unitRef="number">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1586">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during fiscal year 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg. Remaining Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash proceeds from options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-535"
      decimals="-3"
      id="f-1587"
      unitRef="shares">30866000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-535"
      decimals="2"
      id="f-1588"
      unitRef="usdPerShare">93.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-520"
      decimals="-3"
      id="f-1589"
      unitRef="shares">4823000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-520"
      decimals="2"
      id="f-1590"
      unitRef="usdPerShare">86.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-520"
      decimals="-3"
      id="f-1591"
      unitRef="shares">1445000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-520"
      decimals="2"
      id="f-1592"
      unitRef="usdPerShare">65.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-520"
      decimals="-3"
      id="f-1593"
      unitRef="shares">1905000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-520"
      decimals="2"
      id="f-1594"
      unitRef="usdPerShare">98.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-536"
      decimals="-3"
      id="f-1595"
      unitRef="shares">32339000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-536"
      decimals="2"
      id="f-1596"
      unitRef="usdPerShare">93.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-520" id="f-1597">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-536" decimals="-6" id="f-1598" unitRef="usd">30000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-536"
      decimals="-3"
      id="f-1599"
      unitRef="shares">8914000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-536"
      decimals="2"
      id="f-1600"
      unitRef="usdPerShare">95.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-520" id="f-1601">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-536" decimals="-6" id="f-1602" unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-536"
      decimals="-3"
      id="f-1603"
      unitRef="shares">22746000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-536"
      decimals="2"
      id="f-1604"
      unitRef="usdPerShare">92.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-520" id="f-1605">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-536" decimals="-6" id="f-1606" unitRef="usd">28000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-520" decimals="-6" id="f-1607" unitRef="usd">78000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-521" decimals="-6" id="f-1608" unitRef="usd">77000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-522" decimals="-6" id="f-1609" unitRef="usd">209000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-520" decimals="-6" id="f-1610" unitRef="usd">28000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-521" decimals="-6" id="f-1611" unitRef="usd">42000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-522" decimals="-6" id="f-1612" unitRef="usd">174000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-520" decimals="-6" id="f-1613" unitRef="usd">6000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-521" decimals="-6" id="f-1614" unitRef="usd">9000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-522" decimals="-6" id="f-1615" unitRef="usd">40000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-536" decimals="-6" id="f-1616" unitRef="usd">90000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-520" id="f-1617">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-537" id="f-1618">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-538" id="f-1619">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-1620">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock activity during fiscal year 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Grant&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-539"
      decimals="-3"
      id="f-1621"
      unitRef="shares">5189000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-539"
      decimals="2"
      id="f-1622"
      unitRef="usdPerShare">102.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-540"
      decimals="-3"
      id="f-1623"
      unitRef="shares">3297000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-540"
      decimals="2"
      id="f-1624"
      unitRef="usdPerShare">82.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-540"
      decimals="-3"
      id="f-1625"
      unitRef="shares">1819000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-540"
      decimals="2"
      id="f-1626"
      unitRef="usdPerShare">102.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-540"
      decimals="-3"
      id="f-1627"
      unitRef="shares">526000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-540"
      decimals="2"
      id="f-1628"
      unitRef="usdPerShare">99.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-541"
      decimals="-3"
      id="f-1629"
      unitRef="shares">6142000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-541"
      decimals="2"
      id="f-1630"
      unitRef="usdPerShare">92.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-540"
      decimals="2"
      id="f-1631"
      unitRef="usdPerShare">82.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-542"
      decimals="2"
      id="f-1632"
      unitRef="usdPerShare">91.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-543"
      decimals="2"
      id="f-1633"
      unitRef="usdPerShare">127.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-540" decimals="-6" id="f-1634" unitRef="usd">186000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-542" decimals="-6" id="f-1635" unitRef="usd">256000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-543" decimals="-6" id="f-1636" unitRef="usd">194000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-540" decimals="-6" id="f-1637" unitRef="usd">29000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-542" decimals="-6" id="f-1638" unitRef="usd">45000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-543" decimals="-6" id="f-1639" unitRef="usd">52000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-541" decimals="-6" id="f-1640" unitRef="usd">361000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-540" id="f-1641">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-526" id="f-1642">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-526" id="f-1643">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-544"
      decimals="INF"
      id="f-1644"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-545"
      decimals="INF"
      id="f-1645"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock contextRef="c-1" id="f-1646">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes performance share unit activity during fiscal year 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Grant&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2024, 2023, and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per performance share units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of performance share units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to performance share units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-546"
      decimals="-3"
      id="f-1647"
      unitRef="shares">2043000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-546"
      decimals="2"
      id="f-1648"
      unitRef="usdPerShare">119.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-526"
      decimals="-3"
      id="f-1649"
      unitRef="shares">1283000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-526"
      decimals="2"
      id="f-1650"
      unitRef="usdPerShare">104.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-526"
      decimals="-3"
      id="f-1651"
      unitRef="shares">249000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-526"
      decimals="2"
      id="f-1652"
      unitRef="usdPerShare">129.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments
      contextRef="c-526"
      decimals="-3"
      id="f-1653"
      unitRef="shares">455000</mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments>
    <mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments
      contextRef="c-526"
      decimals="2"
      id="f-1654"
      unitRef="usdPerShare">147.92</mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-526"
      decimals="-3"
      id="f-1655"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-526"
      decimals="2"
      id="f-1656"
      unitRef="usdPerShare">113.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-547"
      decimals="-3"
      id="f-1657"
      unitRef="shares">2422000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-547"
      decimals="2"
      id="f-1658"
      unitRef="usdPerShare">106.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-526"
      decimals="2"
      id="f-1659"
      unitRef="usdPerShare">104.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-527"
      decimals="2"
      id="f-1660"
      unitRef="usdPerShare">98.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-528"
      decimals="2"
      id="f-1661"
      unitRef="usdPerShare">149.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-526" decimals="-6" id="f-1662" unitRef="usd">78000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-527" decimals="-6" id="f-1663" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-528" decimals="-6" id="f-1664" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-526" decimals="-6" id="f-1665" unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-527" decimals="-6" id="f-1666" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-528" decimals="-6" id="f-1667" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-547" decimals="-6" id="f-1668" unitRef="usd">89000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-526" id="f-1669">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-548"
      decimals="-6"
      id="f-1670"
      unitRef="shares">30000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="c-549"
      decimals="INF"
      id="f-1671"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod
      contextRef="c-549"
      decimals="-6"
      id="f-1672"
      unitRef="shares">3000000</mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod>
    <mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare
      contextRef="c-549"
      decimals="2"
      id="f-1673"
      unitRef="usdPerShare">71.10</mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-550"
      decimals="-6"
      id="f-1674"
      unitRef="shares">29000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1675">Income Taxes &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision is based on income before income taxes reported for financial statement purposes. The components of income before income taxes, based on tax jurisdiction, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax (benefit) expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss, capital loss, and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalization of research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and post-retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease obligations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state benefit on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on available-for-sale securities and derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,756&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized loss on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis difference of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and post-retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reported as (after valuation allowance and jurisdictional netting):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No deferred taxes have been provided on the approximately $86.3 billion and $83.7 billion of undistributed earnings of the Company&#x2019;s subsidiaries at April&#160;26, 2024 and April&#160;28, 2023, respectively, since these earnings have been, and under current plans will continue to be, permanently reinvested in these subsidiaries. Due to the number of legal entities and jurisdictions involved, the complexity of the legal entity structure of the Company, and the complexity of the tax laws in the relevant jurisdictions, the Company believes it is not practicable to estimate, within any reasonable range, the amount of additional taxes which may be payable upon distribution of these undistributed earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;26, 2024, the Company had approximately $11.3 billion of tax effected net operating loss carryforwards in certain non-U.S. jurisdictions, of which&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.1 billion have no expiration, and the remaining $6.2 billion will expire during fiscal years 2025 through 2041. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in these net operating loss carryforwards are $4.0 billion of tax effected net operating losses generated in fiscal year 2008 as a result of the receipt of a favorable tax ruling from certain non-U.S. taxing authorities; and $5.1&#160;billion of tax effected net operating losses generated during fiscal year 2023 as a result of an intercompany reorganization. The Company has recorded a full valuation allowance against these net operating losses, as management does not believe that it is more likely than not that these net operating losses will be utilized. Certain of the remaining non-U.S. net operating loss carryforwards of $2.2 billion have a valuation allowance recorded against the carryforwards, as management does not believe that it is more likely than not that these net operating losses will be utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;26, 2024, the Company had $81 million of tax effected U.S. federal net operating loss carryforwards, of which $56&#160;million have no expiration. The remaining loss carryforwards will expire during fiscal years 2025 through 2036. For U.S. state purposes, the Company had $90 million of tax effected net operating loss carryforwards at April&#160;26, 2024, $12&#160;million of which have no expiration. The remaining U.S. state loss carryforwards will expire during fiscal years 2025 through 2042.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;26, 2024, the Company also had $292 million of tax credits available to reduce future income taxes payable, of which&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$122 million have no expiration. The remaining credits will expire during fiscal years 2025 through 2043. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established valuation allowances of $13.3 billion and $11.3 billion at April&#160;26, 2024 and April&#160;28, 2023, respectively, primarily related to the uncertainty of the utilization of certain deferred tax assets which are primarily comprised of tax loss and credit carryforwards in various jurisdictions. The increase in the valuation allowance during fiscal year 2024 is primarily related to the finalization of certain tax returns as well as an increase in the Swiss Cantonal tax rate applied to previously recorded deferred tax assets and associated valuation allowances. These valuation allowances would result in a reduction to the income tax provision in the consolidated statements of income if they are ultimately not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease) in tax rate resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. state taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions and interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Base erosion anti-abuse tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign derived intangible income benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Israeli Central-Lod District Court issued its decision in Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office in June 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a $187&#160;million income tax charge during fiscal year 2024 and filed an appeal with the Supreme Court of Israel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2024, the net cost from certain tax adjustments of $299&#160;million, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of income, included the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $187&#160;million associated with a reserve adjustment related to the Israeli Central-Lod District Court decision with respect to a deemed taxable transfer of intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $124&#160;million related to a change in valuation allowance on previously recorded net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A benefit of $95&#160;million related to a Swiss Cantonal tax rate change on previously recorded deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $50&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $33&#160;million associated with a change in the Company&#x2019;s permanent reinvestment assertion on certain historical earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2023, the net benefit from certain tax adjustments of $910&#160;million, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statement of income, included the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A net cost of $764&#160;million associated with the August 18, 2022 U.S. Tax Court (Tax Court) Opinion on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006 (Opinion). While the Opinion rejected the IRS&#x2019;s position and the Tax Court determined the methodology advanced by Medtronic was appropriate for purposes of determining the intercompany royalty rate between Puerto Rico and the U.S., it determined that the royalty rate should be higher, thereby increasing income allocated to the U.S. and consequently subject to U.S. tax. This case relates only to fiscal years 2005 and 2006. The Company has assumed the Tax Court findings will be applied for all years following fiscal year 2006. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $55&#160;million related to the disallowance of certain interest deductions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $30&#160;million related to the change in reporting currency for certain carryover attributes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $28&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A net cost of $33&#160;million primarily associated with the sale of half of the Company&#x2019;s RCS business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2022, the net benefit from certain tax adjustments of&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$50&#160;million, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of income, included the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A benefit of $82&#160;million associated with a step up in tax basis for Swiss Cantonal purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A benefit of $82&#160;million related to a change in tax rates on intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $47&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $41&#160;million associated with a change in the Company&#x2019;s permanent reinvestment assertion on certain historical earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A net cost of $26&#160;million primarily associated with an intercompany sale of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currently, the Company&#x2019;s operations in Puerto Rico, Singapore, Dominican Republic, Costa Rica, and China have various tax holidays and tax incentive grants. The tax reductions as compared to the local statutory rate favorably impacted earnings by $229&#160;million, $115 million, and $248 million in fiscal years 2024, 2023, and 2022, respectively, and diluted earnings per share by $0.17, $0.09, and $0.18, in fiscal years 2024, 2023, and 2022, respectively. The tax holidays are conditional upon the Company meeting certain thresholds required under statutory law. The tax incentive grants, unless extended, will expire between fiscal years 2025 and 2049. The tax incentive grants which expired during fiscal year 2024 did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which will be effective for the Company in fiscal year 2025. The Company is continuing to evaluate the potential impacts of proposed and enacted legislative changes as new guidance becomes available. There are no impacts of this global minimum tax in the consolidated financial statements for the fiscal year ended April&#160;26, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had $2.8 billion, $2.7 billion, and $1.7 billion of gross unrecognized tax benefits at April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022, respectively. A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2024, 2023, and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at beginning of fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross increases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross decreases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statute of limitation lapses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash advance paid to taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of fiscal year, net of cash advance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If all of the Company&#x2019;s unrecognized tax benefits at April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022 were recognized, $2.7 billion, $2.5 billion, and $1.6 billion would impact the Company&#x2019;s effective tax rate, respectively. Although the Company believes that it has adequately reserved for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on the Company&#x2019;s effective tax rate in future periods. The Company has recorded gross unrecognized tax benefits, net of cash advance, of $1.8 billion as a noncurrent liability. The Company estimates that within the next 12 months it is reasonably possible that its uncertain tax positions, excluding interest, could decrease by as much as $15&#160;million, net as a result of statute of limitation lapses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to income tax matters in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income and records the liability in the current or noncurrent &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accrued income taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets, as appropriate. During fiscal years 2024, 2023, and 2022, the Company recognized gross interest expense of $134 million, $86 million, and $17 million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. The Company had $19 million, $61 million, and $117 million of accrued gross interest and penalties at April&#160;26, 2024, April&#160;28, 2023, and April&#160;29, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. These reserves are subject to a high degree of estimation and management judgment. Resolution of these significant unresolved matters, or positions taken by the IRS or other tax authorities during future tax audits, could have a material impact on the Company&#x2019;s financial results in future periods. The Company continues to believe that its reserves for uncertain tax positions are appropriate and that it has meritorious defenses for its tax filings and will vigorously defend them during the audit process, appellate process, and through litigation in courts, as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Jurisdiction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Earliest Year Open&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - federal and state&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2005&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brazil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costa Rica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dominican Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 18 for additional information regarding the status of current tax audits and proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1676">The components of income before income taxes, based on tax jurisdiction, are as follows:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-6" id="f-1677" unitRef="usd">750000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-25" decimals="-6" id="f-1678" unitRef="usd">1295000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-26" decimals="-6" id="f-1679" unitRef="usd">436000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-6" id="f-1680" unitRef="usd">4087000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-25" decimals="-6" id="f-1681" unitRef="usd">4069000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-26" decimals="-6" id="f-1682" unitRef="usd">5081000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-1683" unitRef="usd">4837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-1684" unitRef="usd">5364000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-1685" unitRef="usd">5517000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1686">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax (benefit) expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1687" unitRef="usd">756000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1688" unitRef="usd">1303000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1689" unitRef="usd">467000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1690" unitRef="usd">905000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1691" unitRef="usd">530000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1692" unitRef="usd">599000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1693" unitRef="usd">1661000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1694" unitRef="usd">1833000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1695" unitRef="usd">1066000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1696" unitRef="usd">-435000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1697" unitRef="usd">-336000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1698" unitRef="usd">-402000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1699" unitRef="usd">-93000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1700" unitRef="usd">83000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1701" unitRef="usd">-209000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1702" unitRef="usd">-528000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1703" unitRef="usd">-253000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1704" unitRef="usd">-611000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1705" unitRef="usd">1133000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1706" unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1707" unitRef="usd">456000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1708">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss, capital loss, and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalization of research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and post-retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease obligations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state benefit on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on available-for-sale securities and derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,756&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized loss on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis difference of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and post-retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reported as (after valuation allowance and jurisdictional netting):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards contextRef="c-27" decimals="-6" id="f-1709" unitRef="usd">11775000000</mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards>
    <mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards contextRef="c-28" decimals="-6" id="f-1710" unitRef="usd">10803000000</mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-27" decimals="-6" id="f-1711" unitRef="usd">2858000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-28" decimals="-6" id="f-1712" unitRef="usd">2259000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization contextRef="c-27" decimals="-6" id="f-1713" unitRef="usd">1255000000</mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization>
    <mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization contextRef="c-28" decimals="-6" id="f-1714" unitRef="usd">971000000</mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-27" decimals="-6" id="f-1715" unitRef="usd">404000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-28" decimals="-6" id="f-1716" unitRef="usd">458000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-27" decimals="-6" id="f-1717" unitRef="usd">374000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-28" decimals="-6" id="f-1718" unitRef="usd">312000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <mdt:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions contextRef="c-27" decimals="-6" id="f-1719" unitRef="usd">0</mdt:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions>
    <mdt:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions contextRef="c-28" decimals="-6" id="f-1720" unitRef="usd">66000000</mdt:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-27" decimals="-6" id="f-1721" unitRef="usd">147000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-28" decimals="-6" id="f-1722" unitRef="usd">141000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-27" decimals="-6" id="f-1723" unitRef="usd">138000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-28" decimals="-6" id="f-1724" unitRef="usd">135000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-27" decimals="-6" id="f-1725" unitRef="usd">172000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-28" decimals="-6" id="f-1726" unitRef="usd">37000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <mdt:DeferredTaxAssetsLeaseObligations contextRef="c-27" decimals="-6" id="f-1727" unitRef="usd">157000000</mdt:DeferredTaxAssetsLeaseObligations>
    <mdt:DeferredTaxAssetsLeaseObligations contextRef="c-28" decimals="-6" id="f-1728" unitRef="usd">150000000</mdt:DeferredTaxAssetsLeaseObligations>
    <mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions contextRef="c-27" decimals="-6" id="f-1729" unitRef="usd">21000000</mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions>
    <mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions contextRef="c-28" decimals="-6" id="f-1730" unitRef="usd">79000000</mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions>
    <mdt:DeferredTaxAssetsInterestLimitation contextRef="c-27" decimals="-6" id="f-1731" unitRef="usd">608000000</mdt:DeferredTaxAssetsInterestLimitation>
    <mdt:DeferredTaxAssetsInterestLimitation contextRef="c-28" decimals="-6" id="f-1732" unitRef="usd">377000000</mdt:DeferredTaxAssetsInterestLimitation>
    <mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives contextRef="c-27" decimals="-6" id="f-1733" unitRef="usd">-13000000</mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives>
    <mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives contextRef="c-28" decimals="-6" id="f-1734" unitRef="usd">-39000000</mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-27" decimals="-6" id="f-1735" unitRef="usd">355000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-28" decimals="-6" id="f-1736" unitRef="usd">240000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-27" decimals="-6" id="f-1737" unitRef="usd">18277000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-28" decimals="-6" id="f-1738" unitRef="usd">16067000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-6" id="f-1739" unitRef="usd">13271000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-28" decimals="-6" id="f-1740" unitRef="usd">11311000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-27" decimals="-6" id="f-1741" unitRef="usd">5006000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-28" decimals="-6" id="f-1742" unitRef="usd">4756000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-27" decimals="-6" id="f-1743" unitRef="usd">1406000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-28" decimals="-6" id="f-1744" unitRef="usd">1551000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="c-27" decimals="-6" id="f-1745" unitRef="usd">70000000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="c-28" decimals="-6" id="f-1746" unitRef="usd">70000000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-27" decimals="-6" id="f-1747" unitRef="usd">149000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-28" decimals="-6" id="f-1748" unitRef="usd">147000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-27" decimals="-6" id="f-1749" unitRef="usd">110000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-28" decimals="-6" id="f-1750" unitRef="usd">109000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries contextRef="c-27" decimals="-6" id="f-1751" unitRef="usd">90000000</mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries>
    <mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries contextRef="c-28" decimals="-6" id="f-1752" unitRef="usd">119000000</mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries>
    <mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits contextRef="c-27" decimals="-6" id="f-1753" unitRef="usd">45000000</mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits>
    <mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits contextRef="c-28" decimals="-6" id="f-1754" unitRef="usd">0</mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-27" decimals="-6" id="f-1755" unitRef="usd">90000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-28" decimals="-6" id="f-1756" unitRef="usd">80000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-27" decimals="-6" id="f-1757" unitRef="usd">1960000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-28" decimals="-6" id="f-1758" unitRef="usd">2076000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:PrepaidTaxes contextRef="c-27" decimals="-6" id="f-1759" unitRef="usd">520000000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="c-28" decimals="-6" id="f-1760" unitRef="usd">480000000</us-gaap:PrepaidTaxes>
    <us-gaap:IncomeTaxReceivable contextRef="c-27" decimals="-6" id="f-1761" unitRef="usd">406000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable contextRef="c-28" decimals="-6" id="f-1762" unitRef="usd">494000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-27" decimals="-6" id="f-1763" unitRef="usd">3972000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-28" decimals="-6" id="f-1764" unitRef="usd">3654000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <mdt:DeferredTaxAssetsNetofValuationAllowanceOther contextRef="c-27" decimals="-6" id="f-1765" unitRef="usd">830000000</mdt:DeferredTaxAssetsNetofValuationAllowanceOther>
    <mdt:DeferredTaxAssetsNetofValuationAllowanceOther contextRef="c-28" decimals="-6" id="f-1766" unitRef="usd">885000000</mdt:DeferredTaxAssetsNetofValuationAllowanceOther>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-27" decimals="-6" id="f-1767" unitRef="usd">3657000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-28" decimals="-6" id="f-1768" unitRef="usd">3477000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-27" decimals="-6" id="f-1769" unitRef="usd">515000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-28" decimals="-6" id="f-1770" unitRef="usd">708000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-27" decimals="-6" id="f-1771" unitRef="usd">3972000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-28" decimals="-6" id="f-1772" unitRef="usd">3654000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="c-27" decimals="-8" id="f-1773" unitRef="usd">86300000000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="c-28" decimals="-8" id="f-1774" unitRef="usd">83700000000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:OperatingLossCarryforwards contextRef="c-551" decimals="-8" id="f-1775" unitRef="usd">11300000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-551" decimals="-8" id="f-1776" unitRef="usd">5100000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-551" decimals="-8" id="f-1777" unitRef="usd">6200000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-552" decimals="-8" id="f-1778" unitRef="usd">4000000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-27" decimals="-8" id="f-1779" unitRef="usd">5100000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c-551" decimals="-8" id="f-1780" unitRef="usd">2200000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-553" decimals="-6" id="f-1781" unitRef="usd">81000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-553" decimals="-6" id="f-1782" unitRef="usd">56000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-554" decimals="-6" id="f-1783" unitRef="usd">90000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-554" decimals="-6" id="f-1784" unitRef="usd">12000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-27" decimals="-6" id="f-1785" unitRef="usd">292000000</us-gaap:TaxCreditCarryforwardAmount>
    <mdt:DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration contextRef="c-27" decimals="-6" id="f-1786" unitRef="usd">122000000</mdt:DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-8" id="f-1787" unitRef="usd">13300000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-28" decimals="-8" id="f-1788" unitRef="usd">11300000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1789">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease) in tax rate resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. state taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions and interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Base erosion anti-abuse tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign derived intangible income benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-1"
      decimals="INF"
      id="f-1790"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-25"
      decimals="INF"
      id="f-1791"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-26"
      decimals="INF"
      id="f-1792"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1793" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-25" decimals="3" id="f-1794" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-26" decimals="3" id="f-1795" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-1796" unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-25" decimals="3" id="f-1797" unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-26" decimals="3" id="f-1798" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax contextRef="c-1" decimals="3" id="f-1799" unitRef="number">0</mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax>
    <mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax contextRef="c-25" decimals="3" id="f-1800" unitRef="number">0.010</mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax>
    <mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax contextRef="c-26" decimals="3" id="f-1801" unitRef="number">0.011</mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1802" unitRef="number">-0.067</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-25" decimals="3" id="f-1803" unitRef="number">-0.080</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-26" decimals="3" id="f-1804" unitRef="number">-0.109</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1805" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-25" decimals="3" id="f-1806" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-26" decimals="3" id="f-1807" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent contextRef="c-1" decimals="3" id="f-1808" unitRef="number">0.013</mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent contextRef="c-25" decimals="3" id="f-1809" unitRef="number">0.012</mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent contextRef="c-26" decimals="3" id="f-1810" unitRef="number">0.002</mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent contextRef="c-1" decimals="3" id="f-1811" unitRef="number">0.003</mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent contextRef="c-25" decimals="3" id="f-1812" unitRef="number">0</mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent contextRef="c-26" decimals="3" id="f-1813" unitRef="number">0.009</mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-1" decimals="3" id="f-1814" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-25" decimals="3" id="f-1815" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-26" decimals="3" id="f-1816" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-1817" unitRef="number">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-25" decimals="3" id="f-1818" unitRef="number">0.170</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-26" decimals="3" id="f-1819" unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c-1" decimals="3" id="f-1820" unitRef="number">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c-25" decimals="3" id="f-1821" unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c-26" decimals="3" id="f-1822" unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1823" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-25" decimals="3" id="f-1824" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-26" decimals="3" id="f-1825" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1826" unitRef="number">0.234</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-25" decimals="3" id="f-1827" unitRef="number">0.295</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-26" decimals="3" id="f-1828" unitRef="number">0.083</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-1" decimals="-6" id="f-1829" unitRef="usd">187000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-1" decimals="-6" id="f-1830" unitRef="usd">299000000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets contextRef="c-1" decimals="-6" id="f-1831" unitRef="usd">187000000</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-6" id="f-1832" unitRef="usd">124000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-6" id="f-1833" unitRef="usd">-95000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization contextRef="c-1" decimals="-6" id="f-1834" unitRef="usd">50000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization>
    <mdt:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion contextRef="c-1" decimals="-6" id="f-1835" unitRef="usd">33000000</mdt:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-25" decimals="-6" id="f-1836" unitRef="usd">910000000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <mdt:EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount contextRef="c-25" decimals="-6" id="f-1837" unitRef="usd">764000000</mdt:EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount>
    <mdt:EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount contextRef="c-25" decimals="-6" id="f-1838" unitRef="usd">55000000</mdt:EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="c-28" decimals="-6" id="f-1839" unitRef="usd">30000000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization contextRef="c-25" decimals="-6" id="f-1840" unitRef="usd">28000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets contextRef="c-25" decimals="-6" id="f-1841" unitRef="usd">33000000</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-26" decimals="-6" id="f-1842" unitRef="usd">50000000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationTaxSettlements contextRef="c-26" decimals="-6" id="f-1843" unitRef="usd">-82000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <mdt:EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount contextRef="c-26" decimals="-6" id="f-1844" unitRef="usd">-82000000</mdt:EffectiveIncomeTaxRateReconciliationTaxBasisAdjustmentOfIntangibleAssetsAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization contextRef="c-26" decimals="-6" id="f-1845" unitRef="usd">47000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization>
    <mdt:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion contextRef="c-26" decimals="-6" id="f-1846" unitRef="usd">41000000</mdt:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets contextRef="c-26" decimals="-6" id="f-1847" unitRef="usd">26000000</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationTaxHolidays contextRef="c-555" decimals="-6" id="f-1848" unitRef="usd">229000000</us-gaap:IncomeTaxReconciliationTaxHolidays>
    <us-gaap:IncomeTaxReconciliationTaxHolidays contextRef="c-556" decimals="-6" id="f-1849" unitRef="usd">115000000</us-gaap:IncomeTaxReconciliationTaxHolidays>
    <us-gaap:IncomeTaxReconciliationTaxHolidays contextRef="c-557" decimals="-6" id="f-1850" unitRef="usd">248000000</us-gaap:IncomeTaxReconciliationTaxHolidays>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c-555"
      decimals="2"
      id="f-1851"
      unitRef="usdPerShare">0.17</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c-556"
      decimals="2"
      id="f-1852"
      unitRef="usdPerShare">0.09</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c-557"
      decimals="2"
      id="f-1853"
      unitRef="usdPerShare">0.18</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-8" id="f-1854" unitRef="usd">2800000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-28" decimals="-8" id="f-1855" unitRef="usd">2700000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-48" decimals="-8" id="f-1856" unitRef="usd">1700000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1857">A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2024, 2023, and 2022 is as follows:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at beginning of fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross increases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross decreases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statute of limitation lapses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash advance paid to taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of fiscal year, net of cash advance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-28" decimals="-6" id="f-1858" unitRef="usd">2682000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-48" decimals="-6" id="f-1859" unitRef="usd">1661000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-35" decimals="-6" id="f-1860" unitRef="usd">1668000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1861" unitRef="usd">121000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-25" decimals="-6" id="f-1862" unitRef="usd">980000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-26" decimals="-6" id="f-1863" unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1864" unitRef="usd">85000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-25" decimals="-6" id="f-1865" unitRef="usd">89000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-26" decimals="-6" id="f-1866" unitRef="usd">40000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1867" unitRef="usd">2000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-25" decimals="-6" id="f-1868" unitRef="usd">12000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-26" decimals="-6" id="f-1869" unitRef="usd">29000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-6" id="f-1870" unitRef="usd">55000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-25" decimals="-6" id="f-1871" unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-26" decimals="-6" id="f-1872" unitRef="usd">8000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-6" id="f-1873" unitRef="usd">7000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-25" decimals="-6" id="f-1874" unitRef="usd">32000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-26" decimals="-6" id="f-1875" unitRef="usd">11000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-6" id="f-1876" unitRef="usd">2824000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-28" decimals="-6" id="f-1877" unitRef="usd">2682000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-48" decimals="-6" id="f-1878" unitRef="usd">1661000000</us-gaap:UnrecognizedTaxBenefits>
    <mdt:CashAdvancePaidinConnectionWithProposedSettlements contextRef="c-1" decimals="-6" id="f-1879" unitRef="usd">934000000</mdt:CashAdvancePaidinConnectionWithProposedSettlements>
    <mdt:CashAdvancePaidinConnectionWithProposedSettlements contextRef="c-25" decimals="-6" id="f-1880" unitRef="usd">918000000</mdt:CashAdvancePaidinConnectionWithProposedSettlements>
    <mdt:CashAdvancePaidinConnectionWithProposedSettlements contextRef="c-26" decimals="-6" id="f-1881" unitRef="usd">859000000</mdt:CashAdvancePaidinConnectionWithProposedSettlements>
    <mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid contextRef="c-27" decimals="-6" id="f-1882" unitRef="usd">1890000000</mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid>
    <mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid contextRef="c-28" decimals="-6" id="f-1883" unitRef="usd">1764000000</mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid>
    <mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid contextRef="c-48" decimals="-6" id="f-1884" unitRef="usd">802000000</mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-27" decimals="-8" id="f-1885" unitRef="usd">2700000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-28" decimals="-8" id="f-1886" unitRef="usd">2500000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-48" decimals="-8" id="f-1887" unitRef="usd">1600000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent contextRef="c-27" decimals="-8" id="f-1888" unitRef="usd">1800000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-27" decimals="-6" id="f-1889" unitRef="usd">15000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <mdt:IncomeTaxExaminationInterestIncomeExpenseGross contextRef="c-1" decimals="-6" id="f-1890" unitRef="usd">134000000</mdt:IncomeTaxExaminationInterestIncomeExpenseGross>
    <mdt:IncomeTaxExaminationInterestIncomeExpenseGross contextRef="c-25" decimals="-6" id="f-1891" unitRef="usd">86000000</mdt:IncomeTaxExaminationInterestIncomeExpenseGross>
    <mdt:IncomeTaxExaminationInterestIncomeExpenseGross contextRef="c-26" decimals="-6" id="f-1892" unitRef="usd">17000000</mdt:IncomeTaxExaminationInterestIncomeExpenseGross>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-27" decimals="-6" id="f-1893" unitRef="usd">19000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-28" decimals="-6" id="f-1894" unitRef="usd">61000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-48" decimals="-6" id="f-1895" unitRef="usd">117000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:SummaryOfIncomeTaxExaminationsTextBlock contextRef="c-1" id="f-1896">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Jurisdiction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Earliest Year Open&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - federal and state&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2005&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brazil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costa Rica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dominican Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxExaminationsTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1897">Earnings Per Share&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below sets forth the computation of basic and diluted earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to ordinary shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic &#x2013; weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted &#x2013; weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of weighted average diluted shares outstanding excludes options to purchase approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 23 million, and 5 million ordinary shares in fiscal year 2024, 2023, and 2022, respectively because their effect would have been anti-dilutive on the Company&#x2019;s earnings per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-1898">Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1899">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below sets forth the computation of basic and diluted earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to ordinary shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic &#x2013; weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted &#x2013; weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-1900" unitRef="usd">3676000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-6" id="f-1901" unitRef="usd">3758000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-6" id="f-1902" unitRef="usd">5039000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-1903" unitRef="shares">1327700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-25"
      decimals="-5"
      id="f-1904"
      unitRef="shares">1329800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-26"
      decimals="-5"
      id="f-1905"
      unitRef="shares">1342400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-520"
      decimals="-5"
      id="f-1906"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-521"
      decimals="-5"
      id="f-1907"
      unitRef="shares">1500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-522"
      decimals="-5"
      id="f-1908"
      unitRef="shares">6600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
      contextRef="c-523"
      decimals="-5"
      id="f-1909"
      unitRef="shares">1400000</us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends>
    <us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
      contextRef="c-524"
      decimals="-5"
      id="f-1910"
      unitRef="shares">1000000.0</us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends>
    <us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
      contextRef="c-525"
      decimals="-5"
      id="f-1911"
      unitRef="shares">1600000</us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-526"
      decimals="-5"
      id="f-1912"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-527"
      decimals="-5"
      id="f-1913"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-528"
      decimals="-5"
      id="f-1914"
      unitRef="shares">800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-1915" unitRef="shares">1330200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-25"
      decimals="-5"
      id="f-1916"
      unitRef="shares">1332800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-26"
      decimals="-5"
      id="f-1917"
      unitRef="shares">1351400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1918"
      unitRef="usdPerShare">2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-1919"
      unitRef="usdPerShare">2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-1920"
      unitRef="usdPerShare">3.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1921"
      unitRef="usdPerShare">2.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-1922"
      unitRef="usdPerShare">2.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-1923"
      unitRef="usdPerShare">3.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-558"
      decimals="-6"
      id="f-1924"
      unitRef="shares">28000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-559"
      decimals="-6"
      id="f-1925"
      unitRef="shares">23000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-560"
      decimals="-6"
      id="f-1926"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1927">Retirement Benefit Plans &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net expense related to these plans was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$451 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $494 million, and $459 million in fiscal years 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S., the Company maintains qualified pension plans designed to provide guaranteed minimum retirement benefits to all eligible U.S. participants. Pension coverage for non-U.S. employees is provided, to the extent deemed appropriate, through separate plans. In addition to the benefits provided under the qualified pension plan, retirement benefits associated with wages in excess of the IRS allowable limits are provided to certain employees under a non-qualified plan. U.S. and Puerto Rico employees are also eligible to receive a medical benefit component, in addition to normal retirement benefits, through the Company&#x2019;s post-retirement benefits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;26, 2024 and April&#160;28, 2023, the funded status of the Company&#x2019;s benefit plans was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$484 million overfunded&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $103 million overfunded, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2023, the Company offered certain eligible U.S. employees voluntary early retirement packages, resulting in charges of $94&#160;million, primarily related to U.S. pension benefits. The charges were recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;restructuring charges, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income. See Note 4 for additional information on restructuring charges. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The change in benefit obligation and funded status of the Company&#x2019;s U.S. and Non-U.S. pension benefits are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated benefit obligation at end of year:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in projected benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments, settlements, and amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funded status at end of year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over (under) funded status of the plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts recognized on the consolidated&lt;br/&gt;balance sheets consist of:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts recognized in accumulated other&lt;br/&gt;comprehensive loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service (credit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of April 24, 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;This represents a portion of the total voluntary early retirement package charges for fiscal year &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain countries outside the U.S., fully funding pension plans is not a common practice, as funding provides no income tax benefit. Consequently, certain pension plans were partially funded at April&#160;26, 2024 and April&#160;28, 2023. U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost of the plans includes the following components:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.304%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement and curtailment (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit (credit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of net periodic benefit cost other than the service component are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other changes in plan assets and projected benefit obligations recognized in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other comprehensive income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for fiscal year 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S.&lt;br/&gt;Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization and settlement recognition of actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actuarial assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Critical assumptions &#x2013; projected benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.54% - 5.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23% - 4.48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Critical assumptions &#x2013; net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23% - 4.48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% - 3.46%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25% - 12.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68% - 5.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12% - 4.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50% - 3.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24% - 12.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% - 4.23%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.08% - 2.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08% - 12.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% - 8.10% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.30% - 7.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.60% - 7.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% - 4.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes a full yield curve approach methodology to estimate the service and interest cost components of net periodic pension cost and net periodic post-retirement benefit cost for the Company&#x2019;s pension and other post-retirement benefits. The full yield curve approach applies specific spot rates along the yield curve to their underlying projected cash flows in estimation of the cost components. The current yield curves represent high quality, long-term fixed income instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected long-term rate of return on plan assets assumptions are determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Investment Strategy  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company sponsors trusts that hold the assets for U.S. pension plans and other U.S. post-retirement benefit plans, primarily retiree medical benefits. For investment purposes, the Medtronic U.S. pension and other U.S. post-retirement benefit plans employ similar investment strategies with different asset allocation targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a Qualified Plan Committee (the Plan Committee) that sets investment guidelines for U.S. pension plans and other U.S. post-retirement benefit plans with the assistance of external consultants. These guidelines are established based on market conditions, risk tolerance, funding requirements, and expected benefit payments. The Plan Committee also oversees the investment allocation process, selects the investment managers, and monitors asset performance. As pension liabilities are long-term in nature, the Company employs a long-term total return approach to maximize the long-term rate of return on plan assets for a prudent level of risk. An annual analysis on the risk versus the return of the investment portfolio is conducted to justify the expected long-term rate of return assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The investment portfolios contain a diversified allocation of investment categories, including equities, fixed income securities, hedge funds, and private equity. Securities are also diversified in terms of domestic and international, short- and long-term, growth and value styles, large cap and small cap stocks, and active and passive management.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside the U.S., pension plan assets are typically managed by decentralized fiduciary committees. There is significant variation in policy asset allocation from country to country. Local regulations, funding rules, and financial and tax considerations are part of the funding and investment allocation process in each country. The weighted average target asset allocations at April&#160;26, 2024 for the plans are&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 42% equity securities, 34% debt securities, and 24% other.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The plans did not hold any investments in the Company&#x2019;s ordinary shares at April&#160;26, 2024 or April&#160;28, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. plans target asset allocations at April&#160;26, 2024, compared to the U.S. plans actual asset allocations at April&#160;26, 2024 and April&#160;28, 2023 by asset category, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Target Allocation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Actual Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Category:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Strong performance on equity securities during the fiscal year resulted in asset allocations different than targets. Management expects to move the allocations closer to target over the intermediate term. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Asset Fair Values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The following is a description of the valuation methodologies used for retirement benefit plan assets measured at fair value: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Short-term investments include money market funds. These investments are valued at the closing price reported in the active markets in which the individual security is traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Mutual funds:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Comprised of investments in equity and fixed income securities held in pooled investment vehicles. The valuations of mutual funds are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are publicly reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity commingled trusts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Comprised of investments in equity securities held in pooled investment vehicles. The valuations of equity commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed income commingled trusts: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprised of investments in fixed income securities held in pooled investment vehicles. The valuations of fixed income commingled trusts are based on the respective net asset values which are determined by the fund, either daily or monthly depending on the investment, at market close. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the fund, less its liabilities.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Partnership units:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Partnership units include investment partnerships that provide exposure to long/short equity, absolute return strategies, private equity investments, and real estate investments. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the partnerships, less its liabilities. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Registered investment companies:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Valued at net asset values which are not publicly reported. The net asset values are calculated based on the valuation of the underlying assets. The underlying assets are valued at the quoted market prices of shares held by the plan at year-end in the active market on which the individual securities are traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance contracts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Comprised of investments in collective (group) insurance contracts, consisting of individual insurance policies. The policyholder is the employer, and each member is the owner/beneficiary of their individual insurance policy. These policies are a part of the insurance company&#x2019;s general portfolio and participate in the insurer&#x2019;s profit-sharing policy on an excess yield basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurement using net asset value as a practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported net asset value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The methods described above may produce fair values that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;26, 2024 and April&#160;28, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide a reconciliation of the beginning and ending balances of U.S. pension benefit assets measured at fair value that used significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Partnership Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April&#160;29, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total realized gains, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized gains, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Registered investment companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Registered investment companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. pension benefit assets that are valued using significant unobservable inputs (Level 3) was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$42&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $44&#160;million as of April&#160;26, 2024 and April&#160;28, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the fair value hierarchy classification on an annual basis. During the year, the Company reclassified certain investments in the U.S. pension plan from Level 3 to investments measured using net asset value as a practical expedient. Outside of the reclassification, there were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; no transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; into or out of Level 3 for both the U.S. and non-U.S. pension plans during the fiscal years ended April&#160;26, 2024 and April&#160;28, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Funding  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; It is the Company&#x2019;s policy to fund retirement costs within the limits of allowable tax deductions. During fiscal year 2024, the Company made discretionary contributions of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$32 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the U.S. pension plan. Internationally, the Company contributed approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$40 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for pension benefits during fiscal year 2024. The Company anticipates that it will make contributions of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$30 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$45 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to its U.S. pension benefit plans and non-U.S. pension benefit plans, respectively, in fiscal year 2025. Based on the guidelines under the U.S. Employee Retirement Income Security Act of 1974 and the various guidelines which govern the plans outside the U.S., the majority of anticipated fiscal year 2025 contributions will be discretionary. The Company believes that pension assets, returns on invested pension assets, and Company contributions will be able to meet its pension and other post-retirement obligations in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030 &#x2013; 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Post-retirement Benefit Plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The net periodic benefit cost associated with the Company&#x2019;s post-retirement benefit plans was income of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $11 million, and $20 million in fiscal years 2024, 2023, and 2022, respectively. The Company&#x2019;s projected benefit obligation for all post-retirement benefit plans was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$235 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $261 million at April&#160;26, 2024 and April&#160;28, 2023, respectively. The Company&#x2019;s fair value of plan assets for all post-retirement benefit plans was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$308 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $302 million at April&#160;26, 2024 and April&#160;28, 2023, respectively. The post-retirement benefit plan assets at both April&#160;26, 2024 and April&#160;28, 2023 primarily comprised of equity and fixed commingled trusts, consistent with the U.S. retirement benefit plan assets outlined in the fair value leveling tables above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined Contribution Savings Plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company has defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security during retirement by providing employees with an incentive to make regular savings. Company contributions to the plans are based on employee contributions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Company performance. Expense recognized under these plans was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$471 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $390 million, and $403 million in fiscal years 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="c-1" decimals="-6" id="f-1928" unitRef="usd">451000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="c-25" decimals="-6" id="f-1929" unitRef="usd">494000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="c-26" decimals="-6" id="f-1930" unitRef="usd">459000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-27" decimals="-6" id="f-1931" unitRef="usd">484000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-28" decimals="-6" id="f-1932" unitRef="usd">-103000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <mdt:DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits contextRef="c-25" decimals="-6" id="f-1933" unitRef="usd">94000000</mdt:DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock contextRef="c-1" id="f-1934">The change in benefit obligation and funded status of the Company&#x2019;s U.S. and Non-U.S. pension benefits are as follows:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated benefit obligation at end of year:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in projected benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments, settlements, and amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funded status at end of year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over (under) funded status of the plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts recognized on the consolidated&lt;br/&gt;balance sheets consist of:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts recognized in accumulated other&lt;br/&gt;comprehensive loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service (credit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of April 24, 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;This represents a portion of the total voluntary early retirement package charges for fiscal year &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;.</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-561" decimals="-6" id="f-1935" unitRef="usd">3144000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-562" decimals="-6" id="f-1936" unitRef="usd">3348000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-563" decimals="-6" id="f-1937" unitRef="usd">1513000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-564" decimals="-6" id="f-1938" unitRef="usd">1422000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-562" decimals="-6" id="f-1939" unitRef="usd">3451000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-565" decimals="-6" id="f-1940" unitRef="usd">3526000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-564" decimals="-6" id="f-1941" unitRef="usd">1499000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-566" decimals="-6" id="f-1942" unitRef="usd">1740000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-567" decimals="-6" id="f-1943" unitRef="usd">61000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-568" decimals="-6" id="f-1944" unitRef="usd">77000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-569" decimals="-6" id="f-1945" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-570" decimals="-6" id="f-1946" unitRef="usd">43000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-567" decimals="-6" id="f-1947" unitRef="usd">162000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-568" decimals="-6" id="f-1948" unitRef="usd">142000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-569" decimals="-6" id="f-1949" unitRef="usd">53000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-570" decimals="-6" id="f-1950" unitRef="usd">38000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-567" decimals="-6" id="f-1951" unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-568" decimals="-6" id="f-1952" unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-569" decimals="-6" id="f-1953" unitRef="usd">9000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-570" decimals="-6" id="f-1954" unitRef="usd">9000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation contextRef="c-567" decimals="-6" id="f-1955" unitRef="usd">0</mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation>
    <mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation contextRef="c-568" decimals="-6" id="f-1956" unitRef="usd">19000000</mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation>
    <mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation contextRef="c-569" decimals="-6" id="f-1957" unitRef="usd">10000000</mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation>
    <mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation contextRef="c-570" decimals="-6" id="f-1958" unitRef="usd">8000000</mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-567" decimals="-6" id="f-1959" unitRef="usd">245000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-568" decimals="-6" id="f-1960" unitRef="usd">210000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-569" decimals="-6" id="f-1961" unitRef="usd">-116000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-570" decimals="-6" id="f-1962" unitRef="usd">303000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-567" decimals="-6" id="f-1963" unitRef="usd">234000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-568" decimals="-6" id="f-1964" unitRef="usd">140000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-569" decimals="-6" id="f-1965" unitRef="usd">65000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-570" decimals="-6" id="f-1966" unitRef="usd">63000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits contextRef="c-567" decimals="-6" id="f-1967" unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits contextRef="c-568" decimals="-6" id="f-1968" unitRef="usd">74000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits contextRef="c-569" decimals="-6" id="f-1969" unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits contextRef="c-570" decimals="-6" id="f-1970" unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-567" decimals="-6" id="f-1971" unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-568" decimals="-6" id="f-1972" unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-569" decimals="-6" id="f-1973" unitRef="usd">-41000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-570" decimals="-6" id="f-1974" unitRef="usd">43000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-561" decimals="-6" id="f-1975" unitRef="usd">3194000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-562" decimals="-6" id="f-1976" unitRef="usd">3451000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-563" decimals="-6" id="f-1977" unitRef="usd">1604000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-564" decimals="-6" id="f-1978" unitRef="usd">1499000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-562" decimals="-6" id="f-1979" unitRef="usd">3398000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-565" decimals="-6" id="f-1980" unitRef="usd">3559000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-564" decimals="-6" id="f-1981" unitRef="usd">1614000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-566" decimals="-6" id="f-1982" unitRef="usd">1732000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-567" decimals="-6" id="f-1983" unitRef="usd">356000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-568" decimals="-6" id="f-1984" unitRef="usd">-43000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-569" decimals="-6" id="f-1985" unitRef="usd">103000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-570" decimals="-6" id="f-1986" unitRef="usd">-163000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-567" decimals="-6" id="f-1987" unitRef="usd">32000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-568" decimals="-6" id="f-1988" unitRef="usd">22000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-569" decimals="-6" id="f-1989" unitRef="usd">40000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-570" decimals="-6" id="f-1990" unitRef="usd">57000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-567" decimals="-6" id="f-1991" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-568" decimals="-6" id="f-1992" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-569" decimals="-6" id="f-1993" unitRef="usd">9000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-570" decimals="-6" id="f-1994" unitRef="usd">9000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-567" decimals="-6" id="f-1995" unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-568" decimals="-6" id="f-1996" unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-569" decimals="-6" id="f-1997" unitRef="usd">7000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-570" decimals="-6" id="f-1998" unitRef="usd">8000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-567" decimals="-6" id="f-1999" unitRef="usd">234000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-568" decimals="-6" id="f-2000" unitRef="usd">140000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-569" decimals="-6" id="f-2001" unitRef="usd">65000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-570" decimals="-6" id="f-2002" unitRef="usd">63000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-567" decimals="-6" id="f-2003" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-568" decimals="-6" id="f-2004" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-569" decimals="-6" id="f-2005" unitRef="usd">-36000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-570" decimals="-6" id="f-2006" unitRef="usd">50000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-561" decimals="-6" id="f-2007" unitRef="usd">3551000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-562" decimals="-6" id="f-2008" unitRef="usd">3398000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-563" decimals="-6" id="f-2009" unitRef="usd">1659000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-564" decimals="-6" id="f-2010" unitRef="usd">1614000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-561" decimals="-6" id="f-2011" unitRef="usd">3551000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-562" decimals="-6" id="f-2012" unitRef="usd">3398000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-563" decimals="-6" id="f-2013" unitRef="usd">1659000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-564" decimals="-6" id="f-2014" unitRef="usd">1614000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-561" decimals="-6" id="f-2015" unitRef="usd">3194000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-562" decimals="-6" id="f-2016" unitRef="usd">3451000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-563" decimals="-6" id="f-2017" unitRef="usd">1604000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-564" decimals="-6" id="f-2018" unitRef="usd">1499000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-561" decimals="-6" id="f-2019" unitRef="usd">357000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-562" decimals="-6" id="f-2020" unitRef="usd">-53000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-563" decimals="-6" id="f-2021" unitRef="usd">54000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-564" decimals="-6" id="f-2022" unitRef="usd">115000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-561" decimals="-6" id="f-2023" unitRef="usd">357000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-562" decimals="-6" id="f-2024" unitRef="usd">-53000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-563" decimals="-6" id="f-2025" unitRef="usd">54000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-564" decimals="-6" id="f-2026" unitRef="usd">115000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-561" decimals="-6" id="f-2027" unitRef="usd">617000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-562" decimals="-6" id="f-2028" unitRef="usd">221000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-563" decimals="-6" id="f-2029" unitRef="usd">296000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-564" decimals="-6" id="f-2030" unitRef="usd">350000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-561" decimals="-6" id="f-2031" unitRef="usd">30000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-562" decimals="-6" id="f-2032" unitRef="usd">24000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-563" decimals="-6" id="f-2033" unitRef="usd">7000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-564" decimals="-6" id="f-2034" unitRef="usd">6000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-561" decimals="-6" id="f-2035" unitRef="usd">230000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-562" decimals="-6" id="f-2036" unitRef="usd">250000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-563" decimals="-6" id="f-2037" unitRef="usd">235000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-564" decimals="-6" id="f-2038" unitRef="usd">228000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-561" decimals="-6" id="f-2039" unitRef="usd">357000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-562" decimals="-6" id="f-2040" unitRef="usd">-53000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-563" decimals="-6" id="f-2041" unitRef="usd">54000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-564" decimals="-6" id="f-2042" unitRef="usd">115000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-561" decimals="-6" id="f-2043" unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-562" decimals="-6" id="f-2044" unitRef="usd">-19000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-563" decimals="-6" id="f-2045" unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-564" decimals="-6" id="f-2046" unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-561" decimals="-6" id="f-2047" unitRef="usd">-534000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-562" decimals="-6" id="f-2048" unitRef="usd">-891000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-563" decimals="-6" id="f-2049" unitRef="usd">-161000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-564" decimals="-6" id="f-2050" unitRef="usd">-76000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-561" decimals="-6" id="f-2051" unitRef="usd">517000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-562" decimals="-6" id="f-2052" unitRef="usd">873000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-563" decimals="-6" id="f-2053" unitRef="usd">158000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-564" decimals="-6" id="f-2054" unitRef="usd">73000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock contextRef="c-1" id="f-2055">U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation contextRef="c-571" decimals="-6" id="f-2056" unitRef="usd">773000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation contextRef="c-572" decimals="-6" id="f-2057" unitRef="usd">731000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation contextRef="c-571" decimals="-6" id="f-2058" unitRef="usd">809000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation contextRef="c-572" decimals="-6" id="f-2059" unitRef="usd">772000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets contextRef="c-571" decimals="-6" id="f-2060" unitRef="usd">334000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets contextRef="c-572" decimals="-6" id="f-2061" unitRef="usd">301000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock contextRef="c-1" id="f-2062">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation contextRef="c-571" decimals="-6" id="f-2063" unitRef="usd">1321000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation contextRef="c-572" decimals="-6" id="f-2064" unitRef="usd">1285000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets contextRef="c-571" decimals="-6" id="f-2065" unitRef="usd">819000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets contextRef="c-572" decimals="-6" id="f-2066" unitRef="usd">776000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock contextRef="c-1" id="f-2067">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost of the plans includes the following components:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.304%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement and curtailment (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit (credit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-567" decimals="-6" id="f-2068" unitRef="usd">61000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-568" decimals="-6" id="f-2069" unitRef="usd">77000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-573" decimals="-6" id="f-2070" unitRef="usd">98000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-569" decimals="-6" id="f-2071" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-570" decimals="-6" id="f-2072" unitRef="usd">43000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-574" decimals="-6" id="f-2073" unitRef="usd">64000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-567" decimals="-6" id="f-2074" unitRef="usd">162000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-568" decimals="-6" id="f-2075" unitRef="usd">142000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-573" decimals="-6" id="f-2076" unitRef="usd">102000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-569" decimals="-6" id="f-2077" unitRef="usd">53000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-570" decimals="-6" id="f-2078" unitRef="usd">38000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-574" decimals="-6" id="f-2079" unitRef="usd">26000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-567" decimals="-6" id="f-2080" unitRef="usd">261000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-568" decimals="-6" id="f-2081" unitRef="usd">224000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-573" decimals="-6" id="f-2082" unitRef="usd">226000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-569" decimals="-6" id="f-2083" unitRef="usd">72000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-570" decimals="-6" id="f-2084" unitRef="usd">58000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-574" decimals="-6" id="f-2085" unitRef="usd">64000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-567" decimals="-6" id="f-2086" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-568" decimals="-6" id="f-2087" unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-573" decimals="-6" id="f-2088" unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-569" decimals="-6" id="f-2089" unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-570" decimals="-6" id="f-2090" unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-574" decimals="-6" id="f-2091" unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-567" decimals="-6" id="f-2092" unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-568" decimals="-6" id="f-2093" unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-573" decimals="-6" id="f-2094" unitRef="usd">-64000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-569" decimals="-6" id="f-2095" unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-570" decimals="-6" id="f-2096" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-574" decimals="-6" id="f-2097" unitRef="usd">-22000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-567" decimals="-6" id="f-2098" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-568" decimals="-6" id="f-2099" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-573" decimals="-6" id="f-2100" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-569" decimals="-6" id="f-2101" unitRef="usd">3000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-570" decimals="-6" id="f-2102" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-574" decimals="-6" id="f-2103" unitRef="usd">10000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-567" decimals="-6" id="f-2104" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-568" decimals="-6" id="f-2105" unitRef="usd">74000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-573" decimals="-6" id="f-2106" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-569" decimals="-6" id="f-2107" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-570" decimals="-6" id="f-2108" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-574" decimals="-6" id="f-2109" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-567" decimals="-6" id="f-2110" unitRef="usd">-22000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-568" decimals="-6" id="f-2111" unitRef="usd">89000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-573" decimals="-6" id="f-2112" unitRef="usd">39000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-569" decimals="-6" id="f-2113" unitRef="usd">18000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-570" decimals="-6" id="f-2114" unitRef="usd">26000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-574" decimals="-6" id="f-2115" unitRef="usd">37000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-2116">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other changes in plan assets and projected benefit obligations recognized in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other comprehensive income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for fiscal year 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S.&lt;br/&gt;Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization and settlement recognition of actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-567" decimals="-6" id="f-2117" unitRef="usd">339000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-569" decimals="-6" id="f-2118" unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax contextRef="c-567" decimals="-6" id="f-2119" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax contextRef="c-569" decimals="-6" id="f-2120" unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax contextRef="c-567" decimals="-6" id="f-2121" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax contextRef="c-569" decimals="-6" id="f-2122" unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax contextRef="c-567" decimals="-6" id="f-2123" unitRef="usd">18000000</mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax>
    <mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax contextRef="c-569" decimals="-6" id="f-2124" unitRef="usd">-3000000</mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax>
    <mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment contextRef="c-567" decimals="-6" id="f-2125" unitRef="usd">0</mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment>
    <mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment contextRef="c-569" decimals="-6" id="f-2126" unitRef="usd">-3000000</mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-567" decimals="-6" id="f-2127" unitRef="usd">-355000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-569" decimals="-6" id="f-2128" unitRef="usd">85000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-567" decimals="-6" id="f-2129" unitRef="usd">-378000000</mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-569" decimals="-6" id="f-2130" unitRef="usd">103000000</mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="c-1" id="f-2131">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actuarial assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Critical assumptions &#x2013; projected benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.54% - 5.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23% - 4.48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Critical assumptions &#x2013; net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23% - 4.48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% - 3.46%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25% - 12.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68% - 5.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12% - 4.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50% - 3.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24% - 12.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% - 4.23%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.08% - 2.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08% - 12.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% - 8.10% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.30% - 7.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.60% - 7.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% - 4.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-575"
      decimals="4"
      id="f-2132"
      unitRef="number">0.0554</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-576"
      decimals="4"
      id="f-2133"
      unitRef="number">0.0575</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-577"
      decimals="4"
      id="f-2134"
      unitRef="number">0.0473</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-578"
      decimals="4"
      id="f-2135"
      unitRef="number">0.0499</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-579"
      decimals="4"
      id="f-2136"
      unitRef="number">0.0423</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-580"
      decimals="4"
      id="f-2137"
      unitRef="number">0.0448</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-581"
      decimals="4"
      id="f-2138"
      unitRef="number">0.0140</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-582"
      decimals="4"
      id="f-2139"
      unitRef="number">0.2640</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-583"
      decimals="4"
      id="f-2140"
      unitRef="number">0.0130</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-584"
      decimals="4"
      id="f-2141"
      unitRef="number">0.1070</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-585"
      decimals="4"
      id="f-2142"
      unitRef="number">0.0060</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-586"
      decimals="4"
      id="f-2143"
      unitRef="number">0.2540</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-561"
      decimals="4"
      id="f-2144"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-562"
      decimals="4"
      id="f-2145"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-565"
      decimals="4"
      id="f-2146"
      unitRef="number">0.0483</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-563"
      decimals="4"
      id="f-2147"
      unitRef="number">0.0285</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-564"
      decimals="4"
      id="f-2148"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-566"
      decimals="4"
      id="f-2149"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-587"
      decimals="4"
      id="f-2150"
      unitRef="number">0.0473</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-588"
      decimals="4"
      id="f-2151"
      unitRef="number">0.0499</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-589"
      decimals="4"
      id="f-2152"
      unitRef="number">0.0423</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-590"
      decimals="4"
      id="f-2153"
      unitRef="number">0.0448</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-591"
      decimals="4"
      id="f-2154"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-592"
      decimals="4"
      id="f-2155"
      unitRef="number">0.0346</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-593"
      decimals="4"
      id="f-2156"
      unitRef="number">0.0130</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-594"
      decimals="4"
      id="f-2157"
      unitRef="number">0.1070</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-595"
      decimals="4"
      id="f-2158"
      unitRef="number">0.0060</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-596"
      decimals="4"
      id="f-2159"
      unitRef="number">0.2540</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-597"
      decimals="4"
      id="f-2160"
      unitRef="number">0.0025</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-598"
      decimals="4"
      id="f-2161"
      unitRef="number">0.1280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-587"
      decimals="4"
      id="f-2162"
      unitRef="number">0.0468</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-588"
      decimals="4"
      id="f-2163"
      unitRef="number">0.0507</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-589"
      decimals="4"
      id="f-2164"
      unitRef="number">0.0412</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-590"
      decimals="4"
      id="f-2165"
      unitRef="number">0.0451</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-591"
      decimals="4"
      id="f-2166"
      unitRef="number">0.0250</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-592"
      decimals="4"
      id="f-2167"
      unitRef="number">0.0351</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-593"
      decimals="4"
      id="f-2168"
      unitRef="number">0.0130</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-594"
      decimals="4"
      id="f-2169"
      unitRef="number">0.1070</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-595"
      decimals="4"
      id="f-2170"
      unitRef="number">0.0060</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-596"
      decimals="4"
      id="f-2171"
      unitRef="number">0.2540</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-597"
      decimals="4"
      id="f-2172"
      unitRef="number">0.0024</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-598"
      decimals="4"
      id="f-2173"
      unitRef="number">0.1280</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-587"
      decimals="4"
      id="f-2174"
      unitRef="number">0.0473</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-588"
      decimals="4"
      id="f-2175"
      unitRef="number">0.0490</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-589"
      decimals="4"
      id="f-2176"
      unitRef="number">0.0390</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-590"
      decimals="4"
      id="f-2177"
      unitRef="number">0.0423</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-591"
      decimals="4"
      id="f-2178"
      unitRef="number">0.0208</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-592"
      decimals="4"
      id="f-2179"
      unitRef="number">0.0287</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-593"
      decimals="4"
      id="f-2180"
      unitRef="number">0.0130</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-594"
      decimals="4"
      id="f-2181"
      unitRef="number">0.1070</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-595"
      decimals="4"
      id="f-2182"
      unitRef="number">0.0060</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-596"
      decimals="4"
      id="f-2183"
      unitRef="number">0.2540</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-597"
      decimals="4"
      id="f-2184"
      unitRef="number">0.0008</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-598"
      decimals="4"
      id="f-2185"
      unitRef="number">0.1280</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-587"
      decimals="4"
      id="f-2186"
      unitRef="number">0.0640</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-588"
      decimals="4"
      id="f-2187"
      unitRef="number">0.0810</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-589"
      decimals="4"
      id="f-2188"
      unitRef="number">0.0530</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-590"
      decimals="4"
      id="f-2189"
      unitRef="number">0.0720</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-591"
      decimals="4"
      id="f-2190"
      unitRef="number">0.0560</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-592"
      decimals="4"
      id="f-2191"
      unitRef="number">0.0740</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-569"
      decimals="4"
      id="f-2192"
      unitRef="number">0.0407</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-570"
      decimals="4"
      id="f-2193"
      unitRef="number">0.0348</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-574"
      decimals="4"
      id="f-2194"
      unitRef="number">0.0367</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-567"
      decimals="4"
      id="f-2195"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-568"
      decimals="4"
      id="f-2196"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-591"
      decimals="4"
      id="f-2197"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-592"
      decimals="4"
      id="f-2198"
      unitRef="number">0.0483</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-569"
      decimals="4"
      id="f-2199"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-570"
      decimals="4"
      id="f-2200"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-574"
      decimals="4"
      id="f-2201"
      unitRef="number">0.0290</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-599"
      decimals="2"
      id="f-2202"
      unitRef="number">0.42</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-600"
      decimals="2"
      id="f-2203"
      unitRef="number">0.34</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-601"
      decimals="2"
      id="f-2204"
      unitRef="number">0.24</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock contextRef="c-1" id="f-2205">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. plans target asset allocations at April&#160;26, 2024, compared to the U.S. plans actual asset allocations at April&#160;26, 2024 and April&#160;28, 2023 by asset category, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Target Allocation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Actual Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Category:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-602"
      decimals="INF"
      id="f-2206"
      unitRef="number">0.34</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-602"
      decimals="2"
      id="f-2207"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-603"
      decimals="2"
      id="f-2208"
      unitRef="number">0.36</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-604"
      decimals="INF"
      id="f-2209"
      unitRef="number">0.51</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-604"
      decimals="2"
      id="f-2210"
      unitRef="number">0.40</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-605"
      decimals="2"
      id="f-2211"
      unitRef="number">0.46</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-606"
      decimals="INF"
      id="f-2212"
      unitRef="number">0.15</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-606"
      decimals="2"
      id="f-2213"
      unitRef="number">0.21</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-607"
      decimals="2"
      id="f-2214"
      unitRef="number">0.19</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-561"
      decimals="INF"
      id="f-2215"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-561"
      decimals="INF"
      id="f-2216"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-562"
      decimals="INF"
      id="f-2217"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <mdt:FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock contextRef="c-1" id="f-2218">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;26, 2024 and April&#160;28, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Registered investment companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Registered investment companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdt:FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-608" decimals="-6" id="f-2219" unitRef="usd">80000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-609" decimals="-6" id="f-2220" unitRef="usd">80000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-610" decimals="-6" id="f-2221" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-611" decimals="-6" id="f-2222" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-612" decimals="-6" id="f-2223" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-613" decimals="-6" id="f-2224" unitRef="usd">106000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-614" decimals="-6" id="f-2225" unitRef="usd">106000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-615" decimals="-6" id="f-2226" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-616" decimals="-6" id="f-2227" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-617" decimals="-6" id="f-2228" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-618" decimals="-6" id="f-2229" unitRef="usd">942000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-619" decimals="-6" id="f-2230" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-620" decimals="-6" id="f-2231" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-621" decimals="-6" id="f-2232" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-622" decimals="-6" id="f-2233" unitRef="usd">942000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-623" decimals="-6" id="f-2234" unitRef="usd">1273000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-624" decimals="-6" id="f-2235" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-625" decimals="-6" id="f-2236" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-626" decimals="-6" id="f-2237" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-627" decimals="-6" id="f-2238" unitRef="usd">1273000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-628" decimals="-6" id="f-2239" unitRef="usd">1151000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-629" decimals="-6" id="f-2240" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-630" decimals="-6" id="f-2241" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-631" decimals="-6" id="f-2242" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-632" decimals="-6" id="f-2243" unitRef="usd">1151000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-561" decimals="-6" id="f-2244" unitRef="usd">3551000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-633" decimals="-6" id="f-2245" unitRef="usd">186000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-634" decimals="-6" id="f-2246" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-635" decimals="-6" id="f-2247" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-636" decimals="-6" id="f-2248" unitRef="usd">3366000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-637" decimals="-6" id="f-2249" unitRef="usd">114000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-638" decimals="-6" id="f-2250" unitRef="usd">114000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-639" decimals="-6" id="f-2251" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-640" decimals="-6" id="f-2252" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-641" decimals="-6" id="f-2253" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-642" decimals="-6" id="f-2254" unitRef="usd">114000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-643" decimals="-6" id="f-2255" unitRef="usd">114000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-644" decimals="-6" id="f-2256" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-645" decimals="-6" id="f-2257" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-646" decimals="-6" id="f-2258" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-647" decimals="-6" id="f-2259" unitRef="usd">1211000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-648" decimals="-6" id="f-2260" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-649" decimals="-6" id="f-2261" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-650" decimals="-6" id="f-2262" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-651" decimals="-6" id="f-2263" unitRef="usd">1211000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-652" decimals="-6" id="f-2264" unitRef="usd">968000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-653" decimals="-6" id="f-2265" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-654" decimals="-6" id="f-2266" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-655" decimals="-6" id="f-2267" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-656" decimals="-6" id="f-2268" unitRef="usd">968000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-657" decimals="-6" id="f-2269" unitRef="usd">992000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-658" decimals="-6" id="f-2270" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-659" decimals="-6" id="f-2271" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-660" decimals="-6" id="f-2272" unitRef="usd">992000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-661" decimals="-6" id="f-2273" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-562" decimals="-6" id="f-2274" unitRef="usd">3398000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-662" decimals="-6" id="f-2275" unitRef="usd">227000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-663" decimals="-6" id="f-2276" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-664" decimals="-6" id="f-2277" unitRef="usd">992000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-665" decimals="-6" id="f-2278" unitRef="usd">2179000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <mdt:FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock contextRef="c-1" id="f-2279">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide a reconciliation of the beginning and ending balances of U.S. pension benefit assets measured at fair value that used significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Partnership Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April&#160;29, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total realized gains, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized gains, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April&#160;28, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdt:FairValueRetirementBenefitPlanAssetsUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-666" decimals="-6" id="f-2280" unitRef="usd">1011000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-667" decimals="-6" id="f-2281" unitRef="usd">67000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-667" decimals="-6" id="f-2282" unitRef="usd">151000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements contextRef="c-667" decimals="-6" id="f-2283" unitRef="usd">-238000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-668" decimals="-6" id="f-2284" unitRef="usd">992000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-669" decimals="-6" id="f-2285" unitRef="usd">1617000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-670" decimals="-6" id="f-2286" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-671" decimals="-6" id="f-2287" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-672" decimals="-6" id="f-2288" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-673" decimals="-6" id="f-2289" unitRef="usd">1617000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-674" decimals="-6" id="f-2290" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-675" decimals="-6" id="f-2291" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-676" decimals="-6" id="f-2292" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-677" decimals="-6" id="f-2293" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-678" decimals="-6" id="f-2294" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-563" decimals="-6" id="f-2295" unitRef="usd">1659000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-679" decimals="-6" id="f-2296" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-680" decimals="-6" id="f-2297" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-681" decimals="-6" id="f-2298" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-682" decimals="-6" id="f-2299" unitRef="usd">1617000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-683" decimals="-6" id="f-2300" unitRef="usd">1571000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-684" decimals="-6" id="f-2301" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-685" decimals="-6" id="f-2302" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-686" decimals="-6" id="f-2303" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-687" decimals="-6" id="f-2304" unitRef="usd">1571000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-688" decimals="-6" id="f-2305" unitRef="usd">44000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-689" decimals="-6" id="f-2306" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-690" decimals="-6" id="f-2307" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-691" decimals="-6" id="f-2308" unitRef="usd">44000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-692" decimals="-6" id="f-2309" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-564" decimals="-6" id="f-2310" unitRef="usd">1614000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-693" decimals="-6" id="f-2311" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-694" decimals="-6" id="f-2312" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-695" decimals="-6" id="f-2313" unitRef="usd">44000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-696" decimals="-6" id="f-2314" unitRef="usd">1571000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-681" decimals="-6" id="f-2315" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-695" decimals="-6" id="f-2316" unitRef="usd">44000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-567" decimals="-6" id="f-2317" unitRef="usd">32000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-569" decimals="-6" id="f-2318" unitRef="usd">40000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="c-561" decimals="-6" id="f-2319" unitRef="usd">30000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="c-563" decimals="-6" id="f-2320" unitRef="usd">45000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock contextRef="c-1" id="f-2321">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030 &#x2013; 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths contextRef="c-561" decimals="-6" id="f-2322" unitRef="usd">184000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths contextRef="c-563" decimals="-6" id="f-2323" unitRef="usd">71000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo contextRef="c-561" decimals="-6" id="f-2324" unitRef="usd">193000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo contextRef="c-563" decimals="-6" id="f-2325" unitRef="usd">61000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree contextRef="c-561" decimals="-6" id="f-2326" unitRef="usd">201000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree contextRef="c-563" decimals="-6" id="f-2327" unitRef="usd">66000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour contextRef="c-561" decimals="-6" id="f-2328" unitRef="usd">211000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour contextRef="c-563" decimals="-6" id="f-2329" unitRef="usd">68000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive contextRef="c-561" decimals="-6" id="f-2330" unitRef="usd">218000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive contextRef="c-563" decimals="-6" id="f-2331" unitRef="usd">74000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter contextRef="c-561" decimals="-6" id="f-2332" unitRef="usd">1165000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter contextRef="c-563" decimals="-6" id="f-2333" unitRef="usd">417000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-697" decimals="-6" id="f-2334" unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-698" decimals="-6" id="f-2335" unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-699" decimals="-6" id="f-2336" unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-700" decimals="-6" id="f-2337" unitRef="usd">235000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-701" decimals="-6" id="f-2338" unitRef="usd">261000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-700" decimals="-6" id="f-2339" unitRef="usd">308000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-701" decimals="-6" id="f-2340" unitRef="usd">302000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-6" id="f-2341" unitRef="usd">471000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-25" decimals="-6" id="f-2342" unitRef="usd">390000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-26" decimals="-6" id="f-2343" unitRef="usd">403000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-2344">Leases &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company&#x2019;s leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;typically do not provide an implicit rate, the Company&#x2019;s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for fiscal year 2024, 2023, and 2022 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases were not material to the consolidated financial statements at April&#160;26, 2024 or April&#160;28, 2023 or for fiscal year 2024, 2023 and 2022. Finance lease right-of-use assets are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;property, plant, and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and finance lease liabilities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;current debt obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;26, 2024 and April&#160;28, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2346"&gt;&lt;span style="-sec-ix-hidden:f-2347"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2350"&gt;&lt;span style="-sec-ix-hidden:f-2351"&gt;Other accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2354"&gt;&lt;span style="-sec-ix-hidden:f-2355"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;26, 2024 and April&#160;28, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturities of the Company's operating leases at April&#160;26, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;br/&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total expected lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income and the Company's net investments in sales-type leases are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets. Lessor income and the related assets and lease maturities were not material to the consolidated financial statements at or for the fiscal year ended April&#160;26, 2024 and April&#160;28, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <mdt:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-2345">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;26, 2024 and April&#160;28, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2346"&gt;&lt;span style="-sec-ix-hidden:f-2347"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2350"&gt;&lt;span style="-sec-ix-hidden:f-2351"&gt;Other accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2354"&gt;&lt;span style="-sec-ix-hidden:f-2355"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdt:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-27" decimals="-6" id="f-2348" unitRef="usd">1012000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-28" decimals="-6" id="f-2349" unitRef="usd">1041000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-27" decimals="-6" id="f-2352" unitRef="usd">183000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-28" decimals="-6" id="f-2353" unitRef="usd">180000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-27" decimals="-6" id="f-2356" unitRef="usd">840000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-28" decimals="-6" id="f-2357" unitRef="usd">869000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-2358">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;26, 2024 and April&#160;28, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-27" id="f-2359">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-28" id="f-2360">P9Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-27" decimals="3" id="f-2361" unitRef="number">0.034</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-28" decimals="3" id="f-2362" unitRef="number">0.024</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-6" id="f-2363" unitRef="usd">232000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-25" decimals="-6" id="f-2364" unitRef="usd">211000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-26" decimals="-6" id="f-2365" unitRef="usd">195000000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-6" id="f-2366" unitRef="usd">41000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-25" decimals="-6" id="f-2367" unitRef="usd">62000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-26" decimals="-6" id="f-2368" unitRef="usd">65000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-6" id="f-2369" unitRef="usd">273000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-25" decimals="-6" id="f-2370" unitRef="usd">273000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-26" decimals="-6" id="f-2371" unitRef="usd">260000000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-6" id="f-2372" unitRef="usd">232000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-25" decimals="-6" id="f-2373" unitRef="usd">210000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-26" decimals="-6" id="f-2374" unitRef="usd">174000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-6" id="f-2375" unitRef="usd">220000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-25" decimals="-6" id="f-2376" unitRef="usd">417000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-26" decimals="-6" id="f-2377" unitRef="usd">78000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-2378">&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturities of the Company's operating leases at April&#160;26, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;br/&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total expected lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-27" decimals="-6" id="f-2379" unitRef="usd">203000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-27" decimals="-6" id="f-2380" unitRef="usd">178000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-27" decimals="-6" id="f-2381" unitRef="usd">151000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-27" decimals="-6" id="f-2382" unitRef="usd">113000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-27" decimals="-6" id="f-2383" unitRef="usd">88000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-27" decimals="-6" id="f-2384" unitRef="usd">444000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-27" decimals="-6" id="f-2385" unitRef="usd">1177000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-27" decimals="-6" id="f-2386" unitRef="usd">154000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-27" decimals="-6" id="f-2387" unitRef="usd">1024000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c-1" id="f-2388">Accumulated Other Comprehensive Loss &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.974%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized (Loss) Gain on Investment Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in Retirement Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gain (Loss) on Cash Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during fiscal years 2024, 2023, and 2022 was an expense of $4 million, a benefit of $21&#160;million, and a benefit of $51&#160;million, respectively. During fiscal years 2024, 2023, and 2022, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $5 million, $9&#160;million and $1&#160;million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Refer to Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal years 2024, 2023, and 2022, the income tax on cumulative translation adjustment was an expense of $3 million, a benefit of $5&#160;million, and a benefit of $8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal years 2024, 2023, and 2022, there were no tax impacts on net investment hedges. Refer to Note 7 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. The income tax on the net change in retirement obligations in other comprehensive income before reclassifications during fiscal years 2024, 2023, and 2022 resulted in an expense of $79 million, $6&#160;million, and $134&#160;million, respectively. During fiscal years 2024, 2023, and 2022, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of&#160;$2 million, $9&#160;million, and $20&#160;million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Refer to Note 15 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during fiscal years 2024, 2023, and 2022 was&#160;an expense of $103 million,&#160;$56&#160;million, and $152&#160;million, respectively. Amounts reclassified from AOCI related to cash flow hedges included income taxes of $66 million, $133&#160;million, and $26&#160;million for fiscal years 2024, 2023, and 2022, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other operating expense (income), net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cost of products sold. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 7 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-2389">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.974%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized (Loss) Gain on Investment Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in Retirement Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gain (Loss) on Cash Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-702" decimals="-6" id="f-2390" unitRef="usd">92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-703" decimals="-6" id="f-2391" unitRef="usd">-519000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-704" decimals="-6" id="f-2392" unitRef="usd">-1458000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-705" decimals="-6" id="f-2393" unitRef="usd">-1347000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-706" decimals="-6" id="f-2394" unitRef="usd">-253000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-6" id="f-2395" unitRef="usd">-3485000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-707" decimals="-6" id="f-2396" unitRef="usd">-304000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-708" decimals="-6" id="f-2397" unitRef="usd">-2080000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-709" decimals="-6" id="f-2398" unitRef="usd">2299000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-710" decimals="-6" id="f-2399" unitRef="usd">514000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-711" decimals="-6" id="f-2400" unitRef="usd">781000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-39" decimals="-6" id="f-2401" unitRef="usd">1210000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-707" decimals="-6" id="f-2402" unitRef="usd">-3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-708" decimals="-6" id="f-2403" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-709" decimals="-6" id="f-2404" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-710" decimals="-6" id="f-2405" unitRef="usd">-60000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-711" decimals="-6" id="f-2406" unitRef="usd">54000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-39" decimals="-6" id="f-2407" unitRef="usd">-9000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-707" decimals="-6" id="f-2408" unitRef="usd">-301000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-708" decimals="-6" id="f-2409" unitRef="usd">-2080000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-709" decimals="-6" id="f-2410" unitRef="usd">2299000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-710" decimals="-6" id="f-2411" unitRef="usd">574000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-711" decimals="-6" id="f-2412" unitRef="usd">727000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-39" decimals="-6" id="f-2413" unitRef="usd">1219000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-712" decimals="-6" id="f-2414" unitRef="usd">-209000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-713" decimals="-6" id="f-2415" unitRef="usd">-2599000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-714" decimals="-6" id="f-2416" unitRef="usd">841000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-715" decimals="-6" id="f-2417" unitRef="usd">-773000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-716" decimals="-6" id="f-2418" unitRef="usd">474000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-6" id="f-2419" unitRef="usd">-2265000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-717" decimals="-6" id="f-2420" unitRef="usd">-78000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-718" decimals="-6" id="f-2421" unitRef="usd">-240000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-719" decimals="-6" id="f-2422" unitRef="usd">-596000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-720" decimals="-6" id="f-2423" unitRef="usd">26000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-721" decimals="-6" id="f-2424" unitRef="usd">184000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-52" decimals="-6" id="f-2425" unitRef="usd">-704000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-717" decimals="-6" id="f-2426" unitRef="usd">-29000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-718" decimals="-6" id="f-2427" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-719" decimals="-6" id="f-2428" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-720" decimals="-6" id="f-2429" unitRef="usd">-6000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-721" decimals="-6" id="f-2430" unitRef="usd">565000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-52" decimals="-6" id="f-2431" unitRef="usd">530000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-717" decimals="-6" id="f-2432" unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-718" decimals="-6" id="f-2433" unitRef="usd">-240000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-719" decimals="-6" id="f-2434" unitRef="usd">-596000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-720" decimals="-6" id="f-2435" unitRef="usd">32000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-721" decimals="-6" id="f-2436" unitRef="usd">-381000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-52" decimals="-6" id="f-2437" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-722" decimals="-6" id="f-2438" unitRef="usd">-258000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-723" decimals="-6" id="f-2439" unitRef="usd">-2839000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-724" decimals="-6" id="f-2440" unitRef="usd">245000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-725" decimals="-6" id="f-2441" unitRef="usd">-741000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-726" decimals="-6" id="f-2442" unitRef="usd">93000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-6" id="f-2443" unitRef="usd">-3499000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-727" decimals="-6" id="f-2444" unitRef="usd">29000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-728" decimals="-6" id="f-2445" unitRef="usd">-846000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-729" decimals="-6" id="f-2446" unitRef="usd">633000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-730" decimals="-6" id="f-2447" unitRef="usd">205000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-731" decimals="-6" id="f-2448" unitRef="usd">438000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-64" decimals="-6" id="f-2449" unitRef="usd">457000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-727" decimals="-6" id="f-2450" unitRef="usd">-17000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-728" decimals="-6" id="f-2451" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-729" decimals="-6" id="f-2452" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-730" decimals="-6" id="f-2453" unitRef="usd">-7000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-731" decimals="-6" id="f-2454" unitRef="usd">302000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-64" decimals="-6" id="f-2455" unitRef="usd">278000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-727" decimals="-6" id="f-2456" unitRef="usd">46000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-728" decimals="-6" id="f-2457" unitRef="usd">-846000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-729" decimals="-6" id="f-2458" unitRef="usd">633000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-730" decimals="-6" id="f-2459" unitRef="usd">212000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-731" decimals="-6" id="f-2460" unitRef="usd">136000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-64" decimals="-6" id="f-2461" unitRef="usd">180000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-732" decimals="-6" id="f-2462" unitRef="usd">-212000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-733" decimals="-6" id="f-2463" unitRef="usd">-3686000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-734" decimals="-6" id="f-2464" unitRef="usd">878000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-735" decimals="-6" id="f-2465" unitRef="usd">-529000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-736" decimals="-6" id="f-2466" unitRef="usd">229000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-70" decimals="-6" id="f-2467" unitRef="usd">-3318000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-727" decimals="-6" id="f-2468" unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-717" decimals="-6" id="f-2469" unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-707" decimals="-6" id="f-2470" unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-727" decimals="-6" id="f-2471" unitRef="usd">5000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-717" decimals="-6" id="f-2472" unitRef="usd">9000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-707" decimals="-6" id="f-2473" unitRef="usd">1000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-728" decimals="-6" id="f-2474" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-718" decimals="-6" id="f-2475" unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-708" decimals="-6" id="f-2476" unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-729" decimals="INF" id="f-2477" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-709" decimals="INF" id="f-2478" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-719" decimals="INF" id="f-2479" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-730" decimals="-6" id="f-2480" unitRef="usd">79000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-720" decimals="-6" id="f-2481" unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-710" decimals="-6" id="f-2482" unitRef="usd">134000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-730" decimals="-6" id="f-2483" unitRef="usd">2000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-720" decimals="-6" id="f-2484" unitRef="usd">9000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-710" decimals="-6" id="f-2485" unitRef="usd">20000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-731" decimals="-6" id="f-2486" unitRef="usd">103000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-721" decimals="-6" id="f-2487" unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-711" decimals="-6" id="f-2488" unitRef="usd">152000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-731" decimals="-6" id="f-2489" unitRef="usd">66000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-721" decimals="-6" id="f-2490" unitRef="usd">133000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-711" decimals="-6" id="f-2491" unitRef="usd">26000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:LossContingencyDisclosures contextRef="c-1" id="f-2492">Commitments and Contingencies &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#x2019;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#x2019;s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;certain litigation charges &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income. During fiscal years 2024, 2023, and 2022, the Company recognized $149&#160;million of certain litigation charges, $30&#160;million of certain litigation income, and $95&#160;million of certain litigation charges, respectively. At April 26, 2024 and April 28, 2023, accrued litigation was approximately $0.2&#160;billion and $0.3&#160;billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company&#x2019;s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company&#x2019;s consolidated earnings, financial position, and/or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intellectual Property Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages and/or royalty payments, and negatively impact the Company's ability to sell current or future products, which could have a material adverse impact on the Company's business, results of operations, financial condition, and cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Colibri&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company&#x2019;s Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately $106&#160;million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hernia Mesh Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of May 15, 2024, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately 8,350 individual plaintiffs, and certain plaintiffs&#x2019; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;law firms have advised the Company that they may file additional cases in the future. Approximately 6,700 plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 500 plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately 1,150 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus six one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Diabetes Pump Retainer Ring Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of May 14, 2024, 27 lawsuits have been filed on behalf of a total of 107 individual plaintiffs, and certain plaintiffs&#x2019; law firms have notified the Company that they may file additional lawsuits in the future on behalf of thousands of additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Environmental Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In March 2021, the parties notified the court that they had agreed on a settlement in principle of all issues in this matter, and in September 2022 the parties filed a joint motion for final approval by the court. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of remedial activities. The final court order did not result in a change to the Company's previous accrual for this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accrued expenses for these various environmental proceedings are included within accrued litigation as discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Anti-Corruption Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has regular and ongoing interactions with governmental agencies, and its practice is to cooperate with such inquiries. In addition, from time to time, the Company self-discloses potential concerns to governmental regulators. Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in China regarding certain activities, including in China. The Company is committed to regularly evaluating and, as appropriate, strengthening its anti-corruption compliance programs and practices. Any possible future determination that certain of our operations and activities, and/or those of our third-party distributors, are not in compliance with existing laws could result in the imposition of fines, penalties, and equitable remedies in the United States or in other jurisdictions. The Company has not recorded an expense in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court (Tax Court) reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS&#x2019;s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medtronic, Inc.&#x2019;s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company&#x2019;s consolidated earnings, financial position, and/or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 13 for additional discussion of income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates&#x2019; products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company&#x2019;s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company&#x2019;s consolidated earnings, financial position, and/or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-1" decimals="-6" id="f-2493" unitRef="usd">149000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-25" decimals="-6" id="f-2494" unitRef="usd">-30000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-26" decimals="-6" id="f-2495" unitRef="usd">95000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-27" decimals="-8" id="f-2496" unitRef="usd">200000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-28" decimals="-8" id="f-2497" unitRef="usd">300000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-737" decimals="-6" id="f-2498" unitRef="usd">106000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-738"
      decimals="-1"
      id="f-2499"
      unitRef="plantiff">8350</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-739"
      decimals="-2"
      id="f-2500"
      unitRef="plantiff">6700</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-740"
      decimals="-2"
      id="f-2501"
      unitRef="plantiff">500</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-741"
      decimals="-1"
      id="f-2502"
      unitRef="claim">1150</us-gaap:LossContingencyPendingClaimsNumber>
    <mdt:LossContingencyLawsuitsNumber
      contextRef="c-741"
      decimals="0"
      id="f-2503"
      unitRef="lawsuit">6</mdt:LossContingencyLawsuitsNumber>
    <mdt:LossContingencyLawsuitsNumber
      contextRef="c-742"
      decimals="0"
      id="f-2504"
      unitRef="lawsuit">27</mdt:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-743"
      decimals="0"
      id="f-2505"
      unitRef="plantiff">107</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-2506">Segment and Geographic Information &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no changes to the reportable segments during the fiscal year ended April&#160;26, 2024. We continue to have four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. However, there were changes to the operating segments during fiscal year 2024 as a result of how the Chief Operating Decision Maker (CODM) assesses business performance. During the first quarter of fiscal year 2024, the Medical Surgical Portfolio was separated into two operating segments as a result of the previously contemplated separation of the PMRI businesses, which were previously aggregated based upon similar economic and operating characteristics. In addition, during the first quarter of fiscal year 2024, there were certain Medical Surgical businesses that were moved to the Other line, which primarily related to wind-down activity of the Company's Renal Care Solutions business that was contributed to Mozarc Medical in April 2023. Subsequently, as a result of the February 2024 decision to exit the Company's ventilator product line and retain and combine the remaining PMRI businesses into one business unit as further discussed in Note 3, the two operating segments within the Medical Surgical Portfolio were combined into one operating segment, and the Company's ventilator product line, which was in the Medical Surgical Portfolio, was moved to the Other line during the fourth quarter of fiscal year 2024. Prior period amounts have been recast to reflect the new reporting structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's management has chosen to organize the entity based upon therapy solutions provided by each segment. The four principal segments are strategic businesses that are managed separately, as each one develops and manufactures products and provides services oriented toward targeted therapy solutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary products and services from which the Cardiovascular Portfolio segment derives its revenues include products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart and vascular-related disorders and diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary products and services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary products and services from which the Medical Surgical Portfolio segment derives its revenues include those focused on diseases of the respiratory system, gastrointestinal tract, lungs, pelvic region, obesity, and other preventable complications. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary products from which the Diabetes Operating Unit segment derives its revenues include those focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment disclosures are on a performance basis, consistent with internal management reporting. Net sales of the Company's segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. Refer to Note 2 for discussion on net sales by segment. There are certain corporate and centralized expenses that are not allocated to the segments. The Company's management evaluates the performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest income or expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments. Prior period amounts have been recast to reallocate certain expenses from segment operating profit to centralized distribution costs to conform to classifications used in the current year as a result in a change to the segment operating profit metric used by the CODM to assess business performance and allocate resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Operating Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centralized distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and divestiture-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain litigation charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical device regulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitments to the Medtronic Foundation and Medtronic LABS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2) Includes the net impact of remeasurement and the Company's hedging programs recorded in other operating expense (income), net.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Assets and Depreciation Expense &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Depreciation Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. Geographic property, plant, and equipment are attributed to the country based on the physical location of the assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents net sales for fiscal years 2024, 2023, and 2022, and property, plant, and equipment, net at April&#160;26, 2024 and April&#160;28, 2023 for the Company's country of domicile, countries with significant concentrations, and all other countries: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.504%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other countries, excluding Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No single customer represented over 10 percent of the Company&#x2019;s consolidated net sales in fiscal years 2024, 2023, or 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c-1" decimals="0" id="f-2507" unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-484"
      decimals="0"
      id="f-2508"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-485"
      decimals="0"
      id="f-2509"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments contextRef="c-1" decimals="0" id="f-2510" unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-2511">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Operating Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centralized distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and divestiture-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain litigation charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical device regulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitments to the Medtronic Foundation and Medtronic LABS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2) Includes the net impact of remeasurement and the Company's hedging programs recorded in other operating expense (income), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss contextRef="c-744" decimals="-6" id="f-2512" unitRef="usd">4474000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-745" decimals="-6" id="f-2513" unitRef="usd">4522000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-746" decimals="-6" id="f-2514" unitRef="usd">4596000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-747" decimals="-6" id="f-2515" unitRef="usd">3940000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-748" decimals="-6" id="f-2516" unitRef="usd">3712000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-749" decimals="-6" id="f-2517" unitRef="usd">3858000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-750" decimals="-6" id="f-2518" unitRef="usd">3170000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-751" decimals="-6" id="f-2519" unitRef="usd">3048000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-752" decimals="-6" id="f-2520" unitRef="usd">3698000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-753" decimals="-6" id="f-2521" unitRef="usd">394000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-754" decimals="-6" id="f-2522" unitRef="usd">383000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-755" decimals="-6" id="f-2523" unitRef="usd">588000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-756" decimals="-6" id="f-2524" unitRef="usd">11979000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-757" decimals="-6" id="f-2525" unitRef="usd">11664000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-758" decimals="-6" id="f-2526" unitRef="usd">12740000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-759" decimals="-6" id="f-2527" unitRef="usd">10000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-760" decimals="-6" id="f-2528" unitRef="usd">-89000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-761" decimals="-6" id="f-2529" unitRef="usd">-31000000</us-gaap:OperatingIncomeLoss>
    <mdt:CorporateOverhead contextRef="c-762" decimals="-6" id="f-2530" unitRef="usd">1784000000</mdt:CorporateOverhead>
    <mdt:CorporateOverhead contextRef="c-763" decimals="-6" id="f-2531" unitRef="usd">1763000000</mdt:CorporateOverhead>
    <mdt:CorporateOverhead contextRef="c-764" decimals="-6" id="f-2532" unitRef="usd">1724000000</mdt:CorporateOverhead>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-762" decimals="-6" id="f-2533" unitRef="usd">719000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-763" decimals="-6" id="f-2534" unitRef="usd">636000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-764" decimals="-6" id="f-2535" unitRef="usd">553000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-762" decimals="-6" id="f-2536" unitRef="usd">412000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-763" decimals="-6" id="f-2537" unitRef="usd">515000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-764" decimals="-6" id="f-2538" unitRef="usd">318000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-762" decimals="-6" id="f-2539" unitRef="usd">1693000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-763" decimals="-6" id="f-2540" unitRef="usd">1698000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-764" decimals="-6" id="f-2541" unitRef="usd">1733000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation contextRef="c-762" decimals="-6" id="f-2542" unitRef="usd">393000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-763" decimals="-6" id="f-2543" unitRef="usd">355000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-764" decimals="-6" id="f-2544" unitRef="usd">358000000</us-gaap:ShareBasedCompensation>
    <mdt:CentralizedDistributionCosts contextRef="c-762" decimals="-6" id="f-2545" unitRef="usd">1609000000</mdt:CentralizedDistributionCosts>
    <mdt:CentralizedDistributionCosts contextRef="c-763" decimals="-6" id="f-2546" unitRef="usd">1558000000</mdt:CentralizedDistributionCosts>
    <mdt:CentralizedDistributionCosts contextRef="c-764" decimals="-6" id="f-2547" unitRef="usd">1741000000</mdt:CentralizedDistributionCosts>
    <mdt:ForeignCurrencyCosts contextRef="c-762" decimals="-6" id="f-2548" unitRef="usd">-68000000</mdt:ForeignCurrencyCosts>
    <mdt:ForeignCurrencyCosts contextRef="c-763" decimals="-6" id="f-2549" unitRef="usd">-465000000</mdt:ForeignCurrencyCosts>
    <mdt:ForeignCurrencyCosts contextRef="c-764" decimals="-6" id="f-2550" unitRef="usd">-70000000</mdt:ForeignCurrencyCosts>
    <us-gaap:RestructuringCharges contextRef="c-762" decimals="-6" id="f-2551" unitRef="usd">389000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-763" decimals="-6" id="f-2552" unitRef="usd">647000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-764" decimals="-6" id="f-2553" unitRef="usd">335000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-762" decimals="-6" id="f-2554" unitRef="usd">777000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-763" decimals="-6" id="f-2555" unitRef="usd">345000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-764" decimals="-6" id="f-2556" unitRef="usd">838000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-762" decimals="-6" id="f-2557" unitRef="usd">149000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-763" decimals="-6" id="f-2558" unitRef="usd">-30000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-764" decimals="-6" id="f-2559" unitRef="usd">95000000</us-gaap:LossContingencyAccrualProvision>
    <mdt:ImpairmentofInProcessResearchandDevelopment contextRef="c-762" decimals="-6" id="f-2560" unitRef="usd">0</mdt:ImpairmentofInProcessResearchandDevelopment>
    <mdt:ImpairmentofInProcessResearchandDevelopment contextRef="c-763" decimals="-6" id="f-2561" unitRef="usd">0</mdt:ImpairmentofInProcessResearchandDevelopment>
    <mdt:ImpairmentofInProcessResearchandDevelopment contextRef="c-764" decimals="-6" id="f-2562" unitRef="usd">101000000</mdt:ImpairmentofInProcessResearchandDevelopment>
    <mdt:MedicalDeviceRegulations contextRef="c-762" decimals="-6" id="f-2563" unitRef="usd">119000000</mdt:MedicalDeviceRegulations>
    <mdt:MedicalDeviceRegulations contextRef="c-763" decimals="-6" id="f-2564" unitRef="usd">150000000</mdt:MedicalDeviceRegulations>
    <mdt:MedicalDeviceRegulations contextRef="c-764" decimals="-6" id="f-2565" unitRef="usd">102000000</mdt:MedicalDeviceRegulations>
    <mdt:SpecialChargesGains contextRef="c-762" decimals="-6" id="f-2566" unitRef="usd">0</mdt:SpecialChargesGains>
    <mdt:SpecialChargesGains contextRef="c-763" decimals="-6" id="f-2567" unitRef="usd">70000000</mdt:SpecialChargesGains>
    <mdt:SpecialChargesGains contextRef="c-764" decimals="-6" id="f-2568" unitRef="usd">0</mdt:SpecialChargesGains>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-2569" unitRef="usd">4837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-2570" unitRef="usd">5364000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-2571" unitRef="usd">5517000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock contextRef="c-1" id="f-2572">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Assets and Depreciation Expense &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Depreciation Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets contextRef="c-765" decimals="-6" id="f-2573" unitRef="usd">16128000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-766" decimals="-6" id="f-2574" unitRef="usd">16036000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-744" decimals="-6" id="f-2575" unitRef="usd">199000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-745" decimals="-6" id="f-2576" unitRef="usd">209000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-746" decimals="-6" id="f-2577" unitRef="usd">210000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-767" decimals="-6" id="f-2578" unitRef="usd">18270000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-768" decimals="-6" id="f-2579" unitRef="usd">18346000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-747" decimals="-6" id="f-2580" unitRef="usd">252000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-748" decimals="-6" id="f-2581" unitRef="usd">267000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-749" decimals="-6" id="f-2582" unitRef="usd">265000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-769" decimals="-6" id="f-2583" unitRef="usd">33586000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-770" decimals="-6" id="f-2584" unitRef="usd">34926000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-750" decimals="-6" id="f-2585" unitRef="usd">194000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-751" decimals="-6" id="f-2586" unitRef="usd">203000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-752" decimals="-6" id="f-2587" unitRef="usd">186000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-771" decimals="-6" id="f-2588" unitRef="usd">3996000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-772" decimals="-6" id="f-2589" unitRef="usd">3930000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-753" decimals="-6" id="f-2590" unitRef="usd">94000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-754" decimals="-6" id="f-2591" unitRef="usd">80000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-755" decimals="-6" id="f-2592" unitRef="usd">67000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-773" decimals="-6" id="f-2593" unitRef="usd">71980000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-774" decimals="-6" id="f-2594" unitRef="usd">73238000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-756" decimals="-6" id="f-2595" unitRef="usd">739000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-757" decimals="-6" id="f-2596" unitRef="usd">759000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-758" decimals="-6" id="f-2597" unitRef="usd">728000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-775" decimals="-6" id="f-2598" unitRef="usd">547000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-776" decimals="-6" id="f-2599" unitRef="usd">1337000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-759" decimals="-6" id="f-2600" unitRef="usd">0</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-760" decimals="-6" id="f-2601" unitRef="usd">2000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-761" decimals="-6" id="f-2602" unitRef="usd">18000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-777" decimals="-6" id="f-2603" unitRef="usd">17455000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-778" decimals="-6" id="f-2604" unitRef="usd">16373000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-779" decimals="-6" id="f-2605" unitRef="usd">215000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-780" decimals="-6" id="f-2606" unitRef="usd">238000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-781" decimals="-6" id="f-2607" unitRef="usd">228000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-27" decimals="-6" id="f-2608" unitRef="usd">89981000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-28" decimals="-6" id="f-2609" unitRef="usd">90948000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-1" decimals="-6" id="f-2610" unitRef="usd">954000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-25" decimals="-6" id="f-2611" unitRef="usd">999000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-26" decimals="-6" id="f-2612" unitRef="usd">974000000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c-1" id="f-2613">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents net sales for fiscal years 2024, 2023, and 2022, and property, plant, and equipment, net at April&#160;26, 2024 and April&#160;28, 2023 for the Company's country of domicile, countries with significant concentrations, and all other countries: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.504%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other countries, excluding Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-782" decimals="-6" id="f-2614" unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-783" decimals="-6" id="f-2615" unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-784" decimals="-6" id="f-2616" unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-785" decimals="-6" id="f-2617" unitRef="usd">252000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-786" decimals="-6" id="f-2618" unitRef="usd">184000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-174" decimals="-6" id="f-2619" unitRef="usd">16562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-175" decimals="-6" id="f-2620" unitRef="usd">16373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-176" decimals="-6" id="f-2621" unitRef="usd">16135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-787" decimals="-6" id="f-2622" unitRef="usd">4593000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-788" decimals="-6" id="f-2623" unitRef="usd">4083000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-789" decimals="-6" id="f-2624" unitRef="usd">15689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-790" decimals="-6" id="f-2625" unitRef="usd">14756000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-791" decimals="-6" id="f-2626" unitRef="usd">15450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-792" decimals="-6" id="f-2627" unitRef="usd">1286000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-793" decimals="-6" id="f-2628" unitRef="usd">1302000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-794" decimals="-6" id="f-2629" unitRef="usd">32251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-795" decimals="-6" id="f-2630" unitRef="usd">31129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-796" decimals="-6" id="f-2631" unitRef="usd">31585000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-797" decimals="-6" id="f-2632" unitRef="usd">5879000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-798" decimals="-6" id="f-2633" unitRef="usd">5385000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-2634" unitRef="usd">32364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-6" id="f-2635" unitRef="usd">31227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-6" id="f-2636" unitRef="usd">31686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-27" decimals="-6" id="f-2637" unitRef="usd">6131000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-28" decimals="-6" id="f-2638" unitRef="usd">5569000000</us-gaap:PropertyPlantAndEquipmentNet>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-485" id="f-2639">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-485" id="f-2640">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-485" id="f-2641">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-485" id="f-2642">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-2643">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c-1" id="f-2644">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MEDTRONIC PLC AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II &#x2013; VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;Beginning of&lt;br/&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charges to Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charges to Other Accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Changes (Debit) Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at End of&lt;br/&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allowance for doubtful accounts and credit losses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax valuation allowance: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.342%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:92.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(a) Primarily consists of uncollectible accounts written off, less recoveries.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(b) Reflects the impact from acquisitions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(c) Primarily reflects carryover attribute utilization and expiration.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(d) Primarily reflects the effects of currency fluctuations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(e) Primarily reflects the impacts from tax rate changes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-799" decimals="-6" id="f-2645" unitRef="usd">176000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-800" decimals="-6" id="f-2646" unitRef="usd">90000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-800" decimals="-6" id="f-2647" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-800" decimals="-6" id="f-2648" unitRef="usd">93000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-801" decimals="-6" id="f-2649" unitRef="usd">173000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-802" decimals="-6" id="f-2650" unitRef="usd">230000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-803" decimals="-6" id="f-2651" unitRef="usd">73000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-803" decimals="-6" id="f-2652" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-803" decimals="-6" id="f-2653" unitRef="usd">127000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-799" decimals="-6" id="f-2654" unitRef="usd">176000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-804" decimals="-6" id="f-2655" unitRef="usd">241000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-805" decimals="-6" id="f-2656" unitRef="usd">58000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-805" decimals="-6" id="f-2657" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-805" decimals="-6" id="f-2658" unitRef="usd">69000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-802" decimals="-6" id="f-2659" unitRef="usd">230000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-806" decimals="-6" id="f-2660" unitRef="usd">11311000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-807" decimals="-6" id="f-2661" unitRef="usd">1522000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-807" decimals="-6" id="f-2662" unitRef="usd">3000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-807" decimals="-6" id="f-2663" unitRef="usd">108000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-808" decimals="-6" id="f-2664" unitRef="usd">13271000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <mdt:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments contextRef="c-807" decimals="-6" id="f-2665" unitRef="usd">545000000</mdt:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments>
    <mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet contextRef="c-807" decimals="-6" id="f-2666" unitRef="usd">2000000</mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-809" decimals="-6" id="f-2667" unitRef="usd">6583000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-810" decimals="-6" id="f-2668" unitRef="usd">4779000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-810" decimals="-6" id="f-2669" unitRef="usd">39000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-810" decimals="-6" id="f-2670" unitRef="usd">63000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-806" decimals="-6" id="f-2671" unitRef="usd">11311000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet contextRef="c-810" decimals="-6" id="f-2672" unitRef="usd">1000000</mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-810" decimals="-6" id="f-2673" unitRef="usd">27000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-811" decimals="-6" id="f-2674" unitRef="usd">5822000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-812" decimals="-6" id="f-2675" unitRef="usd">884000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-812" decimals="-6" id="f-2676" unitRef="usd">-19000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-812" decimals="-6" id="f-2677" unitRef="usd">103000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-809" decimals="-6" id="f-2678" unitRef="usd">6583000000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
